Mhc peptide complexes and uses thereof in infectious diseases

ABSTRACT

Novel compounds carrying ligands capable of binding to counter receptors on relevant target cells are disclosed. The compounds possess a number of advantageous features, rendering them very suitable for a wide range of applications, including use as detection systems, detection of relevant target cells as well as a number of other methods. In particular, novel MHC complexes comprising one or more MHC molecules are disclosed. The affinity and specificity of the MHC-peptide complexes are surprisingly high. The possibility of presenting to the target cells a plurality of MHC-peptide complexes makes the MHC complexes according to the present invention an extremely powerful tool e.g. in the field of therapy and diagnosis. The invention generally relates to the field of therapy, including therapeutic methods and therapeutic compositions. Also comprised by the present invention is the sample-mounted use of MHC complexes and MHC multimers.

This application claims priority under 35 U.S.C. §120 as a continuationof U.S. application Ser. No. 12/619,039 filed Nov. 16, 2009, which is acontinuation of U.S. application Ser. No. 12/567,126 filed Sep. 25, 2009which is a continuation of PCT Application No. PCT/DK2008/000118 filedMar. 26, 2008, which claims priority to the following Danish Patentapplications Nos.—PA 2007 00461, filed Mar. 26, 2007, PA 2007 00973,filed Jul. 3, 2007, PA 2007 00975, filed Jul. 3, 2007, PA 2007 00972,filed Jul. 3, 2007, and PA 2007 00974, filed Jul. 3, 2007 and alsoclaims priority to the following U.S. Provisional Patent ApplicationsNos.—U.S. 60/907,217 filed Mar. 26, 2007, U.S. 60/929,583, filed Jul. 3,2007, U.S. 60/929,581, filed Jul. 3, 2007, U.S. 60/929,582, filed Jul.3, 2007, and U.S. 60/929,586, Jul. 3, 2007, the contents of each ofwhich are hereby incorporated by reference.

All patent and non-patent references cited in U.S. 60/907,217 as well asin this application are hereby incorporated by reference in theirentirety. U.S. 60/907,217 is hereby also incorporated herein byreference in its entirety.

FIELD OF INVENTION

The present invention relates to MHC-peptide complexes and uses thereofin the treatment of a disease in an individual.

BACKGROUND OF THE INVENTION

Biochemical interactions between peptide epitope specific membranemolecules encoded by the Major Histocompatibility Complex (MHC, inhumans HLA) and T-cell receptors (TCR) are required to elicit specificimmune responses. This requires activation of T-cells by presentation tothe T-cells of peptides against which a T-cell response should beraised. The peptides are presented to the T-cells by the MHC complexes.

The Immune Response

The immune response is divided into two parts termed the innate immuneresponse and the adaptive immune response. Both responses work togetherto eliminate pathogens (antigens). Innate immunity is present at alltimes and is the first line of defense against invading pathogens. Theimmediate response by means of pre-existing elements, i.e. variousproteins and phagocytic cells that recognize conserved features on thepathogens, is important in clearing and control of spreading ofpathogens. If a pathogen is persistent in the body and thus onlypartially cleared by the actions of the innate immune system, theadaptive immune system initiate a response against the pathogen. Theadaptive immune system is capable of eliciting a response againstvirtually any type of pathogen and is unlike the innate immune systemcapable of establishing immunological memory.

The adaptive response is highly specific to the particular pathogen thatactivated it but it is not so quickly launched as the innate when firstencountering a pathogen. However, due to the generation of memory cells,a fast and more efficient response is generated upon repeated exposureto the same pathogen. The adaptive response is carried out by twodistinct sets of lymphocytes, the B cells producing antibodies leadingto the humoral or antibody mediated immune response, and the T cellsleading to the cell mediated immune response.

T cells express a clonotypic T cell receptor (TCR) on the surface. Thisreceptor enable the T cell to recognize peptide antigens bound to majorhistocompatibility complex (MHC) molecules, called human leukocyteantigens (HLA) in man. Depending on the type of pathogen, beingintracellular or extracellular, the antigenic peptides are bound to MHCclass I or MHC class II, respectively. The two classes of MHC complexesare recognized by different subsets of T cells; Cytotoxic CD8+ T cellsrecognizing MHC class I and CD4+ helper cells recognizing MHC class II.In general, TCR recognition of MHC-peptide complexes result in T cellactivation, clonal expansion and differentiation of the T cells intoeffector, memory and regulatory T cells.

B cells express a membrane bound form of immunoglobulin (Ig) called theB cell receptor (BCR). The BCR recognizes an epitope that is part of anintact three dimensional antigenic molecule. Upon BCR recognition of anantigen the BCR:antigen complex is internalized and fragments from theinternalized antigen is presented in the context of MHC class II on thesurface of the B cell to CD4+ helper T-cells (Th). The specific Th cellwill then activate the B cell leading to differentiation into anantibody producing plasma cell.

A very important feature of the adaptive immune system is its ability todistinguish between self and non-self antigens, and preferably respondagainst non-self. If the immune system fails to discriminate between thetwo, specific immune responses against self-antigens are generated.These autoimmune reactions can lead to damage of self-tissue.

The adaptive immune response is initiated when antigens are taken up byprofessional antigen presenting cells such as dendritic cells,Macrophages, Langerhans cells and B-cells. These cells present peptidefragments, resulting from the degradation of proteins, in the context ofMHC class II proteins (Major Histocompatibility Complex) to helper Tcells. The T helper cells then mediate help to B-cells and antigenspecific cytotoxic T cells, both of which have received primaryactivation signals via their BCR respective TCR. The help from theTh-cell is mediated by means of soluble mediators e.g. cytokines.

In general the interactions between the various cells of the cellularimmune response is governed by receptor-ligand interactions directlybetween the cells and by production of various soluble reportersubstances e.g. cytokines by activated cells.

MHC-Peptide Complexes.

MHC complexes function as antigenic peptide receptors, collectingpeptides inside the cell and transporting them to the cell surface,where the MHC-peptide complex can be recognized by T-lymphocytes. Twoclasses of classical MHC complexes exist, MHC class I and II. The mostimportant difference between these two molecules lies in the proteinsource from which they obtain their associated peptides. MHC class Imolecules present peptides derived from endogenous antigens degraded inthe cytosol and are thus able to display fragments of viral proteins andunique proteins derived from cancerous cells. Almost all nucleated cellsexpress MHC class I on their surface even though the expression levelvaries among different cell types. MHC class II molecules bind peptidesderived from exogenous antigens. Exogenous proteins enter the cells byendocytosis or phagocytosis, and these proteins are degraded byproteases in acidified intracellular vesicles before presentation by MHCclass II molecules. MHC class II molecules are only expressed onprofessional antigen presenting cells like B cells and macrophages.

The three-dimensional structure of MHC class I and II molecules are verysimilar but important differences exist. MHC class I molecules consistof two polypeptide chains, a heavy chain, α, spanning the membrane and alight chain, β2-microglobulin (β2m). The heavy chain is encoded in thegene complex termed the major histocompatibility complex (MHC), and itsextracellular portion comprises three domains, α1, α2 and α3. The β2mchain is not encoded in the MHC gene and consists of a single domain,which together with the α3 domain of the heavy chain make up a foldedstructure that closely resembles that of the immunoglobulin. The α1 andα2 domains pair to form the peptide binding cleft, consisting of twosegmented α helices lying on a sheet of eight β-strands. In humans aswell as in mice three different types of MHC class I molecule exist.HLA-A, B, C are found in humans while MHC class I molecules in mice aredesignated H-2K, H-2D and H-2L.

The MHC class II molecule is composed of two membrane spanningpolypeptide chains, α and β, of similar size (about 30000 Da). Geneslocated in the major histocompatibility complex encode both chains. Eachchain consists of two domains, where α1 and β1 forms a 9-pocketpeptide-binding cleft, where pocket 1, 4, 6 and 9 are considered asmajor peptide binding pockets. The α2 and β2, like the α2 and β2m in theMHC class I molecules, have amino acid sequence and structuralsimilarities to immunoglobulin constant domains. In contrast to MHCclass I complexes, where the ends of the antigenic peptide is buried,peptide-ends in MHC class II complexes are not. HLA-DR, DQ and DP arethe human class II molecules, H-2A, M and E are those of the mice.

A remarkable feature of MHC genes is their polymorphism accomplished bymultiple alleles at each gene. The polygenic and polymorphic nature ofMHC genes is reflected in the peptide-binding cleft so that differentMHC complexes bind different sets of peptides. The variable amino acidsin the peptide binding cleft form pockets where the amino acid sidechains of the bound peptide can be buried. This permits a specificvariant of MHC to bind some peptides better than others.

MHC Multimers

Due to the short half-life of the peptide-MHC-T cell receptor ternarycomplex (typically between 10 and 25 seconds) it is difficult to labelspecific T cells with labelled MHC-peptide complexes, and like-wise, itis difficult to employ such monomers of MHC-peptide for therapeutic andvaccine purposes because of their weak binding. In order to circumventthis problem, MHC multimers have been developed. These are complexesthat include multiple copies of MHC-peptide complexes, providing thesecomplexes with an increased affinity and half-life of interaction,compared to that of the monomer MHC-peptide complex. The multiple copiesof MHC-peptide complexes are attached, covalently or non-covalently, toa multimerization domain. Known examples of such MHC multimers includethe following:

-   -   MHC-dimers: Each MHC dimer contains two copies of MHC-peptide.        IgG is used as multimerization domain, and one of the domains of        the MHC protein is covalently linked to IgG.    -   MHC-tetramers: Each MHC-tetramer contains four copies of        MHC-peptide, each of which is biotinylated. The MHC complexes        are held together in a complex by the streptavidin tetramer        protein, providing a non-covalent linkage between a streptavidin        monomer and the MHC protein. Tetramers are described in U.S.        Pat. No. 5,635,363.    -   MHC pentamers: Five copies of MHC-peptide complexes are        multimerised by a self-assembling coiled-coil domain, to form a        MHC pentamer. MHC pentamers are described in the US patent        2004209295    -   MHC dextramers: A large number of MHC-peptide complexes,        typically more than ten, are attached to a dextran polymer.        MHC-dextramers are described in the patent application WO        02/072631 A2.    -   MHC streptamers: 8-12 MHC-peptide complexes attached to        Streptactin. MHC streptamers are described in Knabel M et al.        Reversibel MHC multimer staining for functional isolation of        T-cell populations and effective adoptive transfer. Nature        medicine 6. 631-637 (2002).

Use of MHC Multimers in Flow Cytometry and Related Techniques

The concentration of antigen specific T-cells in samples from e.g.peripheral blood can be very low. Flow cytometry and related methodsoffer the ability to analyze a large number of cells and simultaneouslyidentify the few of interest. MHC multimers have turned out to be veryvaluable reagents for detection and characterization of antigen specificT-cells in flow cytometer experiments. The relative amount of antigenspecific T cells in a sample can be determined and also the affinity ofthe binding of MHC multimer to the T-cell receptor can be determined.The basic function of a flow cytometer is its ability to analyse andidentify fluorochrome labelled entities in a liquid sample, by means ofits excitation, using a light source such as a laser beam and the lightemission from the bound fluorochrome.

MHC multimers is used as detections molecule for identification ofantigen specific T-cells in flow cytometry, by labelling the MHCmultimer with a specific fluorochrome, which is detectable, by the flowcytometer used.

In order to facilitate the identification of a small amount of cells,the cells can be sub-categorized using antibodies or other fluorochromelabelled detections molecules directed against surface markers otherthan the TCR on the specific T-cells population. Antibodies or otherfluorochrome labelled detections molecules can also be used to identifycells known not to be antigen specific T-cells. Both kinds of detectionsmolecules are in the following referred to as gating reagents. Gatingreagents, helps identify the “true” antigen specific T cells bound byMHC multimers by identifying specific subpopulations in a sample, e.g. Tcells and by excluding cells that for some reason bind MHC mulimerswithout being antigen specific T-cells. Other cytometry methods, e.g.fluorescence microscopy and IHC can like flow cytometry be employed inidentification of antigen specific T cells in a cell sample using MHCmultimers.

Application of MHC Multimers in Immune Monitoring, Diagnostics,Prognostics, Therapy and Vaccines

T cells are pivotal for mounting an adaptive immune response. It istherefore of importance to be able to measure the number of specific Tcells when performing a monitoring of a given immune response, forexample in connection with vaccine development, autologous cancertherapy, transplantation, infectious diseases, toxicity studies etc.

Accordingly, the present invention further provides powerful tools inthe fields of vaccines, therapy and diagnosis. One objective of thepresent invention is to provide methods for anti-tumour and anti-virusimmunotherapy by generating antigen-specific T-cells capable ofinactivating or eliminating undesirable target cells. Another objectiveis to isolate antigen-specific T-cells and culture these in the presenceof co-stimulatory molecules. Ex vivo priming and expansion of T-cellpopulations allows the T-cells to be used in immunotherapy of varioustypes of cancer and infectious diseases. A third objective of thepresent invention is to identify and label specific subsets of cellswith relevance for the development or treatment of diseases.

SUMMARY OF THE INVENTION

Measurement of antigen specific T cells during an immune response areimportant parameters in vaccine development, autologous cancer therapy,transplantation, infectious diseases, inflammation, autoimmunity,toxicity studies etc. MHC multimers are crucial reagents in monitoringof antigen specific T cells. The present invention describes novelmethods to generate MHC multimers and methods to improve existing andnew MHC multimers. The invention also describes improved methods for theuse of MHC multimers in analysis of T cells in samples includingdiagnostic and prognostic methods. Furthermore the use of MHC multimersin therapy are described, e.g. anti-tumour and anti-virus therapy,including isolation of antigen specific T cells capable of inactivationor elimination of undesirable target cells or isolation of specific Tcells capable of regulation of other immune cells.

The present invention in one aspect refers to a MHC monomer comprisinga-b-P, or a MHC multimer comprising (a-b-P)_(n), wherein n>1,

wherein a and b together form a functional MHC protein capable ofbinding the peptide P,wherein (a-b-P) is the MHC-peptide complex formed when the peptide Pbinds to the functional MHC protein, andwherein each MHC peptide complex of a MHC multimer is associated withone or more multimerization domains.

MHC monomers and MHC multimers comprising one or more MHC peptidecomplexes of class I or class 2 MHC are covered by the presentinvention. Accordingly, the peptide P can have a length of e.g. 8, 9,10, 11, 12, 13, 14, 15, 16, 16-20, or 20-30 amino acid residues.

Examples of the peptide P is provided herein below. In one embodiment,the peptide P can be selected from the group consisting of sequencesdisclosed in the electronically enclosed “Sequence Listing” andannotated consecutively (using integers) starting with SEQ ID NO:1 andending with SEQ ID NO:52252.

In another aspect the present invention is directed to a compositioncomprising a plurality of MHC monomers and/or MHC multimers according tothe present invention, wherein the MHC multimers are identical ordifferent, and a carrier.

In yet another aspect there is provided a kit comprising a MHC monomeror a MHC multimer according to the present invention, or a compositionaccording to the present invention, and at least one additionalcomponent, such as a positive control and/or instructions for use.

In a still further aspect there is provided a method for immunemonitoring one or more diseases comprising monitoring of antigenspecific T cells, said method comprising the steps of

-   -   i) providing the MHC monomer or MHC multimer or individual        components thereof according to the present invention, or the        individual components thereof,    -   ii) providing a population of antigen specific T cells or        individual antigen specific T cells, and    -   iii) measuring the number, activity or state and/or presence of        antigen specific of T cells specific for the peptide P of the        said MHC monomer or MHC multimer, thereby immune monitoring said        one or more diseases.

In yet another aspect there is provided a method for diagnosing one ormore diseases comprising immune monitoring of antigen specific T cells,said method comprising the following steps: of

-   -   i) providing the MHC monomer or MHC multimer or individual        components thereof according to the present invention, or        individual components thereof,    -   ii) providing a population of antigen specific T cells or        individual antigen specific T cells, and    -   iii) measuring the number, activity or state and/or presence of        T cells specific for said MHC monomer or the peptide P of the        MHC multimer, thereby diagnosing said one or more diseases.

There is also provided a method for isolation of one or more antigenspecific T cells, said method comprising the steps of

-   -   i) providing the MHC monomer or MHC multimer or individual        components thereof according to the present invention, or        individual components thereof, and    -   ii) providing a population of antigen specific T cells or        individual antigen specific T cells, and    -   iii) thereby isolating said T cells specific for the peptide P        of the said MHC monomer or MHC multimer.

The present invention makes it possible to pursue different immunemonitoring methods using the MHC monomers and MHC multimers according tothe present invention. The immune monitoring methods include e.g. flowcytometry, ELISPOT, LDA, Quantaferon and Quantaferon-like methods. Usingthe above-cited methods, the MHC monomers and/or the MHC multimers canbe provided as a MHC peptide complex, or the peptide and the MHC monomerand/or multimer can be provided separately.

Accordingly, recognition of TCR's can be achieved by direct or indirectdetection, e.g. by using one or more of the following methods:

ELISPOT technique using indirect detection, e.g. by adding the antigenicpeptide optionally associated with a MHC monomer or MHC multimer,followed by measurement of INF-gamma secretion from a population ofcells or from individual cells.

Another technique involves a Quantaferon-like detection assays, e.g. byusing indirect detection, e.g. by adding the antigenic peptideoptionally associated with a MHC monomer or MHC multimer, followed bymeasurement of INF-gamma secretion from a population of cells or fromindividual cells.

Flow cytometry offers another alternative for performing detectionassays, e.g. by using direct detection (e.g. of MHC tetramers), e.g. byadding the antigenic peptide optionally associated with a MHC monomer orMHC multimer, followed by detection of a fluorescein label, therebymeasuring the number of TCRs on specific T-cells.

Flow cytometry can also be used for indirect detection, e.g. by addingthe antigenic peptide optionally associated with a MHC monomer or MHCmultimer, followed by addition of a “cell-permeabilizing factor”, andsubsequent measurement of an intracellular component (e.g. INF-gammamRNA), from individual cells or populations of cells.

By using the above-mentioned and other techniques, one can diagnoseand/or monitor e.g. infectious diseases caused e.g. by mycobacetrium,Gram positive bacteria, Gram negative bacteria, Spirochetes,intracellular bacterium, extracelular bacterium, Borrelia, TB, CMV, HPV,Hepatitis, BK, fungal organisms and microorganisms. The diagnosis and/ormonitoring of a particular disease can greatly aid in directing anoptimal treatment of said disease in an individual. Cancer diagnosticmethods and/or cancer monitoring methods also fall within the scope ofthe present invention.

In still further aspects of the present invention there is provided amethod for performing a vaccination of an individual in need thereof,said method comprising the steps of

-   -   providing a MHC monomer or a MHC multimer according to the        present invention, or the individual components thereof, and    -   administering said MHC monomer or MHC multimer to said        individual and obtaining a protective immune response, thereby        performing a vaccination of the said individual.

In yet another embodiment there is provided a method for performingtherapeutic treatment of an individual comprising the steps of

-   -   Providing the MHC multimer according to the present invention,        or individual components thereof, and    -   Isolating or obtaining T-cells from a source, such as an        individual or an ex-vivo library or cell bank, wherein said        isolated or obtained T-cells are specific for said provided MHC        multimer,    -   Optionally manipulating said T-cells, and    -   Introducing said isolated or obtained T-cells into an individual        to be subjected to a therapeutic treatment, wherein the        individual can be the same individual or a different individual        from the source individual.

There is also provided in accordance with the present invention a methodfor immune monitoring one or more cancer diseases comprising the step ofmonitoring one or more cancer antigen specific T-cells, said methodcomprising the steps of

-   -   providing a MHC monomer or MHC multimer, or individual        components thereof, according to any of the claims 1 to 797,    -   providing a population of cancer antigen specific T cells, or        individual cancer antigen specific T cells, and    -   measuring the number and/or presence of cancer antigen specific        T cells specific for the peptide P of the MHC monomer or MHC        multimer, thereby immune monitoring said one or more cancer        diseases.

In a still further aspect there is provided a method for diagnosing oneor more cancer diseases in an individual, said method comprising thestep of performing an immune monitoration of one or more cancer antigenspecific T cell(s), said method comprising the further steps of

-   -   providing the MHC multimer or individual components thereof        according to the present invention,    -   providing a population of cancer antigen specific T cells, or        individual cancer antigen specific T cells, and    -   measuring the number and/or presence of T cells specific for the        peptide P of the MHC monomer or MHC multimer, thereby diagnosing        said one or more cancer diseases.

In yet another aspect of the present invention there is provided amethod for performing a cancer vaccination of an individual in needthereof, said method comprising the steps of

-   -   providing a MHC monomer or MHC multimer according to any of the        present invention, and    -   administering said MHC monomer or said MHC multimer to said        individual, thereby performing a cancer vaccination of the said        individual.

In a still further aspect of the present invention there is provided amethod for performing a cancer therapeutic treatment of an individualcomprising the steps of

-   -   Providing the MHC multimer according to the present invention,        and    -   Isolation of T cells specific for said MHC multimer, and    -   Optionally manipulation of said T cell and    -   Introduction of said T cells into the same or a different        individual to obtain a cancer therapeutic treatment.

There is also provided a method comprising one or more steps forminimizing undesired binding of the MHC multimer according to thepresent invention. This method is disclosed herein below in more detail.

In further aspects the present invention provides:

A method for performing a control experiment comprising the step ofcounting of particles comprising the MHC multimer according to thepresent invention.

A method for performing a control experiment comprising the step ofsorting of particles comprising the MHC multimer according to thepresent invention.

A method for performing a control experiment comprising the step ofperforming flow cytometry analysis of particles comprising the MHCmultimer according to the present invention.

A method for performing a control experiment comprising the step ofperforming a immunohistochemistry analysis comprising the MHC multimeraccording to the present invention.

A method for performing a control experiment comprising the step ofperforming a immunocytochemistry analysis comprising the MHC multimeraccording to the present invention.

A method for performing a control experiment comprising the step ofperforming an ELISA analysis comprising the MHC multimer according tothe present invention.

In a still further aspect of the present invention there is provided amethod for generating MHC multimers according to the present invention,said method comprising the steps of

-   -   i) providing one or more peptides P; and/or    -   ii) providing one or more functional MHC proteins,    -   iii) optionally providing one or more multimerization domains,        and    -   iv) contacting the one or more peptides P and the one or more        functional MHC proteins and the one or more multimerization        domains simultaneously or sequentially in any order, thereby        obtaining MHC multimers according to the present invention.

The method can also be performed by initially providing one or moreantigenic peptide(s) P and one or more functional MHC proteins togenerate a MHC-peptide complex (a-b-P); subsequently providing one ormore multimerisation domain(s); and reacting the one or more MHC-peptidecomplexes and the one or more multimerization domain(s) to generate aMHC multimer according to the present invention.

DEFINITIONS

As used everywhere herein, the term “a”, “an” or “the” is meant to beone or more, i.e. at least one.

Adjuvant: adjuvants are drugs that have few or no pharmacologicaleffects by themselves, but can increase the efficacy or potency of otherdrugs when given at the same time. In another embodiment, an adjuvant isan agent which, while not having any specific antigenic effect initself, can stimulate the immune system, increasing the response to avaccine.

Agonist: agonist as used herein is a substance that binds to a specificreceptor and triggers a response in the cell. It mimics the action of anendogenous ligand that binds to the same receptor.

Antagonist: antagonist as used herein is a substance that binds to aspecific receptor and blocks the response in the cell. It blocks theaction of an endogenous ligand that binds to the same receptor.

Antibodies: As used herein, the term “antibody” means an isolated orrecombinant binding agent that comprises the necessary variable regionsequences to specifically bind an antigenic epitope. Therefore, anantibody is any form of antibody or fragment thereof that exhibits thedesired biological activity, e.g., binding the specific target antigen.Antibodies can derive from multiple species. For example, antibodiesinclude rodent (such as mouse and rat), rabbit, sheep, camel, and humanantibodies. Antibodies can also include chimeric antibodies, which joinvariable regions from one species to constant regions from anotherspecies. Likewise, antibodies can be humanized, that is constructed byrecombinant DNA technology to produce immunoglobulins which have humanframework regions from one species combined with complementaritydetermining regions (CDR's) from a another species' immunoglobulin. Theantibody can be monoclonal or polyclonal.

Antibodies can be divided into isotypes (IgA, IgG, IgM, IgD, IgE, IgG1,IgG2, IgG3, IgG4, IgA1, IgA2, IgM1, IgM2)

Antibodies: In another embodiment the term “antibody” refers to anintact antibody, or a fragment of an antibody that competes with theintact antibody for antigen binding. In certain embodiments, antibodyfragments are produced by recombinant DNA techniques. In certainembodiments, antibody fragments are produced by enzymatic or chemicalcleavage of intact antibodies. Exemplary antibody fragments include, butare not limited to, Fab, Fab′, F(ab′)2, Fv, and scFv. Exemplary antibodyfragments also include, but are not limited to, domain antibodies,nanobodies, minibodies ((scFv-C.sub.H3).sub.2), maxibodies((scFv-C.sub.H2-C.sub.H3).sub.2), diabodies (noncovalent dimer of scFv).

Antigen presenting cell: An antigen-presenting cell (APC) as used hereinis a cell that displays foreign antigen complexed with MHC on itssurface.

Antigenic peptide: Any peptide molecule that is bound or able to bindinto the binding groove of either MHC class 1 or MHC class 2.

Aptamer: the term aptamer as used herein is defined as oligonucleic acidor peptide molecules that bind a specific target molecule. Aptamers areusually created by selecting them from a large random sequence pool, butnatural aptamers also exist. Aptamers can be divided into DNA amtamers,RNA aptamers and peptide aptamers.

Avidin: Avidin as used herein is a glycoprotein found in the egg whiteand tissues of birds, reptiles and amphibians. It contains fouridentical subunits having a combined mass of 67,000-68,000 daltons. Eachsubunit consists of 128 amino acids and binds one molecule of biotin.

Biologically active molecule: A biologically active molecule is amolecule having itself a biological activity/effect or is able to inducea biological activity/effect when administered to a biological system.Biologically active molecules include adjuvants, immune targets (e.g.antigens), enzymes, regulators of receptor activity, receptor ligands,immune potentiators, drugs, toxins, cytotoxic molecules, co-receptors,proteins and peptides in general, sugar moieties, lipid groups, nucleicacids including siRNA, nanoparticles, small molecules.

Bioluminescent: Bioluminescence, as used herein, is the production andemission of light by a living organism as the result of a chemicalreaction during which chemical energy is converted to light energy.

Biotin: Biotin, as used herein, is also known as vitamin H or B₇. Niotinhas the chemical formula C₁₀H₁₆N₂O₃S.

Bispecific antibodies: The term bispecific antibodies as used herein isdefined as monoclonal, preferably but not limited to human or humanized,antibodies that have binding specificities for at least two differentantigens. The antibody can also be trispecific or multispecific.

Carrier: A carrier as used herein can be any type of molecule that isdirectly or indirectly associated with the MHC peptide complex. In thisinvention, a carrier will typically refer to a functionalized polymer(e.g. dextran) that is capable of reacting with MHC-peptide complexes,thus covalently attaching the MHC-peptide complex to the carrier, orthat is capable of reacting with scaffold molecules (e.g. streptavidin),thus covalently attaching streptavidin to the carrier; the streptavidinthen may bind MHC-peptide complexes. Carrier and scaffold are usedinterchangeably herein where scaffold typically refers to smallermolecules of a multimerization domain and carrier typically refers tolarger molecule and/or cell like structures.

Chelating chemical compound: Chelating chemical compound, as usedherein, is the process of reversible binding of a ligand to a metal ion,forming a metal complex.

Chemiluminescent: Chemiluminescence, as used herein, is the emission oflight (luminescence) without emission of heat as the result of achemical reaction.

Chromophore: A chromophore, as used herein, is the part of a visiblycoloured molecule responsible for light absorption over a range ofwavelengths thus giving rise to the colour. By extension the term can beapplied to uv or it absorbing parts of molecules.

Coiled-coil polypeptide: the term coiled-coil polypeptide as used hereinis a structural motif in proteins, in which 2-7 alpha-helices are coiledtogether like the strands of a rope

Covalent binding: The term covalent binding is used herein to describe aform of chemical bonding that is characterized by the sharing of pairsof electrons between atoms. Attraction-to-repulsion stability that formsbetween atoms when they share electrons is known as covalent bonding.

Crosslinking is the process of chemically joining two or more moleculesby a covalent bond. Crosslinking reagents contain reactive ends tospecific functional groups (primary amines, sulfhydryls, etc.) onproteins or other molecules.

Diagnosis: The act or process of identifying or determining the natureand cause of a disease or injury through evaluation

Diabodies: The term “diabodies” refers to small antibody fragments withtwo antigen-binding sites, which fragments comprise a heavy-chainvariable domain (VH) connected to a light-chain variable domain (VL) inthe same polypeptide chain (VH-VL). By using a linker that is too shortto allow pairing between the two domains on the same chain, the domainsare forced to pair with the complementary domains of another chain andcreate two antigen-binding sites.

Dendritic cell: The term dendritic cell as used herein is a type ofimmune cells. Their main function is to process antigen material andpresent it on the surface to other cells of the immune system, thusfunctioning as antigen-presenting cells.

Detection: In this invention detection means any method capable ofmeasuring one molecule bound to another molecule. The molecules aretypically proteins but can be any type of molecule

Dextran: the term dextran as used herein is a complex, branchedpolysaccharide made of many glucose molecules joined into chains ofvarying lengths. The straight chain consists of α1->6 glycosidiclinkages between glucose molecules, while branches begin from α1->3linkages (and in some cases, α1->2 and α1->4 linkages as well).

Direct detection of T cells: Direct detection of T cells is used hereininterchangeably with direct detection of TCR and direct detection of Tcell receptor. As used herein direct detection of T cells is detectiondirectly of the binding interaction between a specific T cell receptorand a MHC multimer.

DNA: The term DNA (Deoxyribonucleic acid) duplex as used herein is apolymer of simple units called nucleotides, with a backbone made ofsugars and phosphate atoms joined by ester bonds. Attached to each sugaris one of four types of molecules called bases.

DNA duplex: In living organisms, DNA does not usually exist as a singlemolecule, but instead as a tightly-associated pair of molecules. Thesetwo long strands entwine like vines, in the shape of a double helix.

Electrophilic: electrophile, as used herein, is a reagent attracted toelectrons that participates in a chemical reaction by accepting anelectron pair in order to bond to a nucleophile.

Enzyme label: enzyme labelling, as used herein, involves a detectionmethod comprising a reaction catalysed by an enzyme.

Epitope-focused antibody: Antibodies also include epitope-focusedantibodies, which have at least one minimal essential bindingspecificity determinant from a heavy chain or light chain CDR3 from areference antibody, methods for making such epitope-focused antibodiesare described in U.S. patent application Ser. No. 11/040,159, which isincorporated herein by reference in its entirety.

Flow cytometry: The analysis of single cells using a flow cytometer.

Flow cytometer: Instrument that measures cell size, granularity andfluorescence due to bound fluorescent marker molecules as single cellspass in a stream past photodectors. A flow cytometer carry out themeasurements and/or sorting of individual cells.

Fluorescent: the term fluorescent as used herein is to have the abilityto emit light of a certain wavelength when activated by light of anotherwavelength.

Fluorochromes: fluorochrome, as used herein, is any fluorescent compoundused as a dye to mark e.g. protein with a fluorescent label.

Fluorophore: A fluorophore, as used herein, is a component of a moleculewhich causes a molecule to be fluorescent.

Folding: In this invention folding means in vitro or in vivo folding ofproteins in a tertiary structure.

Fusion antibody: As used herein, the term “fusion antibody” refers to amolecule in which an antibody is fused to a non-antibody polypeptide atthe N- or C-terminus of the antibody polypeptide.

Glycosylated: Glycosylation, as used herein, is the process or result ofaddition of saccharides to proteins and lipids.

Hapten: A residue on a molecule for which there is a specific moleculethat can bind, e.g. an antibody.

Heteroconjugate antibodies are composed of two covalently joinedantibodies. Such antibodies have, for example, been proposed to targetimmune system cells to unwanted cells.

IgG: IgG as used herein is a monomeric immunoglobulin, built of twoheavy chains and two light chains. Each molecule has two antigen bindingsites.

Isolated antibody: The term “isolated” antibody as used herein is anantibody which has been identified and separated and/or recovered from acomponent of its natural environment.

Immunoconjugates: The invention also pertains to immunoconjugatescomprising an antibody conjugated to a cytotoxic agent such as achemotherapeutic agent, toxin (e.g., an enzymatically active toxin ofbacterial, fungal, plant, or animal origin, or fragments thereof), or aradioactive isotope (i.e., a radioconjugate) Enzymatically active toxinsand fragments thereof that can be used include diphtheria A chain,nonbinding active fragments of diphtheria toxin, exotoxin A chain (fromPseudomonas aeruginosa), ricin A chain, abrin A chain, modeccin A chain,alpha-sarcin, Aleurites fordii proteins, dianthin proteins, Phytolacaamericana proteins (PAPI, PAPII, and PAP-S), momordica charantiainhibitor, curcin, crotin, sapaonaria officinalis inhibitor, gelonin,mitogellin, restrictocin, phenomycin, enomycin, and the tricothecenes. Avariety of radionuclides are available for the production ofradioconjugated antibodies. Conjugates of the antibody and cytotoxicagent are made using a variety of bifunctional protein-coupling agentssuch as N-succinimidyl-3-(2-pyridyldithiol) propionate (SPDP),iminothiolane (IT), bifunctional derivatives of imidoesters (such asdimethyl adipimidate HCL), active esters (such as disuccinimidylsuberate), aldehydes (such as glutaraldehyde), bis-azido compounds (suchas bis(p-azidobenzoyl)hexanediamine), bis-diazonium derivatives (such asbis-(p-diazoniumbenzoyl)-ethylenediamine), diisocyanates (such astolyene 2,6-diisocyanate), and bis-active fluorine compounds (such as1,5-difluoro-2,4-dinitrobenzene).

Immune monitoring: Immune monitoring of the present invention refers totesting of immune status in the diagnosis and therapy of diseases likebut not limited to cancer, immunoproliferative and immunodeficiencydisorders, autoimmune abnormalities, and infectious disease. It alsorefers to testing of immune status before, during and after vaccinationand transplantation procedures.

Immune monitoring process: a serie of one or more immune monitoringanalysis

Indirect detection of T cells: Indirect detection of T cells is usedinterchangeably herein with Indirect detection of TCR and indirectdetection of T cell receptor. As used herein indirect detection of Tcells is detection of the binding interaction between a specific T cellreceptor and a MHC multimer by measurement of the effect of the bindinginteraction.

Ionophore: ionophore, as used herein, is a lipid-soluble moleculeusually synthesized by microorganisms capable of transporting ions.

Label: Label herein is used interchangeable with labeling molecule.Label as described herein is an identifiable substance that isdetectable in an assay and that can be attached to a molecule creating alabeled molecule. The behavior of the labeled molecule can then bestudied.

Labelling: Labelling herein means attachment of a label to a molecule.

Lanthanide: lanthanide, as used herein, series comprises the 15 elementswith atomic numbers 57 through 71, from lanthanum to lutetium.

Linker molecule: Linker molecule and linker is used interchangeableherein. A linker molecule is a molecule that covalently ornon-covalently connects two or more molecules, thereby creating a largercomplex consisting of all molecules including the linker molecule.

Liposomes: The term liposomes as used herein is defined as a sphericalvesicle with a membrane composed of a phospholipid and cholesterolbilayer. Liposomes, usually but not by definition, contain a core ofaqueous solution; lipid spheres that contain no aqueous material arecalled micelles.

Immunoliposomes: The antibodies disclosed herein can also be formulatedas immunoliposomes. Liposomes comprising the antibody are prepared bymethods known in the art, such as described in Epstein et al., Proc.Natl. Acad. Sci. USA 82: 3688 (1985); Hwang et al., Proc. Natl. Acad.Sci. USA 77: 4030 (1980); and U.S. Pat. Nos. 4,485,045 and 4,544,545.Particularly useful liposomes can be generated by the reverse-phaseevaporation method with a lipid composition comprisingphosphatidylcholine, cholesterol, and PEG-derivatizedphosphatidylethanolamine (PEG-PE).

Marker: Marker is used interchangeably with marker molecule herein. Amarker is molecule that specifically associates covalently ornon-covalently with a molecule belonging to or associated with anentity.

MHC: Denotes the major histocompatibility complex.

A “MHC Class I molecule” as used everywhere herein is defined as amolecule which comprises 1-3 subunits, including a heavy chain, a heavychain combined with a light chain (beta₂m), a heavy chain combined witha light chain (beta₂m) through a flexible linker, a heavy chain combinedwith a peptide, a heavy chain combined with a peptide through a flexiblelinker, a heavy chain/beta₂m dimer combined with a peptide, and a heavychain/beta₂m dimer with a peptide through a flexible linker to the heavyor light chain. The MHC molecule chain can be changed by substitution ofsingle or by cohorts of native amino acids or by inserts, or deletionsto enhance or impair the functions attributed to said molecule. Byexample, it has been shown that substitution of XX with YY in positionnn of human beta₂m enhance the biochemical stability of MHC Class Imolecule complexes and thus can lead to more efficient antigenpresentation of subdominant peptide epitopes.

MHC complex: MHC complex is herein used interchangeably with MHC-peptidecomplex, unless it is specified that the MHC complex is empty, i.e. isnot complexed with peptide.

MHC Class I like molecules (including non-classical MHC Class Imolecules) include CD1d, HLA E, HLA G, HLA F, HLA H, MIC A, MIC B,ULBP-1, ULBP-2, and ULBP-3.

A “MHC Class II molecule” as used everywhere herein is defined as amolecule which comprises 2-3 subunits including an alpha-chain and abeta-chain (alpha/beta-dimer), an alpha/beta dimer with a peptide, andan alpha/beta dimer combined with a peptide through a flexible linker tothe alpha or beta chain, an alpha/beta dimer combined through aninteraction by affinity tags e.g. jun-fos, an alpha/beta dimer combinedthrough an interaction by affinity tags e.g. jun-fos and furthercombined with a peptide through a flexible linker to the alpha or betachain. The MHC molecule chains can be changed by substitution of singleor by cohorts of native amino acids or by inserts, or deletions toenhance or impair the functions attributed to said molecule. Undercircumstances where the alpha-chain and beta-chain have been fused, toform one subunit, the “MHC Class II molecule” can comprise only 1subunit.

MHC Class II like molecules (including non-classical MHC Class IImolecules) include HLA DM, HLA DO, I-A beta2, and I-E beta2.

A “peptide free MHC Class I molecule” as used everywhere herein is meantto be a MHC Class I molecule as defined above with no peptide.

A “peptide free MHC Class II molecule” as used everywhere herein ismeant to be a MHC Class II molecule as defined above with no peptide.

Such peptide free MHC Class I and II molecules are also called “empty”MHC Class I and II molecules.

The MHC molecule may suitably be a vertebrate MHC molecule such as ahuman, a mouse, a rat, a porcine, a bovine or an avian MHC molecule.Such MHC complexes from different species have different names. E.g. inhumans, MHC complexes are denoted HLA. The person skilled in the artwill readily know the name of the MHC complexes from various species.

In general, the term “MHC molecule” is intended to include alleles. Byway of example, in humans e.g. HLA A, HLA B, HLA C, HLA D, HLA E, HLA F,HLA G, HLA H, HLA DR, HLA DQ and HLA DP alleles are of interest, and inthe mouse system, H-2 alleles are of interest. Likewise, in the ratsystem RT1-alleles, in the porcine system SLA-alleles, in the bovinesystem BoLA, in the avian system e.g. chicken-B alleles, are ofinterest.

“MHC complexes” and “MHC constructs” are used interchangeably herein.

“MHC protein” and “MHC molecule” are used interchangeably herein.Accordingly, a functional MHC peptide complex comprises a MHC protein orMHC molecule associated with a peptide to be presented for cells orbinding partners having an affinity for said peptide.

By the terms “MHC complexes” and “MHC multimers” as used herein aremeant such complexes and multimers thereof, which are capable ofperforming at least one of the functions attributed to said complex ormultimer. The terms include both classical and non-classical MHCcomplexes. The meaning of “classical” and “non-classical” in connectionwith MHC complexes is well known to the person skilled in the art.Non-classical MHC complexes are subgroups of MHC-like complexes. Theterm “MHC complex” includes MHC Class I molecules, MHC Class IImolecules, as well as MHC-like molecules (both Class I and Class II),including the subgroup non-classical MHC Class I and Class II molecules.

The MHC molecule can suitably be a vertebrate MHC molecule such as ahuman, a mouse, a rat, a porcine, a bovine or an avian MHC molecule.Such MHC complexes from different species have different names. E.g. inhumans, MHC complexes are denoted HLA. The person skilled in the artwill readily know the name of the MHC complexes from various species.

MHC multimer: The terms MHC multimer, MHCmer and MHC′mer herein are usedinterchangeably, to denote a complex comprising more than oneMHC-peptide complexes, held together by covalent or non-covalent bonds.

Monoclonal antibodies: Monoclonal antibodies, as used herein, areantibodies that are identical because they were produced by one type ofimmune cell and are all clones of a single parent cell.

Monovalent antibodies: The antibodies in the present invention can bemonovalent antibodies. Methods for preparing monovalent antibodies arewell known in the art. For example, one method involves recombinantexpression of immunoglobulin light chain and modified heavy chain. Theheavy chain is truncated generally at any point in the Fc region so asto prevent heavy chain crosslinking. Alternatively, the relevantcysteine residues are substituted with another amino acid residue or aredeleted so as to prevent crosslinking. In vitro methods are alsosuitable for preparing monovalent antibodies. Digestion of antibodies toproduce fragments thereof, particularly, Fab fragments, can beaccomplished using routine techniques known in the art.

Multimerization domain: A multimerization domain is a molecule, acomplex of molecules, or a solid support, to which one or more MHC orMHC-peptide complexes can be attached. A multimerization domain consistof one or more carriers and/or one or more scaffolds and may alsocontain one or more linkers connecting carrier to scaffold, carrier tocarrier, scaffold to scaffold. The multimerization domain may alsocontain one or more linkers that can be used for attachment of MHCcomplexes and/or other molecules to the multimerization domain.Multimerization domains thus include IgG, streptavidin, streptactin,micelles, cells, polymers, beads and other types of solid support, andsmall organic molecules carrying reactive groups or carrying chemicalmotifs that can bind MHC complexes and other molecules.

Nanobodies: Nanobodies as used herein is a type of antibodies derivedfrom camels, and are much smaller than traditional antibodies.

Neutralizing antibodies: neutralizing antibodies as used herein is anantibody which, on mixture with the homologous infectious agent, reducesthe infectious titer.

NMR: NMR (Nuclear magnetic resonance), as used herein, is a physicalphenomenon based upon the quantum mechanical magnetic properties of anatom's nucleus. NMR refers to a family of scientific methods thatexploit nuclear magnetic resonance to study molecules.

Non-covalent: The term noncovalent bond as used herein is a type ofchemical bond, that does not involve the sharing of pairs of electrons,but rather involves more dispersed variations of electromagneticinteractions.

Nucleic acid duplex: A nucleic acid is a complex, high-molecular-weightbiochemical macromolecule composed of nucleotide chains that conveygenetic information. The most common nucleic acids are deoxyribonucleicacid (DNA) and ribonucleic acid (RNA).

Nucleophilic: a nucleophile, as used herein, is a reagent that forms achemical bond to its reaction partner (the electrophile) by donatingboth bonding electrons.

“One or more” as used everywhere herein is intended to include one and aplurality.

A “peptide free MHC Class I molecule” as used everywhere herein is meantto be a MHC Class I molecule as defined above with no peptide.

A “peptide free MHC Class II molecule” as used everywhere herein ismeant to be a MHC Class II molecule as defined above with no peptide.

Such peptide free MHC Class I and II molecules are also called “empty”MHC Class I and II molecules.

Pegylated: pegylated, as used herein, is conjugation of Polyethyleneglycol (PEG) to proteins.

Peptide or protein: Any molecule composed of at least two amino acids.Peptide normally refers to smaller molecules of up to around 30 aminoacids and protein to larger molecules containing more amino acids.

Phosphorylated; phosphorylated, as used herein, is the addition of aphosphate (PO₄) group to a protein molecule or a small molecule.

“A plurality” as used everywhere herein should be interpreted as two ormore.

PNA: PNA (Peptide nucleic acid) as used herein is a chemical similar toDNA or RNA. PNA is not known to occur naturally in existing life onEarth but is artificially synthesized and used in some biologicalresearch and medical treatments. DNA and RNA have a deoxyribose andribose sugar backbone, respectively, whereas PNA's backbone is composedof repeating N-(2-aminoethyl)-glycine units linked by peptide bonds. Thevarious purine and pyrimidine bases are linked to the backbone bymethylene carbonyl bonds. PNAs are depicted like peptides, with theN-terminus at the first (left) position and the C-terminus at the right.

“A plurality” as used everywhere herein should be interpreted as two ormore. This applies i.a. to the MHC peptide complex and the bindingentity. When a plurality of MHC peptide complexes is attached to themultimerization domain, such as a scaffold or a carrier molecule, thenumber of MHC peptide complexes need only be limited by the capacity ofthe multimerization domain.

Polyclonal antibodies: a polyclonal antibody as used herein is anantibody that is derived from different B-cell lines. They are a mixtureof immunoglobulin molecules secreted against a specific antigen, eachrecognising a different epitope.

Polymer: the term polymer as used herein is defined as a compoundcomposed of repeating structural units, or monomers, connected bycovalent chemical bonds.

Polypeptide: Peptides are the family of short molecules formed from thelinking, in a defined order, of various α-amino acids. The link betweenone amino acid residue and the next is an amide bond and is sometimesreferred to as a peptide bond. Longer peptides are referred to asproteins or polypeptide.

Polysaccharide: The term polysaccharide as used herein is defined aspolymers made up of many monosaccharides joined together by glycosidiclinkages.

Radicals: radicals, as used herein, are atomic or molecular species withunpaired electrons on an otherwise open shell configuration. Theseunpaired electrons are usually highly reactive, so radicals are likelyto take part in chemical reactions.

Radioactivity: Radioactive decay is the process in which an unstableatomic nucleus loses energy by emitting radiation in the form ofparticles or electromagnetic waves.

RNA: RNA (Ribonucleic acid) as used herein is a nucleic acid polymerconsisting of nucleotide monomers that plays several important roles inthe processes that translate genetic information from deoxyribonucleicacid (DNA) into protein products

Scaffold: A scaffold is typically an organic molecule carrying reactivegroups, capable of reacting with reactive groups on a MHC-peptidecomplex. Particularly small organic molecules of cyclic structure (e.g.functionalized cycloalkanes or functionalized aromatic ring structures)are termed scaffolds. Scaffold and carrier are used interchangeablyherein where scaffold typically refers to smaller molecules of amultimerization domain and carrier typically refers to larger moleculeand/or cell like structures.

Staining: In this invention staining means specific or unspecificlabelling of cells by binding labeled molecules to defined proteins orother structures on the surface of cells or inside cells. The cells areeither in suspension or part of a tissue. The labeled molecules can beMHC multimers, antibodies or similar molecules capable of bindingspecific structures on the surface of cells.

Streptavidin: Streptavidin as used herein is a tetrameric proteinpurified from the bacterium Streptomyces avidinii. Streptavidin iswidely use in molecular biology through its extraordinarily strongaffinity for biotin.

Sugar: Sugars as used herein include monosaccharides, disaccharides,trisaccharides and the oligosaccharides—comprising 1, 2, 3, and 4 ormore monosaccharide units respectively.

Therapy: Treatment of illness or disability

Vaccine: A vaccine is an antigenic preparation used to establishimmunity to a disease or illness and thereby protects or cure the bodyfrom a specific disease or illness. Vaccines are either prophylactic andprevent disease or therapeutic and treat disease. Vaccines may containmore than one type of antigen and is then called a combined vaccine.

Vaccination: The introduction of vaccine into the body of human oranimals for the purpose of inducing immunity.

B.L. is an abbreviation for Bind level.

Aff. is an abbreviation for affinity.

BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1. Schematic representation of MHC multimer. A MHC multimer consistof a multimerization domain whereto one or more MHC-peptide complexesare attached through one or more linkers. The multimerization domaincomprise one or more carriers and/or one or more scaffolds. TheMHC-peptide complexes comprise a peptide and a MHC molecule.

FIG. 2. Program for peptide sequence motifs prediction.

FIG. 3. Full List of HLA Class I alleles assigned as of January 2007from http://www.anthonynolan.org.uk/HIG/lists/class1list.html.

FIG. 4. List of top 30 HLA class 1 alleles in different human ethnicgroups.

FIG. 5. Illustration of selected reaction groups.

FIG. 6. Illustration of selected cleavable linkers.

FIG. 7. Prediction of MHC class 1 mouse virus LCMV gp 1 protein nonamerpeptide binders for H-2 Kd using the Syfpeithi database. Peptides areranked according to their binding score. Only peptides with bindingscores above the value of 11 are listed.

FIG. 8. Size exclusion chromatography of folded HLA-A*0201-β2m-QLFEELQELpeptide-complex. Purification of HLA-A*0201-β2m-QLFEELQELpeptide-complex by size exclusion chromatography on a HiLoad 16/60Superdex 75 column. Eluted protein was followed by measurement of theabsorbance at 280 nm. The elution profile consisted of 4 peaks,corresponding to aggregated Heavy Chain, correctly folded MHC-complex,β2m and excess biotin and peptide.

FIG. 9. MHC-SHIFT Assay. The SHIFT Assay shows that heavy chain isefficiently biotinylated, since the band corresponding to biotinylatedheavy chain (lane 2) is shifted up-wards upon incubation withstreptavidin.

Lane 1: Benchmark protein-ladder.

Lane 2: Folded HLA-A*0201-β2m-QLFEELQEL peptide-complex.

Lane 3: Folded HLA-A*0201-β2m-QLFEELQEL peptide-complex incubated withmolar excess Streptavidin.

FIG. 10. Composition of Fluorescein-linker molecule. (A) Schematicrepresentation of an example of a Fluorescein-linker molecule. (B)Composition of a L15 linker

FIG. 11. List of the 24 MHC class 1 alleles used for peptide predictionby the database http://www.cbs.dtu.dk/services/NetMHC/ and the 14 MHCclass 2 alleles used for peptide prediction by the databasehttp://www.cbs.dtu.dk/services/NetMHCII/.

FIG. 12. Prediction of MHC class 1 mouse virus LCMV gp 1 protein nonamerpeptide binders for H-2 Kd using the Syfpeithi database. Peptides areranked according to their binding score. Only peptides with bindingscores above the value of 11 are listed.

FIG. 13. Full List of HLA Class I alleles assigned as of January 2007from http://www.anthonynolan.org.uk/HIG/lists/class1list.html.

FIG. 14. List of top 30 HLA class 1 alleles in different human ethnicgroups.

FIG. 15. Ex vivo ELISPOT analysis of BclX(L)-specific, CD8 positive Tcells in PBL from a breast cancer patient either with or without theBclX(L) YLNDHLEPWI peptide. Analysis were performed in doublets andnumber of IFN-gamma producing T-cells are presented. (Reference:Sorensen R B, Hadrup S R, Kollgaard T, Svane I M, Thor Straten P,Andersen M H (2006) Efficient tumor cell lysis mediated by a Bcl-X(L)specific T cell clone isolated from a breast cancer patient. CancerImmunol Immunother April; 56(4)527-33).

FIG. 16. PBL from a breast cancer patient was analyzed by flow cytometryto identify Bcl-X(L)173-182 (peptide YLNDHLEPWI) specific CD8 T cellsusing the dextramer complex HLA-A2/Bcl-X(L)173-182-APC, 7-AAD-PerCP,CD3-FITC, and CD8-APC-Cy7. The dextramer complex HLA-A2/HIV-1pol476-484-APC was used as negative control. (Reference: Sorensen R B,Hadrup S R, Kollgaard T, Svane I M, Thor Straten P, Andersen M H (2006)Efficient tumor cell lysis mediated by a Bcl-X(L) specific T cell cloneisolated from a breast cancer patient. Cancer Immunol Immunother April;56(4) 527-33).

FIG. 17. Ten expanded T cell clones isolated by Flow sorting and thenexpanded were tested for their specificity by analysis in a standard51-Cr release assay. For this purpose, T2 cells loaded with eitherBcl-X(L)173-182, YLNDHLEPWI peptide or an irrelevant peptide(BA4697-105, GLQHWVPEL) were used as target cells. Reference: Sorensen RB, Hadrup S R, Kollgaard T, Svane I M, Thor Straten P, Andersen M H(2006) Efficient tumor cell lysis mediated by a Bcl-X(L) specific T cellclone isolated from a breast cancer patient. Cancer Immunol ImmunotherApril; 56(4)527-33)

FIG. 18. A Bcl-X(L)173-182 specific clone was tested for its cytotoxicpotential in 51Cr-release assays. Two assays were performed a Cell lysisof T2 cells pulsed with Bcl-X(L)173-182 peptide or an irrelevant peptide(BA4697-105, GLQHWVPEL) in three E:T ratios. b Cell lysis of T2 cellspulsed with different concentrations of Bcl-X(L)173-182 peptide at theE:T ratio 1:1. (Reference: Sorensen R B, Hadrup S R, Kollgaard T, SvaneI M, Thor Straten P, Andersen M H (2006) Efficient tumor cell lysismediated by a Bcl-X(L) specific T cell clone isolated from a breastcancer patient. Cancer Immunol Immunother April; 56(4)527-33)

FIG. 19. Detection of Borrelia specific T cells using MHC dextramers.Dot plots showing live gated CD3⁺/CD4⁻ lymphocytes from Borrelia patientstained with (A) Negative Control MHC Dextramer (HLA-A*0201(GLAGDVSAV)or (B) pool of MHC Dextramers containing peptides from Borrelia antigenOsp A and Fla B. pool of MHC Dextramers containing peptides fromBorrelia antigen. 0.05% of the live gated CD3⁺/CD4⁻ lymphocytes arepositive for one or more of the MHC Dextramers in the pool.

FIG. 20. Detection of CMV specific T cells using MHC dextramers Dotplots showing live gated CD3⁺/CD4⁻ lymphocytes from CMV infected patientstained with (A) Negative Control MHC Dextramers (HLA-A*0201(GLAGDVSAV))or (B) MHC Dextramers containing peptides from CMV pp 65 antigen(HLA-A*0201(NLVPMVATV)).

DETAILED DESCRIPTION OF THE INVENTION

In one aspect, the present invention is directed to novel MHC complexesoptionally comprising a multimerization domain preferably comprising acarrier molecule and/or a scaffold.

There is also provided a MHC multimer comprising 2 or more MHC-peptidecomplexes and a multimerization domain to which the 2 or moreMHC-peptide complexes are associated. The MHC multimer can generally beformed by association of the 2 or more MHC-peptide complexes with themultimerization domain to which the 2 or more MHC-peptide complexes arecapable of associating.

The multimerization domain can be a scaffold associated with one or moreMHC-peptide complexes, or a carrier associated with one or more,preferably more than one, MHC-peptide complex(es), or a carrierassociated with a plurality of scaffolds each associated with one ormore MHC-peptide complexes, such as 2 MHC-peptide complexes, 3MHC-peptide complexes, 4 MHC-peptide complexes, 5 MHC-peptide complexesor more than 5 MHC-peptide complexes. Accordingly, multimerizationdomain collectively refers to each and every of the above. It will beclear from the detailed description of the invention provided hereinbelow when the multimerization domain refers to a scaffold or a carrieror a carrier comprising one or more scaffolds.

Generally, when a multimerization domain comprising a carrier and/or ascaffold is present, the MHC complexes can be associated with thisdomain either directly or via one or more binding entities. Theassociation can be covalent or non-covalent.

Accordingly, there is provided in one embodiment a MHC complexcomprising one or more entities (a-b-P)_(n), wherein a and b togetherform a functional MHC protein capable of binding a peptide P, andwherein (a-b-P) is the MHC-peptide complex formed when the peptide Pbinds to the functional MHC protein, said MHC complex optionally furthercomprising a multimerization domain comprising a carrier molecule and/ora scaffold. “MHC complex” refers to any MHC complex, including MHCmonomers in the form of a single MHC-peptide complex and MHC multimerscomprising a multimerization domain to which more than one MHC peptidecomplex is associated.

When the invention is directed to complexes comprising a MHC multimer,i.e. a plurality of MHC peptide complexes of the general composition(a-b-P)_(n) associated with a multimerization domain, n is by definitionmore than 1, i.e. at least 2 or more. Accordingly, the term “MHCmultimer” is used herein specifically to indicate that more than oneMHC-peptide complex is associated with a multimerization domain, such asa scaffold or carrier or carrier comprising one or more scaffolds.Accordingly, a single MHC-peptide complex can be associated with ascaffold or a carrier or a carrier comprising a scaffold and aMHC-multimer comprising 2 or more MHC-peptide complexes can be formed byassociation of the individual MHC-peptide complexes with a scaffold or acarrier or a carrier comprising one or more scaffolds each associatedwith one or more MHC-peptide complexes.

When the MHC complex comprises a multimerization domain to which the nMHC-peptide complexes are associated, the association can be a covalentlinkage so that each or at least some of the n MHC-peptide complexes iscovalently linked to the multimerization domain, or the association canbe a non-covalent association so that each or at least some of the nMHC-peptide complexes are non-covalently associated with themultimerization domain.

The MHC complexes of the invention may be provided in non-soluble orsoluble form, depending on the intended application.

Effective methods to produce a variety of MHC complexes comprisinghighly polymorphic human HLA encoded proteins makes it possible toperform advanced analyses of complex immune responses, which maycomprise a variety of peptide epitope specific T-cell clones.

One of the benefits of the MHC complexes of the present invention isthat the MHC complexes overcome low intrinsic affinities of monomerligands and counter receptors. The MHC complexes have a large variety ofapplications that include targeting of high affinity receptors (e.g.hormone peptide receptors for insulin) on target cells. Taken togetherpoly-ligand binding to target cells has numerous practical, clinical andscientifically uses.

Thus, the present invention provides MHC complexes which presentmono-valent or multi-valent binding sites for MHC recognising cells,such as MHC complexes optionally comprising a multimerization domain,such as a scaffold or a carrier molecule, which multimerization domainhave attached thereto, directly or indirectly via one or more linkers,covalently or non-covalently, one or more MHC peptide complexes. “One ormore” as used herein is intended to include one as well as a plurality,such as at least 2. This applies i.a. to the MHC peptide complexes andto the binding entities of the multimerization domain. The scaffold orcarrier molecule may thus have attached thereto a MHC peptide complex ora plurality of such MHC peptide complexes, and/or a linker or aplurality of linkers.

Product

The product of the present invention is a MHC multimer as describedabove. As used in the description of this invention, the term “MHCmultimers” will be used interchangeably with the terms MHC′mers andMHCmers, and will include any number, (larger than one) of MHC-peptidecomplexes, held together in a large complex by covalent or non-covalentinteractions between a multimerization domain and one or moreMHC-peptide complexes, and will also include the monomeric form of theMHC-peptide complex, i.e. a MHC-peptide complex that is not attached toa multimerization domain. The multimerization domain consists of one ormore carriers and/or one or more scaffolds while the MHC-peptide complexconsists of MHC molecule and antigenic peptide. MHC-peptide complexesmay be attached to the multimerization domain through one or morelinkers. A schematic representation of a MHC multimer is presented inFIG. 1.

In one preferred embodiment the MHC multimer is between 50,000 Da and1,000,000 Da, such as from 50,000 Da to 980,000; for example from 50,000Da to 960,000; such as from 50,000 Da to 940,000; for example from50,000 Da to 920,000; such as from 50,000 Da to 900,000; for examplefrom 50,000 Da to 880,000; such as from 50,000 Da to 860,000; forexample from 50,000 Da to 840,000; such as from 50,000 Da to 820,000;for example from 50,000 Da to 800,000; such as from 50,000 Da to780,000; for example from 50,000 Da to 760,000; such as from 50,000 Dato 740,000; for example from 50,000 Da to 720,000; such as from 50,000Da to 700,000; for example from 50,000 Da to 680,000; such as from50,000 Da to 660,000; for example from 50,000 Da to 640,000; such asfrom 50,000 Da to 620,000; for example from 50,000 Da to 600,000; suchas from 50,000 Da to 580,000; for example from 50,000 Da to 560,000;such as from 50,000 Da to 540,000; for example from 50,000 Da to520,000; such as from 50,000 Da to 500,000; for example from 50,000 Dato 480,000; such as from 50,000 Da to 460,000; for example from 50,000Da to 440,000; such as from 50,000 Da to 420,000; for example from50,000 Da to 400,000; such as from 50,000 Da to 380,000; for examplefrom 50,000 Da to 360,000; such as from 50,000 Da to 340,000; forexample from 50,000 Da to 320,000; such as from 50,000 Da to 300,000;for example from 50,000 Da to 280,000; such as from 50,000 Da to260,000; for example from 50,000 Da to 240,000; such as from 50,000 Dato 220,000; for example from 50,000 Da to 200,000; such as from 50,000Da to 180,000; for example from 50,000 Da to 160,000; such as from50,000 Da to 140,000; for example from 50,000 Da to 120,000; such asfrom 50,000 Da to 100,000; for example from 50,000 Da to 80,000; such asfrom 50,000 Da to 60,000; such as from 100,000 Da to 980,000; forexample from 100,000 Da to 960,000; such as from 100,000 Da to 940,000;for example from 100,000 Da to 920,000; such as from 100,000 Da to900,000; for example from 100,000 Da to 880,000; such as from 100,000 Dato 860,000; for example from 100,000 Da to 840,000; such as from 100,000Da to 820,000; for example from 100,000 Da to 800,000; such as from100,000 Da to 780,000; for example from 100,000 Da to 760,000; such asfrom 100,000 Da to 740,000; for example from 100,000 Da to 720,000; suchas from 100,000 Da to 700,000; for example from 100,000 Da to 680,000;such as from 100,000 Da to 660,000; for example from 100,000 Da to640,000; such as from 100,000 Da to 620,000; for example from 100,000 Dato 600,000; such as from 100,000 Da to 580,000; for example from 100,000Da to 560,000; such as from 100,000 Da to 540,000; for example from100,000 Da to 520,000; such as from 100,000 Da to 500,000; for examplefrom 100,000 Da to 480,000; such as from 100,000 Da to 460,000; forexample from 100,000 Da to 440,000; such as from 100,000 Da to 420,000;for example from 100,000 Da to 400,000; such as from 100,000 Da to380,000; for example from 100,000 Da to 360,000; such as from 100,000 Dato 340,000; for example from 100,000 Da to 320,000; such as from 100,000Da to 300,000; for example from 100,000 Da to 280,000; such as from100,000 Da to 260,000; for example from 100,000 Da to 240,000; such asfrom 100,000 Da to 220,000; for example from 100,000 Da to 200,000; suchas from 100,000 Da to 180,000; for example from 100,000 Da to 160,000;such as from 100,000 Da to 140,000; for example from 100,000 Da to120,000; such as from 150,000 Da to 980,000; for example from 150,000 Dato 960,000; such as from 150,000 Da to 940,000; for example from 150,000Da to 920,000; such as from 150,000 Da to 900,000; for example from150,000 Da to 880,000; such as from 150,000 Da to 860,000; for examplefrom 150,000 Da to 840,000; such as from 150,000 Da to 820,000; forexample from 150,000 Da to 800,000; such as from 150,000 Da to 780,000;for example from 150,000 Da to 760,000; such as from 150,000 Da to740,000; for example from 150,000 Da to 720,000; such as from 150,000 Dato 700,000; for example from 150,000 Da to 680,000; such as from 150,000Da to 660,000; for example from 150,000 Da to 640,000; such as from150,000 Da to 620,000; for example from 150,000 Da to 600,000; such asfrom 150,000 Da to 580,000; for example from 150,000 Da to 560,000; suchas from 150,000 Da to 540,000; for example from 150,000 Da to 520,000;such as from 150,000 Da to 500,000; for example from 150,000 Da to480,000; such as from 150,000 Da to 460,000; for example from 150,000 Dato 440,000; such as from 150,000 Da to 420,000; for example from 150,000Da to 400,000; such as from 150,000 Da to 380,000; for example from150,000 Da to 360,000; such as from 150,000 Da to 340,000; for examplefrom 150,000 Da to 320,000; such as from 150,000 Da to 300,000; forexample from 150,000 Da to 280,000; such as from 150,000 Da to 260,000;for example from 150,000 Da to 240,000; such as from 150,000 Da to220,000; for example from 150,000 Da to 200,000; such as from 150,000 Dato 180,000; for example from 150,000 Da to 160,000.

In another preferred embodiment the MHC multimer is between 1,000,000 Daand 3,000,000 Da, such as from 1,000,000 Da to 2,800,000; for examplefrom 1,000,000 Da to 2,600,000; such as from 1,000,000 Da to 2,400,000;for example from 1,000,000 Da to 2,200,000; such as from 1,000,000 Da to2,000,000; for example from 1,000,000 Da to 1,800,000; such as from1,000,000 Da to 1,600,000; for example from 1,000,000 Da to 1,400,000.

In the following it is described how to generate the product of thepresent invention.

Number of MHC Complexes pr Multimer

A non-exhaustive list of possible MHC mono- and multimers illustratesthe possibilities. n indicates the number of MHC complexes comprised inthe multimer:

a) n=1, Monomersb) n=2, Dimers, multimerization can be based on IgG scaffold, SA withtwo MHC's, coiled-coil dimerization e.g. Fos.Jun dimerizationc) n=3, Trimers, multimerization can be based on SA as scaffold withthree MHC's, TNFalpha-MHC hybrids, triplex DNA-MHC conjugates or othertrimer structuresd) n=4, Tetramers, multimerization can be based on SA with all fourbinding sites occupied by MHC molecules or on dimeric IgAe) n=5, Pentamers, multimerization can take place around a pentamericcoil-coil structuref) n=6, Hexamersg) n=7, Heptamersh) n=8-12, Octa-dodecamers, multimerization can take place usingStreptactini) n=10, Decamers, multimerization could take place using IgMj) 1<n<100, Dextramers, as multimerization domain polymers such aspolypeptide, polysaccharides and Dextrans can be used.k) 1<n<1000, Multimerization make use of DC, APC, micelles, liposomes,beads, surfaces e.g. microtiterplate, tubes, microarray devices,micro-fluidic systemsl) 1<n, n in billions or trillions or higher, multimerization take olaceon beads, and surfaces e.g. microtiterplate, tubes, microarray devices,micro-fluidic systems

MHC Origin

Any of the three components of a MHC complex can be of any of the belowmentioned origins. The list is non-exhaustive. A complete list wouldencompass all Chordate species. By origin is meant that the sequence isidentical or highly homologous to a naturally occurring sequence of thespecific species.

List of Origins:

-   -   Human    -   Mouse    -   Primate        -   Chimpansee        -   Gorilla        -   Orang Utan    -   Monkey        -   Macaques    -   Porcine (Swine/Pig)    -   Bovine (Cattle/Antilopes)    -   Equine (Horse)    -   Camelides (Camels)    -   Ruminants (Deears)    -   Canine (Dog)    -   Feline (Cat)    -   Bird        -   Chicken        -   Turkey    -   Fish    -   Reptiles    -   Amphibians

Generation of MHC Multimers

Different approaches to the generation of various types of MHC multimersare described in U.S. Pat. No. 5,635,363 (Altmann et al.), patentapplication WO 02/072631 A2 (Winther et al.), patent application WO99/42597, US patent 2004209295, U.S. Pat. No. 5,635,363, and isdescribed elsewhere in the present patent application as well. In brief,MHC multimers can be generated by first expressing and purifying theindividual protein components of the MHC protein, and then combining theMHC protein components and the peptide, to form the MHC-peptide complex.Then an appropriate number of MHC-peptide complexes are linked togetherby covalent or non-covalent bonds to a multimerization domain. This canbe done by chemical reactions between reactive groups of themultimerization domain (e.g. vinyl sulfone functionalities on a dextranpolymer) and reactive groups on the MHC protein (e.g. amino groups onthe protein surface), or by non-covalent interaction between a part ofthe MHC protein (e.g. a biotinylated peptide component) and themultimerization domain (e.g. four binding sites for biotin on thestrepavidin tetrameric protein). As an alternative, the MHC multimer canbe formed by the non-covalent association of amino acid helices fused toone component of the MHC protein, to form a pentameric MHC multimer,held together by five helices in a coiled-coil structure making up themultimerization domain.

Appropriate chemical reactions for the covalent coupling of MHC and themultimerization domain include nucleophilic substitution by activationof electrophiles (e.g. acylation such as amide formation, pyrazoloneformation, isoxazolone formation; alkylation; vinylation; disulfideformation), addition to carbon-hetero multiple bonds (e.g. alkeneformation by reaction of phosphonates with aldehydes or ketones;arylation; alkylation of arenes/hetarenes by reaction with alkylboronates or enolethers), nucleophilic substitution using activation ofnucleophiles (e.g. condensations; alkylation of aliphatic halides ortosylates with enolethers or enamines), and cycloadditions.

Appropriate molecules, capable of providing non covalent interactionsbetween the multimerization domain and the MHC-peptide complex, involvethe following molecule pairs and molecules: streptavidin/biotin,avidin/biotin, antibody/antigen, DNA/DNA, DNA/PNA, DNA/RNA, PNA/PNA,LNA/DNA, leucine zipper e.g. Fos/Jun, IgG dimeric protein, IgMmultivalent protein, acid/base coiled-coil helices, chelate/metalion-bound chelate, streptavidin (SA) and avidin and derivatives thereof,biotin, immunoglobulins, antibodies (monoclonal, polyclonal, andrecombinant), antibody fragments and derivatives thereof, leucine zipperdomain of AP-1 (jun and fos), hexa-his (metal chelate moiety), hexa-hatGST (glutathione S-transferase) glutathione affinity, Calmodulin-bindingpeptide (CBP), Strep-tag, Cellulose Binding Domain, Maltose BindingProtein, S-Peptide Tag, Chitin Binding Tag, Immuno-reactive Epitopes,Epitope Tags, E2Tag, HA Epitope Tag, Myc Epitope, FLAG Epitope, AU1 andAU5 Epitopes, Glu-Glu Epitope, KT3 Epitope, IRS Epitope, Btag Epitope,Protein Kinase-C Epitope, VSV Epitope, lectins that mediate binding to adiversity of compounds, including carbohydrates, lipids and proteins,e.g. Con A (Canavalia ensiformis) or WGA (wheat germ agglutinin) andtetranectin or Protein A or G (antibody affinity). Combinations of suchbinding entities are also comprised. In particular, when the MHC complexis tagged, the binding entity can be an “anti-tag”. By “anti-tag” ismeant an antibody binding to the tag and any other molecule capable ofbinding to such tag.

Generation of Components of MHC

When employing MHC multimers for diagnostic purposes, it is preferableto use a MHC allele that corresponds to the tissue type of the person oranimal to be diagnosed. Once the MHC allele has been chosen, a peptidederived from the antigenic protein may be chosen. The choice will dependon factors such as known or expected binding affinity of the MHC proteinand the various possible peptide fragments that may be derived from thefull sequence of the antigenic peptide, and will depend on the expectedor known binding affinity and specificity of the MHC-peptide complex forthe TCR. Preferably, the affinity of the peptide for the MHC molecule,and the affinity and specificity of the MHC-peptide complex for the TCR,should be high.

Similar considerations apply to the choice of MHC allele and peptide fortherapeutic and vaccine purposes. In addition, for some of theseapplications the effect of binding the MHC multimer to the TCR is alsoimportant. Thus, in these cases the effect on the T-cell's general statemust be considered, e.g. it must be decided whether the desired endresult is apoptosis or proliferation of the T-cell.

Likewise, it must be decided whether stability is important. For someapplications low stability may be an advantage, e.g. when a short-termeffect is desired; in other instances, a long-term effect is desired andMHC multimers of high stability is desired. Stabilities of the MHCprotein and of the MHC-peptide complex may be modified as describedelsewhere herein.

Finally, modifications to the protein structure may be advantageous forsome diagnostics purposes, because of e.g. increased stability, while infor vaccine purposes modifications to the MHC protein structure mayinduce undesired allergenic responses.

Generation of Protein Chains of MHC Generation of MHC Class I HeavyChain and β2-Microglobulin

MHC class I heavy chain (HC) and β2-mircroglobulin (β2m) can be obtainedfrom a variety of sources.

-   -   a) Natural sources by means of purification from eukaryotic        cells naturally expressing the MHC class 1 or β2m molecules in        question.    -   b) The molecules can be obtained by recombinant means e.g.        using.        -   a. in vitro translation of mRNA obtained from cells            naturally expressing the MHC or β2m molecules in question        -   b. by expression and purification of HC and/or β2m gene            transfected cells of mammalian, yeast, bacterial or other            origin. This last method will normally be the method of            choice. The genetic material used for            transfection/transformation can be:            -   i. of natural origin isolated from cells, tissue or                organisms            -   ii. of synthetical origin i.e. synthetic genes identical                to the natural DNA sequence or it could be modified to                introduce molecular changes or to ease recombinant                expression.                -   The genetic material can encode all or only a                    fragment of β2m, all or only a fragment of MHC class                    1 heavy chain. Of special interest are MHC class 1                    heavy chain fragments consisting of, the complete                    chain minus the intramembrane domain, a chain                    consisting of only the extracellular α1 and α2 class                    1 heavy chain domains, or any of the mentioned β2m                    and heavy chain fragments containing modified or                    added designer domain(s) or sequence(s).

Generation of MHC Class 2 α- and β-Chains

MHC class 2 α- and β-chains can be obtained from a variety of sources:

-   -   a) Natural sources by means of purification from eukaryotic        cells naturally expressing the MHC class 2 molecules in        question.    -   b) By recombinant means e.g. using:        -   a. in vitro translation of mRNA obtained from cells            naturally expressing the MHC class 2 molecules in question        -   b. By purification from MHC class 2 gene transfected cells            of mammalian, yeast, bacterial or other origin. This last            method will normally be the method of choice. The genetic            material used for transfection/transformation can be            -   i. of natural origin isolated from cells, tissue or                organisms            -   ii. of synthetical origin i.e. synthetic genes identical                to the natural DNA sequence or it could be modified to                introduce molecular changes or to ease recombinant                expression.                -   The genetic material can encode all or only a                    fragment of MHC class 2 α- and β-chains. Of special                    interest are MHC class 2 α- and β-chain fragments                    consisting of, the complete α- and β-chains minus                    the intramembrane domains of either or both chains;                    and α- and β-chains consisting of only the                    extracellular domains of either or both, i.e α1 plus                    α2 and β1 plus β2 domains, respectively.                -   The genetic material can be modified to encode the                    interesting MHC class 2 molecule fragments                    consisting of domains starting from the amino                    terminal in consecutive order, MHC class 2 β1 plus                    MHC class 2 α1 plus MHC class 1 α3 domains or in                    alternative order, MHC class 2 α1 plus MHC class 2                    β1 plus MHC class 1 α3 domains.                -   Lastly, the genetic material can encode any of the                    above mentioned MHC class 2 α- and β-chain molecules                    or fragments containing modified or added designer                    domain(s) or sequence(s).    -   c) The MHC material may also be of exclusively synthetic origin        manufactured by solid phase protein synthesis. Any of the above        mentioned molecules can be made this way.

Modified MHC I or MHC II Complexes

MHC I and MHC II complexes modified in any way as described above, canbind TCR. Modifications include mutations (substitutions, deletions orinsertions of natural or non-natural amino acids, or any other organicmolecule. The mutations are not limited to those that increase thestability of the MHC complex, and could be introduced anywhere in theMHC complex. One example of special interest is mutations introduced inthe α3 subunit of MHC I heavy chain. The α3-subunit interacts with CD8molecules on the surface of T cells. To minimize binding of MHC multimerto CD8 molecules on the surface of non-specific T cells, amino acids inα3 domain involved in the interaction with CD8 can be mutated. Such amutation can result in altered or abrogated binding of MHC to CD8molecules. Another example of special interest is mutations in areas ofthe β2-domain of MHC II molecules responsible for binding CD4 molecules.

Another embodiment is chemically modified MHC complexes where thechemical modification could be introduced anywhere in the complex, e.g.a MHC complex where the peptide in the peptide-binding cleft has adinitrophenyl group attached.

Modified MHC complexes could also be MHC I or MHC II fusion proteinswhere the fusion protein is not necessarily more stable than the nativeprotein. Of special interest is MHC complexes fused with genes encodingan amino acid sequence capable of being biotinylated with a Bir A enzyme(Schatz, P. J., (1993), Biotechnology 11(10):1138-1143). Thisbiotinylation sequence could be fused with the COOH-terminal of β2m orthe heavy chain of MHC I molecules or the COOH-terminal of either theα-chain or β-chain of MHC II. Similarly, other sequences capable ofbeing enzymatically or chemically modified, can be fused to the NH₂ orCOOH-terminal ends of the MHC complex.

Stabilization of Empty MHC Complexes and MHC-Peptide Complexes.

Classical MHC complexes are in nature embedded in the membrane. Apreferred embodiment includes multimers comprising a soluble form of MHCII or I where the transmembrane and cytosolic domains of themembrane-anchored MHC complexes are removed. The removal of themembrane-anchoring parts of the molecules can influence the stability ofthe MHC complexes. The stability of MHC complexes is an importantparameter when generating and using MHC multimers.

MHC I complexes consist of a single membrane-anchored heavy chain thatcontains the complete peptide binding groove and is stable in thesoluble form when complexed with β2m. The long-term stability isdependent on the binding of peptide in the peptide-binding groove.Without a peptide in the peptide binding groove the heavy chain and β2mtend to dissociate. Similarly, peptides with high affinity for bindingin the peptide-binding groove will typically stabilize the soluble formof the MHC complex while peptides with low affinity for thepeptide-binding groove will typically have a smaller stabilizing effect.

In contrast, MHC II complexes consist of two membrane-anchored chains ofalmost equal size. When not attached to the cell membrane the two chainstend to dissociate and are therefore not stable in the soluble formunless a high affinity peptide is bound in the peptide-binding groove orthe two chains are held together in another way.

In nature MHC I molecules consist of a heavy chain combined with β2m,and a peptide of typically 8-11 amino acids. Herein, MHC I moleculesalso include molecules consisting of a heavy chain and β2m (empty MHC),or a heavy chain combined with a peptide or a truncated heavy chaincomprising α1 and α2 subunits combined with a peptide, or a full-lengthor truncated heavy chain combined with a full-length or truncated β2mchain. These MHC I molecules can be produced in E. coli as recombinantproteins, purified and refolded in vitro (Garboczi et al., (1992), Proc.Natl. Acad. Sci. 89, 3429-33). Alternatively, insect cell systems ormammalian cell systems can be used. To produce stable MHC I complexesand thereby generate reliable MHC I multimers several strategies can befollowed. Stabilization strategies for MHC I complexes are described inthe following.

Stabilization Strategies for MHC I Complexes

Generation of Covalent Protein-Fusions.

-   -   MHC I molecules can be stabilized by introduction of one or more        linkers between the individual components of the MHC I complex.        This could be a complex consisting of a heavy chain fused with        β2m through a linker and a soluble peptide, a heavy chain fused        to β2m through a linker, a heavy chain/β2m dimer covalently        linked to a peptide through a linker to either heavy chain or        β2m, and where there can or can not be a linker between the        heavy chain and β2m, a heavy chain fused to a peptide through a        linker, or the α1 and α2 subunits of the heavy chain fused to a        peptide through a linker. In all of these example        protein-fusions, each of the heavy chain, β2m and the peptide        can be truncated.    -   The linker could be a flexible linker, e.g. made of glycine and        serine and e.g. between 5-20 residues long. The linker could        also be rigid with a defined structure, e.g. made of amino acids        like glutamate, alanine, lysine, and leucine creating e.g. a        more rigid structure.    -   In heavy chain-β2m fusion proteins the COOH terminus of β2m can        be covalently linked to the NH₂ terminus of the heavy chain, or        the NH₂ terminus of β2m can be linked to the COOH terminus of        the heavy chain. The fusion-protein can also comprise a β2m        domain, or a truncated β2m domain, inserted into the heavy        chain, to form a fusion-protein of the form “heavy chain (first        part)-β2m-heavy chain (last part)”.    -   Likewise, the fusion-protein can comprise a heavy chain domain,        or a truncated heavy chain, inserted into the β2m chain, to form        a fusion-protein of the form “β2m(first part)-heavy        chain-β2m(last part)”.    -   In peptide-β2m fusion proteins the COOH terminus of the peptide        is preferable linked to the NH₂ terminus of β2m but the peptide        can also be linked to the COOH terminal of β2m via its NH₂        terminus. In heavy chain-peptide fusion proteins it is preferred        to fuse the NH₂ terminus of the heavy chain to the COOH terminus        of the peptide, but the fusion can also be between the COOH        terminus of the heavy chain and the NH₂ terminus of the peptide.        In heavy chain-β2m-peptide fusion proteins the NH₂ terminus of        the heavy chain can be fused to the COOH terminus of β2m and the        NH₂ terminus of β2m can be fused to the COOH terminus of the        peptide.

Non-Covalent Stabilization by Binding to an Unnatural ComponentNon-covalent binding of unnatural components to the MHC I complexes canlead to increased stability. The unnatural component can bind to boththe heavy chain and the β2m, and in this way promote the assemble of thecomplex, and/or stabilize the formed complex. Alternatively, theunnatural component can bind to either β2m or heavy chain, and in thisway stabilize the polypeptide in its correct conformation, and in thisway increase the affinity of the heavy chain for β2m and/or peptide, orincrease the affinity of β2m for peptide.

-   -   Here, unnatural components mean antibodies, peptides, aptamers        or any other molecule with the ability to bind peptides        stretches of the MHC complex. Antibody is here to be understood        as truncated or full-length antibodies (of isotype IgG, IgM,        IgA, IgE), Fab, scFv or bi-Fab fragments or diabodies.    -   An example of special interest is an antibody binding the MHC I        molecule by interaction with the heavy chain as well as β2m. The        antibody can be a bispecific antibody that binds with one arm to        the heavy chain and the other arm to the β2m of the MHC complex.        Alternatively the antibody can be monospecific, and bind at the        interface between heavy chain and β2m.    -   Another example of special interest is an antibody binding the        heavy chain but only when the heavy chain is correct folded.        Correct folded is here a conformation where the MHC complex is        able to bind and present peptide in such a way that a restricted        T cell can recognize the MHC-peptide complex and be activated.        This type of antibody can be an antibody like the one produced        by the clone W6/32 (M0736 from Dako, Denmark) that recognizes a        conformational epitope on intact human and some monkey MHC        complexes containing β2m, heavy chain and peptide.

Generation of Modified Proteins or Protein Components

-   -   One way to improve stability of a MHC I complex am to increase        the affinity of the binding peptide for the MHC complex. This        can be done by mutation/substitution of amino acids at relevant        positions in the peptide, by chemical modifications of amino        acids at relevant positions in the peptide or introduction by        synthesis of non-natural amino acids at relevant positions in        the peptide. Alternatively, mutations, chemical modifications,        insertion of natural or non-natural amino acids or deletions        could be introduced in the peptide binding cleft, i.e. in the        binding pockets that accommodate peptide side chains responsible        for anchoring the peptide to the peptide binding cleft.        Moreover, reactive groups can be introduced into the antigenic        peptide; before, during or upon binding of the peptide, the        reactive groups can react with amino acid residues of the        peptide binding cleft, thus covalently linking the peptide to        the binding pocket.    -   Mutations/substitutions, chemical modifications, insertion of        natural or non-natural amino acids or deletions could also be        introduced in the heavy chain and/or β2m at positions outside        the peptide-binding cleft. By example, it has been shown that        substitution of XX with YY in position nn of human β₂m enhance        the biochemical stability of MHC Class I molecule complexes and        thus may lead to more efficient antigen presentation of        subdominant peptide epitopes.    -   A preferred embodiment is removal of “unwanted cysteine        residues” in the heavy chain by mutation, chemical modification,        amino acid exchange or deletion. “Unwanted cysteine residues” is        here to be understood as cysteines not involved in the correct        folding of the final MHC I molecule. The presence of cysteine        not directly involved in the formation of correctly folded MHC I        molecules can lead to formation of intra molecular disulfide        bridges resulting in a non correct folded MHC complex during in        vitro refolding.    -   Another method for covalent stabilization of MHC I complex am to        covalently attach a linker between two of the subunits of the        MHC complex. This can be a linker between peptide and heavy        chain or between heavy chain and beta2microglobulin.        Stabilization with Soluble Additives.    -   The stability of proteins in aqueous solution depends on the        composition of the solution. Addition of salts, detergents        organic solvent, polymers etc. can influence the stability. Of        special interest are additives that increase surface tension of        the MHC molecule without binding the molecule. Examples are        sucrose, mannose, glycine, betaine, alanine, glutamine, glutamic        acid and ammoniumsulfate. Glycerol, mannitol and sorbitol are        also included in this group even though they are able to bind        polar regions.    -   Another group of additives of special interest are able to        increase surface tension of the MHC molecule and simultaneously        interact with charged groups in the protein. Examples are MgSO₄,        NaCl, polyethylenglycol, 2-methyl-2,4-pentandiol and        guanidiniumsulfate.    -   Correct folding of MHC I complexes is very dependent on binding        of peptide in the peptide-binding cleft and the peptide binding        stabilises correct conformation. Addition of molar excess of        peptide will force the equilibrium against correct folded        MHC-peptide complexes. Likewise is excess β2m also expected to        drive the folding process in direction of correct folded MHC I        complexes. Therefore peptide identical to the peptide bound in        the peptide-binding cleft and β2m are included as stabilizing        soluble additives.    -   Other additives of special interest for stabilization of MHC I        molecules are BSA, fetal and bovine calf serum or individual        protein components in serum with a protein stabilizing effect.    -   All of the above mentioned soluble additives could be added to        any solution containing MHC I molecules in order to increase the        stability of the molecule. That could be during the refolding        process, to the soluble monomer or to a solutions containing MHC        I bound to a carrier.

MHC II molecules as used herein are defined as classical MHC II moleculeconsisting of a α-chain and a β-chain combined with a peptide. It couldalso be a molecule only consisting of α-chain and β-chain (α/β dimer orempty MHC II), a truncated α-chain (e.g. α1 domain alone) combined withfull-length β-chain either empty or loaded with a peptide, a truncatedβ-chain (e.g. β1 domain alone) combined with a full-length α-chaineither empty or loaded with a peptide or a truncated α-chain combinedwith a truncated β-chain (e.g. α1 and β1 domain) either empty or loadedwith a peptide.

In contrast to MHC I molecules MHC II molecules are not easily refoldedin vitro. Only some MHC II alleles may be produced in E. coli followedby refolding in vitro.

Therefore preferred expression systems for production of MHC IImolecules are eukaryotic systems where refolding after expression ofprotein is not necessary. Such expression systems could be stableDrosophila cell transfectants, baculovirus infected insect cells, CHOcells or other mammalian cell lines suitable for expression of proteins.

Stabilization of soluble MHC II molecules is even more important thanfor MHC I molecules since both α- and β-chain are participants information of the peptide binding groove and tend to dissociate when notembedded in the cell membrane.

Stabilization Strategies for MHC II Complexes

Generation of Covalent Protein-Fusions.

-   -   MHC II complexes can be stabilized by introduction of one or        more linkers between the individual components of the MHC II        complex. This can be a α/β dimer with a linker between α-chain        and β-chain; a α/β dimer covalently linked to the peptide via a        linker to either the α-chain or β-chain; a α/β dimer, covalently        linked by a linker between the α-chain and β-chain, and where        the dimer is covalently linked to the peptide; a α/β dimer with        a linker between α-chain and β-chain, where the dimer is        combined with a peptide covalently linked to either α-chain or        β-chain.    -   The linker can be a flexible linker, e.g. made of glycine and        serine, and is typically between 5-20 residues long, but can be        shorter or longer. The linker can also be more rigid with a more        defined structure, e.g. made of amino acids like glutamate,        alanine, lysine, and leucine.    -   The peptides can be linked to the NH₂- or COOH-terminus of        either α-chain or β-chain. Of special interest are peptides        linked to the NH₂-terminus of the β-chain via their        COOH-terminus, since the linker required is shorter than if the        peptide is linked to the COOH-terminus of the β-chain.    -   Linkage of α-chain to β-chain can be via the COOH-terminus of        the β-chain to the NH₂-terminus of the α-chain or from the        COOH-terminus of the α-chain to the NH₂-terminus of the β-chain.    -   In a three-molecule fusion protein consisting of α-chain,        β-chain and peptide a preferred construct is where one linker        connect the COOH-terminus of the β-chain with the NH₂-terminus        of the α-chain and another linker connects the COOH-terminal of        the peptide with the NH₂-terminal of the β-chain. Alternatively        one linker joins the COOH-terminus of the α-chain with the        NH₂-terminus of the β-chain and the second linker joins the        NH₂-terminus of the peptide with the COOH-terminus of the        β-chain. The three peptides of the MHC complex can further be        linked as described above for the three peptides of the MHC        complex, including internal fusion points for the proteins.

Non-Covalent Stabilization by Binding Ligand.

-   -   Non-covalent binding of ligands to the MHC II complex can        promote assembly of α- and β-chain by bridging the two chains,        or by binding to either of the α- or β-chains, and in this way        stabilize the conformation of α or β, that binds β or α,        respectively, and/or that binds the peptide. Ligands here mean        antibodies, peptides, aptamers or any other molecules with the        ability to bind proteins.    -   A particular interesting example is an antibody binding the MHC        complex distal to the interaction site with TCR, i.e. distal to        the peptide-binding cleft. An antibody in this example can be        any truncated or full length antibody of any isotype (e.g. IgG,        IgM, IgA or IgE), a bi-Fab fragment or a diabody. The antibody        could be bispecific with one arm binding to the α-chain and the        other arm binding to the β-chain. Alternatively the antibody        could be monospecific and directed to a sequence fused to the        α-chain as well as to the β-chain.    -   Another example of interest is an antibody binding more central        in the MHC II molecule, but still interacting with both α- and        β-chain. Preferable the antibody binds a conformational epitope,        thereby forcing the MHC molecule into a correct folded        configuration. The antibody can be bispecific binding with one        arm to the α-chain and the other arm to the β-chain.        Alternatively the antibody is monospecific and binds to a        surface of the complex that involves both the α- and β-chain,        e.g. both the α2- and β2-domain or both the α1- and β1-domain.    -   The antibodies described above can be substituted with any other        ligand that binds at the α-/β-chain interface, e.g. peptides and        aptamers. The ligand can also bind the peptide, although, in        this case it is important that the ligand does not interfere        with the interaction of the peptide or binding cleft with the        TCR.

Non-Covalent Stabilization by Induced Multimerization.

-   -   In nature the anchoring of the α- and β-chains in the cell        membrane stabilizes the MHC II complexes considerably. As        mentioned above, a similar concept for stabilization of the        α/β-dimer was employed by attachment of the MHC II chains to the        Fc regions of an antibody, leading to a stable α/β-dimer, where        α and β are held together by the tight interactions between two        Fc domains of an antibody. Other dimerization domains can be        used as well.    -   In one other example of special interest MHC II molecules are        incorporated into artificial membrane spheres like liposomes or        lipospheres. MHC II molecules can be incorporated as monomers in        the membrane or as dimers like the MHC II-antibody constructs        describes above. In addition to stabilization of the MHC II        complex an increased avidity is obtained. The stabilization of        the dimer will in most cases also stabilize the trimeric        MHC-peptide complex.    -   Induced multimerization can also be achieved by biotinylation of        α- as well as β-chain and the two chains brought together by        binding to streptavidin. Long flexible linkers such as extended        glycine-serine tracts can be used to extend both chains, and the        chains can be biotinylated at the end of such extended linkers.        Then streptavidin can be used as a scaffold to bring the chains        together in the presence of the peptide, while the flexible        linkers still allow the chains to orientate properly.

Generation of Modified Proteins or Protein Components

Stability of MHC II complexes can be increased by covalent modificationsof the protein. One method is to increase the affinity of the peptidefor the MHC complex. This can be done by exchange of the natural aminoacids with other natural or non-natural amino acids at relevantpositions in the peptide or by chemical modifications of amino acids atrelevant positions in the peptide. Alternatively, mutations, chemicalmodifications, insertion of natural or non-natural amino acids ordeletions can be introduced in the peptide-binding cleft.

-   -   Mutations, chemical modifications, insertion of natural or        non-natural amino acids or deletions can alternatively be        introduced in α- and/or β-chain at positions outside the        peptide-binding cleft.

In this respect a preferred embodiment is to replace the hydrophobictransmembrane regions of α-chain and β-chain by leucine zipperdimerisation domains (e.g. Fos-Jun leucine zipper; acid-base coiled-coilstructure) to promote assembly of α-chain and β-chain.

-   -   Another preferred embodiment is to introduce one or more        cysteine residues by amino acid exchange at the COOH-terminal of        both α-chain and β-chain, to create disulfide bridges between        the two chains upon assembly of the MHC complex.    -   Another embodiment is removal of “unwanted cysteine residues” in        either of the chains by mutation, chemical modification, amino        acid exchange or deletion. “Unwanted cysteine residues” is here        to be understood as cysteines not involved in correct folding of        the MHC II-peptide complex. The presence of cysteines not        directly involved in the formation of correctly folded MHC II        complexes can lead to formation of intra molecular disulfide        bridges and incorrectly folded MHC complexes.    -   MHC II complexes can also be stabilized by chemically linking        together the subunits and the peptide. That can be a linker        between peptide and α-chain, between peptide and β-chain,        between α-chain and β-chain, and combination thereof.    -   Such linkages can be introduced prior to folding by linking two        of the complex constituents together, then folding this covalent        hetero-dimer in the presence of the third constituent. An        advantage of this method is that it only requires complex        formation between two, rather than three species.    -   Another possibility is to allow all three constituents to fold,        and then to introduce covalent cross-links on the folded        MHC-complex, stabilizing the structure. An advantage of this        method is that the two chains and the peptide will be correctly        positioned relatively to each other when the cross linkages are        introduced.

Stabilization with Soluble Additives.

-   -   Salts, detergents, organic solvent, polymers and any other        soluble additives can be added to increase the stability of MHC        complexes. Of special interest are additives that increase        surface tension of the MHC complex. Examples are sucrose,        mannose, glycine, betaine, alanine, glutamine, glutamic acid and        ammonium sulfate. Glycerol, mannitol and sorbitol are also        included in this group even though they are able to bind polar        regions.    -   Another group of additives of special interest increases surface        tension of the MHC complex and simultaneously can interact with        charged groups in the protein. Examples are MgSO₄, NaCl,        polyethylenglycol, 2-methyl-2,4-pentanediol and        guanidiniumsulphate.    -   Correct formation of MHC complexes is dependent on binding of        peptide in the peptide-binding cleft; the bound peptide appears        to stabilize the complex in its correct conformation. Addition        of molar excess of peptide will force the equilibrium towards        correctly folded MHC-peptide complexes. Likewise, excess β2m is        also expected to drive the folding process in direction of        correctly folded MHC complexes. Therefore peptide identical to        the peptide bound in the peptide-binding cleft and β2m can be        included as stabilizing soluble additives.    -   Other additives of special interest for stabilization of MHC        complexes are BSA, fetal and bovine calf serum, and other        protein components in serum with a protein stabilizing effect.    -   All of the above mentioned soluble additives could be added to        any solution containing MHC complexes in order to increase the        stability of the molecule. This can be during the refolding        process, to the formed MHC complex or to a solution of MHC        multimers comprising several MHC complexes That could be to the        soluble monomer, to a solution containing MHC II bound to a        carrier or to solutions used during analysis of MHC II specific        T cells with MHC II multimers.    -   Other additives of special interest for stabilization of MHC II        molecules are BSA, fetal and bovine calf serum or individual        protein components in serum with a protein stabilizing effect.    -   All of the above mentioned soluble additives could be added to        any solution containing MHC II molecules in order to increase        the stability of the molecule. That could be to the soluble        monomer, to a solution containing MHC II bound to a carrier or        to solutions used during analysis of MHC II specific T cells        with MHC II multimers.

Chemically Modified MHC I and II Complexes

-   -   There are a number of amino acids that are particularly reactive        towards chemical cross linkers. In the following, chemical        reactions are described that are particularly preferable for the        cross-linking or modification of MHC I or MHC II complexes.    -   The amino group at the N-terminal of both chains and of the        peptide, as well as amino groups of lysine side chains, are        nucleophilic and can be used in a number of chemical reactions,        including nucleophilic substitution by activation of        electrophiles (e.g. acylation such as amide formation,        pyrazolone formation, isoxazolone formation; alkylation;        vinylation; disulfide formation), addition to carbon-hetero        multiple bonds (e.g. alkene formation by reaction of        phosphonates with aldehydes or ketones; arylation; alkylation of        arenes/hetarenes by reaction with alkyl boronates or        enolethers), nucleophilic substitution using activation of        nucleophiles (e.g. condensations; alkylation of aliphatic        halides or tosylates with enolethers or enamines), and        cycloadditions. Example reagents that can be used in a reaction        with the amino groups are activated carboxylic acids such as        NHS-ester, tetra and pentafluoro phenolic esters, anhydrides,        acid chlorides and fluorides, to form stable amide bonds.        Likewise, sulphonyl chlorides can react with these amino groups        to form stable sulphone-amides. Iso-Cyanates can also react with        amino groups to form stable ureas, and isothiocyanates can be        used to introduce thio-urea linkages.    -   Aldehydes, such as formaldehyde and glutardialdehyde will react        with amino groups to form shiff's bases, than can be further        reduced to secondary amines. The guanidino group on the side        chain of arginine will undergo similar reactions with the same        type of reagents.    -   Another very useful amino acid is cysteine. The thiol on the        side chain is readily alkylated by maleimides, vinyl sulphones        and halides to form stable thioethers, and reaction with other        thiols will give rise to disulphides.    -   Carboxylic acids at the C-terminal of both chains and peptide,        as well as on the side chains of glutamic and aspartic acid, can        also be used to introduce cross-links. They will require        activation with reagents such as carbodiimides, and can then        react with amino groups to give stable amides.    -   Thus, a large number of chemistries can be employed to form        covalent cross-links. The crucial point is that the chemical        reagents are bi-functional, being capable of reacting with two        amino acid residues.    -   They can be either homo bi-functional, possessing two identical        reactive moieties, such as glutardialdehyde or can be hetero        bi-functional with two different reactive moieties, such as GMBS        (MaleimidoButyryloxy-Succinimide ester).    -   Alternatively, two or more reagents can be used; i.e. GMBS can        be used to introduce maleimides on the α-chain, and        iminothiolane can be used to introduce thiols on the β-chain;        the malemide and thiol can then form a thioether link between        the two chains. For the present invention some types of        cross-links are particularly useful. The folded MHC-complex can        be reacted with dextrans possessing a large number (up to many        hundreds) of vinyl sulphones. These can react with lysine        residues on both the α and β chains as well as with lysine        residues on the peptide protruding from the binding site,        effectively cross linking the entire MHC-complex. Such cross        linking is indeed a favored reaction because as the first lysine        residue reacts with the dextran, the MHC-complex becomes        anchored to the dextran favoring further reactions between the        MHC complex and the dextran multimerization domain. Another        great advantage of this dextran chemistry is that it can be        combined with fluorochrome labelling; i.e. the dextran is        reacted both with one or several MHC-complexes and one or more        fluorescent protein such as APC.    -   Another valuable approach is to combine the molecular biological        tools described above with chemical cross linkers. As an        example, one or more lysine residues can be inserted into the        α-chain, juxtaposed with glutamic acids in the β-chain, where        after the introduced amino groups and carboxylic acids are        reacted by addition of carbodiimide. Such reactions are usually        not very effective in water, unless as in this case, the groups        are well positioned towards reaction. This implies that one        avoids excessive reactions that could otherwise end up        denaturing or changing the conformation of the MHC-complex.    -   Likewise a dextran multimerization domain can be cross-linked        with appropriately modified MHC-complexes; i.e. one or both        chains of the MHC complex can be enriched with lysine residues,        increasing reactivity towards the vinylsulphone dextran. The        lysine's can be inserted at positions opposite the peptide        binding cleft, orienting the MHC-complexes favorably for T-cell        recognition.    -   Another valuable chemical tool is to use extended and flexible        cross-linkers. An extended linker will allow the two chains to        interact with little or no strain resulting from the linker that        connects them, while keeping the chains in the vicinity of each        other should the complex dissociate. An excess of peptide should        further favor reformation of dissociated MHC-complex.

Other TCR Binding Molecules

MHC I and MHC II complexes bind to TCRs. However, other molecules alsobind TCR. Some TCR-biding molecules are described in the following. MHCI and MHC II complexes binding to TCRs may be substituted with othermolecules capable of binding TCR or molecules that have homology to theclassical MHC molecules and therefore potentially could be TCR bindingmolecules. These other TCR binding or MHC like molecules include:

Non-Classical MHC Complexes and Other MHC-Like Molecules:

Non-classical MHC complexes include protein products of MHC Ib and MHCIIb genes. MHC Ib genes encode β2m-associated cell-surface molecules butshow little polymorphism in contrast to classical MHC class I genes.Protein products of MHC class Ib genes include HLA-E, HLA-G, HLA-F,HLA-H, MIC A, MIC B, ULBP-1, ULBP-2, ULBP-3 in humans and H2-M, H2-Q,H2-T and Rae1 in mice.

Non-classical MHC II molecules (protein products of MHC IIb genes)include HLA-DM, HLA-DO in humans and H2-DM and H2-DO in mice that areinvolved in regulation of peptide loading into MHC II molecules.

Another MHC-like molecule of special interest is the MHC I-like moleculeCD1. CD1 is similar to MHC I molecules in its organization of subunitsand association with β2m but presents glycolipids and lipids instead ofpeptides.

Artificial Molecules Capable of Binding Specific TCRs

Of special interest are antibodies that bind TCRs. Antibodies hereininclude full length antibodies of isotype IgG, IgM, IgE, IgA andtruncated versions of these, antibody fragments like Fab fragments andscFv. Antibodies also include antibodies of antibody fragments displayedon various supramolecular structures or solid supports, includingfilamentous phages, yeast, mammalian cells, fungi, artificial cells ormicelles, and beads with various surface chemistries.

Peptide Binding TCR

Another embodiment of special interest is peptides that bind TCRs.Peptides herein include peptides composed of natural, non-natural and/orchemically modified amino acids with a length of 8-20 amino acid. Thepeptides could also be longer than 20 amino acids or shorter than 8amino acids. The peptides can or can not have a defined tertiarystructure.

Aptamers

Aptamers are another preferred group of TCR ligands. Aptamers are hereinunderstood as natural nucleic acids (e.g. RNA and DNA) or unnaturalnucleic acids (e.g. PNA, LNA, morpholinos) capable of binding TCR. Theaptamer molecules consist of natural or modified nucleotides in variouslengths.

Other TCR-binding molecules can be ankyrin repeat proteins or otherrepeat proteins, Avimers, or small chemical molecules, as long as theyare capable of binding TCR with a dissociation constant smaller than10⁻³ M.

Generation of Antigenic Peptide Approaches and Methods for theIdentification and Design of Appropriate Peptides

MHC class 1 molecules normally binds octa-, nona-, deca- or ondecamer(8-, 9-, 10, -11-mer) peptides in their peptide binding groove. Theindividual MHC class 1 alleles have individual preferences for thepeptide length within the given range. MHC class 2 molecules bindpeptides most often with a total length of 13-18 amino acids around a9-mer core motif containing the important amino acid anchor residues.However the total length is not strictly defined as for most MHC class 1molecules.

For some of the MHC alleles the optimal peptide length is known and alsothe demands for specific amino acid residues in the so called anchorpositions.

To identify binding peptides derived from a specific protein for a givenMHC allele it is necessary to systematically work through the amino acidsequence of the protein to identify the putative binding peptides.Although a given peptide is a binder it is not necessarily a functionalT-cell epitope. Functionality needs to be confirmed by a functionalanalysis e.g. ELISPOT, CTL killing assay or flow cytometry assay.

A measure for binding affinity of the peptide to the MHC molecules canfor some MHC molecules be found in databases such as www.syfpeithi.de;http://www-bimas.cit.nih.gov/molbio/hla_bind/;www.cbs.dtu.dk/services/NetMHC/; www.cbs.dtu.dk/services/NetMHCII/

Design of Binding Peptides

a) From Genomic DNA Sequences without Introns

When only the genomic DNA sequences are known and thereby reading frameand direction of transcription of the genes are unknown, the DNAsequence needs to be translated in all three reading frames in bothdirections leading to a total of six amino acid sequences for a givengenome. From these amino acid sequences binding peptides can then beidentified.

b) From Genomic DNA Sequences with Introns

In organisms having intron/exon gene structure the present approach willnot be able to identify peptide sequence motifs that are derived bycombination of amino acid sequences derived partly from two separateintrons.

c) From cDNA Sequences

cDNA sequences can be translated into the actual amino acid sequences toallow peptide identification.

d) From Known Amino Acid Sequences

In the case of known protein sequences these can directly be applied tosoftware analysis for prediction of peptide epitopes.

Binding peptide sequences can be predicted from any protein sequence byeither a total approach generating binding peptide sequences forpotentially any MHC allele or by a directed approach using software thatspecifically can predict the binding peptide sequences for a subset ofMHC alleles for which the binding characteristics of the peptide isknown.

Design of MHC Class I Binding Peptide Sequence a) Total Approach

The MHC class I binding peptide prediction is done as follows using thetotal approach. The actual protein sequence is split up into 8-, 9-,10-, and 11-mer peptide sequences. This is performed by starting atamino acid position 1 identifying the first 8-mer; then move the startposition by one amino acid identifying the second 8-mer; then move thestart position by one amino acid, identifying the third 8-mer. Thisprocedure continues by moving start position by one amino acid for eachround of peptide identification. Generated peptides will be amino acidposition 1-8, 2-9, 3-10 etc. All peptides carrying one or more stopcodons are omitted for further consideration. This procedure can becarried out manually or by means of a software program (FIG. 2). Thisprocedure is then repeated in an identical fashion for 9-, 10 and11-mers, respectively.

b) Directed Approach

Using a directed approach is only possible when working on prediction ofpeptide sequences binding to MHC class I alleles with known bindingpreferences. Examples of such programs are www.syfpeithi.de;www.imtech.res.in/raghava/propred1/index.html;www.cbs.dtu.dk/services/NetMHC/. Identified peptides can then be testedfor biological relevance in functional assays such as Cytokine releaseassays, ELISPOT and CTL killing assays.

Prediction of good HLA class 1 peptide binders can be done at the HLAsuperfamily level even taking the combined action of endocolic andmembrane bound protease activities as well as the TAP1 and TAP2transporter specificities into consideration using the programwww.cbs.dtu.dk/services/NetCTL/.

Design of MHC Class 2 Binding Peptide Sequence. a) Total Approach and b)Directed Approach

The approach to predict putative peptide binders for MHC class 2 issimilar as given above for MHC class 1 binding peptide prediction. Theonly change is the different size of the peptides, which is preferably13-16 amino acids long for MHC class 2. The putative binding peptidesequences only describe the central part of the peptide including the9-mer core peptide; in other words, the peptide sequences shownrepresent the core of the binding peptide with a few important flankingamino acids, which in some cases may be of considerably lengthgenerating binding peptides longer than the 13-16 amino acids.

Choice of MHC Allele

More than 600 MHC alleles (class 1 and 2) are known in humans; for manyof these, the peptide binding characteristics are known. FIG. 3 presentsan updated list of the HLA class 1 alleles. The frequency of thedifferent HLA alleles varies considerably, also between different ethnicgroups (FIG. 4). Thus it is of outmost importance to carefully selectthe MHC alleles that corresponds to the human group that one wish tostudy.

Peptide Modifications Homologous Peptides

Predictions of the primary amino acid sequence for the binding peptidesof MHC class I and class II molecules can be done as described above onthe basis of the genetic information. Peptides homologous to thepredicted peptide sequences may also be bound if they are sufficientlyhomologous i.e. are having an amino acid sequence identity greater thane.g. more than 90%, more than 80% or more than 70%. Identity being mostimportant for the anchor residues.

Homologues MHC peptide sequences may arise from the existence ofmultiple strongly homologous alleles, from small insertions, deletions,inversions or substitutions.

Uncommon Amino Acids

Peptides having un-common amino acids may be bound in the MHC groove aswell. Two un-common amino acids found in nature are selenocysteine andpyrrolysine.

Artificial Amino Acids

Artificial amino acids e.g. having the isomeric D-form may also make upisomeric D-peptides that can bind in the binding groove of the MHCmolecules.

Chemically Modified Amino Acids

Bound peptides may also contain amino acids that are chemically modifiedor being linked to reactive groups that can be activated to inducechanges in or disrupt the peptide.

Split or Combinatorial Peptide

A MHC binding peptide may also be of split- or combinatorial epitopeorigin i.e. formed by linkage of peptide fragments derived from twodifferent peptide fragments and/or proteins. Such peptides can be theresult of either genetic recombination on the DNA level or due topeptide fragment association during the complex break down of proteinsduring protein turnover. Possibly it could also be the result of faultyreactions during protein synthesis i.e. caused by some kind of mixed RNAhandling. A kind of combinatorial peptide epitope can also be seen if aportion of a longer peptide make a loop out leaving only the terminalpart of the peptide bound in the groove.

Position in Peptide of Amino Acid Change

Any of the mentioned changes of the bound peptide amino acid sequence,can be found individually or in combination at any position of thepeptide e.g. position 1, 2, 3, 4, 5, 6, etc up to n, n being the finalamino acid of the peptide.

TABLE 1 Post translational modification of peptides Protein primarystructure and posttranslational modifications N-terminus Acetylation,Formylation, Pyroglutamate, Methylation, Glycation, Myristoylation(Gly), carbamylation C-terminus Amidation, Glycosyl phosphatidylinositol(GPI), O-methylation, Glypiation, Ubiquitmation, Sumoylation. LysineMethylation, Acetylation, Acylation, Hydroxylation, Ubiquitination,SUMOylation, Desmosine formation, ADP-ribosylation, Deamination andOxidation to aldehyde Cysteine Disulfide bond, Prenylation,Palmitoylation Serine/Threonine Phosphorylation, Glycosylation TyrosinePhosphorylation, Sulfation, Porphyrin ring linkage, Flavin linkage GFPprosthetic group (Thr-Tyr-Gly sequence) formation, Lysine tyrosinequinone (LTQ) formation, Topaquinone (TPQ) formation AsparagineDeamidation, Glycosylation Aspartate Succinimide formation GlutamineTransglutamination Glutamate Carboxylation, Methylation,Polyglutamylation, Polyglycylation Arginine Citrullination, MethylationProline Hydroxylation

Post Translationally Modified Peptides

The amino acids of the MHC bound peptides can also be modified invarious ways dependent on the amino acid in question or the modificationcan affect the amino- or carboxy-terminal end of the peptide. Seetable 1. Such peptide modifications are occurring naturally as theresult of post tranlational processing of the parental protein. Anon-exhaustive description of the major post translational modificationsis given below, divided into three main types

a) Involving Addition Include:

-   -   acylation, the addition of an acetyl group, usually at the        N-terminus of the protein    -   alkylation, the addition of an alkyl group (e.g. methyl, ethyl).        Methylation, the addition of a methyl group, usually at lysine        or arginine residues is a type of alkylation. Demethylation        involves the removal of a methyl-group.    -   amidation at C-terminus    -   biotinylation, acylation of conserved lysine residues with a        biotin appendage    -   formylation    -   gamma-carboxylation dependent on Vitamin K    -   glutamylation, covalent linkage of glutamic acid residues to        tubulin and some other proteins by means of tubulin        polyglutamylase    -   glycosylation, the addition of a glycosyl group to either        asparagine, hydroxylysine, serine, or threonine, resulting in a        glycoprotein. Distinct from glycation, which is regarded as a        nonenzymatic attachment of sugars.    -   glycylation, covalent linkage of one to more than 40 glycine        residues to the tubulin C-terminal tail    -   heme moiety may be covalently attached    -   hydroxylation, is any chemical process that introduces one or        more hydroxyl groups (—OH) into a compound (or radical) thereby        oxidizing it. The principal residue to be hydroxylated is        Proline. The hydroxilation occurs at the C^(γ) atom, forming        hydroxyproline (Hyp). In some cases, proline may be hydroxylated        instead on its C^(β) atom. Lysine may also be hydroxylated on        its C^(δ) atom, forming hydroxylysine (Hyl).    -   iodination (e.g. of thyroid hormones)    -   isoprenylation, the addition of an isoprenoid group (e.g.        farnesol and geranylgeraniol)    -   lipoylation, attachment of a lipoate functionality, as in        prenylation, GPI anchor formation, myristoylation,        farnesylation, geranylation    -   nucleotides or derivatives thereof may be covalently attached,        as in ADP-ribosylation and flavin attachment    -   oxidation, lysine can be oxidized to aldehyde    -   pegylation, addition of poly-ethylen-glycol groups to a protein.        Typical reactive amino acids include lysine, cysteine,        histidine, arginine, aspartic acid, glutamic acid, serine,        threonine, tyrosine. The N-terminal amino group and the        C-terminal carboxylic acid can also be used    -   phosphatidylinositol may be covalently attached    -   phosphopantetheinylation, the addition of a        4′-phosphopantetheinyl moiety from coenzyme A, as in fatty acid,        polyketide, non-ribosomal peptide and leucine biosynthesis    -   phosphorylation, the addition of a phosphate group, usually to        serine, tyrosine, threonine or histidine    -   pyroglutamate formation as a result of N-terminal glutamine        self-attack, resulting in formation of a cyclic pyroglutamate        group.    -   racemization of proline by prolyl isomerase    -   tRNA-mediated addition of amino acids such as arginylation    -   sulfation, the addition of a sulfate group to a tyrosine.    -   Selenoylation (co-translational incorporation of selenium in        selenoproteins)

b) Involving Addition of Other Proteins or Peptides

-   -   ISGylation, the covalent linkage to the ISG15 protein        (Interferon-Stimulated Gene 15)    -   SUMOylation, the covalent linkage to the SUMO protein (Small        Ubiquitin-related MOdifier)    -   ubiquitination, the covalent linkage to the protein ubiquitin.

c) Involving Changing the Chemical Nature of Amino Acids

-   -   citrullination, or deimination the conversion of arginine to        citrulline    -   deamidation, the conversion of glutamine to glutamic acid or        asparagine to aspartic acid

The peptide modifications can occur as modification of a single aminoacid or more than one i.e. in combinations. Modifications can be presenton any position within the peptide i.e. on position 1, 2, 3, 4, 5,etc.for the entire length of the peptide.

Sources of Peptides a) From Natural Sources

Peptides can be obtained from natural sources by enzymatic digestion orproteolysis of natural proteins or proteins derived by in vitrotranslation of mRNA. Peptides may also be eluted from the MHC bindinggroove.

b) From Recombinant Sources

1) As Monomeric or Multimeric Peptide

Alternatively peptides can be produced recombinantly by transfectedcells either as monomeric antigenic peptides or as multimeric(contatemeric) antigenic peptides.

2) As Part of a Bigger Recombinant Protein

Binding peptides may also constitute a part of a bigger recombinantprotein e.g. consisting of,

2a) For MHC Class 1 Binding Peptides,

Peptide-linker-β2m, β2m being full length or truncated;

Peptide-linker-MHC class 1 heavy chain, the heavy chain being fulllength or truncated. Most importantly the truncated class I heavy chainwill consist of the extracellular part i.e the α1, α2, and a domains.The heavy chain fragment may also only contain the α1 and α2 domains, orα1 domain alone, or any fragment or full length β2m or heavy chainattached to a designer domain(s) or protein fragment(s).

2b) For MHC Class 2 Binding Peptides the Recombinant Construction canConsist of,

Peptide-linker-MHC class 2 □-chain, full length or truncated;Peptide-linker-MHC class 2 □-chain, full length or truncated;Peptide-linker-MHC class 2 □-chain-linker-MHC class 2 □-chain, bothchains can be full length or truncated, truncation may involve, omissionof □- and/or □-chain intermembrane domain, or omission of □- and/or□-chain intermembrane plus cytoplasmic domains. MHC class 2 part of theconstruction may consist of fused domains from NH2-terminal, MHC class 2□/domain-MHC class 2 □/domain-constant □3 of MHC class 1, oralternatively of fused domains from NH2-terminal, MHC class 2□1domain-MHC class 2 □1domain-constant □3 of MHC class 1. In both cases□2m will be associated non-covalently in the folded MHC complex. □2m canalso be covalently associated in the folded MHC class 2 complex if thefollowing constructs are used from NH2 terminal, MHC class 2□1domain-MHC class 2 □1domain-constant □3 of MHC class 1-linker-□2m, oralternatively of fused domains from NH2-terminal, MHC class 2□1domain-MHC class 2 □1domain-constant □3 of MHC class 1-linker-□2m; theconstruct may also consist of any of the above MHC class 2 constructswith added designer domain(s) or sequence(s).

c) From Chemical Synthesis

MHC binding peptide may also be chemically synthesized by solid phase orfluid phase synthesis.

Loading of the Peptide into the MHCmer

Loading of the peptides into the MHCmer being either MHC class 1 orclass 2 can be performed in a number of ways depending on the source ofthe peptide and the MHC. MHC class 2 molecules can in principle beloaded with peptides in similar ways as MHC class 1. However, due tocomplex instability the most successful approach have been to make thecomplexes recombinant in toto in eukaryotic cells from a gene constructencoding the following form □ chain-flexible linker-□ chain-flexiblelinker-peptide

a) During MHC Complex Folding

a1) As a Free Peptide

MHC class I molecules are most often loaded with peptide during assemblyin vitro by the individual components in a folding reaction i.e.consisting of purified recombinant heavy chain □ with the purifiedrecombinant □2 microglobulin and a peptide or a peptide mix.

a2) As Part of a Recombinant Protein Construct

Alternatively the peptide to be folded into the binding groove can beencoded together with e.g. the □ heavy chain or fragment hereof by agene construct having the structure, heavy chain-flexiblelinker-peptide. This recombinant molecule is then folded in vitro with□2-microglobulin.

b) By Exchange Reaction

b1) In Solution

Loading of desired peptide can also be made by an in vitro exchangereaction where a peptide already in place in the binding groove arebeing exchanged by another peptide species.

b2) “In Situ”

Peptide exchange reactions can also take place when the parent moleculeis attached to other molecules, structures, surfaces, artificial ornatural membranes and nano-particles.

b3) By Aided Exchange

This method can be refined by making the parent construct with a peptidecontaining a meta-stable amino acid analog that is split by either lightor chemically induction thereby leaving the parent structure free foraccess of the desired peptide in the binding groove.

b4) By In Vivo Loading

Loading of MHC class I and II molecules expressed on the cell surfacewith the desired peptides can be performed by an exchange reaction.Alternatively cells can be transfected by the peptides themselves or bythe mother proteins that are then being processed leading to an in vivoanalogous situation where the peptides are bound in the groove duringthe natural cause of MHC expression by the transfected cells. In thecase of professional antigen presenting cells e.g. dendritic cells,macrophages, Langerhans cells, the proteins and peptides can be taken upby the cells themselves by phagocytosis and then bound to the MHCcomplexes the natural way and expressed on the cell surface in thecorrect MHC context.

Verification of Correctly Folded MHC-Peptide Complexes QuantitativeELISA and Other Techniques to Quantify Correctly Folded MHC Complexes

When producing MHC multimers, it is desirable to determine the degree ofcorrectly folded MHC.

The fraction or amount of functional and/or correctly folded MHC can betested in a number of different ways, including:

-   -   Measurement of correctly folded MHC in a quantitative ELISA,        e.g. where the MHC bind to immobilized molecules recognizing the        correctly folded complex.    -   Measurement of functional MHC in an assay where the total        protein concentration is measured before functional MHC is        captured, by binding to e.g. immobilized TCR, and the excess,        non-bound protein are measured. If the dissociation constant for        the interaction is known, the amount of total and the amount of        non-bound protein can be determined. From these numbers, the        fraction of functional MHC complex can be determined.    -   Measurement of functional MHC complex by a non-denaturing        gel-shift assay, where functional MHC complexes bind to TCR (or        another molecule that recognize correctly folded MHC complex),        and thereby shifts the TCR to another position in the gel.

Multimerization Domain

A number of MHC complexes associate with a multimerization domain toform a MHC multimer. The size of the multimerization domain spans a widerange, from multimerisation domains based on small organic moleculescaffolds to large multimers based on a cellular structure or solidsupport. The multimerization domain may thus be based on different typesof carriers or scaffolds, and likewise, the attachment of MHC complexesto the multimerization domain may involve covalent or non-covalentlinkers.

Characteristics of different kinds of multimerization domains aredescribed below.

Molecular Weight of Multimerization Domain.

-   -   In one embodiment the multimerization domain(s) in the present        invention is preferably less than 1,000 Da (small molecule        scaffold). Examples include short peptides (e.g. comprising 10        amino acids), and various small molecule scaffolds (e.g.        aromatic ring structures).    -   In another embodiment the multimerization domain(s) is        preferably between 1,000 Da and 10,000 Da (small molecule        scaffold, small peptides, small polymers). Examples include        polycyclic structures of both aliphatic and aromatic compounds,        peptides comprising e.g. 10-100 amino acids, and other polymers        such as dextran, polyethylenglycol, and polyureas.    -   In another embodiment the multimerization domain(s) is between        10,000 Da and 100,000 Da (Small molecule scaffold, polymers e.g.        dextran, streptavidin, IgG, pentamer structure). Examples        include proteins and large polypeptides, small molecule        scaffolds such as steroids, dextran, dimeric streptavidin, and        multi-subunit proteins such as used in Pentamers.    -   In another embodiment the multimerization domain(s) is        preferably between 100,000 Da and 1,000,000 Da (Small molecule        scaffold, polymers e.g. dextran, streptavidin, IgG, pentamer        structure). Typical examples include larger polymers such as        dextran (used in e.g. Dextramers), and streptavidin tetramers.    -   In another embodiment the multimerization domain(s) is        preferably larger than 1,000,000 Da (Small molecule scaffold,        polymers e.g. dextran, streptavidin, IgG, pentamer structure,        cells, liposomes, artificial lipid bilayers, polystyrene beads        and other beads. Most examples of this size involve cells or        cell-based structures such as micelles and liposomes, as well as        beads and other solid supports.

As mentioned elsewhere herein multimerisation domains can comprisecarrier molecules, scaffolds or combinations of the two.

Type of Multimerization Domain.

In principle any kind of carrier or scaffold can be used asmultimerization domain, including any kind of cell, polymer, protein orother molecular structure, or particles and solid supports. Belowdifferent types and specific examples of multimerization domains arelisted.

-   -   Cell. Cells can be used as carriers. Cells can be either alive        and mitotic active, alive and mitotic inactive as a result of        irradiation or chemically treatment, or the cells may be dead.        The MHC expression may be natural (i.e. not stimulated) or may        be induced/stimulated by e.g. Inf-γ. Of special interest are        natural antigen presenting cells (APCs) such as dendritic cells,        macrophages, Kupfer cells, Langerhans cells, B-cells and any MHC        expressing cell either naturally expressing, being transfected        or being a hybridoma.    -   Cell-like structures. Cell-like carriers include membrane-based        structures carrying MHC-peptide complexes in their membranes        such as micelles, liposomes, and other structures of membranes,        and phages such as filamentous phages.    -   Solid support. Solid support includes beads, particulate matters        and other surfaces. A preferred embodiment include beads        (magnetic or non-magnetic beads) that carry electrophilic groups        e.g. divinyl sulfone activated polysaccharide, polystyrene beads        that have been functionalized with tosyl-activated esters,        magnetic polystyrene beads functionalized with tosyl-activated        esters), and where MHC complexes may be covalently immobilized        to these by reaction of nucleophiles comprised within the MHC        complex with the electrophiles of the beads. Beads may be made        of sepharose, sephacryl, polystyrene, agarose, polysaccharide,        polycarbamate or any other kind of beads that can be suspended        in aqueous buffer.    -   Another embodiment includes surfaces, i.e. solid supports and        particles carrying immobilized MHC complexes on the surface. Of        special interest are wells of a microtiter plate or other plate        formats, reagent tubes, glass slides or other supports for use        in microarray analysis, tubings or channels of micro fluidic        chambers or devices, Biacore chips and beads    -   Molecule. Multimerization domains may also be molecules or        complexes of molecules held together by non-covalent bonds. The        molecules constituting the multimerization domain can be small        organic molecules or large polymers, and may be flexible linear        molecules or rigid, globular structures such as e.g. proteins.        Different kinds of molecules used in multimerization domains are        described below.        -   Small organic molecules. Small organic molecules here            includes steroids, peptides, linear or cyclic structures,            and aromatic or aliphatic structures, and many others. The            prototypical small organic scaffold is a functionalized            benzene ring, i.e. a benzene ring functionalized with a            number of reactive groups such as amines, to which a number            of MHC molecules may be covalently linked. However, the            types of reactive groups constituting the linker connecting            the MHC complex and the multimerization domain, as well as            the type of scaffold structure, can be chosen from a long            list of chemical structures. A non-comprehensive list of            scaffold structures are listed below.    -   Typical scaffolds include aromatic structures, benzodiazepines,        hydantoins, piperazines, indoles, furans, thiazoles, steroids,        diketopiperazines, morpholines, tropanes, coumarines, qinolines,        pyrroles, oxazoles, amino acid precursors, cyclic or aromatic        ring structures, and many others. Typical carriers include        linear and branched polymers such as peptides, polysaccharides,        nucleic acids, and many others. Multimerization domains based on        small organic or polymer molecules thus include a wealth of        different structures, including small compact molecules, linear        structures, polymers, polypeptides, polyureas, polycarbamates,        cyclic structures, natural compound derivatives, alpha-, beta-,        gamma-, and omega-peptides, mono-, di- and tri-substituted        peptides, L- and D-form peptides, cyclohexane- and        cyclopentane-backbone modified beta-peptides, vinylogous        polypeptides, glycopolypeptides, polyamides, vinylogous        sulfonamide peptide, Polysulfonamide-conjugated peptide (i.e.,        having prosthetic groups), Polyesters, Polysaccharides such as        dextran and aminodextran, polycarbamates, polycarbonates,        polyureas, poly-peptidylphosphonates, Azatides, peptoids (oligo        N-substituted glycines), Polyethers, ethoxyformacetal oligomers,        poly-thioethers, polyethylene, glycols (PEG), polyethylenes,        polydisulfides, polyarylene sulfides, Polynucleotides, PNAs,        LNAs, Morpholinos, oligo pyrrolinone, polyoximes, Polyimines,        Polyethyleneimine, Polyacetates, Polystyrenes, Polyacetylene,        Polyvinyl, Lipids, Phospholipids, Glycolipids, polycycles,        (aliphatic), polycycles (aromatic), polyheterocycles,        Proteoglycan, Polysiloxanes, Polyisocyanides, Polyisocyanates,        polymethacrylates, Monofunctional, Difunctional, Trifunctional        and Oligofunctional open-chain hydrocarbons, Monofunctional,        Difunctional, Trifunctional and Oligofunctional Nonaromat        Carbocycles, Monocyclic, Bicyclic, Tricyclic and Polycyclic        Hydrocarbons, Bridged Polycyclic Hydrocarbones, Monofunctional,        Difunctional, Trifunctional and Oligofunctional Nonaromatic,        Heterocycles, Monocyclic, Bicyclic, Tricyclic and Polycyclic        Heterocycles, bridged Polycyclic Heterocycles, Monofunctional,        Difunctional, Trifunctional and Oligofunctional Aromatic        Carbocycles, Monocyclic, Bicyclic, Tricyclic and Polycyclic        Aromatic Carbocycles, Monofunctional, Difunctional,        Trifunctional and Oligofunctional Aromatic Hetero-cycles.        Monocyclic, Bicyclic, Tricyclic and Polycyclic Heterocycles.        Chelates, fullerenes, and any combination of the above and many        others.    -   Biological polymers. Biological molecules here include peptides,        proteins (including antibodies, coiled-coil helices,        streptavidin and many others), nucleic acids such as DNA and        RNA, and polysaccharides such as dextran. The biological        polymers may be reacted with MHC complexes (e.g. a number of MHC        complexes chemically coupled to e.g. the amino groups of a        protein), or may be linked through e.g. DNA duplex formation        between a carrier DNA molecule and a number of DNA        oligonucleotides each coupled to a MHC complex. Another type of        multimerization domain based on a biological polymer is the        streptavidin-based tetramer, where a streptavidin binds up to        four biotinylated MHC complexes, as described above (see        Background of the invention).    -   Self-assembling multimeric structures. Several examples of        commercial MHC multimers exist where the multimer is formed        through self-assembling. Thus, the Pentamers are formed through        formation of a coiled-coil structure that holds together 5 MHC        complexes in an apparently planar structure. In a similar way,        the Streptamers are based on the Streptactin protein which        oligomerizes to form a MHC multimer comprising several MHC        complexes (see Background of the invention).

In the following, alternative ways to make MHC multimers based on amolecule multimerization domain are described. They involve one or moreof the abovementoned types of multimerization domains.

MHC dextramers can be made by coupling MHC complexes to dextran via astreptavidin-biotin interaction. In principle, biotin-streptavdin can bereplaced by any dimerization domain, where one half of the dimerizationdomain is coupled to the MHC-peptide complex and the other half iscoupled to dextran. For example, an acidic helix (one half of acoiled-coil dimer) is coupled or fused to MHC, and a basic helix (otherhalf of a coiled-coil dimmer) is coupled to dextran. Mixing the tworesults in MHC binding to dextran by forming the acid/base coiled-coilstructure.

Antibodies can be used as scaffolds by using their capacity to bind to acarefully selected antigen found naturally or added as a tag to a partof the MHC molecule not involved in peptide binding. For example, IgGand IgE will be able to bind two MHC molecules, IgM having a pentamericstructure will be able to bind 10 MHC molecules. The antibodies can befull-length or truncated; a standard antibody-fragment includes the Fab2fragment.

Peptides involved in coiled-coil structures can act as scaffold bymaking stable dimeric, trimeric, tetrameric and pentameric interactions.Examples hereof are the Fos-Jun heterodimeric coiled coil, the E. colihomo-trimeric coiled-coil domain Lpp-56, the engineered Trp-zipperprotein forming a discrete, stable, α-helical pentamer in water atphysiological pH.

Further examples of suitable scaffolds, carriers and linkers arestreptavidin (SA) and avidin and derivatives thereof, biotin,immunoglobulins, antibodies (monoclonal, polyclonal, and recombinant),antibody fragments and derivatives thereof, leucine zipper domain ofAP-1 (jun and fos), hexa-his (metal chelate moiety), hexa-hat GST(glutathione S-tranferase), glutathione, Calmodulin-binding peptide(CBP), Strep-tag, Cellulose Binding Domain, Maltose Binding Protein,S-Peptide Tag, Chitin Binding Tag, Immuno-reactive Epitopes, EpitopeTags, E2Tag, HA Epitope Tag, Myc Epitope, FLAG Epitope, AU1 and AU5Epitopes, Glu-Glu Epitope, KT3 Epitope, IRS Epitope, Btag Epitope,Protein Kinase-C Epitope, VSV Epitope, lectins that mediate binding to adiversity of compounds, including carbohydrates, lipids and proteins,e.g. Con A (Canavalia ensiformis) or WGA (wheat germ agglutinin) andtetranectin or Protein A or G (antibody affinity). Combinations of suchbinding entities are also comprised. Non-limiting examples arestreptavidin-biotin and jun-fos. In particular, when the MHC molecule istagged, the binding entity may be an “anti-tag”. By “anti-tag” is meantan antibody binding to the tag, or any other molecule capable of bindingto such tag.

MHC complexes can be multimerized by other means than coupling orbinding to a multimerization domain. Thus, the multimerization domainmay be formed during the multimerization of MHCs. One such method is toextend the bound antigenic peptide with dimerization domains. One end ofthe antigenic peptide is extended with dimerization domain A (e.g.acidic helix, half of a coiled-coil dimer) and the other end is extendedwith dimerization domain B (e.g. basic helix, other half of acoiled-coil dimer). When MHC complexes are loaded/mixed with theseextended peptides the following multimer structure will be formed:A-MHC-BA-MHC-BA-MHC-B etc. The antigenic peptides in the mixture caneither be identical or a mixture of peptides with comparable extendeddimerization domains. Alternatively both ends of a peptide are extendedwith the same dimerization domain A and another peptide (same amino acidsequence or a different amino acid sequence) is extended withdimerization domain B. When MHC and peptides are mixed the followingstructures are formed: A-MHC-AB-MHC-BA-MHC-AB-MHC-B etc. Multimerizationof MHC complexes by extension of peptides are restricted to MHC IImolecules since the peptide binding groove of MHC I molecules istypically closed in both ends thereby limiting the size of peptide thatcan be embedded in the groove, and therefore preventing the peptide fromextending out of the groove.

Another multimerization approach applicable to both MHC I and MHC IIcomplexes is based on extension of N- and C-terminal of the MHC complex.For example the N-terminal of the MHC complex is extended withdimerization domain A and the C-terminal is extended with dimerizationdomain B. When MHC complexes are incubated together they pair with eachother and form multimers like: A-MHC-BA-MHC-BA-MHC-BA-MHC-B etc.Alternatively the N-terminal and the C-terminal of a MHC complex areboth extended with dimerization domain A and the N-terminal andC-terminal of another preparation of MHC complex (either the same or adifferent MHC) are extended with dimerization domain B. When these twotypes of MHC complexes are incubated together multimers will be formed:A-MHC-AB-MHC-BA-MHC-AB-MHC-B etc.

In all the above-described examples the extension can be eitherchemically coupled to the peptide/MHC complex or introduced as extensionby gene fusion.

Dimerization domain AB can be any molecule pair able to bind to eachother, such as acid/base coiled-coil helices, antibody-antigen, DNA-DNA,PNA-PNA, DNA-PNA, DNA-RNA, LNA-DNA, leucine zipper e.g. Fos/Jun,streptavidin-biotin and other molecule pairs as described elsewhereherein.

Linker Molecules.

A number of MHC complexes associate with a multimerization domain toform a MHC multimer. The attachment of MHC complexes to themultimerization domain may involve covalent or non-covalent linkers, andmay involve small reactive groups as well as large protein-proteininteractions.

The coupling of multimerization domains and MHC complexes involve theassociation of an entity X (attached to or part of the multimerizationdomain) and an entity Y (attached to or part of the MHC complex). Thus,the linker that connects the multimerization domain and the MHC complexcomprises an XY portion.

-   -   Covalent linker. The XY linkage can be covalent, in which case X        and Y are reactive groups. In this case, X can be a nucleophilic        group (such as —NH₂, —OH, —SH, —NH—NH₂), and Y an electrophilic        group (such as CHO, COOH, CO) that react to form a covalent bond        XY; or Y can be a nucleophilic group and X an electrophilic        group that react to form a covalent bond XY. Other possibilities        exist, e.g either of the reactive groups can be a radical,        capable of reacting with the other reactive group. A number of        reactive groups X and Y, and the bonds that are formed upon        reaction of X and Y, are shown in FIG. 5.    -   X and Y can be reactive groups naturally comprised within the        multimerization domain and/or the MHC complex, or they can be        artificially added reactive groups. Thus, linkers containing        reactive groups can be linked to either of the multimerization        domain and MHC complex; subsequently the introduced reactive        group(s) can be used to covalently link the multimerization        domain and MHC complex.    -   Example natural reactive groups of MHC complexes include amino        acid side chains comprising —NH₂, —OH, —SH, and —NH—. Example        natural reactive groups of multimerization domains include        hydroxyls of polysaccharides such as dextrans, but also include        amino acid side chains comprising —NH₂, —OH, —SH, and —NH— of        polypeptides, when the polypeptide is used as a multimerization        domain. In some MHC multimers, one of the polypeptides of the        MHC complex (i.e. the β2M, heavy chain or the antigenic peptide)        is linked by a protein fusion to the multimerization domain.        Thus, during the translation of the fusion protein, an acyl        group (reactive group X or Y) and an amino group (reactive group        Y or X) react to form an amide bond. Example MHC multimers where        the bond between the multimerization domain and the MHC complex        is covalent and results from reaction between natural reactive        groups, include MHC-pentamers (described in US        patent 2004209295) and MHC-dimers, where the linkage between        multimerization domain and MHC complex is in both cases        generated during the translation of the fusion protein.    -   Example artificial reactive groups include reactive groups that        are attached to the multimerization domain or MHC complex,        through association of a linker molecule comprising the reactive        group. The activation of dextran by reaction of the dextran        hydroxyls with divinyl sulfone, introduces a reactive vinyl        group that can react with e.g. amines of the MHC complex, to        form an amine that now links the multimerization domain (the        dextran polymer) and the MHC complex. An alternative activation        of the dextran multimerization domain involves a multistep        reaction that results in the decoration of the dextran with        maleimide groups, as described in the patent Siiman et al. U.S.        Pat. No. 6,387,622. In this approach, the amino groups of MHC        complexes are converted to —SH groups, capable of reacting with        the maleimide groups of the activated dextran. Thus, in the        latter example, both the reactive group of the multimerization        domain (the maleimide) and the reactive group of the MHC complex        (the thiol) are artificially introduced.    -   Sometimes activating reagents are used in order to make the        reactive groups more reactive. For example, acids such as        glutamate or aspartate can be converted to activated esters by        addition of e.g. carbodiimid and NHS or nitrophenol, or by        converting the acid moiety to a tosyl-activated ester. The        activated ester reacts efficiently with a nucleophile such as        —NH₂, —SH, —OH, etc.    -   For the purpose of this invention, the multimerization domains        (including small organic scaffold molecules, proteins, protein        complexes, polymers, beads, liposomes, micelles, cells) that        form a covalent bond with the MHC complexes can be divided into        separate groups, depending on the nature of the reactive group        that the multimerization domain contains. One group comprise        multimerization domains that carry nucleophilic groups (e.g.        —NH₂, —OH, —SH, —CN, —NH—NH₂), exemplified by polysaccharides,        polypeptides containing e.g. lysine, serine, and cysteine;        another group of multimerization domains carry electrophilic        groups (e.g. —COOH, —CHO, —CO, NHS-ester, tosyl-activated ester,        and other activated esters, acid-anhydrides), exemplified by        polypeptides containing e.g. glutamate and aspartate, or vinyl        sulfone activated dextran; yet another group of multimerization        domains carry radicals or conjugated double bonds.    -   The multimerization domains appropriate for this invention thus        include those that contain any of the reactive groups shown in        FIG. 5 or that can react with other reactive groups to form the        bonds shown in FIG. 5.    -   Likewise, MHC complexes can be divided into separate groups,        depending on the nature of the reactive group comprised within        the MHC complex. One group comprise MHCs that carry nucleophilic        groups (e.g. —NH₂, —OH, —SH, —CN, —NH—NH₂), e.g. lysine, serine,        and cysteine; another group of MHCs carry electrophilic groups        (e.g. —COOH, —CHO, —CO, NHS-ester, tosyl-activated ester, and        other activated esters, acid-anhydrides), exemplified by e.g.        glutamate and aspartate; yet another group of MHCs carry        radicals or conjugated double bonds.    -   The reactive groups of the MHC complex are either carried by the        amino acids of the MHC-peptide complex (and may be comprised by        any of the peptides of the MHC-peptide complex, including the        antigenic peptide), or alternatively, the reactive group of the        MHC complex has been introduced by covalent or non-covalent        attachment of a molecule containing the appropriate reactive        group.    -   Preferred reactive groups in this regard include —CSO₂OH,        phenylchloride, —SH, —SS, aldehydes, hydroxyls, isocyanate,        thiols, amines, esters, thioesters, carboxylic acids, triple        bonds, double bonds, ethers, acid chlorides, phosphates,        imidazoles, halogenated aromatic rings, any precursors thereof,        or any protected reactive groups, and many others. Example pairs        of reactive groups, and the resulting bonds formed, are shown in        FIG. 5.    -   Reactions that may be employed include acylation (formation of        amide, pyrazolone, isoxazolone, pyrimidine, comarine,        quinolinon, phthalhydrazide, diketopiperazine, benzodiazepinone,        and hydantoin), alkylation, vinylation, disulfide formation,        Wittig reaction, Horner-Wittig-Emmans reaction, arylation        (formation of biaryl or vinylarene), condensation reactions,        cycloadditions ((2+4), (3+2)), addition to carbon-carbon        multiplebonds, cycloaddition to multiple bonds, addition to        carbon-hetero multiple bonds, nucleophilic aromatic        substitution, transition metal catalyzed reactions, and may        involve formation of ethers, thioethers, secondary amines,        tertiary amines, beta-hydroxy ethers, beta-hydroxy thioethers,        beta-hydroxy amines, beta-amino ethers, amides, thioamides,        oximes, sulfonamides, di- and tri-functional compounds,        substituted aromatic compounds, vinyl substituted aromatic        compounds, alkyn substituted aromatic compounds, biaryl        compounds, hydrazines, hydroxylamine ethers, substituted        cycloalkenes, substituted cyclodienes, substituted 1, 2, 3        triazoles, substituted cycloalkenes, beta-hydroxy ketones,        beta-hydroxy aldehydes, vinyl ketones, vinyl aldehydes,        substituted alkenes, substituted alkenes, substituted amines,        and many others.    -   MHC dextramers can be made by covalent coupling of MHC complexes        to the dextran backbone, e.g. by chemical coupling of MHC        complexes to dextran backbones. The MHC complexes can be coupled        through either heavy chain or β2-microglobulin if the MHC        complexes are MHC I or through α-chain or β-chain if the MHC        complexes are MHC II. MHC complexes can be coupled as folded        complexes comprising heavy chain/beta2microglobulin or        α-chain/β-chain or either combination together with peptide in        the peptide-binding cleft. Alternatively either of the protein        chains can be coupled to dextran and then folded in vitro        together with the other chain of the MHC complex not coupled to        dextran and together with peptide. Direct coupling of MHC        complexes to dextran multimerization domain can be via an amino        group or via a sulphide group. Either group can be a natural        component of the MHC complex or attached to the MHC complex        chemically. Alternatively, a cysteine may be introduced into the        genes of either chain of the MHC complex.    -   Another way to covalently link MHC complexes to dextran        multimerization domains is to use the antigenic peptide as a        linker between MHC and dextran. Linker containing antigenic        peptide at one end is coupled to dextran. Antigenic peptide here        means a peptide able to bind MHC complexes in the        peptide-binding cleft. As an example, 10 or more antigenic        peptides may be coupled to one dextran molecule. When MHC        complexes are added to such peptide-dextran construct the MHC        complexes will bind the antigenic peptides and thereby        MHC-peptide complexes are displayed around the dextran        multimerization domain. The antigenic peptides can be identical        or different from each other. Similarly MHC complexes can be        either identical or different from each other as long as they        are capable of binding one or more of the peptides on the        dextran multimerization domain.    -   Non-covalent linker. The linker that connects the        multimerization domain and the MHC complex comprises an XY        portion. Above different kinds of covalent linkages XY were        described. However, the XY linkage can also be non-covalent.    -   Non-covalent XY linkages can comprise natural dimerization pairs        such as antigen-antibody pairs, DNA-DNA interactions, or can        include natural interactions between small molecules and        proteins, e.g. between biotin and streptavidin. Artificial XY        examples include XY pairs such as His₆ tag (X) interacting with        Ni-NTA (Y) and PNA-PNA interactions.    -   Protein-protein interactions. The non-covalent linker may        comprise a complex of two or more polypeptides or proteins, held        together by non-covalent interactions. Example polypeptides and        proteins belonging to this group include Fos/Jun, Acid/Base        coiled coil structure, antibody/antigen (where the antigen is a        peptide), and many others.    -   A preferred embodiment involving non-covalent interactions        between polypeptides and/or proteins are represented by the        Pentamer structure described in US patent 2004209295.

Another preferred embodiment involves the use of antibodies, withaffinity for the surface of MHC opposite to the peptide-binding groove.Thus, an anti-MHC antibody, with its two binding site, will bind two MHCcomplexes and in this way generate a bivalent MHC multimer. In addition,the antibody can stabilize the MHC complex through the bindinginteractions. This is particularly relevant for MHC class II complexes,as these are less stable than class I MHC complexes.

-   -   Polynucleotide-polynucleotide interactions. The non-covalent        linker may comprise nucleotides that interact non-covalently.        Example interactions include PNA/PNA, DNA/DNA, RNA/RNA, LNA/DNA,        and any other nucleic acid duplex structure, and any combination        of such natural and unnatural polynucleotides such as DNA/PNA,        RNA/DNA, and PNA/LNA.    -   Protein-small molecule interactions. The non-covalent linker may        comprise a macromolecule (e.g. protein, polynucleotide) and a        small molecule ligand of the macromolecule. The interaction may        be natural (i.e., found in Nature, such as the        Streptavidin/biotin interaction) or non-natural (e.g. His-tag        peptide/Ni-NTA interaction). Example interactions include        Streptavidin/biotin and anti-biotin antibody/biotin.    -   Combinations—non-covalent linker molecules. Other combinations        of proteins, polynucleotides, small organic molecules, and other        molecules, may be used to link the MHC to the multimerization        domain. These other combinations include protein-DNA        interactions (e.g. DNA binding protein such as the gene        regulatory protein CRP interacting with its DNA recognition        sequence), RNA aptamer-protein interactions (e.g. RNA aptamer        specific for growth hormone interacting with growth hormone)    -   Synthetic molecule-synthetic molecule interaction. The        non-covalent linker may comprise a complex of two or more        organic molecules, held together by non-covalent interactions.        Example interactions are two chelate molecules binding to the        same metal ion (e.g. EDTA-Ni⁺⁺-NTA), or a short polyhistidine        peptide (e.g. His₆) bound to NTA-Ni⁺⁺.

In another preferred embodiment the multimerization domain is a bead.The bead is covalently or non-covalently coated with MHC multimers orsingle MHC complexes, through non-cleavable or cleavable linkers. As anexample, the bead can be coated with streptavidin monomers, which inturn are associated with biotinylated MHC complexes; or the bead can becoated with streptavidin tetramers, each of which are associated with 0,1, 2, 3, or 4 biotinylated MHC complexes; or the bead can be coated withMHC-dextramers where e.g. the reactive groups of the MHC-dextramer (e.g.the divinyl sulfone-activated dextran backbone) has reacted withnucleophilic groups on the bead, to form a covalent linkage between thedextran of the dextramer and the beads.

In another preferred embodiment, the MHC multimers described above (e.g.where the multimerization domain is a bead) further contains a flexibleor rigid, and water soluble, linker that allows for the immobilized MHCcomplexes to interact efficiently with cells, such as T-cells withaffinity for the MHC complexes. In yet another embodiment, the linker iscleavable, allowing for release of the MHC complexes from the bead. IfT-cells have been immobilized, by binding to the MHC complexes, theT-cells can very gently be released by cleavage of this cleavable linkerAppropriate cleavable linkers are shown in FIG. 6. Most preferably, thelinker is cleaved at physiological conditions, allowing for theintegrity of the isolated cells.

Further examples of linker molecules that may be employed in the presentinvention include Calmodulin-binding peptide (CBP), 6×HIS, Protein A,Protein G, biotin, Avidine, Streptavidine, Strep-tag, Cellulose BindingDomain, Maltose Binding Protein, S-Peptide Tag, Chitin Binding Tag,Immuno-reactive Epitopes, Epitope Tags, GST tagged proteins, E2Tag, HAEpitope Tag, Myc Epitope, FLAG Epitope, AU1 and AU5 Epitopes, Glu-GluEpitope, KT3 Epitope, IRS Epitope, Btag Epitope, Protein Kinase-CEpitope, VSV Epitope.

The list of dimerization- and multimerization domains, describedelsewhere in this document, define alternative non-covalent linkersbetween the multimerization domain and the MHC complex.

The abovementioned dimerization- and multimerization domains representspecific binding interactions. Another type of non-covalent interactionsinvolves the non-specific adsorption of e.g. proteins onto surfaces. Asan example, the non-covalent adsorption of proteins onto glass beadsrepresents this class of XY interactions. Likewise, the interaction ofMHC complexes (comprising full-length polypeptide chains, including thetransmembrane portion) with the cell membrane of for example dendriticcells is an example of a non-covalent, primarily non-specific XYinteraction.

In some of the abovementioned embodiments, several multimerizationdomains (e.g. streptavidin tetramers bound to biotinylated MHCcomplexes) are linked to another multimerization domain (e.g. the bead).For the purpose of this invention we shall call both the smaller and thebigger multimerization domain, as well as the combined multimerizationdomain, for multimerization domain

Additional Features of Product

Additional components may be coupled to carrier or added as individualcomponents not coupled to carrier

Attachment of Biologically Active Molecules to MHC Multimers

Engagement of MHC complex to the specific T cell receptor leads to asignaling cascade in the T cell. However, T-cells normally respond to asingle signal stimulus by going into apoptosis. T cells needs a secondsignal in order to become activated and start development into aspecific activation state e.g. become an active cytotoxic T cell, helperT cell or regulatory T cell.

It is to be understood that the MHC multimer of the invention mayfurther comprise one or more additional substituents. The definition ofthe terms “one or more”, “a plurality”, “a”, “an”, and “the” also applyhere. Such biologically active molecules may be attached to theconstruct in order to affect the characteristics of the constructs, e.g.with respect to binding properties, effects, MHC molecule specificities,solubility, stability, or detectability. For instance, spacing could beprovided between the MHC complexes, one or both chromophores of aFluorescence Resonance Energy Transfer (FRET) donor/acceptor pair couldbe inserted, functional groups could be attached, or groups having abiological activity could be attached.

MHC multimers can be covalently or non-covalently associated withvarious molecules: having adjuvant effects; being immune targets e.g.antigens; having biological activity e.g. enzymes, regulators ofreceptor activity, receptor ligands, immune potentiators, drugs, toxins,co-receptors, proteins and peptides in general; sugar moieties; lipidgroups; nucleic acids including siRNA; nano particles; small molecules.In the following these molecules are collectively called biologicallyactive molecules. Such molecules can be attached to the MHC multimerusing the same principles as those described for attachment of MHCcomplexes to multimerisation domains as described elsewhere herein. Inbrief, attachment can be done by chemical reactions between reactivegroups on the biologically active molecule and reactive groups of themultimerisation domain and/or between reactive groups on thebiologically active molecule and reactive groups of the MHC-peptidecomplex. Alternatively, attachment is done by non-covalent interactionbetween part of the multimerisation domain and part of the biologicalactive molecule or between part of the MHC-peptide complex and part ofthe biological active molecule. In both covalent and non-covalentattachment of the biologically molecule to the multimerisation domain alinker molecule can connect the two. The linker molecule can be covalentor non-covalent attached to both molecules. Examples of linker moleculesare described elsewhere herein. Some of the MHCmer structures betterallows these kind of modifications than others.

Biological active molecules can be attached repetitively aiding torecognition by and stimulation of the innate immune system via Toll orother receptors.

MHC multimers carrying one or more additional groups can be used astherapeutic or vaccine reagents.

In particular, the biologically active molecule may be selected from

proteins such as MHC Class I-like proteins like MIC A, MIC B, CD1d, HLAE, HLA F, HLA G, HLA H, ULBP-1, ULBP-2, and ULBP-3,co-stimulatory molecules such as CD2, CD3, CD4, CD5, CD8, CD9, CD27,CD28, CD30, CD69, CD134 (OX40), CD137 (4-1BB), CD147, CDw150 (SLAM),CD152 (CTLA-4), CD153 (CD30L), CD40L (CD154), NKG2D, ICOS, HVEM, HLAClass II, PD-1, Fas (CD95), FasL expressed on T and/or NK cells, CD40,CD48, CD58, CD70, CD72, B7.1 (CD80), B7.2 (CD86), B7RP-1, B7-H3, PD-L1,PD-L2, CD134L, CD137L, ICOSL, LIGHT expressed on APC and/or tumourcells,cell modulating molecules such as CD16, NKp30, NKp44, NKp46, NKp80, 2B4,KIR, LIR, CD94/NKG2A, CD94/NKG2C expressed on NK cells, IFN-alpha,IFN-beta, IFN-gamma, IL-1, IL-2, IL-3, IL-4, IL-6, IL-7, IL-8, IL-10,IL-11, IL-12, IL-15, CSFs (colony-stimulating factors), vitamin D3, IL-2toxins, cyclosporin, FK-506, rapamycin, TGF-beta, clotrimazole,nitrendipine, and charybdotoxin,accessory molecules such as LFA-1, CD11a/18, CD54 (ICAM-1), CD106(VCAM), and CD49a,b,c,d,e,f/CD29 (VLA-4),adhesion molecules such as ICAM-1, ICAM-2, GlyCAM-1, CD34, anti-LFA-1,anti-CD44, anti-beta7, chemokines, CXCR4, CCR5, anti-selectin L,anti-selectin E, and anti-selectin P,toxic molecules selected from toxins, enzymes, antibodies,radioisotopes, chemiluminescent substances, bioluminescent substances,polymers, metal particles, and haptens, such as cyclo-phosphamide,methrotrexate, Azathioprine, mizoribine, 15-deoxuspergualin, neomycin,staurosporine, genestein, herbimycin A, Pseudomonas exotoxin A, saporin,Rituxan, Ricin, gemtuzumab ozogamicin, Shiga toxin, heavy metals likeinorganic and organic mercurials, and FN18-CRM9, radioisotopes such asincorporated isotopes of iodide, cobalt, selenium, tritium, andphosphor, and haptens such as DNP, and digoxiginin,and combinations of any of the foregoing, as well as antibodies(monoclonal, polyclonal, and recombinant) to the foregoing, whererelevant. Antibody derivatives or fragments thereof may also be used.

Design and Generation of Product to be Used for Immune Monitoring,Diagnosis, Therapy or Vaccination

The product of the present invention may be used for immune monitoring,diagnosis, therapy and/or vaccination. Generation of a useful productincludes the following basic steps:

-   -   1. Design of antigenic peptides    -   2. Choice of MHC allele    -   3. Generation of product    -   4. Validation and optimization of product

In the following strategies for generation of products are given:

How to Make a MHC Multimer Diagnostic or Immune Monitoring Reagent

-   -   1. Identify disease of interest. Most relevant diseases in this        regard are infectious-, cancer-, auto immune-, transplantation-,        or immuno-suppression-related diseases.    -   2. Identify relevant protein targets. This may be individual        proteins, a group of proteins from a given tissue or all or        subgroups of proteins from a complete organism.    -   3. Identify the protein sequence. Amino acid sequences can be        directly found in databases or deduced from gene- or mRNA        sequence e.g. using the following link        http://www.ncbi.nlm.nih.gov/Genbank/index.html. If not in        databases relevant proteins or genes encoding relevant proteins        may be isolated and sequenced. In some cases only DNA sequences        will be available without knowing which part of the sequence is        protein coding. Then DNA sequence is translated into amino acid        sequence in all reading frames.    -   4. Choose MHC allele. Decide on needed MHC allele population        coverage. If a broad coverage of a given population is needed        (i.e. when a generally applicable reagent is sought) the most        frequently expressed MHC alleles by the population of interest        may be chosen e.g. using the database        http://www.allelefrequencies.net/test/default1.asp or        http://epitope.liai.org:8080/tools/population/iedb_input.        -   In case of personalized medicine the patient is tissue typed            (HLA type) and then MHC alleles may be selected according to            that.    -   5. Run the general peptide epitope generator program described        elsewhere herein on all selected amino acid sequences from step        3, thereby generating all possible epitopes of defined length        (8, 9, 10 and/or 11′mers). This procedure is particularly useful        when the amino acid sequence is derived from a DNA sequence not        knowing the protein encoding areas.    -   6. If searching for broadly applicable epitope sequences, a good        alternative to step 5 is to run the “intelligent” peptide        epitope prediction programs on the selected amino acid sequences        of step 3 using the selected MHC alleles from step 4 e.g. using        epitope prediction programs like http://www.syfpeithi.de/,        http://www.cbs.dtu.dk/services/NetMHC/, and        http://www.cbs.dtu.dk/services/NetMHCII/.        -   This step can also be used supplementary to step 5 by            running selected or all epitopes from the general peptide            epitope generator program through one or more of the            intelligent peptide epitope prediction programs.    -   7. If searching for broadly applicable epitope sequences, select        the best peptide epitopes (the epitopes with highest binding        score) for the chosen MHC alleles and run them through the BLAST        program (http://www.ncbi.nlm.nih.gov/blast/Blast.cgi) to        validate the uniqueness of the peptides. If the peptide        sequences are present in other species, evaluate the potential        risk of disease states caused by the non-relevant species in        relation to causing false positive results. If considered being        a potential problem for evaluating the future analysis outcome,        leave out the peptide. In general, favour unique peptide        sequences only present in the selected protein.    -   8. Make selected peptides as described elsewhere herein, and        optionally test for binding to the desired MHC alleles by e.g in        vitro folding, peptide exchange of already preloaded MHC        complexes or another method able to test of peptide binding to        MHC I or II molecules.    -   9. Generate desired MHC multimer as described elsewhere herein        and test efficacy in detecting specific T-cells using methods        described in the section “Detection”.        -   The MHC multimer reagents may be used in a diagnostic            procedure or kit for testing patient and control samples            e.g. by flow cytometry, immune histochemistry, Elispot or            other methods as described herein.

How to Make a MHC Multimer Therapeutic Reagent

-   -   1. As step 1-8 above for diagnostic reagent.    -   9. Select additional molecules (e.g. biologically active        molecules, toxins) to attach to the MHC multimer as described        elsewhere herein. The additional molecules can have different        functionalities as e.g. adjuvants, specific activators, toxins        etc.    -   10. Test the therapeutic reagent following general guidelines    -   11. Use for therapy

Processes Involving MHC Multimers

Thus, the present invention relates to methods for detecting thepresence of MHC recognising cells in a sample comprising the steps of

(a) providing a sample suspected of comprising MHC recognising cells,(b) contacting the sample with a MHC multimer as defined above, and(c) determining any binding of the MHC multimer, which binding indicatesthe presence of MHC recognising cells.

Such methods are a powerful tool in diagnosing various diseases.Establishing a diagnosis is important in several ways. A diagnosis givesinformation about the disease, thus the patient can be offered asuitable treatment regime. Also, establishing a more specific diagnosismay give important information about a subtype of a disease for which aparticular treatment will be beneficial (i.e. various subtypes ofdiseases may involve display of different peptides which are recognisedby MHC recognising cells, and thus treatment can be targeted effectivelyagainst a particular subtype). In this way, it may also be possible togain information about aberrant cells, which emerge through the progressof the disease or condition, or to investigate whether and how T-cellspecificity is affected. The binding of the MHC multimer makes possiblethese options, since the binding is indicative for the presence of theMHC recognising cells in the sample, and accordingly the presence of MHCmultimeres displaying the peptide.

The present invention also relates to methods for monitoring MHCrecognising cells comprising the steps of

(a) providing a sample suspected of comprising MHC recognising cells,(b) contacting the sample with a MHC complex as defined above, and(c) determining any binding of the MHC multimer, thereby monitoring MHCrecognising cells.

Such methods are a powerful tool in monitoring the progress of adisease, e.g. to closely follow the effect of a treatment. The methodcan i.a. be used to manage or control the disease in a better way, toensure the patient receives the optimum treatment regime, to adjust thetreatment, to confirm remission or recurrence, and to ensure the patientis not treated with a medicament which does not cure or alleviate thedisease. In this way, it may also be possible to monitor aberrant cells,which emerge through the progress of the disease or condition, or toinvestigate whether and how T-cell specificity is affected duringtreatment. The binding of the MHC multimer makes possible these options,since the binding is indicative for the presence of the MHC recognisingcells in the sample, and accordingly the presence of MHC multimersdisplaying the peptide.

The present invention also relates to methods for establishing aprognosis of a disease involving MHC recognising cells comprising thesteps of

(a) providing a sample suspected of comprising MHC recognising cells,(b) contacting the sample with a MHC multimer as defined above, and(c) determining any binding of the MHC multimer, thereby establishing aprognosis of a disease involving MHC recognising cells.

Such methods are a valuable tool in order to manage diseases, i.a. toensure the patient is not treated without effect, to ensure the diseaseis treated in the optimum way, and to predict the chances of survival orcure. In this way, it may also be possible to gain information aboutaberrant cells, which emerge through the progress of the disease orcondition, or to investigate whether and how T-cell specificity isaffected, thereby being able to establish a prognosis. The binding ofthe MHC multimer makes possible these options, since the binding isindicative for the presence of the MHC recognising cells in the sample,and accordingly the presence of MHC complexs displaying the peptide.

The present invention also relates to methods for determining the statusof a disease involving MHC recognising cells comprising the steps of

(a) providing a sample suspected of comprising MHC recognising cells,(b) contacting the sample with a MHC complex as defined above, and(c) determining any binding of the MHC complex, thereby determining thestatus of a disease involving MHC recognising cells.

Such methods are a valuable tool in managing and controlling variousdiseases. A disease could, e.g. change from one stage to another, andthus it is important to be able to determine the disease status. In thisway, it may also be possible to gain information about aberrant cellswhich emerge through the progress of the disease or condition, or toinvestigate whether and how T-cell specificity is affected, therebydetermining the status of a disease or condition. The binding of the MHCcomplex makes possible these options, since the binding is indicativefor the presence of the MHC recognising cells in the sample, andaccordingly the presence of MHC complexs displaying the peptide.

The present invention also relates to methods for the diagnosis of adisease involving MHC recognising cells comprising the steps of

(a) providing a sample suspected of comprising MHC recognising cells,(b) contacting the sample with a MHC multimer as defined above, and(c) determining any binding of the MHC multimer, thereby diagnosing adisease involving MHC recognising cells.

Such diagnostic methods are a powerful tool in the diagnosis of variousdiseases. Establishing a diagnosis is important in several ways. Adiagnosis gives information about the disease, thus the patient can beoffered a suitable treatment regime. Also, establishing a more specificdiagnosis may give important information about a subtype of a diseasefor which a particular treatment will be beneficial (i.e. varioussubtypes of diseases may involve display of different peptides which arerecognised by MHC recognising cells, and thus treatment can be targetedeffectively against a particular subtype). Valuable information may alsobe obtained about aberrant cells emerging through the progress of thedisease or condition as well as whether and how T-cell specificity isaffected. The binding of the MHC multimer makes possible these options,since the binding is indicative for the presence of the MHC recognisingcells in the sample, and accordingly the presence of MHC multimersdisplaying the peptide.

The present invention also relates to methods of correlating cellularmorphology with the presence of MHC recognising cells in a samplecomprising the steps of

(a) providing a sample suspected of comprising MHC recognising cells,(b) contacting the sample with a MHC multimer as defined above, and(c) determining any binding of the MHC multimer, thereby correlating thebinding of the MHC multimer with the cellular morphology.

Such methods are especially valuable as applied in the field ofhistochemical methods, as the binding pattern and distribution of theMHC multimeres can be observed directly. In such methods, the sample istreated so as to preserve the morphology of the individual cells of thesample. The information gained is important i.a. in diagnosticprocedures as sites affected can be observed directly.

The present invention also relates to methods for determining theeffectiveness of a medicament against a disease involving MHCrecognising cells comprising the steps of

(a) providing a sample from a subject receiving treatment with amedicament,(b) contacting the sample with a as defined herein, and(c) determining any binding of the MHC multimer, thereby determining theeffectiveness of the medicament.

Such methods are a valuable tool in several ways. The methods may beused to determine whether a treatment is effectively combating thedisease. The method may also provide information about aberrant cellswhich emerge through the progress of the disease or condition as well aswhether and how T-cell specificity is affected, thereby providinginformation of the effectiveness of a medicament in question. Thebinding of the MHC multimer makes possible these options, since thebinding is indicative for the presence of the MHC recognising cells inthe sample, and accordingly the presence of MHC multimeres displayingthe peptide.

The present invention also relates to methods for manipulating MHCrecognising cells populations comprising the steps of

(a) providing a sample comprising MHC recognising cells,(b) contacting the sample with a MHC multimer immobilised onto a solidsupport as defined above,(c) isolating the relevant MHC recognising cells, and(d) expanding such cells to a clinically relevant number, with orwithout further manipulation.

Such ex vivo methods are a powerful tool to generate antigen-specific,long-lived human effector T-cell populations that, when re-introduced tothe subject, enable killing of target cells and has a great potentialfor use in immunotherapy applications against various types of cancerand infectious diseases.

As used everywhere herein, the term “MHC recognising cells” are intendedto mean such which are able to recognise and bind to MHC multimeres. Theintended meaning of “MHC multimeres” is given above. Such MHCrecognising cells may also be called MHC recognising cell clones, targetcells, target MHC recognising cells, target MHC molecule recognisingcells, MHC molecule receptors, MHC receptors, MHC peptide specificreceptors, or peptide-specific cells. The term “MHC recognising cells”is intended to include all subsets of normal, abnormal and defect cells,which recognise and bind to the MHC molecule. Actually, it is thereceptor on the MHC recognising cell that binds to the MHC molecule.

As described above, in diseases and various conditions, peptides aredisplayed by means of MHC multimeres, which are recognised by the immunesystem, and cells targeting such MHC multimeres are produced (MHCrecognising cells). Thus, the presence of such MHC protein recognisingcells is a direct indication of the presence of MHC multimeresdisplaying the peptides recognised by the MHC protein recognising cells.The peptides displayed are indicative and may involved in variousdiseases and conditions.

For instance, such MHC recognising cells may be involved in diseases ofinflammatory, auto-immune, allergic, viral, cancerous, infectious, allo-or xenogene (graft versus host and host versus graft) origin.

The MHC multimeres of the present invention have numerous uses and are avaluable and powerful tool e.g. in the fields of therapy, diagnosis,prognosis, monitoring, stratification, and determining the status ofdiseases or conditions. Thus, the MHC multimeres may be applied in thevarious methods involving the detection of MHC recognising cells.

Furthermore, the present invention relates to compositions comprisingthe MHC multimeres in a solubilising medium. The present invention alsorelates to compositions comprising the MHC multimeres immobilised onto asolid or semi-solid support.

The MHC multimers can be used in a number of applications, includinganalyses such as flow cytometry, immunohistochemistry (IHC), andELISA-like analyses, and can be used for diagnostic, prognostic ortherapeutic purposes including autologous cancer therapy or vaccinessuch as HIV vaccine or cancer vaccine.

The MHC multimeres are very suitable as detection systems. Thus, thepresent invention relates to the use of the MHC multimeres as definedherein as detection systems.

In another aspect, the present invention relates to the general use ofMHC peptide complexes and multimers of such MHC peptide complexes invarious methods. These methods include therapeutic methods, diagnosticmethods, prognostic methods, methods for determining the progress andstatus of a disease or condition, and methods for the stratification ofa patient.

The MHC multimeres of the present invention are also of value in testingthe expected efficacy of medicaments against or for the treatment ofvarious diseases. Thus, the present invention relates to methods oftesting the effect of medicaments or treatments, the methods comprisingdetecting the binding of the MHC multimeres to MHC recognising cells andestablishing the effectiveness of the medicament or the treatment inquestion based on the specificity of the MHC recognising cells.

As mentioned above, the present invention also relates generally to thefield of therapy. Thus, the present invention relates per se to the MHCmultimer as defined herein for use as medicaments, and to the MHCmultimeres for use in in vivo and ex vivo therapy.

The present invention relates to therapeutic compositions comprising asactive ingredients the MHC multimeres as defined herein.

An important aspect of the present invention is therapeutic compositionscomprising as active ingredients effective amounts of MHC recognisingcells obtained using the MHC multimeres as defined herein to isolaterelevant MHC recognising cells, and expanding such cells to a clinicallyrelevant number.

The present invention further relates to methods for treating,preventing or alleviating diseases, methods for inducing anergy ofcells, as well as to methods for up-regulating, down-regulating,modulating, stimulating, inhibiting, restoring, enhancing and/orotherwise manipulating immune responses.

The invention also relates to methods for obtaining MHC recognisingcells by using the MHC multimeres as described herein.

Also encompassed by the present invention are methods for preparing thetherapeutic compositions of the invention.

The present invention is also directed to generating MHC multimeres fordetecting and analysing receptors on MHC recognising cells, such asepitope specific T-cell clones or other immune competent effector cells.

It is a further object of the present invention to provide new andpowerful strategies for the development of curative vaccines. This inturn will improve the possibilities for directed and efficient immunemanipulations against diseases caused by tumour genesis or infection bypathogenic agent like viruses and bacteria. HIV is an important example.The ability to generate and optionally attach recombinant MHC multimeresto multimerization domains, such as scaffolds and/or carrier molecules,will enable the development of a novel analytical and therapeutical toolfor monitoring immune responses and contribute to a rational platformfor novel therapy and “vaccine” applications.

Therapeutic compositions (e.g. “therapeutical vaccines”) that stimulatespecific T-cell proliferation by peptide-specific stimulation is indeeda possibility within the present invention. Thus, quantitative analysisand ligand-based detection of specific T-cells that proliferate by thepeptide specific stimulation should be performed simultaneously tomonitoring the generated response.

For all of those applications, it is important to choose the right MHCallele as well as a peptide that binds well to the MHC protein. It isalso important that the chosen MHC allele and peptide forms aMHC-peptide complex that is efficiently and specifically recognized bythe TCR. For applications that involve binding as well as activation ofcells, further restrictions on the choice of MHC and peptide can apply.

Application of MHC Multimers in Immune Monitoring, Diagnostics, Therapy,Vaccine

MHC multimers detect antigen specific T cells of the various T cellsubsets. T cells are pivotal for mounting an adaptive immune response.It is therefore of importance to be able to measure the number ofspecific T cells when performing a monitoring of a given immuneresponse. Typically, the adaptive immune response is monitored bymeasuring the specific antibody response, which is only one of theeffector arms of the immune system. This can lead to miss-interpretationof the actual clinical immune status.

In many cases intruders of the organism can hide away inside the cells,which can not provoke a humoral response. In other cases, e.g. in thecase of certain viruses the intruder mutates fast, particularly in thegenes encoding the proteins that are targets for the humoral response.Examples include the influenza and HIV viruses. The high rate ofmutagenesis renders the humoral response unable to cope with theinfection. In these cases the immune system relies on the cellularimmune response. When developing vaccines against such targets one needsto provoke the cellular response in order to get an efficient vaccine.

Developing vaccines that should give rise to lifelong protection isanother case where the cellular immune system needs to be activated.Commonly, various childhood vaccines are expected to give lifelongprotection but will only come to trial many years after the vaccinationhas been performed and then there is only to hope that it actually havecreated effective immunity.

Therapeutically cancer vaccines generally rely on cytotoxic effector Tcells and have short duration of function. Therefore, continuousmonitoring is important.

MHC multimers are therefore very important for immune monitoring ofvaccine responses both during vaccine development, as a means to verifythe obtained immunity for lifelong vaccines and to follow cancerpatients under treatment with therapeutically cancer vaccines.

The number of antigen specific cytotoxic T cells can be used assurrogate markers for the overall wellness of the immune system. Theimmune system can be compromised severely by natural causes such as HIVinfections or big traumas or by immuno suppressive therapy in relationto transplantation. The efficacy of an anti HIV treatment can beevaluated by studying the number of common antigen-specific cytotoxic Tcells, specific against for example Cytomegalovirus (CMV) andEpstein-Barr virus. In this case the measured T cells can be conceivedas surrogate markers. The treatment can then be corrected accordinglyand a prognosis can be made.

A similar situation is found for patients undergoing transplantation asthey are severely immune compromised due to pharmaceutical immunesuppression to avoid organ rejection. The suppression can lead tooutbreak of opportunistic infections caused by reactivation of otherwisedormant viruses residing in the transplanted patients or the grafts.This can be the case for CMV and EBV viruses. Therefore measurement ofthe number of virus specific T cells can be used to give a prognosis forthe outcome of the transplantation and adjustment of the immunesuppressive treatment. Similarly, the BK virus has been implied as acausative reagent for kidney rejection. Therefore measurement ofBK-virus specific T cells can have prognostic value.

In relation to transplantation, the presence of specific T cellsdirected against minor histocompatibility antigens (mHAgs) are importantas they can cause graft versus host reaction/disease that can develop toa fatal situation for the patient. Again, a well-adjusted immunesuppressive treatment is important. A similar reaction denoted graftversus cancer is sometimes employed in the treatment of malignancies ofthe lymphoid system. It is evident that such treatment is balancing onthe edge of a knife and will benefit of specific measurement of relevanteffector T cells.

Due to lack of organs, transplantations across greater mismatches areincreasingly making harsher immune suppressive treatment more common.This calls for more efficient methods to monitor the immune status ofthe patient so that corrective measures in the treatment can be appliedin due cause.

MHC multimers can be of importance in diagnosis of infections caused bybacteria, virus and parasites that hide away inside cells. Serum titerscan be very low and direct measurement of the disease-causing organismsby PCR can be very difficult because the host cells are not identifiedor are inaccessible. Other clinical symptoms of a chronical infectioncan be unrecognizable in an otherwise healthy individuals, even thoughsuch persons still are disease-carriers and at risk of becomingspontaneously ill if being compromised by other diseases or stress.Likewise, cancers can also be diagnosed early in its development ifincreased numbers of cancer specific T cells can be measured incirculation, even though the tumor is not yet localized.

Antigen specific tumor infiltrating lymphocytes can be used to identifytumor lesions and metastases as the antigen specific T cells willmigrate/home to the tumor site to exert their help or immuno modulatoryaction (CD4+ T helper cells) or cytotoxic killing of tumor cellsexpressing the tumor specific/tumor associated peptide MHC multimer(CD8+ T-cells). Likewise identification of sites of infection tumorlesions can be identified as they typically attract antigen specificT-cells.

Localization of tumors and sites of infection can be carried out usingantigen specific T-cells labelled with a paramagnetic isotope inconjunction with magnetic resonance imaging (MRI) or electron spinresonance (ESR). In general, any conventional method for diagnosticimaging visualization can be utilized. Usually gamma and positronemitting radioisotopes are used for camera and paramagnetic isotopes forMRI.

For peripheral cancer lesion in skin (e.g. melanoma) fluorescentlylabeled antigen specific T-cells can be used likewise.

MHC multimers may be used to label the tumor infiltration lymphocytes,e.g. MHC multimers may be labeled with a paramagnetic isotope areinjected into the patient, the labeled MHC multimer binds specific Tcells and are then internalized thereby introducing the paragmagneticisotope to the T cell in this way labelling the T cell.

Antigen-specific T helper cells and regulatory T cells have beenimplicated in the development of autoimmune disorders. In most cases thetiming of events leading to autoimmune disease is unknown and the exactrole of the immune cells not clear. Use of MHC multimers to study thesediseases will lead to greater understanding of the disease-causingscenario and make provisions for development of therapies and vaccinesfor these diseases.

Therapeutically use of MHC multimers can be possible, either directly oras part of therapeutically vaccines. When performing autologous cancertherapy it is often recognized that the in vitro amplifiedcancer-specific effector T cells do not home effectively to the correcttarget sites but ends up in the lungs. If the molecules responsible forinteraction with the correct homing receptor can be identified these canbe added to the MHC multimer making a dual, triple or multiple molecularstructure that are able to aid the antigen-specific T cells home to thecorrect target, as the MHC multimer will bind to the specific T cell andthe additional molecules will mediate binding to the target cells.

In a preferable embodiment, MHC multimers bound to other functionalmolecules are employed to directly block, regulate or kill these cells.

When it become possible to identify and pinpoint the exact function ofregulatory T cells it may be possible to directly block, regulate orkill these cells by means of MHCmers bound other functional molecules.The MHC multimeres specifically recognize the target T cells and directthe action of the other molecules to the target.

Derivatives of MHC multimers can be useful as vaccines, as vaccinecomponents or as engineered intelligent adjuvant. The possibility ofcombining MHC multimeres that specifically bind certain T cells withmolecules that trigger, e.g. the humoral response or the innate immuneresponse, can accelerate vaccine development and improve the efficiencyof vaccines.

Diseases

In relation to the use and application of MHCmers in immune monitoring,diagnostics, prognostics, therapy and vaccines in relation to diseasesseveral organisms and human proteins are of relevance, comprising butnot limited to the following;

Infectious Diseases a) Caused by Virus Such as,

Adenovirus (subgropus A-F), BK-virus, CMV (Cytomegalo virus, HHV-5), EBV(Epstein Barr Virus, HHV-4), HBV (Hepatitis B Virus), HCV (Hepatitis Cvirus), HHV-6a and b (Human Herpes Virus-6a and b), HHV-7, HHV-8, HSV-1(Herpes simplex virus-1, HHV-1), HSV-2 (HHV-2), JC-virus, SV-40 (Simianvirus 40), VZV (Varizella-Zoster-Virus, HHV-3), Parvovirus B19,Haemophilus influenza, HIV-1 (Human immunodeficiency Virus-1), HTLV-1(Human T-lymphotrophic virus-1), HPV (Human Papillomavirus giving riseto clinical manifestions such as Hepatitis, AIDS, Measles, Pox, Chickenpox, Rubella, Herpes and others

b) Caused by Bacteria Such as,

Gram positive bacteria, gram negative bacteria, intracellular bacterium,extracellular bacterium, Mycobacterium tuberculosis, Mycobacteriumbovis, Mycobacterium avium subsp. paratuberculosis Borrelia burgdorferi,other spirochetes, Helicobacter pylori, Streptococcus pneumoniae,Listeria monocytogenes, Histoplasma capsulatum, Bartonella henselae,Bartonella quintana giving rise to clinical manifestations such asTuberculosis, Pneumonia, Stomach ulcers, Paratuberculosis and others

c) Caused by Fungus Such as,

Aspergillus fumigatus, Candida albicans, Cryptococcus neoformans,Pneumocystis carinii giving rise to clinical manifestations such asskin-, nail-, and mucosal infections, Meningitis, Sepsis and others

Parasitic Diseases Caused by Parasites Such as,

Plasmodium falciparum, Plasmodium vivax, Plasmodium malariae,Schistosoma mansoni, Schistosoma japonicum, Schistosoma haematobium,Trypanosoma cruzi, Trypanosoma rhodesiense, Trypanosoma gambiense,Leishmania donovani, Leishmania tropica giving rise to clinicalmanifestations such as

Allergic diseases caused by allergens such as,

Birch, Hazel, Elm, Ragweed, Wormwood, Grass, Mould, Dust Mite givingrise to clinical manifestations such as Asthma

Transplantation Related Disease Caused by

reactions to minor histocompatibility antigens such as HA-1, HA-8,USP9Y, SMCY, TPR-protein, HB-1Y and other antigens in relation to,Graft-versus-host-related disease, allo- or xenogene reactions i.e.graft-versus-host and host-versus-graft disease.

Cancerous Diseases Associated with Antigens Such as

Survivin, Survivin-2B, Livin/ML-IAP, Bcl-2, Mcl-1, Bcl-X(L), Mucin-1,NY-ESO-1, Telomerase, CEA, MART-1, HER-2/neu, bcr-abl, PSA, PSCA,Tyrosinase, p53, hTRT, Leukocyte Proteinase-3, hTRT, gp100, MAGEantigens, GASC, JMJD2C, JARD2 (JMJ), JHDM3a, WT-1, CA 9, Proteinkinases, in relation to clinical manifestations such as malignantmelanoma, renal carcinoma, breast cancer, lung cancer, cancer of theuterus, cervical cancer, prostatic cancer, pancreatic cancer, braincancer, head and neck cancer, leukemia, cutaneous lymphoma, hepaticcarcinoma, colorectal cancer, bladder cancer

Autoimmune and Inflammatory Diseases, Associated with Antigens Such as

GAD64, Collagen, human cartilage glycoprotein 39, □-amyloid, A□42, APP,Presenilin 1, in relation to clinical manifestations such as Diabetestype 1, Rheumatoid arthritis, Alzheimer, chronic inflammatory boweldisease, Crohn's disease, ulcerative colitis uterosa, MultipleSclerosis, Psoriasis

Approaches to the Analysis or Treatment of Diseases.

For each application of a MHC multimer, a number of choices must bemade. These include:

-   -   A. Disease (to be e.g. treated, prevented, diagnosed,        monitored).    -   B. Application (e.g. analyze by flow cytometry, isolate specific        cells, induce an immune response)    -   C. Label (e.g. should the MHC multimer be labelled with a        fluorophore or a chromophore)    -   D. Biologically active molecule (e.g. should a biologically        active molecule such as an interleukin be added or chemically        linked to the complex)    -   E. Peptide (e.g. decide on a peptide to be complexed with MHC)    -   F. MHC (e.g. use a MHC allele that does not interfere with the        patient's immune system in an undesired way).

A number of diseases A₁-A_(n), relevant in connection with MHCmultimeres, have been described herein; a number of applicationsB₁-B_(n), relevant in connection with MHC multimeres, have beendescribed herein; a number of Labels C₁-C_(n), relevant in connectionwith MHC multimeres, have been described herein; a number ofbiologically active molecules D₁-D_(n), relevant in connection with MHCmultimeres, have been described herein; a number of peptides E₁-E_(n),relevant in connection with MHC multimeres, have been described herein;and a number of MHC molecules F₁-F_(n), relevant in connection with MHCmultimeres, have been described herein.

Thus, each approach involves a choice to be made regarding all or someof the parameters A-F. A given application and the choices it involvescan thus be described as follows:

Ai×Bi×Ci×Di×Ei×Fi

Where i specifies a number between 1 and n. n is different for differentchoices A, B, C, D, E, or F. Consequently, the present inventiondescribes a large number of approaches to the diagnosis, monitoring,prognosis, therapeutic or vaccine treatment of diseases. The totalnumber of approaches, as defined by these parameters, are

n(A)×n(B)×n(C)×n(D)×n(E)×n(F),

where n(A) describes the number of different diseases A describedherein, n(B) describes the number of different applications B describedherein, etc.

Detection

Diagnostic procedures, immune monitoring and some therapeutic processesall involve identification and/or enumeration and/or isolation ofantigen specific T cells. Identification and enumeration of antigenspecific T cells may be done in a number of ways, and several assays arecurrently employed to provide this information.

In the following it is described how MHC multimers as described in thepresent invention can be used to detect specific T cell receptors (TCRs)and thereby antigen specific T cells in a variety of methods and assays.In the present invention detection includes detection of the presence ofantigen specific T cell receptors/T cells in a sample, detection of andisolation of cells or entities with antigen specific T cell receptorfrom a sample and detection and enrichment of cells or entities withantigen specific T cell receptor in a sample.

The sample may be a biologic sample including solid tissue, solid tissuesection or a fluid such as, but not limited to, whole blood, serum,plasma, nasal secretions, sputum, urine, sweat, saliva, transdermalexudates, pharyngeal exudates, bronchoalveolar lavage, trachealaspirations, cerebrospinal fluid, synovial fluid, fluid from joints,vitreous fluid, vaginal or urethral secretions, or the like. Herein,disaggregated cellular tissues such as, for example, hair, skin,synovial tissue, tissue biopsies and nail scrapings are also consideredas biological samples.

Many of the assays are particularly useful for assaying T-cells in bloodsamples. Blood samples are whole blood samples or blood processed toremove erythrocytes and platelets (e.g., by Ficoll densitycentrifugation or other such methods known to one of skill in the art)and the remaining PBMC sample, which includes the T-cells of interest,as well as B-cells, macrophages and dendritic cells, is used directly.

In order to be able to measure detection of specific T cells by MHCmultimers, labels and marker molecules can be used.

Marker Molecules

Marker molecules are molecules or complexes of molecules that bind toother molecules. Marker molecules thus may bind to molecules onentities, including the desired entities as well as undesired entities.Labeling molecules are molecules that may be detected in a certainanalysis, i.e. the labeling molecules provide a signal detectable by theused method. Marker molecules, linked to labeling molecules, constitutedetection molecules. Likewise labeling molecules linked to MHC multimersalso constitute detection molecules but in contrast to detectionmolecules made up of marker and labeling molecule labeled MHC multimersare specific for TCR.

Sometimes a marker molecule in itself provides a detectable signal,wherefore attachment to a labeling molecule is not necessary.

Marker molecules are typically antibodies or antibody fragments but canalso be aptamers, proteins, peptides, small organic molecules, naturalcompounds (e.g. steroids), non-peptide polymers, or any other moleculesthat specifically and efficiently bind to other molecules are alsomarker molecules.

Labelling Molecules

Labelling molecules are molecules that can be detected in a certainanalysis, i.e. the labelling molecules provide a signal detectable bythe used method. The amount of labelling molecules can be quantified.

The labelling molecule is preferably such which is directly orindirectly detectable.

The labelling molecule may be any labelling molecule suitable for director indirect detection. By the term “direct” is meant that the labellingmolecule can be detected per se without the need for a secondarymolecule, i.e. is a “primary” labelling molecule. By the term “indirect”is meant that the labelling molecule can be detected by using one ormore “secondary” molecules, i.e. the detection is performed by thedetection of the binding of the secondary molecule(s) to the primarymolecule.

The labelling molecule may further be attached via a suitable linker.Linkers suitable for attachment to labelling molecules would be readilyknown by the person skilled in the art and as described elsewhere hereinfor attachment of MHC molecules to multimerisation domains.

Examples of such suitable labelling compounds are fluorescent labels,enzyme labels, radioisotopes, chemiluminescent labels, bioluminescentlabels, polymers, metal particles, haptens, antibodies, and dyes.

The labelling compound may suitably be selected:

from fluorescent labels such as 5-(and 6)-carboxyfluorescein, 5- or6-carboxyfluorescein, 6-(fluorescein)-5-(and 6)-carboxamido hexanoicacid, fluorescein isothiocyanate (FITC), rhodamine,tetramethylrhodamine, and dyes such as Cy2, Cy3, and Cy5, optionallysubstituted coumarin including AMCA, PerCP, phycobiliproteins includingR-phycoerythrin (RPE) and allophycoerythrin (APC), Texas Red, PrincestonRed, Green fluorescent protein (GFP) and analogues thereof, andconjugates of R-phycoerythrin or allophycoerythrin and e.g. Cy5 or TexasRed, and inorganic fluorescent labels based on semiconductornanocrystals (like quantum dot and Qdot™ nanocrystals), andtime-resolved fluorescent labels based on lanthanides like Eu3+ andSm3+,from haptens such as DNP, biotin, and digoxiginin,from enzymic labels such as horse radish peroxidase (HRP), alkalinephosphatase (AP), beta-galactosidase (GAL), glucose-6-phosphatedehydrogenase, beta-N-acetylglucosaminidase, β-glucuronidase, invertase,Xanthine Oxidase, firefly luciferase and glucose oxidase (GO),from luminiscence labels such as luminol, isoluminol, acridinium esters,1,2-dioxetanes and pyridopyridazines, andfrom radioactivity labels such as incorporated isotopes of iodide,cobalt, selenium, tritium, and phosphor.

Radioactive labels may in particular be interesting in connection withlabelling of the peptides harboured by the MHC multimeres.

Different principles of labelling and detection exist, based on thespecific property of the labelling molecule. Examples of different typesof labelling are emission of radioactive radiation (radionuclide,isotopes), absorption of light (e.g. dyes, chromophores), emission oflight after excitation (fluorescence from fluorochromes), NMR (nuclearmagnetic resonance form paramagnetic molecules) and reflection of light(scatter from e.g. such as gold-, plastic- or glass-beads/particles ofvarious sizes and shapes). Alternatively, the labelling molecules canhave an enzymatic activity, by which they catalyze a reaction betweenchemicals in the near environment of the labelling molecules, producinga signal, which include production of light (chemi-luminescence),precipitation of chromophor dyes, or precipitates that can be detectedby an additional layer of detection molecules. The enzymatic product candeposit at the location of the enzyme or, in a cell based analysissystem, react with the membrane of the cell or diffuse into the cell towhich it is attached. Examples of labelling molecules and associateddetection principles are shown in table 2 below.

TABLE 2 Examples of labelling molecules and associated detectionprinciples. Labelling substance Effect Assay-principle Fluorochromesemission of light ^(¤)Photometry, having a Microscopy, specific spectraspectroscopy PMT, photographic film, CCD's (Color- Capture Device orCharge-coupled device). Radionuclide irradiation, α, β Scintillation orgamma rays counting, GM-tube, photographic film, excitation ofphosphor-imager screen Enzyme; catalysis of H₂O₂ ^(¤)Photometry, HRP,(horse reduction using Microscopy, reddish luminol as Oxygenspectroscopy peroxidase), acceptor, resulting PMT, photographicperoxidases in oxidized film, CCD's (Colour- in general luminal + lightCapture Device or catalysis of H₂O₂ Charge-coupled reduction using adevice), soluble dye, or Secondary label molecule containing linkedantibody a hapten, such as a biotin residue as Oxygen acceptor,resulting in precipitation. The habten can be recognized by a detectionmolecule. Particles; gold, Change of scatter, Microscopy, polystyrenereflection and cytometry, beads, pollen and transparency of electronother particles the associated entity microscopy PMT's, light detectingdevices, flowcytometry scatter AP (Alkaline Catalyze a chemical^(¤)Photometry, Phosphatase) conversion of a non- Microscopy, detectableto a spectroscopy precipitated Secondary label detectable linkedantibody molecule, such as a dye or a hapten Ionophores or Change inabsorption ^(¤)Photometry, chelating chemical and emission Cytometry,compounds binding to spectrums when spectroscopy specific ions, e.g.Ca²⁺ binding. Change in intensity Lanthanides Fluorescence^(¤)photometry, Phosphorescence cytometry, spectroscopy Paramagnetic NMR(Nuclear magnetic resonance) DNA fluorescing Propidium iodide^(¤)Photometry, stains Hoechst stain cytometry, DAPI spectroscopy AMCDraQ5 ™ Acridine orange 7-AAD ^(¤)Photometry; is to be understood as anymethod that can be applied to detect the intensity, analyze thewavelength spectra, and or measure the accumulation of light derivedform a source emitting light of one or multiple wavelength or spectra.

Labelling molecules can be used to label MHC multimers as well as otherreagents used together with MHC multimers, e.g. antibodies, aptamers orother proteins or molecules able to bind specific structures in anotherprotein, in sugars, in DNA or in other molecules. In the followingmolecules able to bind a specific structure in another molecule arenamed a marker. Labelling molecules can be attached to a given MHCmultimer or any other protein marker by covalent linkage as describedfor attachment of MHC multimeres to multimerization domains elsewhereherein. The attachment can be directly between reactive groups in thelabelling molecule and reactive groups in the marker molecule or theattachment can be through a linker covalently attached to labellingmolecule and marker, both as described elsewhere herein. When labellingMHC multimers the label can be attached either to the MHC complex (heavychain, β2m or peptide) or to the multimerization domain.

In particular,

one or more labelling molecules may be attached to the carrier molecule,orone or more labelling molecules may be attached to one or more of thescaffolds, orone or more labelling compounds may be attached to one or more of theMHC complexes, orone or more labelling compounds may be attached to the carrier moleculeand/or one or more of the scaffolds and/or one or more of the MHCcomplexes, orone or more labelling compounds may be attached to the peptide harbouredby the MHC molecule.

A single labelling molecule on a marker does not always generatesufficient signal intensity. The signal intensity can be improved byassembling single label molecules into large multi-labelling compounds,containing two or more label molecule residues. Generation ofmulti-label compounds can be achieved by covalent or non-covalent,association of labelling molecules with a major structural molecule.Examples of such structures are synthetic or natural polymers (e.g.dextramers), proteins (e.g. streptavidin), or polymers. The labellingmolecules in a multi-labelling compound can all be of the same type orcan be a mixture of different labelling molecules.

In some applications, it may be advantageous to apply different MHCcomplexs, either as a combination or in individual steps. Such differentMHC multimeres can be differently labelled (i.e. by labelling withdifferent labelling compounds) enabling visualisation of differenttarget MHC recognising cells. Thus, if several different MHC multimereswith different labelling compounds are present, it is possiblesimultaneously to identify more than one specific receptor, if each ofthe MHC multimeres present a different peptide.

Detection principles, such as listed in Table 2, can be applied to flowcytometry, stationary cytometry, and batch-based analysis. Mostbatch-based approaches can use any of the labelling substances dependingon the purpose of the assay. Flow cytometry primarily employsfluorescence, whereas stationary cytometry primarily employs lightabsorption, e.g. dyes or chromophore deposit from enzymatic activity. Inthe following section, principles involving fluorescence detection willbe exemplified for flow cytometry, and principles involving chromophoredetection will be exemplified in the context of stationary cytometry.However, the labelling molecules can be applied to any of the analysesdescribed in this invention.

Labelling molecules of particular utility in Flow Cytometry:

In flow cytometry the typical label is detected by its fluorescence.Most often a positive detection is based on the presents of light from asingle fluorochrome, but in other techniques the signal is detected by ashift in wavelength of emitted light; as in FRET based techniques, wherethe exited fluorochrome transfer its energy to an adjacent boundfluorochrome that emits light, or when using Ca²⁺ chelating fluorescentprops, which change the emission (and absorption) spectra upon bindingto calcium.

Preferably labelling molecules employed in flow cytometry areillustrated in Table 3 and 4 and described in the following.

Simple fluorescent labels:

-   -   Fluor dyes, Pacific Blue™, Pacific Orange™, Cascade Yellow™,    -   AlexaFluor® (AF);        -   AF405, AF488, AF500, AF514, AF532, AF546, AF555, AF568,            AF594, AF610, AF633, AF635, AF647, AF680, AF700, AF710,            AF750, AF800    -   Quantum Dot based dyes, QDot® Nanocrystals (Invitrogen,        MolecularProbs)        -   Qdot®525, Qdot®565, Qdot®585, Qdot®605, Qdot®655, Qdot®705,            Qdot®800    -   DyLight™ Dyes (Pierce) (DL);        -   DL549, DL649, DL680, DL800    -   Fluorescein (Flu) or any derivate of that, ex. FITC    -   Cy-Dyes        -   Cy2, Cy3, Cy3.5, Cy5, Cy5.5, Cy7    -   Fluorescent Proteins;        -   RPE, PerCp, APC        -   Green fluorescent proteins;            -   GFP and GFP derivated mutant proteins; BFP, CFP, YFP,                DsRed, T1, Dimer2, mRFP1, MBanana, mOrange, dTomato,                tdTomato, mTangerine, mStrawberry, mCherry    -   Tandem dyes:        -   RPE-Cy5, RPE-Cy5.5, RPE-Cy7, RPE-AlexaFluor® tandem            conjugates; RPE-Alexa610, RPE-TxRed        -   APC-Aleca600, APC-Alexa610, APC-Alexa750, APC-Cy5, APC-Cy5.5    -   Ionophors; ion chelating fluorescent props        -   Props that change wavelength when binding a specific ion,            such as Calcium Props that change intensity when binding to            a specific ion, such as Calcium    -   Combinations of fluorochromes on the same marker. Thus, the        marker is not identified by a single fluorochrome but by a code        of identification being a specific combination of fluorochromes,        as well as inter related ratio of intensities.        -   Example: Antibody Ab1 and Ab2, are conjugated to both. FITC            and BP but Ab1 have 1 FITC to 1 BP whereas Ab2 have 2 FITC            to 1 BR Each antibodymay then be identified individually by            the relative intensity of each fluorochrome. Any such            combinations of n fluorochromes with m different ratios can            be generated.

TABLE 3 Examples of preferable fluorochromes Excitation EmissionFluorofor/Fluorochrome nm nm 2-(4′-maleimidylanilino)naphthalene-6- 322417 sulfonic acid, sodium salt 5-((((2-iodoacetyl)amino)ethyl)amino) 336490 naphthalene-1-sulfonic acid Pyrene-1-butanoic acid 340 376AlexaFluor 350 (7-amino-6-sulfonic acid-4- 346 442 methylcoumarin-3-acetic acid) AMCA (7-amino-4-methyl coumarin-3-acetic 353 442acid) 7-hydroxy-4-methyl coumarin-3-acetic acid 360 455 Marina Blue(6,8-difluoro-7-hydroxy-4-methyl 362 459 coumarin-3-acetic acid)7-dimethylamino-coumarin-4-acetic acid 370 459 Fluorescamin-N-butylamine adduct 380 464 7-hydroxy-coumarine-3-carboxylic acid 386 448CascadeBlue (pyrene-trisulphonic acid acetyl 396 410 azide) CascadeYellow 409 558 Pacific Blue (6,8 difluoro-7-hydroxy coumarin- 416 4513-carboxylic acid) 7-diethylamino-coumarin-3-carboxylic acid 420 468N-(((4-azidobenzoyl)amino)ethyl)- 4-amino- 426 5343,6-disulfo-1,8-naphthalimide, dipotassium salt Alexa Fluor 430 434 5393-perylenedodecanoic acid 440 448 8-hydroxypyrene-1,3,6-trisulfonicacid, 454 511 trisodium salt 12-(N-(7-nitrobenz-2-oxa-1,3- diazol-4- 467536 yl)amino)dodecanoic acid N,N′-dimethyl-N-(iodoacetyl)-N′-(7-nitrobenz- 478 541 2-oxa-1,3-diazol-4-yl)ethylenediamine Oregon Green 488 (difluoro carboxy488 518 fluorescein) 5-iodoacetamidofluorescein 492 515 propidiumiodide-DNA adduct 493 636 Carboxy fluorescein 495 519

TABLE 4 Examples of preferable fluorochrome families Fluorochrome familyExample fluorochrome AlexaFluor ®(AF) AF ®350, AF405, AF430, AF488,AF500, AF514, AF532, AF546, AF555, AF568, AF594, AF610, AF633, AF635,AF647, AF680, AF700, AF710, AF750, AF800 Quantum Dot Qdot ®525,Qdot ®565, Qdot ®585, (Qdot ®) based Qdot ®605, Qdot ®655, Qdot ®705,dyes Qdot ®800 DyLight ™ DL549, DL649, DL680, DL800 Dyes (DL) SmallFITC, Pacific B1ue ™, Pacific Orange ™, fluorescing dyes CascadeYellow ™, Marina blue ™, DSred, DSred-2, 7-AAD, TO-Pro-3, Cy-Dyes Cy2,Cy3, Cy3.5, Cy5, Cy5.5, Cy7 Phycobili R-Phycoerythrin (RPE), PerCP,Proteins: Allophycocyanin (APC), B-Phycoerythrin, C-PhycocyaninFluorescent (E)GFP and GFP ((enhanced) green Proteins fluorescentprotein) derived mutant proteins; BFP, CFP, YFP, DsRed, Ti, Dimer2,mRFP1,MBanana, mOrange, dTomato, tdTomato, mTangerine, mStrawberry,mCherry Tandem dyes RPE-Cy5, RPE-Cy5.5, RPE-Cy7, RPE- with RPEAlexaFluor ® tandem conjugates; RPE- Alexa610, RPE-TxRed Tandem dyesAPC-Aleca600, APC-Alexa610, APC- with APC Alexa750, APC-Cy5, APC-Cy5.5Calcium dyes Indo-1-Ca2+ Indo-2-Ca2+

Preferably Labelling Molecules Employed in Stationary Cytometry and IHC

-   -   Enzymatic labelling, as exemplified in Table 5:        -   Horse radish peroxidase; reduces peroxides (H₂O₂), and the            signal is generated by the Oxygen acceptor when being            oxidized.            -   Precipitating dyes; Dyes that when they are reduced they                are soluble, and precipitate when oxidized, generating a                coloured deposit at the site of the reaction.            -   Precipitating agent, carrying a chemical residue, a                hapten, for second layer binding of marker molecules,                for amplification of the primary signal.            -   Luminol reaction, generating a light signal at the site                of reaction.        -   Other enzymes, such as Alkaline Phosphatase, capable of            converting a chemical compound from a non-detectable            molecule to a precipitated detectable molecule, which can be            coloured, or carries a hapten as described above.    -   Fluorescent labels, as exemplified in Table 3 and 4; as those        described for Flow cytometry are likewise important for used in        stationary cytometry, such as in fluorescent microscopy.

TABLE 5 Examples of preferable labels for stationary cytometry Enzymesubstrate, Precipitate or Oxygen acceptor Residue, hapten* for BindingChromogen/ secondary detection partner Label precipitating agent layerto hapten HRP diaminobenzidine Colored — (DAB) precipitate HRP3-amino-9-ethyl- Colored — carbazole (AEC+) precipitate AP Fast red dyeRed precipitate — HRP biotinyl tyramide Exposed Biotin Streptavidin,residue avidine HRP fluorescein Exposed Anti- tyramide FluoresceinFluorecein residue Antibody “Enzyme” Substrate that Primary label;Secondary when reacted being a dye, label in case precipitatechemiluminescence's , the primary or exposure of a hapten label is ahapten

Detection Methods and Principles

Detection of TCRs with multimers may be direct or indirect.

Direct Detection

Direct detection of TCRs is detection directly of the bindinginteraction between the specific T cell receptor and the MHC multimer.Direct detection includes detection of TCR when TCR is attached to lipidbilayer, when TCR is attached to or in a solid medium or when TCR is insolution.

Direct Detection of TCR Attached to Lipid Bilayer

One type of TCRs to detect and measure are TCRs attached to lipidbilayer including but is not limited to naturally occurring T cells(from blood, spleen, lymphnode, brain or any other tissue containing Tcells), TCR transfected cells, T cell hybridomas, TCRs embedded inliposomes or any other membrane structure. In the following methods fordirect detection of entities of TCRs attached to lipid bilayer will bedescribed and any entity consisting of TCR attached to lipid bilayerwill be referred to as T cells.

T cells can be directly detected either when in a fluid solution or whenimmobilized to a support.

Direct Detection of T Cells in Fluid Sample.

T cells can be detected in fluid samples as described elsewhere hereinand in suspension of disrupted tissue, in culture media, in buffers orin other liquids. T cells in fluid samples can be detected individuallyor detected as populations of T cells. In the following differentmethods for direct detection of T cells in fluid samples are shown.

Direct Detection of Individual T Cells

Direct Detection of Individual T Cells Using Flow Cytometry.

-   -   A suspension of T cells are added MHC multimers, the sample        washed and then the amount of MHC multimer bound to each cell        are measured. Bound MHC multimers may be labelled directly or        measured through addition of labelled marker molecules. The        sample is analyzed using a flow cytometer, able to detect and        count individual cells passing in a stream through a laser beam.        For identification of specific T cells using MHC multimers,        cells are stained with fluorescently labeled MHC multimer by        incubating cells with MHC multimer and then forcing the cells        with a large volume of liquid through a nozzle creating a stream        of spaced cells. Each cell passes through a laser beam and any        fluorochrome bound to the cell is excited and thereby        fluoresces. Sensitive photomultipliers detect emitted        fluorescence, providing information about the amount of MHC        multimer bound to the cell. By this method MHC multimers can be        used to identify specific T cell populations in liquid samples        such as synovial fluid or blood.    -   When analyzing blood samples whole blood can be used with or        without lysis of red blood cells. Alternatively lymphocytes can        be purified before flow cytometry analysis using standard        procedures like a Ficoll-Hypaque gradient. Another possibility        is to isolate T cells from the blood sample for example by        binding to antibody coated plastic surfaces, followed by elution        of bound cells. This purified T cell population can then be used        for flow cytometry analysis together with MHC multimers. Instead        of actively isolating T cells unwanted cells like B cells and NK        cells can be removed prior to the analysis. One way to do this        is by affinity chromatography using columns coated with        antibodies specific for the unwanted cells. Alternatively,        specific antibodies can be added to the blood sample together        with complement, thereby killing cells recognized by the        antibodies.    -   Various gating reagents can be included in the analysis. Gating        reagents here means labeled antibodies or other labeled markers        identifying subsets of cells by binding to unique surface        proteins. Preferred gating reagents when using MHC multimers are        antibodies directed against CD3, CD4, and CD8 identifying major        subsets of T cells. Other preferred gating reagents are        antibodies against CD14, CD15, CD19, CD25, CD56, CD27, CD28,        CD45, CD45RA, CD45RO, CCR7, CCR5, CD62L, Foxp3 recognizing        specific proteins unique for different lymphocytes of the immune        system. Following labelling with MHC multimers and before        analysis on a flow cytometer stained cells can be treated with a        fixation reagent like formaldehyde to cross-link bound MHC        multimer to the cell surface. Stained cells can also be analyzed        directly without fixation.    -   The number of cells in a sample can vary. When the target cells        are rare, it is preferable to analyze large amounts of cells. In        contrast, fewer cells are required when looking at T cell lines        or samples containing many cells of the target cell type.    -   The flow cytometer can be equipped to separate and collect        particular types of cells. This is called cell sorting. MHC        multimers in combination with sorting on a flow cytometer can be        used to isolate specific T cell populations. Isolated specific T        cell populations can then be expanded in vitro. This can be        useful in autologous cancer therapy.    -   Direct determination of the concentration of MHC-peptide        specific T cells in a sample can be obtained by staining blood        cells or other cell samples with MHC multimers and relevant        gating reagents followed by addition of an exact amount of        counting beads of known concentration. Counting beads is here to        be understood as any fluorescent bead with a size that can be        visualized by flow cytometry in a sample containing T cells. The        beads could be made of polystyrene with a size of about 1-10 μm.        They could also be made of agarose, polyacrylamide, silica, or        any other material, and have any size between 0.1 μm and 100 m.        The counting beads are used as reference population to measure        the exact volume of analyzed sample. The sample are analyzed on        a flow cytometer and the amount of MHC-specific T cell        determined using a predefined gating strategy and then        correlating this number to the number of counted counting beads        in the same sample using the following equation: Amounts of        MHC-peptide specific T cells in a blood sample can be determined        by flow cytometry by calculating the amount of MHC′mer labeled        cells in a given volume of sample with a given cell density and        then back calculate. Exact enumeration of specific T cells is        better achieved by staining with MHC′mers together with an exact        amount of counting beads followed by flow cytometry analysis.        The amount of T cells detected can then be correlated with the        amount of counting beads in the same volume of the sample and an        exact number of MHC-peptide specific T cells determined:

Concentration of MHC-specific T-cell in sample=(number of MHC-peptidespecific T cells counted/number of counting beads counted)×concentrationof counting beads in sample

Direct Detection of Individual T Cells in Fluid Sample by Microscopy

-   -   A suspension of T cells are added MHC multimers, the sample        washed and then the amount of MHC multimer bound to each cell        are measured. Bound MHC multimers may be labelled directly or        measured through addition of labelled marker molecules. The        sample is then spread out on a slide or similar in a thin layer        able to distinguish individual cells and labelled cells        identified using a microscope. Depending on the type of label        different types of microscopes may be used, e.g. if fluorescent        labels are used a fluorescent microscope is used for the        analysis. For example MHC multimers can be labeled with a        fluorochrome or bound MHC multimer detected with a fluorescent        antibody. Cells with bound fluorescent MHC multimers can then be        visualized using an immunofluorescence microscope or a confocal        fluorescence microscope.

Direct Detection of Individual T Cells in Fluid Sample by Capture onSolid Support Followed by Elution.

-   -   MHC multimers are immobilized to a support e.g. beads,        immunotubes, wells of a microtiterplate, CD, microchip or        similar and as described elsewhere herein, then a suspension of        T cells are added allowing specific T cells to bind MHC multimer        molecules. Following washing bound T cells are recovered/eluted        (e.g. using acid or competition with a competitor molecules) and        counted.

Direct Detection of Populations of T Cells

-   -   Cell suspensions are added labeled MHC multimer, samples are        washed and then total signal from label are measured. The MHC        multimers may be labeled themselves or detected through a        labeled marker molecule.    -   Cell suspensions are added labeled MHC multimer, samples are        washed and then signal from label are amplified and then total        signal from label and/or amplifier are measured.

Direct Detection of Immobilized T Cells.

T cells may be immobilized and then detected directly. Immobilizationcan be on solid support, in solid tissue or in fixator (e.g. paraffin, asugar matrix or another medium fixing the T cells).

Direct Detection of T Cells Immobilized on Solid Support.

In a number of applications, it may be advantageous immobilise the Tcell onto a solid or semi-solid support. Such support may be any whichis suited for immobilisation, separation etc. Non-limiting examplesinclude particles, beads, biodegradable particles, sheets, gels,filters, membranes (e.g. nylon membranes), fibres, capillaries, needles,microtitre strips, tubes, plates or wells, combs, pipette tips, microarrays, chips, slides, or indeed any solid surface material. The solidor semi-solid support may be labelled, if this is desired. The supportmay also have scattering properties or sizes, which enablediscrimination among supports of the same nature, e.g. particles ofdifferent sizes or scattering properties, colour or intensities.

Conveniently the support may be made of glass, silica, latex, plastic orany polymeric material. The support may also be made from abiodegradable material.

Generally speaking, the nature of the support is not critical and avariety of materials may be used. The surface of support may behydrophobic or hydrophilic.

Preferred are materials presenting a high surface area for binding ofthe T cells. Such supports may be for example be porous or particulatee.g. particles, beads, fibres, webs, sinters or sieves.

Particulate materials like particles and beads are generally preferreddue to their greater binding capacity. Particularly polymeric beads andparticles may be of interest.

Conveniently, a particulate support (e.g. beads or particles) may besubstantially spherical. The size of the particulate support is notcritical, but it may for example have a diameter of at least 1 μm andpreferably at least 2 μm, and have a maximum diameter of preferably notmore than 10 μm and more preferably not more than 6 μm. For example,particulate supports having diameters of 2.8 μm and 4.5 μm will workwell.

An example of a particulate support is monodisperse particles, i.e. suchwhich are substantially uniform in size (e.g. size having a diameterstandard deviation of less than 5%). Such have the advantage that theyprovide very uniform reproducibility of reaction. Monodisperseparticles, e.g. made of a polymeric material, produced by the techniquedescribed in U.S. Pat. No. 4,336,173 (ref. 25) are especially suitable.

Non-magnetic polymer beads may also be applicable. Such are availablefrom a wide range of manufactures, e.g. Dynal Particles AS, Qiagen,Amersham Biosciences, Serotec, Seradyne, Merck, Nippon Paint, Chemagen,Promega, Prolabo, Polysciences, Agowa, and Bangs Laboratories.

Another example of a suitable support is magnetic beads or particles.The term “magnetic” as used everywhere herein is intended to mean thatthe support is capable of having a magnetic moment imparted to it whenplaced in a magnetic field, and thus is displaceable under the action ofthat magnetic field. In other words, a support comprising magnetic beadsor particles may readily be removed by magnetic aggregation, whichprovides a quick, simple and efficient way of separating out the beadsor particles from a solution. Magnetic beads and particles may suitablybe paramagnetic or superparamagnetic. Superparamagnetic beads andparticles are e.g. described in EP 0 106 873 (Sintef, ref. 26). Magneticbeads and particles are available from several manufacturers, e.g. DynalBiotech ASA (Oslo, Norway, previously Dynal AS, e.g. Dynabeads®).

The support may suitably have a functionalised surface. Different typesof functionalisation include making the surface of the supportpositively or negatively charged, or hydrophilic or hydrophobic. Thisapplies in particular to beads and particles. Various methods thereforeare e.g. described in U.S. Pat. No. 4,336,173 (ref. 25), U.S. Pat. No.4,459,378 (ref. 27) and U.S. Pat. No. 4,654,267 (ref. 28).

Immobilized T cells may be detected in several ways including:

Direct Detection of T Cells Directly Immobilized on Solid Support.

-   -   T cells may be directly immobilized on solid support e.g. by        non-specifically adhesion.

Then MHC multimers are added to the immobilized T cells thereby allowingspecific T cells to bind the MHC multimers. Bound MHC multimer may bemeasured through label directly attached to the multimer or throughlabeled marker molecules. Individual T cells may be detected if themethod for analysis is able to distinguish individual labeled cells,e.g. cells are immobilized in a monolayer on a cell culture well or aglass slide. Following staining with labeled multimer a digital pictureis taken and labeled cells identified and counted.

-   -   Alternatively a population of T cells is detected by measurement        of total signal from all labeled T cells, e.g. cells are plated        to wells of a microtiter plate, stained with labeled MHC        multimer and total signal from each well are measured.

Direct Detection of T Cells Immobilized on Solid Support Through LinkerMolecule

-   -   T cell can also be immobilized to solid support through a linker        molecule. The linker molecule can be an antibody specific for        the T cell, the linker can be MHC multimer or the linker can be        any molecule able to bind the T cells. In any case the linker        may be attached directly to the solid support, the linker may be        attached to the solid support through another linker or the        linker is embedded in a matrix, e.g. a sugar matrix. Then MHC        multimers are added to the immobilized T cells thereby allowing        specific T cells to bind the MHC multimers. Bound MHC multimer        may be measured through label directly attached to the multimer        or through labeled marker molecules. Individual T cells may be        detected if the method for analysis is able to distinguish        individual labeled cells, e.g. a digital picture is taken and        labeled cells identified and counted. Alternatively a population        of T cells is detected by measurement of total signal from all        labeled T cells.

Phenotyping T Cell Sample Using MHC Multimer Beads.

-   -   Different MHC multimers are immobilized to different beads with        different characteristics (e.g. different size, different        fluorescence's or different fluorescence intensities) where each        kind of bead has a specific type of MHC multimer molecule        immobilized. The immobilization may be direct or through a        linker molecule as described above. The amount of bound T cells        to a specific populations of beads can be analyzed, thereby,        phenotyping the sample. The TCR on the T cell is defined by the        bead to which it binds.

Direct Detection of T Cells Immobilized to Solid Support in a DefinedPattern.

-   -   Different MHC multimers are immobilized to a support to form a        spatial array in a defined pattern, where the position specifies        the identity of the MHC multimer immobilized at this position.        The immobilization may be direct or through a linker molecule as        described above. Then a suspension of labeled T cells are added        or passed over the array of MHC multimers and specific T cells        will bind the immobilized MHC multimer molecules. The label will        thus be located at specific regions of the array, which will        allow identification of the MHC multimers that bind the cells,        and thus, allows the identification of T cells with recognition        specificity for the immobilized MHC multimers. Alternatively,        the cells can be labelled after they have been bound to the MHC        multimers. The label can be specific for the type of cell that        is expected to bind the MHC multimer (e.g. anti-CD4 for the        labelling of T-helper cells in general, where some of the        T-helper cells can be specific for a Class II MHC complex), or        the label can stain cells in general (e.g. a label that binds        DNA).    -   In this way T cells bound to the defined areas of the support        are analyzed, thereby, phenotyping the sample. Each individual T        cell is defined by the TCR it expose and depending on these TCRs        each entity will bind to different types of MHC multimer        molecules immobilized at defined positions on the solid support.

Direct Detection of Immobilized T Cells Followed by Sorting

T cells immobilized to solid support in either of the ways describedabove can following washing be eluted from the solid support and treatedfurther. This is a method to sort out specific T cells from a populationof different T cells. Specific T-cells can e.g. be isolated through theuse of bead-based MHC multimers. Bead-based MHC multimers are beadswhereto monomer MHC-peptide complexes or MHC multimers are immobilized.After the cells have been isolated they can be manipulated in manydifferent ways. The isolated cells can be activated (to differentiate orproliferate), they can undergo induced apoptosis, or undesired cells ofthe isolated cell population can be removed. Then, the manipulated cellpopulation can be re-introduced into the patient, or can be introducedinto another patient.

A typical cell sorting experiment, based on bead-based MHC multimers,would follow some of the steps of the general procedure outlined ingeneral terms in the following:

Acquire the sample, e.g. a cell sample from the bone marrow of a cancerpatient.

Block the sample with a protein solution, e.g. BSA or skim milk.

Block the beads coated with MHC complexes, with BSA or skim milk.

Mix MHC-coated beads and the cell sample, and incubate.

Wash the beads with washing buffer, to remove unbound cells andnon-specifically bound cells. Isolate the immobilized cells, by eithercleavage of the linker that connects MHC complex and bead; oralternatively, release the cells by a change in pH, salt-concentrationaddition of competitive binder or the like. Preferably, the cells arereleased under conditions that do not disrupt the integrity of thecells.

Manipulate the isolated cells (induce apoptosis, proliferation ordifferentiation)

Direct Detection of T Cells in Solid Tissue.

Direct Detection of T Cells in Solid Tissue In Vitro.

-   -   For in vitro methods of the present invention solid tissue        includes tissue, tissue biopsies, frozen tissue or tissue        biopsies, paraffin embedded tissue or tissue biopsies and        sections of either of the above mentioned. In a preferred method        of this invention sections of fixed or frozen tissues are        incubated with MHC multimer, allowing MHC multimer to bind to        specific T cells in the tissue section. The MHC multimer may be        labeled directly or through a labeled marker molecule. As an        example, the MHC multimer can be labeled with a tag that can be        recognized by e.g. a secondary antibody, optionally labeled with        HRP or another label. The bound MHC multimer is then detected by        its fluorescence or absorbance (for fluorophore or chromophore),        or by addition of an enzyme-labeled antibody directed against        this tag, or another component of the MHC multimer (e.g. one of        the protein chains, a label on the multimerization domain). The        enzyme can be Horse Raddish Peroxidase (HRP) or Alkaline        Phosphatase (AP), both of which convert a colorless substrate        into a colored reaction product in situ. This colored deposit        identifies the binding site of the MHC multimer, and can be        visualized under a light microscope. The MHC multimer can also        be directly labeled with e.g. HRP or AP, and used in IHC without        an additional antibody.    -   The tissue sections may derive from blocks of tissue or tissue        biopsies embedded in paraffin, and tissue sections from this        paraffin-tissue block fixed in formalin before staining. This        procedure may influence the structure of the TCR in the fixed T        cells and thereby influence the ability to recognize specific        MHC complexes. In this case, the native structure of TCR needs        to be at least partly preserved in the fixed tissue. Fixation of        tissue therefore should be gentle. Alternatively, the staining        is performed on frozen tissue sections, and the fixation is done        after MHC multimer staining.

Direct Detection of T Cells in Solid Tissue In Vivo

-   -   For in vivo detection of T cells labeled MHC multimers are        injected in to the body of the individual to be investigated.        The MHC multimers may be labeled with e.g. a paramagnetic        isotope. Using a magnetic resonance imaging (MRI) scanner or        electron spin resonance (ESR) scanner MHC multimer binding T        cells can then be measured and localized. In general, any        conventional method for diagnostic imaging visualization can be        utilized. Usually gamma and positron emitting radioisotopes are        used for camera and paramagnetic isotopes for MRI.

The methods described above for direct detection of TCR embedded inlipid bilayers collectively called T cells using MHC multimers alsoapplies to detection of TCR in solution and detection of TCR attached toor in a solid medium. Though detection of individual TCRs may not bepossible when TCR is in solution.

Indirect Detection of TCR

Indirect detection of TCR is primarily useful for detection of TCRsembedded in lipid bilayer, preferably natural occurring T cells, T cellhybridomas or transfected T cells. In indirect detection, the number oractivity of T cells are measured, by detection of events that are theresult of TCR-MHC-peptide complex interaction. Interaction between MHCmultimer and T cell may stimulate the T cell resulting in activation ofT cells, in cell division and proliferation of T cell populations oralternatively result in inactivation of T cells. All these mechanism canbe measured using various detection methods.

Indirect Detection of T Cells by Measurement of Activation.

MHC multimers, e.g. antigen presenting cells, can stimulate T cellsresulting in activation of the stimulated T cells. Activation of T cellcan be detected by measurement of secretion of specific soluble factorfrom the stimulated T cell, e.g. secretion of cytokines like INFγ andIL2.

Stimulation of T cells can also be detected by measurement of changes inexpression of specific surface receptors, or by measurement of T celleffector functions.

Measurement of activation of T cells involves the following steps:

-   a) To a sample of T cells, preferably a suspension of cells, is    added MHC multimer to induce either secretion of soluble factor, up-    or down-regulation of surface receptor or other changes in the T    cell.    -   Alternatively, a sample of T cells containing antigen presenting        cells is added antigenic peptide or protein/protein fragments        that can be processed into antigenic peptides by the antigen        presenting cell and that are able to bind MHC I or MHC II        molecules expressed by the antigen presenting cells thereby        generating a cell based MHC multimer in the sample. Several        different peptides and proteins be added to the sample. The        peptide-loaded antigen presenting cells can then stimulate        specific T cells, and thereby induce the secretion of soluble        factor, up- or down-regulation of surface receptors, or mediate        other changes in the T cell, e.g. enhancing effector functions.    -   Optionally a second soluble factor, e.g. cytokine and/or growth        factor(s) may be added to facilitate continued activation and        expansion of T cell population.-   b) Detect the presence of soluble factor, the presence/absence of    surface receptor or detect effector function-   c) Correlate the measured result with presence of T cells. The    measured signal/response indicate the presence of specific T cells    that have been stimulated with particular MHC multimer.    -   The signal/response of a T lymphocyte population is a measure of        the overall response. The frequency of specific T cells able to        respond to a given MHC multimer can be determined by including a        limiting-dilution culture in the assay also called a Limiting        dilution assay. The limiting-dilution culture method involves        the following steps:        -   a) Sample of T cells in suspension are plated into culture            wells at increasing dilutions        -   b) MHC multimers are added to stimulate specific T cells.            Alternatively antigen presenting cells are provided in the            sample and then antigenic peptide I added to the sample as            described above.            -   Optionally growth factors, cytokines or other factors                helping T cells to proliferate are added.        -   c) Cells are allowed to grow and proliferate (½-several            days). Each well that initially contained a specific T cell            will make a response to the MHC multimer and divide.        -   d) Wells are tested for a specific response e.g. secretion            of soluble factors, cell proliferation, cytotoxicity or            other effector function.        -   The assay is replicated with different numbers of T cells in            the sample, and each well that originally contained a            specific T cell will make a response to the MHC multimer.            The frequency of specific T cells in the sample equals the            reciprocal of the number of cells added to each well when            37% of the wells are negative, because due to Poisson            distribution each well then on average contained one            specific T cell at the beginning of the culture.

In the following various methods to measure secretion of specificsoluble factor, expression of surface receptors, effector functions orproliferation is described.

Indirect Detection of T Cells by Measurement of Secretion of SolubleFactors. Indirect Detection of T Cells by Measurement of ExtracellularSecreted Soluble Factors.

Secreted soluble factors can be measured directly in fluid suspension,captured by immobilization on solid support and then detected or aneffect of the secreted soluble factor can be detected.

Indirect Detection of T Cells by Measurement of Extracellular SecretedSoluble Factor Directly in Fluid Sample.

-   -   A sample of T cells are added MHC multimer or antigenic peptide        as described above to induce secretion of soluble factors from        antigen specific T cells. The secreted soluble factors can be        measured directly in the supernatant using e.g. mass        spectrometry.

Indirect Detection of T Cells by Capture of Extracellular SecretedSoluble Factor on Solid Support.

-   -   A sample of T cells are added MHC multimer or antigenic peptide        as described above to induce secretion of soluble factors from        antigen specific T cells. Secreted soluble factors in the        supernatant are then immobilized on a solid support either        directly or through a linker as described for immobilization of        T cells elsewhere herein. Then immobilized soluble factors can        be detected using labeled marker molecules.    -   Soluble factors secreted from individual T cells can be detected        by capturing of the secreted soluble factors locally by marker        molecules, e.g antibodies specific for the soluble factor.        Soluble factor recognising marker molecules are then immobilised        on a solid support together with T cells and soluble factors        secreted by individual T cells are thereby captured in the        proximity of each T cell. Bound soluble factor can be measured        using labelled marker molecule specific for the captured soluble        factor. The number of T cells that has given rise to labelled        spots on solid support can then be enumerated and these spots        indicate the presence of specific T cells that may be stimulated        with particular MHC multimer.    -   Soluble factors secreted from a population of T cells are        detected by capture and detection of soluble factor secreted        from the entire population of specific T cells. In this case        soluble factor do not have to be captured locally close to each        T cell but the secreted soluble factors my be captured and        detected in the same well as where the T cells are or        transferred to another solid support with marker molecules for        capture and detection e.g. beads or wells of ELISA plate.

Indirect Detection of T Cells Immobilized to Solid Support in a DefinedPattern.

-   -   Different MHC multimers og MHC-peptide complexes are immobilized        to a support to form a spatial array in a defined pattern, where        the position specifies the identity of the MHC        multimer/MHC-peptide complex immobilized at this position.        Marker molecules able to bind T cell secreted soluble factors        are co-spotted together with MHC multimer/MHC-peptide complex.        Such marker molecules can e.g. be antibodies specific for        cytokines like INFγ or IL-2. The immobilization may be direct or        through a linker molecule as described above. Then a suspension        of labeled T cells are added or passed over the array of MHC        multimers/MHC-peptide complexes and specific T cells will bind        to the immobilized MHC multimers/MHC-peptide complexes and upon        binding be stimulated to secrete soluble factors e.g. cytokines        like INFγ ord IL-2. Soluble factors secreted by individual T        cells are then captured in the proximity of each T cell and        bound soluble factor can be measured using labelled marker        molecule specific for the soluble factor. The number and        position of different specific T cells that has given rise to        labelled spots on solid support can then be identified and        enumerated. In this way T cells bound to defined areas of the        support are analyzed, thereby, phenotyping the sample. Each        individual T cell is defined by the TCR it expose and depending        on these TCRs each entity will bind to different types of MHC        multimers/MHC-peptide complexes immobilized at defined positions        on the solid support.

Indirect Detection of T Cells by Measurement of Effect of ExtracellularSecreted Soluble Factor.

-   -   Secreted soluble factors can be measured and quantified        indirectly by measurement of the effect of the soluble factor on        other cell systems. Briefly,    -   a sample of T cells are added MHC multimer or antigenic peptide        as described above to induce secretion of soluble factors from        antigen specific T cells. The supernatant containing secreted        soluble factor are transferred to another cell system and the        effect measured. The soluble factor may induce proliferation,        secretion of other soluble factors, expression/downregulation of        receptors, or the soluble factor may have cytotoxic effects on        these other cells. All effects can be measured as described        elsewhere herein.

Indirect Detection of T Cells by Measurement of Intracellular SecretedSoluble Factors

Soluble factor production by stimulated T cells can be also be measuredintracellular by e.g. flow cytometry. This can be done using block ofsecretion of soluble factor (e.g. by monensin), permeabilization of cell(by e.g. saponine) followed by immunofluorescent staining. The methodinvolves the following steps: 1) Stimulation of T cells by bindingspecific MHC multimers, e.g. antigen presenting cells loaded withantigenic peptide. An reagent able to block extracellular secretion ofcytokine is added, e.g. monensin that interrupt intracellular transportprocesses leading to accumulation of produced soluble factor, e.g.cytokine in the Golgi complex. During stimulation other soluble factorsmay be added to the T cell sample during stimulation to enhanceactivation and/or expansion. This other soluble factor can be cytokineand or growth factors. 2) addition of one or more labelled marker ableto detect special surface receptors (e.g. CD8, CD4, CD3, CD27, CD28,CD2). 3) Fixation of cell membrane using mild fixator followed bypermeabilization of cell membrane by. e.g. saponine. 4) Addition oflabelled marker specific for the produced soluble factor to bedetermined, e.g. INFγ, IL-2, IL-4, IL-10.

5) Measurement of labelled cells using a flow cytometer.

An alternative to this procedure is to trap secreted soluble factors onthe surface of the secreting T cell as described by Manz, R. et al.,Proc. Natl. Acad. Sci. USA 92:1921 (1995).

Indirect Detection of T Cells by Measurement of Expression of Receptors

Activation of T cells can be detected by measurement of expressionand/or down regulation of specific surface receptors. The methodincludes the following steps. A sample of T cells are added MHC multimeror antigenic peptide as described above to induce expression ordownregulation of specific surface receptors on antigen specific Tcells. These receptors include but are not limited to CD28, CD27, CCR7,CD45RO, CD45RA, IL2-receptor, CD62L, CCR5. Their expression level can bedetected by addition of labelled marker specific for the desiredreceptor and then measure the amount of label using flow cytometry,microscopy, immobilization of activated T cell on solid support or anyother method like those described for direct detection of TCR in lipidbilayer.

Indirect Detection of T Cells by Measurement of Effector Function

Activation of T cells can be detected indirectly by measurement ofeffector functions. A sample of T cells are added MHC multimer orantigenic peptide as described above to induce the T cell to be able todo effector function. The effector function is then measured. E.g.activation of antigen specific CD8 positive T cells can be measured in acytotoxicity assay.

Indirect Detection of T Cells by Measurement of Proliferation

T cells can be stimulated to proliferate upon binding specific MHCmultimers. Proliferation of T cells can be measured several waysincluding but not limited to:

Detection of mRNA

-   -   Proliferation of T cells can be detected by measurement of mRNA        inside cell. Cell division and proliferation requires production        of new protein in each cell which as an initial step requires        production of mRNA encoding the proteins to be synthesized.    -   A sample of T cells are added MHC multimer or antigenic peptide        as described above to induce proliferation of antigen specific T        cells. Detection of levels of mRNA inside the proliferating T        cells can be done by quantitative PCR and indirectly measure        activation of a T cell population as a result of interaction        with MHC multimer. An example is measurement of cytokine mRNA by        in sity hybridization.

Detection of Incorporation of Thymidine

-   -   The proliferative capacity of T cells in response to stimulation        by MHC multimer can be determined by a radioactive assay based        on incorporation of [³H]thymidine ([³H]TdR) into newly generated        DNA followed by measurement of radioactive signal.

Detection of Incorporation of BrdU

-   -   T cell proliferation can also be detected by of incorporation of        bromo-2′-deoxyuridine (BrdU) followed by measurement of        incorporated BrdU using a labeled anti-BrdU antibody in an ELISA        based analysis.

Viability of cells may be measured by measurement ATP in a cell culture.

Indirect Detection of T Cells by Measurement of Inactivation

Not all MHC multimers will lead to activation of the T cells they bind.Under certain circumstances some MHC multimers may rather inactivate theT cells they bind to.

Indirect Detection of T Cells by Measurement of Effect of Blockade ofTCR

Inactivation of T cells by MHC multimers may be measured be measuringthe effect of blocking TCR on antigen specific T cells. MHC multimers,e.g. MHC-peptide complexes coupled to IgG scaffold can block the TCR ofan antigen specific T cell by binding the TCR, thereby prevent theblocked T cell receptor interacting with e.g. antigen presenting cells.Blockade of TCRs of a T cell can be detected in any of the abovedescribed methods for detection of TCR by addition of an unlabeledblocking MHC multimer together with the labelled MHC multimer and thenmeasuring the effect of the blockade on the readout.

Indirect Detection of T Cells by Measurement of Induction of Apoptosis

Inactivation of T cells by MHC multimers may be measured be measuringapoptosis of the antigen specific T cell. Binding of some MHC multimersto specific T cells may lead to induction of apoptosis. Inactivation ofT cells by binding MHC multimer may therefore be detected by measuringapoptosis in the T cell population. Methods to measure apoptosis in Tcells include but are not limited to measurement of the following:

-   -   DNA fragmentation    -   Alterations in membrane asymmetry (phosphatidylserine        translocation)    -   Activation of apoptotic caspases    -   Release of cytochrome C and AIF from mitochondria into the        cytoplasm

Positive Control Experiments for the Use of MHC Multimers in FlowCytometry and Related Techniques

When performing flow cytometry experiments, or when using similartechnologies, it is important to include appropriate positive andnegative controls. In addition to establishing proper conditions for theexperiments, positive and negative control reagents can also be used toevaluate the quality (e.g. specificity and affinity) and stability (e.g.shelf life) of produced MHC multimers.

The quality and stability of a given MHC multimer can be tested in anumber of different ways, including:

-   -   Measurement of specific MHC multimer binding to beads, other        types of solid support, or micelles and liposomes, to which        TCR's have been immobilized. Other kinds of molecules that        recognize specifically the MHC-peptide complex can be        immobilized and used as well. Depending on the nature of the        solid support or membrane structure to which the TCR is        immobilized, the TCR can be full-length (i.e. comprise the        intracellular- and intra-membrane domains), or can be truncated        (e.g. only comprise the extracellular domains). Likewise, the        TCR can be recombinant, and can be chemically or enzymatically        modified.    -   Measurement of MHC multimer binding to beads, other types of        solid support, or micelles and liposomes, to which aptamers,        antibodies or other kinds of molecules that recognize correctly        folded MHC-peptide complexes have been immobilized.    -   Measurement of specific MHC multimer binding to specific cell        lines (e.g. T-cell lines) displaying MHC multimer-binding        molecules, e.g. displaying TCRs with appropriate specificity and        affinity for the MHC multimer in question.    -   Measurement of specific MHC multimer binding to cells in blood        samples, preparations of purified lymphocytes (HPBMCs), or other        bodily fluids that contain cells carrying receptor molecules        specific for the MHC multimer in question.    -   Measurement of specific MHC multimer binding to soluble TCRs,        aptamers, antibodies, or other soluble MHC-peptide        complex-binding molecules, by density-gradient centrifugation        (e.g. in CsCl) or by size exclusion chromatography, PAGE or        other type of chromatographic method.

Measurement of specific MHC binding to TCRs, aptamers, antibodies,streptavidin, or other MHC-peptide complex-binding molecules immobilizedon a solid surface (e.g. a microtiter plate). The degree of MHC multimerbinding can be visualized with a secondary component that binds the MHCmultimer, e.g. a biotinylated fluorophore in cases where the MHCmultimer contains streptavidin proteins, not fully loaded with biotin.Alternatively, the secondary component is unlabelled, and a labelledsecond component-specific compound is employed (e.g. EnVision System,Dako) for visualization. This solid surface can be beads, immunotubes,microtiterplates act. The principle for purification are basically thesame I.e. T cells are added to the solid with immobilized MHC′mer,non-binding T cells are washed away and MHC-peptide specific T cells canbe retrieved by elution with mild acid or a competitive binding reagent.

-   -   Measurement of specific MHC multimer binding to TCRs, aptamers,        antibodies, streptavidin, or other MHC-peptide complex-binding        molecules immobilized on a solid surface (e.g. a microtiter        plate) visualized with a secondary component specific to MHC        multimer (e.g. TCRs, aptamers, antibodies, streptavidin, or        other MHC-peptide binding complex-binding molecules).        Alternatively the secondary receptor is unlabelled, and a        labelled second receptor-specific compound is employed (e.g.        EnVision System, Dako) before visualization.

In the above mentioned approaches, positive control reagents include MHCmultimers comprising correctly folded MHC, complexed with an appropriatepeptide that allows the MHC multimer to interact specifically andefficiently with its cognate TCR. Negative control reagents includeempty MHC multimers, or correctly folded MHC multimers complexed withso-called nonsense peptides that support a correct conformation of theMHC-peptide complex, but that do not efficiently bind TCRs through thepeptide-binding site of the MHC complex.

Negative Control Reagents and Negative Control Experiments for the Useof MHC Multimers In Flow Cytometry and Related Techniques

Experiments with MHC multimers require a negative control in order todetermine background staining with MHC multimer. Background staining canbe due to unwanted binding of any of the individual components of theMHC multimer, e.g., MHC complex or individual components of the MHCcomplex, multimerization domain or label molecules. The unwanted bindingcan be to any surface or intracellular protein or other cellularstructure of any cell in the test sample, e.g. undesired binding to Bcells, NK cells or T cells. Unwanted binding to certain cells or certaincomponents on cells can normally be corrected for during the analysis,by staining with antibodies that bind to unique surface markers of thesespecific cells, and thus identifies these as false positives, oralternatively, that bind to other components of the target cells, andthus identifies these cells as true positives. A negative controlreagent can be used in any experiment involving MHC multimers, e.g. flowcytometry analysis, other cytometric methods, immunohistochemistry (IHC)and ELISA. Negative control reagents include the following:

-   -   MHC complexes or MHC multimers comprising MHC complexes carrying        nonsense peptides. A nonsense peptide is here to be understood        as a peptide that binds the MHC protein efficiently, but that        does not support binding of the resultant MHC-peptide complex to        the desired TCR. An example nonsense peptide is a peptide with        an amino acid sequence different from the linear sequence of any        peptide derived from any known protein. When choosing an        appropriate nonsense peptide the following points are taken into        consideration. The peptide should ideally have appropriate amino        acids at relevant positions that can anchor the peptide to the        peptide-binding groove of the MHC. The remaining amino acids        should ideally be chosen in such a way that possible binding to        TCR (through interactions with the peptide or peptide-binding        site of MHC) are minimized. The peptide should ideally be        soluble in water to make proper folding with MHC alpha chain and        β2m possible in aqueous buffer. The length of the peptide should        ideally match the type and allele of MHC complex. The final        peptide sequence should ideally be taken through a blast search        or similar analysis, to ensure that it is not identical with any        peptide sequence found in any known naturally occurring        proteins.    -   MHC complexes or MHC multimers comprising MHC complexes carrying        a chemically modified peptide in the peptide-binding groove. The        modification should ideally allow proper conformation of the        MHC-peptide structure, yet should not allow efficient        interaction of the peptide or peptide-binding site of MHC with        the TCR.    -   MHC complexes or MHC multimers comprising MHC complexes carrying        a naturally occurring peptide different from the peptide used        for analysis of specific T cells in the sample. When choosing        the appropriate natural peptide the following should be taken        into consideration. The peptide in complex with the MHC protein        should ideally not be likely to bind a TCR of any T cell in the        sample with such an affinity that it can be detected with the        applied analysis method. The peptide should ideally be soluble        in water to make proper folding with MHC alpha chain and β2m        possible in aqueous buffer. The length of the peptide should        match the type and allele of MHC complex.    -   Empty MHC complexes or MHC multimers comprising empty MHC        complexes, meaning any correctly folded MHC complex without a        peptide in the peptide-binding groove.    -   MHC heavy chain or MHC multimers comprising MHC heavy chain,        where MHC heavy chain should be understood as full-length MHC I        or MHC II heavy chain or any truncated version of MHC I or MHC        II heavy chain. The MHC heavy chains can be either folded or        unfolded. Of special interest is MHC I alpha chains containing        the α3 domain that binds CD8 molecules on cytotoxic T cells.        Another embodiment of special interest is MHC II β chains        containing the β2 domain that binds CD4 on the surface of helper        T cells.    -   Beta2microglobulin or subunits of beta2microglobulin, or MHC        multimers comprising Beta2microglobulin or subunits of        beta2microglobulin, folded or unfolded.    -   MHC-like complexes or MHC multimers comprising MHC-like        complexes, folded or unfolded. An example could be CD1 molecules        that are able to bind peptides in a peptide-binding groove that        can be recognized by T cells (Russano et al. (2007).        CD1-restricted recognition of exogenous and self-lipid antigens        by duodenal gammadelta+T lymphocytes. J. Immunol. 178(6):3620-6)    -   Multimerization domains without MHC or MHC-like molecules, e.g.        dextran, streptavidin, IgG, coiled-coil-domain liposomes.    -   Labels, e.g. FITC, PE, APC, pacific blue, cascade yellow, or any        other label listed elsewhere herein.

Negative controls 1-4 can provide information about potentiallyundesired binding of the MHC multimer, through interaction of a surfaceof the MHC-peptide complex different from the peptide-binding groove andits surroundings. Negative control 5 and 6 can provide information aboutbinding through interactions through the MHC I or MHC II proteins (inthe absence of peptide). Negative control 7 can provide informationabout binding through surfaces of the MHC complex that is not unique tothe MHC complex. Negative controls 8 and 9 provide information aboutpotential undesired interactions between non-MHC-peptide complexcomponents of the MHC multimer and cell constituents.

Minimization of Undesired Binding of the MHC Multimer

Identification of MHC-peptide specific T cells can give rise tobackground signals due to unwanted binding to cells that do not carryTCRs. This undesired binding can result from binding to cells or othermaterial, by various components of the MHC multimer, e.g. the dextran ina MHC dextramer construct, the labelling molecule (e.g. FITC), orsurface regions of the MHC-peptide complex that do not include thepeptide and the peptide-binding cleft. MHC-peptide complexes bind tospecific T cells through interaction with at least two receptors in thecell membrane of the T-cell. These two receptors are the T-cell receptor(TCR) and CD8 for MHC I-peptide complexes and TCR and CD4 receptorprotein for MHC II-peptide complexes. Therefore, a particularlyinteresting example of undesired binding of a MHC multimer is itsbinding to the CD8 or CD4 molecules of T cells that do not carry a TCRspecific for the actual MHC-peptide complex. The interaction of CD8 orCD4 molecules with the MHC is not very strong; however, because of theavidity gained from the binding of several MHC complexes of a MHCmultimer, the interaction between the MHC multimer and several CD8 orCD4 receptors potentially can result in undesired but efficient bindingof the MHC multimer to these T cells. In an analytical experiment thiswould give rise to an unwanted background signal; in a cell sortingexperiment undesired cells might become isolated. Other particularinteresting examples of undesired binding is binding to lymphoid cellsdifferent from T cells, e.g. NK-cells, B-cells, monocytes, dendriticcells, and granulocytes like eosinophils, neutrophils and basophiles.

Apart from the MHC complex, other components in the MHC multimer cangive rise to unspecific binding. Of special interest are themultimerization domain, multimerization domain molecules, and labellingmolecules.

One way to overcome the problem with unwanted binding is to includenegative controls in the experiment and subtract this signal fromsignals derived from the analyzed sample, as described elsewhere in theinvention.

Alternatively, unwanted binding could be minimized or eliminated duringthe experiment. Methods to minimize or eliminate background signalsinclude:

-   -   Mutations in areas of the MHC complex responsible for binding to        unwanted cells can be introduced. Mutations here mean        substitution, insertion, or deletion of natural or non-natural        amino acids. Sub-domains in the MHC complex can be responsible        for unwanted binding of the MHC multimer to cells without a TCR        specific for the MHC-peptide complex contained in the MHC        multimer. One example of special interest is a small region in        the α3-domain of the α-chain of MHC I molecules that is        responsible for binding to CD8 on all cytotoxic T cells.        Mutations in this area can alter or completely abolish the        interaction between CD8 on cytotoxic T cells and MHC multimer        (Neveu et al. (2006) Int Immunol. 18, 1139-45). Similarly a sub        domain in the β2 domain of the β-chain of MHC II molecules is        responsible for binding CD4 molecules on all CD4 positive T        cells. Mutations in this sub domain can alter or completely        abolish the interaction between MHC 11 and CD4. Another        embodiment is to mutate other areas of MHC I/MHC II complexes        that are involved in interactions with T cell surface receptors        different from TCR, CD8 and CD4, or that bind surface receptors        on B cells, NK cells, Eosiniophils, Neutrophils, Basophiles,        Dendritic cells or monocytes.    -   Chemical alterations in areas of the MHC complex responsible for        binding to unwanted cells can be employed in order to minimize        unwanted binding of MHC multimer to irrelevant cells. Chemical        alteration here means any chemical modification of one or more        amino acids. Regions in MHC complexes that are of special        interest are as mentioned above the α3 domain of the α-chain in        MHC I molecules and β2 domains in the β-chain of MHC II        molecules. Other regions in MHC I/MHC II molecules that can be        chemically modified to decrease the extent of undesired binding        are regions involved in interaction with T cell surface        receptors different from TCR, CD8 and CD4, or that bind surface        receptors on B cells, NK cells, Eosiniophils, Neutrophils,        Basophiles, Dendritic cells or monocytes.    -   Another method to minimize undesired binding involves the        addition of one or more components of a MHC multimer, predicted        to be responsible for the unwanted binding. The added component        is not labeled, or carries a label different from the label of        the MHC multimer used for analysis. Of special interest is        addition of MHC multimers that contain nonsense peptides, i.e.        peptides that interact efficiently with the MHC protein, but        that expectably do not support specific binding of the MHC        multimer to the TCR in question. Another example of interest is        addition of soluble MHC complexes not coupled to a        multimerization domain, and with or without peptide bound in the        peptide binding cleft. In another embodiment, individual        components of the MHC complex can be added to the sample, e.g. I        α-chain or subunits of MHC I α-chain either folded or unfolded,        beta2microglobulin or subunits thereof either folded or        unfolded, α/β-chain of MHC II or subunits thereof either folded        or unfolded. Any of the above mentioned individual components        can also be attached to a multimerization domain identical or        different from the one used in the MHC multimer employed in the        analysis.    -   Of special interest is also addition of multimerization domain        similar or identical to the multimerization domain used in the        MHC multimer or individual components of the multimerization        domain.    -   Reagents able to identify specific cell types either by        selection or exclusion can be included in the analysis to help        identify the population of T cells of interest, and in this way        deselect the signal arising from binding of the MHC multimer to        undesired cells.    -   Of special interest is the use of appropriate gating reagents in        flow cytometry experiments. Thus, fluorescent antibodies        directed against specific surface markers can be used for        identification of specific subpopulations of cells, and in this        way help to deselect signals resulting from MHC-multimers        binding to undesired cells.    -   Gating reagents of special interest that helps identify the        subset of T cells of interest when using MHC I multimers are        reagents binding to CD3 and CD8 identifying all cytotoxic T        cells. These reagents are preferably antibodies but can be any        labeled molecule capable of binding CD3 or CD8. Gating reagents        directed against CD3 and CD8 are preferably used together. As        they stain overlapping cell populations they are preferably        labeled with distinct fluorochromes. However, they can also be        used individually in separate samples. In experiments with MHC        II multimers reagents binding to CD3 and CD4 identifying T        helper cells can be used. These reagents are preferably        antibodies but can be any labeled molecule capable of binding        CD3 or CD4. Gating reagents directed against CD3 and CD4 are        preferable used together. As they stain overlapping cell        populations they are preferably labeled with distinct        fluorochromes. However, they can also be used individually in        separate samples.

Other gating reagents of special interest in experiments with any MHCmultimer, are reagents binding to the cell surface markers CD2, CD27,CD28, CD45RA, CD45RO, CD62L and CCR7. These surface markers are uniqueto T cells in various differentiation states. Co staining with either ofthese reagents or combinations thereof together with MHC multimers helpsto select MHC multimer binding T cells expressing a correct TCR. Thesereagents can also be combined with reagents directed against CD3, CD4and/or CD8.

Another flow cytometric method of special interest to remove signalsfrom MHC multimer stained cells not expressing the specific TCR, is tointroduce an exclusion gate. Antibodies or other reagents specific forsurface markers unique to the unwanted cells are labeled with afluorochrome and added to the test sample together with the MHCmultimer. The number of antibodies or surface marker specific reagentsare not limited to one but can be two, three, four, five, six, seven,eight, nine, ten or more individual reagents recognizing differentsurface markers, all of which are unique to the unwanted cells. Duringor after collection of data all events representing cells labeled withthese antibodies are dumped in the same gate and removed from thedataset. This is possible because all the antibodies/reagents that bindto the wrong cells are labeled with the same fluorochrome.

Reagents of special interest that exclude irrelevant cells includereagents against CD45 expressed on red blood cells, CD19 expressed on Bcells, CD56 expressed on NK cells, CD4 expressed on T helper cells andCD8 expressed on cytotoxic T cells, CD14 expressed on monocytes and CD15expressed on granulocytes and monocytes.

Vaccine Treatment

For the purpose of making cancer vaccines or other types of vaccines itcan be desirable to employ MHC multimers that comprise a polymer such asdextran, or that are cell-based (e.g. specialized dendritic cells suchas described by Banchereau and Palucka, Nature Reviews, Immunology,2005, vol. 5, p. 296-306).

-   -   Preventive vaccination leading to prophylaxis/sterile immunity        by inducing memory in the immune system may be obtained by        immunizing/vaccinating an individual or animal with MHC alone,        or with MHC in combination with other molecules as mentioned        elsewhere in the patent.        -   Vaccine antigens can be administered alone        -   Vaccine can be administered in combination with adjuvant(s).            -   Adjuvant can be mixed with vaccine component or                administered alone, simultaneously or in any order.            -   Adjuvant can be administered by the same route as the                other vaccine components        -   Vaccine administered more than once may change composition            from 1^(st) administration to the 2^(nd), 3^(rd), etc.        -   Vaccine administered more than once can be administered by            alternating routes        -   Vaccine components can be administered alone or in            combinations by the same route or by alternating/mixed            routes        -   Vaccine can be administered by the following routes            -   Cutaneously            -   Subcutaneously (SC)            -   Intramuscular (IM)            -   Intravenous (IV)            -   Per-oral (PO)            -   Inter peritoneally            -   Pulmonally            -   Vaginally            -   Rectally    -   Therapeutic vaccination i.e. vaccination “teaching” the immune        system to fight an existing infection or disease, may be        obtained by immunizing/vaccinating an individual or animal with        MHC alone, or with MHC in combination with other molecules as        mentioned elsewhere in the patent.        -   Vaccine antigens can be administered alone        -   Vaccine can be administered in combination with adjuvant(s).            -   Adjuvant can be mixed with vaccine component or                administered alone, simultaneously or in any order.            -   Adjuvant can be administered by the same route as the                other vaccine components        -   Vaccine administered more than once may change composition            from 1^(st) administration to the 2^(nd), 3^(rd), etc.        -   Vaccine administered more than once can be administered by            alternating routes        -   Vaccine components can be administered alone or in            combinations by the same route or by alternating/mixed            routes        -   Vaccine can be administered by the following routes            -   Cutaneously            -   Subcutaneously (SC)            -   Intramuscular (IM)            -   Intravenous (IV)            -   Per-oral (PO)            -   Inter peritoneally            -   Pulmonally            -   Vaginally            -   Rectally

Therapeutic Treatment

-   -   Therapeutic treatment includes the use of MHC molecules alone or        in any molecular combination mentioned elsewhere in the patent        application for the purpose of treating a disease in any state.        Treatment may be in the form of        -   Per-orally intake            -   Pills            -   Capsules        -   Injections            -   Systemic            -   Local        -   Jet-infusion (micro-drops, micro-spheres, micro-beads)            through skin        -   Drinking solution, suspension or gel        -   Inhalation        -   Nose-drops        -   Eye-drops        -   Ear-drops        -   Skin application as ointment, gel or creme        -   Vaginal application as ointment, gel, crème or washing        -   Gastro-Intestinal flushing        -   Rectal washings or by use of suppositories    -   Treatment can be performed as        -   Single intake, injection, application, washing        -   Multiple intake, injection, application, washing            -   On single day basis            -   Over prolonged time as days, month, years    -   Treatment dose and regimen can be modified during the course        Personalized Medicine Takes Advantage of the Large Diversity of        Peptide Epitopes that May be Generated from a Given Antigen.

The immune system is very complex. Each individual has a very largerepertoire of specific T cells (on the order of 10⁶-10⁹ different T cellspecificities), which again is only a small subset of the total T cellrepertoire of a population of individuals. It is estimated that theCaucasian population represents a T cell diversity of 10¹⁰-10¹². MHCallele diversity combined with large variation among individuals'proteolytic metabolism further enhances the variation among differentindividuals' immune responses. As a result, each individual has its owncharacteristic immune response profile.

This is important when designing a MHC multimer-based immune monitoringreagent or immunotherapeutic agent. If an agent is sought that should beas generally applicable as possible, one should try to identify peptideepitopes and MHC alleles that are common for the majority of individualsof a population. As described elsewhere in this application, suchpeptide epitopes can be identified through computerized searchalgorithms developed for that same purpose, and may be furtherstrengthened by experimental testing of a large set of individuals.

This approach will be advantageous in many cases, but because of thevariability among immune responses of different individuals, is likelyto be inefficient or inactive in certain individuals, because of theseindividuals' non-average profile. In these latter cases one may have toturn to personalized medicine. In the case of immune monitoring andimmunotherapy, this may involve testing a large number of differentepitopes from a given antigen, in order to find peptide epitopes thatmay provide MHC multimers with efficiency for a given individual.

Thus, personalized medicine takes advantage of the wealth of peptideepitopes that may be generated from a given antigen. A large number ofthe e.g. 8-, 9-, 10-, and 11-mer epitopes that may be generated from agiven antigen to be included in a class 1 MHC multimer reagent, for usein immune monitoring or immunotherapy, are therefore of relevance inpersonalized medicine. Only in the case where one wants to generate atherapeutic agent or diagnostic reagent that is applicable to themajority of individuals of a population can the large majority ofepitope sequences be said to be irrelevant, and only those identified bycomputerized search algorithms and experimental testing be said to be ofvalue. For the odd individual with the odd immune response thesedisregarded peptide epitopes may be the epitopes that provide anefficient diagnostic reagent or cures that individual from a deadlydisease.

Antigenic Peptides

The present invention relates to one or more MHC multimers and/or one ormore MHC complexes comprising one or more antigenic peptides such as theantigenic peptides listed in table A, B, C, D, E, F, G, H, I, J, K, L,M, N, O, P, Q, R, S, T, U, V, X and Y.

The one or more antigenic peptides can in one embodiment comprise afragment of one or more cancer antigens.

The one or more cancer antigens can be selected from Table A.

TABLE A Protein designation and accession numbers for the four selectedcancer antigens Bcl-2, BclX(L), Survivin and Mcl-1. The amino acidsequence of each protein is displayed. Protein and accession numberCancer antigen AAH27258.1 MAHAGRTGYDNREIVMKYIHYKLSQRGYEWDAGDVGAAPPGAAPAPB-cell CLL/lymphoma 2, GIFSSQPGHTPHPAASRDPVARTSPLQTPAAPGAAAGPALSPVPPVBcl-2 [Homo sapiens] VHLTLRQAGDDFSRRYRRDFAEMSSQLHLTPFTARGRFATVVEELFRDGVNWGRIVAFFEFGGVMCVESVNREMSPLVDNIALWMTEYLNRHLHTWIQDNGGWDAFVELYGPSMRPLFDFSWLSLKTLLSLALVGACI TLGAYLGHK NP_612815.1MSQSNRELVVDFLSYKLSQKGYSWSQFSDVEENRTEAPEGTESEME Bcl-X(L)TPSAINGNPSWHLADSPAVNGATGHSSSLDAREVIPMAAVKQALRE (BCL2-like 1 isoform 1)AGDEFELRYRRAFSDLTSQLHITPGTAYQSFEQVVNELFRDGVNWG [Homo sapiens]RIVAFFSFGGALCVESVDKEMQVLVSRIAAWMATYLNDHLEPWIQENGGWDTFVELYGNNAAAESRKGQERFNRWFLTGMTVAGVVLLGSLF SRK AAC51660.1MGAPTLPPAWQPFLKDHRISTFKNWPFLEGCACTPERMAEAGFIHC apoptosis inhibitorPTENEPDLAQCFFCFKELEGWEPDDDPIEEHKKHSSGCAFLSVKKQ survivin [Homo sapiens]FEELTLGEFLKLDRERAKNKIAKETNNKKKEFEETAKKVRRAIEQL AAMD AAF64255.1MFGLKRNAVIGLNLYCGGAGLGAGSGGATRPGGRLLATEKEASARR Mcl-1 [Homo sapiens]EIGGGEAGAVIGGSAGASPPSTLTPDSRRVARPPPIGAEVPDVTATPARLLFFAPTRRAAPLEEMEAPAADAIMSPEEELDGYEPEPLGKRPAVLPLLELVGESGNNTSTDGSLPSTPPPAEEEEDDLYRQSLEIISRYLREQATGAKDTKPMGRSGATSRKALETLRRVGDGVQRNHETAFQGMLRKLDIKNEDDVKSLSRVMIHVFSDGVTNWGRIVTLISFGAFVAKHLKTINQESCIEPLAESITDVLVRTKRDWLVKQRGWDGFVEFFHVEDLEGGIRNVLLAFAGVAGVGAGLAYLIR SEQ ID NOS: 44889-44892

The one or more antigenic peptides can in one embodiment comprise one ormore fragments from one or more cancer antigens capable of interactingwith one or more MHC class 1 molecules.

The one or more antigenic peptides can in another embodiment compriseone or more fragments from one or more cancer antigens capable ofinteracting with one or more MHC class 2 molecules.

The one or more antigenic peptides can in one embodiment comprise one ormore fragments from BclX(L).

The one or more antigenic peptides can in one embodiment comprise one ormore fragments from Bcl-2.

The one or more antigenic peptides can in one embodiment comprise one ormore fragments from Survivin.

The one or more antigenic peptides can in one embodiment comprise one ormore fragments from Mcl-1.

Preferred fragments of BclX(L) capable of interacting with one or moreMHC class 1 molecules are listed in table B.

TABLE B Prediction of cancer antigen BclX(L) specific MHC class1,8-, 9-, 10-, 11-mer peptide binders for 42 MHC class 1alleles (see FIG. 11) using the http://www.cbs.dtu.dk/services/NetMHC/ database. The MHC class 1 molecules for which nobinders were found are not listed pos peptide logscore affinity (nM)Bind Level Protein Name Allele 8-mers 57 HLADSPAV 0.691 28 SB SequenceA0201 213 FLTGMTVA 0.687 29 SB Sequence A0201 166 AAWMATYL 0.477 285 WBSequence A0201 160 VLVSRIAA 0.463 333 WB Sequence A0201 119 YQSFEQVV0.436 448 WB Sequence A0201 147 GALCVESV 0.431 472 WB Sequence A0201 223VLLGSLFS 0.427 494 WB Sequence A0201 213 FLTGMTVA 0.777 11 SB SequenceA0202 57 HLADSPAV 0.771 11 SB Sequence A0202 119 YQSFEQVV 0.590 84 WBSequence A0202 218 TVAGVVLL 0.565 110 WB Sequence A0202 11 FLSYKLSQ0.545 137 WB Sequence A0202 82 MAAVKQAL 0.512 195 WB Sequence A0202 73SLDAREVI 0.475 294 WB Sequence A0202 192 ELYGNNAA 0.444 410 WB SequenceA0202 217 MTVAGVVL 0.440 425 WB Sequence A0202 160 VLVSRIAA 0.434 454 WBSequence A0202 1 SQSNRELV 0.434 457 WB Sequence A0202 213 FLTGMTVA 0.8524 SB Sequence A0203 57 HLADSPAV 0.831 6 SB Sequence A0203 160 VLVSRIAA0.642 48 SB Sequence A0203 158 MQVLVSRI 0.602 74 WB Sequence A0203 11FLSYKLSQ 0.582 92 WB Sequence A0203 133 GVNWGRIV 0.581 92 WB SequenceA0203 216 GMTVAGVV 0.579 94 WB Sequence A0203 119 YQSFEQVV 0.578 96 WBSequence A0203 164 RIAAWMAT 0.573 101 WB Sequence A0203 78 EVIPMAAV0.486 261 WB Sequence A0203 1 SQSNRELV 0.481 274 WB Sequence A0203 217MTVAGVVL 0.467 318 WB Sequence A0203 147 GALCVESV 0.464 328 WB SequenceA0203 221 GVVLLGSL 0.443 412 WB Sequence A0203 218 TVAGVVLL 0.440 429 WBSequence A0203 57 HLADSPAV 0.555 122 WB Sequence A0204 153 SVDKEMQV0.431 469 WB Sequence A0204 57 HLADSPAV 0.780 10 SB Sequence A0206 158MQVLVSRI 0.733 18 SB Sequence A0206 213 FLTGMTVA 0.682 31 SB SequenceA0206 1 SQSNRELV 0.677 32 SB Sequence A0206 119 YQSFEQVV 0.677 33 SBSequence A0206 138 RIVAFFSF 0.653 42 SB Sequence A0206 164 RIAAWMAT0.575 99 WB Sequence A0206 147 GALCVESV 0.568 106 WB Sequence A0206 166AAWMATYL 0.567 108 WB Sequence A0206 217 MTVAGVVL 0.563 112 WB SequenceA0206 160 VLVSRIAA 0.517 185 WB Sequence A0206 42 SEMETPSA 0.514 191 WBSequence A0206 78 EVIPMAAV 0.496 233 WB Sequence A0206 153 SVDKEMQV0.493 240 WB Sequence A0206 57 HLADSPAV 0.955 1 SB Sequence A0211 153SVDKEMQV 0.898 3 SB Sequence A0211 213 FLTGMTVA 0.893 3 SB SequenceA0211 73 SLDAREVI 0.877 3 SB Sequence A0211 192 ELYGNNAA 0.834 6 SBSequence A0211 218 TVAGVVLL 0.797 8 SB Sequence A0211 172 YLNDHLEP 0.75114 SB Sequence A0211 78 EVIPMAAV 0.739 16 SB Sequence A0211 216 GMTVAGVV0.718 21 SB Sequence A0211 160 VLVSRIAA 0.684 30 SB Sequence A0211 223VLLGSLFS 0.683 30 SB Sequence A0211 133 GVNWGRIV 0.668 36 SB SequenceA0211 212 WFLTGMTV 0.668 36 SB Sequence A0211 144 SFGGALCV 0.591 83 WBSequence A0211 72 SSLDAREV 0.590 84 WB Sequence A0211 106 DLTSQLHI 0.564111 WB Sequence A0211 119 YQSFEQVV 0.545 136 WB Sequence A0211 81PMAAVKQA 0.532 158 WB Sequence A0211 11 FLSYKLSQ 0.511 198 WB SequenceA0211 166 AAWMATYL 0.456 360 WB Sequence A0211 1 SQSNRELV 0.439 431 WBSequence A0211 147 GALCVESV 0.439 434 WB Sequence A0211 57 HLADSPAV0.915 2 SB Sequence A0212 192 ELYGNNAA 0.813 7 SB Sequence A0212 213FLTGMTVA 0.801 8 SB Sequence A0212 153 SVDKEMQV 0.732 18 SB SequenceA0212 73 SLDAREVI 0.714 22 SB Sequence A0212 160 VLVSRIAA 0.662 38 SBSequence A0212 172 YLNDHLEP 0.662 38 SB Sequence A0212 119 YQSFEQVV0.586 88 WB Sequence A0212 78 EVIPMAAV 0.585 88 WB Sequence A0212 223VLLGSLFS 0.582 92 WB Sequence A0212 11 FLSYKLSQ 0.573 101 WB SequenceA0212 212 WFLTGMTV 0.541 142 WB Sequence A0212 216 GMTVAGVV 0.466 321 WBSequence A0212 57 HLADSPAV 0.892 3 SB Sequence A0216 153 SVDKEMQV 0.8177 SB Sequence A0216 213 FLTGMTVA 0.761 13 SB Sequence A0216 192 ELYGNNAA0.715 21 SB Sequence A0216 78 EVIPMAAV 0.666 37 SB Sequence A0216 218TVAGVVLL 0.657 41 SB Sequence A0216 73 SLDAREVI 0.640 49 SB SequenceA0216 144 SFGGALCV 0.630 54 WB Sequence A0216 216 GMTVAGVV 0.613 65 WBSequence A0216 166 AAWMATYL 0.603 73 WB Sequence A0216 160 VLVSRIAA0.583 91 WB Sequence A0216 212 WFLTGMTV 0.565 110 WB Sequence A0216 11FLSYKLSQ 0.488 255 WB Sequence A0216 106 DLTSQLHI 0.487 258 WB SequenceA0216 133 GVNWGRIV 0.470 308 WB Sequence A0216 81 PMAAVKQA 0.469 311 WBSequence A0216 118 AYQSFEQV 0.461 342 WB Sequence A0216 223 VLLGSLFS0.442 417 WB Sequence A0216 147 GALCVESV 0.438 436 WB Sequence A0216 57HLADSPAV 0.924 2 SB Sequence A0219 213 FLTGMTVA 0.668 36 SB SequenceA0219 153 SVDKEMQV 0.597 78 WB Sequence A0219 73 SLDAREVI 0.576 98 WBSequence A0219 218 TVAGVVLL 0.517 185 WB Sequence A0219 192 ELYGNNAA0.486 259 WB Sequence A0219 212 WFLTGMTV 0.458 352 WB Sequence A0219 166AAWMATYL 0.455 362 WB Sequence A0219 106 DLTSQLHI 0.448 390 WB SequenceA0219 223 VLLGSLFS 0.431 471 WB Sequence A0219 12 LSYKLSQK 0.761 13 SBSequence A0301 8 VVDFLSYK 0.551 128 WB Sequence A0301 224 LLGSLFSR 0.487257 WB Sequence A0301 8 VVDFLSYK 0.751 14 SB Sequence A1101 12 LSYKLSQK0.721 20 SB Sequence A1101 79 VIPMAAVK 0.509 203 WB Sequence A1101 124QVVNELFR 0.472 302 WB Sequence A1101 7 LVVDFLSY 0.457 355 WB SequenceA1101 197 NAAAESRK 0.455 363 WB Sequence A1101 135 NWGRIVAF 0.600 75 WBSequence A2301 138 RIVAFFSF 0.466 321 WB Sequence A2301 222 VVLLGSLF0.461 339 WB Sequence A2301 135 NWGRIVAF 0.617 62 WB Sequence A2402 118AYQSFEQV 0.569 105 WB Sequence A2403 78 EVIPMAAV 0.598 77 WB SequenceA2601 7 LVVDFLSY 0.541 144 WB Sequence A2601 78 EVIPMAAV 0.862 4 SBSequence A2602 7 LVVDFLSY 0.797 9 SB Sequence A2602 112 HITPGTAY 0.75514 SB Sequence A2602 97 ELRYRRAF 0.589 85 WB Sequence A2602 138 RIVAFFSF0.529 164 WB Sequence A2602 112 HITPGTAY 0.597 78 WB Sequence A2902 7LVVDFLSY 0.480 276 WB Sequence A2902 204 KGQERFNR 0.743 16 SB SequenceA3101 224 LLGSLFSR 0.697 26 SB Sequence A3101 157 EMQVLVSR 0.583 90 WBSequence A3101 70 HSSSLDAR 0.577 97 WB Sequence A3101 83 AAVKQALR 0.539146 WB Sequence A3101 95 EFELRYRR 0.509 201 WB Sequence A3101 124QVVNELFR 0.453 369 WB Sequence A3101 12 LSYKLSQK 0.447 397 WB SequenceA3101 95 EFELRYRR 0.823 6 SB Sequence A3301 157 EMQVLVSR 0.738 16 SBSequence A3301 94 DEFELRYR 0.650 43 SB Sequence A3301 201 ESRKGQER 0.60671 WB Sequence A3301 224 LLGSLFSR 0.538 148 WB Sequence A3301 70HSSSLDAR 0.463 332 WB Sequence A3301 124 QVVNELFR 0.803 8 SB SequenceA6801 70 HSSSLDAR 0.775 11 SB Sequence A6801 197 NAAAESRK 0.681 31 SBSequence A6801 12 LSYKLSQK 0.647 45 SB Sequence A6801 157 EMQVLVSR 0.59976 WB Sequence A6801 196 NNAAAESR 0.585 88 WB Sequence A6801 83 AAVKQALR0.535 153 WB Sequence A6801 201 ESRKGQER 0.532 158 WB Sequence A6801 165IAAWMATY 0.532 158 WB Sequence A6801 95 EFELRYRR 0.511 198 WB SequenceA6801 117 TAYQSFEQ 0.507 208 WB Sequence A6801 8 VVDFLSYK 0.481 273 WBSequence A6801 94 DEFELRYR 0.457 357 WB Sequence A6801 26 FSDVEENR 0.442418 WB Sequence A6801 224 LLGSLFSR 0.430 476 WB Sequence A6801 78EVIPMAAV 0.888 3 SB Sequence A6802 218 TVAGVVLL 0.790 9 SB SequenceA6802 215 TGMTVAGV 0.742 16 SB Sequence A6802 217 MTVAGVVL 0.697 26 SBSequence A6802 82 MAAVKQAL 0.633 52 WB Sequence A6802 57 HLADSPAV 0.549131 WB Sequence A6802 207 ERFNRWFL 0.481 273 WB Sequence A6802 60DSPAVNGA 0.473 300 WB Sequence A6802 192 ELYGNNAA 0.447 395 WB SequenceA6802 91 EAGDEFEL 0.436 444 WB Sequence A6802 78 EVIPMAAV 0.812 7 SBSequence A6901 57 HLADSPAV 0.740 16 SB Sequence A6901 192 ELYGNNAA 0.570104 WB Sequence A6901 217 MTVAGVVL 0.544 138 WB Sequence A6901 218TVAGVVLL 0.507 206 WB Sequence A6901 91 EAGDEFEL 0.489 252 WB SequenceA6901 153 SVDKEMQV 0.437 441 WB Sequence A6901 212 WFLTGMTV 0.436 445 WBSequence A6901 61 SPAVNGAT 0.657 41 SB Sequence B0702 82 MAAVKQAL 0.468316 WB Sequence B0702 166 AAWMATYL 0.430 477 WB Sequence B0702 97ELRYRRAF 0.589 85 WB Sequence B0801 7 LVVDFLSY 0.511 198 WB SequenceB1501 138 RIVAFFSF 0.493 240 WB Sequence B1501 112 HITPGTAY 0.492 243 WBSequence B1501 165 IAAWMATY 0.473 300 WB Sequence B1501 97 ELRYRRAF0.439 430 WB Sequence B1501 222 VVLLGSLF 0.433 461 WB Sequence B1501 206QERFNRWF 0.528 165 WB Sequence B1801 5 RELVVDFL 0.517 185 WB SequenceB1801 122 FEQVVNEL 0.508 205 WB Sequence B1801 210 NRWFLTGM 0.510 200 WBSequence B2705 165 IAAWMATY 0.806 8 SB Sequence B3501 7 LVVDFLSY 0.62955 WB Sequence B3501 82 MAAVKQAL 0.591 83 WB Sequence B3501 112 HITPGTAY0.543 140 WB Sequence B3501 75 DAREVIPM 0.516 187 WB Sequence B3501 142FFSFGGAL 0.499 226 WB Sequence B3501 61 SPAVNGAT 0.478 283 WB SequenceB3501 166 AAWMATYL 0.476 289 WB Sequence B3501 217 MTVAGVVL 0.470 307 WBSequence B3501 5 RELVVDFL 0.624 58 WB Sequence B4001 122 FEQVVNEL 0.61862 WB Sequence B4001 5 RELVVDFL 0.442 420 WB Sequence B4002 156 KEMQVLVS0.430 478 WB Sequence B4403 77 REVIPMAA 0.434 456 WB Sequence B4501 161LVSRIAAW 0.626 57 WB Sequence B5801 165 IAAWMATY 0.593 81 WB SequenceB5801 16 LSQKGYSW 0.586 88 WB Sequence B5801 19 KGYSWSQF 0.543 141 WBSequence B5801 138 RIVAFFSF 0.467 320 WB Sequence B5801 49 AINGNPSW0.447 394 WB Sequence B5801 9.mers 104 FSDLTSQLH 0.482 270 WB SequenceA0101 143 FSFGGALCV 0.518 183 WB Sequence A0201 217 MTVAGVVLL 0.478 282WB Sequence A0201 172 YLNDHLEPW 0.739 16 SB Sequence A0202 217 MTVAGVVLL0.604 72 WB Sequence A0202 165 IAAWMATYL 0.568 107 WB Sequence A0202 213FLTGMTVAG 0.564 111 WB Sequence A0202 11 FLSYKLSQK 0.520 179 WB SequenceA0202 161 LVSRIAAWM 0.450 382 WB Sequence A0202 8 VVDFLSYKL 0.449 387 WBSequence A0202 192 ELYGNNAAA 0.447 394 WB Sequence A0202 81 PMAAVKQAL0.437 441 WB Sequence A0202 216 GMTVAGVVL 0.436 448 WB Sequence A0202214 LTGMTVAGV 0.691 28 SB Sequence A0203 217 MTVAGVVLL 0.609 69 WBSequence A0203 165 IAAWMATYL 0.530 161 WB Sequence A0203 84 AVKQALREA0.518 183 WB Sequence A0203 110 QLHITPGTA 0.507 206 WB Sequence A0203172 YLNDHLEPW 0.493 240 WB Sequence A0203 117 TAYQSFEQV 0.473 300 WBSequence A0203 11 FLSYKLSQK 0.447 396 WB Sequence A0203 214 LTGMTVAGV0.504 213 WB Sequence A0204 217 MTVAGVVLL 0.475 291 WB Sequence A0204109 SQLHITPGT 0.712 22 SB Sequence A0206 217 MTVAGVVLL 0.675 33 SBSequence A0206 117 TAYQSFEQV 0.650 43 SB Sequence A0206 1 SQSNRELVV0.648 45 SB Sequence A0206 143 FSFGGALCV 0.584 90 WB Sequence A0206 77REVIPMAAV 0.572 103 WB Sequence A0206 165 IAAWMATYL 0.551 128 WBSequence A0206 158 MQVLVSRIA 0.544 138 WB Sequence A0206 214 LTGMTVAGV0.492 244 WB Sequence A0206 172 YLNDHLEPW 0.464 331 WB Sequence A0206 42SEMETPSAI 0.440 426 WB Sequence A0206 192 ELYGNNAAA 0.863 4 SB SequenceA0211 143 FSFGGALCV 0.797 8 SB Sequence A0211 81 PMAAVKQAL 0.794 9 SBSequence A0211 172 YLNDHLEPW 0.715 21 SB Sequence A0211 153 SVDKEMQVL0.703 24 SB Sequence A0211 8 VVDFLSYKL 0.696 26 SB Sequence A0211 217MTVAGVVLL 0.634 52 WB Sequence A0211 112 HITPGTAYQ 0.618 62 WB SequenceA0211 117 TAYQSFEQV 0.617 63 WB Sequence A0211 223 VLLGSLFSR 0.581 93 WBSequence A0211 213 FLTGMTVAG 0.581 93 WB Sequence A0211 133 GVNWGRIVA0.575 99 WB Sequence A0211 216 GMTVAGVVL 0.553 126 WB Sequence A0211 185GGWDTFVEL 0.550 130 WB Sequence A0211 103 AFSDLTSQL 0.472 302 WBSequence A0211 176 HLEPWIQEN 0.427 493 WB Sequence A0211 192 ELYGNNAAA0.845 5 SB Sequence A0212 81 PMAAVKQAL 0.789 9 SB Sequence A0212 143FSFGGALCV 0.702 25 SB Sequence A0212 172 YLNDHLEPW 0.673 34 SB SequenceA0212 223 VLLGSLFSR 0.573 101 WB Sequence A0212 8 VVDFLSYKL 0.561 115 WBSequence A0212 153 SVDKEMQVL 0.535 153 WB Sequence A0212 213 FLTGMTVAG0.521 178 WB Sequence A0212 118 AYQSFEQVV 0.476 290 WB Sequence A0212192 ELYGNNAAA 0.741 16 SB Sequence A0216 81 PMAAVKQAL 0.710 22 SBSequence A0216 143 FSFGGALCV 0.652 42 SB Sequence A0216 117 TAYQSFEQV0.593 81 WB Sequence A0216 112 HITPGTAYQ 0.512 196 WB Sequence A0216 216GMTVAGVVL 0.430 479 WB Sequence A0216 81 PMAAVKQAL 0.675 33 SB SequenceA0219 143 FSFGGALCV 0.652 43 SB Sequence A0219 192 ELYGNNAAA 0.541 142WB Sequence A0219 117 TAYQSFEQV 0.497 232 WB Sequence A0219 172YLNDHLEPW 0.459 348 WB Sequence A0219 223 VLLGSLFSR 0.456 361 WBSequence A0219 214 LTGMTVAGV 0.450 384 WB Sequence A0219 --- 224LLGSLFSRK 0.762 13 SB Sequence A0301 11 FLSYKLSQK 0.710 23 SB SequenceA0301 164 RIAAWMATY 0.698 26 SB Sequence A0301 223 VLLGSLFSR 0.615 64 WBSequence A0301 7 LVVDFLSYK 0.497 231 WB Sequence A0301 7 LVVDFLSYK 0.76712 SB Sequence A1101 224 LLGSLFSRK 0.612 66 WB Sequence A1101 223VLLGSLFSR 0.595 79 WB Sequence A1101 164 RIAAWMATY 0.575 99 WB SequenceA1101 148 ALCVESVDK 0.529 163 WB Sequence A1101 78 EVIPMAAVK 0.509 201WB Sequence A1101 11 FLSYKLSQK 0.430 477 WB Sequence A1101 99 RYRRAFSDL0.690 28 SB Sequence A2301 135 NWGRIVAFF 0.644 47 SB Sequence A2301 137GRIVAFFSF 0.459 346 WB Sequence A2301 135 NWGRIVAFF 0.739 16 SB SequenceA2402 99 RYRRAFSDL 0.550 129 WB Sequence A2402 99 RYRRAFSDL 0.748 15 SBSequence A2403 121 SFEQVVNEL 0.557 120 WB Sequence A2403 118 AYQSFEQVV0.487 256 WB Sequence A2403 6 ELVVDFLSY 0.532 158 WB Sequence A2601 164RIAAWMATY 0.495 235 WB Sequence A2601 164 RIAAWMATY 0.923 2 SB SequenceA2602 6 ELVVDFLSY 0.873 3 SB Sequence A2602 161 LVSRIAAWM 0.677 32 SBSequence A2602 153 SVDKEMQVL 0.639 49 SB Sequence A2602 78 EVIPMAAVK0.496 234 WB Sequence A2602 217 MTVAGVVLL 0.481 273 WB Sequence A2602111 LHITPGTAY 0.553 125 WB Sequence A2902 6 ELVVDFLSY 0.539 146 WBSequence A2902 164 RIAAWMATY 0.463 334 WB Sequence A3002 82 MAAVKQALR0.766 12 SB Sequence A3101 223 VLLGSLFSR 0.686 30 SB Sequence A3101 7LVVDFLSYK 0.573 101 WB Sequence A3101 156 KEMQVLVSR 0.474 296 WBSequence A3101 94 DEFELRYRR 0.721 20 SB Sequence A3301 82 MAAVKQALR0.665 37 SB Sequence A3301 97 ELRYRRAFS 0.614 65 WB Sequence A3301 223VLLGSLFSR 0.581 92 WB Sequence A3301 91 EAGDEFELR 0.532 157 WB SequenceA3301 25 QFSDVEENR 0.531 159 WB Sequence A3301 78 EVIPMAAVK 0.848 5 SBSequence A6801 82 MAAVKQALR 0.813 7 SB Sequence A6801 7 LVVDFLSYK 0.78610 SB Sequence A6801 91 EAGDEFELR 0.710 23 SB Sequence A6801 123EQVVNELFR 0.635 51 WB Sequence A6801 11 FLSYKLSQK 0.558 119 WB SequenceA6801 94 DEFELRYRR 0.544 139 WB Sequence A6801 25 QFSDVEENR 0.540 145 WBSequence A6801 196 NNAAAESRK 0.474 295 WB Sequence A6801 223 VLLGSLFSR0.430 477 WB Sequence A6801 217 MTVAGVVLL 0.796 9 SB Sequence A6802 117TAYQSFEQV 0.729 18 SB Sequence A6802 215 TGMTVAGVV 0.654 42 SB SequenceA6802 0 MSQSNRELV 0.587 86 WB Sequence A6802 21 YSWSQFSDV 0.549 131 WBSequence A6802 143 FSFGGALCV 0.526 169 WB Sequence A6802 152 ESVDKEMQV0.525 171 WB Sequence A6802 169 MATYLNDHL 0.520 180 WB Sequence A6802192 ELYGNNAAA 0.509 202 WB Sequence A6802 140 VAFFSFGGA 0.500 222 WBSequence A6802 214 LTGMTVAGV 0.464 330 WB Sequence A6802 165 IAAWMATYL0.451 378 WB Sequence A6802 217 MTVAGVVLL 0.705 24 SB Sequence A6901 117TAYQSFEQV 0.623 58 WB Sequence A6901 192 ELYGNNAAA 0.604 72 WB SequenceA6901 143 FSFGGALCV 0.589 85 WB Sequence A6901 214 LTGMTVAGV 0.557 120WB Sequence A6901 21 YSWSQFSDV 0.489 252 WB Sequence A6901 36 APEGTESEM0.519 181 WB Sequence B0702 61 SPAVNGATG 0.454 369 WB Sequence B0702 114TPGTAYQSF 0.450 382 WB Sequence B0702 96 FELRYRRAF 0.497 229 WB SequenceB0801 164 RIAAWMATY 0.586 87 WB Sequence B1501 88 ALREAGDEF 0.520 180 WBSequence B1501 96 FELRYRRAF 0.752 14 SB Sequence B1801 206 QERFNRWFL0.592 82 WB Sequence B1801 122 FEQVVNELF 0.523 174 WB Sequence B1801 182QENGGWDTF 0.476 290 WB Sequence B1801 137 GRIVAFFSF 0.554 124 WBSequence B2705 101 RRAFSDLTS 0.434 459 WB Sequence B2705 114 TPGTAYQSF0.705 24 SB Sequence B3501 165 IAAWMATYL 0.649 44 SB Sequence B3501 36APEGTESEM 0.540 144 WB Sequence B3501 6 ELVVDFLSY 0.531 159 WB SequenceB3501 111 LHITPGTAY 0.437 441 WB Sequence B3501 53 NPSWHLADS 0.429 480WB Sequence B3501 164 RIAAWMATY 0.428 485 WB Sequence B3501 90 REAGDEFEL0.788 9 SB Sequence B4001 206 QERFNRWFL 0.597 78 WB Sequence B4001 182QENGGWDTF 0.525 170 WB Sequence B4001 122 FEQVVNELF 0.453 370 WBSequence B4001 96 FELRYRRAF 0.446 399 WB Sequence B4001 42 SEMETPSAI0.504 215 WB Sequence B4002 96 FELRYRRAF 0.473 299 WB Sequence B4002 182QENGGWDTF 0.434 455 WB Sequence B4402 42 SEMETPSAI 0.467 319 WB SequenceB4403 5 RELVVDFLS 0.444 407 WB Sequence B4403 77 REVIPMAAV 0.438 438 WBSequence B4501 165 IAAWMATYL 0.442 416 WB Sequence B5301 80 IPMAAVKQA0.716 21 SB Sequence B5401 48 SAINGNPSW 0.641 48 SB Sequence B5801 15KLSQKGYSW 0.596 79 WB Sequence B5801 165 IAAWMATYL 0.559 118 WB SequenceB5801 172 YLNDHLEPW 0.506 208 WB Sequence B5801 10-mers 104 FSDLTSQLHI0.427 492 WB Sequence A0101 172 YLNDHLEPWI 0.866 4 SB Sequence A0201 213FLTGMTVAGV 0.841 5 SB Sequence A0201 164 RIAAWMATYL 0.651 43 SB SequenceA0201 168 WMATYLNDHL 0.573 101 WB Sequence A0201 7 LVVDFLSYKL 0.524 173WB Sequence A0201 73 SLDAREVIPM 0.491 246 WB Sequence A0201 160VLVSRIAAWM 0.486 259 WB Sequence A0201 153 SVDKEMQVLV 0.473 298 WBSequence A0201 216 GMTVAGVVLL 0.444 411 WB Sequence A0201 213 FLTGMTVAGV0.811 7 SB Sequence A0202 168 WMATYLNDHL 0.772 11 SB Sequence A0202 164RIAAWMATYL 0.763 13 SB Sequence A0202 7 LVVDFLSYKL 0.651 43 SB SequenceA0202 102 RAFSDLTSQL 0.617 63 WB Sequence A0202 73 SLDAREVIPM 0.616 63WB Sequence A0202 172 YLNDHLEPWI 0.587 87 WB Sequence A0202 216GMTVAGVVLL 0.496 233 WB Sequence A0202 145 FGGALCVESV 0.480 276 WBSequence A0202 160 VLVSRIAAWM 0.430 476 WB Sequence A0202 213 FLTGMTVAGV0.936 2 SB Sequence A0203 172 YLNDHLEPWI 0.891 3 SB Sequence A0203 164RIAAWMATYL 0.837 5 SB Sequence A0203 168 WMATYLNDHL 0.647 45 SB SequenceA0203 160 VLVSRIAAWM 0.613 66 WB Sequence A0203 139 IVAFFSFGGA 0.596 79WB Sequence A0203 7 LVVDFLSYKL 0.581 92 WB Sequence A0203 125 VVNELFRDGV0.570 105 WB Sequence A0203 216 GMTVAGVVLL 0.476 289 WB Sequence A0203102 RAFSDLTSQL 0.470 308 WB Sequence A0203 214 LTGMTVAGVV 0.468 315 WBSequence A0203 116 GTAYQSFEQV 0.463 335 WB Sequence A0203 213 FLTGMTVAGV0.697 26 SB Sequence A0204 172 YLNDHLEPWI 0.664 37 SB Sequence A0204 73SLDAREVIPM 0.477 287 WB Sequence A0204 164 RIAAWMATYL 0.476 290 WBSequence A0204 7 LVVDFLSYKL 0.468 317 WB Sequence A0204 49 AINGNPSWHL0.452 374 WB Sequence A0204 213 FLTGMTVAGV 0.869 4 SB Sequence A0206 164RIAAWMATYL 0.809 7 SB Sequence A0206 172 YLNDHLEPWI 0.722 20 SB SequenceA0206 158 MQVLVSRIAA 0.689 28 SB Sequence A0206 7 LVVDFLSYKL 0.684 30 SBSequence A0206 168 WMATYLNDHL 0.680 31 SB Sequence A0206 109 SQLHITPGTA0.652 43 SB Sequence A0206 116 GTAYQSFEQV 0.572 102 WB Sequence A0206153 SVDKEMQVLV 0.558 119 WB Sequence A0206 102 RAFSDLTSQL 0.543 140 WBSequence A0206 156 KEMQVLVSRI 0.508 204 WB Sequence A0206 181 IQENGGWDTF0.508 205 WB Sequence A0206 139 IVAFFSFGGA 0.495 235 WB Sequence A0206125 VVNELFRDGV 0.483 269 WB Sequence A0206 117 TAYQSFEQVV 0.450 383 WBSequence A0206 213 FLTGMTVAGV 0.966 1 SB Sequence A0211 172 YLNDHLEPWI0.951 1 SB Sequence A0211 153 SVDKEMQVLV 0.905 2 SB Sequence A0211 73SLDAREVIPM 0.826 6 SB Sequence A0211 216 GMTVAGVVLL 0.737 17 SB SequenceA0211 7 LVVDFLSYKL 0.730 18 SB Sequence A0211 164 RIAAWMATYL 0.711 22 SBSequence A0211 125 VVNELFRDGV 0.687 29 SB Sequence A0211 49 AINGNPSWHL0.686 29 SB Sequence A0211 168 WMATYLNDHL 0.685 30 SB Sequence A0211 117TAYQSFEQVV 0.633 52 WB Sequence A0211 160 VLVSRIAAWM 0.632 53 WBSequence A0211 142 FFSFGGALCV 0.567 107 WB Sequence A0211 223 VLLGSLFSRK0.498 228 WB Sequence A0211 102 RAFSDLTSQL 0.453 372 WB Sequence A0211116 GTAYQSFEQV 0.429 481 WB Sequence A0211 213 FLTGMTVAGV 0.932 2 SBSequence A0212 172 YLNDHLEPWI 0.916 2 SB Sequence A0212 153 SVDKEMQVLV0.742 16 SB Sequence A0212 168 WMATYLNDHL 0.697 26 SB Sequence A0212 125VVNELFRDGV 0.695 27 SB Sequence A0212 7 LVVDFLSYKL 0.648 45 SB SequenceA0212 160 VLVSRIAAWM 0.604 72 WB Sequence A0212 73 SLDAREVIPM 0.594 80WB Sequence A0212 49 AINGNPSWHL 0.570 104 WB Sequence A0212 164RIAAWMATYL 0.550 129 WB Sequence A0212 142 FFSFGGALCV 0.494 238 WBSequence A0212 223 VLLGSLFSRK 0.487 258 WB Sequence A0212 117 TAYQSFEQVV0.482 270 WB Sequence A0212 192 ELYGNNAAAE 0.475 293 WB Sequence A0212216 GMTVAGVVLL 0.440 426 WB Sequence A0212 213 FLTGMTVAGV 0.911 2 SBSequence A0216 172 YLNDHLEPWI 0.869 4 SB Sequence A0216 153 SVDKEMQVLV0.772 11 SB Sequence A0216 168 WMATYLNDHL 0.696 26 SB Sequence A0216 164RIAAWMATYL 0.695 27 SB Sequence A0216 49 AINGNPSWHL 0.680 31 SB SequenceA0216 160 VLVSRIAAWM 0.657 41 SB Sequence A0216 7 LVVDFLSYKL 0.643 47 SBSequence A0216 73 SLDAREVIPM 0.617 62 WB Sequence A0216 216 GMTVAGVVLL0.588 85 WB Sequence A0216 117 TAYQSFEQVV 0.530 161 WB Sequence A0216142 FFSFGGALCV 0.487 256 WB Sequence A0216 116 GTAYQSFEQV 0.444 408 WBSequence A0216 213 FLTGMTVAGV 0.927 2 SB Sequence A0219 172 YLNDHLEPWI0.884 3 SB Sequence A0219 168 WMATYLNDHL 0.611 67 WB Sequence A0219 49AINGNPSWHL 0.543 140 WB Sequence A0219 7 LVVDFLSYKL 0.539 146 WBSequence A0219 153 SVDKEMQVLV 0.533 156 WB Sequence A0219 164 RIAAWMATYL0.449 387 WB Sequence A0219 73 SLDAREVIPM 0.445 404 WB Sequence A0219160 VLVSRIAAWM 0.441 421 WB Sequence A0219 223 VLLGSLFSRK 0.767 12 SBSequence A0301 6 ELVVDFLSYK 0.504 213 WB Sequence A0301 147 GALCVESVDK0.488 253 WB Sequence A0301 222 VVLLGSLFSR 0.457 356 WB Sequence A030177 REVIPMAAVK 0.453 372 WB Sequence A0301 223 VLLGSLFSRK 0.742 16 SBSequence A1101 222 VVLLGSLFSR 0.681 31 SB Sequence A1101 147 GALCVESVDK0.515 190 WB Sequence A1101 24 SQFSDVEENR 0.470 310 WB Sequence A1101121 SFEQVVNELF 0.581 92 WB Sequence A2301 171 TYLNDHLEPW 0.547 134 WBSequence A2301 121 SFEQVVNELF 0.528 165 WB Sequence A2402 171 TYLNDHLEPW0.520 180 WB Sequence A2402 113 ITPGTAYQSF 0.460 343 WB Sequence A2402171 TYLNDHLEPW 0.739 16 SB Sequence A2403 121 SFEQVVNELF 0.546 136 WBSequence A2403 113 ITPGTAYQSF 0.508 204 WB Sequence A2403 35 EAPEGTESEM0.448 390 WB Sequence A2601 164 RIAAWMATYL 0.626 57 WB Sequence A2602113 ITPGTAYQSF 0.581 92 WB Sequence A2602 160 VLVSRIAAWM 0.553 126 WBSequence A2602 35 EAPEGTESEM 0.507 207 WB Sequence A2602 152 ESVDKEMQVL0.490 249 WB Sequence A2602 95 EFELRYRRAF 0.483 268 WB Sequence A2602110 QLHITPGTAY 0.506 209 WB Sequence A2902 222 VVLLGSLFSR 0.683 30 SBSequence A3101 129 LFRDGVNWGR 0.667 36 SB Sequence A3101 202 SRKGQERFNR0.608 69 WB Sequence A3101 81 PMAAVKQALR 0.521 177 WB Sequence A3101 222VVLLGSLFSR 0.572 103 WB Sequence A3301 129 LFRDGVNWGR 0.553 126 WBSequence A3301 10 DFLSYKLSQK 0.470 308 WB Sequence A3301 6 ELVVDFLSYK0.702 25 SB Sequence A6801 24 SQFSDVEENR 0.532 158 WB Sequence A6801 222VVLLGSLFSR 0.516 188 WB Sequence A6801 194 YGNNAAAESR 0.493 240 WBSequence A6801 78 EVIPMAAVKQ 0.454 368 WB Sequence A6801 169 MATYLNDHLE0.448 394 WB Sequence A6801 139 IVAFFSFGGA 0.742 16 SB Sequence A6802116 GTAYQSFEQV 0.673 34 SB Sequence A6802 7 LVVDFLSYKL 0.659 39 SBSequence A6802 120 QSFEQVVNEL 0.618 62 WB Sequence A6802 213 FLTGMTVAGV0.577 96 WB Sequence A6802 117 TAYQSFEQVV 0.561 115 WB Sequence A6802164 RIAAWMATYL 0.519 182 WB Sequence A6802 65 NGATGHSSSL 0.496 234 WBSequence A6802 218 TVAGVVLLGS 0.491 246 WB Sequence A6802 145 FGGALCVESV0.474 294 WB Sequence A6802 125 VVNELFRDGV 0.465 328 WB Sequence A6802161 LVSRIAAWMA 0.451 380 WB Sequence A6802 215 TGMTVAGVVL 0.450 382 WBSequence A6802 153 SVDKEMQVLV 0.534 155 WB Sequence A6901 213 FLTGMTVAGV0.527 166 WB Sequence A6901 117 TAYQSFEQVV 0.466 324 WB Sequence A6901 7LVVDFLSYKL 0.451 378 WB Sequence A6901 164 RIAAWMATYL 0.443 412 WBSequence A6901 116 GTAYQSFEQV 0.427 493 WB Sequence A6901 80 IPMAAVKQAL0.704 24 SB Sequence B0702 17 SQKGYSWSQF 0.572 102 WB Sequence B1501 110QLHITPGTAY 0.557 121 WB Sequence B1501 133 GVNWGRIVAF 0.548 132 WBSequence B1501 181 IQENGGWDTF 0.522 175 WB Sequence B1501 12 LSYKLSQKGY0.455 364 WB Sequence B1501 5 RELVVDFLSY 0.759 13 SB Sequence B1801 163SRIAAWMATY 0.588 86 WB Sequence B2705 101 RRAFSDLTSQ 0.461 340 WBSequence B2705 80 IPMAAVKQAL 0.609 69 WB Sequence B3501 178 EPWIQENGGW0.604 72 WB Sequence B3501 91 EAGDEFELRY 0.566 109 WB Sequence B3501 35EAPEGTESEM 0.563 112 WB Sequence B3501 87 QALREAGDEF 0.508 206 WBSequence B3501 61 SPAVNGATGH 0.490 249 WB Sequence B3501 46 TPSAINGNPS0.483 269 WB Sequence B3501 133 GVNWGRIVAF 0.455 362 WB Sequence B3501140 VAFFSFGGAL 0.454 367 WB Sequence B3501 190 FVELYGNNAA 0.439 430 WBSequence B3501 200 AESRKGQERF 0.453 370 WB Sequence B4501 178 EPWIQENGGW0.603 73 WB Sequence B5301 2 QSNRELVVDF 0.474 295 WB Sequence B5801 159QVLVSRIAAW 0.467 320 WB Sequence B5801 47 PSAINGNPSW 0.437 444 WBSequence B5801 11-mers 213 FLTGMTVAGVV 0.627 56 WB Sequence A0201 73SLDAREVIPMA 0.561 115 WB Sequence A0201 160 VLVSRIAAWMA 0.547 135 WBSequence A0201 57 HLADSPAVNGA 0.539 147 WB Sequence A0201 172YLNDHLEPWIQ 0.480 278 WB Sequence A0201 88 ALREAGDEFEL 0.470 309 WBSequence A0201 119 YQSFEQVVNEL 0.426 497 WB Sequence A0201 57HLADSPAVNGA 0.763 12 SB Sequence A0202 213 FLTGMTVAGVV 0.754 14 SBSequence A0202 119 YQSFEQVVNEL 0.734 17 SB Sequence A0202 88 ALREAGDEFEL0.679 32 SB Sequence A0202 172 YLNDHLEPWIQ 0.611 67 WB Sequence A0202139 IVAFFSFGGAL 0.558 119 WB Sequence A0202 218 TVAGVVLLGSL 0.537 149 WBSequence A0202 160 VLVSRIAAWMA 0.525 170 WB Sequence A0202 15KLSQKGYSWSQ 0.450 382 WB Sequence A0202 6 ELVVDFLSYKL 0.449 387 WBSequence A0202 73 SLDAREVIPMA 0.446 401 WB Sequence A0202 213FLTGMTVAGVV 0.864 4 SB Sequence A0203 57 HLADSPAVNGA 0.844 5 SB SequenceA0203 138 RIVAFFSFGGA 0.752 14 SB Sequence A0203 160 VLVSRIAAWMA 0.64944 SB Sequence A0203 218 TVAGVVLLGSL 0.619 61 WB Sequence A0203 88ALREAGDEFEL 0.604 72 WB Sequence A0203 119 YQSFEQVVNEL 0.567 108 WBSequence A0203 172 YLNDHLEPWIQ 0.565 110 WB Sequence A0203 49AINGNPSWHLA 0.562 114 WB Sequence A0203 209 FNRWFLTGMTV 0.494 239 WBSequence A0203 139 IVAFFSFGGAL 0.487 257 WB Sequence A0203 73SLDAREVIPMA 0.480 276 WB Sequence A0203 82 MAAVKQALREA 0.430 477 WBSequence A0203 124 QVVNELFRDGV 0.426 496 WB Sequence A0203 213FLTGMTVAGVV 0.584 90 WB Sequence A0204 88 ALREAGDEFEL 0.526 168 WBSequence A0204 160 VLVSRIAAWMA 0.517 185 WB Sequence A0204 172YLNDHLEPWIQ 0.517 186 WB Sequence A0204 73 SLDAREVIPMA 0.485 263 WBSequence A0204 213 FLTGMTVAGVV 0.746 15 SB Sequence A0206 138RIVAFFSFGGA 0.725 19 SB Sequence A0206 181 IQENGGWDTFV 0.704 24 SBSequence A0206 119 YQSFEQVVNEL 0.671 35 SB Sequence A0206 48 SAINGNPSWHL0.664 38 SB Sequence A0206 124 QVVNELFRDGV 0.619 62 WB Sequence A0206160 VLVSRIAAWMA 0.584 90 WB Sequence A0206 86 KQALREAGDEF 0.547 134 WBSequence A0206 57 HLADSPAVNGA 0.509 201 WB Sequence A0206 218TVAGVVLLGSL 0.456 358 WB Sequence A0206 88 ALREAGDEFEL 0.442 420 WBSequence A0206 109 SQLHITPGTAY 0.441 422 WB Sequence A0206 213FLTGMTVAGVV 0.943 1 SB Sequence A0211 73 SLDAREVIPMA 0.876 3 SB SequenceA0211 172 YLNDHLEPWIQ 0.852 4 SB Sequence A0211 88 ALREAGDEFEL 0.799 8SB Sequence A0211 57 HLADSPAVNGA 0.787 10 SB Sequence A0211 160VLVSRIAAWMA 0.759 13 SB Sequence A0211 15 KLSQKGYSWSQ 0.743 16 SBSequence A0211 6 ELVVDFLSYKL 0.682 31 SB Sequence A0211 218 TVAGVVLLGSL0.628 55 WB Sequence A0211 49 AINGNPSWHLA 0.612 66 WB Sequence A0211 212WFLTGMTVAGV 0.577 97 WB Sequence A0211 141 AFFSFGGALCV 0.571 103 WBSequence A0211 144 SFGGALCVESV 0.569 105 WB Sequence A0211 79VIPMAAVKQAL 0.568 107 WB Sequence A0211 124 QVVNELFRDGV 0.535 152 WBSequence A0211 130 FRDGVNWGRIV 0.516 187 WB Sequence A0211 48SAINGNPSWHL 0.515 189 WB Sequence A0211 192 ELYGNNAAAES 0.504 214 WBSequence A0211 150 CVESVDKEMQV 0.489 252 WB Sequence A0211 116GTAYQSFEQVV 0.452 376 WB Sequence A0211 139 IVAFFSFGGAL 0.444 411 WBSequence A0211 213 FLTGMTVAGVV 0.824 6 SB Sequence A0212 172 YLNDHLEPWIQ0.812 7 SB Sequence A0212 88 ALREAGDEFEL 0.779 10 SB Sequence A0212 73SLDAREVIPMA 0.745 15 SB Sequence A0212 57 HLADSPAVNGA 0.714 22 SBSequence A0212 160 VLVSRIAAWMA 0.681 31 SB Sequence A0212 79 VIPMAAVKQAL0.604 72 WB Sequence A0212 15 KLSQKGYSWSQ 0.568 107 WB Sequence A0212212 WFLTGMTVAGV 0.504 213 WB Sequence A0212 6 ELVVDFLSYKL 0.451 380 WBSequence A0212 130 FRDGVNWGRIV 0.431 473 WB Sequence A0212 213FLTGMTVAGVV 0.862 4 SB Sequence A0216 88 ALREAGDEFEL 0.821 6 SB SequenceA0216 73 SLDAREVIPMA 0.744 16 SB Sequence A0216 160 VLVSRIAAWMA 0.649 44SB Sequence A0216 150 CVESVDKEMQV 0.641 48 SB Sequence A0216 57HLADSPAVNGA 0.595 79 WB Sequence A0216 144 SFGGALCVESV 0.591 83 WBSequence A0216 172 YLNDHLEPWIQ 0.581 92 WB Sequence A0216 15 KLSQKGYSWSQ0.561 115 WB Sequence A0216 6 ELVVDFLSYKL 0.544 138 WB Sequence A0216218 TVAGVVLLGSL 0.534 154 WB Sequence A0216 141 AFFSFGGALCV 0.526 168 WBSequence A0216 181 IQENGGWDTFV 0.497 231 WB Sequence A0216 124QVVNELFRDGV 0.490 249 WB Sequence A0216 79 VIPMAAVKQAL 0.487 257 WBSequence A0216 192 ELYGNNAAAES 0.478 283 WB Sequence A0216 48SAINGNPSWHL 0.468 315 WB Sequence A0216 212 WFLTGMTVAGV 0.437 441 WBSequence A0216 49 AINGNPSWHLA 0.436 447 WB Sequence A0216 213FLTGMTVAGVV 0.781 10 SB Sequence A0219 57 HLADSPAVNGA 0.730 18 SBSequence A0219 172 YLNDHLEPWIQ 0.695 27 SB Sequence A0219 73 SLDAREVIPMA0.609 68 WB Sequence A0219 88 ALREAGDEFEL 0.549 131 WB Sequence A0219212 WFLTGMTVAGV 0.524 172 WB Sequence A0219 160 VLVSRIAAWMA 0.499 225 WBSequence A0219 222 VVLLGSLFSRK 0.688 29 SB Sequence A0301 222VVLLGSLFSRK 0.786 10 SB Sequence A1101 221 GVVLLGSLFSR 0.596 78 WBSequence A1101 67 ATGHSSSLDAR 0.505 212 WB Sequence A1101 5 RELVVDFLSYK0.428 489 WB Sequence A1101 135 NWGRIVAFFSF 0.695 26 SB Sequence A2301171 TYLNDHLEPWI 0.576 98 WB Sequence A2301 167 AWMATYLNDHL 0.534 154 WBSequence A2301 13 SYKLSQKGYSW 0.531 159 WB Sequence A2301 135NWGRIVAFFSF 0.746 15 SB Sequence A2402 171 TYLNDHLEPWI 0.746 15 SBSequence A2402 167 AWMATYLNDHL 0.520 180 WB Sequence A2402 171TYLNDHLEPWI 0.660 39 SB Sequence A2403 167 AWMATYLNDHL 0.523 174 WBSequence A2403 13 SYKLSQKGYSW 0.523 174 WB Sequence A2403 112HITPGTAYQSF 0.431 473 WB Sequence A2403 159 QVLVSRIAAWM 0.640 49 SBSequence A2602 112 HITPGTAYQSF 0.573 101 WB Sequence A2602 180WIQENGGWDTF 0.518 183 WB Sequence A2602 11 FLSYKLSQKGY 0.516 188 WBSequence A2602 132 DGVNWGRIVAF 0.462 336 WB Sequence A2602 218TVAGVVLLGSL 0.443 415 WB Sequence A2602 109 SQLHITPGTAY 0.516 188 WBSequence A2902 222 VVLLGSLFSRK 0.435 453 WB Sequence A3001 99RYRRAFSDLTS 0.428 486 WB Sequence A3001 221 GVVLLGSLFSR 0.598 77 WBSequence A3101 121 SFEQVVNELFR 0.552 127 WB Sequence A3101 201ESRKGQERFNR 0.511 198 WB Sequence A3101 67 ATGHSSSLDAR 0.475 292 WBSequence A3101 5 RELVVDFLSYK 0.442 417 WB Sequence A3101 193 LYGNNAAAESR0.435 449 WB Sequence A3101 201 ESRKGQERFNR 0.690 28 SB Sequence A3301128 ELFRDGVNWGR 0.634 52 WB Sequence A3301 91 EAGDEFELRYR 0.538 148 WBSequence A3301 121 SFEQVVNELFR 0.472 303 WB Sequence A3301 221GVVLLGSLFSR 0.447 396 WB Sequence A3301 95 EFELRYRRAFS 0.435 449 WBSequence A3301 128 ELFRDGVNWGR 0.739 16 SB Sequence A6801 23 WSQFSDVEENR0.667 36 SB Sequence A6801 201 ESRKGQERFNR 0.666 36 SB Sequence A6801 91EAGDEFELRYR 0.643 47 SB Sequence A6801 221 GVVLLGSLFSR 0.638 49 SBSequence A6801 80 IPMAAVKQALR 0.566 109 WB Sequence A6801 121SFEQVVNELFR 0.536 151 WB Sequence A6801 218 TVAGVVLLGSL 0.796 9 SBSequence A6802 124 QVVNELFRDGV 0.712 22 SB Sequence A6802 139IVAFFSFGGAL 0.684 30 SB Sequence A6802 152 ESVDKEMQVLV 0.613 65 WBSequence A6802 215 TGMTVAGVVLL 0.561 116 WB Sequence A6802 6 ELVVDFLSYKL0.551 129 WB Sequence A6802 138 RIVAFFSFGGA 0.548 132 WB Sequence A6802188 DTFVELYGNNA 0.530 161 WB Sequence A6802 78 EVIPMAAVKQA 0.516 188 WBSequence A6802 116 GTAYQSFEQVV 0.514 191 WB Sequence A6802 75DAREVIPMAAV 0.509 203 WB Sequence A6802 57 HLADSPAVNGA 0.508 206 WBSequence A6802 217 MTVAGVVLLGS 0.480 277 WB Sequence A6802 45ETPSAINGNPS 0.479 279 WB Sequence A6802 213 FLTGMTVAGVV 0.470 308 WBSequence A6802 70 HSSSLDAREVI 0.447 397 WB Sequence A6802 48 SAINGNPSWHL0.541 143 WB Sequence A6901 75 DAREVIPMAAV 0.527 166 WB Sequence A6901152 ESVDKEMQVLV 0.511 199 WB Sequence A6901 57 HLADSPAVNGA 0.485 263 WBSequence A6901 54 PSWHLADSPAV 0.469 312 WB Sequence A6901 212WFLTGMTVAGV 0.453 369 WB Sequence A6901 78 EVIPMAAVKQA 0.442 417 WBSequence A6901 6 ELVVDFLSYKL 0.442 417 WB Sequence A6901 218 TVAGVVLLGSL0.430 475 WB Sequence A6901 188 DTFVELYGNNA 0.427 494 WB Sequence A6901139 IVAFFSFGGAL 0.518 183 WB Sequence B0702 53 NPSWHLADSPA 0.499 224 WBSequence B0702 61 SPAVNGATGHS 0.457 355 WB Sequence B0702 109SQLHITPGTAY 0.605 72 WB Sequence B1501 86 KQALREAGDEF 0.567 108 WBSequence B1501 1 SQSNRELVVDF 0.540 144 WB Sequence B1501 119 YQSFEQVVNEL0.515 189 WB Sequence B1501 158 MQVLVSRIAAW 0.512 196 WB Sequence B1501162 VSRIAAWMATY 0.477 285 WB Sequence B1501 11 FLSYKLSQKGY 0.474 294 WBSequence B1501 180 WIQENGGWDTF 0.473 299 WB Sequence B1501 120QSFEQVVNELF 0.450 386 WB Sequence B1501 112 HITPGTAYQSF 0.447 394 WBSequence B1501 133 GVNWGRIVAFF 0.433 463 WB Sequence B1501 94DEFELRYRRAF 0.829 6 SB Sequence B1801 90 REAGDEFELRY 0.560 116 WBSequence B1801 109 SQLHITPGTAY 0.539 146 WB Sequence B1801 151VESVDKEMQVL 0.476 288 WB Sequence B1801 177 LEPWIQENGGW 0.466 321 WBSequence B1801 209 FNRWFLTGMTV 0.444 409 WB Sequence B1801 101RRAFSDLTSQL 0.563 113 WB Sequence B2705 163 SRIAAWMATYL 0.470 310 WBSequence B2705 53 NPSWHLADSPA 0.623 59 WB Sequence B3501 46 TPSAINGNPSW0.485 263 WB Sequence B3501 180 WIQENGGWDTF 0.474 297 WB Sequence B3501132 DGVNWGRIVAF 0.442 419 WB Sequence B3501 119 YQSFEQVVNEL 0.610 68 WBSequence B3901 151 VESVDKEMQVL 0.492 243 WB Sequence B4001 40TESEMETPSAI 0.446 402 WB Sequence B4002 30 EENRTEAPEGT 0.498 228 WBSequence B4501 46 TPSAINGNPSW 0.772 11 SB Sequence B5301 53 NPSWHLADSPA0.430 474 WB Sequence B5401 170 ATYLNDHLEPW 0.540 145 WB Sequence B5701170 ATYLNDHLEPW 0.537 150 WB Sequence B5801 120 QSFEQVVNELF 0.495 235 WBSequence B5801 SEQ ID NOS.: 45801-46593

Preferred fragments of Bcl-2 capable of interacting with one or more MHCclass 1 molecules are listed in table C below.

TABLE C Prediction of cancer antigen Bcl-2 specific MHC class1, 8-,9-, 10-, 11-mer peptide binders for 42 MHC class 1 alleles(see FIG. 11) using the http://www.cbs.dtu.dk/services/NetMHC/ database. The MHC class 1 molecules for whichno binders were found are not listed. pos peptide logscore affinity (nM)Bind Level Protein Name Allele 8-mer 84 ALSPVPPV 0.783 10 SB SequenceA0201 218 TLLSLALV 0.723 20 SB Sequence A0201 173 ALWMTEYL 0.682 31 SBSequence A0201 154 GVMCVESV 0.630 54 WB Sequence A0201 207 PLFDFSWL0.488 253 WB Sequence A0201 215 SLKTLLSL 0.449 387 WB Sequence A0201 84ALSPVPPV 0.710 23 SB Sequence A0202 213 WLSLKTLL 0.709 23 SB SequenceA0202 215 SLKTLLSL 0.661 39 SB Sequence A0202 207 PLFDFSWL 0.653 42 SBSequence A0202 173 ALWMTEYL 0.631 54 WB Sequence A0202 154 GVMCVESV0.630 55 WB Sequence A0202 218 TLLSLALV 0.610 68 WB Sequence A0202 113EMSSQLHL 0.570 105 WB Sequence A0202 224 LVGACITL 0.534 154 WB SequenceA0202 129 FATVVEEL 0.512 195 WB Sequence A0202 167 PLVDNIAL 0.508 204 WBSequence A0202 179 YLNRHLHT 0.435 453 WB Sequence A0202 209 FDFSWLSL0.432 464 WB Sequence A0202 84 ALSPVPPV 0.909 2 SB Sequence A0203 215SLKTLLSL 0.853 4 SB Sequence A0203 154 GVMCVESV 0.754 14 SB SequenceA0203 179 YLNRHLHT 0.682 31 SB Sequence A0203 218 TLLSLALV 0.673 34 SBSequence A0203 213 WLSLKTLL 0.665 37 SB Sequence A0203 140 GVNWGRIV0.581 92 WB Sequence A0203 123 FTARGRFA 0.523 174 WB Sequence A0203 173ALWMTEYL 0.497 229 WB Sequence A0203 207 PLFDFSWL 0.478 284 WB SequenceA0203 84 ALSPVPPV 0.763 13 SB Sequence A0204 173 ALWMTEYL 0.541 144 WBSequence A0204 218 TLLSLALV 0.526 168 WB Sequence A0204 154 GVMCVESV0.478 283 WB Sequence A0204 224 LVGACITL 0.451 381 WB Sequence A0204 84ALSPVPPV 0.764 12 SB Sequence A0206 154 GVMCVESV 0.743 16 SB SequenceA0206 116 SQLHLTPF 0.737 17 SB Sequence A0206 218 TLLSLALV 0.714 21 SBSequence A0206 145 RIVAFFEF 0.623 58 WB Sequence A0206 217 KTLLSLAL0.574 100 WB Sequence A0206 173 ALWMTEYL 0.538 148 WB Sequence A0206 224LVGACITL 0.463 334 WB Sequence A0206 123 FTARGRFA 0.462 335 WB SequenceA0206 213 WLSLKTLL 0.451 378 WB Sequence A0206 129 FATVVEEL 0.450 383 WBSequence A0206 97 RQAGDDFS 0.436 445 WB Sequence A0206 84 ALSPVPPV 0.9561 SB Sequence A0211 218 TLLSLALV 0.954 1 SB Sequence A0211 173 ALWMTEYL0.935 2 SB Sequence A0211 207 PLFDFSWL 0.934 2 SB Sequence A0211 167PLVDNIAL 0.888 3 SB Sequence A0211 215 SLKTLLSL 0.819 7 SB SequenceA0211 213 WLSLKTLL 0.780 10 SB Sequence A0211 179 YLNRHLHT 0.716 21 SBSequence A0211 113 EMSSQLHL 0.686 29 SB Sequence A0211 140 GVNWGRIV0.668 36 SB Sequence A0211 154 GVMCVESV 0.578 95 WB Sequence A0211 148AFFEFGGV 0.534 154 WB Sequence A0211 87 PVPPVVHL 0.512 197 WB SequenceA0211 228 CITLGAYL 0.500 223 WB Sequence A0211 224 LVGACITL 0.500 223 WBSequence A0211 223 ALVGACIT 0.479 281 WB Sequence A0211 27 YEWDAGDV0.472 303 WB Sequence A0211 151 EFGGVMCV 0.452 377 WB Sequence A0211 221SLALVGAC 0.445 405 WB Sequence A0211 84 ALSPVPPV 0.874 3 SB SequenceA0212 173 ALWMTEYL 0.860 4 SB Sequence A0212 218 TLLSLALV 0.857 4 SBSequence A0212 207 PLFDFSWL 0.836 5 SB Sequence A0212 167 PLVDNIAL 0.7879 SB Sequence A0212 215 SLKTLLSL 0.756 13 SB Sequence A0212 179 YLNRHLHT0.720 20 SB Sequence A0212 113 EMSSQLHL 0.594 80 WB Sequence A0212 213WLSLKTLL 0.564 112 WB Sequence A0212 27 YEWDAGDV 0.477 288 WB SequenceA0212 154 GVMCVESV 0.460 344 WB Sequence A0212 84 ALSPVPPV 0.926 2 SBSequence A0216 173 ALWMTEYL 0.916 2 SB Sequence A0216 218 TLLSLALV 0.9022 SB Sequence A0216 207 PLFDFSWL 0.889 3 SB Sequence A0216 167 PLVDNIAL0.767 12 SB Sequence A0216 215 SLKTLLSL 0.723 20 SB Sequence A0216 213WLSLKTLL 0.718 21 SB Sequence A0216 113 EMSSQLHL 0.665 37 SB SequenceA0216 154 GVMCVESV 0.646 46 SB Sequence A0216 179 YLNRHLHT 0.631 53 WBSequence A0216 223 ALVGACIT 0.591 83 WB Sequence A0216 224 LVGACITL0.531 159 WB Sequence A0216 87 PVPPVVHL 0.526 168 WB Sequence A0216 151EFGGVMCV 0.524 173 WB Sequence A0216 228 CITLGAYL 0.522 176 WB SequenceA0216 140 GVNWGRIV 0.470 308 WB Sequence A0216 84 ALSPVPPV 0.898 3 SBSequence A0219 173 ALWMTEYL 0.871 4 SB Sequence A0219 218 TLLSLALV 0.8475 SB Sequence A0219 207 PLFDFSWL 0.785 10 SB Sequence A0219 167 PLVDNIAL0.713 22 SB Sequence A0219 113 EMSSQLHL 0.613 65 WB Sequence A0219 213WLSLKTLL 0.599 76 WB Sequence A0219 154 GVMCVESV 0.468 317 WB SequenceA0219 215 SLKTLLSL 0.466 322 WB Sequence A0219 27 YEWDAGDV 0.437 440 WBSequence A0219 179 YLNRHLHT 0.436 447 WB Sequence A0219 14 VMKYIHYK0.629 55 WB Sequence A0301 13 IVMKYIHY 0.514 193 WB Sequence A0301 119HLTPFTAR 0.467 319 WB Sequence A0301 199 ELYGPSMR 0.456 360 WB SequenceA0301 14 VMKYIHYK 0.645 46 SB Sequence A1101 131 TVVEELFR 0.616 63 WBSequence A1101 13 IVMKYIHY 0.577 97 WB Sequence A1101 142 NWGRIVAF 0.60075 WB Sequence A2301 145 RIVAFFEF 0.518 184 WB Sequence A2301 204SMRPLFDF 0.469 312 WB Sequence A2301 122 PFTARGRF 0.441 424 WB SequenceA2301 142 NWGRIVAF 0.617 62 WB Sequence A2402 212 SWLSLKTL 0.459 349 WBSequence A2402 204 SMRPLFDF 0.547 135 WB Sequence A2403 145 RIVAFFEF0.437 441 WB Sequence A2403 13 IVMKYIHY 0.638 50 WB Sequence A2602 113EMSSQLHL 0.445 406 WB Sequence A2602 145 RIVAFFEF 0.436 445 WB SequenceA2602 12 EIVMKYIH 0.430 478 WB Sequence A2602 130 ATVVEELF 0.428 489 WBSequence A2602 13 IVMKYIHY 0.603 73 WB Sequence A2902 227 ACITLGAY 0.449387 WB Sequence A2902 14 VMKYIHYK 0.593 81 WB Sequence A3001 60 ASRDPVAR0.498 229 WB Sequence A3001 126 RGRFATVV 0.480 276 WB Sequence A3001 113EMSSQLHL 0.446 401 WB Sequence A3002 204 SMRPLFDF 0.444 410 WB SequenceA3002 14 VMKYIHYK 0.842 5 SB Sequence A3101 119 HLTPFTAR 0.709 23 SBSequence A3101 60 ASRDPVAR 0.692 28 SB Sequence A3101 102 DFSRRYRR 0.62259 WB Sequence A3101 175 WMTEYLNR 0.564 112 WB Sequence A3101 131TVVEELFR 0.458 351 WB Sequence A3101 102 DFSRRYRR 0.883 3 SB SequenceA3301 119 HLTPFTAR 0.746 15 SB Sequence A3301 210 DFSWLSLK 0.672 34 SBSequence A3301 101 DDFSRRYR 0.622 60 WB Sequence A3301 199 ELYGPSMR0.615 64 WB Sequence A3301 131 TVVEELFR 0.546 136 WB Sequence A3301 14VMKYIHYK 0.510 199 WB Sequence A3301 131 TVVEELFR 0.843 5 SB SequenceA6801 199 ELYGPSMR 0.792 9 SB Sequence A6801 119 HLTPFTAR 0.733 18 SBSequence A6801 210 DFSWLSLK 0.637 50 WB Sequence A6801 121 TPFTARGR0.625 58 WB Sequence A6801 55 TPHPAASR 0.581 93 WB Sequence A6801 101DDFSRRYR 0.526 168 WB Sequence A6801 14 VMKYIHYK 0.524 171 WB SequenceA6801 98 QAGDDFSR 0.522 176 WB Sequence A6801 175 WMTEYLNR 0.505 211 WBSequence A6801 156 MCVESVNR 0.502 219 WB Sequence A6801 102 DFSRRYRR0.491 247 WB Sequence A6801 90 PVVHLTLR 0.456 358 WB Sequence A6801 154GVMCVESV 0.630 54 WB Sequence A6802 165 MSPLVDNI 0.606 70 WB SequenceA6802 123 FTARGRFA 0.594 80 WB Sequence A6802 129 FATVVEEL 0.501 220 WBSequence A6802 72 QTPAAPGA 0.474 297 WB Sequence A6802 218 TLLSLALV0.607 70 WB Sequence A6901 123 FTARGRFA 0.486 261 WB Sequence A6901 113EMSSQLHL 0.470 309 WB Sequence A6901 84 ALSPVPPV 0.444 409 WB SequenceA6901 202 GPSMRPLF 0.599 76 WB Sequence B0702 73 TPAAPGAA 0.598 77 WBSequence B0702 69 SPLQTPAA 0.539 146 WB Sequence B0702 89 PPVVHLTL 0.503216 WB Sequence B0702 206 RPLFDFSW 0.445 403 WB Sequence B0702 116SQLHLTPF 0.583 91 WB Sequence B1501 204 SMRPLFDF 0.523 173 WB SequenceB1501 13 IVMKYIHY 0.492 243 WB Sequence B1501 145 RIVAFFEF 0.447 397 WBSequence B1501 198 VELYGPSM 0.595 80 WB Sequence B1801 177 TEYLNRHL0.498 228 WB Sequence B1801 172 IALWMTEY 0.475 292 WB Sequence B1801 116SQLHLTPF 0.464 328 WB Sequence B1801 150 FEFGGVMC 0.452 375 WB SequenceB1801 172 IALWMTEY 0.767 12 SB Sequence B3501 149 FFEFGGVM 0.548 132 WBSequence B3501 69 SPLQTPAA 0.503 215 WB Sequence B3501 111 FAEMSSQL0.488 253 WB Sequence B3501 86 SPVPPVVH 0.443 413 WB Sequence B3501 73TPAAPGAA 0.435 452 WB Sequence B3501 129 FATVVEEL 0.430 475 WB SequenceB3501 177 TEYLNRHL 0.547 133 WB Sequence B4001 11 REIVMKYI 0.513 194 WBSequence B4001 150 FEFGGVMC 0.466 324 WB Sequence B4001 11 REIVMKYI0.497 231 WB Sequence B4002 112 AEMSSQLH 0.471 305 WB Sequence B4501 134EELFRDGV 0.465 326 WB Sequence B4501 11 REIVMKYI 0.435 450 WB SequenceB4501 222 LALVGACI 0.470 308 WB Sequence B5101 89 PPVVHLTL 0.448 391 WBSequence B5101 206 RPLFDFSW 0.768 12 SB Sequence B5301 202 GPSMRPLF0.430 474 WB Sequence B5301 73 TPAAPGAA 0.677 32 SB Sequence B5401 69SPLQTPAA 0.605 71 WB Sequence B5401 37 APPGAAPA 0.557 120 WB SequenceB5401 166 SPLVDNIA 0.470 309 WB Sequence B5401 88 VPPVVHLT 0.450 382 WBSequence B5401 22 LSQRGYEW 0.648 45 SB Sequence B5801 145 RIVAFFEF 0.512196 WB Sequence B5801 168 LVDNIALW 0.475 292 WB Sequence B5801 172IALWMTEY 0.460 345 WB Sequence B5801 9-mer 171 NIALWMTEY 0.497 230 WBSequence A0101 84 ALSPVPPVV 0.676 33 SB Sequence A0201 223 ALVGACITL0.631 54 WB Sequence A0201 217 KTLLSLALV 0.613 65 WB Sequence A0201 219LLSLALVGA 0.542 141 WB Sequence A0201 172 IALWMTEYL 0.487 258 WBSequence A0201 219 LLSLALVGA 0.824 6 SB Sequence A0202 14 VMKYIHYKL0.705 24 SB Sequence A0202 223 ALVGACITL 0.654 42 SB Sequence A0202 215SLKTLLSLA 0.635 52 WB Sequence A0202 160 SVNREMSPL 0.619 61 WB SequenceA0202 80 AAGPALSPV 0.617 62 WB Sequence A0202 84 ALSPVPPVV 0.593 81 WBSequence A0202 164 EMSPLVDNI 0.582 91 WB Sequence A0202 221 SLALVGACI0.579 94 WB Sequence A0202 67 RTSPLQTPA 0.554 124 WB Sequence A0202 204SMRPLFDFS 0.495 234 WB Sequence A0202 179 YLNRHLHTW 0.479 280 WBSequence A0202 172 IALWMTEYL 0.459 346 WB Sequence A0202 217 KTLLSLALV0.443 414 WB Sequence A0202 113 EMSSQLHLT 0.432 464 WB Sequence A0202215 SLKTLLSLA 0.875 3 SB Sequence A0203 84 ALSPVPPVV 0.842 5 SB SequenceA0203 219 LLSLALVGA 0.839 5 SB Sequence A0203 80 AAGPALSPV 0.770 11 SBSequence A0203 160 SVNREMSPL 0.699 26 SB Sequence A0203 124 TARGRFATV0.666 37 SB Sequence A0203 14 VMKYIHYKL 0.642 48 SB Sequence A0203 223ALVGACITL 0.629 55 WB Sequence A0203 221 SLALVGACI 0.605 71 WB SequenceA0203 217 KTLLSLALV 0.584 90 WB Sequence A0203 67 RTSPLQTPA 0.539 146 WBSequence A0203 147 VAFFEFGGV 0.520 180 WB Sequence A0203 164 EMSPLVDNI0.516 187 WB Sequence A0203 117 QLHLTPFTA 0.490 249 WB Sequence A0203204 SMRPLFDFS 0.441 425 WB Sequence A0203 179 YLNRHLHTW 0.432 468 WBSequence A0203 84 ALSPVPPVV 0.766 12 SB Sequence A0204 223 ALVGACITL0.571 103 WB Sequence A0204 80 AAGPALSPV 0.454 366 WB Sequence A0204 217KTLLSLALV 0.742 16 SB Sequence A0206 80 AAGPALSPV 0.729 18 SB SequenceA0206 116 SQLHLTPFT 0.684 30 SB Sequence A0206 71 LQTPAAPGA 0.676 33 SBSequence A0206 150 FEFGGVMCV 0.650 44 SB Sequence A0206 223 ALVGACITL0.635 52 WB Sequence A0206 219 LLSLALVGA 0.624 58 WB Sequence A0206 84ALSPVPPVV 0.621 60 WB Sequence A0206 123 FTARGRFAT 0.598 77 WB SequenceA0206 188 IQDNGGWDA 0.594 80 WB Sequence A0206 172 IALWMTEYL 0.589 85 WBSequence A0206 36 AAPPGAAPA 0.569 106 WB Sequence A0206 124 TARGRFATV0.543 140 WB Sequence A0206 147 VAFFEFGGV 0.511 198 WB Sequence A0206 67RTSPLQTPA 0.462 336 WB Sequence A0206 84 ALSPVPPVV 0.951 1 SB SequenceA0211 223 ALVGACITL 0.929 2 SB Sequence A0211 207 PLFDFSWLS 0.902 2 SBSequence A0211 150 FEFGGVMCV 0.812 7 SB Sequence A0211 179 YLNRHLHTW0.742 16 SB Sequence A0211 221 SLALVGACI 0.715 21 SB Sequence A0211 219LLSLALVGA 0.627 56 WB Sequence A0211 164 EMSPLVDNI 0.626 57 WB SequenceA0211 117 QLHLTPFTA 0.626 57 WB Sequence A0211 215 SLKTLLSLA 0.620 61 WBSequence A0211 168 LVDNIALWM 0.592 82 WB Sequence A0211 217 KTLLSLALV0.581 93 WB Sequence A0211 140 GVNWGRIVA 0.575 99 WB Sequence A0211 14VMKYIHYKL 0.561 115 WB Sequence A0211 80 AAGPALSPV 0.551 128 WB SequenceA0211 113 EMSSQLHLT 0.531 159 WB Sequence A0211 6 TGYDNREIV 0.513 194 WBSequence A0211 119 HLTPFTARG 0.505 211 WB Sequence A0211 199 ELYGPSMRP0.504 213 WB Sequence A0211 192 GGWDAFVEL 0.503 216 WB Sequence A0211172 IALWMTEYL 0.462 337 WB Sequence A0211 173 ALWMTEYLN 0.459 347 WBSequence A0211 36 AAPPGAAPA 0.432 467 WB Sequence A0211 84 ALSPVPPVV0.914 2 SB Sequence A0212 223 ALVGACITL 0.760 13 SB Sequence A0212 179YLNRHLHTW 0.739 16 SB Sequence A0212 150 FEFGGVMCV 0.735 17 SB SequenceA0212 207 PLFDFSWLS 0.676 33 SB Sequence A0212 14 VMKYIHYKL 0.596 79 WBSequence A0212 219 LLSLALVGA 0.587 87 WB Sequence A0212 221 SLALVGACI0.529 162 WB Sequence A0212 164 EMSPLVDNI 0.520 180 WB Sequence A0212117 QLHLTPFTA 0.476 290 WB Sequence A0212 123 FTARGRFAT 0.464 328 WBSequence A0212 84 ALSPVPPVV 0.915 2 SB Sequence A0216 223 ALVGACITL0.909 2 SB Sequence A0216 80 AAGPALSPV 0.699 25 SB Sequence A0216 150FEFGGVMCV 0.640 49 SB Sequence A0216 221 SLALVGACI 0.630 54 WB SequenceA0216 14 VMKYIHYKL 0.570 104 WB Sequence A0216 207 PLFDFSWLS 0.530 162WB Sequence A0216 117 QLHLTPFTA 0.490 250 WB Sequence A0216 215SLKTLLSLA 0.489 251 WB Sequence A0216 179 YLNRHLHTW 0.461 340 WBSequence A0216 124 TARGRFATV 0.448 393 WB Sequence A0216 84 ALSPVPPVV0.899 2 SB Sequence A0219 150 FEFGGVMCV 0.686 29 SB Sequence A0219 223ALVGACITL 0.683 30 SB Sequence A0219 80 AAGPALSPV 0.557 120 WB SequenceA0219 219 LLSLALVGA 0.542 142 WB Sequence A0219 83 PALSPVPPV 0.498 229WB Sequence A0219 164 EMSPLVDNI 0.460 345 WB Sequence A0219 113EMSSQLHLT 0.437 443 WB Sequence A0219 179 YLNRHLHTW 0.428 485 WBSequence A0219 13 IVMKYIHYK 0.758 13 SB Sequence A0301 230 TLGAYLGHK0.655 41 SB Sequence A0301 209 FDFSWLSLK 0.457 357 WB Sequence A0301 13IVMKYIHYK 0.834 6 SB Sequence A1101 230 TLGAYLGHK 0.708 23 SB SequenceA1101 130 ATVVEELFR 0.574 100 WB Sequence A1101 142 NWGRIVAFF 0.644 47SB Sequence A2301 203 PSMRPLFDF 0.530 161 WB Sequence A2301 144GRIVAFFEF 0.530 162 WB Sequence A2301 13 IVMKYIHYK 0.499 226 WB SequenceA2301 106 RYRRDFAEM 0.467 321 WB Sequence A2301 128 RFATVVEEL 0.454 366WB Sequence A2301 142 NWGRIVAFF 0.739 16 SB Sequence A2402 128 RFATVVEEL0.568 107 WB Sequence A2402 212 SWLSLKTLL 0.536 151 WB Sequence A2402106 RYRRDFAEM 0.669 35 SB Sequence A2403 128 RFATVVEEL 0.626 57 WBSequence A2403 200 LYGPSMRPL 0.553 125 WB Sequence A2403 12 EIVMKYIHY0.628 55 WB Sequence A2601 171 NIALWMTEY 0.622 60 WB Sequence A2601 12EIVMKYIHY 0.935 2 SB Sequence A2602 171 NIALWMTEY 0.866 4 SB SequenceA2602 160 SVNREMSPL 0.849 5 SB Sequence A2602 179 YLNRHLHTW 0.538 148 WBSequence A2602 197 FVELYGPSM 0.520 180 WB Sequence A2602 168 LVDNIALWM0.432 464 WB Sequence A2602 171 NIALWMTEY 0.586 88 WB Sequence A2902 12EIVMKYIHY 0.516 188 WB Sequence A2902 13 IVMKYIHYK 0.758 13 SB SequenceA3001 0 MAHAGRTGY 0.487 258 WB Sequence A3001 230 TLGAYLGHK 0.475 293 WBSequence A3001 171 NIALWMTEY 0.427 491 WB Sequence A3002 13 IVMKYIHYK0.797 8 SB Sequence A3101 17 YIHYKLSQR 0.715 21 SB Sequence A3101 155VMCVESVNR 0.631 54 WB Sequence A3101 97 RQAGDDFSR 0.588 85 WB SequenceA3101 14 VMKYIHYKL 0.497 230 WB Sequence A3101 130 ATVVEELFR 0.471 307WB Sequence A3101 101 DDFSRRYRR 0.698 26 SB Sequence A3301 17 YIHYKLSQR0.649 44 SB Sequence A3301 54 HTPHPAASR 0.476 290 WB Sequence A3301 13IVMKYIHYK 0.427 493 WB Sequence A3301 13 IVMKYIHYK 0.790 9 SB SequenceA6801 17 YIHYKLSQR 0.747 15 SB Sequence A6801 54 HTPHPAASR 0.729 18 SBSequence A6801 120 LTPFTARGR 0.703 24 SB Sequence A6801 130 ATVVEELFR0.655 41 SB Sequence A6801 101 DDFSRRYRR 0.571 103 WB Sequence A6801 209FDFSWLSLK 0.540 145 WB Sequence A6801 98 QAGDDFSRR 0.529 163 WB SequenceA6801 171 NIALWMTEY 0.477 288 WB Sequence A6801 230 TLGAYLGHK 0.449 388WB Sequence A6801 0 MAHAGRTGY 0.447 398 WB Sequence A6801 123 FTARGRFAT0.692 27 SB Sequence A6802 147 VAFFEFGGV 0.641 48 SB Sequence A6802 57HPAASRDPV 0.627 56 WB Sequence A6802 72 QTPAAPGAA 0.604 72 WB SequenceA6802 160 SVNREMSPL 0.570 104 WB Sequence A6802 124 TARGRFATV 0.531 160WB Sequence A6802 6 TGYDNREIV 0.513 193 WB Sequence A6802 164 EMSPLVDNI0.512 196 WB Sequence A6802 67 RTSPLQTPA 0.488 254 WB Sequence A6802 225VGACITLGA 0.472 303 WB Sequence A6802 165 MSPLVDNIA 0.466 322 WBSequence A6802 150 FEFGGVMCV 0.449 388 WB Sequence A6802 83 PALSPVPPV0.726 19 SB Sequence A6901 33 DVGAAPPGA 0.535 152 WB Sequence A6901 57HPAASRDPV 0.495 235 WB Sequence A6901 164 EMSPLVDNI 0.485 262 WBSequence A6901 123 FTARGRFAT 0.483 267 WB Sequence A6901 217 KTLLSLALV0.460 344 WB Sequence A6901 73 TPAAPGAAA 0.460 344 WB Sequence A6901 172IALWMTEYL 0.426 497 WB Sequence A6901 57 HPAASRDPV 0.770 12 SB SequenceB0702 63 DPVARTSPL 0.750 14 SB Sequence B0702 166 SPLVDNIAL 0.674 33 SBSequence B0702 73 TPAAPGAAA 0.652 43 SB Sequence B0702 206 RPLFDFSWL0.627 56 WB Sequence B0702 86 SPVPPVVHL 0.606 71 WB Sequence B0702 76APGAAAGPA 0.573 101 WB Sequence B0702 88 VPPVVHLTL 0.542 142 WB SequenceB0702 121 TPFTARGRF 0.505 210 WB Sequence B0702 124 TARGRFATV 0.449 389WB Sequence B0702 0 MAHAGRTGY 0.532 158 WB Sequence B1501 115 SSQLHLTPF0.427 490 WB Sequence B1501 150 FEFGGVMCV 0.633 53 WB Sequence B1801 9DNREIVMKY 0.541 143 WB Sequence B1801 172 IALWMTEYL 0.505 211 WBSequence B1801 144 GRIVAFFEF 0.456 360 WB Sequence B2705 105 RRYRRDFAE0.456 361 WB Sequence B2705 166 SPLVDNIAL 0.680 31 SB Sequence B3501 0MAHAGRTGY 0.658 40 SB Sequence B3501 197 FVELYGPSM 0.628 55 WB SequenceB3501 121 TPFTARGRF 0.610 67 WB Sequence B3501 172 IALWMTEYL 0.584 90 WBSequence B3501 63 DPVARTSPL 0.584 90 WB Sequence B3501 129 FATVVEELF0.562 113 WB Sequence B3501 73 TPAAPGAAA 0.551 128 WB Sequence B3501 171NIALWMTEY 0.523 174 WB Sequence B3501 111 FAEMSSQLH 0.460 343 WBSequence B3501 112 AEMSSQLHL 0.740 16 SB Sequence B4001 150 FEFGGVMCV0.588 86 WB Sequence B4001 112 AEMSSQLHL 0.554 124 WB Sequence B4002 150FEFGGVMCV 0.466 323 WB Sequence B4002 112 AEMSSQLHL 0.454 368 WBSequence B4402 112 AEMSSQLHL 0.533 157 WB Sequence B4403 112 AEMSSQLHL0.587 87 WB Sequence B4501 88 VPPVVHLTL 0.548 132 WB Sequence B5101 206RPLFDFSWL 0.470 307 WB Sequence B5301 166 SPLVDNIAL 0.459 348 WBSequence B5301 172 IALWMTEYL 0.450 382 WB Sequence B5301 73 TPAAPGAAA0.715 21 SB Sequence B5401 57 HPAASRDPV 0.684 30 SB Sequence B5401 76APGAAAGPA 0.625 57 WB Sequence B5401 51 QPGHTPHPA 0.515 189 WB SequenceB5401 179 YLNRHLHTW 0.682 31 SB Sequence B5801 21 KLSQRGYEW 0.649 44 SBSequence B5801 129 FATVVEELF 0.547 134 WB Sequence B5801 40 GAAPAPGIF0.483 268 WB Sequence B5801 10-mer 179 YLNRHLHTWI 0.735 17 SB SequenceA0201 13 IVMKYIHYKL 0.638 50 WB Sequence A0201 218 TLLSLALVGA 0.571 103WB Sequence A0201 207 PLFDFSWLSL 0.536 151 WB Sequence A0201 213WLSLKTLLSL 0.530 161 WB Sequence A0201 123 FTARGRFATV 0.522 175 WBSequence A0201 171 NIALWMTEYL 0.521 178 WB Sequence A0201 175 WMTEYLNRHL0.486 260 WB Sequence A0201 218 TLLSLALVGA 0.731 18 SB Sequence A0202171 NIALWMTEYL 0.727 19 SB Sequence A0202 213 WLSLKTLLSL 0.700 25 SBSequence A0202 215 SLKTLLSLAL 0.646 46 SB Sequence A0202 175 WMTEYLNRHL0.642 47 SB Sequence A0202 207 PLFDFSWLSL 0.637 50 WB Sequence A0202 79AAAGPALSPV 0.588 86 WB Sequence A0202 13 IVMKYIHYKL 0.569 106 WBSequence A0202 123 FTARGRFATV 0.568 106 WB Sequence A0202 199 ELYGPSMRPL0.541 143 WB Sequence A0202 179 YLNRHLHTWI 0.540 145 WB Sequence A0202224 LVGACITLGA 0.483 267 WB Sequence A0202 146 IVAFFEFGGV 0.439 431 WBSequence A0202 179 YLNRHLHTWI 0.933 2 SB Sequence A0203 123 FTARGRFATV0.821 6 SB Sequence A0203 213 WLSLKTLLSL 0.782 10 SB Sequence A0203 215SLKTLLSLAL 0.773 11 SB Sequence A0203 171 NIALWMTEYL 0.682 31 SBSequence A0203 160 SVNREMSPLV 0.680 31 SB Sequence A0203 146 IVAFFEFGGV0.667 36 SB Sequence A0203 79 AAAGPALSPV 0.606 71 WB Sequence A0203 175WMTEYLNRHL 0.569 106 WB Sequence A0203 218 TLLSLALVGA 0.545 137 WBSequence A0203 13 IVMKYIHYKL 0.532 157 WB Sequence A0203 224 LVGACITLGA0.532 158 WB Sequence A0203 199 ELYGPSMRPL 0.519 182 WB Sequence A020350 SQPGHTPHPA 0.447 398 WB Sequence A0203 219 LLSLALVGAC 0.444 410 WBSequence A0203 124 TARGRFATVV 0.428 489 WB Sequence A0203 179 YLNRHLHTWI0.655 41 SB Sequence A0204 123 FTARGRFATV 0.613 66 WB Sequence A0204 13IVMKYIHYKL 0.509 203 WB Sequence A0204 79 AAAGPALSPV 0.474 296 WBSequence A0204 160 SVNREMSPLV 0.450 384 WB Sequence A0204 123 FTARGRFATV0.867 4 SB Sequence A0206 116 SQLHLTPFTA 0.776 11 SB Sequence A0206 188IQDNGGWDAF 0.673 34 SB Sequence A0206 213 WLSLKTLLSL 0.667 36 SBSequence A0206 50 SQPGHTPHPA 0.621 60 WB Sequence A0206 179 YLNRHLHTWI0.619 61 WB Sequence A0206 79 AAAGPALSPV 0.602 74 WB Sequence A0206 175WMTEYLNRHL 0.600 75 WB Sequence A0206 160 SVNREMSPLV 0.567 108 WBSequence A0206 171 NIALWMTEYL 0.562 114 WB Sequence A0206 218 TLLSLALVGA0.560 116 WB Sequence A0206 146 IVAFFEFGGV 0.553 125 WB Sequence A020671 LQTPAAPGAA 0.546 135 WB Sequence A0206 13 IVMKYIHYKL 0.525 171 WBSequence A0206 27 YEWDAGDVGA 0.511 199 WB Sequence A0206 207 PLFDFSWLSL0.486 260 WB Sequence A0206 67 RTSPLQTPAA 0.477 286 WB Sequence A0206224 LVGACITLGA 0.471 304 WB Sequence A0206 207 PLFDFSWLSL 0.935 2 SBSequence A0211 179 YLNRHLHTWI 0.925 2 SB Sequence A0211 199 ELYGPSMRPL0.888 3 SB Sequence A0211 213 WLSLKTLLSL 0.835 5 SB Sequence A0211 218TLLSLALVGA 0.829 6 SB Sequence A0211 123 FTARGRFATV 0.823 6 SB SequenceA0211 167 PLVDNIALWM 0.802 8 SB Sequence A0211 215 SLKTLLSLAL 0.799 8 SBSequence A0211 175 WMTEYLNRHL 0.796 9 SB Sequence A0211 160 SVNREMSPLV0.788 9 SB Sequence A0211 87 PVPPVVHLTL 0.705 24 SB Sequence A0211 79AAAGPALSPV 0.635 51 WB Sequence A0211 13 IVMKYIHYKL 0.601 74 WB SequenceA0211 146 IVAFFEFGGV 0.568 107 WB Sequence A0211 132 VVEELFRDGV 0.549131 WB Sequence A0211 171 NIALWMTEYL 0.547 133 WB Sequence A0211 164EMSPLVDNIA 0.488 254 WB Sequence A0211 168 LVDNIALWMT 0.484 266 WBSequence A0211 149 FFEFGGVMCV 0.475 292 WB Sequence A0211 221 SLALVGACIT0.462 336 WB Sequence A0211 187 WIQDNGGWDA 0.453 370 WB Sequence A0211179 YLNRHLHTWI 0.878 3 SB Sequence A0212 207 PLFDFSWLSL 0.859 4 SBSequence A0212 123 FTARGRFATV 0.849 5 SB Sequence A0212 215 SLKTLLSLAL0.730 18 SB Sequence A0212 199 ELYGPSMRPL 0.726 19 SB Sequence A0212 175WMTEYLNRHL 0.716 21 SB Sequence A0212 213 WLSLKTLLSL 0.697 26 SBSequence A0212 218 TLLSLALVGA 0.692 27 SB Sequence A0212 132 VVEELFRDGV0.601 74 WB Sequence A0212 167 PLVDNIALWM 0.560 116 WB Sequence A0212 13IVMKYIHYKL 0.533 156 WB Sequence A0212 160 SVNREMSPLV 0.509 202 WBSequence A0212 187 WIQDNGGWDA 0.479 280 WB Sequence A0212 146 IVAFFEFGGV0.476 288 WB Sequence A0212 87 PVPPVVHLTL 0.475 294 WB Sequence A0212 27YEWDAGDVGA 0.467 321 WB Sequence A0212 179 YLNRHLHTWI 0.854 4 SBSequence A0216 207 PLFDFSWLSL 0.849 5 SB Sequence A0216 123 FTARGRFATV0.812 7 SB Sequence A0216 199 ELYGPSMRPL 0.767 12 SB Sequence A0216 213WLSLKTLLSL 0.745 15 SB Sequence A0216 167 PLVDNIALWM 0.702 25 SBSequence A0216 160 SVNREMSPLV 0.685 30 SB Sequence A0216 13 IVMKYIHYKL0.676 33 SB Sequence A0216 175 WMTEYLNRHL 0.675 33 SB Sequence A0216 79AAAGPALSPV 0.661 39 SB Sequence A0216 87 PVPPVVHLTL 0.638 50 WB SequenceA0216 215 SLKTLLSLAL 0.634 52 WB Sequence A0216 218 TLLSLALVGA 0.574 100WB Sequence A0216 171 NIALWMTEYL 0.557 120 WB Sequence A0216 221SLALVGACIT 0.472 301 WB Sequence A0216 146 IVAFFEFGGV 0.429 483 WBSequence A0216 207 PLFDFSWLSL 0.805 8 SB Sequence A0219 179 YLNRHLHTWI0.789 9 SB Sequence A0219 213 WLSLKTLLSL 0.766 12 SB Sequence A0219 123FTARGRFATV 0.703 24 SB Sequence A0219 199 ELYGPSMRPL 0.585 88 WBSequence A0219 167 PLVDNIALWM 0.574 100 WB Sequence A0219 79 AAAGPALSPV0.563 112 WB Sequence A0219 218 TLLSLALVGA 0.551 129 WB Sequence A0219175 WMTEYLNRHL 0.521 178 WB Sequence A0219 83 PALSPVPPVV 0.486 259 WBSequence A0219 13 IVMKYIHYKL 0.461 341 WB Sequence A0219 171 NIALWMTEYL0.446 401 WB Sequence A0219 229 ITLGAYLGHK 0.760 13 SB Sequence A0301208 LFDFSWLSLK 0.497 232 WB Sequence A0301 12 EIVMKYIHYK 0.475 292 WBSequence A0301 154 GVMCVESVNR 0.444 411 WB Sequence A0301 173 ALWMTEYLNR0.429 480 WB Sequence A0301 229 ITLGAYLGHK 0.752 14 SB Sequence A1101154 GVMCVESVNR 0.637 50 WB Sequence A1101 12 EIVMKYIHYK 0.540 145 WBSequence A1101 173 ALWMTEYLNR 0.455 363 WB Sequence A1101 208 LFDFSWLSLK0.435 453 WB Sequence A1101 178 EYLNRHLHTW 0.686 29 SB Sequence A2301200 LYGPSMRPLF 0.686 29 SB Sequence A2301 128 RFATVVEELF 0.620 60 WBSequence A2301 7 GYDNREIVMK 0.595 80 WB Sequence A2301 102 DFSRRYRRDF0.499 226 WB Sequence A2301 13 IVMKYIHYKL 0.451 381 WB Sequence A2301 94LTLRQAGDDF 0.437 441 WB Sequence A2301 128 RFATVVEELF 0.764 12 SBSequence A2402 200 LYGPSMRPLF 0.733 17 SB Sequence A2402 178 EYLNRHLHTW0.715 21 SB Sequence A2402 178 EYLNRHLHTW 0.718 21 SB Sequence A2403 128RFATVVEELF 0.657 41 SB Sequence A2403 200 LYGPSMRPLF 0.636 51 WBSequence A2403 170 DNIALWMTEY 0.478 283 WB Sequence A2601 159 ESVNREMSPL0.621 60 WB Sequence A2602 199 ELYGPSMRPL 0.595 79 WB Sequence A2602 171NIALWMTEYL 0.549 131 WB Sequence A2602 170 DNIALWMTEY 0.487 258 WBSequence A2602 229 ITLGAYLGHK 0.718 21 SB Sequence A3001 16 KYIHYKLSQR0.837 5 SB Sequence A3101 136 LFRDGVNWGR 0.667 36 SB Sequence A3101 154GVMCVESVNR 0.576 98 WB Sequence A3101 119 HLTPFTARGR 0.573 101 WBSequence A3101 173 ALWMTEYLNR 0.509 203 WB Sequence A3101 99 AGDDFSRRYR0.507 207 WB Sequence A3101 129 FATVVEELFR 0.493 241 WB Sequence A3101117 QLHLTPFTAR 0.431 471 WB Sequence A3101 136 LFRDGVNWGR 0.553 126 WBSequence A3301 16 KYIHYKLSQR 0.520 180 WB Sequence A3301 129 FATVVEELFR0.516 188 WB Sequence A3301 173 ALWMTEYLNR 0.441 423 WB Sequence A3301129 FATVVEELFR 0.829 6 SB Sequence A6801 12 EIVMKYIHYK 0.780 10 SBSequence A6801 119 HLTPFTARGR 0.721 20 SB Sequence A6801 197 FVELYGPSMR0.688 29 SB Sequence A6801 154 GVMCVESVNR 0.646 46 SB Sequence A6801 229ITLGAYLGHK 0.568 106 WB Sequence A6801 176 MTEYLNRHLH 0.485 262 WBSequence A6801 117 QLHLTPFTAR 0.466 322 WB Sequence A6801 2 HAGRTGYDNR0.446 399 WB Sequence A6801 123 FTARGRFATV 0.861 4 SB Sequence A6802 146IVAFFEFGGV 0.809 7 SB Sequence A6802 171 NIALWMTEYL 0.728 18 SB SequenceA6802 13 IVMKYIHYKL 0.680 31 SB Sequence A6802 79 AAAGPALSPV 0.644 47 SBSequence A6802 72 QTPAAPGAAA 0.617 63 WB Sequence A6802 165 MSPLVDNIAL0.591 83 WB Sequence A6802 199 ELYGPSMRPL 0.582 92 WB Sequence A6802 159ESVNREMSPL 0.550 129 WB Sequence A6802 205 MRPLFDFSWL 0.522 175 WBSequence A6802 160 SVNREMSPLV 0.471 306 WB Sequence A6802 124 TARGRFATVV0.441 421 WB Sequence A6802 123 FTARGRFATV 0.792 9 SB Sequence A6901 199ELYGPSMRPL 0.714 22 SB Sequence A6901 83 PALSPVPPVV 0.580 94 WB SequenceA6901 171 NIALWMTEYL 0.558 119 WB Sequence A6901 160 SVNREMSPLV 0.537149 WB Sequence A6901 79 AAAGPALSPV 0.502 219 WB Sequence A6901 33DVGAAPPGAA 0.489 251 WB Sequence A6901 146 IVAFFEFGGV 0.464 330 WBSequence A6901 13 IVMKYIHYKL 0.441 422 WB Sequence A6901 76 APGAAAGPAL0.708 23 SB Sequence B0702 82 GPALSPVPPV 0.604 72 WB Sequence B0702 57HPAASRDPVA 0.536 152 WB Sequence B0702 202 GPSMRPLFDF 0.468 317 WBSequence B0702 124 TARGRFATVV 0.465 327 WB Sequence B0702 42 APAPGIFSSQ0.451 378 WB Sequence B0702 140 GVNWGRIVAF 0.548 132 WB Sequence B1501114 MSSQLHLTPF 0.504 214 WB Sequence B1501 188 IQDNGGWDAF 0.490 249 WBSequence B1501 11 REIVMKYIHY 0.603 73 WB Sequence B1801 105 RRYRRDFAEM0.622 59 WB Sequence B2705 127 GRFATVVEEL 0.493 241 WB Sequence B2705114 MSSQLHLTPF 0.582 91 WB Sequence B3501 147 VAFFEFGGVM 0.561 115 WBSequence B3501 76 APGAAAGPAL 0.526 168 WB Sequence B3501 222 LALVGACITL0.473 297 WB Sequence B3501 156 MCVESVNREM 0.473 299 WB Sequence B350198 QAGDDFSRRY 0.461 340 WB Sequence B3501 73 TPAAPGAAAG 0.459 346 WBSequence B3501 140 GVNWGRIVAF 0.455 362 WB Sequence B3501 166 SPLVDNIALW0.453 371 WB Sequence B3501 11 REIVMKYIHY 0.502 218 WB Sequence B4002112 AEMSSQLHLT 0.472 303 WB Sequence B4002 11 REIVMKYIHY 0.476 289 WBSequence B4402 11 REIVMKYIHY 0.481 273 WB Sequence B4403 134 EELFRDGVNW0.473 300 WB Sequence B4403 112 AEMSSQLHLT 0.523 175 WB Sequence B450111 REIVMKYIHY 0.438 437 WB Sequence B4501 134 EELFRDGVNW 0.367 946Sequence B4501 222 LALVGACITL 0.480 277 WB Sequence B5101 38 PPGAAPAPGI0.427 490 WB Sequence B5101 166 SPLVDNIALW 0.744 15 SB Sequence B5301 57HPAASRDPVA 0.665 37 SB Sequence B5401 121 TPFTARGRFA 0.661 39 SBSequence B5401 51 QPGHTPHPAA 0.476 289 WB Sequence B5401 82 GPALSPVPPV0.461 340 WB Sequence B5401 86 SPVPPVVHLT 0.434 456 WB Sequence B5401185 HTWIQDNGGW 0.427 491 WB Sequence B5701 114 MSSQLHLTPF 0.611 67 WBSequence B5801 185 HTWIQDNGGW 0.580 94 WB Sequence B5801 204 SMRPLFDFSW0.474 294 WB Sequence B5801 11-mer 223 ALVGACITLGA 0.632 53 WB SequenceA0201 84 ALSPVPPVVHL 0.586 88 WB Sequence A0201 215 SLKTLLSLALV 0.543141 WB Sequence A0201 188 IQDNGGWDAFV 0.504 215 WB Sequence A0201 219LLSLALVGACI 0.481 275 WB Sequence A0201 221 SLALVGACITL 0.473 299 WBSequence A0201 145 RIVAFFEFGGV 0.453 373 WB Sequence A0201 21KLSQRGYEWDA 0.449 388 WB Sequence A0201 204 SMRPLFDFSWL 0.772 11 SBSequence A0202 215 SLKTLLSLALV 0.763 12 SB Sequence A0202 221SLALVGACITL 0.710 23 SB Sequence A0202 84 ALSPVPPVVHL 0.708 23 SBSequence A0202 219 LLSLALVGACI 0.692 28 SB Sequence A0202 164EMSPLVDNIAL 0.657 41 SB Sequence A0202 223 ALVGACITLGA 0.630 54 WBSequence A0202 213 WLSLKTLLSLA 0.616 63 WB Sequence A0202 123FTARGRFATVV 0.602 74 WB Sequence A0202 78 GAAAGPALSPV 0.597 78 WBSequence A0202 145 RIVAFFEFGGV 0.569 105 WB Sequence A0202 179YLNRHLHTWIQ 0.529 163 WB Sequence A0202 21 KLSQRGYEWDA 0.499 226 WBSequence A0202 131 TVVEELFRDGV 0.478 284 WB Sequence A0202 225VGACITLGAYL 0.469 312 WB Sequence A0202 215 SLKTLLSLALV 0.899 2 SBSequence A0203 204 SMRPLFDFSWL 0.853 4 SB Sequence A0203 145 RIVAFFEFGGV0.813 7 SB Sequence A0203 78 GAAAGPALSPV 0.774 11 SB Sequence A0203 213WLSLKTLLSLA 0.765 12 SB Sequence A0203 84 ALSPVPPVVHL 0.765 12 SBSequence A0203 223 ALVGACITLGA 0.751 14 SB Sequence A0203 219LLSLALVGACI 0.707 23 SB Sequence A0203 123 FTARGRFATVV 0.672 34 SBSequence A0203 221 SLALVGACITL 0.617 63 WB Sequence A0203 179YLNRHLHTWIQ 0.565 110 WB Sequence A0203 131 TVVEELFRDGV 0.507 206 WBSequence A0203 21 KLSQRGYEWDA 0.476 291 WB Sequence A0203 84 ALSPVPPVVHL0.633 53 WB Sequence A0204 221 SLALVGACITL 0.593 82 WB Sequence A0204123 FTARGRFATVV 0.587 87 WB Sequence A0204 78 GAAAGPALSPV 0.495 235 WBSequence A0204 21 KLSQRGYEWDA 0.488 255 WB Sequence A0204 179YLNRHLHTWIQ 0.461 340 WB Sequence A0204 145 RIVAFFEFGGV 0.868 4 SBSequence A0206 188 IQDNGGWDAFV 0.822 6 SB Sequence A0206 123 FTARGRFATVV0.729 18 SB Sequence A0206 131 TVVEELFRDGV 0.725 19 SB Sequence A0206223 ALVGACITLGA 0.670 35 SB Sequence A0206 50 SQPGHTPHPAA 0.659 40 SBSequence A0206 71 LQTPAAPGAAA 0.657 40 SB Sequence A0206 78 GAAAGPALSPV0.598 77 WB Sequence A0206 217 KTLLSLALVGA 0.537 149 WB Sequence A020684 ALSPVPPVVHL 0.533 157 WB Sequence A0206 204 SMRPLFDFSWL 0.494 239 WBSequence A0206 215 SLKTLLSLALV 0.477 286 WB Sequence A0206 213WLSLKTLLSLA 0.475 293 WB Sequence A0206 27 YEWDAGDVGAA 0.474 295 WBSequence A0206 21 KLSQRGYEWDA 0.453 373 WB Sequence A0206 84 ALSPVPPVVHL0.906 2 SB Sequence A0211 215 SLKTLLSLALV 0.896 3 SB Sequence A0211 221SLALVGACITL 0.892 3 SB Sequence A0211 179 YLNRHLHTWIQ 0.853 4 SBSequence A0211 164 EMSPLVDNIAL 0.832 6 SB Sequence A0211 204 SMRPLFDFSWL0.813 7 SB Sequence A0211 223 ALVGACITLGA 0.803 8 SB Sequence A0211 123FTARGRFATVV 0.782 10 SB Sequence A0211 188 IQDNGGWDAFV 0.746 15 SBSequence A0211 148 AFFEFGGVMCV 0.730 18 SB Sequence A0211 207PLFDFSWLSLK 0.720 20 SB Sequence A0211 131 TVVEELFRDGV 0.717 21 SBSequence A0211 167 PLVDNIALWMT 0.706 24 SB Sequence A0211 21 KLSQRGYEWDA0.702 25 SB Sequence A0211 213 WLSLKTLLSLA 0.655 41 SB Sequence A0211145 RIVAFFEFGGV 0.634 52 WB Sequence A0211 199 ELYGPSMRPLF 0.626 56 WBSequence A0211 219 LLSLALVGACI 0.581 92 WB Sequence A0211 78 GAAAGPALSPV0.533 156 WB Sequence A0211 137 FRDGVNWGRIV 0.516 187 WB Sequence A0211218 TLLSLALVGAC 0.500 223 WB Sequence A0211 119 HLTPFTARGRF 0.462 335 WBSequence A0211 175 WMTEYLNRHLH 0.458 352 WB Sequence A0211 84ALSPVPPVVHL 0.817 7 SB Sequence A0212 179 YLNRHLHTWIQ 0.794 9 SBSequence A0212 123 FTARGRFATVV 0.784 10 SB Sequence A0212 204SMRPLFDFSWL 0.781 10 SB Sequence A0212 215 SLKTLLSLALV 0.719 20 SBSequence A0212 221 SLALVGACITL 0.719 20 SB Sequence A0212 164EMSPLVDNIAL 0.714 22 SB Sequence A0212 21 KLSQRGYEWDA 0.616 63 WBSequence A0212 223 ALVGACITLGA 0.604 72 WB Sequence A0212 131TVVEELFRDGV 0.602 74 WB Sequence A0212 188 IQDNGGWDAFV 0.569 106 WBSequence A0212 148 AFFEFGGVMCV 0.548 133 WB Sequence A0212 145RIVAFFEFGGV 0.511 198 WB Sequence A0212 219 LLSLALVGACI 0.504 213 WBSequence A0212 167 PLVDNIALWMT 0.483 269 WB Sequence A0212 207PLFDFSWLSLK 0.472 301 WB Sequence A0212 137 FRDGVNWGRIV 0.431 473 WBSequence A0212 84 ALSPVPPVVHL 0.878 3 SB Sequence A0216 221 SLALVGACITL0.855 4 SB Sequence A0216 215 SLKTLLSLALV 0.806 8 SB Sequence A0216 204SMRPLFDFSWL 0.753 14 SB Sequence A0216 123 FTARGRFATVV 0.739 16 SBSequence A0216 223 ALVGACITLGA 0.697 26 SB Sequence A0216 188IQDNGGWDAFV 0.637 50 WB Sequence A0216 164 EMSPLVDNIAL 0.625 57 WBSequence A0216 179 YLNRHLHTWIQ 0.613 65 WB Sequence A0216 131TVVEELFRDGV 0.586 88 WB Sequence A0216 78 GAAAGPALSPV 0.571 103 WBSequence A0216 148 AFFEFGGVMCV 0.563 112 WB Sequence A0216 167PLVDNIALWMT 0.535 153 WB Sequence A0216 145 RIVAFFEFGGV 0.503 216 WBSequence A0216 151 EFGGVMCVESV 0.502 217 WB Sequence A0216 213WLSLKTLLSLA 0.493 241 WB Sequence A0216 21 KLSQRGYEWDA 0.490 248 WBSequence A0216 219 LLSLALVGACI 0.478 285 WB Sequence A0216 207PLFDFSWLSLK 0.436 445 WB Sequence A0216 84 ALSPVPPVVHL 0.786 10 SBSequence A0219 188 IQDNGGWDAFV 0.605 71 WB Sequence A0219 123FTARGRFATVV 0.594 81 WB Sequence A0219 164 EMSPLVDNIAL 0.584 89 WBSequence A0219 179 YLNRHLHTWIQ 0.574 100 WB Sequence A0219 221SLALVGACITL 0.561 115 WB Sequence A0219 219 LLSLALVGACI 0.551 128 WBSequence A0219 167 PLVDNIALWMT 0.537 149 WB Sequence A0219 78GAAAGPALSPV 0.496 233 WB Sequence A0219 215 SLKTLLSLALV 0.490 248 WBSequence A0219 204 SMRPLFDFSWL 0.486 259 WB Sequence A0219 223ALVGACITLGA 0.467 320 WB Sequence A0219 207 PLFDFSWLSLK 0.604 72 WBSequence A0301 228 CITLGAYLGHK 0.462 339 WB Sequence A0301 207PLFDFSWLSLK 0.626 57 WB Sequence A1101 116 SQLHLTPFTAR 0.586 88 WBSequence A1101 228 CITLGAYLGHK 0.580 94 WB Sequence A1101 172IALWMTEYLNR 0.524 172 WB Sequence A1101 6 TGYDNREIVMK 0.437 439 WBSequence A1101 142 NWGRIVAFFEF 0.733 18 SB Sequence A2301 178EYLNRHLHTWI 0.592 82 WB Sequence A2301 19 HYKLSQRGYEW 0.563 112 WBSequence A2301 174 LWMTEYLNRHL 0.457 355 WB Sequence A2301 212SWLSLKTLLSL 0.439 431 WB Sequence A2301 178 EYLNRHLHTWI 0.794 9 SBSequence A2402 142 NWGRIVAFFEF 0.744 15 SB Sequence A2402 212SWLSLKTLLSL 0.514 192 WB Sequence A2402 174 LWMTEYLNRHL 0.497 230 WBSequence A2402 178 EYLNRHLHTWI 0.599 76 WB Sequence A2403 19 HYKLSQRGYEW0.573 101 WB Sequence A2403 142 NWGRIVAFFEF 0.486 260 WB Sequence A240317 YIHYKLSQRGY 0.524 172 WB Sequence A2601 113 EMSSQLHLTPF 0.866 4 SBSequence A2602 17 YIHYKLSQRGY 0.817 7 SB Sequence A2602 12 EIVMKYIHYKL0.760 13 SB Sequence A2602 187 WIQDNGGWDAF 0.631 54 WB Sequence A2602199 ELYGPSMRPLF 0.568 106 WB Sequence A2602 224 LVGACITLGAY 0.545 137 WBSequence A2602 139 DGVNWGRIVAF 0.462 336 WB Sequence A2602 207PLFDFSWLSLK 0.456 359 WB Sequence A3001 11 REIVMKYIHYK 0.439 434 WBSequence A3001 113 EMSSQLHLTPF 0.533 156 WB Sequence A3002 128RFATVVEELFR 0.765 12 SB Sequence A3101 116 SQLHLTPFTAR 0.741 16 SBSequence A3101 196 AFVELYGPSMR 0.640 48 SB Sequence A3101 172IALWMTEYLNR 0.614 64 WB Sequence A3101 11 REIVMKYIHYK 0.571 104 WBSequence A3101 15 MKYIHYKLSQR 0.500 224 WB Sequence A3101 98 QAGDDFSRRYR0.483 269 WB Sequence A3101 135 ELFRDGVNWGR 0.634 52 WB Sequence A3301128 RFATVVEELFR 0.492 244 WB Sequence A3301 172 IALWMTEYLNR 0.481 273 WBSequence A3301 196 AFVELYGPSMR 0.467 318 WB Sequence A3301 135ELFRDGVNWGR 0.739 16 SB Sequence A6801 228 CITLGAYLGHK 0.618 62 WBSequence A6801 172 IALWMTEYLNR 0.593 81 WB Sequence A6801 57 HPAASRDPVAR0.579 95 WB Sequence A6801 15 MKYIHYKLSQR 0.540 145 WB Sequence A6801 98QAGDDFSRRYR 0.525 170 WB Sequence A6801 6 TGYDNREIVMK 0.515 190 WBSequence A6801 128 RFATVVEELFR 0.507 207 WB Sequence A6801 95TLRQAGDDFSR 0.490 249 WB Sequence A6801 207 PLFDFSWLSLK 0.470 308 WBSequence A6801 123 FTARGRFATVV 0.809 7 SB Sequence A6802 131 TVVEELFRDGV0.784 10 SB Sequence A6802 145 RIVAFFEFGGV 0.727 19 SB Sequence A6802 12EIVMKYIHYKL 0.592 83 WB Sequence A6802 78 GAAAGPALSPV 0.560 116 WBSequence A6802 164 EMSPLVDNIAL 0.520 179 WB Sequence A6802 159ESVNREMSPLV 0.488 254 WB Sequence A6802 225 VGACITLGAYL 0.459 349 WBSequence A6802 55 TPHPAASRDPV 0.435 453 WB Sequence A6802 123FTARGRFATVV 0.710 23 SB Sequence A6901 164 EMSPLVDNIAL 0.541 144 WBSequence A6901 131 TVVEELFRDGV 0.510 201 WB Sequence A6901 159ESVNREMSPLV 0.485 263 WB Sequence A6901 206 RPLFDFSWLSL 0.747 15 SBSequence B0702 86 SPVPPVVHLTL 0.717 21 SB Sequence B0702 55 TPHPAASRDPV0.567 108 WB Sequence B0702 82 GPALSPVPPVV 0.559 118 WB Sequence B0702166 SPLVDNIALWM 0.469 312 WB Sequence B0702 126 RGRFATVVEEL 0.463 332 WBSequence B0702 121 TPFTARGRFAT 0.443 416 WB Sequence B0702 97RQAGDDFSRRY 0.600 75 WB Sequence B1501 187 WIQDNGGWDAF 0.499 226 WBSequence B1501 224 LVGACITLGAY 0.491 245 WB Sequence B1501 17YIHYKLSQRGY 0.476 290 WB Sequence B1501 113 EMSSQLHLTPF 0.433 461 WBSequence B1501 140 GVNWGRIVAFF 0.433 463 WB Sequence B1501 177TEYLNRHLHTW 0.585 89 WB Sequence B1801 198 VELYGPSMRPL 0.558 119 WBSequence B1801 158 VESVNREMSPL 0.514 191 WB Sequence B1801 133VEELFRDGVNW 0.459 348 WB Sequence B1801 127 GRFATVVEELF 0.512 196 WBSequence B2705 108 RRDFAEMSSQL 0.481 273 WB Sequence B2705 97RQAGDDFSRRY 0.445 405 WB Sequence B2705 166 SPLVDNIALWM 0.573 101 WBSequence B3501 187 WIQDNGGWDAF 0.544 139 WB Sequence B3501 195DAFVELYGPSM 0.543 140 WB Sequence B3501 113 EMSSQLHLTPF 0.543 140 WBSequence B3501 121 TPFTARGRFAT 0.503 217 WB Sequence B3501 224LVGACITLGAY 0.502 218 WB Sequence B3501 146 IVAFFEFGGVM 0.500 222 WBSequence B3501 86 SPVPPVVHLTL 0.443 416 WB Sequence B3501 139DGVNWGRIVAF 0.442 419 WB Sequence B3501 61 SRDPVARTSPL 0.500 223 WBSequence B3901 198 VELYGPSMRPL 0.547 134 WB Sequence B4001 158VESVNREMSPL 0.471 306 WB Sequence B4001 177 TEYLNRHLHTW 0.520 180 WBSequence B4402 112 AEMSSQLHLTP 0.529 163 WB Sequence B4501 37APPGAAPAPGI 0.507 207 WB Sequence B5101 82 GPALSPVPPVV 0.465 326 WBSequence B5101 86 SPVPPVVHLTL 0.433 461 WB Sequence B5101 166SPLVDNIALWM 0.453 373 WB Sequence B5301 206 RPLFDFSWLSL 0.436 448 WBSequence B5301 121 TPFTARGRFAT 0.638 50 WB Sequence B5401 69 SPLQTPAAPGA0.557 121 WB Sequence B5401 89 PPVVHLTLRQA 0.501 220 WB Sequence B540155 TPHPAASRDPV 0.428 489 WB Sequence B5401 165 MSPLVDNIALW 0.462 335 WBSequence B5701 203 PSMRPLFDFSW 0.635 51 WB Sequence B5801 SEQ ID NOS:44893-45800

Preferred fragments of BclX(L) capable of interacting with one or moreMHC class 2 molecules are listed in table D.

TABLE DPrediction of cancer antigen BclX(L) specific MHC class 2, 15-merpeptide binders for 14 MHC class 2 alleles (see FIG. 11) using thehttp://www.cbs.dtu.dk/services/NetMHCII/ database. The MHC class 2molecules for which no binders were found are not listed Allele pospeptide core 1 − log50k(aff) affinity(nM) Bind Level Identity DRB1_0101212 RWFLTGMTVAGVVLL LTGMTVAGV 0.8028 8 SB BclX(L) DRB1_0101 209RFNRWFLTGMTVAGV FLTGMTVAG 0.7932 9 SB BclX(L) DRB1_0101 210FNRWFLTGMTVAGVV LTGMTVAGV 0.7940 9 SB BclX(L) DRB1_0101 211NRWFLTGMTVAGVVL LTGMTVAGV 0.7970 9 SB BclX(L) DRB1_0101 213WFLTGMTVAGVVLLG LTGMTVAGV 0.7753 11 SB BclX(L) DRB1_0101 76DAREVIPMAAVKQAL VIPMAAVKQ 0.7755 11 SB BclX(L) DRB1_0101 77AREVIPMAAVKQALR VIPMAAVKQ 0.7788 11 SB BclX(L) DRB1_0101 78REVIPMAAVKQALRE VIPMAAVKQ 0.7772 11 SB BclX(L) DRB1_0101 75LDAREVIPMAAVKQA VIPMAAVKQ 0.7730 12 SB BclX(L) DRB1_0101 157KEMQVLVSRIAAWMA MQVLVSRIA 0.7458 16 SB BclX(L) DRB1_0101 108LTSQLHITPGTAYQS LHITPGTAY 0.7338 18 SB BclX(L) DRB1_0101 109TSQLHITPGTAYQSF ITPGTAYQS 0.7313 18 SB BclX(L) DRB1_0101 74SLDAREVIPMAAVKQ AREVIPMAA 0.7348 18 SB BclX(L) DRB1_0101 110SQLHITPGTAYQSFE ITPGTAYQS 0.7287 19 SB BclX(L) DRB1_0101 214FLTGMTVAGVVLLGS LTGMTVAGV 0.7282 19 SB BclX(L) DRB1_0101 156DKEMQVLVSRIAAWM MQVLVSRIA 0.7226 20 SB BclX(L) DRB1_0101 111QLHITPGTAYQSFEQ ITPGTAYQS 0.7202 21 SB BclX(L) DRB1_0101 112LHITPGTAYQSFEQV ITPGTAYQS 0.7189 21 SB BclX(L) DRB1_0101 154SVDKEMQVLVSRIAA MQVLVSRIA 0.7165 21 SB BclX(L) DRB1_0101 79EVIPMAAVKQALREA IPMAAVKQA 0.7208 21 SB BclX(L) DRB1_0101 153ESVDKEMQVLVSRIA VDKEMQVLV 0.7145 22 SB BclX(L) DRB1_0101 155VDKEMQVLVSRIAAW MQVLVSRIA 0.7141 22 SB BclX(L) DRB1_0101 215LTGMTVAGVVLLGSL LTGMTVAGV 0.7090 23 SB BclX(L) DRB1_0101 208ERFNRWFLTGMTVAG FNRWFLTGM 0.7077 24 SB BclX(L) DRB1_0101 46ETPSAINGNPSWHLA INGNPSWHL 0.7051 24 SB BclX(L) DRB1_0101 47TPSAINGNPSWHLAD INGNPSWHL 0.7051 24 SB BclX(L) DRB1_0101 48PSAINGNPSWHLADS INGNPSWHL 0.7076 24 SB BclX(L) DRB1_0101 49SAINGNPSWHLADSP INGNPSWHL 0.7072 24 SB BclX(L) DRB1_0101 45METPSAINGNPSWHL PSAINGNPS 0.7034 25 SB BclX(L) DRB1_0101 158EMQVLVSRIAAWMAT MQVLVSRIA 0.6845 30 SB BclX(L) DRB1_0101 80VIPMAAVKQALREAG VIPMAAVKQ 0.6856 30 SB BclX(L) DRB1_0101 159MQVLVSRIAAWMATY MQVLVSRIA 0.6834 31 SB BclX(L) DRB1_0101 161VLVSRIAAWMATYLN IAAWMATYL 0.6838 31 SB BclX(L) DRB1_0101 217GMTVAGVVLLGSLFS MTVAGVVLL 0.6800 32 SB BclX(L) DRB1_0101 218MTVAGVVLLGSLFSR VVLLGSLFS 0.6800 32 SB BclX(L) DRB1_0101 51INGNPSWHLADSPAV INGNPSWHL 0.6778 33 SB BclX(L) DRB1_0101 192VELYGNNAAAESRKG YGNNAAAES 0.6693 36 SB BclX(L) DRB1_0101 219TVAGVVLLGSLFSRK VVLLGSLFS 0.6677 36 SB BclX(L) DRB1_0101 160QVLVSRIAAWMATYL VSRIAAWMA 0.6652 37 SB BclX(L) DRB1_0101 191FVELYGNNAAAESRK YGNNAAAES 0.6658 37 SB BclX(L) DRB1_0101 193ELYGNNAAAESRKGQ YGNNAAAES 0.6661 37 SB BclX(L) DRB1_0101 99LRYRRAFSDLTSQLH YRRAFSDLT 0.6657 37 SB BclX(L) DRB1_0101 162LVSRIAAWMATYLND IAAWMATYL 0.6627 38 SB BclX(L) DRB1_0101 190TFVELYGNNAAAESR YGNNAAAES 0.6628 38 SB BclX(L) DRB1_0101 189DTFVELYGNNAAAES FVELYGNNA 0.6613 39 SB BclX(L) DRB1_0101 54NPSWHLADSPAVNGA WHLADSPAV 0.6617 39 SB BclX(L) DRB1_0101 55PSWHLADSPAVNGAT WHLADSPAV 0.6611 39 SB BclX(L) DRB1_0101 216TGMTVAGVVLLGSLF MTVAGVVLL 0.6543 42 SB BclX(L) DRB1_0101 163VSRIAAWMATYLNDH IAAWMATYL 0.6531 43 SB BclX(L) DRB1_0101 53GNPSWHLADSPAVNG WHLADSPAV 0.6532 43 SB BclX(L) DRB1_0101 59LADSPAVNGATGHSS LADSPAVNG 0.6361 51 WB BclX(L) DRB1_0101 98ELRYRRAFSDLTSQL YRRAFSDLT 0.6357 51 WB BclX(L) DRB1_0101 164SRIAAWMATYLNDHL IAAWMATYL 0.6357 52 WB BclX(L) DRB1_0101 97FELRYRRAFSDLTSQ YRRAFSDLT 0.6337 53 WB BclX(L) DRB1_0101 96EFELRYRRAFSDLTS YRRAFSDLT 0.6321 54 WB BclX(L) DRB1_0101 95DEFELRYRRAFSDLT LRYRRAFSD 0.6294 55 WB BclX(L) DRB1_0101 140IVAFFSFGGALCVES FSFGGALCV 0.6203 61 WB BclX(L) DRB1_0101 56SWHLADSPAVNGATG LADSPAVNG 0.6196 61 WB BclX(L) DRB1_0101 61DSPAVNGATGHSSSL VNGATGHSS 0.6197 61 WB BclX(L) DRB1_0101 62SPAVNGATGHSSSLD VNGATGHSS 0.6205 61 WB BclX(L) DRB1_0101 141VAFFSFGGALCVESV FSFGGALCV 0.6191 62 WB BclX(L) DRB1_0101 60ADSPAVNGATGHSSS VNGATGHSS 0.6174 63 WB BclX(L) DRB1_0101 142AFFSFGGALCVESVD FSFGGALCV 0.6153 64 WB BclX(L) DRB1_0101 57WHLADSPAVNGATGH LADSPAVNG 0.6162 64 WB BclX(L) DRB1_0101 113HITPGTAYQSFEQVV ITPGTAYQS 0.6121 66 WB BclX(L) DRB1_0101 114ITPGTAYQSFEQVVN ITPGTAYQS 0.6131 66 WB BclX(L) DRB1_0101 50AINGNPSWHLADSPA INGNPSWHL 0.6133 66 WB BclX(L) DRB1_0101 63PAVNGATGHSSSLDA VNGATGHSS 0.6078 70 WB BclX(L) DRB1_0101 100RYRRAFSDLTSQLHI YRRAFSDLT 0.6026 74 WB BclX(L) DRB1_0101 101YRRAFSDLTSQLHIT YRRAFSDLT 0.6021 74 WB BclX(L) DRB1_0101 52NGNPSWHLADSPAVN WHLADSPAV 0.6004 75 WB BclX(L) DRB1_0101 138GRIVAFFSFGGALCV IVAFFSFGG 0.5864 88 WB BclX(L) DRB1_0101 194LYGNNAAAESRKGQE YGNNAAAES 0.5808 93 WB BclX(L) DRB1_0101 165RIAAWMATYLNDHLE AAWMATYLN 0.5762 98 WB BclX(L) DRB1_0101 195YGNNAAAESRKGQER YGNNAAAES 0.5731 101 WB BclX(L) DRB1_0101 139RIVAFFSFGGALCVE FSFGGALCV 0.5729 102 WB BclX(L) DRB1_0101 131FRDGVNWGRIVAFFS VNWGRIVAF 0.5627 114 WB BclX(L) DRB1_0101 143FFSFGGALCVESVDK FSFGGALCV 0.5613 115 WB BclX(L) DRB1_0101 144FSFGGALCVESVDKE FSFGGALCV 0.5583 119 WB BclX(L) DRB1_0101 132RDGVNWGRIVAFFSF VNWGRIVAF 0.5561 122 WB BclX(L) DRB1_0101 133DGVNWGRIVAFFSFG VNWGRIVAF 0.5558 122 WB BclX(L) DRB1_0101 81IPMAAVKQALREAGD IPMAAVKQA 0.5527 126 WB BclX(L) DRB1_0101 102RRAFSDLTSQLHITP FSDLTSQLH 0.5334 156 WB BclX(L) DRB1_0101 103RAFSDLTSQLHITPG FSDLTSQLH 0.5314 159 WB BclX(L) DRB1_0101 58HLADSPAVNGATGHS LADSPAVNG 0.5293 163 WB BclX(L) DRB1_0101 134GVNWGRIVAFFSFGG VNWGRIVAF 0.5282 165 WB BclX(L) DRB1_0101 166IAAWMATYLNDHLEP IAAWMATYL 0.5271 167 WB BclX(L) DRB1_0101 64AVNGATGHSSSLDAR VNGATGHSS 0.5266 168 WB BclX(L) DRB1_0101 135VNWGRIVAFFSFGGA VNWGRIVAF 0.5248 171 WB BclX(L) DRB1_0101 7ELVVDFLSYKLSQKG VVDFLSYKL 0.5243 172 WB BclX(L) DRB1_0101 129ELFRDGVNWGRIVAF FRDGVNWGR 0.5154 189 WB BclX(L) DRB1_0101 65VNGATGHSSSLDARE VNGATGHSS 0.5156 189 WB BclX(L) DRB1_0101 130LFRDGVNWGRIVAFF VNWGRIVAF 0.5023 218 WB BclX(L) DRB1_0101 8LVVDFLSYKLSQKGY LSYKLSQKG 0.4921 244 WB BclX(L) DRB1_0101 9VVDFLSYKLSQKGYS LSYKLSQKG 0.4892 251 WB BclX(L) DRB1_0101 207QERFNRWFLTGMTVA FNRWFLTGM 0.4845 264 WB BclX(L) DRB1_0101 42ESEMETPSAINGNPS METPSAING 0.4626 335 WB BclX(L) DRB1_0101 40GTESEMETPSAINGN METPSAING 0.4622 337 WB BclX(L) DRB1_0101 107DLTSQLHITPGTAYQ LHITPGTAY 0.4593 347 WB BclX(L) DRB1_0101 39EGTESEMETPSAING ESEMETPSA 0.4591 348 WB BclX(L) DRB1_0101 43SEMETPSAINGNPSW METPSAING 0.4590 348 WB BclX(L) DRB1_0101 106SDLTSQLHITPGTAY SQLHITPGT 0.4569 356 WB BclX(L) DRB1_0101 10VDFLSYKLSQKGYSW LSYKLSQKG 0.4565 358 WB BclX(L) DRB1_0101 41TESEMETPSAINGNP METPSAING 0.4564 358 WB BclX(L) DRB1_0101 167AAWMATYLNDHLEPW AAWMATYLN 0.4556 361 WB BclX(L) DRB1_0101 11DFLSYKLSQKGYSWS LSYKLSQKG 0.4515 378 WB BclX(L) DRB1_0101 104AFSDLTSQLHITPGT FSDLTSQLH 0.4453 404 WB BclX(L) DRB1_0101 105FSDLTSQLHITPGTA FSDLTSQLH 0.4451 405 WB BclX(L) DRB1_0101 137WGRIVAFFSFGGALC IVAFFSFGG 0.4311 471 WB BclX(L) DRB1_0101 206GQERFNRWFLTGMTV FNRWFLTGM 0.4277 489 WB BclX(L) DRB1_0401 99LRYRRAFSDLTSQLH YRRAFSDLT 0.5618 115 WB BclX(L) DRB1_0401 97FELRYRRAFSDLTSQ YRRAFSDLT 0.5300 162 WB BclX(L) DRB1_0401 96EFELRYRRAFSDLTS YRRAFSDLT 0.5284 164 WB BclX(L) DRB1_0401 95DEFELRYRRAFSDLT DEFELRYRR 0.5275 166 WB BclX(L) DRB1_0401 98ELRYRRAFSDLTSQL YRRAFSDLT 0.5259 169 WB BclX(L) DRB1_0401 185NGGWDTFVELYGNNA WDTFVELYG 0.5189 182 WB BclX(L) DRB1_0401 186GGWDTFVELYGNNAA FVELYGNNA 0.5180 184 WB BclX(L) DRB1_0401 188WDTFVELYGNNAAAE FVELYGNNA 0.5159 188 WB BclX(L) DRB1_0401 187GWDTFVELYGNNAAA FVELYGNNA 0.5157 189 WB BclX(L) DRB1_0401 189DTFVELYGNNAAAES FVELYGNNA 0.5154 189 WB BclX(L) DRB1_0401 100RYRRAFSDLTSQLHI YRRAFSDLT 0.4844 265 WB BclX(L) DRB1_0401 101YRRAFSDLTSQLHIT YRRAFSDLT 0.4813 274 WB BclX(L) DRB1_0401 153ESVDKEMQVLVSRIA KEMQVLVSR 0.4561 360 WB BclX(L) DRB1_0401 155VDKEMQVLVSRIAAW MQVLVSRIA 0.4519 376 WB BclX(L) DRB1_0401 208ERFNRWFLTGMTVAG WFLTGMTVA 0.4512 379 WB BclX(L) DRB1_0401 154SVDKEMQVLVSRIAA MQVLVSRIA 0.4495 386 WB BclX(L) DRB1_0401 209RFNRWFLTGMTVAGV FLTGMTVAG 0.4467 398 WB BclX(L) DRB1_0401 210FNRWFLTGMTVAGVV FLTGMTVAG 0.4427 416 WB BclX(L) DRB1_0401 157KEMQVLVSRIAAWMA MQVLVSRIA 0.4419 419 WB BclX(L) DRB1_0401 156DKEMQVLVSRIAAWM MQVLVSRIA 0.4413 422 WB BclX(L) DRB1_0401 211NRWFLTGMTVAGVVL FLTGMTVAG 0.4327 463 WB BclX(L) DRB1_0404 167AAWMATYLNDHLEPW WMATYLNDH 0.5484 132 WB BclX(L) DRB1_0404 164SRIAAWMATYLNDHL WMATYLNDH 0.5424 141 WB BclX(L) DRB1_0404 165RIAAWMATYLNDHLE WMATYLNDH 0.5417 142 WB BclX(L) DRB1_0404 166IAAWMATYLNDHLEP WMATYLNDH 0.5330 156 WB BclX(L) DRB1_0404 163VSRIAAWMATYLNDH AAWMATYLN 0.5217 177 WB BclX(L) DRB1_0404 219TVAGVVLLGSLFSRK VVLLGSLFS 0.5094 202 WB BclX(L) DRB1_0404 209RFNRWFLTGMTVAGV FLTGMTVAG 0.4902 249 WB BclX(L) DRB1_0404 210FNRWFLTGMTVAGVV FLTGMTVAG 0.4853 262 WB BclX(L) DRB1_0404 211NRWFLTGMTVAGVVL FLTGMTVAG 0.4826 270 WB BclX(L) DRB1_0404 208ERFNRWFLTGMTVAG WFLTGMTVA 0.4761 290 WB BclX(L) DRB1_0404 168AWMATYLNDHLEPWI WMATYLNDH 0.4694 311 WB BclX(L) DRB1_0404 212RWFLTGMTVAGVVLL FLTGMTVAG 0.4547 365 WB BclX(L) DRB1_0404 189DTFVELYGNNAAAES FVELYGNNA 0.4505 382 WB BclX(L) DRB1_0404 187GWDTFVELYGNNAAA FVELYGNNA 0.4498 385 WB BclX(L) DRB1_0404 169WMATYLNDHLEPWIQ WMATYLNDH 0.4478 393 WB BclX(L) DRB1_0404 188WDTFVELYGNNAAAE FVELYGNNA 0.4462 400 WB BclX(L) DRB1_0404 186GGWDTFVELYGNNAA FVELYGNNA 0.4437 411 WB BclX(L) DRB1_0404 185NGGWDTFVELYGNNA GWDTFVELY 0.4388 434 WB BclX(L) DRB1_0405 118TAYQSFEQVVNELFR YQSFEQVVN 0.5794 95 WB BclX(L) DRB1_0405 117GTAYQSFEQVVNELF YQSFEQVVN 0.5772 97 WB BclX(L) DRB1_0405 115TPGTAYQSFEQVVNE YQSFEQVVN 0.5541 124 WB BclX(L) DRB1_0405 116PGTAYQSFEQVVNEL YQSFEQVVN 0.5538 125 WB BclX(L) DRB1_0405 114ITPGTAYQSFEQVVN AYQSFEQVV 0.5505 129 WB BclX(L) DRB1_0405 163VSRIAAWMATYLNDH AAWMATYLN 0.5510 129 WB BclX(L) DRB1_0405 162LVSRIAAWMATYLND AAWMATYLN 0.5473 134 WB BclX(L) DRB1_0405 161VLVSRIAAWMATYLN IAAWMATYL 0.5442 139 WB BclX(L) DRB1_0405 164SRIAAWMATYLNDHL AAWMATYLN 0.5402 145 WB BclX(L) DRB1_0405 99LRYRRAFSDLTSQLH YRRAFSDLT 0.5100 201 WB BclX(L) DRB1_0405 97FELRYRRAFSDLTSQ YRRAFSDLT 0.5085 204 WB BclX(L) DRB1_0405 96EFELRYRRAFSDLTS YRRAFSDLT 0.5069 208 WB BclX(L) DRB1_0405 165RIAAWMATYLNDHLE AAWMATYLN 0.5055 211 WB BclX(L) DRB1_0405 119AYQSFEQVVNELFRD YQSFEQVVN 0.4974 230 WB BclX(L) DRB1_0405 120YQSFEQVVNELFRDG YQSFEQVVN 0.4968 231 WB BclX(L) DRB1_0405 98ELRYRRAFSDLTSQL YRRAFSDLT 0.4923 243 WB BclX(L) DRB1_0405 18SQKGYSWSQFSDVEE GYSWSQFSD 0.4575 354 WB BclX(L) DRB1_0405 95DEFELRYRRAFSDLT LRYRRAFSD 0.4574 355 WB BclX(L) DRB1_0405 19QKGYSWSQFSDVEEN WSQFSDVEE 0.4562 359 WB BclX(L) DRB1_0405 100RYRRAFSDLTSQLHI YRRAFSDLT 0.4475 395 WB BclX(L) DRB1_0405 20KGYSWSQFSDVEENR WSQFSDVEE 0.4430 414 WB BclX(L) DRB1_0405 166IAAWMATYLNDHLEP AAWMATYLN 0.4423 418 WB BclX(L) DRB1_0405 21GYSWSQFSDVEENRT WSQFSDVEE 0.4353 450 WB BclX(L) DRB1_0701 157KEMQVLVSRIAAWMA VLVSRIAAW 0.5228 175 WB BclX(L) DRB1_0701 159MQVLVSRIAAWMATY VLVSRIAAW 0.5194 181 WB BclX(L) DRB1_0701 158EMQVLVSRIAAWMAT VLVSRIAAW 0.5191 182 WB BclX(L) DRB1_0701 156DKEMQVLVSRIAAWM VLVSRIAAW 0.4971 231 WB BclX(L) DRB1_0701 160QVLVSRIAAWMATYL VLVSRIAAW 0.4833 268 WB BclX(L) DRB1_0701 46ETPSAINGNPSWHLA INGNPSWHL 0.4783 283 WB BclX(L) DRB1_0701 45METPSAINGNPSWHL AINGNPSWH 0.4779 284 WB BclX(L) DRB1_0701 155VDKEMQVLVSRIAAW MQVLVSRIA 0.4772 286 WB BclX(L) DRB1_0701 47TPSAINGNPSWHLAD INGNPSWHL 0.4774 286 WB BclX(L) DRB1_0701 48PSAINGNPSWHLADS INGNPSWHL 0.4764 289 WB BclX(L) DRB1_0701 161VLVSRIAAWMATYLN VLVSRIAAW 0.4745 295 WB BclX(L) DRB1_0701 49SAINGNPSWHLADSP INGNPSWHL 0.4718 303 WB BclX(L) DRB1_0701 99LRYRRAFSDLTSQLH YRRAFSDLT 0.4627 335 WB BclX(L) DRB1_0701 100RYRRAFSDLTSQLHI FSDLTSQLH 0.4416 420 WB BclX(L) DRB1_0701 101YRRAFSDLTSQLHIT FSDLTSQLH 0.4344 455 WB BclX(L) DRB1_0701 51INGNPSWHLADSPAV INGNPSWHL 0.4291 481 WB BclX(L) DRB1_0901 55PSWHLADSPAVNGAT WHLADSPAV 0.5482 133 WB BclX(L) DRB1_0901 54NPSWHLADSPAVNGA WHLADSPAV 0.5414 143 WB BclX(L) DRB1_0901 53GNPSWHLADSPAVNG WHLADSPAV 0.5408 144 WB BclX(L) DRB1_0901 51INGNPSWHLADSPAV SWHLADSPA 0.5289 164 WB BclX(L) DRB1_0901 52NGNPSWHLADSPAVN WHLADSPAV 0.5284 164 WB BclX(L) DRB1_0901 56SWHLADSPAVNGATG WHLADSPAV 0.4678 317 WB BclX(L) DRB1_0901 57WHLADSPAVNGATGH WHLADSPAV 0.4636 331 WB BclX(L) DRB1_0901 212RWFLTGMTVAGVVLL FLTGMTVAG 0.4483 391 WB BclX(L) DRB1_0901 213WFLTGMTVAGVVLLG MTVAGVVLL 0.4445 408 WB BclX(L) DRB1_0901 214FLTGMTVAGVVLLGS MTVAGVVLL 0.4327 463 WB BclX(L) DRB1_1101 157KEMQVLVSRIAAWMA MQVLVSRIA 0.4319 467 WB BclX(L) DRB1_1101 131FRDGVNWGRIVAFFS GVNWGRIVA 0.4310 472 WB BclX(L) DRB1_1101 156DKEMQVLVSRIAAWM MQVLVSRIA 0.4308 473 WB BclX(L) DRB1_1101 155VDKEMQVLVSRIAAW MQVLVSRIA 0.4292 481 WB BclX(L) DRB1_1101 132RDGVNWGRIVAFFSF GVNWGRIVA 0.4283 486 WB BclX(L) DRB1_1101 154SVDKEMQVLVSRIAA MQVLVSRIA 0.4267 494 WB BclX(L) DRB1_1302 218MTVAGVVLLGSLFSR VVLLGSLFS 0.4945 237 WB BclX(L) DRB1_1302 216TGMTVAGVVLLGSLF MTVAGVVLL 0.4855 262 WB BclX(L) DRB1_1302 214FLTGMTVAGVVLLGS MTVAGVVLL 0.4842 265 WB BclX(L) DRB1_1302 217GMTVAGVVLLGSLFS MTVAGVVLL 0.4840 266 WB BclX(L) DRB1_1302 212RWFLTGMTVAGVVLL FLTGMTVAG 0.4832 268 WB BclX(L) DRB1_1302 215LTGMTVAGVVLLGSL MTVAGVVLL 0.4775 285 WB BclX(L) DRB1_1302 213WFLTGMTVAGVVLLG MTVAGVVLL 0.4716 304 WB BclX(L) DRB1_1302 189DTFVELYGNNAAAES VELYGNNAA 0.4688 313 WB BclX(L) DRB1_1302 190TFVELYGNNAAAESR YGNNAAAES 0.4615 339 WB BclX(L) DRB1_1302 191FVELYGNNAAAESRK YGNNAAAES 0.4526 373 WB BclX(L) DRB1_1302 192VELYGNNAAAESRKG YGNNAAAES 0.4415 421 WB BclX(L) DRB1_1302 219TVAGVVLLGSLFSRK VVLLGSLFS 0.4384 436 WB BclX(L) DRB1_1302 193ELYGNNAAAESRKGQ YGNNAAAES 0.4275 490 WB BclX(L) DRB1_1501 219TVAGVVLLGSLFSRK VLLGSLFSR 0.6681 36 SB BclX(L) DRB1_1501 218MTVAGVVLLGSLFSR VVLLGSLFS 0.6441 47 SB BclX(L) DRB1_1501 6RELVVDFLSYKLSQK LVVDFLSYK 0.5208 179 WB BclX(L) DRB1_1501 7ELVVDFLSYKLSQKG FLSYKLSQK 0.5009 221 WB BclX(L) DRB1_1501 157KEMQVLVSRIAAWMA MQVLVSRIA 0.4968 231 WB BclX(L) DRB1_1501 156DKEMQVLVSRIAAWM MQVLVSRIA 0.4965 232 WB BclX(L) DRB1_1501 209RFNRWFLTGMTVAGV FNRWFLTGM 0.4870 257 WB BclX(L) DRB1_1501 164SRIAAWMATYLNDHL WMATYLNDH 0.4849 263 WB BclX(L) DRB1_1501 210FNRWFLTGMTVAGVV LTGMTVAGV 0.4836 267 WB BclX(L) DRB1_1501 8LVVDFLSYKLSQKGY FLSYKLSQK 0.4778 284 WB BclX(L) DRB1_1501 5NRELVVDFLSYKLSQ LVVDFLSYK 0.4777 285 WB BclX(L) DRB1_1501 135VNWGRIVAFFSFGGA IVAFFSFGG 0.4756 291 WB BclX(L) DRB1_1501 4SNRELVVDFLSYKLS LVVDFLSYK 0.4755 291 WB BclX(L) DRB1_1501 159MQVLVSRIAAWMATY LVSRIAAWM 0.4693 312 WB BclX(L) DRB1_1501 163VSRIAAWMATYLNDH IAAWMATYL 0.4691 312 WB BclX(L) DRB1_1501 158EMQVLVSRIAAWMAT VLVSRIAAW 0.4683 315 WB BclX(L) DRB1_1501 165RIAAWMATYLNDHLE WMATYLNDH 0.4685 315 WB BclX(L) DRB1_1501 128NELFRDGVNWGRIVA LFRDGVNWG 0.4675 318 WB BclX(L) DRB1_1501 125QVVNELFRDGVNWGR LFRDGVNWG 0.4668 320 WB BclX(L) DRB1_1501 126VVNELFRDGVNWGRI LFRDGVNWG 0.4668 320 WB BclX(L) DRB1_1501 166IAAWMATYLNDHLEP WMATYLNDH 0.4649 327 WB BclX(L) DRB1_1501 137WGRIVAFFSFGGALC IVAFFSFGG 0.4643 329 WB BclX(L) DRB1_1501 136NWGRIVAFFSFGGAL IVAFFSFGG 0.4638 331 WB BclX(L) DRB1_1501 207QERFNRWFLTGMTVA FNRWFLTGM 0.4608 342 WB BclX(L) DRB1_1501 208ERFNRWFLTGMTVAG FNRWFLTGM 0.4602 344 WB BclX(L) DRB1_1501 138GRIVAFFSFGGALCV IVAFFSFGG 0.4587 350 WB BclX(L) DRB1_1501 9VVDFLSYKLSQKGYS FLSYKLSQK 0.4584 351 WB BclX(L) DRB1_1501 155VDKEMQVLVSRIAAW MQVLVSRIA 0.4570 356 WB BclX(L) DRB1_1501 167AAWMATYLNDHLEPW WMATYLNDH 0.4551 364 WB BclX(L) DRB1_1501 3QSNRELVVDFLSYKL LVVDFLSYK 0.4543 367 WB BclX(L) DRB1_1501 127VNELFRDGVNWGRIV LFRDGVNWG 0.4431 414 WB BclX(L) DRB1_1501 134GVNWGRIVAFFSFGG VNWGRIVAF 0.4391 432 WB BclX(L) DRB1_1501 129ELFRDGVNWGRIVAF LFRDGVNWG 0.4390 433 WB BclX(L) DRB1_1501 217GMTVAGVVLLGSLFS VAGVVLLGS 0.4377 439 WB BclX(L) DRB1_1501 124EQVVNELFRDGVNWG VVNELFRDG 0.4373 441 WB BclX(L) DRB1_1501 139RIVAFFSFGGALCVE IVAFFSFGG 0.4300 477 WB BclX(L) DRB1_1501 211NRWFLTGMTVAGVVL LTGMTVAGV 0.4264 496 WB BclX(L) DRB4_0101 99LRYRRAFSDLTSQLH YRRAFSDLT 0.4654 325 WB BclX(L) DRB4_0101 100RYRRAFSDLTSQLHI FSDLTSQLH 0.4328 463 WB BclX(L) SEQ ID NOS: 47134-47645

Preferred fragments of Bcl-2 capable of interacting with one or more MHCclass 2 molecules are listed in table E.

TABLE E Prediction of cancer antigen Bcl-2 specific MHC class 2, 15-merpeptide binders for 14 MHC class 2 alleles (see FIG. 11) using thehttp://www.cbs.dtu.dk/services/NetMHCII/ database. The MHC class 2molecules for which no binders were found are not listed Allele pospeptide core 1 − log50k(aff) affinity(nM) Bind Level Identity DRB1_0101211 DFSWLSLKTLLSLAL WLSLKTLLS 0.8912 3 SB Bcl-2 DRB1_0101 212FSWLSLKTLLSLALV LKTLLSLAL 0.8917 3 SB Bcl-2 DRB1_0101 214WLSLKTLLSLALVGA LKTLLSLAL 0.8933 3 SB Bcl-2 DRB1_0101 215LSLKTLLSLALVGAC LKTLLSLAL 0.8867 3 SB Bcl-2 DRB1_0101 213SWLSLKTLLSLALVG LKTLLSLAL 0.8776 4 SB Bcl-2 DRB1_0101 216SLKTLLSLALVGACI LKTLLSLAL 0.8024 8 SB Bcl-2 DRB1_0101 217LKTLLSLALVGACIT LKTLLSLAL 0.8038 8 SB Bcl-2 DRB1_0101 68RTSPLQTPAAPGAAA LQTPAAPGA 0.7623 13 SB Bcl-2 DRB1_0101 69TSPLQTPAAPGAAAG LQTPAAPGA 0.7650 13 SB Bcl-2 DRB1_0101 70SPLQTPAAPGAAAGP LQTPAAPGA 0.7631 13 SB Bcl-2 DRB1_0101 66VARTSPLQTPAAPGA TSPLQTPAA 0.7565 14 SB Bcl-2 DRB1_0101 67ARTSPLQTPAAPGAA LQTPAAPGA 0.7584 14 SB Bcl-2 DRB1_0101 209LFDFSWLSLKTLLSL WLSLKTLLS 0.7419 16 SB Bcl-2 DRB1_0101 208PLFDFSWLSLKTLLS FSWLSLKTL 0.7389 17 SB Bcl-2 DRB1_0101 210FDFSWLSLKTLLSLA WLSLKTLLS 0.7403 17 SB Bcl-2 DRB1_0101 219TLLSLALVGACITLG LLSLALVGA 0.7270 19 SB Bcl-2 DRB1_0101 220LLSLALVGACITLGA LVGACITLG 0.7299 19 SB Bcl-2 DRB1_0101 223LALVGACITLGAYLG LVGACITLG 0.7079 24 SB Bcl-2 DRB1_0101 221LSLALVGACITLGAY LVGACITLG 0.7021 25 SB Bcl-2 DRB1_0101 222SLALVGACITLGAYL LVGACITLG 0.7016 25 SB Bcl-2 DRB1_0101 106RRYRRDFAEMSSQLH YRRDFAEMS 0.6774 33 SB Bcl-2 DRB1_0101 72LQTPAAPGAAAGPAL LQTPAAPGA 0.6778 33 SB Bcl-2 DRB1_0101 71PLQTPAAPGAAAGPA LQTPAAPGA 0.6750 34 SB Bcl-2 DRB1_0101 108YRRDFAEMSSQLHLT FAEMSSQLH 0.6686 36 SB Bcl-2 DRB1_0101 107RYRRDFAEMSSQLHL FAEMSSQLH 0.6670 37 SB Bcl-2 DRB1_0101 218KTLLSLALVGACITL LLSLALVGA 0.6642 38 SB Bcl-2 DRB1_0101 109RRDFAEMSSQLHLTP FAEMSSQLH 0.6615 39 SB Bcl-2 DRB1_0101 110RDFAEMSSQLHLTPF FAEMSSQLH 0.6572 41 SB Bcl-2 DRB1_0101 31DAGDVGAAPPGAAPA VGAAPPGAA 0.6561 41 SB Bcl-2 DRB1_0101 32AGDVGAAPPGAAPAP VGAAPPGAA 0.6565 41 SB Bcl-2 DRB1_0101 29EWDAGDVGAAPPGAA DVGAAPPGA 0.6512 44 SB Bcl-2 DRB1_0101 30WDAGDVGAAPPGAAP VGAAPPGAA 0.6504 44 SB Bcl-2 DRB1_0101 33GDVGAAPPGAAPAPG VGAAPPGAA 0.6438 47 SB Bcl-2 DRB1_0101 207RPLFDFSWLSLKTLL FSWLSLKTL 0.6332 53 WB Bcl-2 DRB1_0101 224ALVGACITLGAYLGH LVGACITLG 0.6316 54 WB Bcl-2 DRB1_0101 206MRPLFDFSWLSLKTL DFSWLSLKT 0.6303 55 WB Bcl-2 DRB1_0101 225LVGACITLGAYLGHK LVGACITLG 0.6212 60 WB Bcl-2 DRB1_0101 13EIVMKYIHYKLSQRG MKYIHYKLS 0.6124 66 WB Bcl-2 DRB1_0101 14IVMKYIHYKLSQRGY IHYKLSQRG 0.6114 67 WB Bcl-2 DRB1_0101 15VMKYIHYKLSQRGYE IHYKLSQRG 0.6087 69 WB Bcl-2 DRB1_0101 16MKYIHYKLSQRGYEW IHYKLSQRG 0.6059 71 WB Bcl-2 DRB1_0101 17KYIHYKLSQRGYEWD IHYKLSQRG 0.6042 72 WB Bcl-2 DRB1_0101 164REMSPLVDNIALWMT LVDNIALWM 0.5967 79 WB Bcl-2 DRB1_0101 165EMSPLVDNIALWMTE VDNIALWMT 0.5914 83 WB Bcl-2 DRB1_0101 167SPLVDNIALWMTEYL VDNIALWMT 0.5912 83 WB Bcl-2 DRB1_0101 166MSPLVDNIALWMTEY VDNIALWMT 0.5908 84 WB Bcl-2 DRB1_0101 63RDPVARTSPLQTPAA VARTSPLQT 0.5908 84 WB Bcl-2 DRB1_0101 64DPVARTSPLQTPAAP VARTSPLQT 0.5876 87 WB Bcl-2 DRB1_0101 168PLVDNIALWMTEYLN VDNIALWMT 0.5794 95 WB Bcl-2 DRB1_0101 196DAFVELYGPSMRPLF FVELYGPSM 0.5684 107 WB Bcl-2 DRB1_0101 34DVGAAPPGAAPAPGI VGAAPPGAA 0.5672 108 WB Bcl-2 DRB1_0101 62SRDPVARTSPLQTPA VARTSPLQT 0.5669 108 WB Bcl-2 DRB1_0101 195WDAFVELYGPSMRPL FVELYGPSM 0.5666 109 WB Bcl-2 DRB1_0101 61ASRDPVARTSPLQTP VARTSPLQT 0.5637 112 WB Bcl-2 DRB1_0101 86LSPVPPVVHLTLRQA LSPVPPVVH 0.5639 112 WB Bcl-2 DRB1_0101 111DFAEMSSQLHLTPFT FAEMSSQLH 0.5615 115 WB Bcl-2 DRB1_0101 89VPPVVHLTLRQAGDD VVHLTLRQA 0.5593 118 WB Bcl-2 DRB1_0101 87SPVPPVVHLTLRQAG VVHLTLRQA 0.5579 119 WB Bcl-2 DRB1_0101 88PVPPVVHLTLRQAGD VVHLTLRQA 0.5581 119 WB Bcl-2 DRB1_0101 112FAEMSSQLHLTPFTA FAEMSSQLH 0.5577 120 WB Bcl-2 DRB1_0101 35VGAAPPGAAPAPGIF VGAAPPGAA 0.5569 121 WB Bcl-2 DRB1_0101 90PPVVHLTLRQAGDDF VVHLTLRQA 0.5563 122 WB Bcl-2 DRB1_0101 80AAAGPALSPVPPVVH AAAGPALSP 0.5545 124 WB Bcl-2 DRB1_0101 160ESVNREMSPLVDNIA VNREMSPLV 0.5523 127 WB Bcl-2 DRB1_0101 60AASRDPVARTSPLQT SRDPVARTS 0.5524 127 WB Bcl-2 DRB1_0101 117SQLHLTPFTARGRFA LTPFTARGR 0.5480 133 WB Bcl-2 DRB1_0101 115MSSQLHLTPFTARGR LHLTPFTAR 0.5456 137 WB Bcl-2 DRB1_0101 116SSQLHLTPFTARGRF LTPFTARGR 0.5418 142 WB Bcl-2 DRB1_0101 81AAGPALSPVPPVVHL LSPVPPVVH 0.5390 147 WB Bcl-2 DRB1_0101 118QLHLTPFTARGRFAT LTPFTARGR 0.5379 148 WB Bcl-2 DRB1_0101 197AFVELYGPSMRPLFD LYGPSMRPL 0.5381 148 WB Bcl-2 DRB1_0101 156VMCVESVNREMSPLV VMCVESVNR 0.5366 151 WB Bcl-2 DRB1_0101 158CVESVNREMSPLVDN VNREMSPLV 0.5360 151 WB Bcl-2 DRB1_0101 159VESVNREMSPLVDNI VNREMSPLV 0.5364 151 WB Bcl-2 DRB1_0101 198FVELYGPSMRPLFDF LYGPSMRPL 0.5345 154 WB Bcl-2 DRB1_0101 157MCVESVNREMSPLVD VNREMSPLV 0.5315 159 WB Bcl-2 DRB1_0101 119LHLTPFTARGRFATV LTPFTARGR 0.5307 160 WB Bcl-2 DRB1_0101 82AGPALSPVPPVVHLT LSPVPPVVH 0.5312 160 WB Bcl-2 DRB1_0101 83GPALSPVPPVVHLTL LSPVPPVVH 0.5307 160 WB Bcl-2 DRB1_0101 148VAFFEFGGVMCVESV FEFGGVMCV 0.5291 163 WB Bcl-2 DRB1_0101 149AFFEFGGVMCVESVN FEFGGVMCV 0.5288 164 WB Bcl-2 DRB1_0101 46PGIFSSQPGHTPHPA FSSQPGHTP 0.5270 167 WB Bcl-2 DRB1_0101 170VDNIALWMTEYLNRH VDNIALWMT 0.5265 168 WB Bcl-2 DRB1_0101 43APAPGIFSSQPGHTP IFSSQPGHT 0.5223 176 WB Bcl-2 DRB1_0101 84PALSPVPPVVHLTLR LSPVPPVVH 0.5195 181 WB Bcl-2 DRB1_0101 147IVAFFEFGGVMCVES FEFGGVMCV 0.5190 182 WB Bcl-2 DRB1_0101 65PVARTSPLQTPAAPG VARTSPLQT 0.5190 182 WB Bcl-2 DRB1_0101 45APGIFSSQPGHTPHP FSSQPGHTP 0.5186 183 WB Bcl-2 DRB1_0101 120HLTPFTARGRFATVV LTPFTARGR 0.5178 184 WB Bcl-2 DRB1_0101 121LTPFTARGRFATVVE ARGRFATVV 0.5182 184 WB Bcl-2 DRB1_0101 136ELFRDGVNWGRIVAF FRDGVNWGR 0.5154 189 WB Bcl-2 DRB1_0101 44PAPGIFSSQPGHTPH FSSQPGHTP 0.5142 192 WB Bcl-2 DRB1_0101 138FRDGVNWGRIVAFFE VNWGRIVAF 0.5122 196 WB Bcl-2 DRB1_0101 169LVDNIALWMTEYLNR VDNIALWMT 0.5062 209 WB Bcl-2 DRB1_0101 18YIHYKLSQRGYEWDA IHYKLSQRG 0.5057 210 WB Bcl-2 DRB1_0101 137LFRDGVNWGRIVAFF VNWGRIVAF 0.5023 218 WB Bcl-2 DRB1_0101 19IHYKLSQRGYEWDAG IHYKLSQRG 0.5022 218 WB Bcl-2 DRB1_0101 47GIFSSQPGHTPHPAA FSSQPGHTP 0.5023 218 WB Bcl-2 DRB1_0101 76AAPGAAAGPALSPVP AAAGPALSP 0.5005 222 WB Bcl-2 DRB1_0101 139RDGVNWGRIVAFFEF VNWGRIVAF 0.4998 224 WB Bcl-2 DRB1_0101 74TPAAPGAAAGPALSP GAAAGPALS 0.4991 226 WB Bcl-2 DRB1_0101 194GWDAFVELYGPSMRP FVELYGPSM 0.4987 227 WB Bcl-2 DRB1_0101 75PAAPGAAAGPALSPV AAAGPALSP 0.4981 228 WB Bcl-2 DRB1_0101 77APGAAAGPALSPVPP AAAGPALSP 0.4980 229 WB Bcl-2 DRB1_0101 140DGVNWGRIVAFFEFG VNWGRIVAF 0.4959 234 WB Bcl-2 DRB1_0101 105SRRYRRDFAEMSSQL YRRDFAEMS 0.4945 237 WB Bcl-2 DRB1_0101 91PVVHLTLRQAGDDFS VVHLTLRQA 0.4935 240 WB Bcl-2 DRB1_0101 199VELYGPSMRPLFDFS LYGPSMRPL 0.4895 251 WB Bcl-2 DRB1_0101 92VVHLTLRQAGDDFSR VVHLTLRQA 0.4870 257 WB Bcl-2 DRB1_0101 104FSRRYRRDFAEMSSQ YRRDFAEMS 0.4851 263 WB Bcl-2 DRB1_0101 103DFSRRYRRDFAEMSS YRRDFAEMS 0.4834 268 WB Bcl-2 DRB1_0101 102DDFSRRYRRDFAEMS RYRRDFAEM 0.4800 278 WB Bcl-2 DRB1_0101 145GRIVAFFEFGGVMCV FFEFGGVMC 0.4796 279 WB Bcl-2 DRB1_0101 146RIVAFFEFGGVMCVE FEFGGVMCV 0.4791 280 WB Bcl-2 DRB1_0101 78PGAAAGPALSPVPPV AAAGPALSP 0.4771 286 WB Bcl-2 DRB1_0101 161SVNREMSPLVDNIAL VNREMSPLV 0.4763 289 WB Bcl-2 DRB1_0101 150FFEFGGVMCVESVNR FEFGGVMCV 0.4737 297 WB Bcl-2 DRB1_0101 162VNREMSPLVDNIALW VNREMSPLV 0.4734 298 WB Bcl-2 DRB1_0101 151FEFGGVMCVESVNRE FEFGGVMCV 0.4731 299 WB Bcl-2 DRB1_0101 114EMSSQLHLTPFTARG LHLTPFTAR 0.4711 306 WB Bcl-2 DRB1_0101 122TPFTARGRFATVVEE ARGRFATVV 0.4638 331 WB Bcl-2 DRB1_0101 73QTPAAPGAAAGPALS APGAAAGPA 0.4635 332 WB Bcl-2 DRB1_0101 49FSSQPGHTPHPAASR FSSQPGHTP 0.4615 339 WB Bcl-2 DRB1_0101 48IFSSQPGHTPHPAAS FSSQPGHTP 0.4531 371 WB Bcl-2 DRB1_0101 36GAAPPGAAPAPGIFS PGAAPAPGI 0.4518 376 WB Bcl-2 DRB1_0101 123PFTARGRFATVVEEL ARGRFATVV 0.4516 377 WB Bcl-2 DRB1_0101 124FTARGRFATVVEELF ARGRFATVV 0.4490 388 WB Bcl-2 DRB1_0101 174ALWMTEYLNRHLHTW WMTEYLNRH 0.4444 408 WB Bcl-2 DRB1_0101 85ALSPVPPVVHLTLRQ LSPVPPVVH 0.4436 411 WB Bcl-2 DRB1_0101 113AEMSSQLHLTPFTAR SQLHLTPFT 0.4430 414 WB Bcl-2 DRB1_0101 171DNIALWMTEYLNRHL WMTEYLNRH 0.4414 421 WB Bcl-2 DRB1_0101 193GGWDAFVELYGPSMR FVELYGPSM 0.4396 430 WB Bcl-2 DRB1_0101 200ELYGPSMRPLFDFSW LYGPSMRPL 0.4395 430 WB Bcl-2 DRB1_0101 37AAPPGAAPAPGIFSS AAPAPGIFS 0.4393 431 WB Bcl-2 DRB1_0101 79GAAAGPALSPVPPVV AAAGPALSP 0.4394 431 WB Bcl-2 DRB1_0101 172NIALWMTEYLNRHLH WMTEYLNRH 0.4279 488 WB Bcl-2 DRB1_0101 28YEWDAGDVGAAPPGA WDAGDVGAA 0.4274 490 WB Bcl-2 DRB1_0101 42AAPAPGIFSSQPGHT AAPAPGIFS 0.4268 494 WB Bcl-2 DRB1_0101 163NREMSPLVDNIALWM MSPLVDNIA 0.4266 495 WB Bcl-2 DRB1_0401 208PLFDFSWLSLKTLLS DFSWLSLKT 0.5448 138 WB Bcl-2 DRB1_0401 211DFSWLSLKTLLSLAL WLSLKTLLS 0.5436 139 WB Bcl-2 DRB1_0401 212FSWLSLKTLLSLALV WLSLKTLLS 0.5395 146 WB Bcl-2 DRB1_0401 209LFDFSWLSLKTLLSL WLSLKTLLS 0.5358 152 WB Bcl-2 DRB1_0401 210FDFSWLSLKTLLSLA WLSLKTLLS 0.5305 161 WB Bcl-2 DRB1_0401 156VMCVESVNREMSPLV MCVESVNRE 0.4924 243 WB Bcl-2 DRB1_0401 158CVESVNREMSPLVDN VNREMSPLV 0.4915 245 WB Bcl-2 DRB1_0401 157MCVESVNREMSPLVD VNREMSPLV 0.4907 247 WB Bcl-2 DRB1_0401 160ESVNREMSPLVDNIA VNREMSPLV 0.4909 247 WB Bcl-2 DRB1_0401 159VESVNREMSPLVDNI VNREMSPLV 0.4870 257 WB Bcl-2 DRB1_0401 214WLSLKTLLSLALVGA WLSLKTLLS 0.4662 322 WB Bcl-2 DRB1_0401 213SWLSLKTLLSLALVG WLSLKTLLS 0.4661 323 WB Bcl-2 DRB1_0401 106RRYRRDFAEMSSQLH YRRDFAEMS 0.4563 359 WB Bcl-2 DRB1_0401 170VDNIALWMTEYLNRH NIALWMTEY 0.4319 467 WB Bcl-2 DRB1_0404 174ALWMTEYLNRHLHTW WMTEYLNRH 0.5813 93 WB Bcl-2 DRB1_0404 170VDNIALWMTEYLNRH IALWMTEYL 0.5418 142 WB Bcl-2 DRB1_0404 171DNIALWMTEYLNRHL WMTEYLNRH 0.5422 142 WB Bcl-2 DRB1_0404 172NIALWMTEYLNRHLH WMTEYLNRH 0.5371 150 WB Bcl-2 DRB1_0404 173IALWMTEYLNRHLHT WMTEYLNRH 0.5341 155 WB Bcl-2 DRB1_0404 175LWMTEYLNRHLHTWI WMTEYLNRH 0.5171 186 WB Bcl-2 DRB1_0404 115MSSQLHLTPFTARGR HLTPFTARG 0.5121 196 WB Bcl-2 DRB1_0404 114EMSSQLHLTPFTARG LHLTPFTAR 0.5118 197 WB Bcl-2 DRB1_0404 176WMTEYLNRHLHTWIQ WMTEYLNRH 0.5110 199 WB Bcl-2 DRB1_0404 116SSQLHLTPFTARGRF HLTPFTARG 0.5043 213 WB Bcl-2 DRB1_0404 117SQLHLTPFTARGRFA HLTPFTARG 0.5004 223 WB Bcl-2 DRB1_0404 118QLHLTPFTARGRFAT HLTPFTARG 0.4918 244 WB Bcl-2 DRB1_0404 45APGIFSSQPGHTPHP FSSQPGHTP 0.4688 313 WB Bcl-2 DRB1_0404 46PGIFSSQPGHTPHPA FSSQPGHTP 0.4665 321 WB Bcl-2 DRB1_0404 47GIFSSQPGHTPHPAA SQPGHTPHP 0.4485 390 WB Bcl-2 DRB1_0404 109RRDFAEMSSQLHLTP FAEMSSQLH 0.4422 418 WB Bcl-2 DRB1_0404 210FDFSWLSLKTLLSLA WLSLKTLLS 0.4405 426 WB Bcl-2 DRB1_0404 110RDFAEMSSQLHLTPF FAEMSSQLH 0.4393 431 WB Bcl-2 DRB1_0404 211DFSWLSLKTLLSLAL WLSLKTLLS 0.4316 469 WB Bcl-2 DRB1_0404 212FSWLSLKTLLSLALV WLSLKTLLS 0.4313 470 WB Bcl-2 DRB1_0405 208PLFDFSWLSLKTLLS FSWLSLKTL 0.6517 43 SB Bcl-2 DRB1_0405 209LFDFSWLSLKTLLSL WLSLKTLLS 0.6415 48 SB Bcl-2 DRB1_0405 210FDFSWLSLKTLLSLA WLSLKTLLS 0.6398 49 SB Bcl-2 DRB1_0405 211DFSWLSLKTLLSLAL WLSLKTLLS 0.6392 50 WB Bcl-2 DRB1_0405 212FSWLSLKTLLSLALV WLSLKTLLS 0.6381 50 WB Bcl-2 DRB1_0405 213SWLSLKTLLSLALVG WLSLKTLLS 0.5584 119 WB Bcl-2 DRB1_0405 214WLSLKTLLSLALVGA WLSLKTLLS 0.5575 120 WB Bcl-2 DRB1_0405 160ESVNREMSPLVDNIA NREMSPLVD 0.5021 219 WB Bcl-2 DRB1_0405 158CVESVNREMSPLVDN NREMSPLVD 0.4974 230 WB Bcl-2 DRB1_0405 159VESVNREMSPLVDNI NREMSPLVD 0.4930 241 WB Bcl-2 DRB1_0405 170VDNIALWMTEYLNRH IALWMTEYL 0.4903 248 WB Bcl-2 DRB1_0405 168PLVDNIALWMTEYLN IALWMTEYL 0.4841 266 WB Bcl-2 DRB1_0405 171DNIALWMTEYLNRHL IALWMTEYL 0.4841 266 WB Bcl-2 DRB1_0405 169LVDNIALWMTEYLNR IALWMTEYL 0.4812 274 WB Bcl-2 DRB1_0405 157MCVESVNREMSPLVD VNREMSPLV 0.4756 291 WB Bcl-2 DRB1_0405 167SPLVDNIALWMTEYL NIALWMTEY 0.4744 295 WB Bcl-2 DRB1_0405 161SVNREMSPLVDNIAL NREMSPLVD 0.4718 303 WB Bcl-2 DRB1_0405 106RRYRRDFAEMSSQLH YRRDFAEMS 0.4486 390 WB Bcl-2 DRB1_0405 162VNREMSPLVDNIALW NREMSPLVD 0.4294 480 WB Bcl-2 DRB1_0701 83GPALSPVPPVVHLTL LSPVPPVVH 0.5316 159 WB Bcl-2 DRB1_0701 82AGPALSPVPPVVHLT LSPVPPVVH 0.5286 164 WB Bcl-2 DRB1_0701 81AAGPALSPVPPVVHL LSPVPPVVH 0.5256 169 WB Bcl-2 DRB1_0701 84PALSPVPPVVHLTLR LSPVPPVVH 0.5210 178 WB Bcl-2 DRB1_0701 80AAAGPALSPVPPVVH ALSPVPPVV 0.5179 184 WB Bcl-2 DRB1_0701 85ALSPVPPVVHLTLRQ LSPVPPVVH 0.4370 442 WB Bcl-2 DRB1_0701 86LSPVPPVVHLTLRQA LSPVPPVVH 0.4291 482 WB Bcl-2 DRB1_0901 196DAFVELYGPSMRPLF VELYGPSMR 0.4599 345 WB Bcl-2 DRB1_0901 197AFVELYGPSMRPLFD YGPSMRPLF 0.4582 352 WB Bcl-2 DRB1_0901 198FVELYGPSMRPLFDF YGPSMRPLF 0.4429 415 WB Bcl-2 DRB1_0901 199VELYGPSMRPLFDFS YGPSMRPLF 0.4428 415 WB Bcl-2 DRB1_1302 212FSWLSLKTLLSLALV WLSLKTLLS 0.5351 153 WB Bcl-2 DRB1_1302 211DFSWLSLKTLLSLAL WLSLKTLLS 0.5323 158 WB Bcl-2 DRB1_1302 209LFDFSWLSLKTLLSL WLSLKTLLS 0.4963 233 WB Bcl-2 DRB1_1302 210FDFSWLSLKTLLSLA WLSLKTLLS 0.4951 236 WB Bcl-2 DRB1_1302 208PLFDFSWLSLKTLLS FSWLSLKTL 0.4783 283 WB Bcl-2 DRB1_1302 213SWLSLKTLLSLALVG WLSLKTLLS 0.4770 287 WB Bcl-2 DRB1_1302 214WLSLKTLLSLALVGA WLSLKTLLS 0.4769 287 WB Bcl-2 DRB1_1302 196DAFVELYGPSMRPLF VELYGPSMR 0.4640 330 WB Bcl-2 DRB1_1302 197AFVELYGPSMRPLFD VELYGPSMR 0.4607 342 WB Bcl-2 DRB1_1302 167SPLVDNIALWMTEYL VDNIALWMT 0.4494 387 WB Bcl-2 DRB1_1302 168PLVDNIALWMTEYLN VDNIALWMT 0.4385 435 WB Bcl-2 DRB1_1501 13EIVMKYIHYKLSQRG YIHYKLSQR 0.6338 53 WB Bcl-2 DRB1_1501 14IVMKYIHYKLSQRGY YIHYKLSQR 0.6318 54 WB Bcl-2 DRB1_1501 15VMKYIHYKLSQRGYE YIHYKLSQR 0.6170 63 WB Bcl-2 DRB1_1501 16MKYIHYKLSQRGYEW YIHYKLSQR 0.6121 66 WB Bcl-2 DRB1_1501 12REIVMKYIHYKLSQR IVMKYIHYK 0.6057 71 WB Bcl-2 DRB1_1501 17KYIHYKLSQRGYEWD YIHYKLSQR 0.5372 150 WB Bcl-2 DRB1_1501 115MSSQLHLTPFTARGR LHLTPFTAR 0.5174 185 WB Bcl-2 DRB1_1501 116SSQLHLTPFTARGRF LHLTPFTAR 0.5162 188 WB Bcl-2 DRB1_1501 18YIHYKLSQRGYEWDA YIHYKLSQR 0.5136 193 WB Bcl-2 DRB1_1501 117SQLHLTPFTARGRFA LHLTPFTAR 0.5054 211 WB Bcl-2 DRB1_1501 119LHLTPFTARGRFATV LTPFTARGR 0.4756 291 WB Bcl-2 DRB1_1501 135EELFRDGVNWGRIVA LFRDGVNWG 0.4694 311 WB Bcl-2 DRB1_1501 212FSWLSLKTLLSLALV WLSLKTLLS 0.4694 312 WB Bcl-2 DRB1_1501 211DFSWLSLKTLLSLAL WLSLKTLLS 0.4655 325 WB Bcl-2 DRB1_1501 118QLHLTPFTARGRFAT LHLTPFTAR 0.4592 348 WB Bcl-2 DRB1_1501 87SPVPPVVHLTLRQAG VVHLTLRQA 0.4553 363 WB Bcl-2 DRB1_1501 88PVPPVVHLTLRQAGD VVHLTLRQA 0.4528 373 WB Bcl-2 DRB1_1501 214WLSLKTLLSLALVGA LKTLLSLAL 0.4517 377 WB Bcl-2 DRB1_1501 209LFDFSWLSLKTLLSL WLSLKTLLS 0.4495 386 WB Bcl-2 DRB1_1501 156VMCVESVNREMSPLV VMCVESVNR 0.4490 388 WB Bcl-2 DRB1_1501 193GGWDAFVELYGPSMR FVELYGPSM 0.4489 389 WB Bcl-2 DRB1_1501 195WDAFVELYGPSMRPL VELYGPSMR 0.4483 391 WB Bcl-2 DRB1_1501 196DAFVELYGPSMRPLF FVELYGPSM 0.4482 392 WB Bcl-2 DRB1_1501 132TVVEELFRDGVNWGR LFRDGVNWG 0.4470 397 WB Bcl-2 DRB1_1501 133VVEELFRDGVNWGRI LFRDGVNWG 0.4467 398 WB Bcl-2 DRB1_1501 194GWDAFVELYGPSMRP VELYGPSMR 0.4467 398 WB Bcl-2 DRB1_1501 174ALWMTEYLNRHLHTW WMTEYLNRH 0.4463 400 WB Bcl-2 DRB1_1501 208PLFDFSWLSLKTLLS LFDFSWLSL 0.4459 401 WB Bcl-2 DRB1_1501 172NIALWMTEYLNRHLH WMTEYLNRH 0.4448 406 WB Bcl-2 DRB1_1501 173IALWMTEYLNRHLHT WMTEYLNRH 0.4448 407 WB Bcl-2 DRB1_1501 134VEELFRDGVNWGRIV LFRDGVNWG 0.4431 414 WB Bcl-2 DRB1_1501 171DNIALWMTEYLNRHL WMTEYLNRH 0.4431 414 WB Bcl-2 DRB1_1501 89VPPVVHLTLRQAGDD VVHLTLRQA 0.4422 418 WB Bcl-2 DRB1_1501 210FDFSWLSLKTLLSLA WLSLKTLLS 0.4399 429 WB Bcl-2 DRB1_1501 136ELFRDGVNWGRIVAF LFRDGVNWG 0.4390 433 WB Bcl-2 DRB1_1501 86LSPVPPVVHLTLRQA PPVVHLTLR 0.4378 438 WB Bcl-2 DRB1_1501 213SWLSLKTLLSLALVG LKTLLSLAL 0.4330 461 WB Bcl-2 DRB1_1501 90PPVVHLTLRQAGDDF VVHLTLRQA 0.4313 470 WB Bcl-2 DRB4_0101 196DAFVELYGPSMRPLF VELYGPSMR 0.5364 151 WB Bcl-2 DRB4_0101 197AFVELYGPSMRPLFD VELYGPSMR 0.5361 151 WB Bcl-2 DRB4_0101 195WDAFVELYGPSMRPL VELYGPSMR 0.5323 158 WB Bcl-2 DRB4_0101 193GGWDAFVELYGPSMR FVELYGPSM 0.4796 279 WB Bcl-2 DRB4_0101 194GWDAFVELYGPSMRP VELYGPSMR 0.4785 282 WB Bcl-2 DRB4_0101 198FVELYGPSMRPLFDF VELYGPSMR 0.4761 289 WB Bcl-2 DRB4_0101 199VELYGPSMRPLFDFS VELYGPSMR 0.4763 289 WB Bcl-2 DRB4_0101 81AAGPALSPVPPVVHL LSPVPPVVH 0.4638 331 WB Bcl-2 DRB4_0101 80AAAGPALSPVPPVVH ALSPVPPVV 0.4614 339 WB Bcl-2 DRB4_0101 170VDNIALWMTEYLNRH IALWMTEYL 0.4593 347 WB Bcl-2 DRB4_0101 83GPALSPVPPVVHLTL LSPVPPVVH 0.4589 349 WB Bcl-2 DRB4_0101 82AGPALSPVPPVVHLT LSPVPPVVH 0.4574 354 WB Bcl-2 DRB4_0101 84PALSPVPPVVHLTLR LSPVPPVVH 0.4565 358 WB Bcl-2 DRB4_0101 171DNIALWMTEYLNRHL WMTEYLNRH 0.4552 363 WB Bcl-2 DRB4_0101 172NIALWMTEYLNRHLH LWMTEYLNR 0.4326 464 WB Bcl-2 DRB4_0101 173IALWMTEYLNRHLHT WMTEYLNRH 0.4273 491 WB Bcl-2 DRB5_0101 16MKYIHYKLSQRGYEW YIHYKLSQR 0.4394 431 WB Bcl-2 DRB5_0101 15VMKYIHYKLSQRGYE YIHYKLSQR 0.4386 435 WB Bcl-2 SEQ ID NOS: 46594-47133

Preferred fragments of Survivin capable of interacting with one or moreMHC class 1 molecules are listed in table F.

TABLE FPrediction of cancer antigen Survivin specific MHC class 1 peptidesequences. Prediction of 8-, 9-, 10-, 11-mers using the programdisplayed in FIG. 2. 8 mers:MGAPTLPP; GAPTLPPA; APTLPPAW; PTLPPAWQ; TLPPAWQP; LPPAWQPF;PPAWQPFL; PAWQPFLK; AWQPFLKD; WQPFLKDH; QPFLKDHR; PFLKDHRI;FLKDHRIS; LKDHRIST; KDHRISTF; DHRISTFK; HRISTFKN; RISTFKNW;ISTFKNWP; STFKNWPF; TFKNWPFL; FKNWPFLE; KNWPFLEG; NWPFLEGC;WPFLEGCA; PFLEGCAC; FLEGCACT; LEGCACTP; EGCACTPE; GCACTPER;CACTPERM; ACTPERMA; CTPERMAE; TPERMAEA; PERMAEAG; ERMAEAGF;RMAEAGFI; MAEAGFIH; AEAGFIHC; EAGFIHCP; AGFIHCPT; GFIHCPTE;FIHCPTEN; IHCPTENE; HCPTENEP; CPTENEPD; PTENEPDL; TENEPDLA;ENEPDLAQ; NEPDLAQC; EPDLAQCF; PDLAQCFF; DLAQCFFC; LAQCFFCF;AQCFFCFK; QCFFCFKE; CFFCFKEL; FFCFKELE; FCFKELEG; CFKELEGW;FKELEGWE; KELEGWEP; ELEGWEPD; LEGWEPDD; EGWEPDDD; GWEPDDDP;WEPDDDPI; EPDDDPIE; PDDDPIEE; DDDPIEEH; DDPIEEHK; DPIEEHKK;PIEEHKKH; IEEHKKHS; EEHKKHSS; EHKKHSSG; HKKHSSGC; KKHSSGCA;KHSSGCAF; HSSGCAFL; SSGCAFLS; SGCAFLSV; GCAFLSVK; CAFLSVKK;AFLSVKKQ; FLSVKKQF; LSVKKQFE; SVKKQFEE; VKKQFEEL; KKQFEELT;KQFEELTL; QFEELTLG; FEELTLGE; EELTLGEF; ELTLGEFL; LTLGEFLK;TLGEFLKL; LGEFLKLD; GEFLKLDR; EFLKLDRE; FLKLDRER; LKLDRERA;KLDRERAK; LDRERAKN; DRERAKNK; RERAKNKI; ERAKNKIA; RAKNKIAK;AKNKIAKE; KNKIAKET; NKIAKETN; KIAKETNN; IAKETNNK; AKETNNKK;KETNNKKK; ETNNKKKE; TNNKKKEF; NNKKKEFE; NKKKEFEE; KKKEFEET;KKEFEETA; KEFEETAK; EFEETAKK; FEETAKKV; EETAKKVR; ETAKKVRR;TAKKVRRA; AKKVRRAI; KKVRRAIE; KVRRAIEQ; VRRAIEQL; RRAIEQLA;RAIEQLAA; AIEQLAAM; IEQLAAMD; EQLAAMD□ 9 mers:MGAPTLPPA; GAPTLPPAW; APTLPPAWQ; PTLPPAWQP; TLPPAWQPF; LPPAWQPFL;PPAWQPFLK; PAWQPFLKD; AWQPFLKDH; WQPFLKDHR; QPFLKDHRI; PFLKDHRIS;FLKDHRIST; LKDHRISTF; KDHRISTFK; DHRISTFKN; HRISTFKNW; RISTFKNWP;ISTFKNWPF; STFKNWPFL; TFKNWPFLE; FKNWPFLEG; KNWPFLEGC; NWPFLEGCA;WPFLEGCAC; PFLEGCACT; FLEGCACTP; LEGCACTPE; EGCACTPER; GCACTPERM;CACTPERMA; ACTPERMAE; CTPERMAEA; TPERMAEAG; PERMAEAGF; ERMAEAGFI;RMAEAGFIH; MAEAGFIHC; AEAGFIHCP; EAGFIHCPT; AGFIHCPTE; GFIHCPTEN;FIHCPTENE; IHCPTENEP; HCPTENEPD; CPTENEPDL; PTENEPDLA; TENEPDLAQ;ENEPDLAQC; NEPDLAQCF; EPDLAQCFF; PDLAQCFFC; DLAQCFFCF; LAQCFFCFK;AQCFFCFKE; QCFFCFKEL; CFFCFKELE; FFCFKELEG; FCFKELEGW; CFKELEGWE;FKELEGWEP; KELEGWEPD; ELEGWEPDD; LEGWEPDDD; EGWEPDDDP; GWEPDDDPI;WEPDDDPIE; EPDDDPIEE; PDDDPIEEH; DDDPIEEHK; DDPIEEHKK; DPIEEHKKH;PIEEHKKHS; IEEHKKHSS; EEHKKHSSG; EHKKHSSGC; HKKHSSGCA; KKHSSGCAF;KHSSGCAFL; HSSGCAFLS; SSGCAFLSV; SGCAFLSVK; GCAFLSVKK; CAFLSVKKQ;AFLSVKKQF; FLSVKKQFE; LSVKKQFEE; SVKKQFEEL; VKKQFEELT; KKQFEELTL;KQFEELTLG; QFEELTLGE; FEELTLGEF; EELTLGEFL; ELTLGEFLK; LTLGEFLKL;TLGEFLKLD; LGEFLKLDR; GEFLKLDRE; EFLKLDRER; FLKLDRERA; LKLDRERAK;KLDRERAKN; LDRERAKNK; DRERAKNKI; RERAKNKIA; ERAKNKIAK; RAKNKIAKE;AKNKIAKET; KNKIAKETN; NKIAKETNN; KIAKETNNK; IAKETNNKK; AKETNNKKK;KETNNKKKE; ETNNKKKEF; TNNKKKEFE; NNKKKEFEE; NKKKEFEET; KKKEFEETA;KKEFEETAK; KEFEETAKK; EFEETAKKV; FEETAKKVR; EETAKKVRR; ETAKKVRRA;TAKKVRRAI; AKKVRRAIE; KKVRRAIEQ; KVRRAIEQL; VRRAIEQLA; RRAIEQLAA;RAIEQLAAM; AIEQLAAMD; □ 10 mers:MGAPTLPPAW; GAPTLPPAWQ; APTLPPAWQP; PTLPPAWQPF; TLPPAWQPFL;LPPAWQPFLK; PPAWQPFLKD; PAWQPFLKDH; AWQPFLKDHR; WQPFLKDHRI;QPFLKDHRIS; PFLKDHRIST; FLKDHRISTF; LKDHRISTFK; KDHRISTFKN;DHRISTFKNW; HRISTFKNWP; RISTFKNWPF; ISTFKNWPFL; STFKNWPFLE;TFKNWPFLEG; FKNWPFLEGC; KNWPFLEGCA; NWPFLEGCAC; WPFLEGCACT;PFLEGCACTP; FLEGCACTPE; LEGCACTPER; EGCACTPERM; GCACTPERMA;CACTPERMAE; ACTPERMAEA; CTPERMAEAG; TPERMAEAGF; PERMAEAGFI;ERMAEAGFIH; RMAEAGFIHC; MAEAGFIHCP; AEAGFIHCPT; EAGFIHCPTE;AGFIHCPTEN; GFIHCPTENE; FIHCPTENEP; IHCPTENEPD; HCPTENEPDL;CPTENEPDLA; PTENEPDLAQ; TENEPDLAQC; ENEPDLAQCF; NEPDLAQCFF;EPDLAQCFFC; PDLAQCFFCF; DLAQCFFCFK; LAQCFFCFKE; AQCFFCFKEL;QCFFCFKELE; CFFCFKELEG; FFCFKELEGW; FCFKELEGWE; CFKELEGWEP;FKELEGWEPD; KELEGWEPDD; ELEGWEPDDD; LEGWEPDDDP; EGWEPDDDPI;GWEPDDDPIE; WEPDDDPIEE; EPDDDPIEEH; PDDDPIEEHK; DDDPIEEHKK;DDPIEEHKKH; DPIEEHKKHS; PIEEHKKHSS; IEEHKKHSSG; EEHKKHSSGC;EHKKHSSGCA; HKKHSSGCAF; KKHSSGCAFL; KHSSGCAFLS; HSSGCAFLSV;SSGCAFLSVK; SGCAFLSVKK; GCAFLSVKKQ; CAFLSVKKQF; AFLSVKKQFE;FLSVKKQFEE; LSVKKQFEEL; SVKKQFEELT; VKKQFEELTL; KKQFEELTLG;KQFEELTLGE; QFEELTLGEF; FEELTLGEFL; EELTLGEFLK; ELTLGEFLKL;LTLGEFLKLD; TLGEFLKLDR; LGEFLKLDRE; GEFLKLDRER; EFLKLDRERA;FLKLDRERAK; LKLDRERAKN; KLDRERAKNK; LDRERAKNKI; DRERAKNKIA;RERAKNKIAK; ERAKNKIAKE; RAKNKIAKET; AKNKIAKETN; KNKIAKETNN;NKIAKETNNK; KIAKETNNKK; IAKETNNKKK; AKETNNKKKE; KETNNKKKEF;ETNNKKKEFE; TNNKKKEFEE; NNKKKEFEET; NKKKEFEETA; KKKEFEETAK;KKEFEETAKK; KEFEETAKKV; EFEETAKKVR; FEETAKKVRR; EETAKKVRRA;ETAKKVRRAI; TAKKVRRAIE; AKKVRRAIEQ; KKVRRAIEQL; KVRRAIEQLA;VRRAIEQLAA; RRAIEQLAAM; RAIEQLAAMD; 11 mers:MGAPTLPPAWQ; GAPTLPPAWQP; APTLPPAWQPF; PTLPPAWQPFL; TLPPAWQPFLK;LPPAWQPFLKD; PPAWQPFLKDH; PAWQPFLKDHR; AWQPFLKDHRI; WQPFLKDHRIS;QPFLKDHRIST; PFLKDHRISTF; FLKDHRISTFK; LKDHRISTFKN; KDHRISTFKNW;DHRISTFKNWP; HRISTFKNWPF; RISTFKNWPFL; ISTFKNWPFLE; STFKNWPFLEG;TFKNWPFLEGC; FKNWPFLEGCA; KNWPFLEGCAC; NWPFLEGCACT; WPFLEGCACTP;PFLEGCACTPE; FLEGCACTPER; LEGCACTPERM; EGCACTPERMA; GCACTPERMAE;CACTPERMAEA; ACTPERMAEAG; CTPERMAEAGF; TPERMAEAGFI; PERMAEAGFIH;ERMAEAGFIHC; RMAEAGFIHCP; MAEAGFIHCPT; AEAGFIHCPTE; EAGFIHCPTEN;AGFIHCPTENE; GFIHCPTENEP; FIHCPTENEPD; IHCPTENEPDL; HCPTENEPDLA;CPTENEPDLAQ; PTENEPDLAQC; TENEPDLAQCF; ENEPDLAQCFF; NEPDLAQCFFC;EPDLAQCFFCF; PDLAQCFFCFK; DLAQCFFCFKE; LAQCFFCFKEL; AQCFFCFKELE;QCFFCFKELEG; CFFCFKELEGW; FFCFKELEGWE; FCFKELEGWEP; CFKELEGWEPD;FKELEGWEPDD; KELEGWEPDDD; ELEGWEPDDDP; LEGWEPDDDPI; EGWEPDDDPIE;GWEPDDDPIEE; WEPDDDPIEEH; EPDDDPIEEHK; PDDDPIEEHKK; DDDPIEEHKKH;DDPIEEHKKHS; DPIEEHKKHSS; PIEEHKKHSSG; IEEHKKHSSGC; EEHKKHSSGCA;EHKKHSSGCAF; HKKHSSGCAFL; KKHSSGCAFLS; KHSSGCAFLSV; HSSGCAFLSVK;SSGCAFLSVKK; SGCAFLSVKKQ; GCAFLSVKKQF; CAFLSVKKQFE; AFLSVKKQFEE;FLSVKKQFEEL; LSVKKQFEELT; SVKKQFEELTL; VKKQFEELTLG; KKQFEELTLGE;KQFEELTLGEF; QFEELTLGEFL; FEELTLGEFLK; EELTLGEFLKL; ELTLGEFLKLD;LTLGEFLKLDR; TLGEFLKLDRE; LGEFLKLDRER; GEFLKLDRERA; EFLKLDRERAK;FLKLDRERAKN; LKLDRERAKNK; KLDRERAKNKI; LDRERAKNKIA; DRERAKNKIAK;RERAKNKIAKE; ERAKNKIAKET; RAKNKIAKETN; AKNKIAKETNN; KNKIAKETNNK;NKIAKETNNKK; KIAKETNNKKK; IAKETNNKKKE; AKETNNKKKEF; KETNNKKKEFE;ETNNKKKEFEE; TNNKKKEFEET; NNKKKEFEETA; NKKKEFEETAK; KKKEFEETAKK;KKEFEETAKKV; KEFEETAKKVR; EFEETAKKVRR; FEETAKKVRRA; EETAKKVRRAI;ETAKKVRRAIE; TAKKVRRAIEQ; AKKVRRAIEQL; KKVRRAIEQLA; KVRRAIEQLAA;VRRAIEQLAAM; RRAIEQLAAMD SEQ ID NOS: 47646-48180

Preferred fragments of Mcl-1 capable of interacting with one or more MHCclass 2 molecules are listed in table G.

TABLE G Prediction of cancer antigen Mcl-1 specific MHC class 2peptide sequences. Prediction of 13-, 14-, 15-, 16-mers usingthe program displayed in FIG. 2.; 13 mers:MFGLKRNAVIGLN; FGLKRNAVIGLNL; GLKRNAVIGLNLY; LKRNAVIGLNLYC;KRNAVIGLNLYCG; RNAVIGLNLYCGG; NAVIGLNLYCGGA; AVIGLNLYCGGAG;VIGLNLYCGGAGL; IGLNLYCGGAGLG; GLNLYCGGAGLGA; LNLYCGGAGLGAG;NLYCGGAGLGAGS; LYCGGAGLGAGSG; YCGGAGLGAGSGG; CGGAGLGAGSGGA;GGAGLGAGSGGAT; GAGLGAGSGGATR; AGLGAGSGGATRP; GLGAGSGGATRPG;LGAGSGGATRPGG; GAGSGGATRPGGR; AGSGGATRPGGRL; GSGGATRPGGRLL;SGGATRPGGRLLA; GGATRPGGRLLAT; GATRPGGRLLATE; ATRPGGRLLATEK;TRPGGRLLATEKE; RPGGRLLATEKEA; PGGRLLATEKEAS; GGRLLATEKEASA;GRLLATEKEASAR; RLLATEKEASARR; LLATEKEASARRE; LATEKEASARREI;ATEKEASARREIG; TEKEASARREIGG; EKEASARREIGGG; KEASARREIGGGE;EASARREIGGGEA; ASARREIGGGEAG; SARREIGGGEAGA; ARREIGGGEAGAV;RREIGGGEAGAVI; REIGGGEAGAVIG; EIGGGEAGAVIGG; IGGGEAGAVIGGS;GGGEAGAVIGGSA; GGEAGAVIGGSAG; GEAGAVIGGSAGA; EAGAVIGGSAGAS;AGAVIGGSAGASP; GAVIGGSAGASPP; AVIGGSAGASPPS; VIGGSAGASPPST;IGGSAGASPPSTL; GGSAGASPPSTLT; GSAGASPPSTLTP; SAGASPPSTLTPD;AGASPPSTLTPDS; GASPPSTLTPDSR; ASPPSTLTPDSRR; SPPSTLTPDSRRV;PPSTLTPDSRRVA; PSTLTPDSRRVAR; STLTPDSRRVARP; TLTPDSRRVARPP;LTPDSRRVARPPP; TPDSRRVARPPPI; PDSRRVARPPPIG; DSRRVARPPPIGA;SRRVARPPPIGAE; RRVARPPPIGAEV; RVARPPPIGAEVP; VARPPPIGAEVPD;ARPPPIGAEVPDV; RPPPIGAEVPDVT; PPPIGAEVPDVTA; PPIGAEVPDVTAT;PIGAEVPDVTATP; IGAEVPDVTATPA; GAEVPDVTATPAR; AEVPDVTATPARL;EVPDVTATPARLL; VPDVTATPARLLF; PDVTATPARLLFF; DVTATPARLLFFA;VTATPARLLFFAP; TATPARLLFFAPT; ATPARLLFFAPTR; TPARLLFFAPTRR;PARLLFFAPTRRA; ARLLFFAPTRRAA; RLLFFAPTRRAAP; LLFFAPTRRAAPL;LFFAPTRRAAPLE; FFAPTRRAAPLEE; FAPTRRAAPLEEM; APTRRAAPLEEME;PTRRAAPLEEMEA; TRRAAPLEEMEAP; RRAAPLEEMEAPA; RAAPLEEMEAPAA;AAPLEEMEAPAAD; APLEEMEAPAADA; PLEEMEAPAADAI; LEEMEAPAADAIM;EEMEAPAADAIMS; EMEAPAADAIMSP; MEAPAADAIMSPE; EAPAADAIMSPEE;APAADAIMSPEEE; PAADAIMSPEEEL; AADAIMSPEEELD; ADAIMSPEEELDG;DAIMSPEEELDGY; AIMSPEEELDGYE; IMSPEEELDGYEP; MSPEEELDGYEPE;SPEEELDGYEPEP; PEEELDGYEPEPL; EEELDGYEPEPLG; EELDGYEPEPLGK;ELDGYEPEPLGKR; LDGYEPEPLGKRP; DGYEPEPLGKRPA; GYEPEPLGKRPAV;YEPEPLGKRPAVL; EPEPLGKRPAVLP; PEPLGKRPAVLPL; EPLGKRPAVLPLL;PLGKRPAVLPLLE; LGKRPAVLPLLEL; GKRPAVLPLLELV; KRPAVLPLLELVG;RPAVLPLLELVGE; PAVLPLLELVGES; AVLPLLELVGESG; VLPLLELVGESGN;LPLLELVGESGNN; PLLELVGESGNNT; LLELVGESGNNTS; LELVGESGNNTST;ELVGESGNNTSTD; LVGESGNNTSTDG; VGESGNNTSTDGS; GESGNNTSTDGSL;ESGNNTSTDGSLP; SGNNTSTDGSLPS; GNNTSTDGSLPST; NNTSTDGSLPSTP;NTSTDGSLPSTPP; TSTDGSLPSTPPP; STDGSLPSTPPPA; TDGSLPSTPPPAE;DGSLPSTPPPAEE; GSLPSTPPPAEEE; SLPSTPPPAEEEE; LPSTPPPAEEEED;PSTPPPAEEEEDD; STPPPAEEEEDDL; TPPPAEEEEDDLY; PPPAEEEEDDLYR;PPAEEEEDDLYRQ; PAEEEEDDLYRQS; AEEEEDDLYRQSL; EEEEDDLYRQSLE;EEEDDLYRQSLEI; EEDDLYRQSLEII; EDDLYRQSLEIIS; DDLYRQSLEIISR;DLYRQSLEIISRY; LYRQSLEIISRYL; YRQSLEIISRYLR; RQSLEIISRYLRE;QSLEIISRYLREQ; SLEIISRYLREQA; LEIISRYLREQAT; EIISRYLREQATG;IISRYLREQATGA; ISRYLREQATGAK; SRYLREQATGAKD; RYLREQATGAKDT;YLREQATGAKDTK; LREQATGAKDTKP; REQATGAKDTKPM; EQATGAKDTKPMG;QATGAKDTKPMGR; ATGAKDTKPMGRS; TGAKDTKPMGRSG; GAKDTKPMGRSGA;AKDTKPMGRSGAT; KDTKPMGRSGATS; DTKPMGRSGATSR; TKPMGRSGATSRK;KPMGRSGATSRKA; PMGRSGATSRKAL; MGRSGATSRKALE; GRSGATSRKALET;RSGATSRKALETL; SGATSRKALETLR; GATSRKALETLRR; ATSRKALETLRRV;TSRKALETLRRVG; SRKALETLRRVGD; RKALETLRRVGDG; KALETLRRVGDGV;ALETLRRVGDGVQ; LETLRRVGDGVQR; ETLRRVGDGVQRN; TLRRVGDGVQRNH;LRRVGDGVQRNHE; RRVGDGVQRNHET; RVGDGVQRNHETA; VGDGVQRNHETAF;GDGVQRNHETAFQ; DGVQRNHETAFQG; GVQRNHETAFQGM; VQRNHETAFQGML;QRNHETAFQGMLR; RNHETAFQGMLRK; NHETAFQGMLRKL; HETAFQGMLRKLD;ETAFQGMLRKLDI; TAFQGMLRKLDIK; AFQGMLRKLDIKN; FQGMLRKLDIKNE;QGMLRKLDIKNED; GMLRKLDIKNEDD; MLRKLDIKNEDDV; LRKLDIKNEDDVK;RKLDIKNEDDVKS; KLDIKNEDDVKSL; LDIKNEDDVKSLS; DIKNEDDVKSLSR;IKNEDDVKSLSRV; KNEDDVKSLSRVM; NEDDVKSLSRVMI; EDDVKSLSRVMIH;DDVKSLSRVMIHV; DVKSLSRVMIHVF; VKSLSRVMIHVFS; KSLSRVMIHVFSD;SLSRVMIHVFSDG; LSRVMIHVFSDGV; SRVMIHVFSDGVT; RVMIHVFSDGVTN;VMIHVFSDGVTNW; MIHVFSDGVTNWG; IHVFSDGVTNWGR; HVFSDGVTNWGRI;VFSDGVTNWGRIV; FSDGVTNWGRIVT; SDGVTNWGRIVTL; DGVTNWGRIVTLI;GVTNWGRIVTLIS; VTNWGRIVTLISF; TNWGRIVTLISFG; NWGRIVTLISFGA;WGRIVTLISFGAF; GRIVTLISFGAFV; RIVTLISFGAFVA; IVTLISFGAFVAK;VTLISFGAFVAKH; TLISFGAFVAKHL; LISFGAFVAKHLK; ISFGAFVAKHLKT;SFGAFVAKHLKTI; FGAFVAKHLKTIN; GAFVAKHLKTINQ; AFVAKHLKTINQE;FVAKHLKTINQES; VAKHLKTINQESC; AKHLKTINQESCI; KHLKTINQESCIE;HLKTINQESCIEP; LKTINQESCIEPL; KTINQESCIEPLA; TINQESCIEPLAE;INQESCIEPLAES; NQESCIEPLAESI; QESCIEPLAESIT; ESCIEPLAESITD;SCIEPLAESITDV; CIEPLAESITDVL; IEPLAESITDVLV; EPLAESITDVLVR;PLAESITDVLVRT; LAESITDVLVRTK; AESITDVLVRTKR; ESITDVLVRTKRD;SITDVLVRTKRDW; ITDVLVRTKRDWL; TDVLVRTKRDWLV; DVLVRTKRDWLVK;VLVRTKRDWLVKQ; LVRTKRDWLVKQR; VRTKRDWLVKQRG; RTKRDWLVKQRGW;TKRDWLVKQRGWD; KRDWLVKQRGWDG; RDWLVKQRGWDGF; DWLVKQRGWDGFV;WLVKQRGWDGFVE; LVKQRGWDGFVEF; VKQRGWDGFVEFF; KQRGWDGFVEFFH;QRGWDGFVEFFHV; RGWDGFVEFFHVE; GWDGFVEFFHVED; WDGFVEFFHVEDL;DGFVEFFHVEDLE; GFVEFFHVEDLEG; FVEFFHVEDLEGG; VEFFHVEDLEGGI;EFFHVEDLEGGIR; FFHVEDLEGGIRN; FHVEDLEGGIRNV; HVEDLEGGIRNVL;VEDLEGGIRNVLL; EDLEGGIRNVLLA; DLEGGIRNVLLAF; LEGGIRNVLLAFA;EGGIRNVLLAFAG; GGIRNVLLAFAGV; GIRNVLLAFAGVA; IRNVLLAFAGVAG;RNVLLAFAGVAGV; NVLLAFAGVAGVG; VLLAFAGVAGVGA; LLAFAGVAGVGAG;LAFAGVAGVGAGL; AFAGVAGVGAGLA; FAGVAGVGAGLAY; AGVAGVGAGLAYL;GVAGVGAGLAYLI; VAGVGAGLAYLIR 14 mers:MFGLKRNAVIGLNL; FGLKRNAVIGLNLY; GLKRNAVIGLNLYC; LKRNAVIGLNLYCG;KRNAVIGLNLYCGG; RNAVIGLNLYCGGA; NAVIGLNLYCGGAG; AVIGLNLYCGGAGL;VIGLNLYCGGAGLG; IGLNLYCGGAGLGA; GLNLYCGGAGLGAG; LNLYCGGAGLGAGS;NLYCGGAGLGAGSG; LYCGGAGLGAGSGG; YCGGAGLGAGSGGA; CGGAGLGAGSGGAT;GGAGLGAGSGGATR; GAGLGAGSGGATRP; AGLGAGSGGATRPG; GLGAGSGGATRPGG;LGAGSGGATRPGGR; GAGSGGATRPGGRL; AGSGGATRPGGRLL; GSGGATRPGGRLLA;SGGATRPGGRLLAT; GGATRPGGRLLATE; GATRPGGRLLATEK; ATRPGGRLLATEKE;TRPGGRLLATEKEA; RPGGRLLATEKEAS; PGGRLLATEKEASA; GGRLLATEKEASAR;GRLLATEKEASARR; RLLATEKEASARRE; LLATEKEASARREI; LATEKEASARREIG;ATEKEASARREIGG; TEKEASARREIGGG; EKEASARREIGGGE; KEASARREIGGGEA;EASARREIGGGEAG; ASARREIGGGEAGA; SARREIGGGEAGAV; ARREIGGGEAGAVI;RREIGGGEAGAVIG; REIGGGEAGAVIGG; EIGGGEAGAVIGGS; IGGGEAGAVIGGSA;GGGEAGAVIGGSAG; GGEAGAVIGGSAGA; GEAGAVIGGSAGAS; EAGAVIGGSAGASP;AGAVIGGSAGASPP; GAVIGGSAGASPPS; AVIGGSAGASPPST; VIGGSAGASPPSTL;IGGSAGASPPSTLT; GGSAGASPPSTLTP; GSAGASPPSTLTPD; SAGASPPSTLTPDS;AGASPPSTLTPDSR; GASPPSTLTPDSRR; ASPPSTLTPDSRRV; SPPSTLTPDSRRVA;PPSTLTPDSRRVAR; PSTLTPDSRRVARP; STLTPDSRRVARPP; TLTPDSRRVARPPP;LTPDSRRVARPPPI; TPDSRRVARPPPIG; PDSRRVARPPPIGA; DSRRVARPPPIGAE;SRRVARPPPIGAEV; RRVARPPPIGAEVP; RVARPPPIGAEVPD; VARPPPIGAEVPDV;ARPPPIGAEVPDVT; RPPPIGAEVPDVTA; PPPIGAEVPDVTAT; PPIGAEVPDVTATP;PIGAEVPDVTATPA; IGAEVPDVTATPAR; GAEVPDVTATPARL; AEVPDVTATPARLL;EVPDVTATPARLLF; VPDVTATPARLLFF; PDVTATPARLLFFA; DVTATPARLLFFAP;VTATPARLLFFAPT; TATPARLLFFAPTR; ATPARLLFFAPTRR; TPARLLFFAPTRRA;PARLLFFAPTRRAA; ARLLFFAPTRRAAP; RLLFFAPTRRAAPL; LLFFAPTRRAAPLE;LFFAPTRRAAPLEE; FFAPTRRAAPLEEM; FAPTRRAAPLEEME; APTRRAAPLEEMEA;PTRRAAPLEEMEAP; TRRAAPLEEMEAPA; RRAAPLEEMEAPAA; RAAPLEEMEAPAAD;AAPLEEMEAPAADA; APLEEMEAPAADAI; PLEEMEAPAADAIM; LEEMEAPAADAIMS;EEMEAPAADAIMSP; EMEAPAADAIMSPE; MEAPAADAIMSPEE; EAPAADAIMSPEEE;APAADAIMSPEEEL; PAADAIMSPEEELD; AADAIMSPEEELDG; ADAIMSPEEELDGY;DAIMSPEEELDGYE; AIMSPEEELDGYEP; IMSPEEELDGYEPE; MSPEEELDGYEPEP;SPEEELDGYEPEPL; PEEELDGYEPEPLG; EEELDGYEPEPLGK; EELDGYEPEPLGKR;ELDGYEPEPLGKRP; LDGYEPEPLGKRPA; DGYEPEPLGKRPAV; GYEPEPLGKRPAVL;YEPEPLGKRPAVLP; EPEPLGKRPAVLPL; PEPLGKRPAVLPLL; EPLGKRPAVLPLLE;PLGKRPAVLPLLEL; LGKRPAVLPLLELV; GKRPAVLPLLELVG; KRPAVLPLLELVGE;RPAVLPLLELVGES; PAVLPLLELVGESG; AVLPLLELVGESGN; VLPLLELVGESGNN;LPLLELVGESGNNT; PLLELVGESGNNTS; LLELVGESGNNTST; LELVGESGNNTSTD;ELVGESGNNTSTDG; LVGESGNNTSTDGS; VGESGNNTSTDGSL; GESGNNTSTDGSLP;ESGNNTSTDGSLPS; SGNNTSTDGSLPST; GNNTSTDGSLPSTP; NNTSTDGSLPSTPP;NTSTDGSLPSTPPP; TSTDGSLPSTPPPA; STDGSLPSTPPPAE; TDGSLPSTPPPAEE;DGSLPSTPPPAEEE; GSLPSTPPPAEEEE; SLPSTPPPAEEEED; LPSTPPPAEEEEDD;PSTPPPAEEEEDDL; STPPPAEEEEDDLY; TPPPAEEEEDDLYR; PPPAEEEEDDLYRQ;PPAEEEEDDLYRQS; PAEEEEDDLYRQSL; AEEEEDDLYRQSLE; EEEEDDLYRQSLEI;EEEDDLYRQSLEII; EEDDLYRQSLEIIS; EDDLYRQSLEIISR; DDLYRQSLEIISRY;DLYRQSLEIISRYL; LYRQSLEIISRYLR; YRQSLEIISRYLRE; RQSLEIISRYLREQ;QSLEIISRYLREQA; SLEIISRYLREQAT; LEIISRYLREQATG; EIISRYLREQATGA;IISRYLREQATGAK; ISRYLREQATGAKD; SRYLREQATGAKDT; RYLREQATGAKDTK;YLREQATGAKDTKP; LREQATGAKDTKPM; REQATGAKDTKPMG; EQATGAKDTKPMGR;QATGAKDTKPMGRS; ATGAKDTKPMGRSG; TGAKDTKPMGRSGA; GAKDTKPMGRSGAT;AKDTKPMGRSGATS; KDTKPMGRSGATSR; DTKPMGRSGATSRK; TKPMGRSGATSRKA;KPMGRSGATSRKAL; PMGRSGATSRKALE; MGRSGATSRKALET; GRSGATSRKALETL;RSGATSRKALETLR; SGATSRKALETLRR; GATSRKALETLRRV; ATSRKALETLRRVG;TSRKALETLRRVGD; SRKALETLRRVGDG; RKALETLRRVGDGV; KALETLRRVGDGVQ;ALETLRRVGDGVQR; LETLRRVGDGVQRN; ETLRRVGDGVQRNH; TLRRVGDGVQRNHE;LRRVGDGVQRNHET; RRVGDGVQRNHETA; RVGDGVQRNHETAF; VGDGVQRNHETAFQ;GDGVQRNHETAFQG; DGVQRNHETAFQGM; GVQRNHETAFQGML; VQRNHETAFQGMLR;QRNHETAFQGMLRK; RNHETAFQGMLRKL; NHETAFQGMLRKLD; HETAFQGMLRKLDI;ETAFQGMLRKLDIK; TAFQGMLRKLDIKN; AFQGMLRKLDIKNE; FQGMLRKLDIKNED;QGMLRKLDIKNEDD; GMLRKLDIKNEDDV; MLRKLDIKNEDDVK; LRKLDIKNEDDVKS;RKLDIKNEDDVKSL; KLDIKNEDDVKSLS; LDIKNEDDVKSLSR; DIKNEDDVKSLSRV;IKNEDDVKSLSRVM; KNEDDVKSLSRVMI; NEDDVKSLSRVMIH; EDDVKSLSRVMIHV;DDVKSLSRVMIHVF; DVKSLSRVMIHVFS; VKSLSRVMIHVFSD; KSLSRVMIHVFSDG;SLSRVMIHVFSDGV; LSRVMIHVFSDGVT; SRVMIHVFSDGVTN; RVMIHVFSDGVTNW;VMIHVFSDGVTNWG; MIHVFSDGVTNWGR; IHVFSDGVTNWGRI; HVFSDGVTNWGRIV;VFSDGVTNWGRIVT; FSDGVTNWGRIVTL; SDGVTNWGRIVTLI; DGVTNWGRIVTLIS;GVTNWGRIVTLISF; VTNWGRIVTLISFG; TNWGRIVTLISFGA; NWGRIVTLISFGAF;WGRIVTLISFGAFV; GRIVTLISFGAFVA; RIVTLISFGAFVAK; IVTLISFGAFVAKH;VTLISFGAFVAKHL; TLISFGAFVAKHLK; LISFGAFVAKHLKT; ISFGAFVAKHLKTI;SFGAFVAKHLKTIN; FGAFVAKHLKTINQ; GAFVAKHLKTINQE; AFVAKHLKTINQES;FVAKHLKTINQESC; VAKHLKTINQESCI; AKHLKTINQESCIE; KHLKTINQESCIEP;HLKTINQESCIEPL; LKTINQESCIEPLA; KTINQESCIEPLAE; TINQESCIEPLAES;INQESCIEPLAESI; NQESCIEPLAESIT; QESCIEPLAESITD; ESCIEPLAESITDV;SCIEPLAESITDVL; CIEPLAESITDVLV; IEPLAESITDVLVR; EPLAESITDVLVRT;PLAESITDVLVRTK; LAESITDVLVRTKR; AESITDVLVRTKRD; ESITDVLVRTKRDW;SITDVLVRTKRDWL; ITDVLVRTKRDWLV; TDVLVRTKRDWLVK; DVLVRTKRDWLVKQ;VLVRTKRDWLVKQR; LVRTKRDWLVKQRG; VRTKRDWLVKQRGW; RTKRDWLVKQRGWD;TKRDWLVKQRGWDG; KRDWLVKQRGWDGF; RDWLVKQRGWDGFV; DWLVKQRGWDGFVE;WLVKQRGWDGFVEF; LVKQRGWDGFVEFF; VKQRGWDGFVEFFH; KQRGWDGFVEFFHV;QRGWDGFVEFFHVE; RGWDGFVEFFHVED; GWDGFVEFFHVEDL; WDGFVEFFHVEDLE;DGFVEFFHVEDLEG; GFVEFFHVEDLEGG; FVEFFHVEDLEGGI; VEFFHVEDLEGGIR;EFFHVEDLEGGIRN; FFHVEDLEGGIRNV; FHVEDLEGGIRNVL; HVEDLEGGIRNVLL;VEDLEGGIRNVLLA; EDLEGGIRNVLLAF; DLEGGIRNVLLAFA; LEGGIRNVLLAFAG;EGGIRNVLLAFAGV; GGIRNVLLAFAGVA; GIRNVLLAFAGVAG; IRNVLLAFAGVAGV;RNVLLAFAGVAGVG; NVLLAFAGVAGVGA; VLLAFAGVAGVGAG; LLAFAGVAGVGAGL;LAFAGVAGVGAGLA; AFAGVAGVGAGLAY; FAGVAGVGAGLAYL; AGVAGVGAGLAYLI;GVAGVGAGLAYLIR 15 mers:MFGLKRNAVIGLNLY; FGLKRNAVIGLNLYC; GLKRNAVIGLNLYCG;LKRNAVIGLNLYCGG; KRNAVIGLNLYCGGA; RNAVIGLNLYCGGAG;NAVIGLNLYCGGAGL; AVIGLNLYCGGAGLG; VIGLNLYCGGAGLGA;IGLNLYCGGAGLGAG; GLNLYCGGAGLGAGS; LNLYCGGAGLGAGSG;NLYCGGAGLGAGSGG; LYCGGAGLGAGSGGA; YCGGAGLGAGSGGAT;CGGAGLGAGSGGATR; GGAGLGAGSGGATRP; GAGLGAGSGGATRPG;AGLGAGSGGATRPGG; GLGAGSGGATRPGGR; LGAGSGGATRPGGRL;GAGSGGATRPGGRLL; AGSGGATRPGGRLLA; GSGGATRPGGRLLAT;SGGATRPGGRLLATE; GGATRPGGRLLATEK; GATRPGGRLLATEKE;ATRPGGRLLATEKEA; TRPGGRLLATEKEAS; RPGGRLLATEKEASA;PGGRLLATEKEASAR; GGRLLATEKEASARR; GRLLATEKEASARRE;RLLATEKEASARREI; LLATEKEASARREIG; LATEKEASARREIGG;ATEKEASARREIGGG; TEKEASARREIGGGE; EKEASARREIGGGEA;KEASARREIGGGEAG; EASARREIGGGEAGA; ASARREIGGGEAGAV;SARREIGGGEAGAVI; ARREIGGGEAGAVIG; RREIGGGEAGAVIGG;REIGGGEAGAVIGGS; EIGGGEAGAVIGGSA; IGGGEAGAVIGGSAG;GGGEAGAVIGGSAGA; GGEAGAVIGGSAGAS; GEAGAVIGGSAGASP;EAGAVIGGSAGASPP; AGAVIGGSAGASPPS; GAVIGGSAGASPPST;AVIGGSAGASPPSTL; VIGGSAGASPPSTLT; IGGSAGASPPSTLTP;GGSAGASPPSTLTPD; GSAGASPPSTLTPDS; SAGASPPSTLTPDSR;AGASPPSTLTPDSRR; GASPPSTLTPDSRRV; ASPPSTLTPDSRRVA;SPPSTLTPDSRRVAR; PPSTLTPDSRRVARP; PSTLTPDSRRVARPP;STLTPDSRRVARPPP; TLTPDSRRVARPPPI; LTPDSRRVARPPPIG;TPDSRRVARPPPIGA; PDSRRVARPPPIGAE; DSRRVARPPPIGAEV;SRRVARPPPIGAEVP; RRVARPPPIGAEVPD; RVARPPPIGAEVPDV;VARPPPIGAEVPDVT; ARPPPIGAEVPDVTA; RPPPIGAEVPDVTAT;PPPIGAEVPDVTATP; PPIGAEVPDVTATPA; PIGAEVPDVTATPAR;IGAEVPDVTATPARL; GAEVPDVTATPARLL; AEVPDVTATPARLLF;EVPDVTATPARLLFF; VPDVTATPARLLFFA; PDVTATPARLLFFAP;DVTATPARLLFFAPT; VTATPARLLFFAPTR; TATPARLLFFAPTRR;ATPARLLFFAPTRRA; TPARLLFFAPTRRAA; PARLLFFAPTRRAAP;ARLLFFAPTRRAAPL; RLLFFAPTRRAAPLE; LLFFAPTRRAAPLEE;LFFAPTRRAAPLEEM; FFAPTRRAAPLEEME; FAPTRRAAPLEEMEA;APTRRAAPLEEMEAP; PTRRAAPLEEMEAPA; TRRAAPLEEMEAPAA;RRAAPLEEMEAPAAD; RAAPLEEMEAPAADA; AAPLEEMEAPAADAI;APLEEMEAPAADAIM; PLEEMEAPAADAIMS; LEEMEAPAADAIMSP;EEMEAPAADAIMSPE; EMEAPAADAIMSPEE; MEAPAADAIMSPEEE;EAPAADAIMSPEEEL; APAADAIMSPEEELD; PAADAIMSPEEELDG;AADAIMSPEEELDGY; ADAIMSPEEELDGYE; DAIMSPEEELDGYEP;AIMSPEEELDGYEPE; IMSPEEELDGYEPEP; MSPEEELDGYEPEPL;SPEEELDGYEPEPLG; PEEELDGYEPEPLGK; EEELDGYEPEPLGKR;EELDGYEPEPLGKRP; ELDGYEPEPLGKRPA; LDGYEPEPLGKRPAV;DGYEPEPLGKRPAVL; GYEPEPLGKRPAVLP; YEPEPLGKRPAVLPL;EPEPLGKRPAVLPLL; PEPLGKRPAVLPLLE; EPLGKRPAVLPLLEL;PLGKRPAVLPLLELV; LGKRPAVLPLLELVG; GKRPAVLPLLELVGE;KRPAVLPLLELVGES; RPAVLPLLELVGESG; PAVLPLLELVGESGN;AVLPLLELVGESGNN; VLPLLELVGESGNNT; LPLLELVGESGNNTS;PLLELVGESGNNTST; LLELVGESGNNTSTD; LELVGESGNNTSTDG;ELVGESGNNTSTDGS; LVGESGNNTSTDGSL; VGESGNNTSTDGSLP;GESGNNTSTDGSLPS; ESGNNTSTDGSLPST; SGNNTSTDGSLPSTP;GNNTSTDGSLPSTPP; NNTSTDGSLPSTPPP; NTSTDGSLPSTPPPA;TSTDGSLPSTPPPAE; STDGSLPSTPPPAEE; TDGSLPSTPPPAEEE;DGSLPSTPPPAEEEE; GSLPSTPPPAEEEED; SLPSTPPPAEEEEDD;LPSTPPPAEEEEDDL; PSTPPPAEEEEDDLY; STPPPAEEEEDDLYR;TPPPAEEEEDDLYRQ; PPPAEEEEDDLYRQS; PPAEEEEDDLYRQSL;PAEEEEDDLYRQSLE; AEEEEDDLYRQSLEI; EEEEDDLYRQSLEII;EEEDDLYRQSLEIIS; EEDDLYRQSLEIISR; EDDLYRQSLEIISRY;DDLYRQSLEIISRYL; DLYRQSLEIISRYLR; LYRQSLEIISRYLRE;YRQSLEIISRYLREQ; RQSLEIISRYLREQA; QSLEIISRYLREQAT;SLEIISRYLREQATG; LEIISRYLREQATGA; EIISRYLREQATGAK;IISRYLREQATGAKD; ISRYLREQATGAKDT; SRYLREQATGAKDTK;RYLREQATGAKDTKP; YLREQATGAKDTKPM; LREQATGAKDTKPMG;REQATGAKDTKPMGR; EQATGAKDTKPMGRS; QATGAKDTKPMGRSG;ATGAKDTKPMGRSGA; TGAKDTKPMGRSGAT; GAKDTKPMGRSGATS;AKDTKPMGRSGATSR; KDTKPMGRSGATSRK; DTKPMGRSGATSRKA;TKPMGRSGATSRKAL; KPMGRSGATSRKALE; PMGRSGATSRKALET;MGRSGATSRKALETL; GRSGATSRKALETLR; RSGATSRKALETLRR;SGATSRKALETLRRV; GATSRKALETLRRVG; ATSRKALETLRRVGD;TSRKALETLRRVGDG; SRKALETLRRVGDGV; RKALETLRRVGDGVQ;KALETLRRVGDGVQR; ALETLRRVGDGVQRN; LETLRRVGDGVQRNH;ETLRRVGDGVQRNHE; TLRRVGDGVQRNHET; LRRVGDGVQRNHETA;RRVGDGVQRNHETAF; RVGDGVQRNHETAFQ; VGDGVQRNHETAFQG;GDGVQRNHETAFQGM; DGVQRNHETAFQGML; GVQRNHETAFQGMLR;VQRNHETAFQGMLRK; QRNHETAFQGMLRKL; RNHETAFQGMLRKLD;NHETAFQGMLRKLDI; HETAFQGMLRKLDIK; ETAFQGMLRKLDIKN;TAFQGMLRKLDIKNE; AFQGMLRKLDIKNED; FQGMLRKLDIKNEDD;QGMLRKLDIKNEDDV; GMLRKLDIKNEDDVK; MLRKLDIKNEDDVKS;LRKLDIKNEDDVKSL; RKLDIKNEDDVKSLS; KLDIKNEDDVKSLSR;LDIKNEDDVKSLSRV; DIKNEDDVKSLSRVM; IKNEDDVKSLSRVMI;KNEDDVKSLSRVMIH; NEDDVKSLSRVMIHV; EDDVKSLSRVMIHVF;DDVKSLSRVMIHVFS; DVKSLSRVMIHVFSD; VKSLSRVMIHVFSDG;KSLSRVMIHVFSDGV; SLSRVMIHVFSDGVT; LSRVMIHVFSDGVTN;SRVMIHVFSDGVTNW; RVMIHVFSDGVTNWG; VMIHVFSDGVTNWGR;MIHVFSDGVTNWGRI; IHVFSDGVTNWGRIV; HVFSDGVTNWGRIVT;VFSDGVTNWGRIVTL; FSDGVTNWGRIVTLI; SDGVTNWGRIVTLIS;DGVTNWGRIVTLISF; GVTNWGRIVTLISFG; VTNWGRIVTLISFGA;TNWGRIVTLISFGAF; NWGRIVTLISFGAFV; WGRIVTLISFGAFVA;GRIVTLISFGAFVAK; RIVTLISFGAFVAKH; IVTLISFGAFVAKHL;VTLISFGAFVAKHLK; TLISFGAFVAKHLKT; LISFGAFVAKHLKTI;ISFGAFVAKHLKTIN; SFGAFVAKHLKTINQ; FGAFVAKHLKTINQE;GAFVAKHLKTINQES; AFVAKHLKTINQESC; FVAKHLKTINQESCI;VAKHLKTINQESCIE; AKHLKTINQESCIEP; KHLKTINQESCIEPL;HLKTINQESCIEPLA; LKTINQESCIEPLAE; KTINQESCIEPLAES;TINQESCIEPLAESI; INQESCIEPLAESIT; NQESCIEPLAESITD;QESCIEPLAESITDV; ESCIEPLAESITDVL; SCIEPLAESITDVLV;CIEPLAESITDVLVR; IEPLAESITDVLVRT; EPLAESITDVLVRTK;PLAESITDVLVRTKR; LAESITDVLVRTKRD; AESITDVLVRTKRDW;ESITDVLVRTKRDWL; SITDVLVRTKRDWLV; ITDVLVRTKRDWLVK;TDVLVRTKRDWLVKQ; DVLVRTKRDWLVKQR; VLVRTKRDWLVKQRG;LVRTKRDWLVKQRGW; VRTKRDWLVKQRGWD; RTKRDWLVKQRGWDG;TKRDWLVKQRGWDGF; KRDWLVKQRGWDGFV; RDWLVKQRGWDGFVE;DWLVKQRGWDGFVEF; WLVKQRGWDGFVEFF; LVKQRGWDGFVEFFH;VKQRGWDGFVEFFHV; KQRGWDGFVEFFHVE; QRGWDGFVEFFHVED;RGWDGFVEFFHVEDL; GWDGFVEFFHVEDLE; WDGFVEFFHVEDLEG;DGFVEFFHVEDLEGG; GFVEFFHVEDLEGGI; FVEFFHVEDLEGGIR;VEFFHVEDLEGGIRN; EFFHVEDLEGGIRNV; FFHVEDLEGGIRNVL;FHVEDLEGGIRNVLL; HVEDLEGGIRNVLLA; VEDLEGGIRNVLLAF;EDLEGGIRNVLLAFA; DLEGGIRNVLLAFAG; LEGGIRNVLLAFAGV;EGGIRNVLLAFAGVA; GGIRNVLLAFAGVAG; GIRNVLLAFAGVAGV;IRNVLLAFAGVAGVG; RNVLLAFAGVAGVGA; NVLLAFAGVAGVGAG;VLLAFAGVAGVGAGL; LLAFAGVAGVGAGLA; LAFAGVAGVGAGLAY;AFAGVAGVGAGLAYL; FAGVAGVGAGLAYLI; AGVAGVGAGLAYLIR 16 mers:MFGLKRNAVIGLNLYC; FGLKRNAVIGLNLYCG; GLKRNAVIGLNLYCGG;LKRNAVIGLNLYCGGA; KRNAVIGLNLYCGGAG; RNAVIGLNLYCGGAGL;NAVIGLNLYCGGAGLG; AVIGLNLYCGGAGLGA; VIGLNLYCGGAGLGAG;IGLNLYCGGAGLGAGS; GLNLYCGGAGLGAGSG; LNLYCGGAGLGAGSGG;NLYCGGAGLGAGSGGA; LYCGGAGLGAGSGGAT; YCGGAGLGAGSGGATR;CGGAGLGAGSGGATRP; GGAGLGAGSGGATRPG; GAGLGAGSGGATRPGG;AGLGAGSGGATRPGGR; GLGAGSGGATRPGGRL; LGAGSGGATRPGGRLL;GAGSGGATRPGGRLLA; AGSGGATRPGGRLLAT; GSGGATRPGGRLLATE;SGGATRPGGRLLATEK; GGATRPGGRLLATEKE; GATRPGGRLLATEKEA;ATRPGGRLLATEKEAS; TRPGGRLLATEKEASA; RPGGRLLATEKEASAR;PGGRLLATEKEASARR; GGRLLATEKEASARRE; GRLLATEKEASARREI;RLLATEKEASARREIG; LLATEKEASARREIGG; LATEKEASARREIGGG;ATEKEASARREIGGGE; TEKEASARREIGGGEA; EKEASARREIGGGEAG;KEASARREIGGGEAGA; EASARREIGGGEAGAV; ASARREIGGGEAGAVI;SARREIGGGEAGAVIG; ARREIGGGEAGAVIGG; RREIGGGEAGAVIGGS;REIGGGEAGAVIGGSA; EIGGGEAGAVIGGSAG; IGGGEAGAVIGGSAGA;GGGEAGAVIGGSAGAS; GGEAGAVIGGSAGASP; GEAGAVIGGSAGASPP;EAGAVIGGSAGASPPS; AGAVIGGSAGASPPST; GAVIGGSAGASPPSTL;AVIGGSAGASPPSTLT; VIGGSAGASPPSTLTP; IGGSAGASPPSTLTPD;GGSAGASPPSTLTPDS; GSAGASPPSTLTPDSR; SAGASPPSTLTPDSRR;AGASPPSTLTPDSRRV; GASPPSTLTPDSRRVA; ASPPSTLTPDSRRVAR;SPPSTLTPDSRRVARP; PPSTLTPDSRRVARPP; PSTLTPDSRRVARPPP;STLTPDSRRVARPPPI; TLTPDSRRVARPPPIG; LTPDSRRVARPPPIGA;TPDSRRVARPPPIGAE; PDSRRVARPPPIGAEV; DSRRVARPPPIGAEVP;SRRVARPPPIGAEVPD; RRVARPPPIGAEVPDV; RVARPPPIGAEVPDVT;VARPPPIGAEVPDVTA; ARPPPIGAEVPDVTAT; RPPPIGAEVPDVTATP;PPPIGAEVPDVTATPA; PPIGAEVPDVTATPAR; PIGAEVPDVTATPARL;IGAEVPDVTATPARLL; GAEVPDVTATPARLLF; AEVPDVTATPARLLFF;EVPDVTATPARLLFFA; VPDVTATPARLLFFAP; PDVTATPARLLFFAPT;DVTATPARLLFFAPTR; VTATPARLLFFAPTRR; TATPARLLFFAPTRRA;ATPARLLFFAPTRRAA; TPARLLFFAPTRRAAP; PARLLFFAPTRRAAPL;ARLLFFAPTRRAAPLE; RLLFFAPTRRAAPLEE; LLFFAPTRRAAPLEEM;LFFAPTRRAAPLEEME; FFAPTRRAAPLEEMEA; FAPTRRAAPLEEMEAP;APTRRAAPLEEMEAPA; PTRRAAPLEEMEAPAA; TRRAAPLEEMEAPAAD;RRAAPLEEMEAPAADA; RAAPLEEMEAPAADAI; AAPLEEMEAPAADAIM;APLEEMEAPAADAIMS; PLEEMEAPAADAIMSP; LEEMEAPAADAIMSPE;EEMEAPAADAIMSPEE; EMEAPAADAIMSPEEE; MEAPAADAIMSPEEEL;EAPAADAIMSPEEELD; APAADAIMSPEEELDG; PAADAIMSPEEELDGY;AADAIMSPEEELDGYE; ADAIMSPEEELDGYEP; DAIMSPEEELDGYEPE;AIMSPEEELDGYEPEP; IMSPEEELDGYEPEPL; MSPEEELDGYEPEPLG;SPEEELDGYEPEPLGK; PEEELDGYEPEPLGKR; EEELDGYEPEPLGKRP;EELDGYEPEPLGKRPA; ELDGYEPEPLGKRPAV; LDGYEPEPLGKRPAVL;DGYEPEPLGKRPAVLP; GYEPEPLGKRPAVLPL; YEPEPLGKRPAVLPLL;EPEPLGKRPAVLPLLE; PEPLGKRPAVLPLLEL; EPLGKRPAVLPLLELV;PLGKRPAVLPLLELVG; LGKRPAVLPLLELVGE; GKRPAVLPLLELVGES;KRPAVLPLLELVGESG; RPAVLPLLELVGESGN; PAVLPLLELVGESGNN;AVLPLLELVGESGNNT; VLPLLELVGESGNNTS; LPLLELVGESGNNTST;PLLELVGESGNNTSTD; LLELVGESGNNTSTDG; LELVGESGNNTSTDGS;ELVGESGNNTSTDGSL; LVGESGNNTSTDGSLP; VGESGNNTSTDGSLPS;GESGNNTSTDGSLPST; ESGNNTSTDGSLPSTP; SGNNTSTDGSLPSTPP;GNNTSTDGSLPSTPPP; NNTSTDGSLPSTPPPA; NTSTDGSLPSTPPPAE;TSTDGSLPSTPPPAEE; STDGSLPSTPPPAEEE; TDGSLPSTPPPAEEEE;DGSLPSTPPPAEEEED; GSLPSTPPPAEEEEDD; SLPSTPPPAEEEEDDL;LPSTPPPAEEEEDDLY; PSTPPPAEEEEDDLYR; STPPPAEEEEDDLYRQ;TPPPAEEEEDDLYRQS; PPPAEEEEDDLYRQSL; PPAEEEEDDLYRQSLE;PAEEEEDDLYRQSLEI; AEEEEDDLYRQSLEII; EEEEDDLYRQSLEIIS;EEEDDLYRQSLEIISR; EEDDLYRQSLEIISRY; EDDLYRQSLEIISRYL;DDLYRQSLEIISRYLR; DLYRQSLEIISRYLRE; LYRQSLEIISRYLREQ;YRQSLEIISRYLREQA; RQSLEIISRYLREQAT; QSLEIISRYLREQATG;SLEIISRYLREQATGA; LEIISRYLREQATGAK; EIISRYLREQATGAKD;IISRYLREQATGAKDT; ISRYLREQATGAKDTK; SRYLREQATGAKDTKP;RYLREQATGAKDTKPM; YLREQATGAKDTKPMG; LREQATGAKDTKPMGR;REQATGAKDTKPMGRS; EQATGAKDTKPMGRSG; QATGAKDTKPMGRSGA;ATGAKDTKPMGRSGAT; TGAKDTKPMGRSGATS; GAKDTKPMGRSGATSR;AKDTKPMGRSGATSRK; KDTKPMGRSGATSRKA; DTKPMGRSGATSRKAL;TKPMGRSGATSRKALE; KPMGRSGATSRKALET; PMGRSGATSRKALETL;MGRSGATSRKALETLR; GRSGATSRKALETLRR; RSGATSRKALETLRRV;SGATSRKALETLRRVG; GATSRKALETLRRVGD; ATSRKALETLRRVGDG;TSRKALETLRRVGDGV; SRKALETLRRVGDGVQ; RKALETLRRVGDGVQR;KALETLRRVGDGVQRN; ALETLRRVGDGVQRNH; LETLRRVGDGVQRNHE;ETLRRVGDGVQRNHET; TLRRVGDGVQRNHETA; LRRVGDGVQRNHETAF;RRVGDGVQRNHETAFQ; RVGDGVQRNHETAFQG; VGDGVQRNHETAFQGM;GDGVQRNHETAFQGML; DGVQRNHETAFQGMLR; GVQRNHETAFQGMLRK;VQRNHETAFQGMLRKL; QRNHETAFQGMLRKLD; RNHETAFQGMLRKLDI;NHETAFQGMLRKLDIK; HETAFQGMLRKLDIKN; ETAFQGMLRKLDIKNE;TAFQGMLRKLDIKNED; AFQGMLRKLDIKNEDD; FQGMLRKLDIKNEDDV;QGMLRKLDIKNEDDVK; GMLRKLDIKNEDDVKS; MLRKLDIKNEDDVKSL;LRKLDIKNEDDVKSLS; RKLDIKNEDDVKSLSR; KLDIKNEDDVKSLSRV;LDIKNEDDVKSLSRVM; DIKNEDDVKSLSRVMI; IKNEDDVKSLSRVMIH;KNEDDVKSLSRVMIHV; NEDDVKSLSRVMIHVF; EDDVKSLSRVMIHVFS;DDVKSLSRVMIHVFSD; DVKSLSRVMIHVFSDG; VKSLSRVMIHVFSDGV;KSLSRVMIHVFSDGVT; SLSRVMIHVFSDGVTN; LSRVMIHVFSDGVTNW;SRVMIHVFSDGVTNWG; RVMIHVFSDGVTNWGR; VMIHVFSDGVTNWGRI;MIHVFSDGVTNWGRIV; IHVFSDGVTNWGRIVT; HVFSDGVTNWGRIVTL;VFSDGVTNWGRIVTLI; FSDGVTNWGRIVTLIS; SDGVTNWGRIVTLISF;DGVTNWGRIVTLISFG; GVTNWGRIVTLISFGA; VTNWGRIVTLISFGAF;TNWGRIVTLISFGAFV; NWGRIVTLISFGAFVA; WGRIVTLISFGAFVAK;GRIVTLISFGAFVAKH; RIVTLISFGAFVAKHL; IVTLISFGAFVAKHLK;VTLISFGAFVAKHLKT; TLISFGAFVAKHLKTI; LISFGAFVAKHLKTIN;ISFGAFVAKHLKTINQ; SFGAFVAKHLKTINQE; FGAFVAKHLKTINQES;GAFVAKHLKTINQESC; AFVAKHLKTINQESCI; FVAKHLKTINQESCIE;VAKHLKTINQESCIEP; AKHLKTINQESCIEPL; KHLKTINQESCIEPLA;HLKTINQESCIEPLAE; LKTINQESCIEPLAES; KTINQESCIEPLAESI;TINQESCIEPLAESIT; INQESCIEPLAESITD; NQESCIEPLAESITDV;QESCIEPLAESITDVL; ESCIEPLAESITDVLV; SCIEPLAESITDVLVR;CIEPLAESITDVLVRT; IEPLAESITDVLVRTK; EPLAESITDVLVRTKR;PLAESITDVLVRTKRD; LAESITDVLVRTKRDW; AESITDVLVRTKRDWL;ESITDVLVRTKRDWLV; SITDVLVRTKRDWLVK; ITDVLVRTKRDWLVKQ;TDVLVRTKRDWLVKQR; DVLVRTKRDWLVKQRG; VLVRTKRDWLVKQRGW;LVRTKRDWLVKQRGWD; VRTKRDWLVKQRGWDG; RTKRDWLVKQRGWDGF;TKRDWLVKQRGWDGFV; KRDWLVKQRGWDGFVE; RDWLVKQRGWDGFVEF;DWLVKQRGWDGFVEFF; WLVKQRGWDGFVEFFH; LVKQRGWDGFVEFFHV;VKQRGWDGFVEFFHVE; KQRGWDGFVEFFHVED; QRGWDGFVEFFHVEDL;RGWDGFVEFFHVEDLE; GWDGFVEFFHVEDLEG; WDGFVEFFHVEDLEGG;DGFVEFFHVEDLEGGI; GFVEFFHVEDLEGGIR; FVEFFHVEDLEGGIRN;VEFFHVEDLEGGIRNV; EFFHVEDLEGGIRNVL; FFHVEDLEGGIRNVLL;FHVEDLEGGIRNVLLA; HVEDLEGGIRNVLLAF; VEDLEGGIRNVLLAFA;EDLEGGIRNVLLAFAG; DLEGGIRNVLLAFAGV; LEGGIRNVLLAFAGVA;EGGIRNVLLAFAGVAG; GGIRNVLLAFAGVAGV; GIRNVLLAFAGVAGVG;IRNVLLAFAGVAGVGA; RNVLLAFAGVAGVGAG; NVLLAFAGVAGVGAGL;VLLAFAGVAGVGAGLA; LLAFAGVAGVGAGLAY; LAFAGVAGVGAGLAYL;AFAGVAGVGAGLAYLI; FAGVAGVGAGLAYLIR SEQ ID NOS: 48181-49526

The one or more antigenic peptides can in one embodiment comprise afragment of one or more BK virus antigens.

The one or more BK virus antigens can be selected from Table H.

TABLE HProtein designation and accession numbers for the proteins encoded by theBK virus genome. The amino acid sequence of each protein is displayed.BK virus protein accession dataAmino acid sequence >gi|118752|sp|P14998|DNBI_POVBAMFCEPKNLVVLRQLSRQASVKVGKTWTGTKKRAQRIFIFILELL DNA-LEFCRGEDSVDGKNKSTTALPAVKDSVKDS binding protein(Agnoprotein) >gi|135313|sp|P15000|TASM_POVBAMDKVLNREESMELMDLLGLERAAWGNLPLMRKAYLKKCKEFHPD Small TKGGDEDKMKRMNTLYKKMEQDVKVAHQPDFGTWNSSEVCADFPL antigenCPDTLYCKEWPICSKKPSVHCPCMLCQLRLRHLNRKFLRKEPLVWIDCYCIDCFTQWFGLDLTEETLQWWVQIIGETPFRDLKL >gi|135279|sp|P14999|TALA_POVBAMDKVLNREESMELMDLLGLERAAWGNLPLMRKAYLKKCKEFHPD Large TKGGDEDKMKRMNTLYKKMEQDVKVAHQPDFGTWNSSEVPTYGTE antigenEWESWWSSFNEKWDEDLFCHEDMFASDEEATADSQHSTPPKKKRKVEDPKDFPSDLHQFLSQAVFSNRTLACFAVYTTKEKAQILYKKLMEKYSVTFISRHMCAGHNIIFFLTPHRHRVSAINNFCQKLCTFSFLICKGVNKEYLLYSALTRDPYHIIEESIQGGLKEHDFNPEEPEETKQVSWKLITEYAVETKCEDVFLLLGMYLEFQYNVEECKKCQKKDQPYHFKYHEKHFANAIIFAESKNQKSICQQAVDTVLAKKRVDTLHMTREEMLTERFNHILDKMDLIFGAHGNAVLEQYMAGVAWLHCLLPKMDSVIFDFLHCVVFNVPKRRYWLFKGPIDSGKTTLAAGLLDLCGGKALNVNLPMERLTFELGVAIDQYMVVFEDVKGTGAESKDLPSGHGINNLDSLRDYLDGSVKVNLEKKHLNKRTQIFPPGLVTMNEYPVPKTLQARFVRQIDFRPKIYLRKSLQNSEFLLEKRILQSGMTLLLLLIWFRPVADFSKDIQSRIVEWKERLDSEISMYTFSRMKYNICMGKCILDITREEDSETEDSGHGSSTESQSQCSSQVSDTSAPDSENPHSQELHLCKGFQCFKRPKTPPPK >gi|116622|sp|P14996|COA1_POVBAMAPTKRKGECPGAAPKKPKEPVQVPKLLIKGGVEVLEVKTGVDA CoatITEVECFLNPEMGDPDDNLRGYSQHLSAENAFESDSPDRKMLPC protein VP1YSTARIPLPNLNEDLTCGNLLMWEAVTVKTEVIGITSMLNLHAGSQKVHENGGGKPVQGSNFHFFAVGGDPLEMQGVLMNYRTKYPQGTITPKNPTAQSQVMNTDHKAYLDKNNAYPVECWIPDPSRNENTRYFGTYTGGENVPPVLHVTNTATTVLLDEQGVGPLCKADSLYVSAADICGLFTNSSGTQQWRGLARYFKIRLRKRSVKNPYPISFLLSDLINRRTQKVDGQPMYGMESQVEEVRVFDGTEQLPGDPDMIRYIDRQGQLQTKMV >gi|116641|sp|P14997|COA2_POVBAMGAALALLGDLVASVSEAAAATGFSVAEIAAGEAAAAIEVQIAS CoatLATVEGITTTSEAIAAIGLTPQTYAVIAGAPGAIAGFAALIQTV protein VP2/VP3TGISSLAQVGYRFFSDWDHKVSTVGLYQQSGMALELFNPDEYYDILFPGVNTFVNNIQYLDPRHWGPSLFATISQALWHVIRDDIPAITSQELQRRTERFFRDSLARFLEETTWTIVNAPINFYNYIQDYYSNLSPIRPSMVRQVAEREGTHVNFGHTYSIDNADSIEEVTQRMDLRNKESVHSGEFIEKTIAPGGANQRTAPQWMLPLLLGLYGTVTPALEAYEDGPNQKKRRVSRGSSQKAKGTRASAKTTNKRRSRSSRSMAHAGRTGYDNREIVMKYIHYKLSQRGYEWDAGDVGAAPPGAAP APGIFSSQPGHTPHPAASRDPVARTSPLQTPAAPGAAAGPALSPVPPVVHLTLRQAGDDFSRRYRRDFAE MSSQLHLTPFTARGRFATVVEELFRDGVNWGRIVAFFEFGGVMCVESVNREMSPLVDNIALWMTEYLNRH LHTWIQDNGGWDAFVELYGPSMRPLFDFSWLSLKTLLSLALVGACITLGAYLGHK SEQ ID NOS: 1-6

Preferred BK virus fragments capable of interacting with one or more MHCclass 1 molecules are listed in Table I.

TABLE I Predicted MHC class 1 BK virus peptide sequences. Prediction of8-, 9-, 10-, 11-mers from all 6 reading frames of the genome (access no#V01108) obtained using the program displayed in FIG. 2.BK virus reading frame 1 8 mers:FCKNCKRI; CKNCKRIG; KNCKRIGI; NCKRIGIS; CKRIGISP; KRIGISPN; RIGISPNS;IGISPNSF; GISPNSFA; ISPNSFAR; SPNSFARP; PNSFARPQ; NSFARPQK; SFARPQKK;FARPQKKP; ARPQKKPP; RPQKKPPH; PQKKPPHP; QKKPPHPY; KKPPHPYY; KPPHPYYL;PPHPYYLR; PHPYYLRE; HPYYLRER; PYYLRERV; YYLRERVE; YLRERVEA; LRERVEAE;RERVEAEA; ERVEAEAA; RVEAEAAS; VEAEAASA; EAEAASAS; AEAASASY; EAASASYI;AASASYIL; KKRPQGGA; KRPQGGAA; RPQGGAAY; PQGGAAYP; QGGAAYPW; GGAAYPWN;GAAYPWNA; AAYPWNAA; AYPWNAAK; YPWNAAKP; PQEGKCMT; QEGKCMTH; EGKCMTHR;GKCMTHRG; KCMTHRGM; CMTHRGMQ; MTHRGMQP; THRGMQPN; HRGMQPNH; RGMQPNHD;GMQPNHDL; MQPNHDLR; QPNHDLRK; PNHDLRKE; NHDLRKES; HDLRKESA; LTGRSCLP;TGRSCLPM; GRSCLPME; RSCLPMEC; SCLPMECS; CLPMECSQ; LPMECSQT; PMECSQTM;MECSQTMT; ECSQTMTS; CSQTMTSG; SQTMTSGR; QTMTSGRK; TMTSGRKV; MTSGRKVH;TSGRKVHD; SGRKVHDR; GRKVHDRH; RKVHDRHV; KVHDRHVL; VHDRHVLR; HDRHVLRA;ESWPCPQL; SWPCPQLN; WPCPQLNW; PCPQLNWT; CPQLNWTK; PQLNWTKA; QLNWTKAM;LNWTKAMV; NWTKAMVL; WTKAMVLR; TKAMVLRQ; KAMVLRQL; AMVLRQLS; MVLRQLSR;VLRQLSRQ; LRQLSRQA; RQLSRQAS; QLSRQASV; LSRQASVK; SRQASVKV; RQASVKVG;QASVKVGK; ASVKVGKT; SVKVGKTW; VKVGKTWT; KVGKTWTG; VGKTWTGT; GKTWTGTK;KTWTGTKK; TWTGTKKR; WTGTKKRA; TGTKKRAQ; GTKKRAQR; TKKRAQRI; KKRAQRIF;KRAQRIFI; RAQRIFIF; AQRIFIFI; QRIFIFIL; RIFIFILE; IFIFILEL; FIFILELL;IFILELLL; FILELLLE; ILELLLEF; LELLLEFC; ELLLEFCR; LLLEFCRG; LLEFCRGE;LEFCRGED; EFCRGEDS; FCRGEDSV; CRGEDSVD; RGEDSVDG; GEDSVDGK; EDSVDGKN;DSVDGKNK; SVDGKNKS; VDGKNKST; DGKNKSTT; GKNKSTTA; KNKSTTAL; NKSTTALP;KSTTALPA; STTALPAV; TTALPAVK; TALPAVKD; ALPAVKDS; LPAVKDSV; PAVKDSVK;AVKDSVKD; VKDSVKDS; VSNPFFFV; SNPFFFVF; NPFFFVFP; PFFFVFPG; FFFVFPGS;FFVFPGSW; FVFPGSWV; VFPGSWVL; FPGSWVLL; LPVYLRLL; PVYLRLLL; VYLRLLLP;YLRLLLPQ; LRLLLPQD; RLLLPQDF; LLLPQDFQ; LLPQDFQW; LPQDFQWL; PQDFQWLK;QDFQWLKL; DFQWLKLL; FQWLKLLL; QWLKLLLG; WLKLLLGR; LKLLLGRL; KLLLGRLL;LLLGRLLL; LLGRLLLL; KFKLHPLL; FKLHPLLL; LLVLLGLL; LVLLGLLL; VLLGLLLG;LLGLLLGL; LGLLLGLL; GLLLGLLL; FKLLVVLV; KLLVVLVP; GISSLMIG; ISSLMIGI;SSLMIGIT; SLMIGITK; LMIGITKF; MIGITKFP; IGITKFPL; ASISNQAW; SISNQAWL;ISNQAWLW; SNQAWLWN; NQAWLWNC; QAWLWNCL; AWLWNCLT; WLWNCLTQ; LWNCLTQM;WNCLTQMS; NCLTQMST; CLTQMSTM; LTQMSTMI; TQMSTMIF; QMSTMIFC; MSTMIFCF;STMIFCFL; TMIFCFLV; ILLLIIFN; LLLIIFNT; LLIIFNTL; LIIFNTLI; IIFNTLIL;IFNTLILG; FNTLILGI; NTLILGIG; TLILGIGV; LILGIGVL; ILGIGVLL; LGIGVLLC;GIGVLLCL; IGVLLCLL; GVLLCLLL; VLLCLLLF; LLCLLLFP; LCLLLFPR; CLLLFPRL;LLLFPRLC; LLFPRLCG; LFPRLCGM; FPRLCGML; PRLCGMLL; RLCGMLLG; LCGMLLGM;CGMLLGMI; GMLLGMIY; MLLGMIYL; LLGMIYLL; PHRNCREE; HRNCREEQ; RNCREEQK;NCREEQKD; CREEQKDF; REEQKDFL; EEQKDFLE; EQKDFLET; QKDFLETP; KDFLETPW;DFLETPWL; FLETPWLD; LETPWLDF; ETPWLDFW; TPWLDFWR; PWLDFWRK; WLDFWRKL;LDFWRKLP; DFWRKLPG; FWRKLPGQ; WRKLPGQL; TFIIIFNN; FIIIFNNI; IIIFNNII;IIFNNIIL; IFNNIILI; FNNIILIF; NNIILIFP; NIILIFPL; IILIFPLL; ILIFPLLG;LIFPLLGP; IFPLLGPQ; FPLLGPQW; PLLGPQWL; LLGPQWLD; LGPQWLDK; LKGKVPVY;KGKVPVYI; GKVPVYIL; KVPVYILA; VPVYILAI; PVYILAIL; VYILAILI; YILAILIV;KKLHKEWT; EINKVYIQ; INKVYIQE; NKVYIQES; KVYIQESL; KKLLPQEV; KLLPQEVL;LLPQEVLI; LPQEVLIK; PQEVLIKE; QEVLIKEL; EVLIKELL; VLIKELLL; LIKELLLN;IKELLLNG; KELLLNGC; ELLLNGCC; LLLNGCCL; LLNGCCLY; LNGCCLYF; HLLLKHMK;LLLKHMKM; LLKHMKMA; LKHMKMAP; KHMKMAPT; HMKMAPTK; MKMAPTKR; KMAPTKRK;MAPTKRKG; APTKRKGE; PTKRKGEC; TKRKGECP; KRKGECPG; RKGECPGA; KGECPGAA;GECPGAAP; ECPGAAPK; CPGAAPKK; PGAAPKKP; GAAPKKPK; AAPKKPKE; APKKPKEP;PKKPKEPV; KKPKEPVQ; KPKEPVQV; PKEPVQVP; KEPVQVPK; EPVQVPKL; PVQVPKLL;VQVPKLLI; QVPKLLIK; VPKLLIKG; PKLLIKGG; KLLIKGGV; LLIKGGVE; LIKGGVEV;IKGGVEVL; KGGVEVLE; GGVEVLEV; GVEVLEVK; VEVLEVKT; EVLEVKTG; VLEVKTGV;LEVKTGVD; EVKTGVDA; VKTGVDAI; KTGVDAIT; TGVDAITE; GVDAITEV; VDAITEVE;DAITEVEC; AITEVECF; ITEVECFL; TEVECFLN; EVECFLNP; VECFLNPE; ECFLNPEM;CFLNPEMG; FLNPEMGD; LNPEMGDP; NPEMGDPD; PEMGDPDE; EMGDPDEN; MGDPDENL;GDPDENLR; DPDENLRG; PDENLRGF; DENLRGFS; ENLRGFSL; NLRGFSLK; LRGFSLKL;RGFSLKLS; GFSLKLSA; FSLKLSAE; SLKLSAEN; LKLSAEND; KLSAENDF; LSAENDFS;SAENDFSS; AENDFSSD; ENDFSSDS; NDFSSDSP; DFSSDSPE; FSSDSPER; SSDSPERK;SDSPERKM; DSPERKML; SPERKMLP; PERKMLPC; ERKMLPCY; RKMLPCYS; KMLPCYST;MLPCYSTA; LPCYSTAR; PCYSTARI; CYSTARIP; YSTARIPL; STARIPLP; TARIPLPN;ARIPLPNL; RIPLPNLN; IPLPNLNE; PLPNLNED; LPNLNEDL; PNLNEDLT; NLNEDLTC;LNEDLTCG; NEDLTCGN; EDLTCGNL; DLTCGNLL; LTCGNLLM; TCGNLLMW; CGNLLMWE;GNLLMWEA; NLLMWEAV; LLMWEAVT; LMWEAVTV; MWEAVTVQ; WEAVTVQT; EAVTVQTE;AVTVQTEV; VTVQTEVI; TVQTEVIG; VQTEVIGI; QTEVIGIT; TEVIGITS; EVIGITSM;VIGITSML; IGITSMLN; GITSMLNL; ITSMLNLH; TSMLNLHA; SMLNLHAG; MLNLHAGS;LNLHAGSQ; NLHAGSQK; LHAGSQKV; HAGSQKVH; AGSQKVHE; GSQKVHEH; SQKVHEHG;QKVHEHGG; KVHEHGGG; VHEHGGGK; HEHGGGKP; EHGGGKPI; HGGGKPIQ; GGGKPIQG;GGKPIQGS; GKPIQGSN; KPIQGSNF; PIQGSNFH; IQGSNFHF; QGSNFHFF; GSNFHFFA;SNFHFFAV; NFHFFAVG; FHFFAVGG; HFFAVGGE; FFAVGGEP; FAVGGEPL; AVGGEPLE;VGGEPLEM; GGEPLEMQ; GEPLEMQG; EPLEMQGV; PLEMQGVL; LEMQGVLM; EMQGVLMN;MQGVLMNY; QGVLMNYR; GVLMNYRS; VLMNYRSK; LMNYRSKY; MNYRSKYP; NYRSKYPD;YRSKYPDG; RSKYPDGT; SKYPDGTI; KYPDGTIT; YPDGTITP; PDGTITPK; DGTITPKN;GTITPKNP; TITPKNPT; ITPKNPTA; TPKNPTAQ; PKNPTAQS; KNPTAQSQ; NPTAQSQV;PTAQSQVM; TAQSQVMN; AQSQVMNT; QSQVMNTD; SQVMNTDH; QVMNTDHK; VMNTDHKA;MNTDHKAY; NTDHKAYL; TDHKAYLD; DHKAYLDK; HKAYLDKN; KAYLDKNN; AYLDKNNA;YLDKNNAY; LDKNNAYP; DKNNAYPV; KNNAYPVE; NNAYPVEC; NAYPVECW; AYPVECWV;YPVECWVP; PVECWVPD; VECWVPDP; ECWVPDPS; CWVPDPSR; WVPDPSRN; VPDPSRNE;PDPSRNEN; DPSRNENA; PSRNENAR; SRNENARY; RNENARYF; NENARYFG; ENARYFGT;NARYFGTF; ARYFGTFT; RYFGTFTG; YFGTFTGG; FGTFTGGE; GTFTGGEN; TFTGGENV;FTGGENVP; TGGENVPP; GGENVPPV; GENVPPVL; ENVPPVLH; NVPPVLHV; VPPVLHVT;PPVLHVTN; PVLHVTNT; VLHVTNTA; LHVTNTAT; HVTNTATT; VTNTATTV; TNTATTVL;NTATTVLL; TATTVLLD; ATTVLLDE; TTVLLDEQ; TVLLDEQG; VLLDEQGV; LLDEQGVG;LDEQGVGP; DEQGVGPL; EQGVGPLC; QGVGPLCK; GVGPLCKA; VGPLCKAD; GPLCKADS;PLCKADSL; LCKADSLY; CKADSLYV; KADSLYVS; ADSLYVSA; DSLYVSAA; SLYVSAAD;LYVSAADI; YVSAADIC; VSAADICG; SAADICGL; AADICGLF; ADICGLFT; DICGLFTN;ICGLFTNS; CGLFTNSS; GLFTNSSG; LFTNSSGT; FTNSSGTQ; TNSSGTQQ; NSSGTQQW;SSGTQQWR; SGTQQWRG; GTQQWRGL; TQQWRGLA; QQWRGLAR; QWRGLARY; WRGLARYF;RGLARYFK; GLARYFKI; LARYFKIR; ARYFKIRL; RYFKIRLR; YFKIRLRK; FKIRLRKR;KIRLRKRS; IRLRKRSV; RLRKRSVK; LRKRSVKN; RKRSVKNP; KRSVKNPY; RSVKNPYP;SVKNPYPI; VKNPYPIS; KNPYPISF; NPYPISFL; PYPISFLL; YPISFLLS; PISFLLSD;ISFLLSDL; SFLLSDLI; FLLSDLIN; LLSDLINR; LSDLINRR; SDLINRRT; DLINRRTQ;LINRRTQR; INRRTQRV; NRRTQRVD; RRTQRVDG; RTQRVDGQ; TQRVDGQP; QRVDGQPM;RVDGQPMY; VDGQPMYG; DGQPMYGM; GQPMYGME; QPMYGMES; PMYGMESQ; MYGMESQV;YGMESQVE; GMESQVEE; MESQVEEV; ESQVEEVR; SQVEEVRV; QVEEVRVF; VEEVRVFD;EEVRVFDG; EVRVFDGT; VRVFDGTE; RVFDGTER; VFDGTERL; FDGTERLP; DGTERLPG;GTERLPGD; TERLPGDP; ERLPGDPD; RLPGDPDM; LPGDPDMI; PGDPDMIR; GDPDMIRY;DPDMIRYI; PDMIRYID; DMIRYIDK; MIRYIDKQ; IRYIDKQG; RYIDKQGQ; YIDKQGQL;IDKQGQLQ; DKQGQLQT; KQGQLQTK; QGQLQTKM; GQLQTKML; TGAFIVHI; GAFIVHIH;AFIVHIHL; FIVHIHLI; IVHIHLIN; VHIHLINA; HIHLINAA; IHLINAAF; HLINAAFV;ATFKLVLF; TFKLVLFW; FKLVLFWG; KLVLFWGW; LVLFWGWC; VLFWGWCF; LFWGWCFR;FWGWCFRP; WGWCFRPF; GWCFRPFK; WCFRPFKT; CFRPFKTL; FRPFKTLK; RPFKTLKA;PFKTLKAF; FKTLKAFT; KTLKAFTQ; TLKAFTQM; LKAFTQMQ; KAFTQMQL; AFTQMQLL;FTQMQLLT; TQMQLLTM; QMQLLTMG; MQLLTMGV; PLGIFSRG; SMSRVFSF; ILFSCNIK;LFSCNIKN; FSCNIKNT; SCNIKNTF; CNIKNTFP; NIKNTFPH; IKNTFPHA; KNTFPHAY;NTFPHAYI; TFPHAYII; FPHAYIIF; PHAYIIFH; HAYIIFHP; KSIHTYLR; SIHTYLRI;IHTYLRIQ; HTYLRIQP; TYLRIQPF; YLRIQPFL; LRIQPFLP; RIQPFLPF; IQPFLPFN;QPFLPFNN; PFLPFNNS; FLPFNNSR; LPFNNSRL; PFNNSRLY; FNNSRLYI; NNSRLYIS;NSRLYISC; SRLYISCK; RLYISCKI; LYISCKIS; YISCKISY; ISCKISYR; SCKISYRP;CKISYRPK; KISYRPKP; ISYRPKPN; IYFGPKIY; YFGPKIYL; FGPKIYLS; GPKIYLSY;PKIYLSYK; KIYLSYKS; IYLSYKSS; YLSYKSSL; LSYKSSLQ; SYKSSLQG; YKSSLQGF;KSSLQGFR; SSLQGFRD; SLQGFRDR; LQGFRDRI; QGFRDRIL; GFRDRILI; FRDRILIH;RDRILIHC; DRILIHCN; RILIHCNQ; ILIHCNQA; LIHCNQAW; IHCNQAWW; HCNQAWWK;CNQAWWKY; NQAWWKYL; QAWWKYLG; AWWKYLGS; WWKYLGSF; WKYLGSFV; FSSCPFYI;SSCPFYIF; SCPFYIFK; CPFYIFKN; PFYIFKNN; FYIFKNNH; YIFKNNHV; IFKNNHVL;FKNNHVLI; KNNHVLIY; NNHVLIYS; NHVLIYSY; HVLIYSYT; CCFSTING; CFSTINGT;FSTINGTF; STINGTFK; PVSSFRYI; VSSFRYIE; SSFRYIEN; SFRYIENN; FRYIENNT;RYIENNTV; YIENNTVQ; IENNTVQK; ENNTVQKI; NNTVQKIK; NTVQKIKY; TVQKIKYY;VQKIKYYR; QKIKYYRI; KIKYYRIH; IKYYRIHF; KYYRIHFR; QTVQPSNT; TVQPSNTC;VQPSNTCH; QPSNTCHI; PSNTCHIL; SNTCHILF; YSISMSSK; SISMSSKY; HFFPGHMK;FFPGHMKG; FPGHMKGI; PGHMKGIY; GHMKGIYS; HMKGIYSF; MKGIYSFF; KGIYSFFS;NCIYCLLT; CIYCLLTN; IYCLLTNT; YCLLTNTF; CLLTNTFL; LLTNTFLI; LTNTFLIF;TNTFLIFT; NTFLIFTF; TFLIFTFC; FLIFTFCK; LIFTFCKN; IFTFCKNN; FTFCKNNS;TFCKNNSI; FCKNNSIC; CKNNSICK; KNNSICKV; NNSICKVL; NSICKVLF; SICKVLFM;ICKVLFMI; CKVLFMIL; KVLFMILK; VLFMILKV; LFMILKVI; FMILKVIR; MILKVIRL;ILKVIRLV; LKVIRLVF; KVIRLVFF; VIRLVFFL; IRLVFFLT; RLVFFLTL; LVFFLTLF;VFFLTLFT; FFLTLFTL; FLTLFTLL; LTLFTLLY; TLFTLLYI; LFTLLYIV; FTLLYIVL;TLLYIVLK; LLYIVLKF; KHILTLCL; HILTLCLY; ILTLCLYC; LTLCLYCI; TLCLYCIL;LCLYCILS; CLYCILSN; FPRHLLCF; PRHLLCFF; RHLLCFFR; HLLCFFRL; LLCFFRLF;LCFFRLFW; CFFRLFWA; FFRLFWAK; FRLFWAKI; RLFWAKIM; LFWAKIML; FWAKIMLL;APLNAFFY; PLNAFFYS; LNAFFYSM; NAFFYSMV; AFFYSMVW; FFYSMVWI; FYSMVWIS;YSMVWISS; VFLINTLT; FLINTLTN; KTKGTQLL; TKGTQLLT; KGTQLLTE; GTQLLTEI;TQLLTEII; QLLTEIIN; LLTEIINC; LTEIINCR; TEIINCRN; EIINCRNS; IINCRNSM;INCRNSMS; NCRNSMSM; CRNSMSMW; RNSMSMWS; KEYNIMPS; EYNIMPST; YNIMPSTH;NIMPSTHV; IMPSTHVS; MPSTHVST; PSTHVSTN; STHVSTNK; THVSTNKS; HVSTNKSY;VSTNKSYR; STNKSYRI; TNKSYRIF; NKSYRIFF; KSYRIFFH; SYRIFFHK; YRIFFHKF;RIFFHKFF; IFFHKFFI; FFHKFFIQ; FHKFFIQN; HKFFIQNL; KFFIQNLS; FFIQNLSF;FIQNLSFF; IQNLSFFF; QNLSFFFS; NLSFFFSS; LSFFFSSI; SFFFSSIH; FFFSSIHS;FFSSIHSK; FSSIHSKA; SSIHSKAG; SIHSKAGK; IHSKAGKG; HSKAGKGS; SKAGKGSI;KAGKGSIT; AGKGSITK; GKGSITKY; KGSITKYS; GSITKYSL; SITKYSLT; ITKYSLTK;TKYSLTKK; KYSLTKKL; YSLTKKLV; IRGKVFRV; RGKVFRVF; GKVFRVFY; KVFRVFYL;VFRVFYLS; FRVFYLSF; RVFYLSFF; VFYLSFFF; FYLSFFFG; YLSFFFGW; LSFFFGWC;VLRICCCF; LRICCCFF; RICCCFFI; ICCCFFIT; CCCFFITG; CCFFITGK; CFFITGKH;FFITGKHI; FITGKHIF; ITGKHIFM; TGKHIFMA; GKHIFMAK; IFIPFFIK; FIPFFIKG;IPFFIKGT; PFFIKGTP; FFIKGTPP; FIKGTPPG; IKGTPPGL; KGTPPGLP; GTPPGLPL;TPPGLPLF; PPGLPLFC; PGLPLFCS; GLPLFCSI; LPLFCSIG; PLFCSIGW; LFCSIGWH;FCSIGWHL; YFIIYLNI; FIIYLNIS; SFRSLKGV; FRSLKGVS; RSLKGVSP; SLKGVSPI;LKGVSPII; KGVSPIIW; GVSPIIWT; VSPIIWTH; SPIIWTHH; PIIWTHHC; IIWTHHCR;IWTHHCRV; WTHHCRVS; THHCRVSS; HHCRVSSV; HCRVSSVR; CRVSSVRS; RVSSVRSK;VSSVRSKP; SSVRSKPN; SVRSKPNH; VRSKPNHC; RSKPNHCV; SKPNHCVK; KPNHCVKQ;PNHCVKQS; NHCVKQSM; HCVKQSMQ; QSIQTKGS; SIQTKGSF; IQTKGSFL; QTKGSFLK;TKGSFLKN; KGSFLKNF; GSFLKNFL; SFLKNFLF; FLKNFLFK; LKNFLFKC; KNFLFKCL;NFLFKCLN; FLFKCLNL; LFKCLNLS; HSMQGQCT; SMQGQCTE; MQGQCTEG; QGQCTEGF;GQCTEGFL; QCTEGFLE; CTEGFLEQ; TEGFLEQI; EGFLEQIG; GFLEQIGH; FLEQIGHS;LEQIGHSL; EQIGHSLQ; QIGHSLQY; IGHSLQYR; GHSLQYRV; HSLQYRVS; SLQYRVSG;LQYRVSGQ; QYRVSGQR; YRVSGQRG; RVSGQRGK; VSGQRGKS; SGQRGKSA; GQRGKSAQ;QRGKSAQT; RGKSAQTS; GKSAQTSE; KSAQTSEL; SAQTSELL; AQTSELLQ; QTSELLQV;TSELLQVP; SELLQVPK; ELLQVPKS; LLQVPKSG; ATFTSCSI; TFTSCSIF; FTSCSIFL;TSCSIFLY; SCSIFLYK; CSIFLYKV; SIFLYKVF; IFLYKVFI; FLYKVFIL; LYKVFILF;YKVFILFI; KVFILFIL; VFILFILS; FILFILSS; ILFILSSS; LFILSSSP; FILSSSPP;ILSSSPPL; LSSSPPLS; SSSPPLSG; AFLIKGRF; FLIKGRFP; LIKGRFPQ; IKGRFPQA;KGRFPQAA; GRFPQAAL; RFPQAALS; FPQAALSR; PQAALSRP; QAALSRPK; AALSRPKR;ALSRPKRS; LSRPKRSM; SRPKRSMS; RPKRSMSS; PKRSMSSM; KRSMSSMD; RSMSSMDS;SMSSMDSS; MSSMDSSL; SSMDSSLL; SMDSSLLR; MDSSLLRT; DSSLLRTL; SSLLRTLS9 mers:FCKNCKRIG; CKNCKRIGI; KNCKRIGIS; NCKRIGISP; CKRIGISPN; KRIGISPNS;RIGISPNSF; IGISPNSFA; GISPNSFAR; ISPNSFARP; SPNSFARPQ; PNSFARPQK;NSFARPQKK; SFARPQKKP; FARPQKKPP; ARPQKKPPH; RPQKKPPHP; PQKKPPHPY;QKKPPHPYY; KKPPHPYYL; KPPHPYYLR; PPHPYYLRE; PHPYYLRER; HPYYLRERV;PYYLRERVE; YYLRERVEA; YLRERVEAE; LRERVEAEA; RERVEAEAA; ERVEAEAAS;RVEAEAASA; VEAEAASAS; EAEAASASY; AEAASASYI; EAASASYIL; KKRPQGGAA;KRPQGGAAY; RPQGGAAYP; PQGGAAYPW; QGGAAYPWN; GGAAYPWNA; GAAYPWNAA;AAYPWNAAK; AYPWNAAKP; PQEGKCMTH; QEGKCMTHR; EGKCMTHRG; GKCMTHRGM;KCMTHRGMQ; CMTHRGMQP; MTHRGMQPN; THRGMQPNH; HRGMQPNHD; RGMQPNHDL;GMQPNHDLR; MQPNHDLRK; QPNHDLRKE; PNHDLRKES; NHDLRKESA; LTGRSCLPM;TGRSCLPME; GRSCLPMEC; RSCLPMECS; SCLPMECSQ; CLPMECSQT; LPMECSQTM;PMECSQTMT; MECSQTMTS; ECSQTMTSG; CSQTMTSGR; SQTMTSGRK; QTMTSGRKV;TMTSGRKVH; MTSGRKVHD; TSGRKVHDR; SGRKVHDRH; GRKVHDRHV; RKVHDRHVL;KVHDRHVLR; VHDRHVLRA; ESWPCPQLN; SWPCPQLNW; WPCPQLNWT; PCPQLNWTK;CPQLNWTKA; PQLNWTKAM; QLNWTKAMV; LNWTKAMVL; NWTKAMVLR; WTKAMVLRQ;TKAMVLRQL; KAMVLRQLS; AMVLRQLSR; MVLRQLSRQ; VLRQLSRQA; LRQLSRQAS;RQLSRQASV; QLSRQASVK; LSRQASVKV; SRQASVKVG; RQASVKVGK; QASVKVGKT;ASVKVGKTW; SVKVGKTWT; VKVGKTWTG; KVGKTWTGT; VGKTWTGTK; GKTWTGTKK;KTWTGTKKR; TWTGTKKRA; WTGTKKRAQ; TGTKKRAQR; GTKKRAQRI; TKKRAQRIF;KKRAQRIFI; KRAQRIFIF; RAQRIFIFI; AQRIFIFIL; QRIFIFILE; RIFIFILEL;IFIFILELL; FIFILELLL; IFILELLLE; FILELLLEF; ILELLLEFC; LELLLEFCR;ELLLEFCRG; LLLEFCRGE; LLEFCRGED; LEFCRGEDS; EFCRGEDSV; FCRGEDSVD;CRGEDSVDG; RGEDSVDGK; GEDSVDGKN; EDSVDGKNK; DSVDGKNKS; SVDGKNKST;VDGKNKSTT; DGKNKSTTA; GKNKSTTAL; KNKSTTALP; NKSTTALPA; KSTTALPAV;STTALPAVK; TTALPAVKD; TALPAVKDS; ALPAVKDSV; LPAVKDSVK; PAVKDSVKD;AVKDSVKDS; VSNPFFFVF; SNPFFFVFP; NPFFFVFPG; PFFFVFPGS; FFFVFPGSW;FFVFPGSWV; FVFPGSWVL; VFPGSWVLL; LPVYLRLLL; PVYLRLLLP; VYLRLLLPQ;YLRLLLPQD; LRLLLPQDF; RLLLPQDFQ; LLLPQDFQW; LLPQDFQWL; LPQDFQWLK;PQDFQWLKL; QDFQWLKLL; DFQWLKLLL; FQWLKLLLG; QWLKLLLGR; WLKLLLGRL;LKLLLGRLL; KLLLGRLLL; LLLGRLLLL; KFKLHPLLL; LLVLLGLLL; LVLLGLLLG;VLLGLLLGL; LLGLLLGLL; LGLLLGLLL; FKLLVVLVP; GISSLMIGI; ISSLMIGIT;SSLMIGITK; SLMIGITKF; LMIGITKFP; MIGITKFPL; ASISNQAWL; SISNQAWLW;ISNQAWLWN; SNQAWLWNC; NQAWLWNCL; QAWLWNCLT; AWLWNCLTQ; WLWNCLTQM;LWNCLTQMS; WNCLTQMST; NCLTQMSTM; CLTQMSTMI; LTQMSTMIF; TQMSTMIFC;QMSTMIFCF; MSTMIFCFL; STMIFCFLV; ILLLIIFNT; LLLIIFNTL; LLIIFNTLI;LIIFNTLIL; IIFNTLILG; IFNTLILGI; FNTLILGIG; NTLILGIGV; TLILGIGVL;LILGIGVLL; ILGIGVLLC; LGIGVLLCL; GIGVLLCLL; IGVLLCLLL; GVLLCLLLF;VLLCLLLFP; LLCLLLFPR; LCLLLFPRL; CLLLFPRLC; LLLFPRLCG; LLFPRLCGM;LFPRLCGML; FPRLCGMLL; PRLCGMLLG; RLCGMLLGM; LCGMLLGMI; CGMLLGMIY;GMLLGMIYL; MLLGMIYLL; PHRNCREEQ; HRNCREEQK; RNCREEQKD; NCREEQKDF;CREEQKDFL; REEQKDFLE; EEQKDFLET; EQKDFLETP; QKDFLETPW; KDFLETPWL;DFLETPWLD; FLETPWLDF; LETPWLDFW; ETPWLDFWR; TPWLDFWRK; PWLDFWRKL;WLDFWRKLP; LDFWRKLPG; DFWRKLPGQ; FWRKLPGQL; TFIIIFNNI; FIIIFNNII;IIIFNNIIL; IIFNNIILI; IFNNIILIF; FNNIILIFP; NNIILIFPL; NIILIFPLL;IILIFPLLG; ILIFPLLGP; LIFPLLGPQ; IFPLLGPQW; FPLLGPQWL; PLLGPQWLD;LLGPQWLDK; LKGKVPVYI; KGKVPVYIL; GKVPVYILA; KVPVYILAI; VPVYILAIL;PVYILAILI; VYILAILIV; EINKVYIQE; INKVYIQES; NKVYIQESL; KKLLPQEVL;KLLPQEVLI; LLPQEVLIK; LPQEVLIKE; PQEVLIKEL; QEVLIKELL; EVLIKELLL;VLIKELLLN; LIKELLLNG; IKELLLNGC; KELLLNGCC; ELLLNGCCL; LLLNGCCLY;LLNGCCLYF; HLLLKHMKM; LLLKHMKMA; LLKHMKMAP; LKHMKMAPT; KHMKMAPTK;HMKMAPTKR; MKMAPTKRK; KMAPTKRKG; MAPTKRKGE; APTKRKGEC; PTKRKGECP;TKRKGECPG; KRKGECPGA; RKGECPGAA; KGECPGAAP; GECPGAAPK; ECPGAAPKK;CPGAAPKKP; PGAAPKKPK; GAAPKKPKE; AAPKKPKEP; APKKPKEPV; PKKPKEPVQ;KKPKEPVQV; KPKEPVQVP; PKEPVQVPK; KEPVQVPKL; EPVQVPKLL; PVQVPKLLI;VQVPKLLIK; QVPKLLIKG; VPKLLIKGG; PKLLIKGGV; KLLIKGGVE; LLIKGGVEV;LIKGGVEVL; IKGGVEVLE; KGGVEVLEV; GGVEVLEVK; GVEVLEVKT; VEVLEVKTG;EVLEVKTGV; VLEVKTGVD; LEVKTGVDA; EVKTGVDAI; VKTGVDAIT; KTGVDAITE;TGVDAITEV; GVDAITEVE; VDAITEVEC; DAITEVECF; AITEVECFL; ITEVECFLN;TEVECFLNP; EVECFLNPE; VECFLNPEM; ECFLNPEMG; CFLNPEMGD; FLNPEMGDP;LNPEMGDPD; NPEMGDPDE; PEMGDPDEN; EMGDPDENL; MGDPDENLR; GDPDENLRG;DPDENLRGF; PDENLRGFS; DENLRGFSL; ENLRGFSLK; NLRGFSLKL; LRGFSLKLS;RGFSLKLSA; GFSLKLSAE; FSLKLSAEN; SLKLSAEND; LKLSAENDF; KLSAENDFS;LSAENDFSS; SAENDFSSD; AENDFSSDS; ENDFSSDSP; NDFSSDSPE; DFSSDSPER;FSSDSPERK; SSDSPERKM; SDSPERKML; DSPERKMLP; SPERKMLPC; PERKMLPCY;ERKMLPCYS; RKMLPCYST; KMLPCYSTA; MLPCYSTAR; LPCYSTARI; PCYSTARIP;CYSTARIPL; YSTARIPLP; STARIPLPN; TARIPLPNL; ARIPLPNLN; RIPLPNLNE;IPLPNLNED; PLPNLNEDL; LPNLNEDLT; PNLNEDLTC; NLNEDLTCG; LNEDLTCGN;NEDLTCGNL; EDLTCGNLL; DLTCGNLLM; LTCGNLLMW; TCGNLLMWE; CGNLLMWEA;GNLLMWEAV; NLLMWEAVT; LLMWEAVTV; LMWEAVTVQ; MWEAVTVQT; WEAVTVQTE;EAVTVQTEV; AVTVQTEVI; VTVQTEVIG; TVQTEVIGI; VQTEVIGIT; QTEVIGITS;TEVIGITSM; EVIGITSML; VIGITSMLN; IGITSMLNL; GITSMLNLH; ITSMLNLHA;TSMLNLHAG; SMLNLHAGS; MLNLHAGSQ; LNLHAGSQK; NLHAGSQKV; LHAGSQKVH;HAGSQKVHE; AGSQKVHEH; GSQKVHEHG; SQKVHEHGG; QKVHEHGGG; KVHEHGGGK;VHEHGGGKP; HEHGGGKPI; EHGGGKPIQ; HGGGKPIQG; GGGKPIQGS; GGKPIQGSN;GKPIQGSNF; KPIQGSNFH; PIQGSNFHF; IQGSNFHFF; QGSNFHFFA; GSNFHFFAV;SNFHFFAVG; NFHFFAVGG; FHFFAVGGE; HFFAVGGEP; FFAVGGEPL; FAVGGEPLE;AVGGEPLEM; VGGEPLEMQ; GGEPLEMQG; GEPLEMQGV; EPLEMQGVL; PLEMQGVLM;LEMQGVLMN; EMQGVLMNY; MQGVLMNYR; QGVLMNYRS; GVLMNYRSK; VLMNYRSKY;LMNYRSKYP; MNYRSKYPD; NYRSKYPDG; YRSKYPDGT; RSKYPDGTI; SKYPDGTIT;KYPDGTITP; YPDGTITPK; PDGTITPKN; DGTITPKNP; GTITPKNPT; TITPKNPTA;ITPKNPTAQ; TPKNPTAQS; PKNPTAQSQ; KNPTAQSQV; NPTAQSQVM; PTAQSQVMN;TAQSQVMNT; AQSQVMNTD; QSQVMNTDH; SQVMNTDHK; QVMNTDHKA; VMNTDHKAY;MNTDHKAYL; NTDHKAYLD; TDHKAYLDK; DHKAYLDKN; HKAYLDKNN; KAYLDKNNA;AYLDKNNAY; YLDKNNAYP; LDKNNAYPV; DKNNAYPVE; KNNAYPVEC; NNAYPVECW;NAYPVECWV; AYPVECWVP; YPVECWVPD; PVECWVPDP; VECWVPDPS; ECWVPDPSR;CWVPDPSRN; WVPDPSRNE; VPDPSRNEN; PDPSRNENA; DPSRNENAR; PSRNENARY;SRNENARYF; RNENARYFG; NENARYFGT; ENARYFGTF; NARYFGTFT; ARYFGTFTG;RYFGTFTGG; YFGTFTGGE; FGTFTGGEN; GTFTGGENV; TFTGGENVP; FTGGENVPP;TGGENVPPV; GGENVPPVL; GENVPPVLH; ENVPPVLHV; NVPPVLHVT; VPPVLHVTN;PPVLHVTNT; PVLHVTNTA; VLHVTNTAT; LHVTNTATT; HVTNTATTV; VTNTATTVL;TNTATTVLL; NTATTVLLD; TATTVLLDE; ATTVLLDEQ; TTVLLDEQG; TVLLDEQGV;VLLDEQGVG; LLDEQGVGP; LDEQGVGPL; DEQGVGPLC; EQGVGPLCK; QGVGPLCKA;GVGPLCKAD; VGPLCKADS; GPLCKADSL; PLCKADSLY; LCKADSLYV; CKADSLYVS;KADSLYVSA; ADSLYVSAA; DSLYVSAAD; SLYVSAADI; LYVSAADIC; YVSAADICG;VSAADICGL; SAADICGLF; AADICGLFT; ADICGLFTN; DICGLFTNS; ICGLFTNSS;CGLFTNSSG; GLFTNSSGT; LFTNSSGTQ; FTNSSGTQQ; TNSSGTQQW; NSSGTQQWR;SSGTQQWRG; SGTQQWRGL; GTQQWRGLA; TQQWRGLAR; QQWRGLARY; QWRGLARYF;WRGLARYFK; RGLARYFKI; GLARYFKIR; LARYFKIRL; ARYFKIRLR; RYFKIRLRK;YFKIRLRKR; FKIRLRKRS; KIRLRKRSV; IRLRKRSVK; RLRKRSVKN; LRKRSVKNP;RKRSVKNPY; KRSVKNPYP; RSVKNPYPI; SVKNPYPIS; VKNPYPISF; KNPYPISFL;NPYPISFLL; PYPISFLLS; YPISFLLSD; PISFLLSDL; ISFLLSDLI; SFLLSDLIN;FLLSDLINR; LLSDLINRR; LSDLINRRT; SDLINRRTQ; DLINRRTQR; LINRRTQRV;INRRTQRVD; NRRTQRVDG; RRTQRVDGQ; RTQRVDGQP; TQRVDGQPM; QRVDGQPMY;RVDGQPMYG; VDGQPMYGM; DGQPMYGME; GQPMYGMES; QPMYGMESQ; PMYGMESQV;MYGMESQVE; YGMESQVEE; GMESQVEEV; MESQVEEVR; ESQVEEVRV; SQVEEVRVF;QVEEVRVFD; VEEVRVFDG; EEVRVFDGT; EVRVFDGTE; VRVFDGTER; RVFDGTERL;VFDGTERLP; FDGTERLPG; DGTERLPGD; GTERLPGDP; TERLPGDPD; ERLPGDPDM;RLPGDPDMI; LPGDPDMIR; PGDPDMIRY; GDPDMIRYI; DPDMIRYID; PDMIRYIDK;DMIRYIDKQ; MIRYIDKQG; IRYIDKQGQ; RYIDKQGQL; YIDKQGQLQ; IDKQGQLQT;DKQGQLQTK; KQGQLQTKM; QGQLQTKML; TGAFIVHIH; GAFIVHIHL; AFIVHIHLI;FIVHIHLIN; IVHIHLINA; VHIHLINAA; HIHLINAAF; IHLINAAFV; ATFKLVLFW;TFKLVLFWG; FKLVLFWGW; KLVLFWGWC; LVLFWGWCF; VLFWGWCFR; LFWGWCFRP;FWGWCFRPF; WGWCFRPFK; GWCFRPFKT; WCFRPFKTL; CFRPFKTLK; FRPFKTLKA;RPFKTLKAF; PFKTLKAFT; FKTLKAFTQ; KTLKAFTQM; TLKAFTQMQ; LKAFTQMQL;KAFTQMQLL; AFTQMQLLT; FTQMQLLTM; TQMQLLTMG; QMQLLTMGV; ILFSCNIKN;LFSCNIKNT; FSCNIKNTF; SCNIKNTFP; CNIKNTFPH; NIKNTFPHA; IKNTFPHAY;KNTFPHAYI; NTFPHAYII; TFPHAYIIF; FPHAYIIFH; PHAYIIFHP; KSIHTYLRI;SIHTYLRIQ; IHTYLRIQP; HTYLRIQPF; TYLRIQPFL; YLRIQPFLP; LRIQPFLPF;RIQPFLPFN; IQPFLPFNN; QPFLPFNNS; PFLPFNNSR; FLPFNNSRL; LPFNNSRLY;PFNNSRLYI; FNNSRLYIS; NNSRLYISC; NSRLYISCK; SRLYISCKI; RLYISCKIS;LYISCKISY; YISCKISYR; ISCKISYRP; SCKISYRPK; CKISYRPKP; KISYRPKPN;IYFGPKIYL; YFGPKIYLS; FGPKIYLSY; GPKIYLSYK; PKIYLSYKS; KIYLSYKSS;IYLSYKSSL; YLSYKSSLQ; LSYKSSLQG; SYKSSLQGF; YKSSLQGFR; KSSLQGFRD;SSLQGFRDR; SLQGFRDRI; LQGFRDRIL; QGFRDRILI; GFRDRILIH; FRDRILIHC;RDRILIHCN; DRILIHCNQ; RILIHCNQA; ILIHCNQAW; LIHCNQAWW; IHCNQAWWK;HCNQAWWKY; CNQAWWKYL; NQAWWKYLG; QAWWKYLGS; AWWKYLGSF; WWKYLGSFV;FSSCPFYIF; SSCPFYIFK; SCPFYIFKN; CPFYIFKNN; PFYIFKNNH; FYIFKNNHV;YIFKNNHVL; IFKNNHVLI; FKNNHVLIY; KNNHVLIYS; NNHVLIYSY; NHVLIYSYT;CCFSTINGT; CFSTINGTF; FSTINGTFK; PVSSFRYIE; VSSFRYIEN; SSFRYIENN;SFRYIENNT; FRYIENNTV; RYIENNTVQ; YIENNTVQK; IENNTVQKI; ENNTVQKIK;NNTVQKIKY; NTVQKIKYY; TVQKIKYYR; VQKIKYYRI; QKIKYYRIH; KIKYYRIHF;IKYYRIHFR; QTVQPSNTC; TVQPSNTCH; VQPSNTCHI; QPSNTCHIL; PSNTCHILF;YSISMSSKY; HFFPGHMKG; FFPGHMKGI; FPGHMKGIY; PGHMKGIYS; GHMKGIYSF;HMKGIYSFF; MKGIYSFFS; NCIYCLLTN; CIYCLLTNT; IYCLLTNTF; YCLLTNTFL;CLLTNTFLI; LLTNTFLIF; LTNTFLIFT; TNTFLIFTF; NTFLIFTFC; TFLIFTFCK;FLIFTFCKN; LIFTFCKNN; IFTFCKNNS; FTFCKNNSI; TFCKNNSIC; FCKNNSICK;CKNNSICKV; KNNSICKVL; NNSICKVLF; NSICKVLFM; SICKVLFMI; ICKVLFMIL;CKVLFMILK; KVLFMILKV; VLFMILKVI; LFMILKVIR; FMILKVIRL; MILKVIRLV;ILKVIRLVF; LKVIRLVFF; KVIRLVFFL; VIRLVFFLT; IRLVFFLTL; RLVFFLTLF;LVFFLTLFT; VFFLTLFTL; FFLTLFTLL; FLTLFTLLY; LTLFTLLYI; TLFTLLYIV;LFTLLYIVL; FTLLYIVLK; TLLYIVLKF; KHILTLCLY; HILTLCLYC; ILTLCLYCI;LTLCLYCIL; TLCLYCILS; LCLYCILSN; FPRHLLCFF; PRHLLCFFR; RHLLCFFRL;HLLCFFRLF; LLCFFRLFW; LCFFRLFWA; CFFRLFWAK; FFRLFWAKI; FRLFWAKIM;RLFWAKIML; LFWAKIMLL; APLNAFFYS; PLNAFFYSM; LNAFFYSMV; NAFFYSMVW;AFFYSMVWI; FFYSMVWIS; FYSMVWISS; VFLINTLTN; KTKGTQLLT; TKGTQLLTE;KGTQLLTEI; GTQLLTEII; TQLLTEIIN; QLLTEIINC; LLTEIINCR; LTEIINCRN;TEIINCRNS; EIINCRNSM; IINCRNSMS; INCRNSMSM; NCRNSMSMW; CRNSMSMWS;KEYNIMPST; EYNIMPSTH; YNIMPSTHV; NIMPSTHVS; IMPSTHVST; MPSTHVSTN;PSTHVSTNK; STHVSTNKS; THVSTNKSY; HVSTNKSYR; VSTNKSYRI; STNKSYRIF;TNKSYRIFF; NKSYRIFFH; KSYRIFFHK; SYRIFFHKF; YRIFFHKFF; RIFFHKFFI;IFFHKFFIQ; FFHKFFIQN; FHKFFIQNL; HKFFIQNLS; KFFIQNLSF; FFIQNLSFF;FIQNLSFFF; IQNLSFFFS; QNLSFFFSS; NLSFFFSSI; LSFFFSSIH; SFFFSSIHS;FFFSSIHSK; FFSSIHSKA; FSSIHSKAG; SSIHSKAGK; SIHSKAGKG; IHSKAGKGS;HSKAGKGSI; SKAGKGSIT; KAGKGSITK; AGKGSITKY; GKGSITKYS; KGSITKYSL;GSITKYSLT; SITKYSLTK; ITKYSLTKK; TKYSLTKKL; KYSLTKKLV; IRGKVFRVF;RGKVFRVFY; GKVFRVFYL; KVFRVFYLS; VFRVFYLSF; FRVFYLSFF; RVFYLSFFF;VFYLSFFFG; FYLSFFFGW; YLSFFFGWC; VLRICCCFF; LRICCCFFI; RICCCFFIT;ICCCFFITG; CCCFFITGK; CCFFITGKH; CFFITGKHI; FFITGKHIF; FITGKHIFM;ITGKHIFMA; TGKHIFMAK; IFIPFFIKG; FIPFFIKGT; IPFFIKGTP; PFFIKGTPP;FFIKGTPPG; FIKGTPPGL; IKGTPPGLP; KGTPPGLPL; GTPPGLPLF; TPPGLPLFC;PPGLPLFCS; PGLPLFCSI; GLPLFCSIG; LPLFCSIGW; PLFCSIGWH; LFCSIGWHL;YFIIYLNIS; SFRSLKGVS; FRSLKGVSP; RSLKGVSPI; SLKGVSPII; LKGVSPIIW;KGVSPIIWT; GVSPIIWTH; VSPIIWTHH; SPIIWTHHC; PIIWTHHCR; IIWTHHCRV;IWTHHCRVS; WTHHCRVSS; THHCRVSSV; HHCRVSSVR; HCRVSSVRS; CRVSSVRSK;RVSSVRSKP; VSSVRSKPN; SSVRSKPNH; SVRSKPNHC; VRSKPNHCV; RSKPNHCVK;SKPNHCVKQ; KPNHCVKQS; PNHCVKQSM; NHCVKQSMQ; QSIQTKGSF; SIQTKGSFL;IQTKGSFLK; QTKGSFLKN; TKGSFLKNF; KGSFLKNFL; GSFLKNFLF; SFLKNFLFK;FLKNFLFKC; LKNFLFKCL; KNFLFKCLN; NFLFKCLNL; FLFKCLNLS; HSMQGQCTE;SMQGQCTEG; MQGQCTEGF; QGQCTEGFL; GQCTEGFLE; QCTEGFLEQ; CTEGFLEQI;TEGFLEQIG; EGFLEQIGH; GFLEQIGHS; FLEQIGHSL; LEQIGHSLQ; EQIGHSLQY;QIGHSLQYR; IGHSLQYRV; GHSLQYRVS; HSLQYRVSG; SLQYRVSGQ; LQYRVSGQR;QYRVSGQRG; YRVSGQRGK; RVSGQRGKS; VSGQRGKSA; SGQRGKSAQ; GQRGKSAQT;QRGKSAQTS; RGKSAQTSE; GKSAQTSEL; KSAQTSELL; SAQTSELLQ; AQTSELLQV;QTSELLQVP; TSELLQVPK; SELLQVPKS; ELLQVPKSG; ATFTSCSIF; TFTSCSIFL;FTSCSIFLY; TSCSIFLYK; SCSIFLYKV; CSIFLYKVF; SIFLYKVFI; IFLYKVFIL;FLYKVFILF; LYKVFILFI; YKVFILFIL; KVFILFILS; VFILFILSS; FILFILSSS;ILFILSSSP; LFILSSSPP; FILSSSPPL; ILSSSPPLS; LSSSPPLSG; AFLIKGRFP;FLIKGRFPQ; LIKGRFPQA; IKGRFPQAA; KGRFPQAAL; GRFPQAALS; RFPQAALSR;FPQAALSRP; PQAALSRPK; QAALSRPKR; AALSRPKRS; ALSRPKRSM; LSRPKRSMS;SRPKRSMSS; RPKRSMSSM; PKRSMSSMD; KRSMSSMDS; RSMSSMDSS; SMSSMDSSL;MSSMDSSLL; SSMDSSLLR; SMDSSLLRT; MDSSLLRTL; DSSLLRTLS 10 mers:FCKNCKRIGI; CKNCKRIGIS; KNCKRIGISP; NCKRIGISPN; CKRIGISPNS;KRIGISPNSF; RIGISPNSFA; IGISPNSFAR; GISPNSFARP; ISPNSFARPQ;SPNSFARPQK; PNSFARPQKK; NSFARPQKKP; SFARPQKKPP; FARPQKKPPH;ARPQKKPPHP; RPQKKPPHPY; PQKKPPHPYY; QKKPPHPYYL; KKPPHPYYLR;KPPHPYYLRE; PPHPYYLRER; PHPYYLRERV; HPYYLRERVE; PYYLRERVEA;YYLRERVEAE; YLRERVEAEA; LRERVEAEAA; RERVEAEAAS; ERVEAEAASA;RVEAEAASAS; VEAEAASASY; EAEAASASYI; AEAASASYIL; KKRPQGGAAY;KRPQGGAAYP; RPQGGAAYPW; PQGGAAYPWN; QGGAAYPWNA; GGAAYPWNAA;GAAYPWNAAK; AAYPWNAAKP; PQEGKCMTHR; QEGKCMTHRG; EGKCMTHRGM;GKCMTHRGMQ; KCMTHRGMQP; CMTHRGMQPN; MTHRGMQPNH; THRGMQPNHD;HRGMQPNHDL; RGMQPNHDLR; GMQPNHDLRK; MQPNHDLRKE; QPNHDLRKES;PNHDLRKESA; LTGRSCLPME; TGRSCLPMEC; GRSCLPMECS; RSCLPMECSQ;SCLPMECSQT; CLPMECSQTM; LPMECSQTMT; PMECSQTMTS; MECSQTMTSG;ECSQTMTSGR; CSQTMTSGRK; SQTMTSGRKV; QTMTSGRKVH; TMTSGRKVHD;MTSGRKVHDR; TSGRKVHDRH; SGRKVHDRHV; GRKVHDRHVL; RKVHDRHVLR;KVHDRHVLRA; ESWPCPQLNW; SWPCPQLNWT; WPCPQLNWTK; PCPQLNWTKA;CPQLNWTKAM; PQLNWTKAMV; QLNWTKAMVL; LNWTKAMVLR; NWTKAMVLRQ;WTKAMVLRQL; TKAMVLRQLS; KAMVLRQLSR; AMVLRQLSRQ; MVLRQLSRQA;VLRQLSRQAS; LRQLSRQASV; RQLSRQASVK; QLSRQASVKV; LSRQASVKVG;SRQASVKVGK; RQASVKVGKT; QASVKVGKTW; ASVKVGKTWT; SVKVGKTWTG;VKVGKTWTGT; KVGKTWTGTK; VGKTWTGTKK; GKTWTGTKKR; KTWTGTKKRA;TWTGTKKRAQ; WTGTKKRAQR; TGTKKRAQRI; GTKKRAQRIF; TKKRAQRIFI;KKRAQRIFIF; KRAQRIFIFI; RAQRIFIFIL; AQRIFIFILE; QRIFIFILEL;RIFIFILELL; IFIFILELLL; FIFILELLLE; IFILELLLEF; FILELLLEFC;ILELLLEFCR; LELLLEFCRG; ELLLEFCRGE; LLLEFCRGED; LLEFCRGEDS;LEFCRGEDSV; EFCRGEDSVD; FCRGEDSVDG; CRGEDSVDGK; RGEDSVDGKN;GEDSVDGKNK; EDSVDGKNKS; DSVDGKNKST; SVDGKNKSTT; VDGKNKSTTA;DGKNKSTTAL; GKNKSTTALP; KNKSTTALPA; NKSTTALPAV; KSTTALPAVK;STTALPAVKD; TTALPAVKDS; TALPAVKDSV; ALPAVKDSVK; LPAVKDSVKD;PAVKDSVKDS; VSNPFFFVFP; SNPFFFVFPG; NPFFFVFPGS; PFFFVFPGSW;FFFVFPGSWV; FFVFPGSWVL; FVFPGSWVLL; LPVYLRLLLP; PVYLRLLLPQ;VYLRLLLPQD; YLRLLLPQDF; LRLLLPQDFQ; RLLLPQDFQW; LLLPQDFQWL;LLPQDFQWLK; LPQDFQWLKL; PQDFQWLKLL; QDFQWLKLLL; DFQWLKLLLG;FQWLKLLLGR; QWLKLLLGRL; WLKLLLGRLL; LKLLLGRLLL; KLLLGRLLLL;LLVLLGLLLG; LVLLGLLLGL; VLLGLLLGLL; LLGLLLGLLL; GISSLMIGIT;ISSLMIGITK; SSLMIGITKF; SLMIGITKFP; LMIGITKFPL; ASISNQAWLW;SISNQAWLWN; ISNQAWLWNC; SNQAWLWNCL; NQAWLWNCLT; QAWLWNCLTQ;AWLWNCLTQM; WLWNCLTQMS; LWNCLTQMST; WNCLTQMSTM; NCLTQMSTMI;CLTQMSTMIF; LTQMSTMIFC; TQMSTMIFCF; QMSTMIFCFL; MSTMIFCFLV;ILLLIIFNTL; LLLIIFNTLI; LLIIFNTLIL; LIIFNTLILG; IIFNTLILGI;IFNTLILGIG; FNTLILGIGV; NTLILGIGVL; TLILGIGVLL; LILGIGVLLC;ILGIGVLLCL; LGIGVLLCLL; GIGVLLCLLL; IGVLLCLLLF; GVLLCLLLFP;VLLCLLLFPR; LLCLLLFPRL; LCLLLFPRLC; CLLLFPRLCG; LLLFPRLCGM;LLFPRLCGML; LFPRLCGMLL; FPRLCGMLLG; PRLCGMLLGM; RLCGMLLGMI;LCGMLLGMIY; CGMLLGMIYL; GMLLGMIYLL; PHRNCREEQK; HRNCREEQKD;RNCREEQKDF; NCREEQKDFL; CREEQKDFLE; REEQKDFLET; EEQKDFLETP;EQKDFLETPW; QKDFLETPWL; KDFLETPWLD; DFLETPWLDF; FLETPWLDFW;LETPWLDFWR; ETPWLDFWRK; TPWLDFWRKL; PWLDFWRKLP; WLDFWRKLPG;LDFWRKLPGQ; DFWRKLPGQL; TFIIIFNNII; FIIIFNNIIL; IIIFNNIILI;IIFNNIILIF; IFNNIILIFP; FNNIILIFPL; NNIILIFPLL; NIILIFPLLG;IILIFPLLGP; ILIFPLLGPQ; LIFPLLGPQW; IFPLLGPQWL; FPLLGPQWLD;PLLGPQWLDK; LKGKVPVYIL; KGKVPVYILA; GKVPVYILAI; KVPVYILAIL;VPVYILAILI; PVYILAILIV; EINKVYIQES; INKVYIQESL; KKLLPQEVLI;KLLPQEVLIK; LLPQEVLIKE; LPQEVLIKEL; PQEVLIKELL; QEVLIKELLL;EVLIKELLLN; VLIKELLLNG; LIKELLLNGC; IKELLLNGCC; KELLLNGCCL;ELLLNGCCLY; LLLNGCCLYF; HLLLKHMKMA; LLLKHMKMAP; LLKHMKMAPT;LKHMKMAPTK; KHMKMAPTKR; HMKMAPTKRK; MKMAPTKRKG; KMAPTKRKGE;MAPTKRKGEC; APTKRKGECP; PTKRKGECPG; TKRKGECPGA; KRKGECPGAA;RKGECPGAAP; KGECPGAAPK; GECPGAAPKK; ECPGAAPKKP; CPGAAPKKPK;PGAAPKKPKE; GAAPKKPKEP; AAPKKPKEPV; APKKPKEPVQ; PKKPKEPVQV;KKPKEPVQVP; KPKEPVQVPK; PKEPVQVPKL; KEPVQVPKLL; EPVQVPKLLI;PVQVPKLLIK; VQVPKLLIKG; QVPKLLIKGG; VPKLLIKGGV; PKLLIKGGVE;KLLIKGGVEV; LLIKGGVEVL; LIKGGVEVLE; IKGGVEVLEV; KGGVEVLEVK;GGVEVLEVKT; GVEVLEVKTG; VEVLEVKTGV; EVLEVKTGVD; VLEVKTGVDA;LEVKTGVDAI; EVKTGVDAIT; VKTGVDAITE; KTGVDAITEV; TGVDAITEVE;GVDAITEVEC; VDAITEVECF; DAITEVECFL; AITEVECFLN; ITEVECFLNP;TEVECFLNPE; EVECFLNPEM; VECFLNPEMG; ECFLNPEMGD; CFLNPEMGDP;FLNPEMGDPD; LNPEMGDPDE; NPEMGDPDEN; PEMGDPDENL; EMGDPDENLR;MGDPDENLRG; GDPDENLRGF; DPDENLRGFS; PDENLRGFSL; DENLRGFSLK;ENLRGFSLKL; NLRGFSLKLS; LRGFSLKLSA; RGFSLKLSAE; GFSLKLSAEN;FSLKLSAEND; SLKLSAENDF; LKLSAENDFS; KLSAENDFSS; LSAENDFSSD;SAENDFSSDS; AENDFSSDSP; ENDFSSDSPE; NDFSSDSPER; DFSSDSPERK;FSSDSPERKM; SSDSPERKML; SDSPERKMLP; DSPERKMLPC; SPERKMLPCY;PERKMLPCYS; ERKMLPCYST; RKMLPCYSTA; KMLPCYSTAR; MLPCYSTARI;LPCYSTARIP; PCYSTARIPL; CYSTARIPLP; YSTARIPLPN; STARIPLPNL;TARIPLPNLN; ARIPLPNLNE; RIPLPNLNED; IPLPNLNEDL; PLPNLNEDLT;LPNLNEDLTC; PNLNEDLTCG; NLNEDLTCGN; LNEDLTCGNL; NEDLTCGNLL;EDLTCGNLLM; DLTCGNLLMW; LTCGNLLMWE; TCGNLLMWEA; CGNLLMWEAV;GNLLMWEAVT; NLLMWEAVTV; LLMWEAVTVQ; LMWEAVTVQT; MWEAVTVQTE;WEAVTVQTEV; EAVTVQTEVI; AVTVQTEVIG; VTVQTEVIGI; TVQTEVIGIT;VQTEVIGITS; QTEVIGITSM; TEVIGITSML; EVIGITSMLN; VIGITSMLNL;IGITSMLNLH; GITSMLNLHA; ITSMLNLHAG; TSMLNLHAGS; SMLNLHAGSQ;MLNLHAGSQK; LNLHAGSQKV; NLHAGSQKVH; LHAGSQKVHE; HAGSQKVHEH;AGSQKVHEHG; GSQKVHEHGG; SQKVHEHGGG; QKVHEHGGGK; KVHEHGGGKP;VHEHGGGKPI; HEHGGGKPIQ; EHGGGKPIQG; HGGGKPIQGS; GGGKPIQGSN;GGKPIQGSNF; GKPIQGSNFH; KPIQGSNFHF; PIQGSNFHFF; IQGSNFHFFA;QGSNFHFFAV; GSNFHFFAVG; SNFHFFAVGG; NFHFFAVGGE; FHFFAVGGEP;HFFAVGGEPL; FFAVGGEPLE; FAVGGEPLEM; AVGGEPLEMQ; VGGEPLEMQG;GGEPLEMQGV; GEPLEMQGVL; EPLEMQGVLM; PLEMQGVLMN; LEMQGVLMNY;EMQGVLMNYR; MQGVLMNYRS; QGVLMNYRSK; GVLMNYRSKY; VLMNYRSKYP;LMNYRSKYPD; MNYRSKYPDG; NYRSKYPDGT; YRSKYPDGTI; RSKYPDGTIT;SKYPDGTITP; KYPDGTITPK; YPDGTITPKN; PDGTITPKNP; DGTITPKNPT;GTITPKNPTA; TITPKNPTAQ; ITPKNPTAQS; TPKNPTAQSQ; PKNPTAQSQV;KNPTAQSQVM; NPTAQSQVMN; PTAQSQVMNT; TAQSQVMNTD; AQSQVMNTDH;QSQVMNTDHK; SQVMNTDHKA; QVMNTDHKAY; VMNTDHKAYL; MNTDHKAYLD;NTDHKAYLDK; TDHKAYLDKN; DHKAYLDKNN; HKAYLDKNNA; KAYLDKNNAY;AYLDKNNAYP; YLDKNNAYPV; LDKNNAYPVE; DKNNAYPVEC; KNNAYPVECW;NNAYPVECWV; NAYPVECWVP; AYPVECWVPD; YPVECWVPDP; PVECWVPDPS;VECWVPDPSR; ECWVPDPSRN; CWVPDPSRNE; WVPDPSRNEN; VPDPSRNENA;PDPSRNENAR; DPSRNENARY; PSRNENARYF; SRNENARYFG; RNENARYFGT;NENARYFGTF; ENARYFGTFT; NARYFGTFTG; ARYFGTFTGG; RYFGTFTGGE;YFGTFTGGEN; FGTFTGGENV; GTFTGGENVP; TFTGGENVPP; FTGGENVPPV;TGGENVPPVL; GGENVPPVLH; GENVPPVLHV; ENVPPVLHVT; NVPPVLHVTN;VPPVLHVTNT; PPVLHVTNTA; PVLHVTNTAT; VLHVTNTATT; LHVTNTATTV;HVTNTATTVL; VTNTATTVLL; TNTATTVLLD; NTATTVLLDE; TATTVLLDEQ;ATTVLLDEQG; TTVLLDEQGV; TVLLDEQGVG; VLLDEQGVGP; LLDEQGVGPL;LDEQGVGPLC; DEQGVGPLCK; EQGVGPLCKA; QGVGPLCKAD; GVGPLCKADS;VGPLCKADSL; GPLCKADSLY; PLCKADSLYV; LCKADSLYVS; CKADSLYVSA;KADSLYVSAA; ADSLYVSAAD; DSLYVSAADI; SLYVSAADIC; LYVSAADICG;YVSAADICGL; VSAADICGLF; SAADICGLFT; AADICGLFTN; ADICGLFTNS;DICGLFTNSS; ICGLFTNSSG; CGLFTNSSGT; GLFTNSSGTQ; LFTNSSGTQQ;FTNSSGTQQW; TNSSGTQQWR; NSSGTQQWRG; SSGTQQWRGL; SGTQQWRGLA;GTQQWRGLAR; TQQWRGLARY; QQWRGLARYF; QWRGLARYFK; WRGLARYFKI;RGLARYFKIR; GLARYFKIRL; LARYFKIRLR; ARYFKIRLRK; RYFKIRLRKR;YFKIRLRKRS; FKIRLRKRSV; KIRLRKRSVK; IRLRKRSVKN; RLRKRSVKNP;LRKRSVKNPY; RKRSVKNPYP; KRSVKNPYPI; RSVKNPYPIS; SVKNPYPISF;VKNPYPISFL; KNPYPISFLL; NPYPISFLLS; PYPISFLLSD; YPISFLLSDL;PISFLLSDLI; ISFLLSDLIN; SFLLSDLINR; FLLSDLINRR; LLSDLINRRT;LSDLINRRTQ; SDLINRRTQR; DLINRRTQRV; LINRRTQRVD; INRRTQRVDG;NRRTQRVDGQ; RRTQRVDGQP; RTQRVDGQPM; TQRVDGQPMY; QRVDGQPMYG;RVDGQPMYGM; VDGQPMYGME; DGQPMYGMES; GQPMYGMESQ; QPMYGMESQV;PMYGMESQVE; MYGMESQVEE; YGMESQVEEV; GMESQVEEVR; MESQVEEVRV;ESQVEEVRVF; SQVEEVRVFD; QVEEVRVFDG; VEEVRVFDGT; EEVRVFDGTE;EVRVFDGTER; VRVFDGTERL; RVFDGTERLP; VFDGTERLPG; FDGTERLPGD;DGTERLPGDP; GTERLPGDPD; TERLPGDPDM; ERLPGDPDMI; RLPGDPDMIR;LPGDPDMIRY; PGDPDMIRYI; GDPDMIRYID; DPDMIRYIDK; PDMIRYIDKQ;DMIRYIDKQG; MIRYIDKQGQ; IRYIDKQGQL; RYIDKQGQLQ; YIDKQGQLQT;IDKQGQLQTK; DKQGQLQTKM; KQGQLQTKML; TGAFIVHIHL; GAFIVHIHLI;AFIVHIHLIN; FIVHIHLINA; IVHIHLINAA; VHIHLINAAF; HIHLINAAFV;ATFKLVLFWG; TFKLVLFWGW; FKLVLFWGWC; KLVLFWGWCF; LVLFWGWCFR;VLFWGWCFRP; LFWGWCFRPF; FWGWCFRPFK; WGWCFRPFKT; GWCFRPFKTL;WCFRPFKTLK; CFRPFKTLKA; FRPFKTLKAF; RPFKTLKAFT; PFKTLKAFTQ;FKTLKAFTQM; KTLKAFTQMQ; TLKAFTQMQL; LKAFTQMQLL; KAFTQMQLLT;AFTQMQLLTM; FTQMQLLTMG; TQMQLLTMGV; ILFSCNIKNT; LFSCNIKNTF;FSCNIKNTFP; SCNIKNTFPH; CNIKNTFPHA; NIKNTFPHAY; IKNTFPHAYI;KNTFPHAYII; NTFPHAYIIF; TFPHAYIIFH; FPHAYIIFHP; KSIHTYLRIQ;SIHTYLRIQP; IHTYLRIQPF; HTYLRIQPFL; TYLRIQPFLP; YLRIQPFLPF;LRIQPFLPFN; RIQPFLPFNN; IQPFLPFNNS; QPFLPFNNSR; PFLPFNNSRL;FLPFNNSRLY; LPFNNSRLYI; PFNNSRLYIS; FNNSRLYISC; NNSRLYISCK;NSRLYISCKI; SRLYISCKIS; RLYISCKISY; LYISCKISYR; YISCKISYRP;ISCKISYRPK; SCKISYRPKP; CKISYRPKPN; IYFGPKIYLS; YFGPKIYLSY;FGPKIYLSYK; GPKIYLSYKS; PKIYLSYKSS; KIYLSYKSSL; IYLSYKSSLQ;YLSYKSSLQG; LSYKSSLQGF; SYKSSLQGFR; YKSSLQGFRD; KSSLQGFRDR;SSLQGFRDRI; SLQGFRDRIL; LQGFRDRILI; QGFRDRILIH; GFRDRILIHC;FRDRILIHCN; RDRILIHCNQ; DRILIHCNQA; RILIHCNQAW; ILIHCNQAWW;LIHCNQAWWK; IHCNQAWWKY; HCNQAWWKYL; CNQAWWKYLG; NQAWWKYLGS;QAWWKYLGSF; AWWKYLGSFV; FSSCPFYIFK; SSCPFYIFKN; SCPFYIFKNN;CPFYIFKNNH; PFYIFKNNHV; FYIFKNNHVL; YIFKNNHVLI; IFKNNHVLIY;FKNNHVLIYS; KNNHVLIYSY; NNHVLIYSYT; CCFSTINGTF; CFSTINGTFK;PVSSFRYIEN; VSSFRYIENN; SSFRYIENNT; SFRYIENNTV; FRYIENNTVQ;RYIENNTVQK; YIENNTVQKI; IENNTVQKIK; ENNTVQKIKY; NNTVQKIKYY;NTVQKIKYYR; TVQKIKYYRI; VQKIKYYRIH; QKIKYYRIHF; KIKYYRIHFR;QTVQPSNTCH; TVQPSNTCHI; VQPSNTCHIL; QPSNTCHILF; HFFPGHMKGI;FFPGHMKGIY; FPGHMKGIYS; PGHMKGIYSF; GHMKGIYSFF; HMKGIYSFFS;NCIYCLLTNT; CIYCLLTNTF; IYCLLTNTFL; YCLLTNTFLI; CLLTNTFLIF;LLTNTFLIFT; LTNTFLIFTF; TNTFLIFTFC; NTFLIFTFCK; TFLIFTFCKN;FLIFTFCKNN; LIFTFCKNNS; IFTFCKNNSI; FTFCKNNSIC; TFCKNNSICK;FCKNNSICKV; CKNNSICKVL; KNNSICKVLF; NNSICKVLFM; NSICKVLFMI;SICKVLFMIL; ICKVLFMILK; CKVLFMILKV; KVLFMILKVI; VLFMILKVIR;LFMILKVIRL; FMILKVIRLV; MILKVIRLVF; ILKVIRLVFF; LKVIRLVFFL;KVIRLVFFLT; VIRLVFFLTL; IRLVFFLTLF; RLVFFLTLFT; LVFFLTLFTL;VFFLTLFTLL; FFLTLFTLLY; FLTLFTLLYI; LTLFTLLYIV; TLFTLLYIVL;LFTLLYIVLK; FTLLYIVLKF; KHILTLCLYC; HILTLCLYCI; ILTLCLYCIL;LTLCLYCILS; TLCLYCILSN; FPRHLLCFFR; PRHLLCFFRL; RHLLCFFRLF;HLLCFFRLFW; LLCFFRLFWA; LCFFRLFWAK; CFFRLFWAKI; FFRLFWAKIM;FRLFWAKIML; RLFWAKIMLL; APLNAFFYSM; PLNAFFYSMV; LNAFFYSMVW;NAFFYSMVWI; AFFYSMVWIS; FFYSMVWISS; KTKGTQLLTE; TKGTQLLTEI;KGTQLLTEII; GTQLLTEIIN; TQLLTEIINC; QLLTEIINCR; LLTEIINCRN;LTEIINCRNS; TEIINCRNSM; EIINCRNSMS; IINCRNSMSM; INCRNSMSMW;NCRNSMSMWS; KEYNIMPSTH; EYNIMPSTHV; YNIMPSTHVS; NIMPSTHVST;IMPSTHVSTN; MPSTHVSTNK; PSTHVSTNKS; STHVSTNKSY; THVSTNKSYR;HVSTNKSYRI; VSTNKSYRIF; STNKSYRIFF; TNKSYRIFFH; NKSYRIFFHK;KSYRIFFHKF; SYRIFFHKFF; YRIFFHKFFI; RIFFHKFFIQ; IFFHKFFIQN;FFHKFFIQNL; FHKFFIQNLS; HKFFIQNLSF; KFFIQNLSFF; FFIQNLSFFF;FIQNLSFFFS; IQNLSFFFSS; QNLSFFFSSI; NLSFFFSSIH; LSFFFSSIHS;SFFFSSIHSK; FFFSSIHSKA; FFSSIHSKAG; FSSIHSKAGK; SSIHSKAGKG;SIHSKAGKGS; IHSKAGKGSI; HSKAGKGSIT; SKAGKGSITK; KAGKGSITKY;AGKGSITKYS; GKGSITKYSL; KGSITKYSLT; GSITKYSLTK; SITKYSLTKK;ITKYSLTKKL; TKYSLTKKLV; IRGKVFRVFY; RGKVFRVFYL; GKVFRVFYLS;KVFRVFYLSF; VFRVFYLSFF; FRVFYLSFFF; RVFYLSFFFG; VFYLSFFFGW;FYLSFFFGWC; VLRICCCFFI; LRICCCFFIT; RICCCFFITG; ICCCFFITGK;CCCFFITGKH; CCFFITGKHI; CFFITGKHIF; FFITGKHIFM; FITGKHIFMA;ITGKHIFMAK; IFIPFFIKGT; FIPFFIKGTP; IPFFIKGTPP; PFFIKGTPPG;FFIKGTPPGL; FIKGTPPGLP; IKGTPPGLPL; KGTPPGLPLF; GTPPGLPLFC;TPPGLPLFCS; PPGLPLFCSI; PGLPLFCSIG; GLPLFCSIGW; LPLFCSIGWH;PLFCSIGWHL; SFRSLKGVSP; FRSLKGVSPI; RSLKGVSPII; SLKGVSPIIW;LKGVSPIIWT; KGVSPIIWTH; GVSPIIWTHH; VSPIIWTHHC; SPIIWTHHCR;PIIWTHHCRV; IIWTHHCRVS; IWTHHCRVSS; WTHHCRVSSV; THHCRVSSVR;HHCRVSSVRS; HCRVSSVRSK; CRVSSVRSKP; RVSSVRSKPN; VSSVRSKPNH;SSVRSKPNHC; SVRSKPNHCV; VRSKPNHCVK; RSKPNHCVKQ; SKPNHCVKQS;KPNHCVKQSM; PNHCVKQSMQ; QSIQTKGSFL; SIQTKGSFLK; IQTKGSFLKN;QTKGSFLKNF; TKGSFLKNFL; KGSFLKNFLF; GSFLKNFLFK; SFLKNFLFKC;FLKNFLFKCL; LKNFLFKCLN; KNFLFKCLNL; NFLFKCLNLS; HSMQGQCTEG;SMQGQCTEGF; MQGQCTEGFL; QGQCTEGFLE; GQCTEGFLEQ; QCTEGFLEQI;CTEGFLEQIG; TEGFLEQIGH; EGFLEQIGHS; GFLEQIGHSL; FLEQIGHSLQ;LEQIGHSLQY; EQIGHSLQYR; QIGHSLQYRV; IGHSLQYRVS; GHSLQYRVSG;HSLQYRVSGQ; SLQYRVSGQR; LQYRVSGQRG; QYRVSGQRGK; YRVSGQRGKS;RVSGQRGKSA; VSGQRGKSAQ; SGQRGKSAQT; GQRGKSAQTS; QRGKSAQTSE;RGKSAQTSEL; GKSAQTSELL; KSAQTSELLQ; SAQTSELLQV; AQTSELLQVP;QTSELLQVPK; TSELLQVPKS; SELLQVPKSG; ATFTSCSIFL; TFTSCSIFLY;FTSCSIFLYK; TSCSIFLYKV; SCSIFLYKVF; CSIFLYKVFI; SIFLYKVFIL;IFLYKVFILF; FLYKVFILFI; LYKVFILFIL; YKVFILFILS; KVFILFILSS;VFILFILSSS; FILFILSSSP; ILFILSSSPP; LFILSSSPPL; FILSSSPPLS;ILSSSPPLSG; AFLIKGRFPQ; FLIKGRFPQA; LIKGRFPQAA; IKGRFPQAAL;KGRFPQAALS; GRFPQAALSR; RFPQAALSRP; FPQAALSRPK; PQAALSRPKR;QAALSRPKRS; AALSRPKRSM; ALSRPKRSMS; LSRPKRSMSS; SRPKRSMSSM;RPKRSMSSMD; PKRSMSSMDS; KRSMSSMDSS; RSMSSMDSSL; SMSSMDSSLL;MSSMDSSLLR; SSMDSSLLRT; SMDSSLLRTL; MDSSLLRTLS 11 mers:FCKNCKRIGIS; CKNCKRIGISP; KNCKRIGISPN; NCKRIGISPNS; CKRIGISPNSF;KRIGISPNSFA; RIGISPNSFAR; IGISPNSFARP; GISPNSFARPQ; ISPNSFARPQK;SPNSFARPQKK; PNSFARPQKKP; NSFARPQKKPP; SFARPQKKPPH; FARPQKKPPHP;ARPQKKPPHPY; RPQKKPPHPYY; PQKKPPHPYYL; QKKPPHPYYLR; KKPPHPYYLRE;KPPHPYYLRER; PPHPYYLRERV; PHPYYLRERVE; HPYYLRERVEA; PYYLRERVEAE;YYLRERVEAEA; YLRERVEAEAA; LRERVEAEAAS; RERVEAEAASA; ERVEAEAASAS;RVEAEAASASY; VEAEAASASYI; EAEAASASYIL; KKRPQGGAAYP; KRPQGGAAYPW;RPQGGAAYPWN; PQGGAAYPWNA; QGGAAYPWNAA; GGAAYPWNAAK; GAAYPWNAAKP;PQEGKCMTHRG; QEGKCMTHRGM; EGKCMTHRGMQ; GKCMTHRGMQP; KCMTHRGMQPN;CMTHRGMQPNH; MTHRGMQPNHD; THRGMQPNHDL; HRGMQPNHDLR; RGMQPNHDLRK;GMQPNHDLRKE; MQPNHDLRKES; QPNHDLRKESA; LTGRSCLPMEC; TGRSCLPMECS;GRSCLPMECSQ; RSCLPMECSQT; SCLPMECSQTM; CLPMECSQTMT; LPMECSQTMTS;PMECSQTMTSG; MECSQTMTSGR; ECSQTMTSGRK; CSQTMTSGRKV; SQTMTSGRKVH;QTMTSGRKVHD; TMTSGRKVHDR; MTSGRKVHDRH; TSGRKVHDRHV; SGRKVHDRHVL;GRKVHDRHVLR; RKVHDRHVLRA; ESWPCPQLNWT; SWPCPQLNWTK; WPCPQLNWTKA;PCPQLNWTKAM; CPQLNWTKAMV; PQLNWTKAMVL; QLNWTKAMVLR; LNWTKAMVLRQ;NWTKAMVLRQL; WTKAMVLRQLS; TKAMVLRQLSR; KAMVLRQLSRQ; AMVLRQLSRQA;MVLRQLSRQAS; VLRQLSRQASV; LRQLSRQASVK; RQLSRQASVKV; QLSRQASVKVG;LSRQASVKVGK; SRQASVKVGKT; RQASVKVGKTW; QASVKVGKTWT; ASVKVGKTWTG;SVKVGKTWTGT; VKVGKTWTGTK; KVGKTWTGTKK; VGKTWTGTKKR; GKTWTGTKKRA;KTWTGTKKRAQ; TWTGTKKRAQR; WTGTKKRAQRI; TGTKKRAQRIF; GTKKRAQRIFI;TKKRAQRIFIF; KKRAQRIFIFI; KRAQRIFIFIL; RAQRIFIFILE; AQRIFIFILEL;QRIFIFILELL; RIFIFILELLL; IFIFILELLLE; FIFILELLLEF; IFILELLLEFC;FILELLLEFCR; ILELLLEFCRG; LELLLEFCRGE; ELLLEFCRGED; LLLEFCRGEDS;LLEFCRGEDSV; LEFCRGEDSVD; EFCRGEDSVDG; FCRGEDSVDGK; CRGEDSVDGKN;RGEDSVDGKNK; GEDSVDGKNKS; EDSVDGKNKST; DSVDGKNKSTT; SVDGKNKSTTA;VDGKNKSTTAL; DGKNKSTTALP; GKNKSTTALPA; KNKSTTALPAV; NKSTTALPAVK;KSTTALPAVKD; STTALPAVKDS; TTALPAVKDSV; TALPAVKDSVK; ALPAVKDSVKD;LPAVKDSVKDS; VSNPFFFVFPG; SNPFFFVFPGS; NPFFFVFPGSW; PFFFVFPGSWV;FFFVFPGSWVL; FFVFPGSWVLL; LPVYLRLLLPQ; PVYLRLLLPQD; VYLRLLLPQDF;YLRLLLPQDFQ; LRLLLPQDFQW; RLLLPQDFQWL; LLLPQDFQWLK; LLPQDFQWLKL;LPQDFQWLKLL; PQDFQWLKLLL; QDFQWLKLLLG; DFQWLKLLLGR; FQWLKLLLGRL;QWLKLLLGRLL; WLKLLLGRLLL; LKLLLGRLLLL; LLVLLGLLLGL; LVLLGLLLGLL;VLLGLLLGLLL; GISSLMIGITK; ISSLMIGITKF; SSLMIGITKFP; SLMIGITKFPL;ASISNQAWLWN; SISNQAWLWNC; ISNQAWLWNCL; SNQAWLWNCLT; NQAWLWNCLTQ;QAWLWNCLTQM; AWLWNCLTQMS; WLWNCLTQMST; LWNCLTQMSTM; WNCLTQMSTMI;NCLTQMSTMIF; CLTQMSTMIFC; LTQMSTMIFCF; TQMSTMIFCFL; QMSTMIFCFLV;ILLLIIFNTLI; LLLIIFNTLIL; LLIIFNTLILG; LIIFNTLILGI; IIFNTLILGIG;IFNTLILGIGV; FNTLILGIGVL; NTLILGIGVLL; TLILGIGVLLC; LILGIGVLLCL;ILGIGVLLCLL; LGIGVLLCLLL; GIGVLLCLLLF; IGVLLCLLLFP; GVLLCLLLFPR;VLLCLLLFPRL; LLCLLLFPRLC; LCLLLFPRLCG; CLLLFPRLCGM; LLLFPRLCGML;LLFPRLCGMLL; LFPRLCGMLLG; FPRLCGMLLGM; PRLCGMLLGMI; RLCGMLLGMIY;LCGMLLGMIYL; CGMLLGMIYLL; PHRNCREEQKD; HRNCREEQKDF; RNCREEQKDFL;NCREEQKDFLE; CREEQKDFLET; REEQKDFLETP; EEQKDFLETPW; EQKDFLETPWL;QKDFLETPWLD; KDFLETPWLDF; DFLETPWLDFW; FLETPWLDFWR; LETPWLDFWRK;ETPWLDFWRKL; TPWLDFWRKLP; PWLDFWRKLPG; WLDFWRKLPGQ; LDFWRKLPGQL;TFIIIFNNIIL; FIIIFNNIILI; IIIFNNIILIF; IIFNNIILIFP; IFNNIILIFPL;FNNIILIFPLL; NNIILIFPLLG; NIILIFPLLGP; IILIFPLLGPQ; ILIFPLLGPQW;LIFPLLGPQWL; IFPLLGPQWLD; FPLLGPQWLDK; LKGKVPVYILA; KGKVPVYILAI;GKVPVYILAIL; KVPVYILAILI; VPVYILAILIV; EINKVYIQESL; KKLLPQEVLIK;KLLPQEVLIKE; LLPQEVLIKEL; LPQEVLIKELL; PQEVLIKELLL; QEVLIKELLLN;EVLIKELLLNG; VLIKELLLNGC; LIKELLLNGCC; IKELLLNGCCL; KELLLNGCCLY;ELLLNGCCLYF; HLLLKHMKMAP; LLLKHMKMAPT; LLKHMKMAPTK; LKHMKMAPTKR;KHMKMAPTKRK; HMKMAPTKRKG; MKMAPTKRKGE; KMAPTKRKGEC; MAPTKRKGECP;APTKRKGECPG; PTKRKGECPGA; TKRKGECPGAA; KRKGECPGAAP; RKGECPGAAPK;KGECPGAAPKK; GECPGAAPKKP; ECPGAAPKKPK; CPGAAPKKPKE; PGAAPKKPKEP;GAAPKKPKEPV; AAPKKPKEPVQ; APKKPKEPVQV; PKKPKEPVQVP; KKPKEPVQVPK;KPKEPVQVPKL; PKEPVQVPKLL; KEPVQVPKLLI; EPVQVPKLLIK; PVQVPKLLIKG;VQVPKLLIKGG; QVPKLLIKGGV; VPKLLIKGGVE; PKLLIKGGVEV; KLLIKGGVEVL;LLIKGGVEVLE; LIKGGVEVLEV; IKGGVEVLEVK; KGGVEVLEVKT; GGVEVLEVKTG;GVEVLEVKTGV; VEVLEVKTGVD; EVLEVKTGVDA; VLEVKTGVDAI; LEVKTGVDAIT;EVKTGVDAITE; VKTGVDAITEV; KTGVDAITEVE; TGVDAITEVEC; GVDAITEVECF;VDAITEVECFL; DAITEVECFLN; AITEVECFLNP; ITEVECFLNPE; TEVECFLNPEM;EVECFLNPEMG; VECFLNPEMGD; ECFLNPEMGDP; CFLNPEMGDPD; FLNPEMGDPDE;LNPEMGDPDEN; NPEMGDPDENL; PEMGDPDENLR; EMGDPDENLRG; MGDPDENLRGF;GDPDENLRGFS; DPDENLRGFSL; PDENLRGFSLK; DENLRGFSLKL; ENLRGFSLKLS;NLRGFSLKLSA; LRGFSLKLSAE; RGFSLKLSAEN; GFSLKLSAEND; FSLKLSAENDF;SLKLSAENDFS; LKLSAENDFSS; KLSAENDFSSD; LSAENDFSSDS; SAENDFSSDSP;AENDFSSDSPE; ENDFSSDSPER; NDFSSDSPERK; DFSSDSPERKM; FSSDSPERKML;SSDSPERKMLP; SDSPERKMLPC; DSPERKMLPCY; SPERKMLPCYS; PERKMLPCYST;ERKMLPCYSTA; RKMLPCYSTAR; KMLPCYSTARI; MLPCYSTARIP; LPCYSTARIPL;PCYSTARIPLP; CYSTARIPLPN; YSTARIPLPNL; STARIPLPNLN; TARIPLPNLNE;ARIPLPNLNED; RIPLPNLNEDL; IPLPNLNEDLT; PLPNLNEDLTC; LPNLNEDLTCG;PNLNEDLTCGN; NLNEDLTCGNL; LNEDLTCGNLL; NEDLTCGNLLM; EDLTCGNLLMW;DLTCGNLLMWE; LTCGNLLMWEA; TCGNLLMWEAV; CGNLLMWEAVT; GNLLMWEAVTV;NLLMWEAVTVQ; LLMWEAVTVQT; LMWEAVTVQTE; MWEAVTVQTEV; WEAVTVQTEVI;EAVTVQTEVIG; AVTVQTEVIGI; VTVQTEVIGIT; TVQTEVIGITS; VQTEVIGITSM;QTEVIGITSML; TEVIGITSMLN; EVIGITSMLNL; VIGITSMLNLH; IGITSMLNLHA;GITSMLNLHAG; ITSMLNLHAGS; TSMLNLHAGSQ; SMLNLHAGSQK; MLNLHAGSQKV;LNLHAGSQKVH; NLHAGSQKVHE; LHAGSQKVHEH; HAGSQKVHEHG; AGSQKVHEHGG;GSQKVHEHGGG; SQKVHEHGGGK; QKVHEHGGGKP; KVHEHGGGKPI; VHEHGGGKPIQ;HEHGGGKPIQG; EHGGGKPIQGS; HGGGKPIQGSN; GGGKPIQGSNF; GGKPIQGSNFH;GKPIQGSNFHF; KPIQGSNFHFF; PIQGSNFHFFA; IQGSNFHFFAV; QGSNFHFFAVG;GSNFHFFAVGG; SNFHFFAVGGE; NFHFFAVGGEP; FHFFAVGGEPL; HFFAVGGEPLE;FFAVGGEPLEM; FAVGGEPLEMQ; AVGGEPLEMQG; VGGEPLEMQGV; GGEPLEMQGVL;GEPLEMQGVLM; EPLEMQGVLMN; PLEMQGVLMNY; LEMQGVLMNYR; EMQGVLMNYRS;MQGVLMNYRSK; QGVLMNYRSKY; GVLMNYRSKYP; VLMNYRSKYPD; LMNYRSKYPDG;MNYRSKYPDGT; NYRSKYPDGTI; YRSKYPDGTIT; RSKYPDGTITP; SKYPDGTITPK;KYPDGTITPKN; YPDGTITPKNP; PDGTITPKNPT; DGTITPKNPTA; GTITPKNPTAQ;TITPKNPTAQS; ITPKNPTAQSQ; TPKNPTAQSQV; PKNPTAQSQVM; KNPTAQSQVMN;NPTAQSQVMNT; PTAQSQVMNTD; TAQSQVMNTDH; AQSQVMNTDHK; QSQVMNTDHKA;SQVMNTDHKAY; QVMNTDHKAYL; VMNTDHKAYLD; MNTDHKAYLDK; NTDHKAYLDKN;TDHKAYLDKNN; DHKAYLDKNNA; HKAYLDKNNAY; KAYLDKNNAYP; AYLDKNNAYPV;YLDKNNAYPVE; LDKNNAYPVEC; DKNNAYPVECW; KNNAYPVECWV; NNAYPVECWVP;NAYPVECWVPD; AYPVECWVPDP; YPVECWVPDPS; PVECWVPDPSR; VECWVPDPSRN;ECWVPDPSRNE; CWVPDPSRNEN; WVPDPSRNENA; VPDPSRNENAR; PDPSRNENARY;DPSRNENARYF; PSRNENARYFG; SRNENARYFGT; RNENARYFGTF; NENARYFGTFT;ENARYFGTFTG; NARYFGTFTGG; ARYFGTFTGGE; RYFGTFTGGEN; YFGTFTGGENV;FGTFTGGENVP; GTFTGGENVPP; TFTGGENVPPV; FTGGENVPPVL; TGGENVPPVLH;GGENVPPVLHV; GENVPPVLHVT; ENVPPVLHVTN; NVPPVLHVTNT; VPPVLHVTNTA;PPVLHVTNTAT; PVLHVTNTATT; VLHVTNTATTV; LHVTNTATTVL; HVTNTATTVLL;VTNTATTVLLD; TNTATTVLLDE; NTATTVLLDEQ; TATTVLLDEQG; ATTVLLDEQGV;TTVLLDEQGVG; TVLLDEQGVGP; VLLDEQGVGPL; LLDEQGVGPLC; LDEQGVGPLCK;DEQGVGPLCKA; EQGVGPLCKAD; QGVGPLCKADS; GVGPLCKADSL; VGPLCKADSLY;GPLCKADSLYV; PLCKADSLYVS; LCKADSLYVSA; CKADSLYVSAA; KADSLYVSAAD;ADSLYVSAADI; DSLYVSAADIC; SLYVSAADICG; LYVSAADICGL; YVSAADICGLF;VSAADICGLFT; SAADICGLFTN; AADICGLFTNS; ADICGLFTNSS; DICGLFTNSSG;ICGLFTNSSGT; CGLFTNSSGTQ; GLFTNSSGTQQ; LFTNSSGTQQW; FTNSSGTQQWR;TNSSGTQQWRG; NSSGTQQWRGL; SSGTQQWRGLA; SGTQQWRGLAR; GTQQWRGLARY;TQQWRGLARYF; QQWRGLARYFK; QWRGLARYFKI; WRGLARYFKIR; RGLARYFKIRL;GLARYFKIRLR; LARYFKIRLRK; ARYFKIRLRKR; RYFKIRLRKRS; YFKIRLRKRSV;FKIRLRKRSVK; KIRLRKRSVKN; IRLRKRSVKNP; RLRKRSVKNPY; LRKRSVKNPYP;RKRSVKNPYPI; KRSVKNPYPIS; RSVKNPYPISF; SVKNPYPISFL; VKNPYPISFLL;KNPYPISFLLS; NPYPISFLLSD; PYPISFLLSDL; YPISFLLSDLI; PISFLLSDLIN;ISFLLSDLINR; SFLLSDLINRR; FLLSDLINRRT; LLSDLINRRTQ; LSDLINRRTQR;SDLINRRTQRV; DLINRRTQRVD; LINRRTQRVDG; INRRTQRVDGQ; NRRTQRVDGQP;RRTQRVDGQPM; RTQRVDGQPMY; TQRVDGQPMYG; QRVDGQPMYGM; RVDGQPMYGME;VDGQPMYGMES; DGQPMYGMESQ; GQPMYGMESQV; QPMYGMESQVE; PMYGMESQVEE;MYGMESQVEEV; YGMESQVEEVR; GMESQVEEVRV; MESQVEEVRVF; ESQVEEVRVFD;SQVEEVRVFDG; QVEEVRVFDGT; VEEVRVFDGTE; EEVRVFDGTER; EVRVFDGTERL;VRVFDGTERLP; RVFDGTERLPG; VFDGTERLPGD; FDGTERLPGDP; DGTERLPGDPD;GTERLPGDPDM; TERLPGDPDMI; ERLPGDPDMIR; RLPGDPDMIRY; LPGDPDMIRYI;PGDPDMIRYID; GDPDMIRYIDK; DPDMIRYIDKQ; PDMIRYIDKQG; DMIRYIDKQGQ;MIRYIDKQGQL; IRYIDKQGQLQ; RYIDKQGQLQT; YIDKQGQLQTK; IDKQGQLQTKM;DKQGQLQTKML; TGAFIVHIHLI; GAFIVHIHLIN; AFIVHIHLINA; FIVHIHLINAA;IVHIHLINAAF; VHIHLINAAFV; ATFKLVLFWGW; TFKLVLFWGWC; FKLVLFWGWCF;KLVLFWGWCFR; LVLFWGWCFRP; VLFWGWCFRPF; LFWGWCFRPFK; FWGWCFRPFKT;WGWCFRPFKTL; GWCFRPFKTLK; WCFRPFKTLKA; CFRPFKTLKAF; FRPFKTLKAFT;RPFKTLKAFTQ; PFKTLKAFTQM; FKTLKAFTQMQ; KTLKAFTQMQL; TLKAFTQMQLL;LKAFTQMQLLT; KAFTQMQLLTM; AFTQMQLLTMG; FTQMQLLTMGV; ILFSCNIKNTF;LFSCNIKNTFP; FSCNIKNTFPH; SCNIKNTFPHA; CNIKNTFPHAY; NIKNTFPHAYI;IKNTFPHAYII; KNTFPHAYIIF; NTFPHAYIIFH; TFPHAYIIFHP; KSIHTYLRIQP;SIHTYLRIQPF; IHTYLRIQPFL; HTYLRIQPFLP; TYLRIQPFLPF; YLRIQPFLPFN;LRIQPFLPFNN; RIQPFLPFNNS; IQPFLPFNNSR; QPFLPFNNSRL; PFLPFNNSRLY;FLPFNNSRLYI; LPFNNSRLYIS; PFNNSRLYISC; FNNSRLYISCK; NNSRLYISCKI;NSRLYISCKIS; SRLYISCKISY; RLYISCKISYR; LYISCKISYRP; YISCKISYRPK;ISCKISYRPKP; SCKISYRPKPN; IYFGPKIYLSY; YFGPKIYLSYK; FGPKIYLSYKS;GPKIYLSYKSS; PKIYLSYKSSL; KIYLSYKSSLQ; IYLSYKSSLQG; YLSYKSSLQGF;LSYKSSLQGFR; SYKSSLQGFRD; YKSSLQGFRDR; KSSLQGFRDRI; SSLQGFRDRIL;SLQGFRDRILI; LQGFRDRILIH; QGFRDRILIHC; GFRDRILIHCN; FRDRILIHCNQ;RDRILIHCNQA; DRILIHCNQAW; RILIHCNQAWW; ILIHCNQAWWK; LIHCNQAWWKY;IHCNQAWWKYL; HCNQAWWKYLG; CNQAWWKYLGS; NQAWWKYLGSF; QAWWKYLGSFV;FSSCPFYIFKN; SSCPFYIFKNN; SCPFYIFKNNH; CPFYIFKNNHV; PFYIFKNNHVL;FYIFKNNHVLI; YIFKNNHVLIY; IFKNNHVLIYS; FKNNHVLIYSY; KNNHVLIYSYT;CCFSTINGTFK; PVSSFRYIENN; VSSFRYIENNT; SSFRYIENNTV; SFRYIENNTVQ;FRYIENNTVQK; RYIENNTVQKI; YIENNTVQKIK; IENNTVQKIKY; ENNTVQKIKYY;NNTVQKIKYYR; NTVQKIKYYRI; TVQKIKYYRIH; VQKIKYYRIHF; QKIKYYRIHFR;QTVQPSNTCHI; TVQPSNTCHIL; VQPSNTCHILF; HFFPGHMKGIY; FFPGHMKGIYS;FPGHMKGIYSF; PGHMKGIYSFF; GHMKGIYSFFS; NCIYCLLTNTF; CIYCLLTNTFL;IYCLLTNTFLI; YCLLTNTFLIF; CLLTNTFLIFT; LLTNTFLIFTF; LTNTFLIFTFC;TNTFLIFTFCK; NTFLIFTFCKN; TFLIFTFCKNN; FLIFTFCKNNS; LIFTFCKNNSI;IFTFCKNNSIC; FTFCKNNSICK; TFCKNNSICKV; FCKNNSICKVL; CKNNSICKVLF;KNNSICKVLFM; NNSICKVLFMI; NSICKVLFMIL; SICKVLFMILK; ICKVLFMILKV;CKVLFMILKVI; KVLFMILKVIR; VLFMILKVIRL; LFMILKVIRLV; FMILKVIRLVF;MILKVIRLVFF; ILKVIRLVFFL; LKVIRLVFFLT; KVIRLVFFLTL; VIRLVFFLTLF;IRLVFFLTLFT; RLVFFLTLFTL; LVFFLTLFTLL; VFFLTLFTLLY; FFLTLFTLLYI;FLTLFTLLYIV; LTLFTLLYIVL; TLFTLLYIVLK; LFTLLYIVLKF; KHILTLCLYCI;HILTLCLYCIL; ILTLCLYCILS; LTLCLYCILSN; FPRHLLCFFRL; PRHLLCFFRLF;RHLLCFFRLFW; HLLCFFRLFWA; LLCFFRLFWAK; LCFFRLFWAKI; CFFRLFWAKIM;FFRLFWAKIML; FRLFWAKIMLL; APLNAFFYSMV; PLNAFFYSMVW; LNAFFYSMVWI;NAFFYSMVWIS; AFFYSMVWISS; KTKGTQLLTEI; TKGTQLLTEII; KGTQLLTEIIN;GTQLLTEIINC; TQLLTEIINCR; QLLTEIINCRN; LLTEIINCRNS; LTEIINCRNSM;TEIINCRNSMS; EIINCRNSMSM; IINCRNSMSMW; INCRNSMSMWS; KEYNIMPSTHV;EYNIMPSTHVS; YNIMPSTHVST; NIMPSTHVSTN; IMPSTHVSTNK; MPSTHVSTNKS;PSTHVSTNKSY; STHVSTNKSYR; THVSTNKSYRI; HVSTNKSYRIF; VSTNKSYRIFF;STNKSYRIFFH; TNKSYRIFFHK; NKSYRIFFHKF; KSYRIFFHKFF; SYRIFFHKFFI;YRIFFHKFFIQ; RIFFHKFFIQN; IFFHKFFIQNL; FFHKFFIQNLS; FHKFFIQNLSF;HKFFIQNLSFF; KFFIQNLSFFF; FFIQNLSFFFS; FIQNLSFFFSS; IQNLSFFFSSI;QNLSFFFSSIH; NLSFFFSSIHS; LSFFFSSIHSK; SFFFSSIHSKA; FFFSSIHSKAG;FFSSIHSKAGK; FSSIHSKAGKG; SSIHSKAGKGS; SIHSKAGKGSI; IHSKAGKGSIT;HSKAGKGSITK; SKAGKGSITKY; KAGKGSITKYS; AGKGSITKYSL; GKGSITKYSLT;KGSITKYSLTK; GSITKYSLTKK; SITKYSLTKKL; ITKYSLTKKLV; IRGKVFRVFYL;RGKVFRVFYLS; GKVFRVFYLSF; KVFRVFYLSFF; VFRVFYLSFFF; FRVFYLSFFFG;RVFYLSFFFGW; VFYLSFFFGWC; VLRICCCFFIT; LRICCCFFITG; RICCCFFITGK;ICCCFFITGKH; CCCFFITGKHI; CCFFITGKHIF; CFFITGKHIFM; FFITGKHIFMA;FITGKHIFMAK; IFIPFFIKGTP; FIPFFIKGTPP; IPFFIKGTPPG; PFFIKGTPPGL;FFIKGTPPGLP; FIKGTPPGLPL; IKGTPPGLPLF; KGTPPGLPLFC; GTPPGLPLFCS;TPPGLPLFCSI; PPGLPLFCSIG; PGLPLFCSIGW; GLPLFCSIGWH; LPLFCSIGWHL;SFRSLKGVSPI; FRSLKGVSPII; RSLKGVSPIIW; SLKGVSPIIWT; LKGVSPIIWTH;KGVSPIIWTHH; GVSPIIWTHHC; VSPIIWTHHCR; SPIIWTHHCRV; PIIWTHHCRVS;IIWTHHCRVSS; IWTHHCRVSSV; WTHHCRVSSVR; THHCRVSSVRS; HHCRVSSVRSK;HCRVSSVRSKP; CRVSSVRSKPN; RVSSVRSKPNH; VSSVRSKPNHC; SSVRSKPNHCV;SVRSKPNHCVK; VRSKPNHCVKQ; RSKPNHCVKQS; SKPNHCVKQSM; KPNHCVKQSMQ;QSIQTKGSFLK; SIQTKGSFLKN; IQTKGSFLKNF; QTKGSFLKNFL; TKGSFLKNFLF;KGSFLKNFLFK; GSFLKNFLFKC; SFLKNFLFKCL; FLKNFLFKCLN; LKNFLFKCLNL;KNFLFKCLNLS; HSMQGQCTEGF; SMQGQCTEGFL; MQGQCTEGFLE; QGQCTEGFLEQ;GQCTEGFLEQI; QCTEGFLEQIG; CTEGFLEQIGH; TEGFLEQIGHS; EGFLEQIGHSL;GFLEQIGHSLQ; FLEQIGHSLQY; LEQIGHSLQYR; EQIGHSLQYRV; QIGHSLQYRVS;IGHSLQYRVSG; GHSLQYRVSGQ; HSLQYRVSGQR; SLQYRVSGQRG; LQYRVSGQRGK;QYRVSGQRGKS; YRVSGQRGKSA; RVSGQRGKSAQ; VSGQRGKSAQT; SGQRGKSAQTS;GQRGKSAQTSE; QRGKSAQTSEL; RGKSAQTSELL; GKSAQTSELLQ; KSAQTSELLQV;SAQTSELLQVP; AQTSELLQVPK; QTSELLQVPKS; TSELLQVPKSG; ATFTSCSIFLY;TFTSCSIFLYK; FTSCSIFLYKV; TSCSIFLYKVF; SCSIFLYKVFI; CSIFLYKVFIL;SIFLYKVFILF; IFLYKVFILFI; FLYKVFILFIL; LYKVFILFILS; YKVFILFILSS;KVFILFILSSS; VFILFILSSSP; FILFILSSSPP; ILFILSSSPPL; LFILSSSPPLS;FILSSSPPLSG; AFLIKGRFPQA; FLIKGRFPQAA; LIKGRFPQAAL; IKGRFPQAALS;KGRFPQAALSR; GRFPQAALSRP; RFPQAALSRPK; FPQAALSRPKR; PQAALSRPKRS;QAALSRPKRSM; AALSRPKRSMS; ALSRPKRSMSS; LSRPKRSMSSM; SRPKRSMSSMD;RPKRSMSSMDS; PKRSMSSMDSS; KRSMSSMDSSL; RSMSSMDSSLL; SMSSMDSSLLR;MSSMDSSLLRT; SSMDSSLLRTL; SMDSSLLRTLS BK virus reading frame 2 8 mers:GFPQIVLL; FPQIVLLG; PQIVLLGL; QIVLLGLR; IVLLGLRK; VLLGLRKS; LLGLRKSL;LGLRKSLH; GLRKSLHT; LRKSLHTL; RKSLHTLT; KSLHTLTT; EKGWRQRR; KGWRQRRP;GWRQRRPR; WRQRRPRP; RQRRPRPL; QRRPRPLI; RRPRPLIY; RPRPLIYY; PRPLIYYK;RPLIYYKK; PLIYYKKK; LIYYKKKG; IYYKKKGH; YYKKKGHR; YKKKGHRE; KKKGHREE;KKGHREEL; KGHREELL; GHREELLT; HREELLTH; REELLTHG; EELLTHGM; ELLTHGMQ;LLTHGMQP; LTHGMQPN; THGMQPNH; HGMQPNHD; GMQPNHDL; MQPNHDLR; QPNHDLRK;PNHDLRKE; NHDLRKES; HDLRKESA; LTGECSQT; TGECSQTM; GECSQTMT; ECSQTMTS;CSQTMTSG; SQTMTSGR; QTMTSGRK; TMTSGRKV; MTSGRKVH; TSGRKVHD; SGRKVHDS;GRKVHDSQ; RKVHDSQG; KVHDSQGG; VHDSQGGA; HDSQGGAA; DSQGGAAY; SQGGAAYP;QGGAAYPW; GGAAYPWN; GAAYPWNA; AAYPWNAA; AYPWNAAK; YPWNAAKP; PQEGKCMT;QEGKCMTD; EGKCMTDM; GKCMTDMF; KCMTDMFC; CMTDMFCE; MTDMFCEP; TDMFCEPR;DMFCEPRN; MFCEPRNL; FCEPRNLG; CEPRNLGL; EPRNLGLV; PRNLGLVP; RNLGLVPS;TGQRPWFC; GQRPWFCA; QRPWFCAS; RPWFCASC; PWFCASCH; WFCASCHD; FCASCHDK;CASCHDKL; ASCHDKLQ; KLVKPGLE; LVKPGLEQ; VKPGLEQK; KPGLEQKK; PGLEQKKE;GLEQKKEL; LEQKKELR; EQKKELRG; QKKELRGF; KKELRGFL; KELRGFLF; ELRGFLFL;LRGFLFLF; SFCWNFVE; FCWNFVEV; CWNFVEVK; WNFVEVKT; NFVEVKTV; TGKTKVPL;GKTKVPLL; KTKVPLLY; TKVPLLYL; KVPLLYLL; VIPFFLYF; IPFFLYFQ; PFFLYFQV;FFLYFQVH; FLYFQVHG; LYFQVHGC; YFQVHGCC; FQVHGCCS; QVHGCCSS; VHGCCSST;HGCCSSTF; GCCSSTFG; CCSSTFGG; CSSTFGGP; SSTFGGPS; STFGGPSC; TFGGPSCQ;FGGPSCQC; GGPSCQCI; GCCCHRIF; CCCHRIFS; CCHRIFSG; NCCWGGCC; CCWGGCCC;CWGGCCCY; WGGCCCYR; GGCCCYRS; GCCCYRSS; CCCYRSSN; CCYRSSNC; CYRSSNCI;YRSSNCIP; RSSNCIPC; SSNCIPCY; SNCIPCYC; NCIPCYCR; CIPCYCRG; IPCYCRGH;PCYCRGHN; CYCRGHNK; YCRGHNKY; CRGHNKYL; RGHNKYLR; GHNKYLRG; HNKYLRGY;NKYLRGYS; KYLRGYSC; YLRGYSCY; LRGYSCYR; RGYSCYRP; GYSCYRPN; YSCYRPNS;SCYRPNSS; CYRPNSSN; YRPNSSNI; RPNSSNIC; PNSSNICC; NSSNICCN; SSNICCNC;SNICCNCW; NICCNCWC; ICCNCWCS; CCNCWCSW; CNCWCSWG; NCWCSWGY; CWCSWGYC;WCSWGYCW; CSWGYCWV; SWGYCWVC; WGYCWVCC; GYCWVCCF; YCWVCCFN; CWVCCFNS;WVCCFNSN; VCCFNSNC; LGSQSFHC; GSQSFHCR; SQSFHCRP; QSFHCRPL; SFHCRPLS;FHCRPLSA; HCRPLSAI; CRPLSAIR; RPLSAIRH; PLSAIRHG; LSAIRHGF; SAIRHGFG;AIRHGFGI; IRHGFGIV; YSVSWCKY; SVSWCKYF; VSWCKYFC; ALGSFFVC; LGSFFVCY;GSFFVCYY; SFFVCYYF; FFVCYYFP; FVCYYFPG; VCYYFPGF; CYYFPGFV; YYFPGFVA;YFPGFVAC; FPGFVACY; YTFYNLTG; TFYNLTGI; FYNLTGIA; YNLTGIAE; NLTGIAEK;LTGIAEKN; TGIAEKNR; GIAEKNRK; IAEKNRKI; AEKNRKIF; IFGGNYLD; FGGNYLDN;GGNYLDNC; GNYLDNCK; NYLDNCKC; YLDNCKCP; LDNCKCPY; DNCKCPYK; NCKCPYKL;CKCPYKLL; KGRYPCTF; GRYPCTFW; RYPCTFWP; YPCTFWPY; PCTFWPYL; QYRRSYTK;YRRSYTKN; RRSYTKNG; RSYTKNGL; SYTKNGLK; YTKNGLKK; TKNGLKKS; KNGLKKST;NGLKKSTK; GLKKSTKC; LKKSTKCT; KKSTKCTF; KSTKCTFR; STKCTFRR; TKCTFRRV;KCTFRRVY; CTFRRVYR; TFRRVYRK; FRRVYRKN; RRVYRKNY; RVYRKNYC; VYRKNYCP;YRKNYCPR; RKNYCPRR; KNYCPRRC; SKNCSSMD; KNCSSMDV; NCSSMDVA; CSSMDVAF;SSMDVAFT; SMDVAFTS; MDVAFTSR; DVAFTSRP; VAFTSRPV; AFTSRPVR; FTSRPVRD;TSRPVRDC; SRPVRDCN; RPVRDCNT; PVRDCNTC; VRDCNTCS; RWPQPKEK; WPQPKEKE;PQPKEKES; QPKEKESV; PKEKESVQ; KEKESVQG; EKESVQGQ; KESVQGQL; ESVQGQLP;SVQGQLPK; VQGQLPKS; QGQLPKSQ; GQLPKSQR; QLPKSQRN; LPKSQRNP; PKSQRNPC;KSQRNPCK; SQRNPCKC; QRNPCKCQ; RNPCKCQN; NPCKCQNY; TQKWGIQM; QKWGIQMK;KWGIQMKT; WGIQMKTL; GIQMKTLG; IQMKTLGA; QMKTLGAL; MKTLGALV; VLKMTLAV;LKMTLAVI; KMTLAVIA; MTLAVIAQ; TLAVIAQR; LAVIAQRE; AVIAQREK; VIAQREKC;IAQREKCF; AQREKCFP; QREKCFPV; REKCFPVT; EKCFPVTA; KCFPVTAQ; CFPVTAQQ;FPVTAQQE; PVTAQQEF; VTAQQEFP; TAQQEFPS; AQQEFPSP; QQEFPSPI; LYKQRLLE;LACLTFMQ; ACLTFMQG; CLTFMQGH; LTFMQGHK; TFMQGHKK; FMQGHKKC; MQGHKKCM;QGHKKCMS; GHKKCMSM; HKKCMSMV; KKCMSMVE; KCMSMVEE; CMSMVEEN; MSMVEENL;SMVEENLF; MVEENLFK; VEENLFKA; EENLFKAV; ENLFKAVI; NLFKAVIS; LFKAVIST;FKAVISTS; KAVISTSL; AVISTSLL; VENPWKCR; ENPWKCRE; NPWKCREC; ITGQSTLM;TGQSTLMV; GQSTLMVL; PLKTQQPS; LKTQQPSP; KTQQPSPR; ILTIRPIW; LTIRPIWT;TIRPIWTK; IRPIWTKT; RPIWTKTM; PIWTKTML; IWTKTMLI; WTKTMLIQ; TKTMLIQL;KTMLIQLS; TMLIQLSA; MLIQLSAG; LIQLSAGY; IQLSAGYL; QLSAGYLI; LSAGYLIP;SAGYLIPV; AGYLIPVE; GYLIPVEM; YLIPVEMK; LIPVEMKM; IPVEMKML; PVEMKMLG;VEMKMLGI; EMKMLGIL; MKMLGILG; KMLGILGL; MLGILGLS; LGILGLSQ; GILGLSQE;ILGLSQEG; LGLSQEGK; GLSQEGKM; LSQEGKMF; SQEGKMFP; QEGKMFPQ; EGKMFPQY;GKMFPQYF; KMFPQYFM; PTQLPQCC; MNRVWGLF; NRVWGLFV; RVWGLFVK; VWGLFVKL;WGLFVKLI; GLFVKLIA; LFVKLIAC; FVKLIACM; VKLIACMF; KLIACMFQ; LIACMFQL;IACMFQLL; ACMFQLLI; CMFQLLIF; MFQLLIFV; FQLLIFVA; QLLIFVAC; LLIFVACL;LIFVACLL; IFVACLLT; FVACLLTA; VACLLTAL; ACLLTALE; CLLTALEH; LLTALEHN;LTALEHNS; TALEHNSG; ALEHNSGE; LEHNSGEA; EHNSGEAL; HNSGEALQ; NSGEALQD;SGEALQDI; GEALQDIL; EALQDILR; ALQDILRS; LQDILRSA; RILTQFPF; ILTQFPFC;TGEPREWM; GEPREWMG; EPREWMGS; PREWMGSL; REWMGSLC; EWMGSLCM; WMGSLCMV;MGSLCMVW; GSLCMVWN; SLCMVWNP; LCMVWNPR; KRLGCLMA; RLGCLMAQ; LGCLMAQK;GCLMAQKD; CLMAQKDF; LMAQKDFQ; MAQKDFQG; AQKDFQGT; QKDFQGTQ; KDFQGTQI;DILTNRDN; ILTNRDNC; LTNRDNCK; TNRDNCKP; NRDNCKPK; RDNCKPKC; DNCKPKCF;NCKPKCFK; CKPKCFKQ; KPKCFKQV; PKCFKQVL; KCFKQVLL; CFKQVLLL; FKQVLLLY;KQVLLLYI; QVLLLYIY; VLLLYIYI; MLLLYKPL; LLLYKPLL; LLYKPLLS; LYKPLLSL;YKPLLSLC; KPLLSLCY; PLLSLCYF; LLSLCYFG; LSLCYFGG; SLCYFGGG; LCYFGGGV;CYFGGGVL; YFGGGVLG; FGGGVLGL; GGGVLGLL; GGVLGLLK; GVLGLLKH; KPLHKCNS;LWGSDLWE; WGSDLWES; GSDLWESS; SDLWESSA; DLWESSAG; LWESSAGA; WESSAGAE;ESSAGAEV; SSAGAEVS; SAGAEVSE; AGAEVSET; GAEVSETW; AEVSETWE; EVSETWEE;VSETWEEH; SETWEEHC; ETWEEHCD; TWEEHCDW; WEEHCDWD; EEHCDWDS; EHCDWDSV;HCDWDSVL; CDWDSVLD; DWDSVLDP; WDSVLDPC; DSVLDPCP; SVLDPCPE; VLDPCPES;LDPCPESS; DPCPESSV; PCPESSVS; CPESSVSE; PESSVSES; ESSVSESS; SSVSESSS;SVSESSSL; VSESSSLV; SESSSLVI; ESSSLVIS; SSSLVISR; SSLVISRI; SLVISRIH;LVISRIHF; VISRIHFP; ISRIHFPM; SRIHFPMH; RIHFPMHI; IHFPMHIL; HFPMHILY;FPMHILYF; PMHILYFI; MHILYFIL; HILYFILE; ILYFILEK; LYFILEKV; YFILEKVY;FILEKVYI; ILEKVYIL; LEKVYILI; EKVYILIS; KVYILISE; VYILISES; YILISESS;ILISESSL; LISESSLS; ISESSLSF; SESSLSFH; ESSLSFHS; SSLSFHST; SLSFHSTI;LSFHSTIL; SFHSTILD; FHSTILDC; HSTILDCI; STILDCIS; TILDCISV; ILDCISVA;LDCISVAK; DCISVAKS; CISVAKSA; ISVAKSAT; SVAKSATG; VAKSATGL; AKSATGLN;KSATGLNQ; SATGLNQI; ATGLNQIS; TGLNQISS; GLNQISSS; LNQISSSN; NQISSSNK;QISSSNKV; ISSSNKVI; SSSNKVIP; SSNKVIPL; SNKVIPLC; NKVIPLCK; KVIPLCKI;VIPLCKIL; IPLCKILF; PLCKILFS; LCKILFSS; CKILFSSK; KILFSSKN; ILFSSKNS;LFSSKNSE; FSSKNSEF; SSKNSEFC; SKNSEFCK; KNSEFCKD; NSEFCKDF; SEFCKDFL;EFCKDFLK; FCKDFLKY; CKDFLKYI; KDFLKYIL; DFLKYILG; FLKYILGL; LKYILGLK;KYILGLKS; YILGLKSI; ILGLKSIC; LGLKSICL; GLKSICLT; LKSICLTN; KSICLTNL;SICLTNLA; ICLTNLAC; CLTNLACR; LTNLACRV; TNLACRVL; NLACRVLG; LACRVLGT;ACRVLGTG; CRVLGTGY; RVLGTGYS; VLGTGYSF; LGTGYSFI; GTGYSFIV; TGYSFIVT;GYSFIVTK; YSFIVTKP; SFIVTKPG; FIVTKPGG; IVTKPGGN; VTKPGGNI; TKPGGNIW;KPGGNIWV; PGGNIWVL; GGNIWVLL; GNIWVLLF; NIWVLLFK; IWVLLFKC; WVLLFKCF;VLLFKCFF; LLFKCFFS; LFKCFFSK; FKCFFSKF; KCFFSKFT; CFFSKFTL; FFSKFTLT;FSKFTLTL; SKFTLTLP; KFTLTLPS; FTLTLPSK; SLKLSKLF; LKLSKLFI; KLSKLFIP;LSKLFIPC; SKLFIPCP; KLFIPCPE; LFIPCPEG; FIPCPEGK; IPCPEGKS; PCPEGKSF;CPEGKSFD; PEGKSFDS; EGKSFDSA; GKSFDSAP; KSFDSAPV; SFDSAPVP; FDSAPVPF;DSAPVPFT; SAPVPFTS; APVPFTSS; PVPFTSSK; VPFTSSKT; PFTSSKTT; FTSSKTTM;TSSKTTMY; SIATPSSK; IATPSSKV; ATPSSKVS; TPSSKVSL; PSSKVSLS; SSKVSLSM;SKVSLSMG; KVSLSMGR; VSLSMGRF; SLSMGRFT; LSMGRFTF; SMGRFTFK; MGRFTFKA;GRFTFKAL; RFTFKALP; FTFKALPP; TFKALPPH; FKALPPHK; KALPPHKS; ALPPHKSN;LPPHKSNN; PPHKSNNP; PHKSNNPA; HKSNNPAA; KSNNPAAS; SNNPAASV; NNPAASVV;NPAASVVF; PAASVVFP; AASVVFPL; ASVVFPLS; SVVFPLSM; VVFPLSMG; VFPLSMGP;FPLSMGPL; PLSMGPLN; LSMGPLNN; SMGPLNNQ; MGPLNNQY; GPLNNQYL; PLNNQYLL;LNNQYLLL; NNQYLLLG; NQYLLLGT; QYLLLGTL; YLLLGTLK; LLLGTLKT; LLGTLKTI;LGTLKTIQ; GTLKTIQC; TLKTIQCK; LKTIQCKK; KTIQCKKS; TIQCKKSN; IQCKKSNI;QCKKSNIT; CKKSNITE; KKSNITES; KSNITESI; SNITESIL; NITESILG; ITESILGS;TESILGSK; ESILGSKQ; SILGSKQC; ILGSKQCS; LGSKQCSQ; GSKQCSQA; SKQCSQAT;KQCSQATP; QCSQATPA; CSQATPAI; SQATPAIY; QATPAIYC; ATPAIYCS; TPAIYCSS;PAIYCSST; AIYCSSTA; IYCSSTAF; YCSSTAFP; APNIKSIL; PNIKSILS; NIKSILSN;IKSILSNI; LNLSVSIS; NLSVSISS; LSVSISSL; SVSISSLV; VSISSLVI; RVSTLFLA;VSTLFLAK; STLFLAKT; TLFLAKTV; LFLAKTVS; FLAKTVST; LAKTVSTA; AKTVSTAC;FLLSAKII; LLSAKIIA; LSAKIIAF; SAKIIAFA; AKIIAFAK; KIIAFAKC; IIAFAKCF;IAFAKCFS; HFLHSSTL; FLHSSTLY; NSKYIPNN; SKYIPNNK; KYIPNNKN; YIPNNKNT;IPNNKNTS; PNNKNTSS; NNKNTSSH; NKNTSSHF; KNTSSHFV; NTSSHFVS; TSSHFVST;SSHFVSTA; SHFVSTAY; HFVSTAYS; FVSTAYSV; VSTAYSVI; STAYSVIN; TAYSVINF;AYSVINFQ; YSVINFQD; SVINFQDT; VINFQDTC; INFQDTCF; NFQDTCFV; FQDTCFVS;QDTCFVSS; DTCFVSSG; TCFVSSGS; CFVSSGSS; FVSSGSSG; VSSGSSGL; SSGSSGLK;SGSSGLKS; GSSGLKSC; SSGLKSCS; SGLKSCSF; GLKSCSFK; LKSCSFKP; KSCSFKPP;MLSSIVWY; LSSIVWYG; SSIVWYGS; SIVWYGSL; IVWYGSLV; VWYGSLVK; WYGSLVKA;YGSLVKAL; GSLVKALY; SLVKALYS; LVKALYSK; VKALYSKY; KALYSKYS; ALYSKYSL;LYSKYSLL; YSKYSLLT; SKYSLLTP; KYSLLTPL; YSLLTPLQ; SLLTPLQI; LLTPLQIK;LTPLQIKK; TPLQIKKL; PLQIKKLK; LQIKKLKV; QIKKLKVH; IKKLKVHS; KKLKVHSF;QKLLIAET; KLLIAETL; LLIAETLC; LIAETLCL; IAETLCLC; AETLCLCG; ETLCLCGV;TLCLCGVK; LCLCGVKK; CLCGVKKN; LCGVKKNI; CGVKKNII; GVKKNIIL; VKKNIILC;KKNIILCP; KNIILCPA; NIILCPAH; IILCPAHM; ILCPAHMC; LCPAHMCL; CPAHMCLL;PAHMCLLI; AHMCLLIK; HMCLLIKV; MCLLIKVT; CLLIKVTE; LLIKVTEY; LIKVTEYF;IKVTEYFS; KVTEYFSI; VTEYFSIS; TEYFSISF; EYFSISFL; YFSISFLY; FSISFLYR;SISFLYRI; AFSLVVYT; FSLVVYTA; SLVVYTAK; LVVYTAKQ; VVYTAKQA; VYTAKQAR;YTAKQARV; TAKQARVL; AKQARVLL; KQARVLLL; QARVLLLN; ARVLLLNT; RVLLLNTA;LRNWCRSE; RNWCRSEG; NWCRSEGK; WCRSEGKS; CRSEGKSL; RSEGKSLG; SEGKSLGS;EGKSLGSS; GKSLGSST; KSLGSSTF; SLGSSTFL; LGSSTFLF; GSSTFLFF; SSTFLFFL;STFLFFLG; TFLFFLGG; FLFFLGGV; LFFLGGVE; FFLGGVEC; ESAVASSS; SAVASSSL;AVASSSLA; VASSSLAN; ASSSLANI; SSSLANIS; SSLANISS; SLANISSW; LANISSWQ;ANISSWQN; NISSWQNK; ISSWQNKS; SSWQNKSS; SWQNKSSS; WQNKSSSH; QNKSSSHF;NKSSSHFS; KSSSHFSL; SSSHFSLK; SSHFSLKE; SHFSLKEL; HFSLKELH; FSLKELHQ;SLKELHQD; LKELHQDS; KELHQDSH; ELHQDSHS; LHQDSHSS; HQDSHSSV; QDSHSSVP;VGTYKKNN; GTYKKNNY; TYKKNNYL; YKKNNYLG; KKNNYLGP; KNNYLGPF; NNYLGPFN;NYLGPFNI; YLGPFNIL; LGPFNILL; GPFNILLF; PFNILLFI; VSYLKALD; SYLKALDL;REFLQLFG; EFLQLFGP; FLQLFGPT; LQLFGPTI; QLFGPTIA; LFGPTIAE; FGPTIAEF;GPTIAEFL; PTIAEFLQ; TIAEFLQL; IAEFLQLG; AEFLQLGL; EFLQLGLS; FLQLGLSQ;LQLGLSQT; QLGLSQTT; LGLSQTTV; SSQCSSNL; SQCSSNLS; QCSSNLSK; CSSNLSKP;SSNLSKPR; SNLSKPRA; NLSKPRAL; LSKPRALF; SKPRALFL; KPRALFLK; PRALFLKI;RALFLKIF; ALFLKIFY; LFLKIFYL; FLKIFYLN; LKIFYLNA; KIFYLNAL; IFYLNALI;ADIACKGS; DIACKGSA; IACKGSAQ; ACKGSAQK; CKGSAQKA; KGSAQKAF; GSAQKAFW;SAQKAFWN; AQKAFWNK; AIPCSTGY; IPCSTGYL; PCSTGYLG; CSTGYLGK; STGYLGKE;TGYLGKEE; GYLGKEEN; YLGKEENQ; LGKEENQH; GKEENQHK; KEENQHKP; EENQHKPL;ENQHKPLS; NQHKPLSY; QHKPLSYS; HKPLSYSR; KPLSYSRF; PLSYSRFQ; LSYSRFQN;SYSRFQNQ; YSRFQNQA; SRFQNQAD; RFQNQADE; FQNQADEL; QNQADELP; NQADELPL;QADELPLH; ADELPLHP; DELPLHPA; ELPLHPAP; LPLHPAPF; PLHPAPFF; LHPAPFFY;HPAPFFYT; PAPFFYTK; APFFYTKY; PFFYTKYS; FFYTKYSF; FYTKYSFS; YTKYSFSS;TKYSFSSF; KYSFSSFY; YSFSSFYP; SFSSFYPR; FSSFYPRR; SSFYPRRP; SFYPRRPL;FYPRRPLC; YPRRPLCQ; PRRPLCQG; RRPLCQGE; RPLCQGEI; PLCQGEIP; LCQGEIPY;CQGEIPYT; QGEIPYTS; GEIPYTSL; EIPYTSLN; IPYTSLNK; PYTSLNKL; YTSLNKLF;TSLNKLFS; SLNKLFSL; LNKLFSLR; NKLFSLRE; KLFSLRED; LFSLREDF; FSLREDFP;SLREDFPR; LREDFPRQ; REDFPRQL; EDFPRQLF; DFPRQLFQ; FPRQLFQG; PRQLFQGL;RQLFQGLK; QLFQGLKG; LFQGLKGP 9 mers:GFPQIVLLG; FPQIVLLGL; PQIVLLGLR; QIVLLGLRK; IVLLGLRKS; VLLGLRKSL;LLGLRKSLH; LGLRKSLHT; GLRKSLHTL; LRKSLHTLT; RKSLHTLTT; EKGWRQRRP;KGWRQRRPR; GWRQRRPRP; WRQRRPRPL; RQRRPRPLI; QRRPRPLIY; RRPRPLIYY;RPRPLIYYK; PRPLIYYKK; RPLIYYKKK; PLIYYKKKG; LIYYKKKGH; IYYKKKGHR;YYKKKGHRE; YKKKGHREE; KKKGHREEL; KKGHREELL; KGHREELLT; GHREELLTH;HREELLTHG; REELLTHGM; EELLTHGMQ; ELLTHGMQP; LLTHGMQPN; LTHGMQPNH;THGMQPNHD; HGMQPNHDL; GMQPNHDLR; MQPNHDLRK; QPNHDLRKE; PNHDLRKES;NHDLRKESA; LTGECSQTM; TGECSQTMT; GECSQTMTS; ECSQTMTSG; CSQTMTSGR;SQTMTSGRK; QTMTSGRKV; TMTSGRKVH; MTSGRKVHD; TSGRKVHDS; SGRKVHDSQ;GRKVHDSQG; RKVHDSQGG; KVHDSQGGA; VHDSQGGAA; HDSQGGAAY; DSQGGAAYP;SQGGAAYPW; QGGAAYPWN; GGAAYPWNA; GAAYPWNAA; AAYPWNAAK; AYPWNAAKP;PQEGKCMTD; QEGKCMTDM; EGKCMTDMF; GKCMTDMFC; KCMTDMFCE; CMTDMFCEP;MTDMFCEPR; TDMFCEPRN; DMFCEPRNL; MFCEPRNLG; FCEPRNLGL; CEPRNLGLV;EPRNLGLVP; PRNLGLVPS; TGQRPWFCA; GQRPWFCAS; QRPWFCASC; RPWFCASCH;PWFCASCHD; WFCASCHDK; FCASCHDKL; CASCHDKLQ; KLVKPGLEQ; LVKPGLEQK;VKPGLEQKK; KPGLEQKKE; PGLEQKKEL; GLEQKKELR; LEQKKELRG; EQKKELRGF;QKKELRGFL; KKELRGFLF; KELRGFLFL; ELRGFLFLF; SFCWNFVEV; FCWNFVEVK;CWNFVEVKT; WNFVEVKTV; TGKTKVPLL; GKTKVPLLY; KTKVPLLYL; TKVPLLYLL;VIPFFLYFQ; IPFFLYFQV; PFFLYFQVH; FFLYFQVHG; FLYFQVHGC; LYFQVHGCC;YFQVHGCCS; FQVHGCCSS; QVHGCCSST; VHGCCSSTF; HGCCSSTFG; GCCSSTFGG;CCSSTFGGP; CSSTFGGPS; SSTFGGPSC; STFGGPSCQ; TFGGPSCQC; FGGPSCQCI;GCCCHRIFS; CCCHRIFSG; NCCWGGCCC; CCWGGCCCY; CWGGCCCYR; WGGCCCYRS;GGCCCYRSS; GCCCYRSSN; CCCYRSSNC; CCYRSSNCI; CYRSSNCIP; YRSSNCIPC;RSSNCIPCY; SSNCIPCYC; SNCIPCYCR; NCIPCYCRG; CIPCYCRGH; IPCYCRGHN;PCYCRGHNK; CYCRGHNKY; YCRGHNKYL; CRGHNKYLR; RGHNKYLRG; GHNKYLRGY;HNKYLRGYS; NKYLRGYSC; KYLRGYSCY; YLRGYSCYR; LRGYSCYRP; RGYSCYRPN;GYSCYRPNS; YSCYRPNSS; SCYRPNSSN; CYRPNSSNI; YRPNSSNIC; RPNSSNICC;PNSSNICCN; NSSNICCNC; SSNICCNCW; SNICCNCWC; NICCNCWCS; ICCNCWCSW;CCNCWCSWG; CNCWCSWGY; NCWCSWGYC; CWCSWGYCW; WCSWGYCWV; CSWGYCWVC;SWGYCWVCC; WGYCWVCCF; GYCWVCCFN; YCWVCCFNS; CWVCCFNSN; WVCCFNSNC;LGSQSFHCR; GSQSFHCRP; SQSFHCRPL; QSFHCRPLS; SFHCRPLSA; FHCRPLSAI;HCRPLSAIR; CRPLSAIRH; RPLSAIRHG; PLSAIRHGF; LSAIRHGFG; SAIRHGFGI;AIRHGFGIV; YSVSWCKYF; SVSWCKYFC; ALGSFFVCY; LGSFFVCYY; GSFFVCYYF;SFFVCYYFP; FFVCYYFPG; FVCYYFPGF; VCYYFPGFV; CYYFPGFVA; YYFPGFVAC;YFPGFVACY; YTFYNLTGI; TFYNLTGIA; FYNLTGIAE; YNLTGIAEK; NLTGIAEKN;LTGIAEKNR; TGIAEKNRK; GIAEKNRKI; IAEKNRKIF; IFGGNYLDN; FGGNYLDNC;GGNYLDNCK; GNYLDNCKC; NYLDNCKCP; YLDNCKCPY; LDNCKCPYK; DNCKCPYKL;NCKCPYKLL; KGRYPCTFW; GRYPCTFWP; RYPCTFWPY; YPCTFWPYL; QYRRSYTKN;YRRSYTKNG; RRSYTKNGL; RSYTKNGLK; SYTKNGLKK; YTKNGLKKS; TKNGLKKST;KNGLKKSTK; NGLKKSTKC; GLKKSTKCT; LKKSTKCTF; KKSTKCTFR; KSTKCTFRR;STKCTFRRV; TKCTFRRVY; KCTFRRVYR; CTFRRVYRK; TFRRVYRKN; FRRVYRKNY;RRVYRKNYC; RVYRKNYCP; VYRKNYCPR; YRKNYCPRR; RKNYCPRRC; SKNCSSMDV;KNCSSMDVA; NCSSMDVAF; CSSMDVAFT; SSMDVAFTS; SMDVAFTSR; MDVAFTSRP;DVAFTSRPV; VAFTSRPVR; AFTSRPVRD; FTSRPVRDC; TSRPVRDCN; SRPVRDCNT;RPVRDCNTC; PVRDCNTCS; RWPQPKEKE; WPQPKEKES; PQPKEKESV; QPKEKESVQ;PKEKESVQG; KEKESVQGQ; EKESVQGQL; KESVQGQLP; ESVQGQLPK; SVQGQLPKS;VQGQLPKSQ; QGQLPKSQR; GQLPKSQRN; QLPKSQRNP; LPKSQRNPC; PKSQRNPCK;KSQRNPCKC; SQRNPCKCQ; QRNPCKCQN; RNPCKCQNY; TQKWGIQMK; QKWGIQMKT;KWGIQMKTL; WGIQMKTLG; GIQMKTLGA; IQMKTLGAL; QMKTLGALV; VLKMTLAVI;LKMTLAVIA; KMTLAVIAQ; MTLAVIAQR; TLAVIAQRE; LAVIAQREK; AVIAQREKC;VIAQREKCF; IAQREKCFP; AQREKCFPV; QREKCFPVT; REKCFPVTA; EKCFPVTAQ;KCFPVTAQQ; CFPVTAQQE; FPVTAQQEF; PVTAQQEFP; VTAQQEFPS; TAQQEFPSP;AQQEFPSPI; LACLTFMQG; ACLTFMQGH; CLTFMQGHK; LTFMQGHKK; TFMQGHKKC;FMQGHKKCM; MQGHKKCMS; QGHKKCMSM; GHKKCMSMV; HKKCMSMVE; KKCMSMVEE;KCMSMVEEN; CMSMVEENL; MSMVEENLF; SMVEENLFK; MVEENLFKA; VEENLFKAV;EENLFKAVI; ENLFKAVIS; NLFKAVIST; LFKAVISTS; FKAVISTSL; KAVISTSLL;VENPWKCRE; ENPWKCREC; ITGQSTLMV; TGQSTLMVL; PLKTQQPSP; LKTQQPSPR;ILTIRPIWT; LTIRPIWTK; TIRPIWTKT; IRPIWTKTM; RPIWTKTML; PIWTKTMLI;IWTKTMLIQ; WTKTMLIQL; TKTMLIQLS; KTMLIQLSA; TMLIQLSAG; MLIQLSAGY;LIQLSAGYL; IQLSAGYLI; QLSAGYLIP; LSAGYLIPV; SAGYLIPVE; AGYLIPVEM;GYLIPVEMK; YLIPVEMKM; LIPVEMKML; IPVEMKMLG; PVEMKMLGI; VEMKMLGIL;EMKMLGILG; MKMLGILGL; KMLGILGLS; MLGILGLSQ; LGILGLSQE; GILGLSQEG;ILGLSQEGK; LGLSQEGKM; GLSQEGKMF; LSQEGKMFP; SQEGKMFPQ; QEGKMFPQY;EGKMFPQYF; GKMFPQYFM; MNRVWGLFV; NRVWGLFVK; RVWGLFVKL; VWGLFVKLI;WGLFVKLIA; GLFVKLIAC; LFVKLIACM; FVKLIACMF; VKLIACMFQ; KLIACMFQL;LIACMFQLL; IACMFQLLI; ACMFQLLIF; CMFQLLIFV; MFQLLIFVA; FQLLIFVAC;QLLIFVACL; LLIFVACLL; LIFVACLLT; IFVACLLTA; FVACLLTAL; VACLLTALE;ACLLTALEH; CLLTALEHN; LLTALEHNS; LTALEHNSG; TALEHNSGE; ALEHNSGEA;LEHNSGEAL; EHNSGEALQ; HNSGEALQD; NSGEALQDI; SGEALQDIL; GEALQDILR;EALQDILRS; ALQDILRSA; RILTQFPFC; TGEPREWMG; GEPREWMGS; EPREWMGSL;PREWMGSLC; REWMGSLCM; EWMGSLCMV; WMGSLCMVW; MGSLCMVWN; GSLCMVWNP;SLCMVWNPR; KRLGCLMAQ; RLGCLMAQK; LGCLMAQKD; GCLMAQKDF; CLMAQKDFQ;LMAQKDFQG; MAQKDFQGT; AQKDFQGTQ; QKDFQGTQI; DILTNRDNC; ILTNRDNCK;LTNRDNCKP; TNRDNCKPK; NRDNCKPKC; RDNCKPKCF; DNCKPKCFK; NCKPKCFKQ;CKPKCFKQV; KPKCFKQVL; PKCFKQVLL; KCFKQVLLL; CFKQVLLLY; FKQVLLLYI;KQVLLLYIY; QVLLLYIYI; MLLLYKPLL; LLLYKPLLS; LLYKPLLSL; LYKPLLSLC;YKPLLSLCY; KPLLSLCYF; PLLSLCYFG; LLSLCYFGG; LSLCYFGGG; SLCYFGGGV;LCYFGGGVL; CYFGGGVLG; YFGGGVLGL; FGGGVLGLL; GGGVLGLLK; GGVLGLLKH;LWGSDLWES; WGSDLWESS; GSDLWESSA; SDLWESSAG; DLWESSAGA; LWESSAGAE;WESSAGAEV; ESSAGAEVS; SSAGAEVSE; SAGAEVSET; AGAEVSETW; GAEVSETWE;AEVSETWEE; EVSETWEEH; VSETWEEHC; SETWEEHCD; ETWEEHCDW; TWEEHCDWD;WEEHCDWDS; EEHCDWDSV; EHCDWDSVL; HCDWDSVLD; CDWDSVLDP; DWDSVLDPC;WDSVLDPCP; DSVLDPCPE; SVLDPCPES; VLDPCPESS; LDPCPESSV; DPCPESSVS;PCPESSVSE; CPESSVSES; PESSVSESS; ESSVSESSS; SSVSESSSL; SVSESSSLV;VSESSSLVI; SESSSLVIS; ESSSLVISR; SSSLVISRI; SSLVISRIH; SLVISRIHF;LVISRIHFP; VISRIHFPM; ISRIHFPMH; SRIHFPMHI; RIHFPMHIL; IHFPMHILY;HFPMHILYF; FPMHILYFI; PMHILYFIL; MHILYFILE; HILYFILEK; ILYFILEKV;LYFILEKVY; YFILEKVYI; FILEKVYIL; ILEKVYILI; LEKVYILIS; EKVYILISE;KVYILISES; VYILISESS; YILISESSL; ILISESSLS; LISESSLSF; ISESSLSFH;SESSLSFHS; ESSLSFHST; SSLSFHSTI; SLSFHSTIL; LSFHSTILD; SFHSTILDC;FHSTILDCI; HSTILDCIS; STILDCISV; TILDCISVA; ILDCISVAK; LDCISVAKS;DCISVAKSA; CISVAKSAT; ISVAKSATG; SVAKSATGL; VAKSATGLN; AKSATGLNQ;KSATGLNQI; SATGLNQIS; ATGLNQISS; TGLNQISSS; GLNQISSSN; LNQISSSNK;NQISSSNKV; QISSSNKVI; ISSSNKVIP; SSSNKVIPL; SSNKVIPLC; SNKVIPLCK;NKVIPLCKI; KVIPLCKIL; VIPLCKILF; IPLCKILFS; PLCKILFSS; LCKILFSSK;CKILFSSKN; KILFSSKNS; ILFSSKNSE; LFSSKNSEF; FSSKNSEFC; SSKNSEFCK;SKNSEFCKD; KNSEFCKDF; NSEFCKDFL; SEFCKDFLK; EFCKDFLKY; FCKDFLKYI;CKDFLKYIL; KDFLKYILG; DFLKYILGL; FLKYILGLK; LKYILGLKS; KYILGLKSI;YILGLKSIC; ILGLKSICL; LGLKSICLT; GLKSICLTN; LKSICLTNL; KSICLTNLA;SICLTNLAC; ICLTNLACR; CLTNLACRV; LTNLACRVL; TNLACRVLG; NLACRVLGT;LACRVLGTG; ACRVLGTGY; CRVLGTGYS; RVLGTGYSF; VLGTGYSFI; LGTGYSFIV;GTGYSFIVT; TGYSFIVTK; GYSFIVTKP; YSFIVTKPG; SFIVTKPGG; FIVTKPGGN;IVTKPGGNI; VTKPGGNIW; TKPGGNIWV; KPGGNIWVL; PGGNIWVLL; GGNIWVLLF;GNIWVLLFK; NIWVLLFKC; IWVLLFKCF; WVLLFKCFF; VLLFKCFFS; LLFKCFFSK;LFKCFFSKF; FKCFFSKFT; KCFFSKFTL; CFFSKFTLT; FFSKFTLTL; FSKFTLTLP;SKFTLTLPS; KFTLTLPSK; SLKLSKLFI; LKLSKLFIP; KLSKLFIPC; LSKLFIPCP;SKLFIPCPE; KLFIPCPEG; LFIPCPEGK; FIPCPEGKS; IPCPEGKSF; PCPEGKSFD;CPEGKSFDS; PEGKSFDSA; EGKSFDSAP; GKSFDSAPV; KSFDSAPVP; SFDSAPVPF;FDSAPVPFT; DSAPVPFTS; SAPVPFTSS; APVPFTSSK; PVPFTSSKT; VPFTSSKTT;PFTSSKTTM; FTSSKTTMY; SIATPSSKV; IATPSSKVS; ATPSSKVSL; TPSSKVSLS;PSSKVSLSM; SSKVSLSMG; SKVSLSMGR; KVSLSMGRF; VSLSMGRFT; SLSMGRFTF;LSMGRFTFK; SMGRFTFKA; MGRFTFKAL; GRFTFKALP; RFTFKALPP; FTFKALPPH;TFKALPPHK; FKALPPHKS; KALPPHKSN; ALPPHKSNN; LPPHKSNNP; PPHKSNNPA;PHKSNNPAA; HKSNNPAAS; KSNNPAASV; SNNPAASVV; NNPAASVVF; NPAASVVFP;PAASVVFPL; AASVVFPLS; ASVVFPLSM; SVVFPLSMG; VVFPLSMGP; VFPLSMGPL;FPLSMGPLN; PLSMGPLNN; LSMGPLNNQ; SMGPLNNQY; MGPLNNQYL; GPLNNQYLL;PLNNQYLLL; LNNQYLLLG; NNQYLLLGT; NQYLLLGTL; QYLLLGTLK; YLLLGTLKT;LLLGTLKTI; LLGTLKTIQ; LGTLKTIQC; GTLKTIQCK; TLKTIQCKK; LKTIQCKKS;KTIQCKKSN; TIQCKKSNI; IQCKKSNIT; QCKKSNITE; CKKSNITES; KKSNITESI;KSNITESIL; SNITESILG; NITESILGS; ITESILGSK; TESILGSKQ; ESILGSKQC;SILGSKQCS; ILGSKQCSQ; LGSKQCSQA; GSKQCSQAT; SKQCSQATP; KQCSQATPA;QCSQATPAI; CSQATPAIY; SQATPAIYC; QATPAIYCS; ATPAIYCSS; TPAIYCSST;PAIYCSSTA; AIYCSSTAF; IYCSSTAFP; APNIKSILS; PNIKSILSN; NIKSILSNI;LNLSVSISS; NLSVSISSL; LSVSISSLV; SVSISSLVI; RVSTLFLAK; VSTLFLAKT;STLFLAKTV; TLFLAKTVS; LFLAKTVST; FLAKTVSTA; LAKTVSTAC; FLLSAKIIA;LLSAKIIAF; LSAKIIAFA; SAKIIAFAK; AKIIAFAKC; KIIAFAKCF; IIAFAKCFS;HFLHSSTLY; NSKYIPNNK; SKYIPNNKN; KYIPNNKNT; YIPNNKNTS; IPNNKNTSS;PNNKNTSSH; NNKNTSSHF; NKNTSSHFV; KNTSSHFVS; NTSSHFVST; TSSHFVSTA;SSHFVSTAY; SHFVSTAYS; HFVSTAYSV; FVSTAYSVI; VSTAYSVIN; STAYSVINF;TAYSVINFQ; AYSVINFQD; YSVINFQDT; SVINFQDTC; VINFQDTCF; INFQDTCFV;NFQDTCFVS; FQDTCFVSS; QDTCFVSSG; DTCFVSSGS; TCFVSSGSS; CFVSSGSSG;FVSSGSSGL; VSSGSSGLK; SSGSSGLKS; SGSSGLKSC; GSSGLKSCS; SSGLKSCSF;SGLKSCSFK; GLKSCSFKP; LKSCSFKPP; MLSSIVWYG; LSSIVWYGS; SSIVWYGSL;SIVWYGSLV; IVWYGSLVK; VWYGSLVKA; WYGSLVKAL; YGSLVKALY; GSLVKALYS;SLVKALYSK; LVKALYSKY; VKALYSKYS; KALYSKYSL; ALYSKYSLL; LYSKYSLLT;YSKYSLLTP; SKYSLLTPL; KYSLLTPLQ; YSLLTPLQI; SLLTPLQIK; LLTPLQIKK;LTPLQIKKL; TPLQIKKLK; PLQIKKLKV; LQIKKLKVH; QIKKLKVHS; IKKLKVHSF;QKLLIAETL; KLLIAETLC; LLIAETLCL; LIAETLCLC; IAETLCLCG; AETLCLCGV;ETLCLCGVK; TLCLCGVKK; LCLCGVKKN; CLCGVKKNI; LCGVKKNII; CGVKKNIIL;GVKKNIILC; VKKNIILCP; KKNIILCPA; KNIILCPAH; NIILCPAHM; IILCPAHMC;ILCPAHMCL; LCPAHMCLL; CPAHMCLLI; PAHMCLLIK; AHMCLLIKV; HMCLLIKVT;MCLLIKVTE; CLLIKVTEY; LLIKVTEYF; LIKVTEYFS; IKVTEYFSI; KVTEYFSIS;VTEYFSISF; TEYFSISFL; EYFSISFLY; YFSISFLYR; FSISFLYRI; AFSLVVYTA;FSLVVYTAK; SLVVYTAKQ; LVVYTAKQA; VVYTAKQAR; VYTAKQARV; YTAKQARVL;TAKQARVLL; AKQARVLLL; KQARVLLLN; QARVLLLNT; ARVLLLNTA; LRNWCRSEG;RNWCRSEGK; NWCRSEGKS; WCRSEGKSL; CRSEGKSLG; RSEGKSLGS; SEGKSLGSS;EGKSLGSST; GKSLGSSTF; KSLGSSTFL; SLGSSTFLF; LGSSTFLFF; GSSTFLFFL;SSTFLFFLG; STFLFFLGG; TFLFFLGGV; FLFFLGGVE; LFFLGGVEC; ESAVASSSL;SAVASSSLA; AVASSSLAN; VASSSLANI; ASSSLANIS; SSSLANISS; SSLANISSW;SLANISSWQ; LANISSWQN; ANISSWQNK; NISSWQNKS; ISSWQNKSS; SSWQNKSSS;SWQNKSSSH; WQNKSSSHF; QNKSSSHFS; NKSSSHFSL; KSSSHFSLK; SSSHFSLKE;SSHFSLKEL; SHFSLKELH; HFSLKELHQ; FSLKELHQD; SLKELHQDS; LKELHQDSH;KELHQDSHS; ELHQDSHSS; LHQDSHSSV; HQDSHSSVP; VGTYKKNNY; GTYKKNNYL;TYKKNNYLG; YKKNNYLGP; KKNNYLGPF; KNNYLGPFN; NNYLGPFNI; NYLGPFNIL;YLGPFNILL; LGPFNILLF; GPFNILLFI; VSYLKALDL; REFLQLFGP; EFLQLFGPT;FLQLFGPTI; LQLFGPTIA; QLFGPTIAE; LFGPTIAEF; FGPTIAEFL; GPTIAEFLQ;PTIAEFLQL; TIAEFLQLG; IAEFLQLGL; AEFLQLGLS; EFLQLGLSQ; FLQLGLSQT;LQLGLSQTT; QLGLSQTTV; SSQCSSNLS; SQCSSNLSK; QCSSNLSKP; CSSNLSKPR;SSNLSKPRA; SNLSKPRAL; NLSKPRALF; LSKPRALFL; SKPRALFLK; KPRALFLKI;PRALFLKIF; RALFLKIFY; ALFLKIFYL; LFLKIFYLN; FLKIFYLNA; LKIFYLNAL;KIFYLNALI; ADIACKGSA; DIACKGSAQ; IACKGSAQK; ACKGSAQKA; CKGSAQKAF;KGSAQKAFW; GSAQKAFWN; SAQKAFWNK; AIPCSTGYL; IPCSTGYLG; PCSTGYLGK;CSTGYLGKE; STGYLGKEE; TGYLGKEEN; GYLGKEENQ; YLGKEENQH; LGKEENQHK;GKEENQHKP; KEENQHKPL; EENQHKPLS; ENQHKPLSY; NQHKPLSYS; QHKPLSYSR;HKPLSYSRF; KPLSYSRFQ; PLSYSRFQN; LSYSRFQNQ; SYSRFQNQA; YSRFQNQAD;SRFQNQADE; RFQNQADEL; FQNQADELP; QNQADELPL; NQADELPLH; QADELPLHP;ADELPLHPA; DELPLHPAP; ELPLHPAPF; LPLHPAPFF; PLHPAPFFY; LHPAPFFYT;HPAPFFYTK; PAPFFYTKY; APFFYTKYS; PFFYTKYSF; FFYTKYSFS; FYTKYSFSS;YTKYSFSSF; TKYSFSSFY; KYSFSSFYP; YSFSSFYPR; SFSSFYPRR; FSSFYPRRP;SSFYPRRPL; SFYPRRPLC; FYPRRPLCQ; YPRRPLCQG; PRRPLCQGE; RRPLCQGEI;RPLCQGEIP; PLCQGEIPY; LCQGEIPYT; CQGEIPYTS; QGEIPYTSL; GEIPYTSLN;EIPYTSLNK; IPYTSLNKL; PYTSLNKLF; YTSLNKLFS; TSLNKLFSL; SLNKLFSLR;LNKLFSLRE; NKLFSLRED; KLFSLREDF; LFSLREDFP; FSLREDFPR; SLREDFPRQ;LREDFPRQL; REDFPRQLF; EDFPRQLFQ; DFPRQLFQG; FPRQLFQGL; PRQLFQGLK;RQLFQGLKG; QLFQGLKGP 10 mers:GFPQIVLLGL; FPQIVLLGLR; PQIVLLGLRK; QIVLLGLRKS; IVLLGLRKSL;VLLGLRKSLH; LLGLRKSLHT; LGLRKSLHTL; GLRKSLHTLT; LRKSLHTLTT;EKGWRQRRPR; KGWRQRRPRP; GWRQRRPRPL; WRQRRPRPLI; RQRRPRPLIY;QRRPRPLIYY; RRPRPLIYYK; RPRPLIYYKK; PRPLIYYKKK; RPLIYYKKKG;PLIYYKKKGH; LIYYKKKGHR; IYYKKKGHRE; YYKKKGHREE; YKKKGHREEL;KKKGHREELL; KKGHREELLT; KGHREELLTH; GHREELLTHG; HREELLTHGM;REELLTHGMQ; EELLTHGMQP; ELLTHGMQPN; LLTHGMQPNH; LTHGMQPNHD;THGMQPNHDL; HGMQPNHDLR; GMQPNHDLRK; MQPNHDLRKE; QPNHDLRKES;PNHDLRKESA; LTGECSQTMT; TGECSQTMTS; GECSQTMTSG; ECSQTMTSGR;CSQTMTSGRK; SQTMTSGRKV; QTMTSGRKVH; TMTSGRKVHD; MTSGRKVHDS;TSGRKVHDSQ; SGRKVHDSQG; GRKVHDSQGG; RKVHDSQGGA; KVHDSQGGAA;VHDSQGGAAY; HDSQGGAAYP; DSQGGAAYPW; SQGGAAYPWN; QGGAAYPWNA;GGAAYPWNAA; GAAYPWNAAK; AAYPWNAAKP; PQEGKCMTDM; QEGKCMTDMF;EGKCMTDMFC; GKCMTDMFCE; KCMTDMFCEP; CMTDMFCEPR; MTDMFCEPRN;TDMFCEPRNL; DMFCEPRNLG; MFCEPRNLGL; FCEPRNLGLV; CEPRNLGLVP;EPRNLGLVPS; TGQRPWFCAS; GQRPWFCASC; QRPWFCASCH; RPWFCASCHD;PWFCASCHDK; WFCASCHDKL; FCASCHDKLQ; KLVKPGLEQK; LVKPGLEQKK;VKPGLEQKKE; KPGLEQKKEL; PGLEQKKELR; GLEQKKELRG; LEQKKELRGF;EQKKELRGFL; QKKELRGFLF; KKELRGFLFL; KELRGFLFLF; SFCWNFVEVK;FCWNFVEVKT; CWNFVEVKTV; TGKTKVPLLY; GKTKVPLLYL; KTKVPLLYLL;VIPFFLYFQV; IPFFLYFQVH; PFFLYFQVHG; FFLYFQVHGC; FLYFQVHGCC;LYFQVHGCCS; YFQVHGCCSS; FQVHGCCSST; QVHGCCSSTF; VHGCCSSTFG;HGCCSSTFGG; GCCSSTFGGP; CCSSTFGGPS; CSSTFGGPSC; SSTFGGPSCQ;STFGGPSCQC; TFGGPSCQCI; GCCCHRIFSG; NCCWGGCCCY; CCWGGCCCYR;CWGGCCCYRS; WGGCCCYRSS; GGCCCYRSSN; GCCCYRSSNC; CCCYRSSNCI;CCYRSSNCIP; CYRSSNCIPC; YRSSNCIPCY; RSSNCIPCYC; SSNCIPCYCR;SNCIPCYCRG; NCIPCYCRGH; CIPCYCRGHN; IPCYCRGHNK; PCYCRGHNKY;CYCRGHNKYL; YCRGHNKYLR; CRGHNKYLRG; RGHNKYLRGY; GHNKYLRGYS;HNKYLRGYSC; NKYLRGYSCY; KYLRGYSCYR; YLRGYSCYRP; LRGYSCYRPN;RGYSCYRPNS; GYSCYRPNSS; YSCYRPNSSN; SCYRPNSSNI; CYRPNSSNIC;YRPNSSNICC; RPNSSNICCN; PNSSNICCNC; NSSNICCNCW; SSNICCNCWC;SNICCNCWCS; NICCNCWCSW; ICCNCWCSWG; CCNCWCSWGY; CNCWCSWGYC;NCWCSWGYCW; CWCSWGYCWV; WCSWGYCWVC; CSWGYCWVCC; SWGYCWVCCF;WGYCWVCCFN; GYCWVCCFNS; YCWVCCFNSN; CWVCCFNSNC; LGSQSFHCRP;GSQSFHCRPL; SQSFHCRPLS; QSFHCRPLSA; SFHCRPLSAI; FHCRPLSAIR;HCRPLSAIRH; CRPLSAIRHG; RPLSAIRHGF; PLSAIRHGFG; LSAIRHGFGI;SAIRHGFGIV; YSVSWCKYFC; ALGSFFVCYY; LGSFFVCYYF; GSFFVCYYFP;SFFVCYYFPG; FFVCYYFPGF; FVCYYFPGFV; VCYYFPGFVA; CYYFPGFVAC;YYFPGFVACY; YTFYNLTGIA; TFYNLTGIAE; FYNLTGIAEK; YNLTGIAEKN;NLTGIAEKNR; LTGIAEKNRK; TGIAEKNRKI; GIAEKNRKIF; IFGGNYLDNC;FGGNYLDNCK; GGNYLDNCKC; GNYLDNCKCP; NYLDNCKCPY; YLDNCKCPYK;LDNCKCPYKL; DNCKCPYKLL; KGRYPCTFWP; GRYPCTFWPY; RYPCTFWPYL;QYRRSYTKNG; YRRSYTKNGL; RRSYTKNGLK; RSYTKNGLKK; SYTKNGLKKS;YTKNGLKKST; TKNGLKKSTK; KNGLKKSTKC; NGLKKSTKCT; GLKKSTKCTF;LKKSTKCTFR; KKSTKCTFRR; KSTKCTFRRV; STKCTFRRVY; TKCTFRRVYR;KCTFRRVYRK; CTFRRVYRKN; TFRRVYRKNY; FRRVYRKNYC; RRVYRKNYCP;RVYRKNYCPR; VYRKNYCPRR; YRKNYCPRRC; SKNCSSMDVA; KNCSSMDVAF;NCSSMDVAFT; CSSMDVAFTS; SSMDVAFTSR; SMDVAFTSRP; MDVAFTSRPV;DVAFTSRPVR; VAFTSRPVRD; AFTSRPVRDC; FTSRPVRDCN; TSRPVRDCNT;SRPVRDCNTC; RPVRDCNTCS; RWPQPKEKES; WPQPKEKESV; PQPKEKESVQ;QPKEKESVQG; PKEKESVQGQ; KEKESVQGQL; EKESVQGQLP; KESVQGQLPK;ESVQGQLPKS; SVQGQLPKSQ; VQGQLPKSQR; QGQLPKSQRN; GQLPKSQRNP;QLPKSQRNPC; LPKSQRNPCK; PKSQRNPCKC; KSQRNPCKCQ; SQRNPCKCQN;QRNPCKCQNY; TQKWGIQMKT; QKWGIQMKTL; KWGIQMKTLG; WGIQMKTLGA;GIQMKTLGAL; IQMKTLGALV; VLKMTLAVIA; LKMTLAVIAQ; KMTLAVIAQR;MTLAVIAQRE; TLAVIAQREK; LAVIAQREKC; AVIAQREKCF; VIAQREKCFP;IAQREKCFPV; AQREKCFPVT; QREKCFPVTA; REKCFPVTAQ; EKCFPVTAQQ;KCFPVTAQQE; CFPVTAQQEF; FPVTAQQEFP; PVTAQQEFPS; VTAQQEFPSP;TAQQEFPSPI; LACLTFMQGH; ACLTFMQGHK; CLTFMQGHKK; LTFMQGHKKC;TFMQGHKKCM; FMQGHKKCMS; MQGHKKCMSM; QGHKKCMSMV; GHKKCMSMVE;HKKCMSMVEE; KKCMSMVEEN; KCMSMVEENL; CMSMVEENLF; MSMVEENLFK;SMVEENLFKA; MVEENLFKAV; VEENLFKAVI; EENLFKAVIS; ENLFKAVIST;NLFKAVISTS; LFKAVISTSL; FKAVISTSLL; VENPWKCREC; ITGQSTLMVL;PLKTQQPSPR; ILTIRPIWTK; LTIRPIWTKT; TIRPIWTKTM; IRPIWTKTML;RPIWTKTMLI; PIWTKTMLIQ; IWTKTMLIQL; WTKTMLIQLS; TKTMLIQLSA;KTMLIQLSAG; TMLIQLSAGY; MLIQLSAGYL; LIQLSAGYLI; IQLSAGYLIP;QLSAGYLIPV; LSAGYLIPVE; SAGYLIPVEM; AGYLIPVEMK; GYLIPVEMKM;YLIPVEMKML; LIPVEMKMLG; IPVEMKMLGI; PVEMKMLGIL; VEMKMLGILG;EMKMLGILGL; MKMLGILGLS; KMLGILGLSQ; MLGILGLSQE; LGILGLSQEG;GILGLSQEGK; ILGLSQEGKM; LGLSQEGKMF; GLSQEGKMFP; LSQEGKMFPQ;SQEGKMFPQY; QEGKMFPQYF; EGKMFPQYFM; MNRVWGLFVK; NRVWGLFVKL;RVWGLFVKLI; VWGLFVKLIA; WGLFVKLIAC; GLFVKLIACM; LFVKLIACMF;FVKLIACMFQ; VKLIACMFQL; KLIACMFQLL; LIACMFQLLI; IACMFQLLIF;ACMFQLLIFV; CMFQLLIFVA; MFQLLIFVAC; FQLLIFVACL; QLLIFVACLL;LLIFVACLLT; LIFVACLLTA; IFVACLLTAL; FVACLLTALE; VACLLTALEH;ACLLTALEHN; CLLTALEHNS; LLTALEHNSG; LTALEHNSGE; TALEHNSGEA;ALEHNSGEAL; LEHNSGEALQ; EHNSGEALQD; HNSGEALQDI; NSGEALQDIL;SGEALQDILR; GEALQDILRS; EALQDILRSA; TGEPREWMGS; GEPREWMGSL;EPREWMGSLC; PREWMGSLCM; REWMGSLCMV; EWMGSLCMVW; WMGSLCMVWN;MGSLCMVWNP; GSLCMVWNPR; KRLGCLMAQK; RLGCLMAQKD; LGCLMAQKDF;GCLMAQKDFQ; CLMAQKDFQG; LMAQKDFQGT; MAQKDFQGTQ; AQKDFQGTQI;DILTNRDNCK; ILTNRDNCKP; LTNRDNCKPK; TNRDNCKPKC; NRDNCKPKCF;RDNCKPKCFK; DNCKPKCFKQ; NCKPKCFKQV; CKPKCFKQVL; KPKCFKQVLL;PKCFKQVLLL; KCFKQVLLLY; CFKQVLLLYI; FKQVLLLYIY; KQVLLLYIYI;MLLLYKPLLS; LLLYKPLLSL; LLYKPLLSLC; LYKPLLSLCY; YKPLLSLCYF;KPLLSLCYFG; PLLSLCYFGG; LLSLCYFGGG; LSLCYFGGGV; SLCYFGGGVL;LCYFGGGVLG; CYFGGGVLGL; YFGGGVLGLL; FGGGVLGLLK; GGGVLGLLKH;LWGSDLWESS; WGSDLWESSA; GSDLWESSAG; SDLWESSAGA; DLWESSAGAE;LWESSAGAEV; WESSAGAEVS; ESSAGAEVSE; SSAGAEVSET; SAGAEVSETW;AGAEVSETWE; GAEVSETWEE; AEVSETWEEH; EVSETWEEHC; VSETWEEHCD;SETWEEHCDW; ETWEEHCDWD; TWEEHCDWDS; WEEHCDWDSV; EEHCDWDSVL;EHCDWDSVLD; HCDWDSVLDP; CDWDSVLDPC; DWDSVLDPCP; WDSVLDPCPE;DSVLDPCPES; SVLDPCPESS; VLDPCPESSV; LDPCPESSVS; DPCPESSVSE;PCPESSVSES; CPESSVSESS; PESSVSESSS; ESSVSESSSL; SSVSESSSLV;SVSESSSLVI; VSESSSLVIS; SESSSLVISR; ESSSLVISRI; SSSLVISRIH;SSLVISRIHF; SLVISRIHFP; LVISRIHFPM; VISRIHFPMH; ISRIHFPMHI;SRIHFPMHIL; RIHFPMHILY; IHFPMHILYF; HFPMHILYFI; FPMHILYFIL;PMHILYFILE; MHILYFILEK; HILYFILEKV; ILYFILEKVY; LYFILEKVYI;YFILEKVYIL; FILEKVYILI; ILEKVYILIS; LEKVYILISE; EKVYILISES;KVYILISESS; VYILISESSL; YILISESSLS; ILISESSLSF; LISESSLSFH;ISESSLSFHS; SESSLSFHST; ESSLSFHSTI; SSLSFHSTIL; SLSFHSTILD;LSFHSTILDC; SFHSTILDCI; FHSTILDCIS; HSTILDCISV; STILDCISVA;TILDCISVAK; ILDCISVAKS; LDCISVAKSA; DCISVAKSAT; CISVAKSATG;ISVAKSATGL; SVAKSATGLN; VAKSATGLNQ; AKSATGLNQI; KSATGLNQIS;SATGLNQISS; ATGLNQISSS; TGLNQISSSN; GLNQISSSNK; LNQISSSNKV;NQISSSNKVI; QISSSNKVIP; ISSSNKVIPL; SSSNKVIPLC; SSNKVIPLCK;SNKVIPLCKI; NKVIPLCKIL; KVIPLCKILF; VIPLCKILFS; IPLCKILFSS;PLCKILFSSK; LCKILFSSKN; CKILFSSKNS; KILFSSKNSE; ILFSSKNSEF;LFSSKNSEFC; FSSKNSEFCK; SSKNSEFCKD; SKNSEFCKDF; KNSEFCKDFL;NSEFCKDFLK; SEFCKDFLKY; EFCKDFLKYI; FCKDFLKYIL; CKDFLKYILG;KDFLKYILGL; DFLKYILGLK; FLKYILGLKS; LKYILGLKSI; KYILGLKSIC;YILGLKSICL; ILGLKSICLT; LGLKSICLTN; GLKSICLTNL; LKSICLTNLA;KSICLTNLAC; SICLTNLACR; ICLTNLACRV; CLTNLACRVL; LTNLACRVLG;TNLACRVLGT; NLACRVLGTG; LACRVLGTGY; ACRVLGTGYS; CRVLGTGYSF;RVLGTGYSFI; VLGTGYSFIV; LGTGYSFIVT; GTGYSFIVTK; TGYSFIVTKP;GYSFIVTKPG; YSFIVTKPGG; SFIVTKPGGN; FIVTKPGGNI; IVTKPGGNIW;VTKPGGNIWV; TKPGGNIWVL; KPGGNIWVLL; PGGNIWVLLF; GGNIWVLLFK;GNIWVLLFKC; NIWVLLFKCF; IWVLLFKCFF; WVLLFKCFFS; VLLFKCFFSK;LLFKCFFSKF; LFKCFFSKFT; FKCFFSKFTL; KCFFSKFTLT; CFFSKFTLTL;FFSKFTLTLP; FSKFTLTLPS; SKFTLTLPSK; SLKLSKLFIP; LKLSKLFIPC;KLSKLFIPCP; LSKLFIPCPE; SKLFIPCPEG; KLFIPCPEGK; LFIPCPEGKS;FIPCPEGKSF; IPCPEGKSFD; PCPEGKSFDS; CPEGKSFDSA; PEGKSFDSAP;EGKSFDSAPV; GKSFDSAPVP; KSFDSAPVPF; SFDSAPVPFT; FDSAPVPFTS;DSAPVPFTSS; SAPVPFTSSK; APVPFTSSKT; PVPFTSSKTT; VPFTSSKTTM;PFTSSKTTMY; SIATPSSKVS; IATPSSKVSL; ATPSSKVSLS; TPSSKVSLSM;PSSKVSLSMG; SSKVSLSMGR; SKVSLSMGRF; KVSLSMGRFT; VSLSMGRFTF;SLSMGRFTFK; LSMGRFTFKA; SMGRFTFKAL; MGRFTFKALP; GRFTFKALPP;RFTFKALPPH; FTFKALPPHK; TFKALPPHKS; FKALPPHKSN; KALPPHKSNN;ALPPHKSNNP; LPPHKSNNPA; PPHKSNNPAA; PHKSNNPAAS; HKSNNPAASV;KSNNPAASVV; SNNPAASVVF; NNPAASVVFP; NPAASVVFPL; PAASVVFPLS;AASVVFPLSM; ASVVFPLSMG; SVVFPLSMGP; VVFPLSMGPL; VFPLSMGPLN;FPLSMGPLNN; PLSMGPLNNQ; LSMGPLNNQY; SMGPLNNQYL; MGPLNNQYLL;GPLNNQYLLL; PLNNQYLLLG; LNNQYLLLGT; NNQYLLLGTL; NQYLLLGTLK;QYLLLGTLKT; YLLLGTLKTI; LLLGTLKTIQ; LLGTLKTIQC; LGTLKTIQCK;GTLKTIQCKK; TLKTIQCKKS; LKTIQCKKSN; KTIQCKKSNI; TIQCKKSNIT;IQCKKSNITE; QCKKSNITES; CKKSNITESI; KKSNITESIL; KSNITESILG;SNITESILGS; NITESILGSK; ITESILGSKQ; TESILGSKQC; ESILGSKQCS;SILGSKQCSQ; ILGSKQCSQA; LGSKQCSQAT; GSKQCSQATP; SKQCSQATPA;KQCSQATPAI; QCSQATPAIY; CSQATPAIYC; SQATPAIYCS; QATPAIYCSS;ATPAIYCSST; TPAIYCSSTA; PAIYCSSTAF; AIYCSSTAFP; APNIKSILSN;PNIKSILSNI; LNLSVSISSL; NLSVSISSLV; LSVSISSLVI; RVSTLFLAKT;VSTLFLAKTV; STLFLAKTVS; TLFLAKTVST; LFLAKTVSTA; FLAKTVSTAC;FLLSAKIIAF; LLSAKIIAFA; LSAKIIAFAK; SAKIIAFAKC; AKIIAFAKCF;KIIAFAKCFS; NSKYIPNNKN; SKYIPNNKNT; KYIPNNKNTS; YIPNNKNTSS;IPNNKNTSSH; PNNKNTSSHF; NNKNTSSHFV; NKNTSSHFVS; KNTSSHFVST;NTSSHFVSTA; TSSHFVSTAY; SSHFVSTAYS; SHFVSTAYSV; HFVSTAYSVI;FVSTAYSVIN; VSTAYSVINF; STAYSVINFQ; TAYSVINFQD; AYSVINFQDT;YSVINFQDTC; SVINFQDTCF; VINFQDTCFV; INFQDTCFVS; NFQDTCFVSS;FQDTCFVSSG; QDTCFVSSGS; DTCFVSSGSS; TCFVSSGSSG; CFVSSGSSGL;FVSSGSSGLK; VSSGSSGLKS; SSGSSGLKSC; SGSSGLKSCS; GSSGLKSCSF;SSGLKSCSFK; SGLKSCSFKP; GLKSCSFKPP; MLSSIVWYGS; LSSIVWYGSL;SSIVWYGSLV; SIVWYGSLVK; IVWYGSLVKA; VWYGSLVKAL; WYGSLVKALY;YGSLVKALYS; GSLVKALYSK; SLVKALYSKY; LVKALYSKYS; VKALYSKYSL;KALYSKYSLL; ALYSKYSLLT; LYSKYSLLTP; YSKYSLLTPL; SKYSLLTPLQ;KYSLLTPLQI; YSLLTPLQIK; SLLTPLQIKK; LLTPLQIKKL; LTPLQIKKLK;TPLQIKKLKV; PLQIKKLKVH; LQIKKLKVHS; QIKKLKVHSF; QKLLIAETLC;KLLIAETLCL; LLIAETLCLC; LIAETLCLCG; IAETLCLCGV; AETLCLCGVK;ETLCLCGVKK; TLCLCGVKKN; LCLCGVKKNI; CLCGVKKNII; LCGVKKNIIL;CGVKKNIILC; GVKKNIILCP; VKKNIILCPA; KKNIILCPAH; KNIILCPAHM;NIILCPAHMC; IILCPAHMCL; ILCPAHMCLL; LCPAHMCLLI; CPAHMCLLIK;PAHMCLLIKV; AHMCLLIKVT; HMCLLIKVTE; MCLLIKVTEY; CLLIKVTEYF;LLIKVTEYFS; LIKVTEYFSI; IKVTEYFSIS; KVTEYFSISF; VTEYFSISFL;TEYFSISFLY; EYFSISFLYR; YFSISFLYRI; AFSLVVYTAK; FSLVVYTAKQ;SLVVYTAKQA; LVVYTAKQAR; VVYTAKQARV; VYTAKQARVL; YTAKQARVLL;TAKQARVLLL; AKQARVLLLN; KQARVLLLNT; QARVLLLNTA; LRNWCRSEGK;RNWCRSEGKS; NWCRSEGKSL; WCRSEGKSLG; CRSEGKSLGS; RSEGKSLGSS;SEGKSLGSST; EGKSLGSSTF; GKSLGSSTFL; KSLGSSTFLF; SLGSSTFLFF;LGSSTFLFFL; GSSTFLFFLG; SSTFLFFLGG; STFLFFLGGV; TFLFFLGGVE;FLFFLGGVEC; ESAVASSSLA; SAVASSSLAN; AVASSSLANI; VASSSLANIS;ASSSLANISS; SSSLANISSW; SSLANISSWQ; SLANISSWQN; LANISSWQNK;ANISSWQNKS; NISSWQNKSS; ISSWQNKSSS; SSWQNKSSSH; SWQNKSSSHF;WQNKSSSHFS; QNKSSSHFSL; NKSSSHFSLK; KSSSHFSLKE; SSSHFSLKEL;SSHFSLKELH; SHFSLKELHQ; HFSLKELHQD; FSLKELHQDS; SLKELHQDSH;LKELHQDSHS; KELHQDSHSS; ELHQDSHSSV; LHQDSHSSVP; VGTYKKNNYL;GTYKKNNYLG; TYKKNNYLGP; YKKNNYLGPF; KKNNYLGPFN; KNNYLGPFNI;NNYLGPFNIL; NYLGPFNILL; YLGPFNILLF; LGPFNILLFI; REFLQLFGPT;EFLQLFGPTI; FLQLFGPTIA; LQLFGPTIAE; QLFGPTIAEF; LFGPTIAEFL;FGPTIAEFLQ; GPTIAEFLQL; PTIAEFLQLG; TIAEFLQLGL; IAEFLQLGLS;AEFLQLGLSQ; EFLQLGLSQT; FLQLGLSQTT; LQLGLSQTTV; SSQCSSNLSK;SQCSSNLSKP; QCSSNLSKPR; CSSNLSKPRA; SSNLSKPRAL; SNLSKPRALF;NLSKPRALFL; LSKPRALFLK; SKPRALFLKI; KPRALFLKIF; PRALFLKIFY;RALFLKIFYL; ALFLKIFYLN; LFLKIFYLNA; FLKIFYLNAL; LKIFYLNALI;ADIACKGSAQ; DIACKGSAQK; IACKGSAQKA; ACKGSAQKAF; CKGSAQKAFW;KGSAQKAFWN; GSAQKAFWNK; AIPCSTGYLG; IPCSTGYLGK; PCSTGYLGKE;CSTGYLGKEE; STGYLGKEEN; TGYLGKEENQ; GYLGKEENQH; YLGKEENQHK;LGKEENQHKP; GKEENQHKPL; KEENQHKPLS; EENQHKPLSY; ENQHKPLSYS;NQHKPLSYSR; QHKPLSYSRF; HKPLSYSRFQ; KPLSYSRFQN; PLSYSRFQNQ;LSYSRFQNQA; SYSRFQNQAD; YSRFQNQADE; SRFQNQADEL; RFQNQADELP;FQNQADELPL; QNQADELPLH; NQADELPLHP; QADELPLHPA; ADELPLHPAP;DELPLHPAPF; ELPLHPAPFF; LPLHPAPFFY; PLHPAPFFYT; LHPAPFFYTK;HPAPFFYTKY; PAPFFYTKYS; APFFYTKYSF; PFFYTKYSFS; FFYTKYSFSS;FYTKYSFSSF; YTKYSFSSFY; TKYSFSSFYP; KYSFSSFYPR; YSFSSFYPRR;SFSSFYPRRP; FSSFYPRRPL; SSFYPRRPLC; SFYPRRPLCQ; FYPRRPLCQG;YPRRPLCQGE; PRRPLCQGEI; RRPLCQGEIP; RPLCQGEIPY; PLCQGEIPYT;LCQGEIPYTS; CQGEIPYTSL; QGEIPYTSLN; GEIPYTSLNK; EIPYTSLNKL;IPYTSLNKLF; PYTSLNKLFS; YTSLNKLFSL; TSLNKLFSLR; SLNKLFSLRE;LNKLFSLRED; NKLFSLREDF; KLFSLREDFP; LFSLREDFPR; FSLREDFPRQ;SLREDFPRQL; LREDFPRQLF; REDFPRQLFQ; EDFPRQLFQG; DFPRQLFQGL;FPRQLFQGLK; PRQLFQGLKG; RQLFQGLKGP 11 mers:GFPQIVLLGLR; FPQIVLLGLRK; PQIVLLGLRKS; QIVLLGLRKSL; IVLLGLRKSLH;VLLGLRKSLHT; LLGLRKSLHTL; LGLRKSLHTLT; GLRKSLHTLTT; EKGWRQRRPRP;KGWRQRRPRPL; GWRQRRPRPLI; WRQRRPRPLIY; RQRRPRPLIYY; QRRPRPLIYYK;RRPRPLIYYKK; RPRPLIYYKKK; PRPLIYYKKKG; RPLIYYKKKGH; PLIYYKKKGHR;LIYYKKKGHRE; IYYKKKGHREE; YYKKKGHREEL; YKKKGHREELL; KKKGHREELLT;KKGHREELLTH; KGHREELLTHG; GHREELLTHGM; HREELLTHGMQ; REELLTHGMQP;EELLTHGMQPN; ELLTHGMQPNH; LLTHGMQPNHD; LTHGMQPNHDL; THGMQPNHDLR;HGMQPNHDLRK; GMQPNHDLRKE; MQPNHDLRKES; QPNHDLRKESA; LTGECSQTMTS;TGECSQTMTSG; GECSQTMTSGR; ECSQTMTSGRK; CSQTMTSGRKV; SQTMTSGRKVH;QTMTSGRKVHD; TMTSGRKVHDS; MTSGRKVHDSQ; TSGRKVHDSQG; SGRKVHDSQGG;GRKVHDSQGGA; RKVHDSQGGAA; KVHDSQGGAAY; VHDSQGGAAYP; HDSQGGAAYPW;DSQGGAAYPWN; SQGGAAYPWNA; QGGAAYPWNAA; GGAAYPWNAAK; GAAYPWNAAKP;PQEGKCMTDMF; QEGKCMTDMFC; EGKCMTDMFCE; GKCMTDMFCEP; KCMTDMFCEPR;CMTDMFCEPRN; MTDMFCEPRNL; TDMFCEPRNLG; DMFCEPRNLGL; MFCEPRNLGLV;FCEPRNLGLVP; CEPRNLGLVPS; TGQRPWFCASC; GQRPWFCASCH; QRPWFCASCHD;RPWFCASCHDK; PWFCASCHDKL; WFCASCHDKLQ; KLVKPGLEQKK; LVKPGLEQKKE;VKPGLEQKKEL; KPGLEQKKELR; PGLEQKKELRG; GLEQKKELRGF; LEQKKELRGFL;EQKKELRGFLF; QKKELRGFLFL; KKELRGFLFLF; SFCWNFVEVKT; FCWNFVEVKTV;TGKTKVPLLYL; GKTKVPLLYLL; VIPFFLYFQVH; IPFFLYFQVHG; PFFLYFQVHGC;FFLYFQVHGCC; FLYFQVHGCCS; LYFQVHGCCSS; YFQVHGCCSST; FQVHGCCSSTF;QVHGCCSSTFG; VHGCCSSTFGG; HGCCSSTFGGP; GCCSSTFGGPS; CCSSTFGGPSC;CSSTFGGPSCQ; SSTFGGPSCQC; STFGGPSCQCI; NCCWGGCCCYR; CCWGGCCCYRS;CWGGCCCYRSS; WGGCCCYRSSN; GGCCCYRSSNC; GCCCYRSSNCI; CCCYRSSNCIP;CCYRSSNCIPC; CYRSSNCIPCY; YRSSNCIPCYC; RSSNCIPCYCR; SSNCIPCYCRG;SNCIPCYCRGH; NCIPCYCRGHN; CIPCYCRGHNK; IPCYCRGHNKY; PCYCRGHNKYL;CYCRGHNKYLR; YCRGHNKYLRG; CRGHNKYLRGY; RGHNKYLRGYS; GHNKYLRGYSC;HNKYLRGYSCY; NKYLRGYSCYR; KYLRGYSCYRP; YLRGYSCYRPN; LRGYSCYRPNS;RGYSCYRPNSS; GYSCYRPNSSN; YSCYRPNSSNI; SCYRPNSSNIC; CYRPNSSNICC;YRPNSSNICCN; RPNSSNICCNC; PNSSNICCNCW; NSSNICCNCWC; SSNICCNCWCS;SNICCNCWCSW; NICCNCWCSWG; ICCNCWCSWGY; CCNCWCSWGYC; CNCWCSWGYCW;NCWCSWGYCWV; CWCSWGYCWVC; WCSWGYCWVCC; CSWGYCWVCCF; SWGYCWVCCFN;WGYCWVCCFNS; GYCWVCCFNSN; YCWVCCFNSNC; LGSQSFHCRPL; GSQSFHCRPLS;SQSFHCRPLSA; QSFHCRPLSAI; SFHCRPLSAIR; FHCRPLSAIRH; HCRPLSAIRHG;CRPLSAIRHGF; RPLSAIRHGFG; PLSAIRHGFGI; LSAIRHGFGIV; ALGSFFVCYYF;LGSFFVCYYFP; GSFFVCYYFPG; SFFVCYYFPGF; FFVCYYFPGFV; FVCYYFPGFVA;VCYYFPGFVAC; CYYFPGFVACY; YTFYNLTGIAE; TFYNLTGIAEK; FYNLTGIAEKN;YNLTGIAEKNR; NLTGIAEKNRK; LTGIAEKNRKI; TGIAEKNRKIF; IFGGNYLDNCK;FGGNYLDNCKC; GGNYLDNCKCP; GNYLDNCKCPY; NYLDNCKCPYK; YLDNCKCPYKL;LDNCKCPYKLL; KGRYPCTFWPY; GRYPCTFWPYL; QYRRSYTKNGL; YRRSYTKNGLK;RRSYTKNGLKK; RSYTKNGLKKS; SYTKNGLKKST; YTKNGLKKSTK; TKNGLKKSTKC;KNGLKKSTKCT; NGLKKSTKCTF; GLKKSTKCTFR; LKKSTKCTFRR; KKSTKCTFRRV;KSTKCTFRRVY; STKCTFRRVYR; TKCTFRRVYRK; KCTFRRVYRKN; CTFRRVYRKNY;TFRRVYRKNYC; FRRVYRKNYCP; RRVYRKNYCPR; RVYRKNYCPRR; VYRKNYCPRRC;SKNCSSMDVAF; KNCSSMDVAFT; NCSSMDVAFTS; CSSMDVAFTSR; SSMDVAFTSRP;SMDVAFTSRPV; MDVAFTSRPVR; DVAFTSRPVRD; VAFTSRPVRDC; AFTSRPVRDCN;FTSRPVRDCNT; TSRPVRDCNTC; SRPVRDCNTCS; RWPQPKEKESV; WPQPKEKESVQ;PQPKEKESVQG; QPKEKESVQGQ; PKEKESVQGQL; KEKESVQGQLP; EKESVQGQLPK;KESVQGQLPKS; ESVQGQLPKSQ; SVQGQLPKSQR; VQGQLPKSQRN; QGQLPKSQRNP;GQLPKSQRNPC; QLPKSQRNPCK; LPKSQRNPCKC; PKSQRNPCKCQ; KSQRNPCKCQN;SQRNPCKCQNY; TQKWGIQMKTL; QKWGIQMKTLG; KWGIQMKTLGA; WGIQMKTLGAL;GIQMKTLGALV; VLKMTLAVIAQ; LKMTLAVIAQR; KMTLAVIAQRE; MTLAVIAQREK;TLAVIAQREKC; LAVIAQREKCF; AVIAQREKCFP; VIAQREKCFPV; IAQREKCFPVT;AQREKCFPVTA; QREKCFPVTAQ; REKCFPVTAQQ; EKCFPVTAQQE; KCFPVTAQQEF;CFPVTAQQEFP; FPVTAQQEFPS; PVTAQQEFPSP; VTAQQEFPSPI; LACLTFMQGHK;ACLTFMQGHKK; CLTFMQGHKKC; LTFMQGHKKCM; TFMQGHKKCMS; FMQGHKKCMSM;MQGHKKCMSMV; QGHKKCMSMVE; GHKKCMSMVEE; HKKCMSMVEEN; KKCMSMVEENL;KCMSMVEENLF; CMSMVEENLFK; MSMVEENLFKA; SMVEENLFKAV; MVEENLFKAVI;VEENLFKAVIS; EENLFKAVIST; ENLFKAVISTS; NLFKAVISTSL; LFKAVISTSLL;ILTIRPIWTKT; LTIRPIWTKTM; TIRPIWTKTML; IRPIWTKTMLI; RPIWTKTMLIQ;PIWTKTMLIQL; IWTKTMLIQLS; WTKTMLIQLSA; TKTMLIQLSAG; KTMLIQLSAGY;TMLIQLSAGYL; MLIQLSAGYLI; LIQLSAGYLIP; IQLSAGYLIPV; QLSAGYLIPVE;LSAGYLIPVEM; SAGYLIPVEMK; AGYLIPVEMKM; GYLIPVEMKML; YLIPVEMKMLG;LIPVEMKMLGI; IPVEMKMLGIL; PVEMKMLGILG; VEMKMLGILGL; EMKMLGILGLS;MKMLGILGLSQ; KMLGILGLSQE; MLGILGLSQEG; LGILGLSQEGK; GILGLSQEGKM;ILGLSQEGKMF; LGLSQEGKMFP; GLSQEGKMFPQ; LSQEGKMFPQY; SQEGKMFPQYF;QEGKMFPQYFM; MNRVWGLFVKL; NRVWGLFVKLI; RVWGLFVKLIA; VWGLFVKLIAC;WGLFVKLIACM; GLFVKLIACMF; LFVKLIACMFQ; FVKLIACMFQL; VKLIACMFQLL;KLIACMFQLLI; LIACMFQLLIF; IACMFQLLIFV; ACMFQLLIFVA; CMFQLLIFVAC;MFQLLIFVACL; FQLLIFVACLL; QLLIFVACLLT; LLIFVACLLTA; LIFVACLLTAL;IFVACLLTALE; FVACLLTALEH; VACLLTALEHN; ACLLTALEHNS; CLLTALEHNSG;LLTALEHNSGE; LTALEHNSGEA; TALEHNSGEAL; ALEHNSGEALQ; LEHNSGEALQD;EHNSGEALQDI; HNSGEALQDIL; NSGEALQDILR; SGEALQDILRS; GEALQDILRSA;TGEPREWMGSL; GEPREWMGSLC; EPREWMGSLCM; PREWMGSLCMV; REWMGSLCMVW;EWMGSLCMVWN; WMGSLCMVWNP; MGSLCMVWNPR; KRLGCLMAQKD; RLGCLMAQKDF;LGCLMAQKDFQ; GCLMAQKDFQG; CLMAQKDFQGT; LMAQKDFQGTQ; MAQKDFQGTQI;DILTNRDNCKP; ILTNRDNCKPK; LTNRDNCKPKC; TNRDNCKPKCF; NRDNCKPKCFK;RDNCKPKCFKQ; DNCKPKCFKQV; NCKPKCFKQVL; CKPKCFKQVLL; KPKCFKQVLLL;PKCFKQVLLLY; KCFKQVLLLYI; CFKQVLLLYIY; FKQVLLLYIYI; MLLLYKPLLSL;LLLYKPLLSLC; LLYKPLLSLCY; LYKPLLSLCYF; YKPLLSLCYFG; KPLLSLCYFGG;PLLSLCYFGGG; LLSLCYFGGGV; LSLCYFGGGVL; SLCYFGGGVLG; LCYFGGGVLGL;CYFGGGVLGLL; YFGGGVLGLLK; FGGGVLGLLKH; LWGSDLWESSA; WGSDLWESSAG;GSDLWESSAGA; SDLWESSAGAE; DLWESSAGAEV; LWESSAGAEVS; WESSAGAEVSE;ESSAGAEVSET; SSAGAEVSETW; SAGAEVSETWE; AGAEVSETWEE; GAEVSETWEEH;AEVSETWEEHC; EVSETWEEHCD; VSETWEEHCDW; SETWEEHCDWD; ETWEEHCDWDS;TWEEHCDWDSV; WEEHCDWDSVL; EEHCDWDSVLD; EHCDWDSVLDP; HCDWDSVLDPC;CDWDSVLDPCP; DWDSVLDPCPE; WDSVLDPCPES; DSVLDPCPESS; SVLDPCPESSV;VLDPCPESSVS; LDPCPESSVSE; DPCPESSVSES; PCPESSVSESS; CPESSVSESSS;PESSVSESSSL; ESSVSESSSLV; SSVSESSSLVI; SVSESSSLVIS; VSESSSLVISR;SESSSLVISRI; ESSSLVISRIH; SSSLVISRIHF; SSLVISRIHFP; SLVISRIHFPM;LVISRIHFPMH; VISRIHFPMHI; ISRIHFPMHIL; SRIHFPMHILY; RIHFPMHILYF;IHFPMHILYFI; HFPMHILYFIL; FPMHILYFILE; PMHILYFILEK; MHILYFILEKV;HILYFILEKVY; ILYFILEKVYI; LYFILEKVYIL; YFILEKVYILI; FILEKVYILIS;ILEKVYILISE; LEKVYILISES; EKVYILISESS; KVYILISESSL; VYILISESSLS;YILISESSLSF; ILISESSLSFH; LISESSLSFHS; ISESSLSFHST; SESSLSFHSTI;ESSLSFHSTIL; SSLSFHSTILD; SLSFHSTILDC; LSFHSTILDCI; SFHSTILDCIS;FHSTILDCISV; HSTILDCISVA; STILDCISVAK; TILDCISVAKS; ILDCISVAKSA;LDCISVAKSAT; DCISVAKSATG; CISVAKSATGL; ISVAKSATGLN; SVAKSATGLNQ;VAKSATGLNQI; AKSATGLNQIS; KSATGLNQISS; SATGLNQISSS; ATGLNQISSSN;TGLNQISSSNK; GLNQISSSNKV; LNQISSSNKVI; NQISSSNKVIP; QISSSNKVIPL;ISSSNKVIPLC; SSSNKVIPLCK; SSNKVIPLCKI; SNKVIPLCKIL; NKVIPLCKILF;KVIPLCKILFS; VIPLCKILFSS; IPLCKILFSSK; PLCKILFSSKN; LCKILFSSKNS;CKILFSSKNSE; KILFSSKNSEF; ILFSSKNSEFC; LFSSKNSEFCK; FSSKNSEFCKD;SSKNSEFCKDF; SKNSEFCKDFL; KNSEFCKDFLK; NSEFCKDFLKY; SEFCKDFLKYI;EFCKDFLKYIL; FCKDFLKYILG; CKDFLKYILGL; KDFLKYILGLK; DFLKYILGLKS;FLKYILGLKSI; LKYILGLKSIC; KYILGLKSICL; YILGLKSICLT; ILGLKSICLTN;LGLKSICLTNL; GLKSICLTNLA; LKSICLTNLAC; KSICLTNLACR; SICLTNLACRV;ICLTNLACRVL; CLTNLACRVLG; LTNLACRVLGT; TNLACRVLGTG; NLACRVLGTGY;LACRVLGTGYS; ACRVLGTGYSF; CRVLGTGYSFI; RVLGTGYSFIV; VLGTGYSFIVT;LGTGYSFIVTK; GTGYSFIVTKP; TGYSFIVTKPG; GYSFIVTKPGG; YSFIVTKPGGN;SFIVTKPGGNI; FIVTKPGGNIW; IVTKPGGNIWV; VTKPGGNIWVL; TKPGGNIWVLL;KPGGNIWVLLF; PGGNIWVLLFK; GGNIWVLLFKC; GNIWVLLFKCF; NIWVLLFKCFF;IWVLLFKCFFS; WVLLFKCFFSK; VLLFKCFFSKF; LLFKCFFSKFT; LFKCFFSKFTL;FKCFFSKFTLT; KCFFSKFTLTL; CFFSKFTLTLP; FFSKFTLTLPS; FSKFTLTLPSK;SLKLSKLFIPC; LKLSKLFIPCP; KLSKLFIPCPE; LSKLFIPCPEG; SKLFIPCPEGK;KLFIPCPEGKS; LFIPCPEGKSF; FIPCPEGKSFD; IPCPEGKSFDS; PCPEGKSFDSA;CPEGKSFDSAP; PEGKSFDSAPV; EGKSFDSAPVP; GKSFDSAPVPF; KSFDSAPVPFT;SFDSAPVPFTS; FDSAPVPFTSS; DSAPVPFTSSK; SAPVPFTSSKT; APVPFTSSKTT;PVPFTSSKTTM; VPFTSSKTTMY; SIATPSSKVSL; IATPSSKVSLS; ATPSSKVSLSM;TPSSKVSLSMG; PSSKVSLSMGR; SSKVSLSMGRF; SKVSLSMGRFT; KVSLSMGRFTF;VSLSMGRFTFK; SLSMGRFTFKA; LSMGRFTFKAL; SMGRFTFKALP; MGRFTFKALPP;GRFTFKALPPH; RFTFKALPPHK; FTFKALPPHKS; TFKALPPHKSN; FKALPPHKSNN;KALPPHKSNNP; ALPPHKSNNPA; LPPHKSNNPAA; PPHKSNNPAAS; PHKSNNPAASV;HKSNNPAASVV; KSNNPAASVVF; SNNPAASVVFP; NNPAASVVFPL; NPAASVVFPLS;PAASVVFPLSM; AASVVFPLSMG; ASVVFPLSMGP; SVVFPLSMGPL; VVFPLSMGPLN;VFPLSMGPLNN; FPLSMGPLNNQ; PLSMGPLNNQY; LSMGPLNNQYL; SMGPLNNQYLL;MGPLNNQYLLL; GPLNNQYLLLG; PLNNQYLLLGT; LNNQYLLLGTL; NNQYLLLGTLK;NQYLLLGTLKT; QYLLLGTLKTI; YLLLGTLKTIQ; LLLGTLKTIQC; LLGTLKTIQCK;LGTLKTIQCKK; GTLKTIQCKKS; TLKTIQCKKSN; LKTIQCKKSNI; KTIQCKKSNIT;TIQCKKSNITE; IQCKKSNITES; QCKKSNITESI; CKKSNITESIL; KKSNITESILG;KSNITESILGS; SNITESILGSK; NITESILGSKQ; ITESILGSKQC; TESILGSKQCS;ESILGSKQCSQ; SILGSKQCSQA; ILGSKQCSQAT; LGSKQCSQATP; GSKQCSQATPA;SKQCSQATPAI; KQCSQATPAIY; QCSQATPAIYC; CSQATPAIYCS; SQATPAIYCSS;QATPAIYCSST; ATPAIYCSSTA; TPAIYCSSTAF; PAIYCSSTAFP; APNIKSILSNI;LNLSVSISSLV; NLSVSISSLVI; RVSTLFLAKTV; VSTLFLAKTVS; STLFLAKTVST;TLFLAKTVSTA; LFLAKTVSTAC; FLLSAKIIAFA; LLSAKIIAFAK; LSAKIIAFAKC;SAKIIAFAKCF; AKIIAFAKCFS; NSKYIPNNKNT; SKYIPNNKNTS; KYIPNNKNTSS;YIPNNKNTSSH; IPNNKNTSSHF; PNNKNTSSHFV; NNKNTSSHFVS; NKNTSSHFVST;KNTSSHFVSTA; NTSSHFVSTAY; TSSHFVSTAYS; SSHFVSTAYSV; SHFVSTAYSVI;HFVSTAYSVIN; FVSTAYSVINF; VSTAYSVINFQ; STAYSVINFQD; TAYSVINFQDT;AYSVINFQDTC; YSVINFQDTCF; SVINFQDTCFV; VINFQDTCFVS; INFQDTCFVSS;NFQDTCFVSSG; FQDTCFVSSGS; QDTCFVSSGSS; DTCFVSSGSSG; TCFVSSGSSGL;CFVSSGSSGLK; FVSSGSSGLKS; VSSGSSGLKSC; SSGSSGLKSCS; SGSSGLKSCSF;GSSGLKSCSFK; SSGLKSCSFKP; SGLKSCSFKPP; MLSSIVWYGSL; LSSIVWYGSLV;SSIVWYGSLVK; SIVWYGSLVKA; IVWYGSLVKAL; VWYGSLVKALY; WYGSLVKALYS;YGSLVKALYSK; GSLVKALYSKY; SLVKALYSKYS; LVKALYSKYSL; VKALYSKYSLL;KALYSKYSLLT; ALYSKYSLLTP; LYSKYSLLTPL; YSKYSLLTPLQ; SKYSLLTPLQI;KYSLLTPLQIK; YSLLTPLQIKK; SLLTPLQIKKL; LLTPLQIKKLK; LTPLQIKKLKV;TPLQIKKLKVH; PLQIKKLKVHS; LQIKKLKVHSF; QKLLIAETLCL; KLLIAETLCLC;LLIAETLCLCG; LIAETLCLCGV; IAETLCLCGVK; AETLCLCGVKK; ETLCLCGVKKN;TLCLCGVKKNI; LCLCGVKKNII; CLCGVKKNIIL; LCGVKKNIILC; CGVKKNIILCP;GVKKNIILCPA; VKKNIILCPAH; KKNIILCPAHM; KNIILCPAHMC; NIILCPAHMCL;IILCPAHMCLL; ILCPAHMCLLI; LCPAHMCLLIK; CPAHMCLLIKV; PAHMCLLIKVT;AHMCLLIKVTE; HMCLLIKVTEY; MCLLIKVTEYF; CLLIKVTEYFS; LLIKVTEYFSI;LIKVTEYFSIS; IKVTEYFSISF; KVTEYFSISFL; VTEYFSISFLY; TEYFSISFLYR;EYFSISFLYRI; AFSLVVYTAKQ; FSLVVYTAKQA; SLVVYTAKQAR; LVVYTAKQARV;VVYTAKQARVL; VYTAKQARVLL; YTAKQARVLLL; TAKQARVLLLN; AKQARVLLLNT;KQARVLLLNTA; LRNWCRSEGKS; RNWCRSEGKSL; NWCRSEGKSLG; WCRSEGKSLGS;CRSEGKSLGSS; RSEGKSLGSST; SEGKSLGSSTF; EGKSLGSSTFL; GKSLGSSTFLF;KSLGSSTFLFF; SLGSSTFLFFL; LGSSTFLFFLG; GSSTFLFFLGG; SSTFLFFLGGV;STFLFFLGGVE; TFLFFLGGVEC; ESAVASSSLAN; SAVASSSLANI; AVASSSLANIS;VASSSLANISS; ASSSLANISSW; SSSLANISSWQ; SSLANISSWQN; SLANISSWQNK;LANISSWQNKS; ANISSWQNKSS; NISSWQNKSSS; ISSWQNKSSSH; SSWQNKSSSHF;SWQNKSSSHFS; WQNKSSSHFSL; QNKSSSHFSLK; NKSSSHFSLKE; KSSSHFSLKEL;SSSHFSLKELH; SSHFSLKELHQ; SHFSLKELHQD; HFSLKELHQDS; FSLKELHQDSH;SLKELHQDSHS; LKELHQDSHSS; KELHQDSHSSV; ELHQDSHSSVP; VGTYKKNNYLG;GTYKKNNYLGP; TYKKNNYLGPF; YKKNNYLGPFN; KKNNYLGPFNI; KNNYLGPFNIL;NNYLGPFNILL; NYLGPFNILLF; YLGPFNILLFI; REFLQLFGPTI; EFLQLFGPTIA;FLQLFGPTIAE; LQLFGPTIAEF; QLFGPTIAEFL; LFGPTIAEFLQ; FGPTIAEFLQL;GPTIAEFLQLG; PTIAEFLQLGL; TIAEFLQLGLS; IAEFLQLGLSQ; AEFLQLGLSQT;EFLQLGLSQTT; FLQLGLSQTTV; SSQCSSNLSKP; SQCSSNLSKPR; QCSSNLSKPRA;CSSNLSKPRAL; SSNLSKPRALF; SNLSKPRALFL; NLSKPRALFLK; LSKPRALFLKI;SKPRALFLKIF; KPRALFLKIFY; PRALFLKIFYL; RALFLKIFYLN; ALFLKIFYLNA;LFLKIFYLNAL; FLKIFYLNALI; ADIACKGSAQK; DIACKGSAQKA; IACKGSAQKAF;ACKGSAQKAFW; CKGSAQKAFWN; KGSAQKAFWNK; AIPCSTGYLGK; IPCSTGYLGKE;PCSTGYLGKEE; CSTGYLGKEEN; STGYLGKEENQ; TGYLGKEENQH; GYLGKEENQHK;YLGKEENQHKP; LGKEENQHKPL; GKEENQHKPLS; KEENQHKPLSY; EENQHKPLSYS;ENQHKPLSYSR; NQHKPLSYSRF; QHKPLSYSRFQ; HKPLSYSRFQN; KPLSYSRFQNQ;PLSYSRFQNQA; LSYSRFQNQAD; SYSRFQNQADE; YSRFQNQADEL; SRFQNQADELP;RFQNQADELPL; FQNQADELPLH; QNQADELPLHP; NQADELPLHPA; QADELPLHPAP;ADELPLHPAPF; DELPLHPAPFF; ELPLHPAPFFY; LPLHPAPFFYT; PLHPAPFFYTK;LHPAPFFYTKY; HPAPFFYTKYS; PAPFFYTKYSF; APFFYTKYSFS; PFFYTKYSFSS;FFYTKYSFSSF; FYTKYSFSSFY; YTKYSFSSFYP; TKYSFSSFYPR; KYSFSSFYPRR;YSFSSFYPRRP; SFSSFYPRRPL; FSSFYPRRPLC; SSFYPRRPLCQ; SFYPRRPLCQG;FYPRRPLCQGE; YPRRPLCQGEI; PRRPLCQGEIP; RRPLCQGEIPY; RPLCQGEIPYT;PLCQGEIPYTS; LCQGEIPYTSL; CQGEIPYTSLN; QGEIPYTSLNK; GEIPYTSLNKL;EIPYTSLNKLF; IPYTSLNKLFS; PYTSLNKLFSL; YTSLNKLFSLR; TSLNKLFSLRE;SLNKLFSLRED; LNKLFSLREDF; NKLFSLREDFP; KLFSLREDFPR; LFSLREDFPRQ;FSLREDFPRQL; SLREDFPRQLF; LREDFPRQLFQ; REDFPRQLFQG; EDFPRQLFQGL;DFPRQLFQGLK; FPRQLFQGLKG; PRQLFQGLKGP BK reading frame 3 8 mers:LQKLQKNR; QKLQKNRD; KLQKNRDF; LQKNRDFP; QKNRDFPK; ASEKASTP; SEKASTPL;EKASTPLL; KASTPLLL; ASTPLLLE; STPLLLER; TPLLLERK; PLLLERKG; LLLERKGG;LLERKGGG; LERKGGGR; ERKGGGRG; RKGGGRGG; KGGGRGGL; GGGRGGLG; GGRGGLGL;GRGGLGLL; RGGLGLLY; GGLGLLYI; GLGLLYII; LGLLYIIK; GLLYIIKK; LLYIIKKK;LYIIKKKA; YIIKKKAT; IIKKKATG; IKKKATGR; KKKATGRS; KKATGRSC; KATGRSCL;ATGRSCLP; TGRSCLPM; GRSCLPME; RSCLPMEC; SCLPMECS; CLPMECSQ; LPMECSQT;PMECSQTM; MECSQTMT; ECSQTMTS; CSQTMTSG; SQTMTSGR; QTMTSGRK; TMTSGRKV;MTSGRKVH; TSGRKVHD; SGRKVHDS; GRKVHDSQ; RKVHDSQG; KVHDSQGN; VHDSQGNA;HDSQGNAA; DSQGNAAK; SQGNAAKP; PQEGKCMT; QEGKCMTH; EGKCMTHR; GKCMTHRE;KCMTHREE; CMTHREEL; MTHREELL; THREELLT; HREELLTH; REELLTHG; EELLTHGM;ELLTHGMQ; LLTHGMQP; LTHGMQPN; THGMQPNH; HGMQPNHD; GMQPNHDL; MQPNHDLR;QPNHDLRK; PNHDLRKE; NHDLRKES; HDLRKESA; QTCFASLG; TCFASLGI; CFASLGIL;FASLGILA; ASLGILAL; SLGILALS; LGILALSP; GILALSPV; ILALSPVK; LALSPVKL;ALSPVKLD; LSPVKLDK; SPVKLDKG; PVKLDKGH; VKLDKGHG; KLDKGHGS; LDKGHGSA;DKGHGSAP; KGHGSAPA; GHGSAPAV; HGSAPAVT; GSAPAVTT; SAPAVTTS; APAVTTSF;PAVTTSFS; AVTTSFSE; VTTSFSES; TTSFSESW; NLDWNKKK; LDWNKKKS; DWNKKKSS;WNKKKSSE; NKKKSSED; KKKSSEDF; KKSSEDFY; KSSEDFYF; SSEDFYFY; SEDFYFYF;EDFYFYFR; DFYFYFRA; FYFYFRAF; YFYFRAFA; FYFRAFAG; YFRAFAGI; FRAFAGIL;RQCRREKQ; QCRREKQK; CRREKQKY; RREKQKYH; REKQKYHC; EKQKYHCF; KQKYHCFT;QKYHCFTC; KYHCFTCC; YHCFTCCK; HCFTCCKR; CFTCCKRL; FTCCKRLC; TCCKRLCK;CCKRLCKR; CKRLCKRL; KRLCKRLL; RLCKRLLG; LCKRLLGK; SLFFCISR; LFFCISRF;FFCISRFM; FCISRFMG; CISRFMGA; ISRFMGAA; SRFMGAAL; RFMGAALA; FMGAALAL;MGAALALL; GAALALLG; AALALLGD; ALALLGDL; LALLGDLV; ALLGDLVA; LLGDLVAS;LGDLVASV; GDLVASVS; DLVASVSE; LVASVSEA; VASVSEAA; ASVSEAAA; SVSEAAAA;VSEAAAAT; SEAAAATG; EAAAATGF; AAAATGFS; AAATGFSV; AATGFSVA; ATGFSVAE;TGFSVAEI; GFSVAEIA; FSVAEIAA; SVAEIAAG; VAEIAAGE; AEIAAGEA; EIAAGEAA;IAAGEAAA; AAGEAAAA; AGEAAAAI; GEAAAAIE; EAAAAIEV; AAAAIEVQ; AAAIEVQI;AAIEVQIA; AIEVQIAS; IEVQIASL; EVQIASLA; VQIASLAT; QIASLATV; IASLATVE;ASLATVEG; SLATVEGI; LATVEGIT; ATVEGITS; TVEGITST; VEGITSTS; EGITSTSE;GITSTSEA; ITSTSEAI; TSTSEAIA; STSEAIAA; TSEAIAAI; SEAIAAIG; EAIAAIGL;AIAAIGLT; IAAIGLTP; AAIGLTPQ; AIGLTPQT; IGLTPQTY; GLTPQTYA; LTPQTYAV;TPQTYAVI; PQTYAVIA; QTYAVIAG; TYAVIAGA; YAVIAGAP; AVIAGAPG; VIAGAPGA;IAGAPGAI; AGAPGAIA; GAPGAIAG; APGAIAGF; PGAIAGFA; GAIAGFAA; AIAGFAAL;IAGFAALI; AGFAALIQ; GFAALIQT; FAALIQTV; AALIQTVS; ALIQTVSG; LIQTVSGI;IQTVSGIS; QTVSGISS; TVSGISSL; VSGISSLA; SGISSLAQ; GISSLAQV; ISSLAQVG;SSLAQVGY; SLAQVGYK; LAQVGYKF; AQVGYKFF; QVGYKFFD; VGYKFFDD; GYKFFDDW;YKFFDDWD; KFFDDWDH; FFDDWDHK; FDDWDHKV; DDWDHKVS; DWDHKVST; WDHKVSTV;DHKVSTVG; HKVSTVGL; KVSTVGLY; VSTVGLYQ; STVGLYQQ; TVGLYQQS; VGLYQQSG;GLYQQSGM; LYQQSGMA; YQQSGMAL; QQSGMALE; QSGMALEL; SGMALELF; GMALELFN;MALELFNP; ALELFNPD; LELFNPDE; ELFNPDEY; LFNPDEYY; FNPDEYYD; NPDEYYDI;PDEYYDIL; DEYYDILF; EYYDILFP; YYDILFPG; YDILFPGV; DILFPGVN; ILFPGVNT;LFPGVNTF; FPGVNTFV; PGVNTFVN; GVNTFVNN; VNTFVNNI; NTFVNNIQ; TFVNNIQY;FVNNIQYL; VNNIQYLD; NNIQYLDP; NIQYLDPR; IQYLDPRH; QYLDPRHW; YLDPRHWG;LDPRHWGP; DPRHWGPS; PRHWGPSL; RHWGPSLF; HWGPSLFA; WGPSLFAT; GPSLFATI;PSLFATIS; SLFATISQ; LFATISQA; FATISQAL; ATISQALW; TISQALWH; ISQALWHV;SQALWHVI; QALWHVIR; ALWHVIRD; LWHVIRDD; WHVIRDDI; HVIRDDIP; VIRDDIPS;IRDDIPSI; RDDIPSIT; DDIPSITS; DIPSITSQ; IPSITSQE; PSITSQEL; SITSQELQ;ITSQELQR; TSQELQRR; SQELQRRT; QELQRRTE; ELQRRTER; LQRRTERF; QRRTERFF;RRTERFFR; RTERFFRD; TERFFRDS; ERFFRDSL; RFFRDSLA; FFRDSLAR; FRDSLARF;RDSLARFL; DSLARFLE; SLARFLEE; LARFLEET; ARFLEETT; RFLEETTW; FLEETTWT;LEETTWTI; EETTWTIV; ETTWTIVN; TTWTIVNA; TWTIVNAP; WTIVNAPI; TIVNAPIN;IVNAPINF; VNAPINFY; NAPINFYN; APINFYNY; PINFYNYI; INFYNYIQ; NFYNYIQQ;FYNYIQQY; YNYIQQYY; NYIQQYYS; YIQQYYSD; IQQYYSDL; QQYYSDLS; QYYSDLSP;YYSDLSPI; YSDLSPIR; SDLSPIRP; DLSPIRPS; LSPIRPSM; SPIRPSMV; PIRPSMVR;IRPSMVRQ; RPSMVRQV; PSMVRQVA; SMVRQVAE; MVRQVAER; VRQVAERE; RQVAEREG;QVAEREGT; VAEREGTR; AEREGTRV; EREGTRVH; REGTRVHF; EGTRVHFG; GTRVHFGH;TRVHFGHT; RVHFGHTY; VHFGHTYS; HFGHTYSI; FGHTYSID; GHTYSIDD; HTYSIDDA;TYSIDDAD; YSIDDADS; SIDDADSI; IDDADSIE; DDADSIEE; DADSIEEV; ADSIEEVT;DSIEEVTQ; SIEEVTQR; IEEVTQRM; EEVTQRMD; EVTQRMDL; VTQRMDLR; TQRMDLRN;QRMDLRNQ; RMDLRNQQ; MDLRNQQS; DLRNQQSV; LRNQQSVH; RNQQSVHS; NQQSVHSG;QQSVHSGE; QSVHSGEF; SVHSGEFI; VHSGEFIE; HSGEFIEK; SGEFIEKT; GEFIEKTI;EFIEKTIA; FIEKTIAP; IEKTIAPG; EKTIAPGG; KTIAPGGA; TIAPGGAN; IAPGGANQ;APGGANQR; PGGANQRT; GGANQRTA; GANQRTAP; ANQRTAPQ; NQRTAPQW; QRTAPQWM;RTAPQWML; TAPQWMLP; APQWMLPL; PQWMLPLL; QWMLPLLL; WMLPLLLG; MLPLLLGL;LPLLLGLY; PLLLGLYG; LLLGLYGT; LLGLYGTV; LGLYGTVT; GLYGTVTP; LYGTVTPA;YGTVTPAL; GTVTPALE; TVTPALEA; VTPALEAY; TPALEAYE; PALEAYED; ALEAYEDG;LEAYEDGP; EAYEDGPN; AYEDGPNQ; YEDGPNQK; EDGPNQKK; DGPNQKKR; GPNQKKRR;PNQKKRRV; NQKKRRVS; QKKRRVSR; KKRRVSRG; KRRVSRGS; RRVSRGSS; RVSRGSSQ;VSRGSSQK; SRGSSQKA; RGSSQKAK; GSSQKAKG; SSQKAKGT; SQKAKGTR; QKAKGTRA;KAKGTRAS; AKGTRASA; KGTRASAK; GTRASAKT; TRASAKTT; RASAKTTN; ASAKTTNK;SAKTTNKR; AKTTNKRR; KTTNKRRS; TTNKRRSR; TNKRRSRS; NKRRSRSS; KRRSRSSR;RRSRSSRS; NWGRCYYR; WGRCYYRG; GRCYYRGR; RCYYRGRM; CYYRGRML; YYRGRMLP;YRGRMLPK; RGRMLPKP; GRMLPKPR; RMLPKPRN; MLPKPRNG; LPKPRNGG; PKPRNGGS;KPRNGGSR; PREKNASL; REKNASLL; EKNASLLQ; KNASLLQH; NASLLQHS; ASLLQHSK;SLLQHSKN; LLQHSKNS; LQHSKNSP; QHSKNSPP; HSKNSPPQ; SKNSPPQF; KNSPPQFK;GPNLWKST; PNLWKSTD; NLWKSTDV; LWKSTDVG; WKSTDVGG; KSTDVGGC; STDVGGCN;TDVGGCNC; DVGGCNCT; VGGCNCTN; GGCNCTNR; GCNCTNRG; CNCTNRGY; NCTNRGYW;CTNRGYWN; TNRGYWNN; PSCRVTKS; SCRVTKSA; AWWRKTYS; WWRKTYSR; WRKTYSRQ;FPLLCCRW; PLLCCRWR; LLCCRWRT; LCCRWRTL; CCRWRTLG; CRWRTLGN; RWRTLGNA;WRTLGNAG; RTLGNAGS; TLGNAGSA; LGNAGSAN; GNAGSANE; NAGSANEL; AGSANELQ;GSANELQV; SANELQVK; ANELQVKV; NELQVKVP; KPNSPVPG; PNSPVPGN; NSPVPGNE;SPVPGNEY; GLFGQKQC; LFGQKQCL; FGQKQCLS; GQKQCLSS; VFWDFHRR; FWDFHRRG;WDFHRRGK; DFHRRGKC; FHRRGKCS; HRRGKCSP; RRGKCSPS; RGKCSPST; GKCSPSTS;KCSPSTSC; CSPSTSCD; SPSTSCDQ; PSTSCDQH; STSCDQHS; TSCDQHSY; SCDQHSYH;CDQHSYHS; DQHSYHSV; QHSYHSVA; HSYHSVAR; QLWNTTVE; LWNTTVER; WNTTVERP;NTTVERPC; TTVERPCK; TVERPCKI; VERPCKIF; DPPEKKIC; PPEKKICK; PEKKICKE;EKKICKES; KKICKESL; KICKESLP; ICKESLPN; CKESLPNF; KESLPNFL; ESLPNFLF;SLPNFLFA; LPNFLFAK; PYKQENPE; YKQENPES; KQENPESG; QENPESGW; ENPESGWA;NPESGWAA; PESGWAAY; ESGWAAYV; SGWAAYVW; GWAAYVWY; WAAYVWYG; AAYVWYGI;AYVWYGIP; YVWYGIPG; VWYGIPGR; WYGIPGRR; YGIPGRRG; WHRKTSRG; HRKTSRGP;RKTSRGPR; KTSRGPRY; TSRGPRYD; SRGPRYDK; RGPRYDKI; GPRYDKIY; QTGTIANQ;TGTIANQN; GTIANQNA; TIANQNAL; IANQNALN; ANQNALNR; NQNALNRC; QNALNRCF;NALNRCFY; ALNRCFYC; LNRCFYCT; NRCFYCTY; RCFYCTYT; CFYCTYTF; FYCTYTFN;YCTYTFNK; CTYTFNKC; TYTFNKCC; YTFNKCCF; TFNKCCFC; FNKCCFCI; NKCCFCIS;KCCFCISH; CCFCISHF; ACVILGVV; CVILGVVF; NTESLYTN; TESLYTNA; ESLYTNAT;SLYTNATL; LYTNATLD; YTNATLDY; TNATLDYG; NATLDYGG; ATLDYGGL; TLDYGGLT;LDYGGLTF; DYGGLTFG; YGGLTFGN; GGLTFGNL; GLTFGNLQ; LTFGNLQQ; TFGNLQQG;FGNLQQGL; GNLQQGLK; NLQQGLKY; LQQGLKYL; QQGLKYLR; QGLKYLRL; GLKYLRLG;LKYLRLGK; KYLRLGKS; YLRLGKSI; LRLGKSIV; RLGKSIVI; LGKSIVIG; GKSIVIGI;KSIVIGIQ; SIVIGIQC; IVIGIQCL; VIGIQCLI; IGIQCLIH; GIQCLIHV; IQCLIHVQ;QCLIHVQS; CLIHVQSL; LIHVQSLQ; IHVQSLQF; HVQSLQFL; VQSLQFLN; QSLQFLNP;SLQFLNPL; LQFLNPLL; QFLNPLLL; YQEYISPC; QEYISPCI; EYISPCIY; YISPCIYY;ISPCIYYI; SPCIYYIS; PCIYYISS; CIYYISSL; IYYISSLK; YYISSLKK; YISSLKKY;ISSLKKYT; SSLKKYTY; SLKKYTYL; LKKYTYLS; KKYTYLSQ; KYTYLSQN; YTYLSQNP;TYLSQNPA; YLSQNPAF; LSQNPAFP; SQNPAFPS; QNPAFPSI; NPAFPSIQ; PAFPSIQQ;AFPSIQQF; IVYQLQNQ; VYQLQNQL; YQLQNQLQ; QLQNQLQA; TKLAVATR; KLAVATRS;LAVATRSF; AVATRSFH; VATRSFHF; ATRSFHFV; TRSFHFVK; RSFHFVKF; SFHFVKFF;FHFVKFFF; HFVKFFFQ; FVKFFFQV; VKFFFQVR; KFFFQVRT; FFFQVRTL; FFQVRTLS;FQVRTLSF; QVRTLSFV; VRTLSFVR; RTLSFVRI; TLSFVRIF; LSFVRIFL; SFVRIFLN;FVRIFLNI; VRIFLNIF; RIFLNIFW; IFLNIFWA; PSLVEIFG; SLVEIFGF; LVEIFGFF;VEIFGFFC; EIFGFFCL; IFGFFCLN; FGFFCLNV; GFFCLNVS; FFCLNVSF; FCLNVSFL;CLNVSFLN; LNVSFLNL; NVSFLNLP; HFHLNNLS; FHLNNLSN; HLNNLSNC; LNNLSNCL;NNLSNCLN; NLSNCLNC; LSNCLNCL; SNCLNCLF; NCLNCLFH; CLNCLFHV; LNCLFHVL;NCLFHVLK; CLFHVLKA; LFHVLKAN; FHVLKANP; HVLKANPL; VLKANPLI; LKANPLIQ;KANPLIQL; ANPLIQLL; NPLIQLLS; PLIQLLSL; LIQLLSLL; IQLLSLLH; QLLSLLHL;LLSLLHLQ; LSLLHLQK; SLLHLQKQ; LLHLQKQP; LHLQKQPC; HLQKQPCT; LQKQPCTD;QKQPCTDL; LHLAQRLA; HLAQRLAF; LAQRLAFP; AQRLAFPW; QRLAFPWV; RLAFPWVG;LAFPWVGL; AFPWVGLH; FPWVGLHL; PWVGLHLR; WVGLHLRL; VGLHLRLY; GLHLRLYH;LHLRLYHH; HLRLYHHT; LRLYHHTN; RLYHHTNL; LYHHTNLI; YHHTNLIT; HHTNLITL;HTNLITLQ; TNLITLQL; NLITLQLV; LITLQLVL; ITLQLVLF; TLQLVLFF; LQLVLFFH;QLVLFFHY; LVLFFHYQ; VLFFHYQW; LFFHYQWD; FFHYQWDL; KQYSAKNQ; QYSAKNQI;YSAKNQIL; SAKNQILQ; AKNQILQN; KNQILQNP; NQILQNPF; VANSAAKQ; ANSAAKQH;NSAAKQHL; SAAKQHLP; AAKQHLPY; AKQHLPYI; KQHLPYIV; QHLPYIVL; HLPYIVLV;LPYIVLVQ; PYIVLVQH; YIVLVQHF; IVLVQHFH; VLVQHFHE; LVQHFHEL; VQHFHELQ;QHFHELQI; HFHELQIL; FHELQILN; HELQILNP; ELQILNPF; LQILNPFY; QILNPFYL;ILNPFYLI; LNPFYLIY; NPFYLIYD; IFLLAFLP; FLLAFLPW; LLAFLPWS; LAFLPWSY;AFLPWSYE; FLPWSYEG; LPWSYEGY; PWSYEGYL; WSYEGYLL; SYEGYLLF; YEGYLLFF;LKLYLLLA; KLYLLLAD; LYLLLADK; YLLLADKY; LLLADKYF; LLADKYFF; LADKYFFD;ADKYFFDF; DKYFFDFY; KYFFDFYF; YFFDFYFL; FFDFYFLQ; FDFYFLQK; HLQSAFHD;LQSAFHDT; SDKAGLFS; DKAGLFSD; KAGLFSDT; AGLFSDTF; GLFSDTFY; LFSDTFYT;FSDTFYTP; SDTFYTPL; DTFYTPLH; TFYTPLHC; FYTPLHCI; YTPLHCIE; TPLHCIEI;PLHCIEIL; LHCIEILN; HCIEILNT; CIEILNTY; IEILNTYL; EILNTYLI; ILNTYLII;LNTYLIIK; NTYLIIKT; TYLIIKTH; YLIIKTHP; LIIKTHPH; IIKTHPHT; IKTHPHTL;KTHPHTLS; THPHTLSL; HPHTLSLL; PHTLSLLH; HTLSLLHT; TLSLLHTQ; LISKTPAL;ISKTPALF; SKTPALFL; KTPALFLQ; TPALFLQA; PALFLQAL; ALFLQALL; LFLQALLG;NHAPLSPL; HAPLSPLE; APLSPLEC; PLSPLECF; LSPLECFL; SPLECFLL; LRHYIVSI;RHYIVSIP; HYIVSIPY; RYTAFDRN; YTAFDRNY; LQKLYVYV; QKLYVYVE; KLYVYVEL;LYVYVELK; YVYVELKR; VYVELKRI; YYAQHTCV; YAQHTCVY; VFYTEFEL; FYTEFELF;YTEFELFL; YTQQSRQG; TQQSRQGF; QQSRQGFY; QSRQGFYY; ETGVDQRE; TGVDQRES;GVDQRESL; GLLPFFFF; LLPFFFFW; LPFFFFWV; PFFFFWVV; FFFFWVVL; FFFWVVLS;FFWVVLSV; FWVVLSVE; WVVLSVEN; VVLSVENL; VLSVENLL; LSVENLLL; SVENLLLL;VENLLLLL; ENLLLLLH; NLLLLLHH; LLLLLHHW; LLLLHHWQ; LLLHHWQT; LLHHWQTY;LHHWQTYL; HHWQTYLH; HWQTYLHG; WQTYLHGK; QTYLHGKI; TYLHGKIN; YLHGKINL;LHGKINLH; HGKINLHP; GKINLHPI; KINLHPIF; INLHPIFH; RNSTRTPT; NSTRTPTL;STRTPTLL; TRTPTLLF; RTPTLLFH; TPTLLFHR; PTLLFHRL; TLLFHRLA; LLFHRLAP;LFHRLAPI; FHRLAPIK; HRLAPIKK; RLAPIKKI; LAPIKKII; APIKKIIT; GLLIFYYL;LLIFYYLS; LIFYYLSK; IFYYLSKY; FYYLSKYK; YYLSKYKL; YLSKYKLV; LSKYKLVT;SKYKLVTL; KYKLVTLK; YKLVTLKL; ISEGSFSN; SEGSFSNY; EGSFSNYL; GSFSNYLD;SFSNYLDP; FSNYLDPP; SNYLDPPL; NYLDPPLQ; YLDPPLQS; LDPPLQSF; DPPLQSFF;PPLQSFFS; AKPLCEAV; KPLCEAVN; PLCEAVNA; LCEAVNAV; CEAVNAVA; EAVNAVAI;AVNAVAIY; VNAVAIYP; NAVAIYPN; AVAIYPNQ; VAIYPNQG; AIYPNQGL; IYPNQGLF;YPNQGLFS; HARAVHRR; ARAVHRRL; RAVHRRLF; AVHRRLFG; VHRRLFGT; HRRLFGTN;RRLFGTNR; RLFGTNRP; LFGTNRPF; FGTNRPFL; GTNRPFLA; TNRPFLAV; NRPFLAVQ;RPFLAVQG; PFLAVQGI; FLAVQGIW; LAVQGIWA; AVQGIWAK; VQGIWAKR; QGIWAKRK;GIWAKRKI; IWAKRKIS; WAKRKIST; AKRKISTN; KRKISTNL; ATPGSKIR; TPGSKIRL;PGSKIRLM; GSKIRLMS; SKIRLMSY; KIRLMSYL; IRLMSYLY; RLMSYLYI; LMSYLYIL;MSYLYILL; SYLYILLH; YLYILLHF; LYILLHFF; YILLHFFI; ILLHFFIQ; LLHFFIQS;LHFFIQSI; HFFIQSIH; FFIQSIHS; FIQSIHSL; IQSIHSLH; QSIHSLHF; SIHSLHFI;IHSLHFIL; HSLHFILV; SLHFILVA; LHFILVAP; HFILVAPF; FILVAPFV; ILVAPFVR;LVAPFVRV; VAPFVRVK; APFVRVKF; PFVRVKFL; FVRVKFLT; VRVKFLTL; RVKFLTLP;GKISPGSS; KISPGSSF; ISPGSSFK; SPGSSFKA; KVHELHGF; VHELHGFF; HELHGFFP;ELHGFFPV; LHGFFPVK; HGFFPVKN; GFFPVKNF; FFPVKNFI; FPVKNFIH 9 mers:LQKLQKNRD; QKLQKNRDF; KLQKNRDFP; LQKNRDFPK; ASEKASTPL; SEKASTPLL;EKASTPLLL; KASTPLLLE; ASTPLLLER; STPLLLERK; TPLLLERKG; PLLLERKGG;LLLERKGGG; LLERKGGGR; LERKGGGRG; ERKGGGRGG; RKGGGRGGL; KGGGRGGLG;GGGRGGLGL; GGRGGLGLL; GRGGLGLLY; RGGLGLLYI; GGLGLLYII; GLGLLYIIK;LGLLYIIKK; GLLYIIKKK; LLYIIKKKA; LYIIKKKAT; YIIKKKATG; IIKKKATGR;IKKKATGRS; KKKATGRSC; KKATGRSCL; KATGRSCLP; ATGRSCLPM; TGRSCLPME;GRSCLPMEC; RSCLPMECS; SCLPMECSQ; CLPMECSQT; LPMECSQTM; PMECSQTMT;MECSQTMTS; ECSQTMTSG; CSQTMTSGR; SQTMTSGRK; QTMTSGRKV; TMTSGRKVH;MTSGRKVHD; TSGRKVHDS; SGRKVHDSQ; GRKVHDSQG; RKVHDSQGN; KVHDSQGNA;VHDSQGNAA; HDSQGNAAK; DSQGNAAKP; PQEGKCMTH; QEGKCMTHR; EGKCMTHRE;GKCMTHREE; KCMTHREEL; CMTHREELL; MTHREELLT; THREELLTH; HREELLTHG;REELLTHGM; EELLTHGMQ; ELLTHGMQP; LLTHGMQPN; LTHGMQPNH; THGMQPNHD;HGMQPNHDL; GMQPNHDLR; MQPNHDLRK; QPNHDLRKE; PNHDLRKES; NHDLRKESA;QTCFASLGI; TCFASLGIL; CFASLGILA; FASLGILAL; ASLGILALS; SLGILALSP;LGILALSPV; GILALSPVK; ILALSPVKL; LALSPVKLD; ALSPVKLDK; LSPVKLDKG;SPVKLDKGH; PVKLDKGHG; VKLDKGHGS; KLDKGHGSA; LDKGHGSAP; DKGHGSAPA;KGHGSAPAV; GHGSAPAVT; HGSAPAVTT; GSAPAVTTS; SAPAVTTSF; APAVTTSFS;PAVTTSFSE; AVTTSFSES; VTTSFSESW; NLDWNKKKS; LDWNKKKSS; DWNKKKSSE;WNKKKSSED; NKKKSSEDF; KKKSSEDFY; KKSSEDFYF; KSSEDFYFY; SSEDFYFYF;SEDFYFYFR; EDFYFYFRA; DFYFYFRAF; FYFYFRAFA; YFYFRAFAG; FYFRAFAGI;YFRAFAGIL; RQCRREKQK; QCRREKQKY; CRREKQKYH; RREKQKYHC; REKQKYHCF;EKQKYHCFT; KQKYHCFTC; QKYHCFTCC; KYHCFTCCK; YHCFTCCKR; HCFTCCKRL;CFTCCKRLC; FTCCKRLCK; TCCKRLCKR; CCKRLCKRL; CKRLCKRLL; KRLCKRLLG;RLCKRLLGK; SLFFCISRF; LFFCISRFM; FFCISRFMG; FCISRFMGA; CISRFMGAA;ISRFMGAAL; SRFMGAALA; RFMGAALAL; FMGAALALL; MGAALALLG; GAALALLGD;AALALLGDL; ALALLGDLV; LALLGDLVA; ALLGDLVAS; LLGDLVASV; LGDLVASVS;GDLVASVSE; DLVASVSEA; LVASVSEAA; VASVSEAAA; ASVSEAAAA; SVSEAAAAT;VSEAAAATG; SEAAAATGF; EAAAATGFS; AAAATGFSV; AAATGFSVA; AATGFSVAE;ATGFSVAEI; TGFSVAEIA; GFSVAEIAA; FSVAEIAAG; SVAEIAAGE; VAEIAAGEA;AEIAAGEAA; EIAAGEAAA; IAAGEAAAA; AAGEAAAAI; AGEAAAAIE; GEAAAAIEV;EAAAAIEVQ; AAAAIEVQI; AAAIEVQIA; AAIEVQIAS; AIEVQIASL; IEVQIASLA;EVQIASLAT; VQIASLATV; QIASLATVE; IASLATVEG; ASLATVEGI; SLATVEGIT;LATVEGITS; ATVEGITST; TVEGITSTS; VEGITSTSE; EGITSTSEA; GITSTSEAI;ITSTSEAIA; TSTSEAIAA; STSEAIAAI; TSEAIAAIG; SEAIAAIGL; EAIAAIGLT;AIAAIGLTP; IAAIGLTPQ; AAIGLTPQT; AIGLTPQTY; IGLTPQTYA; GLTPQTYAV;LTPQTYAVI; TPQTYAVIA; PQTYAVIAG; QTYAVIAGA; TYAVIAGAP; YAVIAGAPG;AVIAGAPGA; VIAGAPGAI; IAGAPGAIA; AGAPGAIAG; GAPGAIAGF; APGAIAGFA;PGAIAGFAA; GAIAGFAAL; AIAGFAALI; IAGFAALIQ; AGFAALIQT; GFAALIQTV;FAALIQTVS; AALIQTVSG; ALIQTVSGI; LIQTVSGIS; IQTVSGISS; QTVSGISSL;TVSGISSLA; VSGISSLAQ; SGISSLAQV; GISSLAQVG; ISSLAQVGY; SSLAQVGYK;SLAQVGYKF; LAQVGYKFF; AQVGYKFFD; QVGYKFFDD; VGYKFFDDW; GYKFFDDWD;YKFFDDWDH; KFFDDWDHK; FFDDWDHKV; FDDWDHKVS; DDWDHKVST; DWDHKVSTV;WDHKVSTVG; DHKVSTVGL; HKVSTVGLY; KVSTVGLYQ; VSTVGLYQQ; STVGLYQQS;TVGLYQQSG; VGLYQQSGM; GLYQQSGMA; LYQQSGMAL; YQQSGMALE; QQSGMALEL;QSGMALELF; SGMALELFN; GMALELFNP; MALELFNPD; ALELFNPDE; LELFNPDEY;ELFNPDEYY; LFNPDEYYD; FNPDEYYDI; NPDEYYDIL; PDEYYDILF; DEYYDILFP;EYYDILFPG; YYDILFPGV; YDILFPGVN; DILFPGVNT; ILFPGVNTF; LFPGVNTFV;FPGVNTFVN; PGVNTFVNN; GVNTFVNNI; VNTFVNNIQ; NTFVNNIQY; TFVNNIQYL;FVNNIQYLD; VNNIQYLDP; NNIQYLDPR; NIQYLDPRH; IQYLDPRHW; QYLDPRHWG;YLDPRHWGP; LDPRHWGPS; DPRHWGPSL; PRHWGPSLF; RHWGPSLFA; HWGPSLFAT;WGPSLFATI; GPSLFATIS; PSLFATISQ; SLFATISQA; LFATISQAL; FATISQALW;ATISQALWH; TISQALWHV; ISQALWHVI; SQALWHVIR; QALWHVIRD; ALWHVIRDD;LWHVIRDDI; WHVIRDDIP; HVIRDDIPS; VIRDDIPSI; IRDDIPSIT; RDDIPSITS;DDIPSITSQ; DIPSITSQE; IPSITSQEL; PSITSQELQ; SITSQELQR; ITSQELQRR;TSQELQRRT; SQELQRRTE; QELQRRTER; ELQRRTERF; LQRRTERFF; QRRTERFFR;RRTERFFRD; RTERFFRDS; TERFFRDSL; ERFFRDSLA; RFFRDSLAR; FFRDSLARF;FRDSLARFL; RDSLARFLE; DSLARFLEE; SLARFLEET; LARFLEETT; ARFLEETTW;RFLEETTWT; FLEETTWTI; LEETTWTIV; EETTWTIVN; ETTWTIVNA; TTWTIVNAP;TWTIVNAPI; WTIVNAPIN; TIVNAPINF; IVNAPINFY; VNAPINFYN; NAPINFYNY;APINFYNYI; PINFYNYIQ; INFYNYIQQ; NFYNYIQQY; FYNYIQQYY; YNYIQQYYS;NYIQQYYSD; YIQQYYSDL; IQQYYSDLS; QQYYSDLSP; QYYSDLSPI; YYSDLSPIR;YSDLSPIRP; SDLSPIRPS; DLSPIRPSM; LSPIRPSMV; SPIRPSMVR; PIRPSMVRQ;IRPSMVRQV; RPSMVRQVA; PSMVRQVAE; SMVRQVAER; MVRQVAERE; VRQVAEREG;RQVAEREGT; QVAEREGTR; VAEREGTRV; AEREGTRVH; EREGTRVHF; REGTRVHFG;EGTRVHFGH; GTRVHFGHT; TRVHFGHTY; RVHFGHTYS; VHFGHTYSI; HFGHTYSID;FGHTYSIDD; GHTYSIDDA; HTYSIDDAD; TYSIDDADS; YSIDDADSI; SIDDADSIE;IDDADSIEE; DDADSIEEV; DADSIEEVT; ADSIEEVTQ; DSIEEVTQR; SIEEVTQRM;IEEVTQRMD; EEVTQRMDL; EVTQRMDLR; VTQRMDLRN; TQRMDLRNQ; QRMDLRNQQ;RMDLRNQQS; MDLRNQQSV; DLRNQQSVH; LRNQQSVHS; RNQQSVHSG; NQQSVHSGE;QQSVHSGEF; QSVHSGEFI; SVHSGEFIE; VHSGEFIEK; HSGEFIEKT; SGEFIEKTI;GEFIEKTIA; EFIEKTIAP; FIEKTIAPG; IEKTIAPGG; EKTIAPGGA; KTIAPGGAN;TIAPGGANQ; IAPGGANQR; APGGANQRT; PGGANQRTA; GGANQRTAP; GANQRTAPQ;ANQRTAPQW; NQRTAPQWM; QRTAPQWML; RTAPQWMLP; TAPQWMLPL; APQWMLPLL;PQWMLPLLL; QWMLPLLLG; WMLPLLLGL; MLPLLLGLY; LPLLLGLYG; PLLLGLYGT;LLLGLYGTV; LLGLYGTVT; LGLYGTVTP; GLYGTVTPA; LYGTVTPAL; YGTVTPALE;GTVTPALEA; TVTPALEAY; VTPALEAYE; TPALEAYED; PALEAYEDG; ALEAYEDGP;LEAYEDGPN; EAYEDGPNQ; AYEDGPNQK; YEDGPNQKK; EDGPNQKKR; DGPNQKKRR;GPNQKKRRV; PNQKKRRVS; NQKKRRVSR; QKKRRVSRG; KKRRVSRGS; KRRVSRGSS;RRVSRGSSQ; RVSRGSSQK; VSRGSSQKA; SRGSSQKAK; RGSSQKAKG; GSSQKAKGT;SSQKAKGTR; SQKAKGTRA; QKAKGTRAS; KAKGTRASA; AKGTRASAK; KGTRASAKT;GTRASAKTT; TRASAKTTN; RASAKTTNK; ASAKTTNKR; SAKTTNKRR; AKTTNKRRS;KTTNKRRSR; TTNKRRSRS; TNKRRSRSS; NKRRSRSSR; KRRSRSSRS; NWGRCYYRG;WGRCYYRGR; GRCYYRGRM; RCYYRGRML; CYYRGRMLP; YYRGRMLPK; YRGRMLPKP;RGRMLPKPR; GRMLPKPRN; RMLPKPRNG; MLPKPRNGG; LPKPRNGGS; PKPRNGGSR;PREKNASLL; REKNASLLQ; EKNASLLQH; KNASLLQHS; NASLLQHSK; ASLLQHSKN;SLLQHSKNS; LLQHSKNSP; LQHSKNSPP; QHSKNSPPQ; HSKNSPPQF; SKNSPPQFK;GPNLWKSTD; PNLWKSTDV; NLWKSTDVG; LWKSTDVGG; WKSTDVGGC; KSTDVGGCN;STDVGGCNC; TDVGGCNCT; DVGGCNCTN; VGGCNCTNR; GGCNCTNRG; GCNCTNRGY;CNCTNRGYW; NCTNRGYWN; CTNRGYWNN; PSCRVTKSA; AWWRKTYSR; WWRKTYSRQ;FPLLCCRWR; PLLCCRWRT; LLCCRWRTL; LCCRWRTLG; CCRWRTLGN; CRWRTLGNA;RWRTLGNAG; WRTLGNAGS; RTLGNAGSA; TLGNAGSAN; LGNAGSANE; GNAGSANEL;NAGSANELQ; AGSANELQV; GSANELQVK; SANELQVKV; ANELQVKVP; KPNSPVPGN;PNSPVPGNE; NSPVPGNEY; GLFGQKQCL; LFGQKQCLS; FGQKQCLSS; VFWDFHRRG;FWDFHRRGK; WDFHRRGKC; DFHRRGKCS; FHRRGKCSP; HRRGKCSPS; RRGKCSPST;RGKCSPSTS; GKCSPSTSC; KCSPSTSCD; CSPSTSCDQ; SPSTSCDQH; PSTSCDQHS;STSCDQHSY; TSCDQHSYH; SCDQHSYHS; CDQHSYHSV; DQHSYHSVA; QHSYHSVAR;QLWNTTVER; LWNTTVERP; WNTTVERPC; NTTVERPCK; TTVERPCKI; TVERPCKIF;DPPEKKICK; PPEKKICKE; PEKKICKES; EKKICKESL; KKICKESLP; KICKESLPN;ICKESLPNF; CKESLPNFL; KESLPNFLF; ESLPNFLFA; SLPNFLFAK; PYKQENPES;YKQENPESG; KQENPESGW; QENPESGWA; ENPESGWAA; NPESGWAAY; PESGWAAYV;ESGWAAYVW; SGWAAYVWY; GWAAYVWYG; WAAYVWYGI; AAYVWYGIP; AYVWYGIPG;YVWYGIPGR; VWYGIPGRR; WYGIPGRRG; WHRKTSRGP; HRKTSRGPR; RKTSRGPRY;KTSRGPRYD; TSRGPRYDK; SRGPRYDKI; RGPRYDKIY; QTGTIANQN; TGTIANQNA;GTIANQNAL; TIANQNALN; IANQNALNR; ANQNALNRC; NQNALNRCF; QNALNRCFY;NALNRCFYC; ALNRCFYCT; LNRCFYCTY; NRCFYCTYT; RCFYCTYTF; CFYCTYTFN;FYCTYTFNK; YCTYTFNKC; CTYTFNKCC; TYTFNKCCF; YTFNKCCFC; TFNKCCFCI;FNKCCFCIS; NKCCFCISH; KCCFCISHF; ACVILGVVF; NTESLYTNA; TESLYTNAT;ESLYTNATL; SLYTNATLD; LYTNATLDY; YTNATLDYG; TNATLDYGG; NATLDYGGL;ATLDYGGLT; TLDYGGLTF; LDYGGLTFG; DYGGLTFGN; YGGLTFGNL; GGLTFGNLQ;GLTFGNLQQ; LTFGNLQQG; TFGNLQQGL; FGNLQQGLK; GNLQQGLKY; NLQQGLKYL;LQQGLKYLR; QQGLKYLRL; QGLKYLRLG; GLKYLRLGK; LKYLRLGKS; KYLRLGKSI;YLRLGKSIV; LRLGKSIVI; RLGKSIVIG; LGKSIVIGI; GKSIVIGIQ; KSIVIGIQC;SIVIGIQCL; IVIGIQCLI; VIGIQCLIH; IGIQCLIHV; GIQCLIHVQ; IQCLIHVQS;QCLIHVQSL; CLIHVQSLQ; LIHVQSLQF; IHVQSLQFL; HVQSLQFLN; VQSLQFLNP;QSLQFLNPL; SLQFLNPLL; LQFLNPLLL; YQEYISPCI; QEYISPCIY; EYISPCIYY;YISPCIYYI; ISPCIYYIS; SPCIYYISS; PCIYYISSL; CIYYISSLK; IYYISSLKK;YYISSLKKY; YISSLKKYT; ISSLKKYTY; SSLKKYTYL; SLKKYTYLS; LKKYTYLSQ;KKYTYLSQN; KYTYLSQNP; YTYLSQNPA; TYLSQNPAF; YLSQNPAFP; LSQNPAFPS;SQNPAFPSI; QNPAFPSIQ; NPAFPSIQQ; PAFPSIQQF; IVYQLQNQL; VYQLQNQLQ;YQLQNQLQA; TKLAVATRS; KLAVATRSF; LAVATRSFH; AVATRSFHF; VATRSFHFV;ATRSFHFVK; TRSFHFVKF; RSFHFVKFF; SFHFVKFFF; FHFVKFFFQ; HFVKFFFQV;FVKFFFQVR; VKFFFQVRT; KFFFQVRTL; FFFQVRTLS; FFQVRTLSF; FQVRTLSFV;QVRTLSFVR; VRTLSFVRI; RTLSFVRIF; TLSFVRIFL; LSFVRIFLN; SFVRIFLNI;FVRIFLNIF; VRIFLNIFW; RIFLNIFWA; PSLVEIFGF; SLVEIFGFF; LVEIFGFFC;VEIFGFFCL; EIFGFFCLN; IFGFFCLNV; FGFFCLNVS; GFFCLNVSF; FFCLNVSFL;FCLNVSFLN; CLNVSFLNL; LNVSFLNLP; HFHLNNLSN; FHLNNLSNC; HLNNLSNCL;LNNLSNCLN; NNLSNCLNC; NLSNCLNCL; LSNCLNCLF; SNCLNCLFH; NCLNCLFHV;CLNCLFHVL; LNCLFHVLK; NCLFHVLKA; CLFHVLKAN; LFHVLKANP; FHVLKANPL;HVLKANPLI; VLKANPLIQ; LKANPLIQL; KANPLIQLL; ANPLIQLLS; NPLIQLLSL;PLIQLLSLL; LIQLLSLLH; IQLLSLLHL; QLLSLLHLQ; LLSLLHLQK; LSLLHLQKQ;SLLHLQKQP; LLHLQKQPC; LHLQKQPCT; HLQKQPCTD; LQKQPCTDL; LHLAQRLAF;HLAQRLAFP; LAQRLAFPW; AQRLAFPWV; QRLAFPWVG; RLAFPWVGL; LAFPWVGLH;AFPWVGLHL; FPWVGLHLR; PWVGLHLRL; WVGLHLRLY; VGLHLRLYH; GLHLRLYHH;LHLRLYHHT; HLRLYHHTN; LRLYHHTNL; RLYHHTNLI; LYHHTNLIT; YHHTNLITL;HHTNLITLQ; HTNLITLQL; TNLITLQLV; NLITLQLVL; LITLQLVLF; ITLQLVLFF;TLQLVLFFH; LQLVLFFHY; QLVLFFHYQ; LVLFFHYQW; VLFFHYQWD; LFFHYQWDL;KQYSAKNQI; QYSAKNQIL; YSAKNQILQ; SAKNQILQN; AKNQILQNP; KNQILQNPF;VANSAAKQH; ANSAAKQHL; NSAAKQHLP; SAAKQHLPY; AAKQHLPYI; AKQHLPYIV;KQHLPYIVL; QHLPYIVLV; HLPYIVLVQ; LPYIVLVQH; PYIVLVQHF; YIVLVQHFH;IVLVQHFHE; VLVQHFHEL; LVQHFHELQ; VQHFHELQI; QHFHELQIL; HFHELQILN;FHELQILNP; HELQILNPF; ELQILNPFY; LQILNPFYL; QILNPFYLI; ILNPFYLIY;LNPFYLIYD; IFLLAFLPW; FLLAFLPWS; LLAFLPWSY; LAFLPWSYE; AFLPWSYEG;FLPWSYEGY; LPWSYEGYL; PWSYEGYLL; WSYEGYLLF; SYEGYLLFF; LKLYLLLAD;KLYLLLADK; LYLLLADKY; YLLLADKYF; LLLADKYFF; LLADKYFFD; LADKYFFDF;ADKYFFDFY; DKYFFDFYF; KYFFDFYFL; YFFDFYFLQ; FFDFYFLQK; HLQSAFHDT;SDKAGLFSD; DKAGLFSDT; KAGLFSDTF; AGLFSDTFY; GLFSDTFYT; LFSDTFYTP;FSDTFYTPL; SDTFYTPLH; DTFYTPLHC; TFYTPLHCI; FYTPLHCIE; YTPLHCIEI;TPLHCIEIL; PLHCIEILN; LHCIEILNT; HCIEILNTY; CIEILNTYL; IEILNTYLI;EILNTYLII; ILNTYLIIK; LNTYLIIKT; NTYLIIKTH; TYLIIKTHP; YLIIKTHPH;LIIKTHPHT; IIKTHPHTL; IKTHPHTLS; KTHPHTLSL; THPHTLSLL; HPHTLSLLH;PHTLSLLHT; HTLSLLHTQ; LISKTPALF; ISKTPALFL; SKTPALFLQ; KTPALFLQA;TPALFLQAL; PALFLQALL; ALFLQALLG; NHAPLSPLE; HAPLSPLEC; APLSPLECF;PLSPLECFL; LSPLECFLL; LRHYIVSIP; RHYIVSIPY; RYTAFDRNY; LQKLYVYVE;QKLYVYVEL; KLYVYVELK; LYVYVELKR; YVYVELKRI; YYAQHTCVY; VFYTEFELF;FYTEFELFL; YTQQSRQGF; TQQSRQGFY; QQSRQGFYY; ETGVDQRES; TGVDQRESL;GLLPFFFFW; LLPFFFFWV; LPFFFFWVV; PFFFFWVVL; FFFFWVVLS; FFFWVVLSV;FFWVVLSVE; FWVVLSVEN; WVVLSVENL; VVLSVENLL; VLSVENLLL; LSVENLLLL;SVENLLLLL; VENLLLLLH; ENLLLLLHH; NLLLLLHHW; LLLLLHHWQ; LLLLHHWQT;LLLHHWQTY; LLHHWQTYL; LHHWQTYLH; HHWQTYLHG; HWQTYLHGK; WQTYLHGKI;QTYLHGKIN; TYLHGKINL; YLHGKINLH; LHGKINLHP; HGKINLHPI; GKINLHPIF;KINLHPIFH; RNSTRTPTL; NSTRTPTLL; STRTPTLLF; TRTPTLLFH; RTPTLLFHR;TPTLLFHRL; PTLLFHRLA; TLLFHRLAP; LLFHRLAPI; LFHRLAPIK; FHRLAPIKK;HRLAPIKKI; RLAPIKKII; LAPIKKIIT; GLLIFYYLS; LLIFYYLSK; LIFYYLSKY;IFYYLSKYK; FYYLSKYKL; YYLSKYKLV; YLSKYKLVT; LSKYKLVTL; SKYKLVTLK;KYKLVTLKL; ISEGSFSNY; SEGSFSNYL; EGSFSNYLD; GSFSNYLDP; SFSNYLDPP;FSNYLDPPL; SNYLDPPLQ; NYLDPPLQS; YLDPPLQSF; LDPPLQSFF; DPPLQSFFS;AKPLCEAVN; KPLCEAVNA; PLCEAVNAV; LCEAVNAVA; CEAVNAVAI; EAVNAVAIY;AVNAVAIYP; VNAVAIYPN; NAVAIYPNQ; AVAIYPNQG; VAIYPNQGL; AIYPNQGLF;IYPNQGLFS; HARAVHRRL; ARAVHRRLF; RAVHRRLFG; AVHRRLFGT; VHRRLFGTN;HRRLFGTNR; RRLFGTNRP; RLFGTNRPF; LFGTNRPFL; FGTNRPFLA; GTNRPFLAV;TNRPFLAVQ; NRPFLAVQG; RPFLAVQGI; PFLAVQGIW; FLAVQGIWA; LAVQGIWAK;AVQGIWAKR; VQGIWAKRK; QGIWAKRKI; GIWAKRKIS; IWAKRKIST; WAKRKISTN;AKRKISTNL; ATPGSKIRL; TPGSKIRLM; PGSKIRLMS; GSKIRLMSY; SKIRLMSYL;KIRLMSYLY; IRLMSYLYI; RLMSYLYIL; LMSYLYILL; MSYLYILLH; SYLYILLHF;YLYILLHFF; LYILLHFFI; YILLHFFIQ; ILLHFFIQS; LLHFFIQSI; LHFFIQSIH;HFFIQSIHS; FFIQSIHSL; FIQSIHSLH; IQSIHSLHF; QSIHSLHFI; SIHSLHFIL;IHSLHFILV; HSLHFILVA; SLHFILVAP; LHFILVAPF; HFILVAPFV; FILVAPFVR;ILVAPFVRV; LVAPFVRVK; VAPFVRVKF; APFVRVKFL; PFVRVKFLT; FVRVKFLTL;VRVKFLTLP; GKISPGSSF; KISPGSSFK; ISPGSSFKA; KVHELHGFF; VHELHGFFP;HELHGFFPV; ELHGFFPVK; LHGFFPVKN; HGFFPVKNF; GFFPVKNFI; FFPVKNFIH10 mers: LQKLQKNRDF; QKLQKNRDFP; KLQKNRDFPK; ASEKASTPLL; SEKASTPLLL;EKASTPLLLE; KASTPLLLER; ASTPLLLERK; STPLLLERKG; TPLLLERKGG;PLLLERKGGG; LLLERKGGGR; LLERKGGGRG; LERKGGGRGG; ERKGGGRGGL;RKGGGRGGLG; KGGGRGGLGL; GGGRGGLGLL; GGRGGLGLLY; GRGGLGLLYI;RGGLGLLYII; GGLGLLYIIK; GLGLLYIIKK; LGLLYIIKKK; GLLYIIKKKA;LLYIIKKKAT; LYIIKKKATG; YIIKKKATGR; IIKKKATGRS; IKKKATGRSC;KKKATGRSCL; KKATGRSCLP; KATGRSCLPM; ATGRSCLPME; TGRSCLPMEC;GRSCLPMECS; RSCLPMECSQ; SCLPMECSQT; CLPMECSQTM; LPMECSQTMT;PMECSQTMTS; MECSQTMTSG; ECSQTMTSGR; CSQTMTSGRK; SQTMTSGRKV;QTMTSGRKVH; TMTSGRKVHD; MTSGRKVHDS; TSGRKVHDSQ; SGRKVHDSQG;GRKVHDSQGN; RKVHDSQGNA; KVHDSQGNAA; VHDSQGNAAK; HDSQGNAAKP;PQEGKCMTHR; QEGKCMTHRE; EGKCMTHREE; GKCMTHREEL; KCMTHREELL;CMTHREELLT; MTHREELLTH; THREELLTHG; HREELLTHGM; REELLTHGMQ;EELLTHGMQP; ELLTHGMQPN; LLTHGMQPNH; LTHGMQPNHD; THGMQPNHDL;HGMQPNHDLR; GMQPNHDLRK; MQPNHDLRKE; QPNHDLRKES; PNHDLRKESA;QTCFASLGIL; TCFASLGILA; CFASLGILAL; FASLGILALS; ASLGILALSP;SLGILALSPV; LGILALSPVK; GILALSPVKL; ILALSPVKLD; LALSPVKLDK;ALSPVKLDKG; LSPVKLDKGH; SPVKLDKGHG; PVKLDKGHGS; VKLDKGHGSA;KLDKGHGSAP; LDKGHGSAPA; DKGHGSAPAV; KGHGSAPAVT; GHGSAPAVTT;HGSAPAVTTS; GSAPAVTTSF; SAPAVTTSFS; APAVTTSFSE; PAVTTSFSES;AVTTSFSESW; NLDWNKKKSS; LDWNKKKSSE; DWNKKKSSED; WNKKKSSEDF;NKKKSSEDFY; KKKSSEDFYF; KKSSEDFYFY; KSSEDFYFYF; SSEDFYFYFR;SEDFYFYFRA; EDFYFYFRAF; DFYFYFRAFA; FYFYFRAFAG; YFYFRAFAGI;FYFRAFAGIL; RQCRREKQKY; QCRREKQKYH; CRREKQKYHC; RREKQKYHCF;REKQKYHCFT; EKQKYHCFTC; KQKYHCFTCC; QKYHCFTCCK; KYHCFTCCKR;YHCFTCCKRL; HCFTCCKRLC; CFTCCKRLCK; FTCCKRLCKR; TCCKRLCKRL;CCKRLCKRLL; CKRLCKRLLG; KRLCKRLLGK; SLFFCISRFM; LFFCISRFMG;FFCISRFMGA; FCISRFMGAA; CISRFMGAAL; ISRFMGAALA; SRFMGAALAL;RFMGAALALL; FMGAALALLG; MGAALALLGD; GAALALLGDL; AALALLGDLV;ALALLGDLVA; LALLGDLVAS; ALLGDLVASV; LLGDLVASVS; LGDLVASVSE;GDLVASVSEA; DLVASVSEAA; LVASVSEAAA; VASVSEAAAA; ASVSEAAAAT;SVSEAAAATG; VSEAAAATGF; SEAAAATGFS; EAAAATGFSV; AAAATGFSVA;AAATGFSVAE; AATGFSVAEI; ATGFSVAEIA; TGFSVAEIAA; GFSVAEIAAG;FSVAEIAAGE; SVAEIAAGEA; VAEIAAGEAA; AEIAAGEAAA; EIAAGEAAAA;IAAGEAAAAI; AAGEAAAAIE; AGEAAAAIEV; GEAAAAIEVQ; EAAAAIEVQI;AAAAIEVQIA; AAAIEVQIAS; AAIEVQIASL; AIEVQIASLA; IEVQIASLAT;EVQIASLATV; VQIASLATVE; QIASLATVEG; IASLATVEGI; ASLATVEGIT;SLATVEGITS; LATVEGITST; ATVEGITSTS; TVEGITSTSE; VEGITSTSEA;EGITSTSEAI; GITSTSEAIA; ITSTSEAIAA; TSTSEAIAAI; STSEAIAAIG;TSEAIAAIGL; SEAIAAIGLT; EAIAAIGLTP; AIAAIGLTPQ; IAAIGLTPQT;AAIGLTPQTY; AIGLTPQTYA; IGLTPQTYAV; GLTPQTYAVI; LTPQTYAVIA;TPQTYAVIAG; PQTYAVIAGA; QTYAVIAGAP; TYAVIAGAPG; YAVIAGAPGA;AVIAGAPGAI; VIAGAPGAIA; IAGAPGAIAG; AGAPGAIAGF; GAPGAIAGFA;APGAIAGFAA; PGAIAGFAAL; GAIAGFAALI; AIAGFAALIQ; IAGFAALIQT;AGFAALIQTV; GFAALIQTVS; FAALIQTVSG; AALIQTVSGI; ALIQTVSGIS;LIQTVSGISS; IQTVSGISSL; QTVSGISSLA; TVSGISSLAQ; VSGISSLAQV;SGISSLAQVG; GISSLAQVGY; ISSLAQVGYK; SSLAQVGYKF; SLAQVGYKFF;LAQVGYKFFD; AQVGYKFFDD; QVGYKFFDDW; VGYKFFDDWD; GYKFFDDWDH;YKFFDDWDHK; KFFDDWDHKV; FFDDWDHKVS; FDDWDHKVST; DDWDHKVSTV;DWDHKVSTVG; WDHKVSTVGL; DHKVSTVGLY; HKVSTVGLYQ; KVSTVGLYQQ;VSTVGLYQQS; STVGLYQQSG; TVGLYQQSGM; VGLYQQSGMA; GLYQQSGMAL;LYQQSGMALE; YQQSGMALEL; QQSGMALELF; QSGMALELFN; SGMALELFNP;GMALELFNPD; MALELFNPDE; ALELFNPDEY; LELFNPDEYY; ELFNPDEYYD;LFNPDEYYDI; FNPDEYYDIL; NPDEYYDILF; PDEYYDILFP; DEYYDILFPG;EYYDILFPGV; YYDILFPGVN; YDILFPGVNT; DILFPGVNTF; ILFPGVNTFV;LFPGVNTFVN; FPGVNTFVNN; PGVNTFVNNI; GVNTFVNNIQ; VNTFVNNIQY;NTFVNNIQYL; TFVNNIQYLD; FVNNIQYLDP; VNNIQYLDPR; NNIQYLDPRH;NIQYLDPRHW; IQYLDPRHWG; QYLDPRHWGP; YLDPRHWGPS; LDPRHWGPSL;DPRHWGPSLF; PRHWGPSLFA; RHWGPSLFAT; HWGPSLFATI; WGPSLFATIS;GPSLFATISQ; PSLFATISQA; SLFATISQAL; LFATISQALW; FATISQALWH;ATISQALWHV; TISQALWHVI; ISQALWHVIR; SQALWHVIRD; QALWHVIRDD;ALWHVIRDDI; LWHVIRDDIP; WHVIRDDIPS; HVIRDDIPSI; VIRDDIPSIT;IRDDIPSITS; RDDIPSITSQ; DDIPSITSQE; DIPSITSQEL; IPSITSQELQ;PSITSQELQR; SITSQELQRR; ITSQELQRRT; TSQELQRRTE; SQELQRRTER;QELQRRTERF; ELQRRTERFF; LQRRTERFFR; QRRTERFFRD; RRTERFFRDS;RTERFFRDSL; TERFFRDSLA; ERFFRDSLAR; RFFRDSLARF; FFRDSLARFL;FRDSLARFLE; RDSLARFLEE; DSLARFLEET; SLARFLEETT; LARFLEETTW;ARFLEETTWT; RFLEETTWTI; FLEETTWTIV; LEETTWTIVN; EETTWTIVNA;ETTWTIVNAP; TTWTIVNAPI; TWTIVNAPIN; WTIVNAPINF; TIVNAPINFY;IVNAPINFYN; VNAPINFYNY; NAPINFYNYI; APINFYNYIQ; PINFYNYIQQ;INFYNYIQQY; NFYNYIQQYY; FYNYIQQYYS; YNYIQQYYSD; NYIQQYYSDL;YIQQYYSDLS; IQQYYSDLSP; QQYYSDLSPI; QYYSDLSPIR; YYSDLSPIRP;YSDLSPIRPS; SDLSPIRPSM; DLSPIRPSMV; LSPIRPSMVR; SPIRPSMVRQ;PIRPSMVRQV; IRPSMVRQVA; RPSMVRQVAE; PSMVRQVAER; SMVRQVAERE;MVRQVAEREG; VRQVAEREGT; RQVAEREGTR; QVAEREGTRV; VAEREGTRVH;AEREGTRVHF; EREGTRVHFG; REGTRVHFGH; EGTRVHFGHT; GTRVHFGHTY;TRVHFGHTYS; RVHFGHTYSI; VHFGHTYSID; HFGHTYSIDD; FGHTYSIDDA;GHTYSIDDAD; HTYSIDDADS; TYSIDDADSI; YSIDDADSIE; SIDDADSIEE;IDDADSIEEV; DDADSIEEVT; DADSIEEVTQ; ADSIEEVTQR; DSIEEVTQRM;SIEEVTQRMD; IEEVTQRMDL; EEVTQRMDLR; EVTQRMDLRN; VTQRMDLRNQ;TQRMDLRNQQ; QRMDLRNQQS; RMDLRNQQSV; MDLRNQQSVH; DLRNQQSVHS;LRNQQSVHSG; RNQQSVHSGE; NQQSVHSGEF; QQSVHSGEFI; QSVHSGEFIE;SVHSGEFIEK; VHSGEFIEKT; HSGEFIEKTI; SGEFIEKTIA; GEFIEKTIAP;EFIEKTIAPG; FIEKTIAPGG; IEKTIAPGGA; EKTIAPGGAN; KTIAPGGANQ;TIAPGGANQR; IAPGGANQRT; APGGANQRTA; PGGANQRTAP; GGANQRTAPQ;GANQRTAPQW; ANQRTAPQWM; NQRTAPQWML; QRTAPQWMLP; RTAPQWMLPL;TAPQWMLPLL; APQWMLPLLL; PQWMLPLLLG; QWMLPLLLGL; WMLPLLLGLY;MLPLLLGLYG; LPLLLGLYGT; PLLLGLYGTV; LLLGLYGTVT; LLGLYGTVTP;LGLYGTVTPA; GLYGTVTPAL; LYGTVTPALE; YGTVTPALEA; GTVTPALEAY;TVTPALEAYE; VTPALEAYED; TPALEAYEDG; PALEAYEDGP; ALEAYEDGPN;LEAYEDGPNQ; EAYEDGPNQK; AYEDGPNQKK; YEDGPNQKKR; EDGPNQKKRR;DGPNQKKRRV; GPNQKKRRVS; PNQKKRRVSR; NQKKRRVSRG; QKKRRVSRGS;KKRRVSRGSS; KRRVSRGSSQ; RRVSRGSSQK; RVSRGSSQKA; VSRGSSQKAK;SRGSSQKAKG; RGSSQKAKGT; GSSQKAKGTR; SSQKAKGTRA; SQKAKGTRAS;QKAKGTRASA; KAKGTRASAK; AKGTRASAKT; KGTRASAKTT; GTRASAKTTN;TRASAKTTNK; RASAKTTNKR; ASAKTTNKRR; SAKTTNKRRS; AKTTNKRRSR;KTTNKRRSRS; TTNKRRSRSS; TNKRRSRSSR; NKRRSRSSRS; NWGRCYYRGR;WGRCYYRGRM; GRCYYRGRML; RCYYRGRMLP; CYYRGRMLPK; YYRGRMLPKP;YRGRMLPKPR; RGRMLPKPRN; GRMLPKPRNG; RMLPKPRNGG; MLPKPRNGGS;LPKPRNGGSR; PREKNASLLQ; REKNASLLQH; EKNASLLQHS; KNASLLQHSK;NASLLQHSKN; ASLLQHSKNS; SLLQHSKNSP; LLQHSKNSPP; LQHSKNSPPQ;QHSKNSPPQF; HSKNSPPQFK; GPNLWKSTDV; PNLWKSTDVG; NLWKSTDVGG;LWKSTDVGGC; WKSTDVGGCN; KSTDVGGCNC; STDVGGCNCT; TDVGGCNCTN;DVGGCNCTNR; VGGCNCTNRG; GGCNCTNRGY; GCNCTNRGYW; CNCTNRGYWN;NCTNRGYWNN; AWWRKTYSRQ; FPLLCCRWRT; PLLCCRWRTL; LLCCRWRTLG;LCCRWRTLGN; CCRWRTLGNA; CRWRTLGNAG; RWRTLGNAGS; WRTLGNAGSA;RTLGNAGSAN; TLGNAGSANE; LGNAGSANEL; GNAGSANELQ; NAGSANELQV;AGSANELQVK; GSANELQVKV; SANELQVKVP; KPNSPVPGNE; PNSPVPGNEY;GLFGQKQCLS; LFGQKQCLSS; VFWDFHRRGK; FWDFHRRGKC; WDFHRRGKCS;DFHRRGKCSP; FHRRGKCSPS; HRRGKCSPST; RRGKCSPSTS; RGKCSPSTSC;GKCSPSTSCD; KCSPSTSCDQ; CSPSTSCDQH; SPSTSCDQHS; PSTSCDQHSY;STSCDQHSYH; TSCDQHSYHS; SCDQHSYHSV; CDQHSYHSVA; DQHSYHSVAR;QLWNTTVERP; LWNTTVERPC; WNTTVERPCK; NTTVERPCKI; TTVERPCKIF;DPPEKKICKE; PPEKKICKES; PEKKICKESL; EKKICKESLP; KKICKESLPN;KICKESLPNF; ICKESLPNFL; CKESLPNFLF; KESLPNFLFA; ESLPNFLFAK;PYKQENPESG; YKQENPESGW; KQENPESGWA; QENPESGWAA; ENPESGWAAY;NPESGWAAYV; PESGWAAYVW; ESGWAAYVWY; SGWAAYVWYG; GWAAYVWYGI;WAAYVWYGIP; AAYVWYGIPG; AYVWYGIPGR; YVWYGIPGRR; VWYGIPGRRG;WHRKTSRGPR; HRKTSRGPRY; RKTSRGPRYD; KTSRGPRYDK; TSRGPRYDKI;SRGPRYDKIY; QTGTIANQNA; TGTIANQNAL; GTIANQNALN; TIANQNALNR;IANQNALNRC; ANQNALNRCF; NQNALNRCFY; QNALNRCFYC; NALNRCFYCT;ALNRCFYCTY; LNRCFYCTYT; NRCFYCTYTF; RCFYCTYTFN; CFYCTYTFNK;FYCTYTFNKC; YCTYTFNKCC; CTYTFNKCCF; TYTFNKCCFC; YTFNKCCFCI;TFNKCCFCIS; FNKCCFCISH; NKCCFCISHF; NTESLYTNAT; TESLYTNATL;ESLYTNATLD; SLYTNATLDY; LYTNATLDYG; YTNATLDYGG; TNATLDYGGL;NATLDYGGLT; ATLDYGGLTF; TLDYGGLTFG; LDYGGLTFGN; DYGGLTFGNL;YGGLTFGNLQ; GGLTFGNLQQ; GLTFGNLQQG; LTFGNLQQGL; TFGNLQQGLK;FGNLQQGLKY; GNLQQGLKYL; NLQQGLKYLR; LQQGLKYLRL; QQGLKYLRLG;QGLKYLRLGK; GLKYLRLGKS; LKYLRLGKSI; KYLRLGKSIV; YLRLGKSIVI;LRLGKSIVIG; RLGKSIVIGI; LGKSIVIGIQ; GKSIVIGIQC; KSIVIGIQCL;SIVIGIQCLI; IVIGIQCLIH; VIGIQCLIHV; IGIQCLIHVQ; GIQCLIHVQS;IQCLIHVQSL; QCLIHVQSLQ; CLIHVQSLQF; LIHVQSLQFL; IHVQSLQFLN;HVQSLQFLNP; VQSLQFLNPL; QSLQFLNPLL; SLQFLNPLLL; YQEYISPCIY;QEYISPCIYY; EYISPCIYYI; YISPCIYYIS; ISPCIYYISS; SPCIYYISSL;PCIYYISSLK; CIYYISSLKK; IYYISSLKKY; YYISSLKKYT; YISSLKKYTY;ISSLKKYTYL; SSLKKYTYLS; SLKKYTYLSQ; LKKYTYLSQN; KKYTYLSQNP;KYTYLSQNPA; YTYLSQNPAF; TYLSQNPAFP; YLSQNPAFPS; LSQNPAFPSI;SQNPAFPSIQ; QNPAFPSIQQ; NPAFPSIQQF; IVYQLQNQLQ; VYQLQNQLQA;TKLAVATRSF; KLAVATRSFH; LAVATRSFHF; AVATRSFHFV; VATRSFHFVK;ATRSFHFVKF; TRSFHFVKFF; RSFHFVKFFF; SFHFVKFFFQ; FHFVKFFFQV;HFVKFFFQVR; FVKFFFQVRT; VKFFFQVRTL; KFFFQVRTLS; FFFQVRTLSF;FFQVRTLSFV; FQVRTLSFVR; QVRTLSFVRI; VRTLSFVRIF; RTLSFVRIFL;TLSFVRIFLN; LSFVRIFLNI; SFVRIFLNIF; FVRIFLNIFW; VRIFLNIFWA;PSLVEIFGFF; SLVEIFGFFC; LVEIFGFFCL; VEIFGFFCLN; EIFGFFCLNV;IFGFFCLNVS; FGFFCLNVSF; GFFCLNVSFL; FFCLNVSFLN; FCLNVSFLNL;CLNVSFLNLP; HFHLNNLSNC; FHLNNLSNCL; HLNNLSNCLN; LNNLSNCLNC;NNLSNCLNCL; NLSNCLNCLF; LSNCLNCLFH; SNCLNCLFHV; NCLNCLFHVL;CLNCLFHVLK; LNCLFHVLKA; NCLFHVLKAN; CLFHVLKANP; LFHVLKANPL;FHVLKANPLI; HVLKANPLIQ; VLKANPLIQL; LKANPLIQLL; KANPLIQLLS;ANPLIQLLSL; NPLIQLLSLL; PLIQLLSLLH; LIQLLSLLHL; IQLLSLLHLQ;QLLSLLHLQK; LLSLLHLQKQ; LSLLHLQKQP; SLLHLQKQPC; LLHLQKQPCT;LHLQKQPCTD; HLQKQPCTDL; LHLAQRLAFP; HLAQRLAFPW; LAQRLAFPWV;AQRLAFPWVG; QRLAFPWVGL; RLAFPWVGLH; LAFPWVGLHL; AFPWVGLHLR;FPWVGLHLRL; PWVGLHLRLY; WVGLHLRLYH; VGLHLRLYHH; GLHLRLYHHT;LHLRLYHHTN; HLRLYHHTNL; LRLYHHTNLI; RLYHHTNLIT; LYHHTNLITL;YHHTNLITLQ; HHTNLITLQL; HTNLITLQLV; TNLITLQLVL; NLITLQLVLF;LITLQLVLFF; ITLQLVLFFH; TLQLVLFFHY; LQLVLFFHYQ; QLVLFFHYQW;LVLFFHYQWD; VLFFHYQWDL; KQYSAKNQIL; QYSAKNQILQ; YSAKNQILQN;SAKNQILQNP; AKNQILQNPF; VANSAAKQHL; ANSAAKQHLP; NSAAKQHLPY;SAAKQHLPYI; AAKQHLPYIV; AKQHLPYIVL; KQHLPYIVLV; QHLPYIVLVQ;HLPYIVLVQH; LPYIVLVQHF; PYIVLVQHFH; YIVLVQHFHE; IVLVQHFHEL;VLVQHFHELQ; LVQHFHELQI; VQHFHELQIL; QHFHELQILN; HFHELQILNP;FHELQILNPF; HELQILNPFY; ELQILNPFYL; LQILNPFYLI; QILNPFYLIY;ILNPFYLIYD; IFLLAFLPWS; FLLAFLPWSY; LLAFLPWSYE; LAFLPWSYEG;AFLPWSYEGY; FLPWSYEGYL; LPWSYEGYLL; PWSYEGYLLF; WSYEGYLLFF;LKLYLLLADK; KLYLLLADKY; LYLLLADKYF; YLLLADKYFF; LLLADKYFFD;LLADKYFFDF; LADKYFFDFY; ADKYFFDFYF; DKYFFDFYFL; KYFFDFYFLQ;YFFDFYFLQK; SDKAGLFSDT; DKAGLFSDTF; KAGLFSDTFY; AGLFSDTFYT;GLFSDTFYTP; LFSDTFYTPL; FSDTFYTPLH; SDTFYTPLHC; DTFYTPLHCI;TFYTPLHCIE; FYTPLHCIEI; YTPLHCIEIL; TPLHCIEILN; PLHCIEILNT;LHCIEILNTY; HCIEILNTYL; CIEILNTYLI; IEILNTYLII; EILNTYLIIK;ILNTYLIIKT; LNTYLIIKTH; NTYLIIKTHP; TYLIIKTHPH; YLIIKTHPHT;LIIKTHPHTL; IIKTHPHTLS; IKTHPHTLSL; KTHPHTLSLL; THPHTLSLLH;HPHTLSLLHT; PHTLSLLHTQ; LISKTPALFL; ISKTPALFLQ; SKTPALFLQA;KTPALFLQAL; TPALFLQALL; PALFLQALLG; NHAPLSPLEC; HAPLSPLECF;APLSPLECFL; PLSPLECFLL; LRHYIVSIPY; LQKLYVYVEL; QKLYVYVELK;KLYVYVELKR; LYVYVELKRI; VFYTEFELFL; YTQQSRQGFY; TQQSRQGFYY;ETGVDQRESL; GLLPFFFFWV; LLPFFFFWVV; LPFFFFWVVL; PFFFFWVVLS;FFFFWVVLSV; FFFWVVLSVE; FFWVVLSVEN; FWVVLSVENL; WVVLSVENLL;VVLSVENLLL; VLSVENLLLL; LSVENLLLLL; SVENLLLLLH; VENLLLLLHH;ENLLLLLHHW; NLLLLLHHWQ; LLLLLHHWQT; LLLLHHWQTY; LLLHHWQTYL;LLHHWQTYLH; LHHWQTYLHG; HHWQTYLHGK; HWQTYLHGKI; WQTYLHGKIN;QTYLHGKINL; TYLHGKINLH; YLHGKINLHP; LHGKINLHPI; HGKINLHPIF;GKINLHPIFH; RNSTRTPTLL; NSTRTPTLLF; STRTPTLLFH; TRTPTLLFHR;RTPTLLFHRL; TPTLLFHRLA; PTLLFHRLAP; TLLFHRLAPI; LLFHRLAPIK;LFHRLAPIKK; FHRLAPIKKI; HRLAPIKKII; RLAPIKKIIT; GLLIFYYLSK;LLIFYYLSKY; LIFYYLSKYK; IFYYLSKYKL; FYYLSKYKLV; YYLSKYKLVT;YLSKYKLVTL; LSKYKLVTLK; SKYKLVTLKL; ISEGSFSNYL; SEGSFSNYLD;EGSFSNYLDP; GSFSNYLDPP; SFSNYLDPPL; FSNYLDPPLQ; SNYLDPPLQS;NYLDPPLQSF; YLDPPLQSFF; LDPPLQSFFS; AKPLCEAVNA; KPLCEAVNAV;PLCEAVNAVA; LCEAVNAVAI; CEAVNAVAIY; EAVNAVAIYP; AVNAVAIYPN;VNAVAIYPNQ; NAVAIYPNQG; AVAIYPNQGL; VAIYPNQGLF; AIYPNQGLFS;HARAVHRRLF; ARAVHRRLFG; RAVHRRLFGT; AVHRRLFGTN; VHRRLFGTNR;HRRLFGTNRP; RRLFGTNRPF; RLFGTNRPFL; LFGTNRPFLA; FGTNRPFLAV;GTNRPFLAVQ; TNRPFLAVQG; NRPFLAVQGI; RPFLAVQGIW; PFLAVQGIWA;FLAVQGIWAK; LAVQGIWAKR; AVQGIWAKRK; VQGIWAKRKI; QGIWAKRKIS;GIWAKRKIST; IWAKRKISTN; WAKRKISTNL; ATPGSKIRLM; TPGSKIRLMS;PGSKIRLMSY; GSKIRLMSYL; SKIRLMSYLY; KIRLMSYLYI; IRLMSYLYIL;RLMSYLYILL; LMSYLYILLH; MSYLYILLHF; SYLYILLHFF; YLYILLHFFI;LYILLHFFIQ; YILLHFFIQS; ILLHFFIQSI; LLHFFIQSIH; LHFFIQSIHS;HFFIQSIHSL; FFIQSIHSLH; FIQSIHSLHF; IQSIHSLHFI; QSIHSLHFIL;SIHSLHFILV; IHSLHFILVA; HSLHFILVAP; SLHFILVAPF; LHFILVAPFV;HFILVAPFVR; FILVAPFVRV; ILVAPFVRVK; LVAPFVRVKF; VAPFVRVKFL;APFVRVKFLT; PFVRVKFLTL; FVRVKFLTLP; GKISPGSSFK; KISPGSSFKA;KVHELHGFFP; VHELHGFFPV; HELHGFFPVK; ELHGFFPVKN; LHGFFPVKNF;HGFFPVKNFI; GFFPVKNFIH 11 mers:LQKLQKNRDFP; QKLQKNRDFPK; ASEKASTPLLL; SEKASTPLLLE; EKASTPLLLER;KASTPLLLERK; ASTPLLLERKG; STPLLLERKGG; TPLLLERKGGG; PLLLERKGGGR;LLLERKGGGRG; LLERKGGGRGG; LERKGGGRGGL; ERKGGGRGGLG; RKGGGRGGLGL;KGGGRGGLGLL; GGGRGGLGLLY; GGRGGLGLLYI; GRGGLGLLYII; RGGLGLLYIIK;GGLGLLYIIKK; GLGLLYIIKKK; LGLLYIIKKKA; GLLYIIKKKAT; LLYIIKKKATG;LYIIKKKATGR; YIIKKKATGRS; IIKKKATGRSC; IKKKATGRSCL; KKKATGRSCLP;KKATGRSCLPM; KATGRSCLPME; ATGRSCLPMEC; TGRSCLPMECS; GRSCLPMECSQ;RSCLPMECSQT; SCLPMECSQTM; CLPMECSQTMT; LPMECSQTMTS; PMECSQTMTSG;MECSQTMTSGR; ECSQTMTSGRK; CSQTMTSGRKV; SQTMTSGRKVH; QTMTSGRKVHD;TMTSGRKVHDS; MTSGRKVHDSQ; TSGRKVHDSQG; SGRKVHDSQGN; GRKVHDSQGNA;RKVHDSQGNAA; KVHDSQGNAAK; VHDSQGNAAKP; PQEGKCMTHRE; QEGKCMTHREE;EGKCMTHREEL; GKCMTHREELL; KCMTHREELLT; CMTHREELLTH; MTHREELLTHG;THREELLTHGM; HREELLTHGMQ; REELLTHGMQP; EELLTHGMQPN; ELLTHGMQPNH;LLTHGMQPNHD; LTHGMQPNHDL; THGMQPNHDLR; HGMQPNHDLRK; GMQPNHDLRKE;MQPNHDLRKES; QPNHDLRKESA; QTCFASLGILA; TCFASLGILAL; CFASLGILALS;FASLGILALSP; ASLGILALSPV; SLGILALSPVK; LGILALSPVKL; GILALSPVKLD;ILALSPVKLDK; LALSPVKLDKG; ALSPVKLDKGH; LSPVKLDKGHG; SPVKLDKGHGS;PVKLDKGHGSA; VKLDKGHGSAP; KLDKGHGSAPA; LDKGHGSAPAV; DKGHGSAPAVT;KGHGSAPAVTT; GHGSAPAVTTS; HGSAPAVTTSF; GSAPAVTTSFS; SAPAVTTSFSE;APAVTTSFSES; PAVTTSFSESW; NLDWNKKKSSE; LDWNKKKSSED; DWNKKKSSEDF;WNKKKSSEDFY; NKKKSSEDFYF; KKKSSEDFYFY; KKSSEDFYFYF; KSSEDFYFYFR;SSEDFYFYFRA; SEDFYFYFRAF; EDFYFYFRAFA; DFYFYFRAFAG; FYFYFRAFAGI;YFYFRAFAGIL; RQCRREKQKYH; QCRREKQKYHC; CRREKQKYHCF; RREKQKYHCFT;REKQKYHCFTC; EKQKYHCFTCC; KQKYHCFTCCK; QKYHCFTCCKR; KYHCFTCCKRL;YHCFTCCKRLC; HCFTCCKRLCK; CFTCCKRLCKR; FTCCKRLCKRL; TCCKRLCKRLL;CCKRLCKRLLG; CKRLCKRLLGK; SLFFCISRFMG; LFFCISRFMGA; FFCISRFMGAA;FCISRFMGAAL; CISRFMGAALA; ISRFMGAALAL; SRFMGAALALL; RFMGAALALLG;FMGAALALLGD; MGAALALLGDL; GAALALLGDLV; AALALLGDLVA; ALALLGDLVAS;LALLGDLVASV; ALLGDLVASVS; LLGDLVASVSE; LGDLVASVSEA; GDLVASVSEAA;DLVASVSEAAA; LVASVSEAAAA; VASVSEAAAAT; ASVSEAAAATG; SVSEAAAATGF;VSEAAAATGFS; SEAAAATGFSV; EAAAATGFSVA; AAAATGFSVAE; AAATGFSVAEI;AATGFSVAEIA; ATGFSVAEIAA; TGFSVAEIAAG; GFSVAEIAAGE; FSVAEIAAGEA;SVAEIAAGEAA; VAEIAAGEAAA; AEIAAGEAAAA; EIAAGEAAAAI; IAAGEAAAAIE;AAGEAAAAIEV; AGEAAAAIEVQ; GEAAAAIEVQI; EAAAAIEVQIA; AAAAIEVQIAS;AAAIEVQIASL; AAIEVQIASLA; AIEVQIASLAT; IEVQIASLATV; EVQIASLATVE;VQIASLATVEG; QIASLATVEGI; IASLATVEGIT; ASLATVEGITS; SLATVEGITST;LATVEGITSTS; ATVEGITSTSE; TVEGITSTSEA; VEGITSTSEAI; EGITSTSEAIA;GITSTSEAIAA; ITSTSEAIAAI; TSTSEAIAAIG; STSEAIAAIGL; TSEAIAAIGLT;SEAIAAIGLTP; EAIAAIGLTPQ; AIAAIGLTPQT; IAAIGLTPQTY; AAIGLTPQTYA;AIGLTPQTYAV; IGLTPQTYAVI; GLTPQTYAVIA; LTPQTYAVIAG; TPQTYAVIAGA;PQTYAVIAGAP; QTYAVIAGAPG; TYAVIAGAPGA; YAVIAGAPGAI; AVIAGAPGAIA;VIAGAPGAIAG; IAGAPGAIAGF; AGAPGAIAGFA; GAPGAIAGFAA; APGAIAGFAAL;PGAIAGFAALI; GAIAGFAALIQ; AIAGFAALIQT; IAGFAALIQTV; AGFAALIQTVS;GFAALIQTVSG; FAALIQTVSGI; AALIQTVSGIS; ALIQTVSGISS; LIQTVSGISSL;IQTVSGISSLA; QTVSGISSLAQ; TVSGISSLAQV; VSGISSLAQVG; SGISSLAQVGY;GISSLAQVGYK; ISSLAQVGYKF; SSLAQVGYKFF; SLAQVGYKFFD; LAQVGYKFFDD;AQVGYKFFDDW; QVGYKFFDDWD; VGYKFFDDWDH; GYKFFDDWDHK; YKFFDDWDHKV;KFFDDWDHKVS; FFDDWDHKVST; FDDWDHKVSTV; DDWDHKVSTVG; DWDHKVSTVGL;WDHKVSTVGLY; DHKVSTVGLYQ; HKVSTVGLYQQ; KVSTVGLYQQS; VSTVGLYQQSG;STVGLYQQSGM; TVGLYQQSGMA; VGLYQQSGMAL; GLYQQSGMALE; LYQQSGMALEL;YQQSGMALELF; QQSGMALELFN; QSGMALELFNP; SGMALELFNPD; GMALELFNPDE;MALELFNPDEY; ALELFNPDEYY; LELFNPDEYYD; ELFNPDEYYDI; LFNPDEYYDIL;FNPDEYYDILF; NPDEYYDILFP; PDEYYDILFPG; DEYYDILFPGV; EYYDILFPGVN;YYDILFPGVNT; YDILFPGVNTF; DILFPGVNTFV; ILFPGVNTFVN; LFPGVNTFVNN;FPGVNTFVNNI; PGVNTFVNNIQ; GVNTFVNNIQY; VNTFVNNIQYL; NTFVNNIQYLD;TFVNNIQYLDP; FVNNIQYLDPR; VNNIQYLDPRH; NNIQYLDPRHW; NIQYLDPRHWG;IQYLDPRHWGP; QYLDPRHWGPS; YLDPRHWGPSL; LDPRHWGPSLF; DPRHWGPSLFA;PRHWGPSLFAT; RHWGPSLFATI; HWGPSLFATIS; WGPSLFATISQ; GPSLFATISQA;PSLFATISQAL; SLFATISQALW; LFATISQALWH; FATISQALWHV; ATISQALWHVI;TISQALWHVIR; ISQALWHVIRD; SQALWHVIRDD; QALWHVIRDDI; ALWHVIRDDIP;LWHVIRDDIPS; WHVIRDDIPSI; HVIRDDIPSIT; VIRDDIPSITS; IRDDIPSITSQ;RDDIPSITSQE; DDIPSITSQEL; DIPSITSQELQ; IPSITSQELQR; PSITSQELQRR;SITSQELQRRT; ITSQELQRRTE; TSQELQRRTER; SQELQRRTERF; QELQRRTERFF;ELQRRTERFFR; LQRRTERFFRD; QRRTERFFRDS; RRTERFFRDSL; RTERFFRDSLA;TERFFRDSLAR; ERFFRDSLARF; RFFRDSLARFL; FFRDSLARFLE; FRDSLARFLEE;RDSLARFLEET; DSLARFLEETT; SLARFLEETTW; LARFLEETTWT; ARFLEETTWTI;RFLEETTWTIV; FLEETTWTIVN; LEETTWTIVNA; EETTWTIVNAP; ETTWTIVNAPI;TTWTIVNAPIN; TWTIVNAPINF; WTIVNAPINFY; TIVNAPINFYN; IVNAPINFYNY;VNAPINFYNYI; NAPINFYNYIQ; APINFYNYIQQ; PINFYNYIQQY; INFYNYIQQYY;NFYNYIQQYYS; FYNYIQQYYSD; YNYIQQYYSDL; NYIQQYYSDLS; YIQQYYSDLSP;IQQYYSDLSPI; QQYYSDLSPIR; QYYSDLSPIRP; YYSDLSPIRPS; YSDLSPIRPSM;SDLSPIRPSMV; DLSPIRPSMVR; LSPIRPSMVRQ; SPIRPSMVRQV; PIRPSMVRQVA;IRPSMVRQVAE; RPSMVRQVAER; PSMVRQVAERE; SMVRQVAEREG; MVRQVAEREGT;VRQVAEREGTR; RQVAEREGTRV; QVAEREGTRVH; VAEREGTRVHF; AEREGTRVHFG;EREGTRVHFGH; REGTRVHFGHT; EGTRVHFGHTY; GTRVHFGHTYS; TRVHFGHTYSI;RVHFGHTYSID; VHFGHTYSIDD; HFGHTYSIDDA; FGHTYSIDDAD; GHTYSIDDADS;HTYSIDDADSI; TYSIDDADSIE; YSIDDADSIEE; SIDDADSIEEV; IDDADSIEEVT;DDADSIEEVTQ; DADSIEEVTQR; ADSIEEVTQRM; DSIEEVTQRMD; SIEEVTQRMDL;IEEVTQRMDLR; EEVTQRMDLRN; EVTQRMDLRNQ; VTQRMDLRNQQ; TQRMDLRNQQS;QRMDLRNQQSV; RMDLRNQQSVH; MDLRNQQSVHS; DLRNQQSVHSG; LRNQQSVHSGE;RNQQSVHSGEF; NQQSVHSGEFI; QQSVHSGEFIE; QSVHSGEFIEK; SVHSGEFIEKT;VHSGEFIEKTI; HSGEFIEKTIA; SGEFIEKTIAP; GEFIEKTIAPG; EFIEKTIAPGG;FIEKTIAPGGA; IEKTIAPGGAN; EKTIAPGGANQ; KTIAPGGANQR; TIAPGGANQRT;IAPGGANQRTA; APGGANQRTAP; PGGANQRTAPQ; GGANQRTAPQW; GANQRTAPQWM;ANQRTAPQWML; NQRTAPQWMLP; QRTAPQWMLPL; RTAPQWMLPLL; TAPQWMLPLLL;APQWMLPLLLG; PQWMLPLLLGL; QWMLPLLLGLY; WMLPLLLGLYG; MLPLLLGLYGT;LPLLLGLYGTV; PLLLGLYGTVT; LLLGLYGTVTP; LLGLYGTVTPA; LGLYGTVTPAL;GLYGTVTPALE; LYGTVTPALEA; YGTVTPALEAY; GTVTPALEAYE; TVTPALEAYED;VTPALEAYEDG; TPALEAYEDGP; PALEAYEDGPN; ALEAYEDGPNQ; LEAYEDGPNQK;EAYEDGPNQKK; AYEDGPNQKKR; YEDGPNQKKRR; EDGPNQKKRRV; DGPNQKKRRVS;GPNQKKRRVSR; PNQKKRRVSRG; NQKKRRVSRGS; QKKRRVSRGSS; KKRRVSRGSSQ;KRRVSRGSSQK; RRVSRGSSQKA; RVSRGSSQKAK; VSRGSSQKAKG; SRGSSQKAKGT;RGSSQKAKGTR; GSSQKAKGTRA; SSQKAKGTRAS; SQKAKGTRASA; QKAKGTRASAK;KAKGTRASAKT; AKGTRASAKTT; KGTRASAKTTN; GTRASAKTTNK; TRASAKTTNKR;RASAKTTNKRR; ASAKTTNKRRS; SAKTTNKRRSR; AKTTNKRRSRS; KTTNKRRSRSS;TTNKRRSRSSR; TNKRRSRSSRS; NWGRCYYRGRM; WGRCYYRGRML; GRCYYRGRMLP;RCYYRGRMLPK; CYYRGRMLPKP; YYRGRMLPKPR; YRGRMLPKPRN; RGRMLPKPRNG;GRMLPKPRNGG; RMLPKPRNGGS; MLPKPRNGGSR; PREKNASLLQH; REKNASLLQHS;EKNASLLQHSK; KNASLLQHSKN; NASLLQHSKNS; ASLLQHSKNSP; SLLQHSKNSPP;LLQHSKNSPPQ; LQHSKNSPPQF; QHSKNSPPQFK; GPNLWKSTDVG; PNLWKSTDVGG;NLWKSTDVGGC; LWKSTDVGGCN; WKSTDVGGCNC; KSTDVGGCNCT; STDVGGCNCTN;TDVGGCNCTNR; DVGGCNCTNRG; VGGCNCTNRGY; GGCNCTNRGYW; GCNCTNRGYWN;CNCTNRGYWNN; FPLLCCRWRTL; PLLCCRWRTLG; LLCCRWRTLGN; LCCRWRTLGNA;CCRWRTLGNAG; CRWRTLGNAGS; RWRTLGNAGSA; WRTLGNAGSAN; RTLGNAGSANE;TLGNAGSANEL; LGNAGSANELQ; GNAGSANELQV; NAGSANELQVK; AGSANELQVKV;GSANELQVKVP; KPNSPVPGNEY; GLFGQKQCLSS; VFWDFHRRGKC; FWDFHRRGKCS;WDFHRRGKCSP; DFHRRGKCSPS; FHRRGKCSPST; HRRGKCSPSTS; RRGKCSPSTSC;RGKCSPSTSCD; GKCSPSTSCDQ; KCSPSTSCDQH; CSPSTSCDQHS; SPSTSCDQHSY;PSTSCDQHSYH; STSCDQHSYHS; TSCDQHSYHSV; SCDQHSYHSVA; CDQHSYHSVAR;QLWNTTVERPC; LWNTTVERPCK; WNTTVERPCKI; NTTVERPCKIF; DPPEKKICKES;PPEKKICKESL; PEKKICKESLP; EKKICKESLPN; KKICKESLPNF; KICKESLPNFL;ICKESLPNFLF; CKESLPNFLFA; KESLPNFLFAK; PYKQENPESGW; YKQENPESGWA;KQENPESGWAA; QENPESGWAAY; ENPESGWAAYV; NPESGWAAYVW; PESGWAAYVWY;ESGWAAYVWYG; SGWAAYVWYGI; GWAAYVWYGIP; WAAYVWYGIPG; AAYVWYGIPGR;AYVWYGIPGRR; YVWYGIPGRRG; WHRKTSRGPRY; HRKTSRGPRYD; RKTSRGPRYDK;KTSRGPRYDKI; TSRGPRYDKIY; QTGTIANQNAL; TGTIANQNALN; GTIANQNALNR;TIANQNALNRC; IANQNALNRCF; ANQNALNRCFY; NQNALNRCFYC; QNALNRCFYCT;NALNRCFYCTY; ALNRCFYCTYT; LNRCFYCTYTF; NRCFYCTYTFN; RCFYCTYTFNK;CFYCTYTFNKC; FYCTYTFNKCC; YCTYTFNKCCF; CTYTFNKCCFC; TYTFNKCCFCI;YTFNKCCFCIS; TFNKCCFCISH; FNKCCFCISHF; NTESLYTNATL; TESLYTNATLD;ESLYTNATLDY; SLYTNATLDYG; LYTNATLDYGG; YTNATLDYGGL; TNATLDYGGLT;NATLDYGGLTF; ATLDYGGLTFG; TLDYGGLTFGN; LDYGGLTFGNL; DYGGLTFGNLQ;YGGLTFGNLQQ; GGLTFGNLQQG; GLTFGNLQQGL; LTFGNLQQGLK; TFGNLQQGLKY;FGNLQQGLKYL; GNLQQGLKYLR; NLQQGLKYLRL; LQQGLKYLRLG; QQGLKYLRLGK;QGLKYLRLGKS; GLKYLRLGKSI; LKYLRLGKSIV; KYLRLGKSIVI; YLRLGKSIVIG;LRLGKSIVIGI; RLGKSIVIGIQ; LGKSIVIGIQC; GKSIVIGIQCL; KSIVIGIQCLI;SIVIGIQCLIH; IVIGIQCLIHV; VIGIQCLIHVQ; IGIQCLIHVQS; GIQCLIHVQSL;IQCLIHVQSLQ; QCLIHVQSLQF; CLIHVQSLQFL; LIHVQSLQFLN; IHVQSLQFLNP;HVQSLQFLNPL; VQSLQFLNPLL; QSLQFLNPLLL; YQEYISPCIYY; QEYISPCIYYI;EYISPCIYYIS; YISPCIYYISS; ISPCIYYISSL; SPCIYYISSLK; PCIYYISSLKK;CIYYISSLKKY; IYYISSLKKYT; YYISSLKKYTY; YISSLKKYTYL; ISSLKKYTYLS;SSLKKYTYLSQ; SLKKYTYLSQN; LKKYTYLSQNP; KKYTYLSQNPA; KYTYLSQNPAF;YTYLSQNPAFP; TYLSQNPAFPS; YLSQNPAFPSI; LSQNPAFPSIQ; SQNPAFPSIQQ;QNPAFPSIQQF; IVYQLQNQLQA; TKLAVATRSFH; KLAVATRSFHF; LAVATRSFHFV;AVATRSFHFVK; VATRSFHFVKF; ATRSFHFVKFF; TRSFHFVKFFF; RSFHFVKFFFQ;SFHFVKFFFQV; FHFVKFFFQVR; HFVKFFFQVRT; FVKFFFQVRTL; VKFFFQVRTLS;KFFFQVRTLSF; FFFQVRTLSFV; FFQVRTLSFVR; FQVRTLSFVRI; QVRTLSFVRIF;VRTLSFVRIFL; RTLSFVRIFLN; TLSFVRIFLNI; LSFVRIFLNIF; SFVRIFLNIFW;FVRIFLNIFWA; PSLVEIFGFFC; SLVEIFGFFCL; LVEIFGFFCLN; VEIFGFFCLNV;EIFGFFCLNVS; IFGFFCLNVSF; FGFFCLNVSFL; GFFCLNVSFLN; FFCLNVSFLNL;FCLNVSFLNLP; HFHLNNLSNCL; FHLNNLSNCLN; HLNNLSNCLNC; LNNLSNCLNCL;NNLSNCLNCLF; NLSNCLNCLFH; LSNCLNCLFHV; SNCLNCLFHVL; NCLNCLFHVLK;CLNCLFHVLKA; LNCLFHVLKAN; NCLFHVLKANP; CLFHVLKANPL; LFHVLKANPLI;FHVLKANPLIQ; HVLKANPLIQL; VLKANPLIQLL; LKANPLIQLLS; KANPLIQLLSL;ANPLIQLLSLL; NPLIQLLSLLH; PLIQLLSLLHL; LIQLLSLLHLQ; IQLLSLLHLQK;QLLSLLHLQKQ; LLSLLHLQKQP; LSLLHLQKQPC; SLLHLQKQPCT; LLHLQKQPCTD;LHLQKQPCTDL; LHLAQRLAFPW; HLAQRLAFPWV; LAQRLAFPWVG; AQRLAFPWVGL;QRLAFPWVGLH; RLAFPWVGLHL; LAFPWVGLHLR; AFPWVGLHLRL; FPWVGLHLRLY;PWVGLHLRLYH; WVGLHLRLYHH; VGLHLRLYHHT; GLHLRLYHHTN; LHLRLYHHTNL;HLRLYHHTNLI; LRLYHHTNLIT; RLYHHTNLITL; LYHHTNLITLQ; YHHTNLITLQL;HHTNLITLQLV; HTNLITLQLVL; TNLITLQLVLF; NLITLQLVLFF; LITLQLVLFFH;ITLQLVLFFHY; TLQLVLFFHYQ; LQLVLFFHYQW; QLVLFFHYQWD; LVLFFHYQWDL;KQYSAKNQILQ; QYSAKNQILQN; YSAKNQILQNP; SAKNQILQNPF; VANSAAKQHLP;ANSAAKQHLPY; NSAAKQHLPYI; SAAKQHLPYIV; AAKQHLPYIVL; AKQHLPYIVLV;KQHLPYIVLVQ; QHLPYIVLVQH; HLPYIVLVQHF; LPYIVLVQHFH; PYIVLVQHFHE;YIVLVQHFHEL; IVLVQHFHELQ; VLVQHFHELQI; LVQHFHELQIL; VQHFHELQILN;QHFHELQILNP; HFHELQILNPF; FHELQILNPFY; HELQILNPFYL; ELQILNPFYLI;LQILNPFYLIY; QILNPFYLIYD; IFLLAFLPWSY; FLLAFLPWSYE; LLAFLPWSYEG;LAFLPWSYEGY; AFLPWSYEGYL; FLPWSYEGYLL; LPWSYEGYLLF; PWSYEGYLLFF;LKLYLLLADKY; KLYLLLADKYF; LYLLLADKYFF; YLLLADKYFFD; LLLADKYFFDF;LLADKYFFDFY; LADKYFFDFYF; ADKYFFDFYFL; DKYFFDFYFLQ; KYFFDFYFLQK;SDKAGLFSDTF; DKAGLFSDTFY; KAGLFSDTFYT; AGLFSDTFYTP; GLFSDTFYTPL;LFSDTFYTPLH; FSDTFYTPLHC; SDTFYTPLHCI; DTFYTPLHCIE; TFYTPLHCIEI;FYTPLHCIEIL; YTPLHCIEILN; TPLHCIEILNT; PLHCIEILNTY; LHCIEILNTYL;HCIEILNTYLI; CIEILNTYLII; IEILNTYLIIK; EILNTYLIIKT; ILNTYLIIKTH;LNTYLIIKTHP; NTYLIIKTHPH; TYLIIKTHPHT; YLIIKTHPHTL; LIIKTHPHTLS;IIKTHPHTLSL; IKTHPHTLSLL; KTHPHTLSLLH; THPHTLSLLHT; HPHTLSLLHTQ;LISKTPALFLQ; ISKTPALFLQA; SKTPALFLQAL; KTPALFLQALL; TPALFLQALLG;NHAPLSPLECF; HAPLSPLECFL; APLSPLECFLL; LQKLYVYVELK; QKLYVYVELKR;KLYVYVELKRI; YTQQSRQGFYY; GLLPFFFFWVV; LLPFFFFWVVL; LPFFFFWVVLS;PFFFFWVVLSV; FFFFWVVLSVE; FFFWVVLSVEN; FFWVVLSVENL; FWVVLSVENLL;WVVLSVENLLL; VVLSVENLLLL; VLSVENLLLLL; LSVENLLLLLH; SVENLLLLLHH;VENLLLLLHHW; ENLLLLLHHWQ; NLLLLLHHWQT; LLLLLHHWQTY; LLLLHHWQTYL;LLLHHWQTYLH; LLHHWQTYLHG; LHHWQTYLHGK; HHWQTYLHGKI; HWQTYLHGKIN;WQTYLHGKINL; QTYLHGKINLH; TYLHGKINLHP; YLHGKINLHPI; LHGKINLHPIF;HGKINLHPIFH; RNSTRTPTLLF; NSTRTPTLLFH; STRTPTLLFHR; TRTPTLLFHRL;RTPTLLFHRLA; TPTLLFHRLAP; PTLLFHRLAPI; TLLFHRLAPIK; LLFHRLAPIKK;LFHRLAPIKKI; FHRLAPIKKII; HRLAPIKKIIT; GLLIFYYLSKY; LLIFYYLSKYK;LIFYYLSKYKL; IFYYLSKYKLV; FYYLSKYKLVT; YYLSKYKLVTL; YLSKYKLVTLK;LSKYKLVTLKL; ISEGSFSNYLD; SEGSFSNYLDP; EGSFSNYLDPP; GSFSNYLDPPL;SFSNYLDPPLQ; FSNYLDPPLQS; SNYLDPPLQSF; NYLDPPLQSFF; YLDPPLQSFFS;AKPLCEAVNAV; KPLCEAVNAVA; PLCEAVNAVAI; LCEAVNAVAIY; CEAVNAVAIYP;EAVNAVAIYPN; AVNAVAIYPNQ; VNAVAIYPNQG; NAVAIYPNQGL; AVAIYPNQGLF;VAIYPNQGLFS; HARAVHRRLFG; ARAVHRRLFGT; RAVHRRLFGTN; AVHRRLFGTNR;VHRRLFGTNRP; HRRLFGTNRPF; RRLFGTNRPFL; RLFGTNRPFLA; LFGTNRPFLAV;FGTNRPFLAVQ; GTNRPFLAVQG; TNRPFLAVQGI; NRPFLAVQGIW; RPFLAVQGIWA;PFLAVQGIWAK; FLAVQGIWAKR; LAVQGIWAKRK; AVQGIWAKRKI; VQGIWAKRKIS;QGIWAKRKIST; GIWAKRKISTN; IWAKRKISTNL; ATPGSKIRLMS; TPGSKIRLMSY;PGSKIRLMSYL; GSKIRLMSYLY; SKIRLMSYLYI; KIRLMSYLYIL; IRLMSYLYILL;RLMSYLYILLH; LMSYLYILLHF; MSYLYILLHFF; SYLYILLHFFI; YLYILLHFFIQ;LYILLHFFIQS; YILLHFFIQSI; ILLHFFIQSIH; LLHFFIQSIHS; LHFFIQSIHSL;HFFIQSIHSLH; FFIQSIHSLHF; FIQSIHSLHFI; IQSIHSLHFIL; QSIHSLHFILV;SIHSLHFILVA; IHSLHFILVAP; HSLHFILVAPF; SLHFILVAPFV; LHFILVAPFVR;HFILVAPFVRV; FILVAPFVRVK; ILVAPFVRVKF; LVAPFVRVKFL; VAPFVRVKFLT;APFVRVKFLTL; PFVRVKFLTLP; GKISPGSSFKA; KVHELHGFFPV; VHELHGFFPVK;HELHGFFPVKN; ELHGFFPVKNF; LHGFFPVKNFI; HGFFPVKNFIHBK virus complementary reading frame 1 8 mers:MDKVLNRE; DKVLNREE; KVLNREES; VLNREESM; LNREESME; NREESMEL; REESMELM;EESMELMD; ESMELMDL; SMELMDLL; MELMDLLG; ELMDLLGL; LMDLLGLE; MDLLGLER;DLLGLERA; LLGLERAA; LGLERAAW; GLERAAWG; LERAAWGN; ERAAWGNL; RAAWGNLP;AAWGNLPL; AWGNLPLM; WGNLPLMR; GNLPLMRK; NLPLMRKA; LPLMRKAY; PLMRKAYL;LMRKAYLR; MRKAYLRK; RKAYLRKC; KAYLRKCK; AYLRKCKE; YLRKCKEF; LRKCKEFH;RKCKEFHP; KCKEFHPD; CKEFHPDK; KEFHPDKG; EFHPDKGG; FHPDKGGD; HPDKGGDE;PDKGGDED; DKGGDEDK; KGGDEDKM; GGDEDKMK; GDEDKMKR; DEDKMKRM; EDKMKRMN;DKMKRMNT; KMKRMNTL; MKRMNTLY; KRMNTLYK; RMNTLYKK; MNTLYKKM; NTLYKKME;TLYKKMEQ; LYKKMEQD; YKKMEQDV; KKMEQDVK; KMEQDVKV; MEQDVKVA; EQDVKVAH;QDVKVAHQ; DVKVAHQP; VKVAHQPD; KVAHQPDF; VAHQPDFG; AHQPDFGT; HQPDFGTW;QPDFGTWS; PDFGTWSS; DFGTWSSS; FGTWSSSE; GTWSSSEV; TWSSSEVC; WSSSEVCA;SSSEVCAD; SSEVCADF; SEVCADFP; EVCADFPL; VCADFPLC; CADFPLCP; ADFPLCPD;DFPLCPDT; FPLCPDTL; PLCPDTLY; LCPDTLYC; CPDTLYCK; PDTLYCKE; DTLYCKEW;TLYCKEWP; LYCKEWPI; YCKEWPIC; CKEWPICS; KEWPICSK; EWPICSKK; WPICSKKP;PICSKKPS; ICSKKPSV; CSKKPSVH; SKKPSVHC; KKPSVHCP; KPSVHCPC; PSVHCPCM;SVHCPCML; VHCPCMLC; HCPCMLCQ; CPCMLCQL; PCMLCQLR; CMLCQLRL; MLCQLRLR;LCQLRLRH; CQLRLRHL; QLRLRHLN; LRLRHLNR; RLRHLNRK; LRHLNRKF; RHLNRKFL;HLNRKFLR; LNRKFLRK; NRKFLRKE; RKFLRKEP; KFLRKEPL; FLRKEPLV; LRKEPLVW;RKEPLVWI; KEPLVWID; EPLVWIDC; PLVWIDCY; LVWIDCYC; VWIDCYCI; WIDCYCID;IDCYCIDC; DCYCIDCF; CYCIDCFT; YCIDCFTQ; CIDCFTQW; IDCFTQWF; DCFTQWFG;CFTQWFGL; FTQWFGLD; TQWFGLDL; QWFGLDLT; WFGLDLTE; FGLDLTEE; GLDLTEET;LDLTEETL; DLTEETLQ; LTEETLQW; TEETLQWW; EETLQWWV; ETLQWWVQ; TLQWWVQI;LQWWVQII; QWWVQIIG; WWVQIIGE; WVQIIGET; VQIIGETP; QIIGETPF; IIGETPFR;IGETPFRD; GETPFRDL; ETPFRDLK; TPFRDLKL; KALSNYFF; ALSNYFFY; LSNYFFYR;SNYFFYRC; NYFFYRCQ; YFFYRCQP; FFYRCQPM; FYRCQPME; YRCQPMEQ; RCQPMEQK;CQPMEQKS; QPMEQKSG; PMEQKSGS; MEQKSGSP; EQKSGSPG; QKSGSPGG; KSGSPGGV;SGSPGGVP; GSPGGVPL; SPGGVPLM; PGGVPLMK; GGVPLMKN; GVPLMKNG; VPLMKNGM;PLMKNGMK; LMKNGMKI; MKNGMKIY; KNGMKIYF; NGMKIYFA; GMKIYFAM; MKIYFAMK;KIYFAMKI; IYFAMKIC; YFAMKICL; FAMKICLP; AMKICLPV; MKICLPVM; KICLPVMK;ICLPVMKK; CLPVMKKQ; LPVMKKQQ; PVMKKQQQ; VMKKQQQI; MKKQQQIL; KKQQQILN;KQQQILNT; QQQILNTQ; QQILNTQH; QILNTQHH; ILNTQHHP; LNTQHHPK; NTQHHPKK;TQHHPKKK; QHHPKKKE; HHPKKKER; KTLKTFPL; TLKTFPLI; LKTFPLIY; KTFPLIYT;TFPLIYTS; FPLIYTSF; PLIYTSFL; LIYTSFLV; IYTSFLVK; YTSFLVKL; TSFLVKLY;SFLVKLYL; FLVKLYLV; LVKLYLVI; VKLYLVIE; KLYLVIEP; LYLVIEPL; YLVIEPLP;LVIEPLPA; VIEPLPAL; IEPLPALL; EPLPALLC; PLPALLCI; LPALLCIL; PALLCILL;ALLCILLK; LLCILLKK; LCILLKKK; CILLKKKL; ILLKKKLK; LLKKKLKF; LKKKLKFC;KKKLKFCI; KKLKFCIK; KLKFCIKN; LKFCIKNL; KFCIKNLW; FCIKNLWK; CIKNLWKN;IKNLWKNI; KNLWKNIL; LLLVDTCV; LLVDTCVL; LVDTCVLG; VDTCVLGI; DTCVLGII;TCVLGIIL; CVLGIILY; VLGIILYS; LGIILYSF; LHIDIEFL; HIDIEFLQ; IDIEFLQL;DIEFLQLI; IEFLQLII; EFLQLIIS; FLQLIISV; LQLIISVK; QLIISVKS; LIISVKSC;IISVKSCV; ISVKSCVP; SVKSCVPL; VKSCVPLV; KSCVPLVF; FVRVLIRN; VRVLIRNT;RVLIRNTY; VLIRNTYY; LIRNTYYI; IRNTYYIV; RNTYYIVP; RSMILAQK; SMILAQKS;MILAQKSL; ILAQKSLK; LAQKSLKK; AQKSLKKQ; QKSLKKQS; KSLKKQSR; SLKKQSRC;LKKQSRCL; KKQSRCLG; KQSRCLGN; RQSVRMCF; QSVRMCFY; SVRMCFYY; RSVKSVRK;SVKSVRKK; VKSVRKKT; KSVRKKTS; SVRKKTSL; VRKKTSLI; RKKTSLIT; KKTSLITL;KTSLITLS; TSLITLSI; SLITLSIM; LITLSIMK; ITLSIMKS; TLSIMKST; LSIMKSTL;SIMKSTLQ; IMKSTLQM; MKSTLQML; KSTLQMLL; STLQMLLF; TLQMLLFL; LQMLLFLQ;QMLLFLQK; MLLFLQKV; LLFLQKVK; LFLQKVKI; FLQKVKIK; LQKVKIKK; QKVKIKKV;KVKIKKVF; VKIKKVFV; KIKKVFVS; IKKVFVSK; KKVFVSKQ; YLELMEML; LELMEMLY;NNIWQVLL; NIWQVLLG; IWQVLLGC; WQVLLGCT; QVLLGCTV; VLLGCTVC; LLGCTVCY;LGCTVCYL; GCTVCYLK; CTVCYLKW; TVCYLKWI; VCYLKWIL; YLIFCTVL; LIFCTVLF;IFCTVLFS; FCTVLFSM; CTVLFSMY; TVLFSMYL; VLFSMYLK; LFSMYLKE; FSMYLKED;SMYLKEDT; MYLKEDTG; YLKEDTGY; LKEDTGYL; KEDTGYLK; EDTGYLKV; DTGYLKVP;TGYLKVPL; GYLKVPLI; YLKVPLIV; LKVPLIVE; KVPLIVEK; VPLIVEKQ; PLIVEKQH;ISTWLFLK; STWLFLKM; KGQELNQR; GQELNQRI; QELNQRIC; ELNQRICL; LNQRICLQ;NQRICLQD; QRICLQDM; RICLQDME; TKEPKYFH; KEPKYFHQ; EPKYFHQA; PKYFHQAW;KYFHQAWL; YFHQAWLQ; MSILSLKP; SILSLKPC; ILSLKPCK; LSLKPCKL; SLKPCKLD;LKPCKLDL; ENPYKTQS; NPYKTQSS; PYKTQSSY; YKTQSSYL; KTQSSYLK; TQSSYLKK;QSSYLKKE; SSYLKKEF; SYLKKEFY; YLKKEFYK; LKKEFYKV; KKEFYKVE; LILQLIYN;ILQLIYNL; LQLIYNLE; QLIYNLEL; LIYNLELL; IYNLELLN; YNLELLNG; NLELLNGR;LELLNGRK; ELLNGRKG; LLNGRKGW; LNGRKGWI; NGRKGWIL; GRKGWILR; NIIYAWGN;IIYAWGNV; IYAWGNVF; YAWGNVFL; AWGNVFLI; WGNVFLIL; GNVFLILQ; NVFLILQE;VFLILQEK; FLILQEKR; LILQEKRI; ILQEKRIQ; LQEKRIQK; QEKRIQKL; EKRIQKLK;KRIQKLKT; RIQKLKTL; IQKLKTLD; QKLKTLDM; KLKTLDMD; LKTLDMDQ; KTLDMDQA;TLDMDQAL; LDMDQALN; DMDQALNP; MDQALNPN; DQALNPNH; QALNPNHN; ALNPNHNA;LNPNHNAL; NPNHNALP; PNHNALPK; NHNALPKS; HNALPKSQ; NALPKSQI; ALPKSQIL;LPKSQILQ; PKSQILQP; KSQILQPL; SQILQPLL; QILQPLLK; ILQPLLKI; LQPLLKIP;QPLLKIPK; PLLKIPKG; LLKIPKGQ; LKIPKGQT; KIPKGQTP; IPKGQTPI; PKGQTPIV;KGQTPIVK; GQTPIVKS; QTPIVKSC; TPIVKSCI; PIVKSCIC; IVKSCICV; VKSCICVK;KSCICVKA; SCICVKAF; CICVKAFS; ICVKAFSV; CVKAFSVL; VKAFSVLK; KAFSVLKG;AFSVLKGL; FSVLKGLK; SVLKGLKH; VLKGLKHH; LKGLKHHP; KGLKHHPQ; GLKHHPQN;LKHHPQNN; KHHPQNNT; HHPQNNTS; HPQNNTSL; PQNNTSLK; QNNTSLKV; NNTSLKVA;NTSLKVAY; TSLKVAYT; SLKVAYTK; LKVAYTKA; KVAYTKAA; VAYTKAAF; AYTKAAFI;YTKAAFIK; TKAAFIKC; KAAFIKCI; AAFIKCIC; AFIKCICT; FIKCICTI; IKCICTIK;KCICTIKA; CICTIKAP; ICTIKAPV; SILVCNCP; ILVCNCPC; LVCNCPCL; VCNCPCLS;CNCPCLSI; NCPCLSIY; CPCLSIYL; PCLSIYLI; CLSIYLII; LSIYLIIS; SIYLIISG;IYLIISGS; YLIISGSP; LIISGSPG; IISGSPGS; ISGSPGSL; SGSPGSLS; GSPGSLSV;SPGSLSVP; PGSLSVPS; GSLSVPSN; SLSVPSNT; LSVPSNTL; SVPSNTLT; VPSNTLTS;PSNTLTSS; SNTLTSST; NTLTSSTW; TLTSSTWD; LTSSTWDS; TSSTWDSI; SSTWDSIP;STWDSIPY; TWDSIPYI; WDSIPYIG; DSIPYIGC; SIPYIGCP; IPYIGCPS; PYIGCPST;YIGCPSTL; IGCPSTLW; GCPSTLWV; CPSTLWVL; PSTLWVLL; STLWVLLF; TLWVLLFI;LWVLLFIR; WVLLFIRS; VLLFIRSL; LLFIRSLS; LFIRSLSK; FIRSLSKK; IRSLSKKE;RSLSKKEI; SLSKKEIG; GFFTDLFL; FFTDLFLR; FTDLFLRR; TDLFLRRI; DLFLRRIL;LFLRRILK; FLRRILKY; LRRILKYL; RRILKYLA; RILKYLAR; ILKYLARP; LKYLARPL;KYLARPLH; YLARPLHC; LARPLHCC; ARPLHCCV; RPLHCCVP; PLHCCVPE; LHCCVPEL;HCCVPELL; CCVPELLV; CVPELLVN; VPELLVNR; PELLVNRP; ELLVNRPQ; LLVNRPQI;LVNRPQIS; VNRPQISA; NRPQISAA; RPQISAAE; PQISAAET; QISAAETY; ISAAETYR;SAAETYRL; AAETYRLS; AETYRLSA; ETYRLSAL; TYRLSALQ; YRLSALQR; RLSALQRG;LSALQRGP; SALQRGPT; ALQRGPTP; LQRGPTPC; QRGPTPCS; RGPTPCSS; GPTPCSSS;PTPCSSSN; TPCSSSNT; PCSSSNTV; CSSSNTVV; SSSNTVVA; SSNTVVAV; SNTVVAVL;NTVVAVLV; TVVAVLVT; STGGTFSP; TGGTFSPP; GGTFSPPV; GTFSPPVK; TFSPPVKV;FSPPVKVP; SPPVKVPK; PPVKVPKY; PVKVPKYL; VKVPKYLA; KVPKYLAF; VPKYLAFS;PKYLAFSF; KYLAFSFL; YLAFSFLL; LAFSFLLG; AFSFLLGS; FSFLLGSG; SFLLGSGT;FLLGSGTQ; LLGSGTQH; LGSGTQHS; GSGTQHST; SGTQHSTG; ALWSVFIT; LWSVFITW;WSVFITWD; SVFITWDW; VFITWDWA; FITWDWAV; ITWDWAVG; TWDWAVGF; WDWAVGFL;DWAVGFLG; WAVGFLGV; AVGFLGVI; VGFLGVIV; GFLGVIVP; FLGVIVPS; LGVIVPSG;GVIVPSGY; VIVPSGYF; IVPSGYFD; VPSGYFDL; FISTPCIS; ISTPCISK; STPCISKG;TPCISKGS; PCISKGSP; CISKGSPP; ISKGSPPT; SKGSPPTA; KGSPPTAK; GSPPTAKK;SPPTAKKW; PPTAKKWK; PTAKKWKL; TAKKWKLL; AKKWKLLP; IGFPPPCS; GFPPPCSC;FPPPCSCT; PPPCSCTF; PPCSCTFC; PCSCTFCD; CSCTFCDP; SCTFCDPA; RLSMLVIP;LSMLVIPI; SMLVIPIT; MLVIPITS; LVIPITSV; VIPITSVC; IPITSVCT; PITSVCTV;ITSVCTVT; TSVCTVTA; SVCTVTAS; VCTVTASH; CTVTASHI; TVTASHIS; VTASHISR;TASHISRF; ASHISRFP; SHISRFPQ; HISRFPQV; ISRFPQVR; SRFPQVRS; RFPQVRSS;FPQVRSSF; PQVRSSFK; QVRSSFKL; VRSSFKLG; RSSFKLGR; SSFKLGRG; SFKLGRGI;FKLGRGIL; KLGRGILA; LGRGILAV; GRGILAVL; QGSIFLSG; GSIFLSGL; SIFLSGLS;IFLSGLSL; FLSGLSLL; LSGLSLLK; SGLSLLKS; GLSLLKSF; LSLLKSFS; SLLKSFSA;LLKSFSAL; LKSFSALS; KSFSALSF; SFSALSFR; FSALSFRL; SALSFRLK; ALSFRLKP;LSFRLKPL; SFRLKPLR; FRLKPLRF; RLKPLRFS; LKPLRFSS; KPLRFSSG; PLRFSSGS;LRFSSGSP; RFSSGSPI; FSSGSPIS; SSGSPISG; SGSPISGF; GSPISGFR; SPISGFRK;PISGFRKH; ISGFRKHS; SGFRKHST; GFRKHSTS; FRKHSTSV; RKHSTSVI; KHSTSVIA;HSTSVIAS; STSVIAST; TSVIASTP; SVIASTPV; VIASTPVL; IASTPVLT; ASTPVLTS;STPVLTSR; TPVLTSRT; PVLTSRTS; VLTSRTST; LTSRTSTP; TSRTSTPP; SRTSTPPF;RTSTPPFI; TSTPPFIS; STPPFISS; TPPFISSF; PPFISSFG; PFISSFGT; FISSFGTC;ISSFGTCT; SSFGTCTG; SFGTCTGS; FGTCTGSF; GTCTGSFG; TCTGSFGF; CTGSFGFL;TGSFGFLG; GSFGFLGA; SFGFLGAA; FGFLGAAP; GFLGAAPG; FLGAAPGH; LGAAPGHS;GAAPGHSP; AAPGHSPF; APGHSPFL; PGHSPFLL; GHSPFLLV; HSPFLLVG; SPFLLVGA;PFLLVGAI; FLLVGAIF; LLVGAIFI; LVGAIFIC; VGAIFICF; GAIFICFK; AIFICFKS;IFICFKSR; FICFKSRC; ICFKSRCY; CFKSRCYS; FKSRCYSP; KSRCYSPV; SRCYSPVQ;RCYSPVQA; RQHPLRSS; QHPLRSSS; HPLRSSSL; PLRSSSLI; LRSSSLIS; RSSSLIST;SSSLISTS; SSLISTSW; SLISTSWG; LISTSWGN; ISTSWGNS; STSWGNSF; TSWGNSFF;SWGNSFFY; WGNSFFYK; GNSFFYKL; NSFFYKLS; VHSLCNFF; HSLCNFFY; SLCNFFYT;LCNFFYTV; CNFFYTVS; NFFYTVSI; FFYTVSII; FYTVSIIY; YTVSIIYT; TVSIIYTI;VSIIYTIS; SIIYTISM; IIYTISMA; IYTISMAK; YTISMAKM; TISMAKMY; ISMAKMYT;SMAKMYTG; MAKMYTGT; AKMYTGTF; KMYTGTFP; MYTGTFPF; YTGTFPFS; TGTFPFSY;GTFPFSYL; TFPFSYLS; FPFSYLSN; PFSYLSNH; GPNRGKIR; PNRGKIRI; NRGKIRII;RGKIRIIL; GKIRIILL; KIRIILLN; IRIILLNI; RIILLNII; IILLNIII; ILLNIIIK;LLNIIIKV; LNIIIKVY; NIIIKVYR; IIIKVYRG; IIKVYRGI; IKVYRGIY; KVYRGIYN;VYRGIYNC; YRGIYNCP; RGIYNCPG; GIYNCPGS; IYNCPGSF; YNCPGSFL; NCPGSFLQ;CPGSFLQK; PGSFLQKS; GSFLQKSS; SFLQKSSQ; FLQKSSQG; LQKSSQGV; QKSSQGVS;KSSQGVSK; SSQGVSKK; SQGVSKKS; QGVSKKSF; GVSKKSFC; VSKKSFCS; SKKSFCSS;KKSFCSSL; KSFCSSLQ; SFCSSLQF; FCSSLQFL; GYRRYIIP; YRRYIIPN; RRYIIPNN;RYIIPNNM; YIIPNNMP; IIPNNMPQ; IPNNMPQS; PNNMPQSL; NNMPQSLG; NMPQSLGN;MPQSLGNS; PQSLGNSS; QSLGNSSK; SLGNSSKQ; LGNSSKQR; GNSSKQRR; NSSKQRRT;SSKQRRTP; SKQRRTPM; KQRRTPMP; QRRTPMPR; RRTPMPRI; RTPMPRIK; TPMPRIKV;PMPRIKVL; MPRIKVLN; PRIKVLNI; RIKVLNII; IKVLNIIN; KVLNIINK; VLNIINKS;LNIINKSI; NIINKSIY; IINKSIYT; INKSIYTR; NKSIYTRK; KSIYTRKQ; SIYTRKQN;IYTRKQNI; YTRKQNII; TRKQNIIV; RKQNIIVL; KQNIIVLI; QNIIVLIW; NIIVLIWV;IIVLIWVK; IVLIWVKQ; VLIWVKQF; LIWVKQFQ; IWVKQFQS; WVKQFQSH; VKQFQSHA;LLIEAYSG; LIEAYSGN; IEAYSGNF; EAYSGNFV; AYSGNFVI; YSGNFVIP; SGNFVIPI;GNFVIPII; NFVIPIIK; FVIPIIKE; VIPIIKEL; IPIIKELI; PIIKELIP; IIKELIPY;IKELIPYL; KELIPYLS; GTNTTNSL; TNTTNSLN; SSKPSNSP; SKPSNSPR; KPSNSPRS;PSNSPRST; SNSPRSTS; NSPRSTSN; SPRSTSNY; PRSTSNYS; RSTSNYSI; STSNYSIC;TSNYSICL; SNYSICLR; NYSICLRS; GTCYALYS; TCYALYSS; CYALYSSK; YALYSSKG;ALYSSKGC; LYSSKGCN; YSSKGCNL; SSKGCNLN; SKGCNLNF; KGCNLNFY; GCNLNFYS;CNLNFYSS; NLNFYSSS; LNFYSSSS; NFYSSSSL; FYSSSSLP; YSSSSLPS; SSSSLPSS;SSSLPSSN; SSLPSSNF; SLPSSNFS; LPSSNFSH; KSCGSSSL; SCGSSSLR; CGSSSLRY;GSSSLRYT; SSSLRYTG; SSLRYTGN; SSTHEPGN; STHEPGNT; THEPGNTK; HEPGNTKK;EPGNTKKK; PGNTKKKG; GNTKKKGL; NTKKKGLL; TKKKGLLT; ESFTESFT; SFTESFTA;FTESFTAG; TESFTAGK; ESFTAGKA; SFTAGKAV; FTAGKAVV; TAGKAVVL; AGKAVVLL;GKAVVLLF; KAVVLLFF; AVVLLFFP; VVLLFFPS; VLLFFPST; LLFFPSTL; LFFPSTLS;FFPSTLSS; FPSTLSSP; PSTLSSPL; STLSSPLQ; TLSSPLQN; LSSPLQNS; SSPLQNSS;SPLQNSSK; PLQNSSKS; LQNSSKSS; QNSSKSSK; NSSKSSKI; SSKSSKIK; SKSSKIKI;KSSKIKIK; SSKIKIKI; SKIKIKIL; ALFFVPVQ; LFFVPVQV; FFVPVQVL; FVPVQVLP;VPVQVLPT; PVQVLPTF; VQVLPTFT; QVLPTFTE; VLPTFTEA; LPTFTEAC; PTFTEACR;TFTEACRD; FTEACRDS; TEACRDSW; EACRDSWR; ACRDSWRR; CRDSWRRT; RDSWRRTM;DSWRRTMA; SWRRTMAF; WRRTMAFV; RRTMAFVQ; RTMAFVQF; TMAFVQFN; MAFVQFNW;AFVQFNWG; FVQFNWGQ; VQFNWGQG; QFNWGQGQ; FNWGQGQD; NWGQGQDS; ARKTCLSC;RKTCLSCT; KTCLSCTF; TCLSCTFL; CLSCTFLP; LSCTFLPE; SCTFLPEV; CTFLPEVM;TFLPEVMV; FLPEVMVW; LPEVMVWL; PEVMVWLH; EVMVWLHS; VMVWLHSM; MVWLHSMG;VWLHSMGK; WLHSMGKQ; LHSMGKQL; HSMGKQLL; SMGKQLLP; MGKQLLPV; GKQLLPVS;KQLLPVSH; QLLPVSHA; LLPVSHAL; LPVSHALS; PVSHALSF; VSHALSFL; SHALSFLR;HALSFLRS; ALSFLRSW; LSFLRSWF; SFLRSWFG; FLRSWFGC; LRSWFGCI; RSWFGCIP;SWFGCIPL; GHGLAAFH; HGLAAFHG; AAPPCGLF; APPCGLFF; PPCGLFFY; PCGLFFYN;CGLFFYNI; EAEAASAS; AEAASAST; EAASASTL; AASASTLS; ASASTLSL; SASTLSLK;GLAKLFGE; LAKLFGEI; AKLFGEIP; KLFGEIPI; LFGEIPIL; FGEIPILL; GEIPILLQ;EIPILLQF; IPILLQFL; PILLQFLQ 9 mers:MDKVLNREE; DKVLNREES; KVLNREESM; VLNREESME; LNREESMEL; NREESMELM;REESMELMD; EESMELMDL; ESMELMDLL; SMELMDLLG; MELMDLLGL; ELMDLLGLE;LMDLLGLER; MDLLGLERA; DLLGLERAA; LLGLERAAW; LGLERAAWG; GLERAAWGN;LERAAWGNL; ERAAWGNLP; RAAWGNLPL; AAWGNLPLM; AWGNLPLMR; WGNLPLMRK;GNLPLMRKA; NLPLMRKAY; LPLMRKAYL; PLMRKAYLR; LMRKAYLRK; MRKAYLRKC;RKAYLRKCK; KAYLRKCKE; AYLRKCKEF; YLRKCKEFH; LRKCKEFHP; RKCKEFHPD;KCKEFHPDK; CKEFHPDKG; KEFHPDKGG; EFHPDKGGD; FHPDKGGDE; HPDKGGDED;PDKGGDEDK; DKGGDEDKM; KGGDEDKMK; GGDEDKMKR; GDEDKMKRM; DEDKMKRMN;EDKMKRMNT; DKMKRMNTL; KMKRMNTLY; MKRMNTLYK; KRMNTLYKK; RMNTLYKKM;MNTLYKKME; NTLYKKMEQ; TLYKKMEQD; LYKKMEQDV; YKKMEQDVK; KKMEQDVKV;KMEQDVKVA; MEQDVKVAH; EQDVKVAHQ; QDVKVAHQP; DVKVAHQPD; VKVAHQPDF;KVAHQPDFG; VAHQPDFGT; AHQPDFGTW; HQPDFGTWS; QPDFGTWSS; PDFGTWSSS;DFGTWSSSE; FGTWSSSEV; GTWSSSEVC; TWSSSEVCA; WSSSEVCAD; SSSEVCADF;SSEVCADFP; SEVCADFPL; EVCADFPLC; VCADFPLCP; CADFPLCPD; ADFPLCPDT;DFPLCPDTL; FPLCPDTLY; PLCPDTLYC; LCPDTLYCK; CPDTLYCKE; PDTLYCKEW;DTLYCKEWP; TLYCKEWPI; LYCKEWPIC; YCKEWPICS; CKEWPICSK; KEWPICSKK;EWPICSKKP; WPICSKKPS; PICSKKPSV; ICSKKPSVH; CSKKPSVHC; SKKPSVHCP;KKPSVHCPC; KPSVHCPCM; PSVHCPCML; SVHCPCMLC; VHCPCMLCQ; HCPCMLCQL;CPCMLCQLR; PCMLCQLRL; CMLCQLRLR; MLCQLRLRH; LCQLRLRHL; CQLRLRHLN;QLRLRHLNR; LRLRHLNRK; RLRHLNRKF; LRHLNRKFL; RHLNRKFLR; HLNRKFLRK;LNRKFLRKE; NRKFLRKEP; RKFLRKEPL; KFLRKEPLV; FLRKEPLVW; LRKEPLVWI;RKEPLVWID; KEPLVWIDC; EPLVWIDCY; PLVWIDCYC; LVWIDCYCI; VWIDCYCID;WIDCYCIDC; IDCYCIDCF; DCYCIDCFT; CYCIDCFTQ; YCIDCFTQW; CIDCFTQWF;IDCFTQWFG; DCFTQWFGL; CFTQWFGLD; FTQWFGLDL; TQWFGLDLT; QWFGLDLTE;WFGLDLTEE; FGLDLTEET; GLDLTEETL; LDLTEETLQ; DLTEETLQW; LTEETLQWW;TEETLQWWV; EETLQWWVQ; ETLQWWVQI; TLQWWVQII; LQWWVQIIG; QWWVQIIGE;WWVQIIGET; WVQIIGETP; VQIIGETPF; QIIGETPFR; IIGETPFRD; IGETPFRDL;GETPFRDLK; ETPFRDLKL; KALSNYFFY; ALSNYFFYR; LSNYFFYRC; SNYFFYRCQ;NYFFYRCQP; YFFYRCQPM; FFYRCQPME; FYRCQPMEQ; YRCQPMEQK; RCQPMEQKS;CQPMEQKSG; QPMEQKSGS; PMEQKSGSP; MEQKSGSPG; EQKSGSPGG; QKSGSPGGV;KSGSPGGVP; SGSPGGVPL; GSPGGVPLM; SPGGVPLMK; PGGVPLMKN; GGVPLMKNG;GVPLMKNGM; VPLMKNGMK; PLMKNGMKI; LMKNGMKIY; MKNGMKIYF; KNGMKIYFA;NGMKIYFAM; GMKIYFAMK; MKIYFAMKI; KIYFAMKIC; IYFAMKICL; YFAMKICLP;FAMKICLPV; AMKICLPVM; MKICLPVMK; KICLPVMKK; ICLPVMKKQ; CLPVMKKQQ;LPVMKKQQQ; PVMKKQQQI; VMKKQQQIL; MKKQQQILN; KKQQQILNT; KQQQILNTQ;QQQILNTQH; QQILNTQHH; QILNTQHHP; ILNTQHHPK; LNTQHHPKK; NTQHHPKKK;TQHHPKKKE; QHHPKKKER; KTLKTFPLI; TLKTFPLIY; LKTFPLIYT; KTFPLIYTS;TFPLIYTSF; FPLIYTSFL; PLIYTSFLV; LIYTSFLVK; IYTSFLVKL; YTSFLVKLY;TSFLVKLYL; SFLVKLYLV; FLVKLYLVI; LVKLYLVIE; VKLYLVIEP; KLYLVIEPL;LYLVIEPLP; YLVIEPLPA; LVIEPLPAL; VIEPLPALL; IEPLPALLC; EPLPALLCI;PLPALLCIL; LPALLCILL; PALLCILLK; ALLCILLKK; LLCILLKKK; LCILLKKKL;CILLKKKLK; ILLKKKLKF; LLKKKLKFC; LKKKLKFCI; KKKLKFCIK; KKLKFCIKN;KLKFCIKNL; LKFCIKNLW; KFCIKNLWK; FCIKNLWKN; CIKNLWKNI; IKNLWKNIL;LLLVDTCVL; LLVDTCVLG; LVDTCVLGI; VDTCVLGII; DTCVLGIIL; TCVLGIILY;CVLGIILYS; VLGIILYSF; LHIDIEFLQ; HIDIEFLQL; IDIEFLQLI; DIEFLQLII;IEFLQLIIS; EFLQLIISV; FLQLIISVK; LQLIISVKS; QLIISVKSC; LIISVKSCV;IISVKSCVP; ISVKSCVPL; SVKSCVPLV; VKSCVPLVF; FVRVLIRNT; VRVLIRNTY;RVLIRNTYY; VLIRNTYYI; LIRNTYYIV; IRNTYYIVP; RSMILAQKS; SMILAQKSL;MILAQKSLK; ILAQKSLKK; LAQKSLKKQ; AQKSLKKQS; QKSLKKQSR; KSLKKQSRC;SLKKQSRCL; LKKQSRCLG; KKQSRCLGN; RQSVRMCFY; QSVRMCFYY; RSVKSVRKK;SVKSVRKKT; VKSVRKKTS; KSVRKKTSL; SVRKKTSLI; VRKKTSLIT; RKKTSLITL;KKTSLITLS; KTSLITLSI; TSLITLSIM; SLITLSIMK; LITLSIMKS; ITLSIMKST;TLSIMKSTL; LSIMKSTLQ; SIMKSTLQM; IMKSTLQML; MKSTLQMLL; KSTLQMLLF;STLQMLLFL; TLQMLLFLQ; LQMLLFLQK; QMLLFLQKV; MLLFLQKVK; LLFLQKVKI;LFLQKVKIK; FLQKVKIKK; LQKVKIKKV; QKVKIKKVF; KVKIKKVFV; VKIKKVFVS;KIKKVFVSK; IKKVFVSKQ; YLELMEMLY; NNIWQVLLG; NIWQVLLGC; IWQVLLGCT;WQVLLGCTV; QVLLGCTVC; VLLGCTVCY; LLGCTVCYL; LGCTVCYLK; GCTVCYLKW;CTVCYLKWI; TVCYLKWIL; YLIFCTVLF; LIFCTVLFS; IFCTVLFSM; FCTVLFSMY;CTVLFSMYL; TVLFSMYLK; VLFSMYLKE; LFSMYLKED; FSMYLKEDT; SMYLKEDTG;MYLKEDTGY; YLKEDTGYL; LKEDTGYLK; KEDTGYLKV; EDTGYLKVP; DTGYLKVPL;TGYLKVPLI; GYLKVPLIV; YLKVPLIVE; LKVPLIVEK; KVPLIVEKQ; VPLIVEKQH;ISTWLFLKM; KGQELNQRI; GQELNQRIC; QELNQRICL; ELNQRICLQ; LNQRICLQD;NQRICLQDM; QRICLQDME; TKEPKYFHQ; KEPKYFHQA; EPKYFHQAW; PKYFHQAWL;KYFHQAWLQ; MSILSLKPC; SILSLKPCK; ILSLKPCKL; LSLKPCKLD; SLKPCKLDL;ENPYKTQSS; NPYKTQSSY; PYKTQSSYL; YKTQSSYLK; KTQSSYLKK; TQSSYLKKE;QSSYLKKEF; SSYLKKEFY; SYLKKEFYK; YLKKEFYKV; LKKEFYKVE; LILQLIYNL;ILQLIYNLE; LQLIYNLEL; QLIYNLELL; LIYNLELLN; IYNLELLNG; YNLELLNGR;NLELLNGRK; LELLNGRKG; ELLNGRKGW; LLNGRKGWI; LNGRKGWIL; NGRKGWILR;NIIYAWGNV; IIYAWGNVF; IYAWGNVFL; YAWGNVFLI; AWGNVFLIL; WGNVFLILQ;GNVFLILQE; NVFLILQEK; VFLILQEKR; FLILQEKRI; LILQEKRIQ; ILQEKRIQK;LQEKRIQKL; QEKRIQKLK; EKRIQKLKT; KRIQKLKTL; RIQKLKTLD; IQKLKTLDM;QKLKTLDMD; KLKTLDMDQ; LKTLDMDQA; KTLDMDQAL; TLDMDQALN; LDMDQALNP;DMDQALNPN; MDQALNPNH; DQALNPNHN; QALNPNHNA; ALNPNHNAL; LNPNHNALP;NPNHNALPK; PNHNALPKS; NHNALPKSQ; HNALPKSQI; NALPKSQIL; ALPKSQILQ;LPKSQILQP; PKSQILQPL; KSQILQPLL; SQILQPLLK; QILQPLLKI; ILQPLLKIP;LQPLLKIPK; QPLLKIPKG; PLLKIPKGQ; LLKIPKGQT; LKIPKGQTP; KIPKGQTPI;IPKGQTPIV; PKGQTPIVK; KGQTPIVKS; GQTPIVKSC; QTPIVKSCI; TPIVKSCIC;PIVKSCICV; IVKSCICVK; VKSCICVKA; KSCICVKAF; SCICVKAFS; CICVKAFSV;ICVKAFSVL; CVKAFSVLK; VKAFSVLKG; KAFSVLKGL; AFSVLKGLK; FSVLKGLKH;SVLKGLKHH; VLKGLKHHP; LKGLKHHPQ; KGLKHHPQN; GLKHHPQNN; LKHHPQNNT;KHHPQNNTS; HHPQNNTSL; HPQNNTSLK; PQNNTSLKV; QNNTSLKVA; NNTSLKVAY;NTSLKVAYT; TSLKVAYTK; SLKVAYTKA; LKVAYTKAA; KVAYTKAAF; VAYTKAAFI;AYTKAAFIK; YTKAAFIKC; TKAAFIKCI; KAAFIKCIC; AAFIKCICT; AFIKCICTI;FIKCICTIK; IKCICTIKA; KCICTIKAP; CICTIKAPV; SILVCNCPC; ILVCNCPCL;LVCNCPCLS; VCNCPCLSI; CNCPCLSIY; NCPCLSIYL; CPCLSIYLI; PCLSIYLII;CLSIYLIIS; LSIYLIISG; SIYLIISGS; IYLIISGSP; YLIISGSPG; LIISGSPGS;IISGSPGSL; ISGSPGSLS; SGSPGSLSV; GSPGSLSVP; SPGSLSVPS; PGSLSVPSN;GSLSVPSNT; SLSVPSNTL; LSVPSNTLT; SVPSNTLTS; VPSNTLTSS; PSNTLTSST;SNTLTSSTW; NTLTSSTWD; TLTSSTWDS; LTSSTWDSI; TSSTWDSIP; SSTWDSIPY;STWDSIPYI; TWDSIPYIG; WDSIPYIGC; DSIPYIGCP; SIPYIGCPS; IPYIGCPST;PYIGCPSTL; YIGCPSTLW; IGCPSTLWV; GCPSTLWVL; CPSTLWVLL; PSTLWVLLF;STLWVLLFI; TLWVLLFIR; LWVLLFIRS; WVLLFIRSL; VLLFIRSLS; LLFIRSLSK;LFIRSLSKK; FIRSLSKKE; IRSLSKKEI; RSLSKKEIG; GFFTDLFLR; FFTDLFLRR;FTDLFLRRI; TDLFLRRIL; DLFLRRILK; LFLRRILKY; FLRRILKYL; LRRILKYLA;RRILKYLAR; RILKYLARP; ILKYLARPL; LKYLARPLH; KYLARPLHC; YLARPLHCC;LARPLHCCV; ARPLHCCVP; RPLHCCVPE; PLHCCVPEL; LHCCVPELL; HCCVPELLV;CCVPELLVN; CVPELLVNR; VPELLVNRP; PELLVNRPQ; ELLVNRPQI; LLVNRPQIS;LVNRPQISA; VNRPQISAA; NRPQISAAE; RPQISAAET; PQISAAETY; QISAAETYR;ISAAETYRL; SAAETYRLS; AAETYRLSA; AETYRLSAL; ETYRLSALQ; TYRLSALQR;YRLSALQRG; RLSALQRGP; LSALQRGPT; SALQRGPTP; ALQRGPTPC; LQRGPTPCS;QRGPTPCSS; RGPTPCSSS; GPTPCSSSN; PTPCSSSNT; TPCSSSNTV; PCSSSNTVV;CSSSNTVVA; SSSNTVVAV; SSNTVVAVL; SNTVVAVLV; NTVVAVLVT; STGGTFSPP;TGGTFSPPV; GGTFSPPVK; GTFSPPVKV; TFSPPVKVP; FSPPVKVPK; SPPVKVPKY;PPVKVPKYL; PVKVPKYLA; VKVPKYLAF; KVPKYLAFS; VPKYLAFSF; PKYLAFSFL;KYLAFSFLL; YLAFSFLLG; LAFSFLLGS; AFSFLLGSG; FSFLLGSGT; SFLLGSGTQ;FLLGSGTQH; LLGSGTQHS; LGSGTQHST; GSGTQHSTG; ALWSVFITW; LWSVFITWD;WSVFITWDW; SVFITWDWA; VFITWDWAV; FITWDWAVG; ITWDWAVGF; TWDWAVGFL;WDWAVGFLG; DWAVGFLGV; WAVGFLGVI; AVGFLGVIV; VGFLGVIVP; GFLGVIVPS;FLGVIVPSG; LGVIVPSGY; GVIVPSGYF; VIVPSGYFD; IVPSGYFDL; FISTPCISK;ISTPCISKG; STPCISKGS; TPCISKGSP; PCISKGSPP; CISKGSPPT; ISKGSPPTA;SKGSPPTAK; KGSPPTAKK; GSPPTAKKW; SPPTAKKWK; PPTAKKWKL; PTAKKWKLL;TAKKWKLLP; IGFPPPCSC; GFPPPCSCT; FPPPCSCTF; PPPCSCTFC; PPCSCTFCD;PCSCTFCDP; CSCTFCDPA; RLSMLVIPI; LSMLVIPIT; SMLVIPITS; MLVIPITSV;LVIPITSVC; VIPITSVCT; IPITSVCTV; PITSVCTVT; ITSVCTVTA; TSVCTVTAS;SVCTVTASH; VCTVTASHI; CTVTASHIS; TVTASHISR; VTASHISRF; TASHISRFP;ASHISRFPQ; SHISRFPQV; HISRFPQVR; ISRFPQVRS; SRFPQVRSS; RFPQVRSSF;FPQVRSSFK; PQVRSSFKL; QVRSSFKLG; VRSSFKLGR; RSSFKLGRG; SSFKLGRGI;SFKLGRGIL; FKLGRGILA; KLGRGILAV; LGRGILAVL; QGSIFLSGL; GSIFLSGLS;SIFLSGLSL; IFLSGLSLL; FLSGLSLLK; LSGLSLLKS; SGLSLLKSF; GLSLLKSFS;LSLLKSFSA; SLLKSFSAL; LLKSFSALS; LKSFSALSF; KSFSALSFR; SFSALSFRL;FSALSFRLK; SALSFRLKP; ALSFRLKPL; LSFRLKPLR; SFRLKPLRF; FRLKPLRFS;RLKPLRFSS; LKPLRFSSG; KPLRFSSGS; PLRFSSGSP; LRFSSGSPI; RFSSGSPIS;FSSGSPISG; SSGSPISGF; SGSPISGFR; GSPISGFRK; SPISGFRKH; PISGFRKHS;ISGFRKHST; SGFRKHSTS; GFRKHSTSV; FRKHSTSVI; RKHSTSVIA; KHSTSVIAS;HSTSVIAST; STSVIASTP; TSVIASTPV; SVIASTPVL; VIASTPVLT; IASTPVLTS;ASTPVLTSR; STPVLTSRT; TPVLTSRTS; PVLTSRTST; VLTSRTSTP; LTSRTSTPP;TSRTSTPPF; SRTSTPPFI; RTSTPPFIS; TSTPPFISS; STPPFISSF; TPPFISSFG;PPFISSFGT; PFISSFGTC; FISSFGTCT; ISSFGTCTG; SSFGTCTGS; SFGTCTGSF;FGTCTGSFG; GTCTGSFGF; TCTGSFGFL; CTGSFGFLG; TGSFGFLGA; GSFGFLGAA;SFGFLGAAP; FGFLGAAPG; GFLGAAPGH; FLGAAPGHS; LGAAPGHSP; GAAPGHSPF;AAPGHSPFL; APGHSPFLL; PGHSPFLLV; GHSPFLLVG; HSPFLLVGA; SPFLLVGAI;PFLLVGAIF; FLLVGAIFI; LLVGAIFIC; LVGAIFICF; VGAIFICFK; GAIFICFKS;AIFICFKSR; IFICFKSRC; FICFKSRCY; ICFKSRCYS; CFKSRCYSP; FKSRCYSPV;KSRCYSPVQ; SRCYSPVQA; RQHPLRSSS; QHPLRSSSL; HPLRSSSLI; PLRSSSLIS;LRSSSLIST; RSSSLISTS; SSSLISTSW; SSLISTSWG; SLISTSWGN; LISTSWGNS;ISTSWGNSF; STSWGNSFF; TSWGNSFFY; SWGNSFFYK; WGNSFFYKL; GNSFFYKLS;VHSLCNFFY; HSLCNFFYT; SLCNFFYTV; LCNFFYTVS; CNFFYTVSI; NFFYTVSII;FFYTVSIIY; FYTVSIIYT; YTVSIIYTI; TVSIIYTIS; VSIIYTISM; SIIYTISMA;IIYTISMAK; IYTISMAKM; YTISMAKMY; TISMAKMYT; ISMAKMYTG; SMAKMYTGT;MAKMYTGTF; AKMYTGTFP; KMYTGTFPF; MYTGTFPFS; YTGTFPFSY; TGTFPFSYL;GTFPFSYLS; TFPFSYLSN; FPFSYLSNH; GPNRGKIRI; PNRGKIRII; NRGKIRIIL;RGKIRIILL; GKIRIILLN; KIRIILLNI; IRIILLNII; RIILLNIII; IILLNIIIK;ILLNIIIKV; LLNIIIKVY; LNIIIKVYR; NIIIKVYRG; IIIKVYRGI; IIKVYRGIY;IKVYRGIYN; KVYRGIYNC; VYRGIYNCP; YRGIYNCPG; RGIYNCPGS; GIYNCPGSF;IYNCPGSFL; YNCPGSFLQ; NCPGSFLQK; CPGSFLQKS; PGSFLQKSS; GSFLQKSSQ;SFLQKSSQG; FLQKSSQGV; LQKSSQGVS; QKSSQGVSK; KSSQGVSKK; SSQGVSKKS;SQGVSKKSF; QGVSKKSFC; GVSKKSFCS; VSKKSFCSS; SKKSFCSSL; KKSFCSSLQ;KSFCSSLQF; SFCSSLQFL; GYRRYIIPN; YRRYIIPNN; RRYIIPNNM; RYIIPNNMP;YIIPNNMPQ; IIPNNMPQS; IPNNMPQSL; PNNMPQSLG; NNMPQSLGN; NMPQSLGNS;MPQSLGNSS; PQSLGNSSK; QSLGNSSKQ; SLGNSSKQR; LGNSSKQRR; GNSSKQRRT;NSSKQRRTP; SSKQRRTPM; SKQRRTPMP; KQRRTPMPR; QRRTPMPRI; RRTPMPRIK;RTPMPRIKV; TPMPRIKVL; PMPRIKVLN; MPRIKVLNI; PRIKVLNII; RIKVLNIIN;IKVLNIINK; KVLNIINKS; VLNIINKSI; LNIINKSIY; NIINKSIYT; IINKSIYTR;INKSIYTRK; NKSIYTRKQ; KSIYTRKQN; SIYTRKQNI; IYTRKQNII; YTRKQNIIV;TRKQNIIVL; RKQNIIVLI; KQNIIVLIW; QNIIVLIWV; NIIVLIWVK; IIVLIWVKQ;IVLIWVKQF; VLIWVKQFQ; LIWVKQFQS; IWVKQFQSH; WVKQFQSHA; LLIEAYSGN;LIEAYSGNF; IEAYSGNFV; EAYSGNFVI; AYSGNFVIP; YSGNFVIPI; SGNFVIPII;GNFVIPIIK; NFVIPIIKE; FVIPIIKEL; VIPIIKELI; IPIIKELIP; PIIKELIPY;IIKELIPYL; IKELIPYLS; GTNTTNSLN; SSKPSNSPR; SKPSNSPRS; KPSNSPRST;PSNSPRSTS; SNSPRSTSN; NSPRSTSNY; SPRSTSNYS; PRSTSNYSI; RSTSNYSIC;STSNYSICL; TSNYSICLR; SNYSICLRS; GTCYALYSS; TCYALYSSK; CYALYSSKG;YALYSSKGC; ALYSSKGCN; LYSSKGCNL; YSSKGCNLN; SSKGCNLNF; SKGCNLNFY;KGCNLNFYS; GCNLNFYSS; CNLNFYSSS; NLNFYSSSS; LNFYSSSSL; NFYSSSSLP;FYSSSSLPS; YSSSSLPSS; SSSSLPSSN; SSSLPSSNF; SSLPSSNFS; SLPSSNFSH;KSCGSSSLR; SCGSSSLRY; CGSSSLRYT; GSSSLRYTG; SSSLRYTGN; SSTHEPGNT;STHEPGNTK; THEPGNTKK; HEPGNTKKK; EPGNTKKKG; PGNTKKKGL; GNTKKKGLL;NTKKKGLLT; ESFTESFTA; SFTESFTAG; FTESFTAGK; TESFTAGKA; ESFTAGKAV;SFTAGKAVV; FTAGKAVVL; TAGKAVVLL; AGKAVVLLF; GKAVVLLFF; KAVVLLFFP;AVVLLFFPS; VVLLFFPST; VLLFFPSTL; LLFFPSTLS; LFFPSTLSS; FFPSTLSSP;FPSTLSSPL; PSTLSSPLQ; STLSSPLQN; TLSSPLQNS; LSSPLQNSS; SSPLQNSSK;SPLQNSSKS; PLQNSSKSS; LQNSSKSSK; QNSSKSSKI; NSSKSSKIK; SSKSSKIKI;SKSSKIKIK; KSSKIKIKI; SSKIKIKIL; ALFFVPVQV; LFFVPVQVL; FFVPVQVLP;FVPVQVLPT; VPVQVLPTF; PVQVLPTFT; VQVLPTFTE; QVLPTFTEA; VLPTFTEAC;LPTFTEACR; PTFTEACRD; TFTEACRDS; FTEACRDSW; TEACRDSWR; EACRDSWRR;ACRDSWRRT; CRDSWRRTM; RDSWRRTMA; DSWRRTMAF; SWRRTMAFV; WRRTMAFVQ;RRTMAFVQF; RTMAFVQFN; TMAFVQFNW; MAFVQFNWG; AFVQFNWGQ; FVQFNWGQG;VQFNWGQGQ; QFNWGQGQD; FNWGQGQDS; ARKTCLSCT; RKTCLSCTF; KTCLSCTFL;TCLSCTFLP; CLSCTFLPE; LSCTFLPEV; SCTFLPEVM; CTFLPEVMV; TFLPEVMVW;FLPEVMVWL; LPEVMVWLH; PEVMVWLHS; EVMVWLHSM; VMVWLHSMG; MVWLHSMGK;VWLHSMGKQ; WLHSMGKQL; LHSMGKQLL; HSMGKQLLP; SMGKQLLPV; MGKQLLPVS;GKQLLPVSH; KQLLPVSHA; QLLPVSHAL; LLPVSHALS; LPVSHALSF; PVSHALSFL;VSHALSFLR; SHALSFLRS; HALSFLRSW; ALSFLRSWF; LSFLRSWFG; SFLRSWFGC;FLRSWFGCI; LRSWFGCIP; RSWFGCIPL; GHGLAAFHG; AAPPCGLFF; APPCGLFFY;PPCGLFFYN; PCGLFFYNI; EAEAASAST; AEAASASTL; EAASASTLS; AASASTLSL;ASASTLSLK; GLAKLFGEI; LAKLFGEIP; AKLFGEIPI; KLFGEIPIL; LFGEIPILL;FGEIPILLQ; GEIPILLQF; EIPILLQFL; IPILLQFLQ 10 mers:MDKVLNREES; DKVLNREESM; KVLNREESME; VLNREESMEL; LNREESMELM;NREESMELMD; REESMELMDL; EESMELMDLL; ESMELMDLLG; SMELMDLLGL;MELMDLLGLE; ELMDLLGLER; LMDLLGLERA; MDLLGLERAA; DLLGLERAAW;LLGLERAAWG; LGLERAAWGN; GLERAAWGNL; LERAAWGNLP; ERAAWGNLPL;RAAWGNLPLM; AAWGNLPLMR; AWGNLPLMRK; WGNLPLMRKA; GNLPLMRKAY;NLPLMRKAYL; LPLMRKAYLR; PLMRKAYLRK; LMRKAYLRKC; MRKAYLRKCK;RKAYLRKCKE; KAYLRKCKEF; AYLRKCKEFH; YLRKCKEFHP; LRKCKEFHPD;RKCKEFHPDK; KCKEFHPDKG; CKEFHPDKGG; KEFHPDKGGD; EFHPDKGGDE;FHPDKGGDED; HPDKGGDEDK; PDKGGDEDKM; DKGGDEDKMK; KGGDEDKMKR;GGDEDKMKRM; GDEDKMKRMN; DEDKMKRMNT; EDKMKRMNTL; DKMKRMNTLY;KMKRMNTLYK; MKRMNTLYKK; KRMNTLYKKM; RMNTLYKKME; MNTLYKKMEQ;NTLYKKMEQD; TLYKKMEQDV; LYKKMEQDVK; YKKMEQDVKV; KKMEQDVKVA;KMEQDVKVAH; MEQDVKVAHQ; EQDVKVAHQP; QDVKVAHQPD; DVKVAHQPDF;VKVAHQPDFG; KVAHQPDFGT; VAHQPDFGTW; AHQPDFGTWS; HQPDFGTWSS;QPDFGTWSSS; PDFGTWSSSE; DFGTWSSSEV; FGTWSSSEVC; GTWSSSEVCA;TWSSSEVCAD; WSSSEVCADF; SSSEVCADFP; SSEVCADFPL; SEVCADFPLC;EVCADFPLCP; VCADFPLCPD; CADFPLCPDT; ADFPLCPDTL; DFPLCPDTLY;FPLCPDTLYC; PLCPDTLYCK; LCPDTLYCKE; CPDTLYCKEW; PDTLYCKEWP;DTLYCKEWPI; TLYCKEWPIC; LYCKEWPICS; YCKEWPICSK; CKEWPICSKK;KEWPICSKKP; EWPICSKKPS; WPICSKKPSV; PICSKKPSVH; ICSKKPSVHC;CSKKPSVHCP; SKKPSVHCPC; KKPSVHCPCM; KPSVHCPCML; PSVHCPCMLC;SVHCPCMLCQ; VHCPCMLCQL; HCPCMLCQLR; CPCMLCQLRL; PCMLCQLRLR;CMLCQLRLRH; MLCQLRLRHL; LCQLRLRHLN; CQLRLRHLNR; QLRLRHLNRK;LRLRHLNRKF; RLRHLNRKFL; LRHLNRKFLR; RHLNRKFLRK; HLNRKFLRKE;LNRKFLRKEP; NRKFLRKEPL; RKFLRKEPLV; KFLRKEPLVW; FLRKEPLVWI;LRKEPLVWID; RKEPLVWIDC; KEPLVWIDCY; EPLVWIDCYC; PLVWIDCYCI;LVWIDCYCID; VWIDCYCIDC; WIDCYCIDCF; IDCYCIDCFT; DCYCIDCFTQ;CYCIDCFTQW; YCIDCFTQWF; CIDCFTQWFG; IDCFTQWFGL; DCFTQWFGLD;CFTQWFGLDL; FTQWFGLDLT; TQWFGLDLTE; QWFGLDLTEE; WFGLDLTEET;FGLDLTEETL; GLDLTEETLQ; LDLTEETLQW; DLTEETLQWW; LTEETLQWWV;TEETLQWWVQ; EETLQWWVQI; ETLQWWVQII; TLQWWVQIIG; LQWWVQIIGE;QWWVQIIGET; WWVQIIGETP; WVQIIGETPF; VQIIGETPFR; QIIGETPFRD;IIGETPFRDL; IGETPFRDLK; GETPFRDLKL; KALSNYFFYR; ALSNYFFYRC;LSNYFFYRCQ; SNYFFYRCQP; NYFFYRCQPM; YFFYRCQPME; FFYRCQPMEQ;FYRCQPMEQK; YRCQPMEQKS; RCQPMEQKSG; CQPMEQKSGS; QPMEQKSGSP;PMEQKSGSPG; MEQKSGSPGG; EQKSGSPGGV; QKSGSPGGVP; KSGSPGGVPL;SGSPGGVPLM; GSPGGVPLMK; SPGGVPLMKN; PGGVPLMKNG; GGVPLMKNGM;GVPLMKNGMK; VPLMKNGMKI; PLMKNGMKIY; LMKNGMKIYF; MKNGMKIYFA;KNGMKIYFAM; NGMKIYFAMK; GMKIYFAMKI; MKIYFAMKIC; KIYFAMKICL;IYFAMKICLP; YFAMKICLPV; FAMKICLPVM; AMKICLPVMK; MKICLPVMKK;KICLPVMKKQ; ICLPVMKKQQ; CLPVMKKQQQ; LPVMKKQQQI; PVMKKQQQIL;VMKKQQQILN; MKKQQQILNT; KKQQQILNTQ; KQQQILNTQH; QQQILNTQHH;QQILNTQHHP; QILNTQHHPK; ILNTQHHPKK; LNTQHHPKKK; NTQHHPKKKE;TQHHPKKKER; KTLKTFPLIY; TLKTFPLIYT; LKTFPLIYTS; KTFPLIYTSF;TFPLIYTSFL; FPLIYTSFLV; PLIYTSFLVK; LIYTSFLVKL; IYTSFLVKLY;YTSFLVKLYL; TSFLVKLYLV; SFLVKLYLVI; FLVKLYLVIE; LVKLYLVIEP;VKLYLVIEPL; KLYLVIEPLP; LYLVIEPLPA; YLVIEPLPAL; LVIEPLPALL;VIEPLPALLC; IEPLPALLCI; EPLPALLCIL; PLPALLCILL; LPALLCILLK;PALLCILLKK; ALLCILLKKK; LLCILLKKKL; LCILLKKKLK; CILLKKKLKF;ILLKKKLKFC; LLKKKLKFCI; LKKKLKFCIK; KKKLKFCIKN; KKLKFCIKNL;KLKFCIKNLW; LKFCIKNLWK; KFCIKNLWKN; FCIKNLWKNI; CIKNLWKNIL;LLLVDTCVLG; LLVDTCVLGI; LVDTCVLGII; VDTCVLGIIL; DTCVLGIILY;TCVLGIILYS; CVLGIILYSF; LHIDIEFLQL; HIDIEFLQLI; IDIEFLQLII;DIEFLQLIIS; IEFLQLIISV; EFLQLIISVK; FLQLIISVKS; LQLIISVKSC;QLIISVKSCV; LIISVKSCVP; IISVKSCVPL; ISVKSCVPLV; SVKSCVPLVF;FVRVLIRNTY; VRVLIRNTYY; RVLIRNTYYI; VLIRNTYYIV; LIRNTYYIVP;RSMILAQKSL; SMILAQKSLK; MILAQKSLKK; ILAQKSLKKQ; LAQKSLKKQS;AQKSLKKQSR; QKSLKKQSRC; KSLKKQSRCL; SLKKQSRCLG; LKKQSRCLGN;RQSVRMCFYY; RSVKSVRKKT; SVKSVRKKTS; VKSVRKKTSL; KSVRKKTSLI;SVRKKTSLIT; VRKKTSLITL; RKKTSLITLS; KKTSLITLSI; KTSLITLSIM;TSLITLSIMK; SLITLSIMKS; LITLSIMKST; ITLSIMKSTL; TLSIMKSTLQ;LSIMKSTLQM; SIMKSTLQML; IMKSTLQMLL; MKSTLQMLLF; KSTLQMLLFL;STLQMLLFLQ; TLQMLLFLQK; LQMLLFLQKV; QMLLFLQKVK; MLLFLQKVKI;LLFLQKVKIK; LFLQKVKIKK; FLQKVKIKKV; LQKVKIKKVF; QKVKIKKVFV;KVKIKKVFVS; VKIKKVFVSK; KIKKVFVSKQ; NNIWQVLLGC; NIWQVLLGCT;IWQVLLGCTV; WQVLLGCTVC; QVLLGCTVCY; VLLGCTVCYL; LLGCTVCYLK;LGCTVCYLKW; GCTVCYLKWI; CTVCYLKWIL; YLIFCTVLFS; LIFCTVLFSM;IFCTVLFSMY; FCTVLFSMYL; CTVLFSMYLK; TVLFSMYLKE; VLFSMYLKED;LFSMYLKEDT; FSMYLKEDTG; SMYLKEDTGY; MYLKEDTGYL; YLKEDTGYLK;LKEDTGYLKV; KEDTGYLKVP; EDTGYLKVPL; DTGYLKVPLI; TGYLKVPLIV;GYLKVPLIVE; YLKVPLIVEK; LKVPLIVEKQ; KVPLIVEKQH; KGQELNQRIC;GQELNQRICL; QELNQRICLQ; ELNQRICLQD; LNQRICLQDM; NQRICLQDME;TKEPKYFHQA; KEPKYFHQAW; EPKYFHQAWL; PKYFHQAWLQ; MSILSLKPCK;SILSLKPCKL; ILSLKPCKLD; LSLKPCKLDL; ENPYKTQSSY; NPYKTQSSYL;PYKTQSSYLK; YKTQSSYLKK; KTQSSYLKKE; TQSSYLKKEF; QSSYLKKEFY;SSYLKKEFYK; SYLKKEFYKV; YLKKEFYKVE; LILQLIYNLE; ILQLIYNLEL;LQLIYNLELL; QLIYNLELLN; LIYNLELLNG; IYNLELLNGR; YNLELLNGRK;NLELLNGRKG; LELLNGRKGW; ELLNGRKGWI; LLNGRKGWIL; LNGRKGWILR;NIIYAWGNVF; IIYAWGNVFL; IYAWGNVFLI; YAWGNVFLIL; AWGNVFLILQ;WGNVFLILQE; GNVFLILQEK; NVFLILQEKR; VFLILQEKRI; FLILQEKRIQ;LILQEKRIQK; ILQEKRIQKL; LQEKRIQKLK; QEKRIQKLKT; EKRIQKLKTL;KRIQKLKTLD; RIQKLKTLDM; IQKLKTLDMD; QKLKTLDMDQ; KLKTLDMDQA;LKTLDMDQAL; KTLDMDQALN; TLDMDQALNP; LDMDQALNPN; DMDQALNPNH;MDQALNPNHN; DQALNPNHNA; QALNPNHNAL; ALNPNHNALP; LNPNHNALPK;NPNHNALPKS; PNHNALPKSQ; NHNALPKSQI; HNALPKSQIL; NALPKSQILQ;ALPKSQILQP; LPKSQILQPL; PKSQILQPLL; KSQILQPLLK; SQILQPLLKI;QILQPLLKIP; ILQPLLKIPK; LQPLLKIPKG; QPLLKIPKGQ; PLLKIPKGQT;LLKIPKGQTP; LKIPKGQTPI; KIPKGQTPIV; IPKGQTPIVK; PKGQTPIVKS;KGQTPIVKSC; GQTPIVKSCI; QTPIVKSCIC; TPIVKSCICV; PIVKSCICVK;IVKSCICVKA; VKSCICVKAF; KSCICVKAFS; SCICVKAFSV; CICVKAFSVL;ICVKAFSVLK; CVKAFSVLKG; VKAFSVLKGL; KAFSVLKGLK; AFSVLKGLKH;FSVLKGLKHH; SVLKGLKHHP; VLKGLKHHPQ; LKGLKHHPQN; KGLKHHPQNN;GLKHHPQNNT; LKHHPQNNTS; KHHPQNNTSL; HHPQNNTSLK; HPQNNTSLKV;PQNNTSLKVA; QNNTSLKVAY; NNTSLKVAYT; NTSLKVAYTK; TSLKVAYTKA;SLKVAYTKAA; LKVAYTKAAF; KVAYTKAAFI; VAYTKAAFIK; AYTKAAFIKC;YTKAAFIKCI; TKAAFIKCIC; KAAFIKCICT; AAFIKCICTI; AFIKCICTIK;FIKCICTIKA; IKCICTIKAP; KCICTIKAPV; SILVCNCPCL; ILVCNCPCLS;LVCNCPCLSI; VCNCPCLSIY; CNCPCLSIYL; NCPCLSIYLI; CPCLSIYLII;PCLSIYLIIS; CLSIYLIISG; LSIYLIISGS; SIYLIISGSP; IYLIISGSPG;YLIISGSPGS; LIISGSPGSL; IISGSPGSLS; ISGSPGSLSV; SGSPGSLSVP;GSPGSLSVPS; SPGSLSVPSN; PGSLSVPSNT; GSLSVPSNTL; SLSVPSNTLT;LSVPSNTLTS; SVPSNTLTSS; VPSNTLTSST; PSNTLTSSTW; SNTLTSSTWD;NTLTSSTWDS; TLTSSTWDSI; LTSSTWDSIP; TSSTWDSIPY; SSTWDSIPYI;STWDSIPYIG; TWDSIPYIGC; WDSIPYIGCP; DSIPYIGCPS; SIPYIGCPST;IPYIGCPSTL; PYIGCPSTLW; YIGCPSTLWV; IGCPSTLWVL; GCPSTLWVLL;CPSTLWVLLF; PSTLWVLLFI; STLWVLLFIR; TLWVLLFIRS; LWVLLFIRSL;WVLLFIRSLS; VLLFIRSLSK; LLFIRSLSKK; LFIRSLSKKE; FIRSLSKKEI;IRSLSKKEIG; GFFTDLFLRR; FFTDLFLRRI; FTDLFLRRIL; TDLFLRRILK;DLFLRRILKY; LFLRRILKYL; FLRRILKYLA; LRRILKYLAR; RRILKYLARP;RILKYLARPL; ILKYLARPLH; LKYLARPLHC; KYLARPLHCC; YLARPLHCCV;LARPLHCCVP; ARPLHCCVPE; RPLHCCVPEL; PLHCCVPELL; LHCCVPELLV;HCCVPELLVN; CCVPELLVNR; CVPELLVNRP; VPELLVNRPQ; PELLVNRPQI;ELLVNRPQIS; LLVNRPQISA; LVNRPQISAA; VNRPQISAAE; NRPQISAAET;RPQISAAETY; PQISAAETYR; QISAAETYRL; ISAAETYRLS; SAAETYRLSA;AAETYRLSAL; AETYRLSALQ; ETYRLSALQR; TYRLSALQRG; YRLSALQRGP;RLSALQRGPT; LSALQRGPTP; SALQRGPTPC; ALQRGPTPCS; LQRGPTPCSS;QRGPTPCSSS; RGPTPCSSSN; GPTPCSSSNT; PTPCSSSNTV; TPCSSSNTVV;PCSSSNTVVA; CSSSNTVVAV; SSSNTVVAVL; SSNTVVAVLV; SNTVVAVLVT;STGGTFSPPV; TGGTFSPPVK; GGTFSPPVKV; GTFSPPVKVP; TFSPPVKVPK;FSPPVKVPKY; SPPVKVPKYL; PPVKVPKYLA; PVKVPKYLAF; VKVPKYLAFS;KVPKYLAFSF; VPKYLAFSFL; PKYLAFSFLL; KYLAFSFLLG; YLAFSFLLGS;LAFSFLLGSG; AFSFLLGSGT; FSFLLGSGTQ; SFLLGSGTQH; FLLGSGTQHS;LLGSGTQHST; LGSGTQHSTG; ALWSVFITWD; LWSVFITWDW; WSVFITWDWA;SVFITWDWAV; VFITWDWAVG; FITWDWAVGF; ITWDWAVGFL; TWDWAVGFLG;WDWAVGFLGV; DWAVGFLGVI; WAVGFLGVIV; AVGFLGVIVP; VGFLGVIVPS;GFLGVIVPSG; FLGVIVPSGY; LGVIVPSGYF; GVIVPSGYFD; VIVPSGYFDL;FISTPCISKG; ISTPCISKGS; STPCISKGSP; TPCISKGSPP; PCISKGSPPT;CISKGSPPTA; ISKGSPPTAK; SKGSPPTAKK; KGSPPTAKKW; GSPPTAKKWK;SPPTAKKWKL; PPTAKKWKLL; PTAKKWKLLP; IGFPPPCSCT; GFPPPCSCTF;FPPPCSCTFC; PPPCSCTFCD; PPCSCTFCDP; PCSCTFCDPA; RLSMLVIPIT;LSMLVIPITS; SMLVIPITSV; MLVIPITSVC; LVIPITSVCT; VIPITSVCTV;IPITSVCTVT; PITSVCTVTA; ITSVCTVTAS; TSVCTVTASH; SVCTVTASHI;VCTVTASHIS; CTVTASHISR; TVTASHISRF; VTASHISRFP; TASHISRFPQ;ASHISRFPQV; SHISRFPQVR; HISRFPQVRS; ISRFPQVRSS; SRFPQVRSSF;RFPQVRSSFK; FPQVRSSFKL; PQVRSSFKLG; QVRSSFKLGR; VRSSFKLGRG;RSSFKLGRGI; SSFKLGRGIL; SFKLGRGILA; FKLGRGILAV; KLGRGILAVL;QGSIFLSGLS; GSIFLSGLSL; SIFLSGLSLL; IFLSGLSLLK; FLSGLSLLKS;LSGLSLLKSF; SGLSLLKSFS; GLSLLKSFSA; LSLLKSFSAL; SLLKSFSALS;LLKSFSALSF; LKSFSALSFR; KSFSALSFRL; SFSALSFRLK; FSALSFRLKP;SALSFRLKPL; ALSFRLKPLR; LSFRLKPLRF; SFRLKPLRFS; FRLKPLRFSS;RLKPLRFSSG; LKPLRFSSGS; KPLRFSSGSP; PLRFSSGSPI; LRFSSGSPIS;RFSSGSPISG; FSSGSPISGF; SSGSPISGFR; SGSPISGFRK; GSPISGFRKH;SPISGFRKHS; PISGFRKHST; ISGFRKHSTS; SGFRKHSTSV; GFRKHSTSVI;FRKHSTSVIA; RKHSTSVIAS; KHSTSVIAST; HSTSVIASTP; STSVIASTPV;TSVIASTPVL; SVIASTPVLT; VIASTPVLTS; IASTPVLTSR; ASTPVLTSRT;STPVLTSRTS; TPVLTSRTST; PVLTSRTSTP; VLTSRTSTPP; LTSRTSTPPF;TSRTSTPPFI; SRTSTPPFIS; RTSTPPFISS; TSTPPFISSF; STPPFISSFG;TPPFISSFGT; PPFISSFGTC; PFISSFGTCT; FISSFGTCTG; ISSFGTCTGS;SSFGTCTGSF; SFGTCTGSFG; FGTCTGSFGF; GTCTGSFGFL; TCTGSFGFLG;CTGSFGFLGA; TGSFGFLGAA; GSFGFLGAAP; SFGFLGAAPG; FGFLGAAPGH;GFLGAAPGHS; FLGAAPGHSP; LGAAPGHSPF; GAAPGHSPFL; AAPGHSPFLL;APGHSPFLLV; PGHSPFLLVG; GHSPFLLVGA; HSPFLLVGAI; SPFLLVGAIF;PFLLVGAIFI; FLLVGAIFIC; LLVGAIFICF; LVGAIFICFK; VGAIFICFKS;GAIFICFKSR; AIFICFKSRC; IFICFKSRCY; FICFKSRCYS; ICFKSRCYSP;CFKSRCYSPV; FKSRCYSPVQ; KSRCYSPVQA; RQHPLRSSSL; QHPLRSSSLI;HPLRSSSLIS; PLRSSSLIST; LRSSSLISTS; RSSSLISTSW; SSSLISTSWG;SSLISTSWGN; SLISTSWGNS; LISTSWGNSF; ISTSWGNSFF; STSWGNSFFY;TSWGNSFFYK; SWGNSFFYKL; WGNSFFYKLS; VHSLCNFFYT; HSLCNFFYTV;SLCNFFYTVS; LCNFFYTVSI; CNFFYTVSII; NFFYTVSIIY; FFYTVSIIYT;FYTVSIIYTI; YTVSIIYTIS; TVSIIYTISM; VSIIYTISMA; SIIYTISMAK;IIYTISMAKM; IYTISMAKMY; YTISMAKMYT; TISMAKMYTG; ISMAKMYTGT;SMAKMYTGTF; MAKMYTGTFP; AKMYTGTFPF; KMYTGTFPFS; MYTGTFPFSY;YTGTFPFSYL; TGTFPFSYLS; GTFPFSYLSN; TFPFSYLSNH; GPNRGKIRII;PNRGKIRIIL; NRGKIRIILL; RGKIRIILLN; GKIRIILLNI; KIRIILLNII;IRIILLNIII; RIILLNIIIK; IILLNIIIKV; ILLNIIIKVY; LLNIIIKVYR;LNIIIKVYRG; NIIIKVYRGI; IIIKVYRGIY; IIKVYRGIYN; IKVYRGIYNC;KVYRGIYNCP; VYRGIYNCPG; YRGIYNCPGS; RGIYNCPGSF; GIYNCPGSFL;IYNCPGSFLQ; YNCPGSFLQK; NCPGSFLQKS; CPGSFLQKSS; PGSFLQKSSQ;GSFLQKSSQG; SFLQKSSQGV; FLQKSSQGVS; LQKSSQGVSK; QKSSQGVSKK;KSSQGVSKKS; SSQGVSKKSF; SQGVSKKSFC; QGVSKKSFCS; GVSKKSFCSS;VSKKSFCSSL; SKKSFCSSLQ; KKSFCSSLQF; KSFCSSLQFL; GYRRYIIPNN;YRRYIIPNNM; RRYIIPNNMP; RYIIPNNMPQ; YIIPNNMPQS; IIPNNMPQSL;IPNNMPQSLG; PNNMPQSLGN; NNMPQSLGNS; NMPQSLGNSS; MPQSLGNSSK;PQSLGNSSKQ; QSLGNSSKQR; SLGNSSKQRR; LGNSSKQRRT; GNSSKQRRTP;NSSKQRRTPM; SSKQRRTPMP; SKQRRTPMPR; KQRRTPMPRI; QRRTPMPRIK;RRTPMPRIKV; RTPMPRIKVL; TPMPRIKVLN; PMPRIKVLNI; MPRIKVLNII;PRIKVLNIIN; RIKVLNIINK; IKVLNIINKS; KVLNIINKSI; VLNIINKSIY;LNIINKSIYT; NIINKSIYTR; IINKSIYTRK; INKSIYTRKQ; NKSIYTRKQN;KSIYTRKQNI; SIYTRKQNII; IYTRKQNIIV; YTRKQNIIVL; TRKQNIIVLI;RKQNIIVLIW; KQNIIVLIWV; QNIIVLIWVK; NIIVLIWVKQ; IIVLIWVKQF;IVLIWVKQFQ; VLIWVKQFQS; LIWVKQFQSH; IWVKQFQSHA; LLIEAYSGNF;LIEAYSGNFV; IEAYSGNFVI; EAYSGNFVIP; AYSGNFVIPI; YSGNFVIPII;SGNFVIPIIK; GNFVIPIIKE; NFVIPIIKEL; FVIPIIKELI; VIPIIKELIP;IPIIKELIPY; PIIKELIPYL; IIKELIPYLS; SSKPSNSPRS; SKPSNSPRST;KPSNSPRSTS; PSNSPRSTSN; SNSPRSTSNY; NSPRSTSNYS; SPRSTSNYSI;PRSTSNYSIC; RSTSNYSICL; STSNYSICLR; TSNYSICLRS; GTCYALYSSK;TCYALYSSKG; CYALYSSKGC; YALYSSKGCN; ALYSSKGCNL; LYSSKGCNLN;YSSKGCNLNF; SSKGCNLNFY; SKGCNLNFYS; KGCNLNFYSS; GCNLNFYSSS;CNLNFYSSSS; NLNFYSSSSL; LNFYSSSSLP; NFYSSSSLPS; FYSSSSLPSS;YSSSSLPSSN; SSSSLPSSNF; SSSLPSSNFS; SSLPSSNFSH; KSCGSSSLRY;SCGSSSLRYT; CGSSSLRYTG; GSSSLRYTGN; SSTHEPGNTK; STHEPGNTKK;THEPGNTKKK; HEPGNTKKKG; EPGNTKKKGL; PGNTKKKGLL; GNTKKKGLLT;ESFTESFTAG; SFTESFTAGK; FTESFTAGKA; TESFTAGKAV; ESFTAGKAVV;SFTAGKAVVL; FTAGKAVVLL; TAGKAVVLLF; AGKAVVLLFF; GKAVVLLFFP;KAVVLLFFPS; AVVLLFFPST; VVLLFFPSTL; VLLFFPSTLS; LLFFPSTLSS;LFFPSTLSSP; FFPSTLSSPL; FPSTLSSPLQ; PSTLSSPLQN; STLSSPLQNS;TLSSPLQNSS; LSSPLQNSSK; SSPLQNSSKS; SPLQNSSKSS; PLQNSSKSSK;LQNSSKSSKI; QNSSKSSKIK; NSSKSSKIKI; SSKSSKIKIK; SKSSKIKIKI;KSSKIKIKIL; ALFFVPVQVL; LFFVPVQVLP; FFVPVQVLPT; FVPVQVLPTF;VPVQVLPTFT; PVQVLPTFTE; VQVLPTFTEA; QVLPTFTEAC; VLPTFTEACR;LPTFTEACRD; PTFTEACRDS; TFTEACRDSW; FTEACRDSWR; TEACRDSWRR;EACRDSWRRT; ACRDSWRRTM; CRDSWRRTMA; RDSWRRTMAF; DSWRRTMAFV;SWRRTMAFVQ; WRRTMAFVQF; RRTMAFVQFN; RTMAFVQFNW; TMAFVQFNWG;MAFVQFNWGQ; AFVQFNWGQG; FVQFNWGQGQ; VQFNWGQGQD; QFNWGQGQDS;ARKTCLSCTF; RKTCLSCTFL; KTCLSCTFLP; TCLSCTFLPE; CLSCTFLPEV;LSCTFLPEVM; SCTFLPEVMV; CTFLPEVMVW; TFLPEVMVWL; FLPEVMVWLH;LPEVMVWLHS; PEVMVWLHSM; EVMVWLHSMG; VMVWLHSMGK; MVWLHSMGKQ;VWLHSMGKQL; WLHSMGKQLL; LHSMGKQLLP; HSMGKQLLPV; SMGKQLLPVS;MGKQLLPVSH; GKQLLPVSHA; KQLLPVSHAL; QLLPVSHALS; LLPVSHALSF;LPVSHALSFL; PVSHALSFLR; VSHALSFLRS; SHALSFLRSW; HALSFLRSWF;ALSFLRSWFG; LSFLRSWFGC; SFLRSWFGCI; FLRSWFGCIP; LRSWFGCIPL;AAPPCGLFFY; APPCGLFFYN; PPCGLFFYNI; EAEAASASTL; AEAASASTLS;EAASASTLSL; AASASTLSLK; GLAKLFGEIP; LAKLFGEIPI; AKLFGEIPIL;KLFGEIPILL; LFGEIPILLQ; FGEIPILLQF; GEIPILLQFL; EIPILLQFLQ 11 mers:MDKVLNREESM; DKVLNREESME; KVLNREESMEL; VLNREESMELM; LNREESMELMD;NREESMELMDL; REESMELMDLL; EESMELMDLLG; ESMELMDLLGL; SMELMDLLGLE;MELMDLLGLER; ELMDLLGLERA; LMDLLGLERAA; MDLLGLERAAW; DLLGLERAAWG;LLGLERAAWGN; LGLERAAWGNL; GLERAAWGNLP; LERAAWGNLPL; ERAAWGNLPLM;RAAWGNLPLMR; AAWGNLPLMRK; AWGNLPLMRKA; WGNLPLMRKAY; GNLPLMRKAYL;NLPLMRKAYLR; LPLMRKAYLRK; PLMRKAYLRKC; LMRKAYLRKCK; MRKAYLRKCKE;RKAYLRKCKEF; KAYLRKCKEFH; AYLRKCKEFHP; YLRKCKEFHPD; LRKCKEFHPDK;RKCKEFHPDKG; KCKEFHPDKGG; CKEFHPDKGGD; KEFHPDKGGDE; EFHPDKGGDED;FHPDKGGDEDK; HPDKGGDEDKM; PDKGGDEDKMK; DKGGDEDKMKR; KGGDEDKMKRM;GGDEDKMKRMN; GDEDKMKRMNT; DEDKMKRMNTL; EDKMKRMNTLY; DKMKRMNTLYK;KMKRMNTLYKK; MKRMNTLYKKM; KRMNTLYKKME; RMNTLYKKMEQ; MNTLYKKMEQD;NTLYKKMEQDV; TLYKKMEQDVK; LYKKMEQDVKV; YKKMEQDVKVA; KKMEQDVKVAH;KMEQDVKVAHQ; MEQDVKVAHQP; EQDVKVAHQPD; QDVKVAHQPDF; DVKVAHQPDFG;VKVAHQPDFGT; KVAHQPDFGTW; VAHQPDFGTWS; AHQPDFGTWSS; HQPDFGTWSSS;QPDFGTWSSSE; PDFGTWSSSEV; DFGTWSSSEVC; FGTWSSSEVCA; GTWSSSEVCAD;TWSSSEVCADF; WSSSEVCADFP; SSSEVCADFPL; SSEVCADFPLC; SEVCADFPLCP;EVCADFPLCPD; VCADFPLCPDT; CADFPLCPDTL; ADFPLCPDTLY; DFPLCPDTLYC;FPLCPDTLYCK; PLCPDTLYCKE; LCPDTLYCKEW; CPDTLYCKEWP; PDTLYCKEWPI;DTLYCKEWPIC; TLYCKEWPICS; LYCKEWPICSK; YCKEWPICSKK; CKEWPICSKKP;KEWPICSKKPS; EWPICSKKPSV; WPICSKKPSVH; PICSKKPSVHC; ICSKKPSVHCP;CSKKPSVHCPC; SKKPSVHCPCM; KKPSVHCPCML; KPSVHCPCMLC; PSVHCPCMLCQ;SVHCPCMLCQL; VHCPCMLCQLR; HCPCMLCQLRL; CPCMLCQLRLR; PCMLCQLRLRH;CMLCQLRLRHL; MLCQLRLRHLN; LCQLRLRHLNR; CQLRLRHLNRK; QLRLRHLNRKF;LRLRHLNRKFL; RLRHLNRKFLR; LRHLNRKFLRK; RHLNRKFLRKE; HLNRKFLRKEP;LNRKFLRKEPL; NRKFLRKEPLV; RKFLRKEPLVW; KFLRKEPLVWI; FLRKEPLVWID;LRKEPLVWIDC; RKEPLVWIDCY; KEPLVWIDCYC; EPLVWIDCYCI; PLVWIDCYCID;LVWIDCYCIDC; VWIDCYCIDCF; WIDCYCIDCFT; IDCYCIDCFTQ; DCYCIDCFTQW;CYCIDCFTQWF; YCIDCFTQWFG; CIDCFTQWFGL; IDCFTQWFGLD; DCFTQWFGLDL;CFTQWFGLDLT; FTQWFGLDLTE; TQWFGLDLTEE; QWFGLDLTEET; WFGLDLTEETL;FGLDLTEETLQ; GLDLTEETLQW; LDLTEETLQWW; DLTEETLQWWV; LTEETLQWWVQ;TEETLQWWVQI; EETLQWWVQII; ETLQWWVQIIG; TLQWWVQIIGE; LQWWVQIIGET;QWWVQIIGETP; WWVQIIGETPF; WVQIIGETPFR; VQIIGETPFRD; QIIGETPFRDL;IIGETPFRDLK; IGETPFRDLKL; KALSNYFFYRC; ALSNYFFYRCQ; LSNYFFYRCQP;SNYFFYRCQPM; NYFFYRCQPME; YFFYRCQPMEQ; FFYRCQPMEQK; FYRCQPMEQKS;YRCQPMEQKSG; RCQPMEQKSGS; CQPMEQKSGSP; QPMEQKSGSPG; PMEQKSGSPGG;MEQKSGSPGGV; EQKSGSPGGVP; QKSGSPGGVPL; KSGSPGGVPLM; SGSPGGVPLMK;GSPGGVPLMKN; SPGGVPLMKNG; PGGVPLMKNGM; GGVPLMKNGMK; GVPLMKNGMKI;VPLMKNGMKIY; PLMKNGMKIYF; LMKNGMKIYFA; MKNGMKIYFAM; KNGMKIYFAMK;NGMKIYFAMKI; GMKIYFAMKIC; MKIYFAMKICL; KIYFAMKICLP; IYFAMKICLPV;YFAMKICLPVM; FAMKICLPVMK; AMKICLPVMKK; MKICLPVMKKQ; KICLPVMKKQQ;ICLPVMKKQQQ; CLPVMKKQQQI; LPVMKKQQQIL; PVMKKQQQILN; VMKKQQQILNT;MKKQQQILNTQ; KKQQQILNTQH; KQQQILNTQHH; QQQILNTQHHP; QQILNTQHHPK;QILNTQHHPKK; ILNTQHHPKKK; LNTQHHPKKKE; NTQHHPKKKER; KTLKTFPLIYT;TLKTFPLIYTS; LKTFPLIYTSF; KTFPLIYTSFL; TFPLIYTSFLV; FPLIYTSFLVK;PLIYTSFLVKL; LIYTSFLVKLY; IYTSFLVKLYL; YTSFLVKLYLV; TSFLVKLYLVI;SFLVKLYLVIE; FLVKLYLVIEP; LVKLYLVIEPL; VKLYLVIEPLP; KLYLVIEPLPA;LYLVIEPLPAL; YLVIEPLPALL; LVIEPLPALLC; VIEPLPALLCI; IEPLPALLCIL;EPLPALLCILL; PLPALLCILLK; LPALLCILLKK; PALLCILLKKK; ALLCILLKKKL;LLCILLKKKLK; LCILLKKKLKF; CILLKKKLKFC; ILLKKKLKFCI; LLKKKLKFCIK;LKKKLKFCIKN; KKKLKFCIKNL; KKLKFCIKNLW; KLKFCIKNLWK; LKFCIKNLWKN;KFCIKNLWKNI; FCIKNLWKNIL; LLLVDTCVLGI; LLVDTCVLGII; LVDTCVLGIIL;VDTCVLGIILY; DTCVLGIILYS; TCVLGIILYSF; LHIDIEFLQLI; HIDIEFLQLII;IDIEFLQLIIS; DIEFLQLIISV; IEFLQLIISVK; EFLQLIISVKS; FLQLIISVKSC;LQLIISVKSCV; QLIISVKSCVP; LIISVKSCVPL; IISVKSCVPLV; ISVKSCVPLVF;FVRVLIRNTYY; VRVLIRNTYYI; RVLIRNTYYIV; VLIRNTYYIVP; RSMILAQKSLK;SMILAQKSLKK; MILAQKSLKKQ; ILAQKSLKKQS; LAQKSLKKQSR; AQKSLKKQSRC;QKSLKKQSRCL; KSLKKQSRCLG; SLKKQSRCLGN; RSVKSVRKKTS; SVKSVRKKTSL;VKSVRKKTSLI; KSVRKKTSLIT; SVRKKTSLITL; VRKKTSLITLS; RKKTSLITLSI;KKTSLITLSIM; KTSLITLSIMK; TSLITLSIMKS; SLITLSIMKST; LITLSIMKSTL;ITLSIMKSTLQ; TLSIMKSTLQM; LSIMKSTLQML; SIMKSTLQMLL; IMKSTLQMLLF;MKSTLQMLLFL; KSTLQMLLFLQ; STLQMLLFLQK; TLQMLLFLQKV; LQMLLFLQKVK;QMLLFLQKVKI; MLLFLQKVKIK; LLFLQKVKIKK; LFLQKVKIKKV; FLQKVKIKKVF;LQKVKIKKVFV; QKVKIKKVFVS; KVKIKKVFVSK; VKIKKVFVSKQ; NNIWQVLLGCT;NIWQVLLGCTV; IWQVLLGCTVC; WQVLLGCTVCY; QVLLGCTVCYL; VLLGCTVCYLK;LLGCTVCYLKW; LGCTVCYLKWI; GCTVCYLKWIL; YLIFCTVLFSM; LIFCTVLFSMY;IFCTVLFSMYL; FCTVLFSMYLK; CTVLFSMYLKE; TVLFSMYLKED; VLFSMYLKEDT;LFSMYLKEDTG; FSMYLKEDTGY; SMYLKEDTGYL; MYLKEDTGYLK; YLKEDTGYLKV;LKEDTGYLKVP; KEDTGYLKVPL; EDTGYLKVPLI; DTGYLKVPLIV; TGYLKVPLIVE;GYLKVPLIVEK; YLKVPLIVEKQ; LKVPLIVEKQH; KGQELNQRICL; GQELNQRICLQ;QELNQRICLQD; ELNQRICLQDM; LNQRICLQDME; TKEPKYFHQAW; KEPKYFHQAWL;EPKYFHQAWLQ; MSILSLKPCKL; SILSLKPCKLD; ILSLKPCKLDL; ENPYKTQSSYL;NPYKTQSSYLK; PYKTQSSYLKK; YKTQSSYLKKE; KTQSSYLKKEF; TQSSYLKKEFY;QSSYLKKEFYK; SSYLKKEFYKV; SYLKKEFYKVE; LILQLIYNLEL; ILQLIYNLELL;LQLIYNLELLN; QLIYNLELLNG; LIYNLELLNGR; IYNLELLNGRK; YNLELLNGRKG;NLELLNGRKGW; LELLNGRKGWI; ELLNGRKGWIL; LLNGRKGWILR; NIIYAWGNVFL;IIYAWGNVFLI; IYAWGNVFLIL; YAWGNVFLILQ; AWGNVFLILQE; WGNVFLILQEK;GNVFLILQEKR; NVFLILQEKRI; VFLILQEKRIQ; FLILQEKRIQK; LILQEKRIQKL;ILQEKRIQKLK; LQEKRIQKLKT; QEKRIQKLKTL; EKRIQKLKTLD; KRIQKLKTLDM;RIQKLKTLDMD; IQKLKTLDMDQ; QKLKTLDMDQA; KLKTLDMDQAL; LKTLDMDQALN;KTLDMDQALNP; TLDMDQALNPN; LDMDQALNPNH; DMDQALNPNHN; MDQALNPNHNA;DQALNPNHNAL; QALNPNHNALP; ALNPNHNALPK; LNPNHNALPKS; NPNHNALPKSQ;PNHNALPKSQI; NHNALPKSQIL; HNALPKSQILQ; NALPKSQILQP; ALPKSQILQPL;LPKSQILQPLL; PKSQILQPLLK; KSQILQPLLKI; SQILQPLLKIP; QILQPLLKIPK;ILQPLLKIPKG; LQPLLKIPKGQ; QPLLKIPKGQT; PLLKIPKGQTP; LLKIPKGQTPI;LKIPKGQTPIV; KIPKGQTPIVK; IPKGQTPIVKS; PKGQTPIVKSC; KGQTPIVKSCI;GQTPIVKSCIC; QTPIVKSCICV; TPIVKSCICVK; PIVKSCICVKA; IVKSCICVKAF;VKSCICVKAFS; KSCICVKAFSV; SCICVKAFSVL; CICVKAFSVLK; ICVKAFSVLKG;CVKAFSVLKGL; VKAFSVLKGLK; KAFSVLKGLKH; AFSVLKGLKHH; FSVLKGLKHHP;SVLKGLKHHPQ; VLKGLKHHPQN; LKGLKHHPQNN; KGLKHHPQNNT; GLKHHPQNNTS;LKHHPQNNTSL; KHHPQNNTSLK; HHPQNNTSLKV; HPQNNTSLKVA; PQNNTSLKVAY;QNNTSLKVAYT; NNTSLKVAYTK; NTSLKVAYTKA; TSLKVAYTKAA; SLKVAYTKAAF;LKVAYTKAAFI; KVAYTKAAFIK; VAYTKAAFIKC; AYTKAAFIKCI; YTKAAFIKCIC;TKAAFIKCICT; KAAFIKCICTI; AAFIKCICTIK; AFIKCICTIKA; FIKCICTIKAP;IKCICTIKAPV; SILVCNCPCLS; ILVCNCPCLSI; LVCNCPCLSIY; VCNCPCLSIYL;CNCPCLSIYLI; NCPCLSIYLII; CPCLSIYLIIS; PCLSIYLIISG; CLSIYLIISGS;LSIYLIISGSP; SIYLIISGSPG; IYLIISGSPGS; YLIISGSPGSL; LIISGSPGSLS;IISGSPGSLSV; ISGSPGSLSVP; SGSPGSLSVPS; GSPGSLSVPSN; SPGSLSVPSNT;PGSLSVPSNTL; GSLSVPSNTLT; SLSVPSNTLTS; LSVPSNTLTSS; SVPSNTLTSST;VPSNTLTSSTW; PSNTLTSSTWD; SNTLTSSTWDS; NTLTSSTWDSI; TLTSSTWDSIP;LTSSTWDSIPY; TSSTWDSIPYI; SSTWDSIPYIG; STWDSIPYIGC; TWDSIPYIGCP;WDSIPYIGCPS; DSIPYIGCPST; SIPYIGCPSTL; IPYIGCPSTLW; PYIGCPSTLWV;YIGCPSTLWVL; IGCPSTLWVLL; GCPSTLWVLLF; CPSTLWVLLFI; PSTLWVLLFIR;STLWVLLFIRS; TLWVLLFIRSL; LWVLLFIRSLS; WVLLFIRSLSK; VLLFIRSLSKK;LLFIRSLSKKE; LFIRSLSKKEI; FIRSLSKKEIG; GFFTDLFLRRI; FFTDLFLRRIL;FTDLFLRRILK; TDLFLRRILKY; DLFLRRILKYL; LFLRRILKYLA; FLRRILKYLAR;LRRILKYLARP; RRILKYLARPL; RILKYLARPLH; ILKYLARPLHC; LKYLARPLHCC;KYLARPLHCCV; YLARPLHCCVP; LARPLHCCVPE; ARPLHCCVPEL; RPLHCCVPELL;PLHCCVPELLV; LHCCVPELLVN; HCCVPELLVNR; CCVPELLVNRP; CVPELLVNRPQ;VPELLVNRPQI; PELLVNRPQIS; ELLVNRPQISA; LLVNRPQISAA; LVNRPQISAAE;VNRPQISAAET; NRPQISAAETY; RPQISAAETYR; PQISAAETYRL; QISAAETYRLS;ISAAETYRLSA; SAAETYRLSAL; AAETYRLSALQ; AETYRLSALQR; ETYRLSALQRG;TYRLSALQRGP; YRLSALQRGPT; RLSALQRGPTP; LSALQRGPTPC; SALQRGPTPCS;ALQRGPTPCSS; LQRGPTPCSSS; QRGPTPCSSSN; RGPTPCSSSNT; GPTPCSSSNTV;PTPCSSSNTVV; TPCSSSNTVVA; PCSSSNTVVAV; CSSSNTVVAVL; SSSNTVVAVLV;SSNTVVAVLVT; STGGTFSPPVK; TGGTFSPPVKV; GGTFSPPVKVP; GTFSPPVKVPK;TFSPPVKVPKY; FSPPVKVPKYL; SPPVKVPKYLA; PPVKVPKYLAF; PVKVPKYLAFS;VKVPKYLAFSF; KVPKYLAFSFL; VPKYLAFSFLL; PKYLAFSFLLG; KYLAFSFLLGS;YLAFSFLLGSG; LAFSFLLGSGT; AFSFLLGSGTQ; FSFLLGSGTQH; SFLLGSGTQHS;FLLGSGTQHST; LLGSGTQHSTG; ALWSVFITWDW; LWSVFITWDWA; WSVFITWDWAV;SVFITWDWAVG; VFITWDWAVGF; FITWDWAVGFL; ITWDWAVGFLG; TWDWAVGFLGV;WDWAVGFLGVI; DWAVGFLGVIV; WAVGFLGVIVP; AVGFLGVIVPS; VGFLGVIVPSG;GFLGVIVPSGY; FLGVIVPSGYF; LGVIVPSGYFD; GVIVPSGYFDL; FISTPCISKGS;ISTPCISKGSP; STPCISKGSPP; TPCISKGSPPT; PCISKGSPPTA; CISKGSPPTAK;ISKGSPPTAKK; SKGSPPTAKKW; KGSPPTAKKWK; GSPPTAKKWKL; SPPTAKKWKLL;PPTAKKWKLLP; IGFPPPCSCTF; GFPPPCSCTFC; FPPPCSCTFCD; PPPCSCTFCDP;PPCSCTFCDPA; RLSMLVIPITS; LSMLVIPITSV; SMLVIPITSVC; MLVIPITSVCT;LVIPITSVCTV; VIPITSVCTVT; IPITSVCTVTA; PITSVCTVTAS; ITSVCTVTASH;TSVCTVTASHI; SVCTVTASHIS; VCTVTASHISR; CTVTASHISRF; TVTASHISRFP;VTASHISRFPQ; TASHISRFPQV; ASHISRFPQVR; SHISRFPQVRS; HISRFPQVRSS;ISRFPQVRSSF; SRFPQVRSSFK; RFPQVRSSFKL; FPQVRSSFKLG; PQVRSSFKLGR;QVRSSFKLGRG; VRSSFKLGRGI; RSSFKLGRGIL; SSFKLGRGILA; SFKLGRGILAV;FKLGRGILAVL; QGSIFLSGLSL; GSIFLSGLSLL; SIFLSGLSLLK; IFLSGLSLLKS;FLSGLSLLKSF; LSGLSLLKSFS; SGLSLLKSFSA; GLSLLKSFSAL; LSLLKSFSALS;SLLKSFSALSF; LLKSFSALSFR; LKSFSALSFRL; KSFSALSFRLK; SFSALSFRLKP;FSALSFRLKPL; SALSFRLKPLR; ALSFRLKPLRF; LSFRLKPLRFS; SFRLKPLRFSS;FRLKPLRFSSG; RLKPLRFSSGS; LKPLRFSSGSP; KPLRFSSGSPI; PLRFSSGSPIS;LRFSSGSPISG; RFSSGSPISGF; FSSGSPISGFR; SSGSPISGFRK; SGSPISGFRKH;GSPISGFRKHS; SPISGFRKHST; PISGFRKHSTS; ISGFRKHSTSV; SGFRKHSTSVI;GFRKHSTSVIA; FRKHSTSVIAS; RKHSTSVIAST; KHSTSVIASTP; HSTSVIASTPV;STSVIASTPVL; TSVIASTPVLT; SVIASTPVLTS; VIASTPVLTSR; IASTPVLTSRT;ASTPVLTSRTS; STPVLTSRTST; TPVLTSRTSTP; PVLTSRTSTPP; VLTSRTSTPPF;LTSRTSTPPFI; TSRTSTPPFIS; SRTSTPPFISS; RTSTPPFISSF; TSTPPFISSFG;STPPFISSFGT; TPPFISSFGTC; PPFISSFGTCT; PFISSFGTCTG; FISSFGTCTGS;ISSFGTCTGSF; SSFGTCTGSFG; SFGTCTGSFGF; FGTCTGSFGFL; GTCTGSFGFLG;TCTGSFGFLGA; CTGSFGFLGAA; TGSFGFLGAAP; GSFGFLGAAPG; SFGFLGAAPGH;FGFLGAAPGHS; GFLGAAPGHSP; FLGAAPGHSPF; LGAAPGHSPFL; GAAPGHSPFLL;AAPGHSPFLLV; APGHSPFLLVG; PGHSPFLLVGA; GHSPFLLVGAI; HSPFLLVGAIF;SPFLLVGAIFI; PFLLVGAIFIC; FLLVGAIFICF; LLVGAIFICFK; LVGAIFICFKS;VGAIFICFKSR; GAIFICFKSRC; AIFICFKSRCY; IFICFKSRCYS; FICFKSRCYSP;ICFKSRCYSPV; CFKSRCYSPVQ; FKSRCYSPVQA; RQHPLRSSSLI; QHPLRSSSLIS;HPLRSSSLIST; PLRSSSLISTS; LRSSSLISTSW; RSSSLISTSWG; SSSLISTSWGN;SSLISTSWGNS; SLISTSWGNSF; LISTSWGNSFF; ISTSWGNSFFY; STSWGNSFFYK;TSWGNSFFYKL; SWGNSFFYKLS; VHSLCNFFYTV; HSLCNFFYTVS; SLCNFFYTVSI;LCNFFYTVSII; CNFFYTVSIIY; NFFYTVSIIYT; FFYTVSIIYTI; FYTVSIIYTIS;YTVSIIYTISM; TVSIIYTISMA; VSIIYTISMAK; SIIYTISMAKM; IIYTISMAKMY;IYTISMAKMYT; YTISMAKMYTG; TISMAKMYTGT; ISMAKMYTGTF; SMAKMYTGTFP;MAKMYTGTFPF; AKMYTGTFPFS; KMYTGTFPFSY; MYTGTFPFSYL; YTGTFPFSYLS;TGTFPFSYLSN; GTFPFSYLSNH; GPNRGKIRIIL; PNRGKIRIILL; NRGKIRIILLN;RGKIRIILLNI; GKIRIILLNII; KIRIILLNIII; IRIILLNIIIK; RIILLNIIIKV;IILLNIIIKVY; ILLNIIIKVYR; LLNIIIKVYRG; LNIIIKVYRGI; NIIIKVYRGIY;IIIKVYRGIYN; IIKVYRGIYNC; IKVYRGIYNCP; KVYRGIYNCPG; VYRGIYNCPGS;YRGIYNCPGSF; RGIYNCPGSFL; GIYNCPGSFLQ; IYNCPGSFLQK; YNCPGSFLQKS;NCPGSFLQKSS; CPGSFLQKSSQ; PGSFLQKSSQG; GSFLQKSSQGV; SFLQKSSQGVS;FLQKSSQGVSK; LQKSSQGVSKK; QKSSQGVSKKS; KSSQGVSKKSF; SSQGVSKKSFC;SQGVSKKSFCS; QGVSKKSFCSS; GVSKKSFCSSL; VSKKSFCSSLQ; SKKSFCSSLQF;KKSFCSSLQFL; GYRRYIIPNNM; YRRYIIPNNMP; RRYIIPNNMPQ; RYIIPNNMPQS;YIIPNNMPQSL; IIPNNMPQSLG; IPNNMPQSLGN; PNNMPQSLGNS; NNMPQSLGNSS;NMPQSLGNSSK; MPQSLGNSSKQ; PQSLGNSSKQR; QSLGNSSKQRR; SLGNSSKQRRT;LGNSSKQRRTP; GNSSKQRRTPM; NSSKQRRTPMP; SSKQRRTPMPR; SKQRRTPMPRI;KQRRTPMPRIK; QRRTPMPRIKV; RRTPMPRIKVL; RTPMPRIKVLN; TPMPRIKVLNI;PMPRIKVLNII; MPRIKVLNIIN; PRIKVLNIINK; RIKVLNIINKS; IKVLNIINKSI;KVLNIINKSIY; VLNIINKSIYT; LNIINKSIYTR; NIINKSIYTRK; IINKSIYTRKQ;INKSIYTRKQN; NKSIYTRKQNI; KSIYTRKQNII; SIYTRKQNIIV; IYTRKQNIIVL;YTRKQNIIVLI; TRKQNIIVLIW; RKQNIIVLIWV; KQNIIVLIWVK; QNIIVLIWVKQ;NIIVLIWVKQF; IIVLIWVKQFQ; IVLIWVKQFQS; VLIWVKQFQSH; LIWVKQFQSHA;LLIEAYSGNFV; LIEAYSGNFVI; IEAYSGNFVIP; EAYSGNFVIPI; AYSGNFVIPII;YSGNFVIPIIK; SGNFVIPIIKE; GNFVIPIIKEL; NFVIPIIKELI; FVIPIIKELIP;VIPIIKELIPY; IPIIKELIPYL; PIIKELIPYLS; SSKPSNSPRST; SKPSNSPRSTS;KPSNSPRSTSN; PSNSPRSTSNY; SNSPRSTSNYS; NSPRSTSNYSI; SPRSTSNYSIC;PRSTSNYSICL; RSTSNYSICLR; STSNYSICLRS; GTCYALYSSKG; TCYALYSSKGC;CYALYSSKGCN; YALYSSKGCNL; ALYSSKGCNLN; LYSSKGCNLNF; YSSKGCNLNFY;SSKGCNLNFYS; SKGCNLNFYSS; KGCNLNFYSSS; GCNLNFYSSSS; CNLNFYSSSSL;NLNFYSSSSLP; LNFYSSSSLPS; NFYSSSSLPSS; FYSSSSLPSSN; YSSSSLPSSNF;SSSSLPSSNFS; SSSLPSSNFSH; KSCGSSSLRYT; SCGSSSLRYTG; CGSSSLRYTGN;SSTHEPGNTKK; STHEPGNTKKK; THEPGNTKKKG; HEPGNTKKKGL; EPGNTKKKGLL;PGNTKKKGLLT; ESFTESFTAGK; SFTESFTAGKA; FTESFTAGKAV; TESFTAGKAVV;ESFTAGKAVVL; SFTAGKAVVLL; FTAGKAVVLLF; TAGKAVVLLFF; AGKAVVLLFFP;GKAVVLLFFPS; KAVVLLFFPST; AVVLLFFPSTL; VVLLFFPSTLS; VLLFFPSTLSS;LLFFPSTLSSP; LFFPSTLSSPL; FFPSTLSSPLQ; FPSTLSSPLQN; PSTLSSPLQNS;STLSSPLQNSS; TLSSPLQNSSK; LSSPLQNSSKS; SSPLQNSSKSS; SPLQNSSKSSK;PLQNSSKSSKI; LQNSSKSSKIK; QNSSKSSKIKI; NSSKSSKIKIK; SSKSSKIKIKI;SKSSKIKIKIL; ALFFVPVQVLP; LFFVPVQVLPT; FFVPVQVLPTF; FVPVQVLPTFT;VPVQVLPTFTE; PVQVLPTFTEA; VQVLPTFTEAC; QVLPTFTEACR; VLPTFTEACRD;LPTFTEACRDS; PTFTEACRDSW; TFTEACRDSWR; FTEACRDSWRR; TEACRDSWRRT;EACRDSWRRTM; ACRDSWRRTMA; CRDSWRRTMAF; RDSWRRTMAFV; DSWRRTMAFVQ;SWRRTMAFVQF; WRRTMAFVQFN; RRTMAFVQFNW; RTMAFVQFNWG; TMAFVQFNWGQ;MAFVQFNWGQG; AFVQFNWGQGQ; FVQFNWGQGQD; VQFNWGQGQDS; ARKTCLSCTFL;RKTCLSCTFLP; KTCLSCTFLPE; TCLSCTFLPEV; CLSCTFLPEVM; LSCTFLPEVMV;SCTFLPEVMVW; CTFLPEVMVWL; TFLPEVMVWLH; FLPEVMVWLHS; LPEVMVWLHSM;PEVMVWLHSMG; EVMVWLHSMGK; VMVWLHSMGKQ; MVWLHSMGKQL; VWLHSMGKQLL;WLHSMGKQLLP; LHSMGKQLLPV; HSMGKQLLPVS; SMGKQLLPVSH; MGKQLLPVSHA;GKQLLPVSHAL; KQLLPVSHALS; QLLPVSHALSF; LLPVSHALSFL; LPVSHALSFLR;PVSHALSFLRS; VSHALSFLRSW; SHALSFLRSWF; HALSFLRSWFG; ALSFLRSWFGC;LSFLRSWFGCI; SFLRSWFGCIP; FLRSWFGCIPL; AAPPCGLFFYN; APPCGLFFYNI;EAEAASASTLS; AEAASASTLSL; EAASASTLSLK; GLAKLFGEIPI; LAKLFGEIPIL;AKLFGEIPILL; KLFGEIPILLQ; LFGEIPILLQF; FGEIPILLQFL; GEIPILLQFLQBK virus complementary reading frame 2 8 mers:WIKFLTGK; IKFLTGKN; KFLTGKNP; FLTGKNPW; LTGKNPWS; TGKNPWSS; GKNPWSSW;KNPWSSWT; NPWSSWTF; ALKELPGE; LKELPGEI; KELPGEIF; ELPGEIFP; GSVRNFTL;SVRNFTLT; VRNFTLTK; RNFTLTKG; NFTLTKGA; FTLTKGAT; TLTKGATR; LTKGATRI;TKGATRIK; ILCIKKWS; LCIKKWSR; CIKKWSRM; LISLILEP; ISLILEPG; SLILEPGV;LILEPGVA; ILEPGVAQ; LEPGVAQR; EPGVAQRF; PGVAQRFV; GVAQRFVL; VAQRFVLI;AQRFVLIF; QRFVLIFL; RFVLIFLF; FVLIFLFA; VLIFLFAQ; LIFLFAQI; IFLFAQIP;FLFAQIPC; LFAQIPCT; FAQIPCTA; AQIPCTAR; QIPCTARN; IPCTARNG; PCTARNGL;CTARNGLF; TARNGLFV; ARNGLFVP; RNGLFVPK; NGLFVPKS; GLFVPKSL; LFVPKSLL;FVPKSLLC; VPKSLLCT; PKSLLCTA; KSLLCTAL; SLLCTALA; LLCTALAC; LCTALACY;CTALACYV; TALACYVS; ALACYVSL; LACYVSLD; IATALTAS; ATALTASH; TALTASHS;ALTASHSG; LTASHSGL; TASHSGLA; LKKLCNGG; KKLCNGGS; KLCNGGSK; LEKLPSEI;SFKVTNLY; FKVTNLYL; KVTNLYLD; VTNLYLDK; VIIFFIGA; IIFFIGAN; IFFIGANL;FFIGANLW; FIGANLWN; IGANLWNR; GANLWNRR; ANLWNRRV; NLWNRRVG; LWNRRVGV;WNRRVGVL; NRRVGVLV; RRVGVLVE; RVGVLVEF; VGVLVEFL; RSNSRFST; SNSRFSTL;NSRFSTLN; SRFSTLNT; RFSTLNTT; FSTLNTTQ; STLNTTQK; TLNTTQKK; LNTTQKKK;NTTQKKKK; TTQKKKKG; TQKKKKGR; QKKKKGRR; KKKKGRRP; NPCLLCCV; PCLLCCVY;CLLCCVYY; KTYGKIFC; TYGKIFCN; YGKIFCNF; GKIFCNFY; YYILFNST; FLSKAVYL;RSIPYYRR; SIPYYRRK; IPYYRRKH; PYYRRKHS; YYRRKHSR; YRRKHSRG; RRKHSRGL;RKHSRGLK; KHSRGLKG; HSRGLKGA; RNKAGVLE; NKAGVLEI; KAGVLEIN; AGVLEINY;GCVFIIRY; CVFIIRYV; VFIIRYVF; FIIRYVFR; IIRYVFRI; IRYVFRIS; RYVFRISI;YVFRISIQ; VFRISIQC; FRISIQCR; RISIQCRG; ISIQCRGV; KVSEKRPA; VSEKRPAL;SEKRPALS; EKRPALSL; KALCKCYY; ALCKCYYF; LCKCYYFC; CKCYYFCR; KCYYFCRK;KSKKYLSA; SKKYLSAS; KKYLSASS; KYLSASSR; YLSASSRY; LSASSRYS; SASSRYSF;ASSRYSFS; KKSRYPSY; KSRYPSYD; SRYPSYDQ; RYPSYDQG; YPSYDQGR; PSYDQGRN;SYDQGRNA; YDQGRNAN; DQGRNANR; QGRNANRK; GRNANRKI; RNANRKIQ; NANRKIQS;ANRKIQSY; NRKIQSYI; RKIQSYIR; NGFNIWSS; GFNIWSSW; FNIWSSWK; NIWSSWKC;IWSSWKCC; WSSWKCCT; SSWKCCTR; SWKCCTRT; WKCCTRTI; KCCTRTIY; CCTRTIYG;CTRTIYGR; TRTIYGRC; RTIYGRCC; TIYGRCCL; IYGRCCLA; YGRCCLAA; GRCCLAAL;RCCLAALF; CCLAALFA; CLAALFAT; FFALYCFQ; FALYCFQC; ALYCFQCT; WKNNTSCR;KNNTSCRV; NNTSCRVI; NTSCRVIR; TSCRVIRF; SCRVIRFV; CRVIRFVW; RVIRFVWW;SLKCKPTH; LKCKPTHG; KCKPTHGK; CKPTHGKA; KPTHGKAN; PTHGKANL; ARCSYRSV;RCSYRSVH; CSYRSVHG; SYRSVHGC; YRSVHGCF; IKGFAFRT; KGFAFRTW; GFAFRTWN;FAFRTWNK; AFRTWNKQ; FRTWNKQF; RTWNKQFR; TWNKQFRQ; WNKQFRQF; NKQFRQFE;KQFRQFER; QFRQFERL; FRQFERLF; RQFERLFR; QFERLFRW; FERLFRWK; ERLFRWKC;GKFRKETF; KFRKETFK; FRKETFKQ; RKETFKQK; KETFKQKN; ETFKQKNP; TFKQKNPN;FKQKNPNI; KQKNPNIS; QKNPNIST; KNPNISTR; NPNISTRL; PNISTRLG; NISTRLGY;ISTRLGYN; STRLGYNE; AQNIFKKI; QNIFKKIL; NIFKKILT; IFKKILTK; FKKILTKL;KKILTKLR; KILTKLRV; ILTKLRVL; LTKLRVLT; KKNFTKWN; KNFTKWND; NFTKWNDL;FTKWNDLV; TKWNDLVA; KWNDLVAT; WNDLVATA; NDLVATAN; DLVATANL; LVATANLV;DKYVYFFK; KYVYFFKD; YVYFFKDE; VYFFKDEI; YMHGEMYS; YYKRRGFR; YKRRGFRN;RLWTWIKH; IPITMLFP; PITMLFPS; ITMLFPSL; TMLFPSLR; MLFPSLRY; LFPSLRYF;FPSLRYFS; PSLRYFSP; SLRYFSPC; RFPKVRPP; NTTPKITQ; TTPKITQA; KWLIQKQH;WLIQKQHL; LIQKQHLL; IQKQHLLN; QKQHLLNV; KQHLLNVY; QHLLNVYV; HLLNVYVQ;KHLFKAFW; HLFKAFWF; LFKAFWFA; FKAFWFAI; KAFWFAIV; AFWFAIVP; FWFAIVPV;WFAIVPVC; FAIVPVCQ; AIVPVCQY; IVPVCQYI; VPVCQYIL; PVCQYILS; VCQYILSY;CQYILSYL; QYILSYLG; YILSYLGP; ILSYLGPL; LSYLGPLE; SYLGPLEV; YLGPLEVF;LGPLEVFL; GPLEVFLC; PLEVFLCH; LEVFLCHQ; EVFLCHQT; VFLCHQTP; PLLPGIPY;LLPGIPYH; LPGIPYHT; AAHPLSGF; AHPLSGFS; HPLSGFSC; PLSGFSCL; GHLAKRKL;HLAKRKLG; LAKRKLGK; AKRKLGKD; KRKLGKDS; RKLGKDSL; KLGKDSLQ; LGKDSLQI;GKDSLQIF; KDSLQIFF; DSLQIFFS; SLQIFFSG; LQIFFSGG; QIFFSGGS; NILQGLST;ILQGLSTV; LQGLSTVV; QGLSTVVF; GLSTVVFQ; LSTVVFQS; STVVFQSC; TGHKYQQL;GHKYQQLK; HKYQQLKH; KYQQLKHT; YQQLKHTG; QQLKHTGY; QLKHTGYQ; LKHTGYQL;KHTGYQLY; HTGYQLYK; TGYQLYKE; GYQLYKEA; YQLYKEAP; QLYKEAPH; LYKEAPHP;YKEAPHPV; KEAPHPVH; EAPHPVHL; APHPVHLA; PHPVHLAT; HPVHLATL; PVHLATLW;LCWSHEVL; CWSHEVLG; WSHEVLGE; SHEVLGEH; HEVLGEHF; EVLGEHFP; VLGEHFPL;LGEHFPLL; HFHFYWDQ; FHFYWDQV; HFYWDQVP; FYWDQVPS; YWDQVPST; WDQVPSTQ;DQVPSTQL; QVPSTQLD; VPSTQLDK; PSTQLDKH; STQLDKHC; TQLDKHCF; QLDKHCFC;LDKHCFCP; DKHCFCPN; KHCFCPNR; HCFCPNRP; CFCPNRPY; FCPNRPYG; CPNRPYGQ;PNRPYGQY; NRPYGQYS; RPYGQYSL; PYGQYSLP; YGQYSLPG; GQYSLPGT; QYSLPGTG;YSLPGTGL; SLPGTGLL; LPGTGLLG; PGTGLLGF; YHQGTLTC; HQGTLTCN; QGTLTCNS;GTLTCNSL; TLTCNSLA; LTCNSLAL; TCNSLALP; CNSLALPA; NSLALPAF; SLALPAFP;LALPAFPR; ALPAFPRV; LPAFPRVL; PAFPRVLH; AFPRVLHL; FPRVLHLQ; PRVLHLQQ;RVLHLQQR; VLHLQQRS; LHLQQRSG; HLQQRSGN; LQQRSGNY; QQRSGNYC; QRSGNYCL;RSGNYCLE; VFLHHAHA; FLHHAHAL; LHHAHALF; HHAHALFV; HAHALFVT; AHALFVTL;HALFVTLH; ALFVTLHE; LFVTLHEG; PLFVQLQP; LFVQLQPP; FVQLQPPT; VQLQPPTS;QLQPPTSV; LQPPTSVD; QPPTSVDF; PPTSVDFH; PTSVDFHR; TSVDFHRL; SVDFHRLG;VDFHRLGP; DFHRLGPH; FHRLGPHL; HRLGPHLN; RLGPHLNW; LGPHLNWG; GPHLNWGG;PHLNWGGE; HLNWGGEF; LNWGGEFL; NWGGEFLL; WGGEFLLC; GGEFLLCC; GEFLLCCN;EFLLCCNR; FLLCCNRE; LLCCNREA; LCCNREAF; CCNREAFF; CNREAFFS; NREAFFSL;REAFFSLG; EAFFSLGY; AFFSLGYH; FFSLGYHC; SHFQHLAL; HFQHLALD; GFHLDPPF;FHLDPPFL; HLDPPFLG; LDPPFLGL; DPPFLGLG; PPFLGLGS; PFLGLGSI; FLGLGSIL;LGLGSILP; GLGSILPL; LLELLLLL; LELLLLLL; ELLLLLLL; LLLLLLLV; LLLLLLVV;LLLLLVVL; LLLLVVLA; LLLVVLAL; LLVVLALA; LVVLALAR; VVLALARV; VLALARVP;LALARVPL; ALARVPLA; LARVPLAF; ARVPLAFW; RVPLAFWE; VPLAFWEL; PLAFWELP;LAFWELPL; AFWELPLD; FWELPLDT; WELPLDTL; ELPLDTLL; LPLDTLLF; PLDTLLFF;LDTLLFFW; DTLLFFWL; TLLFFWLG; LLFFWLGP; LFFWLGPS; FFWLGPSS; FWLGPSSY;WLGPSSYA; LGPSSYAS; GPSSYASR; PSSYASRA; SSYASRAG; SYASRAGV; YASRAGVT;ASRAGVTV; SRAGVTVP; RAGVTVPY; AGVTVPYR; GVTVPYRP; VTVPYRPR; TVPYRPRS;VPYRPRSK; PYRPRSKG; YRPRSKGN; RPRSKGNI; PRSKGNIH; LAPPGAIV; APPGAIVF;PPGAIVFS; PGAIVFSI; GAIVFSIN; AIVFSINS; IVFSINSP; VFSINSPE; FSINSPEC;SINSPECT; INSPECTL; NSPECTLC; FLKSILCV; LKSILCVT; KSILCVTS; SILCVTSS;ILCVTSSI; LCVTSSIL; CVTSSILS; VTSSILSA; TSSILSAS; SSILSASS; SILSASSI;ILSASSIL; VWPKCTRV; WPKCTRVP; PKCTRVPS; KCTRVPSL; CTRVPSLS; TRVPSLSA;RVPSLSAT; VPSLSATC; PSLSATCL; SLSATCLT; LSATCLTI; SATCLTIE; ATCLTIEG;TCLTIEGL; CLTIEGLI; LTIEGLIG; TIEGLIGE; IEGLIGER; EGLIGERS; GLIGERSE;KFIGAFTI; FIGAFTIV; IGAFTIVQ; GAFTIVQV; AFTIVQVV; FTIVQVVS; TIVQVVSS;IVQVVSSK; VQVVSSKN; QVVSSKNL; VVSSKNLA; VSSKNLAK; SSKNLAKE; SKNLAKES;KNLAKESL; NLAKESLK; LAKESLKN; AKESLKNL; KESLKNLS; ESLKNLSV; SLKNLSVL;LKNLSVLL; KNLSVLLC; NLSVLLCN; LSVLLCNS; SVLLCNSC; VLLCNSCE; LLCNSCEV;LCNSCEVI; CNSCEVIE; NSCEVIEG; SCEVIEGI; CEVIEGIS; EVIEGISS; VIEGISSL;IEGISSLI; EGISSLIT; GISSLITC; ISSLITCH; SSLITCHK; SLITCHKA; LITCHKAW;ITCHKAWE; TCHKAWEI; CHKAWEIV; HKAWEIVA; KAWEIVAN; AWEIVANK; WEIVANKE;EIVANKEG; IVANKEGP; VANKEGPQ; ANKEGPQC; NKEGPQCL; KEGPQCLG; EGPQCLGS;GPQCLGSR; PQCLGSRY; ILLTKVFT; LLTKVFTP; LTKVFTPG; TKVFTPGN; KVFTPGNR;VFTPGNRI; FTPGNRIS; YSSGLNNS; SSGLNNSK; SGLNNSKA; GLNNSKAM; LNNSKAMP;NNSKAMPD; NSKAMPDC; SQSSKNLY; QSSKNLYP; SSKNLYPT; AKELIPLT; KELIPLTV;IKAANPAI; KAANPAIA; AANPAIAP; ANPAIAPG; NPAIAPGA; PAIAPGAP; AIAPGAPA;IAPGAPAI; APGAPAIT; PGAPAITA; GAPAITAY; APAITAYV; GVRPIAAI; VRPIAAIA;RPIAAIAS; PIAAIASE; IAAIASEV; AAIASEVL; AIASEVLV; IASEVLVM; ASEVLVMP;SEVLVMPS; EVLVMPST; VLVMPSTV; LVMPSTVA; VMPSTVAR; MPSTVARD; PSTVARDA;STVARDAI; TSIAAAAS; SIAAAASP; IAAAASPA; AAAASPAA; AAASPAAI; AASPAAIS;ASPAAISA; SPAAISAT; PAAISATE; AAISATEN; AISATENP; ISATENPV; SATENPVA;ATENPVAA; TENPVAAA; ENPVAAAA; NPVAAAAS; PVAAAASD; VAAAASDT; AAAASDTL;AAASDTLA; AASDTLAT; ASDTLATR; SDTLATRS; DTLATRSP; TLATRSPK; LATRSPKS;ATRSPKSA; TRSPKSAR; RSPKSARA; SPKSARAA; PKSARAAP; KSARAAPM; SARAAPMN;ARAAPMNL; RAAPMNLE; AAPMNLEI; APMNLEIQ; PMNLEIQK; MNLEIQKK; NLEIQKKR;LEIQKKRD; EIQKKRDY; IQKKRDYL; QKKRDYLP; KKRDYLPR; KRDYLPRS; RDYLPRSL;DYLPRSLL; YLPRSLLQ; LPRSLLQS; PRSLLQSL; RSLLQSLL; SLLQSLLQ; LLQSLLQQ;LQSLLQQV; QSLLQQVK; SLLQQVKQ; LLQQVKQW; LQQVKQWY; QQVKQWYF; QVKQWYFC;VKQWYFCF; KQWYFCFS; QWYFCFSR; WYFCFSRL; YFCFSRLH; FCFSRLHC; CFSRLHCL;FSRLHCLH; SRLHCLHL; RLHCLHLY; LHCLHLYK; HCLHLYKI; CLHLYKIP; LHLYKIPA;HLYKIPAK; LYKIPAKA; YKIPAKAL; KIPAKALK; KSSELFFL; SSELFFLF; SELFFLFQ;ELFFLFQS; LFFLFQSR; FFLFQSRF; FLFQSRFY; LFQSRFYQ; FQSRFYQL; QSRFYQLS;SRFYQLSL; RFYQLSLK; FYQLSLKL; YQLSLKLV; QLSLKLVV; LSLKLVVT; SLKLVVTA;LKLVVTAG; KLVVTAGA; LVVTAGAE; VVTAGAEP; VTAGAEPW; TAGAEPWP; AGAEPWPL;GAEPWPLS; AEPWPLSS; EPWPLSSL; PWPLSSLT; WPLSSLTG; PLSSLTGD; LSSLTGDK;SSLTGDKA; SLTGDKAK; LTGDKAKI; TGDKAKIP; GDKAKIPR; DKAKIPRL; KAKIPRLA;AKIPRLAK; KIPRLAKH; IPRLAKHV; PRLAKHVC; RLAKHVCH; LAKHVCHA; AKHVCHAL;KHVCHALS; HVCHALSF; VCHALSFL; CHALSFLR; HALSFLRS; ALSFLRSW; LSFLRSWF;SFLRSWFG; FLRSWFGC; LRSWFGCI; RSWFGCIP; SWFGCIPW; WFGCIPWV; FGCIPWVS;GCIPWVSS; CIPWVSSS; IPWVSSSS; PWVSSSSL; GHGLAAFP; HGLAAFPC; GLAAFPCE;LAAFPCES; AAFPCESC; AFPCESCT; FPCESCTF; PCESCTFL; CESCTFLP; ESCTFLPE;SCTFLPEV; CTFLPEVM; TFLPEVMV; FLPEVMVW; LPEVMVWL; PEVMVWLH; EVMVWLHS;VMVWLHSM; MVWLHSMG; VWLHSMGK; WLHSMGKQ; LHSMGKQL; HSMGKQLL; SMGKQLLP;MGKQLLPV; GKQLLPVA; KQLLPVAF; QLLPVAFF; LLPVAFFF; LPVAFFFI; PVAFFFII;VAFFFIIY; AFFFIIYK; FFFIIYKR; FFIIYKRP; FIIYKRPR; IIYKRPRP; IYKRPRPP;YKRPRPPL; KRPRPPLP; RPRPPLPP; PRPPLPPP; RPPLPPPF; PPLPPPFL; PLPPPFLS;LPPPFLSS; PPPFLSSS; PPFLSSSK; PFLSSSKG; FLSSSKGV; LSSSKGVE; SSSKGVEA;SSKGVEAF; SKGVEAFS; KGVEAFSE; GVEAFSEA; QNYLGKSL; NYLGKSLF; YLGKSLFF;LGKSLFFC; GKSLFFCN; KSLFFCNF; SLFFCNFC; LFFCNFCK 9 mers:WIKFLTGKN; IKFLTGKNP; KFLTGKNPW; FLTGKNPWS; LTGKNPWSS; TGKNPWSSW;GKNPWSSWT; KNPWSSWTF; ALKELPGEI; LKELPGEIF; KELPGEIFP; GSVRNFTLT;SVRNFTLTK; VRNFTLTKG; RNFTLTKGA; NFTLTKGAT; FTLTKGATR; TLTKGATRI;LTKGATRIK; ILCIKKWSR; LCIKKWSRM; LISLILEPG; ISLILEPGV; SLILEPGVA;LILEPGVAQ; ILEPGVAQR; LEPGVAQRF; EPGVAQRFV; PGVAQRFVL; GVAQRFVLI;VAQRFVLIF; AQRFVLIFL; QRFVLIFLF; RFVLIFLFA; FVLIFLFAQ; VLIFLFAQI;LIFLFAQIP; IFLFAQIPC; FLFAQIPCT; LFAQIPCTA; FAQIPCTAR; AQIPCTARN;QIPCTARNG; IPCTARNGL; PCTARNGLF; CTARNGLFV; TARNGLFVP; ARNGLFVPK;RNGLFVPKS; NGLFVPKSL; GLFVPKSLL; LFVPKSLLC; FVPKSLLCT; VPKSLLCTA;PKSLLCTAL; KSLLCTALA; SLLCTALAC; LLCTALACY; LCTALACYV; CTALACYVS;TALACYVSL; ALACYVSLD; IATALTASH; ATALTASHS; TALTASHSG; ALTASHSGL;LTASHSGLA; LKKLCNGGS; KKLCNGGSK; SFKVTNLYL; FKVTNLYLD; KVTNLYLDK;VIIFFIGAN; IIFFIGANL; IFFIGANLW; FFIGANLWN; FIGANLWNR; IGANLWNRR;GANLWNRRV; ANLWNRRVG; NLWNRRVGV; LWNRRVGVL; WNRRVGVLV; NRRVGVLVE;RRVGVLVEF; RVGVLVEFL; RSNSRFSTL; SNSRFSTLN; NSRFSTLNT; SRFSTLNTT;RFSTLNTTQ; FSTLNTTQK; STLNTTQKK; TLNTTQKKK; LNTTQKKKK; NTTQKKKKG;TTQKKKKGR; TQKKKKGRR; QKKKKGRRP; NPCLLCCVY; PCLLCCVYY; KTYGKIFCN;TYGKIFCNF; YGKIFCNFY; RSIPYYRRK; SIPYYRRKH; IPYYRRKHS; PYYRRKHSR;YYRRKHSRG; YRRKHSRGL; RRKHSRGLK; RKHSRGLKG; KHSRGLKGA; RNKAGVLEI;NKAGVLEIN; KAGVLEINY; GCVFIIRYV; CVFIIRYVF; VFIIRYVFR; FIIRYVFRI;IIRYVFRIS; IRYVFRISI; RYVFRISIQ; YVFRISIQC; VFRISIQCR; FRISIQCRG;RISIQCRGV; KVSEKRPAL; VSEKRPALS; SEKRPALSL; KALCKCYYF; ALCKCYYFC;LCKCYYFCR; CKCYYFCRK; KSKKYLSAS; SKKYLSASS; KKYLSASSR; KYLSASSRY;YLSASSRYS; LSASSRYSF; SASSRYSFS; KKSRYPSYD; KSRYPSYDQ; SRYPSYDQG;RYPSYDQGR; YPSYDQGRN; PSYDQGRNA; SYDQGRNAN; YDQGRNANR; DQGRNANRK;QGRNANRKI; GRNANRKIQ; RNANRKIQS; NANRKIQSY; ANRKIQSYI; NRKIQSYIR;NGFNIWSSW; GFNIWSSWK; FNIWSSWKC; NIWSSWKCC; IWSSWKCCT; WSSWKCCTR;SSWKCCTRT; SWKCCTRTI; WKCCTRTIY; KCCTRTIYG; CCTRTIYGR; CTRTIYGRC;TRTIYGRCC; RTIYGRCCL; TIYGRCCLA; IYGRCCLAA; YGRCCLAAL; GRCCLAALF;RCCLAALFA; CCLAALFAT; FFALYCFQC; FALYCFQCT; WKNNTSCRV; KNNTSCRVI;NNTSCRVIR; NTSCRVIRF; TSCRVIRFV; SCRVIRFVW; CRVIRFVWW; SLKCKPTHG;LKCKPTHGK; KCKPTHGKA; CKPTHGKAN; KPTHGKANL; ARCSYRSVH; RCSYRSVHG;CSYRSVHGC; SYRSVHGCF; IKGFAFRTW; KGFAFRTWN; GFAFRTWNK; FAFRTWNKQ;AFRTWNKQF; FRTWNKQFR; RTWNKQFRQ; TWNKQFRQF; WNKQFRQFE; NKQFRQFER;KQFRQFERL; QFRQFERLF; FRQFERLFR; RQFERLFRW; QFERLFRWK; FERLFRWKC;GKFRKETFK; KFRKETFKQ; FRKETFKQK; RKETFKQKN; KETFKQKNP; ETFKQKNPN;TFKQKNPNI; FKQKNPNIS; KQKNPNIST; QKNPNISTR; KNPNISTRL; NPNISTRLG;PNISTRLGY; NISTRLGYN; ISTRLGYNE; AQNIFKKIL; QNIFKKILT; NIFKKILTK;IFKKILTKL; FKKILTKLR; KKILTKLRV; KILTKLRVL; ILTKLRVLT; KKNFTKWND;KNFTKWNDL; NFTKWNDLV; FTKWNDLVA; TKWNDLVAT; KWNDLVATA; WNDLVATAN;NDLVATANL; DLVATANLV; DKYVYFFKD; KYVYFFKDE; YVYFFKDEI; YYKRRGFRN;IPITMLFPS; PITMLFPSL; ITMLFPSLR; TMLFPSLRY; MLFPSLRYF; LFPSLRYFS;FPSLRYFSP; PSLRYFSPC; NTTPKITQA; KWLIQKQHL; WLIQKQHLL; LIQKQHLLN;IQKQHLLNV; QKQHLLNVY; KQHLLNVYV; QHLLNVYVQ; KHLFKAFWF; HLFKAFWFA;LFKAFWFAI; FKAFWFAIV; KAFWFAIVP; AFWFAIVPV; FWFAIVPVC; WFAIVPVCQ;FAIVPVCQY; AIVPVCQYI; IVPVCQYIL; VPVCQYILS; PVCQYILSY; VCQYILSYL;CQYILSYLG; QYILSYLGP; YILSYLGPL; ILSYLGPLE; LSYLGPLEV; SYLGPLEVF;YLGPLEVFL; LGPLEVFLC; GPLEVFLCH; PLEVFLCHQ; LEVFLCHQT; EVFLCHQTP;PLLPGIPYH; LLPGIPYHT; AAHPLSGFS; AHPLSGFSC; HPLSGFSCL; GHLAKRKLG;HLAKRKLGK; LAKRKLGKD; AKRKLGKDS; KRKLGKDSL; RKLGKDSLQ; KLGKDSLQI;LGKDSLQIF; GKDSLQIFF; KDSLQIFFS; DSLQIFFSG; SLQIFFSGG; LQIFFSGGS;NILQGLSTV; ILQGLSTVV; LQGLSTVVF; QGLSTVVFQ; GLSTVVFQS; LSTVVFQSC;TGHKYQQLK; GHKYQQLKH; HKYQQLKHT; KYQQLKHTG; YQQLKHTGY; QQLKHTGYQ;QLKHTGYQL; LKHTGYQLY; KHTGYQLYK; HTGYQLYKE; TGYQLYKEA; GYQLYKEAP;YQLYKEAPH; QLYKEAPHP; LYKEAPHPV; YKEAPHPVH; KEAPHPVHL; EAPHPVHLA;APHPVHLAT; PHPVHLATL; HPVHLATLW; LCWSHEVLG; CWSHEVLGE; WSHEVLGEH;SHEVLGEHF; HEVLGEHFP; EVLGEHFPL; VLGEHFPLL; HFHFYWDQV; FHFYWDQVP;HFYWDQVPS; FYWDQVPST; YWDQVPSTQ; WDQVPSTQL; DQVPSTQLD; QVPSTQLDK;VPSTQLDKH; PSTQLDKHC; STQLDKHCF; TQLDKHCFC; QLDKHCFCP; LDKHCFCPN;DKHCFCPNR; KHCFCPNRP; HCFCPNRPY; CFCPNRPYG; FCPNRPYGQ; CPNRPYGQY;PNRPYGQYS; NRPYGQYSL; RPYGQYSLP; PYGQYSLPG; YGQYSLPGT; GQYSLPGTG;QYSLPGTGL; YSLPGTGLL; SLPGTGLLG; LPGTGLLGF; YHQGTLTCN; HQGTLTCNS;QGTLTCNSL; GTLTCNSLA; TLTCNSLAL; LTCNSLALP; TCNSLALPA; CNSLALPAF;NSLALPAFP; SLALPAFPR; LALPAFPRV; ALPAFPRVL; LPAFPRVLH; PAFPRVLHL;AFPRVLHLQ; FPRVLHLQQ; PRVLHLQQR; RVLHLQQRS; VLHLQQRSG; LHLQQRSGN;HLQQRSGNY; LQQRSGNYC; QQRSGNYCL; QRSGNYCLE; VFLHHAHAL; FLHHAHALF;LHHAHALFV; HHAHALFVT; HAHALFVTL; AHALFVTLH; HALFVTLHE; ALFVTLHEG;PLFVQLQPP; LFVQLQPPT; FVQLQPPTS; VQLQPPTSV; QLQPPTSVD; LQPPTSVDF;QPPTSVDFH; PPTSVDFHR; PTSVDFHRL; TSVDFHRLG; SVDFHRLGP; VDFHRLGPH;DFHRLGPHL; FHRLGPHLN; HRLGPHLNW; RLGPHLNWG; LGPHLNWGG; GPHLNWGGE;PHLNWGGEF; HLNWGGEFL; LNWGGEFLL; NWGGEFLLC; WGGEFLLCC; GGEFLLCCN;GEFLLCCNR; EFLLCCNRE; FLLCCNREA; LLCCNREAF; LCCNREAFF; CCNREAFFS;CNREAFFSL; NREAFFSLG; REAFFSLGY; EAFFSLGYH; AFFSLGYHC; SHFQHLALD;GFHLDPPFL; FHLDPPFLG; HLDPPFLGL; LDPPFLGLG; DPPFLGLGS; PPFLGLGSI;PFLGLGSIL; FLGLGSILP; LGLGSILPL; LLELLLLLL; LELLLLLLL; ELLLLLLLV;LLLLLLLVV; LLLLLLVVL; LLLLLVVLA; LLLLVVLAL; LLLVVLALA; LLVVLALAR;LVVLALARV; VVLALARVP; VLALARVPL; LALARVPLA; ALARVPLAF; LARVPLAFW;ARVPLAFWE; RVPLAFWEL; VPLAFWELP; PLAFWELPL; LAFWELPLD; AFWELPLDT;FWELPLDTL; WELPLDTLL; ELPLDTLLF; LPLDTLLFF; PLDTLLFFW; LDTLLFFWL;DTLLFFWLG; TLLFFWLGP; LLFFWLGPS; LFFWLGPSS; FFWLGPSSY; FWLGPSSYA;WLGPSSYAS; LGPSSYASR; GPSSYASRA; PSSYASRAG; SSYASRAGV; SYASRAGVT;YASRAGVTV; ASRAGVTVP; SRAGVTVPY; RAGVTVPYR; AGVTVPYRP; GVTVPYRPR;VTVPYRPRS; TVPYRPRSK; VPYRPRSKG; PYRPRSKGN; YRPRSKGNI; RPRSKGNIH;LAPPGAIVF; APPGAIVFS; PPGAIVFSI; PGAIVFSIN; GAIVFSINS; AIVFSINSP;IVFSINSPE; VFSINSPEC; FSINSPECT; SINSPECTL; INSPECTLC; FLKSILCVT;LKSILCVTS; KSILCVTSS; SILCVTSSI; ILCVTSSIL; LCVTSSILS; CVTSSILSA;VTSSILSAS; TSSILSASS; SSILSASSI; SILSASSIL; VWPKCTRVP; WPKCTRVPS;PKCTRVPSL; KCTRVPSLS; CTRVPSLSA; TRVPSLSAT; RVPSLSATC; VPSLSATCL;PSLSATCLT; SLSATCLTI; LSATCLTIE; SATCLTIEG; ATCLTIEGL; TCLTIEGLI;CLTIEGLIG; LTIEGLIGE; TIEGLIGER; IEGLIGERS; EGLIGERSE; KFIGAFTIV;FIGAFTIVQ; IGAFTIVQV; GAFTIVQVV; AFTIVQVVS; FTIVQVVSS; TIVQVVSSK;IVQVVSSKN; VQVVSSKNL; QVVSSKNLA; VVSSKNLAK; VSSKNLAKE; SSKNLAKES;SKNLAKESL; KNLAKESLK; NLAKESLKN; LAKESLKNL; AKESLKNLS; KESLKNLSV;ESLKNLSVL; SLKNLSVLL; LKNLSVLLC; KNLSVLLCN; NLSVLLCNS; LSVLLCNSC;SVLLCNSCE; VLLCNSCEV; LLCNSCEVI; LCNSCEVIE; CNSCEVIEG; NSCEVIEGI;SCEVIEGIS; CEVIEGISS; EVIEGISSL; VIEGISSLI; IEGISSLIT; EGISSLITC;GISSLITCH; ISSLITCHK; SSLITCHKA; SLITCHKAW; LITCHKAWE; ITCHKAWEI;TCHKAWEIV; CHKAWEIVA; HKAWEIVAN; KAWEIVANK; AWEIVANKE; WEIVANKEG;EIVANKEGP; IVANKEGPQ; VANKEGPQC; ANKEGPQCL; NKEGPQCLG; KEGPQCLGS;EGPQCLGSR; GPQCLGSRY; ILLTKVFTP; LLTKVFTPG; LTKVFTPGN; TKVFTPGNR;KVFTPGNRI; VFTPGNRIS; YSSGLNNSK; SSGLNNSKA; SGLNNSKAM; GLNNSKAMP;LNNSKAMPD; NNSKAMPDC; SQSSKNLYP; QSSKNLYPT; AKELIPLTV; IKAANPAIA;KAANPAIAP; AANPAIAPG; ANPAIAPGA; NPAIAPGAP; PAIAPGAPA; AIAPGAPAI;IAPGAPAIT; APGAPAITA; PGAPAITAY; GAPAITAYV; GVRPIAAIA; VRPIAAIAS;RPIAAIASE; PIAAIASEV; IAAIASEVL; AAIASEVLV; AIASEVLVM; IASEVLVMP;ASEVLVMPS; SEVLVMPST; EVLVMPSTV; VLVMPSTVA; LVMPSTVAR; VMPSTVARD;MPSTVARDA; PSTVARDAI; TSIAAAASP; SIAAAASPA; IAAAASPAA; AAAASPAAI;AAASPAAIS; AASPAAISA; ASPAAISAT; SPAAISATE; PAAISATEN; AAISATENP;AISATENPV; ISATENPVA; SATENPVAA; ATENPVAAA; TENPVAAAA; ENPVAAAAS;NPVAAAASD; PVAAAASDT; VAAAASDTL; AAAASDTLA; AAASDTLAT; AASDTLATR;ASDTLATRS; SDTLATRSP; DTLATRSPK; TLATRSPKS; LATRSPKSA; ATRSPKSAR;TRSPKSARA; RSPKSARAA; SPKSARAAP; PKSARAAPM; KSARAAPMN; SARAAPMNL;ARAAPMNLE; RAAPMNLEI; AAPMNLEIQ; APMNLEIQK; PMNLEIQKK; MNLEIQKKR;NLEIQKKRD; LEIQKKRDY; EIQKKRDYL; IQKKRDYLP; QKKRDYLPR; KKRDYLPRS;KRDYLPRSL; RDYLPRSLL; DYLPRSLLQ; YLPRSLLQS; LPRSLLQSL; PRSLLQSLL;RSLLQSLLQ; SLLQSLLQQ; LLQSLLQQV; LQSLLQQVK; QSLLQQVKQ; SLLQQVKQW;LLQQVKQWY; LQQVKQWYF; QQVKQWYFC; QVKQWYFCF; VKQWYFCFS; KQWYFCFSR;QWYFCFSRL; WYFCFSRLH; YFCFSRLHC; FCFSRLHCL; CFSRLHCLH; FSRLHCLHL;SRLHCLHLY; RLHCLHLYK; LHCLHLYKI; HCLHLYKIP; CLHLYKIPA; LHLYKIPAK;HLYKIPAKA; LYKIPAKAL; YKIPAKALK; KSSELFFLF; SSELFFLFQ; SELFFLFQS;ELFFLFQSR; LFFLFQSRF; FFLFQSRFY; FLFQSRFYQ; LFQSRFYQL; FQSRFYQLS;QSRFYQLSL; SRFYQLSLK; RFYQLSLKL; FYQLSLKLV; YQLSLKLVV; QLSLKLVVT;LSLKLVVTA; SLKLVVTAG; LKLVVTAGA; KLVVTAGAE; LVVTAGAEP; VVTAGAEPW;VTAGAEPWP; TAGAEPWPL; AGAEPWPLS; GAEPWPLSS; AEPWPLSSL; EPWPLSSLT;PWPLSSLTG; WPLSSLTGD; PLSSLTGDK; LSSLTGDKA; SSLTGDKAK; SLTGDKAKI;LTGDKAKIP; TGDKAKIPR; GDKAKIPRL; DKAKIPRLA; KAKIPRLAK; AKIPRLAKH;KIPRLAKHV; IPRLAKHVC; PRLAKHVCH; RLAKHVCHA; LAKHVCHAL; AKHVCHALS;KHVCHALSF; HVCHALSFL; VCHALSFLR; CHALSFLRS; HALSFLRSW; ALSFLRSWF;LSFLRSWFG; SFLRSWFGC; FLRSWFGCI; LRSWFGCIP; RSWFGCIPW; SWFGCIPWV;WFGCIPWVS; FGCIPWVSS; GCIPWVSSS; CIPWVSSSS; IPWVSSSSL; GHGLAAFPC;HGLAAFPCE; GLAAFPCES; LAAFPCESC; AAFPCESCT; AFPCESCTF; FPCESCTFL;PCESCTFLP; CESCTFLPE; ESCTFLPEV; SCTFLPEVM; CTFLPEVMV; TFLPEVMVW;FLPEVMVWL; LPEVMVWLH; PEVMVWLHS; EVMVWLHSM; VMVWLHSMG; MVWLHSMGK;VWLHSMGKQ; WLHSMGKQL; LHSMGKQLL; HSMGKQLLP; SMGKQLLPV; MGKQLLPVA;GKQLLPVAF; KQLLPVAFF; QLLPVAFFF; LLPVAFFFI; LPVAFFFII; PVAFFFIIY;VAFFFIIYK; AFFFIIYKR; FFFIIYKRP; FFIIYKRPR; FIIYKRPRP; IIYKRPRPP;IYKRPRPPL; YKRPRPPLP; KRPRPPLPP; RPRPPLPPP; PRPPLPPPF; RPPLPPPFL;PPLPPPFLS; PLPPPFLSS; LPPPFLSSS; PPPFLSSSK; PPFLSSSKG; PFLSSSKGV;FLSSSKGVE; LSSSKGVEA; SSSKGVEAF; SSKGVEAFS; SKGVEAFSE; KGVEAFSEA;QNYLGKSLF; NYLGKSLFF; YLGKSLFFC; LGKSLFFCN; GKSLFFCNF; KSLFFCNFC;SLFFCNFCK 10 mers:WIKFLTGKNP; IKFLTGKNPW; KFLTGKNPWS; FLTGKNPWSS; LTGKNPWSSW;TGKNPWSSWT; GKNPWSSWTF; ALKELPGEIF; LKELPGEIFP; GSVRNFTLTK;SVRNFTLTKG; VRNFTLTKGA; RNFTLTKGAT; NFTLTKGATR; FTLTKGATRI;TLTKGATRIK; ILCIKKWSRM; LISLILEPGV; ISLILEPGVA; SLILEPGVAQ;LILEPGVAQR; ILEPGVAQRF; LEPGVAQRFV; EPGVAQRFVL; PGVAQRFVLI;GVAQRFVLIF; VAQRFVLIFL; AQRFVLIFLF; QRFVLIFLFA; RFVLIFLFAQ;FVLIFLFAQI; VLIFLFAQIP; LIFLFAQIPC; IFLFAQIPCT; FLFAQIPCTA;LFAQIPCTAR; FAQIPCTARN; AQIPCTARNG; QIPCTARNGL; IPCTARNGLF;PCTARNGLFV; CTARNGLFVP; TARNGLFVPK; ARNGLFVPKS; RNGLFVPKSL;NGLFVPKSLL; GLFVPKSLLC; LFVPKSLLCT; FVPKSLLCTA; VPKSLLCTAL;PKSLLCTALA; KSLLCTALAC; SLLCTALACY; LLCTALACYV; LCTALACYVS;CTALACYVSL; TALACYVSLD; IATALTASHS; ATALTASHSG; TALTASHSGL;ALTASHSGLA; LKKLCNGGSK; SFKVTNLYLD; FKVTNLYLDK; VIIFFIGANL;IIFFIGANLW; IFFIGANLWN; FFIGANLWNR; FIGANLWNRR; IGANLWNRRV;GANLWNRRVG; ANLWNRRVGV; NLWNRRVGVL; LWNRRVGVLV; WNRRVGVLVE;NRRVGVLVEF; RRVGVLVEFL; RSNSRFSTLN; SNSRFSTLNT; NSRFSTLNTT;SRFSTLNTTQ; RFSTLNTTQK; FSTLNTTQKK; STLNTTQKKK; TLNTTQKKKK;LNTTQKKKKG; NTTQKKKKGR; TTQKKKKGRR; TQKKKKGRRP; NPCLLCCVYY;KTYGKIFCNF; TYGKIFCNFY; RSIPYYRRKH; SIPYYRRKHS; IPYYRRKHSR;PYYRRKHSRG; YYRRKHSRGL; YRRKHSRGLK; RRKHSRGLKG; RKHSRGLKGA;RNKAGVLEIN; NKAGVLEINY; GCVFIIRYVF; CVFIIRYVFR; VFIIRYVFRI;FIIRYVFRIS; IIRYVFRISI; IRYVFRISIQ; RYVFRISIQC; YVFRISIQCR;VFRISIQCRG; FRISIQCRGV; KVSEKRPALS; VSEKRPALSL; KALCKCYYFC;ALCKCYYFCR; LCKCYYFCRK; KSKKYLSASS; SKKYLSASSR; KKYLSASSRY;KYLSASSRYS; YLSASSRYSF; LSASSRYSFS; KKSRYPSYDQ; KSRYPSYDQG;SRYPSYDQGR; RYPSYDQGRN; YPSYDQGRNA; PSYDQGRNAN; SYDQGRNANR;YDQGRNANRK; DQGRNANRKI; QGRNANRKIQ; GRNANRKIQS; RNANRKIQSY;NANRKIQSYI; ANRKIQSYIR; NGFNIWSSWK; GFNIWSSWKC; FNIWSSWKCC;NIWSSWKCCT; IWSSWKCCTR; WSSWKCCTRT; SSWKCCTRTI; SWKCCTRTIY;WKCCTRTIYG; KCCTRTIYGR; CCTRTIYGRC; CTRTIYGRCC; TRTIYGRCCL;RTIYGRCCLA; TIYGRCCLAA; IYGRCCLAAL; YGRCCLAALF; GRCCLAALFA;RCCLAALFAT; FFALYCFQCT; WKNNTSCRVI; KNNTSCRVIR; NNTSCRVIRF;NTSCRVIRFV; TSCRVIRFVW; SCRVIRFVWW; SLKCKPTHGK; LKCKPTHGKA;KCKPTHGKAN; CKPTHGKANL; ARCSYRSVHG; RCSYRSVHGC; CSYRSVHGCF;IKGFAFRTWN; KGFAFRTWNK; GFAFRTWNKQ; FAFRTWNKQF; AFRTWNKQFR;FRTWNKQFRQ; RTWNKQFRQF; TWNKQFRQFE; WNKQFRQFER; NKQFRQFERL;KQFRQFERLF; QFRQFERLFR; FRQFERLFRW; RQFERLFRWK; QFERLFRWKC;GKFRKETFKQ; KFRKETFKQK; FRKETFKQKN; RKETFKQKNP; KETFKQKNPN;ETFKQKNPNI; TFKQKNPNIS; FKQKNPNIST; KQKNPNISTR; QKNPNISTRL;KNPNISTRLG; NPNISTRLGY; PNISTRLGYN; NISTRLGYNE; AQNIFKKILT;QNIFKKILTK; NIFKKILTKL; IFKKILTKLR; FKKILTKLRV; KKILTKLRVL;KILTKLRVLT; KKNFTKWNDL; KNFTKWNDLV; NFTKWNDLVA; FTKWNDLVAT;TKWNDLVATA; KWNDLVATAN; WNDLVATANL; NDLVATANLV; DKYVYFFKDE;KYVYFFKDEI; IPITMLFPSL; PITMLFPSLR; ITMLFPSLRY; TMLFPSLRYF;MLFPSLRYFS; LFPSLRYFSP; FPSLRYFSPC; KWLIQKQHLL; WLIQKQHLLN;LIQKQHLLNV; IQKQHLLNVY; QKQHLLNVYV; KQHLLNVYVQ; KHLFKAFWFA;HLFKAFWFAI; LFKAFWFAIV; FKAFWFAIVP; KAFWFAIVPV; AFWFAIVPVC;FWFAIVPVCQ; WFAIVPVCQY; FAIVPVCQYI; AIVPVCQYIL; IVPVCQYILS;VPVCQYILSY; PVCQYILSYL; VCQYILSYLG; CQYILSYLGP; QYILSYLGPL;YILSYLGPLE; ILSYLGPLEV; LSYLGPLEVF; SYLGPLEVFL; YLGPLEVFLC;LGPLEVFLCH; GPLEVFLCHQ; PLEVFLCHQT; LEVFLCHQTP; PLLPGIPYHT;AAHPLSGFSC; AHPLSGFSCL; GHLAKRKLGK; HLAKRKLGKD; LAKRKLGKDS;AKRKLGKDSL; KRKLGKDSLQ; RKLGKDSLQI; KLGKDSLQIF; LGKDSLQIFF;GKDSLQIFFS; KDSLQIFFSG; DSLQIFFSGG; SLQIFFSGGS; NILQGLSTVV;ILQGLSTVVF; LQGLSTVVFQ; QGLSTVVFQS; GLSTVVFQSC; TGHKYQQLKH;GHKYQQLKHT; HKYQQLKHTG; KYQQLKHTGY; YQQLKHTGYQ; QQLKHTGYQL;QLKHTGYQLY; LKHTGYQLYK; KHTGYQLYKE; HTGYQLYKEA; TGYQLYKEAP;GYQLYKEAPH; YQLYKEAPHP; QLYKEAPHPV; LYKEAPHPVH; YKEAPHPVHL;KEAPHPVHLA; EAPHPVHLAT; APHPVHLATL; PHPVHLATLW; LCWSHEVLGE;CWSHEVLGEH; WSHEVLGEHF; SHEVLGEHFP; HEVLGEHFPL; EVLGEHFPLL;HFHFYWDQVP; FHFYWDQVPS; HFYWDQVPST; FYWDQVPSTQ; YWDQVPSTQL;WDQVPSTQLD; DQVPSTQLDK; QVPSTQLDKH; VPSTQLDKHC; PSTQLDKHCF;STQLDKHCFC; TQLDKHCFCP; QLDKHCFCPN; LDKHCFCPNR; DKHCFCPNRP;KHCFCPNRPY; HCFCPNRPYG; CFCPNRPYGQ; FCPNRPYGQY; CPNRPYGQYS;PNRPYGQYSL; NRPYGQYSLP; RPYGQYSLPG; PYGQYSLPGT; YGQYSLPGTG;GQYSLPGTGL; QYSLPGTGLL; YSLPGTGLLG; SLPGTGLLGF; YHQGTLTCNS;HQGTLTCNSL; QGTLTCNSLA; GTLTCNSLAL; TLTCNSLALP; LTCNSLALPA;TCNSLALPAF; CNSLALPAFP; NSLALPAFPR; SLALPAFPRV; LALPAFPRVL;ALPAFPRVLH; LPAFPRVLHL; PAFPRVLHLQ; AFPRVLHLQQ; FPRVLHLQQR;PRVLHLQQRS; RVLHLQQRSG; VLHLQQRSGN; LHLQQRSGNY; HLQQRSGNYC;LQQRSGNYCL; QQRSGNYCLE; VFLHHAHALF; FLHHAHALFV; LHHAHALFVT;HHAHALFVTL; HAHALFVTLH; AHALFVTLHE; HALFVTLHEG; PLFVQLQPPT;LFVQLQPPTS; FVQLQPPTSV; VQLQPPTSVD; QLQPPTSVDF; LQPPTSVDFH;QPPTSVDFHR; PPTSVDFHRL; PTSVDFHRLG; TSVDFHRLGP; SVDFHRLGPH;VDFHRLGPHL; DFHRLGPHLN; FHRLGPHLNW; HRLGPHLNWG; RLGPHLNWGG;LGPHLNWGGE; GPHLNWGGEF; PHLNWGGEFL; HLNWGGEFLL; LNWGGEFLLC;NWGGEFLLCC; WGGEFLLCCN; GGEFLLCCNR; GEFLLCCNRE; EFLLCCNREA;FLLCCNREAF; LLCCNREAFF; LCCNREAFFS; CCNREAFFSL; CNREAFFSLG;NREAFFSLGY; REAFFSLGYH; EAFFSLGYHC; GFHLDPPFLG; FHLDPPFLGL;HLDPPFLGLG; LDPPFLGLGS; DPPFLGLGSI; PPFLGLGSIL; PFLGLGSILP;FLGLGSILPL; LLELLLLLLL; LELLLLLLLV; ELLLLLLLVV; LLLLLLLVVL;LLLLLLVVLA; LLLLLVVLAL; LLLLVVLALA; LLLVVLALAR; LLVVLALARV;LVVLALARVP; VVLALARVPL; VLALARVPLA; LALARVPLAF; ALARVPLAFW;LARVPLAFWE; ARVPLAFWEL; RVPLAFWELP; VPLAFWELPL; PLAFWELPLD;LAFWELPLDT; AFWELPLDTL; FWELPLDTLL; WELPLDTLLF; ELPLDTLLFF;LPLDTLLFFW; PLDTLLFFWL; LDTLLFFWLG; DTLLFFWLGP; TLLFFWLGPS;LLFFWLGPSS; LFFWLGPSSY; FFWLGPSSYA; FWLGPSSYAS; WLGPSSYASR;LGPSSYASRA; GPSSYASRAG; PSSYASRAGV; SSYASRAGVT; SYASRAGVTV;YASRAGVTVP; ASRAGVTVPY; SRAGVTVPYR; RAGVTVPYRP; AGVTVPYRPR;GVTVPYRPRS; VTVPYRPRSK; TVPYRPRSKG; VPYRPRSKGN; PYRPRSKGNI;YRPRSKGNIH; LAPPGAIVFS; APPGAIVFSI; PPGAIVFSIN; PGAIVFSINS;GAIVFSINSP; AIVFSINSPE; IVFSINSPEC; VFSINSPECT; FSINSPECTL;SINSPECTLC; FLKSILCVTS; LKSILCVTSS; KSILCVTSSI; SILCVTSSIL;ILCVTSSILS; LCVTSSILSA; CVTSSILSAS; VTSSILSASS; TSSILSASSI;SSILSASSIL; VWPKCTRVPS; WPKCTRVPSL; PKCTRVPSLS; KCTRVPSLSA;CTRVPSLSAT; TRVPSLSATC; RVPSLSATCL; VPSLSATCLT; PSLSATCLTI;SLSATCLTIE; LSATCLTIEG; SATCLTIEGL; ATCLTIEGLI; TCLTIEGLIG;CLTIEGLIGE; LTIEGLIGER; TIEGLIGERS; IEGLIGERSE; KFIGAFTIVQ;FIGAFTIVQV; IGAFTIVQVV; GAFTIVQVVS; AFTIVQVVSS; FTIVQVVSSK;TIVQVVSSKN; IVQVVSSKNL; VQVVSSKNLA; QVVSSKNLAK; VVSSKNLAKE;VSSKNLAKES; SSKNLAKESL; SKNLAKESLK; KNLAKESLKN; NLAKESLKNL;LAKESLKNLS; AKESLKNLSV; KESLKNLSVL; ESLKNLSVLL; SLKNLSVLLC;LKNLSVLLCN; KNLSVLLCNS; NLSVLLCNSC; LSVLLCNSCE; SVLLCNSCEV;VLLCNSCEVI; LLCNSCEVIE; LCNSCEVIEG; CNSCEVIEGI; NSCEVIEGIS;SCEVIEGISS; CEVIEGISSL; EVIEGISSLI; VIEGISSLIT; IEGISSLITC;EGISSLITCH; GISSLITCHK; ISSLITCHKA; SSLITCHKAW; SLITCHKAWE;LITCHKAWEI; ITCHKAWEIV; TCHKAWEIVA; CHKAWEIVAN; HKAWEIVANK;KAWEIVANKE; AWEIVANKEG; WEIVANKEGP; EIVANKEGPQ; IVANKEGPQC;VANKEGPQCL; ANKEGPQCLG; NKEGPQCLGS; KEGPQCLGSR; EGPQCLGSRY;ILLTKVFTPG; LLTKVFTPGN; LTKVFTPGNR; TKVFTPGNRI; KVFTPGNRIS;YSSGLNNSKA; SSGLNNSKAM; SGLNNSKAMP; GLNNSKAMPD; LNNSKAMPDC;SQSSKNLYPT; IKAANPAIAP; KAANPAIAPG; AANPAIAPGA; ANPAIAPGAP;NPAIAPGAPA; PAIAPGAPAI; AIAPGAPAIT; IAPGAPAITA; APGAPAITAY;PGAPAITAYV; GVRPIAAIAS; VRPIAAIASE; RPIAAIASEV; PIAAIASEVL;IAAIASEVLV; AAIASEVLVM; AIASEVLVMP; IASEVLVMPS; ASEVLVMPST;SEVLVMPSTV; EVLVMPSTVA; VLVMPSTVAR; LVMPSTVARD; VMPSTVARDA;MPSTVARDAI; TSIAAAASPA; SIAAAASPAA; IAAAASPAAI; AAAASPAAIS;AAASPAAISA; AASPAAISAT; ASPAAISATE; SPAAISATEN; PAAISATENP;AAISATENPV; AISATENPVA; ISATENPVAA; SATENPVAAA; ATENPVAAAA;TENPVAAAAS; ENPVAAAASD; NPVAAAASDT; PVAAAASDTL; VAAAASDTLA;AAAASDTLAT; AAASDTLATR; AASDTLATRS; ASDTLATRSP; SDTLATRSPK;DTLATRSPKS; TLATRSPKSA; LATRSPKSAR; ATRSPKSARA; TRSPKSARAA;RSPKSARAAP; SPKSARAAPM; PKSARAAPMN; KSARAAPMNL; SARAAPMNLE;ARAAPMNLEI; RAAPMNLEIQ; AAPMNLEIQK; APMNLEIQKK; PMNLEIQKKR;MNLEIQKKRD; NLEIQKKRDY; LEIQKKRDYL; EIQKKRDYLP; IQKKRDYLPR;QKKRDYLPRS; KKRDYLPRSL; KRDYLPRSLL; RDYLPRSLLQ; DYLPRSLLQS;YLPRSLLQSL; LPRSLLQSLL; PRSLLQSLLQ; RSLLQSLLQQ; SLLQSLLQQV;LLQSLLQQVK; LQSLLQQVKQ; QSLLQQVKQW; SLLQQVKQWY; LLQQVKQWYF;LQQVKQWYFC; QQVKQWYFCF; QVKQWYFCFS; VKQWYFCFSR; KQWYFCFSRL;QWYFCFSRLH; WYFCFSRLHC; YFCFSRLHCL; FCFSRLHCLH; CFSRLHCLHL;FSRLHCLHLY; SRLHCLHLYK; RLHCLHLYKI; LHCLHLYKIP; HCLHLYKIPA;CLHLYKIPAK; LHLYKIPAKA; HLYKIPAKAL; LYKIPAKALK; KSSELFFLFQ;SSELFFLFQS; SELFFLFQSR; ELFFLFQSRF; LFFLFQSRFY; FFLFQSRFYQ;FLFQSRFYQL; LFQSRFYQLS; FQSRFYQLSL; QSRFYQLSLK; SRFYQLSLKL;RFYQLSLKLV; FYQLSLKLVV; YQLSLKLVVT; QLSLKLVVTA; LSLKLVVTAG;SLKLVVTAGA; LKLVVTAGAE; KLVVTAGAEP; LVVTAGAEPW; VVTAGAEPWP;VTAGAEPWPL; TAGAEPWPLS; AGAEPWPLSS; GAEPWPLSSL; AEPWPLSSLT;EPWPLSSLTG; PWPLSSLTGD; WPLSSLTGDK; PLSSLTGDKA; LSSLTGDKAK;SSLTGDKAKI; SLTGDKAKIP; LTGDKAKIPR; TGDKAKIPRL; GDKAKIPRLA;DKAKIPRLAK; KAKIPRLAKH; AKIPRLAKHV; KIPRLAKHVC; IPRLAKHVCH;PRLAKHVCHA; RLAKHVCHAL; LAKHVCHALS; AKHVCHALSF; KHVCHALSFL;HVCHALSFLR; VCHALSFLRS; CHALSFLRSW; HALSFLRSWF; ALSFLRSWFG;LSFLRSWFGC; SFLRSWFGCI; FLRSWFGCIP; LRSWFGCIPW; RSWFGCIPWV;SWFGCIPWVS; WFGCIPWVSS; FGCIPWVSSS; GCIPWVSSSS; CIPWVSSSSL;GHGLAAFPCE; HGLAAFPCES; GLAAFPCESC; LAAFPCESCT; AAFPCESCTF;AFPCESCTFL; FPCESCTFLP; PCESCTFLPE; CESCTFLPEV; ESCTFLPEVM;SCTFLPEVMV; CTFLPEVMVW; TFLPEVMVWL; FLPEVMVWLH; LPEVMVWLHS;PEVMVWLHSM; EVMVWLHSMG; VMVWLHSMGK; MVWLHSMGKQ; VWLHSMGKQL;WLHSMGKQLL; LHSMGKQLLP; HSMGKQLLPV; SMGKQLLPVA; MGKQLLPVAF;GKQLLPVAFF; KQLLPVAFFF; QLLPVAFFFI; LLPVAFFFII; LPVAFFFIIY;PVAFFFIIYK; VAFFFIIYKR; AFFFIIYKRP; FFFIIYKRPR; FFIIYKRPRP;FIIYKRPRPP; IIYKRPRPPL; IYKRPRPPLP; YKRPRPPLPP; KRPRPPLPPP;RPRPPLPPPF; PRPPLPPPFL; RPPLPPPFLS; PPLPPPFLSS; PLPPPFLSSS;LPPPFLSSSK; PPPFLSSSKG; PPFLSSSKGV; PFLSSSKGVE; FLSSSKGVEA;LSSSKGVEAF; SSSKGVEAFS; SSKGVEAFSE; SKGVEAFSEA; QNYLGKSLFF;NYLGKSLFFC; YLGKSLFFCN; LGKSLFFCNF; GKSLFFCNFC; KSLFFCNFCK 11 mers:WIKFLTGKNPW; IKFLTGKNPWS; KFLTGKNPWSS; FLTGKNPWSSW; LTGKNPWSSWT;TGKNPWSSWTF; ALKELPGEIFP; GSVRNFTLTKG; SVRNFTLTKGA; VRNFTLTKGAT;RNFTLTKGATR; NFTLTKGATRI; FTLTKGATRIK; LISLILEPGVA; ISLILEPGVAQ;SLILEPGVAQR; LILEPGVAQRF; ILEPGVAQRFV; LEPGVAQRFVL; EPGVAQRFVLI;PGVAQRFVLIF; GVAQRFVLIFL; VAQRFVLIFLF; AQRFVLIFLFA; QRFVLIFLFAQ;RFVLIFLFAQI; FVLIFLFAQIP; VLIFLFAQIPC; LIFLFAQIPCT; IFLFAQIPCTA;FLFAQIPCTAR; LFAQIPCTARN; FAQIPCTARNG; AQIPCTARNGL; QIPCTARNGLF;IPCTARNGLFV; PCTARNGLFVP; CTARNGLFVPK; TARNGLFVPKS; ARNGLFVPKSL;RNGLFVPKSLL; NGLFVPKSLLC; GLFVPKSLLCT; LFVPKSLLCTA; FVPKSLLCTAL;VPKSLLCTALA; PKSLLCTALAC; KSLLCTALACY; SLLCTALACYV; LLCTALACYVS;LCTALACYVSL; CTALACYVSLD; IATALTASHSG; ATALTASHSGL; TALTASHSGLA;SFKVTNLYLDK; VIIFFIGANLW; IIFFIGANLWN; IFFIGANLWNR; FFIGANLWNRR;FIGANLWNRRV; IGANLWNRRVG; GANLWNRRVGV; ANLWNRRVGVL; NLWNRRVGVLV;LWNRRVGVLVE; WNRRVGVLVEF; NRRVGVLVEFL; RSNSRFSTLNT; SNSRFSTLNTT;NSRFSTLNTTQ; SRFSTLNTTQK; RFSTLNTTQKK; FSTLNTTQKKK; STLNTTQKKKK;TLNTTQKKKKG; LNTTQKKKKGR; NTTQKKKKGRR; TTQKKKKGRRP; KTYGKIFCNFY;RSIPYYRRKHS; SIPYYRRKHSR; IPYYRRKHSRG; PYYRRKHSRGL; YYRRKHSRGLK;YRRKHSRGLKG; RRKHSRGLKGA; RNKAGVLEINY; GCVFIIRYVFR; CVFIIRYVFRI;VFIIRYVFRIS; FIIRYVFRISI; IIRYVFRISIQ; IRYVFRISIQC; RYVFRISIQCR;YVFRISIQCRG; VFRISIQCRGV; KVSEKRPALSL; KALCKCYYFCR; ALCKCYYFCRK;KSKKYLSASSR; SKKYLSASSRY; KKYLSASSRYS; KYLSASSRYSF; YLSASSRYSFS;KKSRYPSYDQG; KSRYPSYDQGR; SRYPSYDQGRN; RYPSYDQGRNA; YPSYDQGRNAN;PSYDQGRNANR; SYDQGRNANRK; YDQGRNANRKI; DQGRNANRKIQ; QGRNANRKIQS;GRNANRKIQSY; RNANRKIQSYI; NANRKIQSYIR; NGFNIWSSWKC; GFNIWSSWKCC;FNIWSSWKCCT; NIWSSWKCCTR; IWSSWKCCTRT; WSSWKCCTRTI; SSWKCCTRTIY;SWKCCTRTIYG; WKCCTRTIYGR; KCCTRTIYGRC; CCTRTIYGRCC; CTRTIYGRCCL;TRTIYGRCCLA; RTIYGRCCLAA; TIYGRCCLAAL; IYGRCCLAALF; YGRCCLAALFA;GRCCLAALFAT; WKNNTSCRVIR; KNNTSCRVIRF; NNTSCRVIRFV; NTSCRVIRFVW;TSCRVIRFVWW; SLKCKPTHGKA; LKCKPTHGKAN; KCKPTHGKANL; ARCSYRSVHGC;RCSYRSVHGCF; IKGFAFRTWNK; KGFAFRTWNKQ; GFAFRTWNKQF; FAFRTWNKQFR;AFRTWNKQFRQ; FRTWNKQFRQF; RTWNKQFRQFE; TWNKQFRQFER; WNKQFRQFERL;NKQFRQFERLF; KQFRQFERLFR; QFRQFERLFRW; FRQFERLFRWK; RQFERLFRWKC;GKFRKETFKQK; KFRKETFKQKN; FRKETFKQKNP; RKETFKQKNPN; KETFKQKNPNI;ETFKQKNPNIS; TFKQKNPNIST; FKQKNPNISTR; KQKNPNISTRL; QKNPNISTRLG;KNPNISTRLGY; NPNISTRLGYN; PNISTRLGYNE; AQNIFKKILTK; QNIFKKILTKL;NIFKKILTKLR; IFKKILTKLRV; FKKILTKLRVL; KKILTKLRVLT; KKNFTKWNDLV;KNFTKWNDLVA; NFTKWNDLVAT; FTKWNDLVATA; TKWNDLVATAN; KWNDLVATANL;WNDLVATANLV; DKYVYFFKDEI; IPITMLFPSLR; PITMLFPSLRY; ITMLFPSLRYF;TMLFPSLRYFS; MLFPSLRYFSP; LFPSLRYFSPC; KWLIQKQHLLN; WLIQKQHLLNV;LIQKQHLLNVY; IQKQHLLNVYV; QKQHLLNVYVQ; KHLFKAFWFAI; HLFKAFWFAIV;LFKAFWFAIVP; FKAFWFAIVPV; KAFWFAIVPVC; AFWFAIVPVCQ; FWFAIVPVCQY;WFAIVPVCQYI; FAIVPVCQYIL; AIVPVCQYILS; IVPVCQYILSY; VPVCQYILSYL;PVCQYILSYLG; VCQYILSYLGP; CQYILSYLGPL; QYILSYLGPLE; YILSYLGPLEV;ILSYLGPLEVF; LSYLGPLEVFL; SYLGPLEVFLC; YLGPLEVFLCH; LGPLEVFLCHQ;GPLEVFLCHQT; PLEVFLCHQTP; AAHPLSGFSCL; GHLAKRKLGKD; HLAKRKLGKDS;LAKRKLGKDSL; AKRKLGKDSLQ; KRKLGKDSLQI; RKLGKDSLQIF; KLGKDSLQIFF;LGKDSLQIFFS; GKDSLQIFFSG; KDSLQIFFSGG; DSLQIFFSGGS; NILQGLSTVVF;ILQGLSTVVFQ; LQGLSTVVFQS; QGLSTVVFQSC; TGHKYQQLKHT; GHKYQQLKHTG;HKYQQLKHTGY; KYQQLKHTGYQ; YQQLKHTGYQL; QQLKHTGYQLY; QLKHTGYQLYK;LKHTGYQLYKE; KHTGYQLYKEA; HTGYQLYKEAP; TGYQLYKEAPH; GYQLYKEAPHP;YQLYKEAPHPV; QLYKEAPHPVH; LYKEAPHPVHL; YKEAPHPVHLA; KEAPHPVHLAT;EAPHPVHLATL; APHPVHLATLW; LCWSHEVLGEH; CWSHEVLGEHF; WSHEVLGEHFP;SHEVLGEHFPL; HEVLGEHFPLL; HFHFYWDQVPS; FHFYWDQVPST; HFYWDQVPSTQ;FYWDQVPSTQL; YWDQVPSTQLD; WDQVPSTQLDK; DQVPSTQLDKH; QVPSTQLDKHC;VPSTQLDKHCF; PSTQLDKHCFC; STQLDKHCFCP; TQLDKHCFCPN; QLDKHCFCPNR;LDKHCFCPNRP; DKHCFCPNRPY; KHCFCPNRPYG; HCFCPNRPYGQ; CFCPNRPYGQY;FCPNRPYGQYS; CPNRPYGQYSL; PNRPYGQYSLP; NRPYGQYSLPG; RPYGQYSLPGT;PYGQYSLPGTG; YGQYSLPGTGL; GQYSLPGTGLL; QYSLPGTGLLG; YSLPGTGLLGF;YHQGTLTCNSL; HQGTLTCNSLA; QGTLTCNSLAL; GTLTCNSLALP; TLTCNSLALPA;LTCNSLALPAF; TCNSLALPAFP; CNSLALPAFPR; NSLALPAFPRV; SLALPAFPRVL;LALPAFPRVLH; ALPAFPRVLHL; LPAFPRVLHLQ; PAFPRVLHLQQ; AFPRVLHLQQR;FPRVLHLQQRS; PRVLHLQQRSG; RVLHLQQRSGN; VLHLQQRSGNY; LHLQQRSGNYC;HLQQRSGNYCL; LQQRSGNYCLE; VFLHHAHALFV; FLHHAHALFVT; LHHAHALFVTL;HHAHALFVTLH; HAHALFVTLHE; AHALFVTLHEG; PLFVQLQPPTS; LFVQLQPPTSV;FVQLQPPTSVD; VQLQPPTSVDF; QLQPPTSVDFH; LQPPTSVDFHR; QPPTSVDFHRL;PPTSVDFHRLG; PTSVDFHRLGP; TSVDFHRLGPH; SVDFHRLGPHL; VDFHRLGPHLN;DFHRLGPHLNW; FHRLGPHLNWG; HRLGPHLNWGG; RLGPHLNWGGE; LGPHLNWGGEF;GPHLNWGGEFL; PHLNWGGEFLL; HLNWGGEFLLC; LNWGGEFLLCC; NWGGEFLLCCN;WGGEFLLCCNR; GGEFLLCCNRE; GEFLLCCNREA; EFLLCCNREAF; FLLCCNREAFF;LLCCNREAFFS; LCCNREAFFSL; CCNREAFFSLG; CNREAFFSLGY; NREAFFSLGYH;REAFFSLGYHC; GFHLDPPFLGL; FHLDPPFLGLG; HLDPPFLGLGS; LDPPFLGLGSI;DPPFLGLGSIL; PPFLGLGSILP; PFLGLGSILPL; LLELLLLLLLV; LELLLLLLLVV;ELLLLLLLVVL; LLLLLLLVVLA; LLLLLLVVLAL; LLLLLVVLALA; LLLLVVLALAR;LLLVVLALARV; LLVVLALARVP; LVVLALARVPL; VVLALARVPLA; VLALARVPLAF;LALARVPLAFW; ALARVPLAFWE; LARVPLAFWEL; ARVPLAFWELP; RVPLAFWELPL;VPLAFWELPLD; PLAFWELPLDT; LAFWELPLDTL; AFWELPLDTLL; FWELPLDTLLF;WELPLDTLLFF; ELPLDTLLFFW; LPLDTLLFFWL; PLDTLLFFWLG; LDTLLFFWLGP;DTLLFFWLGPS; TLLFFWLGPSS; LLFFWLGPSSY; LFFWLGPSSYA; FFWLGPSSYAS;FWLGPSSYASR; WLGPSSYASRA; LGPSSYASRAG; GPSSYASRAGV; PSSYASRAGVT;SSYASRAGVTV; SYASRAGVTVP; YASRAGVTVPY; ASRAGVTVPYR; SRAGVTVPYRP;RAGVTVPYRPR; AGVTVPYRPRS; GVTVPYRPRSK; VTVPYRPRSKG; TVPYRPRSKGN;VPYRPRSKGNI; PYRPRSKGNIH; LAPPGAIVFSI; APPGAIVFSIN; PPGAIVFSINS;PGAIVFSINSP; GAIVFSINSPE; AIVFSINSPEC; IVFSINSPECT; VFSINSPECTL;FSINSPECTLC; FLKSILCVTSS; LKSILCVTSSI; KSILCVTSSIL; SILCVTSSILS;ILCVTSSILSA; LCVTSSILSAS; CVTSSILSASS; VTSSILSASSI; TSSILSASSIL;VWPKCTRVPSL; WPKCTRVPSLS; PKCTRVPSLSA; KCTRVPSLSAT; CTRVPSLSATC;TRVPSLSATCL; RVPSLSATCLT; VPSLSATCLTI; PSLSATCLTIE; SLSATCLTIEG;LSATCLTIEGL; SATCLTIEGLI; ATCLTIEGLIG; TCLTIEGLIGE; CLTIEGLIGER;LTIEGLIGERS; TIEGLIGERSE; KFIGAFTIVQV; FIGAFTIVQVV; IGAFTIVQVVS;GAFTIVQVVSS; AFTIVQVVSSK; FTIVQVVSSKN; TIVQVVSSKNL; IVQVVSSKNLA;VQVVSSKNLAK; QVVSSKNLAKE; VVSSKNLAKES; VSSKNLAKESL; SSKNLAKESLK;SKNLAKESLKN; KNLAKESLKNL; NLAKESLKNLS; LAKESLKNLSV; AKESLKNLSVL;KESLKNLSVLL; ESLKNLSVLLC; SLKNLSVLLCN; LKNLSVLLCNS; KNLSVLLCNSC;NLSVLLCNSCE; LSVLLCNSCEV; SVLLCNSCEVI; VLLCNSCEVIE; LLCNSCEVIEG;LCNSCEVIEGI; CNSCEVIEGIS; NSCEVIEGISS; SCEVIEGISSL; CEVIEGISSLI;EVIEGISSLIT; VIEGISSLITC; IEGISSLITCH; EGISSLITCHK; GISSLITCHKA;ISSLITCHKAW; SSLITCHKAWE; SLITCHKAWEI; LITCHKAWEIV; ITCHKAWEIVA;TCHKAWEIVAN; CHKAWEIVANK; HKAWEIVANKE; KAWEIVANKEG; AWEIVANKEGP;WEIVANKEGPQ; EIVANKEGPQC; IVANKEGPQCL; VANKEGPQCLG; ANKEGPQCLGS;NKEGPQCLGSR; KEGPQCLGSRY; ILLTKVFTPGN; LLTKVFTPGNR; LTKVFTPGNRI;TKVFTPGNRIS; YSSGLNNSKAM; SSGLNNSKAMP; SGLNNSKAMPD; GLNNSKAMPDC;IKAANPAIAPG; KAANPAIAPGA; AANPAIAPGAP; ANPAIAPGAPA; NPAIAPGAPAI;PAIAPGAPAIT; AIAPGAPAITA; IAPGAPAITAY; APGAPAITAYV; GVRPIAAIASE;VRPIAAIASEV; RPIAAIASEVL; PIAAIASEVLV; IAAIASEVLVM; AAIASEVLVMP;AIASEVLVMPS; IASEVLVMPST; ASEVLVMPSTV; SEVLVMPSTVA; EVLVMPSTVAR;VLVMPSTVARD; LVMPSTVARDA; VMPSTVARDAI; TSIAAAASPAA; SIAAAASPAAI;IAAAASPAAIS; AAAASPAAISA; AAASPAAISAT; AASPAAISATE; ASPAAISATEN;SPAAISATENP; PAAISATENPV; AAISATENPVA; AISATENPVAA; ISATENPVAAA;SATENPVAAAA; ATENPVAAAAS; TENPVAAAASD; ENPVAAAASDT; NPVAAAASDTL;PVAAAASDTLA; VAAAASDTLAT; AAAASDTLATR; AAASDTLATRS; AASDTLATRSP;ASDTLATRSPK; SDTLATRSPKS; DTLATRSPKSA; TLATRSPKSAR; LATRSPKSARA;ATRSPKSARAA; TRSPKSARAAP; RSPKSARAAPM; SPKSARAAPMN; PKSARAAPMNL;KSARAAPMNLE; SARAAPMNLEI; ARAAPMNLEIQ; RAAPMNLEIQK; AAPMNLEIQKK;APMNLEIQKKR; PMNLEIQKKRD; MNLEIQKKRDY; NLEIQKKRDYL; LEIQKKRDYLP;EIQKKRDYLPR; IQKKRDYLPRS; QKKRDYLPRSL; KKRDYLPRSLL; KRDYLPRSLLQ;RDYLPRSLLQS; DYLPRSLLQSL; YLPRSLLQSLL; LPRSLLQSLLQ; PRSLLQSLLQQ;RSLLQSLLQQV; SLLQSLLQQVK; LLQSLLQQVKQ; LQSLLQQVKQW; QSLLQQVKQWY;SLLQQVKQWYF; LLQQVKQWYFC; LQQVKQWYFCF; QQVKQWYFCFS; QVKQWYFCFSR;VKQWYFCFSRL; KQWYFCFSRLH; QWYFCFSRLHC; WYFCFSRLHCL; YFCFSRLHCLH;FCFSRLHCLHL; CFSRLHCLHLY; FSRLHCLHLYK; SRLHCLHLYKI; RLHCLHLYKIP;LHCLHLYKIPA; HCLHLYKIPAK; CLHLYKIPAKA; LHLYKIPAKAL; HLYKIPAKALK;KSSELFFLFQS; SSELFFLFQSR; SELFFLFQSRF; ELFFLFQSRFY; LFFLFQSRFYQ;FFLFQSRFYQL; FLFQSRFYQLS; LFQSRFYQLSL; FQSRFYQLSLK; QSRFYQLSLKL;SRFYQLSLKLV; RFYQLSLKLVV; FYQLSLKLVVT; YQLSLKLVVTA; QLSLKLVVTAG;LSLKLVVTAGA; SLKLVVTAGAE; LKLVVTAGAEP; KLVVTAGAEPW; LVVTAGAEPWP;VVTAGAEPWPL; VTAGAEPWPLS; TAGAEPWPLSS; AGAEPWPLSSL; GAEPWPLSSLT;AEPWPLSSLTG; EPWPLSSLTGD; PWPLSSLTGDK; WPLSSLTGDKA; PLSSLTGDKAK;LSSLTGDKAKI; SSLTGDKAKIP; SLTGDKAKIPR; LTGDKAKIPRL; TGDKAKIPRLA;GDKAKIPRLAK; DKAKIPRLAKH; KAKIPRLAKHV; AKIPRLAKHVC; KIPRLAKHVCH;IPRLAKHVCHA; PRLAKHVCHAL; RLAKHVCHALS; LAKHVCHALSF; AKHVCHALSFL;KHVCHALSFLR; HVCHALSFLRS; VCHALSFLRSW; CHALSFLRSWF; HALSFLRSWFG;ALSFLRSWFGC; LSFLRSWFGCI; SFLRSWFGCIP; FLRSWFGCIPW; LRSWFGCIPWV;RSWFGCIPWVS; SWFGCIPWVSS; WFGCIPWVSSS; FGCIPWVSSSS; GCIPWVSSSSL;GHGLAAFPCES; HGLAAFPCESC; GLAAFPCESCT; LAAFPCESCTF; AAFPCESCTFL;AFPCESCTFLP; FPCESCTFLPE; PCESCTFLPEV; CESCTFLPEVM; ESCTFLPEVMV;SCTFLPEVMVW; CTFLPEVMVWL; TFLPEVMVWLH; FLPEVMVWLHS; LPEVMVWLHSM;PEVMVWLHSMG; EVMVWLHSMGK; VMVWLHSMGKQ; MVWLHSMGKQL; VWLHSMGKQLL;WLHSMGKQLLP; LHSMGKQLLPV; HSMGKQLLPVA; SMGKQLLPVAF; MGKQLLPVAFF;GKQLLPVAFFF; KQLLPVAFFFI; QLLPVAFFFII; LLPVAFFFIIY; LPVAFFFIIYK;PVAFFFIIYKR; VAFFFIIYKRP; AFFFIIYKRPR; FFFIIYKRPRP; FFIIYKRPRPP;FIIYKRPRPPL; IIYKRPRPPLP; IYKRPRPPLPP; YKRPRPPLPPP; KRPRPPLPPPF;RPRPPLPPPFL; PRPPLPPPFLS; RPPLPPPFLSS; PPLPPPFLSSS; PLPPPFLSSSK;LPPPFLSSSKG; PPPFLSSSKGV; PPFLSSSKGVE; PFLSSSKGVEA; FLSSSKGVEAF;LSSSKGVEAFS; SSSKGVEAFSE; SSKGVEAFSEA; QNYLGKSLFFC; NYLGKSLFFCN;YLGKSLFFCNF; LGKSLFFCNFC; GKSLFFCNFCKBK virus complementary reading frame 3 8 mers:QGRIHGAH; GRIHGAHG; RIHGAHGP; IHGAHGPF; HGAHGPFR; GAHGPFRP; KSCLGKSS;SCLGKSSL; CLGKSSLN; LGKSSLNE; GKSSLNEK; KSSLNEKS; SSLNEKSL; SLNEKSLF;LNEKSLFK; NEKSLFKE; EKSLFKEV; NEENEYFV; KNGAGCKG; NGAGCKGS; GAGCKGSS;AGCKGSSS; GCKGSSSA; FSSLPRYP; SSLPRYPV; SLPRYPVL; LPRYPVLQ; PRYPVLQG;RYPVLQGM; YPVLQGMA; PVLQGMAY; VLQGMAYL; LQGMAYLF; QGMAYLFQ; GMAYLFQK;MAYLFQKA; AYLFQKAF; YLFQKAFC; LFQKAFCA; FQKAFCAL; QKAFCALP; KAFCALPL;AFCALPLH; FCALPLHA; CALPLHAM; ALPLHAMS; LPLHAMSA; KIFKKRAL; IFKKRALG;FKKRALGL; KKRALGLD; KRALGLDR; RALGLDRL; ALGLDRLL; LGLDRLLL; GLDRLLLH;LLHTVVWL; LHTVVWLR; HTVVWLRP; TVVWLRPN; RNSAMVGP; NSAMVGPN; SAMVGPNN;AMVGPNNW; MVGPNNWR; VGPNNWRN; GPNNWRNS; PNNWRNSL; NNWRNSLQ; NWRNSLQR;WRNSLQRS; RNSLQRSK; NSLQRSKA; SLQRSKAL; LQRSKALR; INNKILKG; NNKILKGP;NKILKGPK; VPTYGTEE; PTYGTEEW; TYGTEEWE; YGTEEWES; GTEEWESW; TEEWESWW;EEWESWWS; EWESWWSS; WESWWSSF; ESWWSSFN; SWWSSFNE; WWSSFNEK; WSSFNEKW;SSFNEKWD; SFNEKWDE; FNEKWDED; NEKWDEDL; EKWDEDLF; KWDEDLFC; WDEDLFCH;DEDLFCHE; EDLFCHED; DLFCHEDM; LFCHEDMF; FCHEDMFA; CHEDMFAS; HEDMFASD;EDMFASDE; DMFASDEE; MFASDEEA; FASDEEAT; ASDEEATA; SDEEATAD; DEEATADS;EEATADSQ; EATADSQH; ATADSQHS; TADSQHST; ADSQHSTP; DSQHSTPP; SQHSTPPK;QHSTPPKK; HSTPPKKK; STPPKKKR; TPPKKKRK; PPKKKRKV; PKKKRKVE; KKKRKVED;KKRKVEDP; KRKVEDPK; RKVEDPKD; KVEDPKDF; VEDPKDFP; EDPKDFPS; DPKDFPSD;PKDFPSDL; KDFPSDLH; DFPSDLHQ; FPSDLHQF; PSDLHQFL; SDLHQFLS; DLHQFLSQ;LHQFLSQA; HQFLSQAV; QFLSQAVF; FLSQAVFS; LSQAVFSN; SQAVFSNR; QAVFSNRT;AVFSNRTL; VFSNRTLA; FSNRTLAC; SNRTLACF; NRTLACFA; RTLACFAV; TLACFAVY;LACFAVYT; ACFAVYTT; CFAVYTTK; FAVYTTKE; AVYTTKEK; VYTTKEKA; YTTKEKAQ;TTKEKAQI; TKEKAQIL; KEKAQILY; EKAQILYK; KAQILYKK; AQILYKKL; QILYKKLM;ILYKKLME; LYKKLMEK; YKKLMEKY; KKLMEKYS; KLMEKYSV; LMEKYSVT; MEKYSVTF;EKYSVTFI; KYSVTFIS; YSVTFISR; SVTFISRH; VTFISRHM; TFISRHMC; FISRHMCA;ISRHMCAG; SRHMCAGH; RHMCAGHN; HMCAGHNI; MCAGHNII; CAGHNIIF; AGHNIIFF;GHNIIFFL; HNIIFFLT; NIIFFLTP; IIFFLTPH; IFFLTPHR; FFLTPHRH; FLTPHRHR;LTPHRHRV; TPHRHRVS; PHRHRVSA; HRHRVSAI; RHRVSAIN; HRVSAINN; RVSAINNF;VSAINNFC; SAINNFCQ; AINNFCQK; INNFCQKL; NNFCQKLC; NFCQKLCT; FCQKLCTF;CQKLCTFS; QKLCTFSF; KLCTFSFL; LCTFSFLI; CTFSFLIC; TFSFLICK; FSFLICKG;SFLICKGV; FLICKGVN; LICKGVNK; ICKGVNKE; CKGVNKEY; KGVNKEYL; GVNKEYLL;VNKEYLLY; NKEYLLYS; KEYLLYSA; EYLLYSAL; YLLYSALT; LLYSALTR; LYSALTRD;YSALTRDP; SALTRDPY; ALTRDPYH; LTRDPYHT; TRDPYHTI; RDPYHTIE; DPYHTIEE;PYHTIEES; YHTIEESI; HTIEESIQ; TIEESIQG; IEESIQGG; EESIQGGL; ESIQGGLK;SIQGGLKE; IQGGLKEH; QGGLKEHD; GGLKEHDF; GLKEHDFS; LKEHDFSP; KEHDFSPE;EHDFSPEE; HDFSPEEP; DFSPEEPE; FSPEEPEE; SPEEPEET; PEEPEETK; EEPEETKQ;EPEETKQV; PEETKQVS; EETKQVSW; ETKQVSWK; TKQVSWKL; KQVSWKLI; QVSWKLIT;VSWKLITE; SWKLITEY; WKLITEYA; KLITEYAV; LITEYAVE; ITEYAVET; TEYAVETK;EYAVETKC; YAVETKCE; AVETKCED; VETKCEDV; ETKCEDVF; TKCEDVFL; KCEDVFLL;CEDVFLLL; EDVFLLLG; DVFLLLGM; VFLLLGMY; FLLLGMYL; LLLGMYLE; LLGMYLEF;LGMYLEFQ; GMYLEFQY; MYLEFQYN; YLEFQYNV; LEFQYNVE; EFQYNVEE; FQYNVEEC;QYNVEECK; YNVEECKK; NVEECKKC; VEECKKCQ; EECKKCQK; ECKKCQKK; CKKCQKKD;KKCQKKDQ; KCQKKDQP; CQKKDQPY; QKKDQPYH; KKDQPYHF; KDQPYHFK; DQPYHFKY;QPYHFKYH; PYHFKYHE; YHFKYHEK; HFKYHEKH; FKYHEKHF; KYHEKHFA; YHEKHFAN;HEKHFANA; EKHFANAI; KHFANAII; HFANAIIF; FANAIIFA; ANAIIFAE; NAIIFAES;AIIFAESK; IIFAESKN; IFAESKNQ; FAESKNQK; AESKNQKS; ESKNQKSI; SKNQKSIC;KNQKSICQ; NQKSICQQ; QKSICQQA; KSICQQAV; SICQQAVD; ICQQAVDT; CQQAVDTV;QQAVDTVL; QAVDTVLA; AVDTVLAK; VDTVLAKK; DTVLAKKR; TVLAKKRV; VLAKKRVD;LAKKRVDT; AKKRVDTL; KKRVDTLH; KRVDTLHM; RVDTLHMT; VDTLHMTR; DTLHMTRE;TLHMTREE; LHMTREEM; HMTREEML; MTREEMLT; TREEMLTE; REEMLTER; EEMLTERF;EMLTERFN; MLTERFNH; LTERFNHI; TERFNHIL; ERFNHILD; RFNHILDK; FNHILDKM;NHILDKMD; HILDKMDL; ILDKMDLI; LDKMDLIF; DKMDLIFG; KMDLIFGA; MDLIFGAH;DLIFGAHG; LIFGAHGN; IFGAHGNA; FGAHGNAV; GAHGNAVL; AHGNAVLE; HGNAVLEQ;GNAVLEQY; NAVLEQYM; AVLEQYMA; VLEQYMAG; LEQYMAGV; EQYMAGVA; QYMAGVAW;YMAGVAWL; MAGVAWLH; AGVAWLHC; GVAWLHCL; VAWLHCLL; AWLHCLLP; WLHCLLPK;LHCLLPKM; HCLLPKMD; CLLPKMDS; LLPKMDSV; LPKMDSVI; PKMDSVIF; KMDSVIFD;MDSVIFDF; DSVIFDFL; SVIFDFLH; VIFDFLHC; IFDFLHCI; FDFLHCIV; DFLHCIVF;FLHCIVFN; LHCIVFNV; HCIVFNVP; CIVFNVPK; IVFNVPKR; VFNVPKRR; FNVPKRRY;NVPKRRYW; VPKRRYWL; PKRRYWLF; KRRYWLFK; RRYWLFKG; RYWLFKGP; YWLFKGPI;WLFKGPID; LFKGPIDS; FKGPIDSG; KGPIDSGK; GPIDSGKT; PIDSGKTT; IDSGKTTL;DSGKTTLA; SGKTTLAA; GKTTLAAG; KTTLAAGL; TTLAAGLL; TLAAGLLD; LAAGLLDL;AAGLLDLC; AGLLDLCG; GLLDLCGG; LLDLCGGK; LDLCGGKA; DLCGGKAL; LCGGKALN;CGGKALNV; GGKALNVN; GKALNVNL; KALNVNLP; ALNVNLPM; LNVNLPME; NVNLPMER;VNLPMERL; NLPMERLT; LPMERLTF; PMERLTFE; MERLTFEL; ERLTFELG; RLTFELGV;LTFELGVA; TFELGVAI; FELGVAID; ELGVAIDQ; LGVAIDQY; GVAIDQYM; VAIDQYMV;AIDQYMVV; IDQYMVVF; DQYMVVFE; QYMVVFED; YMVVFEDV; MVVFEDVK; VVFEDVKG;VFEDVKGT; FEDVKGTG; EDVKGTGA; DVKGTGAE; VKGTGAES; KGTGAESK; GTGAESKD;TGAESKDL; GAESKDLP; AESKDLPS; ESKDLPSG; SKDLPSGH; KDLPSGHG; DLPSGHGI;LPSGHGIN; PSGHGINN; SGHGINNL; GHGINNLD; HGINNLDS; GINNLDSL; INNLDSLR;NNLDSLRD; NLDSLRDY; LDSLRDYL; DSLRDYLD; SLRDYLDG; LRDYLDGS; RDYLDGSV;DYLDGSVK; YLDGSVKV; LDGSVKVN; DGSVKVNL; GSVKVNLE; SVKVNLEK; VKVNLEKK;KVNLEKKH; VNLEKKHL; NLEKKHLN; LEKKHLNK; EKKHLNKR; KKHLNKRT; KHLNKRTQ;HLNKRTQI; LNKRTQIF; NKRTQIFP; KRTQIFPP; RTQIFPPG; TQIFPPGL; QIFPPGLV;IFPPGLVT; FPPGLVTM; PPGLVTMN; PGLVTMNE; GLVTMNEY; LVTMNEYP; VTMNEYPV;TMNEYPVP; MNEYPVPK; NEYPVPKT; EYPVPKTL; YPVPKTLQ; PVPKTLQA; VPKTLQAR;PKTLQARF; KTLQARFV; TLQARFVR; LQARFVRQ; QARFVRQI; ARFVRQID; RFVRQIDF;FVRQIDFR; VRQIDFRP; RQIDFRPK; QIDFRPKI; IDFRPKIY; DFRPKIYL; FRPKIYLR;RPKIYLRK; PKIYLRKS; KIYLRKSL; IYLRKSLQ; YLRKSLQN; LRKSLQNS; RKSLQNSE;KSLQNSEF; SLQNSEFL; LQNSEFLL; QNSEFLLE; NSEFLLEK; SEFLLEKR; EFLLEKRI;FLLEKRIL; LLEKRILQ; LEKRILQS; EKRILQSG; KRILQSGM; RILQSGMT; ILQSGMTL;LQSGMTLL; QSGMTLLL; SGMTLLLL; GMTLLLLL; MTLLLLLI; TLLLLLIW; LLLLLIWF;LLLLIWFR; LLLIWFRP; LLIWFRPV; LIWFRPVA; IWFRPVAD; WFRPVADF; FRPVADFA;RPVADFAT; PVADFATD; VADFATDI; ADFATDIQ; DFATDIQS; FATDIQSR; ATDIQSRI;TDIQSRIV; DIQSRIVE; IQSRIVEW; QSRIVEWK; SRIVEWKE; RIVEWKER; IVEWKERL;VEWKERLD; EWKERLDS; WKERLDSE; KERLDSEI; ERLDSEIS; RLDSEISM; LDSEISMY;DSEISMYT; SEISMYTF; EISMYTFS; ISMYTFSR; SMYTFSRM; MYTFSRMK; YTFSRMKY;TFSRMKYN; FSRMKYNI; SRMKYNIC; RMKYNICM; MKYNICMG; KYNICMGK; YNICMGKC;NICMGKCI; ICMGKCIL; CMGKCILD; MGKCILDI; GKCILDIT; KCILDITR; CILDITRE;ILDITREE; LDITREED; DITREEDS; ITREEDSE; TREEDSET; REEDSETE; EEDSETED;EDSETEDS; DSETEDSG; SETEDSGH; ETEDSGHG; TEDSGHGS; EDSGHGSS; DSGHGSST;SGHGSSTE; GHGSSTES; HGSSTESQ; GSSTESQS; SSTESQSQ; STESQSQC; TESQSQCS;ESQSQCSS; SQSQCSSQ; QSQCSSQV; SQCSSQVS; QCSSQVSD; CSSQVSDT; SSQVSDTS;SQVSDTSA; QVSDTSAP; VSDTSAPA; SDTSAPAE; DTSAPAED; TSAPAEDS; SAPAEDSQ;APAEDSQR; PAEDSQRS; AEDSQRSD; EDSQRSDP; DSQRSDPH; SQRSDPHS; QRSDPHSQ;RSDPHSQE; SDPHSQEL; DPHSQELH; PHSQELHL; HSQELHLC; SQELHLCK; QELHLCKG;ELHLCKGF; LHLCKGFQ; HLCKGFQC; LCKGFQCF; CKGFQCFK; KGFQCFKR; GFQCFKRP;FQCFKRPK; QCFKRPKT; CFKRPKTP; FKRPKTPP; KRPKTPPP; RPKTPPPK; HKLKSGLY;KLKSGLYK; LKSGLYKS; KSGLYKSS; SGLYKSSI; GLYKSSIY; MYMYNKST; YMYNKSTC;MYNKSTCL; YNKSTCLK; NKSTCLKH; KSTCLKHF; STCLKHFG; TCLKHFGL; CLKHFGLQ;LKHFGLQL; KHFGLQLS; HFGLQLSL; FGLQLSLF; GLQLSLFV; LQLSLFVN; QLSLFVNI;LSLFVNIS; SLFVNISY; LFVNISYH; FVNISYHI; VNISYHIW; NISYHIWV; ISYHIWVP;SYHIWVPW; YHIWVPWK; HIWVPWKS; IWVPWKSF; WVPWKSFC; VPWKSFCA; PWKSFCAI;WKSFCAIK; KSFCAIKH; SFCAIKHP; FCAIKHPN; CAIKHPNL; AIKHPNLF; IKHPNLFY;KHPNLFYL; HPNLFYLG; PNLFYLGF; NLFYLGFH; LFYLGFHT; FYLGFHTI; YLGFHTIH;LGFHTIHR; GFHTIHRL; FHTIHRLP; HTIHRLPI; TIHRLPIH; IHRLPIHS; HRLPIHSL;RLPIHSLG; LPIHSLGS; PIHSLGSP; IHSLGSPV; HSLGSPVY; SLGSPVYK; LGSPVYKV;GSPVYKVT; QKGNWVRI; KGNWVRIL; GNWVRILY; NWVRILYR; WVRILYRS; VRILYRSF;RILYRSFS; ILYRSFSQ; LYRSFSQA; YRSFSQAD; RSFSQADL; SFSQADLK; FSQADLKI;SQADLKIS; QADLKISC; ADLKISCK; DLKISCKA; LKISCKAS; KISCKASP; ISCKASPL;SCKASPLL; CKASPLLC; KASPLLCS; ASPLLCSR; SPLLCSRA; PLLCSRAV; LLCSRAVS;LCSRAVSK; CSRAVSKQ; SRAVSKQA; RAVSKQAT; AVSKQATN; VSKQATNI; SKQATNIS;KQATNISS; NIQAISFT; IQAISFTK; QAISFTKR; AISFTKRP; ISFTKRPH; SFTKRPHT;FTKRPHTL; TKRPHTLF; KRPHTLFI; QHCGSCVG; HCGSCVGH; CGSCVGHM; GSCVGHMK;SCVGHMKY; CVGHMKYW; VGHMKYWG; GHMKYWGN; HMKYWGNI; MKYWGNIF; KYWGNIFP;YWGNIFPS; WGNIFPSC; GNIFPSCE; NIFPSCES; IFPSCESP; FPSCESPK; PSCESPKI;SCESPKIP; CESPKIPS; ESPKIPSI; SPKIPSIF; PKIPSIFI; KIPSIFIS; IPSIFIST;PSIFISTG; SIFISTGI; IFISTGIR; FISTGIRY; ISTGIRYP; STGIRYPA; TGIRYPAL;GIRYPALN; IRYPALNW; RYPALNWI; YPALNWIS; PALNWISI; ALNWISIV; LNWISIVF;NWISIVFV; WISIVFVQ; ISIVFVQI; SIVFVQIG; IVFVQIGL; VFVQIGLM; FVQIGLMV;VQIGLMVS; QIGLMVSI; IGLMVSIH; GLMVSIHY; LMVSIHYL; MVSIHYLG; VSIHYLGL;SIHYLGLG; IHYLGLGC; HYLGLGCW; YLGLGCWV; LGLGCWVF; GLGCWVFR; LGCWVFRG;GCWVFRGY; CWVFRGYS; WVFRGYST; VFRGYSTI; FRGYSTIR; RGYSTIRV; GYSTIRVL;HSLHFQGF; SLHFQGFS; LHFQGFST; HFQGFSTY; FQGFSTYS; QGFSTYSK; GFSTYSKE;FSTYSKEV; STYSKEVE; TYSKEVEI; YSKEVEIT; SKEVEITA; KEVEITAL; EVEITALN;VEITALNR; EITALNRF; ITALNRFS; TALNRFSS; ALNRFSST; LNRFSSTM; NRFSSTML;RFSSTMLM; FSSTMLMH; SSTMLMHF; STMLMHFL; PCMKVKHA; CMKVKHAS; MKVKHASY;KVKHASYS; VKHASYSN; KHASYSNN; HASYSNNL; ASYSNNLC; SYSNNLCL; YSNNLCLY;SNNLCLYS; NNLCLYSY; NLCLYSYS; LCLYSYSL; CLYSYSLP; LYSYSLPH; YSYSLPHQ;IGEGNSCC; GEGNSCCA; EGNSCCAV; GNSCCAVT; NSCCAVTG; SCCAVTGK; CCAVTGKH;CAVTGKHF; AVTGKHFS; VTGKHFSL; TGKHFSLW; GKHFSLWA; KHFSLWAI; HFSLWAIT;FSLWAITA; SLWAITAK; LWAITAKV; WAITAKVI; AITAKVIF; ITAKVIFS; TAKVIFST;TKAPKVFI; KAPKVFIW; APKVFIWI; PKVFIWIP; KVFIWIPH; VFIWIPHF; FIWIPHFW;IWIPHFWV; EAFYLCNS; AFYLCNSI; FYLCNSIY; YLCNSIYP; LCNSIYPS; CNSIYPSF;NSIYPSFN; SIYPSFNF; FWHLHGFL; WHLHGFLW; HLHGFLWL; LHGFLWLF; HGFLWLFG;GFLWLFGS; FLWLFGSC; LWLFGSCP; WLFGSCPW; LFGSCPWT; FGSCPWTL; GSCPWTLS;SCPWTLSF; CPWTLSFS; PWTLSFSF; WTLSFSFG; TLSFSFGW; LSFSFGWG; SFSFGWGH;FSFGWGHL; SFGWGHLH; FGWGHLHM; GWGHLHML; WGHLHMLQ; GHLHMLQE; HLHMLQEQ;LHMLQEQV; HMLQEQVL; MLQEQVLQ; LQEQVLQS; QEQVLQSR; EQVLQSRT; QVLQSRTG;VLQSRTGL; LQSRTGLE; QSRTGLEV; SRTGLEVK; RTGLEVKA; TGLEVKAT; GLEVKATS;LEVKATSI; EVKATSIE; VKATSIEE; KATSIEEQ; ATSIEEQF; TSIEEQFF; SIEEQFFD;TLLNVHFV; LLNVHFVD; LNVHFVDF; NVHFVDFL; VHFVDFLS; HFVDFLSP; FVDFLSPF;VDFLSPFF; DFLSPFFV; LLLYCQHH; LLYCQHHL; LYCQHHLY; YCQHHLYY; CQHHLYYK;QHHLYYKY; HHLYYKYG; HLYYKYGQ; LYYKYGQN; YYKYGQNV; YKYGQNVH; KYGQNVHG;YGQNVHGY; GQNVHGYL; QNVHGYLP; NVHGYLPF; VHGYLPFQ; HGYLPFQL; GYLPFQLL;YLPFQLLV; GKDQNNIV; KDQNNIVE; DQNNIVEY; QNNIVEYN; NNIVEYNY; NIVEYNYK;IVEYNYKS; VEYNYKSL; KIFLFFSA; IFLFFSAI; FLFFSAIP; LFFSAIPV; FFSAIPVR;FSAIPVRL; QTKKDPNA; QKYLHQET; KYLHQETE; YLHQETEY; LHQETEYH; HQETEYHS;QETEYHST; ETEYHSTH; TEYHSTHL; EYHSTHLG; TIPKPCLI; IPKPCLIA; PKPCLIAD;KPCLIADR; PCLIADRG; CLIADRGL; LIADRGLQ; IADRGLQW; ADRGLQWK; DRGLQWKL;RGLQWKLC; GLQWKLCD; LQWKLCDP; QWKLCDPN; WKLCDPNH; KLCDPNHQ; LCDPNHQR;CDPNHQRT; DPNHQRTY; PNHQRTYT; NHQRTYTL; HQRTYTLL; QRTYTLLE; RTYTLLEL;TYTLLELR; YTLLELRN; QFELKQQT; FELKQQTQ; ELKQQTQQ; PQEHQQLQ; QEHQQLQH;EHQQLQHM; HQQLQHMF; QQLQHMFE; QLQHMFEE; LQHMFEEL; QHMFEELG; HMFEELGL;PLRYLLCP; LRYLLCPL; RYLLCPLQ; QGMQFELL; QQQPPQQQ; QQPPQQQF; QPPQQQFQ;PPQQQFQP; PQQQFQPL; QQQFQPLK; QQFQPLKI; QFQPLKIL; FQPLKILW; QPLKILWQ;PLKILWQQ; LKILWQQQ; KILWQQQP; ILWQQQPQ; LWQQQPQI; WQQQPQIH; QQQPQIHW;QQPQIHWQ; QPQIHWQL; PQIHWQLG; QIHWQLGP; IHWQLGPP; HWQLGPPK; WQLGPPKV;QLGPPKVL; LGPPKVLE; GPPKVLEQ; PPKVLEQH; PKVLEQHP; TWKYKKKG; WKYKKKGI;KYKKKGIT; YKKKGITY; KKKGITYL; KKGITYLG; KGITYLGV; GITYLGVF; ITYLGVFY;TYLGVFYR; YLGVFYRV; LGVFYRVF; GVFYRVFY; VFYRVFYS; FYRVFYSR; SSGTFVFP;SGTFVFPV; GTFVFPVY; TFVFPVYT; FVFPVYTV; VFPVYTVF; FPVYTVFT; PVYTVFTS;VYTVFTST; YTVFTSTK; TVFTSTKF; VFTSTKFQ; FTSTKFQQ; TSTKFQQK; STKFQQKL;NKNKNPLS; KNKNPLSS; NKNPLSSF; KNPLSSFF; NPLSSFFC; PLSSFFCS; LSSFFCSS;SSFFCSSP; SFFCSSPG; FFCSSPGF; FCSSPGFT; CSSPGFTN; SSPGFTNF; SPGFTNFH;QLAQNHGL; LAQNHGLC; AQNHGLCP; QNHGLCPV; LGTRPRFL; GTRPRFLG; TRPRFLGS;RPRFLGSQ; PRFLGSQN; RFLGSQNM; FLGSQNMS; LGSQNMSV; GSQNMSVM; SQNMSVMH;QNMSVMHF; NMSVMHFP; MSVMHFPS; GHGLAAFH; HGLAAFHG; AAPPCESC; APPCESCT;PPCESCTF; PCESCTFL; CESCTFLP; ESCTFLPE; SCTFLPEV; CTFLPEVM; TFLPEVMV;FLPEVMVW; LPEVMVWL; PEVMVWLH; EVMVWLHS; VMVWLHSP; MVWLHSPV; VWLHSPVS;WLHSPVSH; LHSPVSHA; HSPVSHAL; SPVSHALS; PVSHALSF; VSHALSFL; SHALSFLR;HALSFLRS; ALSFLRSW; LSFLRSWF; SFLRSWFG; FLRSWFGC; LRSWFGCI; RSWFGCIP;SWFGCIPW; WFGCIPWV; FGCIPWVS; GCIPWVSS; CIPWVSSS; IPWVSSSS; PWVSSSSL;WVSSSSLW; VSSSSLWP; SSSSLWPF; SSSLWPFF; SSLWPFFL; YIRGRGRL; IRGRGRLC;RGRGRLCL; GRGRLCLH; RGRLCLHP; GRLCLHPF; RLCLHPFS; LCLHPFSQ; CLHPFSQV;LHPFSQVV; HPFSQVVR; PFSQVVRV; FSQVVRVW; SQVVRVWR; QVVRVWRL; VVRVWRLF;VRVWRLFL; RVWRLFLR; VWRLFLRP; WRLFLRPS; RLFLRPSK; LFLRPSKT; FLRPSKTI;LRPSKTIW; RPSKTIWG; PSKTIWGN; SKTIWGNP; KTIWGNPY; TIWGNPYS; IWGNPYSF;WGNPYSFA; GNPYSFAI; NPYSFAIF; PYSFAIFA; YSFAIFAK 9 mers:QGRIHGAHG; GRIHGAHGP; RIHGAHGPF; IHGAHGPFR; HGAHGPFRP; KSCLGKSSL;SCLGKSSLN; CLGKSSLNE; LGKSSLNEK; GKSSLNEKS; KSSLNEKSL; SSLNEKSLF;SLNEKSLFK; LNEKSLFKE; NEKSLFKEV; KNGAGCKGS; NGAGCKGSS; GAGCKGSSS;AGCKGSSSA; FSSLPRYPV; SSLPRYPVL; SLPRYPVLQ; LPRYPVLQG; PRYPVLQGM;RYPVLQGMA; YPVLQGMAY; PVLQGMAYL; VLQGMAYLF; LQGMAYLFQ; QGMAYLFQK;GMAYLFQKA; MAYLFQKAF; AYLFQKAFC; YLFQKAFCA; LFQKAFCAL; FQKAFCALP;QKAFCALPL; KAFCALPLH; AFCALPLHA; FCALPLHAM; CALPLHAMS; ALPLHAMSA;KIFKKRALG; IFKKRALGL; FKKRALGLD; KKRALGLDR; KRALGLDRL; RALGLDRLL;ALGLDRLLL; LGLDRLLLH; LLHTVVWLR; LHTVVWLRP; HTVVWLRPN; RNSAMVGPN;NSAMVGPNN; SAMVGPNNW; AMVGPNNWR; MVGPNNWRN; VGPNNWRNS; GPNNWRNSL;PNNWRNSLQ; NNWRNSLQR; NWRNSLQRS; WRNSLQRSK; RNSLQRSKA; NSLQRSKAL;SLQRSKALR; INNKILKGP; NNKILKGPK; VPTYGTEEW; PTYGTEEWE; TYGTEEWES;YGTEEWESW; GTEEWESWW; TEEWESWWS; EEWESWWSS; EWESWWSSF; WESWWSSFN;ESWWSSFNE; SWWSSFNEK; WWSSFNEKW; WSSFNEKWD; SSFNEKWDE; SFNEKWDED;FNEKWDEDL; NEKWDEDLF; EKWDEDLFC; KWDEDLFCH; WDEDLFCHE; DEDLFCHED;EDLFCHEDM; DLFCHEDMF; LFCHEDMFA; FCHEDMFAS; CHEDMFASD; HEDMFASDE;EDMFASDEE; DMFASDEEA; MFASDEEAT; FASDEEATA; ASDEEATAD; SDEEATADS;DEEATADSQ; EEATADSQH; EATADSQHS; ATADSQHST; TADSQHSTP; ADSQHSTPP;DSQHSTPPK; SQHSTPPKK; QHSTPPKKK; HSTPPKKKR; STPPKKKRK; TPPKKKRKV;PPKKKRKVE; PKKKRKVED; KKKRKVEDP; KKRKVEDPK; KRKVEDPKD; RKVEDPKDF;KVEDPKDFP; VEDPKDFPS; EDPKDFPSD; DPKDFPSDL; PKDFPSDLH; KDFPSDLHQ;DFPSDLHQF; FPSDLHQFL; PSDLHQFLS; SDLHQFLSQ; DLHQFLSQA; LHQFLSQAV;HQFLSQAVF; QFLSQAVFS; FLSQAVFSN; LSQAVFSNR; SQAVFSNRT; QAVFSNRTL;AVFSNRTLA; VFSNRTLAC; FSNRTLACF; SNRTLACFA; NRTLACFAV; RTLACFAVY;TLACFAVYT; LACFAVYTT; ACFAVYTTK; CFAVYTTKE; FAVYTTKEK; AVYTTKEKA;VYTTKEKAQ; YTTKEKAQI; TTKEKAQIL; TKEKAQILY; KEKAQILYK; EKAQILYKK;KAQILYKKL; AQILYKKLM; QILYKKLME; ILYKKLMEK; LYKKLMEKY; YKKLMEKYS;KKLMEKYSV; KLMEKYSVT; LMEKYSVTF; MEKYSVTFI; EKYSVTFIS; KYSVTFISR;YSVTFISRH; SVTFISRHM; VTFISRHMC; TFISRHMCA; FISRHMCAG; ISRHMCAGH;SRHMCAGHN; RHMCAGHNI; HMCAGHNII; MCAGHNIIF; CAGHNIIFF; AGHNIIFFL;GHNIIFFLT; HNIIFFLTP; NIIFFLTPH; IIFFLTPHR; IFFLTPHRH; FFLTPHRHR;FLTPHRHRV; LTPHRHRVS; TPHRHRVSA; PHRHRVSAI; HRHRVSAIN; RHRVSAINN;HRVSAINNF; RVSAINNFC; VSAINNFCQ; SAINNFCQK; AINNFCQKL; INNFCQKLC;NNFCQKLCT; NFCQKLCTF; FCQKLCTFS; CQKLCTFSF; QKLCTFSFL; KLCTFSFLI;LCTFSFLIC; CTFSFLICK; TFSFLICKG; FSFLICKGV; SFLICKGVN; FLICKGVNK;LICKGVNKE; ICKGVNKEY; CKGVNKEYL; KGVNKEYLL; GVNKEYLLY; VNKEYLLYS;NKEYLLYSA; KEYLLYSAL; EYLLYSALT; YLLYSALTR; LLYSALTRD; LYSALTRDP;YSALTRDPY; SALTRDPYH; ALTRDPYHT; LTRDPYHTI; TRDPYHTIE; RDPYHTIEE;DPYHTIEES; PYHTIEESI; YHTIEESIQ; HTIEESIQG; TIEESIQGG; IEESIQGGL;EESIQGGLK; ESIQGGLKE; SIQGGLKEH; IQGGLKEHD; QGGLKEHDF; GGLKEHDFS;GLKEHDFSP; LKEHDFSPE; KEHDFSPEE; EHDFSPEEP; HDFSPEEPE; DFSPEEPEE;FSPEEPEET; SPEEPEETK; PEEPEETKQ; EEPEETKQV; EPEETKQVS; PEETKQVSW;EETKQVSWK; ETKQVSWKL; TKQVSWKLI; KQVSWKLIT; QVSWKLITE; VSWKLITEY;SWKLITEYA; WKLITEYAV; KLITEYAVE; LITEYAVET; ITEYAVETK; TEYAVETKC;EYAVETKCE; YAVETKCED; AVETKCEDV; VETKCEDVF; ETKCEDVFL; TKCEDVFLL;KCEDVFLLL; CEDVFLLLG; EDVFLLLGM; DVFLLLGMY; VFLLLGMYL; FLLLGMYLE;LLLGMYLEF; LLGMYLEFQ; LGMYLEFQY; GMYLEFQYN; MYLEFQYNV; YLEFQYNVE;LEFQYNVEE; EFQYNVEEC; FQYNVEECK; QYNVEECKK; YNVEECKKC; NVEECKKCQ;VEECKKCQK; EECKKCQKK; ECKKCQKKD; CKKCQKKDQ; KKCQKKDQP; KCQKKDQPY;CQKKDQPYH; QKKDQPYHF; KKDQPYHFK; KDQPYHFKY; DQPYHFKYH; QPYHFKYHE;PYHFKYHEK; YHFKYHEKH; HFKYHEKHF; FKYHEKHFA; KYHEKHFAN; YHEKHFANA;HEKHFANAI; EKHFANAII; KHFANAIIF; HFANAIIFA; FANAIIFAE; ANAIIFAES;NAIIFAESK; AIIFAESKN; IIFAESKNQ; IFAESKNQK; FAESKNQKS; AESKNQKSI;ESKNQKSIC; SKNQKSICQ; KNQKSICQQ; NQKSICQQA; QKSICQQAV; KSICQQAVD;SICQQAVDT; ICQQAVDTV; CQQAVDTVL; QQAVDTVLA; QAVDTVLAK; AVDTVLAKK;VDTVLAKKR; DTVLAKKRV; TVLAKKRVD; VLAKKRVDT; LAKKRVDTL; AKKRVDTLH;KKRVDTLHM; KRVDTLHMT; RVDTLHMTR; VDTLHMTRE; DTLHMTREE; TLHMTREEM;LHMTREEML; HMTREEMLT; MTREEMLTE; TREEMLTER; REEMLTERF; EEMLTERFN;EMLTERFNH; MLTERFNHI; LTERFNHIL; TERFNHILD; ERFNHILDK; RFNHILDKM;FNHILDKMD; NHILDKMDL; HILDKMDLI; ILDKMDLIF; LDKMDLIFG; DKMDLIFGA;KMDLIFGAH; MDLIFGAHG; DLIFGAHGN; LIFGAHGNA; IFGAHGNAV; FGAHGNAVL;GAHGNAVLE; AHGNAVLEQ; HGNAVLEQY; GNAVLEQYM; NAVLEQYMA; AVLEQYMAG;VLEQYMAGV; LEQYMAGVA; EQYMAGVAW; QYMAGVAWL; YMAGVAWLH; MAGVAWLHC;AGVAWLHCL; GVAWLHCLL; VAWLHCLLP; AWLHCLLPK; WLHCLLPKM; LHCLLPKMD;HCLLPKMDS; CLLPKMDSV; LLPKMDSVI; LPKMDSVIF; PKMDSVIFD; KMDSVIFDF;MDSVIFDFL; DSVIFDFLH; SVIFDFLHC; VIFDFLHCI; IFDFLHCIV; FDFLHCIVF;DFLHCIVFN; FLHCIVFNV; LHCIVFNVP; HCIVFNVPK; CIVFNVPKR; IVFNVPKRR;VFNVPKRRY; FNVPKRRYW; NVPKRRYWL; VPKRRYWLF; PKRRYWLFK; KRRYWLFKG;RRYWLFKGP; RYWLFKGPI; YWLFKGPID; WLFKGPIDS; LFKGPIDSG; FKGPIDSGK;KGPIDSGKT; GPIDSGKTT; PIDSGKTTL; IDSGKTTLA; DSGKTTLAA; SGKTTLAAG;GKTTLAAGL; KTTLAAGLL; TTLAAGLLD; TLAAGLLDL; LAAGLLDLC; AAGLLDLCG;AGLLDLCGG; GLLDLCGGK; LLDLCGGKA; LDLCGGKAL; DLCGGKALN; LCGGKALNV;CGGKALNVN; GGKALNVNL; GKALNVNLP; KALNVNLPM; ALNVNLPME; LNVNLPMER;NVNLPMERL; VNLPMERLT; NLPMERLTF; LPMERLTFE; PMERLTFEL; MERLTFELG;ERLTFELGV; RLTFELGVA; LTFELGVAI; TFELGVAID; FELGVAIDQ; ELGVAIDQY;LGVAIDQYM; GVAIDQYMV; VAIDQYMVV; AIDQYMVVF; IDQYMVVFE; DQYMVVFED;QYMVVFEDV; YMVVFEDVK; MVVFEDVKG; VVFEDVKGT; VFEDVKGTG; FEDVKGTGA;EDVKGTGAE; DVKGTGAES; VKGTGAESK; KGTGAESKD; GTGAESKDL; TGAESKDLP;GAESKDLPS; AESKDLPSG; ESKDLPSGH; SKDLPSGHG; KDLPSGHGI; DLPSGHGIN;LPSGHGINN; PSGHGINNL; SGHGINNLD; GHGINNLDS; HGINNLDSL; GINNLDSLR;INNLDSLRD; NNLDSLRDY; NLDSLRDYL; LDSLRDYLD; DSLRDYLDG; SLRDYLDGS;LRDYLDGSV; RDYLDGSVK; DYLDGSVKV; YLDGSVKVN; LDGSVKVNL; DGSVKVNLE;GSVKVNLEK; SVKVNLEKK; VKVNLEKKH; KVNLEKKHL; VNLEKKHLN; NLEKKHLNK;LEKKHLNKR; EKKHLNKRT; KKHLNKRTQ; KHLNKRTQI; HLNKRTQIF; LNKRTQIFP;NKRTQIFPP; KRTQIFPPG; RTQIFPPGL; TQIFPPGLV; QIFPPGLVT; IFPPGLVTM;FPPGLVTMN; PPGLVTMNE; PGLVTMNEY; GLVTMNEYP; LVTMNEYPV; VTMNEYPVP;TMNEYPVPK; MNEYPVPKT; NEYPVPKTL; EYPVPKTLQ; YPVPKTLQA; PVPKTLQAR;VPKTLQARF; PKTLQARFV; KTLQARFVR; TLQARFVRQ; LQARFVRQI; QARFVRQID;ARFVRQIDF; RFVRQIDFR; FVRQIDFRP; VRQIDFRPK; RQIDFRPKI; QIDFRPKIY;IDFRPKIYL; DFRPKIYLR; FRPKIYLRK; RPKIYLRKS; PKIYLRKSL; KIYLRKSLQ;IYLRKSLQN; YLRKSLQNS; LRKSLQNSE; RKSLQNSEF; KSLQNSEFL; SLQNSEFLL;LQNSEFLLE; QNSEFLLEK; NSEFLLEKR; SEFLLEKRI; EFLLEKRIL; FLLEKRILQ;LLEKRILQS; LEKRILQSG; EKRILQSGM; KRILQSGMT; RILQSGMTL; ILQSGMTLL;LQSGMTLLL; QSGMTLLLL; SGMTLLLLL; GMTLLLLLI; MTLLLLLIW; TLLLLLIWF;LLLLLIWFR; LLLLIWFRP; LLLIWFRPV; LLIWFRPVA; LIWFRPVAD; IWFRPVADF;WFRPVADFA; FRPVADFAT; RPVADFATD; PVADFATDI; VADFATDIQ; ADFATDIQS;DFATDIQSR; FATDIQSRI; ATDIQSRIV; TDIQSRIVE; DIQSRIVEW; IQSRIVEWK;QSRIVEWKE; SRIVEWKER; RIVEWKERL; IVEWKERLD; VEWKERLDS; EWKERLDSE;WKERLDSEI; KERLDSEIS; ERLDSEISM; RLDSEISMY; LDSEISMYT; DSEISMYTF;SEISMYTFS; EISMYTFSR; ISMYTFSRM; SMYTFSRMK; MYTFSRMKY; YTFSRMKYN;TFSRMKYNI; FSRMKYNIC; SRMKYNICM; RMKYNICMG; MKYNICMGK; KYNICMGKC;YNICMGKCI; NICMGKCIL; ICMGKCILD; CMGKCILDI; MGKCILDIT; GKCILDITR;KCILDITRE; CILDITREE; ILDITREED; LDITREEDS; DITREEDSE; ITREEDSET;TREEDSETE; REEDSETED; EEDSETEDS; EDSETEDSG; DSETEDSGH; SETEDSGHG;ETEDSGHGS; TEDSGHGSS; EDSGHGSST; DSGHGSSTE; SGHGSSTES; GHGSSTESQ;HGSSTESQS; GSSTESQSQ; SSTESQSQC; STESQSQCS; TESQSQCSS; ESQSQCSSQ;SQSQCSSQV; QSQCSSQVS; SQCSSQVSD; QCSSQVSDT; CSSQVSDTS; SSQVSDTSA;SQVSDTSAP; QVSDTSAPA; VSDTSAPAE; SDTSAPAED; DTSAPAEDS; TSAPAEDSQ;SAPAEDSQR; APAEDSQRS; PAEDSQRSD; AEDSQRSDP; EDSQRSDPH; DSQRSDPHS;SQRSDPHSQ; QRSDPHSQE; RSDPHSQEL; SDPHSQELH; DPHSQELHL; PHSQELHLC;HSQELHLCK; SQELHLCKG; QELHLCKGF; ELHLCKGFQ; LHLCKGFQC; HLCKGFQCF;LCKGFQCFK; CKGFQCFKR; KGFQCFKRP; GFQCFKRPK; FQCFKRPKT; QCFKRPKTP;CFKRPKTPP; FKRPKTPPP; KRPKTPPPK; HKLKSGLYK; KLKSGLYKS; LKSGLYKSS;KSGLYKSSI; SGLYKSSIY; MYMYNKSTC; YMYNKSTCL; MYNKSTCLK; YNKSTCLKH;NKSTCLKHF; KSTCLKHFG; STCLKHFGL; TCLKHFGLQ; CLKHFGLQL; LKHFGLQLS;KHFGLQLSL; HFGLQLSLF; FGLQLSLFV; GLQLSLFVN; LQLSLFVNI; QLSLFVNIS;LSLFVNISY; SLFVNISYH; LFVNISYHI; FVNISYHIW; VNISYHIWV; NISYHIWVP;ISYHIWVPW; SYHIWVPWK; YHIWVPWKS; HIWVPWKSF; IWVPWKSFC; WVPWKSFCA;VPWKSFCAI; PWKSFCAIK; WKSFCAIKH; KSFCAIKHP; SFCAIKHPN; FCAIKHPNL;CAIKHPNLF; AIKHPNLFY; IKHPNLFYL; KHPNLFYLG; HPNLFYLGF; PNLFYLGFH;NLFYLGFHT; LFYLGFHTI; FYLGFHTIH; YLGFHTIHR; LGFHTIHRL; GFHTIHRLP;FHTIHRLPI; HTIHRLPIH; TIHRLPIHS; IHRLPIHSL; HRLPIHSLG; RLPIHSLGS;LPIHSLGSP; PIHSLGSPV; IHSLGSPVY; HSLGSPVYK; SLGSPVYKV; LGSPVYKVT;QKGNWVRIL; KGNWVRILY; GNWVRILYR; NWVRILYRS; WVRILYRSF; VRILYRSFS;RILYRSFSQ; ILYRSFSQA; LYRSFSQAD; YRSFSQADL; RSFSQADLK; SFSQADLKI;FSQADLKIS; SQADLKISC; QADLKISCK; ADLKISCKA; DLKISCKAS; LKISCKASP;KISCKASPL; ISCKASPLL; SCKASPLLC; CKASPLLCS; KASPLLCSR; ASPLLCSRA;SPLLCSRAV; PLLCSRAVS; LLCSRAVSK; LCSRAVSKQ; CSRAVSKQA; SRAVSKQAT;RAVSKQATN; AVSKQATNI; VSKQATNIS; SKQATNISS; NIQAISFTK; IQAISFTKR;QAISFTKRP; AISFTKRPH; ISFTKRPHT; SFTKRPHTL; FTKRPHTLF; TKRPHTLFI;QHCGSCVGH; HCGSCVGHM; CGSCVGHMK; GSCVGHMKY; SCVGHMKYW; CVGHMKYWG;VGHMKYWGN; GHMKYWGNI; HMKYWGNIF; MKYWGNIFP; KYWGNIFPS; YWGNIFPSC;WGNIFPSCE; GNIFPSCES; NIFPSCESP; IFPSCESPK; FPSCESPKI; PSCESPKIP;SCESPKIPS; CESPKIPSI; ESPKIPSIF; SPKIPSIFI; PKIPSIFIS; KIPSIFIST;IPSIFISTG; PSIFISTGI; SIFISTGIR; IFISTGIRY; FISTGIRYP; ISTGIRYPA;STGIRYPAL; TGIRYPALN; GIRYPALNW; IRYPALNWI; RYPALNWIS; YPALNWISI;PALNWISIV; ALNWISIVF; LNWISIVFV; NWISIVFVQ; WISIVFVQI; ISIVFVQIG;SIVFVQIGL; IVFVQIGLM; VFVQIGLMV; FVQIGLMVS; VQIGLMVSI; QIGLMVSIH;IGLMVSIHY; GLMVSIHYL; LMVSIHYLG; MVSIHYLGL; VSIHYLGLG; SIHYLGLGC;IHYLGLGCW; HYLGLGCWV; YLGLGCWVF; LGLGCWVFR; GLGCWVFRG; LGCWVFRGY;GCWVFRGYS; CWVFRGYST; WVFRGYSTI; VFRGYSTIR; FRGYSTIRV; RGYSTIRVL;HSLHFQGFS; SLHFQGFST; LHFQGFSTY; HFQGFSTYS; FQGFSTYSK; QGFSTYSKE;GFSTYSKEV; FSTYSKEVE; STYSKEVEI; TYSKEVEIT; YSKEVEITA; SKEVEITAL;KEVEITALN; EVEITALNR; VEITALNRF; EITALNRFS; ITALNRFSS; TALNRFSST;ALNRFSSTM; LNRFSSTML; NRFSSTMLM; RFSSTMLMH; FSSTMLMHF; SSTMLMHFL;PCMKVKHAS; CMKVKHASY; MKVKHASYS; KVKHASYSN; VKHASYSNN; KHASYSNNL;HASYSNNLC; ASYSNNLCL; SYSNNLCLY; YSNNLCLYS; SNNLCLYSY; NNLCLYSYS;NLCLYSYSL; LCLYSYSLP; CLYSYSLPH; LYSYSLPHQ; IGEGNSCCA; GEGNSCCAV;EGNSCCAVT; GNSCCAVTG; NSCCAVTGK; SCCAVTGKH; CCAVTGKHF; CAVTGKHFS;AVTGKHFSL; VTGKHFSLW; TGKHFSLWA; GKHFSLWAI; KHFSLWAIT; HFSLWAITA;FSLWAITAK; SLWAITAKV; LWAITAKVI; WAITAKVIF; AITAKVIFS; ITAKVIFST;TKAPKVFIW; KAPKVFIWI; APKVFIWIP; PKVFIWIPH; KVFIWIPHF; VFIWIPHFW;FIWIPHFWV; EAFYLCNSI; AFYLCNSIY; FYLCNSIYP; YLCNSIYPS; LCNSIYPSF;CNSIYPSFN; NSIYPSFNF; FWHLHGFLW; WHLHGFLWL; HLHGFLWLF; LHGFLWLFG;HGFLWLFGS; GFLWLFGSC; FLWLFGSCP; LWLFGSCPW; WLFGSCPWT; LFGSCPWTL;FGSCPWTLS; GSCPWTLSF; SCPWTLSFS; CPWTLSFSF; PWTLSFSFG; WTLSFSFGW;TLSFSFGWG; LSFSFGWGH; SFSFGWGHL; FSFGWGHLH; SFGWGHLHM; FGWGHLHML;GWGHLHMLQ; WGHLHMLQE; GHLHMLQEQ; HLHMLQEQV; LHMLQEQVL; HMLQEQVLQ;MLQEQVLQS; LQEQVLQSR; QEQVLQSRT; EQVLQSRTG; QVLQSRTGL; VLQSRTGLE;LQSRTGLEV; QSRTGLEVK; SRTGLEVKA; RTGLEVKAT; TGLEVKATS; GLEVKATSI;LEVKATSIE; EVKATSIEE; VKATSIEEQ; KATSIEEQF; ATSIEEQFF; TSIEEQFFD;TLLNVHFVD; LLNVHFVDF; LNVHFVDFL; NVHFVDFLS; VHFVDFLSP; HFVDFLSPF;FVDFLSPFF; VDFLSPFFV; LLLYCQHHL; LLYCQHHLY; LYCQHHLYY; YCQHHLYYK;CQHHLYYKY; QHHLYYKYG; HHLYYKYGQ; HLYYKYGQN; LYYKYGQNV; YYKYGQNVH;YKYGQNVHG; KYGQNVHGY; YGQNVHGYL; GQNVHGYLP; QNVHGYLPF; NVHGYLPFQ;VHGYLPFQL; HGYLPFQLL; GYLPFQLLV; GKDQNNIVE; KDQNNIVEY; DQNNIVEYN;QNNIVEYNY; NNIVEYNYK; NIVEYNYKS; IVEYNYKSL; KIFLFFSAI; IFLFFSAIP;FLFFSAIPV; LFFSAIPVR; FFSAIPVRL; QKYLHQETE; KYLHQETEY; YLHQETEYH;LHQETEYHS; HQETEYHST; QETEYHSTH; ETEYHSTHL; TEYHSTHLG; TIPKPCLIA;IPKPCLIAD; PKPCLIADR; KPCLIADRG; PCLIADRGL; CLIADRGLQ; LIADRGLQW;IADRGLQWK; ADRGLQWKL; DRGLQWKLC; RGLQWKLCD; GLQWKLCDP; LQWKLCDPN;QWKLCDPNH; WKLCDPNHQ; KLCDPNHQR; LCDPNHQRT; CDPNHQRTY; DPNHQRTYT;PNHQRTYTL; NHQRTYTLL; HQRTYTLLE; QRTYTLLEL; RTYTLLELR; TYTLLELRN;QFELKQQTQ; FELKQQTQQ; PQEHQQLQH; QEHQQLQHM; EHQQLQHMF; HQQLQHMFE;QQLQHMFEE; QLQHMFEEL; LQHMFEELG; QHMFEELGL; PLRYLLCPL; LRYLLCPLQ;QQQPPQQQF; QQPPQQQFQ; QPPQQQFQP; PPQQQFQPL; PQQQFQPLK; QQQFQPLKI;QQFQPLKIL; QFQPLKILW; FQPLKILWQ; QPLKILWQQ; PLKILWQQQ; LKILWQQQP;KILWQQQPQ; ILWQQQPQI; LWQQQPQIH; WQQQPQIHW; QQQPQIHWQ; QQPQIHWQL;QPQIHWQLG; PQIHWQLGP; QIHWQLGPP; IHWQLGPPK; HWQLGPPKV; WQLGPPKVL;QLGPPKVLE; LGPPKVLEQ; GPPKVLEQH; PPKVLEQHP; TWKYKKKGI; WKYKKKGIT;KYKKKGITY; YKKKGITYL; KKKGITYLG; KKGITYLGV; KGITYLGVF; GITYLGVFY;ITYLGVFYR; TYLGVFYRV; YLGVFYRVF; LGVFYRVFY; GVFYRVFYS; VFYRVFYSR;SSGTFVFPV; SGTFVFPVY; GTFVFPVYT; TFVFPVYTV; FVFPVYTVF; VFPVYTVFT;FPVYTVFTS; PVYTVFTST; VYTVFTSTK; YTVFTSTKF; TVFTSTKFQ; VFTSTKFQQ;FTSTKFQQK; TSTKFQQKL; NKNKNPLSS; KNKNPLSSF; NKNPLSSFF; KNPLSSFFC;NPLSSFFCS; PLSSFFCSS; LSSFFCSSP; SSFFCSSPG; SFFCSSPGF; FFCSSPGFT;FCSSPGFTN; CSSPGFTNF; SSPGFTNFH; QLAQNHGLC; LAQNHGLCP; AQNHGLCPV;LGTRPRFLG; GTRPRFLGS; TRPRFLGSQ; RPRFLGSQN; PRFLGSQNM; RFLGSQNMS;FLGSQNMSV; LGSQNMSVM; GSQNMSVMH; SQNMSVMHF; QNMSVMHFP; NMSVMHFPS;GHGLAAFHG; AAPPCESCT; APPCESCTF; PPCESCTFL; PCESCTFLP; CESCTFLPE;ESCTFLPEV; SCTFLPEVM; CTFLPEVMV; TFLPEVMVW; FLPEVMVWL; LPEVMVWLH;PEVMVWLHS; EVMVWLHSP; VMVWLHSPV; MVWLHSPVS; VWLHSPVSH; WLHSPVSHA;LHSPVSHAL; HSPVSHALS; SPVSHALSF; PVSHALSFL; VSHALSFLR; SHALSFLRS;HALSFLRSW; ALSFLRSWF; LSFLRSWFG; SFLRSWFGC; FLRSWFGCI; LRSWFGCIP;RSWFGCIPW; SWFGCIPWV; WFGCIPWVS; FGCIPWVSS; GCIPWVSSS; CIPWVSSSS;IPWVSSSSL; PWVSSSSLW; WVSSSSLWP; VSSSSLWPF; SSSSLWPFF; SSSLWPFFL;YIRGRGRLC; IRGRGRLCL; RGRGRLCLH; GRGRLCLHP; RGRLCLHPF; GRLCLHPFS;RLCLHPFSQ; LCLHPFSQV; CLHPFSQVV; LHPFSQVVR; HPFSQVVRV; PFSQVVRVW;FSQVVRVWR; SQVVRVWRL; QVVRVWRLF; VVRVWRLFL; VRVWRLFLR; RVWRLFLRP;VWRLFLRPS; WRLFLRPSK; RLFLRPSKT; LFLRPSKTI; FLRPSKTIW; LRPSKTIWG;RPSKTIWGN; PSKTIWGNP; SKTIWGNPY; KTIWGNPYS; TIWGNPYSF; IWGNPYSFA;WGNPYSFAI; GNPYSFAIF; NPYSFAIFA; PYSFAIFAK 10 mers:QGRIHGAHGP; GRIHGAHGPF; RIHGAHGPFR; IHGAHGPFRP; KSCLGKSSLN;SCLGKSSLNE; CLGKSSLNEK; LGKSSLNEKS; GKSSLNEKSL; KSSLNEKSLF;SSLNEKSLFK; SLNEKSLFKE; LNEKSLFKEV; KNGAGCKGSS; NGAGCKGSSS;GAGCKGSSSA; FSSLPRYPVL; SSLPRYPVLQ; SLPRYPVLQG; LPRYPVLQGM;PRYPVLQGMA; RYPVLQGMAY; YPVLQGMAYL; PVLQGMAYLF; VLQGMAYLFQ;LQGMAYLFQK; QGMAYLFQKA; GMAYLFQKAF; MAYLFQKAFC; AYLFQKAFCA;YLFQKAFCAL; LFQKAFCALP; FQKAFCALPL; QKAFCALPLH; KAFCALPLHA;AFCALPLHAM; FCALPLHAMS; CALPLHAMSA; KIFKKRALGL; IFKKRALGLD;FKKRALGLDR; KKRALGLDRL; KRALGLDRLL; RALGLDRLLL; ALGLDRLLLH;LLHTVVWLRP; LHTVVWLRPN; RNSAMVGPNN; NSAMVGPNNW; SAMVGPNNWR;AMVGPNNWRN; MVGPNNWRNS; VGPNNWRNSL; GPNNWRNSLQ; PNNWRNSLQR;NNWRNSLQRS; NWRNSLQRSK; WRNSLQRSKA; RNSLQRSKAL; NSLQRSKALR;INNKILKGPK; VPTYGTEEWE; PTYGTEEWES; TYGTEEWESW; YGTEEWESWW;GTEEWESWWS; TEEWESWWSS; EEWESWWSSF; EWESWWSSFN; WESWWSSFNE;ESWWSSFNEK; SWWSSFNEKW; WWSSFNEKWD; WSSFNEKWDE; SSFNEKWDED;SFNEKWDEDL; FNEKWDEDLF; NEKWDEDLFC; EKWDEDLFCH; KWDEDLFCHE;WDEDLFCHED; DEDLFCHEDM; EDLFCHEDMF; DLFCHEDMFA; LFCHEDMFAS;FCHEDMFASD; CHEDMFASDE; HEDMFASDEE; EDMFASDEEA; DMFASDEEAT;MFASDEEATA; FASDEEATAD; ASDEEATADS; SDEEATADSQ; DEEATADSQH;EEATADSQHS; EATADSQHST; ATADSQHSTP; TADSQHSTPP; ADSQHSTPPK;DSQHSTPPKK; SQHSTPPKKK; QHSTPPKKKR; HSTPPKKKRK; STPPKKKRKV;TPPKKKRKVE; PPKKKRKVED; PKKKRKVEDP; KKKRKVEDPK; KKRKVEDPKD;KRKVEDPKDF; RKVEDPKDFP; KVEDPKDFPS; VEDPKDFPSD; EDPKDFPSDL;DPKDFPSDLH; PKDFPSDLHQ; KDFPSDLHQF; DFPSDLHQFL; FPSDLHQFLS;PSDLHQFLSQ; SDLHQFLSQA; DLHQFLSQAV; LHQFLSQAVF; HQFLSQAVFS;QFLSQAVFSN; FLSQAVFSNR; LSQAVFSNRT; SQAVFSNRTL; QAVFSNRTLA;AVFSNRTLAC; VFSNRTLACF; FSNRTLACFA; SNRTLACFAV; NRTLACFAVY;RTLACFAVYT; TLACFAVYTT; LACFAVYTTK; ACFAVYTTKE; CFAVYTTKEK;FAVYTTKEKA; AVYTTKEKAQ; VYTTKEKAQI; YTTKEKAQIL; TTKEKAQILY;TKEKAQILYK; KEKAQILYKK; EKAQILYKKL; KAQILYKKLM; AQILYKKLME;QILYKKLMEK; ILYKKLMEKY; LYKKLMEKYS; YKKLMEKYSV; KKLMEKYSVT;KLMEKYSVTF; LMEKYSVTFI; MEKYSVTFIS; EKYSVTFISR; KYSVTFISRH;YSVTFISRHM; SVTFISRHMC; VTFISRHMCA; TFISRHMCAG; FISRHMCAGH;ISRHMCAGHN; SRHMCAGHNI; RHMCAGHNII; HMCAGHNIIF; MCAGHNIIFF;CAGHNIIFFL; AGHNIIFFLT; GHNIIFFLTP; HNIIFFLTPH; NIIFFLTPHR;IIFFLTPHRH; IFFLTPHRHR; FFLTPHRHRV; FLTPHRHRVS; LTPHRHRVSA;TPHRHRVSAI; PHRHRVSAIN; HRHRVSAINN; RHRVSAINNF; HRVSAINNFC;RVSAINNFCQ; VSAINNFCQK; SAINNFCQKL; AINNFCQKLC; INNFCQKLCT;NNFCQKLCTF; NFCQKLCTFS; FCQKLCTFSF; CQKLCTFSFL; QKLCTFSFLI;KLCTFSFLIC; LCTFSFLICK; CTFSFLICKG; TFSFLICKGV; FSFLICKGVN;SFLICKGVNK; FLICKGVNKE; LICKGVNKEY; ICKGVNKEYL; CKGVNKEYLL;KGVNKEYLLY; GVNKEYLLYS; VNKEYLLYSA; NKEYLLYSAL; KEYLLYSALT;EYLLYSALTR; YLLYSALTRD; LLYSALTRDP; LYSALTRDPY; YSALTRDPYH;SALTRDPYHT; ALTRDPYHTI; LTRDPYHTIE; TRDPYHTIEE; RDPYHTIEES;DPYHTIEESI; PYHTIEESIQ; YHTIEESIQG; HTIEESIQGG; TIEESIQGGL;IEESIQGGLK; EESIQGGLKE; ESIQGGLKEH; SIQGGLKEHD; IQGGLKEHDF;QGGLKEHDFS; GGLKEHDFSP; GLKEHDFSPE; LKEHDFSPEE; KEHDFSPEEP;EHDFSPEEPE; HDFSPEEPEE; DFSPEEPEET; FSPEEPEETK; SPEEPEETKQ;PEEPEETKQV; EEPEETKQVS; EPEETKQVSW; PEETKQVSWK; EETKQVSWKL;ETKQVSWKLI; TKQVSWKLIT; KQVSWKLITE; QVSWKLITEY; VSWKLITEYA;SWKLITEYAV; WKLITEYAVE; KLITEYAVET; LITEYAVETK; ITEYAVETKC;TEYAVETKCE; EYAVETKCED; YAVETKCEDV; AVETKCEDVF; VETKCEDVFL;ETKCEDVFLL; TKCEDVFLLL; KCEDVFLLLG; CEDVFLLLGM; EDVFLLLGMY;DVFLLLGMYL; VFLLLGMYLE; FLLLGMYLEF; LLLGMYLEFQ; LLGMYLEFQY;LGMYLEFQYN; GMYLEFQYNV; MYLEFQYNVE; YLEFQYNVEE; LEFQYNVEEC;EFQYNVEECK; FQYNVEECKK; QYNVEECKKC; YNVEECKKCQ; NVEECKKCQK;VEECKKCQKK; EECKKCQKKD; ECKKCQKKDQ; CKKCQKKDQP; KKCQKKDQPY;KCQKKDQPYH; CQKKDQPYHF; QKKDQPYHFK; KKDQPYHFKY; KDQPYHFKYH;DQPYHFKYHE; QPYHFKYHEK; PYHFKYHEKH; YHFKYHEKHF; HFKYHEKHFA;FKYHEKHFAN; KYHEKHFANA; YHEKHFANAI; HEKHFANAII; EKHFANAIIF;KHFANAIIFA; HFANAIIFAE; FANAIIFAES; ANAIIFAESK; NAIIFAESKN;AIIFAESKNQ; IIFAESKNQK; IFAESKNQKS; FAESKNQKSI; AESKNQKSIC;ESKNQKSICQ; SKNQKSICQQ; KNQKSICQQA; NQKSICQQAV; QKSICQQAVD;KSICQQAVDT; SICQQAVDTV; ICQQAVDTVL; CQQAVDTVLA; QQAVDTVLAK;QAVDTVLAKK; AVDTVLAKKR; VDTVLAKKRV; DTVLAKKRVD; TVLAKKRVDT;VLAKKRVDTL; LAKKRVDTLH; AKKRVDTLHM; KKRVDTLHMT; KRVDTLHMTR;RVDTLHMTRE; VDTLHMTREE; DTLHMTREEM; TLHMTREEML; LHMTREEMLT;HMTREEMLTE; MTREEMLTER; TREEMLTERF; REEMLTERFN; EEMLTERFNH;EMLTERFNHI; MLTERFNHIL; LTERFNHILD; TERFNHILDK; ERFNHILDKM;RFNHILDKMD; FNHILDKMDL; NHILDKMDLI; HILDKMDLIF; ILDKMDLIFG;LDKMDLIFGA; DKMDLIFGAH; KMDLIFGAHG; MDLIFGAHGN; DLIFGAHGNA;LIFGAHGNAV; IFGAHGNAVL; FGAHGNAVLE; GAHGNAVLEQ; AHGNAVLEQY;HGNAVLEQYM; GNAVLEQYMA; NAVLEQYMAG; AVLEQYMAGV; VLEQYMAGVA;LEQYMAGVAW; EQYMAGVAWL; QYMAGVAWLH; YMAGVAWLHC; MAGVAWLHCL;AGVAWLHCLL; GVAWLHCLLP; VAWLHCLLPK; AWLHCLLPKM; WLHCLLPKMD;LHCLLPKMDS; HCLLPKMDSV; CLLPKMDSVI; LLPKMDSVIF; LPKMDSVIFD;PKMDSVIFDF; KMDSVIFDFL; MDSVIFDFLH; DSVIFDFLHC; SVIFDFLHCI;VIFDFLHCIV; IFDFLHCIVF; FDFLHCIVFN; DFLHCIVFNV; FLHCIVFNVP;LHCIVFNVPK; HCIVFNVPKR; CIVFNVPKRR; IVFNVPKRRY; VFNVPKRRYW;FNVPKRRYWL; NVPKRRYWLF; VPKRRYWLFK; PKRRYWLFKG; KRRYWLFKGP;RRYWLFKGPI; RYWLFKGPID; YWLFKGPIDS; WLFKGPIDSG; LFKGPIDSGK;FKGPIDSGKT; KGPIDSGKTT; GPIDSGKTTL; PIDSGKTTLA; IDSGKTTLAA;DSGKTTLAAG; SGKTTLAAGL; GKTTLAAGLL; KTTLAAGLLD; TTLAAGLLDL;TLAAGLLDLC; LAAGLLDLCG; AAGLLDLCGG; AGLLDLCGGK; GLLDLCGGKA;LLDLCGGKAL; LDLCGGKALN; DLCGGKALNV; LCGGKALNVN; CGGKALNVNL;GGKALNVNLP; GKALNVNLPM; KALNVNLPME; ALNVNLPMER; LNVNLPMERL;NVNLPMERLT; VNLPMERLTF; NLPMERLTFE; LPMERLTFEL; PMERLTFELG;MERLTFELGV; ERLTFELGVA; RLTFELGVAI; LTFELGVAID; TFELGVAIDQ;FELGVAIDQY; ELGVAIDQYM; LGVAIDQYMV; GVAIDQYMVV; VAIDQYMVVF;AIDQYMVVFE; IDQYMVVFED; DQYMVVFEDV; QYMVVFEDVK; YMVVFEDVKG;MVVFEDVKGT; VVFEDVKGTG; VFEDVKGTGA; FEDVKGTGAE; EDVKGTGAES;DVKGTGAESK; VKGTGAESKD; KGTGAESKDL; GTGAESKDLP; TGAESKDLPS;GAESKDLPSG; AESKDLPSGH; ESKDLPSGHG; SKDLPSGHGI; KDLPSGHGIN;DLPSGHGINN; LPSGHGINNL; PSGHGINNLD; SGHGINNLDS; GHGINNLDSL;HGINNLDSLR; GINNLDSLRD; INNLDSLRDY; NNLDSLRDYL; NLDSLRDYLD;LDSLRDYLDG; DSLRDYLDGS; SLRDYLDGSV; LRDYLDGSVK; RDYLDGSVKV;DYLDGSVKVN; YLDGSVKVNL; LDGSVKVNLE; DGSVKVNLEK; GSVKVNLEKK;SVKVNLEKKH; VKVNLEKKHL; KVNLEKKHLN; VNLEKKHLNK; NLEKKHLNKR;LEKKHLNKRT; EKKHLNKRTQ; KKHLNKRTQI; KHLNKRTQIF; HLNKRTQIFP;LNKRTQIFPP; NKRTQIFPPG; KRTQIFPPGL; RTQIFPPGLV; TQIFPPGLVT;QIFPPGLVTM; IFPPGLVTMN; FPPGLVTMNE; PPGLVTMNEY; PGLVTMNEYP;GLVTMNEYPV; LVTMNEYPVP; VTMNEYPVPK; TMNEYPVPKT; MNEYPVPKTL;NEYPVPKTLQ; EYPVPKTLQA; YPVPKTLQAR; PVPKTLQARF; VPKTLQARFV;PKTLQARFVR; KTLQARFVRQ; TLQARFVRQI; LQARFVRQID; QARFVRQIDF;ARFVRQIDFR; RFVRQIDFRP; FVRQIDFRPK; VRQIDFRPKI; RQIDFRPKIY;QIDFRPKIYL; IDFRPKIYLR; DFRPKIYLRK; FRPKIYLRKS; RPKIYLRKSL;PKIYLRKSLQ; KIYLRKSLQN; IYLRKSLQNS; YLRKSLQNSE; LRKSLQNSEF;RKSLQNSEFL; KSLQNSEFLL; SLQNSEFLLE; LQNSEFLLEK; QNSEFLLEKR;NSEFLLEKRI; SEFLLEKRIL; EFLLEKRILQ; FLLEKRILQS; LLEKRILQSG;LEKRILQSGM; EKRILQSGMT; KRILQSGMTL; RILQSGMTLL; ILQSGMTLLL;LQSGMTLLLL; QSGMTLLLLL; SGMTLLLLLI; GMTLLLLLIW; MTLLLLLIWF;TLLLLLIWFR; LLLLLIWFRP; LLLLIWFRPV; LLLIWFRPVA; LLIWFRPVAD;LIWFRPVADF; IWFRPVADFA; WFRPVADFAT; FRPVADFATD; RPVADFATDI;PVADFATDIQ; VADFATDIQS; ADFATDIQSR; DFATDIQSRI; FATDIQSRIV;ATDIQSRIVE; TDIQSRIVEW; DIQSRIVEWK; IQSRIVEWKE; QSRIVEWKER;SRIVEWKERL; RIVEWKERLD; IVEWKERLDS; VEWKERLDSE; EWKERLDSEI;WKERLDSEIS; KERLDSEISM; ERLDSEISMY; RLDSEISMYT; LDSEISMYTF;DSEISMYTFS; SEISMYTFSR; EISMYTFSRM; ISMYTFSRMK; SMYTFSRMKY;MYTFSRMKYN; YTFSRMKYNI; TFSRMKYNIC; FSRMKYNICM; SRMKYNICMG;RMKYNICMGK; MKYNICMGKC; KYNICMGKCI; YNICMGKCIL; NICMGKCILD;ICMGKCILDI; CMGKCILDIT; MGKCILDITR; GKCILDITRE; KCILDITREE;CILDITREED; ILDITREEDS; LDITREEDSE; DITREEDSET; ITREEDSETE;TREEDSETED; REEDSETEDS; EEDSETEDSG; EDSETEDSGH; DSETEDSGHG;SETEDSGHGS; ETEDSGHGSS; TEDSGHGSST; EDSGHGSSTE; DSGHGSSTES;SGHGSSTESQ; GHGSSTESQS; HGSSTESQSQ; GSSTESQSQC; SSTESQSQCS;STESQSQCSS; TESQSQCSSQ; ESQSQCSSQV; SQSQCSSQVS; QSQCSSQVSD;SQCSSQVSDT; QCSSQVSDTS; CSSQVSDTSA; SSQVSDTSAP; SQVSDTSAPA;QVSDTSAPAE; VSDTSAPAED; SDTSAPAEDS; DTSAPAEDSQ; TSAPAEDSQR;SAPAEDSQRS; APAEDSQRSD; PAEDSQRSDP; AEDSQRSDPH; EDSQRSDPHS;DSQRSDPHSQ; SQRSDPHSQE; QRSDPHSQEL; RSDPHSQELH; SDPHSQELHL;DPHSQELHLC; PHSQELHLCK; HSQELHLCKG; SQELHLCKGF; QELHLCKGFQ;ELHLCKGFQC; LHLCKGFQCF; HLCKGFQCFK; LCKGFQCFKR; CKGFQCFKRP;KGFQCFKRPK; GFQCFKRPKT; FQCFKRPKTP; QCFKRPKTPP; CFKRPKTPPP;FKRPKTPPPK; HKLKSGLYKS; KLKSGLYKSS; LKSGLYKSSI; KSGLYKSSIY;MYMYNKSTCL; YMYNKSTCLK; MYNKSTCLKH; YNKSTCLKHF; NKSTCLKHFG;KSTCLKHFGL; STCLKHFGLQ; TCLKHFGLQL; CLKHFGLQLS; LKHFGLQLSL;KHFGLQLSLF; HFGLQLSLFV; FGLQLSLFVN; GLQLSLFVNI; LQLSLFVNIS;QLSLFVNISY; LSLFVNISYH; SLFVNISYHI; LFVNISYHIW; FVNISYHIWV;VNISYHIWVP; NISYHIWVPW; ISYHIWVPWK; SYHIWVPWKS; YHIWVPWKSF;HIWVPWKSFC; IWVPWKSFCA; WVPWKSFCAI; VPWKSFCAIK; PWKSFCAIKH;WKSFCAIKHP; KSFCAIKHPN; SFCAIKHPNL; FCAIKHPNLF; CAIKHPNLFY;AIKHPNLFYL; IKHPNLFYLG; KHPNLFYLGF; HPNLFYLGFH; PNLFYLGFHT;NLFYLGFHTI; LFYLGFHTIH; FYLGFHTIHR; YLGFHTIHRL; LGFHTIHRLP;GFHTIHRLPI; FHTIHRLPIH; HTIHRLPIHS; TIHRLPIHSL; IHRLPIHSLG;HRLPIHSLGS; RLPIHSLGSP; LPIHSLGSPV; PIHSLGSPVY; IHSLGSPVYK;HSLGSPVYKV; SLGSPVYKVT; QKGNWVRILY; KGNWVRILYR; GNWVRILYRS;NWVRILYRSF; WVRILYRSFS; VRILYRSFSQ; RILYRSFSQA; ILYRSFSQAD;LYRSFSQADL; YRSFSQADLK; RSFSQADLKI; SFSQADLKIS; FSQADLKISC;SQADLKISCK; QADLKISCKA; ADLKISCKAS; DLKISCKASP; LKISCKASPL;KISCKASPLL; ISCKASPLLC; SCKASPLLCS; CKASPLLCSR; KASPLLCSRA;ASPLLCSRAV; SPLLCSRAVS; PLLCSRAVSK; LLCSRAVSKQ; LCSRAVSKQA;CSRAVSKQAT; SRAVSKQATN; RAVSKQATNI; AVSKQATNIS; VSKQATNISS;NIQAISFTKR; IQAISFTKRP; QAISFTKRPH; AISFTKRPHT; ISFTKRPHTL;SFTKRPHTLF; FTKRPHTLFI; QHCGSCVGHM; HCGSCVGHMK; CGSCVGHMKY;GSCVGHMKYW; SCVGHMKYWG; CVGHMKYWGN; VGHMKYWGNI; GHMKYWGNIF;HMKYWGNIFP; MKYWGNIFPS; KYWGNIFPSC; YWGNIFPSCE; WGNIFPSCES;GNIFPSCESP; NIFPSCESPK; IFPSCESPKI; FPSCESPKIP; PSCESPKIPS;SCESPKIPSI; CESPKIPSIF; ESPKIPSIFI; SPKIPSIFIS; PKIPSIFIST;KIPSIFISTG; IPSIFISTGI; PSIFISTGIR; SIFISTGIRY; IFISTGIRYP;FISTGIRYPA; ISTGIRYPAL; STGIRYPALN; TGIRYPALNW; GIRYPALNWI;IRYPALNWIS; RYPALNWISI; YPALNWISIV; PALNWISIVF; ALNWISIVFV;LNWISIVFVQ; NWISIVFVQI; WISIVFVQIG; ISIVFVQIGL; SIVFVQIGLM;IVFVQIGLMV; VFVQIGLMVS; FVQIGLMVSI; VQIGLMVSIH; QIGLMVSIHY;IGLMVSIHYL; GLMVSIHYLG; LMVSIHYLGL; MVSIHYLGLG; VSIHYLGLGC;SIHYLGLGCW; IHYLGLGCWV; HYLGLGCWVF; YLGLGCWVFR; LGLGCWVFRG;GLGCWVFRGY; LGCWVFRGYS; GCWVFRGYST; CWVFRGYSTI; WVFRGYSTIR;VFRGYSTIRV; FRGYSTIRVL; HSLHFQGFST; SLHFQGFSTY; LHFQGFSTYS;HFQGFSTYSK; FQGFSTYSKE; QGFSTYSKEV; GFSTYSKEVE; FSTYSKEVEI;STYSKEVEIT; TYSKEVEITA; YSKEVEITAL; SKEVEITALN; KEVEITALNR;EVEITALNRF; VEITALNRFS; EITALNRFSS; ITALNRFSST; TALNRFSSTM;ALNRFSSTML; LNRFSSTMLM; NRFSSTMLMH; RFSSTMLMHF; FSSTMLMHFL;PCMKVKHASY; CMKVKHASYS; MKVKHASYSN; KVKHASYSNN; VKHASYSNNL;KHASYSNNLC; HASYSNNLCL; ASYSNNLCLY; SYSNNLCLYS; YSNNLCLYSY;SNNLCLYSYS; NNLCLYSYSL; NLCLYSYSLP; LCLYSYSLPH; CLYSYSLPHQ;IGEGNSCCAV; GEGNSCCAVT; EGNSCCAVTG; GNSCCAVTGK; NSCCAVTGKH;SCCAVTGKHF; CCAVTGKHFS; CAVTGKHFSL; AVTGKHFSLW; VTGKHFSLWA;TGKHFSLWAI; GKHFSLWAIT; KHFSLWAITA; HFSLWAITAK; FSLWAITAKV;SLWAITAKVI; LWAITAKVIF; WAITAKVIFS; AITAKVIFST; TKAPKVFIWI;KAPKVFIWIP; APKVFIWIPH; PKVFIWIPHF; KVFIWIPHFW; VFIWIPHFWV;EAFYLCNSIY; AFYLCNSIYP; FYLCNSIYPS; YLCNSIYPSF; LCNSIYPSFN;CNSIYPSFNF; FWHLHGFLWL; WHLHGFLWLF; HLHGFLWLFG; LHGFLWLFGS;HGFLWLFGSC; GFLWLFGSCP; FLWLFGSCPW; LWLFGSCPWT; WLFGSCPWTL;LFGSCPWTLS; FGSCPWTLSF; GSCPWTLSFS; SCPWTLSFSF; CPWTLSFSFG;PWTLSFSFGW; WTLSFSFGWG; TLSFSFGWGH; LSFSFGWGHL; SFSFGWGHLH;FSFGWGHLHM; SFGWGHLHML; FGWGHLHMLQ; GWGHLHMLQE; WGHLHMLQEQ;GHLHMLQEQV; HLHMLQEQVL; LHMLQEQVLQ; HMLQEQVLQS; MLQEQVLQSR;LQEQVLQSRT; QEQVLQSRTG; EQVLQSRTGL; QVLQSRTGLE; VLQSRTGLEV;LQSRTGLEVK; QSRTGLEVKA; SRTGLEVKAT; RTGLEVKATS; TGLEVKATSI;GLEVKATSIE; LEVKATSIEE; EVKATSIEEQ; VKATSIEEQF; KATSIEEQFF;ATSIEEQFFD; TLLNVHFVDF; LLNVHFVDFL; LNVHFVDFLS; NVHFVDFLSP;VHFVDFLSPF; HFVDFLSPFF; FVDFLSPFFV; LLLYCQHHLY; LLYCQHHLYY;LYCQHHLYYK; YCQHHLYYKY; CQHHLYYKYG; QHHLYYKYGQ; HHLYYKYGQN;HLYYKYGQNV; LYYKYGQNVH; YYKYGQNVHG; YKYGQNVHGY; KYGQNVHGYL;YGQNVHGYLP; GQNVHGYLPF; QNVHGYLPFQ; NVHGYLPFQL; VHGYLPFQLL;HGYLPFQLLV; GKDQNNIVEY; KDQNNIVEYN; DQNNIVEYNY; QNNIVEYNYK;NNIVEYNYKS; NIVEYNYKSL; KIFLFFSAIP; IFLFFSAIPV; FLFFSAIPVR;LFFSAIPVRL; QKYLHQETEY; KYLHQETEYH; YLHQETEYHS; LHQETEYHST;HQETEYHSTH; QETEYHSTHL; ETEYHSTHLG; TIPKPCLIAD; IPKPCLIADR;PKPCLIADRG; KPCLIADRGL; PCLIADRGLQ; CLIADRGLQW; LIADRGLQWK;IADRGLQWKL; ADRGLQWKLC; DRGLQWKLCD; RGLQWKLCDP; GLQWKLCDPN;LQWKLCDPNH; QWKLCDPNHQ; WKLCDPNHQR; KLCDPNHQRT; LCDPNHQRTY;CDPNHQRTYT; DPNHQRTYTL; PNHQRTYTLL; NHQRTYTLLE; HQRTYTLLEL;QRTYTLLELR; RTYTLLELRN; QFELKQQTQQ; PQEHQQLQHM; QEHQQLQHMF;EHQQLQHMFE; HQQLQHMFEE; QQLQHMFEEL; QLQHMFEELG; LQHMFEELGL;PLRYLLCPLQ; QQQPPQQQFQ; QQPPQQQFQP; QPPQQQFQPL; PPQQQFQPLK;PQQQFQPLKI; QQQFQPLKIL; QQFQPLKILW; QFQPLKILWQ; FQPLKILWQQ;QPLKILWQQQ; PLKILWQQQP; LKILWQQQPQ; KILWQQQPQI; ILWQQQPQIH;LWQQQPQIHW; WQQQPQIHWQ; QQQPQIHWQL; QQPQIHWQLG; QPQIHWQLGP;PQIHWQLGPP; QIHWQLGPPK; IHWQLGPPKV; HWQLGPPKVL; WQLGPPKVLE;QLGPPKVLEQ; LGPPKVLEQH; GPPKVLEQHP; TWKYKKKGIT; WKYKKKGITY;KYKKKGITYL; YKKKGITYLG; KKKGITYLGV; KKGITYLGVF; KGITYLGVFY;GITYLGVFYR; ITYLGVFYRV; TYLGVFYRVF; YLGVFYRVFY; LGVFYRVFYS;GVFYRVFYSR; SSGTFVFPVY; SGTFVFPVYT; GTFVFPVYTV; TFVFPVYTVF;FVFPVYTVFT; VFPVYTVFTS; FPVYTVFTST; PVYTVFTSTK; VYTVFTSTKF;YTVFTSTKFQ; TVFTSTKFQQ; VFTSTKFQQK; FTSTKFQQKL; NKNKNPLSSF;KNKNPLSSFF; NKNPLSSFFC; KNPLSSFFCS; NPLSSFFCSS; PLSSFFCSSP;LSSFFCSSPG; SSFFCSSPGF; SFFCSSPGFT; FFCSSPGFTN; FCSSPGFTNF;CSSPGFTNFH; QLAQNHGLCP; LAQNHGLCPV; LGTRPRFLGS; GTRPRFLGSQ;TRPRFLGSQN; RPRFLGSQNM; PRFLGSQNMS; RFLGSQNMSV; FLGSQNMSVM;LGSQNMSVMH; GSQNMSVMHF; SQNMSVMHFP; QNMSVMHFPS; AAPPCESCTF;APPCESCTFL; PPCESCTFLP; PCESCTFLPE; CESCTFLPEV; ESCTFLPEVM;SCTFLPEVMV; CTFLPEVMVW; TFLPEVMVWL; FLPEVMVWLH; LPEVMVWLHS;PEVMVWLHSP; EVMVWLHSPV; VMVWLHSPVS; MVWLHSPVSH; VWLHSPVSHA;WLHSPVSHAL; LHSPVSHALS; HSPVSHALSF; SPVSHALSFL; PVSHALSFLR;VSHALSFLRS; SHALSFLRSW; HALSFLRSWF; ALSFLRSWFG; LSFLRSWFGC;SFLRSWFGCI; FLRSWFGCIP; LRSWFGCIPW; RSWFGCIPWV; SWFGCIPWVS;WFGCIPWVSS; FGCIPWVSSS; GCIPWVSSSS; CIPWVSSSSL; IPWVSSSSLW;PWVSSSSLWP; WVSSSSLWPF; VSSSSLWPFF; SSSSLWPFFL; YIRGRGRLCL;IRGRGRLCLH; RGRGRLCLHP; GRGRLCLHPF; RGRLCLHPFS; GRLCLHPFSQ;RLCLHPFSQV; LCLHPFSQVV; CLHPFSQVVR; LHPFSQVVRV; HPFSQVVRVW;PFSQVVRVWR; FSQVVRVWRL; SQVVRVWRLF; QVVRVWRLFL; VVRVWRLFLR;VRVWRLFLRP; RVWRLFLRPS; VWRLFLRPSK; WRLFLRPSKT; RLFLRPSKTI;LFLRPSKTIW; FLRPSKTIWG; LRPSKTIWGN; RPSKTIWGNP; PSKTIWGNPY;SKTIWGNPYS; KTIWGNPYSF; TIWGNPYSFA; IWGNPYSFAI; WGNPYSFAIF;GNPYSFAIFA; NPYSFAIFAK 11 mers:QGRIHGAHGPF; GRIHGAHGPFR; RIHGAHGPFRP; KSCLGKSSLNE; SCLGKSSLNEK;CLGKSSLNEKS; LGKSSLNEKSL; GKSSLNEKSLF; KSSLNEKSLFK; SSLNEKSLFKE;SLNEKSLFKEV; KNGAGCKGSSS; NGAGCKGSSSA; FSSLPRYPVLQ; SSLPRYPVLQG;SLPRYPVLQGM; LPRYPVLQGMA; PRYPVLQGMAY; RYPVLQGMAYL; YPVLQGMAYLF;PVLQGMAYLFQ; VLQGMAYLFQK; LQGMAYLFQKA; QGMAYLFQKAF; GMAYLFQKAFC;MAYLFQKAFCA; AYLFQKAFCAL; YLFQKAFCALP; LFQKAFCALPL; FQKAFCALPLH;QKAFCALPLHA; KAFCALPLHAM; AFCALPLHAMS; FCALPLHAMSA; KIFKKRALGLD;IFKKRALGLDR; FKKRALGLDRL; KKRALGLDRLL; KRALGLDRLLL; RALGLDRLLLH;LLHTVVWLRPN; RNSAMVGPNNW; NSAMVGPNNWR; SAMVGPNNWRN; AMVGPNNWRNS;MVGPNNWRNSL; VGPNNWRNSLQ; GPNNWRNSLQR; PNNWRNSLQRS; NNWRNSLQRSK;NWRNSLQRSKA; WRNSLQRSKAL; RNSLQRSKALR; VPTYGTEEWES; PTYGTEEWESW;TYGTEEWESWW; YGTEEWESWWS; GTEEWESWWSS; TEEWESWWSSF; EEWESWWSSFN;EWESWWSSFNE; WESWWSSFNEK; ESWWSSFNEKW; SWWSSFNEKWD; WWSSFNEKWDE;WSSFNEKWDED; SSFNEKWDEDL; SFNEKWDEDLF; FNEKWDEDLFC; NEKWDEDLFCH;EKWDEDLFCHE; KWDEDLFCHED; WDEDLFCHEDM; DEDLFCHEDMF; EDLFCHEDMFA;DLFCHEDMFAS; LFCHEDMFASD; FCHEDMFASDE; CHEDMFASDEE; HEDMFASDEEA;EDMFASDEEAT; DMFASDEEATA; MFASDEEATAD; FASDEEATADS; ASDEEATADSQ;SDEEATADSQH; DEEATADSQHS; EEATADSQHST; EATADSQHSTP; ATADSQHSTPP;TADSQHSTPPK; ADSQHSTPPKK; DSQHSTPPKKK; SQHSTPPKKKR; QHSTPPKKKRK;HSTPPKKKRKV; STPPKKKRKVE; TPPKKKRKVED; PPKKKRKVEDP; PKKKRKVEDPK;KKKRKVEDPKD; KKRKVEDPKDF; KRKVEDPKDFP; RKVEDPKDFPS; KVEDPKDFPSD;VEDPKDFPSDL; EDPKDFPSDLH; DPKDFPSDLHQ; PKDFPSDLHQF; KDFPSDLHQFL;DFPSDLHQFLS; FPSDLHQFLSQ; PSDLHQFLSQA; SDLHQFLSQAV; DLHQFLSQAVF;LHQFLSQAVFS; HQFLSQAVFSN; QFLSQAVFSNR; FLSQAVFSNRT; LSQAVFSNRTL;SQAVFSNRTLA; QAVFSNRTLAC; AVFSNRTLACF; VFSNRTLACFA; FSNRTLACFAV;SNRTLACFAVY; NRTLACFAVYT; RTLACFAVYTT; TLACFAVYTTK; LACFAVYTTKE;ACFAVYTTKEK; CFAVYTTKEKA; FAVYTTKEKAQ; AVYTTKEKAQI; VYTTKEKAQIL;YTTKEKAQILY; TTKEKAQILYK; TKEKAQILYKK; KEKAQILYKKL; EKAQILYKKLM;KAQILYKKLME; AQILYKKLMEK; QILYKKLMEKY; ILYKKLMEKYS; LYKKLMEKYSV;YKKLMEKYSVT; KKLMEKYSVTF; KLMEKYSVTFI; LMEKYSVTFIS; MEKYSVTFISR;EKYSVTFISRH; KYSVTFISRHM; YSVTFISRHMC; SVTFISRHMCA; VTFISRHMCAG;TFISRHMCAGH; FISRHMCAGHN; ISRHMCAGHNI; SRHMCAGHNII; RHMCAGHNIIF;HMCAGHNIIFF; MCAGHNIIFFL; CAGHNIIFFLT; AGHNIIFFLTP; GHNIIFFLTPH;HNIIFFLTPHR; NIIFFLTPHRH; IIFFLTPHRHR; IFFLTPHRHRV; FFLTPHRHRVS;FLTPHRHRVSA; LTPHRHRVSAI; TPHRHRVSAIN; PHRHRVSAINN; HRHRVSAINNF;RHRVSAINNFC; HRVSAINNFCQ; RVSAINNFCQK; VSAINNFCQKL; SAINNFCQKLC;AINNFCQKLCT; INNFCQKLCTF; NNFCQKLCTFS; NFCQKLCTFSF; FCQKLCTFSFL;CQKLCTFSFLI; QKLCTFSFLIC; KLCTFSFLICK; LCTFSFLICKG; CTFSFLICKGV;TFSFLICKGVN; FSFLICKGVNK; SFLICKGVNKE; FLICKGVNKEY; LICKGVNKEYL;ICKGVNKEYLL; CKGVNKEYLLY; KGVNKEYLLYS; GVNKEYLLYSA; VNKEYLLYSAL;NKEYLLYSALT; KEYLLYSALTR; EYLLYSALTRD; YLLYSALTRDP; LLYSALTRDPY;LYSALTRDPYH; YSALTRDPYHT; SALTRDPYHTI; ALTRDPYHTIE; LTRDPYHTIEE;TRDPYHTIEES; RDPYHTIEESI; DPYHTIEESIQ; PYHTIEESIQG; YHTIEESIQGG;HTIEESIQGGL; TIEESIQGGLK; IEESIQGGLKE; EESIQGGLKEH; ESIQGGLKEHD;SIQGGLKEHDF; IQGGLKEHDFS; QGGLKEHDFSP; GGLKEHDFSPE; GLKEHDFSPEE;LKEHDFSPEEP; KEHDFSPEEPE; EHDFSPEEPEE; HDFSPEEPEET; DFSPEEPEETK;FSPEEPEETKQ; SPEEPEETKQV; PEEPEETKQVS; EEPEETKQVSW; EPEETKQVSWK;PEETKQVSWKL; EETKQVSWKLI; ETKQVSWKLIT; TKQVSWKLITE; KQVSWKLITEY;QVSWKLITEYA; VSWKLITEYAV; SWKLITEYAVE; WKLITEYAVET; KLITEYAVETK;LITEYAVETKC; ITEYAVETKCE; TEYAVETKCED; EYAVETKCEDV; YAVETKCEDVF;AVETKCEDVFL; VETKCEDVFLL; ETKCEDVFLLL; TKCEDVFLLLG; KCEDVFLLLGM;CEDVFLLLGMY; EDVFLLLGMYL; DVFLLLGMYLE; VFLLLGMYLEF; FLLLGMYLEFQ;LLLGMYLEFQY; LLGMYLEFQYN; LGMYLEFQYNV; GMYLEFQYNVE; MYLEFQYNVEE;YLEFQYNVEEC; LEFQYNVEECK; EFQYNVEECKK; FQYNVEECKKC; QYNVEECKKCQ;YNVEECKKCQK; NVEECKKCQKK; VEECKKCQKKD; EECKKCQKKDQ; ECKKCQKKDQP;CKKCQKKDQPY; KKCQKKDQPYH; KCQKKDQPYHF; CQKKDQPYHFK; QKKDQPYHFKY;KKDQPYHFKYH; KDQPYHFKYHE; DQPYHFKYHEK; QPYHFKYHEKH; PYHFKYHEKHF;YHFKYHEKHFA; HFKYHEKHFAN; FKYHEKHFANA; KYHEKHFANAI; YHEKHFANAII;HEKHFANAIIF; EKHFANAIIFA; KHFANAIIFAE; HFANAIIFAES; FANAIIFAESK;ANAIIFAESKN; NAIIFAESKNQ; AIIFAESKNQK; IIFAESKNQKS; IFAESKNQKSI;FAESKNQKSIC; AESKNQKSICQ; ESKNQKSICQQ; SKNQKSICQQA; KNQKSICQQAV;NQKSICQQAVD; QKSICQQAVDT; KSICQQAVDTV; SICQQAVDTVL; ICQQAVDTVLA;CQQAVDTVLAK; QQAVDTVLAKK; QAVDTVLAKKR; AVDTVLAKKRV; VDTVLAKKRVD;DTVLAKKRVDT; TVLAKKRVDTL; VLAKKRVDTLH; LAKKRVDTLHM; AKKRVDTLHMT;KKRVDTLHMTR; KRVDTLHMTRE; RVDTLHMTREE; VDTLHMTREEM; DTLHMTREEML;TLHMTREEMLT; LHMTREEMLTE; HMTREEMLTER; MTREEMLTERF; TREEMLTERFN;REEMLTERFNH; EEMLTERFNHI; EMLTERFNHIL; MLTERFNHILD; LTERFNHILDK;TERFNHILDKM; ERFNHILDKMD; RFNHILDKMDL; FNHILDKMDLI; NHILDKMDLIF;HILDKMDLIFG; ILDKMDLIFGA; LDKMDLIFGAH; DKMDLIFGAHG; KMDLIFGAHGN;MDLIFGAHGNA; DLIFGAHGNAV; LIFGAHGNAVL; IFGAHGNAVLE; FGAHGNAVLEQ;GAHGNAVLEQY; AHGNAVLEQYM; HGNAVLEQYMA; GNAVLEQYMAG; NAVLEQYMAGV;AVLEQYMAGVA; VLEQYMAGVAW; LEQYMAGVAWL; EQYMAGVAWLH; QYMAGVAWLHC;YMAGVAWLHCL; MAGVAWLHCLL; AGVAWLHCLLP; GVAWLHCLLPK; VAWLHCLLPKM;AWLHCLLPKMD; WLHCLLPKMDS; LHCLLPKMDSV; HCLLPKMDSVI; CLLPKMDSVIF;LLPKMDSVIFD; LPKMDSVIFDF; PKMDSVIFDFL; KMDSVIFDFLH; MDSVIFDFLHC;DSVIFDFLHCI; SVIFDFLHCIV; VIFDFLHCIVF; IFDFLHCIVFN; FDFLHCIVFNV;DFLHCIVFNVP; FLHCIVFNVPK; LHCIVFNVPKR; HCIVFNVPKRR; CIVFNVPKRRY;IVFNVPKRRYW; VFNVPKRRYWL; FNVPKRRYWLF; NVPKRRYWLFK; VPKRRYWLFKG;PKRRYWLFKGP; KRRYWLFKGPI; RRYWLFKGPID; RYWLFKGPIDS; YWLFKGPIDSG;WLFKGPIDSGK; LFKGPIDSGKT; FKGPIDSGKTT; KGPIDSGKTTL; GPIDSGKTTLA;PIDSGKTTLAA; IDSGKTTLAAG; DSGKTTLAAGL; SGKTTLAAGLL; GKTTLAAGLLD;KTTLAAGLLDL; TTLAAGLLDLC; TLAAGLLDLCG; LAAGLLDLCGG; AAGLLDLCGGK;AGLLDLCGGKA; GLLDLCGGKAL; LLDLCGGKALN; LDLCGGKALNV; DLCGGKALNVN;LCGGKALNVNL; CGGKALNVNLP; GGKALNVNLPM; GKALNVNLPME; KALNVNLPMER;ALNVNLPMERL; LNVNLPMERLT; NVNLPMERLTF; VNLPMERLTFE; NLPMERLTFEL;LPMERLTFELG; PMERLTFELGV; MERLTFELGVA; ERLTFELGVAI; RLTFELGVAID;LTFELGVAIDQ; TFELGVAIDQY; FELGVAIDQYM; ELGVAIDQYMV; LGVAIDQYMVV;GVAIDQYMVVF; VAIDQYMVVFE; AIDQYMVVFED; IDQYMVVFEDV; DQYMVVFEDVK;QYMVVFEDVKG; YMVVFEDVKGT; MVVFEDVKGTG; VVFEDVKGTGA; VFEDVKGTGAE;FEDVKGTGAES; EDVKGTGAESK; DVKGTGAESKD; VKGTGAESKDL; KGTGAESKDLP;GTGAESKDLPS; TGAESKDLPSG; GAESKDLPSGH; AESKDLPSGHG; ESKDLPSGHGI;SKDLPSGHGIN; KDLPSGHGINN; DLPSGHGINNL; LPSGHGINNLD; PSGHGINNLDS;SGHGINNLDSL; GHGINNLDSLR; HGINNLDSLRD; GINNLDSLRDY; INNLDSLRDYL;NNLDSLRDYLD; NLDSLRDYLDG; LDSLRDYLDGS; DSLRDYLDGSV; SLRDYLDGSVK;LRDYLDGSVKV; RDYLDGSVKVN; DYLDGSVKVNL; YLDGSVKVNLE; LDGSVKVNLEK;DGSVKVNLEKK; GSVKVNLEKKH; SVKVNLEKKHL; VKVNLEKKHLN; KVNLEKKHLNK;VNLEKKHLNKR; NLEKKHLNKRT; LEKKHLNKRTQ; EKKHLNKRTQI; KKHLNKRTQIF;KHLNKRTQIFP; HLNKRTQIFPP; LNKRTQIFPPG; NKRTQIFPPGL; KRTQIFPPGLV;RTQIFPPGLVT; TQIFPPGLVTM; QIFPPGLVTMN; IFPPGLVTMNE; FPPGLVTMNEY;PPGLVTMNEYP; PGLVTMNEYPV; GLVTMNEYPVP; LVTMNEYPVPK; VTMNEYPVPKT;TMNEYPVPKTL; MNEYPVPKTLQ; NEYPVPKTLQA; EYPVPKTLQAR; YPVPKTLQARF;PVPKTLQARFV; VPKTLQARFVR; PKTLQARFVRQ; KTLQARFVRQI; TLQARFVRQID;LQARFVRQIDF; QARFVRQIDFR; ARFVRQIDFRP; RFVRQIDFRPK; FVRQIDFRPKI;VRQIDFRPKIY; RQIDFRPKIYL; QIDFRPKIYLR; IDFRPKIYLRK; DFRPKIYLRKS;FRPKIYLRKSL; RPKIYLRKSLQ; PKIYLRKSLQN; KIYLRKSLQNS; IYLRKSLQNSE;YLRKSLQNSEF; LRKSLQNSEFL; RKSLQNSEFLL; KSLQNSEFLLE; SLQNSEFLLEK;LQNSEFLLEKR; QNSEFLLEKRI; NSEFLLEKRIL; SEFLLEKRILQ; EFLLEKRILQS;FLLEKRILQSG; LLEKRILQSGM; LEKRILQSGMT; EKRILQSGMTL; KRILQSGMTLL;RILQSGMTLLL; ILQSGMTLLLL; LQSGMTLLLLL; QSGMTLLLLLI; SGMTLLLLLIW;GMTLLLLLIWF; MTLLLLLIWFR; TLLLLLIWFRP; LLLLLIWFRPV; LLLLIWFRPVA;LLLIWFRPVAD; LLIWFRPVADF; LIWFRPVADFA; IWFRPVADFAT; WFRPVADFATD;FRPVADFATDI; RPVADFATDIQ; PVADFATDIQS; VADFATDIQSR; ADFATDIQSRI;DFATDIQSRIV; FATDIQSRIVE; ATDIQSRIVEW; TDIQSRIVEWK; DIQSRIVEWKE;IQSRIVEWKER; QSRIVEWKERL; SRIVEWKERLD; RIVEWKERLDS; IVEWKERLDSE;VEWKERLDSEI; EWKERLDSEIS; WKERLDSEISM; KERLDSEISMY; ERLDSEISMYT;RLDSEISMYTF; LDSEISMYTFS; DSEISMYTFSR; SEISMYTFSRM; EISMYTFSRMK;ISMYTFSRMKY; SMYTFSRMKYN; MYTFSRMKYNI; YTFSRMKYNIC; TFSRMKYNICM;FSRMKYNICMG; SRMKYNICMGK; RMKYNICMGKC; MKYNICMGKCI; KYNICMGKCIL;YNICMGKCILD; NICMGKCILDI; ICMGKCILDIT; CMGKCILDITR; MGKCILDITRE;GKCILDITREE; KCILDITREED; CILDITREEDS; ILDITREEDSE; LDITREEDSET;DITREEDSETE; ITREEDSETED; TREEDSETEDS; REEDSETEDSG; EEDSETEDSGH;EDSETEDSGHG; DSETEDSGHGS; SETEDSGHGSS; ETEDSGHGSST; TEDSGHGSSTE;EDSGHGSSTES; DSGHGSSTESQ; SGHGSSTESQS; GHGSSTESQSQ; HGSSTESQSQC;GSSTESQSQCS; SSTESQSQCSS; STESQSQCSSQ; TESQSQCSSQV; ESQSQCSSQVS;SQSQCSSQVSD; QSQCSSQVSDT; SQCSSQVSDTS; QCSSQVSDTSA; CSSQVSDTSAP;SSQVSDTSAPA; SQVSDTSAPAE; QVSDTSAPAED; VSDTSAPAEDS; SDTSAPAEDSQ;DTSAPAEDSQR; TSAPAEDSQRS; SAPAEDSQRSD; APAEDSQRSDP; PAEDSQRSDPH;AEDSQRSDPHS; EDSQRSDPHSQ; DSQRSDPHSQE; SQRSDPHSQEL; QRSDPHSQELH;RSDPHSQELHL; SDPHSQELHLC; DPHSQELHLCK; PHSQELHLCKG; HSQELHLCKGF;SQELHLCKGFQ; QELHLCKGFQC; ELHLCKGFQCF; LHLCKGFQCFK; HLCKGFQCFKR;LCKGFQCFKRP; CKGFQCFKRPK; KGFQCFKRPKT; GFQCFKRPKTP; FQCFKRPKTPP;QCFKRPKTPPP; CFKRPKTPPPK; HKLKSGLYKSS; KLKSGLYKSSI; LKSGLYKSSIY;MYMYNKSTCLK; YMYNKSTCLKH; MYNKSTCLKHF; YNKSTCLKHFG; NKSTCLKHFGL;KSTCLKHFGLQ; STCLKHFGLQL; TCLKHFGLQLS; CLKHFGLQLSL; LKHFGLQLSLF;KHFGLQLSLFV; HFGLQLSLFVN; FGLQLSLFVNI; GLQLSLFVNIS; LQLSLFVNISY;QLSLFVNISYH; LSLFVNISYHI; SLFVNISYHIW; LFVNISYHIWV; FVNISYHIWVP;VNISYHIWVPW; NISYHIWVPWK; ISYHIWVPWKS; SYHIWVPWKSF; YHIWVPWKSFC;HIWVPWKSFCA; IWVPWKSFCAI; WVPWKSFCAIK; VPWKSFCAIKH; PWKSFCAIKHP;WKSFCAIKHPN; KSFCAIKHPNL; SFCAIKHPNLF; FCAIKHPNLFY; CAIKHPNLFYL;AIKHPNLFYLG; IKHPNLFYLGF; KHPNLFYLGFH; HPNLFYLGFHT; PNLFYLGFHTI;NLFYLGFHTIH; LFYLGFHTIHR; FYLGFHTIHRL; YLGFHTIHRLP; LGFHTIHRLPI;GFHTIHRLPIH; FHTIHRLPIHS; HTIHRLPIHSL; TIHRLPIHSLG; IHRLPIHSLGS;HRLPIHSLGSP; RLPIHSLGSPV; LPIHSLGSPVY; PIHSLGSPVYK; IHSLGSPVYKV;HSLGSPVYKVT; QKGNWVRILYR; KGNWVRILYRS; GNWVRILYRSF; NWVRILYRSFS;WVRILYRSFSQ; VRILYRSFSQA; RILYRSFSQAD; ILYRSFSQADL; LYRSFSQADLK;YRSFSQADLKI; RSFSQADLKIS; SFSQADLKISC; FSQADLKISCK; SQADLKISCKA;QADLKISCKAS; ADLKISCKASP; DLKISCKASPL; LKISCKASPLL; KISCKASPLLC;ISCKASPLLCS; SCKASPLLCSR; CKASPLLCSRA; KASPLLCSRAV; ASPLLCSRAVS;SPLLCSRAVSK; PLLCSRAVSKQ; LLCSRAVSKQA; LCSRAVSKQAT; CSRAVSKQATN;SRAVSKQATNI; RAVSKQATNIS; AVSKQATNISS; NIQAISFTKRP; IQAISFTKRPH;QAISFTKRPHT; AISFTKRPHTL; ISFTKRPHTLF; SFTKRPHTLFI; QHCGSCVGHMK;HCGSCVGHMKY; CGSCVGHMKYW; GSCVGHMKYWG; SCVGHMKYWGN; CVGHMKYWGNI;VGHMKYWGNIF; GHMKYWGNIFP; HMKYWGNIFPS; MKYWGNIFPSC; KYWGNIFPSCE;YWGNIFPSCES; WGNIFPSCESP; GNIFPSCESPK; NIFPSCESPKI; IFPSCESPKIP;FPSCESPKIPS; PSCESPKIPSI; SCESPKIPSIF; CESPKIPSIFI; ESPKIPSIFIS;SPKIPSIFIST; PKIPSIFISTG; KIPSIFISTGI; IPSIFISTGIR; PSIFISTGIRY;SIFISTGIRYP; IFISTGIRYPA; FISTGIRYPAL; ISTGIRYPALN; STGIRYPALNW;TGIRYPALNWI; GIRYPALNWIS; IRYPALNWISI; RYPALNWISIV; YPALNWISIVF;PALNWISIVFV; ALNWISIVFVQ; LNWISIVFVQI; NWISIVFVQIG; WISIVFVQIGL;ISIVFVQIGLM; SIVFVQIGLMV; IVFVQIGLMVS; VFVQIGLMVSI; FVQIGLMVSIH;VQIGLMVSIHY; QIGLMVSIHYL; IGLMVSIHYLG; GLMVSIHYLGL; LMVSIHYLGLG;MVSIHYLGLGC; VSIHYLGLGCW; SIHYLGLGCWV; IHYLGLGCWVF; HYLGLGCWVFR;YLGLGCWVFRG; LGLGCWVFRGY; GLGCWVFRGYS; LGCWVFRGYST; GCWVFRGYSTI;CWVFRGYSTIR; WVFRGYSTIRV; VFRGYSTIRVL; HSLHFQGFSTY; SLHFQGFSTYS;LHFQGFSTYSK; HFQGFSTYSKE; FQGFSTYSKEV; QGFSTYSKEVE; GFSTYSKEVEI;FSTYSKEVEIT; STYSKEVEITA; TYSKEVEITAL; YSKEVEITALN; SKEVEITALNR;KEVEITALNRF; EVEITALNRFS; VEITALNRFSS; EITALNRFSST; ITALNRFSSTM;TALNRFSSTML; ALNRFSSTMLM; LNRFSSTMLMH; NRFSSTMLMHF; RFSSTMLMHFL;PCMKVKHASYS; CMKVKHASYSN; MKVKHASYSNN; KVKHASYSNNL; VKHASYSNNLC;KHASYSNNLCL; HASYSNNLCLY; ASYSNNLCLYS; SYSNNLCLYSY; YSNNLCLYSYS;SNNLCLYSYSL; NNLCLYSYSLP; NLCLYSYSLPH; LCLYSYSLPHQ; IGEGNSCCAVT;GEGNSCCAVTG; EGNSCCAVTGK; GNSCCAVTGKH; NSCCAVTGKHF; SCCAVTGKHFS;CCAVTGKHFSL; CAVTGKHFSLW; AVTGKHFSLWA; VTGKHFSLWAI; TGKHFSLWAIT;GKHFSLWAITA; KHFSLWAITAK; HFSLWAITAKV; FSLWAITAKVI; SLWAITAKVIF;LWAITAKVIFS; WAITAKVIFST; TKAPKVFIWIP; KAPKVFIWIPH; APKVFIWIPHF;PKVFIWIPHFW; KVFIWIPHFWV; EAFYLCNSIYP; AFYLCNSIYPS; FYLCNSIYPSF;YLCNSIYPSFN; LCNSIYPSFNF; FWHLHGFLWLF; WHLHGFLWLFG; HLHGFLWLFGS;LHGFLWLFGSC; HGFLWLFGSCP; GFLWLFGSCPW; FLWLFGSCPWT; LWLFGSCPWTL;WLFGSCPWTLS; LFGSCPWTLSF; FGSCPWTLSFS; GSCPWTLSFSF; SCPWTLSFSFG;CPWTLSFSFGW; PWTLSFSFGWG; WTLSFSFGWGH; TLSFSFGWGHL; LSFSFGWGHLH;SFSFGWGHLHM; FSFGWGHLHML; SFGWGHLHMLQ; FGWGHLHMLQE; GWGHLHMLQEQ;WGHLHMLQEQV; GHLHMLQEQVL; HLHMLQEQVLQ; LHMLQEQVLQS; HMLQEQVLQSR;MLQEQVLQSRT; LQEQVLQSRTG; QEQVLQSRTGL; EQVLQSRTGLE; QVLQSRTGLEV;VLQSRTGLEVK; LQSRTGLEVKA; QSRTGLEVKAT; SRTGLEVKATS; RTGLEVKATSI;TGLEVKATSIE; GLEVKATSIEE; LEVKATSIEEQ; EVKATSIEEQF; VKATSIEEQFF;KATSIEEQFFD; TLLNVHFVDFL; LLNVHFVDFLS; LNVHFVDFLSP; NVHFVDFLSPF;VHFVDFLSPFF; HFVDFLSPFFV; LLLYCQHHLYY; LLYCQHHLYYK; LYCQHHLYYKY;YCQHHLYYKYG; CQHHLYYKYGQ; QHHLYYKYGQN; HHLYYKYGQNV; HLYYKYGQNVH;LYYKYGQNVHG; YYKYGQNVHGY; YKYGQNVHGYL; KYGQNVHGYLP; YGQNVHGYLPF;GQNVHGYLPFQ; QNVHGYLPFQL; NVHGYLPFQLL; VHGYLPFQLLV; GKDQNNIVEYN;KDQNNIVEYNY; DQNNIVEYNYK; QNNIVEYNYKS; NNIVEYNYKSL; KIFLFFSAIPV;IFLFFSAIPVR; FLFFSAIPVRL; QKYLHQETEYH; KYLHQETEYHS; YLHQETEYHST;LHQETEYHSTH; HQETEYHSTHL; QETEYHSTHLG; TIPKPCLIADR; IPKPCLIADRG;PKPCLIADRGL; KPCLIADRGLQ; PCLIADRGLQW; CLIADRGLQWK; LIADRGLQWKL;IADRGLQWKLC; ADRGLQWKLCD; DRGLQWKLCDP; RGLQWKLCDPN; GLQWKLCDPNH;LQWKLCDPNHQ; QWKLCDPNHQR; WKLCDPNHQRT; KLCDPNHQRTY; LCDPNHQRTYT;CDPNHQRTYTL; DPNHQRTYTLL; PNHQRTYTLLE; NHQRTYTLLEL; HQRTYTLLELR;QRTYTLLELRN; PQEHQQLQHMF; QEHQQLQHMFE; EHQQLQHMFEE; HQQLQHMFEEL;QQLQHMFEELG; QLQHMFEELGL; QQQPPQQQFQP; QQPPQQQFQPL; QPPQQQFQPLK;PPQQQFQPLKI; PQQQFQPLKIL; QQQFQPLKILW; QQFQPLKILWQ; QFQPLKILWQQ;FQPLKILWQQQ; QPLKILWQQQP; PLKILWQQQPQ; LKILWQQQPQI; KILWQQQPQIH;ILWQQQPQIHW; LWQQQPQIHWQ; WQQQPQIHWQL; QQQPQIHWQLG; QQPQIHWQLGP;QPQIHWQLGPP; PQIHWQLGPPK; QIHWQLGPPKV; IHWQLGPPKVL; HWQLGPPKVLE;WQLGPPKVLEQ; QLGPPKVLEQH; LGPPKVLEQHP; TWKYKKKGITY; WKYKKKGITYL;KYKKKGITYLG; YKKKGITYLGV; KKKGITYLGVF; KKGITYLGVFY; KGITYLGVFYR;GITYLGVFYRV; ITYLGVFYRVF; TYLGVFYRVFY; YLGVFYRVFYS; LGVFYRVFYSR;SSGTFVFPVYT; SGTFVFPVYTV; GTFVFPVYTVF; TFVFPVYTVFT; FVFPVYTVFTS;VFPVYTVFTST; FPVYTVFTSTK; PVYTVFTSTKF; VYTVFTSTKFQ; YTVFTSTKFQQ;TVFTSTKFQQK; VFTSTKFQQKL; NKNKNPLSSFF; KNKNPLSSFFC; NKNPLSSFFCS;KNPLSSFFCSS; NPLSSFFCSSP; PLSSFFCSSPG; LSSFFCSSPGF; SSFFCSSPGFT;SFFCSSPGFTN; FFCSSPGFTNF; FCSSPGFTNFH; QLAQNHGLCPV; LGTRPRFLGSQ;GTRPRFLGSQN; TRPRFLGSQNM; RPRFLGSQNMS; PRFLGSQNMSV; RFLGSQNMSVM;FLGSQNMSVMH; LGSQNMSVMHF; GSQNMSVMHFP; SQNMSVMHFPS; AAPPCESCTFL;APPCESCTFLP; PPCESCTFLPE; PCESCTFLPEV; CESCTFLPEVM; ESCTFLPEVMV;SCTFLPEVMVW; CTFLPEVMVWL; TFLPEVMVWLH; FLPEVMVWLHS; LPEVMVWLHSP;PEVMVWLHSPV; EVMVWLHSPVS; VMVWLHSPVSH; MVWLHSPVSHA; VWLHSPVSHAL;WLHSPVSHALS; LHSPVSHALSF; HSPVSHALSFL; SPVSHALSFLR; PVSHALSFLRS;VSHALSFLRSW; SHALSFLRSWF; HALSFLRSWFG; ALSFLRSWFGC; LSFLRSWFGCI;SFLRSWFGCIP; FLRSWFGCIPW; LRSWFGCIPWV; RSWFGCIPWVS; SWFGCIPWVSS;WFGCIPWVSSS; FGCIPWVSSSS; GCIPWVSSSSL; CIPWVSSSSLW; IPWVSSSSLWP;PWVSSSSLWPF; WVSSSSLWPFF; VSSSSLWPFFL; YIRGRGRLCLH; IRGRGRLCLHP;RGRGRLCLHPF; GRGRLCLHPFS; RGRLCLHPFSQ; GRLCLHPFSQV; RLCLHPFSQVV;LCLHPFSQVVR; CLHPFSQVVRV; LHPFSQVVRVW; HPFSQVVRVWR; PFSQVVRVWRL;FSQVVRVWRLF; SQVVRVWRLFL; QVVRVWRLFLR; VVRVWRLFLRP; VRVWRLFLRPS;RVWRLFLRPSK; VWRLFLRPSKT; WRLFLRPSKTI; RLFLRPSKTIW; LFLRPSKTIWG;FLRPSKTIWGN; LRPSKTIWGNP; RPSKTIWGNPY; PSKTIWGNPYS; SKTIWGNPYSF;KTIWGNPYSFA; TIWGNPYSFAI; IWGNPYSFAIF; WGNPYSFAIFA; GNPYSFAIFAK SEQ IDNOS.: 7-24956

Preferred BK virus fragments of VP2-3 capable of interacting with one ormore MHC class 1 molecules are listed in Table J.

TABLE J Prediction of BK virus VP2-3 protein specific MHCclass1, 8-, 9-, 10-, 11-mer peptide binders for42 MHC class 1 alleles (see FIG. 11) using thehttp://www.cbs.dtu.dk/services/NetMHC/ database.The MHC class 1 molecules for which no binders were found are not listedpos peptide logscore affinity(nM) Bind Level Protein Name Allele 8-mers107 KVSTVGLY 0.435 454 WB VP2-3 A0101 140 FVNNIQYL 0.674 33 SB VP2-3A0201 80 FAALIQTV 0.581 93 WB VP2-3 A0201 195 FLEETTWT 0.576 98 WB VP2-3A0201 5 ALLGDLVA 0.564 111 WB VP2-3 A0201 43 SLATVEGI 0.559 118 WB VP2-3A0201 293 MLPLLLGL 0.552 127 WB VP2-3 A0201 40 QIASLATV 0.533 155 WBVP2-3 A0201 61 GLTPQTYA 0.533 155 WB VP2-3 A0201 296 LLLGLYGT 0.529 163WB VP2-3 A0201 76 AIAGFAAL 0.469 311 WB VP2-3 A0201 89 GISSLAQV 0.456358 WB VP2-3 A0201 297 LLGLYGTV 0.439 433 WB VP2-3 A0201 132 ILFPGVNT0.434 457 WB VP2-3 A0201 140 FVNNIQYL 0.869 4 SB VP2-3 A0202 293MLPLLLGL 0.799 8 SB VP2-3 A0202 80 FAALIQTV 0.745 15 SB VP2-3 A0202 43SLATVEGI 0.730 18 SB VP2-3 A0202 61 GLTPQTYA 0.709 23 SB VP2-3 A0202 195FLEETTWT 0.686 29 SB VP2-3 A0202 76 AIAGFAAL 0.667 36 SB VP2-3 A0202 89GISSLAQV 0.640 49 SB VP2-3 A0202 3 ALALLGDL 0.630 54 WB VP2-3 A0202 297LLGLYGTV 0.607 69 WB VP2-3 A0202 40 QIASLATV 0.606 71 WB VP2-3 A0202 0MGAALALL 0.581 92 WB VP2-3 A0202 112 GLYQQSGM 0.575 99 WB VP2-3 A0202287 RTAPQWML 0.543 139 WB VP2-3 A0202 6 LLGDLVAS 0.539 146 WB VP2-3A0202 157 FATISQAL 0.530 162 WB VP2-3 A0202 10 LVASVSEA 0.524 173 WBVP2-3 A0202 296 LLLGLYGT 0.477 287 WB VP2-3 A0202 155 SLFATISQ 0.473 298WB VP2-3 A0202 86 TVTGISSL 0.461 341 WB VP2-3 A0202 62 LTPQTYAV 0.458352 WB VP2-3 A0202 114 YQQSGMAL 0.445 405 WB VP2-3 A0202 13 SVSEAAAA0.433 461 WB VP2-3 A0202 18 AAATGFSV 0.427 490 WB VP2-3 A0202 132ILFPGVNT 0.427 491 WB VP2-3 A0202 43 SLATVEGI 0.798 8 SB VP2-3 A0203 140FVNNIQYL 0.775 11 SB VP2-3 A0203 297 LLGLYGTV 0.773 11 SB VP2-3 A0203 40QIASLATV 0.748 15 SB VP2-3 A0203 80 FAALIQTV 0.730 18 SB VP2-3 A0203 61GLTPQTYA 0.706 24 SB VP2-3 A0203 89 GISSLAQV 0.701 25 SB VP2-3 A0203 76AIAGFAAL 0.701 25 SB VP2-3 A0203 83 LIQTVTGI 0.666 37 SB VP2-3 A0203 18AAATGFSV 0.649 44 SB VP2-3 A0203 3 ALALLGDL 0.643 47 SB VP2-3 A0203 112GLYQQSGM 0.624 58 WB VP2-3 A0203 10 LVASVSEA 0.604 72 WB VP2-3 A0203 114YQQSGMAL 0.558 119 WB VP2-3 A0203 296 LLLGLYGT 0.552 127 WB VP2-3 A0203195 FLEETTWT 0.540 144 WB VP2-3 A0203 132 ILFPGVNT 0.534 154 WB VP2-3A0203 62 LTPQTYAV 0.523 175 WB VP2-3 A0203 69 VIAGAPGA 0.516 187 WBVP2-3 A0203 161 SQALWHVI 0.493 241 WB VP2-3 A0203 86 TVTGISSL 0.464 330WB VP2-3 A0203 5 ALLGDLVA 0.455 364 WB VP2-3 A0203 13 SVSEAAAA 0.454 368WB VP2-3 A0203 268 SVHSGEFI 0.440 426 WB VP2-3 A0203 167 VIRDDIPA 0.435450 WB VP2-3 A0203 297 LLGLYGTV 0.613 66 WB VP2-3 A0204 43 SLATVEGI0.584 90 WB VP2-3 A0204 140 FVNNIQYL 0.522 175 WB VP2-3 A0204 80FAALIQTV 0.522 176 WB VP2-3 A0204 287 RTAPQWML 0.509 203 WB VP2-3 A0204114 YQQSGMAL 0.793 9 SB VP2-3 A0206 80 FAALIQTV 0.748 15 SB VP2-3 A020618 AAATGFSV 0.743 16 SB VP2-3 A0206 140 FVNNIQYL 0.719 20 SB VP2-3 A020639 VQIASLAT 0.713 22 SB VP2-3 A0206 161 SQALWHVI 0.700 25 SB VP2-3 A020640 QIASLATV 0.665 37 SB VP2-3 A0206 75 GAIAGFAA 0.665 37 SB VP2-3 A020676 AIAGFAAL 0.657 40 SB VP2-3 A0206 293 MLPLLLGL 0.644 47 SB VP2-3 A020694 AQVGYRFF 0.637 50 WB VP2-3 A0206 62 LTPQTYAV 0.598 77 WB VP2-3 A0206214 IQDYYSNL 0.578 96 WB VP2-3 A0206 201 WTIVNAPI 0.563 112 WB VP2-3A0206 195 FLEETTWT 0.551 129 WB VP2-3 A0206 296 LLLGLYGT 0.550 129 WBVP2-3 A0206 89 GISSLAQV 0.537 149 WB VP2-3 A0206 5 ALLGDLVA 0.535 153 WBVP2-3 A0206 157 FATISQAL 0.507 207 WB VP2-3 A0206 13 SVSEAAAA 0.502 217WB VP2-3 A0206 287 RTAPQWML 0.501 221 WB VP2-3 A0206 61 GLTPQTYA 0.499226 WB VP2-3 A0206 23 FSVAEIAA 0.479 279 WB VP2-3 A0206 297 LLGLYGTV0.477 286 WB VP2-3 A0206 45 ATVEGITT 0.475 292 WB VP2-3 A0206 4 LALLGDLV0.460 346 WB VP2-3 A0206 101 FSDWDHKV 0.454 366 WB VP2-3 A0206 10LVASVSEA 0.443 412 WB VP2-3 A0206 132 ILFPGVNT 0.441 425 WB VP2-3 A0206247 SIDNADSI 0.437 440 WB VP2-3 A0206 303 TVTPALEA 0.437 443 WB VP2-3A0206 43 SLATVEGI 0.433 463 WB VP2-3 A0206 35 AAIEVQIA 0.427 493 WBVP2-3 A0206 5 ALLGDLVA 0.884 3 SB VP2-3 A0211 293 MLPLLLGL 0.861 4 SBVP2-3 A0211 61 GLTPQTYA 0.856 4 SB VP2-3 A0211 297 LLGLYGTV 0.852 4 SBVP2-3 A0211 146 YLDPRHWG 0.842 5 SB VP2-3 A0211 89 GISSLAQV 0.841 5 SBVP2-3 A0211 155 SLFATISQ 0.823 6 SB VP2-3 A0211 76 AIAGFAAL 0.819 7 SBVP2-3 A0211 43 SLATVEGI 0.812 7 SB VP2-3 A0211 40 QIASLATV 0.801 8 SBVP2-3 A0211 296 LLLGLYGT 0.762 13 SB VP2-3 A0211 140 FVNNIQYL 0.727 19SB VP2-3 A0211 132 ILFPGVNT 0.718 21 SB VP2-3 A0211 80 FAALIQTV 0.692 27SB VP2-3 A0211 195 FLEETTWT 0.687 29 SB VP2-3 A0211 86 TVTGISSL 0.686 29SB VP2-3 A0211 101 FSDWDHKV 0.685 30 SB VP2-3 A0211 62 LTPQTYAV 0.680 32SB VP2-3 A0211 18 AAATGFSV 0.673 34 SB VP2-3 A0211 112 GLYQQSGM 0.663 38SB VP2-3 A0211 287 RTAPQWML 0.657 40 SB VP2-3 A0211 247 SIDNADSI 0.65740 SB VP2-3 A0211 250 NADSIEEV 0.652 43 SB VP2-3 A0211 262 DLRNKESV0.628 56 WB VP2-3 A0211 299 GLYGTVTP 0.595 79 WB VP2-3 A0211 6 LLGDLVAS0.595 79 WB VP2-3 A0211 292 WMLPLLLG 0.555 123 WB VP2-3 A0211 268SVHSGEFI 0.540 145 WB VP2-3 A0211 303 TVTPALEA 0.519 182 WB VP2-3 A02113 ALALLGDL 0.514 191 WB VP2-3 A0211 32 EAAAAIEV 0.514 192 WB VP2-3 A0211191 SLARFLEE 0.502 217 WB VP2-3 A0211 13 SVSEAAAA 0.493 240 WB VP2-3A0211 69 VIAGAPGA 0.467 317 WB VP2-3 A0211 4 LALLGDLV 0.450 382 WB VP2-3A0211 167 VIRDDIPA 0.450 384 WB VP2-3 A0211 293 MLPLLLGL 0.799 8 SBVP2-3 A0212 297 LLGLYGTV 0.778 11 SB VP2-3 A0212 5 ALLGDLVA 0.772 11 SBVP2-3 A0212 76 AIAGFAAL 0.741 16 SB VP2-3 A0212 146 YLDPRHWG 0.731 18 SBVP2-3 A0212 43 SLATVEGI 0.730 18 SB VP2-3 A0212 296 LLLGLYGT 0.725 19 SBVP2-3 A0212 140 FVNNIQYL 0.685 30 SB VP2-3 A0212 40 QIASLATV 0.664 37 SBVP2-3 A0212 112 GLYQQSGM 0.661 39 SB VP2-3 A0212 132 ILFPGVNT 0.661 39SB VP2-3 A0212 80 FAALIQTV 0.654 42 SB VP2-3 A0212 155 SLFATISQ 0.649 44SB VP2-3 A0212 62 LTPQTYAV 0.635 51 WB VP2-3 A0212 61 GLTPQTYA 0.635 51WB VP2-3 A0212 195 FLEETTWT 0.616 63 WB VP2-3 A0212 89 GISSLAQV 0.615 64WB VP2-3 A0212 262 DLRNKESV 0.607 70 WB VP2-3 A0212 6 LLGDLVAS 0.562 114WB VP2-3 A0212 114 YQQSGMAL 0.562 114 WB VP2-3 A0212 69 VIAGAPGA 0.521178 WB VP2-3 A0212 101 FSDWDHKV 0.505 211 WB VP2-3 A0212 18 AAATGFSV0.490 249 WB VP2-3 A0212 287 RTAPQWML 0.482 270 WB VP2-3 A0212 299GLYGTVTP 0.463 335 WB VP2-3 A0212 3 ALALLGDL 0.450 383 WB VP2-3 A0212213 YIQDYYSN 0.440 430 WB VP2-3 A0212 297 LLGLYGTV 0.869 4 SB VP2-3A0216 61 GLTPQTYA 0.801 8 SB VP2-3 A0216 89 GISSLAQV 0.801 8 SB VP2-3A0216 40 QIASLATV 0.770 11 SB VP2-3 A0216 262 DLRNKESV 0.743 16 SB VP2-3A0216 76 AIAGFAAL 0.723 20 SB VP2-3 A0216 155 SLFATISQ 0.689 28 SB VP2-3A0216 140 FVNNIQYL 0.684 30 SB VP2-3 A0216 293 MLPLLLGL 0.670 35 SBVP2-3 A0216 5 ALLGDLVA 0.656 41 SB VP2-3 A0216 80 FAALIQTV 0.647 45 SBVP2-3 A0216 195 FLEETTWT 0.641 48 SB VP2-3 A0216 43 SLATVEGI 0.614 64 WBVP2-3 A0216 18 AAATGFSV 0.614 65 WB VP2-3 A0216 86 TVTGISSL 0.612 66 WBVP2-3 A0216 112 GLYQQSGM 0.597 78 WB VP2-3 A0216 132 ILFPGVNT 0.596 79WB VP2-3 A0216 62 LTPQTYAV 0.580 93 WB VP2-3 A0216 250 NADSIEEV 0.545136 WB VP2-3 A0216 296 LLLGLYGT 0.536 152 WB VP2-3 A0216 146 YLDPRHWG0.527 167 WB VP2-3 A0216 32 EAAAAIEV 0.507 206 WB VP2-3 A0216 247SIDNADSI 0.502 219 WB VP2-3 A0216 268 SVHSGEFI 0.451 380 WB VP2-3 A0216250 NADSIEEV 0.620 61 WB VP2-3 A0219 40 QIASLATV 0.614 65 WB VP2-3 A021918 AAATGFSV 0.612 66 WB VP2-3 A0219 293 MLPLLLGL 0.609 68 WB VP2-3 A021943 SLATVEGI 0.596 78 WB VP2-3 A0219 146 YLDPRHWG 0.579 95 WB VP2-3 A021980 FAALIQTV 0.579 95 WB VP2-3 A0219 296 LLLGLYGT 0.567 108 WB VP2-3A0219 140 FVNNIQYL 0.565 110 WB VP2-3 A0219 89 GISSLAQV 0.562 114 WBVP2-3 A0219 297 LLGLYGTV 0.543 139 WB VP2-3 A0219 61 GLTPQTYA 0.537 150WB VP2-3 A0219 76 AIAGFAAL 0.526 168 WB VP2-3 A0219 5 ALLGDLVA 0.523 174WB VP2-3 A0219 62 LTPQTYAV 0.508 205 WB VP2-3 A0219 86 TVTGISSL 0.502220 WB VP2-3 A0219 195 FLEETTWT 0.500 223 WB VP2-3 A0219 32 EAAAAIEV0.455 364 WB VP2-3 A0219 132 ILFPGVNT 0.452 374 WB VP2-3 A0219 114YQQSGMAL 0.451 378 WB VP2-3 A0219 262 DLRNKESV 0.442 418 WB VP2-3 A0219107 KVSTVGLY 0.604 72 WB VP2-3 A0301 322 VSRGSSQK 0.592 83 WB VP2-3A0301 335 ASAKTTNK 0.580 93 WB VP2-3 A0301 239 HVNFGHTY 0.472 302 WBVP2-3 A0301 335 ASAKTTNK 0.732 18 SB VP2-3 A1101 270 HSGEFIEK 0.611 67WB VP2-3 A1101 257 VTQRMDLR 0.584 90 WB VP2-3 A1101 107 KVSTVGLY 0.57598 WB VP2-3 A1101 339 TTNKRRSR 0.528 165 WB VP2-3 A1101 92 SLAQVGYR0.509 202 WB VP2-3 A1101 175 ITSQELQR 0.479 280 WB VP2-3 A1101 91SSLAQVGY 0.475 293 WB VP2-3 A1101 322 VSRGSSQK 0.474 297 WB VP2-3 A1101176 TSQELQRR 0.469 312 WB VP2-3 A1101 97 GYRFFSDW 0.582 91 WB VP2-3A2301 145 QYLDPRHW 0.515 190 WB VP2-3 A2301 133 LFPGVNTF 0.508 205 WBVP2-3 A2301 100 FFSDWDHK 0.478 283 WB VP2-3 A2301 217 YYSNLSPI 0.443 412WB VP2-3 A2301 194 RFLEETTW 0.435 453 WB VP2-3 A2301 217 YYSNLSPI 0.74216 SB VP2-3 A2402 133 LFPGVNTF 0.635 51 WB VP2-3 A2402 291 QWMLPLLL0.529 163 WB VP2-3 A2402 97 GYRFFSDW 0.659 40 SB VP2-3 A2403 194RFLEETTW 0.644 47 SB VP2-3 A2403 217 YYSNLSPI 0.636 51 WB VP2-3 A2403133 LFPGVNTF 0.624 58 WB VP2-3 A2403 145 QYLDPRHW 0.611 67 WB VP2-3A2403 304 VTPALEAY 0.815 7 SB VP2-3 A2602 256 EVTQRMDL 0.685 30 SB VP2-3A2602 122 ELFNPDEY 0.657 40 SB VP2-3 A2602 287 RTAPQWML 0.612 66 WBVP2-3 A2602 239 HVNFGHTY 0.607 69 WB VP2-3 A2602 107 KVSTVGLY 0.569 105WB VP2-3 A2602 76 AIAGFAAL 0.544 138 WB VP2-3 A2602 267 ESVHSGEF 0.496232 WB VP2-3 A2602 158 ATISQALW 0.474 296 WB VP2-3 A2602 140 FVNNIQYL0.465 324 WB VP2-3 A2602 210 FYNYIQDY 0.674 34 SB VP2-3 A2902 239HVNFGHTY 0.663 38 SB VP2-3 A2902 123 LFNPDEYY 0.588 86 WB VP2-3 A2902139 TFVNNIQY 0.582 91 WB VP2-3 A2902 122 ELFNPDEY 0.546 136 WB VP2-3A2902 211 YNYIQDYY 0.522 177 WB VP2-3 A2902 107 KVSTVGLY 0.502 219 WBVP2-3 A2902 204 VNAPINFY 0.450 383 WB VP2-3 A2902 322 VSRGSSQK 0.699 26SB VP2-3 A3001 331 KGTRASAK 0.573 101 WB VP2-3 A3001 228 MVRQVAER 0.521178 WB VP2-3 A3001 342 KRRSRSSR 0.469 312 WB VP2-3 A3001 335 ASAKTTNK0.448 393 WB VP2-3 A3001 324 RGSSQKAK 0.442 420 WB VP2-3 A3001 107KVSTVGLY 0.586 88 WB VP2-3 A3002 210 FYNYIQDY 0.499 226 WB VP2-3 A3002339 TTNKRRSR 0.798 8 SB VP2-3 A3101 228 MVRQVAER 0.756 13 SB VP2-3 A3101327 SQKAKGTR 0.755 14 SB VP2-3 A3101 257 VTQRMDLR 0.637 50 WB VP2-3A3101 336 SAKTTNKR 0.631 53 WB VP2-3 A3101 187 FFRDSLAR 0.594 80 WBVP2-3 A3101 92 SLAQVGYR 0.593 81 WB VP2-3 A3101 218 YSNLSPIR 0.579 95 WBVP2-3 A3101 162 QALWHVIR 0.557 120 WB VP2-3 A3101 176 TSQELQRR 0.511 198WB VP2-3 A3101 179 ELQRRTER 0.476 288 WB VP2-3 A3101 182 RRTERFFR 0.473299 WB VP2-3 A3101 143 NIQYLDPR 0.430 474 WB VP2-3 A3101 179 ELQRRTER0.741 16 SB VP2-3 A3301 228 MVRQVAER 0.701 25 SB VP2-3 A3301 187FFRDSLAR 0.688 29 SB VP2-3 A3301 339 TTNKRRSR 0.662 38 SB VP2-3 A3301143 NIQYLDPR 0.508 205 WB VP2-3 A3301 228 MVRQVAER 0.823 6 SB VP2-3A6801 339 TTNKRRSR 0.774 11 SB VP2-3 A6801 175 ITSQELQR 0.722 20 SBVP2-3 A6801 92 SLAQVGYR 0.704 24 SB VP2-3 A6801 218 YSNLSPIR 0.701 25 SBVP2-3 A6801 253 SIEEVTQR 0.642 48 SB VP2-3 A6801 143 NIQYLDPR 0.634 52WB VP2-3 A6801 162 QALWHVIR 0.599 76 WB VP2-3 A6801 179 ELQRRTER 0.59282 WB VP2-3 A6801 257 VTQRMDLR 0.581 92 WB VP2-3 A6801 336 SAKTTNKR0.571 103 WB VP2-3 A6801 176 TSQELQRR 0.567 107 WB VP2-3 A6801 270HSGEFIEK 0.558 119 WB VP2-3 A6801 239 HVNFGHTY 0.520 180 WB VP2-3 A6801138 NTFVNNIQ 0.471 305 WB VP2-3 A6801 122 ELFNPDEY 0.441 425 WB VP2-3A6801 100 FFSDWDHK 0.434 458 WB VP2-3 A6801 32 EAAAAIEV 0.852 4 SB VP2-3A6802 80 FAALIQTV 0.773 11 SB VP2-3 A6802 86 TVTGISSL 0.765 12 SB VP2-3A6802 201 WTIVNAPI 0.749 15 SB VP2-3 A6802 55 EAIAAIGL 0.732 18 SB VP2-3A6802 140 FVNNIQYL 0.714 22 SB VP2-3 A6802 199 TTWTIVNA 0.686 29 SBVP2-3 A6802 62 LTPQTYAV 0.667 36 SB VP2-3 A6802 244 HTYSIDNA 0.652 43 SBVP2-3 A6802 287 RTAPQWML 0.650 44 SB VP2-3 A6802 40 QIASLATV 0.640 49 SBVP2-3 A6802 0 MGAALALL 0.635 51 WB VP2-3 A6802 52 TTSEAIAA 0.624 58 WBVP2-3 A6802 27 EIAAGEAA 0.616 63 WB VP2-3 A6802 21 TGFSVAEI 0.588 86 WBVP2-3 A6802 10 LVASVSEA 0.583 90 WB VP2-3 A6802 18 AAATGFSV 0.561 115 WBVP2-3 A6802 76 AIAGFAAL 0.537 149 WB VP2-3 A6802 53 TSEAIAAI 0.500 223WB VP2-3 A6802 303 TVTPALEA 0.475 293 WB VP2-3 A6802 185 ERFFRDSL 0.472301 WB VP2-3 A6802 256 EVTQRMDL 0.455 363 WB VP2-3 A6802 157 FATISQAL0.452 375 WB VP2-3 A6802 23 FSVAEIAA 0.451 380 WB VP2-3 A6802 13SVSEAAAA 0.446 400 WB VP2-3 A6802 38 EVQIASLA 0.440 427 WB VP2-3 A680243 SLATVEGI 0.440 430 WB VP2-3 A6802 250 NADSIEEV 0.433 460 WB VP2-3A6802 32 EAAAAIEV 0.788 9 SB VP2-3 A6901 199 TTWTIVNA 0.689 28 SB VP2-3A6901 201 WTIVNAPI 0.671 35 SB VP2-3 A6901 40 QIASLATV 0.635 52 WB VP2-3A6901 55 EAIAAIGL 0.619 61 WB VP2-3 A6901 134 FPGVNTFV 0.612 66 WB VP2-3A6901 80 FAALIQTV 0.611 67 WB VP2-3 A6901 101 FSDWDHKV 0.563 112 WBVP2-3 A6901 27 EIAAGEAA 0.546 135 WB VP2-3 A6901 62 LTPQTYAV 0.541 143WB VP2-3 A6901 140 FVNNIQYL 0.534 154 WB VP2-3 A6901 244 HTYSIDNA 0.533156 WB VP2-3 A6901 250 NADSIEEV 0.521 178 WB VP2-3 A6901 52 TTSEAIAA0.511 198 WB VP2-3 A6901 18 AAATGFSV 0.493 241 WB VP2-3 A6901 287RTAPQWML 0.476 289 WB VP2-3 A6901 222 SPIRPSMV 0.469 313 WB VP2-3 A6901289 APQWMLPL 0.773 11 SB VP2-3 B0702 225 RPSMVRQV 0.705 24 SB VP2-3B0702 222 SPIRPSMV 0.604 72 WB VP2-3 B0702 153 GPSLFATI 0.482 272 WBVP2-3 B0702 134 FPGVNTFV 0.477 287 WB VP2-3 B0702 63 TPQTYAVI 0.476 289WB VP2-3 B0702 73 APGAIAGF 0.460 343 WB VP2-3 B0702 114 YQQSGMAL 0.57994 WB VP2-3 B1501 180 LQRRTERF 0.557 120 WB VP2-3 B1501 94 AQVGYRFF0.550 129 WB VP2-3 B1501 239 HVNFGHTY 0.550 130 WB VP2-3 B1501 203IVNAPINF 0.498 228 WB VP2-3 B1501 39 VQIASLAT 0.466 321 WB VP2-3 B1501107 KVSTVGLY 0.464 331 WB VP2-3 B1501 161 SQALWHVI 0.446 400 WB VP2-3B1501 127 DEYYDILF 0.753 14 SB VP2-3 B1801 37 IEVQIASL 0.745 15 SB VP2-3B1801 233 AEREGTHV 0.477 286 WB VP2-3 B1801 182 RRTERFFR 0.519 182 WBVP2-3 B2705 342 KRRSRSSR 0.514 192 WB VP2-3 B2705 259 QRMDLRNK 0.511 197WB VP2-3 B2705 320 RRVSRGSS 0.459 349 WB VP2-3 B2705 294 LPLLLGLY 0.72918 SB VP2-3 B3501 16 EAAAATGF 0.672 34 SB VP2-3 B3501 239 HVNFGHTY 0.63949 SB VP2-3 B3501 206 APINFYNY 0.606 71 WB VP2-3 B3501 157 FATISQAL0.598 77 WB VP2-3 B3501 289 APQWMLPL 0.579 95 WB VP2-3 B3501 139TFVNNIQY 0.501 221 WB VP2-3 B3501 93 LAQVGYRF 0.486 261 WB VP2-3 B3501123 LFNPDEYY 0.476 289 WB VP2-3 B3501 73 APGAIAGF 0.469 313 WB VP2-3B3501 114 YQQSGMAL 0.547 134 WB VP2-3 B3901 37 IEVQIASL 0.623 59 WBVP2-3 B4001 272 GEFIEKTI 0.558 118 WB VP2-3 B4001 127 DEYYDILF 0.459 346WB VP2-3 B4001 235 REGTHVNF 0.445 404 WB VP2-3 B4001 233 AEREGTHV 0.430476 WB VP2-3 B4001 235 REGTHVNF 0.564 111 WB VP2-3 B4002 197 EETTWTIV0.485 263 WB VP2-3 B4002 272 GEFIEKTI 0.467 318 WB VP2-3 B4002 26AEIAAGEA 0.493 240 WB VP2-3 B4403 235 REGTHVNF 0.426 497 WB VP2-3 B440326 AEIAAGEA 0.624 58 WB VP2-3 B4501 233 AEREGTHV 0.483 269 WB VP2-3B4501 197 EETTWTIV 0.443 413 WB VP2-3 B4501 153 GPSLFATI 0.494 238 WBVP2-3 B5101 63 TPQTYAVI 0.493 241 WB VP2-3 B5101 294 LPLLLGLY 0.483 269WB VP2-3 B5101 134 FPGVNTFV 0.466 321 WB VP2-3 B5101 222 SPIRPSMV 0.440427 WB VP2-3 B5101 206 APINFYNY 0.677 32 SB VP2-3 B5301 134 FPGVNTFV0.594 81 WB VP2-3 B5301 63 TPQTYAVI 0.488 254 WB VP2-3 B5301 153GPSLFATI 0.467 320 WB VP2-3 B5301 134 FPGVNTFV 0.703 24 SB VP2-3 B5401294 LPLLLGLY 0.526 168 WB VP2-3 B5401 80 FAALIQTV 0.437 443 WB VP2-3B5401 158 ATISQALW 0.681 31 SB VP2-3 B5801 194 RFLEETTW 0.580 93 WBVP2-3 B5801 287 RTAPQWML 0.551 129 WB VP2-3 B5801 203 IVNAPINF 0.463 332WB VP2-3 B5801 9-mers 138 NTFVNNIQY 0.453 373 WB VP2-3 A0101 195FLEETTWTI 0.822 6 SB VP2-3 A0201 6 LLGDLVASV 0.810 7 SB VP2-3 A0201 292WMLPLLLGL 0.786 10 SB VP2-3 A0201 213 YIQDYYSNL 0.758 13 SB VP2-3 A020161 GLTPQTYAV 0.678 32 SB VP2-3 A0201 82 ALIQTVTGI 0.643 47 SB VP2-3A0201 299 GLYGTVTPA 0.622 59 WB VP2-3 A0201 159 TISQALWHV 0.608 69 WBVP2-3 A0201 39 VQIASLATV 0.593 81 WB VP2-3 A0201 296 LLLGLYGTV 0.532 157WB VP2-3 A0201 155 SLFATISQA 0.509 203 WB VP2-3 A0201 3 ALALLGDLV 0.509203 WB VP2-3 A0201 76 AIAGFAALI 0.477 288 WB VP2-3 A0201 17 AAAATGFSV0.471 307 WB VP2-3 A0201 100 FFSDWDHKV 0.465 327 WB VP2-3 A0201 191SLARFLEET 0.427 492 WB VP2-3 A0201 61 GLTPQTYAV 0.877 3 SB VP2-3 A0202 6LLGDLVASV 0.801 8 SB VP2-3 A0202 195 FLEETTWTI 0.800 8 SB VP2-3 A0202 3ALALLGDLV 0.789 9 SB VP2-3 A0202 213 YIQDYYSNL 0.759 13 SB VP2-3 A0202159 TISQALWHV 0.692 27 SB VP2-3 A0202 155 SLFATISQA 0.675 33 SB VP2-3A0202 292 WMLPLLLGL 0.671 35 SB VP2-3 A0202 299 GLYGTVTPA 0.656 41 SBVP2-3 A0202 82 ALIQTVTGI 0.656 41 SB VP2-3 A0202 191 SLARFLEET 0.649 44SB VP2-3 A0202 10 LVASVSEAA 0.578 96 WB VP2-3 A0202 52 TTSEAIAAI 0.559118 WB VP2-3 A0202 76 AIAGFAALI 0.550 130 WB VP2-3 A0202 296 LLLGLYGTV0.537 149 WB VP2-3 A0202 39 VQIASLATV 0.505 211 WB VP2-3 A0202 33AAAAIEVQI 0.497 231 WB VP2-3 A0202 220 NLSPIRPSM 0.483 269 WB VP2-3A0202 80 FAALIQTVT 0.482 272 WB VP2-3 A0202 112 GLYQQSGMA 0.457 356 WBVP2-3 A0202 75 GAIAGFAAL 0.449 388 WB VP2-3 A0202 17 AAAATGFSV 0.447 396WB VP2-3 A0202 65 QTYAVIAGA 0.445 405 WB VP2-3 A0202 36 AIEVQIASL 0.443413 WB VP2-3 A0202 136 GVNTFVNNI 0.436 444 WB VP2-3 A0202 132 ILFPGVNTF0.435 454 WB VP2-3 A0202 100 FFSDWDHKV 0.428 488 WB VP2-3 A0202 6LLGDLVASV 0.941 1 SB VP2-3 A0203 299 GLYGTVTPA 0.900 2 SB VP2-3 A0203 61GLTPQTYAV 0.878 3 SB VP2-3 A0203 82 ALIQTVTGI 0.870 4 SB VP2-3 A0203 39VQIASLATV 0.845 5 SB VP2-3 A0203 213 YIQDYYSNL 0.840 5 SB VP2-3 A0203292 WMLPLLLGL 0.787 10 SB VP2-3 A0203 296 LLLGLYGTV 0.779 10 SB VP2-3A0203 195 FLEETTWTI 0.757 13 SB VP2-3 A0203 112 GLYQQSGMA 0.739 16 SBVP2-3 A0203 155 SLFATISQA 0.730 18 SB VP2-3 A0203 65 QTYAVIAGA 0.690 28SB VP2-3 A0203 3 ALALLGDLV 0.687 29 SB VP2-3 A0203 69 VIAGAPGAI 0.670 35SB VP2-3 A0203 136 GVNTFVNNI 0.666 37 SB VP2-3 A0203 76 AIAGFAALI 0.66437 SB VP2-3 A0203 191 SLARFLEET 0.663 38 SB VP2-3 A0203 159 TISQALWHV0.608 69 WB VP2-3 A0203 85 QTVTGISSL 0.606 70 WB VP2-3 A0203 52TTSEAIAAI 0.586 88 WB VP2-3 A0203 167 VIRDDIPAI 0.553 125 WB VP2-3 A020317 AAAATGFSV 0.540 145 WB VP2-3 A0203 75 GAIAGFAAL 0.515 190 WB VP2-3A0203 10 LVASVSEAA 0.487 258 WB VP2-3 A0203 18 AAATGFSVA 0.483 269 WBVP2-3 A0203 20 ATGFSVAEI 0.460 344 WB VP2-3 A0203 79 GFAALIQTV 0.447 396WB VP2-3 A0203 220 NLSPIRPSM 0.428 485 WB VP2-3 A0203 6 LLGDLVASV 0.69327 SB VP2-3 A0204 195 FLEETTWTI 0.675 33 SB VP2-3 A0204 61 GLTPQTYAV0.670 35 SB VP2-3 A0204 82 ALIQTVTGI 0.615 64 WB VP2-3 A0204 155SLFATISQA 0.590 84 WB VP2-3 A0204 296 LLLGLYGTV 0.582 91 WB VP2-3 A0204100 FFSDWDHKV 0.570 104 WB VP2-3 A0204 17 AAAATGFSV 0.494 238 WB VP2-3A0204 292 WMLPLLLGL 0.493 241 WB VP2-3 A0204 213 YIQDYYSNL 0.491 246 WBVP2-3 A0204 299 GLYGTVTPA 0.468 317 WB VP2-3 A0204 159 TISQALWHV 0.463333 WB VP2-3 A0204 191 SLARFLEET 0.455 365 WB VP2-3 A0204 39 VQIASLATV0.928 2 SB VP2-3 A0206 292 WMLPLLLGL 0.907 2 SB VP2-3 A0206 195FLEETTWTI 0.894 3 SB VP2-3 A0206 61 GLTPQTYAV 0.849 5 SB VP2-3 A0206 159TISQALWHV 0.830 6 SB VP2-3 A0206 6 LLGDLVASV 0.811 7 SB VP2-3 A0206 75GAIAGFAAL 0.805 8 SB VP2-3 A0206 68 AVIAGAPGA 0.768 12 SB VP2-3 A0206 17AAAATGFSV 0.719 20 SB VP2-3 A0206 82 ALIQTVTGI 0.701 25 SB VP2-3 A0206296 LLLGLYGTV 0.688 29 SB VP2-3 A0206 45 ATVEGITTT 0.678 32 SB VP2-3A0206 94 AQVGYRFFS 0.625 57 WB VP2-3 A0206 146 YLDPRHWGP 0.622 59 WBVP2-3 A0206 213 YIQDYYSNL 0.593 81 WB VP2-3 A0206 52 TTSEAIAAI 0.579 94WB VP2-3 A0206 10 LVASVSEAA 0.547 133 WB VP2-3 A0206 129 YYDILFPGV 0.545137 WB VP2-3 A0206 288 TAPQWMLPL 0.544 139 WB VP2-3 A0206 114 YQQSGMALE0.542 141 WB VP2-3 A0206 246 YSIDNADSI 0.520 180 WB VP2-3 A0206 18AAATGFSVA 0.517 186 WB VP2-3 A0206 299 GLYGTVTPA 0.516 189 WB VP2-3A0206 85 QTVTGISSL 0.511 198 WB VP2-3 A0206 76 AIAGFAALI 0.511 198 WBVP2-3 A0206 29 AAGEAAAAI 0.508 205 WB VP2-3 A0206 132 ILFPGVNTF 0.505210 WB VP2-3 A0206 230 RQVAEREGT 0.497 230 WB VP2-3 A0206 3 ALALLGDLV0.496 234 WB VP2-3 A0206 65 QTYAVIAGA 0.478 282 WB VP2-3 A0206 5ALLGDLVAS 0.462 337 WB VP2-3 A0206 167 VIRDDIPAI 0.444 409 WB VP2-3A0206 115 QQSGMALEL 0.438 437 WB VP2-3 A0206 61 GLTPQTYAV 0.969 1 SBVP2-3 A0211 6 LLGDLVASV 0.968 1 SB VP2-3 A0211 296 LLLGLYGTV 0.950 1 SBVP2-3 A0211 292 WMLPLLLGL 0.944 1 SB VP2-3 A0211 195 FLEETTWTI 0.936 2SB VP2-3 A0211 159 TISQALWHV 0.904 2 SB VP2-3 A0211 155 SLFATISQA 0.8913 SB VP2-3 A0211 299 GLYGTVTPA 0.884 3 SB VP2-3 A0211 100 FFSDWDHKV0.872 4 SB VP2-3 A0211 146 YLDPRHWGP 0.871 4 SB VP2-3 A0211 3 ALALLGDLV0.860 4 SB VP2-3 A0211 213 YIQDYYSNL 0.850 5 SB VP2-3 A0211 220NLSPIRPSM 0.829 6 SB VP2-3 A0211 132 ILFPGVNTF 0.826 6 SB VP2-3 A0211 76AIAGFAALI 0.816 7 SB VP2-3 A0211 191 SLARFLEET 0.802 8 SB VP2-3 A0211 82ALIQTVTGI 0.775 11 SB VP2-3 A0211 129 YYDILFPGV 0.734 17 SB VP2-3 A021192 SLAQVGYRF 0.679 32 SB VP2-3 A0211 79 GFAALIQTV 0.662 38 SB VP2-3A0211 5 ALLGDLVAS 0.660 39 SB VP2-3 A0211 112 GLYQQSGMA 0.658 40 SBVP2-3 A0211 17 AAAATGFSV 0.657 41 SB VP2-3 A0211 295 PLLLGLYGT 0.632 53WB VP2-3 A0211 133 LFPGVNTFV 0.594 80 WB VP2-3 A0211 167 VIRDDIPAI 0.59481 WB VP2-3 A0211 253 SIEEVTQRM 0.567 108 WB VP2-3 A0211 86 TVTGISSLA0.472 303 WB VP2-3 A0211 288 TAPQWMLPL 0.472 304 WB VP2-3 A0211 27EIAAGEAAA 0.450 383 WB VP2-3 A0211 6 LLGDLVASV 0.931 2 SB VP2-3 A0212 61GLTPQTYAV 0.924 2 SB VP2-3 A0212 296 LLLGLYGTV 0.910 2 SB VP2-3 A0212292 WMLPLLLGL 0.910 2 SB VP2-3 A0212 213 YIQDYYSNL 0.894 3 SB VP2-3A0212 195 FLEETTWTI 0.892 3 SB VP2-3 A0212 146 YLDPRHWGP 0.842 5 SBVP2-3 A0212 100 FFSDWDHKV 0.833 6 SB VP2-3 A0212 299 GLYGTVTPA 0.769 12SB VP2-3 A0212 159 TISQALWHV 0.717 21 SB VP2-3 A0212 132 ILFPGVNTF 0.71621 SB VP2-3 A0212 167 VIRDDIPAI 0.698 26 SB VP2-3 A0212 155 SLFATISQA0.679 32 SB VP2-3 A0212 82 ALIQTVTGI 0.678 32 SB VP2-3 A0212 191SLARFLEET 0.662 38 SB VP2-3 A0212 3 ALALLGDLV 0.654 42 SB VP2-3 A0212129 YYDILFPGV 0.650 43 SB VP2-3 A0212 220 NLSPIRPSM 0.622 59 WB VP2-3A0212 5 ALLGDLVAS 0.593 82 WB VP2-3 A0212 79 GFAALIQTV 0.532 157 WBVP2-3 A0212 133 LFPGVNTFV 0.528 164 WB VP2-3 A0212 295 PLLLGLYGT 0.485261 WB VP2-3 A0212 27 EIAAGEAAA 0.471 306 WB VP2-3 A0212 17 AAAATGFSV0.450 383 WB VP2-3 A0212 76 AIAGFAALI 0.448 393 WB VP2-3 A0212 253SIEEVTQRM 0.430 475 WB VP2-3 A0212 6 LLGDLVASV 0.934 2 SB VP2-3 A0216 61GLTPQTYAV 0.916 2 SB VP2-3 A0216 296 LLLGLYGTV 0.886 3 SB VP2-3 A0216159 TISQALWHV 0.864 4 SB VP2-3 A0216 195 FLEETTWTI 0.847 5 SB VP2-3A0216 155 SLFATISQA 0.847 5 SB VP2-3 A0216 299 GLYGTVTPA 0.835 5 SBVP2-3 A0216 213 YIQDYYSNL 0.801 8 SB VP2-3 A0216 100 FFSDWDHKV 0.789 9SB VP2-3 A0216 133 LFPGVNTFV 0.782 10 SB VP2-3 A0216 292 WMLPLLLGL 0.76412 SB VP2-3 A0216 3 ALALLGDLV 0.763 12 SB VP2-3 A0216 191 SLARFLEET0.721 20 SB VP2-3 A0216 82 ALIQTVTGI 0.677 33 SB VP2-3 A0216 220NLSPIRPSM 0.650 44 SB VP2-3 A0216 76 AIAGFAALI 0.635 51 WB VP2-3 A021617 AAAATGFSV 0.610 67 WB VP2-3 A0216 132 ILFPGVNTF 0.584 90 WB VP2-3A0216 112 GLYQQSGMA 0.570 104 WB VP2-3 A0216 92 SLAQVGYRF 0.552 127 WBVP2-3 A0216 79 GFAALIQTV 0.522 176 WB VP2-3 A0216 6 LLGDLVASV 0.930 2 SBVP2-3 A0219 292 WMLPLLLGL 0.899 2 SB VP2-3 A0219 61 GLTPQTYAV 0.888 3 SBVP2-3 A0219 195 FLEETTWTI 0.848 5 SB VP2-3 A0219 159 TISQALWHV 0.840 5SB VP2-3 A0219 100 FFSDWDHKV 0.782 10 SB VP2-3 A0219 213 YIQDYYSNL 0.73617 SB VP2-3 A0219 296 LLLGLYGTV 0.726 19 SB VP2-3 A0219 146 YLDPRHWGP0.682 31 SB VP2-3 A0219 82 ALIQTVTGI 0.643 47 SB VP2-3 A0219 17AAAATGFSV 0.629 55 WB VP2-3 A0219 155 SLFATISQA 0.603 73 WB VP2-3 A0219299 GLYGTVTPA 0.564 111 WB VP2-3 A0219 295 PLLLGLYGT 0.553 125 WB VP2-3A0219 129 YYDILFPGV 0.529 163 WB VP2-3 A0219 220 NLSPIRPSM 0.528 164 WBVP2-3 A0219 167 VIRDDIPAI 0.507 208 WB VP2-3 A0219 132 ILFPGVNTF 0.504214 WB VP2-3 A0219 3 ALALLGDLV 0.475 291 WB VP2-3 A0219 321 RVSRGSSQK0.719 20 SB VP2-3 A0301 334 RASAKTTNK 0.651 43 SB VP2-3 A0301 203IVNAPINFY 0.555 123 WB VP2-3 A0301 293 MLPLLLGLY 0.473 299 WB VP2-3A0301 334 RASAKTTNK 0.729 18 SB VP2-3 A1101 321 RVSRGSSQK 0.724 19 SBVP2-3 A1101 91 SSLAQVGYR 0.688 29 SB VP2-3 A1101 203 IVNAPINFY 0.666 37SB VP2-3 A1101 99 RFFSDWDHK 0.496 234 WB VP2-3 A1101 158 ATISQALWH 0.460345 WB VP2-3 A1101 161 SQALWHVIR 0.457 356 WB VP2-3 A1101 174 AITSQELQR0.448 392 WB VP2-3 A1101 139 TFVNNIQYL 0.584 90 WB VP2-3 A2301 187FFRDSLARF 0.577 97 WB VP2-3 A2301 113 LYQQSGMAL 0.564 111 WB VP2-3 A2301132 ILFPGVNTF 0.521 178 WB VP2-3 A2301 300 LYGTVTPAL 0.518 183 WB VP2-3A2301 216 DYYSNLSPI 0.482 271 WB VP2-3 A2301 310 AYEDGPNQK 0.478 283 WBVP2-3 A2301 202 TIVNAPINF 0.466 322 WB VP2-3 A2301 99 RFFSDWDHK 0.466323 WB VP2-3 A2301 92 SLAQVGYRF 0.459 348 WB VP2-3 A2301 300 LYGTVTPAL0.661 39 SB VP2-3 A2402 216 DYYSNLSPI 0.637 50 WB VP2-3 A2402 156LFATISQAL 0.560 116 WB VP2-3 A2402 113 LYQQSGMAL 0.530 160 WB VP2-3A2402 200 TWTIVNAPI 0.452 374 WB VP2-3 A2402 113 LYQQSGMAL 0.743 16 SBVP2-3 A2403 139 TFVNNIQYL 0.591 83 WB VP2-3 A2403 187 FFRDSLARF 0.572102 WB VP2-3 A2403 300 LYGTVTPAL 0.502 218 WB VP2-3 A2403 292 WMLPLLLGL0.426 498 WB VP2-3 A2403 122 ELFNPDEYY 0.557 120 WB VP2-3 A2601 303TVTPALEAY 0.843 5 SB VP2-3 A2602 203 IVNAPINFY 0.823 6 SB VP2-3 A2602122 ELFNPDEYY 0.792 9 SB VP2-3 A2602 85 QTVTGISSL 0.778 11 SB VP2-3A2602 213 YIQDYYSNL 0.629 55 WB VP2-3 A2602 293 MLPLLLGLY 0.578 96 WBVP2-3 A2602 179 ELQRRTERF 0.551 128 WB VP2-3 A2602 36 AIEVQIASL 0.518183 WB VP2-3 A2602 138 NTFVNNIQY 0.503 215 WB VP2-3 A2602 187 FFRDSLARF0.468 316 WB VP2-3 A2602 202 TIVNAPINF 0.447 398 WB VP2-3 A2602 62LTPQTYAVI 0.442 416 WB VP2-3 A2602 210 FYNYIQDYY 0.765 12 SB VP2-3 A2902122 ELFNPDEYY 0.716 21 SB VP2-3 A2902 138 NTFVNNIQY 0.580 94 WB VP2-3A2902 203 IVNAPINFY 0.465 327 WB VP2-3 A2902 209 NFYNYIQDY 0.457 357 WBVP2-3 A2902 293 MLPLLLGLY 0.446 402 WB VP2-3 A2902 99 RFFSDWDHK 0.765 12SB VP2-3 A3001 321 RVSRGSSQK 0.639 49 SB VP2-3 A3001 334 RASAKTTNK 0.59381 WB VP2-3 A3001 186 RFFRDSLAR 0.501 222 WB VP2-3 A3001 329 KAKGTRASA0.446 401 WB VP2-3 A3001 210 FYNYIQDYY 0.594 80 WB VP2-3 A3002 203IVNAPINFY 0.508 205 WB VP2-3 A3002 293 MLPLLLGLY 0.466 321 WB VP2-3A3002 338 KTTNKRRSR 0.829 6 SB VP2-3 A3101 316 NQKKRRVSR 0.804 8 SBVP2-3 A3101 227 SMVRQVAER 0.772 11 SB VP2-3 A3101 186 RFFRDSLAR 0.765 12SB VP2-3 A3101 91 SSLAQVGYR 0.756 13 SB VP2-3 A3101 161 SQALWHVIR 0.64148 SB VP2-3 A3101 326 SSQKAKGTR 0.632 53 WB VP2-3 A3101 334 RASAKTTNK0.583 91 WB VP2-3 A3101 217 YYSNLSPIR 0.570 105 WB VP2-3 A3101 336SAKTTNKRR 0.537 149 WB VP2-3 A3101 99 RFFSDWDHK 0.504 214 WB VP2-3 A3101335 ASAKTTNKR 0.479 280 WB VP2-3 A3101 321 RVSRGSSQK 0.435 453 WB VP2-3A3101 256 EVTQRMDLR 0.709 23 SB VP2-3 A3301 316 NQKKRRVSR 0.703 24 SBVP2-3 A3301 252 DSIEEVTQR 0.585 89 WB VP2-3 A3301 341 NKRRSRSSR 0.463333 WB VP2-3 A3301 256 EVTQRMDLR 0.844 5 SB VP2-3 A6801 252 DSIEEVTQR0.787 10 SB VP2-3 A6801 138 NTFVNNIQY 0.711 22 SB VP2-3 A6801 175ITSQELQRR 0.650 44 SB VP2-3 A6801 279 IAPGGANQR 0.616 63 WB VP2-3 A6801217 YYSNLSPIR 0.607 70 WB VP2-3 A6801 91 SSLAQVGYR 0.605 71 WB VP2-3A6801 227 SMVRQVAER 0.599 76 WB VP2-3 A6801 335 ASAKTTNKR 0.531 160 WBVP2-3 A6801 122 ELFNPDEYY 0.510 201 WB VP2-3 A6801 210 FYNYIQDYY 0.503217 WB VP2-3 A6801 174 AITSQELQR 0.462 338 WB VP2-3 A6801 142 NNIQYLDPR0.461 341 WB VP2-3 A6801 326 SSQKAKGTR 0.457 357 WB VP2-3 A6801 321RVSRGSSQK 0.456 360 WB VP2-3 A6801 303 TVTPALEAY 0.454 367 WB VP2-3A6801 161 SQALWHVIR 0.451 379 WB VP2-3 A6801 203 IVNAPINFY 0.449 388 WBVP2-3 A6801 338 KTTNKRRSR 0.428 487 WB VP2-3 A6801 336 SAKTTNKRR 0.427493 WB VP2-3 A6801 65 QTYAVIAGA 0.846 5 SB VP2-3 A6802 52 TTSEAIAAI0.827 6 SB VP2-3 A6802 86 TVTGISSLA 0.764 12 SB VP2-3 A6802 10 LVASVSEAA0.709 23 SB VP2-3 A6802 198 ETTWTIVNA 0.691 28 SB VP2-3 A6802 85QTVTGISSL 0.677 32 SB VP2-3 A6802 16 EAAAATGFS 0.649 44 SB VP2-3 A6802267 ESVHSGEFI 0.602 73 WB VP2-3 A6802 27 EIAAGEAAA 0.596 79 WB VP2-3A6802 17 AAAATGFSV 0.574 100 WB VP2-3 A6802 249 DNADSIEEV 0.562 114 WBVP2-3 A6802 166 HVIRDDIPA 0.561 115 WB VP2-3 A6802 159 TISQALWHV 0.550130 WB VP2-3 A6802 88 TGISSLAQV 0.536 151 WB VP2-3 A6802 48 EGITTTSEA0.535 152 WB VP2-3 A6802 246 YSIDNADSI 0.523 174 WB VP2-3 A6802 76AIAGFAALI 0.521 177 WB VP2-3 A6802 55 EAIAAIGLT 0.484 267 WB VP2-3 A680280 FAALIQTVT 0.481 273 WB VP2-3 A6802 152 WGPSLFATI 0.478 284 WB VP2-3A6802 33 AAAAIEVQI 0.458 353 WB VP2-3 A6802 288 TAPQWMLPL 0.443 416 WBVP2-3 A6802 51 TTTSEAIAA 0.433 463 WB VP2-3 A6802 65 QTYAVIAGA 0.710 23SB VP2-3 A6901 198 ETTWTIVNA 0.703 24 SB VP2-3 A6901 52 TTSEAIAAI 0.68430 SB VP2-3 A6901 159 TISQALWHV 0.622 59 WB VP2-3 A6901 292 WMLPLLLGL0.604 72 WB VP2-3 A6901 17 AAAATGFSV 0.601 74 WB VP2-3 A6901 27EIAAGEAAA 0.579 94 WB VP2-3 A6901 195 FLEETTWTI 0.570 104 WB VP2-3 A6901288 TAPQWMLPL 0.545 137 WB VP2-3 A6901 6 LLGDLVASV 0.506 209 WB VP2-3A6901 296 LLLGLYGTV 0.472 301 WB VP2-3 A6901 100 FFSDWDHKV 0.429 484 WBVP2-3 A6901 225 RPSMVRQVA 0.705 24 SB VP2-3 B0702 172 IPAITSQEL 0.628 55WB VP2-3 B0702 148 DPRHWGPSL 0.610 67 WB VP2-3 B0702 289 APQWMLPLL 0.59877 WB VP2-3 B0702 314 GPNQKKRRV 0.530 162 WB VP2-3 B0702 206 APINFYNYI0.475 294 WB VP2-3 B0702 132 ILFPGVNTF 0.606 70 WB VP2-3 B1501 203IVNAPINFY 0.578 96 WB VP2-3 B1501 180 LQRRTERFF 0.558 118 WB VP2-3 B1501115 QQSGMALEL 0.503 216 WB VP2-3 B1501 39 VQIASLATV 0.477 287 WB VP2-3B1501 122 ELFNPDEYY 0.439 432 WB VP2-3 B1501 92 SLAQVGYRF 0.428 489 WBVP2-3 B1501 184 TERFFRDSL 0.622 59 WB VP2-3 B1801 292 WMLPLLLGL 0.590 84WB VP2-3 B1801 148 DPRHWGPSL 0.584 90 WB VP2-3 B1801 54 SEAIAAIGL 0.546135 WB VP2-3 B1801 255 EEVTQRMDL 0.451 380 WB VP2-3 B1801 15 SEAAAATGF0.435 449 WB VP2-3 B1801 320 RRVSRGSSQ 0.507 206 WB VP2-3 B2705 303TVTPALEAY 0.686 29 SB VP2-3 B3501 172 IPAITSQEL 0.611 67 WB VP2-3 B3501125 NPDEYYDIL 0.606 71 WB VP2-3 B3501 238 THVNFGHTY 0.550 130 WB VP2-3B3501 156 LFATISQAL 0.521 178 WB VP2-3 B3501 67 YAVIAGAPG 0.510 199 WBVP2-3 B3501 288 TAPQWMLPL 0.508 204 WB VP2-3 B3501 289 APQWMLPLL 0.499225 WB VP2-3 B3501 132 ILFPGVNTF 0.484 265 WB VP2-3 B3501 80 FAALIQTVT0.470 310 WB VP2-3 B3501 63 TPQTYAVIA 0.453 372 WB VP2-3 B3501 28IAAGEAAAA 0.446 400 WB VP2-3 B3501 134 FPGVNTFVN 0.445 405 WB VP2-3B3501 205 NAPINFYNY 0.437 442 WB VP2-3 B3501 13 SVSEAAAAT 0.433 461 WBVP2-3 B3501 75 GAIAGFAAL 0.429 483 WB VP2-3 B3501 54 SEAIAAIGL 0.703 24SB VP2-3 B4001 31 GEAAAAIEV 0.632 53 WB VP2-3 B4001 255 EEVTQRMDL 0.542141 WB VP2-3 B4001 15 SEAAAATGF 0.509 202 WB VP2-3 B4001 184 TERFFRDSL0.467 319 WB VP2-3 B4001 266 KESVHSGEF 0.574 99 WB VP2-3 B4002 255EEVTQRMDL 0.532 158 WB VP2-3 B4002 272 GEFIEKTIA 0.496 232 WB VP2-3B4002 15 SEAAAATGF 0.495 235 WB VP2-3 B4002 54 SEAIAAIGL 0.445 405 WBVP2-3 B4002 54 SEAIAAIGL 0.492 243 WB VP2-3 B4403 15 SEAAAATGF 0.476 288WB VP2-3 B4403 26 AEIAAGEAA 0.466 322 WB VP2-3 B4403 26 AEIAAGEAA 0.63949 SB VP2-3 B4501 255 EEVTQRMDL 0.521 178 WB VP2-3 B4501 31 GEAAAAIEV0.456 361 WB VP2-3 B4501 197 EETTWTIVN 0.432 464 WB VP2-3 B4501 206APINFYNYI 0.497 230 WB VP2-3 B5101 294 LPLLLGLYG 0.451 381 WB VP2-3B5101 206 APINFYNYI 0.608 69 WB VP2-3 B5301 289 APQWMLPLL 0.545 136 WBVP2-3 B5301 157 FATISQALW 0.522 176 WB VP2-3 B5301 206 APINFYNYI 0.61464 WB VP2-3 B5401 73 APGAIAGFA 0.573 100 WB VP2-3 B5401 119 MALELFNPD0.511 199 WB VP2-3 B5401 134 FPGVNTFVN 0.502 218 WB VP2-3 B5401 294LPLLLGLYG 0.488 254 WB VP2-3 B5401 63 TPQTYAVIA 0.478 282 WB VP2-3 B540180 FAALIQTVT 0.464 329 WB VP2-3 B5401 157 FATISQALW 0.723 19 SB VP2-3B5801 90 ISSLAQVGY 0.546 136 WB VP2-3 B5801 96 VGYRFFSDW 0.481 274 WBVP2-3 B5801 10-mers 237 GTHVNFGHTY 0.517 185 WB VP2-3 A0101 5 ALLGDLVASV0.820 6 SB VP2-3 A0201 132 ILFPGVNTFV 0.785 10 SB VP2-3 A0201 299GLYGTVTPAL 0.721 20 SB VP2-3 A0201 195 FLEETTWTIV 0.703 24 SB VP2-3A0201 155 SLFATISQAL 0.632 53 WB VP2-3 A0201 114 YQQSGMALEL 0.529 162 WBVP2-3 A0201 158 ATISQALWHV 0.476 288 WB VP2-3 A0201 199 TTWTIVNAPI 0.473298 WB VP2-3 A0201 61 GLTPQTYAVI 0.471 305 WB VP2-3 A0201 112 GLYQQSGMAL0.455 364 WB VP2-3 A0201 260 RMDLRNKESV 0.442 418 WB VP2-3 A0201 220NLSPIRPSMV 0.436 445 WB VP2-3 A0201 163 ALWHVIRDDI 0.430 476 WB VP2-3A0201 132 ILFPGVNTFV 0.798 8 SB VP2-3 A0202 5 ALLGDLVASV 0.785 10 SBVP2-3 A0202 155 SLFATISQAL 0.742 16 SB VP2-3 A0202 299 GLYGTVTPAL 0.68032 SB VP2-3 A0202 112 GLYQQSGMAL 0.654 42 SB VP2-3 A0202 195 FLEETTWTIV0.589 85 WB VP2-3 A0202 3 ALALLGDLVA 0.583 91 WB VP2-3 A0202 191SLARFLEETT 0.557 120 WB VP2-3 A0202 114 YQQSGMALEL 0.554 124 WB VP2-3A0202 296 LLLGLYGTVT 0.537 149 WB VP2-3 A0202 138 NTFVNNIQYL 0.525 170WB VP2-3 A0202 220 NLSPIRPSMV 0.519 182 WB VP2-3 A0202 158 ATISQALWHV0.501 222 WB VP2-3 A0202 10 LVASVSEAAA 0.479 280 WB VP2-3 A0202 61GLTPQTYAVI 0.466 322 WB VP2-3 A0202 124 FNPDEYYDIL 0.461 342 WB VP2-3A0202 295 PLLLGLYGTV 0.450 382 WB VP2-3 A0202 260 RMDLRNKESV 0.447 397WB VP2-3 A0202 293 MLPLLLGLYG 0.427 492 WB VP2-3 A0202 2 AALALLGDLV0.426 498 WB VP2-3 A0202 132 ILFPGVNTFV 0.888 3 SB VP2-3 A0203 5ALLGDLVASV 0.868 4 SB VP2-3 A0203 195 FLEETTWTIV 0.820 7 SB VP2-3 A0203299 GLYGTVTPAL 0.803 8 SB VP2-3 A0203 220 NLSPIRPSMV 0.788 9 SB VP2-3A0203 112 GLYQQSGMAL 0.756 14 SB VP2-3 A0203 61 GLTPQTYAVI 0.703 24 SBVP2-3 A0203 155 SLFATISQAL 0.700 25 SB VP2-3 A0203 239 HVNFGHTYSI 0.66338 SB VP2-3 A0203 287 RTAPQWMLPL 0.629 55 WB VP2-3 A0203 260 RMDLRNKESV0.533 156 WB VP2-3 A0203 191 SLARFLEETT 0.530 161 WB VP2-3 A0203 68AVIAGAPGAI 0.529 163 WB VP2-3 A0203 158 ATISQALWHV 0.516 187 WB VP2-3A0203 24 SVAEIAAGEA 0.513 193 WB VP2-3 A0203 114 YQQSGMALEL 0.513 194 WBVP2-3 A0203 35 AAIEVQIASL 0.509 203 WB VP2-3 A0203 295 PLLLGLYGTV 0.503217 WB VP2-3 A0203 69 VIAGAPGAIA 0.490 248 WB VP2-3 A0203 3 ALALLGDLVA0.472 303 WB VP2-3 A0203 10 LVASVSEAAA 0.471 304 WB VP2-3 A0203 75GAIAGFAALI 0.453 373 WB VP2-3 A0203 85 QTVTGISSLA 0.440 425 WB VP2-3A0203 43 SLATVEGITT 0.431 473 WB VP2-3 A0203 132 ILFPGVNTFV 0.738 17 SBVP2-3 A0204 195 FLEETTWTIV 0.686 30 SB VP2-3 A0204 5 ALLGDLVASV 0.678 32SB VP2-3 A0204 155 SLFATISQAL 0.630 54 WB VP2-3 A0204 158 ATISQALWHV0.567 108 WB VP2-3 A0204 299 GLYGTVTPAL 0.485 263 WB VP2-3 A0204 112GLYQQSGMAL 0.468 317 WB VP2-3 A0204 287 RTAPQWMLPL 0.457 356 WB VP2-3A0204 5 ALLGDLVASV 0.873 3 SB VP2-3 A0206 195 FLEETTWTIV 0.869 4 SBVP2-3 A0206 132 ILFPGVNTFV 0.865 4 SB VP2-3 A0206 114 YQQSGMALEL 0.803 8SB VP2-3 A0206 158 ATISQALWHV 0.779 10 SB VP2-3 A0206 35 AAIEVQIASL0.711 22 SB VP2-3 A0206 75 GAIAGFAALI 0.649 44 SB VP2-3 A0206 287RTAPQWMLPL 0.626 57 WB VP2-3 A0206 299 GLYGTVTPAL 0.599 76 WB VP2-3A0206 68 AVIAGAPGAI 0.591 83 WB VP2-3 A0206 67 YAVIAGAPGA 0.588 86 WBVP2-3 A0206 84 IQTVTGISSL 0.569 105 WB VP2-3 A0206 2 AALALLGDLV 0.550129 WB VP2-3 A0206 94 AQVGYRFFSD 0.537 150 WB VP2-3 A0206 146 YLDPRHWGPS0.525 169 WB VP2-3 A0206 260 RMDLRNKESV 0.525 170 WB VP2-3 A0206 166HVIRDDIPAI 0.513 193 WB VP2-3 A0206 288 TAPQWMLPLL 0.507 208 WB VP2-3A0206 155 SLFATISQAL 0.500 223 WB VP2-3 A0206 39 VQIASLATVE 0.488 254 WBVP2-3 A0206 24 SVAEIAAGEA 0.488 255 WB VP2-3 A0206 194 RFLEETTWTI 0.480276 WB VP2-3 A0206 10 LVASVSEAAA 0.470 309 WB VP2-3 A0206 112 GLYQQSGMAL0.466 322 WB VP2-3 A0206 220 NLSPIRPSMV 0.460 344 WB VP2-3 A0206 159TISQALWHVI 0.458 353 WB VP2-3 A0206 17 AAAATGFSVA 0.457 354 WB VP2-3A0206 45 ATVEGITTTS 0.454 365 WB VP2-3 A0206 231 QVAEREGTHV 0.453 371 WBVP2-3 A0206 78 AGFAALIQTV 0.448 394 WB VP2-3 A0206 115 QQSGMALELF 0.438437 WB VP2-3 A0206 81 AALIQTVTGI 0.433 460 WB VP2-3 A0206 61 GLTPQTYAVI0.432 466 WB VP2-3 A0206 132 ILFPGVNTFV 0.975 1 SB VP2-3 A0211 5ALLGDLVASV 0.972 1 SB VP2-3 A0211 155 SLFATISQAL 0.940 1 SB VP2-3 A0211299 GLYGTVTPAL 0.939 1 SB VP2-3 A0211 195 FLEETTWTIV 0.931 2 SB VP2-3A0211 260 RMDLRNKESV 0.912 2 SB VP2-3 A0211 220 NLSPIRPSMV 0.891 3 SBVP2-3 A0211 295 PLLLGLYGTV 0.885 3 SB VP2-3 A0211 112 GLYQQSGMAL 0.864 4SB VP2-3 A0211 61 GLTPQTYAVI 0.850 5 SB VP2-3 A0211 146 YLDPRHWGPS 0.74016 SB VP2-3 A0211 191 SLARFLEETT 0.737 17 SB VP2-3 A0211 128 EYYDILFPGV0.731 18 SB VP2-3 A0211 159 TISQALWHVI 0.674 34 SB VP2-3 A0211 102SDWDHKVSTV 0.641 48 SB VP2-3 A0211 292 WMLPLLLGLY 0.638 50 WB VP2-3A0211 163 ALWHVIRDDI 0.620 60 WB VP2-3 A0211 3 ALALLGDLVA 0.616 63 WBVP2-3 A0211 92 SLAQVGYRFF 0.615 64 WB VP2-3 A0211 158 ATISQALWHV 0.59877 WB VP2-3 A0211 99 RFFSDWDHKV 0.596 79 WB VP2-3 A0211 287 RTAPQWMLPL0.585 89 WB VP2-3 A0211 78 AGFAALIQTV 0.570 105 WB VP2-3 A0211 43SLATVEGITT 0.568 107 WB VP2-3 A0211 223 PIRPSMVRQV 0.566 109 WB VP2-3A0211 296 LLLGLYGTVT 0.548 133 WB VP2-3 A0211 38 EVQIASLATV 0.532 158 WBVP2-3 A0211 114 YQQSGMALEL 0.530 162 WB VP2-3 A0211 194 RFLEETTWTI 0.518184 WB VP2-3 A0211 239 HVNFGHTYSI 0.510 199 WB VP2-3 A0211 24 SVAEIAAGEA0.497 230 WB VP2-3 A0211 171 DIPAITSQEL 0.484 265 WB VP2-3 A0211 231QVAEREGTHV 0.484 265 WB VP2-3 A0211 288 TAPQWMLPLL 0.470 310 WB VP2-3A0211 16 EAAAATGFSV 0.464 330 WB VP2-3 A0211 87 VTGISSLAQV 0.454 366 WBVP2-3 A0211 6 LLGDLVASVS 0.453 372 WB VP2-3 A0211 35 AAIEVQIASL 0.437439 WB VP2-3 A0211 132 ILFPGVNTFV 0.943 1 SB VP2-3 A0212 5 ALLGDLVASV0.935 2 SB VP2-3 A0212 195 FLEETTWTIV 0.906 2 SB VP2-3 A0212 299GLYGTVTPAL 0.904 2 SB VP2-3 A0212 155 SLFATISQAL 0.880 3 SB VP2-3 A0212260 RMDLRNKESV 0.826 6 SB VP2-3 A0212 220 NLSPIRPSMV 0.779 10 SB VP2-3A0212 112 GLYQQSGMAL 0.778 11 SB VP2-3 A0212 295 PLLLGLYGTV 0.757 13 SBVP2-3 A0212 191 SLARFLEETT 0.661 39 SB VP2-3 A0212 61 GLTPQTYAVI 0.65442 SB VP2-3 A0212 163 ALWHVIRDDI 0.638 50 WB VP2-3 A0212 128 EYYDILFPGV0.616 63 WB VP2-3 A0212 146 YLDPRHWGPS 0.615 64 WB VP2-3 A0212 114YQQSGMALEL 0.540 145 WB VP2-3 A0212 296 LLLGLYGTVT 0.537 149 WB VP2-3A0212 102 SDWDHKVSTV 0.537 150 WB VP2-3 A0212 231 QVAEREGTHV 0.480 278WB VP2-3 A0212 292 WMLPLLLGLY 0.456 358 WB VP2-3 A0212 158 ATISQALWHV0.442 419 WB VP2-3 A0212 99 RFFSDWDHKV 0.441 423 WB VP2-3 A0212 213YIQDYYSNLS 0.431 472 WB VP2-3 A0212 132 ILFPGVNTFV 0.955 1 SB VP2-3A0216 5 ALLGDLVASV 0.929 2 SB VP2-3 A0216 299 GLYGTVTPAL 0.896 3 SBVP2-3 A0216 195 FLEETTWTIV 0.888 3 SB VP2-3 A0216 220 NLSPIRPSMV 0.866 4SB VP2-3 A0216 155 SLFATISQAL 0.857 4 SB VP2-3 A0216 295 PLLLGLYGTV0.819 7 SB VP2-3 A0216 260 RMDLRNKESV 0.787 9 SB VP2-3 A0216 112GLYQQSGMAL 0.782 10 SB VP2-3 A0216 61 GLTPQTYAVI 0.651 43 SB VP2-3 A0216191 SLARFLEETT 0.648 45 SB VP2-3 A0216 158 ATISQALWHV 0.620 60 WB VP2-3A0216 102 SDWDHKVSTV 0.575 99 WB VP2-3 A0216 163 ALWHVIRDDI 0.562 114 WBVP2-3 A0216 231 QVAEREGTHV 0.553 125 WB VP2-3 A0216 128 EYYDILFPGV 0.552126 WB VP2-3 A0216 38 EVQIASLATV 0.550 130 WB VP2-3 A0216 223 PIRPSMVRQV0.520 179 WB VP2-3 A0216 43 SLATVEGITT 0.498 229 WB VP2-3 A0216 99RFFSDWDHKV 0.498 229 WB VP2-3 A0216 171 DIPAITSQEL 0.485 262 WB VP2-3A0216 87 VTGISSLAQV 0.455 363 WB VP2-3 A0216 16 EAAAATGFSV 0.451 379 WBVP2-3 A0216 114 YQQSGMALEL 0.446 401 WB VP2-3 A0216 78 AGFAALIQTV 0.438434 WB VP2-3 A0216 3 ALALLGDLVA 0.434 456 WB VP2-3 A0216 59 AIGLTPQTYA0.433 460 WB VP2-3 A0216 296 LLLGLYGTVT 0.427 492 WB VP2-3 A0216 5ALLGDLVASV 0.918 2 SB VP2-3 A0219 195 FLEETTWTIV 0.849 5 SB VP2-3 A0219299 GLYGTVTPAL 0.826 6 SB VP2-3 A0219 220 NLSPIRPSMV 0.768 12 SB VP2-3A0219 155 SLFATISQAL 0.750 14 SB VP2-3 A0219 260 RMDLRNKESV 0.698 26 SBVP2-3 A0219 295 PLLLGLYGTV 0.664 37 SB VP2-3 A0219 61 GLTPQTYAVI 0.545137 WB VP2-3 A0219 114 YQQSGMALEL 0.523 175 WB VP2-3 A0219 128EYYDILFPGV 0.521 177 WB VP2-3 A0219 159 TISQALWHVI 0.498 228 WB VP2-3A0219 16 EAAAATGFSV 0.480 277 WB VP2-3 A0219 112 GLYQQSGMAL 0.441 424 WBVP2-3 A0219 158 ATISQALWHV 0.439 430 WB VP2-3 A0219 268 SVHSGEFIEK 0.544139 WB VP2-3 A0301 329 KAKGTRASAK 0.506 208 WB VP2-3 A0301 320RRVSRGSSQK 0.471 306 WB VP2-3 A0301 202 TIVNAPINFY 0.464 331 WB VP2-3A0301 292 WMLPLLLGLY 0.456 358 WB VP2-3 A0301 268 SVHSGEFIEK 0.783 10 SBVP2-3 A1101 257 VTQRMDLRNK 0.698 26 SB VP2-3 A1101 160 ISQALWHVIR 0.561115 WB VP2-3 A1101 329 KAKGTRASAK 0.536 152 WB VP2-3 A1101 202TIVNAPINFY 0.497 230 WB VP2-3 A1101 90 ISSLAQVGYR 0.464 329 WB VP2-3A1101 212 NYIQDYYSNL 0.652 43 SB VP2-3 A2301 186 RFFRDSLARF 0.651 43 SBVP2-3 A2301 194 RFLEETTWTI 0.548 132 WB VP2-3 A2301 201 WTIVNAPINF 0.547135 WB VP2-3 A2301 310 AYEDGPNQKK 0.490 250 WB VP2-3 A2301 245TYSIDNADSI 0.489 252 WB VP2-3 A2301 91 SSLAQVGYRF 0.461 340 WB VP2-3A2301 179 ELQRRTERFF 0.429 482 WB VP2-3 A2301 212 NYIQDYYSNL 0.650 44 SBVP2-3 A2402 194 RFLEETTWTI 0.609 69 WB VP2-3 A2402 151 HWGPSLFATI 0.540145 WB VP2-3 A2402 245 TYSIDNADSI 0.529 162 WB VP2-3 A2402 186RFFRDSLARF 0.484 266 WB VP2-3 A2402 156 LFATISQALW 0.476 290 WB VP2-3A2402 194 RFLEETTWTI 0.667 36 SB VP2-3 A2403 186 RFFRDSLARF 0.659 39 SBVP2-3 A2403 212 NYIQDYYSNL 0.619 62 WB VP2-3 A2403 245 TYSIDNADSI 0.461341 WB VP2-3 A2403 291 QWMLPLLLGL 0.429 481 WB VP2-3 A2403 202TIVNAPINFY 0.620 60 WB VP2-3 A2601 252 DSIEEVTQRM 0.617 63 WB VP2-3A2601 202 TIVNAPINFY 0.801 8 SB VP2-3 A2602 302 GTVTPALEAY 0.771 11 SBVP2-3 A2602 287 RTAPQWMLPL 0.760 13 SB VP2-3 A2602 201 WTIVNAPINF 0.74415 SB VP2-3 A2602 179 ELQRRTERFF 0.735 17 SB VP2-3 A2602 171 DIPAITSQEL0.532 158 WB VP2-3 A2602 166 HVIRDDIPAI 0.531 159 WB VP2-3 A2602 131DILFPGVNTF 0.488 253 WB VP2-3 A2602 38 EVQIASLATV 0.471 304 WB VP2-3A2602 209 NFYNYIQDYY 0.572 102 WB VP2-3 A2902 204 VNAPINFYNY 0.549 131WB VP2-3 A2902 292 WMLPLLLGLY 0.547 134 WB VP2-3 A2902 329 KAKGTRASAK0.783 10 SB VP2-3 A3001 322 VSRGSSQKAK 0.757 13 SB VP2-3 A3001 268SVHSGEFIEK 0.678 32 SB VP2-3 A3001 180 LQRRTERFFR 0.485 263 WB VP2-3A3001 237 GTHVNFGHTY 0.479 281 WB VP2-3 A3001 89 GISSLAQVGY 0.518 184 WBVP2-3 A3002 292 WMLPLLLGLY 0.511 198 WB VP2-3 A3002 209 NFYNYIQDYY 0.475292 WB VP2-3 A3002 202 TIVNAPINFY 0.437 443 WB VP2-3 A3002 180LQRRTERFFR 0.756 14 SB VP2-3 A3101 334 RASAKTTNKR 0.645 46 SB VP2-3A3101 337 AKTTNKRRSR 0.606 71 WB VP2-3 A3101 160 ISQALWHVIR 0.591 83 WBVP2-3 A3101 174 AITSQELQRR 0.577 97 WB VP2-3 A3101 177 SQELQRRTER 0.543140 WB VP2-3 A3101 329 KAKGTRASAK 0.520 180 WB VP2-3 A3101 90 ISSLAQVGYR0.491 246 WB VP2-3 A3101 340 TNKRRSRSSR 0.489 252 WB VP2-3 A3101 226PSMVRQVAER 0.471 305 WB VP2-3 A3101 335 ASAKTTNKRR 0.455 363 WB VP2-3A3101 315 PNQKKRRVSR 0.448 393 WB VP2-3 A3101 216 DYYSNLSPIR 0.588 86 WBVP2-3 A3301 180 LQRRTERFFR 0.560 116 WB VP2-3 A3301 160 ISQALWHVIR 0.507206 WB VP2-3 A3301 278 TIAPGGANQR 0.743 16 SB VP2-3 A6801 309 EAYEDGPNQK0.741 16 SB VP2-3 A6801 90 ISSLAQVGYR 0.713 22 SB VP2-3 A6801 216DYYSNLSPIR 0.707 23 SB VP2-3 A6801 268 SVHSGEFIEK 0.645 46 SB VP2-3A6801 185 ERFFRDSLAR 0.541 142 WB VP2-3 A6801 334 RASAKTTNKR 0.535 152WB VP2-3 A6801 202 TIVNAPINFY 0.532 158 WB VP2-3 A6801 160 ISQALWHVIR0.498 228 WB VP2-3 A6801 255 EEVTQRMDLR 0.495 237 WB VP2-3 A6801 209NFYNYIQDYY 0.464 329 WB VP2-3 A6801 221 LSPIRPSMVR 0.439 434 WB VP2-3A6801 16 EAAAATGFSV 0.886 3 SB VP2-3 A6802 199 TTWTIVNAPI 0.877 3 SBVP2-3 A6802 32 EAAAAIEVQI 0.797 8 SB VP2-3 A6802 138 NTFVNNIQYL 0.763 12SB VP2-3 A6802 239 HVNFGHTYSI 0.707 23 SB VP2-3 A6802 287 RTAPQWMLPL0.692 28 SB VP2-3 A6802 24 SVAEIAAGEA 0.669 36 SB VP2-3 A6802 51TTTSEAIAAI 0.664 38 SB VP2-3 A6802 205 NAPINFYNYI 0.663 38 SB VP2-3A6802 27 EIAAGEAAAA 0.642 47 SB VP2-3 A6802 48 EGITTTSEAI 0.641 48 SBVP2-3 A6802 85 QTVTGISSLA 0.637 50 WB VP2-3 A6802 38 EVQIASLATV 0.608 69WB VP2-3 A6802 171 DIPAITSQEL 0.587 86 WB VP2-3 A6802 10 LVASVSEAAA0.570 105 WB VP2-3 A6802 128 EYYDILFPGV 0.563 113 WB VP2-3 A6802 220NLSPIRPSMV 0.549 130 WB VP2-3 A6802 132 ILFPGVNTFV 0.545 138 WB VP2-3A6802 166 HVIRDDIPAI 0.535 152 WB VP2-3 A6802 155 SLFATISQAL 0.516 188WB VP2-3 A6802 159 TISQALWHVI 0.500 223 WB VP2-3 A6802 28 IAAGEAAAAI0.487 257 WB VP2-3 A6802 231 QVAEREGTHV 0.474 296 WB VP2-3 A6802 158ATISQALWHV 0.457 357 WB VP2-3 A6802 41 IASLATVEGI 0.435 450 WB VP2-3A6802 16 EAAAATGFSV 0.809 7 SB VP2-3 A6901 199 TTWTIVNAPI 0.775 11 SBVP2-3 A6901 128 EYYDILFPGV 0.674 34 SB VP2-3 A6901 38 EVQIASLATV 0.65541 SB VP2-3 A6901 138 NTFVNNIQYL 0.647 45 SB VP2-3 A6901 158 ATISQALWHV0.607 69 WB VP2-3 A6901 32 EAAAAIEVQI 0.603 73 WB VP2-3 A6901 27EIAAGEAAAA 0.569 105 WB VP2-3 A6901 239 HVNFGHTYSI 0.516 187 WB VP2-3A6901 287 RTAPQWMLPL 0.511 198 WB VP2-3 A6901 166 HVIRDDIPAI 0.505 210WB VP2-3 A6901 132 ILFPGVNTFV 0.497 229 WB VP2-3 A6901 231 QVAEREGTHV0.482 271 WB VP2-3 A6901 5 ALLGDLVASV 0.460 346 WB VP2-3 A6901 51TTTSEAIAAI 0.451 381 WB VP2-3 A6901 87 VTGISSLAQV 0.440 426 WB VP2-3A6901 288 TAPQWMLPLL 0.437 441 WB VP2-3 A6901 24 SVAEIAAGEA 0.434 456 WBVP2-3 A6901 289 APQWMLPLLL 0.641 48 SB VP2-3 B0702 225 RPSMVRQVAE 0.62160 WB VP2-3 B0702 148 DPRHWGPSLF 0.517 185 WB VP2-3 B0702 73 APGAIAGFAA0.513 194 WB VP2-3 B0702 292 WMLPLLLGLY 0.543 140 WB VP2-3 B1501 115QQSGMALELF 0.542 141 WB VP2-3 B1501 114 YQQSGMALEL 0.537 150 WB VP2-3B1501 84 IQTVTGISSL 0.522 176 WB VP2-3 B1501 155 SLFATISQAL 0.494 238 WBVP2-3 B1501 230 RQVAEREGTH 0.480 276 WB VP2-3 B1501 92 SLAQVGYRFF 0.475291 WB VP2-3 B1501 58 AAIGLTPQTY 0.469 311 WB VP2-3 B1501 237 GTHVNFGHTY0.447 398 WB VP2-3 B1501 299 GLYGTVTPAL 0.434 457 WB VP2-3 B1501 201WTIVNAPINF 0.426 497 WB VP2-3 B1501 233 AEREGTHVNF 0.711 22 SB VP2-3B1801 121 LELFNPDEYY 0.515 189 WB VP2-3 B1801 178 QELQRRTERF 0.507 207WB VP2-3 B1801 37 IEVQIASLAT 0.487 257 WB VP2-3 B1801 148 DPRHWGPSLF0.482 273 WB VP2-3 B1801 292 WMLPLLLGLY 0.445 407 WB VP2-3 B1801 320RRVSRGSSQK 0.631 54 WB VP2-3 B2705 98 YRFFSDWDHK 0.450 383 WB VP2-3B2705 125 NPDEYYDILF 0.757 13 SB VP2-3 B3501 58 AAIGLTPQTY 0.566 109 WBVP2-3 B3501 148 DPRHWGPSLF 0.544 138 WB VP2-3 B3501 28 IAAGEAAAAI 0.514192 WB VP2-3 B3501 202 TIVNAPINFY 0.476 289 WB VP2-3 B3501 67 YAVIAGAPGA0.456 358 WB VP2-3 B3501 292 WMLPLLLGLY 0.447 397 WB VP2-3 B3501 209NFYNYIQDYY 0.429 480 WB VP2-3 B3501 114 YQQSGMALEL 0.466 323 WB VP2-3B3901 233 AEREGTHVNF 0.508 204 WB VP2-3 B4001 254 IEEVTQRMDL 0.497 230WB VP2-3 B4001 266 KESVHSGEFI 0.457 355 WB VP2-3 B4002 233 AEREGTHVNF0.450 382 WB VP2-3 B4002 26 AEIAAGEAAA 0.461 340 WB VP2-3 B4403 26AEIAAGEAAA 0.637 50 WB VP2-3 B4501 197 EETTWTIVNA 0.481 273 WB VP2-3B4501 233 AEREGTHVNF 0.474 297 WB VP2-3 B4501 294 LPLLLGLYGT 0.583 91 WBVP2-3 B5101 289 APQWMLPLLL 0.580 94 WB VP2-3 B5301 125 NPDEYYDILF 0.476289 WB VP2-3 B5301 294 LPLLLGLYGT 0.816 7 SB VP2-3 B5401 73 APGAIAGFAA0.666 36 SB VP2-3 B5401 134 FPGVNTFVNN 0.529 163 WB VP2-3 B5401 192LARFLEETTW 0.441 422 WB VP2-3 B5701 283 GANQRTAPQW 0.661 39 SB VP2-3B5801 192 LARFLEETTW 0.570 105 WB VP2-3 B5801 201 WTIVNAPINF 0.543 139WB VP2-3 B5801 156 LFATISQALW 0.490 247 WB VP2-3 B5801 287 RTAPQWMLPL0.462 337 WB VP2-3 B5801 91 SSLAQVGYRF 0.439 432 WB VP2-3 B5801 11-mers201 WTIVNAPINFY 0.505 212 WB VP2-3 A0101 146 YLDPRHWGPSL 0.844 5 SBVP2-3 A0201 247 SIDNADSIEEV 0.608 69 WB VP2-3 A0201 157 FATISQALWHV0.499 226 WB VP2-3 A0201 297 LLGLYGTVTPA 0.443 413 WB VP2-3 A0201 61GLTPQTYAVIA 0.440 428 WB VP2-3 A0201 80 FAALIQTVTGI 0.740 16 SB VP2-3A0202 146 YLDPRHWGPSL 0.686 29 SB VP2-3 A0202 297 LLGLYGTVTPA 0.612 66WB VP2-3 A0202 293 MLPLLLGLYGT 0.607 69 WB VP2-3 A0202 61 GLTPQTYAVIA0.598 77 WB VP2-3 A0202 24 SVAEIAAGEAA 0.577 96 WB VP2-3 A0202 157FATISQALWHV 0.572 102 WB VP2-3 A0202 52 TTSEAIAAIGL 0.559 117 WB VP2-3A0202 40 QIASLATVEGI 0.554 124 WB VP2-3 A0202 287 RTAPQWMLPLL 0.542 142WB VP2-3 A0202 247 SIDNADSIEEV 0.539 146 WB VP2-3 A0202 92 SLAQVGYRFFS0.525 170 WB VP2-3 A0202 10 LVASVSEAAAA 0.525 170 WB VP2-3 A0202 59AIGLTPQTYAV 0.518 183 WB VP2-3 A0202 86 TVTGISSLAQV 0.493 241 WB VP2-3A0202 43 SLATVEGITTT 0.487 258 WB VP2-3 A0202 3 ALALLGDLVAS 0.480 278 WBVP2-3 A0202 34 AAAIEVQIASL 0.471 305 WB VP2-3 A0202 83 LIQTVTGISSL 0.467318 WB VP2-3 A0202 1 GAALALLGDLV 0.467 320 WB VP2-3 A0202 244HTYSIDNADSI 0.466 324 WB VP2-3 A0202 155 SLFATISQALW 0.458 350 WB VP2-3A0202 274 FIEKTIAPGGA 0.427 490 WB VP2-3 A0202 140 FVNNIQYLDPR 0.427 492WB VP2-3 A0202 146 YLDPRHWGPSL 0.801 8 SB VP2-3 A0203 297 LLGLYGTVTPA0.759 13 SB VP2-3 A0203 83 LIQTVTGISSL 0.719 20 SB VP2-3 A0203 293MLPLLLGLYGT 0.711 22 SB VP2-3 A0203 80 FAALIQTVTGI 0.669 36 SB VP2-3A0203 43 SLATVEGITTT 0.657 40 SB VP2-3 A0203 59 AIGLTPQTYAV 0.639 49 SBVP2-3 A0203 61 GLTPQTYAVIA 0.610 67 WB VP2-3 A0203 18 AAATGFSVAEI 0.562114 WB VP2-3 A0203 40 QIASLATVEGI 0.559 118 WB VP2-3 A0203 86TVTGISSLAQV 0.542 141 WB VP2-3 A0203 287 RTAPQWMLPLL 0.526 168 WB VP2-3A0203 274 FIEKTIAPGGA 0.518 183 WB VP2-3 A0203 10 LVASVSEAAAA 0.513 193WB VP2-3 A0203 4 LALLGDLVASV 0.490 248 WB VP2-3 A0203 24 SVAEIAAGEAA0.488 253 WB VP2-3 A0203 34 AAAIEVQIASL 0.478 283 WB VP2-3 A0203 327SQKAKGTRASA 0.474 294 WB VP2-3 A0203 247 SIDNADSIEEV 0.455 365 WB VP2-3A0203 157 FATISQALWHV 0.447 396 WB VP2-3 A0203 101 FSDWDHKVSTV 0.447 398WB VP2-3 A0203 67 YAVIAGAPGAI 0.430 477 WB VP2-3 A0203 146 YLDPRHWGPSL0.615 64 WB VP2-3 A0204 29 AAGEAAAAIEV 0.520 180 WB VP2-3 A0204 59AIGLTPQTYAV 0.517 185 WB VP2-3 A0204 297 LLGLYGTVTPA 0.495 236 WB VP2-3A0204 247 SIDNADSIEEV 0.488 255 WB VP2-3 A0204 43 SLATVEGITTT 0.466 322WB VP2-3 A0204 146 YLDPRHWGPSL 0.882 3 SB VP2-3 A0206 214 IQDYYSNLSPI0.767 12 SB VP2-3 A0206 230 RQVAEREGTHV 0.764 12 SB VP2-3 A0206 157FATISQALWHV 0.747 15 SB VP2-3 A0206 114 YQQSGMALELF 0.741 16 SB VP2-3A0206 247 SIDNADSIEEV 0.659 40 SB VP2-3 A0206 29 AAGEAAAAIEV 0.632 53 WBVP2-3 A0206 287 RTAPQWMLPLL 0.614 64 WB VP2-3 A0206 80 FAALIQTVTGI 0.61465 WB VP2-3 A0206 35 AAIEVQIASLA 0.587 86 WB VP2-3 A0206 37 IEVQIASLATV0.586 88 WB VP2-3 A0206 24 SVAEIAAGEAA 0.580 93 WB VP2-3 A0206 4LALLGDLVASV 0.580 94 WB VP2-3 A0206 101 FSDWDHKVSTV 0.577 97 WB VP2-3A0206 15 SEAAAATGFSV 0.572 102 WB VP2-3 A0206 86 TVTGISSLAQV 0.557 120WB VP2-3 A0206 59 AIGLTPQTYAV 0.537 150 WB VP2-3 A0206 293 MLPLLLGLYGT0.536 151 WB VP2-3 A0206 58 AAIGLTPQTYA 0.531 159 WB VP2-3 A0206 10LVASVSEAAAA 0.524 173 WB VP2-3 A0206 18 AAATGFSVAEI 0.509 203 WB VP2-3A0206 68 AVIAGAPGAIA 0.503 215 WB VP2-3 A0206 84 IQTVTGISSLA 0.500 223WB VP2-3 A0206 52 TTSEAIAAIGL 0.457 357 WB VP2-3 A0206 1 GAALALLGDLV0.454 366 WB VP2-3 A0206 297 LLGLYGTVTPA 0.442 420 WB VP2-3 A0206 13SVSEAAAATGF 0.441 423 WB VP2-3 A0206 45 ATVEGITTTSE 0.429 481 WB VP2-3A0206 146 YLDPRHWGPSL 0.969 1 SB VP2-3 A0211 247 SIDNADSIEEV 0.903 2 SBVP2-3 A0211 86 TVTGISSLAQV 0.868 4 SB VP2-3 A0211 61 GLTPQTYAVIA 0.808 7SB VP2-3 A0211 92 SLAQVGYRFFS 0.759 13 SB VP2-3 A0211 59 AIGLTPQTYAV0.737 17 SB VP2-3 A0211 122 ELFNPDEYYDI 0.669 35 SB VP2-3 A0211 43SLATVEGITTT 0.657 40 SB VP2-3 A0211 29 AAGEAAAAIEV 0.644 46 SB VP2-3A0211 4 LALLGDLVASV 0.626 56 WB VP2-3 A0211 287 RTAPQWMLPLL 0.626 57 WBVP2-3 A0211 131 DILFPGVNTFV 0.620 60 WB VP2-3 A0211 101 FSDWDHKVSTV0.615 64 WB VP2-3 A0211 157 FATISQALWHV 0.608 69 WB VP2-3 A0211 293MLPLLLGLYGT 0.597 78 WB VP2-3 A0211 132 ILFPGVNTFVN 0.565 110 WB VP2-3A0211 297 LLGLYGTVTPA 0.547 134 WB VP2-3 A0211 76 AIAGFAALIQT 0.537 150WB VP2-3 A0211 292 WMLPLLLGLYG 0.526 167 WB VP2-3 A0211 24 SVAEIAAGEAA0.526 168 WB VP2-3 A0211 253 SIEEVTQRMDL 0.525 170 WB VP2-3 A0211 296LLLGLYGTVTP 0.523 174 WB VP2-3 A0211 98 YRFFSDWDHKV 0.515 190 WB VP2-3A0211 6 LLGDLVASVSE 0.504 213 WB VP2-3 A0211 27 EIAAGEAAAAI 0.496 234 WBVP2-3 A0211 194 RFLEETTWTIV 0.476 288 WB VP2-3 A0211 155 SLFATISQALW0.468 315 WB VP2-3 A0211 5 ALLGDLVASVS 0.465 325 WB VP2-3 A0211 83LIQTVTGISSL 0.454 369 WB VP2-3 A0211 77 IAGFAALIQTV 0.449 386 WB VP2-3A0211 278 TIAPGGANQRT 0.438 437 WB VP2-3 A0211 191 SLARFLEETTW 0.437 444WB VP2-3 A0211 299 GLYGTVTPALE 0.429 482 WB VP2-3 A0211 146 YLDPRHWGPSL0.942 1 SB VP2-3 A0212 247 SIDNADSIEEV 0.724 19 SB VP2-3 A0212 59AIGLTPQTYAV 0.677 32 SB VP2-3 A0212 61 GLTPQTYAVIA 0.591 83 WB VP2-3A0212 43 SLATVEGITTT 0.566 109 WB VP2-3 A0212 122 ELFNPDEYYDI 0.556 121WB VP2-3 A0212 4 LALLGDLVASV 0.541 143 WB VP2-3 A0212 293 MLPLLLGLYGT0.513 194 WB VP2-3 A0212 6 LLGDLVASVSE 0.507 207 WB VP2-3 A0212 83LIQTVTGISSL 0.499 226 WB VP2-3 A0212 253 SIEEVTQRMDL 0.493 242 WB VP2-3A0212 292 WMLPLLLGLYG 0.489 251 WB VP2-3 A0212 92 SLAQVGYRFFS 0.479 281WB VP2-3 A0212 86 TVTGISSLAQV 0.475 292 WB VP2-3 A0212 157 FATISQALWHV0.435 454 WB VP2-3 A0212 132 ILFPGVNTFVN 0.434 457 WB VP2-3 A0212 213YIQDYYSNLSP 0.433 464 WB VP2-3 A0212 98 YRFFSDWDHKV 0.432 468 WB VP2-3A0212 296 LLLGLYGTVTP 0.431 473 WB VP2-3 A0212 146 YLDPRHWGPSL 0.908 2SB VP2-3 A0216 247 SIDNADSIEEV 0.852 4 SB VP2-3 A0216 86 TVTGISSLAQV0.811 7 SB VP2-3 A0216 59 AIGLTPQTYAV 0.755 14 SB VP2-3 A0216 29AAGEAAAAIEV 0.714 22 SB VP2-3 A0216 92 SLAQVGYRFFS 0.674 34 SB VP2-3A0216 131 DILFPGVNTFV 0.671 35 SB VP2-3 A0216 43 SLATVEGITTT 0.635 52 WBVP2-3 A0216 61 GLTPQTYAVIA 0.633 53 WB VP2-3 A0216 297 LLGLYGTVTPA 0.62160 WB VP2-3 A0216 83 LIQTVTGISSL 0.526 169 WB VP2-3 A0216 157FATISQALWHV 0.524 172 WB VP2-3 A0216 122 ELFNPDEYYDI 0.508 205 WB VP2-3A0216 4 LALLGDLVASV 0.499 225 WB VP2-3 A0216 77 IAGFAALIQTV 0.459 350 WBVP2-3 A0216 76 AIAGFAALIQT 0.458 351 WB VP2-3 A0216 146 YLDPRHWGPSL0.941 1 SB VP2-3 A0219 247 SIDNADSIEEV 0.699 26 SB VP2-3 A0219 86TVTGISSLAQV 0.670 35 SB VP2-3 A0219 59 AIGLTPQTYAV 0.566 109 WB VP2-3A0219 4 LALLGDLVASV 0.537 149 WB VP2-3 A0219 157 FATISQALWHV 0.530 161WB VP2-3 A0219 83 LIQTVTGISSL 0.499 225 WB VP2-3 A0219 332 GTRASAKTTNK0.622 59 WB VP2-3 A0301 321 RVSRGSSQKAK 0.580 93 WB VP2-3 A0301 203IVNAPINFYNY 0.501 220 WB VP2-3 A0301 339 TTNKRRSRSSR 0.487 258 WB VP2-3A0301 203 IVNAPINFYNY 0.678 32 SB VP2-3 A1101 339 TTNKRRSRSSR 0.651 43SB VP2-3 A1101 277 KTIAPGGANQR 0.634 52 WB VP2-3 A1101 321 RVSRGSSQKAK0.626 57 WB VP2-3 A1101 332 GTRASAKTTNK 0.606 70 WB VP2-3 A1101 89GISSLAQVGYR 0.521 177 WB VP2-3 A1101 136 GVNTFVNNIQY 0.517 185 WB VP2-3A1101 159 TISQALWHVIR 0.481 274 WB VP2-3 A1101 176 TSQELQRRTER 0.476 289WB VP2-3 A1101 140 FVNNIQYLDPR 0.469 313 WB VP2-3 A1101 267 ESVHSGEFIEK0.437 442 WB VP2-3 A1101 200 TWTIVNAPINF 0.630 54 WB VP2-3 A2301 97GYRFFSDWDHK 0.623 59 WB VP2-3 A2301 113 LYQQSGMALEL 0.597 77 WB VP2-3A2301 186 RFFRDSLARFL 0.449 389 WB VP2-3 A2301 200 TWTIVNAPINF 0.612 66WB VP2-3 A2402 113 LYQQSGMALEL 0.533 156 WB VP2-3 A2402 113 LYQQSGMALEL0.750 14 SB VP2-3 A2403 186 RFFRDSLARFL 0.485 263 WB VP2-3 A2403 91SSLAQVGYRFF 0.459 347 WB VP2-3 A2403 201 WTIVNAPINFY 0.672 34 SB VP2-3A2601 109 STVGLYQQSGM 0.619 61 WB VP2-3 A2601 201 WTIVNAPINFY 0.930 2 SBVP2-3 A2602 109 STVGLYQQSGM 0.769 12 SB VP2-3 A2602 27 EIAAGEAAAAI 0.76512 SB VP2-3 A2602 287 RTAPQWMLPLL 0.678 32 SB VP2-3 A2602 203IVNAPINFYNY 0.672 34 SB VP2-3 A2602 13 SVSEAAAATGF 0.566 109 WB VP2-3A2602 88 TGISSLAQVGY 0.498 228 WB VP2-3 A2602 291 QWMLPLLLGLY 0.553 126WB VP2-3 A2902 203 IVNAPINFYNY 0.517 185 WB VP2-3 A2902 236 EGTHVNFGHTY0.485 262 WB VP2-3 A2902 208 INFYNYIQDYY 0.471 304 WB VP2-3 A2902 136GVNTFVNNIQY 0.468 317 WB VP2-3 A2902 319 KRRVSRGSSQK 0.802 8 SB VP2-3A3001 332 GTRASAKTTNK 0.790 9 SB VP2-3 A3001 97 GYRFFSDWDHK 0.743 16 SBVP2-3 A3001 321 RVSRGSSQKAK 0.684 30 SB VP2-3 A3001 203 IVNAPINFYNY0.460 345 WB VP2-3 A3002 339 TTNKRRSRSSR 0.837 5 SB VP2-3 A3101 277KTIAPGGANQR 0.682 31 SB VP2-3 A3101 334 RASAKTTNKRR 0.664 37 SB VP2-3A3101 336 SAKTTNKRRSR 0.656 41 SB VP2-3 A3101 140 FVNNIQYLDPR 0.655 41SB VP2-3 A3101 176 TSQELQRRTER 0.645 46 SB VP2-3 A3101 179 ELQRRTERFFR0.636 51 WB VP2-3 A3101 225 RPSMVRQVAER 0.580 94 WB VP2-3 A3101 324RGSSQKAKGTR 0.569 105 WB VP2-3 A3101 89 GISSLAQVGYR 0.567 108 WB VP2-3A3101 159 TISQALWHVIR 0.483 268 WB VP2-3 A3101 332 GTRASAKTTNK 0.446 401WB VP2-3 A3101 220 NLSPIRPSMVR 0.432 465 WB VP2-3 A3101 179 ELQRRTERFFR0.812 7 SB VP2-3 A3301 339 TTNKRRSRSSR 0.738 17 SB VP2-3 A3301 140FVNNIQYLDPR 0.519 181 WB VP2-3 A3301 176 TSQELQRRTER 0.516 188 WB VP2-3A3301 220 NLSPIRPSMVR 0.506 210 WB VP2-3 A3301 159 TISQALWHVIR 0.465 326WB VP2-3 A3301 339 TTNKRRSRSSR 0.848 5 SB VP2-3 A6801 140 FVNNIQYLDPR0.795 9 SB VP2-3 A6801 159 TISQALWHVIR 0.758 13 SB VP2-3 A6801 256EVTQRMDLRNK 0.719 20 SB VP2-3 A6801 179 ELQRRTERFFR 0.714 22 SB VP2-3A6801 309 EAYEDGPNQKK 0.713 22 SB VP2-3 A6801 267 ESVHSGEFIEK 0.706 24SB VP2-3 A6801 220 NLSPIRPSMVR 0.687 29 SB VP2-3 A6801 250 NADSIEEVTQR0.655 41 SB VP2-3 A6801 176 TSQELQRRTER 0.647 45 SB VP2-3 A6801 201WTIVNAPINFY 0.600 75 WB VP2-3 A6801 89 GISSLAQVGYR 0.591 83 WB VP2-3A6801 277 KTIAPGGANQR 0.588 86 WB VP2-3 A6801 172 IPAITSQELQR 0.515 190WB VP2-3 A6801 225 RPSMVRQVAER 0.438 438 WB VP2-3 A6801 215 QDYYSNLSPIR0.437 444 WB VP2-3 A6801 198 ETTWTIVNAPI 0.863 4 SB VP2-3 A6802 86TVTGISSLAQV 0.804 8 SB VP2-3 A6802 16 EAAAATGFSVA 0.777 11 SB VP2-3A6802 80 FAALIQTVTGI 0.761 13 SB VP2-3 A6802 27 EIAAGEAAAAI 0.759 13 SBVP2-3 A6802 244 HTYSIDNADSI 0.756 13 SB VP2-3 A6802 52 TTSEAIAAIGL 0.72918 SB VP2-3 A6802 24 SVAEIAAGEAA 0.724 19 SB VP2-3 A6802 40 QIASLATVEGI0.649 44 SB VP2-3 A6802 32 EAAAAIEVQIA 0.633 52 WB VP2-3 A6802 10LVASVSEAAAA 0.605 71 WB VP2-3 A6802 131 DILFPGVNTFV 0.561 115 WB VP2-3A6802 287 RTAPQWMLPLL 0.551 129 WB VP2-3 A6802 259 QRMDLRNKESV 0.550 129WB VP2-3 A6802 122 ELFNPDEYYDI 0.549 131 WB VP2-3 A6802 46 TVEGITTTSEA0.537 150 WB VP2-3 A6802 157 FATISQALWHV 0.500 223 WB VP2-3 A6802 109STVGLYQQSGM 0.495 235 WB VP2-3 A6802 204 VNAPINFYNYI 0.467 319 WB VP2-3A6802 18 AAATGFSVAEI 0.465 326 WB VP2-3 A6802 23 FSVAEIAAGEA 0.463 333WB VP2-3 A6802 15 SEAAAATGFSV 0.457 356 WB VP2-3 A6802 98 YRFFSDWDHKV0.453 371 WB VP2-3 A6802 50 ITTTSEAIAAI 0.442 419 WB VP2-3 A6802 67YAVIAGAPGAI 0.439 430 WB VP2-3 A6802 0 MGAALALLGDL 0.426 497 WB VP2-3A6802 198 ETTWTIVNAPI 0.765 12 SB VP2-3 A6901 27 EIAAGEAAAAI 0.722 20 SBVP2-3 A6901 131 DILFPGVNTFV 0.706 23 SB VP2-3 A6901 157 FATISQALWHV0.625 58 WB VP2-3 A6901 52 TTSEAIAAIGL 0.581 93 WB VP2-3 A6901 244HTYSIDNADSI 0.559 117 WB VP2-3 A6901 86 TVTGISSLAQV 0.494 237 WB VP2-3A6901 24 SVAEIAAGEAA 0.491 245 WB VP2-3 A6901 67 YAVIAGAPGAI 0.465 326WB VP2-3 A6901 146 YLDPRHWGPSL 0.462 338 WB VP2-3 A6901 29 AAGEAAAAIEV0.456 360 WB VP2-3 A6901 101 FSDWDHKVSTV 0.443 416 WB VP2-3 A6901 294LPLLLGLYGTV 0.439 433 WB VP2-3 A6901 40 QIASLATVEGI 0.436 448 WB VP2-3A6901 287 RTAPQWMLPLL 0.433 459 WB VP2-3 A6901 73 APGAIAGFAAL 0.671 35SB VP2-3 B0702 222 SPIRPSMVRQV 0.530 162 WB VP2-3 B0702 67 YAVIAGAPGAI0.489 251 WB VP2-3 B0702 114 YQQSGMALELF 0.567 108 WB VP2-3 B1501 201WTIVNAPINFY 0.536 151 WB VP2-3 B1501 203 IVNAPINFYNY 0.501 221 WB VP2-3B1501 13 SVSEAAAATGF 0.500 223 WB VP2-3 B1501 264 RNKESVHSGEF 0.488 254WB VP2-3 B1501 57 IAAIGLTPQTY 0.455 361 WB VP2-3 B1501 37 IEVQIASLATV0.605 71 WB VP2-3 B1801 127 DEYYDILFPGV 0.591 83 WB VP2-3 B1801 178QELQRRTERFF 0.466 323 WB VP2-3 B1801 130 YDILFPGVNTF 0.426 495 WB VP2-3B1801 182 RRTERFFRDSL 0.564 111 WB VP2-3 B2705 319 KRRVSRGSSQK 0.498 227WB VP2-3 B2705 320 RRVSRGSSQKA 0.461 342 WB VP2-3 B2705 286 QRTAPQWMLPL0.430 477 WB VP2-3 B2705 119 MALELFNPDEY 0.799 8 SB VP2-3 B3501 57IAAIGLTPQTY 0.701 25 SB VP2-3 B3501 67 YAVIAGAPGAI 0.605 71 WB VP2-3B3501 13 SVSEAAAATGF 0.558 119 WB VP2-3 B3501 201 WTIVNAPINFY 0.508 204WB VP2-3 B3501 73 APGAIAGFAAL 0.500 224 WB VP2-3 B3501 301 YGTVTPALEAY0.466 322 WB VP2-3 B3501 11 VASVSEAAAAT 0.445 404 WB VP2-3 B3501 146YLDPRHWGPSL 0.500 223 WB VP2-3 B3901 211 YNYIQDYYSNL 0.445 405 WB VP2-3B3901 31 GEAAAAIEVQI 0.587 87 WB VP2-3 B4001 15 SEAAAATGFSV 0.513 194 WBVP2-3 B4001 37 IEVQIASLATV 0.477 287 WB VP2-3 B4001 127 DEYYDILFPGV0.451 380 WB VP2-3 B4001 178 QELQRRTERFF 0.497 231 WB VP2-3 B4002 26AEIAAGEAAAA 0.428 489 WB VP2-3 B4002 26 AEIAAGEAAAA 0.484 264 WB VP2-3B4403 26 AEIAAGEAAAA 0.620 61 WB VP2-3 B4501 294 LPLLLGLYGTV 0.749 15 SBVP2-3 B5101 134 FPGVNTFVNNI 0.632 53 WB VP2-3 B5101 134 FPGVNTFVNNI0.791 9 SB VP2-3 B5301 294 LPLLLGLYGTV 0.479 281 WB VP2-3 B5301 119MALELFNPDEY 0.477 287 WB VP2-3 B5301 294 LPLLLGLYGTV 0.839 5 SB VP2-3B5401 134 FPGVNTFVNNI 0.750 14 SB VP2-3 B5401 63 TPQTYAVIAGA 0.491 245WB VP2-3 B5401 80 FAALIQTVTGI 0.454 369 WB VP2-3 B5401 222 SPIRPSMVRQV0.451 378 WB VP2-3 B5401 90 ISSLAQVGYRF 0.685 30 SB VP2-3 B5801 191SLARFLEETTW 0.631 54 WB VP2-3 B5801 155 SLFATISQALW 0.572 102 WB VP2-3B5801 57 IAAIGLTPQTY 0.539 145 WB VP2-3 B5801 282 GGANQRTAPQW 0.529 162WB VP2-3 B5801 287 RTAPQWMLPLL 0.488 253 WB VP2-3 B5801 SEQ ID NOS:52253-53779

Preferred BK virus fragments of VP1 capable of interacting with one ormore MHC class 1 molecules are listed in Table K.

TABLE K Prediction of BK virus VP1 protein specificMHC class1, 8-, 9-, 10-, 11-mer peptidebinders for 42 MHC class 1 alleles (see FIG.11) using the http://www.cbs.dtu.dk/services/NetMHC/ database. The MHC class 1molecules for which no binders were found are not listed. Pro- affinityBind tein pos peptide logscore (nM) Level Name Allele 8-mers 196YLDKNNAY 0.756 14 SB VP1 A0101 108 LMWEAVTV 0.819 7 SB VP1 A0201 243VLLDEQGV 0.703 24 SB VP1 A0201 83 KMLPCYST 0.657 41 SB VP1 A0201 40GVDAITEV 0.595 79 WB VP1 A0201 281 GLARYFKI 0.591 83 WB VP1 A0201 106NLLMWEAV 0.580 94 WB VP1 A0201 84 MLPCYSTA 0.562 114 WB VP1 A0201 107LLMWEAVT 0.498 229 WB VP1 A0201 281 GLARYFKI 0.717 21 SB VP1 A0202 108LMWEAVTV 0.668 36 SB VP1 A0202 84 MLPCYSTA 0.666 37 SB VP1 A0202 243VLLDEQGV 0.663 38 SB VP1 A0202 262 SAADICGL 0.662 38 SB VP1 A0202 40GVDAITEV 0.633 52 WB VP1 A0202 34 VLEVKTGV 0.510 200 WB VP1 A0202 152FAVGGDPL 0.508 205 WB VP1 A0202 121 GITSMLNL 0.475 291 WB VP1 A0202 125MLNLHAGS 0.470 310 WB VP1 A0202 25 KLLIKGGV 0.457 354 WB VP1 A0202 107LLMWEAVT 0.451 379 WB VP1 A0202 238 NTATTVLL 0.447 394 WB VP1 A0202 84MLPCYSTA 0.841 5 SB VP1 A0203 108 LMWEAVTV 0.784 10 SB VP1 A0203 27LIKGGVEV 0.779 10 SB VP1 A0203 281 GLARYFKI 0.762 13 SB VP1 A0203 243VLLDEQGV 0.746 15 SB VP1 A0203 236 VTNTATTV 0.674 33 SB VP1 A0203 25KLLIKGGV 0.657 41 SB VP1 A0203 106 NLLMWEAV 0.643 47 SB VP1 A0203 34VLEVKTGV 0.635 51 WB VP1 A0203 233 VLHVTNTA 0.633 52 WB VP1 A0203 107LLMWEAVT 0.563 113 WB VP1 A0203 262 SAADICGL 0.538 148 WB VP1 A0203 188VMNTDHKA 0.531 159 WB VP1 A0203 83 KMLPCYST 0.509 203 WB VP1 A0203 125MLNLHAGS 0.509 203 WB VP1 A0203 326 SQVEEVRV 0.501 221 WB VP1 A0203 229NVPPVLHV 0.492 244 WB VP1 A0203 121 GITSMLNL 0.490 248 WB VP1 A0203 40GVDAITEV 0.488 255 WB VP1 A0203 294 SVKNPYPI 0.470 308 WB VP1 A0203 112AVTVKTEV 0.456 358 WB VP1 A0203 119 VIGITSML 0.439 433 WB VP1 A0203 108LMWEAVTV 0.780 10 SB VP1 A0204 243 VLLDEQGV 0.740 16 SB VP1 A0204 25KLLIKGGV 0.582 91 WB VP1 A0204 281 GLARYFKI 0.510 201 WB VP1 A0204 34VLEVKTGV 0.498 228 WB VP1 A0204 236 VTNTATTV 0.489 253 WB VP1 A0204 326SQVEEVRV 0.453 371 WB VP1 A0204 106 NLLMWEAV 0.441 423 WB VP1 A0204 27LIKGGVEV 0.432 465 WB VP1 A0204 40 GVDAITEV 0.431 472 WB VP1 A0204 108LMWEAVTV 0.852 4 SB VP1 A0206 326 SQVEEVRV 0.789 9 SB VP1 A0206 106NLLMWEAV 0.731 18 SB VP1 A0206 152 FAVGGDPL 0.729 18 SB VP1 A0206 243VLLDEQGV 0.720 20 SB VP1 A0206 40 GVDAITEV 0.691 28 SB VP1 A0206 21VQVPKLLI 0.685 30 SB VP1 A0206 84 MLPCYSTA 0.624 58 WB VP1 A0206 83KMLPCYST 0.623 59 WB VP1 A0206 354 GQLQTKMV 0.584 89 WB VP1 A0206 229NVPPVLHV 0.574 99 WB VP1 A0206 25 KLLIKGGV 0.543 139 WB VP1 A0206 262SAADICGL 0.513 193 WB VP1 A0206 236 VTNTATTV 0.506 208 WB VP1 A0206 281GLARYFKI 0.505 211 WB VP1 A0206 144 VQGSNFHF 0.481 275 WB VP1 A0206 112AVTVKTEV 0.454 368 WB VP1 A0206 276 TQQWRGLA 0.439 434 WB VP1 A0206 184AQSQVMNT 0.432 465 WB VP1 A0206 147 SNFHFFAV 0.432 467 WB VP1 A0206 108LMWEAVTV 0.966 1 SB VP1 A0211 243 VLLDEQGV 0.965 1 SB VP1 A0211 106NLLMWEAV 0.910 2 SB VP1 A0211 40 GVDAITEV 0.856 4 SB VP1 A0211 27LIKGGVEV 0.838 5 SB VP1 A0211 229 NVPPVLHV 0.830 6 SB VP1 A0211 25KLLIKGGV 0.823 6 SB VP1 A0211 349 YIDRQGQL 0.819 7 SB VP1 A0211 281GLARYFKI 0.788 9 SB VP1 A0211 84 MLPCYSTA 0.786 10 SB VP1 A0211 196YLDKNNAY 0.751 14 SB VP1 A0211 83 KMLPCYST 0.746 15 SB VP1 A0211 34VLEVKTGV 0.731 18 SB VP1 A0211 101 DLTCGNLL 0.639 49 SB VP1 A0211 262SAADICGL 0.614 65 WB VP1 A0211 97 NLNEDLTC 0.603 73 WB VP1 A0211 188VMNTDHKA 0.602 74 WB VP1 A0211 233 VLHVTNTA 0.594 80 WB VP1 A0211 112AVTVKTEV 0.578 96 WB VP1 A0211 320 PMYGMESQ 0.573 102 WB VP1 A0211 326SQVEEVRV 0.548 133 WB VP1 A0211 332 RVFDGTEQ 0.542 141 WB VP1 A0211 333VFDGTEQL 0.505 211 WB VP1 A0211 254 CKADSLYV 0.500 224 WB VP1 A0211 236VTNTATTV 0.498 229 WB VP1 A0211 124 SMLNLHAG 0.491 246 WB VP1 A0211 121GITSMLNL 0.481 276 WB VP1 A0211 147 SNFHFFAV 0.471 305 WB VP1 A0211 107LLMWEAVT 0.456 358 WB VP1 A0211 252 PLCKADSL 0.453 370 WB VP1 A0211 223TYTGGENV 0.451 378 WB VP1 A0211 339 QLPGDPDM 0.440 428 WB VP1 A0211 119VIGITSML 0.437 439 WB VP1 A0211 243 VLLDEQGV 0.938 1 SB VP1 A0212 108LMWEAVTV 0.932 2 SB VP1 A0212 106 NLLMWEAV 0.866 4 SB VP1 A0212 27LIKGGVEV 0.758 13 SB VP1 A0212 281 GLARYFKI 0.738 17 SB VP1 A0212 34VLEVKTGV 0.730 18 SB VP1 A0212 196 YLDKNNAY 0.708 23 SB VP1 A0212 25KLLIKGGV 0.691 28 SB VP1 A0212 349 YIDRQGQL 0.659 40 SB VP1 A0212 84MLPCYSTA 0.645 46 SB VP1 A0212 40 GVDAITEV 0.626 57 WB VP1 A0212 229NVPPVLHV 0.625 57 WB VP1 A0212 320 PMYGMESQ 0.570 104 WB VP1 A0212 188VMNTDHKA 0.557 120 WB VP1 A0212 233 VLHVTNTA 0.537 149 WB VP1 A0212 83KMLPCYST 0.496 234 WB VP1 A0212 339 QLPGDPDM 0.474 295 WB VP1 A0212 107LLMWEAVT 0.462 337 WB VP1 A0212 124 SMLNLHAG 0.437 443 WB VP1 A0212 50FLNPEMGD 0.437 444 WB VP1 A0212 236 VTNTATTV 0.435 450 WB VP1 A0212 97NLNEDLTC 0.431 469 WB VP1 A0212 326 SQVEEVRV 0.429 483 WB VP1 A0212 108LMWEAVTV 0.930 2 SB VP1 A0216 243 VLLDEQGV 0.867 4 SB VP1 A0216 106NLLMWEAV 0.829 6 SB VP1 A0216 27 LIKGGVEV 0.816 7 SB VP1 A0216 229NVPPVLHV 0.794 9 SB VP1 A0216 40 GVDAITEV 0.784 10 SB VP1 A0216 281GLARYFKI 0.745 15 SB VP1 A0216 34 VLEVKTGV 0.709 23 SB VP1 A0216 84MLPCYSTA 0.699 26 SB VP1 A0216 349 YIDRQGQL 0.698 26 SB VP1 A0216 25KLLIKGGV 0.668 36 SB VP1 A0216 112 AVTVKTEV 0.647 45 SB VP1 A0216 252PLCKADSL 0.627 56 WB VP1 A0216 101 DLTCGNLL 0.529 163 WB VP1 A0216 233VLHVTNTA 0.520 179 WB VP1 A0216 119 VIGITSML 0.493 241 WB VP1 A0216 83KMLPCYST 0.490 250 WB VP1 A0216 320 PMYGMESQ 0.474 296 WB VP1 A0216 236VTNTATTV 0.470 309 WB VP1 A0216 196 YLDKNNAY 0.461 339 WB VP1 A0216 321MYGMESQV 0.456 360 WB VP1 A0216 152 FAVGGDPL 0.438 439 WB VP1 A0216 223TYTGGENV 0.434 457 WB VP1 A0216 108 LMWEAVTV 0.930 2 SB VP1 A0219 243VLLDEQGV 0.896 3 SB VP1 A0219 106 NLLMWEAV 0.798 8 SB VP1 A0219 40GVDAITEV 0.662 38 SB VP1 A0219 229 NVPPVLHV 0.606 70 WB VP1 A0219 27LIKGGVEV 0.540 144 WB VP1 A0219 349 YIDRQGQL 0.526 168 WB VP1 A0219 34VLEVKTGV 0.485 262 WB VP1 A0219 254 CKADSLYV 0.484 265 WB VP1 A0219 196YLDKNNAY 0.451 381 WB VP1 A0219 236 VTNTATTV 0.446 399 WB VP1 A0219 333VFDGTEQL 0.439 432 WB VP1 A0219 281 GLARYFKI 0.434 456 WB VP1 A0219 101DLTCGNLL 0.430 474 WB VP1 A0219 289 RLRKRSVK 0.776 11 SB VP1 A0301 308LINRRTQK 0.697 26 SB VP1 A0301 164 VLMNYRTK 0.693 27 SB VP1 A0301 127NLHAGSQK 0.656 41 SB VP1 A0301 165 LMNYRTKY 0.467 318 WB VP1 A0301 280RGLARYFK 0.446 399 WB VP1 A0301 352 RQGQLQTK 0.432 468 WB VP1 A0301 187QVMNTDHK 0.705 24 SB VP1 A1101 164 VLMNYRTK 0.620 60 WB VP1 A1101 308LINRRTQK 0.613 65 WB VP1 A1101 280 RGLARYFK 0.596 79 WB VP1 A1101 22QVPKLLIK 0.510 200 WB VP1 A1101 31 GVEVLEVK 0.506 210 WB VP1 A1101 11GAAPKKPK 0.444 408 WB VP1 A1101 352 RQGQLQTK 0.436 447 WB VP1 A1101 298PYPISFLL 0.570 104 WB VP1 A2301 259 LYVSAADI 0.509 203 WB VP1 A2301 144VQGSNFHF 0.499 225 WB VP1 A2301 109 MWEAVTVK 0.470 310 WB VP1 A2301 284RYFKIRLR 0.448 393 WB VP1 A2301 298 PYPISFLL 0.771 11 SB VP1 A2402 202AYPVECWI 0.672 34 SB VP1 A2402 259 LYVSAADI 0.538 148 WB VP1 A2402 302SFLLSDLI 0.533 156 WB VP1 A2402 144 VQGSNFHF 0.441 422 WB VP1 A2402 202AYPVECWI 0.721 20 SB VP1 A2403 298 PYPISFLL 0.614 65 WB VP1 A2403 259LYVSAADI 0.464 329 WB VP1 A2403 118 EVIGITSM 0.834 6 SB VP1 A2601 118EVIGITSM 0.909 2 SB VP1 A2602 315 KVDGQPMY 0.730 18 SB VP1 A2602 196YLDKNNAY 0.675 33 SB VP1 A2602 182 PTAQSQVM 0.599 76 WB VP1 A2602 217NTRYFGTY 0.573 101 WB VP1 A2602 349 YIDRQGQL 0.555 123 WB VP1 A2602 327QVEEVRVF 0.491 245 WB VP1 A2602 190 NTDHKAYL 0.463 332 WB VP1 A2602 238NTATTVLL 0.462 338 WB VP1 A2602 196 YLDKNNAY 0.550 130 WB VP1 A2902 165LMNYRTKY 0.498 228 WB VP1 A2902 289 RLRKRSVK 0.873 3 SB VP1 A3001 280RGLARYFK 0.802 8 SB VP1 A3001 187 QVMNTDHK 0.563 113 WB VP1 A3001 308LINRRTQK 0.535 153 WB VP1 A3001 164 VLMNYRTK 0.534 153 WB VP1 A3001 285YFKIRLRK 0.497 231 WB VP1 A3001 84 RYFKIRLR 0.452 377 WB VP1 A3001 127NLHAGSQK 0.426 497 WB VP1 A3001 315 KVDGQPMY 0.436 447 WB VP1 A3002 165LMNYRTKY 0.431 473 WB VP1 A3002 284 RYFKIRLR 0.898 3 SB VP1 A3101 280RGLARYFK 0.716 21 SB VP1 A3101 289 RLRKRSVK 0.670 35 SB VP1 A3101 282LARYFKIR 0.663 38 SB VP1 A3101 277 QQWRGLAR 0.643 47 SB VP1 A3101 285YFKIRLRK 0.581 93 WB VP1 A3101 304 LLSDLINR 0.569 106 WB VP1 A3101 308LINRRTQK 0.542 141 WB VP1 A3101 273 SSGTQQWR 0.503 215 WB VP1 A3101 164VLMNYRTK 0.434 458 WB VP1 A3101 345 DMIRYIDR 0.767 12 SB VP1 A3301 284RYFKIRLR 0.631 54 WB VP1 A3301 282 LARYFKIR 0.515 190 WB VP1 A3301 285YFKIRLRK 0.504 213 WB VP1 A3301 277 QQWRGLAR 0.444 410 WB VP1 A3301 187QVMNTDHK 0.708 23 SB VP1 A6801 345 DMIRYIDR 0.627 56 WB VP1 A6801 325ESQVEEVR 0.606 70 WB VP1 A6801 85 LPCYSTAR 0.568 107 WB VP1 A6801 127NLHAGSQK 0.503 217 WB VP1 A6801 304 LLSDLINR 0.497 230 WB VP1 A6801 308LINRRTQK 0.497 231 WB VP1 A6801 284 RYFKIRLR 0.488 254 WB VP1 A6801 162QGVLMNYR 0.487 257 WB VP1 A6801 305 LSDLINRR 0.439 431 WB VP1 A6801 282LARYFKIR 0.438 439 WB VP1 A6801 238 NTATTVLL 0.723 19 SB VP1 A6802 262SAADICGL 0.718 21 SB VP1 A6802 118 EVIGITSM 0.718 21 SB VP1 A6802 147SNFHFFAV 0.659 39 SB VP1 A6802 229 NVPPVLHV 0.647 45 SB VP1 A6802 297NPYPISFL 0.515 191 WB VP1 A6802 152 FAVGGDPL 0.506 210 WB VP1 A6802 88YSTARIPL 0.473 300 WB VP1 A6802 294 SVKNPYPI 0.458 351 WB VP1 A6802 254CKADSLYV 0.441 421 WB VP1 A6802 108 LMWEAVTV 0.730 18 SB VP1 A6901 238NTATTVLL 0.636 51 WB VP1 A6901 157 DPLEMQGV 0.635 51 WB VP1 A6901 297NPYPISFL 0.557 120 WB VP1 A6901 118 EVIGITSM 0.548 132 WB VP1 A6901 229NVPPVLHV 0.545 137 WB VP1 A6901 106 NLLMWEAV 0.539 147 WB VP1 A6901 262SAADICGL 0.441 421 WB VP1 A6901 19 EPVQVPKL 0.431 471 WB VP1 A6901 142KPVQGSNF 0.685 30 SB VP1 B0702 297 NPYPISFL 0.489 251 WB VP1 B0702 16KPKEPVQV 0.433 462 WB VP1 B0702 95 LPNLNEDL 0.428 488 WB VP1 B0702 68HLSAENAF 0.555 123 WB VP1 B1501 165 LMNYRTKY 0.542 142 WB VP1 B1501 161MQGVLMNY 0.509 202 WB VP1 B1501 144 VQGSNFHF 0.453 369 WB VP1 B1501 196YLDKNNAY 0.448 393 WB VP1 B1501 246 DEQGVGPL 0.554 124 WB VP1 B1801 324MESQVEEV 0.449 389 WB VP1 B1801 159 LEMQGVLM 0.439 432 WB VP1 B1801 283ARYFKIRL 0.453 371 WB VP1 B2705 292 KRSVKNPY 0.436 446 WB VP1 B2705 279WRGLARYF 0.426 496 WB VP1 B2705 152 FAVGGDPL 0.737 17 SB VP1 B3501 142KPVQGSNF 0.631 54 WB VP1 B3501 19 EPVQVPKL 0.547 134 WB VP1 B3501 196YLDKNNAY 0.544 138 WB VP1 B3501 118 EVIGITSM 0.533 157 WB VP1 B3501 95LPNLNEDL 0.482 270 WB VP1 B3501 299 YPISFLLS 0.480 278 WB VP1 B3501 68HLSAENAF 0.472 304 WB VP1 B3501 297 NPYPISFL 0.470 309 WB VP1 B3501 227GENVPPVL 0.576 98 WB VP1 B4001 159 LEMQGVLM 0.513 194 WB VP1 B4001 324MESQVEEV 0.433 462 WB VP1 B4001 246 DEQGVGPL 0.430 476 WB VP1 B4001 227GENVPPVL 0.457 357 WB VP1 B4002 71 AENAFESD 0.469 312 WB VP1 B4501 340LPGDPDMI 0.621 60 WB VP1 B5101 230 VPPVLHVT 0.446 401 WB VP1 B5101 203YPVECWIP 0.426 498 WB VP1 B5101 297 NPYPISFL 0.568 107 WB VP1 B5301 142KPVQGSNF 0.533 156 WB VP1 B5301 19 EPVQVPKL 0.525 171 WB VP1 B5301 340LPGDPDMI 0.522 176 WB VP1 B5301 95 LPNLNEDL 0.434 456 WB VP1 B5301 299YPISFLLS 0.612 66 WB VP1 B5401 203 YPVECWIP 0.524 172 WB VP1 B5401 230VPPVLHVT 0.521 178 WB VP1 B5401 85 LPCYSTAR 0.450 382 WB VP1 B5401 340LPGDPDMI 0.436 448 WB VP1 B5401 272 NSSGTQQW 0.527 166 WB VP1 B5701 201NAYPVECW 0.479 280 WB VP1 B5701 201 NAYPVECW 0.691 28 SB VP1 B5801 272NSSGTQQW 0.675 33 SB VP1 B5801 9-mers 107 LLMWEAVTV 0.761 13 SB VP1A0201 83 KMLPCYSTA 0.724 19 SB VP1 A0201 26 LLIKGGVEV 0.573 101 WB VP1A0201 323 GMESQVEEV 0.550 129 WB VP1 A0201 332 RVFDGTEQL 0.550 130 WBVP1 A0201 107 LLMWEAVTV 0.769 12 SB VP1 A0202 332 RVFDGTEQL 0.681 31 SBVP1 A0202 323 GMESQVEEV 0.678 32 SB VP1 A0202 26 LLIKGGVEV 0.632 53 WBVP1 A0202 83 KMLPCYSTA 0.540 145 WB VP1 A0202 308 LINRRTQKV 0.539 146 WBVP1 A0202 61 NLRGYSQHL 0.534 154 WB VP1 A0202 127 NLHAGSQKV 0.529 163 WBVP1 A0202 43 AITEVECFL 0.504 213 WB VP1 A0202 118 EVIGITSML 0.480 277 WBVP1 A0202 304 LLSDLINRR 0.474 295 WB VP1 A0202 268 GLFTNSSGT 0.463 333WB VP1 A0202 339 QLPGDPDMI 0.455 363 WB VP1 A0202 146 GSNFHFFAV 0.439430 WB VP1 A0202 236 VTNTATTVL 0.439 434 WB VP1 A0202 107 LLMWEAVTV0.839 5 SB VP1 A0203 308 LINRRTQKV 0.820 6 SB VP1 A0203 26 LLIKGGVEV0.818 7 SB VP1 A0203 127 NLHAGSQKV 0.786 10 SB VP1 A0203 83 KMLPCYSTA0.761 13 SB VP1 A0203 27 LIKGGVEVL 0.623 59 WB VP1 A0203 61 NLRGYSQHL0.616 64 WB VP1 A0203 332 RVFDGTEQL 0.609 68 WB VP1 A0203 323 GMESQVEEV0.604 72 WB VP1 A0203 222 GTYTGGENV 0.586 88 WB VP1 A0203 258 SLYVSAADI0.570 104 WB VP1 A0203 268 GLFTNSSGT 0.535 153 WB VP1 A0203 235HVTNTATTV 0.512 195 WB VP1 A0203 320 PMYGMESQV 0.509 203 WB VP1 A0203125 MLNLHAGSQ 0.480 277 WB VP1 A0203 114 TVKTEVIGI 0.476 288 WB VP1A0203 287 KIRLRKRSV 0.452 374 WB VP1 A0203 236 VTNTATTVL 0.450 384 WBVP1 A0203 107 LLMWEAVTV 0.751 14 SB VP1 A0204 26 LLIKGGVEV 0.688 29 SBVP1 A0204 323 GMESQVEEV 0.648 45 SB VP1 A0204 127 NLHAGSQKV 0.613 65 WBVP1 A0204 308 LINRRTQKV 0.547 133 WB VP1 A0204 83 KMLPCYSTA 0.504 214 WBVP1 A0204 33 EVLEVKTGV 0.476 289 WB VP1 A0204 43 AITEVECFL 0.428 488 WBVP1 A0204 107 LLMWEAVTV 0.865 4 SB VP1 A0206 26 LLIKGGVEV 0.808 7 SB VP1A0206 332 RVFDGTEQL 0.797 8 SB VP1 A0206 83 KMLPCYSTA 0.723 20 SB VP1A0206 235 HVTNTATTV 0.591 83 WB VP1 A0206 144 VQGSNFHFF 0.586 88 WB VP1A0206 146 GSNFHFFAV 0.555 123 WB VP1 A0206 43 AITEVECFL 0.542 142 WB VP1A0206 326 SQVEEVRVF 0.472 303 WB VP1 A0206 39 TGVDAITEV 0.460 344 WB VP1A0206 127 NLHAGSQKV 0.451 378 WB VP1 A0206 107 LLMWEAVTV 0.952 1 SB VP1A0211 26 LLIKGGVEV 0.946 1 SB VP1 A0211 127 NLHAGSQKV 0.943 1 SB VP1A0211 320 PMYGMESQV 0.941 1 SB VP1 A0211 332 RVFDGTEQL 0.923 2 SB VP1A0211 83 KMLPCYSTA 0.869 4 SB VP1 A0211 43 AITEVECFL 0.830 6 SB VP1A0211 33 EVLEVKTGV 0.818 7 SB VP1 A0211 61 NLRGYSQHL 0.804 8 SB VP1A0211 323 GMESQVEEV 0.800 8 SB VP1 A0211 308 LINRRTQKV 0.688 29 SB VP1A0211 235 HVTNTATTV 0.687 29 SB VP1 A0211 242 TVLLDEQGV 0.669 35 SB VP1A0211 196 YLDKNNAYP 0.642 48 SB VP1 A0211 339 QLPGDPDMI 0.623 59 WB VP1A0211 101 DLTCGNLLM 0.603 73 WB VP1 A0211 54 EMGDPDDNL 0.589 85 WB VP1A0211 27 LIKGGVEVL 0.568 107 WB VP1 A0211 258 SLYVSAADI 0.564 111 WB VP1A0211 176 TITPKNPTA 0.543 140 WB VP1 A0211 349 YIDRQGQLQ 0.525 169 WBVP1 A0211 222 GTYTGGENV 0.521 178 WB VP1 A0211 124 SMLNLHAGS 0.494 238WB VP1 A0211 108 LMWEAVTVK 0.489 251 WB VP1 A0211 39 TGVDAITEV 0.488 253WB VP1 A0211 94 PLPNLNEDL 0.487 256 WB VP1 A0211 255 KADSLYVSA 0.475 292WB VP1 A0211 118 EVIGITSML 0.472 304 WB VP1 A0211 201 NAYPVECWI 0.470310 WB VP1 A0211 106 NLLMWEAVT 0.467 320 WB VP1 A0211 268 GLFTNSSGT0.463 332 WB VP1 A0211 244 LLDEQGVGP 0.443 415 WB VP1 A0211 26 LLIKGGVEV0.905 2 SB VP1 A0212 107 LLMWEAVTV 0.903 2 SB VP1 A0212 127 NLHAGSQKV0.895 3 SB VP1 A0212 320 PMYGMESQV 0.883 3 SB VP1 A0212 61 NLRGYSQHL0.837 5 SB VP1 A0212 33 EVLEVKTGV 0.810 7 SB VP1 A0212 332 RVFDGTEQL0.768 12 SB VP1 A0212 308 LINRRTQKV 0.710 23 SB VP1 A0212 43 AITEVECFL0.696 26 SB VP1 A0212 323 GMESQVEEV 0.680 31 SB VP1 A0212 242 TVLLDEQGV0.643 47 SB VP1 A0212 196 YLDKNNAYP 0.604 72 WB VP1 A0212 54 EMGDPDDNL0.597 78 WB VP1 A0212 83 KMLPCYSTA 0.575 99 WB VP1 A0212 339 QLPGDPDMI0.548 132 WB VP1 A0212 108 LMWEAVTVK 0.537 149 WB VP1 A0212 268GLFTNSSGT 0.534 155 WB VP1 A0212 222 GTYTGGENV 0.527 166 WB VP1 A0212 27LIKGGVEVL 0.505 212 WB VP1 A0212 124 SMLNLHAGS 0.492 243 WB VP1 A0212244 LLDEQGVGP 0.484 266 WB VP1 A0212 164 VLMNYRTKY 0.481 274 WB VP1A0212 94 PLPNLNEDL 0.480 276 WB VP1 A0212 235 HVTNTATTV 0.457 356 WB VP1A0212 304 LLSDLINRR 0.443 414 WB VP1 A0212 258 SLYVSAADI 0.436 449 WBVP1 A0212 349 YIDRQGQLQ 0.435 452 WB VP1 A0212 201 NAYPVECWI 0.435 453WB VP1 A0212 26 LLIKGGVEV 0.935 2 SB VP1 A0216 320 PMYGMESQV 0.926 2 SBVP1 A0216 127 NLHAGSQKV 0.887 3 SB VP1 A0216 107 LLMWEAVTV 0.872 3 SBVP1 A0216 332 RVFDGTEQL 0.838 5 SB VP1 A0216 61 NLRGYSQHL 0.835 5 SB VP1A0216 43 AITEVECFL 0.834 6 SB VP1 A0216 323 GMESQVEEV 0.826 6 SB VP1A0216 235 HVTNTATTV 0.762 13 SB VP1 A0216 33 EVLEVKTGV 0.742 16 SB VP1A0216 308 LINRRTQKV 0.701 25 SB VP1 A0216 83 KMLPCYSTA 0.653 42 SB VP1A0216 54 EMGDPDDNL 0.649 44 SB VP1 A0216 201 NAYPVECWI 0.593 81 WB VP1A0216 111 EAVTVKTEV 0.540 145 WB VP1 A0216 39 TGVDAITEV 0.524 171 WB VP1A0216 118 EVIGITSML 0.513 194 WB VP1 A0216 196 YLDKNNAYP 0.512 196 WBVP1 A0216 339 QLPGDPDMI 0.491 245 WB VP1 A0216 222 GTYTGGENV 0.485 262WB VP1 A0216 27 LIKGGVEVL 0.467 318 WB VP1 A0216 176 TITPKNPTA 0.462 336WB VP1 A0216 94 PLPNLNEDL 0.426 496 WB VP1 A0216 127 NLHAGSQKV 0.862 4SB VP1 A0219 107 LLMWEAVTV 0.811 7 SB VP1 A0219 320 PMYGMESQV 0.786 10SB VP1 A0219 26 LLIKGGVEV 0.776 11 SB VP1 A0219 332 RVFDGTEQL 0.762 13SB VP1 A0219 323 GMESQVEEV 0.643 47 SB VP1 A0219 61 NLRGYSQHL 0.621 60WB VP1 A0219 54 EMGDPDDNL 0.581 93 WB VP1 A0219 235 HVTNTATTV 0.537 150WB VP1 A0219 33 EVLEVKTGV 0.529 162 WB VP1 A0219 308 LINRRTQKV 0.528 165WB VP1 A0219 39 TGVDAITEV 0.492 242 WB VP1 A0219 108 LMWEAVTVK 0.442 417WB VP1 A0219 27 LIKGGVEVL 0.438 437 WB VP1 A0219 284 RYFKIRLRK 0.643 47SB VP1 A0301 108 LMWEAVTVK 0.570 104 WB VP1 A0301 134 KVHENGGGK 0.525170 WB VP1 A0301 164 VLMNYRTKY 0.453 370 WB VP1 A0301 163 GVLMNYRTK0.440 426 WB VP1 A0301 163 GVLMNYRTK 0.621 60 WB VP1 A1101 186 SQVMNTDHK0.599 76 WB VP1 A1101 284 RYFKIRLRK 0.586 88 WB VP1 A1101 276 TQQWRGLAR0.561 115 WB VP1 A1101 134 KVHENGGGK 0.556 121 WB VP1 A1101 284RYFKIRLRK 0.724 19 SB VP1 A2301 87 CYSTARIPL 0.572 102 WB VP1 A2301 143PVQGSNFHF 0.555 123 WB VP1 A2301 348 RYIDRQGQL 0.538 147 WB VP1 A2301144 VQGSNFHFF 0.480 277 WB VP1 A2301 144 VQGSNFHFF 0.521 178 WB VP1A2402 348 RYIDRQGQL 0.506 210 WB VP1 A2402 348 RYIDRQGQL 0.602 73 WB VP1A2403 195 AYLDKNNAY 0.502 218 WB VP1 A2403 278 QWRGLARYF 0.434 457 WBVP1 A2403 118 EVIGITSML 0.663 38 SB VP1 A2601 160 EMQGVLMNY 0.553 126 WBVP1 A2601 118 EVIGITSML 0.898 3 SB VP1 A2602 160 EMQGVLMNY 0.659 39 SBVP1 A2602 36 EVKTGVDAI 0.584 90 WB VP1 A2602 164 VLMNYRTKY 0.620 61 WBVP1 A2902 188 VMNTDHKAY 0.535 153 WB VP1 A2902 195 AYLDKNNAY 0.524 172WB VP1 A2902 284 RYFKIRLRK 0.812 7 SB VP1 A3001 134 KVHENGGGK 0.791 9 SBVP1 A3001 163 GVLMNYRTK 0.563 113 WB VP1 A3001 291 RKRSVKNPY 0.543 141WB VP1 A3001 169 RTKYPQGTI 0.492 243 WB VP1 A3001 191 TDHKAYLDK 0.436444 WB VP1 A3001 287 KIRLRKRSV 0.436 446 WB VP1 A3001 289 RLRKRSVKN0.436 447 WB VP1 A3001 186 SQVMNTDHK 0.434 455 WB VP1 A3001 161MQGVLMNYR 0.811 7 SB VP1 A3101 285 YFKIRLRKR 0.800 8 SB VP1 A3101 284RYFKIRLRK 0.762 13 SB VP1 A3101 276 TQQWRGLAR 0.627 56 WB VP1 A3101 84MLPCYSTAR 0.578 95 WB VP1 A3101 304 LLSDLINRR 0.573 101 WB VP1 A3101 281GLARYFKIR 0.520 180 WB VP1 A3101 108 LMWEAVTVK 0.502 219 WB VP1 A3101303 FLLSDLINR 0.441 422 WB VP1 A3101 285 YFKIRLRKR 0.782 10 SB VP1 A3301307 DLINRRTQK 0.659 39 SB VP1 A3301 272 NSSGTQQWR 0.732 18 SB VP1 A680184 MLPCYSTAR 0.720 20 SB VP1 A6801 307 DLINRRTQK 0.593 81 WB VP1 A6801324 MESQVEEVR 0.548 132 WB VP1 A6801 304 LLSDLINRR 0.543 140 WB VP1A6801 118 EVIGITSML 0.509 202 WB VP1 A6801 161 MQGVLMNYR 0.437 442 WBVP1 A6801 284 RYFKIRLRK 0.437 444 WB VP1 A6801 118 EVIGITSML 0.903 2 SBVP1 A6802 111 EAVTVKTEV 0.739 16 SB VP1 A6802 33 EVLEVKTGV 0.728 18 SBVP1 A6802 39 TGVDAITEV 0.683 30 SB VP1 A6802 297 NPYPISFLL 0.632 53 WBVP1 A6802 332 RVFDGTEQL 0.578 95 WB VP1 A6802 145 QGSNFHFFA 0.563 113 WBVP1 A6802 201 NAYPVECWI 0.556 121 WB VP1 A6802 187 QVMNTDHKA 0.527 167WB VP1 A6802 146 GSNFHFFAV 0.497 231 WB VP1 A6802 293 RSVKNPYPI 0.457357 WB VP1 A6802 261 VSAADICGL 0.455 364 WB VP1 A6802 235 HVTNTATTV0.444 410 WB VP1 A6802 229 NVPPVLHVT 0.441 422 WB VP1 A6802 297NPYPISFLL 0.673 34 SB VP1 A6901 118 EVIGITSML 0.636 51 WB VP1 A6901 235HVTNTATTV 0.546 136 WB VP1 A6901 107 LLMWEAVTV 0.499 225 WB VP1 A6901201 NAYPVECWI 0.485 262 WB VP1 A6901 111 EAVTVKTEV 0.483 268 WB VP1A6901 225 TGGENVPPV 0.469 311 WB VP1 A6901 222 GTYTGGENV 0.437 440 WBVP1 A6901 127 NLHAGSQKV 0.433 463 WB VP1 A6901 332 RVFDGTEQL 0.430 474WB VP1 A6901 85 LPCYSTARI 0.692 28 SB VP1 B0702 13 APKKPKEPV 0.688 29 SBVP1 B0702 1 APTKRKGEC 0.619 61 WB VP1 B0702 282 LARYFKIRL 0.535 153 WBVP1 B0702 287 KIRLRKRSV 0.520 179 WB VP1 B0702 181 NPTAQSQVM 0.498 227WB VP1 B0702 79 SPDRKMLPC 0.482 272 WB VP1 B0702 19 EPVQVPKLL 0.474 295WB VP1 B0702 251 GPLCKADSL 0.455 364 WB VP1 B0702 287 KIRLRKRSV 0.431472 WB VP1 B0801 326 SQVEEVRVF 0.598 77 WB VP1 B1501 188 VMNTDHKAY 0.58985 WB VP1 B1501 313 TQKVDGQPM 0.566 108 WB VP1 B1501 277 QQWRGLARY 0.543140 WB VP1 B1501 160 EMQGVLMNY 0.456 360 WB VP1 B1501 295 VKNPYPISF0.595 79 WB VP1 B1801 117 TEVIGITSM 0.472 303 WB VP1 B1801 288 IRLRKRSVK0.523 174 WB VP1 B2705 279 WRGLARYFK 0.486 259 WB VP1 B2705 181NPTAQSQVM 0.758 13 SB VP1 B3501 57 DPDDNLRGY 0.613 65 WB VP1 B3501 157DPLEMQGVL 0.577 97 WB VP1 B3501 142 KPVQGSNFH 0.574 99 WB VP1 B3501 297NPYPISFLL 0.568 107 WB VP1 B3501 151 FFAVGGDPL 0.565 110 WB VP1 B3501 67QHLSAENAF 0.495 235 WB VP1 B3501 203 YPVECWIPD 0.491 247 WB VP1 B3501 19EPVQVPKLL 0.475 292 WB VP1 B3501 42 DAITEVECF 0.468 317 WB VP1 B3501 95LPNLNEDLT 0.441 424 WB VP1 B3501 136 HENGGGKPV 0.448 391 WB VP1 B4001 47VECFLNPEM 0.431 469 WB VP1 B4001 71 AENAFESDS 0.600 75 WB VP1 B4501 85LPCYSTARI 0.659 39 SB VP1 B5101 19 EPVQVPKLL 0.475 292 WB VP1 B5101 297NPYPISFLL 0.459 350 WB VP1 B5101 85 LPCYSTARI 0.655 41 SB VP1 B5301 297NPYPISFLL 0.623 59 WB VP1 B5301 19 EPVQVPKLL 0.535 152 WB VP1 B5301 95LPNLNEDLT 0.636 51 WB VP1 B5401 85 LPCYSTARI 0.591 83 WB VP1 B5401 203YPVECWIPD 0.481 273 WB VP1 B5401 299 YPISFLLSD 0.435 452 WB VP1 B5401102 LTCGNLLMW 0.453 371 WB VP1 B5701 102 LTCGNLLMW 0.624 58 WB VP1 B580110-mers 196 YLDKNNAYPV 0.866 4 SB VP1 A0201 108 LMWEAVTVKT 0.691 28 SBVP1 A0201 84 MLPCYSTARI 0.675 33 SB VP1 A0201 106 NLLMWEAVTV 0.634 52 WBVP1 A0201 224 YTGGENVPPV 0.608 69 WB VP1 A0201 260 YVSAADICGL 0.589 85WB VP1 A0201 244 LLDEQGVGPL 0.537 150 WB VP1 A0201 25 KLLIKGGVEV 0.517185 WB VP1 A0201 188 VMNTDHKAYL 0.504 214 WB VP1 A0201 281 GLARYFKIRL0.482 271 WB VP1 A0201 322 YGMESQVEEV 0.465 325 WB VP1 A0201 26LLIKGGVEVL 0.465 328 WB VP1 A0201 196 YLDKNNAYPV 0.722 20 SB VP1 A0202260 YVSAADICGL 0.676 33 SB VP1 A0202 244 LLDEQGVGPL 0.652 43 SB VP1A0202 26 LLIKGGVEVL 0.621 60 WB VP1 A0202 188 VMNTDHKAYL 0.613 66 WB VP1A0202 84 MLPCYSTARI 0.604 72 WB VP1 A0202 106 NLLMWEAVTV 0.571 104 WBVP1 A0202 224 YTGGENVPPV 0.554 124 WB VP1 A0202 281 GLARYFKIRL 0.520 179WB VP1 A0202 303 FLLSDLINRR 0.495 236 WB VP1 A0202 304 LLSDLINRRT 0.487257 WB VP1 A0202 322 YGMESQVEEV 0.470 308 WB VP1 A0202 25 KLLIKGGVEV0.462 338 WB VP1 A0202 38 KTGVDAITEV 0.453 372 WB VP1 A0202 255KADSLYVSAA 0.442 419 WB VP1 A0202 84 MLPCYSTARI 0.854 4 SB VP1 A0203 196YLDKNNAYPV 0.801 8 SB VP1 A0203 244 LLDEQGVGPL 0.704 24 SB VP1 A0203 188VMNTDHKAYL 0.702 25 SB VP1 A0203 26 LLIKGGVEVL 0.663 38 SB VP1 A0203 106NLLMWEAVTV 0.660 39 SB VP1 A0203 224 YTGGENVPPV 0.611 67 WB VP1 A0203260 YVSAADICGL 0.606 70 WB VP1 A0203 25 KLLIKGGVEV 0.596 79 WB VP1 A0203281 GLARYFKIRL 0.590 84 WB VP1 A0203 304 LLSDLINRRT 0.530 162 WB VP1A0203 108 LMWEAVTVKT 0.467 319 WB VP1 A0203 233 VLHVTNTATT 0.462 338 WBVP1 A0203 352 RQGQLQTKMV 0.448 391 WB VP1 A0203 236 VTNTATTVLL 0.446 399WB VP1 A0203 38 KTGVDAITEV 0.441 424 WB VP1 A0203 307 DLINRRTQKV 0.438437 WB VP1 A0203 196 YLDKNNAYPV 0.658 40 SB VP1 A0204 25 KLLIKGGVEV0.650 44 SB VP1 A0204 244 LLDEQGVGPL 0.598 77 WB VP1 A0204 224YTGGENVPPV 0.596 78 WB VP1 A0204 108 LMWEAVTVKT 0.548 133 WB VP1 A0204106 NLLMWEAVTV 0.541 142 WB VP1 A0204 38 KTGVDAITEV 0.517 185 WB VP1A0204 322 YGMESQVEEV 0.499 226 WB VP1 A0204 188 VMNTDHKAYL 0.473 299 WBVP1 A0204 26 LLIKGGVEVL 0.468 315 WB VP1 A0204 89 STARIPLPNL 0.433 459WB VP1 A0204 196 YLDKNNAYPV 0.873 3 SB VP1 A0206 144 VQGSNFHFFA 0.733 17SB VP1 A0206 106 NLLMWEAVTV 0.694 27 SB VP1 A0206 260 YVSAADICGL 0.67732 SB VP1 A0206 84 MLPCYSTARI 0.671 35 SB VP1 A0206 244 LLDEQGVGPL 0.63750 WB VP1 A0206 224 YTGGENVPPV 0.606 71 WB VP1 A0206 38 KTGVDAITEV 0.59084 WB VP1 A0206 25 KLLIKGGVEV 0.588 86 WB VP1 A0206 186 SQVMNTDHKA 0.58886 WB VP1 A0206 352 RQGQLQTKMV 0.559 118 WB VP1 A0206 152 FAVGGDPLEM0.550 129 WB VP1 A0206 26 LLIKGGVEVL 0.549 131 WB VP1 A0206 322YGMESQVEEV 0.514 191 WB VP1 A0206 277 QQWRGLARYF 0.509 202 WB VP1 A0206108 LMWEAVTVKT 0.503 216 WB VP1 A0206 161 MQGVLMNYRT 0.428 486 WB VP1A0206 196 YLDKNNAYPV 0.976 1 SB VP1 A0211 106 NLLMWEAVTV 0.926 2 SB VP1A0211 244 LLDEQGVGPL 0.906 2 SB VP1 A0211 25 KLLIKGGVEV 0.849 5 SB VP1A0211 26 LLIKGGVEVL 0.843 5 SB VP1 A0211 224 YTGGENVPPV 0.820 7 SB VP1A0211 281 GLARYFKIRL 0.817 7 SB VP1 A0211 252 PLCKADSLYV 0.801 8 SB VP1A0211 188 VMNTDHKAYL 0.798 8 SB VP1 A0211 84 MLPCYSTARI 0.773 11 SB VP1A0211 307 DLINRRTQKV 0.751 14 SB VP1 A0211 108 LMWEAVTVKT 0.740 16 SBVP1 A0211 260 YVSAADICGL 0.693 27 SB VP1 A0211 349 YIDRQGQLQT 0.652 43SB VP1 A0211 304 LLSDLINRRT 0.628 55 WB VP1 A0211 322 YGMESQVEEV 0.60869 WB VP1 A0211 155 GGDPLEMQGV 0.597 78 WB VP1 A0211 315 KVDGQPMYGM0.593 82 WB VP1 A0211 124 SMLNLHAGSQ 0.578 96 WB VP1 A0211 38 KTGVDAITEV0.533 156 WB VP1 A0211 268 GLFTNSSGTQ 0.499 226 WB VP1 A0211 243VLLDEQGVGP 0.427 494 WB VP1 A0211 196 YLDKNNAYPV 0.940 1 SB VP1 A0212106 NLLMWEAVTV 0.863 4 SB VP1 A0212 26 LLIKGGVEVL 0.799 8 SB VP1 A0212244 LLDEQGVGPL 0.763 12 SB VP1 A0212 281 GLARYFKIRL 0.762 13 SB VP1A0212 224 YTGGENVPPV 0.734 17 SB VP1 A0212 188 VMNTDHKAYL 0.728 19 SBVP1 A0212 108 LMWEAVTVKT 0.718 21 SB VP1 A0212 25 KLLIKGGVEV 0.705 24 SBVP1 A0212 84 MLPCYSTARI 0.659 40 SB VP1 A0212 260 YVSAADICGL 0.646 46 SBVP1 A0212 307 DLINRRTQKV 0.625 57 WB VP1 A0212 252 PLCKADSLYV 0.620 60WB VP1 A0212 304 LLSDLINRRT 0.541 143 WB VP1 A0212 349 YIDRQGQLQT 0.533157 WB VP1 A0212 155 GGDPLEMQGV 0.513 195 WB VP1 A0212 243 VLLDEQGVGP0.504 213 WB VP1 A0212 303 FLLSDLINRR 0.481 274 WB VP1 A0212 322YGMESQVEEV 0.474 297 WB VP1 A0212 124 SMLNLHAGSQ 0.430 477 WB VP1 A0212196 YLDKNNAYPV 0.945 1 SB VP1 A0216 106 NLLMWEAVTV 0.882 3 SB VP1 A0216252 PLCKADSLYV 0.866 4 SB VP1 A0216 281 GLARYFKIRL 0.844 5 SB VP1 A0216307 DLINRRTQKV 0.820 7 SB VP1 A0216 26 LLIKGGVEVL 0.800 8 SB VP1 A021625 KLLIKGGVEV 0.779 10 SB VP1 A0216 244 LLDEQGVGPL 0.740 16 SB VP1 A0216224 YTGGENVPPV 0.726 19 SB VP1 A0216 84 MLPCYSTARI 0.723 19 SB VP1 A0216188 VMNTDHKAYL 0.662 38 SB VP1 A0216 108 LMWEAVTVKT 0.606 70 WB VP1A0216 260 YVSAADICGL 0.545 136 WB VP1 A0216 38 KTGVDAITEV 0.510 199 WBVP1 A0216 304 LLSDLINRRT 0.477 285 WB VP1 A0216 349 YIDRQGQLQT 0.470 309WB VP1 A0216 28 IKGGVEVLEV 0.430 478 WB VP1 A0216 196 YLDKNNAYPV 0.940 1SB VP1 A0219 106 NLLMWEAVTV 0.763 12 SB VP1 A0219 224 YTGGENVPPV 0.67832 SB VP1 A0219 26 LLIKGGVEVL 0.671 35 SB VP1 A0219 260 YVSAADICGL 0.65641 SB VP1 A0219 244 LLDEQGVGPL 0.644 46 SB VP1 A0219 108 LMWEAVTVKT0.615 64 WB VP1 A0219 188 VMNTDHKAYL 0.555 122 WB VP1 A0219 84MLPCYSTARI 0.508 204 WB VP1 A0219 322 YGMESQVEEV 0.492 243 WB VP1 A0219252 PLCKADSLYV 0.482 270 WB VP1 A0219 307 DLINRRTQKV 0.457 354 WB VP1A0219 25 KLLIKGGVEV 0.429 484 WB VP1 A0219 107 LLMWEAVTVK 0.689 28 SBVP1 A0301 283 ARYFKIRLRK 0.645 46 SB VP1 A0301 287 KIRLRKRSVK 0.641 48SB VP1 A0301 83 KMLPCYSTAR 0.532 157 WB VP1 A0301 171 KYPQGTITPK 0.503216 WB VP1 A0301 278 QWRGLARYFK 0.449 387 WB VP1 A0301 190 NTDHKAYLDK0.449 388 WB VP1 A0301 125 MLNLHAGSQK 0.679 32 SB VP1 A1101 275GTQQWRGLAR 0.611 67 WB VP1 A1101 107 LLMWEAVTVK 0.606 70 WB VP1 A1101185 QSQVMNTDHK 0.571 103 WB VP1 A1101 20 PVQVPKLLIK 0.498 228 WB VP1A1101 190 NTDHKAYLDK 0.491 247 WB VP1 A1101 83 KMLPCYSTAR 0.430 478 WBVP1 A1101 143 PVQGSNFHFF 0.511 199 WB VP1 A2301 171 KYPQGTITPK 0.457 356WB VP1 A2301 284 RYFKIRLRKR 0.441 423 WB VP1 A2301 187 QVMNTDHKAY 0.75214 SB VP1 A2602 46 EVECFLNPEM 0.733 17 SB VP1 A2602 315 KVDGQPMYGM 0.71521 SB VP1 A2602 294 SVKNPYPISF 0.643 47 SB VP1 A2602 89 STARIPLPNL 0.60274 WB VP1 A2602 143 PVQGSNFHFF 0.581 92 WB VP1 A2602 260 YVSAADICGL0.510 201 WB VP1 A2602 116 KTEVIGITSM 0.460 343 WB VP1 A2602 187QVMNTDHKAY 0.558 119 WB VP1 A2902 163 GVLMNYRTKY 0.462 337 WB VP1 A2902287 KIRLRKRSVK 0.842 5 SB VP1 A3001 278 QWRGLARYFK 0.767 12 SB VP1 A30016 KGECPGAAPK 0.695 27 SB VP1 A3001 16 KPKEPVQVPK 0.691 28 SB VP1 A3001171 KYPQGTITPK 0.665 37 SB VP1 A3001 125 MLNLHAGSQK 0.599 76 WB VP1A3001 185 QSQVMNTDHK 0.499 225 WB VP1 A3001 83 KMLPCYSTAR 0.463 333 WBVP1 A3001 282 LARYFKIRLR 0.426 496 WB VP1 A3001 284 RYFKIRLRKR 0.859 4SB VP1 A3101 83 KMLPCYSTAR 0.777 11 SB VP1 A3101 282 LARYFKIRLR 0.689 28SB VP1 A3101 287 KIRLRKRSVK 0.682 31 SB VP1 A3101 160 EMQGVLMNYR 0.66836 SB VP1 A3101 278 QWRGLARYFK 0.657 40 SB VP1 A3101 275 GTQQWRGLAR0.580 93 WB VP1 A3101 283 ARYFKIRLRK 0.575 99 WB VP1 A3101 302SFLLSDLINR 0.565 110 WB VP1 A3101 160 EMQGVLMNYR 0.552 127 WB VP1 A3301302 SFLLSDLINR 0.464 328 WB VP1 A3301 282 LARYFKIRLR 0.443 412 WB VP1A3301 284 RYFKIRLRKR 0.438 439 WB VP1 A3301 73 NAFESDSPDR 0.798 8 SB VP1A6801 160 EMQGVLMNYR 0.747 15 SB VP1 A6801 125 MLNLHAGSQK 0.647 45 SBVP1 A6801 282 LARYFKIRLR 0.540 145 WB VP1 A6801 271 TNSSGTQQWR 0.508 205WB VP1 A6801 107 LLMWEAVTVK 0.504 213 WB VP1 A6801 118 EVIGITSMLN 0.492243 WB VP1 A6801 54 EMGDPDDNLR 0.481 275 WB VP1 A6801 185 QSQVMNTDHK0.480 278 WB VP1 A6801 303 FLLSDLINRR 0.453 372 WB VP1 A6801 275GTQQWRGLAR 0.443 413 WB VP1 A6801 145 QGSNFHFFAV 0.746 15 SB VP1 A6802241 TTVLLDEQGV 0.705 24 SB VP1 A6802 260 YVSAADICGL 0.681 31 SB VP1A6802 84 MLPCYSTARI 0.661 39 SB VP1 A6802 89 STARIPLPNL 0.658 40 SB VP1A6802 111 EAVTVKTEVI 0.641 48 SB VP1 A6802 322 YGMESQVEEV 0.619 61 WBVP1 A6802 224 YTGGENVPPV 0.529 163 WB VP1 A6802 104 CGNLLMWEAV 0.498 228WB VP1 A6802 200 NNAYPVECWI 0.458 354 WB VP1 A6802 42 DAITEVECFL 0.447397 WB VP1 A6802 319 QPMYGMESQV 0.444 411 WB VP1 A6802 224 YTGGENVPPV0.750 14 SB VP1 A6901 196 YLDKNNAYPV 0.662 38 SB VP1 A6901 89 STARIPLPNL0.596 79 WB VP1 A6901 106 NLLMWEAVTV 0.558 119 WB VP1 A6901 322YGMESQVEEV 0.518 184 WB VP1 A6901 46 EVECFLNPEM 0.482 271 WB VP1 A690119 EPVQVPKLLI 0.478 283 WB VP1 A6901 319 QPMYGMESQV 0.476 289 WB VP1A6901 157 DPLEMQGVLM 0.439 432 WB VP1 A6901 142 KPVQGSNFHF 0.666 37 SBVP1 B0702 299 YPISFLLSDL 0.604 72 WB VP1 B0702 235 HVTNTATTVL 0.525 170WB VP1 B0702 319 QPMYGMESQV 0.457 357 WB VP1 B0702 93 IPLPNLNEDL 0.429484 WB VP1 B0702 66 SQHLSAENAF 0.595 79 WB VP1 B1501 313 TQKVDGQPMY0.589 85 WB VP1 B1501 187 QVMNTDHKAY 0.570 104 WB VP1 B1501 277QQWRGLARYF 0.566 109 WB VP1 B1501 276 TQQWRGLARY 0.565 110 WB VP1 B1501294 SVKNPYPISF 0.507 207 WB VP1 B1501 194 KAYLDKNNAY 0.474 297 WB VP1B1501 261 VSAADICGLF 0.433 461 WB VP1 B1501 26 LLIKGGVEVL 0.430 478 WBVP1 B1501 159 LEMQGVLMNY 0.712 22 SB VP1 B1801 117 TEVIGITSML 0.548 133WB VP1 B1801 215 NENTRYFGTY 0.514 192 WB VP1 B1801 110 WEAVTVKTEV 0.509202 WB VP1 B1801 32 VEVLEVKTGV 0.462 335 WB VP1 B1801 283 ARYFKIRLRK0.558 119 WB VP1 B2705 152 FAVGGDPLEM 0.756 13 SB VP1 B3501 157DPLEMQGVLM 0.715 21 SB VP1 B3501 211 DPSRNENTRY 0.683 30 SB VP1 B3501340 LPGDPDMIRY 0.676 33 SB VP1 B3501 142 KPVQGSNFHF 0.645 46 SB VP1B3501 187 QVMNTDHKAY 0.604 72 WB VP1 B3501 194 KAYLDKNNAY 0.600 75 WBVP1 B3501 299 YPISFLLSDL 0.560 117 WB VP1 B3501 46 EVECFLNPEM 0.533 156WB VP1 B3501 79 SPDRKMLPCY 0.513 194 WB VP1 B3501 95 LPNLNEDLTC 0.454367 WB VP1 B3501 251 GPLCKADSLY 0.435 453 WB VP1 B3501 117 TEVIGITSML0.570 104 WB VP1 B4001 324 MESQVEEVRV 0.475 293 WB VP1 B4001 53PEMGDPDDNL 0.473 298 WB VP1 B4001 99 NEDLTCGNLL 0.471 304 WB VP1 B4001110 WEAVTVKTEV 0.428 488 WB VP1 B4001 215 NENTRYFGTY 0.430 476 WB VP1B4402 71 AENAFESDSP 0.495 235 WB VP1 B4501 19 EPVQVPKLLI 0.654 42 SB VP1B5101 299 YPISFLLSDL 0.557 120 WB VP1 B5101 19 EPVQVPKLLI 0.658 40 SBVP1 B5301 299 YPISFLLSDL 0.604 72 WB VP1 B5301 142 KPVQGSNFHF 0.531 159WB VP1 B5301 340 LPGDPDMIRY 0.523 174 WB VP1 B5301 79 SPDRKMLPCY 0.468315 WB VP1 B5301 211 DPSRNENTRY 0.468 316 WB VP1 B5301 23 VPKLLIKGGV0.607 70 WB VP1 B5401 231 PPVLHVTNTA 0.590 84 WB VP1 B5401 85 LPCYSTARIP0.533 157 WB VP1 B5401 19 EPVQVPKLLI 0.463 332 WB VP1 B5401 203YPVECWIPDP 0.456 358 WB VP1 B5401 270 FTNSSGTQQW 0.478 285 WB VP1 B5701270 FTNSSGTQQW 0.738 16 SB VP1 B5801 199 KNNAYPVECW 0.634 52 WB VP1B5801 261 VSAADICGLF 0.458 351 WB VP1 B5801 11-mers 83 KMLPCYSTARI 0.77811 SB VP1 A0201 107 LLMWEAVTVKT 0.594 80 WB VP1 A0201 243 VLLDEQGVGPL0.577 97 WB VP1 A0201 303 FLLSDLINRRT 0.551 129 WB VP1 A0201 233VLHVTNTATTV 0.497 230 WB VP1 A0201 144 VQGSNFHFFAV 0.461 342 WB VP1A0201 125 MLNLHAGSQKV 0.459 348 WB VP1 A0201 187 QVMNTDHKAYL 0.444 407WB VP1 A0201 323 GMESQVEEVRV 0.434 458 WB VP1 A0201 125 MLNLHAGSQKV0.757 13 SB VP1 A0202 97 NLNEDLTCGNL 0.678 32 SB VP1 A0202 243VLLDEQGVGPL 0.618 62 WB VP1 A0202 83 KMLPCYSTARI 0.597 78 WB VP1 A0202107 LLMWEAVTVKT 0.592 82 WB VP1 A0202 323 GMESQVEEVRV 0.558 119 WB VP1A0202 144 VQGSNFHFFAV 0.548 133 WB VP1 A0202 233 VLHVTNTATTV 0.506 209WB VP1 A0202 187 QVMNTDHKAYL 0.482 270 WB VP1 A0202 303 FLLSDLINRRT0.438 436 WB VP1 A0202 125 MLNLHAGSQKV 0.897 3 SB VP1 A0203 27LIKGGVEVLEV 0.784 10 SB VP1 A0203 83 KMLPCYSTARI 0.744 15 SB VP1 A0203233 VLHVTNTATTV 0.743 16 SB VP1 A0203 97 NLNEDLTCGNL 0.709 23 SB VP1A0203 243 VLLDEQGVGPL 0.708 23 SB VP1 A0203 61 NLRGYSQHLSA 0.693 27 SBVP1 A0203 107 LLMWEAVTVKT 0.605 71 WB VP1 A0203 134 KVHENGGGKPV 0.574 99WB VP1 A0203 144 VQGSNFHFFAV 0.520 180 WB VP1 A0203 294 SVKNPYPISFL0.475 292 WB VP1 A0203 346 MIRYIDRQGQL 0.471 306 WB VP1 A0203 323GMESQVEEVRV 0.459 348 WB VP1 A0203 303 FLLSDLINRRT 0.454 367 WB VP1A0203 125 MLNLHAGSQKV 0.687 29 SB VP1 A0204 233 VLHVTNTATTV 0.655 41 SBVP1 A0204 243 VLLDEQGVGPL 0.629 55 WB VP1 A0204 134 KVHENGGGKPV 0.544138 WB VP1 A0204 323 GMESQVEEVRV 0.544 138 WB VP1 A0204 83 KMLPCYSTARI0.497 230 WB VP1 A0204 144 VQGSNFHFFAV 0.476 290 WB VP1 A0204 107LLMWEAVTVKT 0.464 328 WB VP1 A0204 195 AYLDKNNAYPV 0.460 345 WB VP1A0204 25 KLLIKGGVEVL 0.443 415 WB VP1 A0204 224 YTGGENVPPVL 0.428 487 WBVP1 A0204 144 VQGSNFHFFAV 0.865 4 SB VP1 A0206 83 KMLPCYSTARI 0.720 20SB VP1 A0206 125 MLNLHAGSQKV 0.576 97 WB VP1 A0206 243 VLLDEQGVGPL 0.571103 WB VP1 A0206 318 GQPMYGMESQV 0.519 181 WB VP1 A0206 107 LLMWEAVTVKT0.498 229 WB VP1 A0206 187 QVMNTDHKAYL 0.485 261 WB VP1 A0206 233VLHVTNTATTV 0.435 450 WB VP1 A0206 303 FLLSDLINRRT 0.433 462 WB VP1A0206 243 VLLDEQGVGPL 0.906 2 SB VP1 A0211 233 VLHVTNTATTV 0.899 2 SBVP1 A0211 125 MLNLHAGSQKV 0.897 3 SB VP1 A0211 83 KMLPCYSTARI 0.831 6 SBVP1 A0211 27 LIKGGVEVLEV 0.813 7 SB VP1 A0211 323 GMESQVEEVRV 0.770 12SB VP1 A0211 244 LLDEQGVGPLC 0.735 17 SB VP1 A0211 61 NLRGYSQHLSA 0.70324 SB VP1 A0211 304 LLSDLINRRTQ 0.696 26 SB VP1 A0211 25 KLLIKGGVEVL0.681 31 SB VP1 A0211 134 KVHENGGGKPV 0.674 34 SB VP1 A0211 97NLNEDLTCGNL 0.669 35 SB VP1 A0211 195 AYLDKNNAYPV 0.636 51 WB VP1 A0211303 FLLSDLINRRT 0.612 66 WB VP1 A0211 164 VLMNYRTKYPQ 0.607 70 WB VP1A0211 223 TYTGGENVPPV 0.585 89 WB VP1 A0211 196 YLDKNNAYPVE 0.560 116 WBVP1 A0211 107 LLMWEAVTVKT 0.551 128 WB VP1 A0211 235 HVTNTATTVLL 0.525171 WB VP1 A0211 22 QVPKLLIKGGV 0.523 174 WB VP1 A0211 268 GLFTNSSGTQQ0.506 209 WB VP1 A0211 339 QLPGDPDMIRY 0.501 222 WB VP1 A0211 144VQGSNFHFFAV 0.500 224 WB VP1 A0211 187 QVMNTDHKAYL 0.499 225 WB VP1A0211 11 GAAPKKPKEPV 0.474 297 WB VP1 A0211 224 YTGGENVPPVL 0.472 302 WBVP1 A0211 160 EMQGVLMNYRT 0.468 317 WB VP1 A0211 349 YIDRQGQLQTK 0.450385 WB VP1 A0211 240 ATTVLLDEQGV 0.437 443 WB VP1 A0211 233 VLHVTNTATTV0.838 5 SB VP1 A0212 243 VLLDEQGVGPL 0.823 6 SB VP1 A0212 125MLNLHAGSQKV 0.813 7 SB VP1 A0212 323 GMESQVEEVRV 0.713 22 SB VP1 A021227 LIKGGVEVLEV 0.697 26 SB VP1 A0212 61 NLRGYSQHLSA 0.690 28 SB VP1A0212 144 VQGSNFHFFAV 0.652 42 SB VP1 A0212 244 LLDEQGVGPLC 0.645 46 SBVP1 A0212 304 LLSDLINRRTQ 0.599 76 WB VP1 A0212 83 KMLPCYSTARI 0.596 79WB VP1 A0212 164 VLMNYRTKYPQ 0.576 98 WB VP1 A0212 196 YLDKNNAYPVE 0.569106 WB VP1 A0212 303 FLLSDLINRRT 0.561 115 WB VP1 A0212 224 YTGGENVPPVL0.543 140 WB VP1 A0212 25 KLLIKGGVEVL 0.530 161 WB VP1 A0212 107LLMWEAVTVKT 0.511 199 WB VP1 A0212 97 NLNEDLTCGNL 0.491 247 WB VP1 A0212195 AYLDKNNAYPV 0.490 249 WB VP1 A0212 349 YIDRQGQLQTK 0.465 325 WB VP1A0212 154 VGGDPLEMQGV 0.464 329 WB VP1 A0212 160 EMQGVLMNYRT 0.460 345WB VP1 A0212 108 LMWEAVTVKTE 0.438 434 WB VP1 A0212 233 VLHVTNTATTV0.865 4 SB VP1 A0216 125 MLNLHAGSQKV 0.827 6 SB VP1 A0216 323GMESQVEEVRV 0.804 8 SB VP1 A0216 27 LIKGGVEVLEV 0.752 14 SB VP1 A0216243 VLLDEQGVGPL 0.724 19 SB VP1 A0216 83 KMLPCYSTARI 0.660 39 SB VP1A0216 61 NLRGYSQHLSA 0.647 45 SB VP1 A0216 187 QVMNTDHKAYL 0.643 47 SBVP1 A0216 164 VLMNYRTKYPQ 0.619 61 WB VP1 A0216 195 AYLDKNNAYPV 0.616 64WB VP1 A0216 11 GAAPKKPKEPV 0.542 142 WB VP1 A0216 294 SVKNPYPISFL 0.530162 WB VP1 A0216 318 GQPMYGMESQV 0.525 170 WB VP1 A0216 25 KLLIKGGVEVL0.517 186 WB VP1 A0216 223 TYTGGENVPPV 0.512 196 WB VP1 A0216 268GLFTNSSGTQQ 0.495 236 WB VP1 A0216 97 NLNEDLTCGNL 0.481 274 WB VP1 A021622 QVPKLLIKGGV 0.478 284 WB VP1 A0216 304 LLSDLINRRTQ 0.474 295 WB VP1A0216 160 EMQGVLMNYRT 0.464 329 WB VP1 A0216 31 GVEVLEVKTGV 0.459 348 WBVP1 A0216 144 VQGSNFHFFAV 0.456 361 WB VP1 A0216 235 HVTNTATTVLL 0.454368 WB VP1 A0216 303 FLLSDLINRRT 0.453 372 WB VP1 A0216 249 GVGPLCKADSL0.450 383 WB VP1 A0216 220 YFGTYTGGENV 0.447 394 WB VP1 A0216 37VKTGVDAITEV 0.439 433 WB VP1 A0216 134 KVHENGGGKPV 0.434 454 WB VP1A0216 233 VLHVTNTATTV 0.703 24 SB VP1 A0219 125 MLNLHAGSQKV 0.697 26 SBVP1 A0219 243 VLLDEQGVGPL 0.673 34 SB VP1 A0219 27 LIKGGVEVLEV 0.581 93WB VP1 A0219 144 VQGSNFHFFAV 0.546 135 WB VP1 A0219 323 GMESQVEEVRV0.511 198 WB VP1 A0219 83 KMLPCYSTARI 0.501 221 WB VP1 A0219 223TYTGGENVPPV 0.457 357 WB VP1 A0219 154 VGGDPLEMQGV 0.443 413 WB VP1A0219 224 YTGGENVPPVL 0.428 485 WB VP1 A0219 124 SMLNLHAGSQK 0.698 26 SBVP1 A0301 289 RLRKRSVKNPY 0.560 117 WB VP1 A0301 281 GLARYFKIRLR 0.520180 WB VP1 A0301 106 NLLMWEAVTVK 0.478 285 WB VP1 A0301 270 FTNSSGTQQWR0.447 395 WB VP1 A0301 124 SMLNLHAGSQK 0.754 14 SB VP1 A1101 184AQSQVMNTDHK 0.640 49 SB VP1 A1101 301 ISFLLSDLINR 0.631 54 WB VP1 A1101277 QQWRGLARYFK 0.573 101 WB VP1 A1101 73 NAFESDSPDRK 0.538 148 WB VP1A1101 275 GTQQWRGLARY 0.477 288 WB VP1 A1101 106 NLLMWEAVTVK 0.462 336WB VP1 A1101 161 MQGVLMNYRTK 0.448 390 WB VP1 A1101 312 RTQKVDGQPMY0.441 421 WB VP1 A1101 282 LARYFKIRLRK 0.432 467 WB VP1 A1101 305LSDLINRRTQK 0.431 473 WB VP1 A1101 259 LYVSAADICGL 0.573 102 WB VP1A2301 298 PYPISFLLSDL 0.474 295 WB VP1 A2301 298 PYPISFLLSDL 0.564 111WB VP1 A2402 167 NYRTKYPQGTI 0.552 128 WB VP1 A2402 278 QWRGLARYFKI0.438 439 WB VP1 A2402 65 YSQHLSAENAF 0.655 41 SB VP1 A2403 298PYPISFLLSDL 0.628 56 WB VP1 A2403 259 LYVSAADICGL 0.536 151 WB VP1 A2403269 LFTNSSGTQQW 0.434 458 WB VP1 A2403 118 EVIGITSMLNL 0.705 24 SB VP1A2601 78 DSPDRKMLPCY 0.602 74 WB VP1 A2601 118 EVIGITSMLNL 0.894 3 SBVP1 A2602 294 SVKNPYPISFL 0.778 11 SB VP1 A2602 78 DSPDRKMLPCY 0.715 21SB VP1 A2602 260 YVSAADICGLF 0.691 28 SB VP1 A2602 339 QLPGDPDMIRY 0.66935 SB VP1 A2602 187 QVMNTDHKAYL 0.618 62 WB VP1 A2602 275 GTQQWRGLARY0.593 81 WB VP1 A2602 312 RTQKVDGQPMY 0.482 273 WB VP1 A2602 289RLRKRSVKNPY 0.805 8 SB VP1 A3001 282 LARYFKIRLRK 0.787 10 SB VP1 A3001 6KGECPGAAPKK 0.656 41 SB VP1 A3001 134 KVHENGGGKPV 0.525 169 WB VP1 A3001132 SQKVHENGGGK 0.508 205 WB VP1 A3001 312 RTQKVDGQPMY 0.498 227 WB VP1A3001 277 QQWRGLARYFK 0.477 286 WB VP1 A3001 161 MQGVLMNYRTK 0.455 362WB VP1 A3001 291 RKRSVKNPYPI 0.432 468 WB VP1 A3001 312 RTQKVDGQPMY0.474 295 WB VP1 A3002 277 QQWRGLARYFK 0.695 27 SB VP1 A3101 301ISFLLSDLINR 0.646 46 SB VP1 A3101 302 SFLLSDLINRR 0.634 52 WB VP1 A3101270 FTNSSGTQQWR 0.615 64 WB VP1 A3101 124 SMLNLHAGSQK 0.602 74 WB VP1A3101 281 GLARYFKIRLR 0.598 77 WB VP1 A3101 282 LARYFKIRLRK 0.457 355 WBVP1 A3101 161 MQGVLMNYRTK 0.453 371 WB VP1 A3101 82 RKMLPCYSTAR 0.428486 WB VP1 A3101 301 ISFLLSDLINR 0.516 187 WB VP1 A3301 302 SFLLSDLINRR0.486 259 WB VP1 A3301 270 FTNSSGTQQWR 0.792 9 SB VP1 A6801 301ISFLLSDLINR 0.717 21 SB VP1 A6801 73 NAFESDSPDRK 0.709 23 SB VP1 A680172 ENAFESDSPDR 0.595 80 WB VP1 A6801 322 YGMESQVEEVR 0.478 284 WB VP1A6801 282 LARYFKIRLRK 0.478 284 WB VP1 A6801 118 EVIGITSMLNL 0.811 7 SBVP1 A6802 187 QVMNTDHKAYL 0.666 36 SB VP1 A6802 22 QVPKLLIKGGV 0.649 44SB VP1 A6802 235 HVTNTATTVLL 0.487 257 WB VP1 A6802 330 EVRVFDGTEQL0.471 306 WB VP1 A6802 103 TCGNLLMWEAV 0.457 354 WB VP1 A6802 118EVIGITSMLNL 0.681 31 SB VP1 A6901 33 EVLEVKTGVDA 0.574 99 WB VP1 A6901187 QVMNTDHKAYL 0.533 155 WB VP1 A6901 99 YPISFLLSDLI 0.456 361 WB VP1A6901 224 YTGGENVPPVL 0.454 366 WB VP1 A6901 235 HVTNTATTVLL 0.449 389WB VP1 A6901 85 LPCYSTARIPL 0.805 8 SB VP1 B0702 142 KPVQGSNFHFF 0.68629 SB VP1 B0702 13 APKKPKEPVQV 0.564 112 WB VP1 B0702 1 APTKRKGECPG0.493 242 WB VP1 B0702 16 KPKEPVQVPKL 0.491 245 WB VP1 B0702 178TPKNPTAQSQV 0.486 259 WB VP1 B0702 299 YPISFLLSDLI 0.435 452 WB VP1B0702 285 YFKIRLRKRSV 0.492 244 WB VP1 B0801 276 TQQWRGLARYF 0.585 89 WBVP1 B1501 289 RLRKRSVKNPY 0.578 96 WB VP1 B1501 186 SQVMNTDHKAY 0.565110 WB VP1 B1501 65 YSQHLSAENAF 0.559 118 WB VP1 B1501 60 YVSAADICGLF0.550 130 WB VP1 B1501 312 RTQKVDGQPMY 0.427 492 WB VP1 B1501 324MESQVEEVRVF 0.678 32 SB VP1 B1801 45 TEVECFLNPEM 0.554 124 WB VP1 B180175 FESDSPDRKML 0.525 171 WB VP1 B1801 110 WEAVTVKTEVI 0.483 267 WB VP1B1801 311 RRTQKVDGQPM 0.521 177 WB VP1 B2705 277 QQWRGLARYFK 0.429 480WB VP1 B2705 142 KPVQGSNFHFF 0.739 16 SB VP1 B3501 203 YPVECWIPDPS 0.71222 SB VP1 B3501 85 LPCYSTARIPL 0.676 33 SB VP1 B3501 211 DPSRNENTRYF0.625 57 WB VP1 B3501 65 YSQHLSAENAF 0.609 68 WB VP1 B3501 151FFAVGGDPLEM 0.579 95 WB VP1 B3501 260 YVSAADICGLF 0.578 96 WB VP1 B3501299 YPISFLLSDLI 0.498 227 WB VP1 B3501 52 NPEMGDPDDNL 0.470 310 WB VP1B3501 193 HKAYLDKNNAY 0.461 342 WB VP1 B3501 149 FHFFAVGGDPL 0.586 88 WBVP1 B3901 234 LHVTNTATTVL 0.579 94 WB VP1 B3901 224 YTGGENVPPVL 0.498227 WB VP1 B3901 75 FESDSPDRKML 0.556 121 WB VP1 B4001 45 TEVECFLNPEM0.446 402 WB VP1 B4001 45 TEVECFLNPEM 0.451 379 WB VP1 B4002 45TEVECFLNPEM 0.477 287 WB VP1 B4403 71 AENAFESDSPD 0.487 257 WB VP1 B4501299 YPISFLLSDLI 0.706 24 SB VP1 B5101 340 LPGDPDMIRYI 0.600 75 WB VP1B5101 30 VPPVLHVTNTA 0.508 206 WB VP1 B5101 85 LPCYSTARIPL 0.492 243 WBVP1 B5101 299 YPISFLLSDLI 0.735 17 SB VP1 B5301 340 LPGDPDMIRYI 0.564112 WB VP1 B5301 142 KPVQGSNFHFF 0.534 154 WB VP1 B5301 85 LPCYSTARIPL0.434 455 WB VP1 B5301 299 YPISFLLSDLI 0.778 11 SB VP1 B5401 230VPPVLHVTNTA 0.720 20 SB VP1 B5401 203 YPVECWIPDPS 0.657 40 SB VP1 B540193 IPLPNLNEDLT 0.542 142 WB VP1 B5401 85 LPCYSTARIPL 0.510 200 WB VP1B5401 340 LPGDPDMIRYI 0.458 350 WB VP1 B5401 293 RSVKNPYPISF 0.691 28 SBVP1 B5801 SEQ ID NOS.: 53780-54917

Preferred BK virus fragments of small T antigen capable of interactingwith one or more MHC class 1 molecules are listed in Table L.

TABLE L Prediction of BK virus small t protein specific MHC class1,8-, 9-, 10-, 11-mer peptide binders for 42 MHC class 1alleles (see FIG. 11) using the http://www.cbs.dtu.dk/services/NetMHC/ database. The MHC class 1 molecules for whichno binders were found are not listed. pos peptide logscore affinity (nM)Bind Level Protein Name Allele 8-mers 124 FLRKEPLV 0.663 38 SB Small tA0201 11 ELMDLLGL 0.599 76 WB Small t A0201 153 TLQWWVQI 0.543 141 WBSmall t A0201 74 GTWNSSEV 0.542 141 WB Small t A0201 154 LQWWVQII 0.520179 WB Small t A0201 110 CMLCQLRL 0.509 202 WB Small t A0201 21 AAWGNLPL0.473 297 WB Small t A0201 60 KMEQDVKV 0.452 375 WB Small t A0201 11ELMDLLGL 0.762 13 SB Small t A0202 124 FLRKEPLV 0.715 21 SB Small tA0202 9 SMELMDLL 0.628 56 WB Small t A0202 50 KMKRMNTL 0.586 88 WBSmall t A0202 60 KMEQDVKV 0.505 211 WB Small t A0202 27 PLMRKAYL 0.488254 WB Small t A0202 110 CMLCQLRL 0.475 292 WB Small t A0202 124FLRKEPLV 0.863 4 SB Small t A0203 50 KMKRMNTL 0.758 13 SB Small t A020311 ELMDLLGL 0.712 22 SB Small t A0203 153 TLQWWVQI 0.690 28 SB Small tA0203 110 CMLCQLRL 0.515 189 WB Small t A0203 105 SVHCPCML 0.430 474 WBSmall t A0203 60 KMEQDVKV 0.429 484 WB Small t A0203 60 KMEQDVKV 0.61564 WB Small t A0204 124 FLRKEPLV 0.573 100 WB Small t A0204 153 TLQWWVQI0.524 172 WB Small t A0204 11 ELMDLLGL 0.521 178 WB Small t A0204 50KMKRMNTL 0.443 412 WB Small t A0204 154 LQWWVQII 0.679 32 SB Small tA0206 74 GTWNSSEV 0.645 46 SB Small t A0206 11 ELMDLLGL 0.594 80 WBSmall t A0206 124 FLRKEPLV 0.581 92 WB Small t A0206 21 AAWGNLPL 0.571104 WB Small t A0206 110 CMLCQLRL 0.496 233 WB Small t A0206 142TQWFGLDL 0.494 239 WB Small t A0206 153 TLQWWVQI 0.468 315 WB Small tA0206 60 KMEQDVKV 0.427 490 WB Small t A0206 11 ELMDLLGL 0.904 2 SBSmall t A0211 124 FLRKEPLV 0.865 4 SB Small t A0211 153 TLQWWVQI 0.861 4SB Small t A0211 60 KMEQDVKV 0.845 5 SB Small t A0211 14 DLLGLERA 0.72519 SB Small t A0211 74 GTWNSSEV 0.720 20 SB Small t A0211 110 CMLCQLRL0.666 37 SB Small t A0211 27 PLMRKAYL 0.666 37 SB Small t A0211 21AAWGNLPL 0.638 50 WB Small t A0211 9 SMELMDLL 0.635 51 WB Small t A021156 TLYKKMEQ 0.625 57 WB Small t A0211 50 KMKRMNTL 0.582 92 WB Small tA0211 146 GLDLTEET 0.563 113 WB Small t A0211 3 VLNREESM 0.494 239 WBSmall t A0211 105 SVHCPCML 0.430 474 WB Small t A0211 148 DLTEETLQ 0.428487 WB Small t A0211 124 FLRKEPLV 0.884 3 SB Small t A0212 11 ELMDLLGL0.842 5 SB Small t A0212 153 TLQWWVQI 0.692 28 SB Small t A0212 60KMEQDVKV 0.666 37 SB Small t A0212 3 VLNREESM 0.639 49 SB Small t A021227 PLMRKAYL 0.597 78 WB Small t A0212 110 CMLCQLRL 0.580 94 WB Small tA0212 50 KMKRMNTL 0.579 94 WB Small t A0212 14 DLLGLERA 0.523 174 WBSmall t A0212 74 GTWNSSEV 0.521 178 WB Small t A0212 56 TLYKKMEQ 0.520180 WB Small t A0212 21 AAWGNLPL 0.511 197 WB Small t A0212 9 SMELMDLL0.426 495 WB Small t A0212 124 FLRKEPLV 0.876 3 SB Small t A0216 27PLMRKAYL 0.829 6 SB Small t A0216 11 ELMDLLGL 0.740 16 SB Small t A021674 GTWNSSEV 0.734 17 SB Small t A0216 60 KMEQDVKV 0.732 18 SB Small tA0216 153 TLQWWVQI 0.684 30 SB Small t A0216 56 TLYKKMEQ 0.662 38 SBSmall t A0216 50 KMKRMNTL 0.651 43 SB Small t A0216 21 AAWGNLPL 0.600 75WB Small t A0216 110 CMLCQLRL 0.577 97 WB Small t A0216 14 DLLGLERA0.566 109 WB Small t A0216 9 SMELMDLL 0.532 158 WB Small t A0216 146GLDLTEET 0.453 370 WB Small t A0216 3 VLNREESM 0.429 482 WB Small tA0216 11 ELMDLLGL 0.807 8 SB Small t A0219 124 FLRKEPLV 0.736 17 SBSmall t A0219 21 AAWGNLPL 0.637 51 WB Small t A0219 153 TLQWWVQI 0.60869 WB Small t A0219 27 PLMRKAYL 0.589 85 WB Small t A0219 110 CMLCQLRL0.548 133 WB Small t A0219 74 GTWNSSEV 0.540 145 WB Small t A0219 116RLRHLNRK 0.728 19 SB Small t A0301 53 RMNTLYKK 0.719 20 SB Small t A0301119 HLNRKFLR 0.676 33 SB Small t A0301 28 LMRKAYLK 0.671 35 SB Small tA0301 31 KAYLKKCK 0.506 210 WB Small t A0301 53 RMNTLYKK 0.727 19 SBSmall t A1101 31 KAYLKKCK 0.639 49 SB Small t A1101 52 KRMNTLYK 0.454367 WB Small t A1101 119 HLNRKFLR 0.443 415 WB Small t A1101 160IIGETPFR 0.438 436 WB Small t A1101 28 LMRKAYLK 0.435 452 WB Small tA1101 131 VWIDCYCI 0.479 280 WB Small t A2301 92 LYCKEWPI 0.458 351 WBSmall t A2301 131 VWIDCYCI 0.675 33 SB Small t A2402 92 LYCKEWPI 0.62260 WB Small t A2402 11 ELMDLLGL 0.486 259 WB Small t A2601 159 QIIGETPF0.823 6 SB Small t A2602 80 EVCADFPL 0.594 80 WB Small t A2602 66KVAHQPDF 0.563 112 WB Small t A2602 11 ELMDLLGL 0.500 224 WB Small tA2602 86 PLCPDTLY 0.515 189 WB Small t A2902 116 RLRHLNRK 0.810 7 SBSmall t A3001 28 LMRKAYLK 0.805 8 SB Small t A3001 53 RMNTLYKK 0.672 34SB Small t A3001 31 KAYLKKCK 0.628 55 WB Small t A3001 52 KRMNTLYK 0.62060 WB Small t A3001 29 MRKAYLKK 0.612 66 WB Small t A3001 120 LNRKFLRK0.571 104 WB Small t A3001 119 HLNRKFLR 0.850 5 SB Small t A3101 53RMNTLYKK 0.816 7 SB Small t A3101 111 MLCQLRLR 0.684 30 SB Small t A310128 LMRKAYLK 0.646 46 SB Small t A3101 116 RLRHLNRK 0.541 142 WB Small tA3101 160 IIGETPFR 0.540 145 WB Small t A3101 31 KAYLKKCK 0.504 214 WBSmall t A3101 119 HLNRKFLR 0.745 15 SB Small t A3301 111 MLCQLRLR 0.521177 WB Small t A3301 160 IIGETPFR 0.469 313 WB Small t A3301 163ETPFRDLK 0.799 8 SB Small t A6801 111 MLCQLRLR 0.725 19 SB Small t A6801119 HLNRKFLR 0.654 42 SB Small t A6801 160 IIGETPFR 0.568 107 WB Small tA6801 80 EVCADFPL 0.773 11 SB Small t A6802 11 ELMDLLGL 0.583 90 WBSmall t A6802 8 ESMELMDL 0.563 113 WB Small t A6802 105 SVHCPCML 0.510200 WB Small t A6802 19 ERAAWGNL 0.434 456 WB Small t A6802 11 ELMDLLGL0.667 36 SB Small t A6901 80 EVCADFPL 0.549 131 WB Small t A6901 74GTWNSSEV 0.545 137 WB Small t A6901 85 FPLCPDTL 0.537 150 WB Small tA6901 21 AAWGNLPL 0.513 193 WB Small t A6901 8 ESMELMDL 0.453 372 WBSmall t A6901 103 KPSVHCPC 0.540 145 WB Small t B0702 21 AAWGNLPL 0.482270 WB Small t B0702 26 LPLMRKAY 0.431 472 WB Small t B0702 50 KMKRMNTL0.479 282 WB Small t B0801 33 YLKKCKEF 0.446 401 WB Small t B0801 159QIIGETPF 0.529 163 WB Small t B1501 33 YLKKCKEF 0.496 232 WB Small tB1501 50 KMKRMNTL 0.474 294 WB Small t B1501 52 KRMNTLYK 0.623 58 WBSmall t B2705 29 MRKAYLKK 0.430 477 WB Small t B2705 26 LPLMRKAY 0.74915 SB Small t B3501 85 FPLCPDTL 0.706 24 SB Small t B3501 21 AAWGNLPL0.509 203 WB Small t B3501 159 QIIGETPF 0.457 355 WB Small t B3501 5NREESMEL 0.555 123 WB Small t B3901 162 GETPFRDL 0.607 69 WB Small tB4001 6 REESMELM 0.511 197 WB Small t B4001 6 REESMELM 0.433 463 WBSmall t B4002 151 EETLQWWV 0.428 488 WB Small t B4002 150 TEETLQWW 0.443414 WB Small t B4402 151 EETLQWWV 0.426 497 WB Small t B4403 151EETLQWWV 0.447 397 WB Small t B4501 — 85 FPLCPDTL 0.509 202 WB Small tB5101 108 CPCMLCQL 0.480 276 WB Small t B5101 26 LPLMRKAY 0.636 51 WBSmall t B5301 85 FPLCPDTL 0.559 117 WB Small t B5301 26 LPLMRKAY 0.482271 WB Small t B5401 149 LTEETLQW 0.602 74 WB Small t B5701 149 LTEETLQW0.555 123 WB Small t B5801 66 KVAHQPDF 0.491 246 WB Small t B5801 16LGLERAAW 0.439 430 WB Small t B5801 9-mers 91 TLYCKEWPI 0.629 55 WBSmall t A0201 153 TLQWWVQII 0.605 71 WB Small t A0201 130 LVWIDCYCI0.509 201 WB Small t A0201 91 TLYCKEWPI 0.697 26 SB Small t A0202 146GLDLTEETL 0.429 483 WB Small t A0202 153 TLQWWVQII 0.838 5 SB Small tA0203 91 TLYCKEWPI 0.728 18 SB Small t A0203 20 RAAWGNLPL 0.491 246 WBSmall t A0203 53 RMNTLYKKM 0.490 249 WB Small t A0203 153 TLQWWVQII0.535 152 WB Small t A0204 91 TLYCKEWPI 0.525 170 WB Small t A0204 59KKMEQDVKV 0.514 191 WB Small t A0204 158 VQIIGETPF 0.700 25 SB Small tA0206 142 TQWFGLDLT 0.667 36 SB Small t A0206 91 TLYCKEWPI 0.660 39 SBSmall t A0206 20 RAAWGNLPL 0.634 52 WB Small t A0206 79 SEVCADFPL 0.515189 WB Small t A0206 10 MELMDLLGL 0.496 233 WB Small t A0206 21AAWGNLPLM 0.457 357 WB Small t A0206 146 GLDLTEETL 0.857 4 SB Small tA0211 91 TLYCKEWPI 0.856 4 SB Small t A0211 153 TLQWWVQII 0.797 8 SBSmall t A0211 20 RAAWGNLPL 0.620 61 WB Small t A0211 14 DLLGLERAA 0.61465 WB Small t A0211 86 PLCPDTLYC 0.564 111 WB Small t A0211 130LVWIDCYCI 0.505 210 WB Small t A0211 73 FGTWNSSEV 0.481 274 WB Small tA0211 21 AAWGNLPLM 0.448 394 WB Small t A0211 152 ETLQWWVQI 0.445 404 WBSmall t A0211 98 PICSKKPSV 0.436 448 WB Small t A0211 129 PLVWIDCYC0.432 465 WB Small t A0211 146 GLDLTEETL 0.773 11 SB Small t A0212 91TLYCKEWPI 0.751 14 SB Small t A0212 153 TLQWWVQII 0.666 37 SB Small tA0212 14 DLLGLERAA 0.548 133 WB Small t A0212 141 FTQWFGLDL 0.521 178 WBSmall t A0212 98 PICSKKPSV 0.430 474 WB Small t A0212 146 GLDLTEETL0.773 11 SB Small t A0216 91 TLYCKEWPI 0.720 20 SB Small t A0216 98PICSKKPSV 0.617 62 WB Small t A0216 153 TLQWWVQII 0.518 184 WB Small tA0216 129 PLVWIDCYC 0.472 302 WB Small t A0216 146 GLDLTEETL 0.704 24 SBSmall t A0219 153 TLQWWVQII 0.531 160 WB Small t A0219 21 AAWGNLPLM0.506 209 WB Small t A0219 91 TLYCKEWPI 0.505 211 WB Small t A0219 119HLNRKFLRK 0.834 6 SB Small t A0301 28 LMRKAYLKK 0.703 24 SB Small tA0301 50 KMKRMNTLY 0.654 42 SB Small t A0301 27 PLMRKAYLK 0.578 96 WBSmall t A0301 114 QLRLRHLNR 0.447 397 WB Small t A0301 119 HLNRKFLRK0.694 27 SB Small t A1101 27 PLMRKAYLK 0.576 98 WB Small t A1101 159QIIGETPFR 0.516 187 WB Small t A1101 32 AYLKKCKEF 0.708 23 SB Small tA2301 32 AYLKKCKEF 0.523 174 WB Small t A2402 32 AYLKKCKEF 0.859 4 SBSmall t A2403 68 AHQPDFGTW 0.542 142 WB Small t A2403 8 ESMELMDLL 0.463335 WB Small t A2601 163 ETPFRDLKL 0.795 9 SB Small t A2602 152ETLQWWVQI 0.499 225 WB Small t A2602 8 ESMELMDLL 0.476 290 WB Small tA2602 50 KMKRMNTLY 0.576 98 WB Small t A2902 85 FPLCPDTLY 0.475 291 WBSmall t A2902 28 LMRKAYLKK 0.830 6 SB Small t A3001 51 MKRMNTLYK 0.827 6SB Small t A3001 36 KCKEFHPDK 0.817 7 SB Small t A3001 114 QLRLRHLNR0.516 187 WB Small t A3001 50 KMKRMNTLY 0.501 220 WB Small t A3001 119HLNRKFLRK 0.445 405 WB Small t A3001 27 PLMRKAYLK 0.439 431 WB Small tA3001 52 KRMNTLYKK 0.435 453 WB Small t A3001 50 KMKRMNTLY 0.561 115 WBSmall t A3002 118 RHLNRKFLR 0.820 7 SB Small t A3101 110 CMLCQLRLR 0.64944 SB Small t A3101 114 QLRLRHLNR 0.628 56 WB Small t A3101 50 KMKRMNTLY0.540 144 WB Small t A3101 119 HLNRKFLRK 0.514 191 WB Small t A3101 28LMRKAYLKK 0.436 447 WB Small t A3101 114 QLRLRHLNR 0.699 25 SB Small tA3301 159 QIIGETPFR 0.822 6 SB Small t A6801 108 CPCMLCQLR 0.553 125 WBSmall t A6801 8 ESMELMDLL 0.767 12 SB Small t A6802 139 DCFTQWFGL 0.65940 SB Small t A6802 73 FGTWNSSEV 0.580 94 WB Small t A6802 152 ETLQWWVQI0.522 175 WB Small t A6802 134 DCYCIDCFT 0.491 247 WB Small t A6802 163ETPFRDLKL 0.490 247 WB Small t A6802 152 ETLQWWVQI 0.832 6 SB Small tA6901 8 ESMELMDLL 0.609 68 WB Small t A6901 91 TLYCKEWPI 0.506 210 WBSmall t A6901 130 LVWIDCYCI 0.492 244 WB Small t A6901 21 AAWGNLPLM0.483 267 WB Small t A6901 20 RAAWGNLPL 0.721 20 SB Small t B0702 26LPLMRKAYL 0.719 20 SB Small t B0702 103 KPSVHCPCM 0.431 472 WB Small tB0702 158 VQIIGETPF 0.615 64 WB Small t B1501 50 KMKRMNTLY 0.561 115 WBSmall t B1501 116 RLRHLNRKF 0.503 216 WB Small t B1501 20 RAAWGNLPL0.444 411 WB Small t B1501 10 MELMDLLGL 0.722 20 SB Small t B1801 150TEETLQWWV 0.497 230 WB Small t B1801 79 SEVCADFPL 0.470 308 WB Small tB1801 52 KRMNTLYKK 0.656 41 SB Small t B2705 85 FPLCPDTLY 0.805 8 SBSmall t B3501 128 EPLVWIDCY 0.750 14 SB Small t B3501 20 RAAWGNLPL 0.61862 WB Small t B3501 21 AAWGNLPLM 0.545 137 WB Small t B3501 103KPSVHCPCM 0.451 377 WB Small t B3501 10 MELMDLLGL 0.751 14 SB Small tB4001 79 SEVCADFPL 0.738 16 SB Small t B4001 7 EESMELMDL 0.561 115 WBSmall t B4001 18 LERAAWGNL 0.497 231 WB Small t B4001 79 SEVCADFPL 0.455365 WB Small t B4002 79 SEVCADFPL 0.591 83 WB Small t B4403 151EETLQWWVQ 0.463 334 WB Small t B4403 85 FPLCPDTLY 0.710 23 SB Small tB5301 128 EPLVWIDCY 0.651 43 SB Small t B5301 26 LPLMRKAYL 0.625 57 WBSmall t B5301 97 WPICSKKPS 0.548 132 WB Small t B5401 149 LTEETLQWW0.564 112 WB Small t B5701 124 FLRKEPLVW 0.534 154 WB Small t B5801 20RAAWGNLPL 0.460 344 WB Small t B5801 10-mers 124 FLRKEPLVWI 0.574 100 WBSmall t A0201 56 TLYKKMEQDV 0.485 263 WB Small t A0201 12 LMDLLGLERA0.456 361 WB Small t A0201 3 VLNREESMEL 0.434 454 WB Small t A0201 111MLCQLRLRHL 0.647 45 SB Small t A0202 124 FLRKEPLVWI 0.608 69 WB Small tA0202 12 LMDLLGLERA 0.607 70 WB Small t A0202 3 VLNREESMEL 0.562 114 WBSmall t A0202 56 TLYKKMEQDV 0.516 187 WB Small t A0202 145 FGLDLTEETL0.516 188 WB Small t A0202 9 SMELMDLLGL 0.507 206 WB Small t A0202 25NLPLMRKAYL 0.483 269 WB Small t A0202 124 FLRKEPLVWI 0.870 4 SB Small tA0203 56 TLYKKMEQDV 0.707 23 SB Small t A0203 3 VLNREESMEL 0.666 37 SBSmall t A0203 111 MLCQLRLRHL 0.549 131 WB Small t A0203 12 LMDLLGLERA0.468 314 WB Small t A0203 9 SMELMDLLGL 0.462 338 WB Small t A0203 116RLRHLNRKFL 0.429 484 WB Small t A0203 149 LTEETLQWWV 0.571 104 WBSmall t A0204 3 VLNREESMEL 0.557 120 WB Small t A0204 124 FLRKEPLVWI0.500 223 WB Small t A0204 149 LTEETLQWWV 0.581 93 WB Small t A0206 154LQWWVQIIGE 0.521 177 WB Small t A0206 20 RAAWGNLPLM 0.518 184 WB Small tA0206 142 TQWFGLDLTE 0.463 334 WB Small t A0206 124 FLRKEPLVWI 0.430 474WB Small t A0206 56 TLYKKMEQDV 0.875 3 SB Small t A0211 3 VLNREESMEL0.824 6 SB Small t A0211 149 LTEETLQWWV 0.779 10 SB Small t A0211 12LMDLLGLERA 0.757 13 SB Small t A0211 124 FLRKEPLVWI 0.715 21 SB Small tA0211 9 SMELMDLLGL 0.706 24 SB Small t A0211 111 MLCQLRLRHL 0.689 28 SBSmall t A0211 25 NLPLMRKAYL 0.682 31 SB Small t A0211 129 PLVWIDCYCI0.681 31 SB Small t A0211 116 RLRHLNRKFL 0.554 124 WB Small t A0211 146GLDLTEETLQ 0.516 188 WB Small t A0211 17 GLERAAWGNL 0.502 219 WB Small tA0211 145 FGLDLTEETL 0.451 381 WB Small t A0211 56 TLYKKMEQDV 0.893 3 SBSmall t A0212 3 VLNREESMEL 0.788 9 SB Small t A0212 124 FLRKEPLVWI 0.75613 SB Small t A0212 149 LTEETLQWWV 0.727 19 SB Small t A0212 12LMDLLGLERA 0.604 72 WB Small t A0212 111 MLCQLRLRHL 0.584 90 WB Small tA0212 9 SMELMDLLGL 0.579 95 WB Small t A0212 145 FGLDLTEETL 0.484 264 WBSmall t A0212 25 NLPLMRKAYL 0.477 287 WB Small t A0212 116 RLRHLNRKFL0.449 386 WB Small t A0212 17 GLERAAWGNL 0.430 474 WB Small t A0212 56TLYKKMEQDV 0.842 5 SB Small t A0216 3 VLNREESMEL 0.768 12 SB Small tA0216 25 NLPLMRKAYL 0.703 24 SB Small t A0216 124 FLRKEPLVWI 0.687 29 SBSmall t A0216 149 LTEETLQWWV 0.632 53 WB Small t A0216 111 MLCQLRLRHL0.627 56 WB Small t A0216 116 RLRHLNRKFL 0.566 110 WB Small t A0216 17GLERAAWGNL 0.545 137 WB Small t A0216 129 PLVWIDCYCI 0.522 175 WBSmall t A0216 12 LMDLLGLERA 0.484 265 WB Small t A0216 9 SMELMDLLGL0.468 316 WB Small t A0216 149 LTEETLQWWV 0.627 56 WB Small t A0219 3VLNREESMEL 0.573 101 WB Small t A0219 56 TLYKKMEQDV 0.570 104 WB Small tA0219 124 FLRKEPLVWI 0.551 128 WB Small t A0219 12 LMDLLGLERA 0.486 260WB Small t A0219 50 KMKRMNTLYK 0.754 14 SB Small t A0301 118 RHLNRKFLRK0.678 32 SB Small t A0301 27 PLMRKAYLKK 0.663 38 SB Small t A0301 114QLRLRHLNRK 0.562 114 WB Small t A0301 22 AWGNLPLMRK 0.533 156 WB Small tA0301 26 LPLMRKAYLK 0.500 222 WB Small t A0301 50 KMKRMNTLYK 0.700 25 SBSmall t A1101 27 PLMRKAYLKK 0.478 284 WB Small t A1101 21 AAWGNLPLMR0.475 293 WB Small t A1101 22 AWGNLPLMRK 0.449 387 WB Small t A1101 86PLCPDTLYCK 0.444 410 WB Small t A1101 135 CYCIDCFTQW 0.623 58 WB Small tA2301 57 LYKKMEQDVK 0.531 160 WB Small t A2301 136 YCIDCFTQWF 0.433 463WB Small t A2301 135 CYCIDCFTQW 0.616 63 WB Small t A2403 123 KFLRKEPLVW0.549 132 WB Small t A2403 64 DVKVAHQPDF 0.665 37 SB Small t A2602 152ETLQWWVQII 0.483 269 WB Small t A2602 84 DFPLCPDTLY 0.458 353 WB Small tA2902 50 KMKRMNTLYK 0.848 5 SB Small t A3001 114 QLRLRHLNRK 0.729 18 SBSmall t A3001 51 MKRMNTLYKK 0.685 30 SB Small t A3001 27 PLMRKAYLKK0.500 224 WB Small t A3001 116 RLRHLNRKFL 0.497 231 WB Small t A3001 29MRKAYLKKCK 0.488 255 WB Small t A3001 117 LRHLNRKFLR 0.676 33 SB Small tA3101 113 CQLRLRHLNR 0.674 34 SB Small t A3101 50 KMKRMNTLYK 0.640 49 SBSmall t A3101 51 MKRMNTLYKK 0.468 316 WB Small t A3101 118 RHLNRKFLRK0.446 400 WB Small t A3101 11 ELMDLLGLER 0.512 196 WB Small t A3301 117LRHLNRKFLR 0.430 476 WB Small t A3301 11 ELMDLLGLER 0.720 20 SB Small tA6801 90 DTLYCKEWPI 0.574 99 WB Small t A6802 152 ETLQWWVQII 0.456 358WB Small t A6802 19 ERAAWGNLPL 0.452 375 WB Small t A6802 152 ETLQWWVQII0.795 9 SB Small t A6901 90 DTLYCKEWPI 0.586 88 WB Small t A6901 149LTEETLQWWV 0.575 98 WB Small t A6901 97 WPICSKKPSV 0.518 184 WB Small tA6901 103 KPSVHCPCML 0.703 24 SB Small t B0702 97 WPICSKKPSV 0.563 113WB Small t B0702 116 RLRHLNRKFL 0.471 304 WB Small t B0702 157WVQIIGETPF 0.540 145 WB Small t B1501 52 KRMNTLYKKM 0.591 83 WB Small tB2705 157 WVQIIGETPF 0.638 50 WB Small t B3501 20 RAAWGNLPLM 0.595 80 WBSmall t B3501 136 YCIDCFTQWF 0.429 483 WB Small t B3501 19 ERAAWGNLPL0.539 147 WB Small t B3901 6 REESMELMDL 0.707 23 SB Small t B4001 162GETPFRDLKL 0.618 62 WB Small t B4001 7 EESMELMDLL 0.488 253 WB Small tB4001 7 EESMELMDLL 0.482 271 WB Small t B4002 127 KEPLVWIDCY 0.429 481WB Small t B4402 151 EETLQWWVQI 0.495 235 WB Small t B4403 127KEPLVWIDCY 0.434 456 WB Small t B4403 97 WPICSKKPSV 0.434 454 WB Small tB5101 97 WPICSKKPSV 0.735 17 SB Small t B5401 26 LPLMRKAYLK 0.511 197 WBSmall t B5401 67 VAHQPDFGTW 0.448 393 WB Small t B5701 123 KFLRKEPLVW0.620 60 WB Small t B5801 67 VAHQPDFGTW 0.537 149 WB Small t B5801 20RAAWGNLPLM 0.485 263 WB Small t B5801 31 KAYLKKCKEF 0.431 473 WB Small tB5801 11-mers 11 ELMDLLGLERA 0.458 351 WB Small t A0201 2 KVLNREESMEL0.432 467 WB Small t A0201 11 ELMDLLGLERA 0.582 92 WB Small t A0202 137CIDCFTQWFGL 0.516 187 WB Small t A0202 3 VLNREESMELM 0.491 245 WBSmall t A0202 148 DLTEETLQWWV 0.445 404 WB Small t A0202 11 ELMDLLGLERA0.652 42 SB Small t A0203 110 CMLCQLRLRHL 0.520 180 WB Small t A0203 3VLNREESMELM 0.473 298 WB Small t A0203 105 SVHCPCMLCQL 0.449 389 WBSmall t A0203 2 KVLNREESMEL 0.525 170 WB Small t A0204 148 DLTEETLQWWV0.453 372 WB Small t A0204 105 SVHCPCMLCQL 0.450 384 WB Small t A0204 2KVLNREESMEL 0.620 61 WB Small t A0206 154 LQWWVQIIGET 0.600 75 WBSmall t A0206 137 CIDCFTQWFGL 0.565 110 WB Small t A0206 142 TQWFGLDLTEE0.519 182 WB Small t A0206 132 WIDCYCIDCFT 0.435 452 WB Small t A0206148 DLTEETLQWWV 0.957 1 SB Small t A0211 11 ELMDLLGLERA 0.815 7 SBSmall t A0211 137 CIDCFTQWFGL 0.698 26 SB Small t A0211 12 LMDLLGLERAA0.669 35 SB Small t A0211 2 KVLNREESMEL 0.597 77 WB Small t A0211 105SVHCPCMLCQL 0.539 146 WB Small t A0211 3 VLNREESMELM 0.535 153 WBSmall t A0211 148 DLTEETLQWWV 0.806 8 SB Small t A0212 11 ELMDLLGLERA0.654 42 SB Small t A0212 12 LMDLLGLERAA 0.577 96 WB Small t A0212 137CIDCFTQWFGL 0.551 128 WB Small t A0212 3 VLNREESMELM 0.514 192 WBSmall t A0212 2 KVLNREESMEL 0.481 273 WB Small t A0212 148 DLTEETLQWWV0.886 3 SB Small t A0216 11 ELMDLLGLERA 0.650 43 SB Small t A0216 2KVLNREESMEL 0.514 191 WB Small t A0216 105 SVHCPCMLCQL 0.496 233 WBSmall t A0216 137 CIDCFTQWFGL 0.440 427 WB Small t A0216 148 DLTEETLQWWV0.849 5 SB Small t A0219 11 ELMDLLGLERA 0.602 73 WB Small t A0219 137CIDCFTQWFGL 0.566 109 WB Small t A0219 50 KMKRMNTLYKK 0.667 36 SBSmall t A0301 116 RLRHLNRKFLR 0.645 46 SB Small t A0301 56 TLYKKMEQDVK0.645 46 SB Small t A0301 21 AAWGNLPLMRK 0.508 205 WB Small t A0301 28LMRKAYLKKCK 0.454 369 WB Small t A0301 160 IIGETPFRDLK 0.432 464 WBSmall t A0301 21 AAWGNLPLMRK 0.742 16 SB Small t A1101 56 TLYKKMEQDVK0.640 49 SB Small t A1101 50 KMKRMNTLYKK 0.634 52 WB Small t A1101 160IIGETPFRDLK 0.632 53 WB Small t A1101 113 CQLRLRHLNRK 0.537 149 WBSmall t A1101 20 RAAWGNLPLMR 0.531 160 WB Small t A1101 135 CYCIDCFTQWF0.785 10 SB Small t A2301 131 VWIDCYCIDCF 0.697 26 SB Small t A2301 92LYCKEWPICSK 0.544 139 WB Small t A2301 156 WWVQIIGETPF 0.530 161 WBSmall t A2301 75 TWNSSEVCADF 0.493 240 WB Small t A2301 131 VWIDCYCIDCF0.708 23 SB Small t A2402 135 CYCIDCFTQWF 0.672 34 SB Small t A2402 156WWVQIIGETPF 0.515 190 WB Small t A2402 123 KFLRKEPLVWI 0.489 251 WBSmall t A2402 75 TWNSSEVCADF 0.462 339 WB Small t A2402 135 CYCIDCFTQWF0.775 11 SB Small t A2403 123 KFLRKEPLVWI 0.525 170 WB Small t A2403 75TWNSSEVCADF 0.428 485 WB Small t A2403 8 ESMELMDLLGL 0.474 297 WBSmall t A2601 159 QIIGETPFRDL 0.618 62 WB Small t A2602 8 ESMELMDLLGL0.433 462 WB Small t A2602 50 KMKRMNTLYKK 0.760 13 SB Small t A3001 28LMRKAYLKKCK 0.745 15 SB Small t A3001 116 RLRHLNRKFLR 0.667 36 SBSmall t A3001 117 LRHLNRKFLRK 0.531 160 WB Small t A3001 34 LKKCKEFHPDK0.429 482 WB Small t A3001 116 RLRHLNRKFLR 0.853 4 SB Small t A3101 50KMKRMNTLYKK 0.838 5 SB Small t A3101 20 RAAWGNLPLMR 0.617 63 WB Small tA3101 157 WVQIIGETPFR 0.496 232 WB Small t A3101 112 LCQLRLRHLNR 0.451380 WB Small t A3101 31 KAYLKKCKEFH 0.448 392 WB Small t A3101 113CQLRLRHLNRK 0.434 458 WB Small t A3101 28 LMRKAYLKKCK 0.433 461 WBSmall t A3101 116 RLRHLNRKFLR 0.594 80 WB Small t A3301 157 WVQIIGETPFR0.716 21 SB Small t A6801 20 RAAWGNLPLMR 0.562 114 WB Small t A6801 56TLYKKMEQDVK 0.549 131 WB Small t A6801 25 NLPLMRKAYLK 0.482 272 WBSmall t A6801 108 CPCMLCQLRLR 0.467 319 WB Small t A6801 8 ESMELMDLLGL0.653 42 SB Small t A6802 77 NSSEVCADFPL 0.649 44 SB Small t A6802 11ELMDLLGLERA 0.570 105 WB Small t A6802 105 SVHCPCMLCQL 0.506 209 WBSmall t A6802 137 CIDCFTQWFGL 0.468 315 WB Small t A6802 128 EPLVWIDCYCI0.606 71 WB Small t A6901 8 ESMELMDLLGL 0.560 116 WB Small t A6901 11ELMDLLGLERA 0.539 145 WB Small t A6901 148 DLTEETLQWWV 0.482 273 WBSmall t A6901 55 NTLYKKMEQDV 0.432 464 WB Small t A6901 114 QLRLRHLNRKF0.463 333 WB Small t B0801 114 QLRLRHLNRKF 0.473 298 WB Small t B1501 18LERAAWGNLPL 0.572 102 WB Small t B1801 41 HPDKGGDEDKM 0.545 136 WBSmall t B3501 97 WPICSKKPSVH 0.529 164 WB Small t B3501 156 WWVQIIGETPF0.482 270 WB Small t B3501 6 REESMELMDLL 0.673 34 SB Small t B4001 18LERAAWGNLPL 0.630 54 WB Small t B4001 47 DEDKMKRMNTL 0.434 458 WBSmall t B4001 6 REESMELMDLL 0.511 198 WB Small t B4002 151 EETLQWWVQII0.500 224 WB Small t B4002 128 EPLVWIDCYCI 0.605 72 WB Small t B5101 128EPLVWIDCYCI 0.529 163 WB Small t B5301 85 FPLCPDTLYCK 0.471 304 WBSmall t B5401 66 KVAHQPDFGTW 0.658 40 SB Small t B5801 122 RKFLRKEPLVW0.499 225 WB Small t B5801 SEQ ID NOS.: 54918-55453

Preferred BK virus fragments of large T antigen capable of interactingwith one or more MHC class 1 molecules are listed in Table M.

TABLE M Prediction of BK virus Large T protein specific MHC class1,8-, 9-, 10-, 11-mer peptide binders for 42 MHC class 1 alleles(see FIG. 11) using the http://www.cbs.dtu.dk/services/NetMHC/ database. The MHC class 1 molecules for whichno binders were found are not listed. pos peptide logscore affinity (nM)Bind Level Protein Name Allele 8-mers 77 NSSEVPTY 0.514 193 WB Large TA0101 611 YTFSRMKY 0.480 276 WB Large T A0101 175 KLMEKYSV 0.847 5 SBLarge T A0201 388 YMAGVAWL 0.833 6 SB Large T A0201 287 FLLLGMYL 0.807 8SB Large T A0201 501 YLDGSVKV 0.800 8 SB Large T A0201 272 KLITEYAV0.733 18 SB Large T A0201 469 YMVVFEDV 0.711 22 SB Large T A0201 579LLIWFRPV 0.705 24 SB Large T A0201 372 KMDLIFGA 0.695 27 SB Large TA0201 155 RTLACFAV 0.663 38 SB Large T A0201 293 YLEFQYNV 0.656 41 SBLarge T A0201 527 VTMNEYPV 0.629 55 WB Large T A0201 563 FLLEKRIL 0.62061 WB Large T A0201 322 FANAIIFA 0.612 66 WB Large T A0201 231 YLLYSALT0.611 67 WB Large T A0201 557 SLQNSEFL 0.608 69 WB Large T A0201 11ELMDLLGL 0.599 76 WB Large T A0201 215 KLCTFSFL 0.590 84 WB Large TA0201 457 RLTFELGV 0.587 86 WB Large T A0201 398 LLPKMDSV 0.582 91 WBLarge T A0201 465 AIDQYMVV 0.565 111 WB Large T A0201 369 ILDKMDLI 0.551128 WB Large T A0201 74 GTWNSSEV 0.542 141 WB Large T A0201 603 RLDSEISM0.535 153 WB Large T A0201 569 ILQSGMTL 0.529 164 WB Large T A0201 573GMTLLLLL 0.519 181 WB Large T A0201 146 FLSQAVFS 0.495 234 WB Large TA0201 21 AAWGNLPL 0.473 297 WB Large T A0201 448 ALNVNLPM 0.468 316 WBLarge T A0201 609 SMYTFSRM 0.459 347 WB Large T A0201 574 MTLLLLLI 0.458350 WB Large T A0201 60 KMEQDVKV 0.452 375 WB Large T A0201 388 YMAGVAWL0.861 4 SB Large T A0202 175 KLMEKYSV 0.858 4 SB Large T A0202 293YLEFQYNV 0.811 7 SB Large T A0202 287 FLLLGMYL 0.800 8 SB Large T A0202272 KLITEYAV 0.772 11 SB Large T A0202 11 ELMDLLGL 0.762 13 SB Large TA0202 146 FLSQAVFS 0.740 16 SB Large T A0202 322 FANAIIFA 0.740 16 SBLarge T A0202 215 KLCTFSFL 0.732 18 SB Large T A0202 398 LLPKMDSV 0.72120 SB Large T A0202 501 YLDGSVKV 0.716 21 SB Large T A0202 557 SLQNSEFL0.712 22 SB Large T A0202 570 LQSGMTLL 0.696 26 SB Large T A0202 372KMDLIFGA 0.672 34 SB Large T A0202 457 RLTFELGV 0.666 37 SB Large TA0202 573 GMTLLLLL 0.655 41 SB Large T A0202 579 LLIWFRPV 0.643 47 SBLarge T A0202 9 SMELMDLL 0.628 56 WB Large T A0202 469 YMVVFEDV 0.606 70WB Large T A0202 558 LQNSEFLL 0.596 78 WB Large T A0202 563 FLLEKRIL0.593 81 WB Large T A0202 50 KMKRMNTL 0.586 88 WB Large T A0202 369ILDKMDLI 0.585 89 WB Large T A0202 391 GVAWLHCL 0.577 96 WB Large TA0202 491 GINNLDSL 0.576 98 WB Large T A0202 184 FISRHMCA 0.571 103 WBLarge T A0202 514 HLNKRTQI 0.561 115 WB Large T A0202 377 FGAHGNAV 0.549131 WB Large T A0202 569 ILQSGMTL 0.546 135 WB Large T A0202 527VTMNEYPV 0.533 156 WB Large T A0202 226 GVNKEYLL 0.525 171 WB Large TA0202 448 ALNVNLPM 0.512 196 WB Large T A0202 355 HMTREEML 0.510 200 WBLarge T A0202 60 KMEQDVKV 0.505 211 WB Large T A0202 27 PLMRKAYL 0.488254 WB Large T A0202 603 RLDSEISM 0.481 276 WB Large T A0202 144HQFLSQAV 0.472 301 WB Large T A0202 465 AIDQYMVV 0.458 353 WB Large TA0202 155 RTLACFAV 0.443 412 WB Large T A0202 609 SMYTFSRM 0.442 419 WBLarge T A0202 464 VAIDQYMV 0.429 483 WB Large T A0202 388 YMAGVAWL 0.8933 SB Large T A0203 579 LLIWFRPV 0.884 3 SB Large T A0203 175 KLMEKYSV0.870 4 SB Large T A0203 501 YLDGSVKV 0.811 7 SB Large T A0203 457RLTFELGV 0.781 10 SB Large T A0203 287 FLLLGMYL 0.780 10 SB Large TA0203 272 KLITEYAV 0.779 10 SB Large T A0203 398 LLPKMDSV 0.777 11 SBLarge T A0203 293 YLEFQYNV 0.769 12 SB Large T A0203 50 KMKRMNTL 0.75813 SB Large T A0203 469 YMVVFEDV 0.736 17 SB Large T A0203 11 ELMDLLGL0.712 22 SB Large T A0203 569 ILQSGMTL 0.711 22 SB Large T A0203 322FANAIIFA 0.697 26 SB Large T A0203 184 FISRHMCA 0.689 28 SB Large TA0203 514 HLNKRTQI 0.680 31 SB Large T A0203 609 SMYTFSRM 0.642 48 SBLarge T A0203 563 FLLEKRIL 0.628 55 WB Large T A0203 372 KMDLIFGA 0.62259 WB Large T A0203 570 LQSGMTLL 0.608 69 WB Large T A0203 215 KLCTFSFL0.607 70 WB Large T A0203 391 GVAWLHCL 0.570 104 WB Large T A0203 448ALNVNLPM 0.556 122 WB Large T A0203 188 HMCAGHNI 0.551 128 WB Large TA0203 527 VTMNEYPV 0.548 132 WB Large T A0203 573 GMTLLLLL 0.535 153 WBLarge T A0203 520 QIFPPGLV 0.531 159 WB Large T A0203 146 FLSQAVFS 0.528165 WB Large T A0203 144 HQFLSQAV 0.527 166 WB Large T A0203 491GINNLDSL 0.526 168 WB Large T A0203 557 SLQNSEFL 0.517 186 WB Large TA0203 465 AIDQYMVV 0.513 193 WB Large T A0203 155 RTLACFAV 0.509 202 WBLarge T A0203 464 VAIDQYMV 0.497 232 WB Large T A0203 551 KIYLRKSL 0.489252 WB Large T A0203 369 ILDKMDLI 0.466 321 WB Large T A0203 654SQVSDTSA 0.462 338 WB Large T A0203 231 YLLYSALT 0.453 372 WB Large TA0203 199 LTPHRHRV 0.447 394 WB Large T A0203 60 KMEQDVKV 0.429 484 WBLarge T A0203 615 RMKYNICM 0.427 490 WB Large T A0203 175 KLMEKYSV 0.76213 SB Large T A0204 388 YMAGVAWL 0.708 23 SB Large T A0204 272 KLITEYAV0.652 43 SB Large T A0204 527 VTMNEYPV 0.635 52 WB Large T A0204 579LLIWFRPV 0.627 56 WB Large T A0204 60 KMEQDVKV 0.615 64 WB Large T A0204287 FLLLGMYL 0.601 75 WB Large T A0204 569 ILQSGMTL 0.572 102 WB Large TA0204 501 YLDGSVKV 0.571 104 WB Large T A0204 557 SLQNSEFL 0.565 110 WBLarge T A0204 563 FLLEKRIL 0.554 124 WB Large T A0204 293 YLEFQYNV 0.537149 WB Large T A0204 215 KLCTFSFL 0.534 154 WB Large T A0204 11 ELMDLLGL0.521 178 WB Large T A0204 469 YMVVFEDV 0.512 195 WB Large T A0204 464VAIDQYMV 0.512 196 WB Large T A0204 536 KTLQARFV 0.494 239 WB Large TA0204 155 RTLACFAV 0.475 293 WB Large T A0204 398 LLPKMDSV 0.460 345 WBLarge T A0204 465 AIDQYMVV 0.459 349 WB Large T A0204 457 RLTFELGV 0.448393 WB Large T A0204 50 KMKRMNTL 0.443 412 WB Large T A0204 175 KLMEKYSV0.879 3 SB Large T A0206 155 RTLACFAV 0.822 6 SB Large T A0206 272KLITEYAV 0.820 6 SB Large T A0206 579 LLIWFRPV 0.813 7 SB Large T A0206287 FLLLGMYL 0.784 10 SB Large T A0206 654 SQVSDTSA 0.782 10 SB Large TA0206 501 YLDGSVKV 0.771 11 SB Large T A0206 388 YMAGVAWL 0.737 17 SBLarge T A0206 469 YMVVFEDV 0.730 18 SB Large T A0206 267 KQVSWKLI 0.72020 SB Large T A0206 144 HQFLSQAV 0.705 24 SB Large T A0206 372 KMDLIFGA0.695 27 SB Large T A0206 570 LQSGMTLL 0.694 27 SB Large T A0206 296FQYNVEEC 0.688 29 SB Large T A0206 457 RLTFELGV 0.678 32 SB Large TA0206 398 LLPKMDSV 0.673 34 SB Large T A0206 558 LQNSEFLL 0.665 37 SBLarge T A0206 338 CQQAVDTV 0.654 42 SB Large T A0206 322 FANAIIFA 0.64845 SB Large T A0206 465 AIDQYMVV 0.646 45 SB Large T A0206 74 GTWNSSEV0.645 46 SB Large T A0206 527 VTMNEYPV 0.615 64 WB Large T A0206 293YLEFQYNV 0.613 65 WB Large T A0206 11 ELMDLLGL 0.594 80 WB Large T A0206536 KTLQARFV 0.593 81 WB Large T A0206 464 VAIDQYMV 0.572 102 WB Large TA0206 21 AAWGNLPL 0.571 104 WB Large T A0206 383 AVLEQYMA 0.539 146 WBLarge T A0206 563 FLLEKRIL 0.534 155 WB Large T A0206 574 MTLLLLLI 0.517185 WB Large T A0206 215 KLCTFSFL 0.512 195 WB Large T A0206 184FISRHMCA 0.511 197 WB Large T A0206 519 TQIFPPGL 0.505 210 WB Large TA0206 377 FGAHGNAV 0.470 308 WB Large T A0206 335 KSICQQAV 0.469 311 WBLarge T A0206 369 ILDKMDLI 0.464 328 WB Large T A0206 520 QIFPPGLV 0.458352 WB Large T A0206 391 GVAWLHCL 0.457 355 WB Large T A0206 231YLLYSALT 0.451 380 WB Large T A0206 569 ILQSGMTL 0.445 406 WB Large TA0206 339 QQAVDTVL 0.443 414 WB Large T A0206 146 FLSQAVFS 0.438 436 WBLarge T A0206 169 AQILYKKL 0.435 453 WB Large T A0206 60 KMEQDVKV 0.427490 WB Large T A0206 501 YLDGSVKV 0.977 1 SB Large T A0211 388 YMAGVAWL0.963 1 SB Large T A0211 175 KLMEKYSV 0.945 1 SB Large T A0211 287FLLLGMYL 0.937 1 SB Large T A0211 579 LLIWFRPV 0.922 2 SB Large T A0211465 AIDQYMVV 0.919 2 SB Large T A0211 272 KLITEYAV 0.906 2 SB Large TA0211 11 ELMDLLGL 0.904 2 SB Large T A0211 398 LLPKMDSV 0.900 2 SBLarge T A0211 457 RLTFELGV 0.899 2 SB Large T A0211 293 YLEFQYNV 0.897 3SB Large T A0211 557 SLQNSEFL 0.882 3 SB Large T A0211 569 ILQSGMTL0.870 4 SB Large T A0211 469 YMVVFEDV 0.866 4 SB Large T A0211 563FLLEKRIL 0.862 4 SB Large T A0211 603 RLDSEISM 0.848 5 SB Large T A021160 KMEQDVKV 0.845 5 SB Large T A0211 369 ILDKMDLI 0.828 6 SB Large TA0211 573 GMTLLLLL 0.824 6 SB Large T A0211 215 KLCTFSFL 0.821 6 SBLarge T A0211 520 QIFPPGLV 0.811 7 SB Large T A0211 609 SMYTFSRM 0.78010 SB Large T A0211 372 KMDLIFGA 0.777 11 SB Large T A0211 464 VAIDQYMV0.743 16 SB Large T A0211 14 DLLGLERA 0.725 19 SB Large T A0211 74GTWNSSEV 0.720 20 SB Large T A0211 391 GVAWLHCL 0.719 20 SB Large TA0211 485 DLPSGHGI 0.719 21 SB Large T A0211 155 RTLACFAV 0.693 27 SBLarge T A0211 442 DLCGGKAL 0.686 29 SB Large T A0211 231 YLLYSALT 0.68231 SB Large T A0211 536 KTLQARFV 0.668 36 SB Large T A0211 355 HMTREEML0.667 36 SB Large T A0211 27 PLMRKAYL 0.666 37 SB Large T A0211 406IFDFLHCV 0.646 46 SB Large T A0211 514 HLNKRTQI 0.642 48 SB Large TA0211 21 AAWGNLPL 0.638 50 WB Large T A0211 9 SMELMDLL 0.635 51 WBLarge T A0211 56 TLYKKMEQ 0.625 57 WB Large T A0211 188 HMCAGHNI 0.61862 WB Large T A0211 576 LLLLLIWF 0.614 64 WB Large T A0211 146 FLSQAVFS0.597 78 WB Large T A0211 383 AVLEQYMA 0.594 81 WB Large T A0211 405VIFDFLHC 0.587 87 WB Large T A0211 344 TVLAKKRV 0.583 91 WB Large TA0211 50 KMKRMNTL 0.582 92 WB Large T A0211 288 LLLGMYLE 0.577 96 WBLarge T A0211 448 ALNVNLPM 0.573 100 WB Large T A0211 368 HILDKMDL 0.570104 WB Large T A0211 527 VTMNEYPV 0.561 115 WB Large T A0211 150AVFSNRTL 0.555 122 WB Large T A0211 184 FISRHMCA 0.545 137 WB Large TA0211 199 LTPHRHRV 0.543 140 WB Large T A0211 551 KIYLRKSL 0.523 173 WBLarge T A0211 3 VLNREESM 0.494 239 WB Large T A0211 491 GINNLDSL 0.485262 WB Large T A0211 291 GMYLEFQY 0.468 315 WB Large T A0211 350RVDTLHMT 0.466 322 WB Large T A0211 142 DLHQFLSQ 0.459 348 WB Large TA0211 401 KMDSVIFD 0.458 350 WB Large T A0211 673 HLCKGFQC 0.458 350 WBLarge T A0211 289 LLGMYLEF 0.450 383 WB Large T A0211 577 LLLLIWFR 0.450384 WB Large T A0211 439 GLLDLCGG 0.448 390 WB Large T A0211 501YLDGSVKV 0.940 1 SB Large T A0212 388 YMAGVAWL 0.924 2 SB Large T A0212175 KLMEKYSV 0.912 2 SB Large T A0212 287 FLLLGMYL 0.903 2 SB Large TA0212 398 LLPKMDSV 0.879 3 SB Large T A0212 469 YMVVFEDV 0.878 3 SBLarge T A0212 293 YLEFQYNV 0.872 4 SB Large T A0212 579 LLIWFRPV 0.853 4SB Large T A0212 563 FLLEKRIL 0.852 4 SB Large T A0212 272 KLITEYAV0.852 4 SB Large T A0212 465 AIDQYMVV 0.843 5 SB Large T A0212 11ELMDLLGL 0.842 5 SB Large T A0212 569 ILQSGMTL 0.821 6 SB Large T A0212457 RLTFELGV 0.787 10 SB Large T A0212 557 SLQNSEFL 0.757 13 SB Large TA0212 609 SMYTFSRM 0.711 22 SB Large T A0212 464 VAIDQYMV 0.698 26 SBLarge T A0212 60 KMEQDVKV 0.666 37 SB Large T A0212 355 HMTREEML 0.66338 SB Large T A0212 603 RLDSEISM 0.662 38 SB Large T A0212 368 HILDKMDL0.659 39 SB Large T A0212 3 VLNREESM 0.639 49 SB Large T A0212 184FISRHMCA 0.635 52 WB Large T A0212 405 VIFDFLHC 0.629 55 WB Large TA0212 215 KLCTFSFL 0.615 64 WB Large T A0212 369 ILDKMDLI 0.609 68 WBLarge T A0212 27 PLMRKAYL 0.597 78 WB Large T A0212 372 KMDLIFGA 0.58886 WB Large T A0212 50 KMKRMNTL 0.579 94 WB Large T A0212 520 QIFPPGLV0.577 96 WB Large T A0212 573 GMTLLLLL 0.577 96 WB Large T A0212 527VTMNEYPV 0.571 104 WB Large T A0212 188 HMCAGHNI 0.546 135 WB Large TA0212 14 DLLGLERA 0.523 174 WB Large T A0212 442 DLCGGKAL 0.521 178 WBLarge T A0212 74 GTWNSSEV 0.521 178 WB Large T A0212 56 TLYKKMEQ 0.520180 WB Large T A0212 485 DLPSGHGI 0.518 183 WB Large T A0212 21 AAWGNLPL0.511 197 WB Large T A0212 391 GVAWLHCL 0.511 199 WB Large T A0212 231YLLYSALT 0.504 213 WB Large T A0212 288 LLLGMYLE 0.486 259 WB Large TA0212 514 HLNKRTQI 0.480 276 WB Large T A0212 199 LTPHRHRV 0.477 285 WBLarge T A0212 155 RTLACFAV 0.476 290 WB Large T A0212 377 FGAHGNAV 0.461340 WB Large T A0212 146 FLSQAVFS 0.442 418 WB Large T A0212 9 SMELMDLL0.426 495 WB Large T A0212 501 YLDGSVKV 0.928 2 SB Large T A0216 388YMAGVAWL 0.917 2 SB Large T A0216 175 KLMEKYSV 0.905 2 SB Large T A0216398 LLPKMDSV 0.895 3 SB Large T A0216 287 FLLLGMYL 0.891 3 SB Large TA0216 293 YLEFQYNV 0.849 5 SB Large T A0216 557 SLQNSEFL 0.846 5 SBLarge T A0216 569 ILQSGMTL 0.836 5 SB Large T A0216 272 KLITEYAV 0.832 6SB Large T A0216 465 AIDQYMVV 0.829 6 SB Large T A0216 27 PLMRKAYL 0.8296 SB Large T A0216 579 LLIWFRPV 0.804 8 SB Large T A0216 215 KLCTFSFL0.784 10 SB Large T A0216 11 ELMDLLGL 0.740 16 SB Large T A0216 74GTWNSSEV 0.734 17 SB Large T A0216 60 KMEQDVKV 0.732 18 SB Large T A0216457 RLTFELGV 0.727 19 SB Large T A0216 469 YMVVFEDV 0.718 21 SB Large TA0216 563 FLLEKRIL 0.709 23 SB Large T A0216 520 QIFPPGLV 0.701 25 SBLarge T A0216 514 HLNKRTQI 0.689 29 SB Large T A0216 369 ILDKMDLI 0.67334 SB Large T A0216 56 TLYKKMEQ 0.662 38 SB Large T A0216 50 KMKRMNTL0.651 43 SB Large T A0216 609 SMYTFSRM 0.647 45 SB Large T A0216 603RLDSEISM 0.626 56 WB Large T A0216 355 HMTREEML 0.623 58 WB Large TA0216 21 AAWGNLPL 0.600 75 WB Large T A0216 442 DLCGGKAL 0.597 78 WBLarge T A0216 573 GMTLLLLL 0.595 79 WB Large T A0216 464 VAIDQYMV 0.59382 WB Large T A0216 344 TVLAKKRV 0.583 91 WB Large T A0216 199 LTPHRHRV0.568 106 WB Large T A0216 14 DLLGLERA 0.566 109 WB Large T A0216 485DLPSGHGI 0.550 130 WB Large T A0216 536 KTLQARFV 0.548 132 WB Large TA0216 9 SMELMDLL 0.532 158 WB Large T A0216 391 GVAWLHCL 0.522 176 WBLarge T A0216 150 AVFSNRTL 0.516 187 WB Large T A0216 188 HMCAGHNI 0.512195 WB Large T A0216 527 VTMNEYPV 0.506 210 WB Large T A0216 146FLSQAVFS 0.504 213 WB Large T A0216 231 YLLYSALT 0.501 220 WB Large TA0216 491 GINNLDSL 0.476 290 WB Large T A0216 184 FISRHMCA 0.474 296 WBLarge T A0216 551 KIYLRKSL 0.468 315 WB Large T A0216 155 RTLACFAV 0.465327 WB Large T A0216 673 HLCKGFQC 0.463 334 WB Large T A0216 448ALNVNLPM 0.442 418 WB Large T A0216 372 KMDLIFGA 0.442 419 WB Large TA0216 406 IFDFLHCV 0.433 460 WB Large T A0216 3 VLNREESM 0.429 482 WBLarge T A0216 501 YLDGSVKV 0.939 1 SB Large T A0219 388 YMAGVAWL 0.930 2SB Large T A0219 287 FLLLGMYL 0.835 5 SB Large T A0219 11 ELMDLLGL 0.8078 SB Large T A0219 175 KLMEKYSV 0.800 8 SB Large T A0219 569 ILQSGMTL0.780 10 SB Large T A0219 398 LLPKMDSV 0.713 22 SB Large T A0219 293YLEFQYNV 0.711 22 SB Large T A0219 557 SLQNSEFL 0.660 39 SB Large TA0219 465 AIDQYMVV 0.659 39 SB Large T A0219 272 KLITEYAV 0.651 43 SBLarge T A0219 21 AAWGNLPL 0.637 51 WB Large T A0219 457 RLTFELGV 0.59976 WB Large T A0219 27 PLMRKAYL 0.589 85 WB Large T A0219 603 RLDSEISM0.574 100 WB Large T A0219 369 ILDKMDLI 0.567 108 WB Large T A0219 469YMVVFEDV 0.565 111 WB Large T A0219 579 LLIWFRPV 0.564 112 WB Large TA0219 563 FLLEKRIL 0.555 123 WB Large T A0219 485 DLPSGHGI 0.542 142 WBLarge T A0219 74 GTWNSSEV 0.540 145 WB Large T A0219 464 VAIDQYMV 0.507208 WB Large T A0219 355 HMTREEML 0.497 230 WB Large T A0219 372KMDLIFGA 0.431 469 WB Large T A0219 406 IFDFLHCV 0.429 482 WB Large TA0219 573 GMTLLLLL 0.426 497 WB Large T A0219 53 RMNTLYKK 0.719 20 SBLarge T A0301 232 LLYSALTR 0.673 34 SB Large T A0301 28 LMRKAYLK 0.67135 SB Large T A0301 394 WLHCLLPK 0.536 150 WB Large T A0301 208 AINNFCQK0.529 162 WB Large T A0301 161 AVYTTKEK 0.526 169 WB Large T A0301 577LLLLIWFR 0.513 193 WB Large T A0301 365 RFNHILDK 0.512 196 WB Large TA0301 291 GMYLEFQY 0.507 207 WB Large T A0301 31 KAYLKKCK 0.506 210 WBLarge T A0301 608 ISMYTFSR 0.489 252 WB Large T A0301 413 VVFNVPKR 0.483270 WB Large T A0301 121 SQHSTPPK 0.481 274 WB Large T A0301 156TLACFAVY 0.475 294 WB Large T A0301 222 LICKGVNK 0.438 435 WB Large TA0301 195 IIFFLTPH 0.434 456 WB Large T A0301 412 CVVFNVPK 0.428 486 WBLarge T A0301 208 AINNFCQK 0.764 12 SB Large T A1101 161 AVYTTKEK 0.76113 SB Large T A1101 121 SQHSTPPK 0.746 15 SB Large T A1101 325 AIIFAESK0.737 17 SB Large T A1101 341 AVDTVLAK 0.732 18 SB Large T A1101 53RMNTLYKK 0.727 19 SB Large T A1101 608 ISMYTFSR 0.721 20 SB Large TA1101 544 RQIDFRPK 0.709 23 SB Large T A1101 505 SVKVNLEK 0.695 27 SBLarge T A1101 168 KAQILYKK 0.672 34 SB Large T A1101 412 CVVFNVPK 0.66537 SB Large T A1101 669 SQELHLCK 0.657 40 SB Large T A1101 31 KAYLKKCK0.639 49 SB Large T A1101 218 TFSFLICK 0.626 57 WB Large T A1101 413VVFNVPKR 0.613 65 WB Large T A1101 537 TLQARFVR 0.609 68 WB Large TA1101 470 MVVFEDVK 0.604 72 WB Large T A1101 404 SVIFDFLH 0.596 79 WBLarge T A1101 222 LICKGVNK 0.581 93 WB Large T A1101 560 NSEFLLEK 0.574100 WB Large T A1101 611 YTFSRMKY 0.568 107 WB Large T A1101 148SQAVFSNR 0.553 125 WB Large T A1101 450 NVNLPMER 0.526 168 WB Large TA1101 394 WLHCLLPK 0.499 226 WB Large T A1101 291 GMYLEFQY 0.497 231 WBLarge T A1101 617 KYNICMGK 0.464 328 WB Large T A1101 247 ESIQGGLK 0.464331 WB Large T A1101 577 LLLLIWFR 0.462 338 WB Large T A1101 52 KRMNTLYK0.454 367 WB Large T A1101 678 FQCFKRPK 0.440 426 WB Large T A1101 28LMRKAYLK 0.435 452 WB Large T A1101 365 RFNHILDK 0.427 494 WB Large TA1101 408 DFLHCVVF 0.671 35 SB Large T A2301 541 RFVRQIDF 0.664 37 SBLarge T A2301 610 MYTFSRMK 0.660 39 SB Large T A2301 321 HFANAIIF 0.63353 WB Large T A2301 172 LYKKLMEK 0.626 57 WB Large T A2301 104 LFCHEDMF0.617 63 WB Large T A2301 500 DYLDGSVK 0.609 68 WB Large T A2301 582WFRPVADF 0.608 69 WB Large T A2301 230 EYLLYSAL 0.601 75 WB Large TA2301 617 KYNICMGK 0.599 76 WB Large T A2301 205 RVSAINNF 0.504 214 WBLarge T A2301 387 QYMAGVAW 0.502 219 WB Large T A2301 576 LLLLLIWF 0.493241 WB Large T A2301 92 WWSSFNEK 0.492 243 WB Large T A2301 145 QFLSQAVF0.489 252 WB Large T A2301 365 RFNHILDK 0.475 292 WB Large T A2301 556KSLQNSEF 0.460 343 WB Large T A2301 159 CFAVYTTK 0.441 423 WB Large TA2301 230 EYLLYSAL 0.680 32 SB Large T A2402 145 QFLSQAVF 0.522 176 WBLarge T A2402 408 DFLHCVVF 0.519 182 WB Large T A2402 531 EYPVPKTL 0.510199 WB Large T A2402 321 HFANAIIF 0.507 206 WB Large T A2402 422YWLFKGPI 0.506 210 WB Large T A2402 541 RFVRQIDF 0.460 344 WB Large TA2402 387 QYMAGVAW 0.445 405 WB Large T A2402 387 QYMAGVAW 0.768 12 SBLarge T A2403 582 WFRPVADF 0.765 12 SB Large T A2403 145 QFLSQAVF 0.71322 SB Large T A2403 541 RFVRQIDF 0.706 24 SB Large T A2403 321 HFANAIIF0.691 28 SB Large T A2403 230 EYLLYSAL 0.591 83 WB Large T A2403 408DFLHCVVF 0.567 108 WB Large T A2403 556 KSLQNSEF 0.546 135 WB Large TA2403 104 LFCHEDMF 0.497 230 WB Large T A2403 531 EYPVPKTL 0.496 233 WBLarge T A2403 611 YTFSRMKY 0.680 31 SB Large T A2601 285 DVFLLLGM 0.58886 WB Large T A2601 11 ELMDLLGL 0.486 259 WB Large T A2601 611 YTFSRMKY0.903 2 SB Large T A2602 285 DVFLLLGM 0.810 7 SB Large T A2602 280ETKCEDVF 0.737 17 SB Large T A2602 66 KVAHQPDF 0.563 112 WB Large TA2602 11 ELMDLLGL 0.500 224 WB Large T A2602 463 GVAIDQYM 0.486 261 WBLarge T A2602 80 EVPTYGTE 0.485 262 WB Large T A2602 291 GMYLEFQY 0.68031 SB Large T A2902 286 VFLLLGMY 0.624 58 WB Large T A2902 611 YTFSRMKY0.617 63 WB Large T A2902 156 TLACFAVY 0.552 127 WB Large T A2902 270SWKLITEY 0.500 223 WB Large T A2902 121 SQHSTPPK 0.836 5 SB Large TA3001 419 KRRYWLFK 0.811 7 SB Large T A3001 28 LMRKAYLK 0.805 8 SBLarge T A3001 544 RQIDFRPK 0.771 11 SB Large T A3001 683 RPKTPPPK 0.74016 SB Large T A3001 505 SVKVNLEK 0.732 18 SB Large T A3001 53 RMNTLYKK0.672 34 SB Large T A3001 394 WLHCLLPK 0.669 36 SB Large T A3001 309KDQPYHFK 0.647 45 SB Large T A3001 31 KAYLKKCK 0.628 55 WB Large T A300152 KRMNTLYK 0.620 60 WB Large T A3001 161 AVYTTKEK 0.613 65 WB Large TA3001 29 MRKAYLKK 0.612 66 WB Large T A3001 594 QSRIVEWK 0.594 80 WBLarge T A3001 168 KAQILYKK 0.583 91 WB Large T A3001 549 RPKIYLRK 0.571103 WB Large T A3001 172 LYKKLMEK 0.566 109 WB Large T A3001 130KRKVEDPK 0.560 116 WB Large T A3001 617 KYNICMGK 0.549 131 WB Large TA3001 610 MYTFSRMK 0.541 142 WB Large T A3001 365 RFNHILDK 0.516 188 WBLarge T A3001 196 IFFLTPHR 0.458 350 WB Large T A3001 208 AINNFCQK 0.450382 WB Large T A3001 237 LTRDPYHI 0.443 416 WB Large T A3001 205RVSAINNF 0.506 210 WB Large T A3002 611 YTFSRMKY 0.440 428 WB Large TA3002 577 LLLLIWFR 0.818 7 SB Large T A3101 53 RMNTLYKK 0.816 7 SBLarge T A3101 608 ISMYTFSR 0.791 9 SB Large T A3101 537 TLQARFVR 0.77311 SB Large T A3101 196 IFFLTPHR 0.772 11 SB Large T A3101 414 VFNVPKRR0.682 31 SB Large T A3101 148 SQAVFSNR 0.678 32 SB Large T A3101 180YSVTFISR 0.672 34 SB Large T A3101 676 KGFQCFKR 0.671 35 SB Large TA3101 413 VVFNVPKR 0.665 37 SB Large T A3101 617 KYNICMGK 0.648 45 SBLarge T A3101 28 LMRKAYLK 0.646 46 SB Large T A3101 544 RQIDFRPK 0.64646 SB Large T A3101 232 LLYSALTR 0.630 55 WB Large T A3101 168 KAQILYKK0.618 62 WB Large T A3101 542 FVRQIDFR 0.590 84 WB Large T A3101 589FSKDIQSR 0.590 84 WB Large T A3101 596 RIVEWKER 0.580 93 WB Large TA3101 198 FLTPHRHR 0.569 106 WB Large T A3101 172 LYKKLMEK 0.550 129 WBLarge T A3101 365 RFNHILDK 0.540 145 WB Large T A3101 610 MYTFSRMK 0.532157 WB Large T A3101 450 NVNLPMER 0.515 189 WB Large T A3101 31 KAYLKKCK0.504 214 WB Large T A3101 208 AINNFCQK 0.461 339 WB Large T A3101 155RTLACFAV 0.460 345 WB Large T A3101 121 SQHSTPPK 0.452 376 WB Large TA3101 577 LLLLIWFR 0.795 9 SB Large T A3301 196 IFFLTPHR 0.758 13 SBLarge T A3301 608 ISMYTFSR 0.631 54 WB Large T A3301 450 NVNLPMER 0.63154 WB Large T A3301 542 FVRQIDFR 0.628 55 WB Large T A3301 537 TLQARFVR0.608 69 WB Large T A3301 343 DTVLAKKR 0.575 99 WB Large T A3301 180YSVTFISR 0.574 100 WB Large T A3301 589 FSKDIQSR 0.535 152 WB Large TA3301 547 DFRPKIYL 0.526 169 WB Large T A3301 500 DYLDGSVK 0.521 178 WBLarge T A3301 198 FLTPHRHR 0.504 215 WB Large T A3301 265 ETKQVSWK 0.447397 WB Large T A3301 265 ETKQVSWK 0.836 5 SB Large T A6801 608 ISMYTFSR0.827 6 SB Large T A6801 470 MVVFEDVK 0.812 7 SB Large T A6801 180YSVTFISR 0.805 8 SB Large T A6801 343 DTVLAKKR 0.798 8 SB Large T A6801412 CVVFNVPK 0.772 11 SB Large T A6801 450 NVNLPMER 0.771 11 SB Large TA6801 542 FVRQIDFR 0.764 12 SB Large T A6801 611 YTFSRMKY 0.753 14 SBLarge T A6801 610 MYTFSRMK 0.746 15 SB Large T A6801 413 VVFNVPKR 0.72819 SB Large T A6801 247 ESIQGGLK 0.662 38 SB Large T A6801 232 LLYSALTR0.652 43 SB Large T A6801 589 FSKDIQSR 0.648 44 SB Large T A6801 537TLQARFVR 0.632 53 WB Large T A6801 196 IFFLTPHR 0.626 57 WB Large TA6801 577 LLLLIWFR 0.606 71 WB Large T A6801 218 TFSFLICK 0.597 78 WBLarge T A6801 560 NSEFLLEK 0.575 99 WB Large T A6801 325 AIIFAESK 0.570105 WB Large T A6801 198 FLTPHRHR 0.567 108 WB Large T A6801 505SVKVNLEK 0.553 126 WB Large T A6801 167 EKAQILYK 0.548 132 WB Large TA6801 148 SQAVFSNR 0.536 151 WB Large T A6801 159 CFAVYTTK 0.531 159 WBLarge T A6801 161 AVYTTKEK 0.529 163 WB Large T A6801 208 AINNFCQK 0.516188 WB Large T A6801 328 FAESKNQK 0.505 212 WB Large T A6801 596RIVEWKER 0.471 306 WB Large T A6801 492 INNLDSLR 0.464 329 WB Large TA6801 156 TLACFAVY 0.458 351 WB Large T A6801 124 STPPKKKR 0.453 371 WBLarge T A6801 275 TEYAVETK 0.432 465 WB Large T A6801 123 HSTPPKKK 0.429482 WB Large T A6801 404 SVIFDFLH 0.427 492 WB Large T A6801 313YHFKYHEK 0.426 496 WB Large T A6801 322 FANAIIFA 0.703 24 SB Large TA6802 520 QIFPPGLV 0.669 35 SB Large T A6802 155 RTLACFAV 0.653 42 SBLarge T A6802 377 FGAHGNAV 0.634 52 WB Large T A6802 527 VTMNEYPV 0.61763 WB Large T A6802 403 DSVIFDFL 0.603 73 WB Large T A6802 11 ELMDLLGL0.583 90 WB Large T A6802 189 MCAGHNII 0.575 99 WB Large T A6802 8ESMELMDL 0.563 113 WB Large T A6802 199 LTPHRHRV 0.555 123 WB Large TA6802 178 EKYSVTFI 0.531 160 WB Large T A6802 388 YMAGVAWL 0.523 174 WBLarge T A6802 574 MTLLLLLI 0.480 278 WB Large T A6802 464 VAIDQYMV 0.479281 WB Large T A6802 579 LLIWFRPV 0.477 286 WB Large T A6802 649QSQCSSQV 0.455 365 WB Large T A6802 19 ERAAWGNL 0.434 456 WB Large TA6802 434 TTLAAGLL 0.431 470 WB Large T A6802 216 LCTFSFLI 0.428 489 WBLarge T A6802 520 QIFPPGLV 0.711 22 SB Large T A6901 11 ELMDLLGL 0.66736 SB Large T A6901 155 RTLACFAV 0.636 51 WB Large T A6901 574 MTLLLLLI0.613 66 WB Large T A6901 527 VTMNEYPV 0.575 99 WB Large T A6901 434TTLAAGLL 0.571 103 WB Large T A6901 501 YLDGSVKV 0.546 135 WB Large TA6901 74 GTWNSSEV 0.545 137 WB Large T A6901 464 VAIDQYMV 0.523 175 WBLarge T A6901 322 FANAIIFA 0.514 192 WB Large T A6901 21 AAWGNLPL 0.513193 WB Large T A6901 579 LLIWFRPV 0.508 205 WB Large T A6901 287FLLLGMYL 0.504 214 WB Large T A6901 388 YMAGVAWL 0.494 238 WB Large TA6901 340 QAVDTVLA 0.464 328 WB Large T A6901 8 ESMELMDL 0.453 372 WBLarge T A6901 458 LTFELGVA 0.433 462 WB Large T A6901 377 FGAHGNAV 0.431472 WB Large T A6901 383 AVLEQYMA 0.426 499 WB Large T A6901 453LPMERLTF 0.735 17 SB Large T B0702 417 VPKRRYWL 0.608 69 WB Large TB0702 399 LPKMDSVI 0.500 223 WB Large T B0702 21 AAWGNLPL 0.482 270 WBLarge T B0702 139 FPSDLHQF 0.479 281 WB Large T B0702 26 LPLMRKAY 0.431472 WB Large T B0702 417 VPKRRYWL 0.555 123 WB Large T B0801 50 KMKRMNTL0.479 282 WB Large T B0801 33 YLKKCKEF 0.446 401 WB Large T B0801 205RVSAINNF 0.544 139 WB Large T B1501 306 CQKKDQPY 0.511 199 WB Large TB1501 339 QQAVDTVL 0.504 214 WB Large T B1501 615 RMKYNICM 0.498 228 WBLarge T B1501 33 YLKKCKEF 0.496 232 WB Large T B1501 388 YMAGVAWL 0.493240 WB Large T B1501 611 YTFSRMKY 0.492 244 WB Large T B1501 291GMYLEFQY 0.486 261 WB Large T B1501 144 HQFLSQAV 0.476 288 WB Large TB1501 50 KMKRMNTL 0.474 294 WB Large T B1501 156 TLACFAVY 0.469 311 WBLarge T B1501 570 LQSGMTLL 0.441 424 WB Large T B1501 89 WESWWSSF 0.8147 SB Large T B1801 455 MERLTFEL 0.686 29 SB Large T B1801 606 SEISMYTF0.646 45 SB Large T B1801 177 MEKYSVTF 0.627 56 WB Large T B1801 363TERFNHIL 0.449 388 WB Large T B1801 86 TEEWESWW 0.434 458 WB Large TB1801 52 KRMNTLYK 0.623 58 WB Large T B2705 567 KRILQSGM 0.555 122 WBLarge T B2705 544 RQIDFRPK 0.533 155 WB Large T B2705 419 KRRYWLFK 0.506209 WB Large T B2705 349 KRVDTLHM 0.461 341 WB Large T B2705 29 MRKAYLKK0.430 477 WB Large T B2705 139 FPSDLHQF 0.796 9 SB Large T B3501 522FPPGLVTM 0.773 11 SB Large T B3501 453 LPMERLTF 0.752 14 SB Large TB3501 26 LPLMRKAY 0.749 15 SB Large T B3501 235 SALTRDPY 0.599 76 WBLarge T B3501 382 NAVLEQYM 0.558 119 WB Large T B3501 111 FASDEEAT 0.538148 WB Large T B3501 156 TLACFAVY 0.533 156 WB Large T B3501 321HFANAIIF 0.513 193 WB Large T B3501 21 AAWGNLPL 0.509 203 WB Large TB3501 77 NSSEVPTY 0.502 218 WB Large T B3501 98 EKWDEDLF 0.451 381 WBLarge T B3501 145 QFLSQAVF 0.450 384 WB Large T B3501 89 WESWWSSF 0.445407 WB Large T B3501 5 NREESMEL 0.555 123 WB Large T B3901 339 QQAVDTVL0.464 330 WB Large T B3901 388 YMAGVAWL 0.429 483 WB Large T B3901 455MERLTFEL 0.676 33 SB Large T B4001 363 TERFNHIL 0.626 57 WB Large TB4001 283 CEDVFLLL 0.595 80 WB Large T B4001 606 SEISMYTF 0.593 81 WBLarge T B4001 6 REESMELM 0.511 197 WB Large T B4001 177 MEKYSVTF 0.487257 WB Large T B4001 246 EESIQGGL 0.432 465 WB Large T B4001 606SEISMYTF 0.568 107 WB Large T B4002 89 WESWWSSF 0.495 237 WB Large TB4002 166 KEKAQILY 0.489 250 WB Large T B4002 359 EEMLTERF 0.489 251 WBLarge T B4002 246 EESIQGGL 0.464 328 WB Large T B4002 177 MEKYSVTF 0.454367 WB Large T B4002 264 EETKQVSW 0.446 403 WB Large T B4002 6 REESMELM0.433 463 WB Large T B4002 264 EETKQVSW 0.514 193 WB Large T B4402 606SEISMYTF 0.472 303 WB Large T B4402 86 TEEWESWW 0.464 329 WB Large TB4402 166 KEKAQILY 0.461 342 WB Large T B4402 359 EEMLTERF 0.449 388 WBLarge T B4402 606 SEISMYTF 0.549 131 WB Large T B4403 359 EEMLTERF 0.526167 WB Large T B4403 359 EEMLTERF 0.512 196 WB Large T B4501 329AESKNQKS 0.443 415 WB Large T B4501 246 EESIQGGL 0.433 460 WB Large TB4501 481 AESKDLPS 0.431 470 WB Large T B4501 522 FPPGLVTM 0.629 55 WBLarge T B5101 453 LPMERLTF 0.621 60 WB Large T B5101 399 LPKMDSVI 0.59877 WB Large T B5101 453 LPMERLTF 0.755 14 SB Large T B5301 139 FPSDLHQF0.729 18 SB Large T B5301 26 LPLMRKAY 0.636 51 WB Large T B5301 399LPKMDSVI 0.632 53 WB Large T B5301 522 FPPGLVTM 0.582 91 WB Large TB5301 522 FPPGLVTM 0.577 97 WB Large T B5401 322 FANAIIFA 0.511 198 WBLarge T B5401 26 LPLMRKAY 0.482 271 WB Large T B5401 82 PTYGTEEW 0.517186 WB Large T B5701 93 WSSFNEKW 0.678 32 SB Large T B5801 556 KSLQNSEF0.602 74 WB Large T B5801 593 IQSRIVEW 0.573 101 WB Large T B5801 205RVSAINNF 0.525 169 WB Large T B5801 82 PTYGTEEW 0.504 215 WB Large TB5801 66 KVAHQPDF 0.491 246 WB Large T B5801 16 LGLERAAW 0.439 430 WBLarge T B5801 77 NSSEVPTY 0.431 469 WB Large T B5801 9-mers 603RLDSEISMY 0.648 44 SB Large T A0101 226 GVNKEYLLY 0.477 286 WB Large TA0101 234 YSALTRDPY 0.471 304 WB Large T A0101 409 FLHCVVFNV 0.891 3 SBLarge T A0201 405 VIFDFLHCV 0.842 5 SB Large T A0201 215 KLCTFSFLI 0.74715 SB Large T A0201 198 FLTPHRHRV 0.693 27 SB Large T A0201 578LLLIWFRPV 0.690 28 SB Large T A0201 384 VLEQYMAGV 0.680 31 SB Large TA0201 557 SLQNSEFLL 0.658 40 SB Large T A0201 397 CLLPKMDSV 0.639 49 SBLarge T A0201 569 ILQSGMTLL 0.614 64 WB Large T A0201 175 KLMEKYSVT0.580 94 WB Large T A0201 435 TLAAGLLDL 0.578 95 WB Large T A0201 361MLTERFNHI 0.562 114 WB Large T A0201 579 LLIWFRPVA 0.505 212 WB Large TA0201 573 GMTLLLLLI 0.494 237 WB Large T A0201 368 HILDKMDLI 0.488 254WB Large T A0201 621 CMGKCILDI 0.465 327 WB Large T A0201 394 WLHCLLPKM0.443 412 WB Large T A0201 156 TLACFAVYT 0.437 440 WB Large T A0201 409FLHCVVFNV 0.885 3 SB Large T A0202 198 FLTPHRHRV 0.824 6 SB Large TA0202 361 MLTERFNHI 0.774 11 SB Large T A0202 569 ILQSGMTLL 0.765 12 SBLarge T A0202 405 VIFDFLHCV 0.742 16 SB Large T A0202 384 VLEQYMAGV0.728 19 SB Large T A0202 494 NLDSLRDYL 0.687 29 SB Large T A0202 557SLQNSEFLL 0.676 33 SB Large T A0202 570 LQSGMTLLL 0.676 33 SB Large TA0202 397 CLLPKMDSV 0.658 40 SB Large T A0202 402 MDSVIFDFL 0.642 48 SBLarge T A0202 215 KLCTFSFLI 0.640 49 SB Large T A0202 497 SLRDYLDGS0.630 54 WB Large T A0202 463 GVAIDQYMV 0.614 65 WB Large T A0202 435TLAAGLLDL 0.605 71 WB Large T A0202 175 KLMEKYSVT 0.560 116 WB Large TA0202 573 GMTLLLLLI 0.558 119 WB Large T A0202 156 TLACFAVYT 0.554 124WB Large T A0202 289 LLGMYLEFQ 0.542 142 WB Large T A0202 648 SQSQCSSQV0.542 142 WB Large T A0202 391 GVAWLHCLL 0.529 163 WB Large T A0202 219FSFLICKGV 0.528 165 WB Large T A0202 208 AINNFCQKL 0.524 173 WB Large TA0202 191 AGHNIIFFL 0.514 191 WB Large T A0202 111 FASDEEATA 0.506 208WB Large T A0202 139 FPSDLHQFL 0.505 211 WB Large T A0202 236 ALTRDPYHI0.501 220 WB Large T A0202 589 FSKDIQSRI 0.499 226 WB Large T A0202 526LVTMNEYPV 0.493 240 WB Large T A0202 146 FLSQAVFSN 0.480 278 WB Large TA0202 578 LLLIWFRPV 0.466 321 WB Large T A0202 377 FGAHGNAVL 0.465 327WB Large T A0202 458 LTFELGVAI 0.452 376 WB Large T A0202 572 SGMTLLLLL0.450 385 WB Large T A0202 398 LLPKMDSVI 0.448 392 WB Large T A0202 368HILDKMDLI 0.438 438 WB Large T A0202 409 FLHCVVFNV 0.911 2 SB Large TA0203 198 FLTPHRHRV 0.891 3 SB Large T A0203 361 MLTERFNHI 0.884 3 SBLarge T A0203 384 VLEQYMAGV 0.838 5 SB Large T A0203 578 LLLIWFRPV 0.8197 SB Large T A0203 397 CLLPKMDSV 0.815 7 SB Large T A0203 569 ILQSGMTLL0.803 8 SB Large T A0203 405 VIFDFLHCV 0.796 9 SB Large T A0203 435TLAAGLLDL 0.744 16 SB Large T A0203 175 KLMEKYSVT 0.694 27 SB Large TA0203 457 RLTFELGVA 0.683 30 SB Large T A0203 497 SLRDYLDGS 0.596 79 WBLarge T A0203 579 LLIWFRPVA 0.575 99 WB Large T A0203 553 YLRKSLQNS0.569 105 WB Large T A0203 215 KLCTFSFLI 0.566 108 WB Large T A0203 236ALTRDPYHI 0.540 144 WB Large T A0203 375 LIFGAHGNA 0.540 145 WB Large TA0203 573 GMTLLLLLI 0.537 150 WB Large T A0203 570 LQSGMTLLL 0.528 165WB Large T A0203 156 TLACFAVYT 0.527 166 WB Large T A0203 648 SQSQCSSQV0.520 179 WB Large T A0203 391 GVAWLHCLL 0.517 185 WB Large T A0203 398LLPKMDSVI 0.516 188 WB Large T A0203 394 WLHCLLPKM 0.513 194 WB Large TA0203 464 VAIDQYMVV 0.512 195 WB Large T A0203 188 HMCAGHNII 0.510 199WB Large T A0203 519 TQIFPPGLV 0.506 210 WB Large T A0203 208 AINNFCQKL0.501 220 WB Large T A0203 368 HILDKMDLI 0.496 232 WB Large T A0203 20RAAWGNLPL 0.491 246 WB Large T A0203 53 RMNTLYKKM 0.490 249 WB Large TA0203 568 RILQSGMTL 0.485 263 WB Large T A0203 538 LQARFVRQI 0.458 352WB Large T A0203 289 LLGMYLEFQ 0.456 360 WB Large T A0203 557 SLQNSEFLL0.447 396 WB Large T A0203 596 RIVEWKERL 0.441 423 WB Large T A0203 463GVAIDQYMV 0.432 464 WB Large T A0203 198 FLTPHRHRV 0.766 12 SB Large TA0204 409 FLHCVVFNV 0.744 15 SB Large T A0204 405 VIFDFLHCV 0.645 46 SBLarge T A0204 578 LLLIWFRPV 0.640 48 SB Large T A0204 384 VLEQYMAGV0.607 70 WB Large T A0204 464 VAIDQYMVV 0.564 111 WB Large T A0204 557SLQNSEFLL 0.552 127 WB Large T A0204 59 KKMEQDVKV 0.514 191 WB Large TA0204 526 LVTMNEYPV 0.512 196 WB Large T A0204 435 TLAAGLLDL 0.489 251WB Large T A0204 292 MYLEFQYNV 0.488 255 WB Large T A0204 569 ILQSGMTLL0.485 264 WB Large T A0204 208 AINNFCQKL 0.474 296 WB Large T A0204 397CLLPKMDSV 0.468 315 WB Large T A0204 175 KLMEKYSVT 0.464 329 WB Large TA0204 361 MLTERFNHI 0.447 395 WB Large T A0204 236 ALTRDPYHI 0.447 398WB Large T A0204 215 KLCTFSFLI 0.445 404 WB Large T A0204 361 MLTERFNHI0.848 5 SB Large T A0206 397 CLLPKMDSV 0.834 6 SB Large T A0206 409FLHCVVFNV 0.819 7 SB Large T A0206 578 LLLIWFRPV 0.801 8 SB Large TA0206 198 FLTPHRHRV 0.793 9 SB Large T A0206 405 VIFDFLHCV 0.746 15 SBLarge T A0206 544 RQIDFRPKI 0.739 16 SB Large T A0206 648 SQSQCSSQV0.729 18 SB Large T A0206 384 VLEQYMAGV 0.692 27 SB Large T A0206 570LQSGMTLLL 0.683 30 SB Large T A0206 596 RIVEWKERL 0.674 34 SB Large TA0206 568 RILQSGMTL 0.638 50 WB Large T A0206 20 RAAWGNLPL 0.634 52 WBLarge T A0206 435 TLAAGLLDL 0.583 91 WB Large T A0206 215 KLCTFSFLI0.560 116 WB Large T A0206 464 VAIDQYMVV 0.560 117 WB Large T A0206 368HILDKMDLI 0.550 130 WB Large T A0206 339 QQAVDTVLA 0.549 131 WB Large TA0206 569 ILQSGMTLL 0.520 180 WB Large T A0206 111 FASDEEATA 0.520 180WB Large T A0206 267 KQVSWKLIT 0.516 188 WB Large T A0206 579 LLIWFRPVA0.507 206 WB Large T A0206 458 LTFELGVAI 0.503 216 WB Large T A0206 10MELMDLLGL 0.496 233 WB Large T A0206 391 GVAWLHCLL 0.476 291 WB Large TA0206 287 FLLLGMYLE 0.473 298 WB Large T A0206 519 TQIFPPGLV 0.470 308WB Large T A0206 288 LLLGMYLEF 0.469 312 WB Large T A0206 447 KALNVNLPM0.457 357 WB Large T A0206 21 AAWGNLPLM 0.457 357 WB Large T A0206 394WLHCLLPKM 0.451 379 WB Large T A0206 526 LVTMNEYPV 0.441 421 WB Large TA0206 175 KLMEKYSVT 0.439 432 WB Large T A0206 148 SQAVFSNRT 0.438 437WB Large T A0206 198 FLTPHRHRV 0.978 1 SB Large T A0211 405 VIFDFLHCV0.968 1 SB Large T A0211 409 FLHCVVFNV 0.933 2 SB Large T A0211 397CLLPKMDSV 0.929 2 SB Large T A0211 384 VLEQYMAGV 0.926 2 SB Large TA0211 557 SLQNSEFLL 0.912 2 SB Large T A0211 494 NLDSLRDYL 0.903 2 SBLarge T A0211 569 ILQSGMTLL 0.890 3 SB Large T A0211 435 TLAAGLLDL 0.8903 SB Large T A0211 215 KLCTFSFLI 0.876 3 SB Large T A0211 578 LLLIWFRPV0.862 4 SB Large T A0211 563 FLLEKRILQ 0.862 4 SB Large T A0211 579LLIWFRPVA 0.849 5 SB Large T A0211 292 MYLEFQYNV 0.832 6 SB Large TA0211 388 YMAGVAWLH 0.799 8 SB Large T A0211 463 GVAIDQYMV 0.796 9 SBLarge T A0211 428 PIDSGKTTL 0.778 11 SB Large T A0211 573 GMTLLLLLI0.771 11 SB Large T A0211 500 DYLDGSVKV 0.751 14 SB Large T A0211 454PMERLTFEL 0.736 17 SB Large T A0211 288 LLLGMYLEF 0.733 17 SB Large TA0211 526 LVTMNEYPV 0.733 18 SB Large T A0211 391 GVAWLHCLL 0.725 19 SBLarge T A0211 464 VAIDQYMVV 0.721 20 SB Large T A0211 568 RILQSGMTL0.720 20 SB Large T A0211 142 DLHQFLSQA 0.703 24 SB Large T A0211 361MLTERFNHI 0.692 28 SB Large T A0211 236 ALTRDPYHI 0.685 30 SB Large TA0211 596 RIVEWKERL 0.685 30 SB Large T A0211 156 TLACFAVYT 0.663 38 SBLarge T A0211 287 FLLLGMYLE 0.659 40 SB Large T A0211 208 AINNFCQKL0.637 50 WB Large T A0211 575 TLLLLLIWF 0.632 53 WB Large T A0211 20RAAWGNLPL 0.620 61 WB Large T A0211 14 DLLGLERAA 0.614 65 WB Large TA0211 289 LLGMYLEFQ 0.602 74 WB Large T A0211 603 RLDSEISMY 0.592 82 WBLarge T A0211 368 HILDKMDLI 0.590 84 WB Large T A0211 576 LLLLLIWFR0.575 99 WB Large T A0211 394 WLHCLLPKM 0.569 106 WB Large T A0211 353TLHMTREEM 0.558 119 WB Large T A0211 273 LITEYAVET 0.545 137 WB Large TA0211 398 LLPKMDSVI 0.535 152 WB Large T A0211 401 KMDSVIFDF 0.531 160WB Large T A0211 146 FLSQAVFSN 0.527 166 WB Large T A0211 188 HMCAGHNII0.524 172 WB Large T A0211 406 IFDFLHCVV 0.519 181 WB Large T A0211 648SQSQCSSQV 0.514 191 WB Large T A0211 458 LTFELGVAI 0.508 204 WB Large TA0211 497 SLRDYLDGS 0.503 216 WB Large T A0211 501 YLDGSVKVN 0.501 220WB Large T A0211 171 ILYKKLMEK 0.485 264 WB Large T A0211 73 FGTWNSSEV0.481 274 WB Large T A0211 609 SMYTFSRMK 0.474 295 WB Large T A0211 416NVPKRRYWL 0.464 330 WB Large T A0211 109 DMFASDEEA 0.459 346 WB Large TA0211 139 FPSDLHQFL 0.459 349 WB Large T A0211 439 GLLDLCGGK 0.452 377WB Large T A0211 465 AIDQYMVVF 0.449 389 WB Large T A0211 21 AAWGNLPLM0.448 394 WB Large T A0211 521 IFPPGLVTM 0.438 438 WB Large T A0211 175KLMEKYSVT 0.437 440 WB Large T A0211 457 RLTFELGVA 0.430 478 WB Large TA0211 150 AVFSNRTLA 0.428 486 WB Large T A0211 198 FLTPHRHRV 0.950 1 SBLarge T A0212 405 VIFDFLHCV 0.944 1 SB Large T A0212 384 VLEQYMAGV 0.9152 SB Large T A0212 397 CLLPKMDSV 0.909 2 SB Large T A0212 409 FLHCVVFNV0.905 2 SB Large T A0212 435 TLAAGLLDL 0.836 5 SB Large T A0212 569ILQSGMTLL 0.822 6 SB Large T A0212 292 MYLEFQYNV 0.776 11 SB Large TA0212 578 LLLIWFRPV 0.774 11 SB Large T A0212 557 SLQNSEFLL 0.763 12 SBLarge T A0212 563 FLLEKRILQ 0.736 17 SB Large T A0212 464 VAIDQYMVV0.723 20 SB Large T A0212 494 NLDSLRDYL 0.711 22 SB Large T A0212 361MLTERFNHI 0.692 27 SB Large T A0212 579 LLIWFRPVA 0.684 30 SB Large TA0212 288 LLLGMYLEF 0.636 51 WB Large T A0212 497 SLRDYLDGS 0.636 51 WBLarge T A0212 215 KLCTFSFLI 0.619 61 WB Large T A0212 596 RIVEWKERL0.610 68 WB Large T A0212 388 YMAGVAWLH 0.607 69 WB Large T A0212 287FLLLGMYLE 0.598 77 WB Large T A0212 428 PIDSGKTTL 0.561 115 WB Large TA0212 14 DLLGLERAA 0.548 133 WB Large T A0212 454 PMERLTFEL 0.545 137 WBLarge T A0212 526 LVTMNEYPV 0.533 155 WB Large T A0212 458 LTFELGVAI0.531 160 WB Large T A0212 236 ALTRDPYHI 0.525 171 WB Large T A0212 208AINNFCQKL 0.521 177 WB Large T A0212 500 DYLDGSVKV 0.517 185 WB Large TA0212 111 FASDEEATA 0.507 206 WB Large T A0212 289 LLGMYLEFQ 0.505 212WB Large T A0212 188 HMCAGHNII 0.504 214 WB Large T A0212 368 HILDKMDLI0.496 232 WB Large T A0212 398 LLPKMDSVI 0.494 239 WB Large T A0212 463GVAIDQYMV 0.481 275 WB Large T A0212 401 KMDSVIFDF 0.477 286 WB Large TA0212 171 ILYKKLMEK 0.476 289 WB Large T A0212 568 RILQSGMTL 0.453 370WB Large T A0212 139 FPSDLHQFL 0.450 385 WB Large T A0212 394 WLHCLLPKM0.439 434 WB Large T A0212 198 FLTPHRHRV 0.957 1 SB Large T A0216 405VIFDFLHCV 0.924 2 SB Large T A0216 384 VLEQYMAGV 0.898 2 SB Large TA0216 397 CLLPKMDSV 0.898 3 SB Large T A0216 409 FLHCVVFNV 0.881 3 SBLarge T A0216 569 ILQSGMTLL 0.861 4 SB Large T A0216 494 NLDSLRDYL 0.8604 SB Large T A0216 557 SLQNSEFLL 0.844 5 SB Large T A0216 454 PMERLTFEL0.756 13 SB Large T A0216 428 PIDSGKTTL 0.749 15 SB Large T A0216 578LLLIWFRPV 0.694 27 SB Large T A0216 435 TLAAGLLDL 0.679 32 SB Large TA0216 526 LVTMNEYPV 0.669 36 SB Large T A0216 289 LLGMYLEFQ 0.657 40 SBLarge T A0216 215 KLCTFSFLI 0.657 41 SB Large T A0216 142 DLHQFLSQA0.655 41 SB Large T A0216 292 MYLEFQYNV 0.655 41 SB Large T A0216 563FLLEKRILQ 0.646 45 SB Large T A0216 596 RIVEWKERL 0.646 46 SB Large TA0216 236 ALTRDPYHI 0.645 46 SB Large T A0216 416 NVPKRRYWL 0.628 55 WBLarge T A0216 463 GVAIDQYMV 0.626 57 WB Large T A0216 361 MLTERFNHI0.601 74 WB Large T A0216 156 TLACFAVYT 0.590 84 WB Large T A0216 208AINNFCQKL 0.578 96 WB Large T A0216 568 RILQSGMTL 0.574 99 WB Large TA0216 500 DYLDGSVKV 0.539 146 WB Large T A0216 398 LLPKMDSVI 0.537 149WB Large T A0216 579 LLIWFRPVA 0.529 163 WB Large T A0216 391 GVAWLHCLL0.519 181 WB Large T A0216 353 TLHMTREEM 0.510 200 WB Large T A0216 619NICMGKCIL 0.500 224 WB Large T A0216 648 SQSQCSSQV 0.495 236 WB Large TA0216 171 ILYKKLMEK 0.463 333 WB Large T A0216 464 VAIDQYMVV 0.456 359WB Large T A0216 188 HMCAGHNII 0.440 428 WB Large T A0216 368 HILDKMDLI0.426 497 WB Large T A0216 198 FLTPHRHRV 0.947 1 SB Large T A0219 405VIFDFLHCV 0.932 2 SB Large T A0219 409 FLHCVVFNV 0.879 3 SB Large TA0219 397 CLLPKMDSV 0.868 4 SB Large T A0219 569 ILQSGMTLL 0.849 5 SBLarge T A0219 435 TLAAGLLDL 0.795 9 SB Large T A0219 384 VLEQYMAGV 0.76612 SB Large T A0219 494 NLDSLRDYL 0.716 21 SB Large T A0219 428PIDSGKTTL 0.697 26 SB Large T A0219 557 SLQNSEFLL 0.621 60 WB Large TA0219 578 LLLIWFRPV 0.588 86 WB Large T A0219 292 MYLEFQYNV 0.530 162 WBLarge T A0219 526 LVTMNEYPV 0.519 182 WB Large T A0219 361 MLTERFNHI0.518 183 WB Large T A0219 500 DYLDGSVKV 0.508 205 WB Large T A0219 21AAWGNLPLM 0.506 209 WB Large T A0219 454 PMERLTFEL 0.461 340 WB Large TA0219 236 ALTRDPYHI 0.459 349 WB Large T A0219 146 FLSQAVFSN 0.428 486WB Large T A0219 171 ILYKKLMEK 0.858 4 SB Large T A0301 609 SMYTFSRMK0.762 13 SB Large T A0301 28 LMRKAYLKK 0.703 24 SB Large T A0301 195IIFFLTPHR 0.658 40 SB Large T A0301 50 KMKRMNTLY 0.654 42 SB Large TA0301 217 CTFSFLICK 0.640 49 SB Large T A0301 221 FLICKGVNK 0.633 52 WBLarge T A0301 528 TMNEYPVPK 0.599 76 WB Large T A0301 155 RTLACFAVY0.595 79 WB Large T A0301 27 PLMRKAYLK 0.578 96 WB Large T A0301 226GVNKEYLLY 0.545 137 WB Large T A0301 121 SQHSTPPKK 0.490 248 WB Large TA0301 231 YLLYSALTR 0.475 294 WB Large T A0301 341 AVDTVLAKK 0.472 302WB Large T A0301 576 LLLLLIWFR 0.467 318 WB Large T A0301 668 HSQELHLCK0.464 331 WB Large T A0301 504 GSVKVNLEK 0.452 376 WB Large T A0301 509NLEKKHLNK 0.452 377 WB Large T A0301 350 RVDTLHMTR 0.444 409 WB Large TA0301 603 RLDSEISMY 0.433 461 WB Large T A0301 217 CTFSFLICK 0.826 6 SBLarge T A1101 528 TMNEYPVPK 0.817 7 SB Large T A1101 609 SMYTFSRMK 0.8028 SB Large T A1101 207 SAINNFCQK 0.774 11 SB Large T A1101 171 ILYKKLMEK0.747 15 SB Large T A1101 668 HSQELHLCK 0.730 18 SB Large T A1101 341AVDTVLAKK 0.703 24 SB Large T A1101 195 IIFFLTPHR 0.686 30 SB Large TA1101 504 GSVKVNLEK 0.679 32 SB Large T A1101 121 SQHSTPPKK 0.674 33 SBLarge T A1101 147 LSQAVFSNR 0.654 42 SB Large T A1101 536 KTLQARFVR0.650 44 SB Large T A1101 155 RTLACFAVY 0.646 46 SB Large T A1101 340QAVDTVLAK 0.602 74 WB Large T A1101 505 SVKVNLEKK 0.583 91 WB Large TA1101 27 PLMRKAYLK 0.576 98 WB Large T A1101 120 DSQHSTPPK 0.567 108 WBLarge T A1101 393 AWLHCLLPK 0.566 109 WB Large T A1101 413 VVFNVPKRR0.559 118 WB Large T A1101 439 GLLDLCGGK 0.551 129 WB Large T A1101 324NAIIFAESK 0.539 146 WB Large T A1101 350 RVDTLHMTR 0.529 163 WB Large TA1101 226 GVNKEYLLY 0.518 184 WB Large T A1101 607 EISMYTFSR 0.496 233WB Large T A1101 274 ITEYAVETK 0.491 247 WB Large T A1101 593 IQSRIVEWK0.489 252 WB Large T A1101 491 GINNLDSLR 0.488 254 WB Large T A1101 296FQYNVEECK 0.478 285 WB Large T A1101 576 LLLLLIWFR 0.466 321 WB Large TA1101 91 SWWSSFNEK 0.461 340 WB Large T A1101 158 ACFAVYTTK 0.456 360 WBLarge T A1101 221 FLICKGVNK 0.446 399 WB Large T A1101 32 AYLKKCKEF0.708 23 SB Large T A2301 581 IWFRPVADF 0.678 32 SB Large T A2301 312PYHFKYHEK 0.647 45 SB Large T A2301 91 SWWSSFNEK 0.552 126 WB Large TA2301 387 QYMAGVAWL 0.546 135 WB Large T A2301 190 CAGHNIIFF 0.527 166WB Large T A2301 401 KMDSVIFDF 0.522 176 WB Large T A2301 286 VFLLLGMYL0.518 183 WB Large T A2301 292 MYLEFQYNV 0.512 196 WB Large T A2301 138DFPSDLHQF 0.501 220 WB Large T A2301 314 HFKYHEKHF 0.501 222 WB Large TA2301 575 TLLLLLIWF 0.496 233 WB Large T A2301 213 CQKLCTFSF 0.485 263WB Large T A2301 393 AWLHCLLPK 0.471 305 WB Large T A2301 288 LLLGMYLEF0.464 331 WB Large T A2301 320 KHFANAIIF 0.463 334 WB Large T A2301 327IFAESKNQK 0.458 352 WB Large T A2301 610 MYTFSRMKY 0.455 365 WB Large TA2301 211 NFCQKLCTF 0.454 368 WB Large T A2301 612 TFSRMKYNI 0.440 427WB Large T A2301 88 EWESWWSSF 0.597 78 WB Large T A2402 387 QYMAGVAWL0.587 87 WB Large T A2402 138 DFPSDLHQF 0.544 138 WB Large T A2402 241PYHIIEESI 0.536 150 WB Large T A2402 32 AYLKKCKEF 0.523 174 WB Large TA2402 581 IWFRPVADF 0.503 216 WB Large T A2402 468 QYMVVFEDV 0.502 219WB Large T A2402 612 TFSRMKYNI 0.451 381 WB Large T A2402 286 VFLLLGMYL0.434 456 WB Large T A2402 417 VPKRRYWLF 0.432 466 WB Large T A2402 32AYLKKCKEF 0.859 4 SB Large T A2403 387 QYMAGVAWL 0.773 11 SB Large TA2403 138 DFPSDLHQF 0.618 62 WB Large T A2403 320 KHFANAIIF 0.569 105 WBLarge T A2403 521 IFPPGLVTM 0.551 129 WB Large T A2403 68 AHQPDFGTW0.542 142 WB Large T A2403 286 VFLLLGMYL 0.532 158 WB Large T A2403 581IWFRPVADF 0.506 209 WB Large T A2403 401 KMDSVIFDF 0.462 338 WB Large TA2403 190 CAGHNIIFF 0.458 351 WB Large T A2403 468 QYMVVFEDV 0.446 400WB Large T A2403 211 NFCQKLCTF 0.433 461 WB Large T A2403 285 DVFLLLGMY0.689 29 SB Large T A2601 265 ETKQVSWKL 0.506 209 WB Large T A2601 8ESMELMDLL 0.463 335 WB Large T A2601 285 DVFLLLGMY 0.923 2 SB Large TA2602 465 AIDQYMVVF 0.801 8 SB Large T A2602 280 ETKCEDVFL 0.742 16 SBLarge T A2602 545 QIDFRPKIY 0.724 19 SB Large T A2602 138 DFPSDLHQF0.617 63 WB Large T A2602 226 GVNKEYLLY 0.612 66 WB Large T A2602 155RTLACFAVY 0.609 68 WB Large T A2602 152 FSNRTLACF 0.590 84 WB Large TA2602 265 ETKQVSWKL 0.518 183 WB Large T A2602 8 ESMELMDLL 0.476 290 WBLarge T A2602 103 DLFCHEDMF 0.457 358 WB Large T A2602 450 NVNLPMERL0.447 396 WB Large T A2602 164 TTKEKAQIL 0.437 441 WB Large T A2602 290LGMYLEFQY 0.593 81 WB Large T A2902 50 KMKRMNTLY 0.576 98 WB Large TA2902 269 VSWKLITEY 0.552 127 WB Large T A2902 285 DVFLLLGMY 0.538 148WB Large T A2902 226 GVNKEYLLY 0.508 204 WB Large T A2902 610 MYTFSRMKY0.474 295 WB Large T A2902 414 VFNVPKRRY 0.429 480 WB Large T A2902 28LMRKAYLKK 0.830 6 SB Large T A3001 51 MKRMNTLYK 0.827 6 SB Large T A300136 KCKEFHPDK 0.817 7 SB Large T A3001 418 PKRRYWLFK 0.813 7 SB Large TA3001 121 SQHSTPPKK 0.755 14 SB Large T A3001 682 KRPKTPPPK 0.723 19 SBLarge T A3001 528 TMNEYPVPK 0.716 21 SB Large T A3001 677 GFQCFKRPK0.683 30 SB Large T A3001 120 DSQHSTPPK 0.675 33 SB Large T A3001 674LCKGFQCFK 0.669 36 SB Large T A3001 129 KKRKVEDPK 0.666 37 SB Large TA3001 158 ACFAVYTTK 0.657 40 SB Large T A3001 536 KTLQARFVR 0.637 51 WBLarge T A3001 505 SVKVNLEKK 0.634 52 WB Large T A3001 609 SMYTFSRMK0.598 77 WB Large T A3001 166 KEKAQILYK 0.579 95 WB Large T A3001 312PYHFKYHEK 0.574 100 WB Large T A3001 195 IIFFLTPHR 0.569 105 WB Large TA3001 393 AWLHCLLPK 0.519 181 WB Large T A3001 50 KMKRMNTLY 0.501 220 WBLarge T A3001 340 QAVDTVLAK 0.481 273 WB Large T A3001 274 ITEYAVETK0.481 274 WB Large T A3001 124 STPPKKKRK 0.478 282 WB Large T A3001 171ILYKKLMEK 0.467 318 WB Large T A3001 411 HCVVFNVPK 0.465 325 WB Large TA3001 27 PLMRKAYLK 0.439 431 WB Large T A3001 544 RQIDFRPKI 0.437 440 WBLarge T A3001 668 HSQELHLCK 0.436 445 WB Large T A3001 52 KRMNTLYKK0.435 453 WB Large T A3001 50 KMKRMNTLY 0.561 115 WB Large T A3002 401KMDSVIFDF 0.525 169 WB Large T A3002 172 LYKKLMEKY 0.524 172 WB Large TA3002 285 DVFLLLGMY 0.509 201 WB Large T A3002 610 MYTFSRMKY 0.502 218WB Large T A3002 226 GVNKEYLLY 0.497 231 WB Large T A3002 603 RLDSEISMY0.483 269 WB Large T A3002 536 KTLQARFVR 0.856 4 SB Large T A3101 576LLLLLIWFR 0.848 5 SB Large T A3101 179 KYSVTFISR 0.844 5 SB Large TA3101 541 RFVRQIDFR 0.836 5 SB Large T A3101 147 LSQAVFSNR 0.821 6 SBLarge T A3101 547 DFRPKIYLR 0.799 8 SB Large T A3101 195 IIFFLTPHR 0.72020 SB Large T A3101 528 TMNEYPVPK 0.713 22 SB Large T A3101 350RVDTLHMTR 0.712 22 SB Large T A3101 197 FFLTPHRHR 0.682 31 SB Large TA3101 491 GINNLDSLR 0.668 36 SB Large T A3101 413 VVFNVPKRR 0.651 43 SBLarge T A3101 607 EISMYTFSR 0.604 72 WB Large T A3101 155 RTLACFAVY0.573 101 WB Large T A3101 609 SMYTFSRMK 0.567 108 WB Large T A3101 217CTFSFLICK 0.563 113 WB Large T A3101 50 KMKRMNTLY 0.540 144 WB Large TA3101 91 SWWSSFNEK 0.515 190 WB Large T A3101 123 HSTPPKKKR 0.487 257 WBLarge T A3101 292 MYLEFQYNV 0.476 289 WB Large T A3101 677 GFQCFKRPK0.472 301 WB Large T A3101 231 YLLYSALTR 0.438 439 WB Large T A3101 28LMRKAYLKK 0.436 447 WB Large T A3101 547 DFRPKIYLR 0.938 1 SB Large TA3301 576 LLLLLIWFR 0.827 6 SB Large T A3301 607 EISMYTFSR 0.826 6 SBLarge T A3301 195 IIFFLTPHR 0.692 27 SB Large T A3301 588 DFSKDIQSR0.669 35 SB Large T A3301 197 FFLTPHRHR 0.615 64 WB Large T A3301 147LSQAVFSNR 0.592 82 WB Large T A3301 231 YLLYSALTR 0.473 299 WB Large TA3301 607 EISMYTFSR 0.908 2 SB Large T A6801 412 CVVFNVPKR 0.851 5 SBLarge T A6801 195 IIFFLTPHR 0.838 5 SB Large T A6801 217 CTFSFLICK 0.8137 SB Large T A6801 324 NAIIFAESK 0.796 9 SB Large T A6801 207 SAINNFCQK0.749 15 SB Large T A6801 160 FAVYTTKEK 0.721 20 SB Large T A6801 274ITEYAVETK 0.648 44 SB Large T A6801 147 LSQAVFSNR 0.643 47 SB Large TA6801 536 KTLQARFVR 0.643 47 SB Large T A6801 231 YLLYSALTR 0.628 56 WBLarge T A6801 616 MKYNICMGK 0.625 58 WB Large T A6801 491 GINNLDSLR0.625 58 WB Large T A6801 413 VVFNVPKRR 0.622 60 WB Large T A6801 560NSEFLLEKR 0.620 61 WB Large T A6801 609 SMYTFSRMK 0.595 80 WB Large TA6801 167 EKAQILYKK 0.595 80 WB Large T A6801 610 MYTFSRMKY 0.588 86 WBLarge T A6801 576 LLLLLIWFR 0.573 101 WB Large T A6801 469 YMVVFEDVK0.567 108 WB Large T A6801 296 FQYNVEECK 0.534 153 WB Large T A6801 123HSTPPKKKR 0.530 162 WB Large T A6801 340 QAVDTVLAK 0.527 167 WB Large TA6801 668 HSQELHLCK 0.512 196 WB Large T A6801 505 SVKVNLEKK 0.501 220WB Large T A6801 120 DSQHSTPPK 0.485 263 WB Large T A6801 528 TMNEYPVPK0.481 275 WB Large T A6801 171 ILYKKLMEK 0.479 281 WB Large T A6801 504GSVKVNLEK 0.451 380 WB Large T A6801 285 DVFLLLGMY 0.450 385 WB Large TA6801 449 LNVNLPMER 0.448 390 WB Large T A6801 350 RVDTLHMTR 0.441 422WB Large T A6801 403 DSVIFDFLH 0.439 432 WB Large T A6801 388 YMAGVAWLH0.437 440 WB Large T A6801 588 DFSKDIQSR 0.437 444 WB Large T A6801 547DFRPKIYLR 0.427 492 WB Large T A6801 8 ESMELMDLL 0.767 12 SB Large TA6802 409 FLHCVVFNV 0.700 25 SB Large T A6802 402 MDSVIFDFL 0.694 27 SBLarge T A6802 450 NVNLPMERL 0.691 28 SB Large T A6802 219 FSFLICKGV0.689 28 SB Large T A6802 265 ETKQVSWKL 0.607 70 WB Large T A6802 280ETKCEDVFL 0.589 85 WB Large T A6802 416 NVPKRRYWL 0.585 89 WB Large TA6802 526 LVTMNEYPV 0.585 89 WB Large T A6802 405 VIFDFLHCV 0.583 91 WBLarge T A6802 73 FGTWNSSEV 0.580 94 WB Large T A6802 458 LTFELGVAI 0.57796 WB Large T A6802 371 DKMDLIFGA 0.565 110 WB Large T A6802 589FSKDIQSRI 0.558 119 WB Large T A6802 198 FLTPHRHRV 0.543 140 WB Large TA6802 519 TQIFPPGLV 0.515 189 WB Large T A6802 377 FGAHGNAVL 0.502 218WB Large T A6802 156 TLACFAVYT 0.493 239 WB Large T A6802 464 VAIDQYMVV0.486 261 WB Large T A6802 468 QYMVVFEDV 0.482 271 WB Large T A6802 608ISMYTFSRM 0.465 326 WB Large T A6802 343 DTVLAKKRV 0.459 348 WB Large TA6802 361 MLTERFNHI 0.450 382 WB Large T A6802 191 AGHNIIFFL 0.447 396WB Large T A6802 154 NRTLACFAV 0.432 468 WB Large T A6802 458 LTFELGVAI0.702 25 SB Large T A6901 405 VIFDFLHCV 0.691 28 SB Large T A6901 409FLHCVVFNV 0.683 30 SB Large T A6901 578 LLLIWFRPV 0.630 54 WB Large TA6901 8 ESMELMDLL 0.609 68 WB Large T A6901 368 HILDKMDLI 0.587 87 WBLarge T A6901 139 FPSDLHQFL 0.553 125 WB Large T A6901 292 MYLEFQYNV0.522 176 WB Large T A6901 21 AAWGNLPLM 0.483 267 WB Large T A6901 198FLTPHRHRV 0.481 274 WB Large T A6901 265 ETKQVSWKL 0.457 355 WB Large TA6901 500 DYLDGSVKV 0.449 389 WB Large T A6901 464 VAIDQYMVV 0.431 472WB Large T A6901 20 RAAWGNLPL 0.721 20 SB Large T B0702 26 LPLMRKAYL0.719 20 SB Large T B0702 200 TPHRHRVSA 0.662 38 SB Large T B0702 532YPVPKTLQA 0.651 43 SB Large T B0702 399 LPKMDSVIF 0.516 187 WB Large TB0702 568 RILQSGMTL 0.499 226 WB Large T B0702 81 VPTYGTEEW 0.497 232 WBLarge T B0702 139 FPSDLHQFL 0.467 320 WB Large T B0702 417 VPKRRYWLF0.461 339 WB Large T B0702 417 VPKRRYWLF 0.587 87 WB Large T B0801 144HQFLSQAVF 0.618 62 WB Large T B1501 234 YSALTRDPY 0.569 105 WB Large TB1501 50 KMKRMNTLY 0.561 115 WB Large T B1501 213 CQKLCTFSF 0.528 165 WBLarge T B1501 155 RTLACFAVY 0.522 176 WB Large T B1501 514 HLNKRTQIF0.501 221 WB Large T B1501 288 LLLGMYLEF 0.495 236 WB Large T B1501 570LQSGMTLLL 0.479 280 WB Large T B1501 152 FSNRTLACF 0.468 315 WB Large TB1501 176 LMEKYSVTF 0.466 324 WB Large T B1501 20 RAAWGNLPL 0.444 411 WBLarge T B1501 388 YMAGVAWLH 0.439 434 WB Large T B1501 10 MELMDLLGL0.722 20 SB Large T B1801 530 NEYPVPKTL 0.706 24 SB Large T B1801 670QELHLCKGF 0.692 27 SB Large T B1801 229 KEYLLYSAL 0.571 104 WB Large TB1801 664 SENPHSQEL 0.520 179 WB Large T B1801 52 KRMNTLYKK 0.656 41 SBLarge T B2705 548 FRPKIYLRK 0.526 169 WB Large T B2705 420 RRYWLFKGP0.518 184 WB Large T B2705 364 ERFNHILDK 0.460 343 WB Large T B2705 614SRMKYNICM 0.452 375 WB Large T B2705 540 ARFVRQIDF 0.436 448 WB Large TB2705 682 KRPKTPPPK 0.430 477 WB Large T B2705 399 LPKMDSVIF 0.752 14 SBLarge T B3501 139 FPSDLHQFL 0.633 52 WB Large T B3501 20 RAAWGNLPL 0.61862 WB Large T B3501 234 YSALTRDPY 0.565 111 WB Large T B3501 447KALNVNLPM 0.561 115 WB Large T B3501 21 AAWGNLPLM 0.545 137 WB Large TB3501 189 MCAGHNIIF 0.537 149 WB Large T B3501 111 FASDEEATA 0.509 202WB Large T B3501 534 VPKTLQARF 0.498 229 WB Large T B3501 81 VPTYGTEEW0.486 260 WB Large T B3501 269 VSWKLITEY 0.463 334 WB Large T B3501 285DVFLLLGMY 0.447 394 WB Large T B3501 532 YPVPKTLQA 0.445 403 WB Large TB3501 176 LMEKYSVTF 0.441 423 WB Large T B3501 155 RTLACFAVY 0.434 455WB Large T B3501 666 NPHSQELHL 0.426 495 WB Large T B3501 377 FGAHGNAVL0.547 133 WB Large T B3901 10 MELMDLLGL 0.751 14 SB Large T B4001 229KEYLLYSAL 0.690 28 SB Large T B4001 664 SENPHSQEL 0.681 31 SB Large TB4001 530 NEYPVPKTL 0.592 82 WB Large T B4001 7 EESMELMDL 0.561 115 WBLarge T B4001 245 IEESIQGGL 0.552 127 WB Large T B4001 561 SEFLLEKRI0.498 227 WB Large T B4001 18 LERAAWGNL 0.497 231 WB Large T B4001 358REEMLTERF 0.441 422 WB Large T B4001 664 SENPHSQEL 0.630 54 WB Large TB4002 229 KEYLLYSAL 0.583 91 WB Large T B4002 606 SEISMYTFS 0.489 252 WBLarge T B4002 279 VETKCEDVF 0.469 314 WB Large T B4002 177 MEKYSVTFI0.462 335 WB Large T B4002 606 SEISMYTFS 0.521 177 WB Large T B4403 561SEFLLEKRI 0.458 353 WB Large T B4403 664 SENPHSQEL 0.446 403 WB Large TB4403 — 329 AESKNQKSI 0.497 229 WB Large T B4501 453 LPMERLTFE 0.451 378WB Large T B5101 139 FPSDLHQFL 0.438 437 WB Large T B5101 81 VPTYGTEEW0.673 34 SB Large T B5301 399 LPKMDSVIF 0.628 55 WB Large T B5301 26LPLMRKAYL 0.625 57 WB Large T B5301 666 NPHSQELHL 0.553 126 WB Large TB5301 139 FPSDLHQFL 0.509 202 WB Large T B5301 574 MTLLLLLIW 0.454 366WB Large T B5301 522 FPPGLVTMN 0.672 34 SB Large T B5401 200 TPHRHRVSA0.530 162 WB Large T B5401 219 FSFLICKGV 0.453 373 WB Large T B5401 453LPMERLTFE 0.432 466 WB Large T B5401 574 MTLLLLLIW 0.446 399 WB Large TB5701 401 KMDSVIFDF 0.615 64 WB Large T B5801 574 MTLLLLLIW 0.594 80 WBLarge T B5801 152 FSNRTLACF 0.562 114 WB Large T B5801 84 YGTEEWESW0.553 125 WB Large T B5801 20 RAAWGNLPL 0.460 344 WB Large T B5801 447KALNVNLPM 0.442 419 WB Large T B5801 269 VSWKLITEY 0.429 482 WB Large TB5801 10-mers 164 TTKEKAQILY 0.528 165 WB Large T A0101 401 KMDSVIFDFL0.830 6 SB Large T A0201 291 GMYLEFQYNV 0.761 13 SB Large T A0201 405VIFDFLHCVV 0.679 32 SB Large T A0201 525 GLVTMNEYPV 0.676 33 SB Large TA0201 501 YLDGSVKVNL 0.671 35 SB Large T A0201 569 ILQSGMTLLL 0.658 40SB Large T A0201 577 LLLLIWFRPV 0.657 40 SB Large T A0201 383 AVLEQYMAGV0.637 50 WB Large T A0201 361 MLTERFNHIL 0.616 63 WB Large T A0201 176LMEKYSVTFI 0.609 68 WB Large T A0201 404 SVIFDFLHCV 0.585 89 WB Large TA0201 603 RLDSEISMYT 0.583 90 WB Large T A0201 497 SLRDYLDGSV 0.570 104WB Large T A0201 272 KLITEYAVET 0.543 140 WB Large T A0201 578LLLIWFRPVA 0.503 216 WB Large T A0201 563 FLLEKRILQS 0.500 222 WBLarge T A0201 56 TLYKKMEQDV 0.485 263 WB Large T A0201 528 TMNEYPVPKT0.457 354 WB Large T A0201 12 LMDLLGLERA 0.456 361 WB Large T A0201 568RILQSGMTLL 0.454 367 WB Large T A0201 288 LLLGMYLEFQ 0.448 391 WBLarge T A0201 3 VLNREESMEL 0.434 454 WB Large T A0201 401 KMDSVIFDFL0.773 11 SB Large T A0202 603 RLDSEISMYT 0.720 20 SB Large T A0202 569ILQSGMTLLL 0.716 21 SB Large T A0202 291 GMYLEFQYNV 0.681 31 SB Large TA0202 525 GLVTMNEYPV 0.674 33 SB Large T A0202 497 SLRDYLDGSV 0.665 37SB Large T A0202 405 VIFDFLHCVV 0.649 44 SB Large T A0202 501 YLDGSVKVNL0.648 44 SB Large T A0202 288 LLLGMYLEFQ 0.645 46 SB Large T A0202 577LLLLIWFRPV 0.628 55 WB Large T A0202 287 FLLLGMYLEF 0.618 62 WB Large TA0202 570 LQSGMTLLLL 0.609 69 WB Large T A0202 12 LMDLLGLERA 0.607 70 WBLarge T A0202 388 YMAGVAWLHC 0.582 91 WB Large T A0202 156 TLACFAVYTT0.566 109 WB Large T A0202 175 KLMEKYSVTF 0.566 109 WB Large T A0202 3VLNREESMEL 0.562 114 WB Large T A0202 397 CLLPKMDSVI 0.561 115 WBLarge T A0202 285 DVFLLLGMYL 0.560 117 WB Large T A0202 435 TLAAGLLDLC0.550 130 WB Large T A0202 361 MLTERFNHIL 0.543 140 WB Large T A0202 383AVLEQYMAGV 0.535 153 WB Large T A0202 353 TLHMTREEML 0.532 157 WBLarge T A0202 461 ELGVAIDQYM 0.520 180 WB Large T A0202 56 TLYKKMEQDV0.516 187 WB Large T A0202 103 DLFCHEDMFA 0.516 187 WB Large T A0202 463GVAIDQYMVV 0.509 202 WB Large T A0202 9 SMELMDLLGL 0.507 206 WB Large TA0202 142 DLHQFLSQAV 0.497 230 WB Large T A0202 611 YTFSRMKYNI 0.493 240WB Large T A0202 272 KLITEYAVET 0.492 243 WB Large T A0202 375LIFGAHGNAV 0.491 247 WB Large T A0202 563 FLLEKRILQS 0.488 253 WBLarge T A0202 440 LLDLCGGKAL 0.488 255 WB Large T A0202 25 NLPLMRKAYL0.483 269 WB Large T A0202 568 RILQSGMTLL 0.478 285 WB Large T A0202 176LMEKYSVTFI 0.471 305 WB Large T A0202 236 ALTRDPYHII 0.461 341 WBLarge T A0202 493 NNLDSLRDYL 0.454 366 WB Large T A0202 572 SGMTLLLLLI0.453 371 WB Large T A0202 148 SQAVFSNRTL 0.450 383 WB Large T A0202 439GLLDLCGGKA 0.445 406 WB Large T A0202 609 SMYTFSRMKY 0.445 406 WBLarge T A0202 345 VLAKKRVDTL 0.445 407 WB Large T A0202 360 EMLTERFNHI0.440 427 WB Large T A0202 578 LLLIWFRPVA 0.438 435 WB Large T A0202 556KSLQNSEFLL 0.437 441 WB Large T A0202 213 CQKLCTFSFL 0.433 461 WBLarge T A0202 497 SLRDYLDGSV 0.883 3 SB Large T A0203 361 MLTERFNHIL0.815 7 SB Large T A0203 291 GMYLEFQYNV 0.792 9 SB Large T A0203 525GLVTMNEYPV 0.769 12 SB Large T A0203 383 AVLEQYMAGV 0.755 14 SB Large TA0203 569 ILQSGMTLLL 0.731 18 SB Large T A0203 375 LIFGAHGNAV 0.731 18SB Large T A0203 577 LLLLIWFRPV 0.708 23 SB Large T A0203 56 TLYKKMEQDV0.707 23 SB Large T A0203 405 VIFDFLHCVV 0.674 34 SB Large T A0203 3VLNREESMEL 0.666 37 SB Large T A0203 457 RLTFELGVAI 0.665 37 SB Large TA0203 404 SVIFDFLHCV 0.654 42 SB Large T A0203 501 YLDGSVKVNL 0.627 56WB Large T A0203 345 VLAKKRVDTL 0.625 57 WB Large T A0203 176 LMEKYSVTFI0.611 67 WB Large T A0203 156 TLACFAVYTT 0.600 75 WB Large T A0203 236ALTRDPYHII 0.576 98 WB Large T A0203 401 KMDSVIFDFL 0.549 132 WB Large TA0203 537 TLQARFVRQI 0.548 132 WB Large T A0203 439 GLLDLCGGKA 0.546 136WB Large T A0203 570 LQSGMTLLLL 0.542 142 WB Large T A0203 568RILQSGMTLL 0.541 143 WB Large T A0203 397 CLLPKMDSVI 0.534 154 WBLarge T A0203 611 YTFSRMKYNI 0.521 177 WB Large T A0203 142 DLHQFLSQAV0.503 217 WB Large T A0203 603 RLDSEISMYT 0.488 254 WB Large T A0203 578LLLIWFRPVA 0.485 261 WB Large T A0203 272 KLITEYAVET 0.485 263 WBLarge T A0203 213 CQKLCTFSFL 0.480 277 WB Large T A0203 463 GVAIDQYMVV0.473 298 WB Large T A0203 12 LMDLLGLERA 0.468 314 WB Large T A0203 528TMNEYPVPKT 0.465 326 WB Large T A0203 9 SMELMDLLGL 0.462 338 WB Large TA0203 333 NQKSICQQAV 0.456 361 WB Large T A0203 336 SICQQAVDTV 0.435 451WB Large T A0203 383 AVLEQYMAGV 0.666 37 SB Large T A0204 525 GLVTMNEYPV0.603 73 WB Large T A0204 577 LLLLIWFRPV 0.591 83 WB Large T A0204 361MLTERFNHIL 0.573 101 WB Large T A0204 497 SLRDYLDGSV 0.565 110 WBLarge T A0204 336 SICQQAVDTV 0.557 120 WB Large T A0204 3 VLNREESMEL0.557 120 WB Large T A0204 291 GMYLEFQYNV 0.549 132 WB Large T A0204 405VIFDFLHCVV 0.533 155 WB Large T A0204 375 LIFGAHGNAV 0.515 190 WBLarge T A0204 537 TLQARFVRQI 0.496 234 WB Large T A0204 236 ALTRDPYHII0.494 238 WB Large T A0204 401 KMDSVIFDFL 0.484 266 WB Large T A0204 528TMNEYPVPKT 0.473 300 WB Large T A0204 345 VLAKKRVDTL 0.461 339 WBLarge T A0204 175 KLMEKYSVTF 0.451 380 WB Large T A0204 569 ILQSGMTLLL0.446 401 WB Large T A0204 176 LMEKYSVTFI 0.437 440 WB Large T A0204 463GVAIDQYMVV 0.434 454 WB Large T A0204 518 RTQIFPPGLV 0.431 473 WBLarge T A0204 383 AVLEQYMAGV 0.832 6 SB Large T A0206 404 SVIFDFLHCV0.773 11 SB Large T A0206 401 KMDSVIFDFL 0.762 13 SB Large T A0206 577LLLLIWFRPV 0.744 15 SB Large T A0206 570 LQSGMTLLLL 0.714 22 SB Large TA0206 525 GLVTMNEYPV 0.698 26 SB Large T A0206 291 GMYLEFQYNV 0.682 31SB Large T A0206 405 VIFDFLHCVV 0.674 33 SB Large T A0206 568 RILQSGMTLL0.670 35 SB Large T A0206 361 MLTERFNHIL 0.650 43 SB Large T A0206 375LIFGAHGNAV 0.644 47 SB Large T A0206 287 FLLLGMYLEF 0.607 70 WB Large TA0206 497 SLRDYLDGSV 0.596 79 WB Large T A0206 267 KQVSWKLITE 0.564 112WB Large T A0206 175 KLMEKYSVTF 0.553 125 WB Large T A0206 148SQAVFSNRTL 0.535 153 WB Large T A0206 20 RAAWGNLPLM 0.518 184 WB Large TA0206 388 YMAGVAWLHC 0.510 201 WB Large T A0206 213 CQKLCTFSFL 0.505 212WB Large T A0206 272 KLITEYAVET 0.494 237 WB Large T A0206 578LLLIWFRPVA 0.494 238 WB Large T A0206 336 SICQQAVDTV 0.493 242 WBLarge T A0206 501 YLDGSVKVNL 0.487 257 WB Large T A0206 569 ILQSGMTLLL0.483 269 WB Large T A0206 520 QIFPPGLVTM 0.482 272 WB Large T A0206 338CQQAVDTVLA 0.481 275 WB Large T A0206 277 YAVETKCEDV 0.480 278 WBLarge T A0206 155 RTLACFAVYT 0.469 312 WB Large T A0206 563 FLLEKRILQS0.454 368 WB Large T A0206 603 RLDSEISMYT 0.445 405 WB Large T A0206 397CLLPKMDSVI 0.441 422 WB Large T A0206 457 RLTFELGVAI 0.437 440 WBLarge T A0206 207 SAINNFCQKL 0.433 463 WB Large T A0206 463 GVAIDQYMVV0.429 481 WB Large T A0206 501 YLDGSVKVNL 0.958 1 SB Large T A0211 405VIFDFLHCVV 0.936 2 SB Large T A0211 525 GLVTMNEYPV 0.915 2 SB Large TA0211 291 GMYLEFQYNV 0.909 2 SB Large T A0211 569 ILQSGMTLLL 0.902 2 SBLarge T A0211 142 DLHQFLSQAV 0.898 3 SB Large T A0211 497 SLRDYLDGSV0.895 3 SB Large T A0211 401 KMDSVIFDFL 0.890 3 SB Large T A0211 577LLLLIWFRPV 0.888 3 SB Large T A0211 56 TLYKKMEQDV 0.875 3 SB Large TA0211 361 MLTERFNHIL 0.874 3 SB Large T A0211 383 AVLEQYMAGV 0.866 4 SBLarge T A0211 442 DLCGGKALNV 0.854 4 SB Large T A0211 375 LIFGAHGNAV0.829 6 SB Large T A0211 3 VLNREESMEL 0.824 6 SB Large T A0211 288LLLGMYLEFQ 0.816 7 SB Large T A0211 603 RLDSEISMYT 0.797 9 SB Large TA0211 404 SVIFDFLHCV 0.791 9 SB Large T A0211 236 ALTRDPYHII 0.782 10 SBLarge T A0211 388 YMAGVAWLHC 0.782 10 SB Large T A0211 12 LMDLLGLERA0.757 13 SB Large T A0211 287 FLLLGMYLEF 0.747 15 SB Large T A0211 463GVAIDQYMVV 0.742 16 SB Large T A0211 336 SICQQAVDTV 0.736 17 SB Large TA0211 345 VLAKKRVDTL 0.725 19 SB Large T A0211 353 TLHMTREEML 0.722 20SB Large T A0211 568 RILQSGMTLL 0.720 20 SB Large T A0211 440 LLDLCGGKAL0.713 22 SB Large T A0211 578 LLLIWFRPVA 0.712 22 SB Large T A0211 563FLLEKRILQS 0.708 23 SB Large T A0211 9 SMELMDLLGL 0.706 24 SB Large TA0211 439 GLLDLCGGKA 0.690 28 SB Large T A0211 520 QIFPPGLVTM 0.684 30SB Large T A0211 25 NLPLMRKAYL 0.682 31 SB Large T A0211 457 RLTFELGVAI0.675 33 SB Large T A0211 156 TLACFAVYTT 0.669 35 SB Large T A0211 435TLAAGLLDLC 0.649 44 SB Large T A0211 397 CLLPKMDSVI 0.648 44 SB Large TA0211 197 FFLTPHRHRV 0.635 51 WB Large T A0211 537 TLQARFVRQI 0.630 55WB Large T A0211 609 SMYTFSRMKY 0.624 58 WB Large T A0211 176 LMEKYSVTFI0.612 66 WB Large T A0211 175 KLMEKYSVTF 0.575 98 WB Large T A0211 103DLFCHEDMFA 0.573 101 WB Large T A0211 289 LLGMYLEFQY 0.539 146 WBLarge T A0211 428 PIDSGKTTLA 0.534 155 WB Large T A0211 272 KLITEYAVET0.531 160 WB Large T A0211 545 QIDFRPKIYL 0.527 166 WB Large T A0211 575TLLLLLIWFR 0.518 183 WB Large T A0211 198 FLTPHRHRVS 0.517 185 WBLarge T A0211 528 TMNEYPVPKT 0.509 203 WB Large T A0211 17 GLERAAWGNL0.502 219 WB Large T A0211 384 VLEQYMAGVA 0.492 244 WB Large T A0211 277YAVETKCEDV 0.480 278 WB Large T A0211 124 STPPKKKRKV 0.477 287 WBLarge T A0211 360 EMLTERFNHI 0.458 351 WB Large T A0211 171 ILYKKLMEKY0.456 358 WB Large T A0211 369 ILDKMDLIFG 0.442 418 WB Large T A0211 215KLCTFSFLIC 0.432 464 WB Large T A0211 461 ELGVAIDQYM 0.429 479 WBLarge T A0211 501 YLDGSVKVNL 0.900 2 SB Large T A0212 405 VIFDFLHCVV0.897 3 SB Large T A0212 56 TLYKKMEQDV 0.893 3 SB Large T A0212 291GMYLEFQYNV 0.886 3 SB Large T A0212 497 SLRDYLDGSV 0.867 4 SB Large TA0212 383 AVLEQYMAGV 0.855 4 SB Large T A0212 525 GLVTMNEYPV 0.825 6 SBLarge T A0212 361 MLTERFNHIL 0.824 6 SB Large T A0212 375 LIFGAHGNAV0.806 8 SB Large T A0212 142 DLHQFLSQAV 0.795 9 SB Large T A0212 3VLNREESMEL 0.788 9 SB Large T A0212 401 KMDSVIFDFL 0.784 10 SB Large TA0212 569 ILQSGMTLLL 0.783 10 SB Large T A0212 577 LLLLIWFRPV 0.783 10SB Large T A0212 388 YMAGVAWLHC 0.765 12 SB Large T A0212 345 VLAKKRVDTL0.754 14 SB Large T A0212 288 LLLGMYLEFQ 0.715 21 SB Large T A0212 287FLLLGMYLEF 0.683 30 SB Large T A0212 563 FLLEKRILQS 0.666 37 SB Large TA0212 442 DLCGGKALNV 0.657 40 SB Large T A0212 397 CLLPKMDSVI 0.632 53WB Large T A0212 12 LMDLLGLERA 0.604 72 WB Large T A0212 404 SVIFDFLHCV0.604 72 WB Large T A0212 9 SMELMDLLGL 0.579 95 WB Large T A0212 603RLDSEISMYT 0.573 101 WB Large T A0212 236 ALTRDPYHII 0.570 104 WBLarge T A0212 277 YAVETKCEDV 0.569 106 WB Large T A0212 578 LLLIWFRPVA0.558 119 WB Large T A0212 353 TLHMTREEML 0.552 126 WB Large T A0212 197FFLTPHRHRV 0.549 131 WB Large T A0212 520 QIFPPGLVTM 0.543 139 WBLarge T A0212 176 LMEKYSVTFI 0.536 150 WB Large T A0212 175 KLMEKYSVTF0.528 165 WB Large T A0212 463 GVAIDQYMVV 0.500 222 WB Large T A0212 336SICQQAVDTV 0.495 235 WB Large T A0212 457 RLTFELGVAI 0.489 252 WBLarge T A0212 198 FLTPHRHRVS 0.484 266 WB Large T A0212 609 SMYTFSRMKY0.480 276 WB Large T A0212 171 ILYKKLMEKY 0.477 285 WB Large T A0212 25NLPLMRKAYL 0.477 287 WB Large T A0212 439 GLLDLCGGKA 0.476 288 WBLarge T A0212 611 YTFSRMKYNI 0.472 304 WB Large T A0212 435 TLAAGLLDLC0.461 342 WB Large T A0212 440 LLDLCGGKAL 0.459 349 WB Large T A0212 568RILQSGMTLL 0.458 352 WB Large T A0212 360 EMLTERFNHI 0.457 354 WBLarge T A0212 537 TLQARFVRQI 0.452 375 WB Large T A0212 17 GLERAAWGNL0.430 474 WB Large T A0212 528 TMNEYPVPKT 0.428 488 WB Large T A0212 525GLVTMNEYPV 0.882 3 SB Large T A0216 405 VIFDFLHCVV 0.863 4 SB Large TA0216 497 SLRDYLDGSV 0.861 4 SB Large T A0216 56 TLYKKMEQDV 0.842 5 SBLarge T A0216 291 GMYLEFQYNV 0.841 5 SB Large T A0216 569 ILQSGMTLLL0.838 5 SB Large T A0216 501 YLDGSVKVNL 0.833 6 SB Large T A0216 361MLTERFNHIL 0.812 7 SB Large T A0216 142 DLHQFLSQAV 0.809 7 SB Large TA0216 401 KMDSVIFDFL 0.806 8 SB Large T A0216 442 DLCGGKALNV 0.802 8 SBLarge T A0216 375 LIFGAHGNAV 0.773 11 SB Large T A0216 3 VLNREESMEL0.768 12 SB Large T A0216 345 VLAKKRVDTL 0.765 12 SB Large T A0216 577LLLLIWFRPV 0.743 16 SB Large T A0216 383 AVLEQYMAGV 0.739 16 SB Large TA0216 336 SICQQAVDTV 0.721 20 SB Large T A0216 25 NLPLMRKAYL 0.703 24 SBLarge T A0216 288 LLLGMYLEFQ 0.679 32 SB Large T A0216 176 LMEKYSVTFI0.675 33 SB Large T A0216 236 ALTRDPYHII 0.671 35 SB Large T A0216 353TLHMTREEML 0.668 36 SB Large T A0216 404 SVIFDFLHCV 0.647 45 SB Large TA0216 603 RLDSEISMYT 0.630 54 WB Large T A0216 197 FFLTPHRHRV 0.615 64WB Large T A0216 388 YMAGVAWLHC 0.602 73 WB Large T A0216 568 RILQSGMTLL0.598 77 WB Large T A0216 156 TLACFAVYTT 0.567 108 WB Large T A0216 397CLLPKMDSVI 0.562 114 WB Large T A0216 461 ELGVAIDQYM 0.550 130 WBLarge T A0216 17 GLERAAWGNL 0.545 137 WB Large T A0216 103 DLFCHEDMFA0.537 149 WB Large T A0216 463 GVAIDQYMVV 0.534 155 WB Large T A0216 537TLQARFVRQI 0.528 165 WB Large T A0216 563 FLLEKRILQS 0.511 198 WBLarge T A0216 545 QIDFRPKIYL 0.493 240 WB Large T A0216 12 LMDLLGLERA0.484 265 WB Large T A0216 287 FLLLGMYLEF 0.483 270 WB Large T A0216 289LLGMYLEFQY 0.482 270 WB Large T A0216 439 GLLDLCGGKA 0.477 287 WBLarge T A0216 9 SMELMDLLGL 0.468 316 WB Large T A0216 673 HLCKGFQCFK0.468 317 WB Large T A0216 520 QIFPPGLVTM 0.463 334 WB Large T A0216 190CAGHNIIFFL 0.447 397 WB Large T A0216 440 LLDLCGGKAL 0.445 406 WBLarge T A0216 124 STPPKKKRKV 0.438 439 WB Large T A0216 578 LLLIWFRPVA0.428 485 WB Large T A0216 501 YLDGSVKVNL 0.885 3 SB Large T A0219 569ILQSGMTLLL 0.833 6 SB Large T A0219 401 KMDSVIFDFL 0.761 13 SB Large TA0219 361 MLTERFNHIL 0.747 15 SB Large T A0219 405 VIFDFLHCVV 0.704 24SB Large T A0219 291 GMYLEFQYNV 0.679 32 SB Large T A0219 142 DLHQFLSQAV0.676 33 SB Large T A0219 577 LLLLIWFRPV 0.646 45 SB Large T A0219 525GLVTMNEYPV 0.631 54 WB Large T A0219 497 SLRDYLDGSV 0.622 59 WB Large TA0219 388 YMAGVAWLHC 0.582 91 WB Large T A0219 3 VLNREESMEL 0.573 101 WBLarge T A0219 288 LLLGMYLEFQ 0.572 102 WB Large T A0219 56 TLYKKMEQDV0.570 104 WB Large T A0219 375 LIFGAHGNAV 0.565 110 WB Large T A0219 442DLCGGKALNV 0.557 120 WB Large T A0219 383 AVLEQYMAGV 0.556 122 WBLarge T A0219 236 ALTRDPYHII 0.545 137 WB Large T A0219 345 VLAKKRVDTL0.515 189 WB Large T A0219 603 RLDSEISMYT 0.498 227 WB Large T A0219 12LMDLLGLERA 0.486 260 WB Large T A0219 397 CLLPKMDSVI 0.475 293 WBLarge T A0219 404 SVIFDFLHCV 0.474 294 WB Large T A0219 435 TLAAGLLDLC0.459 347 WB Large T A0219 197 FFLTPHRHRV 0.449 389 WB Large T A0219 353TLHMTREEML 0.433 463 WB Large T A0219 537 TLQARFVRQI 0.427 492 WBLarge T A0219 170 QILYKKLMEK 0.764 12 SB Large T A0301 50 KMKRMNTLYK0.754 14 SB Large T A0301 615 RMKYNICMGK 0.751 14 SB Large T A0301 608ISMYTFSRMK 0.734 17 SB Large T A0301 609 SMYTFSRMKY 0.707 23 SB Large TA0301 527 VTMNEYPVPK 0.691 28 SB Large T A0301 673 HLCKGFQCFK 0.668 36SB Large T A0301 27 PLMRKAYLKK 0.663 38 SB Large T A0301 157 LACFAVYTTK0.654 42 SB Large T A0301 392 VAWLHCLLPK 0.582 92 WB Large T A0301 575TLLLLLIWFR 0.574 100 WB Large T A0301 220 SFLICKGVNK 0.554 124 WBLarge T A0301 22 AWGNLPLMRK 0.533 156 WB Large T A0301 326 IIFAESKNQK0.519 181 WB Large T A0301 26 LPLMRKAYLK 0.500 222 WB Large T A0301 558LQNSEFLLEK 0.484 265 WB Large T A0301 311 QPYHFKYHEK 0.465 326 WBLarge T A0301 417 VPKRRYWLFK 0.462 338 WB Large T A0301 206 VSAINNFCQK0.448 391 WB Large T A0301 448 ALNVNLPMER 0.447 396 WB Large T A0301 273LITEYAVETK 0.446 399 WB Large T A0301 171 ILYKKLMEKY 0.433 462 WBLarge T A0301 527 VTMNEYPVPK 0.811 7 SB Large T A1101 608 ISMYTFSRMK0.760 13 SB Large T A1101 392 VAWLHCLLPK 0.708 23 SB Large T A1101 558LQNSEFLLEK 0.705 24 SB Large T A1101 50 KMKRMNTLYK 0.700 25 SB Large TA1101 326 IIFAESKNQK 0.695 27 SB Large T A1101 206 VSAINNFCQK 0.692 28SB Large T A1101 609 SMYTFSRMKY 0.665 37 SB Large T A1101 575 TLLLLLIWFR0.648 45 SB Large T A1101 170 QILYKKLMEK 0.643 47 SB Large T A1101 157LACFAVYTTK 0.635 51 WB Large T A1101 673 HLCKGFQCFK 0.622 59 WB Large TA1101 90 ESWWSSFNEK 0.565 110 WB Large T A1101 615 RMKYNICMGK 0.556 121WB Large T A1101 121 SQHSTPPKKK 0.552 127 WB Large T A1101 504GSVKVNLEKK 0.541 143 WB Large T A1101 339 QQAVDTVLAK 0.540 145 WBLarge T A1101 340 QAVDTVLAKK 0.534 154 WB Large T A1101 448 ALNVNLPMER0.528 165 WB Large T A1101 194 NIIFFLTPHR 0.516 188 WB Large T A1101 27PLMRKAYLKK 0.478 284 WB Large T A1101 21 AAWGNLPLMR 0.475 293 WB Large TA1101 273 LITEYAVETK 0.470 310 WB Large T A1101 120 DSQHSTPPKK 0.450 383WB Large T A1101 22 AWGNLPLMRK 0.449 387 WB Large T A1101 220 SFLICKGVNK0.445 404 WB Large T A1101 468 QYMVVFEDVK 0.626 57 WB Large T A2301 151VFSNRTLACF 0.608 69 WB Large T A2301 287 FLLLGMYLEF 0.575 99 WB Large TA2301 582 WFRPVADFSK 0.548 133 WB Large T A2301 57 LYKKMEQDVK 0.531 160WB Large T A2301 574 MTLLLLLIWF 0.524 171 WB Large T A2301 83 TYGTEEWESW0.500 224 WB Large T A2301 406 IFDFLHCVVF 0.486 260 WB Large T A2301 416NVPKRRYWLF 0.477 288 WB Large T A2301 220 SFLICKGVNK 0.469 311 WBLarge T A2301 159 CFAVYTTKEK 0.465 326 WB Large T A2301 203 RHRVSAINNF0.458 351 WB Large T A2301 295 EFQYNVEECK 0.447 396 WB Large T A2301 175KLMEKYSVTF 0.446 401 WB Large T A2301 91 SWWSSFNEKW 0.436 447 WB Large TA2301 464 VAIDQYMVVF 0.430 478 WB Large T A2301 212 FCQKLCTFSF 0.426 499WB Large T A2301 151 VFSNRTLACF 0.606 71 WB Large T A2402 162 VYTTKEKAQI0.518 183 WB Large T A2402 617 KYNICMGKCI 0.510 200 WB Large T A2402 416NVPKRRYWLF 0.506 209 WB Large T A2402 406 IFDFLHCVVF 0.483 269 WBLarge T A2402 83 TYGTEEWESW 0.472 301 WB Large T A2402 138 DFPSDLHQFL0.430 477 WB Large T A2402 83 TYGTEEWESW 0.622 59 WB Large T A2403 513KHLNKRTQIF 0.548 132 WB Large T A2403 287 FLLLGMYLEF 0.533 155 WBLarge T A2403 212 FCQKLCTFSF 0.510 201 WB Large T A2403 162 VYTTKEKAQI0.492 243 WB Large T A2403 175 KLMEKYSVTF 0.491 245 WB Large T A2403 151VFSNRTLACF 0.479 280 WB Large T A2403 313 YHFKYHEKHF 0.456 358 WBLarge T A2403 406 IFDFLHCVVF 0.453 370 WB Large T A2403 416 NVPKRRYWLF0.449 389 WB Large T A2403 203 RHRVSAINNF 0.444 408 WB Large T A2403 574MTLLLLLIWF 0.429 480 WB Large T A2403 164 TTKEKAQILY 0.552 127 WBLarge T A2601 607 EISMYTFSRM 0.466 322 WB Large T A2601 607 EISMYTFSRM0.857 4 SB Large T A2602 520 QIFPPGLVTM 0.811 7 SB Large T A2602 268QVSWKLITEY 0.726 19 SB Large T A2602 164 TTKEKAQILY 0.721 20 SB Large TA2602 416 NVPKRRYWLF 0.714 22 SB Large T A2602 533 PVPKTLQARF 0.685 30SB Large T A2602 64 DVKVAHQPDF 0.665 37 SB Large T A2602 280 ETKCEDVFLL0.646 46 SB Large T A2602 285 DVFLLLGMYL 0.612 66 WB Large T A2602 368HILDKMDLIF 0.589 85 WB Large T A2602 80 EVPTYGTEEW 0.587 86 WB Large TA2602 184 FISRHMCAGH 0.532 158 WB Large T A2602 163 YTTKEKAQIL 0.514 192WB Large T A2602 284 EDVFLLLGMY 0.470 308 WB Large T A2602 138DFPSDLHQFL 0.465 326 WB Large T A2602 611 YTFSRMKYNI 0.465 327 WBLarge T A2602 574 MTLLLLLIWF 0.463 333 WB Large T A2602 464 VAIDQYMVVF0.457 354 WB Large T A2602 404 SVIFDFLHCV 0.451 380 WB Large T A2602 609SMYTFSRMKY 0.700 25 SB Large T A2902 413 VVFNVPKRRY 0.524 172 WB Large TA2902 171 ILYKKLMEKY 0.501 221 WB Large T A2902 289 LLGMYLEFQY 0.496 232WB Large T A2902 75 TWNSSEVPTY 0.466 321 WB Large T A2902 268 QVSWKLITEY0.455 364 WB Large T A2902 50 KMKRMNTLYK 0.848 5 SB Large T A3001 676KGFQCFKRPK 0.733 17 SB Large T A3001 681 FKRPKTPPPK 0.723 20 SB Large TA3001 51 MKRMNTLYKK 0.685 30 SB Large T A3001 615 RMKYNICMGK 0.677 33 SBLarge T A3001 527 VTMNEYPVPK 0.661 39 SB Large T A3001 417 VPKRRYWLFK0.637 50 WB Large T A3001 121 SQHSTPPKKK 0.623 59 WB Large T A3001 582WFRPVADFSK 0.622 59 WB Large T A3001 542 FVRQIDFRPK 0.556 121 WB Large TA3001 608 ISMYTFSRMK 0.552 126 WB Large T A3001 128 KKKRKVEDPK 0.548 132WB Large T A3001 547 DFRPKIYLRK 0.507 207 WB Large T A3001 307QKKDQPYHFK 0.501 220 WB Large T A3001 27 PLMRKAYLKK 0.500 224 WB Large TA3001 356 MTREEMLTER 0.494 238 WB Large T A3001 29 MRKAYLKKCK 0.488 255WB Large T A3001 119 ADSQHSTPPK 0.460 344 WB Large T A3001 363TERFNHILDK 0.445 405 WB Large T A3001 166 KEKAQILYKK 0.442 418 WBLarge T A3001 164 TTKEKAQILY 0.439 432 WB Large T A3001 120 DSQHSTPPKK0.428 485 WB Large T A3001 233 LYSALTRDPY 0.534 155 WB Large T A3002 609SMYTFSRMKY 0.528 165 WB Large T A3002 268 QVSWKLITEY 0.485 262 WBLarge T A3002 75 TWNSSEVPTY 0.446 400 WB Large T A3002 575 TLLLLLIWFR0.750 14 SB Large T A3101 230 EYLLYSALTR 0.642 48 SB Large T A3101 50KMKRMNTLYK 0.640 49 SB Large T A3101 674 LCKGFQCFKR 0.638 50 WB Large TA3101 609 SMYTFSRMKY 0.623 58 WB Large T A3101 615 RMKYNICMGK 0.604 72WB Large T A3101 194 NIIFFLTPHR 0.586 88 WB Large T A3101 448 ALNVNLPMER0.583 90 WB Large T A3101 673 HLCKGFQCFK 0.573 101 WB Large T A3101 146FLSQAVFSNR 0.570 104 WB Large T A3101 412 CVVFNVPKRR 0.565 110 WBLarge T A3101 196 IFFLTPHRHR 0.550 130 WB Large T A3101 356 MTREEMLTER0.548 132 WB Large T A3101 349 KRVDTLHMTR 0.530 161 WB Large T A3101 220SFLICKGVNK 0.524 172 WB Large T A3101 51 MKRMNTLYKK 0.468 316 WB Large TA3101 157 LACFAVYTTK 0.456 358 WB Large T A3101 535 PKTLQARFVR 0.445 403WB Large T A3101 606 SEISMYTFSR 0.445 404 WB Large T A3101 594QSRIVEWKER 0.442 417 WB Large T A3101 205 RVSAINNFCQ 0.434 458 WBLarge T A3101 230 EYLLYSALTR 0.653 42 SB Large T A3301 575 TLLLLLIWFR0.600 76 WB Large T A3301 674 LCKGFQCFKR 0.537 150 WB Large T A3301 196IFFLTPHRHR 0.529 162 WB Large T A3301 194 NIIFFLTPHR 0.529 163 WBLarge T A3301 11 ELMDLLGLER 0.512 196 WB Large T A3301 146 FLSQAVFSNR0.482 271 WB Large T A3301 178 EKYSVTFISR 0.464 330 WB Large T A3301 547DFRPKIYLRK 0.429 482 WB Large T A3301 Large T A3301 194 NIIFFLTPHR 0.8664 SB Large T A6801 412 CVVFNVPKRR 0.785 10 SB Large T A6801 356MTREEMLTER 0.784 10 SB Large T A6801 90 ESWWSSFNEK 0.756 13 SB Large TA6801 146 FLSQAVFSNR 0.739 16 SB Large T A6801 11 ELMDLLGLER 0.720 20 SBLarge T A6801 178 EKYSVTFISR 0.713 22 SB Large T A6801 157 LACFAVYTTK0.693 27 SB Large T A6801 608 ISMYTFSRMK 0.660 39 SB Large T A6801 673HLCKGFQCFK 0.645 46 SB Large T A6801 230 EYLLYSALTR 0.644 47 SB Large TA6801 575 TLLLLLIWFR 0.643 47 SB Large T A6801 326 IIFAESKNQK 0.639 49SB Large T A6801 273 LITEYAVETK 0.632 53 WB Large T A6801 206 VSAINNFCQK0.629 55 WB Large T A6801 340 QAVDTVLAKK 0.623 59 WB Large T A6801 490HGINNLDSLR 0.593 81 WB Large T A6801 475 DVKGTGAESK 0.581 93 WB Large TA6801 606 SEISMYTFSR 0.572 102 WB Large T A6801 592 DIQSRIVEWK 0.563 113WB Large T A6801 311 QPYHFKYHEK 0.556 122 WB Large T A6801 527VTMNEYPVPK 0.541 143 WB Large T A6801 295 EFQYNVEECK 0.539 146 WBLarge T A6801 299 NVEECKKCQK 0.534 155 WB Large T A6801 159 CFAVYTTKEK0.524 171 WB Large T A6801 296 FQYNVEECKK 0.510 200 WB Large T A6801 196IFFLTPHRHR 0.505 212 WB Large T A6801 622 MGKCILDITR 0.480 277 WBLarge T A6801 542 FVRQIDFRPK 0.478 282 WB Large T A6801 411 HCVVFNVPKR0.476 290 WB Large T A6801 120 DSQHSTPPKK 0.461 341 WB Large T A6801 546IDFRPKIYLR 0.437 443 WB Large T A6801 164 TTKEKAQILY 0.433 460 WBLarge T A6801 404 SVIFDFLHCV 0.762 13 SB Large T A6802 611 YTFSRMKYNI0.677 32 SB Large T A6802 285 DVFLLLGMYL 0.632 53 WB Large T A6802 322FANAIIFAES 0.613 66 WB Large T A6802 280 ETKCEDVFLL 0.609 69 WB Large TA6802 462 LGVAIDQYMV 0.574 100 WB Large T A6802 607 EISMYTFSRM 0.562 114WB Large T A6802 375 LIFGAHGNAV 0.557 120 WB Large T A6802 405VIFDFLHCVV 0.536 151 WB Large T A6802 647 ESQSQCSSQV 0.517 185 WBLarge T A6802 190 CAGHNIIFFL 0.488 253 WB Large T A6802 383 AVLEQYMAGV0.479 281 WB Large T A6802 77 NSSEVPTYGT 0.467 320 WB Large T A6802 19ERAAWGNLPL 0.452 375 WB Large T A6802 108 EDMFASDEEA 0.451 379 WBLarge T A6802 265 ETKQVSWKLI 0.451 380 WB Large T A6802 207 SAINNFCQKL0.440 428 WB Large T A6802 463 GVAIDQYMVV 0.433 459 WB Large T A6802 156TLACFAVYTT 0.432 465 WB Large T A6802 383 AVLEQYMAGV 0.745 15 SB Large TA6901 404 SVIFDFLHCV 0.639 49 SB Large T A6901 611 YTFSRMKYNI 0.596 79WB Large T A6901 375 LIFGAHGNAV 0.575 99 WB Large T A6901 405 VIFDFLHCVV0.552 127 WB Large T A6901 360 EMLTERFNHI 0.545 137 WB Large T A6901 520QIFPPGLVTM 0.541 143 WB Large T A6901 453 LPMERLTFEL 0.477 287 WBLarge T A6901 434 TTLAAGLLDL 0.466 324 WB Large T A6901 277 YAVETKCEDV0.458 352 WB Large T A6901 197 FFLTPHRHRV 0.452 374 WB Large T A6901 577LLLLIWFRPV 0.435 451 WB Large T A6901 285 DVFLLLGMYL 0.431 470 WBLarge T A6901 549 RPKIYLRKSL 0.785 10 SB Large T B0702 200 TPHRHRVSAI0.752 14 SB Large T B0702 453 LPMERLTFEL 0.722 20 SB Large T B0702 427GPIDSGKTTL 0.704 24 SB Large T B0702 486 LPSGHGINNL 0.573 101 WB Large TB0702 584 RPVADFSKDI 0.560 117 WB Large T B0702 549 RPKIYLRKSL 0.479 280WB Large T B0801 200 TPHRHRVSAI 0.453 373 WB Large T B0801 544RQIDFRPKIY 0.584 89 WB Large T B1501 188 HMCAGHNIIF 0.577 97 WB Large TB1501 175 KLMEKYSVTF 0.568 107 WB Large T B1501 609 SMYTFSRMKY 0.536 150WB Large T B1501 148 SQAVFSNRTL 0.502 218 WB Large T B1501 268QVSWKLITEY 0.478 284 WB Large T B1501 287 FLLLGMYLEF 0.475 292 WBLarge T B1501 249 IQGGLKEHDF 0.467 318 WB Large T B1501 464 VAIDQYMVVF0.445 406 WB Large T B1501 570 LQSGMTLLLL 0.439 434 WB Large T B1501 460FELGVAIDQY 0.795 9 SB Large T B1801 87 EEWESWWSSF 0.653 42 SB Large TB1801 455 MERLTFELGV 0.576 98 WB Large T B1801 574 MTLLLLLIWF 0.498 227WB Large T B1801 420 RRYWLFKGPI 0.605 71 WB Large T B2705 52 KRMNTLYKKM0.591 83 WB Large T B2705 567 KRILQSGMTL 0.564 111 WB Large T B2705 349KRVDTLHMTR 0.487 258 WB Large T B2705 517 KRTQIFPPGL 0.471 305 WBLarge T B2705 464 VAIDQYMVVF 0.679 32 SB Large T B3501 453 LPMERLTFEL0.600 75 WB Large T B3501 20 RAAWGNLPLM 0.595 80 WB Large T B3501 268QVSWKLITEY 0.558 119 WB Large T B3501 486 LPSGHGINNL 0.549 131 WBLarge T B3501 287 FLLLGMYLEF 0.479 279 WB Large T B3501 523 PPGLVTMNEY0.479 281 WB Large T B3501 532 YPVPKTLQAR 0.470 310 WB Large T B3501 139FPSDLHQFLS 0.459 347 WB Large T B3501 189 MCAGHNIIFF 0.451 379 WBLarge T B3501 389 MAGVAWLHCL 0.449 390 WB Large T B3501 262 EPEETKQVSW0.433 460 WB Large T B3501 317 YHEKHFANAI 0.608 69 WB Large T B3901 148SQAVFSNRTL 0.545 137 WB Large T B3901 19 ERAAWGNLPL 0.539 147 WB Large TB3901 501 YLDGSVKVNL 0.498 228 WB Large T B3901 6 REESMELMDL 0.707 23 SBLarge T B4001 561 SEFLLEKRIL 0.683 30 SB Large T B4001 279 VETKCEDVFL0.502 218 WB Large T B4001 264 EETKQVSWKL 0.500 224 WB Large T B4001 7EESMELMDLL 0.488 253 WB Large T B4001 455 MERLTFELGV 0.485 263 WBLarge T B4001 561 SEFLLEKRIL 0.595 80 WB Large T B4002 7 EESMELMDLL0.482 271 WB Large T B4002 229 KEYLLYSALT 0.482 272 WB Large T B4002 279VETKCEDVFL 0.472 303 WB Large T B4002 87 EEWESWWSSF 0.458 353 WB Large TB4002 561 SEFLLEKRIL 0.496 233 WB Large T B4403 606 SEISMYTFSR 0.427 493WB Large T B4403 453 LPMERLTFEL 0.695 27 SB Large T B5101 240 DPYHIIEESI0.492 244 WB Large T B5101 486 LPSGHGINNL 0.447 397 WB Large T B5101 453LPMERLTFEL 0.721 20 SB Large T B5301 262 EPEETKQVSW 0.716 21 SB Large TB5301 486 LPSGHGINNL 0.585 89 WB Large T B5301 427 GPIDSGKTTL 0.470 308WB Large T B5301 200 TPHRHRVSAI 0.457 356 WB Large T B5301 139FPSDLHQFLS 0.584 89 WB Large T B5401 26 LPLMRKAYLK 0.511 197 WB Large TB5401 160 FAVYTTKEKA 0.489 252 WB Large T B5401 453 LPMERLTFEL 0.483 267WB Large T B5401 67 VAHQPDFGTW 0.448 393 WB Large T B5701 67 VAHQPDFGTW0.537 149 WB Large T B5801 464 VAIDQYMVVF 0.503 216 WB Large T B5801 20RAAWGNLPLM 0.485 263 WB Large T B5801 556 KSLQNSEFLL 0.475 293 WBLarge T B5801 175 KLMEKYSVTF 0.437 440 WB Large T B5801 31 KAYLKKCKEF0.431 473 WB Large T B5801 591 KDIQSRIVEW 0.430 474 WB Large T B580111-mers 163 YTTKEKAQILY 0.682 31 SB Large T A0101 388 YMAGVAWLHCL 0.8624 SB Large T A0201 175 KLMEKYSVTFI 0.854 4 SB Large T A0201 576LLLLLIWFRPV 0.708 23 SB Large T A0201 369 ILDKMDLIFGA 0.641 48 SBLarge T A0201 569 ILQSGMTLLLL 0.609 68 WB Large T A0201 146 FLSQAVFSNRT0.563 113 WB Large T A0201 198 FLTPHRHRVSA 0.558 119 WB Large T A0201287 FLLLGMYLEFQ 0.530 162 WB Large T A0201 568 RILQSGMTLLL 0.506 209 WBLarge T A0201 528 TMNEYPVPKTL 0.501 222 WB Large T A0201 439 GLLDLCGGKAL0.469 312 WB Large T A0201 448 ALNVNLPMERL 0.469 313 WB Large T A0201577 LLLLIWFRPVA 0.462 336 WB Large T A0201 11 ELMDLLGLERA 0.458 351 WBLarge T A0201 217 CTFSFLICKGV 0.447 398 WB Large T A0201 152 FSNRTLACFAV0.439 431 WB Large T A0201 269 VSWKLITEYAV 0.439 432 WB Large T A0201570 LQSGMTLLLLL 0.434 457 WB Large T A0201 2 KVLNREESMEL 0.432 467 WBLarge T A0201 388 YMAGVAWLHCL 0.869 4 SB Large T A0202 175 KLMEKYSVTFI0.858 4 SB Large T A0202 189 MCAGHNIIFFL 0.726 19 SB Large T A0202 198FLTPHRHRVSA 0.718 21 SB Large T A0202 146 FLSQAVFSNRT 0.718 21 SBLarge T A0202 570 LQSGMTLLLLL 0.667 36 SB Large T A0202 569 ILQSGMTLLLL0.666 36 SB Large T A0202 448 ALNVNLPMERL 0.624 58 WB Large T A0202 576LLLLLIWFRPV 0.621 60 WB Large T A0202 152 FSNRTLACFAV 0.601 74 WBLarge T A0202 287 FLLLGMYLEFQ 0.593 82 WB Large T A0202 528 TMNEYPVPKTL0.587 87 WB Large T A0202 11 ELMDLLGLERA 0.582 92 WB Large T A0202 243HIIEESIQGGL 0.571 103 WB Large T A0202 369 ILDKMDLIFGA 0.561 115 WBLarge T A0202 212 FCQKLCTFSFL 0.560 116 WB Large T A0202 375 LIFGAHGNAVL0.541 142 WB Large T A0202 461 ELGVAIDQYMV 0.541 143 WB Large T A0202409 FLHCVVFNVPK 0.524 171 WB Large T A0202 439 GLLDLCGGKAL 0.519 181 WBLarge T A0202 452 NLPMERLTFEL 0.515 189 WB Large T A0202 407 FDFLHCVVFNV0.493 239 WB Large T A0202 3 VLNREESMELM 0.491 245 WB Large T A0202 268QVSWKLITEYA 0.488 255 WB Large T A0202 290 LGMYLEFQYNV 0.481 273 WBLarge T A0202 217 CTFSFLICKGV 0.464 330 WB Large T A0202 564 LLEKRILQSGM0.447 398 WB Large T A0202 222 LICKGVNKEYL 0.436 448 WB Large T A0202226 GVNKEYLLYSA 0.428 485 WB Large T A0202 388 YMAGVAWLHCL 0.868 4 SBLarge T A0203 175 KLMEKYSVTFI 0.862 4 SB Large T A0203 198 FLTPHRHRVSA0.779 10 SB Large T A0203 528 TMNEYPVPKTL 0.766 12 SB Large T A0203 576LLLLLIWFRPV 0.728 19 SB Large T A0203 569 ILQSGMTLLLL 0.703 24 SBLarge T A0203 146 FLSQAVFSNRT 0.702 25 SB Large T A0203 448 ALNVNLPMERL0.668 36 SB Large T A0203 11 ELMDLLGLERA 0.652 42 SB Large T A0203 439GLLDLCGGKAL 0.593 81 WB Large T A0203 268 QVSWKLITEYA 0.577 97 WBLarge T A0203 570 LQSGMTLLLLL 0.548 132 WB Large T A0203 226 GVNKEYLLYSA0.540 144 WB Large T A0203 243 HIIEESIQGGL 0.523 174 WB Large T A0203375 LIFGAHGNAVL 0.522 176 WB Large T A0203 382 NAVLEQYMAGV 0.516 188 WBLarge T A0203 217 CTFSFLICKGV 0.515 190 WB Large T A0203 374 DLIFGAHGNAV0.511 197 WB Large T A0203 404 SVIFDFLHCVV 0.498 229 WB Large T A0203152 FSNRTLACFAV 0.491 245 WB Large T A0203 3 VLNREESMELM 0.473 298 WBLarge T A0203 287 FLLLGMYLEFQ 0.469 312 WB Large T A0203 452 NLPMERLTFEL0.465 327 WB Large T A0203 369 ILDKMDLIFGA 0.464 328 WB Large T A0203568 RILQSGMTLLL 0.457 356 WB Large T A0203 199 LTPHRHRVSAI 0.453 373 WBLarge T A0203 471 VVFEDVKGTGA 0.450 383 WB Large T A0203 469 YMVVFEDVKGT0.450 385 WB Large T A0203 388 YMAGVAWLHCL 0.691 28 SB Large T A0204 528TMNEYPVPKTL 0.687 29 SB Large T A0204 175 KLMEKYSVTFI 0.670 35 SBLarge T A0204 576 LLLLLIWFRPV 0.616 63 WB Large T A0204 198 FLTPHRHRVSA0.583 91 WB Large T A0204 2 KVLNREESMEL 0.525 170 WB Large T A0204 569ILQSGMTLLLL 0.449 386 WB Large T A0204 336 SICQQAVDTVL 0.431 472 WBLarge T A0204 544 RQIDFRPKIYL 0.801 8 SB Large T A0206 388 YMAGVAWLHCL0.796 9 SB Large T A0206 175 KLMEKYSVTFI 0.743 16 SB Large T A0206 576LLLLLIWFRPV 0.738 16 SB Large T A0206 570 LQSGMTLLLLL 0.711 22 SBLarge T A0206 198 FLTPHRHRVSA 0.706 24 SB Large T A0206 404 SVIFDFLHCVV0.688 29 SB Large T A0206 152 FSNRTLACFAV 0.646 46 SB Large T A0206 568RILQSGMTLLL 0.644 47 SB Large T A0206 369 ILDKMDLIFGA 0.622 59 WBLarge T A0206 2 KVLNREESMEL 0.620 61 WB Large T A0206 148 SQAVFSNRTLA0.618 62 WB Large T A0206 335 KSICQQAVDTV 0.568 106 WB Large T A0206 382NAVLEQYMAGV 0.548 133 WB Large T A0206 519 TQIFPPGLVTM 0.539 146 WBLarge T A0206 243 HIIEESIQGGL 0.519 182 WB Large T A0206 287 FLLLGMYLEFQ0.515 191 WB Large T A0206 146 FLSQAVFSNRT 0.506 210 WB Large T A0206569 ILQSGMTLLLL 0.487 256 WB Large T A0206 439 GLLDLCGGKAL 0.478 284 WBLarge T A0206 213 CQKLCTFSFLI 0.469 312 WB Large T A0206 542 FVRQIDFRPKI0.464 330 WB Large T A0206 267 KQVSWKLITEY 0.462 336 WB Large T A0206471 VVFEDVKGTGA 0.460 343 WB Large T A0206 383 AVLEQYMAGVA 0.445 407 WBLarge T A0206 577 LLLLIWFRPVA 0.444 408 WB Large T A0206 155 RTLACFAVYTT0.442 419 WB Large T A0206 268 QVSWKLITEYA 0.438 437 WB Large T A0206375 LIFGAHGNAVL 0.437 441 WB Large T A0206 452 NLPMERLTFEL 0.429 479 WBLarge T A0206 296 FQYNVEECKKC 0.427 490 WB Large T A0206 388 YMAGVAWLHCL0.966 1 SB Large T A0211 198 FLTPHRHRVSA 0.943 1 SB Large T A0211 576LLLLLIWFRPV 0.898 3 SB Large T A0211 569 ILQSGMTLLLL 0.893 3 SB Large TA0211 439 GLLDLCGGKAL 0.887 3 SB Large T A0211 452 NLPMERLTFEL 0.875 3SB Large T A0211 369 ILDKMDLIFGA 0.868 4 SB Large T A0211 528TMNEYPVPKTL 0.858 4 SB Large T A0211 461 ELGVAIDQYMV 0.854 4 SB Large TA0211 287 FLLLGMYLEFQ 0.832 6 SB Large T A0211 454 PMERLTFELGV 0.823 6SB Large T A0211 11 ELMDLLGLERA 0.815 7 SB Large T A0211 360 EMLTERFNHIL0.779 10 SB Large T A0211 374 DLIFGAHGNAV 0.775 11 SB Large T A0211 175KLMEKYSVTFI 0.773 11 SB Large T A0211 577 LLLLIWFRPVA 0.765 12 SBLarge T A0211 568 RILQSGMTLLL 0.755 14 SB Large T A0211 288 LLLGMYLEFQY0.753 14 SB Large T A0211 341 AVDTVLAKKRV 0.752 14 SB Large T A0211 448ALNVNLPMERL 0.747 15 SB Large T A0211 375 LIFGAHGNAVL 0.691 28 SBLarge T A0211 603 RLDSEISMYTF 0.681 31 SB Large T A0211 404 SVIFDFLHCVV0.671 35 SB Large T A0211 12 LMDLLGLERAA 0.669 35 SB Large T A0211 146FLSQAVFSNRT 0.648 45 SB Large T A0211 485 DLPSGHGINNL 0.644 47 SBLarge T A0211 563 FLLEKRILQSG 0.601 74 WB Large T A0211 2 KVLNREESMEL0.597 77 WB Large T A0211 501 YLDGSVKVNLE 0.596 78 WB Large T A0211 189MCAGHNIIFFL 0.591 83 WB Large T A0211 428 PIDSGKTTLAA 0.577 97 WBLarge T A0211 405 VIFDFLHCVVF 0.563 112 WB Large T A0211 196 IFFLTPHRHRV0.551 128 WB Large T A0211 217 CTFSFLICKGV 0.550 130 WB Large T A0211269 VSWKLITEYAV 0.549 132 WB Large T A0211 109 DMFASDEEATA 0.544 138 WBLarge T A0211 544 RQIDFRPKIYL 0.542 141 WB Large T A0211 3 VLNREESMELM0.535 153 WB Large T A0211 557 SLQNSEFLLEK 0.517 186 WB Large T A0211533 PVPKTLQARFV 0.511 198 WB Large T A0211 243 HIIEESIQGGL 0.500 224 WBLarge T A0211 401 KMDSVIFDFLH 0.486 260 WB Large T A0211 222 LICKGVNKEYL0.462 338 WB Large T A0211 353 TLHMTREEMLT 0.459 349 WB Large T A0211232 LLYSALTRDPY 0.435 449 WB Large T A0211 215 KLCTFSFLICK 0.435 452 WBLarge T A0211 573 GMTLLLLLIWF 0.433 459 WB Large T A0211 423 WLFKGPIDSGK0.428 487 WB Large T A0211 388 YMAGVAWLHCL 0.936 1 SB Large T A0212 198FLTPHRHRVSA 0.906 2 SB Large T A0212 439 GLLDLCGGKAL 0.823 6 SB Large TA0212 528 TMNEYPVPKTL 0.817 7 SB Large T A0212 576 LLLLLIWFRPV 0.817 7SB Large T A0212 454 PMERLTFELGV 0.806 8 SB Large T A0212 569ILQSGMTLLLL 0.801 8 SB Large T A0212 287 FLLLGMYLEFQ 0.777 11 SB Large TA0212 369 ILDKMDLIFGA 0.756 13 SB Large T A0212 374 DLIFGAHGNAV 0.706 24SB Large T A0212 360 EMLTERFNHIL 0.682 31 SB Large T A0212 461ELGVAIDQYMV 0.658 40 SB Large T A0212 288 LLLGMYLEFQY 0.655 41 SBLarge T A0212 11 ELMDLLGLERA 0.654 42 SB Large T A0212 452 NLPMERLTFEL0.645 46 SB Large T A0212 563 FLLEKRILQSG 0.643 47 SB Large T A0212 375LIFGAHGNAVL 0.631 54 WB Large T A0212 175 KLMEKYSVTFI 0.620 60 WBLarge T A0212 577 LLLLIWFRPVA 0.601 74 WB Large T A0212 269 VSWKLITEYAV0.598 77 WB Large T A0212 12 LMDLLGLERAA 0.577 96 WB Large T A0212 146FLSQAVFSNRT 0.577 97 WB Large T A0212 448 ALNVNLPMERL 0.574 100 WBLarge T A0212 341 AVDTVLAKKRV 0.549 132 WB Large T A0212 485 DLPSGHGINNL0.537 149 WB Large T A0212 405 VIFDFLHCVVF 0.536 151 WB Large T A0212 3VLNREESMELM 0.514 192 WB Large T A0212 423 WLFKGPIDSGK 0.499 225 WBLarge T A0212 2 KVLNREESMEL 0.481 273 WB Large T A0212 404 SVIFDFLHCVV0.458 350 WB Large T A0212 564 LLEKRILQSGM 0.452 374 WB Large T A0212469 YMVVFEDVKGT 0.452 377 WB Large T A0212 243 HIIEESIQGGL 0.441 421 WBLarge T A0212 222 LICKGVNKEYL 0.440 428 WB Large T A0212 217 CTFSFLICKGV0.437 444 WB Large T A0212 196 IFFLTPHRHRV 0.436 445 WB Large T A0212189 MCAGHNIIFFL 0.432 469 WB Large T A0212 471 VVFEDVKGTGA 0.426 495 WBLarge T A0212 388 YMAGVAWLHCL 0.907 2 SB Large T A0216 198 FLTPHRHRVSA0.867 4 SB Large T A0216 461 ELGVAIDQYMV 0.859 4 SB Large T A0216 569ILQSGMTLLLL 0.824 6 SB Large T A0216 452 NLPMERLTFEL 0.778 11 SB Large TA0216 454 PMERLTFELGV 0.771 11 SB Large T A0216 576 LLLLLIWFRPV 0.754 14SB Large T A0216 528 TMNEYPVPKTL 0.752 14 SB Large T A0216 374DLIFGAHGNAV 0.737 17 SB Large T A0216 287 FLLLGMYLEFQ 0.712 22 SBLarge T A0216 341 AVDTVLAKKRV 0.711 22 SB Large T A0216 369 ILDKMDLIFGA0.696 26 SB Large T A0216 448 ALNVNLPMERL 0.693 27 SB Large T A0216 175KLMEKYSVTFI 0.691 28 SB Large T A0216 439 GLLDLCGGKAL 0.678 32 SBLarge T A0216 146 FLSQAVFSNRT 0.661 39 SB Large T A0216 11 ELMDLLGLERA0.650 43 SB Large T A0216 485 DLPSGHGINNL 0.642 48 SB Large T A0216 375LIFGAHGNAVL 0.639 49 SB Large T A0216 360 EMLTERFNHIL 0.631 54 WBLarge T A0216 222 LICKGVNKEYL 0.620 60 WB Large T A0216 568 RILQSGMTLLL0.559 118 WB Large T A0216 196 IFFLTPHRHRV 0.554 124 WB Large T A0216533 PVPKTLQARFV 0.551 128 WB Large T A0216 404 SVIFDFLHCVV 0.528 165 WBLarge T A0216 189 MCAGHNIIFFL 0.523 173 WB Large T A0216 288 LLLGMYLEFQY0.517 186 WB Large T A0216 2 KVLNREESMEL 0.514 191 WB Large T A0216 577LLLLIWFRPVA 0.493 240 WB Large T A0216 544 RQIDFRPKIYL 0.485 264 WBLarge T A0216 269 VSWKLITEYAV 0.483 267 WB Large T A0216 161 AVYTTKEKAQI0.475 293 WB Large T A0216 109 DMFASDEEATA 0.457 355 WB Large T A0216388 YMAGVAWLHCL 0.952 1 SB Large T A0219 569 ILQSGMTLLLL 0.841 5 SBLarge T A0219 198 FLTPHRHRVSA 0.685 30 SB Large T A0219 576 LLLLLIWFRPV0.681 31 SB Large T A0219 287 FLLLGMYLEFQ 0.664 37 SB Large T A0219 461ELGVAIDQYMV 0.655 41 SB Large T A0219 369 ILDKMDLIFGA 0.647 45 SBLarge T A0219 11 ELMDLLGLERA 0.602 73 WB Large T A0219 454 PMERLTFELGV0.584 90 WB Large T A0219 448 ALNVNLPMERL 0.562 114 WB Large T A0219 146FLSQAVFSNRT 0.559 118 WB Large T A0219 374 DLIFGAHGNAV 0.556 121 WBLarge T A0219 360 EMLTERFNHIL 0.537 149 WB Large T A0219 528 TMNEYPVPKTL0.532 157 WB Large T A0219 485 DLPSGHGINNL 0.524 172 WB Large T A0219452 NLPMERLTFEL 0.507 206 WB Large T A0219 341 AVDTVLAKKRV 0.499 226 WBLarge T A0219 439 GLLDLCGGKAL 0.485 262 WB Large T A0219 189 MCAGHNIIFFL0.462 337 WB Large T A0219 175 KLMEKYSVTFI 0.454 367 WB Large T A0219269 VSWKLITEYAV 0.448 394 WB Large T A0219 156 TLACFAVYTTK 0.728 18 SBLarge T A0301 409 FLHCVVFNVPK 0.709 23 SB Large T A0301 215 KLCTFSFLICK0.671 35 SB Large T A0301 50 KMKRMNTLYKK 0.667 36 SB Large T A0301 391GVAWLHCLLPK 0.656 41 SB Large T A0301 205 RVSAINNFCQK 0.650 44 SBLarge T A0301 56 TLYKKMEQDVK 0.645 46 SB Large T A0301 507 KVNLEKKHLNK0.586 88 WB Large T A0301 219 FSFLICKGVNK 0.581 92 WB Large T A0301 195IIFFLTPHRHR 0.575 99 WB Large T A0301 164 TTKEKAQILYK 0.549 131 WBLarge T A0301 557 SLQNSEFLLEK 0.539 146 WB Large T A0301 272 KLITEYAVETK0.533 156 WB Large T A0301 21 AAWGNLPLMRK 0.508 205 WB Large T A0301 416NVPKRRYWLFK 0.507 206 WB Large T A0301 608 ISMYTFSRMKY 0.491 247 WBLarge T A0301 574 MTLLLLLIWFR 0.485 261 WB Large T A0301 673 HLCKGFQCFKR0.459 348 WB Large T A0301 28 LMRKAYLKKCK 0.454 369 WB Large T A0301 244IIEESIQGGLK 0.448 393 WB Large T A0301 497 SLRDYLDGSVK 0.443 416 WBLarge T A0301 423 WLFKGPIDSGK 0.432 464 WB Large T A0301 401 KMDSVIFDFLH0.427 490 WB Large T A0301 391 GVAWLHCLLPK 0.825 6 SB Large T A1101 215KLCTFSFLICK 0.800 8 SB Large T A1101 557 SLQNSEFLLEK 0.791 9 SB Large TA1101 205 RVSAINNFCQK 0.784 10 SB Large T A1101 574 MTLLLLLIWFR 0.768 12SB Large T A1101 21 AAWGNLPLMRK 0.742 16 SB Large T A1101 164TTKEKAQILYK 0.721 20 SB Large T A1101 156 TLACFAVYTTK 0.719 20 SBLarge T A1101 526 LVTMNEYPVPK 0.716 21 SB Large T A1101 507 KVNLEKKHLNK0.706 24 SB Large T A1101 325 AIIFAESKNQK 0.702 25 SB Large T A1101 169AQILYKKLMEK 0.699 25 SB Large T A1101 118 TADSQHSTPPK 0.677 32 SBLarge T A1101 416 NVPKRRYWLFK 0.651 43 SB Large T A1101 56 TLYKKMEQDVK0.640 49 SB Large T A1101 50 KMKRMNTLYKK 0.634 52 WB Large T A1101 447KALNVNLPMER 0.627 56 WB Large T A1101 322 FANAIIFAESK 0.620 61 WBLarge T A1101 608 ISMYTFSRMKY 0.609 68 WB Large T A1101 219 FSFLICKGVNK0.594 80 WB Large T A1101 338 CQQAVDTVLAK 0.593 81 WB Large T A1101 362LTERFNHILDK 0.588 86 WB Large T A1101 409 FLHCVVFNVPK 0.555 122 WBLarge T A1101 195 IIFFLTPHRHR 0.547 134 WB Large T A1101 437 AAGLLDLCGGK0.547 134 WB Large T A1101 20 RAAWGNLPLMR 0.531 160 WB Large T A1101 272KLITEYAVETK 0.526 169 WB Large T A1101 607 EISMYTFSRMK 0.523 174 WBLarge T A1101 244 IIEESIQGGLK 0.506 209 WB Large T A1101 339 QQAVDTVLAKK0.471 307 WB Large T A1101 467 DQYMVVFEDVK 0.445 404 WB Large T A1101497 SLRDYLDGSVK 0.436 448 WB Large T A1101 581 IWFRPVADFSK 0.434 454 WBLarge T A1101 312 PYHFKYHEKHF 0.709 23 SB Large T A2301 286 VFLLLGMYLEF0.704 24 SB Large T A2301 610 MYTFSRMKYNI 0.668 36 SB Large T A2301 581IWFRPVADFSK 0.626 57 WB Large T A2301 500 DYLDGSVKVNL 0.598 77 WBLarge T A2301 211 NFCQKLCTFSF 0.575 99 WB Large T A2301 83 TYGTEEWESWW0.560 116 WB Large T A2301 187 RHMCAGHNIIF 0.491 245 WB Large T A2301179 KYSVTFISRHM 0.485 263 WB Large T A2301 316 KYHEKHFANAI 0.478 282 WBLarge T A2301 295 EFQYNVEECKK 0.478 283 WB Large T A2301 617 KYNICMGKCIL0.477 288 WB Large T A2301 95 SFNEKWDEDLF 0.476 289 WB Large T A2301 553YLRKSLQNSEF 0.468 316 WB Large T A2301 162 VYTTKEKAQIL 0.451 380 WBLarge T A2301 405 VIFDFLHCVVF 0.442 417 WB Large T A2301 316 KYHEKHFANAI0.677 33 SB Large T A2402 286 VFLLLGMYLEF 0.676 33 SB Large T A2402 312PYHFKYHEKHF 0.617 62 WB Large T A2402 610 MYTFSRMKYNI 0.570 105 WBLarge T A2402 83 TYGTEEWESWW 0.514 192 WB Large T A2402 179 KYSVTFISRHM0.513 193 WB Large T A2402 162 VYTTKEKAQIL 0.482 272 WB Large T A2402211 NFCQKLCTFSF 0.461 341 WB Large T A2402 286 VFLLLGMYLEF 0.742 16 SBLarge T A2403 316 KYHEKHFANAI 0.713 22 SB Large T A2403 83 TYGTEEWESWW0.653 42 SB Large T A2403 312 PYHFKYHEKHF 0.613 66 WB Large T A2403 397CLLPKMDSVIF 0.571 103 WB Large T A2403 162 VYTTKEKAQIL 0.563 112 WBLarge T A2403 365 RFNHILDKMDL 0.554 124 WB Large T A2403 553 YLRKSLQNSEF0.528 165 WB Large T A2403 617 KYNICMGKCIL 0.509 202 WB Large T A2403211 NFCQKLCTFSF 0.504 213 WB Large T A2403 95 SFNEKWDEDLF 0.478 285 WBLarge T A2403 187 RHMCAGHNIIF 0.466 321 WB Large T A2403 163 YTTKEKAQILY0.631 54 WB Large T A2601 8 ESMELMDLLGL 0.474 297 WB Large T A2601 163YTTKEKAQILY 0.728 19 SB Large T A2602 150 AVFSNRTLACF 0.703 24 SBLarge T A2602 170 QILYKKLMEKY 0.637 51 WB Large T A2602 405 VIFDFLHCVVF0.629 55 WB Large T A2602 280 ETKCEDVFLLL 0.628 56 WB Large T A2602 463GVAIDQYMVVF 0.624 58 WB Large T A2602 243 HIIEESIQGGL 0.535 153 WBLarge T A2602 356 MTREEMLTERF 0.491 247 WB Large T A2602 142 DLHQFLSQAVF0.472 304 WB Large T A2602 450 NVNLPMERLTF 0.453 372 WB Large T A2602553 YLRKSLQNSEF 0.450 382 WB Large T A2602 74 GTWNSSEVPTY 0.435 453 WBLarge T A2602 8 ESMELMDLLGL 0.433 462 WB Large T A2602 221 FLICKGVNKEY0.621 60 WB Large T A2902 288 LLLGMYLEFQY 0.600 75 WB Large T A2902 163YTTKEKAQILY 0.475 293 WB Large T A2902 286 VFLLLGMYLEF 0.470 307 WBLarge T A2902 170 QILYKKLMEKY 0.430 478 WB Large T A2902 405 VIFDFLHCVVF0.427 492 WB Large T A2902 50 KMKRMNTLYKK 0.760 13 SB Large T A3001 28LMRKAYLKKCK 0.745 15 SB Large T A3001 164 TTKEKAQILYK 0.727 19 SBLarge T A3001 507 KVNLEKKHLNK 0.707 23 SB Large T A3001 680 CFKRPKTPPPK0.688 29 SB Large T A3001 409 FLHCVVFNVPK 0.668 36 SB Large T A3001 497SLRDYLDGSVK 0.662 38 SB Large T A3001 158 ACFAVYTTKEK 0.661 39 SBLarge T A3001 416 NVPKRRYWLFK 0.594 80 WB Large T A3001 541 RFVRQIDFRPK0.587 87 WB Large T A3001 215 KLCTFSFLICK 0.567 107 WB Large T A3001 348KKRVDTLHMTR 0.563 112 WB Large T A3001 205 RVSAINNFCQK 0.546 136 WBLarge T A3001 526 LVTMNEYPVPK 0.536 151 WB Large T A3001 306 CQKKDQPYHFK0.508 204 WB Large T A3001 118 TADSQHSTPPK 0.505 211 WB Large T A3001272 KLITEYAVETK 0.489 252 WB Large T A3001 156 TLACFAVYTTK 0.486 259 WBLarge T A3001 557 SLQNSEFLLEK 0.482 271 WB Large T A3001 169 AQILYKKLMEK0.470 309 WB Large T A3001 539 QARFVRQIDFR 0.458 353 WB Large T A3001581 IWFRPVADFSK 0.451 378 WB Large T A3001 574 MTLLLLLIWFR 0.433 462 WBLarge T A3001 34 LKKCKEFHPDK 0.429 482 WB Large T A3001 267 KQVSWKLITEY0.523 175 WB Large T A3002 170 QILYKKLMEKY 0.442 420 WB Large T A3002574 MTLLLLLIWFR 0.869 4 SB Large T A3101 50 KMKRMNTLYKK 0.838 5 SBLarge T A3101 447 KALNVNLPMER 0.794 9 SB Large T A3101 145 QFLSQAVFSNR0.744 15 SB Large T A3101 195 IIFFLTPHRHR 0.736 17 SB Large T A3101 673HLCKGFQCFKR 0.670 35 SB Large T A3101 539 QARFVRQIDFR 0.653 42 SBLarge T A3101 355 HMTREEMLTER 0.647 45 SB Large T A3101 205 RVSAINNFCQK0.637 50 WB Large T A3101 558 LQNSEFLLEKR 0.626 57 WB Large T A3101 541RFVRQIDFRPK 0.624 58 WB Large T A3101 20 RAAWGNLPLMR 0.617 63 WB Large TA3101 121 SQHSTPPKKKR 0.607 70 WB Large T A3101 621 CMGKCILDITR 0.587 87WB Large T A3101 177 MEKYSVTFISR 0.582 91 WB Large T A3101 215KLCTFSFLICK 0.554 124 WB Large T A3101 164 TTKEKAQILYK 0.536 151 WBLarge T A3101 680 CFKRPKTPPPK 0.526 169 WB Large T A3101 534 VPKTLQARFVR0.518 183 WB Large T A3101 193 HNIIFFLTPHR 0.500 223 WB Large T A3101507 KVNLEKKHLNK 0.492 244 WB Large T A3101 306 CQKKDQPYHFK 0.486 259 WBLarge T A3101 526 LVTMNEYPVPK 0.467 319 WB Large T A3101 229 KEYLLYSALTR0.466 321 WB Large T A3101 593 IQSRIVEWKER 0.449 389 WB Large T A3101 31KAYLKKCKEFH 0.448 392 WB Large T A3101 545 QIDFRPKIYLR 0.448 393 WBLarge T A3101 401 KMDSVIFDFLH 0.443 415 WB Large T A3101 605 DSEISMYTFSR0.438 435 WB Large T A3101 28 LMRKAYLKKCK 0.433 461 WB Large T A3101 574MTLLLLLIWFR 0.838 5 SB Large T A3301 195 IIFFLTPHRHR 0.685 30 SB Large TA3301 605 DSEISMYTFSR 0.684 30 SB Large T A3301 539 QARFVRQIDFR 0.650 44SB Large T A3301 145 QFLSQAVFSNR 0.639 49 SB Large T A3301 355HMTREEMLTER 0.625 57 WB Large T A3301 673 HLCKGFQCFKR 0.606 70 WBLarge T A3301 531 EYPVPKTLQAR 0.582 92 WB Large T A3301 545 QIDFRPKIYLR0.484 264 WB Large T A3301 285 DVFLLLGMYLE 0.462 337 WB Large T A3301416 NVPKRRYWLFK 0.441 424 WB Large T A3301 177 MEKYSVTFISR 0.440 428 WBLarge T A3301 574 MTLLLLLIWFR 0.820 7 SB Large T A6801 607 EISMYTFSRMK0.808 7 SB Large T A6801 322 FANAIIFAESK 0.780 10 SB Large T A6801 605DSEISMYTFSR 0.765 12 SB Large T A6801 195 IIFFLTPHRHR 0.762 13 SBLarge T A6801 156 TLACFAVYTTK 0.756 14 SB Large T A6801 205 RVSAINNFCQK0.712 22 SB Large T A6801 539 QARFVRQIDFR 0.695 27 SB Large T A6801 219FSFLICKGVNK 0.676 33 SB Large T A6801 193 HNIIFFLTPHR 0.673 34 SBLarge T A6801 673 HLCKGFQCFKR 0.665 37 SB Large T A6801 164 TTKEKAQILYK0.656 41 SB Large T A6801 355 HMTREEMLTER 0.654 42 SB Large T A6801 526LVTMNEYPVPK 0.641 48 SB Large T A6801 416 NVPKRRYWLFK 0.635 51 WBLarge T A6801 340 QAVDTVLAKKR 0.620 61 WB Large T A6801 409 FLHCVVFNVPK0.589 85 WB Large T A6801 20 RAAWGNLPLMR 0.562 114 WB Large T A6801 325AIIFAESKNQK 0.554 124 WB Large T A6801 56 TLYKKMEQDVK 0.549 131 WBLarge T A6801 163 YTTKEKAQILY 0.548 132 WB Large T A6801 467 DQYMVVFEDVK0.534 155 WB Large T A6801 391 GVAWLHCLLPK 0.521 178 WB Large T A6801608 ISMYTFSRMKY 0.493 240 WB Large T A6801 295 EFQYNVEECKK 0.489 251 WBLarge T A6801 25 NLPLMRKAYLK 0.482 272 WB Large T A6801 447 KALNVNLPMER0.477 288 WB Large T A6801 545 QIDFRPKIYLR 0.471 305 WB Large T A6801362 LTERFNHILDK 0.463 332 WB Large T A6801 177 MEKYSVTFISR 0.463 335 WBLarge T A6801 145 QFLSQAVFSNR 0.460 343 WB Large T A6801 423 WLFKGPIDSGK0.456 361 WB Large T A6801 118 TADSQHSTPPK 0.435 450 WB Large T A6801557 SLQNSEFLLEK 0.430 477 WB Large T A6801 189 MCAGHNIIFFL 0.792 9 SBLarge T A6802 217 CTFSFLICKGV 0.752 14 SB Large T A6802 404 SVIFDFLHCVV0.734 17 SB Large T A6802 382 NAVLEQYMAGV 0.680 31 SB Large T A6802 403DSVIFDFLHCV 0.654 42 SB Large T A6802 8 ESMELMDLLGL 0.653 42 SB Large TA6802 152 FSNRTLACFAV 0.617 62 WB Large T A6802 290 LGMYLEFQYNV 0.606 70WB Large T A6802 462 LGVAIDQYMVV 0.591 83 WB Large T A6802 268QVSWKLITEYA 0.576 98 WB Large T A6802 280 ETKCEDVFLLL 0.573 101 WBLarge T A6802 11 ELMDLLGLERA 0.570 105 WB Large T A6802 234 YSALTRDPYHI0.549 132 WB Large T A6802 388 YMAGVAWLHCL 0.531 159 WB Large T A6802243 HIIEESIQGGL 0.507 206 WB Large T A6802 181 SVTFISRHMCA 0.503 216 WBLarge T A6802 407 FDFLHCVVFNV 0.489 251 WB Large T A6802 374 DLIFGAHGNAV0.480 277 WB Large T A6802 542 FVRQIDFRPKI 0.446 400 WB Large T A6802212 FCQKLCTFSFL 0.433 460 WB Large T A6802 461 ELGVAIDQYMV 0.429 484 WBLarge T A6802 388 YMAGVAWLHCL 0.652 42 SB Large T A6901 461 ELGVAIDQYMV0.575 99 WB Large T A6901 374 DLIFGAHGNAV 0.573 102 WB Large T A6901 8ESMELMDLLGL 0.560 116 WB Large T A6901 152 FSNRTLACFAV 0.541 143 WBLarge T A6901 11 ELMDLLGLERA 0.539 145 WB Large T A6901 576 LLLLLIWFRPV0.519 182 WB Large T A6901 404 SVIFDFLHCVV 0.512 196 WB Large T A6901360 EMLTERFNHIL 0.498 228 WB Large T A6901 189 MCAGHNIIFFL 0.474 297 WBLarge T A6901 243 HIIEESIQGGL 0.472 303 WB Large T A6901 382 NAVLEQYMAGV0.470 309 WB Large T A6901 217 CTFSFLICKGV 0.457 355 WB Large T A6901269 VSWKLITEYAV 0.443 414 WB Large T A6901 55 NTLYKKMEQDV 0.432 464 WBLarge T A6901 532 YPVPKTLQARF 0.646 46 SB Large T B0702 553 YLRKSLQNSEF0.492 244 WB Large T B0801 267 KQVSWKLITEY 0.566 109 WB Large T B1501538 LQARFVRQIDF 0.565 110 WB Large T B1501 553 YLRKSLQNSEF 0.561 116 WBLarge T B1501 188 HMCAGHNIIFF 0.554 124 WB Large T B1501 388 YMAGVAWLHCL0.542 141 WB Large T B1501 221 FLICKGVNKEY 0.541 142 WB Large T B1501544 RQIDFRPKIYL 0.521 178 WB Large T B1501 579 LLIWFRPVADF 0.518 183 WBLarge T B1501 519 TQIFPPGLVTM 0.480 276 WB Large T B1501 232 LLYSALTRDPY0.478 283 WB Large T B1501 405 VIFDFLHCVVF 0.474 295 WB Large T B1501608 ISMYTFSRMKY 0.450 384 WB Large T B1501 150 AVFSNRTLACF 0.434 457 WBLarge T B1501 570 LQSGMTLLLLL 0.429 483 WB Large T B1501 668 HSQELHLCKGF0.426 495 WB Large T B1501 86 TEEWESWWSSF 0.650 44 SB Large T B1801 460FELGVAIDQYM 0.643 47 SB Large T B1801 318 HEKHFANAIIF 0.625 57 WBLarge T B1801 18 LERAAWGNLPL 0.572 102 WB Large T B1801 79 SEVPTYGTEEW0.556 122 WB Large T B1801 601 KERLDSEISMY 0.505 210 WB Large T B1801664 SENPHSQELHL 0.497 230 WB Large T B1801 532 YPVPKTLQARF 0.461 341 WBLarge T B1801 614 SRMKYNICMGK 0.547 134 WB Large T B2705 567 KRILQSGMTLL0.507 207 WB Large T B2705 544 RQIDFRPKIYL 0.450 382 WB Large T B2705548 FRPKIYLRKSL 0.450 385 WB Large T B2705 522 FPPGLVTMNEY 0.812 7 SBLarge T B3501 532 YPVPKTLQARF 0.780 10 SB Large T B3501 277 YAVETKCEDVF0.742 16 SB Large T B3501 399 LPKMDSVIFDF 0.560 116 WB Large T B3501 41HPDKGGDEDKM 0.545 136 WB Large T B3501 392 VAWLHCLLPKM 0.532 158 WBLarge T B3501 139 FPSDLHQFLSQ 0.494 238 WB Large T B3501 232 LLYSALTRDPY0.453 371 WB Large T B3501 459 TFELGVAIDQY 0.442 417 WB Large T B3501317 YHEKHFANAII 0.586 88 WB Large T B3901 388 YMAGVAWLHCL 0.549 130 WBLarge T B3901 6 REESMELMDLL 0.673 34 SB Large T B4001 664 SENPHSQELHL0.668 36 SB Large T B4001 18 LERAAWGNLPL 0.630 54 WB Large T B4001 385LEQYMAGVAWL 0.562 114 WB Large T B4001 460 FELGVAIDQYM 0.552 126 WBLarge T B4001 279 VETKCEDVFLL 0.540 145 WB Large T B4001 606 SEISMYTFSRM0.498 228 WB Large T B4001 133 VEDPKDFPSDL 0.446 399 WB Large T B4001166 KEKAQILYKKL 0.440 428 WB Large T B4001 47 DEDKMKRMNTL 0.434 458 WBLarge T B4001 664 SENPHSQELHL 0.540 144 WB Large T B4002 6 REESMELMDLL0.511 198 WB Large T B4002 264 EETKQVSWKLI 0.502 219 WB Large T B4002318 HEKHFANAIIF 0.459 347 WB Large T B4002 359 EEMLTERFNHI 0.445 403 WBLarge T B4002 279 VETKCEDVFLL 0.432 464 WB Large T B4002 79 SEVPTYGTEEW0.512 196 WB Large T B4402 261 EEPEETKQVSW 0.484 267 WB Large T B4402561 SEFLLEKRILQ 0.477 287 WB Large T B4403 664 SENPHSQELHL 0.464 331 WBLarge T B4403 606 SEISMYTFSRM 0.457 356 WB Large T B4403 79 SEVPTYGTEEW0.452 375 WB Large T B4403 261 EEPEETKQVSW 0.438 438 WB Large T B4403359 EEMLTERFNHI 0.482 271 WB Large T B4501 115 EEATADSQHST 0.450 383 WBLarge T B4501 453 LPMERLTFELG 0.470 309 WB Large T B5101 532 YPVPKTLQARF0.433 463 WB Large T B5101 522 FPPGLVTMNEY 0.689 28 SB Large T B5301 532YPVPKTLQARF 0.645 46 SB Large T B5301 399 LPKMDSVIFDF 0.555 122 WBLarge T B5301 277 YAVETKCEDVF 0.474 296 WB Large T B5301 453 LPMERLTFELG0.580 93 WB Large T B5401 522 FPPGLVTMNEY 0.544 138 WB Large T B5401 427GPIDSGKTTLA 0.508 204 WB Large T B5401 82 PTYGTEEWESW 0.576 98 WBLarge T B5701 90 ESWWSSFNEKW 0.678 32 SB Large T B5801 66 KVAHQPDFGTW0.658 40 SB Large T B5801 572 SGMTLLLLLIW 0.539 146 WB Large T B5801 413VVFNVPKRRYW 0.527 167 WB Large T B5801 277 YAVETKCEDVF 0.495 235 WBLarge T B5801 608 ISMYTFSRMKY 0.487 258 WB Large T B5801 82 PTYGTEEWESW0.458 353 WB Large T B5801 SEQ ID NOS.: 55454-58054

Preferred BK virus fragments of agnoprotein capable of interacting withone or more MHC class 1 molecules are listed in Table N.

TABLE N Prediction of BK virus Agnoprotein specific MHC class1, 8-, 9-,10-, 11-mer peptide binders for 42 MHC class 1 alleles (see FIG. 11)using the http://www.cbs.dtu.dk/services/NetMHC/ database. The MHC class1 molecules for which no binders were found are not listed. Pro-affinity Bind tein pos peptide logscore (nM) Level Name Allele 8-mers 36FIFILELL 0.641 48 SB Agno A0201 59 STTALPAV 0.453 373 WB Agno A0201 36FIFILELL 0.785 10 SB Agno A0202 12 QLSRQASV 0.702 25 SB Agno A0202 12QLSRQASV 0.712 22 SB Agno A0203 59 STTALPAV 0.537 149 WB Agno A0203 36FIFILELL 0.524 171 WB Agno A0203 32 AQRIFIFI 0.503 216 WB Agno A0203 6NLVVLRQL 0.431 473 WB Agno A0203 12 QLSRQASV 0.508 206 WB Agno A0204 59STTALPAV 0.489 252 WB Agno A0204 32 AQRIFIFI 0.646 46 SB Agno A0206 36FIFILELL 0.585 89 WB Agno A0206 59 STTALPAV 0.582 92 WB Agno A0206 12QLSRQASV 0.479 281 WB Agno A0206 38 FILELLLE 0.474 297 WB Agno A0206 12QLSRQASV 0.883 3 SB Agno A0211 36 FIFILELL 0.782 10 SB Agno A0211 59STTALPAV 0.695 27 SB Agno A0211 6 NLVVLRQL 0.688 29 SB Agno A0211 12QLSRQASV 0.825 6 SB Agno A0212 36 FIFILELL 0.705 24 SB Agno A0212 59STTALPAV 0.504 214 WB Agno A0212 46 FCRGEDSV 0.502 219 WB Agno A0212 12QLSRQASV 0.877 3 SB Agno A0216 36 FIFILELL 0.643 47 SB Agno A0216 6NLVVLRQL 0.580 93 WB Agno A0216 59 STTALPAV 0.474 294 WB Agno A0216 1FCEPKNLV 0.427 494 WB Agno A0216 12 QLSRQASV 0.746 15 SB Agno A0219 59STTALPAV 0.455 364 WB Agno A0219 23 KTWTGTKK 0.662 38 SB Agno A0301 60TTALPAVK 0.568 107 WB Agno A0301 8 VVLRQLSR 0.444 408 WB Agno A0301 13LSRQASVK 0.436 444 WB Agno A0301 60 TTALPAVK 0.785 10 SB Agno A1101 23KTWTGTKK 0.637 50 WB Agno A1101 8 VVLRQLSR 0.554 124 WB Agno A1101 16QASVKVGK 0.458 351 WB Agno A1101 35 IFIFILEL 0.573 101 WB Agno A2301 31RAQRIFIF 0.514 191 WB Agno A2301 37 IFILELLL 0.454 367 WB Agno A2301 37IFILELLL 0.536 150 WB Agno A2402 35 IFIFILEL 0.478 284 WB Agno A2402 31RAQRIFIF 0.431 472 WB Agno A2402 31 RAQRIFIF 0.449 386 WB Agno A2403 13LSRQASVK 0.690 28 SB Agno A3001 23 KTWTGTKK 0.659 40 SB Agno A3001 27GTKKRAQR 0.803 8 SB Agno A3101 23 KTWTGTKK 0.648 45 SB Agno A3101 8VVLRQLSR 0.587 87 WB Agno A3101 41 ELLLEFCR 0.701 25 SB Agno A3301 27GTKKRAQR 0.564 111 WB Agno A3301 8 VVLRQLSR 0.466 323 WB Agno A3301 60TTALPAVK 0.774 11 SB Agno A6801 41 ELLLEFCR 0.627 56 WB Agno A6801 27GTKKRAQR 0.537 150 WB Agno A6801 16 QASVKVGK 0.459 349 WB Agno A6801 51DSVDGKNK 0.431 473 WB Agno A6801 59 STTALPAV 0.655 42 SB Agno A6802 33QRIFIFIL 0.552 127 WB Agno A6802 36 FIFILELL 0.512 195 WB Agno A6802 59STTALPAV 0.674 34 SB Agno A6901 36 FIFILELL 0.441 424 WB Agno A6901 63LPAVKDSV 0.582 91 WB Agno B0702 3 EPKNLVVL 0.427 490 WB Agno B0702 33QRIFIFIL 0.431 472 WB Agno B2705 3 EPKNLVVL 0.518 184 WB Agno B3501 63LPAVKDSV 0.585 88 WB Agno B5101 3 EPKNLVVL 0.456 358 WB Agno B5301 63LPAVKDSV 0.745 15 SB Agno B5401 31 RAQRIFIF 0.503 215 WB Agno B58019-mers 34 RIFIFILEL 0.674 34 SB Agno A0201 36 FIFILELLL 0.613 66 WB AgnoA0201 11 RQLSRQASV 0.561 115 WB Agno A0201 62 ALPAVKDSV 0.503 215 WBAgno A0201 38 FILELLLEF 0.448 392 WB Agno A0201 36 FIFILELLL 0.698 26 SBAgno A0202 62 ALPAVKDSV 0.609 68 WB Agno A0202 34 RIFIFILEL 0.540 144 WBAgno A0202 11 RQLSRQASV 0.688 29 SB Agno A0203 62 ALPAVKDSV 0.667 36 SBAgno A0203 9 VLRQLSRQA 0.455 362 WB Agno A0203 34 RIFIFILEL 0.439 433 WBAgno A0203 62 ALPAVKDSV 0.515 190 WB Agno A0204 11 RQLSRQASV 0.855 4 SBAgno A0206 38 FILELLLEF 0.731 18 SB Agno A0206 62 ALPAVKDSV 0.588 86 WBAgno A0206 32 AQRIFIFIL 0.561 116 WB Agno A0206 58 KSTTALPAV 0.559 118WB Agno A0206 34 RIFIFILEL 0.506 208 WB Agno A0206 31 RAQRIFIFI 0.487256 WB Agno A0206 36 FIFILELLL 0.455 365 WB Agno A0206 62 ALPAVKDSV0.927 2 SB Agno A0211 34 RIFIFILEL 0.836 5 SB Agno A0211 36 FIFILELLL0.796 9 SB Agno A0211 38 FILELLLEF 0.621 60 WB Agno A0211 9 VLRQLSRQA0.546 135 WB Agno A0211 11 RQLSRQASV 0.445 405 WB Agno A0211 62ALPAVKDSV 0.904 2 SB Agno A0212 36 FIFILELLL 0.746 15 SB Agno A0212 34RIFIFILEL 0.679 32 SB Agno A0212 38 FILELLLEF 0.614 65 WB Agno A0212 11RQLSRQASV 0.545 138 WB Agno A0212 1 FCEPKNLVV 0.473 300 WB Agno A0212 42LLLEFCRGE 0.465 327 WB Agno A0212 9 VLRQLSRQA 0.442 416 WB Agno A0212 62ALPAVKDSV 0.922 2 SB Agno A0216 34 RIFIFILEL 0.732 18 SB Agno A0216 36FIFILELLL 0.654 42 SB Agno A0216 11 RQLSRQASV 0.490 247 WB Agno A0216 62ALPAVKDSV 0.778 11 SB Agno A0219 12 QLSRQASVK 0.643 47 SB Agno A0301 15RQASVKVGK 0.538 148 WB Agno A0301 59 STTALPAVK 0.461 341 WB Agno A030159 STTALPAVK 0.825 6 SB Agno A1101 15 RQASVKVGK 0.624 58 WB Agno A1101 7LVVLRQLSR 0.460 345 WB Agno A1101 35 IFIFILELL 0.514 192 WB Agno A230138 FILELLLEF 0.473 300 WB Agno A2301 35 IFIFILELL 0.610 67 WB Agno A240238 FILELLLEF 0.532 157 WB Agno A2403 38 FILELLLEF 0.598 77 WB Agno A260238 FILELLLEF 0.463 334 WB Agno A2902 21 VGKTWTGTK 0.528 165 WB AgnoA3001 59 STTALPAVK 0.477 285 WB Agno A3001 29 KKRAQRIFI 0.452 377 WBAgno A3001 23 KTWTGTKKR 0.727 19 SB Agno A3101 15 RQASVKVGK 0.617 62 WBAgno A3101 26 TGTKKRAQR 0.524 172 WB Agno A3101 7 LVVLRQLSR 0.506 210 WBAgno A3101 59 STTALPAVK 0.486 260 WB Agno A3101 7 LVVLRQLSR 0.666 37 SBAgno A3301 3 EPKNLVVLR 0.510 201 WB Agno A3301 59 STTALPAVK 0.728 19 SBAgno A6801 3 EPKNLVVLR 0.667 36 SB Agno A6801 7 LVVLRQLSR 0.664 37 SBAgno A6801 31 RAQRIFIFI 0.609 68 WB Agno A6802 38 FILELLLEF 0.453 371 WBAgno B1801 15 RQASVKVGK 0.566 109 WB Agno B2705 30 KRAQRIFIF 0.523 174WB Agno B2705 11 RQLSRQASV 0.449 390 WB Agno B2705 3 38 FILELLLEF 0.505211 WB Agno B3501 2 CEPKNLVVL 0.521 179 WB Agno B4001 17 ASVKVGKTW 0.443414 WB Agno B5701 17 ASVKVGKTW 0.572 103 WB Agno B5801 10-mers 34RIFIFILELL 0.605 71 WB Agno A0201 38 FILELLLEFC 0.449 388 WB Agno A020134 RIFIFILELL 0.719 20 SB Agno A0202 38 FILELLLEFC 0.622 59 WB AgnoA0202 12 QLSRQASVKV 0.449 386 WB Agno A0202 12 QLSRQASVKV 0.588 86 WBAgno A0203 34 RIFIFILELL 0.456 359 WB Agno A0203 12 QLSRQASVKV 0.503 215WB Agno A0204 38 FILELLLEFC 0.656 41 SB Agno A0206 34 RIFIFILELL 0.549131 WB Agno A0206 61 TALPAVKDSV 0.450 382 WB Agno A0206 12 QLSRQASVKV0.859 4 SB Agno A0211 34 RIFIFILELL 0.772 11 SB Agno A0211 38 FILELLLEFC0.626 57 WB Agno A0211 61 TALPAVKDSV 0.569 106 WB Agno A0211 12QLSRQASVKV 0.754 14 SB Agno A0212 38 FILELLLEFC 0.627 56 WB Agno A021234 RIFIFILELL 0.497 231 WB Agno A0212 61 TALPAVKDSV 0.433 461 WB AgnoA0212 12 QLSRQASVKV 0.843 5 SB Agno A0216 34 RIFIFILELL 0.581 92 WB AgnoA0216 61 TALPAVKDSV 0.550 130 WB Agno A0216 12 QLSRQASVKV 0.632 53 WBAgno A0219 61 TALPAVKDSV 0.549 131 WB Agno A0219 11 RQLSRQASVK 0.636 51WB Agno A0301 58 KSTTALPAVK 0.532 158 WB Agno A0301 20 KVGKTWTGTK 0.496234 WB Agno A0301 62 ALPAVKDSVK 0.452 375 WB Agno A0301 58 KSTTALPAVK0.688 29 SB Agno A1101 20 KVGKTWTGTK 0.671 35 SB Agno A1101 11RQLSRQASVK 0.620 60 WB Agno A1101 62 ALPAVKDSVK 0.445 404 WB Agno A110137 IFILELLLEF 0.695 27 SB Agno A2301 35 IFIFILELLL 0.487 256 WB AgnoA2301 37 IFILELLLEF 0.663 38 SB Agno A2402 35 IFIFILELLL 0.622 59 WBAgno A2402 37 IFILELLLEF 0.663 38 SB Agno A2403 37 IFILELLLEF 0.470 309WB Agno A2902 20 KVGKTWTGTK 0.787 10 SB Agno A3001 58 KSTTALPAVK 0.557120 WB Agno A3001 11 RQLSRQASVK 0.509 202 WB Agno A3001 6 NLVVLRQLSR0.567 108 WB Agno A3101 39 ILELLLEFCR 0.521 177 WB Agno A3101 25WTGTKKRAQR 0.504 214 WB Agno A3101 39 ILELLLEFCR 0.523 173 WB Agno A33016 NLVVLRQLSR 0.485 262 WB Agno A3301 6 NLVVLRQLSR 0.604 72 WB Agno A680139 ILELLLEFCR 0.479 279 WB Agno A6801 25 WTGTKKRAQR 0.465 326 WB AgnoA6801 33 QRIFIFILEL 0.528 164 WB Agno A6802 61 TALPAVKDSV 0.473 301 WBAgno A6802 34 RIFIFILELL 0.467 321 WB Agno A6802 61 TALPAVKDSV 0.448 394WB Agno A6901 11 RQLSRQASVK 0.534 154 WB Agno B2705 14 SRQASVKVGK 0.516188 WB Agno B2705 33 QRIFIFILEL 0.469 312 WB Agno B2705 16 QASVKVGKTW0.632 53 WB Agno B5801 11-mers 34 RIFIFILELLL 0.552 127 WB Agno A0201 11RQLSRQASVKV 0.460 344 WB Agno A0201 43 LLEFCRGEDSV 0.586 87 WB AgnoA0202 34 RIFIFILELLL 0.503 216 WB Agno A0202 9 VLRQLSRQASV 0.497 229 WBAgno A0202 9 VLRQLSRQASV 0.814 7 SB Agno A0203 11 RQLSRQASVKV 0.508 205WB Agno A0203 43 LLEFCRGEDSV 0.483 267 WB Agno A0203 32 AQRIFIFILEL0.446 400 WB Agno A0203 9 VLRQLSRQASV 0.447 398 WB Agno A0204 11RQLSRQASVKV 0.776 11 SB Agno A0206 32 AQRIFIFILEL 0.584 90 WB Agno A02069 VLRQLSRQASV 0.887 3 SB Agno A0211 34 RIFIFILELLL 0.793 9 SB Agno A021143 LLEFCRGEDSV 0.747 15 SB Agno A0211 52 SVDGKNKSTTA 0.612 66 WB AgnoA0211 11 RQLSRQASVKV 0.433 463 WB Agno A0211 36 FIFILELLLEF 0.429 481 WBAgno A0211 9 VLRQLSRQASV 0.876 3 SB Agno A0212 34 RIFIFILELLL 0.586 88WB Agno A0212 43 LLEFCRGEDSV 0.585 89 WB Agno A0212 38 FILELLLEFCR 0.454369 WB Agno A0212 11 RQLSRQASVKV 0.442 417 WB Agno A0212 9 VLRQLSRQASV0.838 5 SB Agno A0216 43 LLEFCRGEDSV 0.725 19 SB Agno A0216 34RIFIFILELLL 0.606 71 WB Agno A0216 60 TTALPAVKDSV 0.460 346 WB AgnoA0216 52 SVDGKNKSTTA 0.455 365 WB Agno A0216 9 VLRQLSRQASV 0.674 33 SBAgno A0219 43 LLEFCRGEDSV 0.477 285 WB Agno A0219 20 KVGKTWTGTKK 0.66039 SB Agno A0301 20 KVGKTWTGTKK 0.617 63 WB Agno A1101 61 TALPAVKDSVK0.508 204 WB Agno A1101 36 FIFILELLLEF 0.535 152 WB Agno A2602 36FIFILELLLEF 0.571 103 WB Agno A2902 13 LSRQASVKVGK 0.753 14 SB AgnoA3001 20 KVGKTWTGTKK 0.713 22 SB Agno A3001 5 KNLVVLRQLSR 0.558 119 WBAgno A3101 24 TWTGTKKRAQR 0.496 232 WB Agno A3101 38 FILELLLEFCR 0.469313 WB Agno A3101 38 FILELLLEFCR 0.616 63 WB Agno A3301 38 FILELLLEFCR0.611 67 WB Agno A6801 24 TWTGTKKRAQR 0.442 419 WB Agno A6801 61TALPAVKDSVK 0.439 434 WB Agno A6801 60 TTALPAVKDSV 0.850 5 SB Agno A680233 QRIFIFILELL 0.650 43 SB Agno A6802 60 TTALPAVKDSV 0.545 136 WB AgnoA6901 32 AQRIFIFILEL 0.471 305 WB Agno B1501 36 FIFILELLLEF 0.436 448 WBAgno B1501 15 RQASVKVGKTW 0.427 491 WB Agno B1501 30 KRAQRIFIFIL 0.478284 WB Agno B2705 36 FIFILELLLEF 0.451 378 WB Agno B3501 30 KRAQRIFIFIL0.455 362 WB Agno B3901 15 RQASVKVGKTW 0.573 100 WB Agno B5801 SEQ IDNOS: 58055-58311

Preferred BK virus fragments capable of interacting with one or more MHCclass 2 molecules are listed in Table O.

TABLE O Predicted MHC class 2 BK virus peptide sequences. Prediction of13-, 14-, 15-,16-mers from all 6 reading frames of the genome (access no#V01108) obtained using the program displayed in FIG. 2. BK virus,reading frame 1 13 mers: FCKNCKRIGISPN; CKNCKRIGISPNS; KNCKRIGISPNSF;NCKRIGISPNSFA; CKRIGISPNSFAR; KRIGISPNSFARP; RIGISPNSFARPQ;IGISPNSFARPQK; GISPNSFARPQKK; ISPNSFARPQKKP; SPNSFARPQKKPP;PNSFARPQKKPPH; NSFARPQKKPPHP; SFARPQKKPPHPY; FARPQKKPPHPYY;ARPQKKPPHPYYL; RPQKKPPHPYYLR; PQKKPPHPYYLRE; QKKPPHPYYLRER;KKPPHPYYLRERV; KPPHPYYLRERVE; PPHPYYLRERVEA; PHPYYLRERVEAE;HPYYLRERVEAEA; PYYLRERVEAEAA; YYLRERVEAEAAS; YLRERVEAEAASA;LRERVEAEAASAS; RERVEAEAASASY; ERVEAEAASASYI; RVEAEAASASYIL;KKRPQGGAAYPWN; KRPQGGAAYPWNA; RPQGGAAYPWNAA; PQGGAAYPWNAAK;QGGAAYPWNAAKP; PQEGKCMTHRGMQ; QEGKCMTHRGMQP; EGKCMTHRGMQPN;GKCMTHRGMQPNH; KCMTHRGMQPNHD; CMTHRGMQPNHDL; MTHRGMQPNHDLR;THRGMQPNHDLRK; HRGMQPNHDLRKE; RGMQPNHDLRKES; GMQPNHDLRKESA;LTGRSCLPMECSQ; TGRSCLPMECSQT; GRSCLPMECSQTM; RSCLPMECSQTMT;SCLPMECSQTMTS; CLPMECSQTMTSG; LPMECSQTMTSGR; PMECSQTMTSGRK;MECSQTMTSGRKV; ECSQTMTSGRKVH; CSQTMTSGRKVHD; SQTMTSGRKVHDR;QTMTSGRKVHDRH; TMTSGRKVHDRHV; MTSGRKVHDRHVL; TSGRKVHDRHVLR;SGRKVHDRHVLRA; ESWPCPQLNWTKA; SWPCPQLNWTKAM; WPCPQLNWTKAMV;PCPQLNWTKAMVL; CPQLNWTKAMVLR; PQLNWTKAMVLRQ; QLNWTKAMVLRQL;LNWTKAMVLRQLS; NWTKAMVLRQLSR; WTKAMVLRQLSRQ; TKAMVLRQLSRQA;KAMVLRQLSRQAS; AMVLRQLSRQASV; MVLRQLSRQASVK; VLRQLSRQASVKV;LRQLSRQASVKVG; RQLSRQASVKVGK; QLSRQASVKVGKT; LSRQASVKVGKTW;SRQASVKVGKTWT; RQASVKVGKTWTG; QASVKVGKTWTGT; ASVKVGKTWTGTK;SVKVGKTWTGTKK; VKVGKTWTGTKKR; KVGKTWTGTKKRA; VGKTWTGTKKRAQ;GKTWTGTKKRAQR; KTWTGTKKRAQRI; TWTGTKKRAQRIF; WTGTKKRAQRIFI;TGTKKRAQRIFIF; GTKKRAQRIFIFI; TKKRAQRIFIFIL; KKRAQRIFIFILE;KRAQRIFIFILEL; RAQRIFIFILELL; AQRIFIFILELLL; QRIFIFILELLLE;RIFIFILELLLEF; IFIFILELLLEFC; FIFILELLLEFCR; IFILELLLEFCRG;FILELLLEFCRGE; ILELLLEFCRGED; LELLLEFCRGEDS; ELLLEFCRGEDSV;LLLEFCRGEDSVD; LLEFCRGEDSVDG; LEFCRGEDSVDGK; EFCRGEDSVDGKN;FCRGEDSVDGKNK; CRGEDSVDGKNKS; RGEDSVDGKNKST; GEDSVDGKNKSTT;EDSVDGKNKSTTA; DSVDGKNKSTTAL; SVDGKNKSTTALP; VDGKNKSTTALPA;DGKNKSTTALPAV; GKNKSTTALPAVK; KNKSTTALPAVKD; NKSTTALPAVKDS;KSTTALPAVKDSV; STTALPAVKDSVK; TTALPAVKDSVKD; TALPAVKDSVKDS;VSNPFFFVFPGSW; SNPFFFVFPGSWV; NPFFFVFPGSWVL; PFFFVFPGSWVLL;LPVYLRLLLPQDF; PVYLRLLLPQDFQ; VYLRLLLPQDFQW; YLRLLLPQDFQWL;LRLLLPQDFQWLK; RLLLPQDFQWLKL; LLLPQDFQWLKLL; LLPQDFQWLKLLL;LPQDFQWLKLLLG; PQDFQWLKLLLGR; QDFQWLKLLLGRL; DFQWLKLLLGRLL;FQWLKLLLGRLLL; QWLKLLLGRLLLL; LLVLLGLLLGLLL; GISSLMIGITKFP;ISSLMIGITKFPL; ASISNQAWLWNCL; SISNQAWLWNCLT; ISNQAWLWNCLTQ;SNQAWLWNCLTQM; NQAWLWNCLTQMS; QAWLWNCLTQMST; AWLWNCLTQMSTM;WLWNCLTQMSTMI; LWNCLTQMSTMIF; WNCLTQMSTMIFC; NCLTQMSTMIFCF;CLTQMSTMIFCFL; LTQMSTMIFCFLV; ILLLIIFNTLILG; LLLIIFNTLILGI;LLIIFNTLILGIG; LIIFNTLILGIGV; IIFNTLILGIGVL; IFNTLILGIGVLL;FNTLILGIGVLLC; NTLILGIGVLLCL; TLILGIGVLLCLL; LILGIGVLLCLLL;ILGIGVLLCLLLF; LGIGVLLCLLLFP; GIGVLLCLLLFPR; IGVLLCLLLFPRL;GVLLCLLLFPRLC; VLLCLLLFPRLCG; LLCLLLFPRLCGM; LCLLLFPRLCGML;CLLLFPRLCGMLL; LLLFPRLCGMLLG; LLFPRLCGMLLGM; LFPRLCGMLLGMI;FPRLCGMLLGMIY; PRLCGMLLGMIYL; RLCGMLLGMIYLL; PHRNCREEQKDFL;HRNCREEQKDFLE; RNCREEQKDFLET; NCREEQKDFLETP; CREEQKDFLETPW;REEQKDFLETPWL; EEQKDFLETPWLD; EQKDFLETPWLDF; QKDFLETPWLDFW;KDFLETPWLDFWR; DFLETPWLDFWRK; FLETPWLDFWRKL; LETPWLDFWRKLP;ETPWLDFWRKLPG; TPWLDFWRKLPGQ; PWLDFWRKLPGQL; TFIIIFNNIILIF;FIIIFNNIILIFP; IIIFNNIILIFPL; IIFNNIILIFPLL; IFNNIILIFPLLG;FNNIILIFPLLGP; NNIILIFPLLGPQ; NIILIFPLLGPQW; IILIFPLLGPQWL;ILIFPLLGPQWLD; LIFPLLGPQWLDK; LKGKVPVYILAIL; KGKVPVYILAILI;GKVPVYILAILIV; KKLLPQEVLIKEL; KLLPQEVLIKELL; LLPQEVLIKELLL;LPQEVLIKELLLN; PQEVLIKELLLNG; QEVLIKELLLNGC; EVLIKELLLNGCC;VLIKELLLNGCCL; LIKELLLNGCCLY; IKELLLNGCCLYF; HLLLKHMKMAPTK;LLLKHMKMAPTKR; LLKHMKMAPTKRK; LKHMKMAPTKRKG; KHMKMAPTKRKGE;HMKMAPTKRKGEC; MKMAPTKRKGECP; KMAPTKRKGECPG; MAPTKRKGECPGA;APTKRKGECPGAA; PTKRKGECPGAAP; TKRKGECPGAAPK; KRKGECPGAAPKK;RKGECPGAAPKKP; KGECPGAAPKKPK; GECPGAAPKKPKE; ECPGAAPKKPKEP;CPGAAPKKPKEPV; PGAAPKKPKEPVQ; GAAPKKPKEPVQV; AAPKKPKEPVQVP;APKKPKEPVQVPK; PKKPKEPVQVPKL; KKPKEPVQVPKLL; KPKEPVQVPKLLI;PKEPVQVPKLLIK; KEPVQVPKLLIKG; EPVQVPKLLIKGG; PVQVPKLLIKGGV;VQVPKLLIKGGVE; QVPKLLIKGGVEV; VPKLLIKGGVEVL; PKLLIKGGVEVLE;KLLIKGGVEVLEV; LLIKGGVEVLEVK; LIKGGVEVLEVKT; IKGGVEVLEVKTG;KGGVEVLEVKTGV; GGVEVLEVKTGVD; GVEVLEVKTGVDA; VEVLEVKTGVDAI;EVLEVKTGVDAIT; VLEVKTGVDAITE; LEVKTGVDAITEV; EVKTGVDAITEVE;VKTGVDAITEVEC; KTGVDAITEVECF; TGVDAITEVECFL; GVDAITEVECFLN;VDAITEVECFLNP; DAITEVECFLNPE; AITEVECFLNPEM; ITEVECFLNPEMG;TEVECFLNPEMGD; EVECFLNPEMGDP; VECFLNPEMGDPD; ECFLNPEMGDPDE;CFLNPEMGDPDEN; FLNPEMGDPDENL; LNPEMGDPDENLR; NPEMGDPDENLRG;PEMGDPDENLRGF; EMGDPDENLRGFS; MGDPDENLRGFSL; GDPDENLRGFSLK;DPDENLRGFSLKL; PDENLRGFSLKLS; DENLRGFSLKLSA; ENLRGFSLKLSAE;NLRGFSLKLSAEN; LRGFSLKLSAEND; RGFSLKLSAENDF; GFSLKLSAENDFS;FSLKLSAENDFSS; SLKLSAENDFSSD; LKLSAENDFSSDS; KLSAENDFSSDSP;LSAENDFSSDSPE; SAENDFSSDSPER; AENDFSSDSPERK; ENDFSSDSPERKM;NDFSSDSPERKML; DFSSDSPERKMLP; FSSDSPERKMLPC; SSDSPERKMLPCY;SDSPERKMLPCYS; DSPERKMLPCYST; SPERKMLPCYSTA; PERKMLPCYSTAR;ERKMLPCYSTARI; RKMLPCYSTARIP; KMLPCYSTARIPL; MLPCYSTARIPLP;LPCYSTARIPLPN; PCYSTARIPLPNL; CYSTARIPLPNLN; YSTARIPLPNLNE;STARIPLPNLNED; TARIPLPNLNEDL; ARIPLPNLNEDLT; RIPLPNLNEDLTC;IPLPNLNEDLTCG; PLPNLNEDLTCGN; LPNLNEDLTCGNL; PNLNEDLTCGNLL;NLNEDLTCGNLLM; LNEDLTCGNLLMW; NEDLTCGNLLMWE; EDLTCGNLLMWEA;DLTCGNLLMWEAV; LTCGNLLMWEAVT; TCGNLLMWEAVTV; CGNLLMWEAVTVQ;GNLLMWEAVTVQT; NLLMWEAVTVQTE; LLMWEAVTVQTEV; LMWEAVTVQTEVI;MWEAVTVQTEVIG; WEAVTVQTEVIGI; EAVTVQTEVIGIT; AVTVQTEVIGITS;VTVQTEVIGITSM; TVQTEVIGITSML; VQTEVIGITSMLN; QTEVIGITSMLNL;TEVIGITSMLNLH; EVIGITSMLNLHA; VIGITSMLNLHAG; IGITSMLNLHAGS;GITSMLNLHAGSQ; ITSMLNLHAGSQK; TSMLNLHAGSQKV; SMLNLHAGSQKVH;MLNLHAGSQKVHE; LNLHAGSQKVHEH; NLHAGSQKVHEHG; LHAGSQKVHEHGG;HAGSQKVHEHGGG; AGSQKVHEHGGGK; GSQKVHEHGGGKP; SQKVHEHGGGKPI;QKVHEHGGGKPIQ; KVHEHGGGKPIQG; VHEHGGGKPIQGS; HEHGGGKPIQGSN;EHGGGKPIQGSNF; HGGGKPIQGSNFH; GGGKPIQGSNFHF; GGKPIQGSNFHFF;GKPIQGSNFHFFA; KPIQGSNFHFFAV; PIQGSNFHFFAVG; IQGSNFHFFAVGG;QGSNFHFFAVGGE; GSNFHFFAVGGEP; SNFHFFAVGGEPL; NFHFFAVGGEPLE;FHFFAVGGEPLEM; HFFAVGGEPLEMQ; FFAVGGEPLEMQG; FAVGGEPLEMQGV;AVGGEPLEMQGVL; VGGEPLEMQGVLM; GGEPLEMQGVLMN; GEPLEMQGVLMNY;EPLEMQGVLMNYR; PLEMQGVLMNYRS; LEMQGVLMNYRSK; EMQGVLMNYRSKY;MQGVLMNYRSKYP; QGVLMNYRSKYPD; GVLMNYRSKYPDG; VLMNYRSKYPDGT;LMNYRSKYPDGTI; MNYRSKYPDGTIT; NYRSKYPDGTITP; YRSKYPDGTITPK;RSKYPDGTITPKN; SKYPDGTITPKNP; KYPDGTITPKNPT; YPDGTITPKNPTA;PDGTITPKNPTAQ; DGTITPKNPTAQS; GTITPKNPTAQSQ; TITPKNPTAQSQV;ITPKNPTAQSQVM; TPKNPTAQSQVMN; PKNPTAQSQVMNT; KNPTAQSQVMNTD;NPTAQSQVMNTDH; PTAQSQVMNTDHK; TAQSQVMNTDHKA; AQSQVMNTDHKAY;QSQVMNTDHKAYL; SQVMNTDHKAYLD; QVMNTDHKAYLDK; VMNTDHKAYLDKN;MNTDHKAYLDKNN; NTDHKAYLDKNNA; TDHKAYLDKNNAY; DHKAYLDKNNAYP;HKAYLDKNNAYPV; KAYLDKNNAYPVE; AYLDKNNAYPVEC; YLDKNNAYPVECW;LDKNNAYPVECWV; DKNNAYPVECWVP; KNNAYPVECWVPD; NNAYPVECWVPDP;NAYPVECWVPDPS; AYPVECWVPDPSR; YPVECWVPDPSRN; PVECWVPDPSRNE;VECWVPDPSRNEN; ECWVPDPSRNENA; CWVPDPSRNENAR; WVPDPSRNENARY;VPDPSRNENARYF; PDPSRNENARYFG; DPSRNENARYFGT; PSRNENARYFGTF;SRNENARYFGTFT; RNENARYFGTFTG; NENARYFGTFTGG; ENARYFGTFTGGE;NARYFGTFTGGEN; ARYFGTFTGGENV; RYFGTFTGGENVP; YFGTFTGGENVPP;FGTFTGGENVPPV; GTFTGGENVPPVL; TFTGGENVPPVLH; FTGGENVPPVLHV;TGGENVPPVLHVT; GGENVPPVLHVTN; GENVPPVLHVTNT; ENVPPVLHVTNTA;NVPPVLHVTNTAT; VPPVLHVTNTATT; PPVLHVTNTATTV; PVLHVTNTATTVL;VLHVTNTATTVLL; LHVTNTATTVLLD; HVTNTATTVLLDE; VTNTATTVLLDEQ;TNTATTVLLDEQG; NTATTVLLDEQGV; TATTVLLDEQGVG; ATTVLLDEQGVGP;TTVLLDEQGVGPL; TVLLDEQGVGPLC; VLLDEQGVGPLCK; LLDEQGVGPLCKA;LDEQGVGPLCKAD; DEQGVGPLCKADS; EQGVGPLCKADSL; QGVGPLCKADSLY;GVGPLCKADSLYV; VGPLCKADSLYVS; GPLCKADSLYVSA; PLCKADSLYVSAA;LCKADSLYVSAAD; CKADSLYVSAADI; KADSLYVSAADIC; ADSLYVSAADICG;DSLYVSAADICGL; SLYVSAADICGLF; LYVSAADICGLFT; YVSAADICGLFTN;VSAADICGLFTNS; SAADICGLFTNSS; AADICGLFTNSSG; ADICGLFTNSSGT;DICGLFTNSSGTQ; ICGLFTNSSGTQQ; CGLFTNSSGTQQW; GLFTNSSGTQQWR;LFTNSSGTQQWRG; FTNSSGTQQWRGL; TNSSGTQQWRGLA; NSSGTQQWRGLAR;SSGTQQWRGLARY; SGTQQWRGLARYF; GTQQWRGLARYFK; TQQWRGLARYFKI;QQWRGLARYFKIR; QWRGLARYFKIRL; WRGLARYFKIRLR; RGLARYFKIRLRK;GLARYFKIRLRKR; LARYFKIRLRKRS; ARYFKIRLRKRSV; RYFKIRLRKRSVK;YFKIRLRKRSVKN; FKIRLRKRSVKNP; KIRLRKRSVKNPY; IRLRKRSVKNPYP;RLRKRSVKNPYPI; LRKRSVKNPYPIS; RKRSVKNPYPISF; KRSVKNPYPISFL;RSVKNPYPISFLL; SVKNPYPISFLLS; VKNPYPISFLLSD; KNPYPISFLLSDL;NPYPISFLLSDLI; PYPISFLLSDLIN; YPISFLLSDLINR; PISFLLSDLINRR;ISFLLSDLINRRT; SFLLSDLINRRTQ; FLLSDLINRRTQR; LLSDLINRRTQRV;LSDLINRRTQRVD; SDLINRRTQRVDG; DLINRRTQRVDGQ; LINRRTQRVDGQP;INRRTQRVDGQPM; NRRTQRVDGQPMY; RRTQRVDGQPMYG; RTQRVDGQPMYGM;TQRVDGQPMYGME; QRVDGQPMYGMES; RVDGQPMYGMESQ; VDGQPMYGMESQV;DGQPMYGMESQVE; GQPMYGMESQVEE; QPMYGMESQVEEV; PMYGMESQVEEVR;MYGMESQVEEVRV; YGMESQVEEVRVF; GMESQVEEVRVFD; MESQVEEVRVFDG;ESQVEEVRVFDGT; SQVEEVRVFDGTE; QVEEVRVFDGTER; VEEVRVFDGTERL;EEVRVFDGTERLP; EVRVFDGTERLPG; VRVFDGTERLPGD; RVFDGTERLPGDP;VFDGTERLPGDPD; FDGTERLPGDPDM; DGTERLPGDPDMI; GTERLPGDPDMIR;TERLPGDPDMIRY; ERLPGDPDMIRYI; RLPGDPDMIRYID; LPGDPDMIRYIDK;PGDPDMIRYIDKQ; GDPDMIRYIDKQG; DPDMIRYIDKQGQ; PDMIRYIDKQGQL;DMIRYIDKQGQLQ; MIRYIDKQGQLQT; IRYIDKQGQLQTK; RYIDKQGQLQTKM;YIDKQGQLQTKML; TGAFIVHIHLINA; GAFIVHIHLINAA; AFIVHIHLINAAF;FIVHIHLINAAFV; ATFKLVLFWGWCF; TFKLVLFWGWCFR; FKLVLFWGWCFRP;KLVLFWGWCFRPF; LVLFWGWCFRPFK; VLFWGWCFRPFKT; LFWGWCFRPFKTL;FWGWCFRPFKTLK; WGWCFRPFKTLKA; GWCFRPFKTLKAF; WCFRPFKTLKAFT;CFRPFKTLKAFTQ; FRPFKTLKAFTQM; RPFKTLKAFTQMQ; PFKTLKAFTQMQL;FKTLKAFTQMQLL; KTLKAFTQMQLLT; TLKAFTQMQLLTM; LKAFTQMQLLTMG;KAFTQMQLLTMGV; ILFSCNIKNTFPH; LFSCNIKNTFPHA; FSCNIKNTFPHAY;SCNIKNTFPHAYI; CNIKNTFPHAYII; NIKNTFPHAYIIF; IKNTFPHAYIIFH;KNTFPHAYIIFHP; KSIHTYLRIQPFL; SIHTYLRIQPFLP; IHTYLRIQPFLPF;HTYLRIQPFLPFN; TYLRIQPFLPFNN; YLRIQPFLPFNNS; LRIQPFLPFNNSR;RIQPFLPFNNSRL; IQPFLPFNNSRLY; QPFLPFNNSRLYI; PFLPFNNSRLYIS;FLPFNNSRLYISC; LPFNNSRLYISCK; PFNNSRLYISCKI; FNNSRLYISCKIS;NNSRLYISCKISY; NSRLYISCKISYR; SRLYISCKISYRP; RLYISCKISYRPK;LYISCKISYRPKP; YISCKISYRPKPN; IYFGPKIYLSYKS; YFGPKIYLSYKSS;FGPKIYLSYKSSL; GPKIYLSYKSSLQ; PKIYLSYKSSLQG; KIYLSYKSSLQGF;IYLSYKSSLQGFR; YLSYKSSLQGFRD; LSYKSSLQGFRDR; SYKSSLQGFRDRI;YKSSLQGFRDRIL; KSSLQGFRDRILI; SSLQGFRDRILIH; SLQGFRDRILIHC;LQGFRDRILIHCN; QGFRDRILIHCNQ; GFRDRILIHCNQA; FRDRILIHCNQAW;RDRILIHCNQAWW; DRILIHCNQAWWK; RILIHCNQAWWKY; ILIHCNQAWWKYL;LIHCNQAWWKYLG; IHCNQAWWKYLGS; HCNQAWWKYLGSF; CNQAWWKYLGSFV;FSSCPFYIFKNNH; SSCPFYIFKNNHV; SCPFYIFKNNHVL; CPFYIFKNNHVLI;PFYIFKNNHVLIY; FYIFKNNHVLIYS; YIFKNNHVLIYSY; IFKNNHVLIYSYT;PVSSFRYIENNTV; VSSFRYIENNTVQ; SSFRYIENNTVQK; SFRYIENNTVQKI;FRYIENNTVQKIK; RYIENNTVQKIKY; YIENNTVQKIKYY; IENNTVQKIKYYR;ENNTVQKIKYYRI; NNTVQKIKYYRIH; NTVQKIKYYRIHF; TVQKIKYYRIHFR;QTVQPSNTCHILF; HFFPGHMKGIYSF; FFPGHMKGIYSFF; FPGHMKGIYSFFS;NCIYCLLTNTFLI; CIYCLLTNTFLIF; IYCLLTNTFLIFT; YCLLTNTFLIFTF;CLLTNTFLIFTFC; LLTNTFLIFTFCK; LTNTFLIFTFCKN; TNTFLIFTFCKNN;NTFLIFTFCKNNS; TFLIFTFCKNNSI; FLIFTFCKNNSIC; LIFTFCKNNSICK;IFTFCKNNSICKV; FTFCKNNSICKVL; TFCKNNSICKVLF; FCKNNSICKVLFM;CKNNSICKVLFMI; KNNSICKVLFMIL; NNSICKVLFMILK; NSICKVLFMILKV;SICKVLFMILKVI; ICKVLFMILKVIR; CKVLFMILKVIRL; KVLFMILKVIRLV;VLFMILKVIRLVF; LFMILKVIRLVFF; FMILKVIRLVFFL; MILKVIRLVFFLT;ILKVIRLVFFLTL; LKVIRLVFFLTLF; KVIRLVFFLTLFT; VIRLVFFLTLFTL;IRLVFFLTLFTLL; RLVFFLTLFTLLY; LVFFLTLFTLLYI; VFFLTLFTLLYIV;FFLTLFTLLYIVL; FLTLFTLLYIVLK; LTLFTLLYIVLKF; KHILTLCLYCILS;HILTLCLYCILSN; FPRHLLCFFRLFW; PRHLLCFFRLFWA; RHLLCFFRLFWAK;HLLCFFRLFWAKI; LLCFFRLFWAKIM; LCFFRLFWAKIML; CFFRLFWAKIMLL;APLNAFFYSMVWI; PLNAFFYSMVWIS; LNAFFYSMVWISS; KTKGTQLLTEIIN;TKGTQLLTEIINC; KGTQLLTEIINCR; GTQLLTEIINCRN; TQLLTEIINCRNS;QLLTEIINCRNSM; LLTEIINCRNSMS; LTEIINCRNSMSM; TEIINCRNSMSMW;EIINCRNSMSMWS; KEYNIMPSTHVST; EYNIMPSTHVSTN; YNIMPSTHVSTNK;NIMPSTHVSTNKS; IMPSTHVSTNKSY; MPSTHVSTNKSYR; PSTHVSTNKSYRI;STHVSTNKSYRIF; THVSTNKSYRIFF; HVSTNKSYRIFFH; VSTNKSYRIFFHK;STNKSYRIFFHKF; TNKSYRIFFHKFF; NKSYRIFFHKFFI; KSYRIFFHKFFIQ;SYRIFFHKFFIQN; YRIFFHKFFIQNL; RIFFHKFFIQNLS; IFFHKFFIQNLSF;FFHKFFIQNLSFF; FHKFFIQNLSFFF; HKFFIQNLSFFFS; KFFIQNLSFFFSS;FFIQNLSFFFSSI; FIQNLSFFFSSIH; IQNLSFFFSSIHS; QNLSFFFSSIHSK;NLSFFFSSIHSKA; LSFFFSSIHSKAG; SFFFSSIHSKAGK; FFFSSIHSKAGKG;FFSSIHSKAGKGS; FSSIHSKAGKGSI; SSIHSKAGKGSIT; SIHSKAGKGSITK;IHSKAGKGSITKY; HSKAGKGSITKYS; SKAGKGSITKYSL; KAGKGSITKYSLT;AGKGSITKYSLTK; GKGSITKYSLTKK; KGSITKYSLTKKL; GSITKYSLTKKLV;IRGKVFRVFYLSF; RGKVFRVFYLSFF; GKVFRVFYLSFFF; KVFRVFYLSFFFG;VFRVFYLSFFFGW; FRVFYLSFFFGWC; VLRICCCFFITGK; LRICCCFFITGKH;RICCCFFITGKHI; ICCCFFITGKHIF; CCCFFITGKHIFM; CCFFITGKHIFMA;CFFITGKHIFMAK; IFIPFFIKGTPPG; FIPFFIKGTPPGL; IPFFIKGTPPGLP;PFFIKGTPPGLPL; FFIKGTPPGLPLF; FIKGTPPGLPLFC; IKGTPPGLPLFCS;KGTPPGLPLFCSI; GTPPGLPLFCSIG; TPPGLPLFCSIGW; PPGLPLFCSIGWH;PGLPLFCSIGWHL; SFRSLKGVSPIIW; FRSLKGVSPIIWT; RSLKGVSPIIWTH;SLKGVSPIIWTHH; LKGVSPIIWTHHC; KGVSPIIWTHHCR; GVSPIIWTHHCRV;VSPIIWTHHCRVS; SPIIWTHHCRVSS; PIIWTHHCRVSSV; IIWTHHCRVSSVR;IWTHHCRVSSVRS; WTHHCRVSSVRSK; THHCRVSSVRSKP; HHCRVSSVRSKPN;HCRVSSVRSKPNH; CRVSSVRSKPNHC; RVSSVRSKPNHCV; VSSVRSKPNHCVK;SSVRSKPNHCVKQ; SVRSKPNHCVKQS; VRSKPNHCVKQSM; RSKPNHCVKQSMQ;QSIQTKGSFLKNF; SIQTKGSFLKNFL; IQTKGSFLKNFLF; QTKGSFLKNFLFK;TKGSFLKNFLFKC; KGSFLKNFLFKCL; GSFLKNFLFKCLN; SFLKNFLFKCLNL;FLKNFLFKCLNLS; HSMQGQCTEGFLE; SMQGQCTEGFLEQ; MQGQCTEGFLEQI;QGQCTEGFLEQIG; GQCTEGFLEQIGH; QCTEGFLEQIGHS; CTEGFLEQIGHSL;TEGFLEQIGHSLQ; EGFLEQIGHSLQY; GFLEQIGHSLQYR; FLEQIGHSLQYRV;LEQIGHSLQYRVS; EQIGHSLQYRVSG; QIGHSLQYRVSGQ; IGHSLQYRVSGQR;GHSLQYRVSGQRG; HSLQYRVSGQRGK; SLQYRVSGQRGKS; LQYRVSGQRGKSA;QYRVSGQRGKSAQ; YRVSGQRGKSAQT; RVSGQRGKSAQTS; VSGQRGKSAQTSE;SGQRGKSAQTSEL; GQRGKSAQTSELL; QRGKSAQTSELLQ; RGKSAQTSELLQV;GKSAQTSELLQVP; KSAQTSELLQVPK; SAQTSELLQVPKS; AQTSELLQVPKSG;ATFTSCSIFLYKV; TFTSCSIFLYKVF; FTSCSIFLYKVFI; TSCSIFLYKVFIL;SCSIFLYKVFILF; CSIFLYKVFILFI; SIFLYKVFILFIL; IFLYKVFILFILS;FLYKVFILFILSS; LYKVFILFILSSS; YKVFILFILSSSP; KVFILFILSSSPP;VFILFILSSSPPL; FILFILSSSPPLS; ILFILSSSPPLSG; AFLIKGRFPQAAL;FLIKGRFPQAALS; LIKGRFPQAALSR; IKGRFPQAALSRP; KGRFPQAALSRPK;GRFPQAALSRPKR; RFPQAALSRPKRS; FPQAALSRPKRSM; PQAALSRPKRSMS;QAALSRPKRSMSS; AALSRPKRSMSSM; ALSRPKRSMSSMD; LSRPKRSMSSMDS;SRPKRSMSSMDSS; RPKRSMSSMDSSL; PKRSMSSMDSSLL; KRSMSSMDSSLLR;RSMSSMDSSLLRT; SMSSMDSSLLRTL; MSSMDSSLLRTLS 14 mers: FCKNCKRIGISPNS;CKNCKRIGISPNSF; KNCKRIGISPNSFA; NCKRIGISPNSFAR; CKRIGISPNSFARP;KRIGISPNSFARPQ; RIGISPNSFARPQK; IGISPNSFARPQKK; GISPNSFARPQKKP;ISPNSFARPQKKPP; SPNSFARPQKKPPH; PNSFARPQKKPPHP; NSFARPQKKPPHPY;SFARPQKKPPHPYY; FARPQKKPPHPYYL; ARPQKKPPHPYYLR; RPQKKPPHPYYLRE;PQKKPPHPYYLRER; QKKPPHPYYLRERV; KKPPHPYYLRERVE; KPPHPYYLRERVEA;PPHPYYLRERVEAE; PHPYYLRERVEAEA; HPYYLRERVEAEAA; PYYLRERVEAEAAS;YYLRERVEAEAASA; YLRERVEAEAASAS; LRERVEAEAASASY; RERVEAEAASASYI;ERVEAEAASASYIL; KKRPQGGAAYPWNA; KRPQGGAAYPWNAA; RPQGGAAYPWNAAK;PQGGAAYPWNAAKP; PQEGKCMTHRGMQP; QEGKCMTHRGMQPN; EGKCMTHRGMQPNH;GKCMTHRGMQPNHD; KCMTHRGMQPNHDL; CMTHRGMQPNHDLR; MTHRGMQPNHDLRK;THRGMQPNHDLRKE; HRGMQPNHDLRKES; RGMQPNHDLRKESA; LTGRSCLPMECSQT;TGRSCLPMECSQTM; GRSCLPMECSQTMT; RSCLPMECSQTMTS; SCLPMECSQTMTSG;CLPMECSQTMTSGR; LPMECSQTMTSGRK; PMECSQTMTSGRKV; MECSQTMTSGRKVH;ECSQTMTSGRKVHD; CSQTMTSGRKVHDR; SQTMTSGRKVHDRH; QTMTSGRKVHDRHV;TMTSGRKVHDRHVL; MTSGRKVHDRHVLR; TSGRKVHDRHVLRA; ESWPCPQLNWTKAM;SWPCPQLNWTKAMV; WPCPQLNWTKAMVL; PCPQLNWTKAMVLR; CPQLNWTKAMVLRQ;PQLNWTKAMVLRQL; QLNWTKAMVLRQLS; LNWTKAMVLRQLSR; NWTKAMVLRQLSRQ;WTKAMVLRQLSRQA; TKAMVLRQLSRQAS; KAMVLRQLSRQASV; AMVLRQLSRQASVK;MVLRQLSRQASVKV; VLRQLSRQASVKVG; LRQLSRQASVKVGK; RQLSRQASVKVGKT;QLSRQASVKVGKTW; LSRQASVKVGKTWT; SRQASVKVGKTWTG; RQASVKVGKTWTGT;QASVKVGKTWTGTK; ASVKVGKTWTGTKK; SVKVGKTWTGTKKR; VKVGKTWTGTKKRA;KVGKTWTGTKKRAQ; VGKTWTGTKKRAQR; GKTWTGTKKRAQRI; KTWTGTKKRAQRIF;TWTGTKKRAQRIFI; WTGTKKRAQRIFIF; TGTKKRAQRIFIFI; GTKKRAQRIFIFIL;TKKRAQRIFIFILE; KKRAQRIFIFILEL; KRAQRIFIFILELL; RAQRIFIFILELLL;AQRIFIFILELLLE; QRIFIFILELLLEF; RIFIFILELLLEFC; IFIFILELLLEFCR;FIFILELLLEFCRG; IFILELLLEFCRGE; FILELLLEFCRGED; ILELLLEFCRGEDS;LELLLEFCRGEDSV; ELLLEFCRGEDSVD; LLLEFCRGEDSVDG; LLEFCRGEDSVDGK;LEFCRGEDSVDGKN; EFCRGEDSVDGKNK; FCRGEDSVDGKNKS; CRGEDSVDGKNKST;RGEDSVDGKNKSTT; GEDSVDGKNKSTTA; EDSVDGKNKSTTAL; DSVDGKNKSTTALP;SVDGKNKSTTALPA; VDGKNKSTTALPAV; DGKNKSTTALPAVK; GKNKSTTALPAVKD;KNKSTTALPAVKDS; NKSTTALPAVKDSV; KSTTALPAVKDSVK; STTALPAVKDSVKD;TTALPAVKDSVKDS; VSNPFFFVFPGSWV; SNPFFFVFPGSWVL; NPFFFVFPGSWVLL;LPVYLRLLLPQDFQ; PVYLRLLLPQDFQW; VYLRLLLPQDFQWL; YLRLLLPQDFQWLK;LRLLLPQDFQWLKL; RLLLPQDFQWLKLL; LLLPQDFQWLKLLL; LLPQDFQWLKLLLG;LPQDFQWLKLLLGR; PQDFQWLKLLLGRL; QDFQWLKLLLGRLL; DFQWLKLLLGRLLL;FQWLKLLLGRLLLL; GISSLMIGITKFPL; ASISNQAWLWNCLT; SISNQAWLWNCLTQ;ISNQAWLWNCLTQM; SNQAWLWNCLTQMS; NQAWLWNCLTQMST; QAWLWNCLTQMSTM;AWLWNCLTQMSTMI; WLWNCLTQMSTMIF; LWNCLTQMSTMIFC; WNCLTQMSTMIFCF;NCLTQMSTMIFCFL; CLTQMSTMIFCFLV; ILLLIIFNTLILGI; LLLIIFNTLILGIG;LLIIFNTLILGIGV; LIIFNTLILGIGVL; IIFNTLILGIGVLL; IFNTLILGIGVLLC;FNTLILGIGVLLCL; NTLILGIGVLLCLL; TLILGIGVLLCLLL; LILGIGVLLCLLLF;ILGIGVLLCLLLFP; LGIGVLLCLLLFPR; GIGVLLCLLLFPRL; IGVLLCLLLFPRLC;GVLLCLLLFPRLCG; VLLCLLLFPRLCGM; LLCLLLFPRLCGML; LCLLLFPRLCGMLL;CLLLFPRLCGMLLG; LLLFPRLCGMLLGM; LLFPRLCGMLLGMI; LFPRLCGMLLGMIY;FPRLCGMLLGMIYL; PRLCGMLLGMIYLL; PHRNCREEQKDFLE; HRNCREEQKDFLET;RNCREEQKDFLETP; NCREEQKDFLETPW; CREEQKDFLETPWL; REEQKDFLETPWLD;EEQKDFLETPWLDF; EQKDFLETPWLDFW; QKDFLETPWLDFWR; KDFLETPWLDFWRK;DFLETPWLDFWRKL; FLETPWLDFWRKLP; LETPWLDFWRKLPG; ETPWLDFWRKLPGQ;TPWLDFWRKLPGQL; TFIIIFNNIILIFP; FIIIFNNIILIFPL; IIIFNNIILIFPLL;IIFNNIILIFPLLG; IFNNIILIFPLLGP; FNNIILIFPLLGPQ; NNIILIFPLLGPQW;NIILIFPLLGPQWL; IILIFPLLGPQWLD; ILIFPLLGPQWLDK; LKGKVPVYILAILI;KGKVPVYILAILIV; KKLLPQEVLIKELL; KLLPQEVLIKELLL; LLPQEVLIKELLLN;LPQEVLIKELLLNG; PQEVLIKELLLNGC; QEVLIKELLLNGCC; EVLIKELLLNGCCL;VLIKELLLNGCCLY; LIKELLLNGCCLYF; HLLLKHMKMAPTKR; LLLKHMKMAPTKRK;LLKHMKMAPTKRKG; LKHMKMAPTKRKGE; KHMKMAPTKRKGEC; HMKMAPTKRKGECP;MKMAPTKRKGECPG; KMAPTKRKGECPGA; MAPTKRKGECPGAA; APTKRKGECPGAAP;PTKRKGECPGAAPK; TKRKGECPGAAPKK; KRKGECPGAAPKKP; RKGECPGAAPKKPK;KGECPGAAPKKPKE; GECPGAAPKKPKEP; ECPGAAPKKPKEPV; CPGAAPKKPKEPVQ;PGAAPKKPKEPVQV; GAAPKKPKEPVQVP; AAPKKPKEPVQVPK; APKKPKEPVQVPKL;PKKPKEPVQVPKLL; KKPKEPVQVPKLLI; KPKEPVQVPKLLIK; PKEPVQVPKLLIKG;KEPVQVPKLLIKGG; EPVQVPKLLIKGGV; PVQVPKLLIKGGVE; VQVPKLLIKGGVEV;QVPKLLIKGGVEVL; VPKLLIKGGVEVLE; PKLLIKGGVEVLEV; KLLIKGGVEVLEVK;LLIKGGVEVLEVKT; LIKGGVEVLEVKTG; IKGGVEVLEVKTGV; KGGVEVLEVKTGVD;GGVEVLEVKTGVDA; GVEVLEVKTGVDAI; VEVLEVKTGVDAIT; EVLEVKTGVDAITE;VLEVKTGVDAITEV; LEVKTGVDAITEVE; EVKTGVDAITEVEC; VKTGVDAITEVECF;KTGVDAITEVECFL; TGVDAITEVECFLN; GVDAITEVECFLNP; VDAITEVECFLNPE;DAITEVECFLNPEM; AITEVECFLNPEMG; ITEVECFLNPEMGD; TEVECFLNPEMGDP;EVECFLNPEMGDPD; VECFLNPEMGDPDE; ECFLNPEMGDPDEN; CFLNPEMGDPDENL;FLNPEMGDPDENLR; LNPEMGDPDENLRG; NPEMGDPDENLRGF; PEMGDPDENLRGFS;EMGDPDENLRGFSL; MGDPDENLRGFSLK; GDPDENLRGFSLKL; DPDENLRGFSLKLS;PDENLRGFSLKLSA; DENLRGFSLKLSAE; ENLRGFSLKLSAEN; NLRGFSLKLSAEND;LRGFSLKLSAENDF; RGFSLKLSAENDFS; GFSLKLSAENDFSS; FSLKLSAENDFSSD;SLKLSAENDFSSDS; LKLSAENDFSSDSP; KLSAENDFSSDSPE; LSAENDFSSDSPER;SAENDFSSDSPERK; AENDFSSDSPERKM; ENDFSSDSPERKML; NDFSSDSPERKMLP;DFSSDSPERKMLPC; FSSDSPERKMLPCY; SSDSPERKMLPCYS; SDSPERKMLPCYST;DSPERKMLPCYSTA; SPERKMLPCYSTAR; PERKMLPCYSTARI; ERKMLPCYSTARIP;RKMLPCYSTARIPL; KMLPCYSTARIPLP; MLPCYSTARIPLPN; LPCYSTARIPLPNL;PCYSTARIPLPNLN; CYSTARIPLPNLNE; YSTARIPLPNLNED; STARIPLPNLNEDL;TARIPLPNLNEDLT; ARIPLPNLNEDLTC; RIPLPNLNEDLTCG; IPLPNLNEDLTCGN;PLPNLNEDLTCGNL; LPNLNEDLTCGNLL; PNLNEDLTCGNLLM; NLNEDLTCGNLLMW;LNEDLTCGNLLMWE; NEDLTCGNLLMWEA; EDLTCGNLLMWEAV; DLTCGNLLMWEAVT;LTCGNLLMWEAVTV; TCGNLLMWEAVTVQ; CGNLLMWEAVTVQT; GNLLMWEAVTVQTE;NLLMWEAVTVQTEV; LLMWEAVTVQTEVI; LMWEAVTVQTEVIG; MWEAVTVQTEVIGI;WEAVTVQTEVIGIT; EAVTVQTEVIGITS; AVTVQTEVIGITSM; VTVQTEVIGITSML;TVQTEVIGITSMLN; VQTEVIGITSMLNL; QTEVIGITSMLNLH; TEVIGITSMLNLHA;EVIGITSMLNLHAG; VIGITSMLNLHAGS; IGITSMLNLHAGSQ; GITSMLNLHAGSQK;ITSMLNLHAGSQKV; TSMLNLHAGSQKVH; SMLNLHAGSQKVHE; MLNLHAGSQKVHEH;LNLHAGSQKVHEHG; NLHAGSQKVHEHGG; LHAGSQKVHEHGGG; HAGSQKVHEHGGGK;AGSQKVHEHGGGKP; GSQKVHEHGGGKPI; SQKVHEHGGGKPIQ; QKVHEHGGGKPIQG;KVHEHGGGKPIQGS; VHEHGGGKPIQGSN; HEHGGGKPIQGSNF; EHGGGKPIQGSNFH;HGGGKPIQGSNFHF; GGGKPIQGSNFHFF; GGKPIQGSNFHFFA; GKPIQGSNFHFFAV;KPIQGSNFHFFAVG; PIQGSNFHFFAVGG; IQGSNFHFFAVGGE; QGSNFHFFAVGGEP;GSNFHFFAVGGEPL; SNFHFFAVGGEPLE; NFHFFAVGGEPLEM; FHFFAVGGEPLEMQ;HFFAVGGEPLEMQG; FFAVGGEPLEMQGV; FAVGGEPLEMQGVL; AVGGEPLEMQGVLM;VGGEPLEMQGVLMN; GGEPLEMQGVLMNY; GEPLEMQGVLMNYR; EPLEMQGVLMNYRS;PLEMQGVLMNYRSK; LEMQGVLMNYRSKY; EMQGVLMNYRSKYP; MQGVLMNYRSKYPD;QGVLMNYRSKYPDG; GVLMNYRSKYPDGT; VLMNYRSKYPDGTI; LMNYRSKYPDGTIT;MNYRSKYPDGTITP; NYRSKYPDGTITPK; YRSKYPDGTITPKN; RSKYPDGTITPKNP;SKYPDGTITPKNPT; KYPDGTITPKNPTA; YPDGTITPKNPTAQ; PDGTITPKNPTAQS;DGTITPKNPTAQSQ; GTITPKNPTAQSQV; TITPKNPTAQSQVM; ITPKNPTAQSQVMN;TPKNPTAQSQVMNT; PKNPTAQSQVMNTD; KNPTAQSQVMNTDH; NPTAQSQVMNTDHK;PTAQSQVMNTDHKA; TAQSQVMNTDHKAY; AQSQVMNTDHKAYL; QSQVMNTDHKAYLD;SQVMNTDHKAYLDK; QVMNTDHKAYLDKN; VMNTDHKAYLDKNN; MNTDHKAYLDKNNA;NTDHKAYLDKNNAY; TDHKAYLDKNNAYP; DHKAYLDKNNAYPV; HKAYLDKNNAYPVE;KAYLDKNNAYPVEC; AYLDKNNAYPVECW; YLDKNNAYPVECWV; LDKNNAYPVECWVP;DKNNAYPVECWVPD; KNNAYPVECWVPDP; NNAYPVECWVPDPS; NAYPVECWVPDPSR;AYPVECWVPDPSRN; YPVECWVPDPSRNE; PVECWVPDPSRNEN; VECWVPDPSRNENA;ECWVPDPSRNENAR; CWVPDPSRNENARY; WVPDPSRNENARYF; VPDPSRNENARYFG;PDPSRNENARYFGT; DPSRNENARYFGTF; PSRNENARYFGTFT; SRNENARYFGTFTG;RNENARYFGTFTGG; NENARYFGTFTGGE; ENARYFGTFTGGEN; NARYFGTFTGGENV;ARYFGTFTGGENVP; RYFGTFTGGENVPP; YFGTFTGGENVPPV; FGTFTGGENVPPVL;GTFTGGENVPPVLH; TFTGGENVPPVLHV; FTGGENVPPVLHVT; TGGENVPPVLHVTN;GGENVPPVLHVTNT; GENVPPVLHVTNTA; ENVPPVLHVTNTAT; NVPPVLHVTNTATT;VPPVLHVTNTATTV; PPVLHVTNTATTVL; PVLHVTNTATTVLL; VLHVTNTATTVLLD;LHVTNTATTVLLDE; HVTNTATTVLLDEQ; VTNTATTVLLDEQG; TNTATTVLLDEQGV;NTATTVLLDEQGVG; TATTVLLDEQGVGP; ATTVLLDEQGVGPL; TTVLLDEQGVGPLC;TVLLDEQGVGPLCK; VLLDEQGVGPLCKA; LLDEQGVGPLCKAD; LDEQGVGPLCKADS;DEQGVGPLCKADSL; EQGVGPLCKADSLY; QGVGPLCKADSLYV; GVGPLCKADSLYVS;VGPLCKADSLYVSA; GPLCKADSLYVSAA; PLCKADSLYVSAAD; LCKADSLYVSAADI;CKADSLYVSAADIC; KADSLYVSAADICG; ADSLYVSAADICGL; DSLYVSAADICGLF;SLYVSAADICGLFT; LYVSAADICGLFTN; YVSAADICGLFTNS; VSAADICGLFTNSS;SAADICGLFTNSSG; AADICGLFTNSSGT; ADICGLFTNSSGTQ; DICGLFTNSSGTQQ;ICGLFTNSSGTQQW; CGLFTNSSGTQQWR; GLFTNSSGTQQWRG; LFTNSSGTQQWRGL;FTNSSGTQQWRGLA; TNSSGTQQWRGLAR; NSSGTQQWRGLARY; SSGTQQWRGLARYF;SGTQQWRGLARYFK; GTQQWRGLARYFKI; TQQWRGLARYFKIR; QQWRGLARYFKIRL;QWRGLARYFKIRLR; WRGLARYFKIRLRK; RGLARYFKIRLRKR; GLARYFKIRLRKRS;LARYFKIRLRKRSV; ARYFKIRLRKRSVK; RYFKIRLRKRSVKN; YFKIRLRKRSVKNP;FKIRLRKRSVKNPY; KIRLRKRSVKNPYP; IRLRKRSVKNPYPI; RLRKRSVKNPYPIS;LRKRSVKNPYPISF; RKRSVKNPYPISFL; KRSVKNPYPISFLL; RSVKNPYPISFLLS;SVKNPYPISFLLSD; VKNPYPISFLLSDL; KNPYPISFLLSDLI; NPYPISFLLSDLIN;PYPISFLLSDLINR; YPISFLLSDLINRR; PISFLLSDLINRRT; ISFLLSDLINRRTQ;SFLLSDLINRRTQR; FLLSDLINRRTQRV; LLSDLINRRTQRVD; LSDLINRRTQRVDG;SDLINRRTQRVDGQ; DLINRRTQRVDGQP; LINRRTQRVDGQPM; INRRTQRVDGQPMY;NRRTQRVDGQPMYG; RRTQRVDGQPMYGM; RTQRVDGQPMYGME; TQRVDGQPMYGMES;QRVDGQPMYGMESQ; RVDGQPMYGMESQV; VDGQPMYGMESQVE; DGQPMYGMESQVEE;GQPMYGMESQVEEV; QPMYGMESQVEEVR; PMYGMESQVEEVRV; MYGMESQVEEVRVF;YGMESQVEEVRVFD; GMESQVEEVRVFDG; MESQVEEVRVFDGT; ESQVEEVRVFDGTE;SQVEEVRVFDGTER; QVEEVRVFDGTERL; VEEVRVFDGTERLP; EEVRVFDGTERLPG;EVRVFDGTERLPGD; VRVFDGTERLPGDP; RVFDGTERLPGDPD; VFDGTERLPGDPDM;FDGTERLPGDPDMI; DGTERLPGDPDMIR; GTERLPGDPDMIRY; TERLPGDPDMIRYI;ERLPGDPDMIRYID; RLPGDPDMIRYIDK; LPGDPDMIRYIDKQ; PGDPDMIRYIDKQG;GDPDMIRYIDKQGQ; DPDMIRYIDKQGQL; PDMIRYIDKQGQLQ; DMIRYIDKQGQLQT;MIRYIDKQGQLQTK; IRYIDKQGQLQTKM; RYIDKQGQLQTKML; TGAFIVHIHLINAA;GAFIVHIHLINAAF; AFIVHIHLINAAFV; ATFKLVLFWGWCFR; TFKLVLFWGWCFRP;FKLVLFWGWCFRPF; KLVLFWGWCFRPFK; LVLFWGWCFRPFKT; VLFWGWCFRPFKTL;LFWGWCFRPFKTLK; FWGWCFRPFKTLKA; WGWCFRPFKTLKAF; GWCFRPFKTLKAFT;WCFRPFKTLKAFTQ; CFRPFKTLKAFTQM; FRPFKTLKAFTQMQ; RPFKTLKAFTQMQL;PFKTLKAFTQMQLL; FKTLKAFTQMQLLT; KTLKAFTQMQLLTM; TLKAFTQMQLLTMG;LKAFTQMQLLTMGV; ILFSCNIKNTFPHA; LFSCNIKNTFPHAY; FSCNIKNTFPHAYI;SCNIKNTFPHAYII; CNIKNTFPHAYIIF; NIKNTFPHAYIIFH; IKNTFPHAYIIFHP;KSIHTYLRIQPFLP; SIHTYLRIQPFLPF; IHTYLRIQPFLPFN; HTYLRIQPFLPFNN;TYLRIQPFLPFNNS; YLRIQPFLPFNNSR; LRIQPFLPFNNSRL; RIQPFLPFNNSRLY;IQPFLPFNNSRLYI; QPFLPFNNSRLYIS; PFLPFNNSRLYISC; FLPFNNSRLYISCK;LPFNNSRLYISCKI; PFNNSRLYISCKIS; FNNSRLYISCKISY; NNSRLYISCKISYR;NSRLYISCKISYRP; SRLYISCKISYRPK; RLYISCKISYRPKP; LYISCKISYRPKPN;IYFGPKIYLSYKSS; YFGPKIYLSYKSSL; FGPKIYLSYKSSLQ; GPKIYLSYKSSLQG;PKIYLSYKSSLQGF; KIYLSYKSSLQGFR; IYLSYKSSLQGFRD; YLSYKSSLQGFRDR;LSYKSSLQGFRDRI; SYKSSLQGFRDRIL; YKSSLQGFRDRILI; KSSLQGFRDRILIH;SSLQGFRDRILIHC; SLQGFRDRILIHCN; LQGFRDRILIHCNQ; QGFRDRILIHCNQA;GFRDRILIHCNQAW; FRDRILIHCNQAWW; RDRILIHCNQAWWK; DRILIHCNQAWWKY;RILIHCNQAWWKYL; ILIHCNQAWWKYLG; LIHCNQAWWKYLGS; IHCNQAWWKYLGSF;HCNQAWWKYLGSFV; FSSCPFYIFKNNHV; SSCPFYIFKNNHVL; SCPFYIFKNNHVLI;CPFYIFKNNHVLIY; PFYIFKNNHVLIYS; FYIFKNNHVLIYSY; YIFKNNHVLIYSYT;PVSSFRYIENNTVQ; VSSFRYIENNTVQK; SSFRYIENNTVQKI; SFRYIENNTVQKIK;FRYIENNTVQKIKY; RYIENNTVQKIKYY; YIENNTVQKIKYYR; IENNTVQKIKYYRI;ENNTVQKIKYYRIH; NNTVQKIKYYRIHF; NTVQKIKYYRIHFR; HFFPGHMKGIYSFF;FFPGHMKGIYSFFS; NCIYCLLTNTFLIF; CIYCLLTNTFLIFT; IYCLLTNTFLIFTF;YCLLTNTFLIFTFC; CLLTNTFLIFTFCK; LLTNTFLIFTFCKN; LTNTFLIFTFCKNN;TNTFLIFTFCKNNS; NTFLIFTFCKNNSI; TFLIFTFCKNNSIC; FLIFTFCKNNSICK;LIFTFCKNNSICKV; IFTFCKNNSICKVL; FTFCKNNSICKVLF; TFCKNNSICKVLFM;FCKNNSICKVLFMI; CKNNSICKVLFMIL; KNNSICKVLFMILK; NNSICKVLFMILKV;NSICKVLFMILKVI; SICKVLFMILKVIR; ICKVLFMILKVIRL; CKVLFMILKVIRLV;KVLFMILKVIRLVF; VLFMILKVIRLVFF; LFMILKVIRLVFFL; FMILKVIRLVFFLT;MILKVIRLVFFLTL; ILKVIRLVFFLTLF; LKVIRLVFFLTLFT; KVIRLVFFLTLFTL;VIRLVFFLTLFTLL; IRLVFFLTLFTLLY; RLVFFLTLFTLLYI; LVFFLTLFTLLYIV;VFFLTLFTLLYIVL; FFLTLFTLLYIVLK; FLTLFTLLYIVLKF; KHILTLCLYCILSN;FPRHLLCFFRLFWA; PRHLLCFFRLFWAK; RHLLCFFRLFWAKI; HLLCFFRLFWAKIM;LLCFFRLFWAKIML; LCFFRLFWAKIMLL; APLNAFFYSMVWIS; PLNAFFYSMVWISS;KTKGTQLLTEIINC; TKGTQLLTEIINCR; KGTQLLTEIINCRN; GTQLLTEIINCRNS;TQLLTEIINCRNSM; QLLTEIINCRNSMS; LLTEIINCRNSMSM; LTEIINCRNSMSMW;TEIINCRNSMSMWS; KEYNIMPSTHVSTN; EYNIMPSTHVSTNK; YNIMPSTHVSTNKS;NIMPSTHVSTNKSY; IMPSTHVSTNKSYR; MPSTHVSTNKSYRI; PSTHVSTNKSYRIF;STHVSTNKSYRIFF; THVSTNKSYRIFFH; HVSTNKSYRIFFHK; VSTNKSYRIFFHKF;STNKSYRIFFHKFF; TNKSYRIFFHKFFI; NKSYRIFFHKFFIQ; KSYRIFFHKFFIQN;SYRIFFHKFFIQNL; YRIFFHKFFIQNLS; RIFFHKFFIQNLSF; IFFHKFFIQNLSFF;FFHKFFIQNLSFFF; FHKFFIQNLSFFFS; HKFFIQNLSFFFSS; KFFIQNLSFFFSSI;FFIQNLSFFFSSIH; FIQNLSFFFSSIHS; IQNLSFFFSSIHSK; QNLSFFFSSIHSKA;NLSFFFSSIHSKAG; LSFFFSSIHSKAGK; SFFFSSIHSKAGKG; FFFSSIHSKAGKGS;FFSSIHSKAGKGSI; FSSIHSKAGKGSIT; SSIHSKAGKGSITK; SIHSKAGKGSITKY;IHSKAGKGSITKYS; HSKAGKGSITKYSL; SKAGKGSITKYSLT; KAGKGSITKYSLTK;AGKGSITKYSLTKK; GKGSITKYSLTKKL; KGSITKYSLTKKLV; IRGKVFRVFYLSFF;RGKVFRVFYLSFFF; GKVFRVFYLSFFFG; KVFRVFYLSFFFGW; VFRVFYLSFFFGWC;VLRICCCFFITGKH; LRICCCFFITGKHI; RICCCFFITGKHIF; ICCCFFITGKHIFM;CCCFFITGKHIFMA; CCFFITGKHIFMAK; IFIPFFIKGTPPGL; FIPFFIKGTPPGLP;IPFFIKGTPPGLPL; PFFIKGTPPGLPLF; FFIKGTPPGLPLFC; FIKGTPPGLPLFCS;IKGTPPGLPLFCSI; KGTPPGLPLFCSIG; GTPPGLPLFCSIGW; TPPGLPLFCSIGWH;PPGLPLFCSIGWHL; SFRSLKGVSPIIWT; FRSLKGVSPIIWTH; RSLKGVSPIIWTHH;SLKGVSPIIWTHHC; LKGVSPIIWTHHCR; KGVSPIIWTHHCRV; GVSPIIWTHHCRVS;VSPIIWTHHCRVSS; SPIIWTHHCRVSSV; PIIWTHHCRVSSVR; IIWTHHCRVSSVRS;IWTHHCRVSSVRSK; WTHHCRVSSVRSKP; THHCRVSSVRSKPN; HHCRVSSVRSKPNH;HCRVSSVRSKPNHC; CRVSSVRSKPNHCV; RVSSVRSKPNHCVK; VSSVRSKPNHCVKQ;SSVRSKPNHCVKQS; SVRSKPNHCVKQSM; VRSKPNHCVKQSMQ; QSIQTKGSFLKNFL;SIQTKGSFLKNFLF; IQTKGSFLKNFLFK; QTKGSFLKNFLFKC; TKGSFLKNFLFKCL;KGSFLKNFLFKCLN; GSFLKNFLFKCLNL; SFLKNFLFKCLNLS; HSMQGQCTEGFLEQ;SMQGQCTEGFLEQI; MQGQCTEGFLEQIG; QGQCTEGFLEQIGH; GQCTEGFLEQIGHS;QCTEGFLEQIGHSL; CTEGFLEQIGHSLQ; TEGFLEQIGHSLQY; EGFLEQIGHSLQYR;GFLEQIGHSLQYRV; FLEQIGHSLQYRVS; LEQIGHSLQYRVSG; EQIGHSLQYRVSGQ;QIGHSLQYRVSGQR; IGHSLQYRVSGQRG; GHSLQYRVSGQRGK; HSLQYRVSGQRGKS;SLQYRVSGQRGKSA; LQYRVSGQRGKSAQ; QYRVSGQRGKSAQT; YRVSGQRGKSAQTS;RVSGQRGKSAQTSE; VSGQRGKSAQTSEL; SGQRGKSAQTSELL; GQRGKSAQTSELLQ;QRGKSAQTSELLQV; RGKSAQTSELLQVP; GKSAQTSELLQVPK; KSAQTSELLQVPKS;SAQTSELLQVPKSG; ATFTSCSIFLYKVF; TFTSCSIFLYKVFI; FTSCSIFLYKVFIL;TSCSIFLYKVFILF; SCSIFLYKVFILFI; CSIFLYKVFILFIL; SIFLYKVFILFILS;IFLYKVFILFILSS; FLYKVFILFILSSS; LYKVFILFILSSSP; YKVFILFILSSSPP;KVFILFILSSSPPL; VFILFILSSSPPLS; FILFILSSSPPLSG; AFLIKGRFPQAALS;FLIKGRFPQAALSR; LIKGRFPQAALSRP; IKGRFPQAALSRPK; KGRFPQAALSRPKR;GRFPQAALSRPKRS; RFPQAALSRPKRSM; FPQAALSRPKRSMS; PQAALSRPKRSMSS;QAALSRPKRSMSSM; AALSRPKRSMSSMD; ALSRPKRSMSSMDS; LSRPKRSMSSMDSS;SRPKRSMSSMDSSL; RPKRSMSSMDSSLL; PKRSMSSMDSSLLR; KRSMSSMDSSLLRT;RSMSSMDSSLLRTL; SMSSMDSSLLRTLS 15 mers: FCKNCKRIGISPNSF;CKNCKRIGISPNSFA; KNCKRIGISPNSFAR; NCKRIGISPNSFARP; CKRIGISPNSFARPQ;KRIGISPNSFARPQK; RIGISPNSFARPQKK; IGISPNSFARPQKKP; GISPNSFARPQKKPP;ISPNSFARPQKKPPH; SPNSFARPQKKPPHP; PNSFARPQKKPPHPY; NSFARPQKKPPHPYY;SFARPQKKPPHPYYL; FARPQKKPPHPYYLR; ARPQKKPPHPYYLRE; RPQKKPPHPYYLRER;PQKKPPHPYYLRERV; QKKPPHPYYLRERVE; KKPPHPYYLRERVEA; KPPHPYYLRERVEAE;PPHPYYLRERVEAEA; PHPYYLRERVEAEAA; HPYYLRERVEAEAAS; PYYLRERVEAEAASA;YYLRERVEAEAASAS; YLRERVEAEAASASY; LRERVEAEAASASYI; RERVEAEAASASYIL;KKRPQGGAAYPWNAA; KRPQGGAAYPWNAAK; RPQGGAAYPWNAAKP; PQEGKCMTHRGMQPN;QEGKCMTHRGMQPNH; EGKCMTHRGMQPNHD; GKCMTHRGMQPNHDL; KCMTHRGMQPNHDLR;CMTHRGMQPNHDLRK; MTHRGMQPNHDLRKE; THRGMQPNHDLRKES; HRGMQPNHDLRKESA;LTGRSCLPMECSQTM; TGRSCLPMECSQTMT; GRSCLPMECSQTMTS; RSCLPMECSQTMTSG;SCLPMECSQTMTSGR; CLPMECSQTMTSGRK; LPMECSQTMTSGRKV; PMECSQTMTSGRKVH;MECSQTMTSGRKVHD; ECSQTMTSGRKVHDR; CSQTMTSGRKVHDRH; SQTMTSGRKVHDRHV;QTMTSGRKVHDRHVL; TMTSGRKVHDRHVLR; MTSGRKVHDRHVLRA; ESWPCPQLNWTKAMV;SWPCPQLNWTKAMVL; WPCPQLNWTKAMVLR; PCPQLNWTKAMVLRQ; CPQLNWTKAMVLRQL;PQLNWTKAMVLRQLS; QLNWTKAMVLRQLSR; LNWTKAMVLRQLSRQ; NWTKAMVLRQLSRQA;WTKAMVLRQLSRQAS; TKAMVLRQLSRQASV; KAMVLRQLSRQASVK; AMVLRQLSRQASVKV;MVLRQLSRQASVKVG; VLRQLSRQASVKVGK; LRQLSRQASVKVGKT; RQLSRQASVKVGKTW;QLSRQASVKVGKTWT; LSRQASVKVGKTWTG; SRQASVKVGKTWTGT; RQASVKVGKTWTGTK;QASVKVGKTWTGTKK; ASVKVGKTWTGTKKR; SVKVGKTWTGTKKRA; VKVGKTWTGTKKRAQ;KVGKTWTGTKKRAQR; VGKTWTGTKKRAQRI; GKTWTGTKKRAQRIF; KTWTGTKKRAQRIFI;TWTGTKKRAQRIFIF; WTGTKKRAQRIFIFI; TGTKKRAQRIFIFIL; GTKKRAQRIFIFILE;TKKRAQRIFIFILEL; KKRAQRIFIFILELL; KRAQRIFIFILELLL; RAQRIFIFILELLLE;AQRIFIFILELLLEF; QRIFIFILELLLEFC; RIFIFILELLLEFCR; IFIFILELLLEFCRG;FIFILELLLEFCRGE; IFILELLLEFCRGED; FILELLLEFCRGEDS; ILELLLEFCRGEDSV;LELLLEFCRGEDSVD; ELLLEFCRGEDSVDG; LLLEFCRGEDSVDGK; LLEFCRGEDSVDGKN;LEFCRGEDSVDGKNK; EFCRGEDSVDGKNKS; FCRGEDSVDGKNKST; CRGEDSVDGKNKSTT;RGEDSVDGKNKSTTA; GEDSVDGKNKSTTAL; EDSVDGKNKSTTALP; DSVDGKNKSTTALPA;SVDGKNKSTTALPAV; VDGKNKSTTALPAVK; DGKNKSTTALPAVKD; GKNKSTTALPAVKDS;KNKSTTALPAVKDSV; NKSTTALPAVKDSVK; KSTTALPAVKDSVKD; STTALPAVKDSVKDS;VSNPFFFVFPGSWVL; SNPFFFVFPGSWVLL; LPVYLRLLLPQDFQW; PVYLRLLLPQDFQWL;VYLRLLLPQDFQWLK; YLRLLLPQDFQWLKL; LRLLLPQDFQWLKLL; RLLLPQDFQWLKLLL;LLLPQDFQWLKLLLG; LLPQDFQWLKLLLGR; LPQDFQWLKLLLGRL; PQDFQWLKLLLGRLL;QDFQWLKLLLGRLLL; DFQWLKLLLGRLLLL; ASISNQAWLWNCLTQ; SISNQAWLWNCLTQM;ISNQAWLWNCLTQMS; SNQAWLWNCLTQMST; NQAWLWNCLTQMSTM; QAWLWNCLTQMSTMI;AWLWNCLTQMSTMIF; WLWNCLTQMSTMIFC; LWNCLTQMSTMIFCF; WNCLTQMSTMIFCFL;NCLTQMSTMIFCFLV; ILLLIIFNTLILGIG; LLLIIFNTLILGIGV; LLIIFNTLILGIGVL;LIIFNTLILGIGVLL; IIFNTLILGIGVLLC; IFNTLILGIGVLLCL; FNTLILGIGVLLCLL;NTLILGIGVLLCLLL; TLILGIGVLLCLLLF; LILGIGVLLCLLLFP; ILGIGVLLCLLLFPR;LGIGVLLCLLLFPRL; GIGVLLCLLLFPRLC; IGVLLCLLLFPRLCG; GVLLCLLLFPRLCGM;VLLCLLLFPRLCGML; LLCLLLFPRLCGMLL; LCLLLFPRLCGMLLG; CLLLFPRLCGMLLGM;LLLFPRLCGMLLGMI; LLFPRLCGMLLGMIY; LFPRLCGMLLGMIYL; FPRLCGMLLGMIYLL;PHRNCREEQKDFLET; HRNCREEQKDFLETP; RNCREEQKDFLETPW; NCREEQKDFLETPWL;CREEQKDFLETPWLD; REEQKDFLETPWLDF; EEQKDFLETPWLDFW; EQKDFLETPWLDFWR;QKDFLETPWLDFWRK; KDFLETPWLDFWRKL; DFLETPWLDFWRKLP; FLETPWLDFWRKLPG;LETPWLDFWRKLPGQ; ETPWLDFWRKLPGQL; TFIIIFNNIILIFPL; FIIIFNNIILIFPLL;IIIFNNIILIFPLLG; IIFNNIILIFPLLGP; IFNNIILIFPLLGPQ; FNNIILIFPLLGPQW;NNIILIFPLLGPQWL; NIILIFPLLGPQWLD; IILIFPLLGPQWLDK; LKGKVPVYILAILIV;KKLLPQEVLIKELLL; KLLPQEVLIKELLLN; LLPQEVLIKELLLNG; LPQEVLIKELLLNGC;PQEVLIKELLLNGCC; QEVLIKELLLNGCCL; EVLIKELLLNGCCLY; VLIKELLLNGCCLYF;HLLLKHMKMAPTKRK; LLLKHMKMAPTKRKG; LLKHMKMAPTKRKGE; LKHMKMAPTKRKGEC;KHMKMAPTKRKGECP; HMKMAPTKRKGECPG; MKMAPTKRKGECPGA; KMAPTKRKGECPGAA;MAPTKRKGECPGAAP; APTKRKGECPGAAPK; PTKRKGECPGAAPKK; TKRKGECPGAAPKKP;KRKGECPGAAPKKPK; RKGECPGAAPKKPKE; KGECPGAAPKKPKEP; GECPGAAPKKPKEPV;ECPGAAPKKPKEPVQ; CPGAAPKKPKEPVQV; PGAAPKKPKEPVQVP; GAAPKKPKEPVQVPK;AAPKKPKEPVQVPKL; APKKPKEPVQVPKLL; PKKPKEPVQVPKLLI; KKPKEPVQVPKLLIK;KPKEPVQVPKLLIKG; PKEPVQVPKLLIKGG; KEPVQVPKLLIKGGV; EPVQVPKLLIKGGVE;PVQVPKLLIKGGVEV; VQVPKLLIKGGVEVL; QVPKLLIKGGVEVLE; VPKLLIKGGVEVLEV;PKLLIKGGVEVLEVK; KLLIKGGVEVLEVKT; LLIKGGVEVLEVKTG; LIKGGVEVLEVKTGV;IKGGVEVLEVKTGVD; KGGVEVLEVKTGVDA; GGVEVLEVKTGVDAI; GVEVLEVKTGVDAIT;VEVLEVKTGVDAITE; EVLEVKTGVDAITEV; VLEVKTGVDAITEVE; LEVKTGVDAITEVEC;EVKTGVDAITEVECF; VKTGVDAITEVECFL; KTGVDAITEVECFLN; TGVDAITEVECFLNP;GVDAITEVECFLNPE; VDAITEVECFLNPEM; DAITEVECFLNPEMG; AITEVECFLNPEMGD;ITEVECFLNPEMGDP; TEVECFLNPEMGDPD; EVECFLNPEMGDPDE; VECFLNPEMGDPDEN;ECFLNPEMGDPDENL; CFLNPEMGDPDENLR; FLNPEMGDPDENLRG; LNPEMGDPDENLRGF;NPEMGDPDENLRGFS; PEMGDPDENLRGFSL; EMGDPDENLRGFSLK; MGDPDENLRGFSLKL;GDPDENLRGFSLKLS; DPDENLRGFSLKLSA; PDENLRGFSLKLSAE; DENLRGFSLKLSAEN;ENLRGFSLKLSAEND; NLRGFSLKLSAENDF; LRGFSLKLSAENDFS; RGFSLKLSAENDFSS;GFSLKLSAENDFSSD; FSLKLSAENDFSSDS; SLKLSAENDFSSDSP; LKLSAENDFSSDSPE;KLSAENDFSSDSPER; LSAENDFSSDSPERK; SAENDFSSDSPERKM; AENDFSSDSPERKML;ENDFSSDSPERKMLP; NDFSSDSPERKMLPC; DFSSDSPERKMLPCY; FSSDSPERKMLPCYS;SSDSPERKMLPCYST; SDSPERKMLPCYSTA; DSPERKMLPCYSTAR; SPERKMLPCYSTARI;PERKMLPCYSTARIP; ERKMLPCYSTARIPL; RKMLPCYSTARIPLP; KMLPCYSTARIPLPN;MLPCYSTARIPLPNL; LPCYSTARIPLPNLN; PCYSTARIPLPNLNE; CYSTARIPLPNLNED;YSTARIPLPNLNEDL; STARIPLPNLNEDLT; TARIPLPNLNEDLTC; ARIPLPNLNEDLTCG;RIPLPNLNEDLTCGN; IPLPNLNEDLTCGNL; PLPNLNEDLTCGNLL; LPNLNEDLTCGNLLM;PNLNEDLTCGNLLMW; NLNEDLTCGNLLMWE; LNEDLTCGNLLMWEA; NEDLTCGNLLMWEAV;EDLTCGNLLMWEAVT; DLTCGNLLMWEAVTV; LTCGNLLMWEAVTVQ; TCGNLLMWEAVTVQT;CGNLLMWEAVTVQTE; GNLLMWEAVTVQTEV; NLLMWEAVTVQTEVI; LLMWEAVTVQTEVIG;LMWEAVTVQTEVIGI; MWEAVTVQTEVIGIT; WEAVTVQTEVIGITS; EAVTVQTEVIGITSM;AVTVQTEVIGITSML; VTVQTEVIGITSMLN; TVQTEVIGITSMLNL; VQTEVIGITSMLNLH;QTEVIGITSMLNLHA; TEVIGITSMLNLHAG; EVIGITSMLNLHAGS; VIGITSMLNLHAGSQ;IGITSMLNLHAGSQK; GITSMLNLHAGSQKV; ITSMLNLHAGSQKVH; TSMLNLHAGSQKVHE;SMLNLHAGSQKVHEH; MLNLHAGSQKVHEHG; LNLHAGSQKVHEHGG; NLHAGSQKVHEHGGG;LHAGSQKVHEHGGGK; HAGSQKVHEHGGGKP; AGSQKVHEHGGGKPI; GSQKVHEHGGGKPIQ;SQKVHEHGGGKPIQG; QKVHEHGGGKPIQGS; KVHEHGGGKPIQGSN; VHEHGGGKPIQGSNF;HEHGGGKPIQGSNFH; EHGGGKPIQGSNFHF; HGGGKPIQGSNFHFF; GGGKPIQGSNFHFFA;GGKPIQGSNFHFFAV; GKPIQGSNFHFFAVG; KPIQGSNFHFFAVGG; PIQGSNFHFFAVGGE;IQGSNFHFFAVGGEP; QGSNFHFFAVGGEPL; GSNFHFFAVGGEPLE; SNFHFFAVGGEPLEM;NFHFFAVGGEPLEMQ; FHFFAVGGEPLEMQG; HFFAVGGEPLEMQGV; FFAVGGEPLEMQGVL;FAVGGEPLEMQGVLM; AVGGEPLEMQGVLMN; VGGEPLEMQGVLMNY; GGEPLEMQGVLMNYR;GEPLEMQGVLMNYRS; EPLEMQGVLMNYRSK; PLEMQGVLMNYRSKY; LEMQGVLMNYRSKYP;EMQGVLMNYRSKYPD; MQGVLMNYRSKYPDG; QGVLMNYRSKYPDGT; GVLMNYRSKYPDGTI;VLMNYRSKYPDGTIT; LMNYRSKYPDGTITP; MNYRSKYPDGTITPK; NYRSKYPDGTITPKN;YRSKYPDGTITPKNP; RSKYPDGTITPKNPT; SKYPDGTITPKNPTA; KYPDGTITPKNPTAQ;YPDGTITPKNPTAQS; PDGTITPKNPTAQSQ; DGTITPKNPTAQSQV; GTITPKNPTAQSQVM;TITPKNPTAQSQVMN; ITPKNPTAQSQVMNT; TPKNPTAQSQVMNTD; PKNPTAQSQVMNTDH;KNPTAQSQVMNTDHK; NPTAQSQVMNTDHKA; PTAQSQVMNTDHKAY; TAQSQVMNTDHKAYL;AQSQVMNTDHKAYLD; QSQVMNTDHKAYLDK; SQVMNTDHKAYLDKN; QVMNTDHKAYLDKNN;VMNTDHKAYLDKNNA; MNTDHKAYLDKNNAY; NTDHKAYLDKNNAYP; TDHKAYLDKNNAYPV;DHKAYLDKNNAYPVE; HKAYLDKNNAYPVEC; KAYLDKNNAYPVECW; AYLDKNNAYPVECWV;YLDKNNAYPVECWVP; LDKNNAYPVECWVPD; DKNNAYPVECWVPDP; KNNAYPVECWVPDPS;NNAYPVECWVPDPSR; NAYPVECWVPDPSRN; AYPVECWVPDPSRNE; YPVECWVPDPSRNEN;PVECWVPDPSRNENA; VECWVPDPSRNENAR; ECWVPDPSRNENARY; CWVPDPSRNENARYF;WVPDPSRNENARYFG; VPDPSRNENARYFGT; PDPSRNENARYFGTF; DPSRNENARYFGTFT;PSRNENARYFGTFTG; SRNENARYFGTFTGG; RNENARYFGTFTGGE; NENARYFGTFTGGEN;ENARYFGTFTGGENV; NARYFGTFTGGENVP; ARYFGTFTGGENVPP; RYFGTFTGGENVPPV;YFGTFTGGENVPPVL; FGTFTGGENVPPVLH; GTFTGGENVPPVLHV; TFTGGENVPPVLHVT;FTGGENVPPVLHVTN; TGGENVPPVLHVTNT; GGENVPPVLHVTNTA; GENVPPVLHVTNTAT;ENVPPVLHVTNTATT; NVPPVLHVTNTATTV; VPPVLHVTNTATTVL; PPVLHVTNTATTVLL;PVLHVTNTATTVLLD; VLHVTNTATTVLLDE; LHVTNTATTVLLDEQ; HVTNTATTVLLDEQG;VTNTATTVLLDEQGV; TNTATTVLLDEQGVG; NTATTVLLDEQGVGP; TATTVLLDEQGVGPL;ATTVLLDEQGVGPLC; TTVLLDEQGVGPLCK; TVLLDEQGVGPLCKA; VLLDEQGVGPLCKAD;LLDEQGVGPLCKADS; LDEQGVGPLCKADSL; DEQGVGPLCKADSLY; EQGVGPLCKADSLYV;QGVGPLCKADSLYVS; GVGPLCKADSLYVSA; VGPLCKADSLYVSAA; GPLCKADSLYVSAAD;PLCKADSLYVSAADI; LCKADSLYVSAADIC; CKADSLYVSAADICG; KADSLYVSAADICGL;ADSLYVSAADICGLF; DSLYVSAADICGLFT; SLYVSAADICGLFTN; LYVSAADICGLFTNS;YVSAADICGLFTNSS; VSAADICGLFTNSSG; SAADICGLFTNSSGT; AADICGLFTNSSGTQ;ADICGLFTNSSGTQQ; DICGLFTNSSGTQQW; ICGLFTNSSGTQQWR; CGLFTNSSGTQQWRG;GLFTNSSGTQQWRGL; LFTNSSGTQQWRGLA; FTNSSGTQQWRGLAR; TNSSGTQQWRGLARY;NSSGTQQWRGLARYF; SSGTQQWRGLARYFK; SGTQQWRGLARYFKI; GTQQWRGLARYFKIR;TQQWRGLARYFKIRL; QQWRGLARYFKIRLR; QWRGLARYFKIRLRK; WRGLARYFKIRLRKR;RGLARYFKIRLRKRS; GLARYFKIRLRKRSV; LARYFKIRLRKRSVK; ARYFKIRLRKRSVKN;RYFKIRLRKRSVKNP; YFKIRLRKRSVKNPY; FKIRLRKRSVKNPYP; KIRLRKRSVKNPYPI;IRLRKRSVKNPYPIS; RLRKRSVKNPYPISF; LRKRSVKNPYPISFL; RKRSVKNPYPISFLL;KRSVKNPYPISFLLS; RSVKNPYPISFLLSD; SVKNPYPISFLLSDL; VKNPYPISFLLSDLI;KNPYPISFLLSDLIN; NPYPISFLLSDLINR; PYPISFLLSDLINRR; YPISFLLSDLINRRT;PISFLLSDLINRRTQ; ISFLLSDLINRRTQR; SFLLSDLINRRTQRV; FLLSDLINRRTQRVD;LLSDLINRRTQRVDG; LSDLINRRTQRVDGQ; SDLINRRTQRVDGQP; DLINRRTQRVDGQPM;LINRRTQRVDGQPMY; INRRTQRVDGQPMYG; NRRTQRVDGQPMYGM; RRTQRVDGQPMYGME;RTQRVDGQPMYGMES; TQRVDGQPMYGMESQ; QRVDGQPMYGMESQV; RVDGQPMYGMESQVE;VDGQPMYGMESQVEE; DGQPMYGMESQVEEV; GQPMYGMESQVEEVR; QPMYGMESQVEEVRV;PMYGMESQVEEVRVF; MYGMESQVEEVRVFD; YGMESQVEEVRVFDG; GMESQVEEVRVFDGT;MESQVEEVRVFDGTE; ESQVEEVRVFDGTER; SQVEEVRVFDGTERL; QVEEVRVFDGTERLP;VEEVRVFDGTERLPG; EEVRVFDGTERLPGD; EVRVFDGTERLPGDP; VRVFDGTERLPGDPD;RVFDGTERLPGDPDM; VFDGTERLPGDPDMI; FDGTERLPGDPDMIR; DGTERLPGDPDMIRY;GTERLPGDPDMIRYI; TERLPGDPDMIRYID; ERLPGDPDMIRYIDK; RLPGDPDMIRYIDKQ;LPGDPDMIRYIDKQG; PGDPDMIRYIDKQGQ; GDPDMIRYIDKQGQL; DPDMIRYIDKQGQLQ;PDMIRYIDKQGQLQT; DMIRYIDKQGQLQTK; MIRYIDKQGQLQTKM; IRYIDKQGQLQTKML;TGAFIVHIHLINAAF; GAFIVHIHLINAAFV; ATFKLVLFWGWCFRP; TFKLVLFWGWCFRPF;FKLVLFWGWCFRPFK; KLVLFWGWCFRPFKT; LVLFWGWCFRPFKTL; VLFWGWCFRPFKTLK;LFWGWCFRPFKTLKA; FWGWCFRPFKTLKAF; WGWCFRPFKTLKAFT; GWCFRPFKTLKAFTQ;WCFRPFKTLKAFTQM; CFRPFKTLKAFTQMQ; FRPFKTLKAFTQMQL; RPFKTLKAFTQMQLL;PFKTLKAFTQMQLLT; FKTLKAFTQMQLLTM; KTLKAFTQMQLLTMG; TLKAFTQMQLLTMGV;ILFSCNIKNTFPHAY; LFSCNIKNTFPHAYI; FSCNIKNTFPHAYII; SCNIKNTFPHAYIIF;CNIKNTFPHAYIIFH; NIKNTFPHAYIIFHP; KSIHTYLRIQPFLPF; SIHTYLRIQPFLPFN;IHTYLRIQPFLPFNN; HTYLRIQPFLPFNNS; TYLRIQPFLPFNNSR; YLRIQPFLPFNNSRL;LRIQPFLPFNNSRLY; RIQPFLPFNNSRLYI; IQPFLPFNNSRLYIS; QPFLPFNNSRLYISC;PFLPFNNSRLYISCK; FLPFNNSRLYISCKI; LPFNNSRLYISCKIS; PFNNSRLYISCKISY;FNNSRLYISCKISYR; NNSRLYISCKISYRP; NSRLYISCKISYRPK; SRLYISCKISYRPKP;RLYISCKISYRPKPN; IYFGPKIYLSYKSSL; YFGPKIYLSYKSSLQ; FGPKIYLSYKSSLQG;GPKIYLSYKSSLQGF; PKIYLSYKSSLQGFR; KIYLSYKSSLQGFRD; IYLSYKSSLQGFRDR;YLSYKSSLQGFRDRI; LSYKSSLQGFRDRIL; SYKSSLQGFRDRILI; YKSSLQGFRDRILIH;KSSLQGFRDRILIHC; SSLQGFRDRILIHCN; SLQGFRDRILIHCNQ; LQGFRDRILIHCNQA;QGFRDRILIHCNQAW; GFRDRILIHCNQAWW; FRDRILIHCNQAWWK; RDRILIHCNQAWWKY;DRILIHCNQAWWKYL; RILIHCNQAWWKYLG; ILIHCNQAWWKYLGS; LIHCNQAWWKYLGSF;IHCNQAWWKYLGSFV; FSSCPFYIFKNNHVL; SSCPFYIFKNNHVLI; SCPFYIFKNNHVLIY;CPFYIFKNNHVLIYS; PFYIFKNNHVLIYSY; FYIFKNNHVLIYSYT; PVSSFRYIENNTVQK;VSSFRYIENNTVQKI; SSFRYIENNTVQKIK; SFRYIENNTVQKIKY; FRYIENNTVQKIKYY;RYIENNTVQKIKYYR; YIENNTVQKIKYYRI; IENNTVQKIKYYRIH; ENNTVQKIKYYRIHF;NNTVQKIKYYRIHFR; HFFPGHMKGIYSFFS; NCIYCLLTNTFLIFT; CIYCLLTNTFLIFTF;IYCLLTNTFLIFTFC; YCLLTNTFLIFTFCK; CLLTNTFLIFTFCKN; LLTNTFLIFTFCKNN;LTNTFLIFTFCKNNS; TNTFLIFTFCKNNSI; NTFLIFTFCKNNSIC; TFLIFTFCKNNSICK;FLIFTFCKNNSICKV; LIFTFCKNNSICKVL; IFTFCKNNSICKVLF; FTFCKNNSICKVLFM;TFCKNNSICKVLFMI; FCKNNSICKVLFMIL; CKNNSICKVLFMILK; KNNSICKVLFMILKV;NNSICKVLFMILKVI; NSICKVLFMILKVIR; SICKVLFMILKVIRL; ICKVLFMILKVIRLV;CKVLFMILKVIRLVF; KVLFMILKVIRLVFF; VLFMILKVIRLVFFL; LFMILKVIRLVFFLT;FMILKVIRLVFFLTL; MILKVIRLVFFLTLF; ILKVIRLVFFLTLFT; LKVIRLVFFLTLFTL;KVIRLVFFLTLFTLL; VIRLVFFLTLFTLLY; IRLVFFLTLFTLLYI; RLVFFLTLFTLLYIV;LVFFLTLFTLLYIVL; VFFLTLFTLLYIVLK; FFLTLFTLLYIVLKF; FPRHLLCFFRLFWAK;PRHLLCFFRLFWAKI; RHLLCFFRLFWAKIM; HLLCFFRLFWAKIML; LLCFFRLFWAKIMLL;APLNAFFYSMVWISS; KTKGTQLLTEIINCR; TKGTQLLTEIINCRN; KGTQLLTEIINCRNS;GTQLLTEIINCRNSM; TQLLTEIINCRNSMS; QLLTEIINCRNSMSM; LLTEIINCRNSMSMW;LTEIINCRNSMSMWS; KEYNIMPSTHVSTNK; EYNIMPSTHVSTNKS; YNIMPSTHVSTNKSY;NIMPSTHVSTNKSYR; IMPSTHVSTNKSYRI; MPSTHVSTNKSYRIF; PSTHVSTNKSYRIFF;STHVSTNKSYRIFFH; THVSTNKSYRIFFHK; HVSTNKSYRIFFHKF; VSTNKSYRIFFHKFF;STNKSYRIFFHKFFI; TNKSYRIFFHKFFIQ; NKSYRIFFHKFFIQN; KSYRIFFHKFFIQNL;SYRIFFHKFFIQNLS; YRIFFHKFFIQNLSF; RIFFHKFFIQNLSFF; IFFHKFFIQNLSFFF;FFHKFFIQNLSFFFS; FHKFFIQNLSFFFSS; HKFFIQNLSFFFSSI; KFFIQNLSFFFSSIH;FFIQNLSFFFSSIHS; FIQNLSFFFSSIHSK; IQNLSFFFSSIHSKA; QNLSFFFSSIHSKAG;NLSFFFSSIHSKAGK; LSFFFSSIHSKAGKG; SFFFSSIHSKAGKGS; FFFSSIHSKAGKGSI;FFSSIHSKAGKGSIT; FSSIHSKAGKGSITK; SSIHSKAGKGSITKY; SIHSKAGKGSITKYS;IHSKAGKGSITKYSL; HSKAGKGSITKYSLT; SKAGKGSITKYSLTK; KAGKGSITKYSLTKK;AGKGSITKYSLTKKL; GKGSITKYSLTKKLV; IRGKVFRVFYLSFFF; RGKVFRVFYLSFFFG;GKVFRVFYLSFFFGW; KVFRVFYLSFFFGWC; VLRICCCFFITGKHI; LRICCCFFITGKHIF;RICCCFFITGKHIFM; ICCCFFITGKHIFMA; CCCFFITGKHIFMAK; IFIPFFIKGTPPGLP;FIPFFIKGTPPGLPL; IPFFIKGTPPGLPLF; PFFIKGTPPGLPLFC; FFIKGTPPGLPLFCS;FIKGTPPGLPLFCSI; IKGTPPGLPLFCSIG; KGTPPGLPLFCSIGW; GTPPGLPLFCSIGWH;TPPGLPLFCSIGWHL; SFRSLKGVSPIIWTH; FRSLKGVSPIIWTHH; RSLKGVSPIIWTHHC;SLKGVSPIIWTHHCR; LKGVSPIIWTHHCRV; KGVSPIIWTHHCRVS; GVSPIIWTHHCRVSS;VSPIIWTHHCRVSSV; SPIIWTHHCRVSSVR; PIIWTHHCRVSSVRS; IIWTHHCRVSSVRSK;IWTHHCRVSSVRSKP; WTHHCRVSSVRSKPN; THHCRVSSVRSKPNH; HHCRVSSVRSKPNHC;HCRVSSVRSKPNHCV; CRVSSVRSKPNHCVK; RVSSVRSKPNHCVKQ; VSSVRSKPNHCVKQS;SSVRSKPNHCVKQSM; SVRSKPNHCVKQSMQ; QSIQTKGSFLKNFLF; SIQTKGSFLKNFLFK;IQTKGSFLKNFLFKC; QTKGSFLKNFLFKCL; TKGSFLKNFLFKCLN; KGSFLKNFLFKCLNL;GSFLKNFLFKCLNLS; HSMQGQCTEGFLEQI; SMQGQCTEGFLEQIG; MQGQCTEGFLEQIGH;QGQCTEGFLEQIGHS; GQCTEGFLEQIGHSL; QCTEGFLEQIGHSLQ; CTEGFLEQIGHSLQY;TEGFLEQIGHSLQYR; EGFLEQIGHSLQYRV; GFLEQIGHSLQYRVS; FLEQIGHSLQYRVSG;LEQIGHSLQYRVSGQ; EQIGHSLQYRVSGQR; QIGHSLQYRVSGQRG; IGHSLQYRVSGQRGK;GHSLQYRVSGQRGKS; HSLQYRVSGQRGKSA; SLQYRVSGQRGKSAQ; LQYRVSGQRGKSAQT;QYRVSGQRGKSAQTS; YRVSGQRGKSAQTSE; RVSGQRGKSAQTSEL; VSGQRGKSAQTSELL;SGQRGKSAQTSELLQ; GQRGKSAQTSELLQV; QRGKSAQTSELLQVP; RGKSAQTSELLQVPK;GKSAQTSELLQVPKS; KSAQTSELLQVPKSG; ATFTSCSIFLYKVFI; TFTSCSIFLYKVFIL;FTSCSIFLYKVFILF; TSCSIFLYKVFILFI; SCSIFLYKVFILFIL; CSIFLYKVFILFILS;SIFLYKVFILFILSS; IFLYKVFILFILSSS; FLYKVFILFILSSSP; LYKVFILFILSSSPP;YKVFILFILSSSPPL; KVFILFILSSSPPLS; VFILFILSSSPPLSG; AFLIKGRFPQAALSR;FLIKGRFPQAALSRP; LIKGRFPQAALSRPK; IKGRFPQAALSRPKR; KGRFPQAALSRPKRS;GRFPQAALSRPKRSM; RFPQAALSRPKRSMS; FPQAALSRPKRSMSS; PQAALSRPKRSMSSM;QAALSRPKRSMSSMD; AALSRPKRSMSSMDS; ALSRPKRSMSSMDSS; LSRPKRSMSSMDSSL;SRPKRSMSSMDSSLL; RPKRSMSSMDSSLLR; PKRSMSSMDSSLLRT; KRSMSSMDSSLLRTL;RSMSSMDSSLLRTLS 16 mers: FCKNCKRIGISPNSFA; CKNCKRIGISPNSFAR;KNCKRIGISPNSFARP; NCKRIGISPNSFARPQ; CKRIGISPNSFARPQK; KRIGISPNSFARPQKK;RIGISPNSFARPQKKP; IGISPNSFARPQKKPP; GISPNSFARPQKKPPH; ISPNSFARPQKKPPHP;SPNSFARPQKKPPHPY; PNSFARPQKKPPHPYY; NSFARPQKKPPHPYYL; SFARPQKKPPHPYYLR;FARPQKKPPHPYYLRE; ARPQKKPPHPYYLRER; RPQKKPPHPYYLRERV; PQKKPPHPYYLRERVE;QKKPPHPYYLRERVEA; KKPPHPYYLRERVEAE; KPPHPYYLRERVEAEA; PPHPYYLRERVEAEAA;PHPYYLRERVEAEAAS; HPYYLRERVEAEAASA; PYYLRERVEAEAASAS; YYLRERVEAEAASASY;YLRERVEAEAASASYI; LRERVEAEAASASYIL; KKRPQGGAAYPWNAAK; KRPQGGAAYPWNAAKP;PQEGKCMTHRGMQPNH; QEGKCMTHRGMQPNHD; EGKCMTHRGMQPNHDL; GKCMTHRGMQPNHDLR;KCMTHRGMQPNHDLRK; CMTHRGMQPNHDLRKE; MTHRGMQPNHDLRKES; THRGMQPNHDLRKESA;LTGRSCLPMECSQTMT; TGRSCLPMECSQTMTS; GRSCLPMECSQTMTSG; RSCLPMECSQTMTSGR;SCLPMECSQTMTSGRK; CLPMECSQTMTSGRKV; LPMECSQTMTSGRKVH; PMECSQTMTSGRKVHD;MECSQTMTSGRKVHDR; ECSQTMTSGRKVHDRH; CSQTMTSGRKVHDRHV; SQTMTSGRKVHDRHVL;QTMTSGRKVHDRHVLR; TMTSGRKVHDRHVLRA; ESWPCPQLNWTKAMVL; SWPCPQLNWTKAMVLR;WPCPQLNWTKAMVLRQ; PCPQLNWTKAMVLRQL; CPQLNWTKAMVLRQLS; PQLNWTKAMVLRQLSR;QLNWTKAMVLRQLSRQ; LNWTKAMVLRQLSRQA; NWTKAMVLRQLSRQAS; WTKAMVLRQLSRQASV;TKAMVLRQLSRQASVK; KAMVLRQLSRQASVKV; AMVLRQLSRQASVKVG; MVLRQLSRQASVKVGK;VLRQLSRQASVKVGKT; LRQLSRQASVKVGKTW; RQLSRQASVKVGKTWT; QLSRQASVKVGKTWTG;LSRQASVKVGKTWTGT; SRQASVKVGKTWTGTK; RQASVKVGKTWTGTKK; QASVKVGKTWTGTKKR;ASVKVGKTWTGTKKRA; SVKVGKTWTGTKKRAQ; VKVGKTWTGTKKRAQR; KVGKTWTGTKKRAQRI;VGKTWTGTKKRAQRIF; GKTWTGTKKRAQRIFI; KTWTGTKKRAQRIFIF; TWTGTKKRAQRIFIFI;WTGTKKRAQRIFIFIL; TGTKKRAQRIFIFILE; GTKKRAQRIFIFILEL; TKKRAQRIFIFILELL;KKRAQRIFIFILELLL; KRAQRIFIFILELLLE; RAQRIFIFILELLLEF; AQRIFIFILELLLEFC;QRIFIFILELLLEFCR; RIFIFILELLLEFCRG; IFIFILELLLEFCRGE; FIFILELLLEFCRGED;IFILELLLEFCRGEDS; FILELLLEFCRGEDSV; ILELLLEFCRGEDSVD; LELLLEFCRGEDSVDG;ELLLEFCRGEDSVDGK; LLLEFCRGEDSVDGKN; LLEFCRGEDSVDGKNK; LEFCRGEDSVDGKNKS;EFCRGEDSVDGKNKST; FCRGEDSVDGKNKSTT; CRGEDSVDGKNKSTTA; RGEDSVDGKNKSTTAL;GEDSVDGKNKSTTALP; EDSVDGKNKSTTALPA; DSVDGKNKSTTALPAV; SVDGKNKSTTALPAVK;VDGKNKSTTALPAVKD; DGKNKSTTALPAVKDS; GKNKSTTALPAVKDSV; KNKSTTALPAVKDSVK;NKSTTALPAVKDSVKD; KSTTALPAVKDSVKDS; VSNPFFFVFPGSWVLL; LPVYLRLLLPQDFQWL;PVYLRLLLPQDFQWLK; VYLRLLLPQDFQWLKL; YLRLLLPQDFQWLKLL; LRLLLPQDFQWLKLLL;RLLLPQDFQWLKLLLG; LLLPQDFQWLKLLLGR; LLPQDFQWLKLLLGRL; LPQDFQWLKLLLGRLL;PQDFQWLKLLLGRLLL; QDFQWLKLLLGRLLLL; ASISNQAWLWNCLTQM; SISNQAWLWNCLTQMS;ISNQAWLWNCLTQMST; SNQAWLWNCLTQMSTM; NQAWLWNCLTQMSTMI; QAWLWNCLTQMSTMIF;AWLWNCLTQMSTMIFC; WLWNCLTQMSTMIFCF; LWNCLTQMSTMIFCFL; WNCLTQMSTMIFCFLV;ILLLIIFNTLILGIGV; LLLIIFNTLILGIGVL; LLIIFNTLILGIGVLL; LIIFNTLILGIGVLLC;IIFNTLILGIGVLLCL; IFNTLILGIGVLLCLL; FNTLILGIGVLLCLLL; NTLILGIGVLLCLLLF;TLILGIGVLLCLLLFP; LILGIGVLLCLLLFPR; ILGIGVLLCLLLFPRL; LGIGVLLCLLLFPRLC;GIGVLLCLLLFPRLCG; IGVLLCLLLFPRLCGM; GVLLCLLLFPRLCGML; VLLCLLLFPRLCGMLL;LLCLLLFPRLCGMLLG; LCLLLFPRLCGMLLGM; CLLLFPRLCGMLLGMI; LLLFPRLCGMLLGMIY;LLFPRLCGMLLGMIYL; LFPRLCGMLLGMIYLL; PHRNCREEQKDFLETP; HRNCREEQKDFLETPW;RNCREEQKDFLETPWL; NCREEQKDFLETPWLD; CREEQKDFLETPWLDF; REEQKDFLETPWLDFW;EEQKDFLETPWLDFWR; EQKDFLETPWLDFWRK; QKDFLETPWLDFWRKL; KDFLETPWLDFWRKLP;DFLETPWLDFWRKLPG; FLETPWLDFWRKLPGQ; LETPWLDFWRKLPGQL; TFIIIFNNIILIFPLL;FIIIFNNIILIFPLLG; IIIFNNIILIFPLLGP; IIFNNIILIFPLLGPQ; IFNNIILIFPLLGPQW;FNNIILIFPLLGPQWL; NNIILIFPLLGPQWLD; NIILIFPLLGPQWLDK; KKLLPQEVLIKELLLN;KLLPQEVLIKELLLNG; LLPQEVLIKELLLNGC; LPQEVLIKELLLNGCC; PQEVLIKELLLNGCCL;QEVLIKELLLNGCCLY; EVLIKELLLNGCCLYF; HLLLKHMKMAPTKRKG; LLLKHMKMAPTKRKGE;LLKHMKMAPTKRKGEC; LKHMKMAPTKRKGECP; KHMKMAPTKRKGECPG; HMKMAPTKRKGECPGA;MKMAPTKRKGECPGAA; KMAPTKRKGECPGAAP; MAPTKRKGECPGAAPK; APTKRKGECPGAAPKK;PTKRKGECPGAAPKKP; TKRKGECPGAAPKKPK; KRKGECPGAAPKKPKE; RKGECPGAAPKKPKEP;KGECPGAAPKKPKEPV; GECPGAAPKKPKEPVQ; ECPGAAPKKPKEPVQV; CPGAAPKKPKEPVQVP;PGAAPKKPKEPVQVPK; GAAPKKPKEPVQVPKL; AAPKKPKEPVQVPKLL; APKKPKEPVQVPKLLI;PKKPKEPVQVPKLLIK; KKPKEPVQVPKLLIKG; KPKEPVQVPKLLIKGG; PKEPVQVPKLLIKGGV;KEPVQVPKLLIKGGVE; EPVQVPKLLIKGGVEV; PVQVPKLLIKGGVEVL; VQVPKLLIKGGVEVLE;QVPKLLIKGGVEVLEV; VPKLLIKGGVEVLEVK; PKLLIKGGVEVLEVKT; KLLIKGGVEVLEVKTG;LLIKGGVEVLEVKTGV; LIKGGVEVLEVKTGVD; IKGGVEVLEVKTGVDA; KGGVEVLEVKTGVDAI;GGVEVLEVKTGVDAIT; GVEVLEVKTGVDAITE; VEVLEVKTGVDAITEV; EVLEVKTGVDAITEVE;VLEVKTGVDAITEVEC; LEVKTGVDAITEVECF; EVKTGVDAITEVECFL; VKTGVDAITEVECFLN;KTGVDAITEVECFLNP; TGVDAITEVECFLNPE; GVDAITEVECFLNPEM; VDAITEVECFLNPEMG;DAITEVECFLNPEMGD; AITEVECFLNPEMGDP; ITEVECFLNPEMGDPD; TEVECFLNPEMGDPDE;EVECFLNPEMGDPDEN; VECFLNPEMGDPDENL; ECFLNPEMGDPDENLR; CFLNPEMGDPDENLRG;FLNPEMGDPDENLRGF; LNPEMGDPDENLRGFS; NPEMGDPDENLRGFSL; PEMGDPDENLRGFSLK;EMGDPDENLRGFSLKL; MGDPDENLRGFSLKLS; GDPDENLRGFSLKLSA; DPDENLRGFSLKLSAE;PDENLRGFSLKLSAEN; DENLRGFSLKLSAEND; ENLRGFSLKLSAENDF; NLRGFSLKLSAENDFS;LRGFSLKLSAENDFSS; RGFSLKLSAENDFSSD; GFSLKLSAENDFSSDS; FSLKLSAENDFSSDSP;SLKLSAENDFSSDSPE; LKLSAENDFSSDSPER; KLSAENDFSSDSPERK; LSAENDFSSDSPERKM;SAENDFSSDSPERKML; AENDFSSDSPERKMLP; ENDFSSDSPERKMLPC; NDFSSDSPERKMLPCY;DFSSDSPERKMLPCYS; FSSDSPERKMLPCYST; SSDSPERKMLPCYSTA; SDSPERKMLPCYSTAR;DSPERKMLPCYSTARI; SPERKMLPCYSTARIP; PERKMLPCYSTARIPL; ERKMLPCYSTARIPLP;RKMLPCYSTARIPLPN; KMLPCYSTARIPLPNL; MLPCYSTARIPLPNLN; LPCYSTARIPLPNLNE;PCYSTARIPLPNLNED; CYSTARIPLPNLNEDL; YSTARIPLPNLNEDLT; STARIPLPNLNEDLTC;TARIPLPNLNEDLTCG; ARIPLPNLNEDLTCGN; RIPLPNLNEDLTCGNL; IPLPNLNEDLTCGNLL;PLPNLNEDLTCGNLLM; LPNLNEDLTCGNLLMW; PNLNEDLTCGNLLMWE; NLNEDLTCGNLLMWEA;LNEDLTCGNLLMWEAV; NEDLTCGNLLMWEAVT; EDLTCGNLLMWEAVTV; DLTCGNLLMWEAVTVQ;LTCGNLLMWEAVTVQT; TCGNLLMWEAVTVQTE; CGNLLMWEAVTVQTEV; GNLLMWEAVTVQTEVI;NLLMWEAVTVQTEVIG; LLMWEAVTVQTEVIGI; LMWEAVTVQTEVIGIT; MWEAVTVQTEVIGITS;WEAVTVQTEVIGITSM; EAVTVQTEVIGITSML; AVTVQTEVIGITSMLN; VTVQTEVIGITSMLNL;TVQTEVIGITSMLNLH; VQTEVIGITSMLNLHA; QTEVIGITSMLNLHAG; TEVIGITSMLNLHAGS;EVIGITSMLNLHAGSQ; VIGITSMLNLHAGSQK; IGITSMLNLHAGSQKV; GITSMLNLHAGSQKVH;ITSMLNLHAGSQKVHE; TSMLNLHAGSQKVHEH; SMLNLHAGSQKVHEHG; MLNLHAGSQKVHEHGG;LNLHAGSQKVHEHGGG; NLHAGSQKVHEHGGGK; LHAGSQKVHEHGGGKP; HAGSQKVHEHGGGKPI;AGSQKVHEHGGGKPIQ; GSQKVHEHGGGKPIQG; SQKVHEHGGGKPIQGS; QKVHEHGGGKPIQGSN;KVHEHGGGKPIQGSNF; VHEHGGGKPIQGSNFH; HEHGGGKPIQGSNFHF; EHGGGKPIQGSNFHFF;HGGGKPIQGSNFHFFA; GGGKPIQGSNFHFFAV; GGKPIQGSNFHFFAVG; GKPIQGSNFHFFAVGG;KPIQGSNFHFFAVGGE; PIQGSNFHFFAVGGEP; IQGSNFHFFAVGGEPL; QGSNFHFFAVGGEPLE;GSNFHFFAVGGEPLEM; SNFHFFAVGGEPLEMQ; NFHFFAVGGEPLEMQG; FHFFAVGGEPLEMQGV;HFFAVGGEPLEMQGVL; FFAVGGEPLEMQGVLM; FAVGGEPLEMQGVLMN; AVGGEPLEMQGVLMNY;VGGEPLEMQGVLMNYR; GGEPLEMQGVLMNYRS; GEPLEMQGVLMNYRSK; EPLEMQGVLMNYRSKY;PLEMQGVLMNYRSKYP; LEMQGVLMNYRSKYPD; EMQGVLMNYRSKYPDG; MQGVLMNYRSKYPDGT;QGVLMNYRSKYPDGTI; GVLMNYRSKYPDGTIT; VLMNYRSKYPDGTITP; LMNYRSKYPDGTITPK;MNYRSKYPDGTITPKN; NYRSKYPDGTITPKNP; YRSKYPDGTITPKNPT; RSKYPDGTITPKNPTA;SKYPDGTITPKNPTAQ; KYPDGTITPKNPTAQS; YPDGTITPKNPTAQSQ; PDGTITPKNPTAQSQV;DGTITPKNPTAQSQVM; GTITPKNPTAQSQVMN; TITPKNPTAQSQVMNT; ITPKNPTAQSQVMNTD;TPKNPTAQSQVMNTDH; PKNPTAQSQVMNTDHK; KNPTAQSQVMNTDHKA; NPTAQSQVMNTDHKAY;PTAQSQVMNTDHKAYL; TAQSQVMNTDHKAYLD; AQSQVMNTDHKAYLDK; QSQVMNTDHKAYLDKN;SQVMNTDHKAYLDKNN; QVMNTDHKAYLDKNNA; VMNTDHKAYLDKNNAY; MNTDHKAYLDKNNAYP;NTDHKAYLDKNNAYPV; TDHKAYLDKNNAYPVE; DHKAYLDKNNAYPVEC; HKAYLDKNNAYPVECW;KAYLDKNNAYPVECWV; AYLDKNNAYPVECWVP; YLDKNNAYPVECWVPD; LDKNNAYPVECWVPDP;DKNNAYPVECWVPDPS; KNNAYPVECWVPDPSR; NNAYPVECWVPDPSRN; NAYPVECWVPDPSRNE;AYPVECWVPDPSRNEN; YPVECWVPDPSRNENA; PVECWVPDPSRNENAR; VECWVPDPSRNENARY;ECWVPDPSRNENARYF; CWVPDPSRNENARYFG; WVPDPSRNENARYFGT; VPDPSRNENARYFGTF;PDPSRNENARYFGTFT; DPSRNENARYFGTFTG; PSRNENARYFGTFTGG; SRNENARYFGTFTGGE;RNENARYFGTFTGGEN; NENARYFGTFTGGENV; ENARYFGTFTGGENVP; NARYFGTFTGGENVPP;ARYFGTFTGGENVPPV; RYFGTFTGGENVPPVL; YFGTFTGGENVPPVLH; FGTFTGGENVPPVLHV;GTFTGGENVPPVLHVT; TFTGGENVPPVLHVTN; FTGGENVPPVLHVTNT; TGGENVPPVLHVTNTA;GGENVPPVLHVTNTAT; GENVPPVLHVTNTATT; ENVPPVLHVTNTATTV; NVPPVLHVTNTATTVL;VPPVLHVTNTATTVLL; PPVLHVTNTATTVLLD; PVLHVTNTATTVLLDE; VLHVTNTATTVLLDEQ;LHVTNTATTVLLDEQG; HVTNTATTVLLDEQGV; VTNTATTVLLDEQGVG; TNTATTVLLDEQGVGP;NTATTVLLDEQGVGPL; TATTVLLDEQGVGPLC; ATTVLLDEQGVGPLCK; TTVLLDEQGVGPLCKA;TVLLDEQGVGPLCKAD; VLLDEQGVGPLCKADS; LLDEQGVGPLCKADSL; LDEQGVGPLCKADSLY;DEQGVGPLCKADSLYV; EQGVGPLCKADSLYVS; QGVGPLCKADSLYVSA; GVGPLCKADSLYVSAA;VGPLCKADSLYVSAAD; GPLCKADSLYVSAADI; PLCKADSLYVSAADIC; LCKADSLYVSAADICG;CKADSLYVSAADICGL; KADSLYVSAADICGLF; ADSLYVSAADICGLFT; DSLYVSAADICGLFTN;SLYVSAADICGLFTNS; LYVSAADICGLFTNSS; YVSAADICGLFTNSSG; VSAADICGLFTNSSGT;SAADICGLFTNSSGTQ; AADICGLFTNSSGTQQ; ADICGLFTNSSGTQQW; DICGLFTNSSGTQQWR;ICGLFTNSSGTQQWRG; CGLFTNSSGTQQWRGL; GLFTNSSGTQQWRGLA; LFTNSSGTQQWRGLAR;FTNSSGTQQWRGLARY; TNSSGTQQWRGLARYF; NSSGTQQWRGLARYFK; SSGTQQWRGLARYFKI;SGTQQWRGLARYFKIR; GTQQWRGLARYFKIRL; TQQWRGLARYFKIRLR; QQWRGLARYFKIRLRK;QWRGLARYFKIRLRKR; WRGLARYFKIRLRKRS; RGLARYFKIRLRKRSV; GLARYFKIRLRKRSVK;LARYFKIRLRKRSVKN; ARYFKIRLRKRSVKNP; RYFKIRLRKRSVKNPY; YFKIRLRKRSVKNPYP;FKIRLRKRSVKNPYPI; KIRLRKRSVKNPYPIS; IRLRKRSVKNPYPISF; RLRKRSVKNPYPISFL;LRKRSVKNPYPISFLL; RKRSVKNPYPISFLLS; KRSVKNPYPISFLLSD; RSVKNPYPISFLLSDL;SVKNPYPISFLLSDLI; VKNPYPISFLLSDLIN; KNPYPISFLLSDLINR; NPYPISFLLSDLINRR;PYPISFLLSDLINRRT; YPISFLLSDLINRRTQ; PISFLLSDLINRRTQR; ISFLLSDLINRRTQRV;SFLLSDLINRRTQRVD; FLLSDLINRRTQRVDG; LLSDLINRRTQRVDGQ; LSDLINRRTQRVDGQP;SDLINRRTQRVDGQPM; DLINRRTQRVDGQPMY; LINRRTQRVDGQPMYG; INRRTQRVDGQPMYGM;NRRTQRVDGQPMYGME; RRTQRVDGQPMYGMES; RTQRVDGQPMYGMESQ; TQRVDGQPMYGMESQV;QRVDGQPMYGMESQVE; RVDGQPMYGMESQVEE; VDGQPMYGMESQVEEV; DGQPMYGMESQVEEVR;GQPMYGMESQVEEVRV; QPMYGMESQVEEVRVF; PMYGMESQVEEVRVFD; MYGMESQVEEVRVFDG;YGMESQVEEVRVFDGT; GMESQVEEVRVFDGTE; MESQVEEVRVFDGTER; ESQVEEVRVFDGTERL;SQVEEVRVFDGTERLP; QVEEVRVFDGTERLPG; VEEVRVFDGTERLPGD; EEVRVFDGTERLPGDP;EVRVFDGTERLPGDPD; VRVFDGTERLPGDPDM; RVFDGTERLPGDPDMI; VFDGTERLPGDPDMIR;FDGTERLPGDPDMIRY; DGTERLPGDPDMIRYI; GTERLPGDPDMIRYID; TERLPGDPDMIRYIDK;ERLPGDPDMIRYIDKQ; RLPGDPDMIRYIDKQG; LPGDPDMIRYIDKQGQ; PGDPDMIRYIDKQGQL;GDPDMIRYIDKQGQLQ; DPDMIRYIDKQGQLQT; PDMIRYIDKQGQLQTK; DMIRYIDKQGQLQTKM;MIRYIDKQGQLQTKML; TGAFIVHIHLINAAFV; ATFKLVLFWGWCFRPF; TFKLVLFWGWCFRPFK;FKLVLFWGWCFRPFKT; KLVLFWGWCFRPFKTL; LVLFWGWCFRPFKTLK; VLFWGWCFRPFKTLKA;LFWGWCFRPFKTLKAF; FWGWCFRPFKTLKAFT; WGWCFRPFKTLKAFTQ; GWCFRPFKTLKAFTQM;WCFRPFKTLKAFTQMQ; CFRPFKTLKAFTQMQL; FRPFKTLKAFTQMQLL; RPFKTLKAFTQMQLLT;PFKTLKAFTQMQLLTM; FKTLKAFTQMQLLTMG; KTLKAFTQMQLLTMGV; ILFSCNIKNTFPHAYI;LFSCNIKNTFPHAYII; FSCNIKNTFPHAYIIF; SCNIKNTFPHAYIIFH; CNIKNTFPHAYIIFHP;KSIHTYLRIQPFLPFN; SIHTYLRIQPFLPFNN; IHTYLRIQPFLPFNNS; HTYLRIQPFLPFNNSR;TYLRIQPFLPFNNSRL; YLRIQPFLPFNNSRLY; LRIQPFLPFNNSRLYI; RIQPFLPFNNSRLYIS;IQPFLPFNNSRLYISC; QPFLPFNNSRLYISCK; PFLPFNNSRLYISCKI; FLPFNNSRLYISCKIS;LPFNNSRLYISCKISY; PFNNSRLYISCKISYR; FNNSRLYISCKISYRP; NNSRLYISCKISYRPK;NSRLYISCKISYRPKP; SRLYISCKISYRPKPN; IYFGPKIYLSYKSSLQ; YFGPKIYLSYKSSLQG;FGPKIYLSYKSSLQGF; GPKIYLSYKSSLQGFR; PKIYLSYKSSLQGFRD; KIYLSYKSSLQGFRDR;IYLSYKSSLQGFRDRI; YLSYKSSLQGFRDRIL; LSYKSSLQGFRDRILI; SYKSSLQGFRDRILIH;YKSSLQGFRDRILIHC; KSSLQGFRDRILIHCN; SSLQGFRDRILIHCNQ; SLQGFRDRILIHCNQA;LQGFRDRILIHCNQAW; QGFRDRILIHCNQAWW; GFRDRILIHCNQAWWK; FRDRILIHCNQAWWKY;RDRILIHCNQAWWKYL; DRILIHCNQAWWKYLG; RILIHCNQAWWKYLGS; ILIHCNQAWWKYLGSF;LIHCNQAWWKYLGSFV; FSSCPFYIFKNNHVLI; SSCPFYIFKNNHVLIY; SCPFYIFKNNHVLIYS;CPFYIFKNNHVLIYSY; PFYIFKNNHVLIYSYT; PVSSFRYIENNTVQKI; VSSFRYIENNTVQKIK;SSFRYIENNTVQKIKY; SFRYIENNTVQKIKYY; FRYIENNTVQKIKYYR; RYIENNTVQKIKYYRI;YIENNTVQKIKYYRIH; IENNTVQKIKYYRIHF; ENNTVQKIKYYRIHFR; NCIYCLLTNTFLIFTF;CIYCLLTNTFLIFTFC; IYCLLTNTFLIFTFCK; YCLLTNTFLIFTFCKN; CLLTNTFLIFTFCKNN;LLTNTFLIFTFCKNNS; LTNTFLIFTFCKNNSI; TNTFLIFTFCKNNSIC; NTFLIFTFCKNNSICK;TFLIFTFCKNNSICKV; FLIFTFCKNNSICKVL; LIFTFCKNNSICKVLF; IFTFCKNNSICKVLFM;FTFCKNNSICKVLFMI; TFCKNNSICKVLFMIL; FCKNNSICKVLFMILK; CKNNSICKVLFMILKV;KNNSICKVLFMILKVI; NNSICKVLFMILKVIR; NSICKVLFMILKVIRL; SICKVLFMILKVIRLV;ICKVLFMILKVIRLVF; CKVLFMILKVIRLVFF; KVLFMILKVIRLVFFL; VLFMILKVIRLVFFLT;LFMILKVIRLVFFLTL; FMILKVIRLVFFLTLF; MILKVIRLVFFLTLFT; ILKVIRLVFFLTLFTL;LKVIRLVFFLTLFTLL; KVIRLVFFLTLFTLLY; VIRLVFFLTLFTLLYI; IRLVFFLTLFTLLYIV;RLVFFLTLFTLLYIVL; LVFFLTLFTLLYIVLK; VFFLTLFTLLYIVLKF; FPRHLLCFFRLFWAKI;PRHLLCFFRLFWAKIM; RHLLCFFRLFWAKIML; HLLCFFRLFWAKIMLL; KTKGTQLLTEIINCRN;TKGTQLLTEIINCRNS; KGTQLLTEIINCRNSM; GTQLLTEIINCRNSMS; TQLLTEIINCRNSMSM;QLLTEIINCRNSMSMW; LLTEIINCRNSMSMWS; KEYNIMPSTHVSTNKS; EYNIMPSTHVSTNKSY;YNIMPSTHVSTNKSYR; NIMPSTHVSTNKSYRI; IMPSTHVSTNKSYRIF; MPSTHVSTNKSYRIFF;PSTHVSTNKSYRIFFH; STHVSTNKSYRIFFHK; THVSTNKSYRIFFHKF; HVSTNKSYRIFFHKFF;VSTNKSYRIFFHKFFI; STNKSYRIFFHKFFIQ; TNKSYRIFFHKFFIQN; NKSYRIFFHKFFIQNL;KSYRIFFHKFFIQNLS; SYRIFFHKFFIQNLSF; YRIFFHKFFIQNLSFF; RIFFHKFFIQNLSFFF;IFFHKFFIQNLSFFFS; FFHKFFIQNLSFFFSS; FHKFFIQNLSFFFSSI; HKFFIQNLSFFFSSIH;KFFIQNLSFFFSSIHS; FFIQNLSFFFSSIHSK; FIQNLSFFFSSIHSKA; IQNLSFFFSSIHSKAG;QNLSFFFSSIHSKAGK; NLSFFFSSIHSKAGKG; LSFFFSSIHSKAGKGS; SFFFSSIHSKAGKGSI;FFFSSIHSKAGKGSIT; FFSSIHSKAGKGSITK; FSSIHSKAGKGSITKY; SSIHSKAGKGSITKYS;SIHSKAGKGSITKYSL; IHSKAGKGSITKYSLT; HSKAGKGSITKYSLTK; SKAGKGSITKYSLTKK;KAGKGSITKYSLTKKL; AGKGSITKYSLTKKLV; IRGKVFRVFYLSFFFG; RGKVFRVFYLSFFFGW;GKVFRVFYLSFFFGWC; VLRICCCFFITGKHIF; LRICCCFFITGKHIFM; RICCCFFITGKHIFMA;ICCCFFITGKHIFMAK; IFIPFFIKGTPPGLPL; FIPFFIKGTPPGLPLF; IPFFIKGTPPGLPLFC;PFFIKGTPPGLPLFCS; FFIKGTPPGLPLFCSI; FIKGTPPGLPLFCSIG; IKGTPPGLPLFCSIGW;KGTPPGLPLFCSIGWH; GTPPGLPLFCSIGWHL; SFRSLKGVSPIIWTHH; FRSLKGVSPIIWTHHC;RSLKGVSPIIWTHHCR; SLKGVSPIIWTHHCRV; LKGVSPIIWTHHCRVS; KGVSPIIWTHHCRVSS;GVSPIIWTHHCRVSSV; VSPIIWTHHCRVSSVR; SPIIWTHHCRVSSVRS; PIIWTHHCRVSSVRSK;IIWTHHCRVSSVRSKP; IWTHHCRVSSVRSKPN; WTHHCRVSSVRSKPNH; THHCRVSSVRSKPNHC;HHCRVSSVRSKPNHCV; HCRVSSVRSKPNHCVK; CRVSSVRSKPNHCVKQ; RVSSVRSKPNHCVKQS;VSSVRSKPNHCVKQSM; SSVRSKPNHCVKQSMQ; QSIQTKGSFLKNFLFK; SIQTKGSFLKNFLFKC;IQTKGSFLKNFLFKCL; QTKGSFLKNFLFKCLN; TKGSFLKNFLFKCLNL; KGSFLKNFLFKCLNLS;HSMQGQCTEGFLEQIG; SMQGQCTEGFLEQIGH; MQGQCTEGFLEQIGHS; QGQCTEGFLEQIGHSL;GQCTEGFLEQIGHSLQ; QCTEGFLEQIGHSLQY; CTEGFLEQIGHSLQYR; TEGFLEQIGHSLQYRV;EGFLEQIGHSLQYRVS; GFLEQIGHSLQYRVSG; FLEQIGHSLQYRVSGQ; LEQIGHSLQYRVSGQR;EQIGHSLQYRVSGQRG; QIGHSLQYRVSGQRGK; IGHSLQYRVSGQRGKS; GHSLQYRVSGQRGKSA;HSLQYRVSGQRGKSAQ; SLQYRVSGQRGKSAQT; LQYRVSGQRGKSAQTS; QYRVSGQRGKSAQTSE;YRVSGQRGKSAQTSEL; RVSGQRGKSAQTSELL; VSGQRGKSAQTSELLQ; SGQRGKSAQTSELLQV;GQRGKSAQTSELLQVP; QRGKSAQTSELLQVPK; RGKSAQTSELLQVPKS; GKSAQTSELLQVPKSG;ATFTSCSIFLYKVFIL; TFTSCSIFLYKVFILF; FTSCSIFLYKVFILFI; TSCSIFLYKVFILFIL;SCSIFLYKVFILFILS; CSIFLYKVFILFILSS; SIFLYKVFILFILSSS; IFLYKVFILFILSSSP;FLYKVFILFILSSSPP; LYKVFILFILSSSPPL; YKVFILFILSSSPPLS; KVFILFILSSSPPLSG;AFLIKGRFPQAALSRP; FLIKGRFPQAALSRPK; LIKGRFPQAALSRPKR; IKGRFPQAALSRPKRS;KGRFPQAALSRPKRSM; GRFPQAALSRPKRSMS; RFPQAALSRPKRSMSS; FPQAALSRPKRSMSSM;PQAALSRPKRSMSSMD; QAALSRPKRSMSSMDS; AALSRPKRSMSSMDSS; ALSRPKRSMSSMDSSL;LSRPKRSMSSMDSSLL; SRPKRSMSSMDSSLLR; RPKRSMSSMDSSLLRT; PKRSMSSMDSSLLRTL;KRSMSSMDSSLLRTLS BK virus, reading frame 2 13 mers: GFPQIVLLGLRKS;FPQIVLLGLRKSL; PQIVLLGLRKSLH; QIVLLGLRKSLHT; IVLLGLRKSLHTL;VLLGLRKSLHTLT; LLGLRKSLHTLTT; EKGWRQRRPRPLI; KGWRQRRPRPLIY;GWRQRRPRPLIYY; WRQRRPRPLIYYK; RQRRPRPLIYYKK; QRRPRPLIYYKKK;RRPRPLIYYKKKG; RPRPLIYYKKKGH; PRPLIYYKKKGHR; RPLIYYKKKGHRE;PLIYYKKKGHREE; LIYYKKKGHREEL; IYYKKKGHREELL; YYKKKGHREELLT;YKKKGHREELLTH; KKKGHREELLTHG; KKGHREELLTHGM; KGHREELLTHGMQ;GHREELLTHGMQP; HREELLTHGMQPN; REELLTHGMQPNH; EELLTHGMQPNHD;ELLTHGMQPNHDL; LLTHGMQPNHDLR; LTHGMQPNHDLRK; THGMQPNHDLRKE;HGMQPNHDLRKES; GMQPNHDLRKESA; LTGECSQTMTSGR; TGECSQTMTSGRK;GECSQTMTSGRKV; ECSQTMTSGRKVH; CSQTMTSGRKVHD; SQTMTSGRKVHDS;QTMTSGRKVHDSQ; TMTSGRKVHDSQG; MTSGRKVHDSQGG; TSGRKVHDSQGGA;SGRKVHDSQGGAA; GRKVHDSQGGAAY; RKVHDSQGGAAYP; KVHDSQGGAAYPW;VHDSQGGAAYPWN; HDSQGGAAYPWNA; DSQGGAAYPWNAA; SQGGAAYPWNAAK;QGGAAYPWNAAKP; PQEGKCMTDMFCE; QEGKCMTDMFCEP; EGKCMTDMFCEPR;GKCMTDMFCEPRN; KCMTDMFCEPRNL; CMTDMFCEPRNLG; MTDMFCEPRNLGL;TDMFCEPRNLGLV; DMFCEPRNLGLVP; MFCEPRNLGLVPS; TGQRPWFCASCHD;GQRPWFCASCHDK; QRPWFCASCHDKL; RPWFCASCHDKLQ; KLVKPGLEQKKEL;LVKPGLEQKKELR; VKPGLEQKKELRG; KPGLEQKKELRGF; PGLEQKKELRGFL;GLEQKKELRGFLF; LEQKKELRGFLFL; EQKKELRGFLFLF; VIPFFLYFQVHGC;IPFFLYFQVHGCC; PFFLYFQVHGCCS; FFLYFQVHGCCSS; FLYFQVHGCCSST;LYFQVHGCCSSTF; YFQVHGCCSSTFG; FQVHGCCSSTFGG; QVHGCCSSTFGGP;VHGCCSSTFGGPS; HGCCSSTFGGPSC; GCCSSTFGGPSCQ; CCSSTFGGPSCQC;CSSTFGGPSCQCI; NCCWGGCCCYRSS; CCWGGCCCYRSSN; CWGGCCCYRSSNC;WGGCCCYRSSNCI; GGCCCYRSSNCIP; GCCCYRSSNCIPC; CCCYRSSNCIPCY;CCYRSSNCIPCYC; CYRSSNCIPCYCR; YRSSNCIPCYCRG; RSSNCIPCYCRGH;SSNCIPCYCRGHN; SNCIPCYCRGHNK; NCIPCYCRGHNKY; CIPCYCRGHNKYL;IPCYCRGHNKYLR; PCYCRGHNKYLRG; CYCRGHNKYLRGY; YCRGHNKYLRGYS;CRGHNKYLRGYSC; RGHNKYLRGYSCY; GHNKYLRGYSCYR; HNKYLRGYSCYRP;NKYLRGYSCYRPN; KYLRGYSCYRPNS; YLRGYSCYRPNSS; LRGYSCYRPNSSN;RGYSCYRPNSSNI; GYSCYRPNSSNIC; YSCYRPNSSNICC; SCYRPNSSNICCN;CYRPNSSNICCNC; YRPNSSNICCNCW; RPNSSNICCNCWC; PNSSNICCNCWCS;NSSNICCNCWCSW; SSNICCNCWCSWG; SNICCNCWCSWGY; NICCNCWCSWGYC;ICCNCWCSWGYCW; CCNCWCSWGYCWV; CNCWCSWGYCWVC; NCWCSWGYCWVCC;CWCSWGYCWVCCF; WCSWGYCWVCCFN; CSWGYCWVCCFNS; SWGYCWVCCFNSN;WGYCWVCCFNSNC; LGSQSFHCRPLSA; GSQSFHCRPLSAI; SQSFHCRPLSAIR;QSFHCRPLSAIRH; SFHCRPLSAIRHG; FHCRPLSAIRHGF; HCRPLSAIRHGFG;CRPLSAIRHGFGI; RPLSAIRHGFGIV; ALGSFFVCYYFPG; LGSFFVCYYFPGF;GSFFVCYYFPGFV; SFFVCYYFPGFVA; FFVCYYFPGFVAC; FVCYYFPGFVACY;YTFYNLTGIAEKN; TFYNLTGIAEKNR; FYNLTGIAEKNRK; YNLTGIAEKNRKI;NLTGIAEKNRKIF; IFGGNYLDNCKCP; FGGNYLDNCKCPY; GGNYLDNCKCPYK;GNYLDNCKCPYKL; NYLDNCKCPYKLL; QYRRSYTKNGLKK; YRRSYTKNGLKKS;RRSYTKNGLKKST; RSYTKNGLKKSTK; SYTKNGLKKSTKC; YTKNGLKKSTKCT;TKNGLKKSTKCTF; KNGLKKSTKCTFR; NGLKKSTKCTFRR; GLKKSTKCTFRRV;LKKSTKCTFRRVY; KKSTKCTFRRVYR; KSTKCTFRRVYRK; STKCTFRRVYRKN;TKCTFRRVYRKNY; KCTFRRVYRKNYC; CTFRRVYRKNYCP; TFRRVYRKNYCPR;FRRVYRKNYCPRR; RRVYRKNYCPRRC; SKNCSSMDVAFTS; KNCSSMDVAFTSR;NCSSMDVAFTSRP; CSSMDVAFTSRPV; SSMDVAFTSRPVR; SMDVAFTSRPVRD;MDVAFTSRPVRDC; DVAFTSRPVRDCN; VAFTSRPVRDCNT; AFTSRPVRDCNTC;FTSRPVRDCNTCS; RWPQPKEKESVQG; WPQPKEKESVQGQ; PQPKEKESVQGQL;QPKEKESVQGQLP; PKEKESVQGQLPK; KEKESVQGQLPKS; EKESVQGQLPKSQ;KESVQGQLPKSQR; ESVQGQLPKSQRN; SVQGQLPKSQRNP; VQGQLPKSQRNPC;QGQLPKSQRNPCK; GQLPKSQRNPCKC; QLPKSQRNPCKCQ; LPKSQRNPCKCQN;PKSQRNPCKCQNY; TQKWGIQMKTLGA; QKWGIQMKTLGAL; KWGIQMKTLGALV;VLKMTLAVIAQRE; LKMTLAVIAQREK; KMTLAVIAQREKC; MTLAVIAQREKCF;TLAVIAQREKCFP; LAVIAQREKCFPV; AVIAQREKCFPVT; VIAQREKCFPVTA;IAQREKCFPVTAQ; AQREKCFPVTAQQ; QREKCFPVTAQQE; REKCFPVTAQQEF;EKCFPVTAQQEFP; KCFPVTAQQEFPS; CFPVTAQQEFPSP; FPVTAQQEFPSPI;LACLTFMQGHKKC; ACLTFMQGHKKCM; CLTFMQGHKKCMS; LTFMQGHKKCMSM;TFMQGHKKCMSMV; FMQGHKKCMSMVE; MQGHKKCMSMVEE; QGHKKCMSMVEEN;GHKKCMSMVEENL; HKKCMSMVEENLF; KKCMSMVEENLFK; KCMSMVEENLFKA;CMSMVEENLFKAV; MSMVEENLFKAVI; SMVEENLFKAVIS; MVEENLFKAVIST;VEENLFKAVISTS; EENLFKAVISTSL; ENLFKAVISTSLL; ILTIRPIWTKTML;LTIRPIWTKTMLI; TIRPIWTKTMLIQ; IRPIWTKTMLIQL; RPIWTKTMLIQLS;PIWTKTMLIQLSA; IWTKTMLIQLSAG; WTKTMLIQLSAGY; TKTMLIQLSAGYL;KTMLIQLSAGYLI; TMLIQLSAGYLIP; MLIQLSAGYLIPV; LIQLSAGYLIPVE;IQLSAGYLIPVEM; QLSAGYLIPVEMK; LSAGYLIPVEMKM; SAGYLIPVEMKML;AGYLIPVEMKMLG; GYLIPVEMKMLGI; YLIPVEMKMLGIL; LIPVEMKMLGILG;IPVEMKMLGILGL; PVEMKMLGILGLS; VEMKMLGILGLSQ; EMKMLGILGLSQE;MKMLGILGLSQEG; KMLGILGLSQEGK; MLGILGLSQEGKM; LGILGLSQEGKMF;GILGLSQEGKMFP; ILGLSQEGKMFPQ; LGLSQEGKMFPQY; GLSQEGKMFPQYF;LSQEGKMFPQYFM; MNRVWGLFVKLIA; NRVWGLFVKLIAC; RVWGLFVKLIACM;VWGLFVKLIACMF; WGLFVKLIACMFQ; GLFVKLIACMFQL; LFVKLIACMFQLL;FVKLIACMFQLLI; VKLIACMFQLLIF; KLIACMFQLLIFV; LIACMFQLLIFVA;IACMFQLLIFVAC; ACMFQLLIFVACL; CMFQLLIFVACLL; MFQLLIFVACLLT;FQLLIFVACLLTA; QLLIFVACLLTAL; LLIFVACLLTALE; LIFVACLLTALEH;IFVACLLTALEHN; FVACLLTALEHNS; VACLLTALEHNSG; ACLLTALEHNSGE;CLLTALEHNSGEA; LLTALEHNSGEAL; LTALEHNSGEALQ; TALEHNSGEALQD;ALEHNSGEALQDI; LEHNSGEALQDIL; EHNSGEALQDILR; HNSGEALQDILRS;NSGEALQDILRSA; TGEPREWMGSLCM; GEPREWMGSLCMV; EPREWMGSLCMVW;PREWMGSLCMVWN; REWMGSLCMVWNP; EWMGSLCMVWNPR; KRLGCLMAQKDFQ;RLGCLMAQKDFQG; LGCLMAQKDFQGT; GCLMAQKDFQGTQ; CLMAQKDFQGTQI;DILTNRDNCKPKC; ILTNRDNCKPKCF; LTNRDNCKPKCFK; TNRDNCKPKCFKQ;NRDNCKPKCFKQV; RDNCKPKCFKQVL; DNCKPKCFKQVLL; NCKPKCFKQVLLL;CKPKCFKQVLLLY; KPKCFKQVLLLYI; PKCFKQVLLLYIY; KCFKQVLLLYIYI;MLLLYKPLLSLCY; LLLYKPLLSLCYF; LLYKPLLSLCYFG; LYKPLLSLCYFGG;YKPLLSLCYFGGG; KPLLSLCYFGGGV; PLLSLCYFGGGVL; LLSLCYFGGGVLG;LSLCYFGGGVLGL; SLCYFGGGVLGLL; LCYFGGGVLGLLK; CYFGGGVLGLLKH;LWGSDLWESSAGA; WGSDLWESSAGAE; GSDLWESSAGAEV; SDLWESSAGAEVS;DLWESSAGAEVSE; LWESSAGAEVSET; WESSAGAEVSETW; ESSAGAEVSETWE;SSAGAEVSETWEE; SAGAEVSETWEEH; AGAEVSETWEEHC; GAEVSETWEEHCD;AEVSETWEEHCDW; EVSETWEEHCDWD; VSETWEEHCDWDS; SETWEEHCDWDSV;ETWEEHCDWDSVL; TWEEHCDWDSVLD; WEEHCDWDSVLDP; EEHCDWDSVLDPC;EHCDWDSVLDPCP; HCDWDSVLDPCPE; CDWDSVLDPCPES; DWDSVLDPCPESS;WDSVLDPCPESSV; DSVLDPCPESSVS; SVLDPCPESSVSE; VLDPCPESSVSES;LDPCPESSVSESS; DPCPESSVSESSS; PCPESSVSESSSL; CPESSVSESSSLV;PESSVSESSSLVI; ESSVSESSSLVIS; SSVSESSSLVISR; SVSESSSLVISRI;VSESSSLVISRIH; SESSSLVISRIHF; ESSSLVISRIHFP; SSSLVISRIHFPM;SSLVISRIHFPMH; SLVISRIHFPMHI; LVISRIHFPMHIL; VISRIHFPMHILY;ISRIHFPMHILYF; SRIHFPMHILYFI; RIHFPMHILYFIL; IHFPMHILYFILE;HFPMHILYFILEK; FPMHILYFILEKV; PMHILYFILEKVY; MHILYFILEKVYI;HILYFILEKVYIL; ILYFILEKVYILI; LYFILEKVYILIS; YFILEKVYILISE;FILEKVYILISES; ILEKVYILISESS; LEKVYILISESSL; EKVYILISESSLS;KVYILISESSLSF; VYILISESSLSFH; YILISESSLSFHS; ILISESSLSFHST;LISESSLSFHSTI; ISESSLSFHSTIL; SESSLSFHSTILD; ESSLSFHSTILDC;SSLSFHSTILDCI; SLSFHSTILDCIS; LSFHSTILDCISV; SFHSTILDCISVA;FHSTILDCISVAK; HSTILDCISVAKS; STILDCISVAKSA; TILDCISVAKSAT;ILDCISVAKSATG; LDCISVAKSATGL; DCISVAKSATGLN; CISVAKSATGLNQ;ISVAKSATGLNQI; SVAKSATGLNQIS; VAKSATGLNQISS; AKSATGLNQISSS;KSATGLNQISSSN; SATGLNQISSSNK; ATGLNQISSSNKV; TGLNQISSSNKVI;GLNQISSSNKVIP; LNQISSSNKVIPL; NQISSSNKVIPLC; QISSSNKVIPLCK;ISSSNKVIPLCKI; SSSNKVIPLCKIL; SSNKVIPLCKILF; SNKVIPLCKILFS;NKVIPLCKILFSS; KVIPLCKILFSSK; VIPLCKILFSSKN; IPLCKILFSSKNS;PLCKILFSSKNSE; LCKILFSSKNSEF; CKILFSSKNSEFC; KILFSSKNSEFCK;ILFSSKNSEFCKD; LFSSKNSEFCKDF; FSSKNSEFCKDFL; SSKNSEFCKDFLK;SKNSEFCKDFLKY; KNSEFCKDFLKYI; NSEFCKDFLKYIL; SEFCKDFLKYILG;EFCKDFLKYILGL; FCKDFLKYILGLK; CKDFLKYILGLKS; KDFLKYILGLKSI;DFLKYILGLKSIC; FLKYILGLKSICL; LKYILGLKSICLT; KYILGLKSICLTN;YILGLKSICLTNL; ILGLKSICLTNLA; LGLKSICLTNLAC; GLKSICLTNLACR;LKSICLTNLACRV; KSICLTNLACRVL; SICLTNLACRVLG; ICLTNLACRVLGT;CLTNLACRVLGTG; LTNLACRVLGTGY; TNLACRVLGTGYS; NLACRVLGTGYSF;LACRVLGTGYSFI; ACRVLGTGYSFIV; CRVLGTGYSFIVT; RVLGTGYSFIVTK;VLGTGYSFIVTKP; LGTGYSFIVTKPG; GTGYSFIVTKPGG; TGYSFIVTKPGGN;GYSFIVTKPGGNI; YSFIVTKPGGNIW; SFIVTKPGGNIWV; FIVTKPGGNIWVL;IVTKPGGNIWVLL; VTKPGGNIWVLLF; TKPGGNIWVLLFK; KPGGNIWVLLFKC;PGGNIWVLLFKCF; GGNIWVLLFKCFF; GNIWVLLFKCFFS; NIWVLLFKCFFSK;IWVLLFKCFFSKF; WVLLFKCFFSKFT; VLLFKCFFSKFTL; LLFKCFFSKFTLT;LFKCFFSKFTLTL; FKCFFSKFTLTLP; KCFFSKFTLTLPS; CFFSKFTLTLPSK;SLKLSKLFIPCPE; LKLSKLFIPCPEG; KLSKLFIPCPEGK; LSKLFIPCPEGKS;SKLFIPCPEGKSF; KLFIPCPEGKSFD; LFIPCPEGKSFDS; FIPCPEGKSFDSA;IPCPEGKSFDSAP; PCPEGKSFDSAPV; CPEGKSFDSAPVP; PEGKSFDSAPVPF;EGKSFDSAPVPFT; GKSFDSAPVPFTS; KSFDSAPVPFTSS; SFDSAPVPFTSSK;FDSAPVPFTSSKT; DSAPVPFTSSKTT; SAPVPFTSSKTTM; APVPFTSSKTTMY;SIATPSSKVSLSM; IATPSSKVSLSMG; ATPSSKVSLSMGR; TPSSKVSLSMGRF;PSSKVSLSMGRFT; SSKVSLSMGRFTF; SKVSLSMGRFTFK; KVSLSMGRFTFKA;VSLSMGRFTFKAL; SLSMGRFTFKALP; LSMGRFTFKALPP; SMGRFTFKALPPH;MGRFTFKALPPHK; GRFTFKALPPHKS; RFTFKALPPHKSN; FTFKALPPHKSNN;TFKALPPHKSNNP; FKALPPHKSNNPA; KALPPHKSNNPAA; ALPPHKSNNPAAS;LPPHKSNNPAASV; PPHKSNNPAASVV; PHKSNNPAASVVF; HKSNNPAASVVFP;KSNNPAASVVFPL; SNNPAASVVFPLS; NNPAASVVFPLSM; NPAASVVFPLSMG;PAASVVFPLSMGP; AASVVFPLSMGPL; ASVVFPLSMGPLN; SVVFPLSMGPLNN;VVFPLSMGPLNNQ; VFPLSMGPLNNQY; FPLSMGPLNNQYL; PLSMGPLNNQYLL;LSMGPLNNQYLLL; SMGPLNNQYLLLG; MGPLNNQYLLLGT; GPLNNQYLLLGTL;PLNNQYLLLGTLK; LNNQYLLLGTLKT; NNQYLLLGTLKTI; NQYLLLGTLKTIQ;QYLLLGTLKTIQC; YLLLGTLKTIQCK; LLLGTLKTIQCKK; LLGTLKTIQCKKS;LGTLKTIQCKKSN; GTLKTIQCKKSNI; TLKTIQCKKSNIT; LKTIQCKKSNITE;KTIQCKKSNITES; TIQCKKSNITESI; IQCKKSNITESIL; QCKKSNITESILG;CKKSNITESILGS; KKSNITESILGSK; KSNITESILGSKQ; SNITESILGSKQC;NITESILGSKQCS; ITESILGSKQCSQ; TESILGSKQCSQA; ESILGSKQCSQAT;SILGSKQCSQATP; ILGSKQCSQATPA; LGSKQCSQATPAI; GSKQCSQATPAIY;SKQCSQATPAIYC; KQCSQATPAIYCS; QCSQATPAIYCSS; CSQATPAIYCSST;SQATPAIYCSSTA; QATPAIYCSSTAF; ATPAIYCSSTAFP; RVSTLFLAKTVST;VSTLFLAKTVSTA; STLFLAKTVSTAC; FLLSAKIIAFAKC; LLSAKIIAFAKCF;LSAKIIAFAKCFS; NSKYIPNNKNTSS; SKYIPNNKNTSSH; KYIPNNKNTSSHF;YIPNNKNTSSHFV; IPNNKNTSSHFVS; PNNKNTSSHFVST; NNKNTSSHFVSTA;NKNTSSHFVSTAY; KNTSSHFVSTAYS; NTSSHFVSTAYSV; TSSHFVSTAYSVI;SSHFVSTAYSVIN; SHFVSTAYSVINF; HFVSTAYSVINFQ; FVSTAYSVINFQD;VSTAYSVINFQDT; STAYSVINFQDTC; TAYSVINFQDTCF; AYSVINFQDTCFV;YSVINFQDTCFVS; SVINFQDTCFVSS; VINFQDTCFVSSG; INFQDTCFVSSGS;NFQDTCFVSSGSS; FQDTCFVSSGSSG; QDTCFVSSGSSGL; DTCFVSSGSSGLK;TCFVSSGSSGLKS; CFVSSGSSGLKSC; FVSSGSSGLKSCS; VSSGSSGLKSCSF;SSGSSGLKSCSFK; SGSSGLKSCSFKP; GSSGLKSCSFKPP; MLSSIVWYGSLVK;LSSIVWYGSLVKA; SSIVWYGSLVKAL; SIVWYGSLVKALY; IVWYGSLVKALYS;VWYGSLVKALYSK; WYGSLVKALYSKY; YGSLVKALYSKYS; GSLVKALYSKYSL;SLVKALYSKYSLL; LVKALYSKYSLLT; VKALYSKYSLLTP; KALYSKYSLLTPL;ALYSKYSLLTPLQ; LYSKYSLLTPLQI; YSKYSLLTPLQIK; SKYSLLTPLQIKK;KYSLLTPLQIKKL; YSLLTPLQIKKLK; SLLTPLQIKKLKV; LLTPLQIKKLKVH;LTPLQIKKLKVHS; TPLQIKKLKVHSF; QKLLIAETLCLCG; KLLIAETLCLCGV;LLIAETLCLCGVK; LIAETLCLCGVKK; IAETLCLCGVKKN; AETLCLCGVKKNI;ETLCLCGVKKNII; TLCLCGVKKNIIL; LCLCGVKKNIILC; CLCGVKKNIILCP;LCGVKKNIILCPA; CGVKKNIILCPAH; GVKKNIILCPAHM; VKKNIILCPAHMC;KKNIILCPAHMCL; KNIILCPAHMCLL; NIILCPAHMCLLI; IILCPAHMCLLIK;ILCPAHMCLLIKV; LCPAHMCLLIKVT; CPAHMCLLIKVTE; PAHMCLLIKVTEY;AHMCLLIKVTEYF; HMCLLIKVTEYFS; MCLLIKVTEYFSI; CLLIKVTEYFSIS;LLIKVTEYFSISF; LIKVTEYFSISFL; IKVTEYFSISFLY; KVTEYFSISFLYR;VTEYFSISFLYRI; AFSLVVYTAKQAR; FSLVVYTAKQARV; SLVVYTAKQARVL;LVVYTAKQARVLL; VVYTAKQARVLLL; VYTAKQARVLLLN; YTAKQARVLLLNT;TAKQARVLLLNTA; LRNWCRSEGKSLG; RNWCRSEGKSLGS; NWCRSEGKSLGSS;WCRSEGKSLGSST; CRSEGKSLGSSTF; RSEGKSLGSSTFL; SEGKSLGSSTFLF;EGKSLGSSTFLFF; GKSLGSSTFLFFL; KSLGSSTFLFFLG; SLGSSTFLFFLGG;LGSSTFLFFLGGV; GSSTFLFFLGGVE; SSTFLFFLGGVEC; ESAVASSSLANIS;SAVASSSLANISS; AVASSSLANISSW; VASSSLANISSWQ; ASSSLANISSWQN;SSSLANISSWQNK; SSLANISSWQNKS; SLANISSWQNKSS; LANISSWQNKSSS;ANISSWQNKSSSH; NISSWQNKSSSHF; ISSWQNKSSSHFS; SSWQNKSSSHFSL;SWQNKSSSHFSLK; WQNKSSSHFSLKE; QNKSSSHFSLKEL; NKSSSHFSLKELH;KSSSHFSLKELHQ; SSSHFSLKELHQD; SSHFSLKELHQDS; SHFSLKELHQDSH;HFSLKELHQDSHS; FSLKELHQDSHSS; SLKELHQDSHSSV; LKELHQDSHSSVP;VGTYKKNNYLGPF; GTYKKNNYLGPFN; TYKKNNYLGPFNI; YKKNNYLGPFNIL;KKNNYLGPFNILL; KNNYLGPFNILLF; NNYLGPFNILLFI; REFLQLFGPTIAE;EFLQLFGPTIAEF; FLQLFGPTIAEFL; LQLFGPTIAEFLQ; QLFGPTIAEFLQL;LFGPTIAEFLQLG; FGPTIAEFLQLGL; GPTIAEFLQLGLS; PTIAEFLQLGLSQ;TIAEFLQLGLSQT; IAEFLQLGLSQTT; AEFLQLGLSQTTV; SSQCSSNLSKPRA;SQCSSNLSKPRAL; QCSSNLSKPRALF; CSSNLSKPRALFL; SSNLSKPRALFLK;SNLSKPRALFLKI; NLSKPRALFLKIF; LSKPRALFLKIFY; SKPRALFLKIFYL;KPRALFLKIFYLN; PRALFLKIFYLNA; RALFLKIFYLNAL; ALFLKIFYLNALI;ADIACKGSAQKAF; DIACKGSAQKAFW; IACKGSAQKAFWN; ACKGSAQKAFWNK;AIPCSTGYLGKEE; IPCSTGYLGKEEN; PCSTGYLGKEENQ; CSTGYLGKEENQH;STGYLGKEENQHK; TGYLGKEENQHKP; GYLGKEENQHKPL; YLGKEENQHKPLS;LGKEENQHKPLSY; GKEENQHKPLSYS; KEENQHKPLSYSR; EENQHKPLSYSRF;ENQHKPLSYSRFQ; NQHKPLSYSRFQN; QHKPLSYSRFQNQ; HKPLSYSRFQNQA;KPLSYSRFQNQAD; PLSYSRFQNQADE; LSYSRFQNQADEL; SYSRFQNQADELP;YSRFQNQADELPL; SRFQNQADELPLH; RFQNQADELPLHP; FQNQADELPLHPA;QNQADELPLHPAP; NQADELPLHPAPF; QADELPLHPAPFF; ADELPLHPAPFFY;DELPLHPAPFFYT; ELPLHPAPFFYTK; LPLHPAPFFYTKY; PLHPAPFFYTKYS;LHPAPFFYTKYSF; HPAPFFYTKYSFS; PAPFFYTKYSFSS; APFFYTKYSFSSF;PFFYTKYSFSSFY; FFYTKYSFSSFYP; FYTKYSFSSFYPR; YTKYSFSSFYPRR;TKYSFSSFYPRRP; KYSFSSFYPRRPL; YSFSSFYPRRPLC; SFSSFYPRRPLCQ;FSSFYPRRPLCQG; SSFYPRRPLCQGE; SFYPRRPLCQGEI; FYPRRPLCQGEIP;YPRRPLCQGEIPY; PRRPLCQGEIPYT; RRPLCQGEIPYTS; RPLCQGEIPYTSL;PLCQGEIPYTSLN; LCQGEIPYTSLNK; CQGEIPYTSLNKL; QGEIPYTSLNKLF;GEIPYTSLNKLFS; EIPYTSLNKLFSL; IPYTSLNKLFSLR; PYTSLNKLFSLRE;YTSLNKLFSLRED; TSLNKLFSLREDF; SLNKLFSLREDFP; LNKLFSLREDFPR;NKLFSLREDFPRQ; KLFSLREDFPRQL; LFSLREDFPRQLF; FSLREDFPRQLFQ;SLREDFPRQLFQG; LREDFPRQLFQGL; REDFPRQLFQGLK; EDFPRQLFQGLKG;DFPRQLFQGLKGP 14 mers: GFPQIVLLGLRKSL; FPQIVLLGLRKSLH; PQIVLLGLRKSLHT;QIVLLGLRKSLHTL; IVLLGLRKSLHTLT; VLLGLRKSLHTLTT; EKGWRQRRPRPLIY;KGWRQRRPRPLIYY; GWRQRRPRPLIYYK; WRQRRPRPLIYYKK; RQRRPRPLIYYKKK;QRRPRPLIYYKKKG; RRPRPLIYYKKKGH; RPRPLIYYKKKGHR; PRPLIYYKKKGHRE;RPLIYYKKKGHREE; PLIYYKKKGHREEL; LIYYKKKGHREELL; IYYKKKGHREELLT;YYKKKGHREELLTH; YKKKGHREELLTHG; KKKGHREELLTHGM; KKGHREELLTHGMQ;KGHREELLTHGMQP; GHREELLTHGMQPN; HREELLTHGMQPNH; REELLTHGMQPNHD;EELLTHGMQPNHDL; ELLTHGMQPNHDLR; LLTHGMQPNHDLRK; LTHGMQPNHDLRKE;THGMQPNHDLRKES; HGMQPNHDLRKESA; LTGECSQTMTSGRK; TGECSQTMTSGRKV;GECSQTMTSGRKVH; ECSQTMTSGRKVHD; CSQTMTSGRKVHDS; SQTMTSGRKVHDSQ;QTMTSGRKVHDSQG; TMTSGRKVHDSQGG; MTSGRKVHDSQGGA; TSGRKVHDSQGGAA;SGRKVHDSQGGAAY; GRKVHDSQGGAAYP; RKVHDSQGGAAYPW; KVHDSQGGAAYPWN;VHDSQGGAAYPWNA; HDSQGGAAYPWNAA; DSQGGAAYPWNAAK; SQGGAAYPWNAAKP;PQEGKCMTDMFCEP; QEGKCMTDMFCEPR; EGKCMTDMFCEPRN; GKCMTDMFCEPRNL;KCMTDMFCEPRNLG; CMTDMFCEPRNLGL; MTDMFCEPRNLGLV; TDMFCEPRNLGLVP;DMFCEPRNLGLVPS; TGQRPWFCASCHDK; GQRPWFCASCHDKL; QRPWFCASCHDKLQ;KLVKPGLEQKKELR; LVKPGLEQKKELRG; VKPGLEQKKELRGF; KPGLEQKKELRGFL;PGLEQKKELRGFLF; GLEQKKELRGFLFL; LEQKKELRGFLFLF; VIPFFLYFQVHGCC;IPFFLYFQVHGCCS; PFFLYFQVHGCCSS; FFLYFQVHGCCSST; FLYFQVHGCCSSTF;LYFQVHGCCSSTFG; YFQVHGCCSSTFGG; FQVHGCCSSTFGGP; QVHGCCSSTFGGPS;VHGCCSSTFGGPSC; HGCCSSTFGGPSCQ; GCCSSTFGGPSCQC; CCSSTFGGPSCQCI;NCCWGGCCCYRSSN; CCWGGCCCYRSSNC; CWGGCCCYRSSNCI; WGGCCCYRSSNCIP;GGCCCYRSSNCIPC; GCCCYRSSNCIPCY; CCCYRSSNCIPCYC; CCYRSSNCIPCYCR;CYRSSNCIPCYCRG; YRSSNCIPCYCRGH; RSSNCIPCYCRGHN; SSNCIPCYCRGHNK;SNCIPCYCRGHNKY; NCIPCYCRGHNKYL; CIPCYCRGHNKYLR; IPCYCRGHNKYLRG;PCYCRGHNKYLRGY; CYCRGHNKYLRGYS; YCRGHNKYLRGYSC; CRGHNKYLRGYSCY;RGHNKYLRGYSCYR; GHNKYLRGYSCYRP; HNKYLRGYSCYRPN; NKYLRGYSCYRPNS;KYLRGYSCYRPNSS; YLRGYSCYRPNSSN; LRGYSCYRPNSSNI; RGYSCYRPNSSNIC;GYSCYRPNSSNICC; YSCYRPNSSNICCN; SCYRPNSSNICCNC; CYRPNSSNICCNCW;YRPNSSNICCNCWC; RPNSSNICCNCWCS; PNSSNICCNCWCSW; NSSNICCNCWCSWG;SSNICCNCWCSWGY; SNICCNCWCSWGYC; NICCNCWCSWGYCW; ICCNCWCSWGYCWV;CCNCWCSWGYCWVC; CNCWCSWGYCWVCC; NCWCSWGYCWVCCF; CWCSWGYCWVCCFN;WCSWGYCWVCCFNS; CSWGYCWVCCFNSN; SWGYCWVCCFNSNC; LGSQSFHCRPLSAI;GSQSFHCRPLSAIR; SQSFHCRPLSAIRH; QSFHCRPLSAIRHG; SFHCRPLSAIRHGF;FHCRPLSAIRHGFG; HCRPLSAIRHGFGI; CRPLSAIRHGFGIV; ALGSFFVCYYFPGF;LGSFFVCYYFPGFV; GSFFVCYYFPGFVA; SFFVCYYFPGFVAC; FFVCYYFPGFVACY;YTFYNLTGIAEKNR; TFYNLTGIAEKNRK; FYNLTGIAEKNRKI; YNLTGIAEKNRKIF;IFGGNYLDNCKCPY; FGGNYLDNCKCPYK; GGNYLDNCKCPYKL; GNYLDNCKCPYKLL;QYRRSYTKNGLKKS; YRRSYTKNGLKKST; RRSYTKNGLKKSTK; RSYTKNGLKKSTKC;SYTKNGLKKSTKCT; YTKNGLKKSTKCTF; TKNGLKKSTKCTFR; KNGLKKSTKCTFRR;NGLKKSTKCTFRRV; GLKKSTKCTFRRVY; LKKSTKCTFRRVYR; KKSTKCTFRRVYRK;KSTKCTFRRVYRKN; STKCTFRRVYRKNY; TKCTFRRVYRKNYC; KCTFRRVYRKNYCP;CTFRRVYRKNYCPR; TFRRVYRKNYCPRR; FRRVYRKNYCPRRC; SKNCSSMDVAFTSR;KNCSSMDVAFTSRP; NCSSMDVAFTSRPV; CSSMDVAFTSRPVR; SSMDVAFTSRPVRD;SMDVAFTSRPVRDC; MDVAFTSRPVRDCN; DVAFTSRPVRDCNT; VAFTSRPVRDCNTC;AFTSRPVRDCNTCS; RWPQPKEKESVQGQ; WPQPKEKESVQGQL; PQPKEKESVQGQLP;QPKEKESVQGQLPK; PKEKESVQGQLPKS; KEKESVQGQLPKSQ; EKESVQGQLPKSQR;KESVQGQLPKSQRN; ESVQGQLPKSQRNP; SVQGQLPKSQRNPC; VQGQLPKSQRNPCK;QGQLPKSQRNPCKC; GQLPKSQRNPCKCQ; QLPKSQRNPCKCQN; LPKSQRNPCKCQNY;TQKWGIQMKTLGAL; QKWGIQMKTLGALV; VLKMTLAVIAQREK; LKMTLAVIAQREKC;KMTLAVIAQREKCF; MTLAVIAQREKCFP; TLAVIAQREKCFPV; LAVIAQREKCFPVT;AVIAQREKCFPVTA; VIAQREKCFPVTAQ; IAQREKCFPVTAQQ; AQREKCFPVTAQQE;QREKCFPVTAQQEF; REKCFPVTAQQEFP; EKCFPVTAQQEFPS; KCFPVTAQQEFPSP;CFPVTAQQEFPSPI; LACLTFMQGHKKCM; ACLTFMQGHKKCMS; CLTFMQGHKKCMSM;LTFMQGHKKCMSMV; TFMQGHKKCMSMVE; FMQGHKKCMSMVEE; MQGHKKCMSMVEEN;QGHKKCMSMVEENL; GHKKCMSMVEENLF; HKKCMSMVEENLFK; KKCMSMVEENLFKA;KCMSMVEENLFKAV; CMSMVEENLFKAVI; MSMVEENLFKAVIS; SMVEENLFKAVIST;MVEENLFKAVISTS; VEENLFKAVISTSL; EENLFKAVISTSLL; ILTIRPIWTKTMLI;LTIRPIWTKTMLIQ; TIRPIWTKTMLIQL; IRPIWTKTMLIQLS; RPIWTKTMLIQLSA;PIWTKTMLIQLSAG; IWTKTMLIQLSAGY; WTKTMLIQLSAGYL; TKTMLIQLSAGYLI;KTMLIQLSAGYLIP; TMLIQLSAGYLIPV; MLIQLSAGYLIPVE; LIQLSAGYLIPVEM;IQLSAGYLIPVEMK; QLSAGYLIPVEMKM; LSAGYLIPVEMKML; SAGYLIPVEMKMLG;AGYLIPVEMKMLGI; GYLIPVEMKMLGIL; YLIPVEMKMLGILG; LIPVEMKMLGILGL;IPVEMKMLGILGLS; PVEMKMLGILGLSQ; VEMKMLGILGLSQE; EMKMLGILGLSQEG;MKMLGILGLSQEGK; KMLGILGLSQEGKM; MLGILGLSQEGKMF; LGILGLSQEGKMFP;GILGLSQEGKMFPQ; ILGLSQEGKMFPQY; LGLSQEGKMFPQYF; GLSQEGKMFPQYFM;MNRVWGLFVKLIAC; NRVWGLFVKLIACM; RVWGLFVKLIACMF; VWGLFVKLIACMFQ;WGLFVKLIACMFQL; GLFVKLIACMFQLL; LFVKLIACMFQLLI; FVKLIACMFQLLIF;VKLIACMFQLLIFV; KLIACMFQLLIFVA; LIACMFQLLIFVAC; IACMFQLLIFVACL;ACMFQLLIFVACLL; CMFQLLIFVACLLT; MFQLLIFVACLLTA; FQLLIFVACLLTAL;QLLIFVACLLTALE; LLIFVACLLTALEH; LIFVACLLTALEHN; IFVACLLTALEHNS;FVACLLTALEHNSG; VACLLTALEHNSGE; ACLLTALEHNSGEA; CLLTALEHNSGEAL;LLTALEHNSGEALQ; LTALEHNSGEALQD; TALEHNSGEALQDI; ALEHNSGEALQDIL;LEHNSGEALQDILR; EHNSGEALQDILRS; HNSGEALQDILRSA; TGEPREWMGSLCMV;GEPREWMGSLCMVW; EPREWMGSLCMVWN; PREWMGSLCMVWNP; REWMGSLCMVWNPR;KRLGCLMAQKDFQG; RLGCLMAQKDFQGT; LGCLMAQKDFQGTQ; GCLMAQKDFQGTQI;DILTNRDNCKPKCF; ILTNRDNCKPKCFK; LTNRDNCKPKCFKQ; TNRDNCKPKCFKQV;NRDNCKPKCFKQVL; RDNCKPKCFKQVLL; DNCKPKCFKQVLLL; NCKPKCFKQVLLLY;CKPKCFKQVLLLYI; KPKCFKQVLLLYIY; PKCFKQVLLLYIYI; MLLLYKPLLSLCYF;LLLYKPLLSLCYFG; LLYKPLLSLCYFGG; LYKPLLSLCYFGGG; YKPLLSLCYFGGGV;KPLLSLCYFGGGVL; PLLSLCYFGGGVLG; LLSLCYFGGGVLGL; LSLCYFGGGVLGLL;SLCYFGGGVLGLLK; LCYFGGGVLGLLKH; LWGSDLWESSAGAE; WGSDLWESSAGAEV;GSDLWESSAGAEVS; SDLWESSAGAEVSE; DLWESSAGAEVSET; LWESSAGAEVSETW;WESSAGAEVSETWE; ESSAGAEVSETWEE; SSAGAEVSETWEEH; SAGAEVSETWEEHC;AGAEVSETWEEHCD; GAEVSETWEEHCDW; AEVSETWEEHCDWD; EVSETWEEHCDWDS;VSETWEEHCDWDSV; SETWEEHCDWDSVL; ETWEEHCDWDSVLD; TWEEHCDWDSVLDP;WEEHCDWDSVLDPC; EEHCDWDSVLDPCP; EHCDWDSVLDPCPE; HCDWDSVLDPCPES;CDWDSVLDPCPESS; DWDSVLDPCPESSV; WDSVLDPCPESSVS; DSVLDPCPESSVSE;SVLDPCPESSVSES; VLDPCPESSVSESS; LDPCPESSVSESSS; DPCPESSVSESSSL;PCPESSVSESSSLV; CPESSVSESSSLVI; PESSVSESSSLVIS; ESSVSESSSLVISR;SSVSESSSLVISRI; SVSESSSLVISRIH; VSESSSLVISRIHF; SESSSLVISRIHFP;ESSSLVISRIHFPM; SSSLVISRIHFPMH; SSLVISRIHFPMHI; SLVISRIHFPMHIL;LVISRIHFPMHILY; VISRIHFPMHILYF; ISRIHFPMHILYFI; SRIHFPMHILYFIL;RIHFPMHILYFILE; IHFPMHILYFILEK; HFPMHILYFILEKV; FPMHILYFILEKVY;PMHILYFILEKVYI; MHILYFILEKVYIL; HILYFILEKVYILI; ILYFILEKVYILIS;LYFILEKVYILISE; YFILEKVYILISES; FILEKVYILISESS; ILEKVYILISESSL;LEKVYILISESSLS; EKVYILISESSLSF; KVYILISESSLSFH; VYILISESSLSFHS;YILISESSLSFHST; ILISESSLSFHSTI; LISESSLSFHSTIL; ISESSLSFHSTILD;SESSLSFHSTILDC; ESSLSFHSTILDCI; SSLSFHSTILDCIS; SLSFHSTILDCISV;LSFHSTILDCISVA; SFHSTILDCISVAK; FHSTILDCISVAKS; HSTILDCISVAKSA;STILDCISVAKSAT; TILDCISVAKSATG; ILDCISVAKSATGL; LDCISVAKSATGLN;DCISVAKSATGLNQ; CISVAKSATGLNQI; ISVAKSATGLNQIS; SVAKSATGLNQISS;VAKSATGLNQISSS; AKSATGLNQISSSN; KSATGLNQISSSNK; SATGLNQISSSNKV;ATGLNQISSSNKVI; TGLNQISSSNKVIP; GLNQISSSNKVIPL; LNQISSSNKVIPLC;NQISSSNKVIPLCK; QISSSNKVIPLCKI; ISSSNKVIPLCKIL; SSSNKVIPLCKILF;SSNKVIPLCKILFS; SNKVIPLCKILFSS; NKVIPLCKILFSSK; KVIPLCKILFSSKN;VIPLCKILFSSKNS; IPLCKILFSSKNSE; PLCKILFSSKNSEF; LCKILFSSKNSEFC;CKILFSSKNSEFCK; KILFSSKNSEFCKD; ILFSSKNSEFCKDF; LFSSKNSEFCKDFL;FSSKNSEFCKDFLK; SSKNSEFCKDFLKY; SKNSEFCKDFLKYI; KNSEFCKDFLKYIL;NSEFCKDFLKYILG; SEFCKDFLKYILGL; EFCKDFLKYILGLK; FCKDFLKYILGLKS;CKDFLKYILGLKSI; KDFLKYILGLKSIC; DFLKYILGLKSICL; FLKYILGLKSICLT;LKYILGLKSICLTN; KYILGLKSICLTNL; YILGLKSICLTNLA; ILGLKSICLTNLAC;LGLKSICLTNLACR; GLKSICLTNLACRV; LKSICLTNLACRVL; KSICLTNLACRVLG;SICLTNLACRVLGT; ICLTNLACRVLGTG; CLTNLACRVLGTGY; LTNLACRVLGTGYS;TNLACRVLGTGYSF; NLACRVLGTGYSFI; LACRVLGTGYSFIV; ACRVLGTGYSFIVT;CRVLGTGYSFIVTK; RVLGTGYSFIVTKP; VLGTGYSFIVTKPG; LGTGYSFIVTKPGG;GTGYSFIVTKPGGN; TGYSFIVTKPGGNI; GYSFIVTKPGGNIW; YSFIVTKPGGNIWV;SFIVTKPGGNIWVL; FIVTKPGGNIWVLL; IVTKPGGNIWVLLF; VTKPGGNIWVLLFK;TKPGGNIWVLLFKC; KPGGNIWVLLFKCF; PGGNIWVLLFKCFF; GGNIWVLLFKCFFS;GNIWVLLFKCFFSK; NIWVLLFKCFFSKF; IWVLLFKCFFSKFT; WVLLFKCFFSKFTL;VLLFKCFFSKFTLT; LLFKCFFSKFTLTL; LFKCFFSKFTLTLP; FKCFFSKFTLTLPS;KCFFSKFTLTLPSK; SLKLSKLFIPCPEG; LKLSKLFIPCPEGK; KLSKLFIPCPEGKS;LSKLFIPCPEGKSF; SKLFIPCPEGKSFD; KLFIPCPEGKSFDS; LFIPCPEGKSFDSA;FIPCPEGKSFDSAP; IPCPEGKSFDSAPV; PCPEGKSFDSAPVP; CPEGKSFDSAPVPF;PEGKSFDSAPVPFT; EGKSFDSAPVPFTS; GKSFDSAPVPFTSS; KSFDSAPVPFTSSK;SFDSAPVPFTSSKT; FDSAPVPFTSSKTT; DSAPVPFTSSKTTM; SAPVPFTSSKTTMY;SIATPSSKVSLSMG; IATPSSKVSLSMGR; ATPSSKVSLSMGRF; TPSSKVSLSMGRFT;PSSKVSLSMGRFTF; SSKVSLSMGRFTFK; SKVSLSMGRFTFKA; KVSLSMGRFTFKAL;VSLSMGRFTFKALP; SLSMGRFTFKALPP; LSMGRFTFKALPPH; SMGRFTFKALPPHK;MGRFTFKALPPHKS; GRFTFKALPPHKSN; RFTFKALPPHKSNN; FTFKALPPHKSNNP;TFKALPPHKSNNPA; FKALPPHKSNNPAA; KALPPHKSNNPAAS; ALPPHKSNNPAASV;LPPHKSNNPAASVV; PPHKSNNPAASVVF; PHKSNNPAASVVFP; HKSNNPAASVVFPL;KSNNPAASVVFPLS; SNNPAASVVFPLSM; NNPAASVVFPLSMG; NPAASVVFPLSMGP;PAASVVFPLSMGPL; AASVVFPLSMGPLN; ASVVFPLSMGPLNN; SVVFPLSMGPLNNQ;VVFPLSMGPLNNQY; VFPLSMGPLNNQYL; FPLSMGPLNNQYLL; PLSMGPLNNQYLLL;LSMGPLNNQYLLLG; SMGPLNNQYLLLGT; MGPLNNQYLLLGTL; GPLNNQYLLLGTLK;PLNNQYLLLGTLKT; LNNQYLLLGTLKTI; NNQYLLLGTLKTIQ; NQYLLLGTLKTIQC;QYLLLGTLKTIQCK; YLLLGTLKTIQCKK; LLLGTLKTIQCKKS; LLGTLKTIQCKKSN;LGTLKTIQCKKSNI; GTLKTIQCKKSNIT; TLKTIQCKKSNITE; LKTIQCKKSNITES;KTIQCKKSNITESI; TIQCKKSNITESIL; IQCKKSNITESILG; QCKKSNITESILGS;CKKSNITESILGSK; KKSNITESILGSKQ; KSNITESILGSKQC; SNITESILGSKQCS;NITESILGSKQCSQ; ITESILGSKQCSQA; TESILGSKQCSQAT; ESILGSKQCSQATP;SILGSKQCSQATPA; ILGSKQCSQATPAI; LGSKQCSQATPAIY; GSKQCSQATPAIYC;SKQCSQATPAIYCS; KQCSQATPAIYCSS; QCSQATPAIYCSST; CSQATPAIYCSSTA;SQATPAIYCSSTAF; QATPAIYCSSTAFP; RVSTLFLAKTVSTA; VSTLFLAKTVSTAC;FLLSAKIIAFAKCF; LLSAKIIAFAKCFS; NSKYIPNNKNTSSH; SKYIPNNKNTSSHF;KYIPNNKNTSSHFV; YIPNNKNTSSHFVS; IPNNKNTSSHFVST; PNNKNTSSHFVSTA;NNKNTSSHFVSTAY; NKNTSSHFVSTAYS; KNTSSHFVSTAYSV; NTSSHFVSTAYSVI;TSSHFVSTAYSVIN; SSHFVSTAYSVINF; SHFVSTAYSVINFQ; HFVSTAYSVINFQD;FVSTAYSVINFQDT; VSTAYSVINFQDTC; STAYSVINFQDTCF; TAYSVINFQDTCFV;AYSVINFQDTCFVS; YSVINFQDTCFVSS; SVINFQDTCFVSSG; VINFQDTCFVSSGS;INFQDTCFVSSGSS; NFQDTCFVSSGSSG; FQDTCFVSSGSSGL; QDTCFVSSGSSGLK;DTCFVSSGSSGLKS; TCFVSSGSSGLKSC; CFVSSGSSGLKSCS; FVSSGSSGLKSCSF;VSSGSSGLKSCSFK; SSGSSGLKSCSFKP; SGSSGLKSCSFKPP; MLSSIVWYGSLVKA;LSSIVWYGSLVKAL; SSIVWYGSLVKALY; SIVWYGSLVKALYS; IVWYGSLVKALYSK;VWYGSLVKALYSKY; WYGSLVKALYSKYS; YGSLVKALYSKYSL; GSLVKALYSKYSLL;SLVKALYSKYSLLT; LVKALYSKYSLLTP; VKALYSKYSLLTPL; KALYSKYSLLTPLQ;ALYSKYSLLTPLQI; LYSKYSLLTPLQIK; YSKYSLLTPLQIKK; SKYSLLTPLQIKKL;KYSLLTPLQIKKLK; YSLLTPLQIKKLKV; SLLTPLQIKKLKVH; LLTPLQIKKLKVHS;LTPLQIKKLKVHSF; QKLLIAETLCLCGV; KLLIAETLCLCGVK; LLIAETLCLCGVKK;LIAETLCLCGVKKN; IAETLCLCGVKKNI; AETLCLCGVKKNII; ETLCLCGVKKNIIL;TLCLCGVKKNIILC; LCLCGVKKNIILCP; CLCGVKKNIILCPA; LCGVKKNIILCPAH;CGVKKNIILCPAHM; GVKKNIILCPAHMC; VKKNIILCPAHMCL; KKNIILCPAHMCLL;KNIILCPAHMCLLI; NIILCPAHMCLLIK; IILCPAHMCLLIKV; ILCPAHMCLLIKVT;LCPAHMCLLIKVTE; CPAHMCLLIKVTEY; PAHMCLLIKVTEYF; AHMCLLIKVTEYFS;HMCLLIKVTEYFSI; MCLLIKVTEYFSIS; CLLIKVTEYFSISF; LLIKVTEYFSISFL;LIKVTEYFSISFLY; IKVTEYFSISFLYR; KVTEYFSISFLYRI; AFSLVVYTAKQARV;FSLVVYTAKQARVL; SLVVYTAKQARVLL; LVVYTAKQARVLLL; VVYTAKQARVLLLN;VYTAKQARVLLLNT; YTAKQARVLLLNTA; LRNWCRSEGKSLGS; RNWCRSEGKSLGSS;NWCRSEGKSLGSST; WCRSEGKSLGSSTF; CRSEGKSLGSSTFL; RSEGKSLGSSTFLF;SEGKSLGSSTFLFF; EGKSLGSSTFLFFL; GKSLGSSTFLFFLG; KSLGSSTFLFFLGG;SLGSSTFLFFLGGV; LGSSTFLFFLGGVE; GSSTFLFFLGGVEC; ESAVASSSLANISS;SAVASSSLANISSW; AVASSSLANISSWQ; VASSSLANISSWQN; ASSSLANISSWQNK;SSSLANISSWQNKS; SSLANISSWQNKSS; SLANISSWQNKSSS; LANISSWQNKSSSH;ANISSWQNKSSSHF; NISSWQNKSSSHFS; ISSWQNKSSSHFSL; SSWQNKSSSHFSLK;SWQNKSSSHFSLKE; WQNKSSSHFSLKEL; QNKSSSHFSLKELH; NKSSSHFSLKELHQ;KSSSHFSLKELHQD; SSSHFSLKELHQDS; SSHFSLKELHQDSH; SHFSLKELHQDSHS;HFSLKELHQDSHSS; FSLKELHQDSHSSV; SLKELHQDSHSSVP; VGTYKKNNYLGPFN;GTYKKNNYLGPFNI; TYKKNNYLGPFNIL; YKKNNYLGPFNILL; KKNNYLGPFNILLF;KNNYLGPFNILLFI; REFLQLFGPTIAEF; EFLQLFGPTIAEFL; FLQLFGPTIAEFLQ;LQLFGPTIAEFLQL; QLFGPTIAEFLQLG; LFGPTIAEFLQLGL; FGPTIAEFLQLGLS;GPTIAEFLQLGLSQ; PTIAEFLQLGLSQT; TIAEFLQLGLSQTT; IAEFLQLGLSQTTV;SSQCSSNLSKPRAL; SQCSSNLSKPRALF; QCSSNLSKPRALFL; CSSNLSKPRALFLK;SSNLSKPRALFLKI; SNLSKPRALFLKIF; NLSKPRALFLKIFY; LSKPRALFLKIFYL;SKPRALFLKIFYLN; KPRALFLKIFYLNA; PRALFLKIFYLNAL; RALFLKIFYLNALI;ADIACKGSAQKAFW; DIACKGSAQKAFWN; IACKGSAQKAFWNK; AIPCSTGYLGKEEN;IPCSTGYLGKEENQ; PCSTGYLGKEENQH; CSTGYLGKEENQHK; STGYLGKEENQHKP;TGYLGKEENQHKPL; GYLGKEENQHKPLS; YLGKEENQHKPLSY; LGKEENQHKPLSYS;GKEENQHKPLSYSR; KEENQHKPLSYSRF; EENQHKPLSYSRFQ; ENQHKPLSYSRFQN;NQHKPLSYSRFQNQ; QHKPLSYSRFQNQA; HKPLSYSRFQNQAD; KPLSYSRFQNQADE;PLSYSRFQNQADEL; LSYSRFQNQADELP; SYSRFQNQADELPL; YSRFQNQADELPLH;SRFQNQADELPLHP; RFQNQADELPLHPA; FQNQADELPLHPAP; QNQADELPLHPAPF;NQADELPLHPAPFF; QADELPLHPAPFFY; ADELPLHPAPFFYT; DELPLHPAPFFYTK;ELPLHPAPFFYTKY; LPLHPAPFFYTKYS; PLHPAPFFYTKYSF; LHPAPFFYTKYSFS;HPAPFFYTKYSFSS; PAPFFYTKYSFSSF; APFFYTKYSFSSFY; PFFYTKYSFSSFYP;FFYTKYSFSSFYPR; FYTKYSFSSFYPRR; YTKYSFSSFYPRRP; TKYSFSSFYPRRPL;KYSFSSFYPRRPLC; YSFSSFYPRRPLCQ; SFSSFYPRRPLCQG; FSSFYPRRPLCQGE;SSFYPRRPLCQGEI; SFYPRRPLCQGEIP; FYPRRPLCQGEIPY; YPRRPLCQGEIPYT;PRRPLCQGEIPYTS; RRPLCQGEIPYTSL; RPLCQGEIPYTSLN; PLCQGEIPYTSLNK;LCQGEIPYTSLNKL; CQGEIPYTSLNKLF; QGEIPYTSLNKLFS; GEIPYTSLNKLFSL;EIPYTSLNKLFSLR; IPYTSLNKLFSLRE; PYTSLNKLFSLRED; YTSLNKLFSLREDF;TSLNKLFSLREDFP; SLNKLFSLREDFPR; LNKLFSLREDFPRQ; NKLFSLREDFPRQL;KLFSLREDFPRQLF; LFSLREDFPRQLFQ; FSLREDFPRQLFQG; SLREDFPRQLFQGL;LREDFPRQLFQGLK; REDFPRQLFQGLKG; EDFPRQLFQGLKGP 15 mers: GFPQIVLLGLRKSLH;FPQIVLLGLRKSLHT; PQIVLLGLRKSLHTL; QIVLLGLRKSLHTLT; IVLLGLRKSLHTLTT;EKGWRQRRPRPLIYY; KGWRQRRPRPLIYYK; GWRQRRPRPLIYYKK; WRQRRPRPLIYYKKK;RQRRPRPLIYYKKKG; QRRPRPLIYYKKKGH; RRPRPLIYYKKKGHR; RPRPLIYYKKKGHRE;PRPLIYYKKKGHREE; RPLIYYKKKGHREEL; PLIYYKKKGHREELL; LIYYKKKGHREELLT;IYYKKKGHREELLTH; YYKKKGHREELLTHG; YKKKGHREELLTHGM; KKKGHREELLTHGMQ;KKGHREELLTHGMQP; KGHREELLTHGMQPN; GHREELLTHGMQPNH; HREELLTHGMQPNHD;REELLTHGMQPNHDL; EELLTHGMQPNHDLR; ELLTHGMQPNHDLRK; LLTHGMQPNHDLRKE;LTHGMQPNHDLRKES; THGMQPNHDLRKESA; LTGECSQTMTSGRKV; TGECSQTMTSGRKVH;GECSQTMTSGRKVHD; ECSQTMTSGRKVHDS; CSQTMTSGRKVHDSQ; SQTMTSGRKVHDSQG;QTMTSGRKVHDSQGG; TMTSGRKVHDSQGGA; MTSGRKVHDSQGGAA; TSGRKVHDSQGGAAY;SGRKVHDSQGGAAYP; GRKVHDSQGGAAYPW; RKVHDSQGGAAYPWN; KVHDSQGGAAYPWNA;VHDSQGGAAYPWNAA; HDSQGGAAYPWNAAK; DSQGGAAYPWNAAKP; PQEGKCMTDMFCEPR;QEGKCMTDMFCEPRN; EGKCMTDMFCEPRNL; GKCMTDMFCEPRNLG; KCMTDMFCEPRNLGL;CMTDMFCEPRNLGLV; MTDMFCEPRNLGLVP; TDMFCEPRNLGLVPS; TGQRPWFCASCHDKL;GQRPWFCASCHDKLQ; KLVKPGLEQKKELRG; LVKPGLEQKKELRGF; VKPGLEQKKELRGFL;KPGLEQKKELRGFLF; PGLEQKKELRGFLFL; GLEQKKELRGFLFLF; VIPFFLYFQVHGCCS;IPFFLYFQVHGCCSS; PFFLYFQVHGCCSST; FFLYFQVHGCCSSTF; FLYFQVHGCCSSTFG;LYFQVHGCCSSTFGG; YFQVHGCCSSTFGGP; FQVHGCCSSTFGGPS; QVHGCCSSTFGGPSC;VHGCCSSTFGGPSCQ; HGCCSSTFGGPSCQC; GCCSSTFGGPSCQCI; NCCWGGCCCYRSSNC;CCWGGCCCYRSSNCI; CWGGCCCYRSSNCIP; WGGCCCYRSSNCIPC; GGCCCYRSSNCIPCY;GCCCYRSSNCIPCYC; CCCYRSSNCIPCYCR; CCYRSSNCIPCYCRG; CYRSSNCIPCYCRGH;YRSSNCIPCYCRGHN; RSSNCIPCYCRGHNK; SSNCIPCYCRGHNKY; SNCIPCYCRGHNKYL;NCIPCYCRGHNKYLR; CIPCYCRGHNKYLRG; IPCYCRGHNKYLRGY; PCYCRGHNKYLRGYS;CYCRGHNKYLRGYSC; YCRGHNKYLRGYSCY; CRGHNKYLRGYSCYR; RGHNKYLRGYSCYRP;GHNKYLRGYSCYRPN; HNKYLRGYSCYRPNS; NKYLRGYSCYRPNSS; KYLRGYSCYRPNSSN;YLRGYSCYRPNSSNI; LRGYSCYRPNSSNIC; RGYSCYRPNSSNICC; GYSCYRPNSSNICCN;YSCYRPNSSNICCNC; SCYRPNSSNICCNCW; CYRPNSSNICCNCWC; YRPNSSNICCNCWCS;RPNSSNICCNCWCSW; PNSSNICCNCWCSWG; NSSNICCNCWCSWGY; SSNICCNCWCSWGYC;SNICCNCWCSWGYCW; NICCNCWCSWGYCWV; ICCNCWCSWGYCWVC; CCNCWCSWGYCWVCC;CNCWCSWGYCWVCCF; NCWCSWGYCWVCCFN; CWCSWGYCWVCCFNS; WCSWGYCWVCCFNSN;CSWGYCWVCCFNSNC; LGSQSFHCRPLSAIR; GSQSFHCRPLSAIRH; SQSFHCRPLSAIRHG;QSFHCRPLSAIRHGF; SFHCRPLSAIRHGFG; FHCRPLSAIRHGFGI; HCRPLSAIRHGFGIV;ALGSFFVCYYFPGFV; LGSFFVCYYFPGFVA; GSFFVCYYFPGFVAC; SFFVCYYFPGFVACY;YTFYNLTGIAEKNRK; TFYNLTGIAEKNRKI; FYNLTGIAEKNRKIF; IFGGNYLDNCKCPYK;FGGNYLDNCKCPYKL; GGNYLDNCKCPYKLL; QYRRSYTKNGLKKST; YRRSYTKNGLKKSTK;RRSYTKNGLKKSTKC; RSYTKNGLKKSTKCT; SYTKNGLKKSTKCTF; YTKNGLKKSTKCTFR;TKNGLKKSTKCTFRR; KNGLKKSTKCTFRRV; NGLKKSTKCTFRRVY; GLKKSTKCTFRRVYR;LKKSTKCTFRRVYRK; KKSTKCTFRRVYRKN; KSTKCTFRRVYRKNY; STKCTFRRVYRKNYC;TKCTFRRVYRKNYCP; KCTFRRVYRKNYCPR; CTFRRVYRKNYCPRR; TFRRVYRKNYCPRRC;SKNCSSMDVAFTSRP; KNCSSMDVAFTSRPV; NCSSMDVAFTSRPVR; CSSMDVAFTSRPVRD;SSMDVAFTSRPVRDC; SMDVAFTSRPVRDCN; MDVAFTSRPVRDCNT; DVAFTSRPVRDCNTC;VAFTSRPVRDCNTCS; RWPQPKEKESVQGQL; WPQPKEKESVQGQLP; PQPKEKESVQGQLPK;QPKEKESVQGQLPKS; PKEKESVQGQLPKSQ; KEKESVQGQLPKSQR; EKESVQGQLPKSQRN;KESVQGQLPKSQRNP; ESVQGQLPKSQRNPC; SVQGQLPKSQRNPCK; VQGQLPKSQRNPCKC;QGQLPKSQRNPCKCQ; GQLPKSQRNPCKCQN; QLPKSQRNPCKCQNY; TQKWGIQMKTLGALV;VLKMTLAVIAQREKC; LKMTLAVIAQREKCF; KMTLAVIAQREKCFP; MTLAVIAQREKCFPV;TLAVIAQREKCFPVT; LAVIAQREKCFPVTA; AVIAQREKCFPVTAQ; VIAQREKCFPVTAQQ;IAQREKCFPVTAQQE; AQREKCFPVTAQQEF; QREKCFPVTAQQEFP; REKCFPVTAQQEFPS;EKCFPVTAQQEFPSP; KCFPVTAQQEFPSPI; LACLTFMQGHKKCMS; ACLTFMQGHKKCMSM;CLTFMQGHKKCMSMV; LTFMQGHKKCMSMVE; TFMQGHKKCMSMVEE; FMQGHKKCMSMVEEN;MQGHKKCMSMVEENL; QGHKKCMSMVEENLF; GHKKCMSMVEENLFK; HKKCMSMVEENLFKA;KKCMSMVEENLFKAV; KCMSMVEENLFKAVI; CMSMVEENLFKAVIS; MSMVEENLFKAVIST;SMVEENLFKAVISTS; MVEENLFKAVISTSL; VEENLFKAVISTSLL; ILTIRPIWTKTMLIQ;LTIRPIWTKTMLIQL; TIRPIWTKTMLIQLS; IRPIWTKTMLIQLSA; RPIWTKTMLIQLSAG;PIWTKTMLIQLSAGY; IWTKTMLIQLSAGYL; WTKTMLIQLSAGYLI; TKTMLIQLSAGYLIP;KTMLIQLSAGYLIPV; TMLIQLSAGYLIPVE; MLIQLSAGYLIPVEM; LIQLSAGYLIPVEMK;IQLSAGYLIPVEMKM; QLSAGYLIPVEMKML; LSAGYLIPVEMKMLG; SAGYLIPVEMKMLGI;AGYLIPVEMKMLGIL; GYLIPVEMKMLGILG; YLIPVEMKMLGILGL; LIPVEMKMLGILGLS;IPVEMKMLGILGLSQ; PVEMKMLGILGLSQE; VEMKMLGILGLSQEG; EMKMLGILGLSQEGK;MKMLGILGLSQEGKM; KMLGILGLSQEGKMF; MLGILGLSQEGKMFP; LGILGLSQEGKMFPQ;GILGLSQEGKMFPQY; ILGLSQEGKMFPQYF; LGLSQEGKMFPQYFM; MNRVWGLFVKLIACM;NRVWGLFVKLIACMF; RVWGLFVKLIACMFQ; VWGLFVKLIACMFQL; WGLFVKLIACMFQLL;GLFVKLIACMFQLLI; LFVKLIACMFQLLIF; FVKLIACMFQLLIFV; VKLIACMFQLLIFVA;KLIACMFQLLIFVAC; LIACMFQLLIFVACL; IACMFQLLIFVACLL; ACMFQLLIFVACLLT;CMFQLLIFVACLLTA; MFQLLIFVACLLTAL; FQLLIFVACLLTALE; QLLIFVACLLTALEH;LLIFVACLLTALEHN; LIFVACLLTALEHNS; IFVACLLTALEHNSG; FVACLLTALEHNSGE;VACLLTALEHNSGEA; ACLLTALEHNSGEAL; CLLTALEHNSGEALQ; LLTALEHNSGEALQD;LTALEHNSGEALQDI; TALEHNSGEALQDIL; ALEHNSGEALQDILR; LEHNSGEALQDILRS;EHNSGEALQDILRSA; TGEPREWMGSLCMVW; GEPREWMGSLCMVWN; EPREWMGSLCMVWNP;PREWMGSLCMVWNPR; KRLGCLMAQKDFQGT; RLGCLMAQKDFQGTQ; LGCLMAQKDFQGTQI;DILTNRDNCKPKCFK; ILTNRDNCKPKCFKQ; LTNRDNCKPKCFKQV; TNRDNCKPKCFKQVL;NRDNCKPKCFKQVLL; RDNCKPKCFKQVLLL; DNCKPKCFKQVLLLY; NCKPKCFKQVLLLYI;CKPKCFKQVLLLYIY; KPKCFKQVLLLYIYI; MLLLYKPLLSLCYFG; LLLYKPLLSLCYFGG;LLYKPLLSLCYFGGG; LYKPLLSLCYFGGGV; YKPLLSLCYFGGGVL; KPLLSLCYFGGGVLG;PLLSLCYFGGGVLGL; LLSLCYFGGGVLGLL; LSLCYFGGGVLGLLK; SLCYFGGGVLGLLKH;LWGSDLWESSAGAEV; WGSDLWESSAGAEVS; GSDLWESSAGAEVSE; SDLWESSAGAEVSET;DLWESSAGAEVSETW; LWESSAGAEVSETWE; WESSAGAEVSETWEE; ESSAGAEVSETWEEH;SSAGAEVSETWEEHC; SAGAEVSETWEEHCD; AGAEVSETWEEHCDW; GAEVSETWEEHCDWD;AEVSETWEEHCDWDS; EVSETWEEHCDWDSV; VSETWEEHCDWDSVL; SETWEEHCDWDSVLD;ETWEEHCDWDSVLDP; TWEEHCDWDSVLDPC; WEEHCDWDSVLDPCP; EEHCDWDSVLDPCPE;EHCDWDSVLDPCPES; HCDWDSVLDPCPESS; CDWDSVLDPCPESSV; DWDSVLDPCPESSVS;WDSVLDPCPESSVSE; DSVLDPCPESSVSES; SVLDPCPESSVSESS; VLDPCPESSVSESSS;LDPCPESSVSESSSL; DPCPESSVSESSSLV; PCPESSVSESSSLVI; CPESSVSESSSLVIS;PESSVSESSSLVISR; ESSVSESSSLVISRI; SSVSESSSLVISRIH; SVSESSSLVISRIHF;VSESSSLVISRIHFP; SESSSLVISRIHFPM; ESSSLVISRIHFPMH; SSSLVISRIHFPMHI;SSLVISRIHFPMHIL; SLVISRIHFPMHILY; LVISRIHFPMHILYF; VISRIHFPMHILYFI;ISRIHFPMHILYFIL; SRIHFPMHILYFILE; RIHFPMHILYFILEK; IHFPMHILYFILEKV;HFPMHILYFILEKVY; FPMHILYFILEKVYI; PMHILYFILEKVYIL; MHILYFILEKVYILI;HILYFILEKVYILIS; ILYFILEKVYILISE; LYFILEKVYILISES; YFILEKVYILISESS;FILEKVYILISESSL; ILEKVYILISESSLS; LEKVYILISESSLSF; EKVYILISESSLSFH;KVYILISESSLSFHS; VYILISESSLSFHST; YILISESSLSFHSTI; ILISESSLSFHSTIL;LISESSLSFHSTILD; ISESSLSFHSTILDC; SESSLSFHSTILDCI; ESSLSFHSTILDCIS;SSLSFHSTILDCISV; SLSFHSTILDCISVA; LSFHSTILDCISVAK; SFHSTILDCISVAKS;FHSTILDCISVAKSA; HSTILDCISVAKSAT; STILDCISVAKSATG; TILDCISVAKSATGL;ILDCISVAKSATGLN; LDCISVAKSATGLNQ; DCISVAKSATGLNQI; CISVAKSATGLNQIS;ISVAKSATGLNQISS; SVAKSATGLNQISSS; VAKSATGLNQISSSN; AKSATGLNQISSSNK;KSATGLNQISSSNKV; SATGLNQISSSNKVI; ATGLNQISSSNKVIP; TGLNQISSSNKVIPL;GLNQISSSNKVIPLC; LNQISSSNKVIPLCK; NQISSSNKVIPLCKI; QISSSNKVIPLCKIL;ISSSNKVIPLCKILF; SSSNKVIPLCKILFS; SSNKVIPLCKILFSS; SNKVIPLCKILFSSK;NKVIPLCKILFSSKN; KVIPLCKILFSSKNS; VIPLCKILFSSKNSE; IPLCKILFSSKNSEF;PLCKILFSSKNSEFC; LCKILFSSKNSEFCK; CKILFSSKNSEFCKD; KILFSSKNSEFCKDF;ILFSSKNSEFCKDFL; LFSSKNSEFCKDFLK; FSSKNSEFCKDFLKY; SSKNSEFCKDFLKYI;SKNSEFCKDFLKYIL; KNSEFCKDFLKYILG; NSEFCKDFLKYILGL; SEFCKDFLKYILGLK;EFCKDFLKYILGLKS; FCKDFLKYILGLKSI; CKDFLKYILGLKSIC; KDFLKYILGLKSICL;DFLKYILGLKSICLT; FLKYILGLKSICLTN; LKYILGLKSICLTNL; KYILGLKSICLTNLA;YILGLKSICLTNLAC; ILGLKSICLTNLACR; LGLKSICLTNLACRV; GLKSICLTNLACRVL;LKSICLTNLACRVLG; KSICLTNLACRVLGT; SICLTNLACRVLGTG; ICLTNLACRVLGTGY;CLTNLACRVLGTGYS; LTNLACRVLGTGYSF; TNLACRVLGTGYSFI; NLACRVLGTGYSFIV;LACRVLGTGYSFIVT; ACRVLGTGYSFIVTK; CRVLGTGYSFIVTKP; RVLGTGYSFIVTKPG;VLGTGYSFIVTKPGG; LGTGYSFIVTKPGGN; GTGYSFIVTKPGGNI; TGYSFIVTKPGGNIW;GYSFIVTKPGGNIWV; YSFIVTKPGGNIWVL; SFIVTKPGGNIWVLL; FIVTKPGGNIWVLLF;IVTKPGGNIWVLLFK; VTKPGGNIWVLLFKC; TKPGGNIWVLLFKCF; KPGGNIWVLLFKCFF;PGGNIWVLLFKCFFS; GGNIWVLLFKCFFSK; GNIWVLLFKCFFSKF; NIWVLLFKCFFSKFT;IWVLLFKCFFSKFTL; WVLLFKCFFSKFTLT; VLLFKCFFSKFTLTL; LLFKCFFSKFTLTLP;LFKCFFSKFTLTLPS; FKCFFSKFTLTLPSK; SLKLSKLFIPCPEGK; LKLSKLFIPCPEGKS;KLSKLFIPCPEGKSF; LSKLFIPCPEGKSFD; SKLFIPCPEGKSFDS; KLFIPCPEGKSFDSA;LFIPCPEGKSFDSAP; FIPCPEGKSFDSAPV; IPCPEGKSFDSAPVP; PCPEGKSFDSAPVPF;CPEGKSFDSAPVPFT; PEGKSFDSAPVPFTS; EGKSFDSAPVPFTSS; GKSFDSAPVPFTSSK;KSFDSAPVPFTSSKT; SFDSAPVPFTSSKTT; FDSAPVPFTSSKTTM; DSAPVPFTSSKTTMY;SIATPSSKVSLSMGR; IATPSSKVSLSMGRF; ATPSSKVSLSMGRFT; TPSSKVSLSMGRFTF;PSSKVSLSMGRFTFK; SSKVSLSMGRFTFKA; SKVSLSMGRFTFKAL; KVSLSMGRFTFKALP;VSLSMGRFTFKALPP; SLSMGRFTFKALPPH; LSMGRFTFKALPPHK; SMGRFTFKALPPHKS;MGRFTFKALPPHKSN; GRFTFKALPPHKSNN; RFTFKALPPHKSNNP; FTFKALPPHKSNNPA;TFKALPPHKSNNPAA; FKALPPHKSNNPAAS; KALPPHKSNNPAASV; ALPPHKSNNPAASVV;LPPHKSNNPAASVVF; PPHKSNNPAASVVFP; PHKSNNPAASVVFPL; HKSNNPAASVVFPLS;KSNNPAASVVFPLSM; SNNPAASVVFPLSMG; NNPAASVVFPLSMGP; NPAASVVFPLSMGPL;PAASVVFPLSMGPLN; AASVVFPLSMGPLNN; ASVVFPLSMGPLNNQ; SVVFPLSMGPLNNQY;VVFPLSMGPLNNQYL; VFPLSMGPLNNQYLL; FPLSMGPLNNQYLLL; PLSMGPLNNQYLLLG;LSMGPLNNQYLLLGT; SMGPLNNQYLLLGTL; MGPLNNQYLLLGTLK; GPLNNQYLLLGTLKT;PLNNQYLLLGTLKTI; LNNQYLLLGTLKTIQ; NNQYLLLGTLKTIQC; NQYLLLGTLKTIQCK;QYLLLGTLKTIQCKK; YLLLGTLKTIQCKKS; LLLGTLKTIQCKKSN; LLGTLKTIQCKKSNI;LGTLKTIQCKKSNIT; GTLKTIQCKKSNITE; TLKTIQCKKSNITES; LKTIQCKKSNITESI;KTIQCKKSNITESIL; TIQCKKSNITESILG; IQCKKSNITESILGS; QCKKSNITESILGSK;CKKSNITESILGSKQ; KKSNITESILGSKQC; KSNITESILGSKQCS; SNITESILGSKQCSQ;NITESILGSKQCSQA; ITESILGSKQCSQAT; TESILGSKQCSQATP; ESILGSKQCSQATPA;SILGSKQCSQATPAI; ILGSKQCSQATPAIY; LGSKQCSQATPAIYC; GSKQCSQATPAIYCS;SKQCSQATPAIYCSS; KQCSQATPAIYCSST; QCSQATPAIYCSSTA; CSQATPAIYCSSTAF;SQATPAIYCSSTAFP; RVSTLFLAKTVSTAC; FLLSAKIIAFAKCFS; NSKYIPNNKNTSSHF;SKYIPNNKNTSSHFV; KYIPNNKNTSSHFVS; YIPNNKNTSSHFVST; IPNNKNTSSHFVSTA;PNNKNTSSHFVSTAY; NNKNTSSHFVSTAYS; NKNTSSHFVSTAYSV; KNTSSHFVSTAYSVI;NTSSHFVSTAYSVIN; TSSHFVSTAYSVINF; SSHFVSTAYSVINFQ; SHFVSTAYSVINFQD;HFVSTAYSVINFQDT; FVSTAYSVINFQDTC; VSTAYSVINFQDTCF; STAYSVINFQDTCFV;TAYSVINFQDTCFVS; AYSVINFQDTCFVSS; YSVINFQDTCFVSSG; SVINFQDTCFVSSGS;VINFQDTCFVSSGSS; INFQDTCFVSSGSSG; NFQDTCFVSSGSSGL; FQDTCFVSSGSSGLK;QDTCFVSSGSSGLKS; DTCFVSSGSSGLKSC; TCFVSSGSSGLKSCS; CFVSSGSSGLKSCSF;FVSSGSSGLKSCSFK; VSSGSSGLKSCSFKP; SSGSSGLKSCSFKPP; MLSSIVWYGSLVKAL;LSSIVWYGSLVKALY; SSIVWYGSLVKALYS; SIVWYGSLVKALYSK; IVWYGSLVKALYSKY;VWYGSLVKALYSKYS; WYGSLVKALYSKYSL; YGSLVKALYSKYSLL; GSLVKALYSKYSLLT;SLVKALYSKYSLLTP; LVKALYSKYSLLTPL; VKALYSKYSLLTPLQ; KALYSKYSLLTPLQI;ALYSKYSLLTPLQIK; LYSKYSLLTPLQIKK; YSKYSLLTPLQIKKL; SKYSLLTPLQIKKLK;KYSLLTPLQIKKLKV; YSLLTPLQIKKLKVH; SLLTPLQIKKLKVHS; LLTPLQIKKLKVHSF;QKLLIAETLCLCGVK; KLLIAETLCLCGVKK; LLIAETLCLCGVKKN; LIAETLCLCGVKKNI;IAETLCLCGVKKNII; AETLCLCGVKKNIIL; ETLCLCGVKKNIILC; TLCLCGVKKNIILCP;LCLCGVKKNIILCPA; CLCGVKKNIILCPAH; LCGVKKNIILCPAHM; CGVKKNIILCPAHMC;GVKKNIILCPAHMCL; VKKNIILCPAHMCLL; KKNIILCPAHMCLLI; KNIILCPAHMCLLIK;NIILCPAHMCLLIKV; IILCPAHMCLLIKVT; ILCPAHMCLLIKVTE; LCPAHMCLLIKVTEY;CPAHMCLLIKVTEYF; PAHMCLLIKVTEYFS; AHMCLLIKVTEYFSI; HMCLLIKVTEYFSIS;MCLLIKVTEYFSISF; CLLIKVTEYFSISFL; LLIKVTEYFSISFLY; LIKVTEYFSISFLYR;IKVTEYFSISFLYRI; AFSLVVYTAKQARVL; FSLVVYTAKQARVLL; SLVVYTAKQARVLLL;LVVYTAKQARVLLLN; VVYTAKQARVLLLNT; VYTAKQARVLLLNTA; LRNWCRSEGKSLGSS;RNWCRSEGKSLGSST; NWCRSEGKSLGSSTF; WCRSEGKSLGSSTFL; CRSEGKSLGSSTFLF;RSEGKSLGSSTFLFF; SEGKSLGSSTFLFFL; EGKSLGSSTFLFFLG; GKSLGSSTFLFFLGG;KSLGSSTFLFFLGGV; SLGSSTFLFFLGGVE; LGSSTFLFFLGGVEC; ESAVASSSLANISSW;SAVASSSLANISSWQ; AVASSSLANISSWQN; VASSSLANISSWQNK; ASSSLANISSWQNKS;SSSLANISSWQNKSS; SSLANISSWQNKSSS; SLANISSWQNKSSSH; LANISSWQNKSSSHF;ANISSWQNKSSSHFS; NISSWQNKSSSHFSL; ISSWQNKSSSHFSLK; SSWQNKSSSHFSLKE;SWQNKSSSHFSLKEL; WQNKSSSHFSLKELH; QNKSSSHFSLKELHQ; NKSSSHFSLKELHQD;KSSSHFSLKELHQDS; SSSHFSLKELHQDSH; SSHFSLKELHQDSHS; SHFSLKELHQDSHSS;HFSLKELHQDSHSSV; FSLKELHQDSHSSVP; VGTYKKNNYLGPFNI; GTYKKNNYLGPFNIL;TYKKNNYLGPFNILL; YKKNNYLGPFNILLF; KKNNYLGPFNILLFI; REFLQLFGPTIAEFL;EFLQLFGPTIAEFLQ; FLQLFGPTIAEFLQL; LQLFGPTIAEFLQLG; QLFGPTIAEFLQLGL;LFGPTIAEFLQLGLS; FGPTIAEFLQLGLSQ; GPTIAEFLQLGLSQT; PTIAEFLQLGLSQTT;TIAEFLQLGLSQTTV; SSQCSSNLSKPRALF; SQCSSNLSKPRALFL; QCSSNLSKPRALFLK;CSSNLSKPRALFLKI; SSNLSKPRALFLKIF; SNLSKPRALFLKIFY; NLSKPRALFLKIFYL;LSKPRALFLKIFYLN; SKPRALFLKIFYLNA; KPRALFLKIFYLNAL; PRALFLKIFYLNALI;ADIACKGSAQKAFWN; DIACKGSAQKAFWNK; AIPCSTGYLGKEENQ; IPCSTGYLGKEENQH;PCSTGYLGKEENQHK; CSTGYLGKEENQHKP; STGYLGKEENQHKPL; TGYLGKEENQHKPLS;GYLGKEENQHKPLSY; YLGKEENQHKPLSYS; LGKEENQHKPLSYSR; GKEENQHKPLSYSRF;KEENQHKPLSYSRFQ; EENQHKPLSYSRFQN; ENQHKPLSYSRFQNQ; NQHKPLSYSRFQNQA;QHKPLSYSRFQNQAD; HKPLSYSRFQNQADE; KPLSYSRFQNQADEL; PLSYSRFQNQADELP;LSYSRFQNQADELPL; SYSRFQNQADELPLH; YSRFQNQADELPLHP; SRFQNQADELPLHPA;RFQNQADELPLHPAP; FQNQADELPLHPAPF; QNQADELPLHPAPFF; NQADELPLHPAPFFY;QADELPLHPAPFFYT; ADELPLHPAPFFYTK; DELPLHPAPFFYTKY; ELPLHPAPFFYTKYS;LPLHPAPFFYTKYSF; PLHPAPFFYTKYSFS; LHPAPFFYTKYSFSS; HPAPFFYTKYSFSSF;PAPFFYTKYSFSSFY; APFFYTKYSFSSFYP; PFFYTKYSFSSFYPR; FFYTKYSFSSFYPRR;FYTKYSFSSFYPRRP; YTKYSFSSFYPRRPL; TKYSFSSFYPRRPLC; KYSFSSFYPRRPLCQ;YSFSSFYPRRPLCQG; SFSSFYPRRPLCQGE; FSSFYPRRPLCQGEI; SSFYPRRPLCQGEIP;SFYPRRPLCQGEIPY; FYPRRPLCQGEIPYT; YPRRPLCQGEIPYTS; PRRPLCQGEIPYTSL;RRPLCQGEIPYTSLN; RPLCQGEIPYTSLNK; PLCQGEIPYTSLNKL; LCQGEIPYTSLNKLF;CQGEIPYTSLNKLFS; QGEIPYTSLNKLFSL; GEIPYTSLNKLFSLR; EIPYTSLNKLFSLRE;IPYTSLNKLFSLRED; PYTSLNKLFSLREDF; YTSLNKLFSLREDFP; TSLNKLFSLREDFPR;SLNKLFSLREDFPRQ; LNKLFSLREDFPRQL; NKLFSLREDFPRQLF; KLFSLREDFPRQLFQ;LFSLREDFPRQLFQG; FSLREDFPRQLFQGL; SLREDFPRQLFQGLK; LREDFPRQLFQGLKG;REDFPRQLFQGLKGP 16 mers: GFPQIVLLGLRKSLHT; FPQIVLLGLRKSLHTL;PQIVLLGLRKSLHTLT; QIVLLGLRKSLHTLTT; EKGWRQRRPRPLIYYK; KGWRQRRPRPLIYYKK;GWRQRRPRPLIYYKKK; WRQRRPRPLIYYKKKG; RQRRPRPLIYYKKKGH; QRRPRPLIYYKKKGHR;RRPRPLIYYKKKGHRE; RPRPLIYYKKKGHREE; PRPLIYYKKKGHREEL; RPLIYYKKKGHREELL;PLIYYKKKGHREELLT; LIYYKKKGHREELLTH; IYYKKKGHREELLTHG; YYKKKGHREELLTHGM;YKKKGHREELLTHGMQ; KKKGHREELLTHGMQP; KKGHREELLTHGMQPN; KGHREELLTHGMQPNH;GHREELLTHGMQPNHD; HREELLTHGMQPNHDL; REELLTHGMQPNHDLR; EELLTHGMQPNHDLRK;ELLTHGMQPNHDLRKE; LLTHGMQPNHDLRKES; LTHGMQPNHDLRKESA; LTGECSQTMTSGRKVH;TGECSQTMTSGRKVHD; GECSQTMTSGRKVHDS; ECSQTMTSGRKVHDSQ; CSQTMTSGRKVHDSQG;SQTMTSGRKVHDSQGG; QTMTSGRKVHDSQGGA; TMTSGRKVHDSQGGAA; MTSGRKVHDSQGGAAY;TSGRKVHDSQGGAAYP; SGRKVHDSQGGAAYPW; GRKVHDSQGGAAYPWN; RKVHDSQGGAAYPWNA;KVHDSQGGAAYPWNAA; VHDSQGGAAYPWNAAK; HDSQGGAAYPWNAAKP; PQEGKCMTDMFCEPRN;QEGKCMTDMFCEPRNL; EGKCMTDMFCEPRNLG; GKCMTDMFCEPRNLGL; KCMTDMFCEPRNLGLV;CMTDMFCEPRNLGLVP; MTDMFCEPRNLGLVPS; TGQRPWFCASCHDKLQ; KLVKPGLEQKKELRGF;LVKPGLEQKKELRGFL; VKPGLEQKKELRGFLF; KPGLEQKKELRGFLFL; PGLEQKKELRGFLFLF;VIPFFLYFQVHGCCSS; IPFFLYFQVHGCCSST; PFFLYFQVHGCCSSTF; FFLYFQVHGCCSSTFG;FLYFQVHGCCSSTFGG; LYFQVHGCCSSTFGGP; YFQVHGCCSSTFGGPS; FQVHGCCSSTFGGPSC;QVHGCCSSTFGGPSCQ; VHGCCSSTFGGPSCQC; HGCCSSTFGGPSCQCI; NCCWGGCCCYRSSNCI;CCWGGCCCYRSSNCIP; CWGGCCCYRSSNCIPC; WGGCCCYRSSNCIPCY; GGCCCYRSSNCIPCYC;GCCCYRSSNCIPCYCR; CCCYRSSNCIPCYCRG; CCYRSSNCIPCYCRGH; CYRSSNCIPCYCRGHN;YRSSNCIPCYCRGHNK; RSSNCIPCYCRGHNKY; SSNCIPCYCRGHNKYL; SNCIPCYCRGHNKYLR;NCIPCYCRGHNKYLRG; CIPCYCRGHNKYLRGY; IPCYCRGHNKYLRGYS; PCYCRGHNKYLRGYSC;CYCRGHNKYLRGYSCY; YCRGHNKYLRGYSCYR; CRGHNKYLRGYSCYRP; RGHNKYLRGYSCYRPN;GHNKYLRGYSCYRPNS; HNKYLRGYSCYRPNSS; NKYLRGYSCYRPNSSN; KYLRGYSCYRPNSSNI;YLRGYSCYRPNSSNIC; LRGYSCYRPNSSNICC; RGYSCYRPNSSNICCN; GYSCYRPNSSNICCNC;YSCYRPNSSNICCNCW; SCYRPNSSNICCNCWC; CYRPNSSNICCNCWCS; YRPNSSNICCNCWCSW;RPNSSNICCNCWCSWG; PNSSNICCNCWCSWGY; NSSNICCNCWCSWGYC; SSNICCNCWCSWGYCW;SNICCNCWCSWGYCWV; NICCNCWCSWGYCWVC; ICCNCWCSWGYCWVCC; CCNCWCSWGYCWVCCF;CNCWCSWGYCWVCCFN; NCWCSWGYCWVCCFNS; CWCSWGYCWVCCFNSN; WCSWGYCWVCCFNSNC;LGSQSFHCRPLSAIRH; GSQSFHCRPLSAIRHG; SQSFHCRPLSAIRHGF; QSFHCRPLSAIRHGFG;SFHCRPLSAIRHGFGI; FHCRPLSAIRHGFGIV; ALGSFFVCYYFPGFVA; LGSFFVCYYFPGFVAC;GSFFVCYYFPGFVACY; YTFYNLTGIAEKNRKI; TFYNLTGIAEKNRKIF; IFGGNYLDNCKCPYKL;FGGNYLDNCKCPYKLL; QYRRSYTKNGLKKSTK; YRRSYTKNGLKKSTKC; RRSYTKNGLKKSTKCT;RSYTKNGLKKSTKCTF; SYTKNGLKKSTKCTFR; YTKNGLKKSTKCTFRR; TKNGLKKSTKCTFRRV;KNGLKKSTKCTFRRVY; NGLKKSTKCTFRRVYR; GLKKSTKCTFRRVYRK; LKKSTKCTFRRVYRKN;KKSTKCTFRRVYRKNY; KSTKCTFRRVYRKNYC; STKCTFRRVYRKNYCP; TKCTFRRVYRKNYCPR;KCTFRRVYRKNYCPRR; CTFRRVYRKNYCPRRC; SKNCSSMDVAFTSRPV; KNCSSMDVAFTSRPVR;NCSSMDVAFTSRPVRD; CSSMDVAFTSRPVRDC; SSMDVAFTSRPVRDCN; SMDVAFTSRPVRDCNT;MDVAFTSRPVRDCNTC; DVAFTSRPVRDCNTCS; RWPQPKEKESVQGQLP; WPQPKEKESVQGQLPK;PQPKEKESVQGQLPKS; QPKEKESVQGQLPKSQ; PKEKESVQGQLPKSQR; KEKESVQGQLPKSQRN;EKESVQGQLPKSQRNP; KESVQGQLPKSQRNPC; ESVQGQLPKSQRNPCK; SVQGQLPKSQRNPCKC;VQGQLPKSQRNPCKCQ; QGQLPKSQRNPCKCQN; GQLPKSQRNPCKCQNY; VLKMTLAVIAQREKCF;LKMTLAVIAQREKCFP; KMTLAVIAQREKCFPV; MTLAVIAQREKCFPVT; TLAVIAQREKCFPVTA;LAVIAQREKCFPVTAQ; AVIAQREKCFPVTAQQ; VIAQREKCFPVTAQQE; IAQREKCFPVTAQQEF;AQREKCFPVTAQQEFP; QREKCFPVTAQQEFPS; REKCFPVTAQQEFPSP; EKCFPVTAQQEFPSPI;LACLTFMQGHKKCMSM; ACLTFMQGHKKCMSMV; CLTFMQGHKKCMSMVE; LTFMQGHKKCMSMVEE;TFMQGHKKCMSMVEEN; FMQGHKKCMSMVEENL; MQGHKKCMSMVEENLF; QGHKKCMSMVEENLFK;GHKKCMSMVEENLFKA; HKKCMSMVEENLFKAV; KKCMSMVEENLFKAVI; KCMSMVEENLFKAVIS;CMSMVEENLFKAVIST; MSMVEENLFKAVISTS; SMVEENLFKAVISTSL; MVEENLFKAVISTSLL;ILTIRPIWTKTMLIQL; LTIRPIWTKTMLIQLS; TIRPIWTKTMLIQLSA; IRPIWTKTMLIQLSAG;RPIWTKTMLIQLSAGY; PIWTKTMLIQLSAGYL; IWTKTMLIQLSAGYLI; WTKTMLIQLSAGYLIP;TKTMLIQLSAGYLIPV; KTMLIQLSAGYLIPVE; TMLIQLSAGYLIPVEM; MLIQLSAGYLIPVEMK;LIQLSAGYLIPVEMKM; IQLSAGYLIPVEMKML; QLSAGYLIPVEMKMLG; LSAGYLIPVEMKMLGI;SAGYLIPVEMKMLGIL; AGYLIPVEMKMLGILG; GYLIPVEMKMLGILGL; YLIPVEMKMLGILGLS;LIPVEMKMLGILGLSQ; IPVEMKMLGILGLSQE; PVEMKMLGILGLSQEG; VEMKMLGILGLSQEGK;EMKMLGILGLSQEGKM; MKMLGILGLSQEGKMF; KMLGILGLSQEGKMFP; MLGILGLSQEGKMFPQ;LGILGLSQEGKMFPQY; GILGLSQEGKMFPQYF; ILGLSQEGKMFPQYFM; MNRVWGLFVKLIACMF;NRVWGLFVKLIACMFQ; RVWGLFVKLIACMFQL; VWGLFVKLIACMFQLL; WGLFVKLIACMFQLLI;GLFVKLIACMFQLLIF; LFVKLIACMFQLLIFV; FVKLIACMFQLLIFVA; VKLIACMFQLLIFVAC;KLIACMFQLLIFVACL; LIACMFQLLIFVACLL; IACMFQLLIFVACLLT; ACMFQLLIFVACLLTA;CMFQLLIFVACLLTAL; MFQLLIFVACLLTALE; FQLLIFVACLLTALEH; QLLIFVACLLTALEHN;LLIFVACLLTALEHNS; LIFVACLLTALEHNSG; IFVACLLTALEHNSGE; FVACLLTALEHNSGEA;VACLLTALEHNSGEAL; ACLLTALEHNSGEALQ; CLLTALEHNSGEALQD; LLTALEHNSGEALQDI;LTALEHNSGEALQDIL; TALEHNSGEALQDILR; ALEHNSGEALQDILRS; LEHNSGEALQDILRSA;TGEPREWMGSLCMVWN; GEPREWMGSLCMVWNP; EPREWMGSLCMVWNPR; KRLGCLMAQKDFQGTQ;RLGCLMAQKDFQGTQI; DILTNRDNCKPKCFKQ; ILTNRDNCKPKCFKQV; LTNRDNCKPKCFKQVL;TNRDNCKPKCFKQVLL; NRDNCKPKCFKQVLLL; RDNCKPKCFKQVLLLY; DNCKPKCFKQVLLLYI;NCKPKCFKQVLLLYIY; CKPKCFKQVLLLYIYI; MLLLYKPLLSLCYFGG; LLLYKPLLSLCYFGGG;LLYKPLLSLCYFGGGV; LYKPLLSLCYFGGGVL; YKPLLSLCYFGGGVLG; KPLLSLCYFGGGVLGL;PLLSLCYFGGGVLGLL; LLSLCYFGGGVLGLLK; LSLCYFGGGVLGLLKH; LWGSDLWESSAGAEVS;WGSDLWESSAGAEVSE; GSDLWESSAGAEVSET; SDLWESSAGAEVSETW; DLWESSAGAEVSETWE;LWESSAGAEVSETWEE; WESSAGAEVSETWEEH; ESSAGAEVSETWEEHC; SSAGAEVSETWEEHCD;SAGAEVSETWEEHCDW; AGAEVSETWEEHCDWD; GAEVSETWEEHCDWDS; AEVSETWEEHCDWDSV;EVSETWEEHCDWDSVL; VSETWEEHCDWDSVLD; SETWEEHCDWDSVLDP; ETWEEHCDWDSVLDPC;TWEEHCDWDSVLDPCP; WEEHCDWDSVLDPCPE; EEHCDWDSVLDPCPES; EHCDWDSVLDPCPESS;HCDWDSVLDPCPESSV; CDWDSVLDPCPESSVS; DWDSVLDPCPESSVSE; WDSVLDPCPESSVSES;DSVLDPCPESSVSESS; SVLDPCPESSVSESSS; VLDPCPESSVSESSSL; LDPCPESSVSESSSLV;DPCPESSVSESSSLVI; PCPESSVSESSSLVIS; CPESSVSESSSLVISR; PESSVSESSSLVISRI;ESSVSESSSLVISRIH; SSVSESSSLVISRIHF; SVSESSSLVISRIHFP; VSESSSLVISRIHFPM;SESSSLVISRIHFPMH; ESSSLVISRIHFPMHI; SSSLVISRIHFPMHIL; SSLVISRIHFPMHILY;SLVISRIHFPMHILYF; LVISRIHFPMHILYFI; VISRIHFPMHILYFIL; ISRIHFPMHILYFILE;SRIHFPMHILYFILEK; RIHFPMHILYFILEKV; IHFPMHILYFILEKVY; HFPMHILYFILEKVYI;FPMHILYFILEKVYIL; PMHILYFILEKVYILI; MHILYFILEKVYILIS; HILYFILEKVYILISE;ILYFILEKVYILISES; LYFILEKVYILISESS; YFILEKVYILISESSL; FILEKVYILISESSLS;ILEKVYILISESSLSF; LEKVYILISESSLSFH; EKVYILISESSLSFHS; KVYILISESSLSFHST;VYILISESSLSFHSTI; YILISESSLSFHSTIL; ILISESSLSFHSTILD; LISESSLSFHSTILDC;ISESSLSFHSTILDCI; SESSLSFHSTILDCIS; ESSLSFHSTILDCISV; SSLSFHSTILDCISVA;SLSFHSTILDCISVAK; LSFHSTILDCISVAKS; SFHSTILDCISVAKSA; FHSTILDCISVAKSAT;HSTILDCISVAKSATG; STILDCISVAKSATGL; TILDCISVAKSATGLN; ILDCISVAKSATGLNQ;LDCISVAKSATGLNQI; DCISVAKSATGLNQIS; CISVAKSATGLNQISS; ISVAKSATGLNQISSS;SVAKSATGLNQISSSN; VAKSATGLNQISSSNK; AKSATGLNQISSSNKV; KSATGLNQISSSNKVI;SATGLNQISSSNKVIP; ATGLNQISSSNKVIPL; TGLNQISSSNKVIPLC; GLNQISSSNKVIPLCK;LNQISSSNKVIPLCKI; NQISSSNKVIPLCKIL; QISSSNKVIPLCKILF; ISSSNKVIPLCKILFS;SSSNKVIPLCKILFSS; SSNKVIPLCKILFSSK; SNKVIPLCKILFSSKN; NKVIPLCKILFSSKNS;KVIPLCKILFSSKNSE; VIPLCKILFSSKNSEF; IPLCKILFSSKNSEFC; PLCKILFSSKNSEFCK;LCKILFSSKNSEFCKD; CKILFSSKNSEFCKDF; KILFSSKNSEFCKDFL; ILFSSKNSEFCKDFLK;LFSSKNSEFCKDFLKY; FSSKNSEFCKDFLKYI; SSKNSEFCKDFLKYIL; SKNSEFCKDFLKYILG;KNSEFCKDFLKYILGL; NSEFCKDFLKYILGLK; SEFCKDFLKYILGLKS; EFCKDFLKYILGLKSI;FCKDFLKYILGLKSIC; CKDFLKYILGLKSICL; KDFLKYILGLKSICLT; DFLKYILGLKSICLTN;FLKYILGLKSICLTNL; LKYILGLKSICLTNLA; KYILGLKSICLTNLAC; YILGLKSICLTNLACR;ILGLKSICLTNLACRV; LGLKSICLTNLACRVL; GLKSICLTNLACRVLG; LKSICLTNLACRVLGT;KSICLTNLACRVLGTG; SICLTNLACRVLGTGY; ICLTNLACRVLGTGYS; CLTNLACRVLGTGYSF;LTNLACRVLGTGYSFI; TNLACRVLGTGYSFIV; NLACRVLGTGYSFIVT; LACRVLGTGYSFIVTK;ACRVLGTGYSFIVTKP; CRVLGTGYSFIVTKPG; RVLGTGYSFIVTKPGG; VLGTGYSFIVTKPGGN;LGTGYSFIVTKPGGNI; GTGYSFIVTKPGGNIW; TGYSFIVTKPGGNIWV; GYSFIVTKPGGNIWVL;YSFIVTKPGGNIWVLL; SFIVTKPGGNIWVLLF; FIVTKPGGNIWVLLFK; IVTKPGGNIWVLLFKC;VTKPGGNIWVLLFKCF; TKPGGNIWVLLFKCFF; KPGGNIWVLLFKCFFS; PGGNIWVLLFKCFFSK;GGNIWVLLFKCFFSKF; GNIWVLLFKCFFSKFT; NIWVLLFKCFFSKFTL; IWVLLFKCFFSKFTLT;WVLLFKCFFSKFTLTL; VLLFKCFFSKFTLTLP; LLFKCFFSKFTLTLPS; LFKCFFSKFTLTLPSK;SLKLSKLFIPCPEGKS; LKLSKLFIPCPEGKSF; KLSKLFIPCPEGKSFD; LSKLFIPCPEGKSFDS;SKLFIPCPEGKSFDSA; KLFIPCPEGKSFDSAP; LFIPCPEGKSFDSAPV; FIPCPEGKSFDSAPVP;IPCPEGKSFDSAPVPF; PCPEGKSFDSAPVPFT; CPEGKSFDSAPVPFTS; PEGKSFDSAPVPFTSS;EGKSFDSAPVPFTSSK; GKSFDSAPVPFTSSKT; KSFDSAPVPFTSSKTT; SFDSAPVPFTSSKTTM;FDSAPVPFTSSKTTMY; SIATPSSKVSLSMGRF; IATPSSKVSLSMGRFT; ATPSSKVSLSMGRFTF;TPSSKVSLSMGRFTFK; PSSKVSLSMGRFTFKA; SSKVSLSMGRFTFKAL; SKVSLSMGRFTFKALP;KVSLSMGRFTFKALPP; VSLSMGRFTFKALPPH; SLSMGRFTFKALPPHK; LSMGRFTFKALPPHKS;SMGRFTFKALPPHKSN; MGRFTFKALPPHKSNN; GRFTFKALPPHKSNNP; RFTFKALPPHKSNNPA;FTFKALPPHKSNNPAA; TFKALPPHKSNNPAAS; FKALPPHKSNNPAASV; KALPPHKSNNPAASVV;ALPPHKSNNPAASVVF; LPPHKSNNPAASVVFP; PPHKSNNPAASVVFPL; PHKSNNPAASVVFPLS;HKSNNPAASVVFPLSM; KSNNPAASVVFPLSMG; SNNPAASVVFPLSMGP; NNPAASVVFPLSMGPL;NPAASVVFPLSMGPLN; PAASVVFPLSMGPLNN; AASVVFPLSMGPLNNQ; ASVVFPLSMGPLNNQY;SVVFPLSMGPLNNQYL; VVFPLSMGPLNNQYLL; VFPLSMGPLNNQYLLL; FPLSMGPLNNQYLLLG;PLSMGPLNNQYLLLGT; LSMGPLNNQYLLLGTL; SMGPLNNQYLLLGTLK; MGPLNNQYLLLGTLKT;GPLNNQYLLLGTLKTI; PLNNQYLLLGTLKTIQ; LNNQYLLLGTLKTIQC; NNQYLLLGTLKTIQCK;NQYLLLGTLKTIQCKK; QYLLLGTLKTIQCKKS; YLLLGTLKTIQCKKSN; LLLGTLKTIQCKKSNI;LLGTLKTIQCKKSNIT; LGTLKTIQCKKSNITE; GTLKTIQCKKSNITES; TLKTIQCKKSNITESI;LKTIQCKKSNITESIL; KTIQCKKSNITESILG; TIQCKKSNITESILGS; IQCKKSNITESILGSK;QCKKSNITESILGSKQ; CKKSNITESILGSKQC; KKSNITESILGSKQCS; KSNITESILGSKQCSQ;SNITESILGSKQCSQA; NITESILGSKQCSQAT; ITESILGSKQCSQATP; TESILGSKQCSQATPA;ESILGSKQCSQATPAI; SILGSKQCSQATPAIY; ILGSKQCSQATPAIYC; LGSKQCSQATPAIYCS;GSKQCSQATPAIYCSS; SKQCSQATPAIYCSST; KQCSQATPAIYCSSTA; QCSQATPAIYCSSTAF;CSQATPAIYCSSTAFP; NSKYIPNNKNTSSHFV; SKYIPNNKNTSSHFVS; KYIPNNKNTSSHFVST;YIPNNKNTSSHFVSTA; IPNNKNTSSHFVSTAY; PNNKNTSSHFVSTAYS; NNKNTSSHFVSTAYSV;NKNTSSHFVSTAYSVI; KNTSSHFVSTAYSVIN; NTSSHFVSTAYSVINF; TSSHFVSTAYSVINFQ;SSHFVSTAYSVINFQD; SHFVSTAYSVINFQDT; HFVSTAYSVINFQDTC; FVSTAYSVINFQDTCF;VSTAYSVINFQDTCFV; STAYSVINFQDTCFVS; TAYSVINFQDTCFVSS; AYSVINFQDTCFVSSG;YSVINFQDTCFVSSGS; SVINFQDTCFVSSGSS; VINFQDTCFVSSGSSG; INFQDTCFVSSGSSGL;NFQDTCFVSSGSSGLK; FQDTCFVSSGSSGLKS; QDTCFVSSGSSGLKSC; DTCFVSSGSSGLKSCS;TCFVSSGSSGLKSCSF; CFVSSGSSGLKSCSFK; FVSSGSSGLKSCSFKP; VSSGSSGLKSCSFKPP;MLSSIVWYGSLVKALY; LSSIVWYGSLVKALYS; SSIVWYGSLVKALYSK; SIVWYGSLVKALYSKY;IVWYGSLVKALYSKYS; VWYGSLVKALYSKYSL; WYGSLVKALYSKYSLL; YGSLVKALYSKYSLLT;GSLVKALYSKYSLLTP; SLVKALYSKYSLLTPL; LVKALYSKYSLLTPLQ; VKALYSKYSLLTPLQI;KALYSKYSLLTPLQIK; ALYSKYSLLTPLQIKK; LYSKYSLLTPLQIKKL; YSKYSLLTPLQIKKLK;SKYSLLTPLQIKKLKV; KYSLLTPLQIKKLKVH; YSLLTPLQIKKLKVHS; SLLTPLQIKKLKVHSF;QKLLIAETLCLCGVKK; KLLIAETLCLCGVKKN; LLIAETLCLCGVKKNI; LIAETLCLCGVKKNII;IAETLCLCGVKKNIIL; AETLCLCGVKKNIILC; ETLCLCGVKKNIILCP; TLCLCGVKKNIILCPA;LCLCGVKKNIILCPAH; CLCGVKKNIILCPAHM; LCGVKKNIILCPAHMC; CGVKKNIILCPAHMCL;GVKKNIILCPAHMCLL; VKKNIILCPAHMCLLI; KKNIILCPAHMCLLIK; KNIILCPAHMCLLIKV;NIILCPAHMCLLIKVT; IILCPAHMCLLIKVTE; ILCPAHMCLLIKVTEY; LCPAHMCLLIKVTEYF;CPAHMCLLIKVTEYFS; PAHMCLLIKVTEYFSI; AHMCLLIKVTEYFSIS; HMCLLIKVTEYFSISF;MCLLIKVTEYFSISFL; CLLIKVTEYFSISFLY; LLIKVTEYFSISFLYR; LIKVTEYFSISFLYRI;AFSLVVYTAKQARVLL; FSLVVYTAKQARVLLL; SLVVYTAKQARVLLLN; LVVYTAKQARVLLLNT;VVYTAKQARVLLLNTA; LRNWCRSEGKSLGSST; RNWCRSEGKSLGSSTF; NWCRSEGKSLGSSTFL;WCRSEGKSLGSSTFLF; CRSEGKSLGSSTFLFF; RSEGKSLGSSTFLFFL; SEGKSLGSSTFLFFLG;EGKSLGSSTFLFFLGG; GKSLGSSTFLFFLGGV; KSLGSSTFLFFLGGVE; SLGSSTFLFFLGGVEC;ESAVASSSLANISSWQ; SAVASSSLANISSWQN; AVASSSLANISSWQNK; VASSSLANISSWQNKS;ASSSLANISSWQNKSS; SSSLANISSWQNKSSS; SSLANISSWQNKSSSH; SLANISSWQNKSSSHF;LANISSWQNKSSSHFS; ANISSWQNKSSSHFSL; NISSWQNKSSSHFSLK; ISSWQNKSSSHFSLKE;SSWQNKSSSHFSLKEL; SWQNKSSSHFSLKELH; WQNKSSSHFSLKELHQ; QNKSSSHFSLKELHQD;NKSSSHFSLKELHQDS; KSSSHFSLKELHQDSH; SSSHFSLKELHQDSHS; SSHFSLKELHQDSHSS;SHFSLKELHQDSHSSV; HFSLKELHQDSHSSVP; VGTYKKNNYLGPFNIL; GTYKKNNYLGPFNILL;TYKKNNYLGPFNILLF; YKKNNYLGPFNILLFI; REFLQLFGPTIAEFLQ; EFLQLFGPTIAEFLQL;FLQLFGPTIAEFLQLG; LQLFGPTIAEFLQLGL; QLFGPTIAEFLQLGLS; LFGPTIAEFLQLGLSQ;FGPTIAEFLQLGLSQT; GPTIAEFLQLGLSQTT; PTIAEFLQLGLSQTTV; SSQCSSNLSKPRALFL;SQCSSNLSKPRALFLK; QCSSNLSKPRALFLKI; CSSNLSKPRALFLKIF; SSNLSKPRALFLKIFY;SNLSKPRALFLKIFYL; NLSKPRALFLKIFYLN; LSKPRALFLKIFYLNA; SKPRALFLKIFYLNAL;KPRALFLKIFYLNALI; ADIACKGSAQKAFWNK; AIPCSTGYLGKEENQH; IPCSTGYLGKEENQHK;PCSTGYLGKEENQHKP; CSTGYLGKEENQHKPL; STGYLGKEENQHKPLS; TGYLGKEENQHKPLSY;GYLGKEENQHKPLSYS; YLGKEENQHKPLSYSR; LGKEENQHKPLSYSRF; GKEENQHKPLSYSRFQ;KEENQHKPLSYSRFQN; EENQHKPLSYSRFQNQ; ENQHKPLSYSRFQNQA; NQHKPLSYSRFQNQAD;QHKPLSYSRFQNQADE; HKPLSYSRFQNQADEL; KPLSYSRFQNQADELP; PLSYSRFQNQADELPL;LSYSRFQNQADELPLH; SYSRFQNQADELPLHP; YSRFQNQADELPLHPA; SRFQNQADELPLHPAP;RFQNQADELPLHPAPF; FQNQADELPLHPAPFF; QNQADELPLHPAPFFY; NQADELPLHPAPFFYT;QADELPLHPAPFFYTK; ADELPLHPAPFFYTKY; DELPLHPAPFFYTKYS; ELPLHPAPFFYTKYSF;LPLHPAPFFYTKYSFS; PLHPAPFFYTKYSFSS; LHPAPFFYTKYSFSSF; HPAPFFYTKYSFSSFY;PAPFFYTKYSFSSFYP; APFFYTKYSFSSFYPR; PFFYTKYSFSSFYPRR; FFYTKYSFSSFYPRRP;FYTKYSFSSFYPRRPL; YTKYSFSSFYPRRPLC; TKYSFSSFYPRRPLCQ; KYSFSSFYPRRPLCQG;YSFSSFYPRRPLCQGE; SFSSFYPRRPLCQGEI; FSSFYPRRPLCQGEIP; SSFYPRRPLCQGEIPY;SFYPRRPLCQGEIPYT; FYPRRPLCQGEIPYTS; YPRRPLCQGEIPYTSL; PRRPLCQGEIPYTSLN;RRPLCQGEIPYTSLNK; RPLCQGEIPYTSLNKL; PLCQGEIPYTSLNKLF; LCQGEIPYTSLNKLFS;CQGEIPYTSLNKLFSL; QGEIPYTSLNKLFSLR; GEIPYTSLNKLFSLRE; EIPYTSLNKLFSLRED;IPYTSLNKLFSLREDF; PYTSLNKLFSLREDFP; YTSLNKLFSLREDFPR; TSLNKLFSLREDFPRQ;SLNKLFSLREDFPRQL; LNKLFSLREDFPRQLF; NKLFSLREDFPRQLFQ; KLFSLREDFPRQLFQG;LFSLREDFPRQLFQGL; FSLREDFPRQLFQGLK; SLREDFPRQLFQGLKG; LREDFPRQLFQGLKGPBK virus, reading frame 3 13 mers: ASEKASTPLLLER; SEKASTPLLLERK;EKASTPLLLERKG; KASTPLLLERKGG; ASTPLLLERKGGG; STPLLLERKGGGR;TPLLLERKGGGRG; PLLLERKGGGRGG; LLLERKGGGRGGL; LLERKGGGRGGLG;LERKGGGRGGLGL; ERKGGGRGGLGLL; RKGGGRGGLGLLY; KGGGRGGLGLLYI;GGGRGGLGLLYII; GGRGGLGLLYIIK; GRGGLGLLYIIKK; RGGLGLLYIIKKK;GGLGLLYIIKKKA; GLGLLYIIKKKAT; LGLLYIIKKKATG; GLLYIIKKKATGR;LLYIIKKKATGRS; LYIIKKKATGRSC; YIIKKKATGRSCL; IIKKKATGRSCLP;IKKKATGRSCLPM; KKKATGRSCLPME; KKATGRSCLPMEC; KATGRSCLPMECS;ATGRSCLPMECSQ; TGRSCLPMECSQT; GRSCLPMECSQTM; RSCLPMECSQTMT;SCLPMECSQTMTS; CLPMECSQTMTSG; LPMECSQTMTSGR; PMECSQTMTSGRK;MECSQTMTSGRKV; ECSQTMTSGRKVH; CSQTMTSGRKVHD; SQTMTSGRKVHDS;QTMTSGRKVHDSQ; TMTSGRKVHDSQG; MTSGRKVHDSQGN; TSGRKVHDSQGNA;SGRKVHDSQGNAA; GRKVHDSQGNAAK; RKVHDSQGNAAKP; PQEGKCMTHREEL;QEGKCMTHREELL; EGKCMTHREELLT; GKCMTHREELLTH; KCMTHREELLTHG;CMTHREELLTHGM; MTHREELLTHGMQ; THREELLTHGMQP; HREELLTHGMQPN;REELLTHGMQPNH; EELLTHGMQPNHD; ELLTHGMQPNHDL; LLTHGMQPNHDLR;LTHGMQPNHDLRK; THGMQPNHDLRKE; HGMQPNHDLRKES; GMQPNHDLRKESA;QTCFASLGILALS; TCFASLGILALSP; CFASLGILALSPV; FASLGILALSPVK;ASLGILALSPVKL; SLGILALSPVKLD; LGILALSPVKLDK; GILALSPVKLDKG;ILALSPVKLDKGH; LALSPVKLDKGHG; ALSPVKLDKGHGS; LSPVKLDKGHGSA;SPVKLDKGHGSAP; PVKLDKGHGSAPA; VKLDKGHGSAPAV; KLDKGHGSAPAVT;LDKGHGSAPAVTT; DKGHGSAPAVTTS; KGHGSAPAVTTSF; GHGSAPAVTTSFS;HGSAPAVTTSFSE; GSAPAVTTSFSES; SAPAVTTSFSESW; NLDWNKKKSSEDF;LDWNKKKSSEDFY; DWNKKKSSEDFYF; WNKKKSSEDFYFY; NKKKSSEDFYFYF;KKKSSEDFYFYFR; KKSSEDFYFYFRA; KSSEDFYFYFRAF; SSEDFYFYFRAFA;SEDFYFYFRAFAG; EDFYFYFRAFAGI; DFYFYFRAFAGIL; RQCRREKQKYHCF;QCRREKQKYHCFT; CRREKQKYHCFTC; RREKQKYHCFTCC; REKQKYHCFTCCK;EKQKYHCFTCCKR; KQKYHCFTCCKRL; QKYHCFTCCKRLC; KYHCFTCCKRLCK;YHCFTCCKRLCKR; HCFTCCKRLCKRL; CFTCCKRLCKRLL; FTCCKRLCKRLLG;TCCKRLCKRLLGK; SLFFCISRFMGAA; LFFCISRFMGAAL; FFCISRFMGAALA;FCISRFMGAALAL; CISRFMGAALALL; ISRFMGAALALLG; SRFMGAALALLGD;RFMGAALALLGDL; FMGAALALLGDLV; MGAALALLGDLVA; GAALALLGDLVAS;AALALLGDLVASV; ALALLGDLVASVS; LALLGDLVASVSE; ALLGDLVASVSEA;LLGDLVASVSEAA; LGDLVASVSEAAA; GDLVASVSEAAAA; DLVASVSEAAAAT;LVASVSEAAAATG; VASVSEAAAATGF; ASVSEAAAATGFS; SVSEAAAATGFSV;VSEAAAATGFSVA; SEAAAATGFSVAE; EAAAATGFSVAEI; AAAATGFSVAEIA;AAATGFSVAEIAA; AATGFSVAEIAAG; ATGFSVAEIAAGE; TGFSVAEIAAGEA;GFSVAEIAAGEAA; FSVAEIAAGEAAA; SVAEIAAGEAAAA; VAEIAAGEAAAAI;AEIAAGEAAAAIE; EIAAGEAAAAIEV; IAAGEAAAAIEVQ; AAGEAAAAIEVQI;AGEAAAAIEVQIA; GEAAAAIEVQIAS; EAAAAIEVQIASL; AAAAIEVQIASLA;AAAIEVQIASLAT; AAIEVQIASLATV; AIEVQIASLATVE; IEVQIASLATVEG;EVQIASLATVEGI; VQIASLATVEGIT; QIASLATVEGITS; IASLATVEGITST;ASLATVEGITSTS; SLATVEGITSTSE; LATVEGITSTSEA; ATVEGITSTSEAI;TVEGITSTSEAIA; VEGITSTSEAIAA; EGITSTSEAIAAI; GITSTSEAIAAIG;ITSTSEAIAAIGL; TSTSEAIAAIGLT; STSEAIAAIGLTP; TSEAIAAIGLTPQ;SEAIAAIGLTPQT; EAIAAIGLTPQTY; AIAAIGLTPQTYA; IAAIGLTPQTYAV;AAIGLTPQTYAVI; AIGLTPQTYAVIA; IGLTPQTYAVIAG; GLTPQTYAVIAGA;LTPQTYAVIAGAP; TPQTYAVIAGAPG; PQTYAVIAGAPGA; QTYAVIAGAPGAI;TYAVIAGAPGAIA; YAVIAGAPGAIAG; AVIAGAPGAIAGF; VIAGAPGAIAGFA;IAGAPGAIAGFAA; AGAPGAIAGFAAL; GAPGAIAGFAALI; APGAIAGFAALIQ;PGAIAGFAALIQT; GAIAGFAALIQTV; AIAGFAALIQTVS; IAGFAALIQTVSG;AGFAALIQTVSGI; GFAALIQTVSGIS; FAALIQTVSGISS; AALIQTVSGISSL;ALIQTVSGISSLA; LIQTVSGISSLAQ; IQTVSGISSLAQV; QTVSGISSLAQVG;TVSGISSLAQVGY; VSGISSLAQVGYK; SGISSLAQVGYKF; GISSLAQVGYKFF;ISSLAQVGYKFFD; SSLAQVGYKFFDD; SLAQVGYKFFDDW; LAQVGYKFFDDWD;AQVGYKFFDDWDH; QVGYKFFDDWDHK; VGYKFFDDWDHKV; GYKFFDDWDHKVS;YKFFDDWDHKVST; KFFDDWDHKVSTV; FFDDWDHKVSTVG; FDDWDHKVSTVGL;DDWDHKVSTVGLY; DWDHKVSTVGLYQ; WDHKVSTVGLYQQ; DHKVSTVGLYQQS;HKVSTVGLYQQSG; KVSTVGLYQQSGM; VSTVGLYQQSGMA; STVGLYQQSGMAL;TVGLYQQSGMALE; VGLYQQSGMALEL; GLYQQSGMALELF; LYQQSGMALELFN;YQQSGMALELFNP; QQSGMALELFNPD; QSGMALELFNPDE; SGMALELFNPDEY;GMALELFNPDEYY; MALELFNPDEYYD; ALELFNPDEYYDI; LELFNPDEYYDIL;ELFNPDEYYDILF; LFNPDEYYDILFP; FNPDEYYDILFPG; NPDEYYDILFPGV;PDEYYDILFPGVN; DEYYDILFPGVNT; EYYDILFPGVNTF; YYDILFPGVNTFV;YDILFPGVNTFVN; DILFPGVNTFVNN; ILFPGVNTFVNNI; LFPGVNTFVNNIQ;FPGVNTFVNNIQY; PGVNTFVNNIQYL; GVNTFVNNIQYLD; VNTFVNNIQYLDP;NTFVNNIQYLDPR; TFVNNIQYLDPRH; FVNNIQYLDPRHW; VNNIQYLDPRHWG;NNIQYLDPRHWGP; NIQYLDPRHWGPS; IQYLDPRHWGPSL; QYLDPRHWGPSLF;YLDPRHWGPSLFA; LDPRHWGPSLFAT; DPRHWGPSLFATI; PRHWGPSLFATIS;RHWGPSLFATISQ; HWGPSLFATISQA; WGPSLFATISQAL; GPSLFATISQALW;PSLFATISQALWH; SLFATISQALWHV; LFATISQALWHVI; FATISQALWHVIR;ATISQALWHVIRD; TISQALWHVIRDD; ISQALWHVIRDDI; SQALWHVIRDDIP;QALWHVIRDDIPS; ALWHVIRDDIPSI; LWHVIRDDIPSIT; WHVIRDDIPSITS;HVIRDDIPSITSQ; VIRDDIPSITSQE; IRDDIPSITSQEL; RDDIPSITSQELQ;DDIPSITSQELQR; DIPSITSQELQRR; IPSITSQELQRRT; PSITSQELQRRTE;SITSQELQRRTER; ITSQELQRRTERF; TSQELQRRTERFF; SQELQRRTERFFR;QELQRRTERFFRD; ELQRRTERFFRDS; LQRRTERFFRDSL; QRRTERFFRDSLA;RRTERFFRDSLAR; RTERFFRDSLARF; TERFFRDSLARFL; ERFFRDSLARFLE;RFFRDSLARFLEE; FFRDSLARFLEET; FRDSLARFLEETT; RDSLARFLEETTW;DSLARFLEETTWT; SLARFLEETTWTI; LARFLEETTWTIV; ARFLEETTWTIVN;RFLEETTWTIVNA; FLEETTWTIVNAP; LEETTWTIVNAPI; EETTWTIVNAPIN;ETTWTIVNAPINF; TTWTIVNAPINFY; TWTIVNAPINFYN; WTIVNAPINFYNY;TIVNAPINFYNYI; IVNAPINFYNYIQ; VNAPINFYNYIQQ; NAPINFYNYIQQY;APINFYNYIQQYY; PINFYNYIQQYYS; INFYNYIQQYYSD; NFYNYIQQYYSDL;FYNYIQQYYSDLS; YNYIQQYYSDLSP; NYIQQYYSDLSPI; YIQQYYSDLSPIR;IQQYYSDLSPIRP; QQYYSDLSPIRPS; QYYSDLSPIRPSM; YYSDLSPIRPSMV;YSDLSPIRPSMVR; SDLSPIRPSMVRQ; DLSPIRPSMVRQV; LSPIRPSMVRQVA;SPIRPSMVRQVAE; PIRPSMVRQVAER; IRPSMVRQVAERE; RPSMVRQVAEREG;PSMVRQVAEREGT; SMVRQVAEREGTR; MVRQVAEREGTRV; VRQVAEREGTRVH;RQVAEREGTRVHF; QVAEREGTRVHFG; VAEREGTRVHFGH; AEREGTRVHFGHT;EREGTRVHFGHTY; REGTRVHFGHTYS; EGTRVHFGHTYSI; GTRVHFGHTYSID;TRVHFGHTYSIDD; RVHFGHTYSIDDA; VHFGHTYSIDDAD; HFGHTYSIDDADS;FGHTYSIDDADSI; GHTYSIDDADSIE; HTYSIDDADSIEE; TYSIDDADSIEEV;YSIDDADSIEEVT; SIDDADSIEEVTQ; IDDADSIEEVTQR; DDADSIEEVTQRM;DADSIEEVTQRMD; ADSIEEVTQRMDL; DSIEEVTQRMDLR; SIEEVTQRMDLRN;IEEVTQRMDLRNQ; EEVTQRMDLRNQQ; EVTQRMDLRNQQS; VTQRMDLRNQQSV;TQRMDLRNQQSVH; QRMDLRNQQSVHS; RMDLRNQQSVHSG; MDLRNQQSVHSGE;DLRNQQSVHSGEF; LRNQQSVHSGEFI; RNQQSVHSGEFIE; NQQSVHSGEFIEK;QQSVHSGEFIEKT; QSVHSGEFIEKTI; SVHSGEFIEKTIA; VHSGEFIEKTIAP;HSGEFIEKTIAPG; SGEFIEKTIAPGG; GEFIEKTIAPGGA; EFIEKTIAPGGAN;FIEKTIAPGGANQ; IEKTIAPGGANQR; EKTIAPGGANQRT; KTIAPGGANQRTA;TIAPGGANQRTAP; IAPGGANQRTAPQ; APGGANQRTAPQW; PGGANQRTAPQWM;GGANQRTAPQWML; GANQRTAPQWMLP; ANQRTAPQWMLPL; NQRTAPQWMLPLL;QRTAPQWMLPLLL; RTAPQWMLPLLLG; TAPQWMLPLLLGL; APQWMLPLLLGLY;PQWMLPLLLGLYG; QWMLPLLLGLYGT; WMLPLLLGLYGTV; MLPLLLGLYGTVT;LPLLLGLYGTVTP; PLLLGLYGTVTPA; LLLGLYGTVTPAL; LLGLYGTVTPALE;LGLYGTVTPALEA; GLYGTVTPALEAY; LYGTVTPALEAYE; YGTVTPALEAYED;GTVTPALEAYEDG; TVTPALEAYEDGP; VTPALEAYEDGPN; TPALEAYEDGPNQ;PALEAYEDGPNQK; ALEAYEDGPNQKK; LEAYEDGPNQKKR; EAYEDGPNQKKRR;AYEDGPNQKKRRV; YEDGPNQKKRRVS; EDGPNQKKRRVSR; DGPNQKKRRVSRG;GPNQKKRRVSRGS; PNQKKRRVSRGSS; NQKKRRVSRGSSQ; QKKRRVSRGSSQK;KKRRVSRGSSQKA; KRRVSRGSSQKAK; RRVSRGSSQKAKG; RVSRGSSQKAKGT;VSRGSSQKAKGTR; SRGSSQKAKGTRA; RGSSQKAKGTRAS; GSSQKAKGTRASA;SSQKAKGTRASAK; SQKAKGTRASAKT; QKAKGTRASAKTT; KAKGTRASAKTTN;AKGTRASAKTTNK; KGTRASAKTTNKR; GTRASAKTTNKRR; TRASAKTTNKRRS;RASAKTTNKRRSR; ASAKTTNKRRSRS; SAKTTNKRRSRSS; AKTTNKRRSRSSR;KTTNKRRSRSSRS; NWGRCYYRGRMLP; WGRCYYRGRMLPK; GRCYYRGRMLPKP;RCYYRGRMLPKPR; CYYRGRMLPKPRN; YYRGRMLPKPRNG; YRGRMLPKPRNGG;RGRMLPKPRNGGS; GRMLPKPRNGGSR; PREKNASLLQHSK; REKNASLLQHSKN;EKNASLLQHSKNS; KNASLLQHSKNSP; NASLLQHSKNSPP; ASLLQHSKNSPPQ;SLLQHSKNSPPQF; LLQHSKNSPPQFK; GPNLWKSTDVGGC; PNLWKSTDVGGCN;NLWKSTDVGGCNC; LWKSTDVGGCNCT; WKSTDVGGCNCTN; KSTDVGGCNCTNR;STDVGGCNCTNRG; TDVGGCNCTNRGY; DVGGCNCTNRGYW; VGGCNCTNRGYWN;GGCNCTNRGYWNN; FPLLCCRWRTLGN; PLLCCRWRTLGNA; LLCCRWRTLGNAG;LCCRWRTLGNAGS; CCRWRTLGNAGSA; CRWRTLGNAGSAN; RWRTLGNAGSANE;WRTLGNAGSANEL; RTLGNAGSANELQ; TLGNAGSANELQV; LGNAGSANELQVK;GNAGSANELQVKV; NAGSANELQVKVP; VFWDFHRRGKCSP; FWDFHRRGKCSPS;WDFHRRGKCSPST; DFHRRGKCSPSTS; FHRRGKCSPSTSC; HRRGKCSPSTSCD;RRGKCSPSTSCDQ; RGKCSPSTSCDQH; GKCSPSTSCDQHS; KCSPSTSCDQHSY;CSPSTSCDQHSYH; SPSTSCDQHSYHS; PSTSCDQHSYHSV; STSCDQHSYHSVA;TSCDQHSYHSVAR; QLWNTTVERPCKI; LWNTTVERPCKIF; DPPEKKICKESLP;PPEKKICKESLPN; PEKKICKESLPNF; EKKICKESLPNFL; KKICKESLPNFLF;KICKESLPNFLFA; ICKESLPNFLFAK; PYKQENPESGWAA; YKQENPESGWAAY;KQENPESGWAAYV; QENPESGWAAYVW; ENPESGWAAYVWY; NPESGWAAYVWYG;PESGWAAYVWYGI; ESGWAAYVWYGIP; SGWAAYVWYGIPG; GWAAYVWYGIPGR;WAAYVWYGIPGRR; AAYVWYGIPGRRG; WHRKTSRGPRYDK; HRKTSRGPRYDKI;RKTSRGPRYDKIY; QTGTIANQNALNR; TGTIANQNALNRC; GTIANQNALNRCF;TIANQNALNRCFY; IANQNALNRCFYC; ANQNALNRCFYCT; NQNALNRCFYCTY;QNALNRCFYCTYT; NALNRCFYCTYTF; ALNRCFYCTYTFN; LNRCFYCTYTFNK;NRCFYCTYTFNKC; RCFYCTYTFNKCC; CFYCTYTFNKCCF; FYCTYTFNKCCFC;YCTYTFNKCCFCI; CTYTFNKCCFCIS; TYTFNKCCFCISH; YTFNKCCFCISHF;NTESLYTNATLDY; TESLYTNATLDYG; ESLYTNATLDYGG; SLYTNATLDYGGL;LYTNATLDYGGLT; YTNATLDYGGLTF; TNATLDYGGLTFG; NATLDYGGLTFGN;ATLDYGGLTFGNL; TLDYGGLTFGNLQ; LDYGGLTFGNLQQ; DYGGLTFGNLQQG;YGGLTFGNLQQGL; GGLTFGNLQQGLK; GLTFGNLQQGLKY; LTFGNLQQGLKYL;TFGNLQQGLKYLR; FGNLQQGLKYLRL; GNLQQGLKYLRLG; NLQQGLKYLRLGK;LQQGLKYLRLGKS; QQGLKYLRLGKSI; QGLKYLRLGKSIV; GLKYLRLGKSIVI;LKYLRLGKSIVIG; KYLRLGKSIVIGI; YLRLGKSIVIGIQ; LRLGKSIVIGIQC;RLGKSIVIGIQCL; LGKSIVIGIQCLI; GKSIVIGIQCLIH; KSIVIGIQCLIHV;SIVIGIQCLIHVQ; IVIGIQCLIHVQS; VIGIQCLIHVQSL; IGIQCLIHVQSLQ;GIQCLIHVQSLQF; IQCLIHVQSLQFL; QCLIHVQSLQFLN; CLIHVQSLQFLNP;LIHVQSLQFLNPL; IHVQSLQFLNPLL; HVQSLQFLNPLLL; YQEYISPCIYYIS;QEYISPCIYYISS; EYISPCIYYISSL; YISPCIYYISSLK; ISPCIYYISSLKK;SPCIYYISSLKKY; PCIYYISSLKKYT; CIYYISSLKKYTY; IYYISSLKKYTYL;YYISSLKKYTYLS; YISSLKKYTYLSQ; ISSLKKYTYLSQN; SSLKKYTYLSQNP;SLKKYTYLSQNPA; LKKYTYLSQNPAF; KKYTYLSQNPAFP; KYTYLSQNPAFPS;YTYLSQNPAFPSI; TYLSQNPAFPSIQ; YLSQNPAFPSIQQ; LSQNPAFPSIQQF;TKLAVATRSFHFV; KLAVATRSFHFVK; LAVATRSFHFVKF; AVATRSFHFVKFF;VATRSFHFVKFFF; ATRSFHFVKFFFQ; TRSFHFVKFFFQV; RSFHFVKFFFQVR;SFHFVKFFFQVRT; FHFVKFFFQVRTL; HFVKFFFQVRTLS; FVKFFFQVRTLSF;VKFFFQVRTLSFV; KFFFQVRTLSFVR; FFFQVRTLSFVRI; FFQVRTLSFVRIF;FQVRTLSFVRIFL; QVRTLSFVRIFLN; VRTLSFVRIFLNI; RTLSFVRIFLNIF;TLSFVRIFLNIFW; LSFVRIFLNIFWA; PSLVEIFGFFCLN; SLVEIFGFFCLNV;LVEIFGFFCLNVS; VEIFGFFCLNVSF; EIFGFFCLNVSFL; IFGFFCLNVSFLN;FGFFCLNVSFLNL; GFFCLNVSFLNLP; HFHLNNLSNCLNC; FHLNNLSNCLNCL;HLNNLSNCLNCLF; LNNLSNCLNCLFH; NNLSNCLNCLFHV; NLSNCLNCLFHVL;LSNCLNCLFHVLK; SNCLNCLFHVLKA; NCLNCLFHVLKAN; CLNCLFHVLKANP;LNCLFHVLKANPL; NCLFHVLKANPLI; CLFHVLKANPLIQ; LFHVLKANPLIQL;FHVLKANPLIQLL; HVLKANPLIQLLS; VLKANPLIQLLSL; LKANPLIQLLSLL;KANPLIQLLSLLH; ANPLIQLLSLLHL; NPLIQLLSLLHLQ; PLIQLLSLLHLQK;LIQLLSLLHLQKQ; IQLLSLLHLQKQP; QLLSLLHLQKQPC; LLSLLHLQKQPCT;LSLLHLQKQPCTD; SLLHLQKQPCTDL; LHLAQRLAFPWVG; HLAQRLAFPWVGL;LAQRLAFPWVGLH; AQRLAFPWVGLHL; QRLAFPWVGLHLR; RLAFPWVGLHLRL;LAFPWVGLHLRLY; AFPWVGLHLRLYH; FPWVGLHLRLYHH; PWVGLHLRLYHHT;WVGLHLRLYHHTN; VGLHLRLYHHTNL; GLHLRLYHHTNLI; LHLRLYHHTNLIT;HLRLYHHTNLITL; LRLYHHTNLITLQ; RLYHHTNLITLQL; LYHHTNLITLQLV;YHHTNLITLQLVL; HHTNLITLQLVLF; HTNLITLQLVLFF; TNLITLQLVLFFH;NLITLQLVLFFHY; LITLQLVLFFHYQ; ITLQLVLFFHYQW; TLQLVLFFHYQWD;LQLVLFFHYQWDL; KQYSAKNQILQNP; QYSAKNQILQNPF; VANSAAKQHLPYI;ANSAAKQHLPYIV; NSAAKQHLPYIVL; SAAKQHLPYIVLV; AAKQHLPYIVLVQ;AKQHLPYIVLVQH; KQHLPYIVLVQHF; QHLPYIVLVQHFH; HLPYIVLVQHFHE;LPYIVLVQHFHEL; PYIVLVQHFHELQ; YIVLVQHFHELQI; IVLVQHFHELQIL;VLVQHFHELQILN; LVQHFHELQILNP; VQHFHELQILNPF; QHFHELQILNPFY;HFHELQILNPFYL; FHELQILNPFYLI; HELQILNPFYLIY; ELQILNPFYLIYD;IFLLAFLPWSYEG; FLLAFLPWSYEGY; LLAFLPWSYEGYL; LAFLPWSYEGYLL;AFLPWSYEGYLLF; FLPWSYEGYLLFF; LKLYLLLADKYFF; KLYLLLADKYFFD;LYLLLADKYFFDF; YLLLADKYFFDFY; LLLADKYFFDFYF; LLADKYFFDFYFL;LADKYFFDFYFLQ; ADKYFFDFYFLQK; SDKAGLFSDTFYT; DKAGLFSDTFYTP;KAGLFSDTFYTPL; AGLFSDTFYTPLH; GLFSDTFYTPLHC; LFSDTFYTPLHCI;FSDTFYTPLHCIE; SDTFYTPLHCIEI; DTFYTPLHCIEIL; TFYTPLHCIEILN;FYTPLHCIEILNT; YTPLHCIEILNTY; TPLHCIEILNTYL; PLHCIEILNTYLI;LHCIEILNTYLII; HCIEILNTYLIIK; CIEILNTYLIIKT; IEILNTYLIIKTH;EILNTYLIIKTHP; ILNTYLIIKTHPH; LNTYLIIKTHPHT; NTYLIIKTHPHTL;TYLIIKTHPHTLS; YLIIKTHPHTLSL; LIIKTHPHTLSLL; IIKTHPHTLSLLH;IKTHPHTLSLLHT; KTHPHTLSLLHTQ; LISKTPALFLQAL; ISKTPALFLQALL;SKTPALFLQALLG; NHAPLSPLECFLL; LQKLYVYVELKRI; GLLPFFFFWVVLS;LLPFFFFWVVLSV; LPFFFFWVVLSVE; PFFFFWVVLSVEN; FFFFWVVLSVENL;FFFWVVLSVENLL; FFWVVLSVENLLL; FWVVLSVENLLLL; WVVLSVENLLLLL;VVLSVENLLLLLH; VLSVENLLLLLHH; LSVENLLLLLHHW; SVENLLLLLHHWQ;VENLLLLLHHWQT; ENLLLLLHHWQTY; NLLLLLHHWQTYL; LLLLLHHWQTYLH;LLLLHHWQTYLHG; LLLHHWQTYLHGK; LLHHWQTYLHGKI; LHHWQTYLHGKIN;HHWQTYLHGKINL; HWQTYLHGKINLH; WQTYLHGKINLHP; QTYLHGKINLHPI;TYLHGKINLHPIF; YLHGKINLHPIFH; RNSTRTPTLLFHR; NSTRTPTLLFHRL;STRTPTLLFHRLA; TRTPTLLFHRLAP; RTPTLLFHRLAPI; TPTLLFHRLAPIK;PTLLFHRLAPIKK; TLLFHRLAPIKKI; LLFHRLAPIKKII; LFHRLAPIKKIIT;GLLIFYYLSKYKL; LLIFYYLSKYKLV; LIFYYLSKYKLVT; IFYYLSKYKLVTL;FYYLSKYKLVTLK; YYLSKYKLVTLKL; ISEGSFSNYLDPP; SEGSFSNYLDPPL;EGSFSNYLDPPLQ; GSFSNYLDPPLQS; SFSNYLDPPLQSF; FSNYLDPPLQSFF;SNYLDPPLQSFFS; AKPLCEAVNAVAI; KPLCEAVNAVAIY; PLCEAVNAVAIYP;LCEAVNAVAIYPN; CEAVNAVAIYPNQ; EAVNAVAIYPNQG; AVNAVAIYPNQGL;VNAVAIYPNQGLF; NAVAIYPNQGLFS; HARAVHRRLFGTN; ARAVHRRLFGTNR;RAVHRRLFGTNRP; AVHRRLFGTNRPF; VHRRLFGTNRPFL; HRRLFGTNRPFLA;RRLFGTNRPFLAV; RLFGTNRPFLAVQ; LFGTNRPFLAVQG; FGTNRPFLAVQGI;GTNRPFLAVQGIW; TNRPFLAVQGIWA; NRPFLAVQGIWAK; RPFLAVQGIWAKR;PFLAVQGIWAKRK; FLAVQGIWAKRKI; LAVQGIWAKRKIS; AVQGIWAKRKIST;VQGIWAKRKISTN; QGIWAKRKISTNL; ATPGSKIRLMSYL; TPGSKIRLMSYLY;PGSKIRLMSYLYI; GSKIRLMSYLYIL; SKIRLMSYLYILL; KIRLMSYLYILLH;IRLMSYLYILLHF; RLMSYLYILLHFF; LMSYLYILLHFFI; MSYLYILLHFFIQ;SYLYILLHFFIQS; YLYILLHFFIQSI; LYILLHFFIQSIH; YILLHFFIQSIHS;ILLHFFIQSIHSL; LLHFFIQSIHSLH; LHFFIQSIHSLHF; HFFIQSIHSLHFI;FFIQSIHSLHFIL; FIQSIHSLHFILV; IQSIHSLHFILVA; QSIHSLHFILVAP;SIHSLHFILVAPF; IHSLHFILVAPFV; HSLHFILVAPFVR; SLHFILVAPFVRV;LHFILVAPFVRVK; HFILVAPFVRVKF; FILVAPFVRVKFL; ILVAPFVRVKFLT 14 mers:ASEKASTPLLLERK; SEKASTPLLLERKG; EKASTPLLLERKGG; KASTPLLLERKGGG;ASTPLLLERKGGGR; STPLLLERKGGGRG; TPLLLERKGGGRGG; PLLLERKGGGRGGL;LLLERKGGGRGGLG; LLERKGGGRGGLGL; LERKGGGRGGLGLL; ERKGGGRGGLGLLY;RKGGGRGGLGLLYI; KGGGRGGLGLLYII; GGGRGGLGLLYIIK; GGRGGLGLLYIIKK;GRGGLGLLYIIKKK; RGGLGLLYIIKKKA; GGLGLLYIIKKKAT; GLGLLYIIKKKATG;LGLLYIIKKKATGR; GLLYIIKKKATGRS; LLYIIKKKATGRSC; LYIIKKKATGRSCL;YIIKKKATGRSCLP; IIKKKATGRSCLPM; IKKKATGRSCLPME; KKKATGRSCLPMEC;KKATGRSCLPMECS; KATGRSCLPMECSQ; ATGRSCLPMECSQT; TGRSCLPMECSQTM;GRSCLPMECSQTMT; RSCLPMECSQTMTS; SCLPMECSQTMTSG; CLPMECSQTMTSGR;LPMECSQTMTSGRK; PMECSQTMTSGRKV; MECSQTMTSGRKVH; ECSQTMTSGRKVHD;CSQTMTSGRKVHDS; SQTMTSGRKVHDSQ; QTMTSGRKVHDSQG; TMTSGRKVHDSQGN;MTSGRKVHDSQGNA; TSGRKVHDSQGNAA; SGRKVHDSQGNAAK; GRKVHDSQGNAAKP;PQEGKCMTHREELL; QEGKCMTHREELLT; EGKCMTHREELLTH; GKCMTHREELLTHG;KCMTHREELLTHGM; CMTHREELLTHGMQ; MTHREELLTHGMQP; THREELLTHGMQPN;HREELLTHGMQPNH; REELLTHGMQPNHD; EELLTHGMQPNHDL; ELLTHGMQPNHDLR;LLTHGMQPNHDLRK; LTHGMQPNHDLRKE; THGMQPNHDLRKES; HGMQPNHDLRKESA;QTCFASLGILALSP; TCFASLGILALSPV; CFASLGILALSPVK; FASLGILALSPVKL;ASLGILALSPVKLD; SLGILALSPVKLDK; LGILALSPVKLDKG; GILALSPVKLDKGH;ILALSPVKLDKGHG; LALSPVKLDKGHGS; ALSPVKLDKGHGSA; LSPVKLDKGHGSAP;SPVKLDKGHGSAPA; PVKLDKGHGSAPAV; VKLDKGHGSAPAVT; KLDKGHGSAPAVTT;LDKGHGSAPAVTTS; DKGHGSAPAVTTSF; KGHGSAPAVTTSFS; GHGSAPAVTTSFSE;HGSAPAVTTSFSES; GSAPAVTTSFSESW; NLDWNKKKSSEDFY; LDWNKKKSSEDFYF;DWNKKKSSEDFYFY; WNKKKSSEDFYFYF; NKKKSSEDFYFYFR; KKKSSEDFYFYFRA;KKSSEDFYFYFRAF; KSSEDFYFYFRAFA; SSEDFYFYFRAFAG; SEDFYFYFRAFAGI;EDFYFYFRAFAGIL; RQCRREKQKYHCFT; QCRREKQKYHCFTC; CRREKQKYHCFTCC;RREKQKYHCFTCCK; REKQKYHCFTCCKR; EKQKYHCFTCCKRL; KQKYHCFTCCKRLC;QKYHCFTCCKRLCK; KYHCFTCCKRLCKR; YHCFTCCKRLCKRL; HCFTCCKRLCKRLL;CFTCCKRLCKRLLG; FTCCKRLCKRLLGK; SLFFCISRFMGAAL; LFFCISRFMGAALA;FFCISRFMGAALAL; FCISRFMGAALALL; CISRFMGAALALLG; ISRFMGAALALLGD;SRFMGAALALLGDL; RFMGAALALLGDLV; FMGAALALLGDLVA; MGAALALLGDLVAS;GAALALLGDLVASV; AALALLGDLVASVS; ALALLGDLVASVSE; LALLGDLVASVSEA;ALLGDLVASVSEAA; LLGDLVASVSEAAA; LGDLVASVSEAAAA; GDLVASVSEAAAAT;DLVASVSEAAAATG; LVASVSEAAAATGF; VASVSEAAAATGFS; ASVSEAAAATGFSV;SVSEAAAATGFSVA; VSEAAAATGFSVAE; SEAAAATGFSVAEI; EAAAATGFSVAEIA;AAAATGFSVAEIAA; AAATGFSVAEIAAG; AATGFSVAEIAAGE; ATGFSVAEIAAGEA;TGFSVAEIAAGEAA; GFSVAEIAAGEAAA; FSVAEIAAGEAAAA; SVAEIAAGEAAAAI;VAEIAAGEAAAAIE; AEIAAGEAAAAIEV; EIAAGEAAAAIEVQ; IAAGEAAAAIEVQI;AAGEAAAAIEVQIA; AGEAAAAIEVQIAS; GEAAAAIEVQIASL; EAAAAIEVQIASLA;AAAAIEVQIASLAT; AAAIEVQIASLATV; AAIEVQIASLATVE; AIEVQIASLATVEG;IEVQIASLATVEGI; EVQIASLATVEGIT; VQIASLATVEGITS; QIASLATVEGITST;IASLATVEGITSTS; ASLATVEGITSTSE; SLATVEGITSTSEA; LATVEGITSTSEAI;ATVEGITSTSEAIA; TVEGITSTSEAIAA; VEGITSTSEAIAAI; EGITSTSEAIAAIG;GITSTSEAIAAIGL; ITSTSEAIAAIGLT; TSTSEAIAAIGLTP; STSEAIAAIGLTPQ;TSEAIAAIGLTPQT; SEAIAAIGLTPQTY; EAIAAIGLTPQTYA; AIAAIGLTPQTYAV;IAAIGLTPQTYAVI; AAIGLTPQTYAVIA; AIGLTPQTYAVIAG; IGLTPQTYAVIAGA;GLTPQTYAVIAGAP; LTPQTYAVIAGAPG; TPQTYAVIAGAPGA; PQTYAVIAGAPGAI;QTYAVIAGAPGAIA; TYAVIAGAPGAIAG; YAVIAGAPGAIAGF; AVIAGAPGAIAGFA;VIAGAPGAIAGFAA; IAGAPGAIAGFAAL; AGAPGAIAGFAALI; GAPGAIAGFAALIQ;APGAIAGFAALIQT; PGAIAGFAALIQTV; GAIAGFAALIQTVS; AIAGFAALIQTVSG;IAGFAALIQTVSGI; AGFAALIQTVSGIS; GFAALIQTVSGISS; FAALIQTVSGISSL;AALIQTVSGISSLA; ALIQTVSGISSLAQ; LIQTVSGISSLAQV; IQTVSGISSLAQVG;QTVSGISSLAQVGY; TVSGISSLAQVGYK; VSGISSLAQVGYKF; SGISSLAQVGYKFF;GISSLAQVGYKFFD; ISSLAQVGYKFFDD; SSLAQVGYKFFDDW; SLAQVGYKFFDDWD;LAQVGYKFFDDWDH; AQVGYKFFDDWDHK; QVGYKFFDDWDHKV; VGYKFFDDWDHKVS;GYKFFDDWDHKVST; YKFFDDWDHKVSTV; KFFDDWDHKVSTVG; FFDDWDHKVSTVGL;FDDWDHKVSTVGLY; DDWDHKVSTVGLYQ; DWDHKVSTVGLYQQ; WDHKVSTVGLYQQS;DHKVSTVGLYQQSG; HKVSTVGLYQQSGM; KVSTVGLYQQSGMA; VSTVGLYQQSGMAL;STVGLYQQSGMALE; TVGLYQQSGMALEL; VGLYQQSGMALELF; GLYQQSGMALELFN;LYQQSGMALELFNP; YQQSGMALELFNPD; QQSGMALELFNPDE; QSGMALELFNPDEY;SGMALELFNPDEYY; GMALELFNPDEYYD; MALELFNPDEYYDI; ALELFNPDEYYDIL;LELFNPDEYYDILF; ELFNPDEYYDILFP; LFNPDEYYDILFPG; FNPDEYYDILFPGV;NPDEYYDILFPGVN; PDEYYDILFPGVNT; DEYYDILFPGVNTF; EYYDILFPGVNTFV;YYDILFPGVNTFVN; YDILFPGVNTFVNN; DILFPGVNTFVNNI; ILFPGVNTFVNNIQ;LFPGVNTFVNNIQY; FPGVNTFVNNIQYL; PGVNTFVNNIQYLD; GVNTFVNNIQYLDP;VNTFVNNIQYLDPR; NTFVNNIQYLDPRH; TFVNNIQYLDPRHW; FVNNIQYLDPRHWG;VNNIQYLDPRHWGP; NNIQYLDPRHWGPS; NIQYLDPRHWGPSL; IQYLDPRHWGPSLF;QYLDPRHWGPSLFA; YLDPRHWGPSLFAT; LDPRHWGPSLFATI; DPRHWGPSLFATIS;PRHWGPSLFATISQ; RHWGPSLFATISQA; HWGPSLFATISQAL; WGPSLFATISQALW;GPSLFATISQALWH; PSLFATISQALWHV; SLFATISQALWHVI; LFATISQALWHVIR;FATISQALWHVIRD; ATISQALWHVIRDD; TISQALWHVIRDDI; ISQALWHVIRDDIP;SQALWHVIRDDIPS; QALWHVIRDDIPSI; ALWHVIRDDIPSIT; LWHVIRDDIPSITS;WHVIRDDIPSITSQ; HVIRDDIPSITSQE; VIRDDIPSITSQEL; IRDDIPSITSQELQ;RDDIPSITSQELQR; DDIPSITSQELQRR; DIPSITSQELQRRT; IPSITSQELQRRTE;PSITSQELQRRTER; SITSQELQRRTERF; ITSQELQRRTERFF; TSQELQRRTERFFR;SQELQRRTERFFRD; QELQRRTERFFRDS; ELQRRTERFFRDSL; LQRRTERFFRDSLA;QRRTERFFRDSLAR; RRTERFFRDSLARF; RTERFFRDSLARFL; TERFFRDSLARFLE;ERFFRDSLARFLEE; RFFRDSLARFLEET; FFRDSLARFLEETT; FRDSLARFLEETTW;RDSLARFLEETTWT; DSLARFLEETTWTI; SLARFLEETTWTIV; LARFLEETTWTIVN;ARFLEETTWTIVNA; RFLEETTWTIVNAP; FLEETTWTIVNAPI; LEETTWTIVNAPIN;EETTWTIVNAPINF; ETTWTIVNAPINFY; TTWTIVNAPINFYN; TWTIVNAPINFYNY;WTIVNAPINFYNYI; TIVNAPINFYNYIQ; IVNAPINFYNYIQQ; VNAPINFYNYIQQY;NAPINFYNYIQQYY; APINFYNYIQQYYS; PINFYNYIQQYYSD; INFYNYIQQYYSDL;NFYNYIQQYYSDLS; FYNYIQQYYSDLSP; YNYIQQYYSDLSPI; NYIQQYYSDLSPIR;YIQQYYSDLSPIRP; IQQYYSDLSPIRPS; QQYYSDLSPIRPSM; QYYSDLSPIRPSMV;YYSDLSPIRPSMVR; YSDLSPIRPSMVRQ; SDLSPIRPSMVRQV; DLSPIRPSMVRQVA;LSPIRPSMVRQVAE; SPIRPSMVRQVAER; PIRPSMVRQVAERE; IRPSMVRQVAEREG;RPSMVRQVAEREGT; PSMVRQVAEREGTR; SMVRQVAEREGTRV; MVRQVAEREGTRVH;VRQVAEREGTRVHF; RQVAEREGTRVHFG; QVAEREGTRVHFGH; VAEREGTRVHFGHT;AEREGTRVHFGHTY; EREGTRVHFGHTYS; REGTRVHFGHTYSI; EGTRVHFGHTYSID;GTRVHFGHTYSIDD; TRVHFGHTYSIDDA; RVHFGHTYSIDDAD; VHFGHTYSIDDADS;HFGHTYSIDDADSI; FGHTYSIDDADSIE; GHTYSIDDADSIEE; HTYSIDDADSIEEV;TYSIDDADSIEEVT; YSIDDADSIEEVTQ; SIDDADSIEEVTQR; IDDADSIEEVTQRM;DDADSIEEVTQRMD; DADSIEEVTQRMDL; ADSIEEVTQRMDLR; DSIEEVTQRMDLRN;SIEEVTQRMDLRNQ; IEEVTQRMDLRNQQ; EEVTQRMDLRNQQS; EVTQRMDLRNQQSV;VTQRMDLRNQQSVH; TQRMDLRNQQSVHS; QRMDLRNQQSVHSG; RMDLRNQQSVHSGE;MDLRNQQSVHSGEF; DLRNQQSVHSGEFI; LRNQQSVHSGEFIE; RNQQSVHSGEFIEK;NQQSVHSGEFIEKT; QQSVHSGEFIEKTI; QSVHSGEFIEKTIA; SVHSGEFIEKTIAP;VHSGEFIEKTIAPG; HSGEFIEKTIAPGG; SGEFIEKTIAPGGA; GEFIEKTIAPGGAN;EFIEKTIAPGGANQ; FIEKTIAPGGANQR; IEKTIAPGGANQRT; EKTIAPGGANQRTA;KTIAPGGANQRTAP; TIAPGGANQRTAPQ; IAPGGANQRTAPQW; APGGANQRTAPQWM;PGGANQRTAPQWML; GGANQRTAPQWMLP; GANQRTAPQWMLPL; ANQRTAPQWMLPLL;NQRTAPQWMLPLLL; QRTAPQWMLPLLLG; RTAPQWMLPLLLGL; TAPQWMLPLLLGLY;APQWMLPLLLGLYG; PQWMLPLLLGLYGT; QWMLPLLLGLYGTV; WMLPLLLGLYGTVT;MLPLLLGLYGTVTP; LPLLLGLYGTVTPA; PLLLGLYGTVTPAL; LLLGLYGTVTPALE;LLGLYGTVTPALEA; LGLYGTVTPALEAY; GLYGTVTPALEAYE; LYGTVTPALEAYED;YGTVTPALEAYEDG; GTVTPALEAYEDGP; TVTPALEAYEDGPN; VTPALEAYEDGPNQ;TPALEAYEDGPNQK; PALEAYEDGPNQKK; ALEAYEDGPNQKKR; LEAYEDGPNQKKRR;EAYEDGPNQKKRRV; AYEDGPNQKKRRVS; YEDGPNQKKRRVSR; EDGPNQKKRRVSRG;DGPNQKKRRVSRGS; GPNQKKRRVSRGSS; PNQKKRRVSRGSSQ; NQKKRRVSRGSSQK;QKKRRVSRGSSQKA; KKRRVSRGSSQKAK; KRRVSRGSSQKAKG; RRVSRGSSQKAKGT;RVSRGSSQKAKGTR; VSRGSSQKAKGTRA; SRGSSQKAKGTRAS; RGSSQKAKGTRASA;GSSQKAKGTRASAK; SSQKAKGTRASAKT; SQKAKGTRASAKTT; QKAKGTRASAKTTN;KAKGTRASAKTTNK; AKGTRASAKTTNKR; KGTRASAKTTNKRR; GTRASAKTTNKRRS;TRASAKTTNKRRSR; RASAKTTNKRRSRS; ASAKTTNKRRSRSS; SAKTTNKRRSRSSR;AKTTNKRRSRSSRS; NWGRCYYRGRMLPK; WGRCYYRGRMLPKP; GRCYYRGRMLPKPR;RCYYRGRMLPKPRN; CYYRGRMLPKPRNG; YYRGRMLPKPRNGG; YRGRMLPKPRNGGS;RGRMLPKPRNGGSR; PREKNASLLQHSKN; REKNASLLQHSKNS; EKNASLLQHSKNSP;KNASLLQHSKNSPP; NASLLQHSKNSPPQ; ASLLQHSKNSPPQF; SLLQHSKNSPPQFK;GPNLWKSTDVGGCN; PNLWKSTDVGGCNC; NLWKSTDVGGCNCT; LWKSTDVGGCNCTN;WKSTDVGGCNCTNR; KSTDVGGCNCTNRG; STDVGGCNCTNRGY; TDVGGCNCTNRGYW;DVGGCNCTNRGYWN; VGGCNCTNRGYWNN; FPLLCCRWRTLGNA; PLLCCRWRTLGNAG;LLCCRWRTLGNAGS; LCCRWRTLGNAGSA; CCRWRTLGNAGSAN; CRWRTLGNAGSANE;RWRTLGNAGSANEL; WRTLGNAGSANELQ; RTLGNAGSANELQV; TLGNAGSANELQVK;LGNAGSANELQVKV; GNAGSANELQVKVP; VFWDFHRRGKCSPS; FWDFHRRGKCSPST;WDFHRRGKCSPSTS; DFHRRGKCSPSTSC; FHRRGKCSPSTSCD; HRRGKCSPSTSCDQ;RRGKCSPSTSCDQH; RGKCSPSTSCDQHS; GKCSPSTSCDQHSY; KCSPSTSCDQHSYH;CSPSTSCDQHSYHS; SPSTSCDQHSYHSV; PSTSCDQHSYHSVA; STSCDQHSYHSVAR;QLWNTTVERPCKIF; DPPEKKICKESLPN; PPEKKICKESLPNF; PEKKICKESLPNFL;EKKICKESLPNFLF; KKICKESLPNFLFA; KICKESLPNFLFAK; PYKQENPESGWAAY;YKQENPESGWAAYV; KQENPESGWAAYVW; QENPESGWAAYVWY; ENPESGWAAYVWYG;NPESGWAAYVWYGI; PESGWAAYVWYGIP; ESGWAAYVWYGIPG; SGWAAYVWYGIPGR;GWAAYVWYGIPGRR; WAAYVWYGIPGRRG; WHRKTSRGPRYDKI; HRKTSRGPRYDKIY;QTGTIANQNALNRC; TGTIANQNALNRCF; GTIANQNALNRCFY; TIANQNALNRCFYC;IANQNALNRCFYCT; ANQNALNRCFYCTY; NQNALNRCFYCTYT; QNALNRCFYCTYTF;NALNRCFYCTYTFN; ALNRCFYCTYTFNK; LNRCFYCTYTFNKC; NRCFYCTYTFNKCC;RCFYCTYTFNKCCF; CFYCTYTFNKCCFC; FYCTYTFNKCCFCI; YCTYTFNKCCFCIS;CTYTFNKCCFCISH; TYTFNKCCFCISHF; NTESLYTNATLDYG; TESLYTNATLDYGG;ESLYTNATLDYGGL; SLYTNATLDYGGLT; LYTNATLDYGGLTF; YTNATLDYGGLTFG;TNATLDYGGLTFGN; NATLDYGGLTFGNL; ATLDYGGLTFGNLQ; TLDYGGLTFGNLQQ;LDYGGLTFGNLQQG; DYGGLTFGNLQQGL; YGGLTFGNLQQGLK; GGLTFGNLQQGLKY;GLTFGNLQQGLKYL; LTFGNLQQGLKYLR; TFGNLQQGLKYLRL; FGNLQQGLKYLRLG;GNLQQGLKYLRLGK; NLQQGLKYLRLGKS; LQQGLKYLRLGKSI; QQGLKYLRLGKSIV;QGLKYLRLGKSIVI; GLKYLRLGKSIVIG; LKYLRLGKSIVIGI; KYLRLGKSIVIGIQ;YLRLGKSIVIGIQC; LRLGKSIVIGIQCL; RLGKSIVIGIQCLI; LGKSIVIGIQCLIH;GKSIVIGIQCLIHV; KSIVIGIQCLIHVQ; SIVIGIQCLIHVQS; IVIGIQCLIHVQSL;VIGIQCLIHVQSLQ; IGIQCLIHVQSLQF; GIQCLIHVQSLQFL; IQCLIHVQSLQFLN;QCLIHVQSLQFLNP; CLIHVQSLQFLNPL; LIHVQSLQFLNPLL; IHVQSLQFLNPLLL;YQEYISPCIYYISS; QEYISPCIYYISSL; EYISPCIYYISSLK; YISPCIYYISSLKK;ISPCIYYISSLKKY; SPCIYYISSLKKYT; PCIYYISSLKKYTY; CIYYISSLKKYTYL;IYYISSLKKYTYLS; YYISSLKKYTYLSQ; YISSLKKYTYLSQN; ISSLKKYTYLSQNP;SSLKKYTYLSQNPA; SLKKYTYLSQNPAF; LKKYTYLSQNPAFP; KKYTYLSQNPAFPS;KYTYLSQNPAFPSI; YTYLSQNPAFPSIQ; TYLSQNPAFPSIQQ; YLSQNPAFPSIQQF;TKLAVATRSFHFVK; KLAVATRSFHFVKF; LAVATRSFHFVKFF; AVATRSFHFVKFFF;VATRSFHFVKFFFQ; ATRSFHFVKFFFQV; TRSFHFVKFFFQVR; RSFHFVKFFFQVRT;SFHFVKFFFQVRTL; FHFVKFFFQVRTLS; HFVKFFFQVRTLSF; FVKFFFQVRTLSFV;VKFFFQVRTLSFVR; KFFFQVRTLSFVRI; FFFQVRTLSFVRIF; FFQVRTLSFVRIFL;FQVRTLSFVRIFLN; QVRTLSFVRIFLNI; VRTLSFVRIFLNIF; RTLSFVRIFLNIFW;TLSFVRIFLNIFWA; PSLVEIFGFFCLNV; SLVEIFGFFCLNVS; LVEIFGFFCLNVSF;VEIFGFFCLNVSFL; EIFGFFCLNVSFLN; IFGFFCLNVSFLNL; FGFFCLNVSFLNLP;HFHLNNLSNCLNCL; FHLNNLSNCLNCLF; HLNNLSNCLNCLFH; LNNLSNCLNCLFHV;NNLSNCLNCLFHVL; NLSNCLNCLFHVLK; LSNCLNCLFHVLKA; SNCLNCLFHVLKAN;NCLNCLFHVLKANP; CLNCLFHVLKANPL; LNCLFHVLKANPLI; NCLFHVLKANPLIQ;CLFHVLKANPLIQL; LFHVLKANPLIQLL; FHVLKANPLIQLLS; HVLKANPLIQLLSL;VLKANPLIQLLSLL; LKANPLIQLLSLLH; KANPLIQLLSLLHL; ANPLIQLLSLLHLQ;NPLIQLLSLLHLQK; PLIQLLSLLHLQKQ; LIQLLSLLHLQKQP; IQLLSLLHLQKQPC;QLLSLLHLQKQPCT; LLSLLHLQKQPCTD; LSLLHLQKQPCTDL; LHLAQRLAFPWVGL;HLAQRLAFPWVGLH; LAQRLAFPWVGLHL; AQRLAFPWVGLHLR; QRLAFPWVGLHLRL;RLAFPWVGLHLRLY; LAFPWVGLHLRLYH; AFPWVGLHLRLYHH; FPWVGLHLRLYHHT;PWVGLHLRLYHHTN; WVGLHLRLYHHTNL; VGLHLRLYHHTNLI; GLHLRLYHHTNLIT;LHLRLYHHTNLITL; HLRLYHHTNLITLQ; LRLYHHTNLITLQL; RLYHHTNLITLQLV;LYHHTNLITLQLVL; YHHTNLITLQLVLF; HHTNLITLQLVLFF; HTNLITLQLVLFFH;TNLITLQLVLFFHY; NLITLQLVLFFHYQ; LITLQLVLFFHYQW; ITLQLVLFFHYQWD;TLQLVLFFHYQWDL; KQYSAKNQILQNPF; VANSAAKQHLPYIV; ANSAAKQHLPYIVL;NSAAKQHLPYIVLV; SAAKQHLPYIVLVQ; AAKQHLPYIVLVQH; AKQHLPYIVLVQHF;KQHLPYIVLVQHFH; QHLPYIVLVQHFHE; HLPYIVLVQHFHEL; LPYIVLVQHFHELQ;PYIVLVQHFHELQI; YIVLVQHFHELQIL; IVLVQHFHELQILN; VLVQHFHELQILNP;LVQHFHELQILNPF; VQHFHELQILNPFY; QHFHELQILNPFYL; HFHELQILNPFYLI;FHELQILNPFYLIY; HELQILNPFYLIYD; IFLLAFLPWSYEGY; FLLAFLPWSYEGYL;LLAFLPWSYEGYLL; LAFLPWSYEGYLLF; AFLPWSYEGYLLFF; LKLYLLLADKYFFD;KLYLLLADKYFFDF; LYLLLADKYFFDFY; YLLLADKYFFDFYF; LLLADKYFFDFYFL;LLADKYFFDFYFLQ; LADKYFFDFYFLQK; SDKAGLFSDTFYTP; DKAGLFSDTFYTPL;KAGLFSDTFYTPLH; AGLFSDTFYTPLHC; GLFSDTFYTPLHCI; LFSDTFYTPLHCIE;FSDTFYTPLHCIEI; SDTFYTPLHCIEIL; DTFYTPLHCIEILN; TFYTPLHCIEILNT;FYTPLHCIEILNTY; YTPLHCIEILNTYL; TPLHCIEILNTYLI; PLHCIEILNTYLII;LHCIEILNTYLIIK; HCIEILNTYLIIKT; CIEILNTYLIIKTH; IEILNTYLIIKTHP;EILNTYLIIKTHPH; ILNTYLIIKTHPHT; LNTYLIIKTHPHTL; NTYLIIKTHPHTLS;TYLIIKTHPHTLSL; YLIIKTHPHTLSLL; LIIKTHPHTLSLLH; IIKTHPHTLSLLHT;IKTHPHTLSLLHTQ; LISKTPALFLQALL; ISKTPALFLQALLG; GLLPFFFFWVVLSV;LLPFFFFWVVLSVE; LPFFFFWVVLSVEN; PFFFFWVVLSVENL; FFFFWVVLSVENLL;FFFWVVLSVENLLL; FFWVVLSVENLLLL; FWVVLSVENLLLLL; WVVLSVENLLLLLH;VVLSVENLLLLLHH; VLSVENLLLLLHHW; LSVENLLLLLHHWQ; SVENLLLLLHHWQT;VENLLLLLHHWQTY; ENLLLLLHHWQTYL; NLLLLLHHWQTYLH; LLLLLHHWQTYLHG;LLLLHHWQTYLHGK; LLLHHWQTYLHGKI; LLHHWQTYLHGKIN; LHHWQTYLHGKINL;HHWQTYLHGKINLH; HWQTYLHGKINLHP; WQTYLHGKINLHPI; QTYLHGKINLHPIF;TYLHGKINLHPIFH; RNSTRTPTLLFHRL; NSTRTPTLLFHRLA; STRTPTLLFHRLAP;TRTPTLLFHRLAPI; RTPTLLFHRLAPIK; TPTLLFHRLAPIKK; PTLLFHRLAPIKKI;TLLFHRLAPIKKII; LLFHRLAPIKKIIT; GLLIFYYLSKYKLV; LLIFYYLSKYKLVT;LIFYYLSKYKLVTL; IFYYLSKYKLVTLK; FYYLSKYKLVTLKL; ISEGSFSNYLDPPL;SEGSFSNYLDPPLQ; EGSFSNYLDPPLQS; GSFSNYLDPPLQSF; SFSNYLDPPLQSFF;FSNYLDPPLQSFFS; AKPLCEAVNAVAIY; KPLCEAVNAVAIYP; PLCEAVNAVAIYPN;LCEAVNAVAIYPNQ; CEAVNAVAIYPNQG; EAVNAVAIYPNQGL; AVNAVAIYPNQGLF;VNAVAIYPNQGLFS; HARAVHRRLFGTNR; ARAVHRRLFGTNRP; RAVHRRLFGTNRPF;AVHRRLFGTNRPFL; VHRRLFGTNRPFLA; HRRLFGTNRPFLAV; RRLFGTNRPFLAVQ;RLFGTNRPFLAVQG; LFGTNRPFLAVQGI; FGTNRPFLAVQGIW; GTNRPFLAVQGIWA;TNRPFLAVQGIWAK; NRPFLAVQGIWAKR; RPFLAVQGIWAKRK; PFLAVQGIWAKRKI;FLAVQGIWAKRKIS; LAVQGIWAKRKIST; AVQGIWAKRKISTN; VQGIWAKRKISTNL;ATPGSKIRLMSYLY; TPGSKIRLMSYLYI; PGSKIRLMSYLYIL; GSKIRLMSYLYILL;SKIRLMSYLYILLH; KIRLMSYLYILLHF; IRLMSYLYILLHFF; RLMSYLYILLHFFI;LMSYLYILLHFFIQ; MSYLYILLHFFIQS; SYLYILLHFFIQSI; YLYILLHFFIQSIH;LYILLHFFIQSIHS; YILLHFFIQSIHSL; ILLHFFIQSIHSLH; LLHFFIQSIHSLHF;LHFFIQSIHSLHFI; HFFIQSIHSLHFIL; FFIQSIHSLHFILV; FIQSIHSLHFILVA;IQSIHSLHFILVAP; QSIHSLHFILVAPF; SIHSLHFILVAPFV; IHSLHFILVAPFVR;HSLHFILVAPFVRV; SLHFILVAPFVRVK; LHFILVAPFVRVKF; HFILVAPFVRVKFL;FILVAPFVRVKFLT 15 mers: ASEKASTPLLLERKG; SEKASTPLLLERKGG;EKASTPLLLERKGGG; KASTPLLLERKGGGR; ASTPLLLERKGGGRG; STPLLLERKGGGRGG;TPLLLERKGGGRGGL; PLLLERKGGGRGGLG; LLLERKGGGRGGLGL; LLERKGGGRGGLGLL;LERKGGGRGGLGLLY; ERKGGGRGGLGLLYI; RKGGGRGGLGLLYII; KGGGRGGLGLLYIIK;GGGRGGLGLLYIIKK; GGRGGLGLLYIIKKK; GRGGLGLLYIIKKKA; RGGLGLLYIIKKKAT;GGLGLLYIIKKKATG; GLGLLYIIKKKATGR; LGLLYIIKKKATGRS; GLLYIIKKKATGRSC;LLYIIKKKATGRSCL; LYIIKKKATGRSCLP; YIIKKKATGRSCLPM; IIKKKATGRSCLPME;IKKKATGRSCLPMEC; KKKATGRSCLPMECS; KKATGRSCLPMECSQ; KATGRSCLPMECSQT;ATGRSCLPMECSQTM; TGRSCLPMECSQTMT; GRSCLPMECSQTMTS; RSCLPMECSQTMTSG;SCLPMECSQTMTSGR; CLPMECSQTMTSGRK; LPMECSQTMTSGRKV; PMECSQTMTSGRKVH;MECSQTMTSGRKVHD; ECSQTMTSGRKVHDS; CSQTMTSGRKVHDSQ; SQTMTSGRKVHDSQG;QTMTSGRKVHDSQGN; TMTSGRKVHDSQGNA; MTSGRKVHDSQGNAA; TSGRKVHDSQGNAAK;SGRKVHDSQGNAAKP; PQEGKCMTHREELLT; QEGKCMTHREELLTH; EGKCMTHREELLTHG;GKCMTHREELLTHGM; KCMTHREELLTHGMQ; CMTHREELLTHGMQP; MTHREELLTHGMQPN;THREELLTHGMQPNH; HREELLTHGMQPNHD; REELLTHGMQPNHDL; EELLTHGMQPNHDLR;ELLTHGMQPNHDLRK; LLTHGMQPNHDLRKE; LTHGMQPNHDLRKES; THGMQPNHDLRKESA;QTCFASLGILALSPV; TCFASLGILALSPVK; CFASLGILALSPVKL; FASLGILALSPVKLD;ASLGILALSPVKLDK; SLGILALSPVKLDKG; LGILALSPVKLDKGH; GILALSPVKLDKGHG;ILALSPVKLDKGHGS; LALSPVKLDKGHGSA; ALSPVKLDKGHGSAP; LSPVKLDKGHGSAPA;SPVKLDKGHGSAPAV; PVKLDKGHGSAPAVT; VKLDKGHGSAPAVTT; KLDKGHGSAPAVTTS;LDKGHGSAPAVTTSF; DKGHGSAPAVTTSFS; KGHGSAPAVTTSFSE; GHGSAPAVTTSFSES;HGSAPAVTTSFSESW; NLDWNKKKSSEDFYF; LDWNKKKSSEDFYFY; DWNKKKSSEDFYFYF;WNKKKSSEDFYFYFR; NKKKSSEDFYFYFRA; KKKSSEDFYFYFRAF; KKSSEDFYFYFRAFA;KSSEDFYFYFRAFAG; SSEDFYFYFRAFAGI; SEDFYFYFRAFAGIL; RQCRREKQKYHCFTC;QCRREKQKYHCFTCC; CRREKQKYHCFTCCK; RREKQKYHCFTCCKR; REKQKYHCFTCCKRL;EKQKYHCFTCCKRLC; KQKYHCFTCCKRLCK; QKYHCFTCCKRLCKR; KYHCFTCCKRLCKRL;YHCFTCCKRLCKRLL; HCFTCCKRLCKRLLG; CFTCCKRLCKRLLGK; SLFFCISRFMGAALA;LFFCISRFMGAALAL; FFCISRFMGAALALL; FCISRFMGAALALLG; CISRFMGAALALLGD;ISRFMGAALALLGDL; SRFMGAALALLGDLV; RFMGAALALLGDLVA; FMGAALALLGDLVAS;MGAALALLGDLVASV; GAALALLGDLVASVS; AALALLGDLVASVSE; ALALLGDLVASVSEA;LALLGDLVASVSEAA; ALLGDLVASVSEAAA; LLGDLVASVSEAAAA; LGDLVASVSEAAAAT;GDLVASVSEAAAATG; DLVASVSEAAAATGF; LVASVSEAAAATGFS; VASVSEAAAATGFSV;ASVSEAAAATGFSVA; SVSEAAAATGFSVAE; VSEAAAATGFSVAEI; SEAAAATGFSVAEIA;EAAAATGFSVAEIAA; AAAATGFSVAEIAAG; AAATGFSVAEIAAGE; AATGFSVAEIAAGEA;ATGFSVAEIAAGEAA; TGFSVAEIAAGEAAA; GFSVAEIAAGEAAAA; FSVAEIAAGEAAAAI;SVAEIAAGEAAAAIE; VAEIAAGEAAAAIEV; AEIAAGEAAAAIEVQ; EIAAGEAAAAIEVQI;IAAGEAAAAIEVQIA; AAGEAAAAIEVQIAS; AGEAAAAIEVQIASL; GEAAAAIEVQIASLA;EAAAAIEVQIASLAT; AAAAIEVQIASLATV; AAAIEVQIASLATVE; AAIEVQIASLATVEG;AIEVQIASLATVEGI; IEVQIASLATVEGIT; EVQIASLATVEGITS; VQIASLATVEGITST;QIASLATVEGITSTS; IASLATVEGITSTSE; ASLATVEGITSTSEA; SLATVEGITSTSEAI;LATVEGITSTSEAIA; ATVEGITSTSEAIAA; TVEGITSTSEAIAAI; VEGITSTSEAIAAIG;EGITSTSEAIAAIGL; GITSTSEAIAAIGLT; ITSTSEAIAAIGLTP; TSTSEAIAAIGLTPQ;STSEAIAAIGLTPQT; TSEAIAAIGLTPQTY; SEAIAAIGLTPQTYA; EAIAAIGLTPQTYAV;AIAAIGLTPQTYAVI; IAAIGLTPQTYAVIA; AAIGLTPQTYAVIAG; AIGLTPQTYAVIAGA;IGLTPQTYAVIAGAP; GLTPQTYAVIAGAPG; LTPQTYAVIAGAPGA; TPQTYAVIAGAPGAI;PQTYAVIAGAPGAIA; QTYAVIAGAPGAIAG; TYAVIAGAPGAIAGF; YAVIAGAPGAIAGFA;AVIAGAPGAIAGFAA; VIAGAPGAIAGFAAL; IAGAPGAIAGFAALI; AGAPGAIAGFAALIQ;GAPGAIAGFAALIQT; APGAIAGFAALIQTV; PGAIAGFAALIQTVS; GAIAGFAALIQTVSG;AIAGFAALIQTVSGI; IAGFAALIQTVSGIS; AGFAALIQTVSGISS; GFAALIQTVSGISSL;FAALIQTVSGISSLA; AALIQTVSGISSLAQ; ALIQTVSGISSLAQV; LIQTVSGISSLAQVG;IQTVSGISSLAQVGY; QTVSGISSLAQVGYK; TVSGISSLAQVGYKF; VSGISSLAQVGYKFF;SGISSLAQVGYKFFD; GISSLAQVGYKFFDD; ISSLAQVGYKFFDDW; SSLAQVGYKFFDDWD;SLAQVGYKFFDDWDH; LAQVGYKFFDDWDHK; AQVGYKFFDDWDHKV; QVGYKFFDDWDHKVS;VGYKFFDDWDHKVST; GYKFFDDWDHKVSTV; YKFFDDWDHKVSTVG; KFFDDWDHKVSTVGL;FFDDWDHKVSTVGLY; FDDWDHKVSTVGLYQ; DDWDHKVSTVGLYQQ; DWDHKVSTVGLYQQS;WDHKVSTVGLYQQSG; DHKVSTVGLYQQSGM; HKVSTVGLYQQSGMA; KVSTVGLYQQSGMAL;VSTVGLYQQSGMALE; STVGLYQQSGMALEL; TVGLYQQSGMALELF; VGLYQQSGMALELFN;GLYQQSGMALELFNP; LYQQSGMALELFNPD; YQQSGMALELFNPDE; QQSGMALELFNPDEY;QSGMALELFNPDEYY; SGMALELFNPDEYYD; GMALELFNPDEYYDI; MALELFNPDEYYDIL;ALELFNPDEYYDILF; LELFNPDEYYDILFP; ELFNPDEYYDILFPG; LFNPDEYYDILFPGV;FNPDEYYDILFPGVN; NPDEYYDILFPGVNT; PDEYYDILFPGVNTF; DEYYDILFPGVNTFV;EYYDILFPGVNTFVN; YYDILFPGVNTFVNN; YDILFPGVNTFVNNI; DILFPGVNTFVNNIQ;ILFPGVNTFVNNIQY; LFPGVNTFVNNIQYL; FPGVNTFVNNIQYLD; PGVNTFVNNIQYLDP;GVNTFVNNIQYLDPR; VNTFVNNIQYLDPRH; NTFVNNIQYLDPRHW; TFVNNIQYLDPRHWG;FVNNIQYLDPRHWGP; VNNIQYLDPRHWGPS; NNIQYLDPRHWGPSL; NIQYLDPRHWGPSLF;IQYLDPRHWGPSLFA; QYLDPRHWGPSLFAT; YLDPRHWGPSLFATI; LDPRHWGPSLFATIS;DPRHWGPSLFATISQ; PRHWGPSLFATISQA; RHWGPSLFATISQAL; HWGPSLFATISQALW;WGPSLFATISQALWH; GPSLFATISQALWHV; PSLFATISQALWHVI; SLFATISQALWHVIR;LFATISQALWHVIRD; FATISQALWHVIRDD; ATISQALWHVIRDDI; TISQALWHVIRDDIP;ISQALWHVIRDDIPS; SQALWHVIRDDIPSI; QALWHVIRDDIPSIT; ALWHVIRDDIPSITS;LWHVIRDDIPSITSQ; WHVIRDDIPSITSQE; HVIRDDIPSITSQEL; VIRDDIPSITSQELQ;IRDDIPSITSQELQR; RDDIPSITSQELQRR; DDIPSITSQELQRRT; DIPSITSQELQRRTE;IPSITSQELQRRTER; PSITSQELQRRTERF; SITSQELQRRTERFF; ITSQELQRRTERFFR;TSQELQRRTERFFRD; SQELQRRTERFFRDS; QELQRRTERFFRDSL; ELQRRTERFFRDSLA;LQRRTERFFRDSLAR; QRRTERFFRDSLARF; RRTERFFRDSLARFL; RTERFFRDSLARFLE;TERFFRDSLARFLEE; ERFFRDSLARFLEET; RFFRDSLARFLEETT; FFRDSLARFLEETTW;FRDSLARFLEETTWT; RDSLARFLEETTWTI; DSLARFLEETTWTIV; SLARFLEETTWTIVN;LARFLEETTWTIVNA; ARFLEETTWTIVNAP; RFLEETTWTIVNAPI; FLEETTWTIVNAPIN;LEETTWTIVNAPINF; EETTWTIVNAPINFY; ETTWTIVNAPINFYN; TTWTIVNAPINFYNY;TWTIVNAPINFYNYI; WTIVNAPINFYNYIQ; TIVNAPINFYNYIQQ; IVNAPINFYNYIQQY;VNAPINFYNYIQQYY; NAPINFYNYIQQYYS; APINFYNYIQQYYSD; PINFYNYIQQYYSDL;INFYNYIQQYYSDLS; NFYNYIQQYYSDLSP; FYNYIQQYYSDLSPI; YNYIQQYYSDLSPIR;NYIQQYYSDLSPIRP; YIQQYYSDLSPIRPS; IQQYYSDLSPIRPSM; QQYYSDLSPIRPSMV;QYYSDLSPIRPSMVR; YYSDLSPIRPSMVRQ; YSDLSPIRPSMVRQV; SDLSPIRPSMVRQVA;DLSPIRPSMVRQVAE; LSPIRPSMVRQVAER; SPIRPSMVRQVAERE; PIRPSMVRQVAEREG;IRPSMVRQVAEREGT; RPSMVRQVAEREGTR; PSMVRQVAEREGTRV; SMVRQVAEREGTRVH;MVRQVAEREGTRVHF; VRQVAEREGTRVHFG; RQVAEREGTRVHFGH; QVAEREGTRVHFGHT;VAEREGTRVHFGHTY; AEREGTRVHFGHTYS; EREGTRVHFGHTYSI; REGTRVHFGHTYSID;EGTRVHFGHTYSIDD; GTRVHFGHTYSIDDA; TRVHFGHTYSIDDAD; RVHFGHTYSIDDADS;VHFGHTYSIDDADSI; HFGHTYSIDDADSIE; FGHTYSIDDADSIEE; GHTYSIDDADSIEEV;HTYSIDDADSIEEVT; TYSIDDADSIEEVTQ; YSIDDADSIEEVTQR; SIDDADSIEEVTQRM;IDDADSIEEVTQRMD; DDADSIEEVTQRMDL; DADSIEEVTQRMDLR; ADSIEEVTQRMDLRN;DSIEEVTQRMDLRNQ; SIEEVTQRMDLRNQQ; IEEVTQRMDLRNQQS; EEVTQRMDLRNQQSV;EVTQRMDLRNQQSVH; VTQRMDLRNQQSVHS; TQRMDLRNQQSVHSG; QRMDLRNQQSVHSGE;RMDLRNQQSVHSGEF; MDLRNQQSVHSGEFI; DLRNQQSVHSGEFIE; LRNQQSVHSGEFIEK;RNQQSVHSGEFIEKT; NQQSVHSGEFIEKTI; QQSVHSGEFIEKTIA; QSVHSGEFIEKTIAP;SVHSGEFIEKTIAPG; VHSGEFIEKTIAPGG; HSGEFIEKTIAPGGA; SGEFIEKTIAPGGAN;GEFIEKTIAPGGANQ; EFIEKTIAPGGANQR; FIEKTIAPGGANQRT; IEKTIAPGGANQRTA;EKTIAPGGANQRTAP; KTIAPGGANQRTAPQ; TIAPGGANQRTAPQW; IAPGGANQRTAPQWM;APGGANQRTAPQWML; PGGANQRTAPQWMLP; GGANQRTAPQWMLPL; GANQRTAPQWMLPLL;ANQRTAPQWMLPLLL; NQRTAPQWMLPLLLG; QRTAPQWMLPLLLGL; RTAPQWMLPLLLGLY;TAPQWMLPLLLGLYG; APQWMLPLLLGLYGT; PQWMLPLLLGLYGTV; QWMLPLLLGLYGTVT;WMLPLLLGLYGTVTP; MLPLLLGLYGTVTPA; LPLLLGLYGTVTPAL; PLLLGLYGTVTPALE;LLLGLYGTVTPALEA; LLGLYGTVTPALEAY; LGLYGTVTPALEAYE; GLYGTVTPALEAYED;LYGTVTPALEAYEDG; YGTVTPALEAYEDGP; GTVTPALEAYEDGPN; TVTPALEAYEDGPNQ;VTPALEAYEDGPNQK; TPALEAYEDGPNQKK; PALEAYEDGPNQKKR; ALEAYEDGPNQKKRR;LEAYEDGPNQKKRRV; EAYEDGPNQKKRRVS; AYEDGPNQKKRRVSR; YEDGPNQKKRRVSRG;EDGPNQKKRRVSRGS; DGPNQKKRRVSRGSS; GPNQKKRRVSRGSSQ; PNQKKRRVSRGSSQK;NQKKRRVSRGSSQKA; QKKRRVSRGSSQKAK; KKRRVSRGSSQKAKG; KRRVSRGSSQKAKGT;RRVSRGSSQKAKGTR; RVSRGSSQKAKGTRA; VSRGSSQKAKGTRAS; SRGSSQKAKGTRASA;RGSSQKAKGTRASAK; GSSQKAKGTRASAKT; SSQKAKGTRASAKTT; SQKAKGTRASAKTTN;QKAKGTRASAKTTNK; KAKGTRASAKTTNKR; AKGTRASAKTTNKRR; KGTRASAKTTNKRRS;GTRASAKTTNKRRSR; TRASAKTTNKRRSRS; RASAKTTNKRRSRSS; ASAKTTNKRRSRSSR;SAKTTNKRRSRSSRS; NWGRCYYRGRMLPKP; WGRCYYRGRMLPKPR; GRCYYRGRMLPKPRN;RCYYRGRMLPKPRNG; CYYRGRMLPKPRNGG; YYRGRMLPKPRNGGS; YRGRMLPKPRNGGSR;PREKNASLLQHSKNS; REKNASLLQHSKNSP; EKNASLLQHSKNSPP; KNASLLQHSKNSPPQ;NASLLQHSKNSPPQF; ASLLQHSKNSPPQFK; GPNLWKSTDVGGCNC; PNLWKSTDVGGCNCT;NLWKSTDVGGCNCTN; LWKSTDVGGCNCTNR; WKSTDVGGCNCTNRG; KSTDVGGCNCTNRGY;STDVGGCNCTNRGYW; TDVGGCNCTNRGYWN; DVGGCNCTNRGYWNN; FPLLCCRWRTLGNAG;PLLCCRWRTLGNAGS; LLCCRWRTLGNAGSA; LCCRWRTLGNAGSAN; CCRWRTLGNAGSANE;CRWRTLGNAGSANEL; RWRTLGNAGSANELQ; WRTLGNAGSANELQV; RTLGNAGSANELQVK;TLGNAGSANELQVKV; LGNAGSANELQVKVP; VFWDFHRRGKCSPST; FWDFHRRGKCSPSTS;WDFHRRGKCSPSTSC; DFHRRGKCSPSTSCD; FHRRGKCSPSTSCDQ; HRRGKCSPSTSCDQH;RRGKCSPSTSCDQHS; RGKCSPSTSCDQHSY; GKCSPSTSCDQHSYH; KCSPSTSCDQHSYHS;CSPSTSCDQHSYHSV; SPSTSCDQHSYHSVA; PSTSCDQHSYHSVAR; DPPEKKICKESLPNF;PPEKKICKESLPNFL; PEKKICKESLPNFLF; EKKICKESLPNFLFA; KKICKESLPNFLFAK;PYKQENPESGWAAYV; YKQENPESGWAAYVW; KQENPESGWAAYVWY; QENPESGWAAYVWYG;ENPESGWAAYVWYGI; NPESGWAAYVWYGIP; PESGWAAYVWYGIPG; ESGWAAYVWYGIPGR;SGWAAYVWYGIPGRR; GWAAYVWYGIPGRRG; WHRKTSRGPRYDKIY; QTGTIANQNALNRCF;TGTIANQNALNRCFY; GTIANQNALNRCFYC; TIANQNALNRCFYCT; IANQNALNRCFYCTY;ANQNALNRCFYCTYT; NQNALNRCFYCTYTF; QNALNRCFYCTYTFN; NALNRCFYCTYTFNK;ALNRCFYCTYTFNKC; LNRCFYCTYTFNKCC; NRCFYCTYTFNKCCF; RCFYCTYTFNKCCFC;CFYCTYTFNKCCFCI; FYCTYTFNKCCFCIS; YCTYTFNKCCFCISH; CTYTFNKCCFCISHF;NTESLYTNATLDYGG; TESLYTNATLDYGGL; ESLYTNATLDYGGLT; SLYTNATLDYGGLTF;LYTNATLDYGGLTFG; YTNATLDYGGLTFGN; TNATLDYGGLTFGNL; NATLDYGGLTFGNLQ;ATLDYGGLTFGNLQQ; TLDYGGLTFGNLQQG; LDYGGLTFGNLQQGL; DYGGLTFGNLQQGLK;YGGLTFGNLQQGLKY; GGLTFGNLQQGLKYL; GLTFGNLQQGLKYLR; LTFGNLQQGLKYLRL;TFGNLQQGLKYLRLG; FGNLQQGLKYLRLGK; GNLQQGLKYLRLGKS; NLQQGLKYLRLGKSI;LQQGLKYLRLGKSIV; QQGLKYLRLGKSIVI; QGLKYLRLGKSIVIG; GLKYLRLGKSIVIGI;LKYLRLGKSIVIGIQ; KYLRLGKSIVIGIQC; YLRLGKSIVIGIQCL; LRLGKSIVIGIQCLI;RLGKSIVIGIQCLIH; LGKSIVIGIQCLIHV; GKSIVIGIQCLIHVQ; KSIVIGIQCLIHVQS;SIVIGIQCLIHVQSL; IVIGIQCLIHVQSLQ; VIGIQCLIHVQSLQF; IGIQCLIHVQSLQFL;GIQCLIHVQSLQFLN; IQCLIHVQSLQFLNP; QCLIHVQSLQFLNPL; CLIHVQSLQFLNPLL;LIHVQSLQFLNPLLL; YQEYISPCIYYISSL; QEYISPCIYYISSLK; EYISPCIYYISSLKK;YISPCIYYISSLKKY; ISPCIYYISSLKKYT; SPCIYYISSLKKYTY; PCIYYISSLKKYTYL;CIYYISSLKKYTYLS; IYYISSLKKYTYLSQ; YYISSLKKYTYLSQN; YISSLKKYTYLSQNP;ISSLKKYTYLSQNPA; SSLKKYTYLSQNPAF; SLKKYTYLSQNPAFP; LKKYTYLSQNPAFPS;KKYTYLSQNPAFPSI; KYTYLSQNPAFPSIQ; YTYLSQNPAFPSIQQ; TYLSQNPAFPSIQQF;TKLAVATRSFHFVKF; KLAVATRSFHFVKFF; LAVATRSFHFVKFFF; AVATRSFHFVKFFFQ;VATRSFHFVKFFFQV; ATRSFHFVKFFFQVR; TRSFHFVKFFFQVRT; RSFHFVKFFFQVRTL;SFHFVKFFFQVRTLS; FHFVKFFFQVRTLSF; HFVKFFFQVRTLSFV; FVKFFFQVRTLSFVR;VKFFFQVRTLSFVRI; KFFFQVRTLSFVRIF; FFFQVRTLSFVRIFL; FFQVRTLSFVRIFLN;FQVRTLSFVRIFLNI; QVRTLSFVRIFLNIF; VRTLSFVRIFLNIFW; RTLSFVRIFLNIFWA;PSLVEIFGFFCLNVS; SLVEIFGFFCLNVSF; LVEIFGFFCLNVSFL; VEIFGFFCLNVSFLN;EIFGFFCLNVSFLNL; IFGFFCLNVSFLNLP; HFHLNNLSNCLNCLF; FHLNNLSNCLNCLFH;HLNNLSNCLNCLFHV; LNNLSNCLNCLFHVL; NNLSNCLNCLFHVLK; NLSNCLNCLFHVLKA;LSNCLNCLFHVLKAN; SNCLNCLFHVLKANP; NCLNCLFHVLKANPL; CLNCLFHVLKANPLI;LNCLFHVLKANPLIQ; NCLFHVLKANPLIQL; CLFHVLKANPLIQLL; LFHVLKANPLIQLLS;FHVLKANPLIQLLSL; HVLKANPLIQLLSLL; VLKANPLIQLLSLLH; LKANPLIQLLSLLHL;KANPLIQLLSLLHLQ; ANPLIQLLSLLHLQK; NPLIQLLSLLHLQKQ; PLIQLLSLLHLQKQP;LIQLLSLLHLQKQPC; IQLLSLLHLQKQPCT; QLLSLLHLQKQPCTD; LLSLLHLQKQPCTDL;LHLAQRLAFPWVGLH; HLAQRLAFPWVGLHL; LAQRLAFPWVGLHLR; AQRLAFPWVGLHLRL;QRLAFPWVGLHLRLY; RLAFPWVGLHLRLYH; LAFPWVGLHLRLYHH; AFPWVGLHLRLYHHT;FPWVGLHLRLYHHTN; PWVGLHLRLYHHTNL; WVGLHLRLYHHTNLI; VGLHLRLYHHTNLIT;GLHLRLYHHTNLITL; LHLRLYHHTNLITLQ; HLRLYHHTNLITLQL; LRLYHHTNLITLQLV;RLYHHTNLITLQLVL; LYHHTNLITLQLVLF; YHHTNLITLQLVLFF; HHTNLITLQLVLFFH;HTNLITLQLVLFFHY; TNLITLQLVLFFHYQ; NLITLQLVLFFHYQW; LITLQLVLFFHYQWD;ITLQLVLFFHYQWDL; VANSAAKQHLPYIVL; ANSAAKQHLPYIVLV; NSAAKQHLPYIVLVQ;SAAKQHLPYIVLVQH; AAKQHLPYIVLVQHF; AKQHLPYIVLVQHFH; KQHLPYIVLVQHFHE;QHLPYIVLVQHFHEL; HLPYIVLVQHFHELQ; LPYIVLVQHFHELQI; PYIVLVQHFHELQIL;YIVLVQHFHELQILN; IVLVQHFHELQILNP; VLVQHFHELQILNPF; LVQHFHELQILNPFY;VQHFHELQILNPFYL; QHFHELQILNPFYLI; HFHELQILNPFYLIY; FHELQILNPFYLIYD;IFLLAFLPWSYEGYL; FLLAFLPWSYEGYLL; LLAFLPWSYEGYLLF; LAFLPWSYEGYLLFF;LKLYLLLADKYFFDF; KLYLLLADKYFFDFY; LYLLLADKYFFDFYF; YLLLADKYFFDFYFL;LLLADKYFFDFYFLQ; LLADKYFFDFYFLQK; SDKAGLFSDTFYTPL; DKAGLFSDTFYTPLH;KAGLFSDTFYTPLHC; AGLFSDTFYTPLHCI; GLFSDTFYTPLHCIE; LFSDTFYTPLHCIEI;FSDTFYTPLHCIEIL; SDTFYTPLHCIEILN; DTFYTPLHCIEILNT; TFYTPLHCIEILNTY;FYTPLHCIEILNTYL; YTPLHCIEILNTYLI; TPLHCIEILNTYLII; PLHCIEILNTYLIIK;LHCIEILNTYLIIKT; HCIEILNTYLIIKTH; CIEILNTYLIIKTHP; IEILNTYLIIKTHPH;EILNTYLIIKTHPHT; ILNTYLIIKTHPHTL; LNTYLIIKTHPHTLS; NTYLIIKTHPHTLSL;TYLIIKTHPHTLSLL; YLIIKTHPHTLSLLH; LIIKTHPHTLSLLHT; IIKTHPHTLSLLHTQ;LISKTPALFLQALLG; GLLPFFFFWVVLSVE; LLPFFFFWVVLSVEN; LPFFFFWVVLSVENL;PFFFFWVVLSVENLL; FFFFWVVLSVENLLL; FFFWVVLSVENLLLL; FFWVVLSVENLLLLL;FWVVLSVENLLLLLH; WVVLSVENLLLLLHH; VVLSVENLLLLLHHW; VLSVENLLLLLHHWQ;LSVENLLLLLHHWQT; SVENLLLLLHHWQTY; VENLLLLLHHWQTYL; ENLLLLLHHWQTYLH;NLLLLLHHWQTYLHG; LLLLLHHWQTYLHGK; LLLLHHWQTYLHGKI; LLLHHWQTYLHGKIN;LLHHWQTYLHGKINL; LHHWQTYLHGKINLH; HHWQTYLHGKINLHP; HWQTYLHGKINLHPI;WQTYLHGKINLHPIF; QTYLHGKINLHPIFH; RNSTRTPTLLFHRLA; NSTRTPTLLFHRLAP;STRTPTLLFHRLAPI; TRTPTLLFHRLAPIK; RTPTLLFHRLAPIKK; TPTLLFHRLAPIKKI;PTLLFHRLAPIKKII; TLLFHRLAPIKKIIT; GLLIFYYLSKYKLVT; LLIFYYLSKYKLVTL;LIFYYLSKYKLVTLK; IFYYLSKYKLVTLKL; ISEGSFSNYLDPPLQ; SEGSFSNYLDPPLQS;EGSFSNYLDPPLQSF; GSFSNYLDPPLQSFF; SFSNYLDPPLQSFFS; AKPLCEAVNAVAIYP;KPLCEAVNAVAIYPN; PLCEAVNAVAIYPNQ; LCEAVNAVAIYPNQG; CEAVNAVAIYPNQGL;EAVNAVAIYPNQGLF; AVNAVAIYPNQGLFS; HARAVHRRLFGTNRP; ARAVHRRLFGTNRPF;RAVHRRLFGTNRPFL; AVHRRLFGTNRPFLA; VHRRLFGTNRPFLAV; HRRLFGTNRPFLAVQ;RRLFGTNRPFLAVQG; RLFGTNRPFLAVQGI; LFGTNRPFLAVQGIW; FGTNRPFLAVQGIWA;GTNRPFLAVQGIWAK; TNRPFLAVQGIWAKR; NRPFLAVQGIWAKRK; RPFLAVQGIWAKRKI;PFLAVQGIWAKRKIS; FLAVQGIWAKRKIST; LAVQGIWAKRKISTN; AVQGIWAKRKISTNL;ATPGSKIRLMSYLYI; TPGSKIRLMSYLYIL; PGSKIRLMSYLYILL; GSKIRLMSYLYILLH;SKIRLMSYLYILLHF; KIRLMSYLYILLHFF; IRLMSYLYILLHFFI; RLMSYLYILLHFFIQ;LMSYLYILLHFFIQS; MSYLYILLHFFIQSI; SYLYILLHFFIQSIH; YLYILLHFFIQSIHS;LYILLHFFIQSIHSL; YILLHFFIQSIHSLH; ILLHFFIQSIHSLHF; LLHFFIQSIHSLHFI;LHFFIQSIHSLHFIL; HFFIQSIHSLHFILV; FFIQSIHSLHFILVA; FIQSIHSLHFILVAP;IQSIHSLHFILVAPF; QSIHSLHFILVAPFV; SIHSLHFILVAPFVR; IHSLHFILVAPFVRV;HSLHFILVAPFVRVK; SLHFILVAPFVRVKF; LHFILVAPFVRVKFL; HFILVAPFVRVKFLT;KVHELHGFFPVKNFI; VHELHGFFPVKNFIH 16 mers: ASEKASTPLLLERKGG;SEKASTPLLLERKGGG; EKASTPLLLERKGGGR; KASTPLLLERKGGGRG; ASTPLLLERKGGGRGG;STPLLLERKGGGRGGL; TPLLLERKGGGRGGLG; PLLLERKGGGRGGLGL; LLLERKGGGRGGLGLL;LLERKGGGRGGLGLLY; LERKGGGRGGLGLLYI; ERKGGGRGGLGLLYII; RKGGGRGGLGLLYIIK;KGGGRGGLGLLYIIKK; GGGRGGLGLLYIIKKK; GGRGGLGLLYIIKKKA; GRGGLGLLYIIKKKAT;RGGLGLLYIIKKKATG; GGLGLLYIIKKKATGR; GLGLLYIIKKKATGRS; LGLLYIIKKKATGRSC;GLLYIIKKKATGRSCL; LLYIIKKKATGRSCLP; LYIIKKKATGRSCLPM; YIIKKKATGRSCLPME;IIKKKATGRSCLPMEC; IKKKATGRSCLPMECS; KKKATGRSCLPMECSQ; KKATGRSCLPMECSQT;KATGRSCLPMECSQTM; ATGRSCLPMECSQTMT; TGRSCLPMECSQTMTS; GRSCLPMECSQTMTSG;RSCLPMECSQTMTSGR; SCLPMECSQTMTSGRK; CLPMECSQTMTSGRKV; LPMECSQTMTSGRKVH;PMECSQTMTSGRKVHD; MECSQTMTSGRKVHDS; ECSQTMTSGRKVHDSQ; CSQTMTSGRKVHDSQG;SQTMTSGRKVHDSQGN; QTMTSGRKVHDSQGNA; TMTSGRKVHDSQGNAA; MTSGRKVHDSQGNAAK;TSGRKVHDSQGNAAKP; PQEGKCMTHREELLTH; QEGKCMTHREELLTHG; EGKCMTHREELLTHGM;GKCMTHREELLTHGMQ; KCMTHREELLTHGMQP; CMTHREELLTHGMQPN; MTHREELLTHGMQPNH;THREELLTHGMQPNHD; HREELLTHGMQPNHDL; REELLTHGMQPNHDLR; EELLTHGMQPNHDLRK;ELLTHGMQPNHDLRKE; LLTHGMQPNHDLRKES; LTHGMQPNHDLRKESA; QTCFASLGILALSPVK;TCFASLGILALSPVKL; CFASLGILALSPVKLD; FASLGILALSPVKLDK; ASLGILALSPVKLDKG;SLGILALSPVKLDKGH; LGILALSPVKLDKGHG; GILALSPVKLDKGHGS; ILALSPVKLDKGHGSA;LALSPVKLDKGHGSAP; ALSPVKLDKGHGSAPA; LSPVKLDKGHGSAPAV; SPVKLDKGHGSAPAVT;PVKLDKGHGSAPAVTT; VKLDKGHGSAPAVTTS; KLDKGHGSAPAVTTSF; LDKGHGSAPAVTTSFS;DKGHGSAPAVTTSFSE; KGHGSAPAVTTSFSES; GHGSAPAVTTSFSESW; NLDWNKKKSSEDFYFY;LDWNKKKSSEDFYFYF; DWNKKKSSEDFYFYFR; WNKKKSSEDFYFYFRA; NKKKSSEDFYFYFRAF;KKKSSEDFYFYFRAFA; KKSSEDFYFYFRAFAG; KSSEDFYFYFRAFAGI; SSEDFYFYFRAFAGIL;RQCRREKQKYHCFTCC; QCRREKQKYHCFTCCK; CRREKQKYHCFTCCKR; RREKQKYHCFTCCKRL;REKQKYHCFTCCKRLC; EKQKYHCFTCCKRLCK; KQKYHCFTCCKRLCKR; QKYHCFTCCKRLCKRL;KYHCFTCCKRLCKRLL; YHCFTCCKRLCKRLLG; HCFTCCKRLCKRLLGK; SLFFCISRFMGAALAL;LFFCISRFMGAALALL; FFCISRFMGAALALLG; FCISRFMGAALALLGD; CISRFMGAALALLGDL;ISRFMGAALALLGDLV; SRFMGAALALLGDLVA; RFMGAALALLGDLVAS; FMGAALALLGDLVASV;MGAALALLGDLVASVS; GAALALLGDLVASVSE; AALALLGDLVASVSEA; ALALLGDLVASVSEAA;LALLGDLVASVSEAAA; ALLGDLVASVSEAAAA; LLGDLVASVSEAAAAT; LGDLVASVSEAAAATG;GDLVASVSEAAAATGF; DLVASVSEAAAATGFS; LVASVSEAAAATGFSV; VASVSEAAAATGFSVA;ASVSEAAAATGFSVAE; SVSEAAAATGFSVAEI; VSEAAAATGFSVAEIA; SEAAAATGFSVAEIAA;EAAAATGFSVAEIAAG; AAAATGFSVAEIAAGE; AAATGFSVAEIAAGEA; AATGFSVAEIAAGEAA;ATGFSVAEIAAGEAAA; TGFSVAEIAAGEAAAA; GFSVAEIAAGEAAAAI; FSVAEIAAGEAAAAIE;SVAEIAAGEAAAAIEV; VAEIAAGEAAAAIEVQ; AEIAAGEAAAAIEVQI; EIAAGEAAAAIEVQIA;IAAGEAAAAIEVQIAS; AAGEAAAAIEVQIASL; AGEAAAAIEVQIASLA; GEAAAAIEVQIASLAT;EAAAAIEVQIASLATV; AAAAIEVQIASLATVE; AAAIEVQIASLATVEG; AAIEVQIASLATVEGI;AIEVQIASLATVEGIT; IEVQIASLATVEGITS; EVQIASLATVEGITST; VQIASLATVEGITSTS;QIASLATVEGITSTSE; IASLATVEGITSTSEA; ASLATVEGITSTSEAI; SLATVEGITSTSEAIA;LATVEGITSTSEAIAA; ATVEGITSTSEAIAAI; TVEGITSTSEAIAAIG; VEGITSTSEAIAAIGL;EGITSTSEAIAAIGLT; GITSTSEAIAAIGLTP; ITSTSEAIAAIGLTPQ; TSTSEAIAAIGLTPQT;STSEAIAAIGLTPQTY; TSEAIAAIGLTPQTYA; SEAIAAIGLTPQTYAV; EAIAAIGLTPQTYAVI;AIAAIGLTPQTYAVIA; IAAIGLTPQTYAVIAG; AAIGLTPQTYAVIAGA; AIGLTPQTYAVIAGAP;IGLTPQTYAVIAGAPG; GLTPQTYAVIAGAPGA; LTPQTYAVIAGAPGAI; TPQTYAVIAGAPGAIA;PQTYAVIAGAPGAIAG; QTYAVIAGAPGAIAGF; TYAVIAGAPGAIAGFA; YAVIAGAPGAIAGFAA;AVIAGAPGAIAGFAAL; VIAGAPGAIAGFAALI; IAGAPGAIAGFAALIQ; AGAPGAIAGFAALIQT;GAPGAIAGFAALIQTV; APGAIAGFAALIQTVS; PGAIAGFAALIQTVSG; GAIAGFAALIQTVSGI;AIAGFAALIQTVSGIS; IAGFAALIQTVSGISS; AGFAALIQTVSGISSL; GFAALIQTVSGISSLA;FAALIQTVSGISSLAQ; AALIQTVSGISSLAQV; ALIQTVSGISSLAQVG; LIQTVSGISSLAQVGY;IQTVSGISSLAQVGYK; QTVSGISSLAQVGYKF; TVSGISSLAQVGYKFF; VSGISSLAQVGYKFFD;SGISSLAQVGYKFFDD; GISSLAQVGYKFFDDW; ISSLAQVGYKFFDDWD; SSLAQVGYKFFDDWDH;SLAQVGYKFFDDWDHK; LAQVGYKFFDDWDHKV; AQVGYKFFDDWDHKVS; QVGYKFFDDWDHKVST;VGYKFFDDWDHKVSTV; GYKFFDDWDHKVSTVG; YKFFDDWDHKVSTVGL; KFFDDWDHKVSTVGLY;FFDDWDHKVSTVGLYQ; FDDWDHKVSTVGLYQQ; DDWDHKVSTVGLYQQS; DWDHKVSTVGLYQQSG;WDHKVSTVGLYQQSGM; DHKVSTVGLYQQSGMA; HKVSTVGLYQQSGMAL; KVSTVGLYQQSGMALE;VSTVGLYQQSGMALEL; STVGLYQQSGMALELF; TVGLYQQSGMALELFN; VGLYQQSGMALELFNP;GLYQQSGMALELFNPD; LYQQSGMALELFNPDE; YQQSGMALELFNPDEY; QQSGMALELFNPDEYY;QSGMALELFNPDEYYD; SGMALELFNPDEYYDI; GMALELFNPDEYYDIL; MALELFNPDEYYDILF;ALELFNPDEYYDILFP; LELFNPDEYYDILFPG; ELFNPDEYYDILFPGV; LFNPDEYYDILFPGVN;FNPDEYYDILFPGVNT; NPDEYYDILFPGVNTF; PDEYYDILFPGVNTFV; DEYYDILFPGVNTFVN;EYYDILFPGVNTFVNN; YYDILFPGVNTFVNNI; YDILFPGVNTFVNNIQ; DILFPGVNTFVNNIQY;ILFPGVNTFVNNIQYL; LFPGVNTFVNNIQYLD; FPGVNTFVNNIQYLDP; PGVNTFVNNIQYLDPR;GVNTFVNNIQYLDPRH; VNTFVNNIQYLDPRHW; NTFVNNIQYLDPRHWG; TFVNNIQYLDPRHWGP;FVNNIQYLDPRHWGPS; VNNIQYLDPRHWGPSL; NNIQYLDPRHWGPSLF; NIQYLDPRHWGPSLFA;IQYLDPRHWGPSLFAT; QYLDPRHWGPSLFATI; YLDPRHWGPSLFATIS; LDPRHWGPSLFATISQ;DPRHWGPSLFATISQA; PRHWGPSLFATISQAL; RHWGPSLFATISQALW; HWGPSLFATISQALWH;WGPSLFATISQALWHV; GPSLFATISQALWHVI; PSLFATISQALWHVIR; SLFATISQALWHVIRD;LFATISQALWHVIRDD; FATISQALWHVIRDDI; ATISQALWHVIRDDIP; TISQALWHVIRDDIPS;ISQALWHVIRDDIPSI; SQALWHVIRDDIPSIT; QALWHVIRDDIPSITS; ALWHVIRDDIPSITSQ;LWHVIRDDIPSITSQE; WHVIRDDIPSITSQEL; HVIRDDIPSITSQELQ; VIRDDIPSITSQELQR;IRDDIPSITSQELQRR; RDDIPSITSQELQRRT; DDIPSITSQELQRRTE; DIPSITSQELQRRTER;IPSITSQELQRRTERF; PSITSQELQRRTERFF; SITSQELQRRTERFFR; ITSQELQRRTERFFRD;TSQELQRRTERFFRDS; SQELQRRTERFFRDSL; QELQRRTERFFRDSLA; ELQRRTERFFRDSLAR;LQRRTERFFRDSLARF; QRRTERFFRDSLARFL; RRTERFFRDSLARFLE; RTERFFRDSLARFLEE;TERFFRDSLARFLEET; ERFFRDSLARFLEETT; RFFRDSLARFLEETTW; FFRDSLARFLEETTWT;FRDSLARFLEETTWTI; RDSLARFLEETTWTIV; DSLARFLEETTWTIVN; SLARFLEETTWTIVNA;LARFLEETTWTIVNAP; ARFLEETTWTIVNAPI; RFLEETTWTIVNAPIN; FLEETTWTIVNAPINF;LEETTWTIVNAPINFY; EETTWTIVNAPINFYN; ETTWTIVNAPINFYNY; TTWTIVNAPINFYNYI;TWTIVNAPINFYNYIQ; WTIVNAPINFYNYIQQ; TIVNAPINFYNYIQQY; IVNAPINFYNYIQQYY;VNAPINFYNYIQQYYS; NAPINFYNYIQQYYSD; APINFYNYIQQYYSDL; PINFYNYIQQYYSDLS;INFYNYIQQYYSDLSP; NFYNYIQQYYSDLSPI; FYNYIQQYYSDLSPIR; YNYIQQYYSDLSPIRP;NYIQQYYSDLSPIRPS; YIQQYYSDLSPIRPSM; IQQYYSDLSPIRPSMV; QQYYSDLSPIRPSMVR;QYYSDLSPIRPSMVRQ; YYSDLSPIRPSMVRQV; YSDLSPIRPSMVRQVA; SDLSPIRPSMVRQVAE;DLSPIRPSMVRQVAER; LSPIRPSMVRQVAERE; SPIRPSMVRQVAEREG; PIRPSMVRQVAEREGT;IRPSMVRQVAEREGTR; RPSMVRQVAEREGTRV; PSMVRQVAEREGTRVH; SMVRQVAEREGTRVHF;MVRQVAEREGTRVHFG; VRQVAEREGTRVHFGH; RQVAEREGTRVHFGHT; QVAEREGTRVHFGHTY;VAEREGTRVHFGHTYS; AEREGTRVHFGHTYSI; EREGTRVHFGHTYSID; REGTRVHFGHTYSIDD;EGTRVHFGHTYSIDDA; GTRVHFGHTYSIDDAD; TRVHFGHTYSIDDADS; RVHFGHTYSIDDADSI;VHFGHTYSIDDADSIE; HFGHTYSIDDADSIEE; FGHTYSIDDADSIEEV; GHTYSIDDADSIEEVT;HTYSIDDADSIEEVTQ; TYSIDDADSIEEVTQR; YSIDDADSIEEVTQRM; SIDDADSIEEVTQRMD;IDDADSIEEVTQRMDL; DDADSIEEVTQRMDLR; DADSIEEVTQRMDLRN; ADSIEEVTQRMDLRNQ;DSIEEVTQRMDLRNQQ; SIEEVTQRMDLRNQQS; IEEVTQRMDLRNQQSV; EEVTQRMDLRNQQSVH;EVTQRMDLRNQQSVHS; VTQRMDLRNQQSVHSG; TQRMDLRNQQSVHSGE; QRMDLRNQQSVHSGEF;RMDLRNQQSVHSGEFI; MDLRNQQSVHSGEFIE; DLRNQQSVHSGEFIEK; LRNQQSVHSGEFIEKT;RNQQSVHSGEFIEKTI; NQQSVHSGEFIEKTIA; QQSVHSGEFIEKTIAP; QSVHSGEFIEKTIAPG;SVHSGEFIEKTIAPGG; VHSGEFIEKTIAPGGA; HSGEFIEKTIAPGGAN; SGEFIEKTIAPGGANQ;GEFIEKTIAPGGANQR; EFIEKTIAPGGANQRT; FIEKTIAPGGANQRTA; IEKTIAPGGANQRTAP;EKTIAPGGANQRTAPQ; KTIAPGGANQRTAPQW; TIAPGGANQRTAPQWM; IAPGGANQRTAPQWML;APGGANQRTAPQWMLP; PGGANQRTAPQWMLPL; GGANQRTAPQWMLPLL; GANQRTAPQWMLPLLL;ANQRTAPQWMLPLLLG; NQRTAPQWMLPLLLGL; QRTAPQWMLPLLLGLY; RTAPQWMLPLLLGLYG;TAPQWMLPLLLGLYGT; APQWMLPLLLGLYGTV; PQWMLPLLLGLYGTVT; QWMLPLLLGLYGTVTP;WMLPLLLGLYGTVTPA; MLPLLLGLYGTVTPAL; LPLLLGLYGTVTPALE; PLLLGLYGTVTPALEA;LLLGLYGTVTPALEAY; LLGLYGTVTPALEAYE; LGLYGTVTPALEAYED; GLYGTVTPALEAYEDG;LYGTVTPALEAYEDGP; YGTVTPALEAYEDGPN; GTVTPALEAYEDGPNQ; TVTPALEAYEDGPNQK;VTPALEAYEDGPNQKK; TPALEAYEDGPNQKKR; PALEAYEDGPNQKKRR; ALEAYEDGPNQKKRRV;LEAYEDGPNQKKRRVS; EAYEDGPNQKKRRVSR; AYEDGPNQKKRRVSRG; YEDGPNQKKRRVSRGS;EDGPNQKKRRVSRGSS; DGPNQKKRRVSRGSSQ; GPNQKKRRVSRGSSQK; PNQKKRRVSRGSSQKA;NQKKRRVSRGSSQKAK; QKKRRVSRGSSQKAKG; KKRRVSRGSSQKAKGT; KRRVSRGSSQKAKGTR;RRVSRGSSQKAKGTRA; RVSRGSSQKAKGTRAS; VSRGSSQKAKGTRASA; SRGSSQKAKGTRASAK;RGSSQKAKGTRASAKT; GSSQKAKGTRASAKTT; SSQKAKGTRASAKTTN; SQKAKGTRASAKTTNK;QKAKGTRASAKTTNKR; KAKGTRASAKTTNKRR; AKGTRASAKTTNKRRS; KGTRASAKTTNKRRSR;GTRASAKTTNKRRSRS; TRASAKTTNKRRSRSS; RASAKTTNKRRSRSSR; ASAKTTNKRRSRSSRS;NWGRCYYRGRMLPKPR; WGRCYYRGRMLPKPRN; GRCYYRGRMLPKPRNG; RCYYRGRMLPKPRNGG;CYYRGRMLPKPRNGGS; YYRGRMLPKPRNGGSR; PREKNASLLQHSKNSP; REKNASLLQHSKNSPP;EKNASLLQHSKNSPPQ; KNASLLQHSKNSPPQF; NASLLQHSKNSPPQFK; GPNLWKSTDVGGCNCT;PNLWKSTDVGGCNCTN; NLWKSTDVGGCNCTNR; LWKSTDVGGCNCTNRG; WKSTDVGGCNCTNRGY;KSTDVGGCNCTNRGYW; STDVGGCNCTNRGYWN; TDVGGCNCTNRGYWNN; FPLLCCRWRTLGNAGS;PLLCCRWRTLGNAGSA; LLCCRWRTLGNAGSAN; LCCRWRTLGNAGSANE; CCRWRTLGNAGSANEL;CRWRTLGNAGSANELQ; RWRTLGNAGSANELQV; WRTLGNAGSANELQVK; RTLGNAGSANELQVKV;TLGNAGSANELQVKVP; VFWDFHRRGKCSPSTS; FWDFHRRGKCSPSTSC; WDFHRRGKCSPSTSCD;DFHRRGKCSPSTSCDQ; FHRRGKCSPSTSCDQH; HRRGKCSPSTSCDQHS; RRGKCSPSTSCDQHSY;RGKCSPSTSCDQHSYH; GKCSPSTSCDQHSYHS; KCSPSTSCDQHSYHSV; CSPSTSCDQHSYHSVA;SPSTSCDQHSYHSVAR; DPPEKKICKESLPNFL; PPEKKICKESLPNFLF; PEKKICKESLPNFLFA;EKKICKESLPNFLFAK; PYKQENPESGWAAYVW; YKQENPESGWAAYVWY; KQENPESGWAAYVWYG;QENPESGWAAYVWYGI; ENPESGWAAYVWYGIP; NPESGWAAYVWYGIPG; PESGWAAYVWYGIPGR;ESGWAAYVWYGIPGRR; SGWAAYVWYGIPGRRG; QTGTIANQNALNRCFY; TGTIANQNALNRCFYC;GTIANQNALNRCFYCT; TIANQNALNRCFYCTY; IANQNALNRCFYCTYT; ANQNALNRCFYCTYTF;NQNALNRCFYCTYTFN; QNALNRCFYCTYTFNK; NALNRCFYCTYTFNKC; ALNRCFYCTYTFNKCC;LNRCFYCTYTFNKCCF; NRCFYCTYTFNKCCFC; RCFYCTYTFNKCCFCI; CFYCTYTFNKCCFCIS;FYCTYTFNKCCFCISH; YCTYTFNKCCFCISHF; NTESLYTNATLDYGGL; TESLYTNATLDYGGLT;ESLYTNATLDYGGLTF; SLYTNATLDYGGLTFG; LYTNATLDYGGLTFGN; YTNATLDYGGLTFGNL;TNATLDYGGLTFGNLQ; NATLDYGGLTFGNLQQ; ATLDYGGLTFGNLQQG; TLDYGGLTFGNLQQGL;LDYGGLTFGNLQQGLK; DYGGLTFGNLQQGLKY; YGGLTFGNLQQGLKYL; GGLTFGNLQQGLKYLR;GLTFGNLQQGLKYLRL; LTFGNLQQGLKYLRLG; TFGNLQQGLKYLRLGK; FGNLQQGLKYLRLGKS;GNLQQGLKYLRLGKSI; NLQQGLKYLRLGKSIV; LQQGLKYLRLGKSIVI; QQGLKYLRLGKSIVIG;QGLKYLRLGKSIVIGI; GLKYLRLGKSIVIGIQ; LKYLRLGKSIVIGIQC; KYLRLGKSIVIGIQCL;YLRLGKSIVIGIQCLI; LRLGKSIVIGIQCLIH; RLGKSIVIGIQCLIHV; LGKSIVIGIQCLIHVQ;GKSIVIGIQCLIHVQS; KSIVIGIQCLIHVQSL; SIVIGIQCLIHVQSLQ; IVIGIQCLIHVQSLQF;VIGIQCLIHVQSLQFL; IGIQCLIHVQSLQFLN; GIQCLIHVQSLQFLNP; IQCLIHVQSLQFLNPL;QCLIHVQSLQFLNPLL; CLIHVQSLQFLNPLLL; YQEYISPCIYYISSLK; QEYISPCIYYISSLKK;EYISPCIYYISSLKKY; YISPCIYYISSLKKYT; ISPCIYYISSLKKYTY; SPCIYYISSLKKYTYL;PCIYYISSLKKYTYLS; CIYYISSLKKYTYLSQ; IYYISSLKKYTYLSQN; YYISSLKKYTYLSQNP;YISSLKKYTYLSQNPA; ISSLKKYTYLSQNPAF; SSLKKYTYLSQNPAFP; SLKKYTYLSQNPAFPS;LKKYTYLSQNPAFPSI; KKYTYLSQNPAFPSIQ; KYTYLSQNPAFPSIQQ; YTYLSQNPAFPSIQQF;TKLAVATRSFHFVKFF; KLAVATRSFHFVKFFF; LAVATRSFHFVKFFFQ; AVATRSFHFVKFFFQV;VATRSFHFVKFFFQVR; ATRSFHFVKFFFQVRT; TRSFHFVKFFFQVRTL; RSFHFVKFFFQVRTLS;SFHFVKFFFQVRTLSF; FHFVKFFFQVRTLSFV; HFVKFFFQVRTLSFVR; FVKFFFQVRTLSFVRI;VKFFFQVRTLSFVRIF; KFFFQVRTLSFVRIFL; FFFQVRTLSFVRIFLN; FFQVRTLSFVRIFLNI;FQVRTLSFVRIFLNIF; QVRTLSFVRIFLNIFW; VRTLSFVRIFLNIFWA; PSLVEIFGFFCLNVSF;SLVEIFGFFCLNVSFL; LVEIFGFFCLNVSFLN; VEIFGFFCLNVSFLNL; EIFGFFCLNVSFLNLP;HFHLNNLSNCLNCLFH; FHLNNLSNCLNCLFHV; HLNNLSNCLNCLFHVL; LNNLSNCLNCLFHVLK;NNLSNCLNCLFHVLKA; NLSNCLNCLFHVLKAN; LSNCLNCLFHVLKANP; SNCLNCLFHVLKANPL;NCLNCLFHVLKANPLI; CLNCLFHVLKANPLIQ; LNCLFHVLKANPLIQL; NCLFHVLKANPLIQLL;CLFHVLKANPLIQLLS; LFHVLKANPLIQLLSL; FHVLKANPLIQLLSLL; HVLKANPLIQLLSLLH;VLKANPLIQLLSLLHL; LKANPLIQLLSLLHLQ; KANPLIQLLSLLHLQK; ANPLIQLLSLLHLQKQ;NPLIQLLSLLHLQKQP; PLIQLLSLLHLQKQPC; LIQLLSLLHLQKQPCT; IQLLSLLHLQKQPCTD;QLLSLLHLQKQPCTDL; LHLAQRLAFPWVGLHL; HLAQRLAFPWVGLHLR; LAQRLAFPWVGLHLRL;AQRLAFPWVGLHLRLY; QRLAFPWVGLHLRLYH; RLAFPWVGLHLRLYHH; LAFPWVGLHLRLYHHT;AFPWVGLHLRLYHHTN; FPWVGLHLRLYHHTNL; PWVGLHLRLYHHTNLI; WVGLHLRLYHHTNLIT;VGLHLRLYHHTNLITL; GLHLRLYHHTNLITLQ; LHLRLYHHTNLITLQL; HLRLYHHTNLITLQLV;LRLYHHTNLITLQLVL; RLYHHTNLITLQLVLF; LYHHTNLITLQLVLFF; YHHTNLITLQLVLFFH;HHTNLITLQLVLFFHY; HTNLITLQLVLFFHYQ; TNLITLQLVLFFHYQW; NLITLQLVLFFHYQWD;LITLQLVLFFHYQWDL; VANSAAKQHLPYIVLV; ANSAAKQHLPYIVLVQ; NSAAKQHLPYIVLVQH;SAAKQHLPYIVLVQHF; AAKQHLPYIVLVQHFH; AKQHLPYIVLVQHFHE; KQHLPYIVLVQHFHEL;QHLPYIVLVQHFHELQ; HLPYIVLVQHFHELQI; LPYIVLVQHFHELQIL; PYIVLVQHFHELQILN;YIVLVQHFHELQILNP; IVLVQHFHELQILNPF; VLVQHFHELQILNPFY; LVQHFHELQILNPFYL;VQHFHELQILNPFYLI; QHFHELQILNPFYLIY; HFHELQILNPFYLIYD; IFLLAFLPWSYEGYLL;FLLAFLPWSYEGYLLF; LLAFLPWSYEGYLLFF; LKLYLLLADKYFFDFY; KLYLLLADKYFFDFYF;LYLLLADKYFFDFYFL; YLLLADKYFFDFYFLQ; LLLADKYFFDFYFLQK; SDKAGLFSDTFYTPLH;DKAGLFSDTFYTPLHC; KAGLFSDTFYTPLHCI; AGLFSDTFYTPLHCIE; GLFSDTFYTPLHCIEI;LFSDTFYTPLHCIEIL; FSDTFYTPLHCIEILN; SDTFYTPLHCIEILNT; DTFYTPLHCIEILNTY;TFYTPLHCIEILNTYL; FYTPLHCIEILNTYLI; YTPLHCIEILNTYLII; TPLHCIEILNTYLIIK;PLHCIEILNTYLIIKT; LHCIEILNTYLIIKTH; HCIEILNTYLIIKTHP; CIEILNTYLIIKTHPH;IEILNTYLIIKTHPHT; EILNTYLIIKTHPHTL; ILNTYLIIKTHPHTLS; LNTYLIIKTHPHTLSL;NTYLIIKTHPHTLSLL; TYLIIKTHPHTLSLLH; YLIIKTHPHTLSLLHT; LIIKTHPHTLSLLHTQ;GLLPFFFFWVVLSVEN; LLPFFFFWVVLSVENL; LPFFFFWVVLSVENLL; PFFFFWVVLSVENLLL;FFFFWVVLSVENLLLL; FFFWVVLSVENLLLLL; FFWVVLSVENLLLLLH; FWVVLSVENLLLLLHH;WVVLSVENLLLLLHHW; VVLSVENLLLLLHHWQ; VLSVENLLLLLHHWQT; LSVENLLLLLHHWQTY;SVENLLLLLHHWQTYL; VENLLLLLHHWQTYLH; ENLLLLLHHWQTYLHG; NLLLLLHHWQTYLHGK;LLLLLHHWQTYLHGKI; LLLLHHWQTYLHGKIN; LLLHHWQTYLHGKINL; LLHHWQTYLHGKINLH;LHHWQTYLHGKINLHP; HHWQTYLHGKINLHPI; HWQTYLHGKINLHPIF; WQTYLHGKINLHPIFH;RNSTRTPTLLFHRLAP; NSTRTPTLLFHRLAPI; STRTPTLLFHRLAPIK; TRTPTLLFHRLAPIKK;RTPTLLFHRLAPIKKI; TPTLLFHRLAPIKKII; PTLLFHRLAPIKKIIT; GLLIFYYLSKYKLVTL;LLIFYYLSKYKLVTLK; LIFYYLSKYKLVTLKL; ISEGSFSNYLDPPLQS; SEGSFSNYLDPPLQSF;EGSFSNYLDPPLQSFF; GSFSNYLDPPLQSFFS; AKPLCEAVNAVAIYPN; KPLCEAVNAVAIYPNQ;PLCEAVNAVAIYPNQG; LCEAVNAVAIYPNQGL; CEAVNAVAIYPNQGLF; EAVNAVAIYPNQGLFS;HARAVHRRLFGTNRPF; ARAVHRRLFGTNRPFL; RAVHRRLFGTNRPFLA; AVHRRLFGTNRPFLAV;VHRRLFGTNRPFLAVQ; HRRLFGTNRPFLAVQG; RRLFGTNRPFLAVQGI; RLFGTNRPFLAVQGIW;LFGTNRPFLAVQGIWA; FGTNRPFLAVQGIWAK; GTNRPFLAVQGIWAKR; TNRPFLAVQGIWAKRK;NRPFLAVQGIWAKRKI; RPFLAVQGIWAKRKIS; PFLAVQGIWAKRKIST; FLAVQGIWAKRKISTN;LAVQGIWAKRKISTNL; ATPGSKIRLMSYLYIL; TPGSKIRLMSYLYILL; PGSKIRLMSYLYILLH;GSKIRLMSYLYILLHF; SKIRLMSYLYILLHFF; KIRLMSYLYILLHFFI; IRLMSYLYILLHFFIQ;RLMSYLYILLHFFIQS; LMSYLYILLHFFIQSI; MSYLYILLHFFIQSIH; SYLYILLHFFIQSIHS;YLYILLHFFIQSIHSL; LYILLHFFIQSIHSLH; YILLHFFIQSIHSLHF; ILLHFFIQSIHSLHFI;LLHFFIQSIHSLHFIL; LHFFIQSIHSLHFILV; HFFIQSIHSLHFILVA; FFIQSIHSLHFILVAP;FIQSIHSLHFILVAPF; IQSIHSLHFILVAPFV; QSIHSLHFILVAPFVR; SIHSLHFILVAPFVRV;IHSLHFILVAPFVRVK; HSLHFILVAPFVRVKF; SLHFILVAPFVRVKFL; LHFILVAPFVRVKFLT;HFILVAPFVRVKFLT BK virus reverse reading frame 1 13 mers: MDKVLNREESMEL;DKVLNREESMELM; KVLNREESMELMD; VLNREESMELMDL; LNREESMELMDLL;NREESMELMDLLG; REESMELMDLLGL; EESMELMDLLGLE; ESMELMDLLGLER;SMELMDLLGLERA; MELMDLLGLERAA; ELMDLLGLERAAW; LMDLLGLERAAWG;MDLLGLERAAWGN; DLLGLERAAWGNL; LLGLERAAWGNLP; LGLERAAWGNLPL;GLERAAWGNLPLM; LERAAWGNLPLMR; ERAAWGNLPLMRK; RAAWGNLPLMRKA;AAWGNLPLMRKAY; AWGNLPLMRKAYL; WGNLPLMRKAYLR; GNLPLMRKAYLRK;NLPLMRKAYLRKC; LPLMRKAYLRKCK; PLMRKAYLRKCKE; LMRKAYLRKCKEF;MRKAYLRKCKEFH; RKAYLRKCKEFHP; KAYLRKCKEFHPD; AYLRKCKEFHPDK;YLRKCKEFHPDKG; LRKCKEFHPDKGG; RKCKEFHPDKGGD; KCKEFHPDKGGDE;CKEFHPDKGGDED; KEFHPDKGGDEDK; EFHPDKGGDEDKM; FHPDKGGDEDKMK;HPDKGGDEDKMKR; PDKGGDEDKMKRM; DKGGDEDKMKRMN; KGGDEDKMKRMNT;GGDEDKMKRMNTL; GDEDKMKRMNTLY; DEDKMKRMNTLYK; EDKMKRMNTLYKK;DKMKRMNTLYKKM; KMKRMNTLYKKME; MKRMNTLYKKMEQ; KRMNTLYKKMEQD;RMNTLYKKMEQDV; MNTLYKKMEQDVK; NTLYKKMEQDVKV; TLYKKMEQDVKVA;LYKKMEQDVKVAH; YKKMEQDVKVAHQ; KKMEQDVKVAHQP; KMEQDVKVAHQPD;MEQDVKVAHQPDF; EQDVKVAHQPDFG; QDVKVAHQPDFGT; DVKVAHQPDFGTW;VKVAHQPDFGTWS; KVAHQPDFGTWSS; VAHQPDFGTWSSS; AHQPDFGTWSSSE;HQPDFGTWSSSEV; QPDFGTWSSSEVC; PDFGTWSSSEVCA; DFGTWSSSEVCAD;FGTWSSSEVCADF; GTWSSSEVCADFP; TWSSSEVCADFPL; WSSSEVCADFPLC;SSSEVCADFPLCP; SSEVCADFPLCPD; SEVCADFPLCPDT; EVCADFPLCPDTL;VCADFPLCPDTLY; CADFPLCPDTLYC; ADFPLCPDTLYCK; DFPLCPDTLYCKE;FPLCPDTLYCKEW; PLCPDTLYCKEWP; LCPDTLYCKEWPI; CPDTLYCKEWPIC;PDTLYCKEWPICS; DTLYCKEWPICSK; TLYCKEWPICSKK; LYCKEWPICSKKP;YCKEWPICSKKPS; CKEWPICSKKPSV; KEWPICSKKPSVH; EWPICSKKPSVHC;WPICSKKPSVHCP; PICSKKPSVHCPC; ICSKKPSVHCPCM; CSKKPSVHCPCML;SKKPSVHCPCMLC; KKPSVHCPCMLCQ; KPSVHCPCMLCQL; PSVHCPCMLCQLR;SVHCPCMLCQLRL; VHCPCMLCQLRLR; HCPCMLCQLRLRH; CPCMLCQLRLRHL;PCMLCQLRLRHLN; CMLCQLRLRHLNR; MLCQLRLRHLNRK; LCQLRLRHLNRKF;CQLRLRHLNRKFL; QLRLRHLNRKFLR; LRLRHLNRKFLRK; RLRHLNRKFLRKE;LRHLNRKFLRKEP; RHLNRKFLRKEPL; HLNRKFLRKEPLV; LNRKFLRKEPLVW;NRKFLRKEPLVWI; RKFLRKEPLVWID; KFLRKEPLVWIDC; FLRKEPLVWIDCY;LRKEPLVWIDCYC; RKEPLVWIDCYCI; KEPLVWIDCYCID; EPLVWIDCYCIDC;PLVWIDCYCIDCF; LVWIDCYCIDCFT; VWIDCYCIDCFTQ; WIDCYCIDCFTQW;IDCYCIDCFTQWF; DCYCIDCFTQWFG; CYCIDCFTQWFGL; YCIDCFTQWFGLD;CIDCFTQWFGLDL; IDCFTQWFGLDLT; DCFTQWFGLDLTE; CFTQWFGLDLTEE;FTQWFGLDLTEET; TQWFGLDLTEETL; QWFGLDLTEETLQ; WFGLDLTEETLQW;FGLDLTEETLQWW; GLDLTEETLQWWV; LDLTEETLQWWVQ; DLTEETLQWWVQI;LTEETLQWWVQII; TEETLQWWVQIIG; EETLQWWVQIIGE; ETLQWWVQIIGET;TLQWWVQIIGETP; LQWWVQIIGETPF; QWWVQIIGETPFR; WWVQIIGETPFRD;WVQIIGETPFRDL; VQIIGETPFRDLK; QIIGETPFRDLKL; KALSNYFFYRCQP;ALSNYFFYRCQPM; LSNYFFYRCQPME; SNYFFYRCQPMEQ; NYFFYRCQPMEQK;YFFYRCQPMEQKS; FFYRCQPMEQKSG; FYRCQPMEQKSGS; YRCQPMEQKSGSP;RCQPMEQKSGSPG; CQPMEQKSGSPGG; QPMEQKSGSPGGV; PMEQKSGSPGGVP;MEQKSGSPGGVPL; EQKSGSPGGVPLM; QKSGSPGGVPLMK; KSGSPGGVPLMKN;SGSPGGVPLMKNG; GSPGGVPLMKNGM; SPGGVPLMKNGMK; PGGVPLMKNGMKI;GGVPLMKNGMKIY; GVPLMKNGMKIYF; VPLMKNGMKIYFA; PLMKNGMKIYFAM;LMKNGMKIYFAMK; MKNGMKIYFAMKI; KNGMKIYFAMKIC; NGMKIYFAMKICL;GMKIYFAMKICLP; MKIYFAMKICLPV; KIYFAMKICLPVM; IYFAMKICLPVMK;YFAMKICLPVMKK; FAMKICLPVMKKQ; AMKICLPVMKKQQ; MKICLPVMKKQQQ;KICLPVMKKQQQI; ICLPVMKKQQQIL; CLPVMKKQQQILN; LPVMKKQQQILNT;PVMKKQQQILNTQ; VMKKQQQILNTQH; MKKQQQILNTQHH; KKQQQILNTQHHP;KQQQILNTQHHPK; QQQILNTQHHPKK; QQILNTQHHPKKK; QILNTQHHPKKKE;ILNTQHHPKKKER; KTLKTFPLIYTSF; TLKTFPLIYTSFL; LKTFPLIYTSFLV;KTFPLIYTSFLVK; TFPLIYTSFLVKL; FPLIYTSFLVKLY; PLIYTSFLVKLYL;LIYTSFLVKLYLV; IYTSFLVKLYLVI; YTSFLVKLYLVIE; TSFLVKLYLVIEP;SFLVKLYLVIEPL; FLVKLYLVIEPLP; LVKLYLVIEPLPA; VKLYLVIEPLPAL;KLYLVIEPLPALL; LYLVIEPLPALLC; YLVIEPLPALLCI; LVIEPLPALLCIL;VIEPLPALLCILL; IEPLPALLCILLK; EPLPALLCILLKK; PLPALLCILLKKK;LPALLCILLKKKL; PALLCILLKKKLK; ALLCILLKKKLKF; LLCILLKKKLKFC;LCILLKKKLKFCI; CILLKKKLKFCIK; ILLKKKLKFCIKN; LLKKKLKFCIKNL;LKKKLKFCIKNLW; KKKLKFCIKNLWK; KKLKFCIKNLWKN; KLKFCIKNLWKNI;LKFCIKNLWKNIL; LLLVDTCVLGIIL; LLVDTCVLGIILY; LVDTCVLGIILYS;VDTCVLGIILYSF; LHIDIEFLQLIIS; HIDIEFLQLIISV; IDIEFLQLIISVK;DIEFLQLIISVKS; IEFLQLIISVKSC; EFLQLIISVKSCV; FLQLIISVKSCVP;LQLIISVKSCVPL; QLIISVKSCVPLV; LIISVKSCVPLVF; FVRVLIRNTYYIV;VRVLIRNTYYIVP; RSMILAQKSLKKQ; SMILAQKSLKKQS; MILAQKSLKKQSR;ILAQKSLKKQSRC; LAQKSLKKQSRCL; AQKSLKKQSRCLG; QKSLKKQSRCLGN;RSVKSVRKKTSLI; SVKSVRKKTSLIT; VKSVRKKTSLITL; KSVRKKTSLITLS;SVRKKTSLITLSI; VRKKTSLITLSIM; RKKTSLITLSIMK; KKTSLITLSIMKS;KTSLITLSIMKST; TSLITLSIMKSTL; SLITLSIMKSTLQ; LITLSIMKSTLQM;ITLSIMKSTLQML; TLSIMKSTLQMLL; LSIMKSTLQMLLF; SIMKSTLQMLLFL;IMKSTLQMLLFLQ; MKSTLQMLLFLQK; KSTLQMLLFLQKV; STLQMLLFLQKVK;TLQMLLFLQKVKI; LQMLLFLQKVKIK; QMLLFLQKVKIKK; MLLFLQKVKIKKV;LLFLQKVKIKKVF; LFLQKVKIKKVFV; FLQKVKIKKVFVS; LQKVKIKKVFVSK;QKVKIKKVFVSKQ; NNIWQVLLGCTVC; NIWQVLLGCTVCY; IWQVLLGCTVCYL;WQVLLGCTVCYLK; QVLLGCTVCYLKW; VLLGCTVCYLKWI; LLGCTVCYLKWIL;YLIFCTVLFSMYL; LIFCTVLFSMYLK; IFCTVLFSMYLKE; FCTVLFSMYLKED;CTVLFSMYLKEDT; TVLFSMYLKEDTG; VLFSMYLKEDTGY; LFSMYLKEDTGYL;FSMYLKEDTGYLK; SMYLKEDTGYLKV; MYLKEDTGYLKVP; YLKEDTGYLKVPL;LKEDTGYLKVPLI; KEDTGYLKVPLIV; EDTGYLKVPLIVE; DTGYLKVPLIVEK;TGYLKVPLIVEKQ; GYLKVPLIVEKQH; KGQELNQRICLQD; GQELNQRICLQDM;QELNQRICLQDME; TKEPKYFHQAWLQ; MSILSLKPCKLDL; ENPYKTQSSYLKK;NPYKTQSSYLKKE; PYKTQSSYLKKEF; YKTQSSYLKKEFY; KTQSSYLKKEFYK;TQSSYLKKEFYKV; QSSYLKKEFYKVE; LILQLIYNLELLN; ILQLIYNLELLNG;LQLIYNLELLNGR; QLIYNLELLNGRK; LIYNLELLNGRKG; IYNLELLNGRKGW;YNLELLNGRKGWI; NLELLNGRKGWIL; LELLNGRKGWILR; NIIYAWGNVFLIL;IIYAWGNVFLILQ; IYAWGNVFLILQE; YAWGNVFLILQEK; AWGNVFLILQEKR;WGNVFLILQEKRI; GNVFLILQEKRIQ; NVFLILQEKRIQK; VFLILQEKRIQKL;FLILQEKRIQKLK; LILQEKRIQKLKT; ILQEKRIQKLKTL; LQEKRIQKLKTLD;QEKRIQKLKTLDM; EKRIQKLKTLDMD; KRIQKLKTLDMDQ; RIQKLKTLDMDQA;IQKLKTLDMDQAL; QKLKTLDMDQALN; KLKTLDMDQALNP; LKTLDMDQALNPN;KTLDMDQALNPNH; TLDMDQALNPNHN; LDMDQALNPNHNA; DMDQALNPNHNAL;MDQALNPNHNALP; DQALNPNHNALPK; QALNPNHNALPKS; ALNPNHNALPKSQ;LNPNHNALPKSQI; NPNHNALPKSQIL; PNHNALPKSQILQ; NHNALPKSQILQP;HNALPKSQILQPL; NALPKSQILQPLL; ALPKSQILQPLLK; LPKSQILQPLLKI;PKSQILQPLLKIP; KSQILQPLLKIPK; SQILQPLLKIPKG; QILQPLLKIPKGQ;ILQPLLKIPKGQT; LQPLLKIPKGQTP; QPLLKIPKGQTPI; PLLKIPKGQTPIV;LLKIPKGQTPIVK; LKIPKGQTPIVKS; KIPKGQTPIVKSC; IPKGQTPIVKSCI;PKGQTPIVKSCIC; KGQTPIVKSCICV; GQTPIVKSCICVK; QTPIVKSCICVKA;TPIVKSCICVKAF; PIVKSCICVKAFS; IVKSCICVKAFSV; VKSCICVKAFSVL;KSCICVKAFSVLK; SCICVKAFSVLKG; CICVKAFSVLKGL; ICVKAFSVLKGLK;CVKAFSVLKGLKH; VKAFSVLKGLKHH; KAFSVLKGLKHHP; AFSVLKGLKHHPQ;FSVLKGLKHHPQN; SVLKGLKHHPQNN; VLKGLKHHPQNNT; LKGLKHHPQNNTS;KGLKHHPQNNTSL; GLKHHPQNNTSLK; LKHHPQNNTSLKV; KHHPQNNTSLKVA;HHPQNNTSLKVAY; HPQNNTSLKVAYT; PQNNTSLKVAYTK; QNNTSLKVAYTKA;NNTSLKVAYTKAA; NTSLKVAYTKAAF; TSLKVAYTKAAFI; SLKVAYTKAAFIK;LKVAYTKAAFIKC; KVAYTKAAFIKCI; VAYTKAAFIKCIC; AYTKAAFIKCICT;YTKAAFIKCICTI; TKAAFIKCICTIK; KAAFIKCICTIKA; AAFIKCICTIKAP;AFIKCICTIKAPV; SILVCNCPCLSIY; ILVCNCPCLSIYL; LVCNCPCLSIYLI;VCNCPCLSIYLII; CNCPCLSIYLIIS; NCPCLSIYLIISG; CPCLSIYLIISGS;PCLSIYLIISGSP; CLSIYLIISGSPG; LSIYLIISGSPGS; SIYLIISGSPGSL;IYLIISGSPGSLS; YLIISGSPGSLSV; LIISGSPGSLSVP; IISGSPGSLSVPS;ISGSPGSLSVPSN; SGSPGSLSVPSNT; GSPGSLSVPSNTL; SPGSLSVPSNTLT;PGSLSVPSNTLTS; GSLSVPSNTLTSS; SLSVPSNTLTSST; LSVPSNTLTSSTW;SVPSNTLTSSTWD; VPSNTLTSSTWDS; PSNTLTSSTWDSI; SNTLTSSTWDSIP;NTLTSSTWDSIPY; TLTSSTWDSIPYI; LTSSTWDSIPYIG; TSSTWDSIPYIGC;SSTWDSIPYIGCP; STWDSIPYIGCPS; TWDSIPYIGCPST; WDSIPYIGCPSTL;DSIPYIGCPSTLW; SIPYIGCPSTLWV; IPYIGCPSTLWVL; PYIGCPSTLWVLL;YIGCPSTLWVLLF; IGCPSTLWVLLFI; GCPSTLWVLLFIR; CPSTLWVLLFIRS;PSTLWVLLFIRSL; STLWVLLFIRSLS; TLWVLLFIRSLSK; LWVLLFIRSLSKK;WVLLFIRSLSKKE; VLLFIRSLSKKEI; LLFIRSLSKKEIG; GFFTDLFLRRILK;FFTDLFLRRILKY; FTDLFLRRILKYL; TDLFLRRILKYLA; DLFLRRILKYLAR;LFLRRILKYLARP; FLRRILKYLARPL; LRRILKYLARPLH; RRILKYLARPLHC;RILKYLARPLHCC; ILKYLARPLHCCV; LKYLARPLHCCVP; KYLARPLHCCVPE;YLARPLHCCVPEL; LARPLHCCVPELL; ARPLHCCVPELLV; RPLHCCVPELLVN;PLHCCVPELLVNR; LHCCVPELLVNRP; HCCVPELLVNRPQ; CCVPELLVNRPQI;CVPELLVNRPQIS; VPELLVNRPQISA; PELLVNRPQISAA; ELLVNRPQISAAE;LLVNRPQISAAET; LVNRPQISAAETY; VNRPQISAAETYR; NRPQISAAETYRL;RPQISAAETYRLS; PQISAAETYRLSA; QISAAETYRLSAL; ISAAETYRLSALQ;SAAETYRLSALQR; AAETYRLSALQRG; AETYRLSALQRGP; ETYRLSALQRGPT;TYRLSALQRGPTP; YRLSALQRGPTPC; RLSALQRGPTPCS; LSALQRGPTPCSS;SALQRGPTPCSSS; ALQRGPTPCSSSN; LQRGPTPCSSSNT; QRGPTPCSSSNTV;RGPTPCSSSNTVV; GPTPCSSSNTVVA; PTPCSSSNTVVAV; TPCSSSNTVVAVL;PCSSSNTVVAVLV; CSSSNTVVAVLVT; STGGTFSPPVKVP; TGGTFSPPVKVPK;GGTFSPPVKVPKY; GTFSPPVKVPKYL; TFSPPVKVPKYLA; FSPPVKVPKYLAF;SPPVKVPKYLAFS; PPVKVPKYLAFSF; PVKVPKYLAFSFL; VKVPKYLAFSFLL;KVPKYLAFSFLLG; VPKYLAFSFLLGS; PKYLAFSFLLGSG; KYLAFSFLLGSGT;YLAFSFLLGSGTQ; LAFSFLLGSGTQH; AFSFLLGSGTQHS; FSFLLGSGTQHST;SFLLGSGTQHSTG; ALWSVFITWDWAV; LWSVFITWDWAVG; WSVFITWDWAVGF;SVFITWDWAVGFL; VFITWDWAVGFLG; FITWDWAVGFLGV; ITWDWAVGFLGVI;TWDWAVGFLGVIV; WDWAVGFLGVIVP; DWAVGFLGVIVPS; WAVGFLGVIVPSG;AVGFLGVIVPSGY; VGFLGVIVPSGYF; GFLGVIVPSGYFD; FLGVIVPSGYFDL;FISTPCISKGSPP; ISTPCISKGSPPT; STPCISKGSPPTA; TPCISKGSPPTAK;PCISKGSPPTAKK; CISKGSPPTAKKW; ISKGSPPTAKKWK; SKGSPPTAKKWKL;KGSPPTAKKWKLL; GSPPTAKKWKLLP; IGFPPPCSCTFCD; GFPPPCSCTFCDP;FPPPCSCTFCDPA; RLSMLVIPITSVC; LSMLVIPITSVCT; SMLVIPITSVCTV;MLVIPITSVCTVT; LVIPITSVCTVTA; VIPITSVCTVTAS; IPITSVCTVTASH;PITSVCTVTASHI; ITSVCTVTASHIS; TSVCTVTASHISR; SVCTVTASHISRF;VCTVTASHISRFP; CTVTASHISRFPQ; TVTASHISRFPQV; VTASHISRFPQVR;TASHISRFPQVRS; ASHISRFPQVRSS; SHISRFPQVRSSF; HISRFPQVRSSFK;ISRFPQVRSSFKL; SRFPQVRSSFKLG; RFPQVRSSFKLGR; FPQVRSSFKLGRG;PQVRSSFKLGRGI; QVRSSFKLGRGIL; VRSSFKLGRGILA; RSSFKLGRGILAV;SSFKLGRGILAVL; QGSIFLSGLSLLK; GSIFLSGLSLLKS; SIFLSGLSLLKSF;IFLSGLSLLKSFS; FLSGLSLLKSFSA; LSGLSLLKSFSAL; SGLSLLKSFSALS;GLSLLKSFSALSF; LSLLKSFSALSFR; SLLKSFSALSFRL; LLKSFSALSFRLK;LKSFSALSFRLKP; KSFSALSFRLKPL; SFSALSFRLKPLR; FSALSFRLKPLRF;SALSFRLKPLRFS; ALSFRLKPLRFSS; LSFRLKPLRFSSG; SFRLKPLRFSSGS;FRLKPLRFSSGSP; RLKPLRFSSGSPI; LKPLRFSSGSPIS; KPLRFSSGSPISG;PLRFSSGSPISGF; LRFSSGSPISGFR; RFSSGSPISGFRK; FSSGSPISGFRKH;SSGSPISGFRKHS; SGSPISGFRKHST; GSPISGFRKHSTS; SPISGFRKHSTSV;PISGFRKHSTSVI; ISGFRKHSTSVIA; SGFRKHSTSVIAS; GFRKHSTSVIAST;FRKHSTSVIASTP; RKHSTSVIASTPV; KHSTSVIASTPVL; HSTSVIASTPVLT;STSVIASTPVLTS; TSVIASTPVLTSR; SVIASTPVLTSRT; VIASTPVLTSRTS;IASTPVLTSRTST; ASTPVLTSRTSTP; STPVLTSRTSTPP; TPVLTSRTSTPPF;PVLTSRTSTPPFI; VLTSRTSTPPFIS; LTSRTSTPPFISS; TSRTSTPPFISSF;SRTSTPPFISSFG; RTSTPPFISSFGT; TSTPPFISSFGTC; STPPFISSFGTCT;TPPFISSFGTCTG; PPFISSFGTCTGS; PFISSFGTCTGSF; FISSFGTCTGSFG;ISSFGTCTGSFGF; SSFGTCTGSFGFL; SFGTCTGSFGFLG; FGTCTGSFGFLGA;GTCTGSFGFLGAA; TCTGSFGFLGAAP; CTGSFGFLGAAPG; TGSFGFLGAAPGH;GSFGFLGAAPGHS; SFGFLGAAPGHSP; FGFLGAAPGHSPF; GFLGAAPGHSPFL;FLGAAPGHSPFLL; LGAAPGHSPFLLV; GAAPGHSPFLLVG; AAPGHSPFLLVGA;APGHSPFLLVGAI; PGHSPFLLVGAIF; GHSPFLLVGAIFI; HSPFLLVGAIFIC;SPFLLVGAIFICF; PFLLVGAIFICFK; FLLVGAIFICFKS; LLVGAIFICFKSR;LVGAIFICFKSRC; VGAIFICFKSRCY; GAIFICFKSRCYS; AIFICFKSRCYSP;IFICFKSRCYSPV; FICFKSRCYSPVQ; ICFKSRCYSPVQA; RQHPLRSSSLIST;QHPLRSSSLISTS; HPLRSSSLISTSW; PLRSSSLISTSWG; LRSSSLISTSWGN;RSSSLISTSWGNS; SSSLISTSWGNSF; SSLISTSWGNSFF; SLISTSWGNSFFY;LISTSWGNSFFYK; ISTSWGNSFFYKL; STSWGNSFFYKLS; VHSLCNFFYTVSI;HSLCNFFYTVSII; SLCNFFYTVSIIY; LCNFFYTVSIIYT; CNFFYTVSIIYTI;NFFYTVSIIYTIS; FFYTVSIIYTISM; FYTVSIIYTISMA; YTVSIIYTISMAK;TVSIIYTISMAKM; VSIIYTISMAKMY; SIIYTISMAKMYT; IIYTISMAKMYTG;IYTISMAKMYTGT; YTISMAKMYTGTF; TISMAKMYTGTFP; ISMAKMYTGTFPF;SMAKMYTGTFPFS; MAKMYTGTFPFSY; AKMYTGTFPFSYL; KMYTGTFPFSYLS;MYTGTFPFSYLSN; YTGTFPFSYLSNH; GPNRGKIRIILLN; PNRGKIRIILLNI;NRGKIRIILLNII; RGKIRIILLNIII; GKIRIILLNIIIK; KIRIILLNIIIKV;IRIILLNIIIKVY; RIILLNIIIKVYR; IILLNIIIKVYRG; ILLNIIIKVYRGI;LLNIIIKVYRGIY; LNIIIKVYRGIYN; NIIIKVYRGIYNC; IIIKVYRGIYNCP;IIKVYRGIYNCPG; IKVYRGIYNCPGS; KVYRGIYNCPGSF; VYRGIYNCPGSFL;YRGIYNCPGSFLQ; RGIYNCPGSFLQK; GIYNCPGSFLQKS; IYNCPGSFLQKSS;YNCPGSFLQKSSQ; NCPGSFLQKSSQG; CPGSFLQKSSQGV; PGSFLQKSSQGVS;GSFLQKSSQGVSK; SFLQKSSQGVSKK; FLQKSSQGVSKKS; LQKSSQGVSKKSF;QKSSQGVSKKSFC; KSSQGVSKKSFCS; SSQGVSKKSFCSS; SQGVSKKSFCSSL;QGVSKKSFCSSLQ; GVSKKSFCSSLQF; VSKKSFCSSLQFL; GYRRYIIPNNMPQ;YRRYIIPNNMPQS; RRYIIPNNMPQSL; RYIIPNNMPQSLG; YIIPNNMPQSLGN;IIPNNMPQSLGNS; IPNNMPQSLGNSS; PNNMPQSLGNSSK; NNMPQSLGNSSKQ;NMPQSLGNSSKQR; MPQSLGNSSKQRR; PQSLGNSSKQRRT; QSLGNSSKQRRTP;SLGNSSKQRRTPM; LGNSSKQRRTPMP; GNSSKQRRTPMPR; NSSKQRRTPMPRI;SSKQRRTPMPRIK; SKQRRTPMPRIKV; KQRRTPMPRIKVL; QRRTPMPRIKVLN;RRTPMPRIKVLNI; RTPMPRIKVLNII; TPMPRIKVLNIIN; PMPRIKVLNIINK;MPRIKVLNIINKS; PRIKVLNIINKSI; RIKVLNIINKSIY; IKVLNIINKSIYT;KVLNIINKSIYTR; VLNIINKSIYTRK; LNIINKSIYTRKQ; NIINKSIYTRKQN;IINKSIYTRKQNI; INKSIYTRKQNII; NKSIYTRKQNIIV; KSIYTRKQNIIVL;SIYTRKQNIIVLI; IYTRKQNIIVLIW; YTRKQNIIVLIWV; TRKQNIIVLIWVK;RKQNIIVLIWVKQ; KQNIIVLIWVKQF; QNIIVLIWVKQFQ; NIIVLIWVKQFQS;IIVLIWVKQFQSH; IVLIWVKQFQSHA; LLIEAYSGNFVIP; LIEAYSGNFVIPI;IEAYSGNFVIPII; EAYSGNFVIPIIK; AYSGNFVIPIIKE; YSGNFVIPIIKEL;SGNFVIPIIKELI; GNFVIPIIKELIP; NFVIPIIKELIPY; FVIPIIKELIPYL;VIPIIKELIPYLS; SSKPSNSPRSTSN; SKPSNSPRSTSNY; KPSNSPRSTSNYS;PSNSPRSTSNYSI; SNSPRSTSNYSIC; NSPRSTSNYSICL; SPRSTSNYSICLR;PRSTSNYSICLRS; GTCYALYSSKGCN; TCYALYSSKGCNL; CYALYSSKGCNLN;YALYSSKGCNLNF; ALYSSKGCNLNFY; LYSSKGCNLNFYS; YSSKGCNLNFYSS;SSKGCNLNFYSSS; SKGCNLNFYSSSS; KGCNLNFYSSSSL; GCNLNFYSSSSLP;CNLNFYSSSSLPS; NLNFYSSSSLPSS; LNFYSSSSLPSSN; NFYSSSSLPSSNF;FYSSSSLPSSNFS; YSSSSLPSSNFSH; KSCGSSSLRYTGN; SSTHEPGNTKKKG;STHEPGNTKKKGL; THEPGNTKKKGLL; HEPGNTKKKGLLT; ESFTESFTAGKAV;SFTESFTAGKAVV; FTESFTAGKAVVL; TESFTAGKAVVLL; ESFTAGKAVVLLF;SFTAGKAVVLLFF; FTAGKAVVLLFFP; TAGKAVVLLFFPS; AGKAVVLLFFPST;GKAVVLLFFPSTL; KAVVLLFFPSTLS; AVVLLFFPSTLSS; VVLLFFPSTLSSP;VLLFFPSTLSSPL; LLFFPSTLSSPLQ; LFFPSTLSSPLQN; FFPSTLSSPLQNS;FPSTLSSPLQNSS; PSTLSSPLQNSSK; STLSSPLQNSSKS; TLSSPLQNSSKSS;LSSPLQNSSKSSK; SSPLQNSSKSSKI; SPLQNSSKSSKIK; PLQNSSKSSKIKI;LQNSSKSSKIKIK; QNSSKSSKIKIKI; NSSKSSKIKIKIL; ALFFVPVQVLPTF;LFFVPVQVLPTFT; FFVPVQVLPTFTE; FVPVQVLPTFTEA; VPVQVLPTFTEAC;PVQVLPTFTEACR; VQVLPTFTEACRD; QVLPTFTEACRDS; VLPTFTEACRDSW;LPTFTEACRDSWR; PTFTEACRDSWRR; TFTEACRDSWRRT; FTEACRDSWRRTM;TEACRDSWRRTMA; EACRDSWRRTMAF; ACRDSWRRTMAFV; CRDSWRRTMAFVQ;RDSWRRTMAFVQF; DSWRRTMAFVQFN; SWRRTMAFVQFNW; WRRTMAFVQFNWG;RRTMAFVQFNWGQ; RTMAFVQFNWGQG; TMAFVQFNWGQGQ; MAFVQFNWGQGQD;AFVQFNWGQGQDS; ARKTCLSCTFLPE; RKTCLSCTFLPEV; KTCLSCTFLPEVM;TCLSCTFLPEVMV; CLSCTFLPEVMVW; LSCTFLPEVMVWL; SCTFLPEVMVWLH;CTFLPEVMVWLHS; TFLPEVMVWLHSM; FLPEVMVWLHSMG; LPEVMVWLHSMGK;PEVMVWLHSMGKQ; EVMVWLHSMGKQL; VMVWLHSMGKQLL; MVWLHSMGKQLLP;VWLHSMGKQLLPV; WLHSMGKQLLPVS; LHSMGKQLLPVSH; HSMGKQLLPVSHA;SMGKQLLPVSHAL; MGKQLLPVSHALS; GKQLLPVSHALSF; KQLLPVSHALSFL;QLLPVSHALSFLR; LLPVSHALSFLRS; LPVSHALSFLRSW; PVSHALSFLRSWF;VSHALSFLRSWFG; SHALSFLRSWFGC; HALSFLRSWFGCI; ALSFLRSWFGCIP;LSFLRSWFGCIPL; EAEAASASTLSLK; GLAKLFGEIPILL; LAKLFGEIPILLQ;AKLFGEIPILLQF; KLFGEIPILLQFL; LFGEIPILLQFLQ 14 mers: MDKVLNREESMELM;DKVLNREESMELMD; KVLNREESMELMDL; VLNREESMELMDLL; LNREESMELMDLLG;NREESMELMDLLGL; REESMELMDLLGLE; EESMELMDLLGLER; ESMELMDLLGLERA;SMELMDLLGLERAA; MELMDLLGLERAAW; ELMDLLGLERAAWG; LMDLLGLERAAWGN;MDLLGLERAAWGNL; DLLGLERAAWGNLP; LLGLERAAWGNLPL; LGLERAAWGNLPLM;GLERAAWGNLPLMR; LERAAWGNLPLMRK; ERAAWGNLPLMRKA; RAAWGNLPLMRKAY;AAWGNLPLMRKAYL; AWGNLPLMRKAYLR; WGNLPLMRKAYLRK; GNLPLMRKAYLRKC;NLPLMRKAYLRKCK; LPLMRKAYLRKCKE; PLMRKAYLRKCKEF; LMRKAYLRKCKEFH;MRKAYLRKCKEFHP; RKAYLRKCKEFHPD; KAYLRKCKEFHPDK; AYLRKCKEFHPDKG;YLRKCKEFHPDKGG; LRKCKEFHPDKGGD; RKCKEFHPDKGGDE; KCKEFHPDKGGDED;CKEFHPDKGGDEDK; KEFHPDKGGDEDKM; EFHPDKGGDEDKMK; FHPDKGGDEDKMKR;HPDKGGDEDKMKRM; PDKGGDEDKMKRMN; DKGGDEDKMKRMNT; KGGDEDKMKRMNTL;GGDEDKMKRMNTLY; GDEDKMKRMNTLYK; DEDKMKRMNTLYKK; EDKMKRMNTLYKKM;DKMKRMNTLYKKME; KMKRMNTLYKKMEQ; MKRMNTLYKKMEQD; KRMNTLYKKMEQDV;RMNTLYKKMEQDVK; MNTLYKKMEQDVKV; NTLYKKMEQDVKVA; TLYKKMEQDVKVAH;LYKKMEQDVKVAHQ; YKKMEQDVKVAHQP; KKMEQDVKVAHQPD; KMEQDVKVAHQPDF;MEQDVKVAHQPDFG; EQDVKVAHQPDFGT; QDVKVAHQPDFGTW; DVKVAHQPDFGTWS;VKVAHQPDFGTWSS; KVAHQPDFGTWSSS; VAHQPDFGTWSSSE; AHQPDFGTWSSSEV;HQPDFGTWSSSEVC; QPDFGTWSSSEVCA; PDFGTWSSSEVCAD; DFGTWSSSEVCADF;FGTWSSSEVCADFP; GTWSSSEVCADFPL; TWSSSEVCADFPLC; WSSSEVCADFPLCP;SSSEVCADFPLCPD; SSEVCADFPLCPDT; SEVCADFPLCPDTL; EVCADFPLCPDTLY;VCADFPLCPDTLYC; CADFPLCPDTLYCK; ADFPLCPDTLYCKE; DFPLCPDTLYCKEW;FPLCPDTLYCKEWP; PLCPDTLYCKEWPI; LCPDTLYCKEWPIC; CPDTLYCKEWPICS;PDTLYCKEWPICSK; DTLYCKEWPICSKK; TLYCKEWPICSKKP; LYCKEWPICSKKPS;YCKEWPICSKKPSV; CKEWPICSKKPSVH; KEWPICSKKPSVHC; EWPICSKKPSVHCP;WPICSKKPSVHCPC; PICSKKPSVHCPCM; ICSKKPSVHCPCML; CSKKPSVHCPCMLC;SKKPSVHCPCMLCQ; KKPSVHCPCMLCQL; KPSVHCPCMLCQLR; PSVHCPCMLCQLRL;SVHCPCMLCQLRLR; VHCPCMLCQLRLRH; HCPCMLCQLRLRHL; CPCMLCQLRLRHLN;PCMLCQLRLRHLNR; CMLCQLRLRHLNRK; MLCQLRLRHLNRKF; LCQLRLRHLNRKFL;CQLRLRHLNRKFLR; QLRLRHLNRKFLRK; LRLRHLNRKFLRKE; RLRHLNRKFLRKEP;LRHLNRKFLRKEPL; RHLNRKFLRKEPLV; HLNRKFLRKEPLVW; LNRKFLRKEPLVWI;NRKFLRKEPLVWID; RKFLRKEPLVWIDC; KFLRKEPLVWIDCY; FLRKEPLVWIDCYC;LRKEPLVWIDCYCI; RKEPLVWIDCYCID; KEPLVWIDCYCIDC; EPLVWIDCYCIDCF;PLVWIDCYCIDCFT; LVWIDCYCIDCFTQ; VWIDCYCIDCFTQW; WIDCYCIDCFTQWF;IDCYCIDCFTQWFG; DCYCIDCFTQWFGL; CYCIDCFTQWFGLD; YCIDCFTQWFGLDL;CIDCFTQWFGLDLT; IDCFTQWFGLDLTE; DCFTQWFGLDLTEE; CFTQWFGLDLTEET;FTQWFGLDLTEETL; TQWFGLDLTEETLQ; QWFGLDLTEETLQW; WFGLDLTEETLQWW;FGLDLTEETLQWWV; GLDLTEETLQWWVQ; LDLTEETLQWWVQI; DLTEETLQWWVQII;LTEETLQWWVQIIG; TEETLQWWVQIIGE; EETLQWWVQIIGET; ETLQWWVQIIGETP;TLQWWVQIIGETPF; LQWWVQIIGETPFR; QWWVQIIGETPFRD; WWVQIIGETPFRDL;WVQIIGETPFRDLK; VQIIGETPFRDLKL; KALSNYFFYRCQPM; ALSNYFFYRCQPME;LSNYFFYRCQPMEQ; SNYFFYRCQPMEQK; NYFFYRCQPMEQKS; YFFYRCQPMEQKSG;FFYRCQPMEQKSGS; FYRCQPMEQKSGSP; YRCQPMEQKSGSPG; RCQPMEQKSGSPGG;CQPMEQKSGSPGGV; QPMEQKSGSPGGVP; PMEQKSGSPGGVPL; MEQKSGSPGGVPLM;EQKSGSPGGVPLMK; QKSGSPGGVPLMKN; KSGSPGGVPLMKNG; SGSPGGVPLMKNGM;GSPGGVPLMKNGMK; SPGGVPLMKNGMKI; PGGVPLMKNGMKIY; GGVPLMKNGMKIYF;GVPLMKNGMKIYFA; VPLMKNGMKIYFAM; PLMKNGMKIYFAMK; LMKNGMKIYFAMKI;MKNGMKIYFAMKIC; KNGMKIYFAMKICL; NGMKIYFAMKICLP; GMKIYFAMKICLPV;MKIYFAMKICLPVM; KIYFAMKICLPVMK; IYFAMKICLPVMKK; YFAMKICLPVMKKQ;FAMKICLPVMKKQQ; AMKICLPVMKKQQQ; MKICLPVMKKQQQI; KICLPVMKKQQQIL;ICLPVMKKQQQILN; CLPVMKKQQQILNT; LPVMKKQQQILNTQ; PVMKKQQQILNTQH;VMKKQQQILNTQHH; MKKQQQILNTQHHP; KKQQQILNTQHHPK; KQQQILNTQHHPKK;QQQILNTQHHPKKK; QQILNTQHHPKKKE; QILNTQHHPKKKER; KTLKTFPLIYTSFL;TLKTFPLIYTSFLV; LKTFPLIYTSFLVK; KTFPLIYTSFLVKL; TFPLIYTSFLVKLY;FPLIYTSFLVKLYL; PLIYTSFLVKLYLV; LIYTSFLVKLYLVI; IYTSFLVKLYLVIE;YTSFLVKLYLVIEP; TSFLVKLYLVIEPL; SFLVKLYLVIEPLP; FLVKLYLVIEPLPA;LVKLYLVIEPLPAL; VKLYLVIEPLPALL; KLYLVIEPLPALLC; LYLVIEPLPALLCI;YLVIEPLPALLCIL; LVIEPLPALLCILL; VIEPLPALLCILLK; IEPLPALLCILLKK;EPLPALLCILLKKK; PLPALLCILLKKKL; LPALLCILLKKKLK; PALLCILLKKKLKF;ALLCILLKKKLKFC; LLCILLKKKLKFCI; LCILLKKKLKFCIK; CILLKKKLKFCIKN;ILLKKKLKFCIKNL; LLKKKLKFCIKNLW; LKKKLKFCIKNLWK; KKKLKFCIKNLWKN;KKLKFCIKNLWKNI; KLKFCIKNLWKNIL; LLLVDTCVLGIILY; LLVDTCVLGIILYS;LVDTCVLGIILYSF; LHIDIEFLQLIISV; HIDIEFLQLIISVK; IDIEFLQLIISVKS;DIEFLQLIISVKSC; IEFLQLIISVKSCV; EFLQLIISVKSCVP; FLQLIISVKSCVPL;LQLIISVKSCVPLV; QLIISVKSCVPLVF; FVRVLIRNTYYIVP; RSMILAQKSLKKQS;SMILAQKSLKKQSR; MILAQKSLKKQSRC; ILAQKSLKKQSRCL; LAQKSLKKQSRCLG;AQKSLKKQSRCLGN; RSVKSVRKKTSLIT; SVKSVRKKTSLITL; VKSVRKKTSLITLS;KSVRKKTSLITLSI; SVRKKTSLITLSIM; VRKKTSLITLSIMK; RKKTSLITLSIMKS;KKTSLITLSIMKST; KTSLITLSIMKSTL; TSLITLSIMKSTLQ; SLITLSIMKSTLQM;LITLSIMKSTLQML; ITLSIMKSTLQMLL; TLSIMKSTLQMLLF; LSIMKSTLQMLLFL;SIMKSTLQMLLFLQ; IMKSTLQMLLFLQK; MKSTLQMLLFLQKV; KSTLQMLLFLQKVK;STLQMLLFLQKVKI; TLQMLLFLQKVKIK; LQMLLFLQKVKIKK; QMLLFLQKVKIKKV;MLLFLQKVKIKKVF; LLFLQKVKIKKVFV; LFLQKVKIKKVFVS; FLQKVKIKKVFVSK;LQKVKIKKVFVSKQ; NNIWQVLLGCTVCY; NIWQVLLGCTVCYL; IWQVLLGCTVCYLK;WQVLLGCTVCYLKW; QVLLGCTVCYLKWI; VLLGCTVCYLKWIL; YLIFCTVLFSMYLK;LIFCTVLFSMYLKE; IFCTVLFSMYLKED; FCTVLFSMYLKEDT; CTVLFSMYLKEDTG;TVLFSMYLKEDTGY; VLFSMYLKEDTGYL; LFSMYLKEDTGYLK; FSMYLKEDTGYLKV;SMYLKEDTGYLKVP; MYLKEDTGYLKVPL; YLKEDTGYLKVPLI; LKEDTGYLKVPLIV;KEDTGYLKVPLIVE; EDTGYLKVPLIVEK; DTGYLKVPLIVEKQ; TGYLKVPLIVEKQH;KGQELNQRICLQDM; GQELNQRICLQDME; ENPYKTQSSYLKKE; NPYKTQSSYLKKEF;PYKTQSSYLKKEFY; YKTQSSYLKKEFYK; KTQSSYLKKEFYKV; TQSSYLKKEFYKVE;LILQLIYNLELLNG; ILQLIYNLELLNGR; LQLIYNLELLNGRK; QLIYNLELLNGRKG;LIYNLELLNGRKGW; IYNLELLNGRKGWI; YNLELLNGRKGWIL; NLELLNGRKGWILR;NIIYAWGNVFLILQ; IIYAWGNVFLILQE; IYAWGNVFLILQEK; YAWGNVFLILQEKR;AWGNVFLILQEKRI; WGNVFLILQEKRIQ; GNVFLILQEKRIQK; NVFLILQEKRIQKL;VFLILQEKRIQKLK; FLILQEKRIQKLKT; LILQEKRIQKLKTL; ILQEKRIQKLKTLD;LQEKRIQKLKTLDM; QEKRIQKLKTLDMD; EKRIQKLKTLDMDQ; KRIQKLKTLDMDQA;RIQKLKTLDMDQAL; IQKLKTLDMDQALN; QKLKTLDMDQALNP; KLKTLDMDQALNPN;LKTLDMDQALNPNH; KTLDMDQALNPNHN; TLDMDQALNPNHNA; LDMDQALNPNHNAL;DMDQALNPNHNALP; MDQALNPNHNALPK; DQALNPNHNALPKS; QALNPNHNALPKSQ;ALNPNHNALPKSQI; LNPNHNALPKSQIL; NPNHNALPKSQILQ; PNHNALPKSQILQP;NHNALPKSQILQPL; HNALPKSQILQPLL; NALPKSQILQPLLK; ALPKSQILQPLLKI;LPKSQILQPLLKIP; PKSQILQPLLKIPK; KSQILQPLLKIPKG; SQILQPLLKIPKGQ;QILQPLLKIPKGQT; ILQPLLKIPKGQTP; LQPLLKIPKGQTPI; QPLLKIPKGQTPIV;PLLKIPKGQTPIVK; LLKIPKGQTPIVKS; LKIPKGQTPIVKSC; KIPKGQTPIVKSCI;IPKGQTPIVKSCIC; PKGQTPIVKSCICV; KGQTPIVKSCICVK; GQTPIVKSCICVKA;QTPIVKSCICVKAF; TPIVKSCICVKAFS; PIVKSCICVKAFSV; IVKSCICVKAFSVL;VKSCICVKAFSVLK; KSCICVKAFSVLKG; SCICVKAFSVLKGL; CICVKAFSVLKGLK;ICVKAFSVLKGLKH; CVKAFSVLKGLKHH; VKAFSVLKGLKHHP; KAFSVLKGLKHHPQ;AFSVLKGLKHHPQN; FSVLKGLKHHPQNN; SVLKGLKHHPQNNT; VLKGLKHHPQNNTS;LKGLKHHPQNNTSL; KGLKHHPQNNTSLK; GLKHHPQNNTSLKV; LKHHPQNNTSLKVA;KHHPQNNTSLKVAY; HHPQNNTSLKVAYT; HPQNNTSLKVAYTK; PQNNTSLKVAYTKA;QNNTSLKVAYTKAA; NNTSLKVAYTKAAF; NTSLKVAYTKAAFI; TSLKVAYTKAAFIK;SLKVAYTKAAFIKC; LKVAYTKAAFIKCI; KVAYTKAAFIKCIC; VAYTKAAFIKCICT;AYTKAAFIKCICTI; YTKAAFIKCICTIK; TKAAFIKCICTIKA; KAAFIKCICTIKAP;AAFIKCICTIKAPV; SILVCNCPCLSIYL; ILVCNCPCLSIYLI; LVCNCPCLSIYLII;VCNCPCLSIYLIIS; CNCPCLSIYLIISG; NCPCLSIYLIISGS; CPCLSIYLIISGSP;PCLSIYLIISGSPG; CLSIYLIISGSPGS; LSIYLIISGSPGSL; SIYLIISGSPGSLS;IYLIISGSPGSLSV; YLIISGSPGSLSVP; LIISGSPGSLSVPS; IISGSPGSLSVPSN;ISGSPGSLSVPSNT; SGSPGSLSVPSNTL; GSPGSLSVPSNTLT; SPGSLSVPSNTLTS;PGSLSVPSNTLTSS; GSLSVPSNTLTSST; SLSVPSNTLTSSTW; LSVPSNTLTSSTWD;SVPSNTLTSSTWDS; VPSNTLTSSTWDSI; PSNTLTSSTWDSIP; SNTLTSSTWDSIPY;NTLTSSTWDSIPYI; TLTSSTWDSIPYIG; LTSSTWDSIPYIGC; TSSTWDSIPYIGCP;SSTWDSIPYIGCPS; STWDSIPYIGCPST; TWDSIPYIGCPSTL; WDSIPYIGCPSTLW;DSIPYIGCPSTLWV; SIPYIGCPSTLWVL; IPYIGCPSTLWVLL; PYIGCPSTLWVLLF;YIGCPSTLWVLLFI; IGCPSTLWVLLFIR; GCPSTLWVLLFIRS; CPSTLWVLLFIRSL;PSTLWVLLFIRSLS; STLWVLLFIRSLSK; TLWVLLFIRSLSKK; LWVLLFIRSLSKKE;WVLLFIRSLSKKEI; VLLFIRSLSKKEIG; GFFTDLFLRRILKY; FFTDLFLRRILKYL;FTDLFLRRILKYLA; TDLFLRRILKYLAR; DLFLRRILKYLARP; LFLRRILKYLARPL;FLRRILKYLARPLH; LRRILKYLARPLHC; RRILKYLARPLHCC; RILKYLARPLHCCV;ILKYLARPLHCCVP; LKYLARPLHCCVPE; KYLARPLHCCVPEL; YLARPLHCCVPELL;LARPLHCCVPELLV; ARPLHCCVPELLVN; RPLHCCVPELLVNR; PLHCCVPELLVNRP;LHCCVPELLVNRPQ; HCCVPELLVNRPQI; CCVPELLVNRPQIS; CVPELLVNRPQISA;VPELLVNRPQISAA; PELLVNRPQISAAE; ELLVNRPQISAAET; LLVNRPQISAAETY;LVNRPQISAAETYR; VNRPQISAAETYRL; NRPQISAAETYRLS; RPQISAAETYRLSA;PQISAAETYRLSAL; QISAAETYRLSALQ; ISAAETYRLSALQR; SAAETYRLSALQRG;AAETYRLSALQRGP; AETYRLSALQRGPT; ETYRLSALQRGPTP; TYRLSALQRGPTPC;YRLSALQRGPTPCS; RLSALQRGPTPCSS; LSALQRGPTPCSSS; SALQRGPTPCSSSN;ALQRGPTPCSSSNT; LQRGPTPCSSSNTV; QRGPTPCSSSNTVV; RGPTPCSSSNTVVA;GPTPCSSSNTVVAV; PTPCSSSNTVVAVL; TPCSSSNTVVAVLV; PCSSSNTVVAVLVT;STGGTFSPPVKVPK; TGGTFSPPVKVPKY; GGTFSPPVKVPKYL; GTFSPPVKVPKYLA;TFSPPVKVPKYLAF; FSPPVKVPKYLAFS; SPPVKVPKYLAFSF; PPVKVPKYLAFSFL;PVKVPKYLAFSFLL; VKVPKYLAFSFLLG; KVPKYLAFSFLLGS; VPKYLAFSFLLGSG;PKYLAFSFLLGSGT; KYLAFSFLLGSGTQ; YLAFSFLLGSGTQH; LAFSFLLGSGTQHS;AFSFLLGSGTQHST; FSFLLGSGTQHSTG; ALWSVFITWDWAVG; LWSVFITWDWAVGF;WSVFITWDWAVGFL; SVFITWDWAVGFLG; VFITWDWAVGFLGV; FITWDWAVGFLGVI;ITWDWAVGFLGVIV; TWDWAVGFLGVIVP; WDWAVGFLGVIVPS; DWAVGFLGVIVPSG;WAVGFLGVIVPSGY; AVGFLGVIVPSGYF; VGFLGVIVPSGYFD; GFLGVIVPSGYFDL;FISTPCISKGSPPT; ISTPCISKGSPPTA; STPCISKGSPPTAK; TPCISKGSPPTAKK;PCISKGSPPTAKKW; CISKGSPPTAKKWK; ISKGSPPTAKKWKL; SKGSPPTAKKWKLL;KGSPPTAKKWKLLP; IGFPPPCSCTFCDP; GFPPPCSCTFCDPA; RLSMLVIPITSVCT;LSMLVIPITSVCTV; SMLVIPITSVCTVT; MLVIPITSVCTVTA; LVIPITSVCTVTAS;VIPITSVCTVTASH; IPITSVCTVTASHI; PITSVCTVTASHIS; ITSVCTVTASHISR;TSVCTVTASHISRF; SVCTVTASHISRFP; VCTVTASHISRFPQ; CTVTASHISRFPQV;TVTASHISRFPQVR; VTASHISRFPQVRS; TASHISRFPQVRSS; ASHISRFPQVRSSF;SHISRFPQVRSSFK; HISRFPQVRSSFKL; ISRFPQVRSSFKLG; SRFPQVRSSFKLGR;RFPQVRSSFKLGRG; FPQVRSSFKLGRGI; PQVRSSFKLGRGIL; QVRSSFKLGRGILA;VRSSFKLGRGILAV; RSSFKLGRGILAVL; QGSIFLSGLSLLKS; GSIFLSGLSLLKSF;SIFLSGLSLLKSFS; IFLSGLSLLKSFSA; FLSGLSLLKSFSAL; LSGLSLLKSFSALS;SGLSLLKSFSALSF; GLSLLKSFSALSFR; LSLLKSFSALSFRL; SLLKSFSALSFRLK;LLKSFSALSFRLKP; LKSFSALSFRLKPL; KSFSALSFRLKPLR; SFSALSFRLKPLRF;FSALSFRLKPLRFS; SALSFRLKPLRFSS; ALSFRLKPLRFSSG; LSFRLKPLRFSSGS;SFRLKPLRFSSGSP; FRLKPLRFSSGSPI; RLKPLRFSSGSPIS; LKPLRFSSGSPISG;KPLRFSSGSPISGF; PLRFSSGSPISGFR; LRFSSGSPISGFRK; RFSSGSPISGFRKH;FSSGSPISGFRKHS; SSGSPISGFRKHST; SGSPISGFRKHSTS; GSPISGFRKHSTSV;SPISGFRKHSTSVI; PISGFRKHSTSVIA; ISGFRKHSTSVIAS; SGFRKHSTSVIAST;GFRKHSTSVIASTP; FRKHSTSVIASTPV; RKHSTSVIASTPVL; KHSTSVIASTPVLT;HSTSVIASTPVLTS; STSVIASTPVLTSR; TSVIASTPVLTSRT; SVIASTPVLTSRTS;VIASTPVLTSRTST; IASTPVLTSRTSTP; ASTPVLTSRTSTPP; STPVLTSRTSTPPF;TPVLTSRTSTPPFI; PVLTSRTSTPPFIS; VLTSRTSTPPFISS; LTSRTSTPPFISSF;TSRTSTPPFISSFG; SRTSTPPFISSFGT; RTSTPPFISSFGTC; TSTPPFISSFGTCT;STPPFISSFGTCTG; TPPFISSFGTCTGS; PPFISSFGTCTGSF; PFISSFGTCTGSFG;FISSFGTCTGSFGF; ISSFGTCTGSFGFL; SSFGTCTGSFGFLG; SFGTCTGSFGFLGA;FGTCTGSFGFLGAA; GTCTGSFGFLGAAP; TCTGSFGFLGAAPG; CTGSFGFLGAAPGH;TGSFGFLGAAPGHS; GSFGFLGAAPGHSP; SFGFLGAAPGHSPF; FGFLGAAPGHSPFL;GFLGAAPGHSPFLL; FLGAAPGHSPFLLV; LGAAPGHSPFLLVG; GAAPGHSPFLLVGA;AAPGHSPFLLVGAI; APGHSPFLLVGAIF; PGHSPFLLVGAIFI; GHSPFLLVGAIFIC;HSPFLLVGAIFICF; SPFLLVGAIFICFK; PFLLVGAIFICFKS; FLLVGAIFICFKSR;LLVGAIFICFKSRC; LVGAIFICFKSRCY; VGAIFICFKSRCYS; GAIFICFKSRCYSP;AIFICFKSRCYSPV; IFICFKSRCYSPVQ; FICFKSRCYSPVQA; RQHPLRSSSLISTS;QHPLRSSSLISTSW; HPLRSSSLISTSWG; PLRSSSLISTSWGN; LRSSSLISTSWGNS;RSSSLISTSWGNSF; SSSLISTSWGNSFF; SSLISTSWGNSFFY; SLISTSWGNSFFYK;LISTSWGNSFFYKL; ISTSWGNSFFYKLS; VHSLCNFFYTVSII; HSLCNFFYTVSIIY;SLCNFFYTVSIIYT; LCNFFYTVSIIYTI; CNFFYTVSIIYTIS; NFFYTVSIIYTISM;FFYTVSIIYTISMA; FYTVSIIYTISMAK; YTVSIIYTISMAKM; TVSIIYTISMAKMY;VSIIYTISMAKMYT; SIIYTISMAKMYTG; IIYTISMAKMYTGT; IYTISMAKMYTGTF;YTISMAKMYTGTFP; TISMAKMYTGTFPF; ISMAKMYTGTFPFS; SMAKMYTGTFPFSY;MAKMYTGTFPFSYL; AKMYTGTFPFSYLS; KMYTGTFPFSYLSN; MYTGTFPFSYLSNH;GPNRGKIRIILLNI; PNRGKIRIILLNII; NRGKIRIILLNIII; RGKIRIILLNIIIK;GKIRIILLNIIIKV; KIRIILLNIIIKVY; IRIILLNIIIKVYR; RIILLNIIIKVYRG;IILLNIIIKVYRGI; ILLNIIIKVYRGIY; LLNIIIKVYRGIYN; LNIIIKVYRGIYNC;NIIIKVYRGIYNCP; IIIKVYRGIYNCPG; IIKVYRGIYNCPGS; IKVYRGIYNCPGSF;KVYRGIYNCPGSFL; VYRGIYNCPGSFLQ; YRGIYNCPGSFLQK; RGIYNCPGSFLQKS;GIYNCPGSFLQKSS; IYNCPGSFLQKSSQ; YNCPGSFLQKSSQG; NCPGSFLQKSSQGV;CPGSFLQKSSQGVS; PGSFLQKSSQGVSK; GSFLQKSSQGVSKK; SFLQKSSQGVSKKS;FLQKSSQGVSKKSF; LQKSSQGVSKKSFC; QKSSQGVSKKSFCS; KSSQGVSKKSFCSS;SSQGVSKKSFCSSL; SQGVSKKSFCSSLQ; QGVSKKSFCSSLQF; GVSKKSFCSSLQFL;GYRRYIIPNNMPQS; YRRYIIPNNMPQSL; RRYIIPNNMPQSLG; RYIIPNNMPQSLGN;YIIPNNMPQSLGNS; IIPNNMPQSLGNSS; IPNNMPQSLGNSSK; PNNMPQSLGNSSKQ;NNMPQSLGNSSKQR; NMPQSLGNSSKQRR; MPQSLGNSSKQRRT; PQSLGNSSKQRRTP;QSLGNSSKQRRTPM; SLGNSSKQRRTPMP; LGNSSKQRRTPMPR; GNSSKQRRTPMPRI;NSSKQRRTPMPRIK; SSKQRRTPMPRIKV; SKQRRTPMPRIKVL; KQRRTPMPRIKVLN;QRRTPMPRIKVLNI; RRTPMPRIKVLNII; RTPMPRIKVLNIIN; TPMPRIKVLNIINK;PMPRIKVLNIINKS; MPRIKVLNIINKSI; PRIKVLNIINKSIY; RIKVLNIINKSIYT;IKVLNIINKSIYTR; KVLNIINKSIYTRK; VLNIINKSIYTRKQ; LNIINKSIYTRKQN;NIINKSIYTRKQNI; IINKSIYTRKQNII; INKSIYTRKQNIIV; NKSIYTRKQNIIVL;KSIYTRKQNIIVLI; SIYTRKQNIIVLIW; IYTRKQNIIVLIWV; YTRKQNIIVLIWVK;TRKQNIIVLIWVKQ; RKQNIIVLIWVKQF; KQNIIVLIWVKQFQ; QNIIVLIWVKQFQS;NIIVLIWVKQFQSH; IIVLIWVKQFQSHA; LLIEAYSGNFVIPI; LIEAYSGNFVIPII;IEAYSGNFVIPIIK; EAYSGNFVIPIIKE; AYSGNFVIPIIKEL; YSGNFVIPIIKELI;SGNFVIPIIKELIP; GNFVIPIIKELIPY; NFVIPIIKELIPYL; FVIPIIKELIPYLS;SSKPSNSPRSTSNY; SKPSNSPRSTSNYS; KPSNSPRSTSNYSI; PSNSPRSTSNYSIC;SNSPRSTSNYSICL; NSPRSTSNYSICLR; SPRSTSNYSICLRS; GTCYALYSSKGCNL;TCYALYSSKGCNLN; CYALYSSKGCNLNF; YALYSSKGCNLNFY; ALYSSKGCNLNFYS;LYSSKGCNLNFYSS; YSSKGCNLNFYSSS; SSKGCNLNFYSSSS; SKGCNLNFYSSSSL;KGCNLNFYSSSSLP; GCNLNFYSSSSLPS; CNLNFYSSSSLPSS; NLNFYSSSSLPSSN;LNFYSSSSLPSSNF; NFYSSSSLPSSNFS; FYSSSSLPSSNFSH; SSTHEPGNTKKKGL;STHEPGNTKKKGLL; THEPGNTKKKGLLT; ESFTESFTAGKAVV; SFTESFTAGKAVVL;FTESFTAGKAVVLL; TESFTAGKAVVLLF; ESFTAGKAVVLLFF; SFTAGKAVVLLFFP;FTAGKAVVLLFFPS; TAGKAVVLLFFPST; AGKAVVLLFFPSTL; GKAVVLLFFPSTLS;KAVVLLFFPSTLSS; AVVLLFFPSTLSSP; VVLLFFPSTLSSPL; VLLFFPSTLSSPLQ;LLFFPSTLSSPLQN; LFFPSTLSSPLQNS; FFPSTLSSPLQNSS; FPSTLSSPLQNSSK;PSTLSSPLQNSSKS; STLSSPLQNSSKSS; TLSSPLQNSSKSSK; LSSPLQNSSKSSKI;SSPLQNSSKSSKIK; SPLQNSSKSSKIKI; PLQNSSKSSKIKIK; LQNSSKSSKIKIKI;QNSSKSSKIKIKIL; ALFFVPVQVLPTFT; LFFVPVQVLPTFTE; FFVPVQVLPTFTEA;FVPVQVLPTFTEAC; VPVQVLPTFTEACR; PVQVLPTFTEACRD; VQVLPTFTEACRDS;QVLPTFTEACRDSW; VLPTFTEACRDSWR; LPTFTEACRDSWRR; PTFTEACRDSWRRT;TFTEACRDSWRRTM; FTEACRDSWRRTMA; TEACRDSWRRTMAF; EACRDSWRRTMAFV;ACRDSWRRTMAFVQ; CRDSWRRTMAFVQF; RDSWRRTMAFVQFN; DSWRRTMAFVQFNW;SWRRTMAFVQFNWG; WRRTMAFVQFNWGQ; RRTMAFVQFNWGQG; RTMAFVQFNWGQGQ;TMAFVQFNWGQGQD; MAFVQFNWGQGQDS; ARKTCLSCTFLPEV; RKTCLSCTFLPEVM;KTCLSCTFLPEVMV; TCLSCTFLPEVMVW; CLSCTFLPEVMVWL; LSCTFLPEVMVWLH;SCTFLPEVMVWLHS; CTFLPEVMVWLHSM; TFLPEVMVWLHSMG; FLPEVMVWLHSMGK;LPEVMVWLHSMGKQ; PEVMVWLHSMGKQL; EVMVWLHSMGKQLL; VMVWLHSMGKQLLP;MVWLHSMGKQLLPV; VWLHSMGKQLLPVS; WLHSMGKQLLPVSH; LHSMGKQLLPVSHA;HSMGKQLLPVSHAL; SMGKQLLPVSHALS; MGKQLLPVSHALSF; GKQLLPVSHALSFL;KQLLPVSHALSFLR; QLLPVSHALSFLRS; LLPVSHALSFLRSW; LPVSHALSFLRSWF;PVSHALSFLRSWFG; VSHALSFLRSWFGC; SHALSFLRSWFGCI; HALSFLRSWFGCIP;ALSFLRSWFGCIPL; GLAKLFGEIPILLQ; LAKLFGEIPILLQF; AKLFGEIPILLQFL;KLFGEIPILLQFLQ 15 mers: MDKVLNREESMELMD; DKVLNREESMELMDL;KVLNREESMELMDLL; VLNREESMELMDLLG; LNREESMELMDLLGL; NREESMELMDLLGLE;REESMELMDLLGLER; EESMELMDLLGLERA; ESMELMDLLGLERAA; SMELMDLLGLERAAW;MELMDLLGLERAAWG; ELMDLLGLERAAWGN; LMDLLGLERAAWGNL; MDLLGLERAAWGNLP;DLLGLERAAWGNLPL; LLGLERAAWGNLPLM; LGLERAAWGNLPLMR; GLERAAWGNLPLMRK;LERAAWGNLPLMRKA; ERAAWGNLPLMRKAY; RAAWGNLPLMRKAYL; AAWGNLPLMRKAYLR;AWGNLPLMRKAYLRK; WGNLPLMRKAYLRKC; GNLPLMRKAYLRKCK; NLPLMRKAYLRKCKE;LPLMRKAYLRKCKEF; PLMRKAYLRKCKEFH; LMRKAYLRKCKEFHP; MRKAYLRKCKEFHPD;RKAYLRKCKEFHPDK; KAYLRKCKEFHPDKG; AYLRKCKEFHPDKGG; YLRKCKEFHPDKGGD;LRKCKEFHPDKGGDE; RKCKEFHPDKGGDED; KCKEFHPDKGGDEDK; CKEFHPDKGGDEDKM;KEFHPDKGGDEDKMK; EFHPDKGGDEDKMKR; FHPDKGGDEDKMKRM; HPDKGGDEDKMKRMN;PDKGGDEDKMKRMNT; DKGGDEDKMKRMNTL; KGGDEDKMKRMNTLY; GGDEDKMKRMNTLYK;GDEDKMKRMNTLYKK; DEDKMKRMNTLYKKM; EDKMKRMNTLYKKME; DKMKRMNTLYKKMEQ;KMKRMNTLYKKMEQD; MKRMNTLYKKMEQDV; KRMNTLYKKMEQDVK; RMNTLYKKMEQDVKV;MNTLYKKMEQDVKVA; NTLYKKMEQDVKVAH; TLYKKMEQDVKVAHQ; LYKKMEQDVKVAHQP;YKKMEQDVKVAHQPD; KKMEQDVKVAHQPDF; KMEQDVKVAHQPDFG; MEQDVKVAHQPDFGT;EQDVKVAHQPDFGTW; QDVKVAHQPDFGTWS; DVKVAHQPDFGTWSS; VKVAHQPDFGTWSSS;KVAHQPDFGTWSSSE; VAHQPDFGTWSSSEV; AHQPDFGTWSSSEVC; HQPDFGTWSSSEVCA;QPDFGTWSSSEVCAD; PDFGTWSSSEVCADF; DFGTWSSSEVCADFP; FGTWSSSEVCADFPL;GTWSSSEVCADFPLC; TWSSSEVCADFPLCP; WSSSEVCADFPLCPD; SSSEVCADFPLCPDT;SSEVCADFPLCPDTL; SEVCADFPLCPDTLY; EVCADFPLCPDTLYC; VCADFPLCPDTLYCK;CADFPLCPDTLYCKE; ADFPLCPDTLYCKEW; DFPLCPDTLYCKEWP; FPLCPDTLYCKEWPI;PLCPDTLYCKEWPIC; LCPDTLYCKEWPICS; CPDTLYCKEWPICSK; PDTLYCKEWPICSKK;DTLYCKEWPICSKKP; TLYCKEWPICSKKPS; LYCKEWPICSKKPSV; YCKEWPICSKKPSVH;CKEWPICSKKPSVHC; KEWPICSKKPSVHCP; EWPICSKKPSVHCPC; WPICSKKPSVHCPCM;PICSKKPSVHCPCML; ICSKKPSVHCPCMLC; CSKKPSVHCPCMLCQ; SKKPSVHCPCMLCQL;KKPSVHCPCMLCQLR; KPSVHCPCMLCQLRL; PSVHCPCMLCQLRLR; SVHCPCMLCQLRLRH;VHCPCMLCQLRLRHL; HCPCMLCQLRLRHLN; CPCMLCQLRLRHLNR; PCMLCQLRLRHLNRK;CMLCQLRLRHLNRKF; MLCQLRLRHLNRKFL; LCQLRLRHLNRKFLR; CQLRLRHLNRKFLRK;QLRLRHLNRKFLRKE; LRLRHLNRKFLRKEP; RLRHLNRKFLRKEPL; LRHLNRKFLRKEPLV;RHLNRKFLRKEPLVW; HLNRKFLRKEPLVWI; LNRKFLRKEPLVWID; NRKFLRKEPLVWIDC;RKFLRKEPLVWIDCY; KFLRKEPLVWIDCYC; FLRKEPLVWIDCYCI; LRKEPLVWIDCYCID;RKEPLVWIDCYCIDC; KEPLVWIDCYCIDCF; EPLVWIDCYCIDCFT; PLVWIDCYCIDCFTQ;LVWIDCYCIDCFTQW; VWIDCYCIDCFTQWF; WIDCYCIDCFTQWFG; IDCYCIDCFTQWFGL;DCYCIDCFTQWFGLD; CYCIDCFTQWFGLDL; YCIDCFTQWFGLDLT; CIDCFTQWFGLDLTE;IDCFTQWFGLDLTEE; DCFTQWFGLDLTEET; CFTQWFGLDLTEETL; FTQWFGLDLTEETLQ;TQWFGLDLTEETLQW; QWFGLDLTEETLQWW; WFGLDLTEETLQWWV; FGLDLTEETLQWWVQ;GLDLTEETLQWWVQI; LDLTEETLQWWVQII; DLTEETLQWWVQIIG; LTEETLQWWVQIIGE;TEETLQWWVQIIGET; EETLQWWVQIIGETP; ETLQWWVQIIGETPF; TLQWWVQIIGETPFR;LQWWVQIIGETPFRD; QWWVQIIGETPFRDL; WWVQIIGETPFRDLK; WVQIIGETPFRDLKL;KALSNYFFYRCQPME; ALSNYFFYRCQPMEQ; LSNYFFYRCQPMEQK; SNYFFYRCQPMEQKS;NYFFYRCQPMEQKSG; YFFYRCQPMEQKSGS; FFYRCQPMEQKSGSP; FYRCQPMEQKSGSPG;YRCQPMEQKSGSPGG; RCQPMEQKSGSPGGV; CQPMEQKSGSPGGVP; QPMEQKSGSPGGVPL;PMEQKSGSPGGVPLM; MEQKSGSPGGVPLMK; EQKSGSPGGVPLMKN; QKSGSPGGVPLMKNG;KSGSPGGVPLMKNGM; SGSPGGVPLMKNGMK; GSPGGVPLMKNGMKI; SPGGVPLMKNGMKIY;PGGVPLMKNGMKIYF; GGVPLMKNGMKIYFA; GVPLMKNGMKIYFAM; VPLMKNGMKIYFAMK;PLMKNGMKIYFAMKI; LMKNGMKIYFAMKIC; MKNGMKIYFAMKICL; KNGMKIYFAMKICLP;NGMKIYFAMKICLPV; GMKIYFAMKICLPVM; MKIYFAMKICLPVMK; KIYFAMKICLPVMKK;IYFAMKICLPVMKKQ; YFAMKICLPVMKKQQ; FAMKICLPVMKKQQQ; AMKICLPVMKKQQQI;MKICLPVMKKQQQIL; KICLPVMKKQQQILN; ICLPVMKKQQQILNT; CLPVMKKQQQILNTQ;LPVMKKQQQILNTQH; PVMKKQQQILNTQHH; VMKKQQQILNTQHHP; MKKQQQILNTQHHPK;KKQQQILNTQHHPKK; KQQQILNTQHHPKKK; QQQILNTQHHPKKKE; QQILNTQHHPKKKER;KTLKTFPLIYTSFLV; TLKTFPLIYTSFLVK; LKTFPLIYTSFLVKL; KTFPLIYTSFLVKLY;TFPLIYTSFLVKLYL; FPLIYTSFLVKLYLV; PLIYTSFLVKLYLVI; LIYTSFLVKLYLVIE;IYTSFLVKLYLVIEP; YTSFLVKLYLVIEPL; TSFLVKLYLVIEPLP; SFLVKLYLVIEPLPA;FLVKLYLVIEPLPAL; LVKLYLVIEPLPALL; VKLYLVIEPLPALLC; KLYLVIEPLPALLCI;LYLVIEPLPALLCIL; YLVIEPLPALLCILL; LVIEPLPALLCILLK; VIEPLPALLCILLKK;IEPLPALLCILLKKK; EPLPALLCILLKKKL; PLPALLCILLKKKLK; LPALLCILLKKKLKF;PALLCILLKKKLKFC; ALLCILLKKKLKFCI; LLCILLKKKLKFCIK; LCILLKKKLKFCIKN;CILLKKKLKFCIKNL; ILLKKKLKFCIKNLW; LLKKKLKFCIKNLWK; LKKKLKFCIKNLWKN;KKKLKFCIKNLWKNI; KKLKFCIKNLWKNIL; LLLVDTCVLGIILYS; LLVDTCVLGIILYSF;LHIDIEFLQLIISVK; HIDIEFLQLIISVKS; IDIEFLQLIISVKSC; DIEFLQLIISVKSCV;IEFLQLIISVKSCVP; EFLQLIISVKSCVPL; FLQLIISVKSCVPLV; LQLIISVKSCVPLVF;RSMILAQKSLKKQSR; SMILAQKSLKKQSRC; MILAQKSLKKQSRCL; ILAQKSLKKQSRCLG;LAQKSLKKQSRCLGN; RSVKSVRKKTSLITL; SVKSVRKKTSLITLS; VKSVRKKTSLITLSI;KSVRKKTSLITLSIM; SVRKKTSLITLSIMK; VRKKTSLITLSIMKS; RKKTSLITLSIMKST;KKTSLITLSIMKSTL; KTSLITLSIMKSTLQ; TSLITLSIMKSTLQM; SLITLSIMKSTLQML;LITLSIMKSTLQMLL; ITLSIMKSTLQMLLF; TLSIMKSTLQMLLFL; LSIMKSTLQMLLFLQ;SIMKSTLQMLLFLQK; IMKSTLQMLLFLQKV; MKSTLQMLLFLQKVK; KSTLQMLLFLQKVKI;STLQMLLFLQKVKIK; TLQMLLFLQKVKIKK; LQMLLFLQKVKIKKV; QMLLFLQKVKIKKVF;MLLFLQKVKIKKVFV; LLFLQKVKIKKVFVS; LFLQKVKIKKVFVSK; FLQKVKIKKVFVSKQ;NNIWQVLLGCTVCYL; NIWQVLLGCTVCYLK; IWQVLLGCTVCYLKW; WQVLLGCTVCYLKWI;QVLLGCTVCYLKWIL; YLIFCTVLFSMYLKE; LIFCTVLFSMYLKED; IFCTVLFSMYLKEDT;FCTVLFSMYLKEDTG; CTVLFSMYLKEDTGY; TVLFSMYLKEDTGYL; VLFSMYLKEDTGYLK;LFSMYLKEDTGYLKV; FSMYLKEDTGYLKVP; SMYLKEDTGYLKVPL; MYLKEDTGYLKVPLI;YLKEDTGYLKVPLIV; LKEDTGYLKVPLIVE; KEDTGYLKVPLIVEK; EDTGYLKVPLIVEKQ;DTGYLKVPLIVEKQH; KGQELNQRICLQDME; ENPYKTQSSYLKKEF; NPYKTQSSYLKKEFY;PYKTQSSYLKKEFYK; YKTQSSYLKKEFYKV; KTQSSYLKKEFYKVE; LILQLIYNLELLNGR;ILQLIYNLELLNGRK; LQLIYNLELLNGRKG; QLIYNLELLNGRKGW; LIYNLELLNGRKGWI;IYNLELLNGRKGWIL; YNLELLNGRKGWILR; NIIYAWGNVFLILQE; IIYAWGNVFLILQEK;IYAWGNVFLILQEKR; YAWGNVFLILQEKRI; AWGNVFLILQEKRIQ; WGNVFLILQEKRIQK;GNVFLILQEKRIQKL; NVFLILQEKRIQKLK; VFLILQEKRIQKLKT; FLILQEKRIQKLKTL;LILQEKRIQKLKTLD; ILQEKRIQKLKTLDM; LQEKRIQKLKTLDMD; QEKRIQKLKTLDMDQ;EKRIQKLKTLDMDQA; KRIQKLKTLDMDQAL; RIQKLKTLDMDQALN; IQKLKTLDMDQALNP;QKLKTLDMDQALNPN; KLKTLDMDQALNPNH; LKTLDMDQALNPNHN; KTLDMDQALNPNHNA;TLDMDQALNPNHNAL; LDMDQALNPNHNALP; DMDQALNPNHNALPK; MDQALNPNHNALPKS;DQALNPNHNALPKSQ; QALNPNHNALPKSQI; ALNPNHNALPKSQIL; LNPNHNALPKSQILQ;NPNHNALPKSQILQP; PNHNALPKSQILQPL; NHNALPKSQILQPLL; HNALPKSQILQPLLK;NALPKSQILQPLLKI; ALPKSQILQPLLKIP; LPKSQILQPLLKIPK; PKSQILQPLLKIPKG;KSQILQPLLKIPKGQ; SQILQPLLKIPKGQT; QILQPLLKIPKGQTP; ILQPLLKIPKGQTPI;LQPLLKIPKGQTPIV; QPLLKIPKGQTPIVK; PLLKIPKGQTPIVKS; LLKIPKGQTPIVKSC;LKIPKGQTPIVKSCI; KIPKGQTPIVKSCIC; IPKGQTPIVKSCICV; PKGQTPIVKSCICVK;KGQTPIVKSCICVKA; GQTPIVKSCICVKAF; QTPIVKSCICVKAFS; TPIVKSCICVKAFSV;PIVKSCICVKAFSVL; IVKSCICVKAFSVLK; VKSCICVKAFSVLKG; KSCICVKAFSVLKGL;SCICVKAFSVLKGLK; CICVKAFSVLKGLKH; ICVKAFSVLKGLKHH; CVKAFSVLKGLKHHP;VKAFSVLKGLKHHPQ; KAFSVLKGLKHHPQN; AFSVLKGLKHHPQNN; FSVLKGLKHHPQNNT;SVLKGLKHHPQNNTS; VLKGLKHHPQNNTSL; LKGLKHHPQNNTSLK; KGLKHHPQNNTSLKV;GLKHHPQNNTSLKVA; LKHHPQNNTSLKVAY; KHHPQNNTSLKVAYT; HHPQNNTSLKVAYTK;HPQNNTSLKVAYTKA; PQNNTSLKVAYTKAA; QNNTSLKVAYTKAAF; NNTSLKVAYTKAAFI;NTSLKVAYTKAAFIK; TSLKVAYTKAAFIKC; SLKVAYTKAAFIKCI; LKVAYTKAAFIKCIC;KVAYTKAAFIKCICT; VAYTKAAFIKCICTI; AYTKAAFIKCICTIK; YTKAAFIKCICTIKA;TKAAFIKCICTIKAP; KAAFIKCICTIKAPV; SILVCNCPCLSIYLI; ILVCNCPCLSIYLII;LVCNCPCLSIYLIIS; VCNCPCLSIYLIISG; CNCPCLSIYLIISGS; NCPCLSIYLIISGSP;CPCLSIYLIISGSPG; PCLSIYLIISGSPGS; CLSIYLIISGSPGSL; LSIYLIISGSPGSLS;SIYLIISGSPGSLSV; IYLIISGSPGSLSVP; YLIISGSPGSLSVPS; LIISGSPGSLSVPSN;IISGSPGSLSVPSNT; ISGSPGSLSVPSNTL; SGSPGSLSVPSNTLT; GSPGSLSVPSNTLTS;SPGSLSVPSNTLTSS; PGSLSVPSNTLTSST; GSLSVPSNTLTSSTW; SLSVPSNTLTSSTWD;LSVPSNTLTSSTWDS; SVPSNTLTSSTWDSI; VPSNTLTSSTWDSIP; PSNTLTSSTWDSIPY;SNTLTSSTWDSIPYI; NTLTSSTWDSIPYIG; TLTSSTWDSIPYIGC; LTSSTWDSIPYIGCP;TSSTWDSIPYIGCPS; SSTWDSIPYIGCPST; STWDSIPYIGCPSTL; TWDSIPYIGCPSTLW;WDSIPYIGCPSTLWV; DSIPYIGCPSTLWVL; SIPYIGCPSTLWVLL; IPYIGCPSTLWVLLF;PYIGCPSTLWVLLFI; YIGCPSTLWVLLFIR; IGCPSTLWVLLFIRS; GCPSTLWVLLFIRSL;CPSTLWVLLFIRSLS; PSTLWVLLFIRSLSK; STLWVLLFIRSLSKK; TLWVLLFIRSLSKKE;LWVLLFIRSLSKKEI; WVLLFIRSLSKKEIG; GFFTDLFLRRILKYL; FFTDLFLRRILKYLA;FTDLFLRRILKYLAR; TDLFLRRILKYLARP; DLFLRRILKYLARPL; LFLRRILKYLARPLH;FLRRILKYLARPLHC; LRRILKYLARPLHCC; RRILKYLARPLHCCV; RILKYLARPLHCCVP;ILKYLARPLHCCVPE; LKYLARPLHCCVPEL; KYLARPLHCCVPELL; YLARPLHCCVPELLV;LARPLHCCVPELLVN; ARPLHCCVPELLVNR; RPLHCCVPELLVNRP; PLHCCVPELLVNRPQ;LHCCVPELLVNRPQI; HCCVPELLVNRPQIS; CCVPELLVNRPQISA; CVPELLVNRPQISAA;VPELLVNRPQISAAE; PELLVNRPQISAAET; ELLVNRPQISAAETY; LLVNRPQISAAETYR;LVNRPQISAAETYRL; VNRPQISAAETYRLS; NRPQISAAETYRLSA; RPQISAAETYRLSAL;PQISAAETYRLSALQ; QISAAETYRLSALQR; ISAAETYRLSALQRG; SAAETYRLSALQRGP;AAETYRLSALQRGPT; AETYRLSALQRGPTP; ETYRLSALQRGPTPC; TYRLSALQRGPTPCS;YRLSALQRGPTPCSS; RLSALQRGPTPCSSS; LSALQRGPTPCSSSN; SALQRGPTPCSSSNT;ALQRGPTPCSSSNTV; LQRGPTPCSSSNTVV; QRGPTPCSSSNTVVA; RGPTPCSSSNTVVAV;GPTPCSSSNTVVAVL; PTPCSSSNTVVAVLV; TPCSSSNTVVAVLVT; STGGTFSPPVKVPKY;TGGTFSPPVKVPKYL; GGTFSPPVKVPKYLA; GTFSPPVKVPKYLAF; TFSPPVKVPKYLAFS;FSPPVKVPKYLAFSF; SPPVKVPKYLAFSFL; PPVKVPKYLAFSFLL; PVKVPKYLAFSFLLG;VKVPKYLAFSFLLGS; KVPKYLAFSFLLGSG; VPKYLAFSFLLGSGT; PKYLAFSFLLGSGTQ;KYLAFSFLLGSGTQH; YLAFSFLLGSGTQHS; LAFSFLLGSGTQHST; AFSFLLGSGTQHSTG;ALWSVFITWDWAVGF; LWSVFITWDWAVGFL; WSVFITWDWAVGFLG; SVFITWDWAVGFLGV;VFITWDWAVGFLGVI; FITWDWAVGFLGVIV; ITWDWAVGFLGVIVP; TWDWAVGFLGVIVPS;WDWAVGFLGVIVPSG; DWAVGFLGVIVPSGY; WAVGFLGVIVPSGYF; AVGFLGVIVPSGYFD;VGFLGVIVPSGYFDL; FISTPCISKGSPPTA; ISTPCISKGSPPTAK; STPCISKGSPPTAKK;TPCISKGSPPTAKKW; PCISKGSPPTAKKWK; CISKGSPPTAKKWKL; ISKGSPPTAKKWKLL;SKGSPPTAKKWKLLP; IGFPPPCSCTFCDPA; RLSMLVIPITSVCTV; LSMLVIPITSVCTVT;SMLVIPITSVCTVTA; MLVIPITSVCTVTAS; LVIPITSVCTVTASH; VIPITSVCTVTASHI;IPITSVCTVTASHIS; PITSVCTVTASHISR; ITSVCTVTASHISRF; TSVCTVTASHISRFP;SVCTVTASHISRFPQ; VCTVTASHISRFPQV; CTVTASHISRFPQVR; TVTASHISRFPQVRS;VTASHISRFPQVRSS; TASHISRFPQVRSSF; ASHISRFPQVRSSFK; SHISRFPQVRSSFKL;HISRFPQVRSSFKLG; ISRFPQVRSSFKLGR; SRFPQVRSSFKLGRG; RFPQVRSSFKLGRGI;FPQVRSSFKLGRGIL; PQVRSSFKLGRGILA; QVRSSFKLGRGILAV; VRSSFKLGRGILAVL;QGSIFLSGLSLLKSF; GSIFLSGLSLLKSFS; SIFLSGLSLLKSFSA; IFLSGLSLLKSFSAL;FLSGLSLLKSFSALS; LSGLSLLKSFSALSF; SGLSLLKSFSALSFR; GLSLLKSFSALSFRL;LSLLKSFSALSFRLK; SLLKSFSALSFRLKP; LLKSFSALSFRLKPL; LKSFSALSFRLKPLR;KSFSALSFRLKPLRF; SFSALSFRLKPLRFS; FSALSFRLKPLRFSS; SALSFRLKPLRFSSG;ALSFRLKPLRFSSGS; LSFRLKPLRFSSGSP; SFRLKPLRFSSGSPI; FRLKPLRFSSGSPIS;RLKPLRFSSGSPISG; LKPLRFSSGSPISGF; KPLRFSSGSPISGFR; PLRFSSGSPISGFRK;LRFSSGSPISGFRKH; RFSSGSPISGFRKHS; FSSGSPISGFRKHST; SSGSPISGFRKHSTS;SGSPISGFRKHSTSV; GSPISGFRKHSTSVI; SPISGFRKHSTSVIA; PISGFRKHSTSVIAS;ISGFRKHSTSVIAST; SGFRKHSTSVIASTP; GFRKHSTSVIASTPV; FRKHSTSVIASTPVL;RKHSTSVIASTPVLT; KHSTSVIASTPVLTS; HSTSVIASTPVLTSR; STSVIASTPVLTSRT;TSVIASTPVLTSRTS; SVIASTPVLTSRTST; VIASTPVLTSRTSTP; IASTPVLTSRTSTPP;ASTPVLTSRTSTPPF; STPVLTSRTSTPPFI; TPVLTSRTSTPPFIS; PVLTSRTSTPPFISS;VLTSRTSTPPFISSF; LTSRTSTPPFISSFG; TSRTSTPPFISSFGT; SRTSTPPFISSFGTC;RTSTPPFISSFGTCT; TSTPPFISSFGTCTG; STPPFISSFGTCTGS; TPPFISSFGTCTGSF;PPFISSFGTCTGSFG; PFISSFGTCTGSFGF; FISSFGTCTGSFGFL; ISSFGTCTGSFGFLG;SSFGTCTGSFGFLGA; SFGTCTGSFGFLGAA; FGTCTGSFGFLGAAP; GTCTGSFGFLGAAPG;TCTGSFGFLGAAPGH; CTGSFGFLGAAPGHS; TGSFGFLGAAPGHSP; GSFGFLGAAPGHSPF;SFGFLGAAPGHSPFL; FGFLGAAPGHSPFLL; GFLGAAPGHSPFLLV; FLGAAPGHSPFLLVG;LGAAPGHSPFLLVGA; GAAPGHSPFLLVGAI; AAPGHSPFLLVGAIF; APGHSPFLLVGAIFI;PGHSPFLLVGAIFIC; GHSPFLLVGAIFICF; HSPFLLVGAIFICFK; SPFLLVGAIFICFKS;PFLLVGAIFICFKSR; FLLVGAIFICFKSRC; LLVGAIFICFKSRCY; LVGAIFICFKSRCYS;VGAIFICFKSRCYSP; GAIFICFKSRCYSPV; AIFICFKSRCYSPVQ; IFICFKSRCYSPVQA;RQHPLRSSSLISTSW; QHPLRSSSLISTSWG; HPLRSSSLISTSWGN; PLRSSSLISTSWGNS;LRSSSLISTSWGNSF; RSSSLISTSWGNSFF; SSSLISTSWGNSFFY; SSLISTSWGNSFFYK;SLISTSWGNSFFYKL; LISTSWGNSFFYKLS; VHSLCNFFYTVSIIY; HSLCNFFYTVSIIYT;SLCNFFYTVSIIYTI; LCNFFYTVSIIYTIS; CNFFYTVSIIYTISM; NFFYTVSIIYTISMA;FFYTVSIIYTISMAK; FYTVSIIYTISMAKM; YTVSIIYTISMAKMY; TVSIIYTISMAKMYT;VSIIYTISMAKMYTG; SIIYTISMAKMYTGT; IIYTISMAKMYTGTF; IYTISMAKMYTGTFP;YTISMAKMYTGTFPF; TISMAKMYTGTFPFS; ISMAKMYTGTFPFSY; SMAKMYTGTFPFSYL;MAKMYTGTFPFSYLS; AKMYTGTFPFSYLSN; KMYTGTFPFSYLSNH; GPNRGKIRIILLNII;PNRGKIRIILLNIII; NRGKIRIILLNIIIK; RGKIRIILLNIIIKV; GKIRIILLNIIIKVY;KIRIILLNIIIKVYR; IRIILLNIIIKVYRG; RIILLNIIIKVYRGI; IILLNIIIKVYRGIY;ILLNIIIKVYRGIYN; LLNIIIKVYRGIYNC; LNIIIKVYRGIYNCP; NIIIKVYRGIYNCPG;IIIKVYRGIYNCPGS; IIKVYRGIYNCPGSF; IKVYRGIYNCPGSFL; KVYRGIYNCPGSFLQ;VYRGIYNCPGSFLQK; YRGIYNCPGSFLQKS; RGIYNCPGSFLQKSS; GIYNCPGSFLQKSSQ;IYNCPGSFLQKSSQG; YNCPGSFLQKSSQGV; NCPGSFLQKSSQGVS; CPGSFLQKSSQGVSK;PGSFLQKSSQGVSKK; GSFLQKSSQGVSKKS; SFLQKSSQGVSKKSF; FLQKSSQGVSKKSFC;LQKSSQGVSKKSFCS; QKSSQGVSKKSFCSS; KSSQGVSKKSFCSSL; SSQGVSKKSFCSSLQ;SQGVSKKSFCSSLQF; QGVSKKSFCSSLQFL; GYRRYIIPNNMPQSL; YRRYIIPNNMPQSLG;RRYIIPNNMPQSLGN; RYIIPNNMPQSLGNS; YIIPNNMPQSLGNSS; IIPNNMPQSLGNSSK;IPNNMPQSLGNSSKQ; PNNMPQSLGNSSKQR; NNMPQSLGNSSKQRR; NMPQSLGNSSKQRRT;MPQSLGNSSKQRRTP; PQSLGNSSKQRRTPM; QSLGNSSKQRRTPMP; SLGNSSKQRRTPMPR;LGNSSKQRRTPMPRI; GNSSKQRRTPMPRIK; NSSKQRRTPMPRIKV; SSKQRRTPMPRIKVL;SKQRRTPMPRIKVLN; KQRRTPMPRIKVLNI; QRRTPMPRIKVLNII; RRTPMPRIKVLNIIN;RTPMPRIKVLNIINK; TPMPRIKVLNIINKS; PMPRIKVLNIINKSI; MPRIKVLNIINKSIY;PRIKVLNIINKSIYT; RIKVLNIINKSIYTR; IKVLNIINKSIYTRK; KVLNIINKSIYTRKQ;VLNIINKSIYTRKQN; LNIINKSIYTRKQNI; NIINKSIYTRKQNII; IINKSIYTRKQNIIV;INKSIYTRKQNIIVL; NKSIYTRKQNIIVLI; KSIYTRKQNIIVLIW; SIYTRKQNIIVLIWV;IYTRKQNIIVLIWVK; YTRKQNIIVLIWVKQ; TRKQNIIVLIWVKQF; RKQNIIVLIWVKQFQ;KQNIIVLIWVKQFQS; QNIIVLIWVKQFQSH; NIIVLIWVKQFQSHA; LLIEAYSGNFVIPII;LIEAYSGNFVIPIIK; IEAYSGNFVIPIIKE; EAYSGNFVIPIIKEL; AYSGNFVIPIIKELI;YSGNFVIPIIKELIP; SGNFVIPIIKELIPY; GNFVIPIIKELIPYL; NFVIPIIKELIPYLS;SSKPSNSPRSTSNYS; SKPSNSPRSTSNYSI; KPSNSPRSTSNYSIC; PSNSPRSTSNYSICL;SNSPRSTSNYSICLR; NSPRSTSNYSICLRS; GTCYALYSSKGCNLN; TCYALYSSKGCNLNF;CYALYSSKGCNLNFY; YALYSSKGCNLNFYS; ALYSSKGCNLNFYSS; LYSSKGCNLNFYSSS;YSSKGCNLNFYSSSS; SSKGCNLNFYSSSSL; SKGCNLNFYSSSSLP; KGCNLNFYSSSSLPS;GCNLNFYSSSSLPSS; CNLNFYSSSSLPSSN; NLNFYSSSSLPSSNF; LNFYSSSSLPSSNFS;NFYSSSSLPSSNFSH; SSTHEPGNTKKKGLL; STHEPGNTKKKGLLT; ESFTESFTAGKAVVL;SFTESFTAGKAVVLL; FTESFTAGKAVVLLF; TESFTAGKAVVLLFF; ESFTAGKAVVLLFFP;SFTAGKAVVLLFFPS; FTAGKAVVLLFFPST; TAGKAVVLLFFPSTL; AGKAVVLLFFPSTLS;GKAVVLLFFPSTLSS; KAVVLLFFPSTLSSP; AVVLLFFPSTLSSPL; VVLLFFPSTLSSPLQ;VLLFFPSTLSSPLQN; LLFFPSTLSSPLQNS; LFFPSTLSSPLQNSS; FFPSTLSSPLQNSSK;FPSTLSSPLQNSSKS; PSTLSSPLQNSSKSS; STLSSPLQNSSKSSK; TLSSPLQNSSKSSKI;LSSPLQNSSKSSKIK; SSPLQNSSKSSKIKI; SPLQNSSKSSKIKIK; PLQNSSKSSKIKIKI;LQNSSKSSKIKIKIL; ALFFVPVQVLPTFTE; LFFVPVQVLPTFTEA; FFVPVQVLPTFTEAC;FVPVQVLPTFTEACR; VPVQVLPTFTEACRD; PVQVLPTFTEACRDS; VQVLPTFTEACRDSW;QVLPTFTEACRDSWR; VLPTFTEACRDSWRR; LPTFTEACRDSWRRT; PTFTEACRDSWRRTM;TFTEACRDSWRRTMA; FTEACRDSWRRTMAF; TEACRDSWRRTMAFV; EACRDSWRRTMAFVQ;ACRDSWRRTMAFVQF; CRDSWRRTMAFVQFN; RDSWRRTMAFVQFNW; DSWRRTMAFVQFNWG;SWRRTMAFVQFNWGQ; WRRTMAFVQFNWGQG; RRTMAFVQFNWGQGQ; RTMAFVQFNWGQGQD;TMAFVQFNWGQGQDS; ARKTCLSCTFLPEVM; RKTCLSCTFLPEVMV; KTCLSCTFLPEVMVW;TCLSCTFLPEVMVWL; CLSCTFLPEVMVWLH; LSCTFLPEVMVWLHS; SCTFLPEVMVWLHSM;CTFLPEVMVWLHSMG; TFLPEVMVWLHSMGK; FLPEVMVWLHSMGKQ; LPEVMVWLHSMGKQL;PEVMVWLHSMGKQLL; EVMVWLHSMGKQLLP; VMVWLHSMGKQLLPV; MVWLHSMGKQLLPVS;VWLHSMGKQLLPVSH; WLHSMGKQLLPVSHA; LHSMGKQLLPVSHAL; HSMGKQLLPVSHALS;SMGKQLLPVSHALSF; MGKQLLPVSHALSFL; GKQLLPVSHALSFLR; KQLLPVSHALSFLRS;QLLPVSHALSFLRSW; LLPVSHALSFLRSWF; LPVSHALSFLRSWFG; PVSHALSFLRSWFGC;VSHALSFLRSWFGCI; SHALSFLRSWFGCIP; HALSFLRSWFGCIPL; GLAKLFGEIPILLQF;LAKLFGEIPILLQFL; AKLFGEIPILLQFLQ 16 mers: MDKVLNREESMELMDL;DKVLNREESMELMDLL; KVLNREESMELMDLLG; VLNREESMELMDLLGL; LNREESMELMDLLGLE;NREESMELMDLLGLER; REESMELMDLLGLERA; EESMELMDLLGLERAA; ESMELMDLLGLERAAW;SMELMDLLGLERAAWG; MELMDLLGLERAAWGN; ELMDLLGLERAAWGNL; LMDLLGLERAAWGNLP;MDLLGLERAAWGNLPL; DLLGLERAAWGNLPLM; LLGLERAAWGNLPLMR; LGLERAAWGNLPLMRK;GLERAAWGNLPLMRKA; LERAAWGNLPLMRKAY; ERAAWGNLPLMRKAYL; RAAWGNLPLMRKAYLR;AAWGNLPLMRKAYLRK; AWGNLPLMRKAYLRKC; WGNLPLMRKAYLRKCK; GNLPLMRKAYLRKCKE;NLPLMRKAYLRKCKEF; LPLMRKAYLRKCKEFH; PLMRKAYLRKCKEFHP; LMRKAYLRKCKEFHPD;MRKAYLRKCKEFHPDK; RKAYLRKCKEFHPDKG; KAYLRKCKEFHPDKGG; AYLRKCKEFHPDKGGD;YLRKCKEFHPDKGGDE; LRKCKEFHPDKGGDED; RKCKEFHPDKGGDEDK; KCKEFHPDKGGDEDKM;CKEFHPDKGGDEDKMK; KEFHPDKGGDEDKMKR; EFHPDKGGDEDKMKRM; FHPDKGGDEDKMKRMN;HPDKGGDEDKMKRMNT; PDKGGDEDKMKRMNTL; DKGGDEDKMKRMNTLY; KGGDEDKMKRMNTLYK;GGDEDKMKRMNTLYKK; GDEDKMKRMNTLYKKM; DEDKMKRMNTLYKKME; EDKMKRMNTLYKKMEQ;DKMKRMNTLYKKMEQD; KMKRMNTLYKKMEQDV; MKRMNTLYKKMEQDVK; KRMNTLYKKMEQDVKV;RMNTLYKKMEQDVKVA; MNTLYKKMEQDVKVAH; NTLYKKMEQDVKVAHQ; TLYKKMEQDVKVAHQP;LYKKMEQDVKVAHQPD; YKKMEQDVKVAHQPDF; KKMEQDVKVAHQPDFG; KMEQDVKVAHQPDFGT;MEQDVKVAHQPDFGTW; EQDVKVAHQPDFGTWS; QDVKVAHQPDFGTWSS; DVKVAHQPDFGTWSSS;VKVAHQPDFGTWSSSE; KVAHQPDFGTWSSSEV; VAHQPDFGTWSSSEVC; AHQPDFGTWSSSEVCA;HQPDFGTWSSSEVCAD; QPDFGTWSSSEVCADF; PDFGTWSSSEVCADFP; DFGTWSSSEVCADFPL;FGTWSSSEVCADFPLC; GTWSSSEVCADFPLCP; TWSSSEVCADFPLCPD; WSSSEVCADFPLCPDT;SSSEVCADFPLCPDTL; SSEVCADFPLCPDTLY; SEVCADFPLCPDTLYC; EVCADFPLCPDTLYCK;VCADFPLCPDTLYCKE; CADFPLCPDTLYCKEW; ADFPLCPDTLYCKEWP; DFPLCPDTLYCKEWPI;FPLCPDTLYCKEWPIC; PLCPDTLYCKEWPICS; LCPDTLYCKEWPICSK; CPDTLYCKEWPICSKK;PDTLYCKEWPICSKKP; DTLYCKEWPICSKKPS; TLYCKEWPICSKKPSV; LYCKEWPICSKKPSVH;YCKEWPICSKKPSVHC; CKEWPICSKKPSVHCP; KEWPICSKKPSVHCPC; EWPICSKKPSVHCPCM;WPICSKKPSVHCPCML; PICSKKPSVHCPCMLC; ICSKKPSVHCPCMLCQ; CSKKPSVHCPCMLCQL;SKKPSVHCPCMLCQLR; KKPSVHCPCMLCQLRL; KPSVHCPCMLCQLRLR; PSVHCPCMLCQLRLRH;SVHCPCMLCQLRLRHL; VHCPCMLCQLRLRHLN; HCPCMLCQLRLRHLNR; CPCMLCQLRLRHLNRK;PCMLCQLRLRHLNRKF; CMLCQLRLRHLNRKFL; MLCQLRLRHLNRKFLR; LCQLRLRHLNRKFLRK;CQLRLRHLNRKFLRKE; QLRLRHLNRKFLRKEP; LRLRHLNRKFLRKEPL; RLRHLNRKFLRKEPLV;LRHLNRKFLRKEPLVW; RHLNRKFLRKEPLVWI; HLNRKFLRKEPLVWID; LNRKFLRKEPLVWIDC;NRKFLRKEPLVWIDCY; RKFLRKEPLVWIDCYC; KFLRKEPLVWIDCYCI; FLRKEPLVWIDCYCID;LRKEPLVWIDCYCIDC; RKEPLVWIDCYCIDCF; KEPLVWIDCYCIDCFT; EPLVWIDCYCIDCFTQ;PLVWIDCYCIDCFTQW; LVWIDCYCIDCFTQWF; VWIDCYCIDCFTQWFG; WIDCYCIDCFTQWFGL;IDCYCIDCFTQWFGLD; DCYCIDCFTQWFGLDL; CYCIDCFTQWFGLDLT; YCIDCFTQWFGLDLTE;CIDCFTQWFGLDLTEE; IDCFTQWFGLDLTEET; DCFTQWFGLDLTEETL; CFTQWFGLDLTEETLQ;FTQWFGLDLTEETLQW; TQWFGLDLTEETLQWW; QWFGLDLTEETLQWWV; WFGLDLTEETLQWWVQ;FGLDLTEETLQWWVQI; GLDLTEETLQWWVQII; LDLTEETLQWWVQIIG; DLTEETLQWWVQIIGE;LTEETLQWWVQIIGET; TEETLQWWVQIIGETP; EETLQWWVQIIGETPF; ETLQWWVQIIGETPFR;TLQWWVQIIGETPFRD; LQWWVQIIGETPFRDL; QWWVQIIGETPFRDLK; WWVQIIGETPFRDLKL;KALSNYFFYRCQPMEQ; ALSNYFFYRCQPMEQK; LSNYFFYRCQPMEQKS; SNYFFYRCQPMEQKSG;NYFFYRCQPMEQKSGS; YFFYRCQPMEQKSGSP; FFYRCQPMEQKSGSPG; FYRCQPMEQKSGSPGG;YRCQPMEQKSGSPGGV; RCQPMEQKSGSPGGVP; CQPMEQKSGSPGGVPL; QPMEQKSGSPGGVPLM;PMEQKSGSPGGVPLMK; MEQKSGSPGGVPLMKN; EQKSGSPGGVPLMKNG; QKSGSPGGVPLMKNGM;KSGSPGGVPLMKNGMK; SGSPGGVPLMKNGMKI; GSPGGVPLMKNGMKIY; SPGGVPLMKNGMKIYF;PGGVPLMKNGMKIYFA; GGVPLMKNGMKIYFAM; GVPLMKNGMKIYFAMK; VPLMKNGMKIYFAMKI;PLMKNGMKIYFAMKIC; LMKNGMKIYFAMKICL; MKNGMKIYFAMKICLP; KNGMKIYFAMKICLPV;NGMKIYFAMKICLPVM; GMKIYFAMKICLPVMK; MKIYFAMKICLPVMKK; KIYFAMKICLPVMKKQ;IYFAMKICLPVMKKQQ; YFAMKICLPVMKKQQQ; FAMKICLPVMKKQQQI; AMKICLPVMKKQQQIL;MKICLPVMKKQQQILN; KICLPVMKKQQQILNT; ICLPVMKKQQQILNTQ; CLPVMKKQQQILNTQH;LPVMKKQQQILNTQHH; PVMKKQQQILNTQHHP; VMKKQQQILNTQHHPK; MKKQQQILNTQHHPKK;KKQQQILNTQHHPKKK; KQQQILNTQHHPKKKE; QQQILNTQHHPKKKER; KTLKTFPLIYTSFLVK;TLKTFPLIYTSFLVKL; LKTFPLIYTSFLVKLY; KTFPLIYTSFLVKLYL; TFPLIYTSFLVKLYLV;FPLIYTSFLVKLYLVI; PLIYTSFLVKLYLVIE; LIYTSFLVKLYLVIEP; IYTSFLVKLYLVIEPL;YTSFLVKLYLVIEPLP; TSFLVKLYLVIEPLPA; SFLVKLYLVIEPLPAL; FLVKLYLVIEPLPALL;LVKLYLVIEPLPALLC; VKLYLVIEPLPALLCI; KLYLVIEPLPALLCIL; LYLVIEPLPALLCILL;YLVIEPLPALLCILLK; LVIEPLPALLCILLKK; VIEPLPALLCILLKKK; IEPLPALLCILLKKKL;EPLPALLCILLKKKLK; PLPALLCILLKKKLKF; LPALLCILLKKKLKFC; PALLCILLKKKLKFCI;ALLCILLKKKLKFCIK; LLCILLKKKLKFCIKN; LCILLKKKLKFCIKNL; CILLKKKLKFCIKNLW;ILLKKKLKFCIKNLWK; LLKKKLKFCIKNLWKN; LKKKLKFCIKNLWKNI; KKKLKFCIKNLWKNIL;LLLVDTCVLGIILYSF; LHIDIEFLQLIISVKS; HIDIEFLQLIISVKSC; IDIEFLQLIISVKSCV;DIEFLQLIISVKSCVP; IEFLQLIISVKSCVPL; EFLQLIISVKSCVPLV; FLQLIISVKSCVPLVF;RSMILAQKSLKKQSRC; SMILAQKSLKKQSRCL; MILAQKSLKKQSRCLG; ILAQKSLKKQSRCLGN;RSVKSVRKKTSLITLS; SVKSVRKKTSLITLSI; VKSVRKKTSLITLSIM; KSVRKKTSLITLSIMK;SVRKKTSLITLSIMKS; VRKKTSLITLSIMKST; RKKTSLITLSIMKSTL; KKTSLITLSIMKSTLQ;KTSLITLSIMKSTLQM; TSLITLSIMKSTLQML; SLITLSIMKSTLQMLL; LITLSIMKSTLQMLLF;ITLSIMKSTLQMLLFL; TLSIMKSTLQMLLFLQ; LSIMKSTLQMLLFLQK; SIMKSTLQMLLFLQKV;IMKSTLQMLLFLQKVK; MKSTLQMLLFLQKVKI; KSTLQMLLFLQKVKIK; STLQMLLFLQKVKIKK;TLQMLLFLQKVKIKKV; LQMLLFLQKVKIKKVF; QMLLFLQKVKIKKVFV; MLLFLQKVKIKKVFVS;LLFLQKVKIKKVFVSK; LFLQKVKIKKVFVSKQ; NNIWQVLLGCTVCYLK; NIWQVLLGCTVCYLKW;IWQVLLGCTVCYLKWI; WQVLLGCTVCYLKWIL; YLIFCTVLFSMYLKED; LIFCTVLFSMYLKEDT;IFCTVLFSMYLKEDTG; FCTVLFSMYLKEDTGY; CTVLFSMYLKEDTGYL; TVLFSMYLKEDTGYLK;VLFSMYLKEDTGYLKV; LFSMYLKEDTGYLKVP; FSMYLKEDTGYLKVPL; SMYLKEDTGYLKVPLI;MYLKEDTGYLKVPLIV; YLKEDTGYLKVPLIVE; LKEDTGYLKVPLIVEK; KEDTGYLKVPLIVEKQ;EDTGYLKVPLIVEKQH; ENPYKTQSSYLKKEFY; NPYKTQSSYLKKEFYK; PYKTQSSYLKKEFYKV;YKTQSSYLKKEFYKVE; LILQLIYNLELLNGRK; ILQLIYNLELLNGRKG; LQLIYNLELLNGRKGW;QLIYNLELLNGRKGWI; LIYNLELLNGRKGWIL; IYNLELLNGRKGWILR; NIIYAWGNVFLILQEK;IIYAWGNVFLILQEKR; IYAWGNVFLILQEKRI; YAWGNVFLILQEKRIQ; AWGNVFLILQEKRIQK;WGNVFLILQEKRIQKL; GNVFLILQEKRIQKLK; NVFLILQEKRIQKLKT; VFLILQEKRIQKLKTL;FLILQEKRIQKLKTLD; LILQEKRIQKLKTLDM; ILQEKRIQKLKTLDMD; LQEKRIQKLKTLDMDQ;QEKRIQKLKTLDMDQA; EKRIQKLKTLDMDQAL; KRIQKLKTLDMDQALN; RIQKLKTLDMDQALNP;IQKLKTLDMDQALNPN; QKLKTLDMDQALNPNH; KLKTLDMDQALNPNHN; LKTLDMDQALNPNHNA;KTLDMDQALNPNHNAL; TLDMDQALNPNHNALP; LDMDQALNPNHNALPK; DMDQALNPNHNALPKS;MDQALNPNHNALPKSQ; DQALNPNHNALPKSQI; QALNPNHNALPKSQIL; ALNPNHNALPKSQILQ;LNPNHNALPKSQILQP; NPNHNALPKSQILQPL; PNHNALPKSQILQPLL; NHNALPKSQILQPLLK;HNALPKSQILQPLLKI; NALPKSQILQPLLKIP; ALPKSQILQPLLKIPK; LPKSQILQPLLKIPKG;PKSQILQPLLKIPKGQ; KSQILQPLLKIPKGQT; SQILQPLLKIPKGQTP; QILQPLLKIPKGQTPI;ILQPLLKIPKGQTPIV; LQPLLKIPKGQTPIVK; QPLLKIPKGQTPIVKS; PLLKIPKGQTPIVKSC;LLKIPKGQTPIVKSCI; LKIPKGQTPIVKSCIC; KIPKGQTPIVKSCICV; IPKGQTPIVKSCICVK;PKGQTPIVKSCICVKA; KGQTPIVKSCICVKAF; GQTPIVKSCICVKAFS; QTPIVKSCICVKAFSV;TPIVKSCICVKAFSVL; PIVKSCICVKAFSVLK; IVKSCICVKAFSVLKG; VKSCICVKAFSVLKGL;KSCICVKAFSVLKGLK; SCICVKAFSVLKGLKH; CICVKAFSVLKGLKHH; ICVKAFSVLKGLKHHP;CVKAFSVLKGLKHHPQ; VKAFSVLKGLKHHPQN; KAFSVLKGLKHHPQNN; AFSVLKGLKHHPQNNT;FSVLKGLKHHPQNNTS; SVLKGLKHHPQNNTSL; VLKGLKHHPQNNTSLK; LKGLKHHPQNNTSLKV;KGLKHHPQNNTSLKVA; GLKHHPQNNTSLKVAY; LKHHPQNNTSLKVAYT; KHHPQNNTSLKVAYTK;HHPQNNTSLKVAYTKA; HPQNNTSLKVAYTKAA; PQNNTSLKVAYTKAAF; QNNTSLKVAYTKAAFI;NNTSLKVAYTKAAFIK; NTSLKVAYTKAAFIKC; TSLKVAYTKAAFIKCI; SLKVAYTKAAFIKCIC;LKVAYTKAAFIKCICT; KVAYTKAAFIKCICTI; VAYTKAAFIKCICTIK; AYTKAAFIKCICTIKA;YTKAAFIKCICTIKAP; TKAAFIKCICTIKAPV; SILVCNCPCLSIYLII; ILVCNCPCLSIYLIIS;LVCNCPCLSIYLIISG; VCNCPCLSIYLIISGS; CNCPCLSIYLIISGSP; NCPCLSIYLIISGSPG;CPCLSIYLIISGSPGS; PCLSIYLIISGSPGSL; CLSIYLIISGSPGSLS; LSIYLIISGSPGSLSV;SIYLIISGSPGSLSVP; IYLIISGSPGSLSVPS; YLIISGSPGSLSVPSN; LIISGSPGSLSVPSNT;IISGSPGSLSVPSNTL; ISGSPGSLSVPSNTLT; SGSPGSLSVPSNTLTS; GSPGSLSVPSNTLTSS;SPGSLSVPSNTLTSST; PGSLSVPSNTLTSSTW; GSLSVPSNTLTSSTWD; SLSVPSNTLTSSTWDS;LSVPSNTLTSSTWDSI; SVPSNTLTSSTWDSIP; VPSNTLTSSTWDSIPY; PSNTLTSSTWDSIPYI;SNTLTSSTWDSIPYIG; NTLTSSTWDSIPYIGC; TLTSSTWDSIPYIGCP; LTSSTWDSIPYIGCPS;TSSTWDSIPYIGCPST; SSTWDSIPYIGCPSTL; STWDSIPYIGCPSTLW; TWDSIPYIGCPSTLWV;WDSIPYIGCPSTLWVL; DSIPYIGCPSTLWVLL; SIPYIGCPSTLWVLLF; IPYIGCPSTLWVLLFI;PYIGCPSTLWVLLFIR; YIGCPSTLWVLLFIRS; IGCPSTLWVLLFIRSL; GCPSTLWVLLFIRSLS;CPSTLWVLLFIRSLSK; PSTLWVLLFIRSLSKK; STLWVLLFIRSLSKKE; TLWVLLFIRSLSKKEI;LWVLLFIRSLSKKEIG; GFFTDLFLRRILKYLA; FFTDLFLRRILKYLAR; FTDLFLRRILKYLARP;TDLFLRRILKYLARPL; DLFLRRILKYLARPLH; LFLRRILKYLARPLHC; FLRRILKYLARPLHCC;LRRILKYLARPLHCCV; RRILKYLARPLHCCVP; RILKYLARPLHCCVPE; ILKYLARPLHCCVPEL;LKYLARPLHCCVPELL; KYLARPLHCCVPELLV; YLARPLHCCVPELLVN; LARPLHCCVPELLVNR;ARPLHCCVPELLVNRP; RPLHCCVPELLVNRPQ; PLHCCVPELLVNRPQI; LHCCVPELLVNRPQIS;HCCVPELLVNRPQISA; CCVPELLVNRPQISAA; CVPELLVNRPQISAAE; VPELLVNRPQISAAET;PELLVNRPQISAAETY; ELLVNRPQISAAETYR; LLVNRPQISAAETYRL; LVNRPQISAAETYRLS;VNRPQISAAETYRLSA; NRPQISAAETYRLSAL; RPQISAAETYRLSALQ; PQISAAETYRLSALQR;QISAAETYRLSALQRG; ISAAETYRLSALQRGP; SAAETYRLSALQRGPT; AAETYRLSALQRGPTP;AETYRLSALQRGPTPC; ETYRLSALQRGPTPCS; TYRLSALQRGPTPCSS; YRLSALQRGPTPCSSS;RLSALQRGPTPCSSSN; LSALQRGPTPCSSSNT; SALQRGPTPCSSSNTV; ALQRGPTPCSSSNTVV;LQRGPTPCSSSNTVVA; QRGPTPCSSSNTVVAV; RGPTPCSSSNTVVAVL; GPTPCSSSNTVVAVLV;PTPCSSSNTVVAVLVT; STGGTFSPPVKVPKYL; TGGTFSPPVKVPKYLA; GGTFSPPVKVPKYLAF;GTFSPPVKVPKYLAFS; TFSPPVKVPKYLAFSF; FSPPVKVPKYLAFSFL; SPPVKVPKYLAFSFLL;PPVKVPKYLAFSFLLG; PVKVPKYLAFSFLLGS; VKVPKYLAFSFLLGSG; KVPKYLAFSFLLGSGT;VPKYLAFSFLLGSGTQ; PKYLAFSFLLGSGTQH; KYLAFSFLLGSGTQHS; YLAFSFLLGSGTQHST;LAFSFLLGSGTQHSTG; ALWSVFITWDWAVGFL; LWSVFITWDWAVGFLG; WSVFITWDWAVGFLGV;SVFITWDWAVGFLGVI; VFITWDWAVGFLGVIV; FITWDWAVGFLGVIVP; ITWDWAVGFLGVIVPS;TWDWAVGFLGVIVPSG; WDWAVGFLGVIVPSGY; DWAVGFLGVIVPSGYF; WAVGFLGVIVPSGYFD;AVGFLGVIVPSGYFDL; FISTPCISKGSPPTAK; ISTPCISKGSPPTAKK; STPCISKGSPPTAKKW;TPCISKGSPPTAKKWK; PCISKGSPPTAKKWKL; CISKGSPPTAKKWKLL; ISKGSPPTAKKWKLLP;RLSMLVIPITSVCTVT; LSMLVIPITSVCTVTA; SMLVIPITSVCTVTAS; MLVIPITSVCTVTASH;LVIPITSVCTVTASHI; VIPITSVCTVTASHIS; IPITSVCTVTASHISR; PITSVCTVTASHISRF;ITSVCTVTASHISRFP; TSVCTVTASHISRFPQ; SVCTVTASHISRFPQV; VCTVTASHISRFPQVR;CTVTASHISRFPQVRS; TVTASHISRFPQVRSS; VTASHISRFPQVRSSF; TASHISRFPQVRSSFK;ASHISRFPQVRSSFKL; SHISRFPQVRSSFKLG; HISRFPQVRSSFKLGR; ISRFPQVRSSFKLGRG;SRFPQVRSSFKLGRGI; RFPQVRSSFKLGRGIL; FPQVRSSFKLGRGILA; PQVRSSFKLGRGILAV;QVRSSFKLGRGILAVL; QGSIFLSGLSLLKSFS; GSIFLSGLSLLKSFSA; SIFLSGLSLLKSFSAL;IFLSGLSLLKSFSALS; FLSGLSLLKSFSALSF; LSGLSLLKSFSALSFR; SGLSLLKSFSALSFRL;GLSLLKSFSALSFRLK; LSLLKSFSALSFRLKP; SLLKSFSALSFRLKPL; LLKSFSALSFRLKPLR;LKSFSALSFRLKPLRF; KSFSALSFRLKPLRFS; SFSALSFRLKPLRFSS; FSALSFRLKPLRFSSG;SALSFRLKPLRFSSGS; ALSFRLKPLRFSSGSP; LSFRLKPLRFSSGSPI; SFRLKPLRFSSGSPIS;FRLKPLRFSSGSPISG; RLKPLRFSSGSPISGF; LKPLRFSSGSPISGFR; KPLRFSSGSPISGFRK;PLRFSSGSPISGFRKH; LRFSSGSPISGFRKHS; RFSSGSPISGFRKHST; FSSGSPISGFRKHSTS;SSGSPISGFRKHSTSV; SGSPISGFRKHSTSVI; GSPISGFRKHSTSVIA; SPISGFRKHSTSVIAS;PISGFRKHSTSVIAST; ISGFRKHSTSVIASTP; SGFRKHSTSVIASTPV; GFRKHSTSVIASTPVL;FRKHSTSVIASTPVLT; RKHSTSVIASTPVLTS; KHSTSVIASTPVLTSR; HSTSVIASTPVLTSRT;STSVIASTPVLTSRTS; TSVIASTPVLTSRTST; SVIASTPVLTSRTSTP; VIASTPVLTSRTSTPP;IASTPVLTSRTSTPPF; ASTPVLTSRTSTPPFI; STPVLTSRTSTPPFIS; TPVLTSRTSTPPFISS;PVLTSRTSTPPFISSF; VLTSRTSTPPFISSFG; LTSRTSTPPFISSFGT; TSRTSTPPFISSFGTC;SRTSTPPFISSFGTCT; RTSTPPFISSFGTCTG; TSTPPFISSFGTCTGS; STPPFISSFGTCTGSF;TPPFISSFGTCTGSFG; PPFISSFGTCTGSFGF; PFISSFGTCTGSFGFL; FISSFGTCTGSFGFLG;ISSFGTCTGSFGFLGA; SSFGTCTGSFGFLGAA; SFGTCTGSFGFLGAAP; FGTCTGSFGFLGAAPG;GTCTGSFGFLGAAPGH; TCTGSFGFLGAAPGHS; CTGSFGFLGAAPGHSP; TGSFGFLGAAPGHSPF;GSFGFLGAAPGHSPFL; SFGFLGAAPGHSPFLL; FGFLGAAPGHSPFLLV; GFLGAAPGHSPFLLVG;FLGAAPGHSPFLLVGA; LGAAPGHSPFLLVGAI; GAAPGHSPFLLVGAIF; AAPGHSPFLLVGAIFI;APGHSPFLLVGAIFIC; PGHSPFLLVGAIFICF; GHSPFLLVGAIFICFK; HSPFLLVGAIFICFKS;SPFLLVGAIFICFKSR; PFLLVGAIFICFKSRC; FLLVGAIFICFKSRCY; LLVGAIFICFKSRCYS;LVGAIFICFKSRCYSP; VGAIFICFKSRCYSPV; GAIFICFKSRCYSPVQ; AIFICFKSRCYSPVQA;RQHPLRSSSLISTSWG; QHPLRSSSLISTSWGN; HPLRSSSLISTSWGNS; PLRSSSLISTSWGNSF;LRSSSLISTSWGNSFF; RSSSLISTSWGNSFFY; SSSLISTSWGNSFFYK; SSLISTSWGNSFFYKL;SLISTSWGNSFFYKLS; VHSLCNFFYTVSIIYT; HSLCNFFYTVSIIYTI; SLCNFFYTVSIIYTIS;LCNFFYTVSIIYTISM; CNFFYTVSIIYTISMA; NFFYTVSIIYTISMAK; FFYTVSIIYTISMAKM;FYTVSIIYTISMAKMY; YTVSIIYTISMAKMYT; TVSIIYTISMAKMYTG; VSIIYTISMAKMYTGT;SIIYTISMAKMYTGTF; IIYTISMAKMYTGTFP; IYTISMAKMYTGTFPF; YTISMAKMYTGTFPFS;TISMAKMYTGTFPFSY; ISMAKMYTGTFPFSYL; SMAKMYTGTFPFSYLS; MAKMYTGTFPFSYLSN;AKMYTGTFPFSYLSNH; GPNRGKIRIILLNIII; PNRGKIRIILLNIIIK; NRGKIRIILLNIIIKV;RGKIRIILLNIIIKVY; GKIRIILLNIIIKVYR; KIRIILLNIIIKVYRG; IRIILLNIIIKVYRGI;RIILLNIIIKVYRGIY; IILLNIIIKVYRGIYN; ILLNIIIKVYRGIYNC; LLNIIIKVYRGIYNCP;LNIIIKVYRGIYNCPG; NIIIKVYRGIYNCPGS; IIIKVYRGIYNCPGSF; IIKVYRGIYNCPGSFL;IKVYRGIYNCPGSFLQ; KVYRGIYNCPGSFLQK; VYRGIYNCPGSFLQKS; YRGIYNCPGSFLQKSS;RGIYNCPGSFLQKSSQ; GIYNCPGSFLQKSSQG; IYNCPGSFLQKSSQGV; YNCPGSFLQKSSQGVS;NCPGSFLQKSSQGVSK; CPGSFLQKSSQGVSKK; PGSFLQKSSQGVSKKS; GSFLQKSSQGVSKKSF;SFLQKSSQGVSKKSFC; FLQKSSQGVSKKSFCS; LQKSSQGVSKKSFCSS; QKSSQGVSKKSFCSSL;KSSQGVSKKSFCSSLQ; SSQGVSKKSFCSSLQF; SQGVSKKSFCSSLQFL; GYRRYIIPNNMPQSLG;YRRYIIPNNMPQSLGN; RRYIIPNNMPQSLGNS; RYIIPNNMPQSLGNSS; YIIPNNMPQSLGNSSK;IIPNNMPQSLGNSSKQ; IPNNMPQSLGNSSKQR; PNNMPQSLGNSSKQRR; NNMPQSLGNSSKQRRT;NMPQSLGNSSKQRRTP; MPQSLGNSSKQRRTPM; PQSLGNSSKQRRTPMP; QSLGNSSKQRRTPMPR;SLGNSSKQRRTPMPRI; LGNSSKQRRTPMPRIK; GNSSKQRRTPMPRIKV; NSSKQRRTPMPRIKVL;SSKQRRTPMPRIKVLN; SKQRRTPMPRIKVLNI; KQRRTPMPRIKVLNII; QRRTPMPRIKVLNIIN;RRTPMPRIKVLNIINK; RTPMPRIKVLNIINKS; TPMPRIKVLNIINKSI; PMPRIKVLNIINKSIY;MPRIKVLNIINKSIYT; PRIKVLNIINKSIYTR; RIKVLNIINKSIYTRK; IKVLNIINKSIYTRKQ;KVLNIINKSIYTRKQN; VLNIINKSIYTRKQNI; LNIINKSIYTRKQNII; NIINKSIYTRKQNIIV;IINKSIYTRKQNIIVL; INKSIYTRKQNIIVLI; NKSIYTRKQNIIVLIW; KSIYTRKQNIIVLIWV;SIYTRKQNIIVLIWVK; IYTRKQNIIVLIWVKQ; YTRKQNIIVLIWVKQF; TRKQNIIVLIWVKQFQ;RKQNIIVLIWVKQFQS; KQNIIVLIWVKQFQSH; QNIIVLIWVKQFQSHA; LLIEAYSGNFVIPIIK;LIEAYSGNFVIPIIKE; IEAYSGNFVIPIIKEL; EAYSGNFVIPIIKELI; AYSGNFVIPIIKELIP;YSGNFVIPIIKELIPY; SGNFVIPIIKELIPYL; GNFVIPIIKELIPYLS; SSKPSNSPRSTSNYSI;SKPSNSPRSTSNYSIC; KPSNSPRSTSNYSICL; PSNSPRSTSNYSICLR; SNSPRSTSNYSICLRS;GTCYALYSSKGCNLNF; TCYALYSSKGCNLNFY; CYALYSSKGCNLNFYS; YALYSSKGCNLNFYSS;ALYSSKGCNLNFYSSS; LYSSKGCNLNFYSSSS; YSSKGCNLNFYSSSSL; SSKGCNLNFYSSSSLP;SKGCNLNFYSSSSLPS; KGCNLNFYSSSSLPSS; GCNLNFYSSSSLPSSN; CNLNFYSSSSLPSSNF;NLNFYSSSSLPSSNFS; LNFYSSSSLPSSNFSH; SSTHEPGNTKKKGLLT; ESFTESFTAGKAVVLL;SFTESFTAGKAVVLLF; FTESFTAGKAVVLLFF; TESFTAGKAVVLLFFP; ESFTAGKAVVLLFFPS;SFTAGKAVVLLFFPST; FTAGKAVVLLFFPSTL; TAGKAVVLLFFPSTLS; AGKAVVLLFFPSTLSS;GKAVVLLFFPSTLSSP; KAVVLLFFPSTLSSPL; AVVLLFFPSTLSSPLQ; VVLLFFPSTLSSPLQN;VLLFFPSTLSSPLQNS; LLFFPSTLSSPLQNSS; LFFPSTLSSPLQNSSK; FFPSTLSSPLQNSSKS;FPSTLSSPLQNSSKSS; PSTLSSPLQNSSKSSK; STLSSPLQNSSKSSKI; TLSSPLQNSSKSSKIK;LSSPLQNSSKSSKIKI; SSPLQNSSKSSKIKIK; SPLQNSSKSSKIKIKI; PLQNSSKSSKIKIKIL;ALFFVPVQVLPTFTEA; LFFVPVQVLPTFTEAC; FFVPVQVLPTFTEACR; FVPVQVLPTFTEACRD;VPVQVLPTFTEACRDS; PVQVLPTFTEACRDSW; VQVLPTFTEACRDSWR; QVLPTFTEACRDSWRR;VLPTFTEACRDSWRRT; LPTFTEACRDSWRRTM; PTFTEACRDSWRRTMA; TFTEACRDSWRRTMAF;FTEACRDSWRRTMAFV; TEACRDSWRRTMAFVQ; EACRDSWRRTMAFVQF; ACRDSWRRTMAFVQFN;CRDSWRRTMAFVQFNW; RDSWRRTMAFVQFNWG; DSWRRTMAFVQFNWGQ; SWRRTMAFVQFNWGQG;WRRTMAFVQFNWGQGQ; RRTMAFVQFNWGQGQD; RTMAFVQFNWGQGQDS; ARKTCLSCTFLPEVMV;RKTCLSCTFLPEVMVW; KTCLSCTFLPEVMVWL; TCLSCTFLPEVMVWLH; CLSCTFLPEVMVWLHS;LSCTFLPEVMVWLHSM; SCTFLPEVMVWLHSMG; CTFLPEVMVWLHSMGK; TFLPEVMVWLHSMGKQ;FLPEVMVWLHSMGKQL; LPEVMVWLHSMGKQLL; PEVMVWLHSMGKQLLP; EVMVWLHSMGKQLLPV;VMVWLHSMGKQLLPVS; MVWLHSMGKQLLPVSH; VWLHSMGKQLLPVSHA; WLHSMGKQLLPVSHAL;LHSMGKQLLPVSHALS; HSMGKQLLPVSHALSF; SMGKQLLPVSHALSFL; MGKQLLPVSHALSFLR;GKQLLPVSHALSFLRS; KQLLPVSHALSFLRSW; QLLPVSHALSFLRSWF; LLPVSHALSFLRSWFG;LPVSHALSFLRSWFGC; PVSHALSFLRSWFGCI; VSHALSFLRSWFGCIP; SHALSFLRSWFGCIPL;GLAKLFGEIPILLQFL; LAKLFGEIPILLQFLQ BK virus reverse reading frame 2 13mers: WIKFLTGKNPWSS; IKFLTGKNPWSSW; KFLTGKNPWSSWT; FLTGKNPWSSWTF;GSVRNFTLTKGAT; SVRNFTLTKGATR; VRNFTLTKGATRI; RNFTLTKGATRIK;LISLILEPGVAQR; ISLILEPGVAQRF; SLILEPGVAQRFV; LILEPGVAQRFVL;ILEPGVAQRFVLI; LEPGVAQRFVLIF; EPGVAQRFVLIFL; PGVAQRFVLIFLF;GVAQRFVLIFLFA; VAQRFVLIFLFAQ; AQRFVLIFLFAQI; QRFVLIFLFAQIP;RFVLIFLFAQIPC; FVLIFLFAQIPCT; VLIFLFAQIPCTA; LIFLFAQIPCTAR;IFLFAQIPCTARN; FLFAQIPCTARNG; LFAQIPCTARNGL; FAQIPCTARNGLF;AQIPCTARNGLFV; QIPCTARNGLFVP; IPCTARNGLFVPK; PCTARNGLFVPKS;CTARNGLFVPKSL; TARNGLFVPKSLL; ARNGLFVPKSLLC; RNGLFVPKSLLCT;NGLFVPKSLLCTA; GLFVPKSLLCTAL; LFVPKSLLCTALA; FVPKSLLCTALAC;VPKSLLCTALACY; PKSLLCTALACYV; KSLLCTALACYVS; SLLCTALACYVSL;LLCTALACYVSLD; IATALTASHSGLA; VIIFFIGANLWNR; IIFFIGANLWNRR;IFFIGANLWNRRV; FFIGANLWNRRVG; FIGANLWNRRVGV; IGANLWNRRVGVL;GANLWNRRVGVLV; ANLWNRRVGVLVE; NLWNRRVGVLVEF; LWNRRVGVLVEFL;RSNSRFSTLNTTQ; SNSRFSTLNTTQK; NSRFSTLNTTQKK; SRFSTLNTTQKKK;RFSTLNTTQKKKK; FSTLNTTQKKKKG; STLNTTQKKKKGR; TLNTTQKKKKGRR;LNTTQKKKKGRRP; RSIPYYRRKHSRG; SIPYYRRKHSRGL; IPYYRRKHSRGLK;PYYRRKHSRGLKG; YYRRKHSRGLKGA; GCVFIIRYVFRIS; CVFIIRYVFRISI;VFIIRYVFRISIQ; FIIRYVFRISIQC; IIRYVFRISIQCR; IRYVFRISIQCRG;RYVFRISIQCRGV; KSKKYLSASSRYS; SKKYLSASSRYSF; KKYLSASSRYSFS;KKSRYPSYDQGRN; KSRYPSYDQGRNA; SRYPSYDQGRNAN; RYPSYDQGRNANR;YPSYDQGRNANRK; PSYDQGRNANRKI; SYDQGRNANRKIQ; YDQGRNANRKIQS;DQGRNANRKIQSY; QGRNANRKIQSYI; GRNANRKIQSYIR; NGFNIWSSWKCCT;GFNIWSSWKCCTR; FNIWSSWKCCTRT; NIWSSWKCCTRTI; IWSSWKCCTRTIY;WSSWKCCTRTIYG; SSWKCCTRTIYGR; SWKCCTRTIYGRC; WKCCTRTIYGRCC;KCCTRTIYGRCCL; CCTRTIYGRCCLA; CTRTIYGRCCLAA; TRTIYGRCCLAAL;RTIYGRCCLAALF; TIYGRCCLAALFA; IYGRCCLAALFAT; WKNNTSCRVIRFV;KNNTSCRVIRFVW; NNTSCRVIRFVWW; SLKCKPTHGKANL; IKGFAFRTWNKQF;KGFAFRTWNKQFR; GFAFRTWNKQFRQ; FAFRTWNKQFRQF; AFRTWNKQFRQFE;FRTWNKQFRQFER; RTWNKQFRQFERL; TWNKQFRQFERLF; WNKQFRQFERLFR;NKQFRQFERLFRW; KQFRQFERLFRWK; QFRQFERLFRWKC; GKFRKETFKQKNP;KFRKETFKQKNPN; FRKETFKQKNPNI; RKETFKQKNPNIS; KETFKQKNPNIST;ETFKQKNPNISTR; TFKQKNPNISTRL; FKQKNPNISTRLG; KQKNPNISTRLGY;QKNPNISTRLGYN; KNPNISTRLGYNE; AQNIFKKILTKLR; QNIFKKILTKLRV;NIFKKILTKLRVL; IFKKILTKLRVLT; KKNFTKWNDLVAT; KNFTKWNDLVATA;NFTKWNDLVATAN; FTKWNDLVATANL; TKWNDLVATANLV; IPITMLFPSLRYF;PITMLFPSLRYFS; ITMLFPSLRYFSP; TMLFPSLRYFSPC; KWLIQKQHLLNVY;WLIQKQHLLNVYV; LIQKQHLLNVYVQ; KHLFKAFWFAIVP; HLFKAFWFAIVPV;LFKAFWFAIVPVC; FKAFWFAIVPVCQ; KAFWFAIVPVCQY; AFWFAIVPVCQYI;FWFAIVPVCQYIL; WFAIVPVCQYILS; FAIVPVCQYILSY; AIVPVCQYILSYL;IVPVCQYILSYLG; VPVCQYILSYLGP; PVCQYILSYLGPL; VCQYILSYLGPLE;CQYILSYLGPLEV; QYILSYLGPLEVF; YILSYLGPLEVFL; ILSYLGPLEVFLC;LSYLGPLEVFLCH; SYLGPLEVFLCHQ; YLGPLEVFLCHQT; LGPLEVFLCHQTP;GHLAKRKLGKDSL; HLAKRKLGKDSLQ; LAKRKLGKDSLQI; AKRKLGKDSLQIF;KRKLGKDSLQIFF; RKLGKDSLQIFFS; KLGKDSLQIFFSG; LGKDSLQIFFSGG;GKDSLQIFFSGGS; NILQGLSTVVFQS; ILQGLSTVVFQSC; TGHKYQQLKHTGY;GHKYQQLKHTGYQ; HKYQQLKHTGYQL; KYQQLKHTGYQLY; YQQLKHTGYQLYK;QQLKHTGYQLYKE; QLKHTGYQLYKEA; LKHTGYQLYKEAP; KHTGYQLYKEAPH;HTGYQLYKEAPHP; TGYQLYKEAPHPV; GYQLYKEAPHPVH; YQLYKEAPHPVHL;QLYKEAPHPVHLA; LYKEAPHPVHLAT; YKEAPHPVHLATL; KEAPHPVHLATLW;LCWSHEVLGEHFP; CWSHEVLGEHFPL; WSHEVLGEHFPLL; HFHFYWDQVPSTQ;FHFYWDQVPSTQL; HFYWDQVPSTQLD; FYWDQVPSTQLDK; YWDQVPSTQLDKH;WDQVPSTQLDKHC; DQVPSTQLDKHCF; QVPSTQLDKHCFC; VPSTQLDKHCFCP;PSTQLDKHCFCPN; STQLDKHCFCPNR; TQLDKHCFCPNRP; QLDKHCFCPNRPY;LDKHCFCPNRPYG; DKHCFCPNRPYGQ; KHCFCPNRPYGQY; HCFCPNRPYGQYS;CFCPNRPYGQYSL; FCPNRPYGQYSLP; CPNRPYGQYSLPG; PNRPYGQYSLPGT;NRPYGQYSLPGTG; RPYGQYSLPGTGL; PYGQYSLPGTGLL; YGQYSLPGTGLLG;GQYSLPGTGLLGF; YHQGTLTCNSLAL; HQGTLTCNSLALP; QGTLTCNSLALPA;GTLTCNSLALPAF; TLTCNSLALPAFP; LTCNSLALPAFPR; TCNSLALPAFPRV;CNSLALPAFPRVL; NSLALPAFPRVLH; SLALPAFPRVLHL; LALPAFPRVLHLQ;ALPAFPRVLHLQQ; LPAFPRVLHLQQR; PAFPRVLHLQQRS; AFPRVLHLQQRSG;FPRVLHLQQRSGN; PRVLHLQQRSGNY; RVLHLQQRSGNYC; VLHLQQRSGNYCL;LHLQQRSGNYCLE; VFLHHAHALFVTL; FLHHAHALFVTLH; LHHAHALFVTLHE;HHAHALFVTLHEG; PLFVQLQPPTSVD; LFVQLQPPTSVDF; FVQLQPPTSVDFH;VQLQPPTSVDFHR; QLQPPTSVDFHRL; LQPPTSVDFHRLG; QPPTSVDFHRLGP;PPTSVDFHRLGPH; PTSVDFHRLGPHL; TSVDFHRLGPHLN; SVDFHRLGPHLNW;VDFHRLGPHLNWG; DFHRLGPHLNWGG; FHRLGPHLNWGGE; HRLGPHLNWGGEF;RLGPHLNWGGEFL; LGPHLNWGGEFLL; GPHLNWGGEFLLC; PHLNWGGEFLLCC;HLNWGGEFLLCCN; LNWGGEFLLCCNR; NWGGEFLLCCNRE; WGGEFLLCCNREA;GGEFLLCCNREAF; GEFLLCCNREAFF; EFLLCCNREAFFS; FLLCCNREAFFSL;LLCCNREAFFSLG; LCCNREAFFSLGY; CCNREAFFSLGYH; CNREAFFSLGYHC;GFHLDPPFLGLGS; FHLDPPFLGLGSI; HLDPPFLGLGSIL; LDPPFLGLGSILP;DPPFLGLGSILPL; LLELLLLLLLVVL; LELLLLLLLVVLA; ELLLLLLLVVLAL;LLLLLLLVVLALA; LLLLLLVVLALAR; LLLLLVVLALARV; LLLLVVLALARVP;LLLVVLALARVPL; LLVVLALARVPLA; LVVLALARVPLAF; VVLALARVPLAFW;VLALARVPLAFWE; LALARVPLAFWEL; ALARVPLAFWELP; LARVPLAFWELPL;ARVPLAFWELPLD; RVPLAFWELPLDT; VPLAFWELPLDTL; PLAFWELPLDTLL;LAFWELPLDTLLF; AFWELPLDTLLFF; FWELPLDTLLFFW; WELPLDTLLFFWL;ELPLDTLLFFWLG; LPLDTLLFFWLGP; PLDTLLFFWLGPS; LDTLLFFWLGPSS;DTLLFFWLGPSSY; TLLFFWLGPSSYA; LLFFWLGPSSYAS; LFFWLGPSSYASR;FFWLGPSSYASRA; FWLGPSSYASRAG; WLGPSSYASRAGV; LGPSSYASRAGVT;GPSSYASRAGVTV; PSSYASRAGVTVP; SSYASRAGVTVPY; SYASRAGVTVPYR;YASRAGVTVPYRP; ASRAGVTVPYRPR; SRAGVTVPYRPRS; RAGVTVPYRPRSK;AGVTVPYRPRSKG; GVTVPYRPRSKGN; VTVPYRPRSKGNI; TVPYRPRSKGNIH;LAPPGAIVFSINS; APPGAIVFSINSP; PPGAIVFSINSPE; PGAIVFSINSPEC;GAIVFSINSPECT; AIVFSINSPECTL; IVFSINSPECTLC; FLKSILCVTSSIL;LKSILCVTSSILS; KSILCVTSSILSA; SILCVTSSILSAS; ILCVTSSILSASS;LCVTSSILSASSI; CVTSSILSASSIL; VWPKCTRVPSLSA; WPKCTRVPSLSAT;PKCTRVPSLSATC; KCTRVPSLSATCL; CTRVPSLSATCLT; TRVPSLSATCLTI;RVPSLSATCLTIE; VPSLSATCLTIEG; PSLSATCLTIEGL; SLSATCLTIEGLI;LSATCLTIEGLIG; SATCLTIEGLIGE; ATCLTIEGLIGER; TCLTIEGLIGERS;CLTIEGLIGERSE; KFIGAFTIVQVVS; FIGAFTIVQVVSS; IGAFTIVQVVSSK;GAFTIVQVVSSKN; AFTIVQVVSSKNL; FTIVQVVSSKNLA; TIVQVVSSKNLAK;IVQVVSSKNLAKE; VQVVSSKNLAKES; QVVSSKNLAKESL; VVSSKNLAKESLK;VSSKNLAKESLKN; SSKNLAKESLKNL; SKNLAKESLKNLS; KNLAKESLKNLSV;NLAKESLKNLSVL; LAKESLKNLSVLL; AKESLKNLSVLLC; KESLKNLSVLLCN;ESLKNLSVLLCNS; SLKNLSVLLCNSC; LKNLSVLLCNSCE; KNLSVLLCNSCEV;NLSVLLCNSCEVI; LSVLLCNSCEVIE; SVLLCNSCEVIEG; VLLCNSCEVIEGI;LLCNSCEVIEGIS; LCNSCEVIEGISS; CNSCEVIEGISSL; NSCEVIEGISSLI;SCEVIEGISSLIT; CEVIEGISSLITC; EVIEGISSLITCH; VIEGISSLITCHK;IEGISSLITCHKA; EGISSLITCHKAW; GISSLITCHKAWE; ISSLITCHKAWEI;SSLITCHKAWEIV; SLITCHKAWEIVA; LITCHKAWEIVAN; ITCHKAWEIVANK;TCHKAWEIVANKE; CHKAWEIVANKEG; HKAWEIVANKEGP; KAWEIVANKEGPQ;AWEIVANKEGPQC; WEIVANKEGPQCL; EIVANKEGPQCLG; IVANKEGPQCLGS;VANKEGPQCLGSR; ANKEGPQCLGSRY; ILLTKVFTPGNRI; LLTKVFTPGNRIS;YSSGLNNSKAMPD; SSGLNNSKAMPDC; IKAANPAIAPGAP; KAANPAIAPGAPA;AANPAIAPGAPAI; ANPAIAPGAPAIT; NPAIAPGAPAITA; PAIAPGAPAITAY;AIAPGAPAITAYV; GVRPIAAIASEVL; VRPIAAIASEVLV; RPIAAIASEVLVM;PIAAIASEVLVMP; IAAIASEVLVMPS; AAIASEVLVMPST; AIASEVLVMPSTV;IASEVLVMPSTVA; ASEVLVMPSTVAR; SEVLVMPSTVARD; EVLVMPSTVARDA;VLVMPSTVARDAI; TSIAAAASPAAIS; SIAAAASPAAISA; IAAAASPAAISAT;AAAASPAAISATE; AAASPAAISATEN; AASPAAISATENP; ASPAAISATENPV;SPAAISATENPVA; PAAISATENPVAA; AAISATENPVAAA; AISATENPVAAAA;ISATENPVAAAAS; SATENPVAAAASD; ATENPVAAAASDT; TENPVAAAASDTL;ENPVAAAASDTLA; NPVAAAASDTLAT; PVAAAASDTLATR; VAAAASDTLATRS;AAAASDTLATRSP; AAASDTLATRSPK; AASDTLATRSPKS; ASDTLATRSPKSA;SDTLATRSPKSAR; DTLATRSPKSARA; TLATRSPKSARAA; LATRSPKSARAAP;ATRSPKSARAAPM; TRSPKSARAAPMN; RSPKSARAAPMNL; SPKSARAAPMNLE;PKSARAAPMNLEI; KSARAAPMNLEIQ; SARAAPMNLEIQK; ARAAPMNLEIQKK;RAAPMNLEIQKKR; AAPMNLEIQKKRD; APMNLEIQKKRDY; PMNLEIQKKRDYL;MNLEIQKKRDYLP; NLEIQKKRDYLPR; LEIQKKRDYLPRS; EIQKKRDYLPRSL;IQKKRDYLPRSLL; QKKRDYLPRSLLQ; KKRDYLPRSLLQS; KRDYLPRSLLQSL;RDYLPRSLLQSLL; DYLPRSLLQSLLQ; YLPRSLLQSLLQQ; LPRSLLQSLLQQV;PRSLLQSLLQQVK; RSLLQSLLQQVKQ; SLLQSLLQQVKQW; LLQSLLQQVKQWY;LQSLLQQVKQWYF; QSLLQQVKQWYFC; SLLQQVKQWYFCF; LLQQVKQWYFCFS;LQQVKQWYFCFSR; QQVKQWYFCFSRL; QVKQWYFCFSRLH; VKQWYFCFSRLHC;KQWYFCFSRLHCL; QWYFCFSRLHCLH; WYFCFSRLHCLHL; YFCFSRLHCLHLY;FCFSRLHCLHLYK; CFSRLHCLHLYKI; FSRLHCLHLYKIP; SRLHCLHLYKIPA;RLHCLHLYKIPAK; LHCLHLYKIPAKA; HCLHLYKIPAKAL; CLHLYKIPAKALK;KSSELFFLFQSRF; SSELFFLFQSRFY; SELFFLFQSRFYQ; ELFFLFQSRFYQL;LFFLFQSRFYQLS; FFLFQSRFYQLSL; FLFQSRFYQLSLK; LFQSRFYQLSLKL;FQSRFYQLSLKLV; QSRFYQLSLKLVV; SRFYQLSLKLVVT; RFYQLSLKLVVTA;FYQLSLKLVVTAG; YQLSLKLVVTAGA; QLSLKLVVTAGAE; LSLKLVVTAGAEP;SLKLVVTAGAEPW; LKLVVTAGAEPWP; KLVVTAGAEPWPL; LVVTAGAEPWPLS;VVTAGAEPWPLSS; VTAGAEPWPLSSL; TAGAEPWPLSSLT; AGAEPWPLSSLTG;GAEPWPLSSLTGD; AEPWPLSSLTGDK; EPWPLSSLTGDKA; PWPLSSLTGDKAK;WPLSSLTGDKAKI; PLSSLTGDKAKIP; LSSLTGDKAKIPR; SSLTGDKAKIPRL;SLTGDKAKIPRLA; LTGDKAKIPRLAK; TGDKAKIPRLAKH; GDKAKIPRLAKHV;DKAKIPRLAKHVC; KAKIPRLAKHVCH; AKIPRLAKHVCHA; KIPRLAKHVCHAL;IPRLAKHVCHALS; PRLAKHVCHALSF; RLAKHVCHALSFL; LAKHVCHALSFLR;AKHVCHALSFLRS; KHVCHALSFLRSW; HVCHALSFLRSWF; VCHALSFLRSWFG;CHALSFLRSWFGC; HALSFLRSWFGCI; ALSFLRSWFGCIP; LSFLRSWFGCIPW;SFLRSWFGCIPWV; FLRSWFGCIPWVS; LRSWFGCIPWVSS; RSWFGCIPWVSSS;SWFGCIPWVSSSS; WFGCIPWVSSSSL; GHGLAAFPCESCT; HGLAAFPCESCTF;GLAAFPCESCTFL; LAAFPCESCTFLP; AAFPCESCTFLPE; AFPCESCTFLPEV;FPCESCTFLPEVM; PCESCTFLPEVMV; CESCTFLPEVMVW; ESCTFLPEVMVWL;SCTFLPEVMVWLH; CTFLPEVMVWLHS; TFLPEVMVWLHSM; FLPEVMVWLHSMG;LPEVMVWLHSMGK; PEVMVWLHSMGKQ; EVMVWLHSMGKQL; VMVWLHSMGKQLL;MVWLHSMGKQLLP; VWLHSMGKQLLPV; WLHSMGKQLLPVA; LHSMGKQLLPVAF;HSMGKQLLPVAFF; SMGKQLLPVAFFF; MGKQLLPVAFFFI; GKQLLPVAFFFII;KQLLPVAFFFIIY; QLLPVAFFFIIYK; LLPVAFFFIIYKR; LPVAFFFIIYKRP;PVAFFFIIYKRPR; VAFFFIIYKRPRP; AFFFIIYKRPRPP; FFFIIYKRPRPPL;FFIIYKRPRPPLP; FIIYKRPRPPLPP; IIYKRPRPPLPPP; IYKRPRPPLPPPF;YKRPRPPLPPPFL; KRPRPPLPPPFLS; RPRPPLPPPFLSS; PRPPLPPPFLSSS;RPPLPPPFLSSSK; PPLPPPFLSSSKG; PLPPPFLSSSKGV; LPPPFLSSSKGVE;PPPFLSSSKGVEA; PPFLSSSKGVEAF; PFLSSSKGVEAFS; FLSSSKGVEAFSE;LSSSKGVEAFSEA; QNYLGKSLFFCNF; NYLGKSLFFCNFC; YLGKSLFFCNFCK 14 mers:WIKFLTGKNPWSSW; IKFLTGKNPWSSWT; KFLTGKNPWSSWTF; GSVRNFTLTKGATR;SVRNFTLTKGATRI; VRNFTLTKGATRIK; LISLILEPGVAQRF; ISLILEPGVAQRFV;SLILEPGVAQRFVL; LILEPGVAQRFVLI; ILEPGVAQRFVLIF; LEPGVAQRFVLIFL;EPGVAQRFVLIFLF; PGVAQRFVLIFLFA; GVAQRFVLIFLFAQ; VAQRFVLIFLFAQI;AQRFVLIFLFAQIP; QRFVLIFLFAQIPC; RFVLIFLFAQIPCT; FVLIFLFAQIPCTA;VLIFLFAQIPCTAR; LIFLFAQIPCTARN; IFLFAQIPCTARNG; FLFAQIPCTARNGL;LFAQIPCTARNGLF; FAQIPCTARNGLFV; AQIPCTARNGLFVP; QIPCTARNGLFVPK;IPCTARNGLFVPKS; PCTARNGLFVPKSL; CTARNGLFVPKSLL; TARNGLFVPKSLLC;ARNGLFVPKSLLCT; RNGLFVPKSLLCTA; NGLFVPKSLLCTAL; GLFVPKSLLCTALA;LFVPKSLLCTALAC; FVPKSLLCTALACY; VPKSLLCTALACYV; PKSLLCTALACYVS;KSLLCTALACYVSL; SLLCTALACYVSLD; VIIFFIGANLWNRR; IIFFIGANLWNRRV;IFFIGANLWNRRVG; FFIGANLWNRRVGV; FIGANLWNRRVGVL; IGANLWNRRVGVLV;GANLWNRRVGVLVE; ANLWNRRVGVLVEF; NLWNRRVGVLVEFL; RSNSRFSTLNTTQK;SNSRFSTLNTTQKK; NSRFSTLNTTQKKK; SRFSTLNTTQKKKK; RFSTLNTTQKKKKG;FSTLNTTQKKKKGR; STLNTTQKKKKGRR; TLNTTQKKKKGRRP; RSIPYYRRKHSRGL;SIPYYRRKHSRGLK; IPYYRRKHSRGLKG; PYYRRKHSRGLKGA; GCVFIIRYVFRISI;CVFIIRYVFRISIQ; VFIIRYVFRISIQC; FIIRYVFRISIQCR; IIRYVFRISIQCRG;IRYVFRISIQCRGV; KSKKYLSASSRYSF; SKKYLSASSRYSFS; KKSRYPSYDQGRNA;KSRYPSYDQGRNAN; SRYPSYDQGRNANR; RYPSYDQGRNANRK; YPSYDQGRNANRKI;PSYDQGRNANRKIQ; SYDQGRNANRKIQS; YDQGRNANRKIQSY; DQGRNANRKIQSYI;QGRNANRKIQSYIR; NGFNIWSSWKCCTR; GFNIWSSWKCCTRT; FNIWSSWKCCTRTI;NIWSSWKCCTRTIY; IWSSWKCCTRTIYG; WSSWKCCTRTIYGR; SSWKCCTRTIYGRC;SWKCCTRTIYGRCC; WKCCTRTIYGRCCL; KCCTRTIYGRCCLA; CCTRTIYGRCCLAA;CTRTIYGRCCLAAL; TRTIYGRCCLAALF; RTIYGRCCLAALFA; TIYGRCCLAALFAT;WKNNTSCRVIRFVW; KNNTSCRVIRFVWW; IKGFAFRTWNKQFR; KGFAFRTWNKQFRQ;GFAFRTWNKQFRQF; FAFRTWNKQFRQFE; AFRTWNKQFRQFER; FRTWNKQFRQFERL;RTWNKQFRQFERLF; TWNKQFRQFERLFR; WNKQFRQFERLFRW; NKQFRQFERLFRWK;KQFRQFERLFRWKC; GKFRKETFKQKNPN; KFRKETFKQKNPNI; FRKETFKQKNPNIS;RKETFKQKNPNIST; KETFKQKNPNISTR; ETFKQKNPNISTRL; TFKQKNPNISTRLG;FKQKNPNISTRLGY; KQKNPNISTRLGYN; QKNPNISTRLGYNE; AQNIFKKILTKLRV;QNIFKKILTKLRVL; NIFKKILTKLRVLT; KKNFTKWNDLVATA; KNFTKWNDLVATAN;NFTKWNDLVATANL; FTKWNDLVATANLV; IPITMLFPSLRYFS; PITMLFPSLRYFSP;ITMLFPSLRYFSPC; KWLIQKQHLLNVYV; WLIQKQHLLNVYVQ; KHLFKAFWFAIVPV;HLFKAFWFAIVPVC; LFKAFWFAIVPVCQ; FKAFWFAIVPVCQY; KAFWFAIVPVCQYI;AFWFAIVPVCQYIL; FWFAIVPVCQYILS; WFAIVPVCQYILSY; FAIVPVCQYILSYL;AIVPVCQYILSYLG; IVPVCQYILSYLGP; VPVCQYILSYLGPL; PVCQYILSYLGPLE;VCQYILSYLGPLEV; CQYILSYLGPLEVF; QYILSYLGPLEVFL; YILSYLGPLEVFLC;ILSYLGPLEVFLCH; LSYLGPLEVFLCHQ; SYLGPLEVFLCHQT; YLGPLEVFLCHQTP;GHLAKRKLGKDSLQ; HLAKRKLGKDSLQI; LAKRKLGKDSLQIF; AKRKLGKDSLQIFF;KRKLGKDSLQIFFS; RKLGKDSLQIFFSG; KLGKDSLQIFFSGG; LGKDSLQIFFSGGS;NILQGLSTVVFQSC; TGHKYQQLKHTGYQ; GHKYQQLKHTGYQL; HKYQQLKHTGYQLY;KYQQLKHTGYQLYK; YQQLKHTGYQLYKE; QQLKHTGYQLYKEA; QLKHTGYQLYKEAP;LKHTGYQLYKEAPH; KHTGYQLYKEAPHP; HTGYQLYKEAPHPV; TGYQLYKEAPHPVH;GYQLYKEAPHPVHL; YQLYKEAPHPVHLA; QLYKEAPHPVHLAT; LYKEAPHPVHLATL;YKEAPHPVHLATLW; LCWSHEVLGEHFPL; CWSHEVLGEHFPLL; HFHFYWDQVPSTQL;FHFYWDQVPSTQLD; HFYWDQVPSTQLDK; FYWDQVPSTQLDKH; YWDQVPSTQLDKHC;WDQVPSTQLDKHCF; DQVPSTQLDKHCFC; QVPSTQLDKHCFCP; VPSTQLDKHCFCPN;PSTQLDKHCFCPNR; STQLDKHCFCPNRP; TQLDKHCFCPNRPY; QLDKHCFCPNRPYG;LDKHCFCPNRPYGQ; DKHCFCPNRPYGQY; KHCFCPNRPYGQYS; HCFCPNRPYGQYSL;CFCPNRPYGQYSLP; FCPNRPYGQYSLPG; CPNRPYGQYSLPGT; PNRPYGQYSLPGTG;NRPYGQYSLPGTGL; RPYGQYSLPGTGLL; PYGQYSLPGTGLLG; YGQYSLPGTGLLGF;YHQGTLTCNSLALP; HQGTLTCNSLALPA; QGTLTCNSLALPAF; GTLTCNSLALPAFP;TLTCNSLALPAFPR; LTCNSLALPAFPRV; TCNSLALPAFPRVL; CNSLALPAFPRVLH;NSLALPAFPRVLHL; SLALPAFPRVLHLQ; LALPAFPRVLHLQQ; ALPAFPRVLHLQQR;LPAFPRVLHLQQRS; PAFPRVLHLQQRSG; AFPRVLHLQQRSGN; FPRVLHLQQRSGNY;PRVLHLQQRSGNYC; RVLHLQQRSGNYCL; VLHLQQRSGNYCLE; VFLHHAHALFVTLH;FLHHAHALFVTLHE; LHHAHALFVTLHEG; PLFVQLQPPTSVDF; LFVQLQPPTSVDFH;FVQLQPPTSVDFHR; VQLQPPTSVDFHRL; QLQPPTSVDFHRLG; LQPPTSVDFHRLGP;QPPTSVDFHRLGPH; PPTSVDFHRLGPHL; PTSVDFHRLGPHLN; TSVDFHRLGPHLNW;SVDFHRLGPHLNWG; VDFHRLGPHLNWGG; DFHRLGPHLNWGGE; FHRLGPHLNWGGEF;HRLGPHLNWGGEFL; RLGPHLNWGGEFLL; LGPHLNWGGEFLLC; GPHLNWGGEFLLCC;PHLNWGGEFLLCCN; HLNWGGEFLLCCNR; LNWGGEFLLCCNRE; NWGGEFLLCCNREA;WGGEFLLCCNREAF; GGEFLLCCNREAFF; GEFLLCCNREAFFS; EFLLCCNREAFFSL;FLLCCNREAFFSLG; LLCCNREAFFSLGY; LCCNREAFFSLGYH; CCNREAFFSLGYHC;GFHLDPPFLGLGSI; FHLDPPFLGLGSIL; HLDPPFLGLGSILP; LDPPFLGLGSILPL;LLELLLLLLLVVLA; LELLLLLLLVVLAL; ELLLLLLLVVLALA; LLLLLLLVVLALAR;LLLLLLVVLALARV; LLLLLVVLALARVP; LLLLVVLALARVPL; LLLVVLALARVPLA;LLVVLALARVPLAF; LVVLALARVPLAFW; VVLALARVPLAFWE; VLALARVPLAFWEL;LALARVPLAFWELP; ALARVPLAFWELPL; LARVPLAFWELPLD; ARVPLAFWELPLDT;RVPLAFWELPLDTL; VPLAFWELPLDTLL; PLAFWELPLDTLLF; LAFWELPLDTLLFF;AFWELPLDTLLFFW; FWELPLDTLLFFWL; WELPLDTLLFFWLG; ELPLDTLLFFWLGP;LPLDTLLFFWLGPS; PLDTLLFFWLGPSS; LDTLLFFWLGPSSY; DTLLFFWLGPSSYA;TLLFFWLGPSSYAS; LLFFWLGPSSYASR; LFFWLGPSSYASRA; FFWLGPSSYASRAG;FWLGPSSYASRAGV; WLGPSSYASRAGVT; LGPSSYASRAGVTV; GPSSYASRAGVTVP;PSSYASRAGVTVPY; SSYASRAGVTVPYR; SYASRAGVTVPYRP; YASRAGVTVPYRPR;ASRAGVTVPYRPRS; SRAGVTVPYRPRSK; RAGVTVPYRPRSKG; AGVTVPYRPRSKGN;GVTVPYRPRSKGNI; VTVPYRPRSKGNIH; LAPPGAIVFSINSP; APPGAIVFSINSPE;PPGAIVFSINSPEC; PGAIVFSINSPECT; GAIVFSINSPECTL; AIVFSINSPECTLC;FLKSILCVTSSILS; LKSILCVTSSILSA; KSILCVTSSILSAS; SILCVTSSILSASS;ILCVTSSILSASSI; LCVTSSILSASSIL; VWPKCTRVPSLSAT; WPKCTRVPSLSATC;PKCTRVPSLSATCL; KCTRVPSLSATCLT; CTRVPSLSATCLTI; TRVPSLSATCLTIE;RVPSLSATCLTIEG; VPSLSATCLTIEGL; PSLSATCLTIEGLI; SLSATCLTIEGLIG;LSATCLTIEGLIGE; SATCLTIEGLIGER; ATCLTIEGLIGERS; TCLTIEGLIGERSE;KFIGAFTIVQVVSS; FIGAFTIVQVVSSK; IGAFTIVQVVSSKN; GAFTIVQVVSSKNL;AFTIVQVVSSKNLA; FTIVQVVSSKNLAK; TIVQVVSSKNLAKE; IVQVVSSKNLAKES;VQVVSSKNLAKESL; QVVSSKNLAKESLK; VVSSKNLAKESLKN; VSSKNLAKESLKNL;SSKNLAKESLKNLS; SKNLAKESLKNLSV; KNLAKESLKNLSVL; NLAKESLKNLSVLL;LAKESLKNLSVLLC; AKESLKNLSVLLCN; KESLKNLSVLLCNS; ESLKNLSVLLCNSC;SLKNLSVLLCNSCE; LKNLSVLLCNSCEV; KNLSVLLCNSCEVI; NLSVLLCNSCEVIE;LSVLLCNSCEVIEG; SVLLCNSCEVIEGI; VLLCNSCEVIEGIS; LLCNSCEVIEGISS;LCNSCEVIEGISSL; CNSCEVIEGISSLI; NSCEVIEGISSLIT; SCEVIEGISSLITC;CEVIEGISSLITCH; EVIEGISSLITCHK; VIEGISSLITCHKA; IEGISSLITCHKAW;EGISSLITCHKAWE; GISSLITCHKAWEI; ISSLITCHKAWEIV; SSLITCHKAWEIVA;SLITCHKAWEIVAN; LITCHKAWEIVANK; ITCHKAWEIVANKE; TCHKAWEIVANKEG;CHKAWEIVANKEGP; HKAWEIVANKEGPQ; KAWEIVANKEGPQC; AWEIVANKEGPQCL;WEIVANKEGPQCLG; EIVANKEGPQCLGS; IVANKEGPQCLGSR; VANKEGPQCLGSRY;ILLTKVFTPGNRIS; YSSGLNNSKAMPDC; IKAANPAIAPGAPA; KAANPAIAPGAPAI;AANPAIAPGAPAIT; ANPAIAPGAPAITA; NPAIAPGAPAITAY; PAIAPGAPAITAYV;GVRPIAAIASEVLV; VRPIAAIASEVLVM; RPIAAIASEVLVMP; PIAAIASEVLVMPS;IAAIASEVLVMPST; AAIASEVLVMPSTV; AIASEVLVMPSTVA; IASEVLVMPSTVAR;ASEVLVMPSTVARD; SEVLVMPSTVARDA; EVLVMPSTVARDAI; TSIAAAASPAAISA;SIAAAASPAAISAT; IAAAASPAAISATE; AAAASPAAISATEN; AAASPAAISATENP;AASPAAISATENPV; ASPAAISATENPVA; SPAAISATENPVAA; PAAISATENPVAAA;AAISATENPVAAAA; AISATENPVAAAAS; ISATENPVAAAASD; SATENPVAAAASDT;ATENPVAAAASDTL; TENPVAAAASDTLA; ENPVAAAASDTLAT; NPVAAAASDTLATR;PVAAAASDTLATRS; VAAAASDTLATRSP; AAAASDTLATRSPK; AAASDTLATRSPKS;AASDTLATRSPKSA; ASDTLATRSPKSAR; SDTLATRSPKSARA; DTLATRSPKSARAA;TLATRSPKSARAAP; LATRSPKSARAAPM; ATRSPKSARAAPMN; TRSPKSARAAPMNL;RSPKSARAAPMNLE; SPKSARAAPMNLEI; PKSARAAPMNLEIQ; KSARAAPMNLEIQK;SARAAPMNLEIQKK; ARAAPMNLEIQKKR; RAAPMNLEIQKKRD; AAPMNLEIQKKRDY;APMNLEIQKKRDYL; PMNLEIQKKRDYLP; MNLEIQKKRDYLPR; NLEIQKKRDYLPRS;LEIQKKRDYLPRSL; EIQKKRDYLPRSLL; IQKKRDYLPRSLLQ; QKKRDYLPRSLLQS;KKRDYLPRSLLQSL; KRDYLPRSLLQSLL; RDYLPRSLLQSLLQ; DYLPRSLLQSLLQQ;YLPRSLLQSLLQQV; LPRSLLQSLLQQVK; PRSLLQSLLQQVKQ; RSLLQSLLQQVKQW;SLLQSLLQQVKQWY; LLQSLLQQVKQWYF; LQSLLQQVKQWYFC; QSLLQQVKQWYFCF;SLLQQVKQWYFCFS; LLQQVKQWYFCFSR; LQQVKQWYFCFSRL; QQVKQWYFCFSRLH;QVKQWYFCFSRLHC; VKQWYFCFSRLHCL; KQWYFCFSRLHCLH; QWYFCFSRLHCLHL;WYFCFSRLHCLHLY; YFCFSRLHCLHLYK; FCFSRLHCLHLYKI; CFSRLHCLHLYKIP;FSRLHCLHLYKIPA; SRLHCLHLYKIPAK; RLHCLHLYKIPAKA; LHCLHLYKIPAKAL;HCLHLYKIPAKALK; KSSELFFLFQSRFY; SSELFFLFQSRFYQ; SELFFLFQSRFYQL;ELFFLFQSRFYQLS; LFFLFQSRFYQLSL; FFLFQSRFYQLSLK; FLFQSRFYQLSLKL;LFQSRFYQLSLKLV; FQSRFYQLSLKLVV; QSRFYQLSLKLVVT; SRFYQLSLKLVVTA;RFYQLSLKLVVTAG; FYQLSLKLVVTAGA; YQLSLKLVVTAGAE; QLSLKLVVTAGAEP;LSLKLVVTAGAEPW; SLKLVVTAGAEPWP; LKLVVTAGAEPWPL; KLVVTAGAEPWPLS;LVVTAGAEPWPLSS; VVTAGAEPWPLSSL; VTAGAEPWPLSSLT; TAGAEPWPLSSLTG;AGAEPWPLSSLTGD; GAEPWPLSSLTGDK; AEPWPLSSLTGDKA; EPWPLSSLTGDKAK;PWPLSSLTGDKAKI; WPLSSLTGDKAKIP; PLSSLTGDKAKIPR; LSSLTGDKAKIPRL;SSLTGDKAKIPRLA; SLTGDKAKIPRLAK; LTGDKAKIPRLAKH; TGDKAKIPRLAKHV;GDKAKIPRLAKHVC; DKAKIPRLAKHVCH; KAKIPRLAKHVCHA; AKIPRLAKHVCHAL;KIPRLAKHVCHALS; IPRLAKHVCHALSF; PRLAKHVCHALSFL; RLAKHVCHALSFLR;LAKHVCHALSFLRS; AKHVCHALSFLRSW; KHVCHALSFLRSWF; HVCHALSFLRSWFG;VCHALSFLRSWFGC; CHALSFLRSWFGCI; HALSFLRSWFGCIP; ALSFLRSWFGCIPW;LSFLRSWFGCIPWV; SFLRSWFGCIPWVS; FLRSWFGCIPWVSS; LRSWFGCIPWVSSS;RSWFGCIPWVSSSS; SWFGCIPWVSSSSL; GHGLAAFPCESCTF; HGLAAFPCESCTFL;GLAAFPCESCTFLP; LAAFPCESCTFLPE; AAFPCESCTFLPEV; AFPCESCTFLPEVM;FPCESCTFLPEVMV; PCESCTFLPEVMVW; CESCTFLPEVMVWL; ESCTFLPEVMVWLH;SCTFLPEVMVWLHS; CTFLPEVMVWLHSM; TFLPEVMVWLHSMG; FLPEVMVWLHSMGK;LPEVMVWLHSMGKQ; PEVMVWLHSMGKQL; EVMVWLHSMGKQLL; VMVWLHSMGKQLLP;MVWLHSMGKQLLPV; VWLHSMGKQLLPVA; WLHSMGKQLLPVAF; LHSMGKQLLPVAFF;HSMGKQLLPVAFFF; SMGKQLLPVAFFFI; MGKQLLPVAFFFII; GKQLLPVAFFFIIY;KQLLPVAFFFIIYK; QLLPVAFFFIIYKR; LLPVAFFFIIYKRP; LPVAFFFIIYKRPR;PVAFFFIIYKRPRP; VAFFFIIYKRPRPP; AFFFIIYKRPRPPL; FFFIIYKRPRPPLP;FFIIYKRPRPPLPP; FIIYKRPRPPLPPP; IIYKRPRPPLPPPF; IYKRPRPPLPPPFL;YKRPRPPLPPPFLS; KRPRPPLPPPFLSS; RPRPPLPPPFLSSS; PRPPLPPPFLSSSK;RPPLPPPFLSSSKG; PPLPPPFLSSSKGV; PLPPPFLSSSKGVE; LPPPFLSSSKGVEA;PPPFLSSSKGVEAF; PPFLSSSKGVEAFS; PFLSSSKGVEAFSE; FLSSSKGVEAFSEA;QNYLGKSLFFCNFC; NYLGKSLFFCNFCK 15 mers: WIKFLTGKNPWSSWT;IKFLTGKNPWSSWTF; GSVRNFTLTKGATRI; SVRNFTLTKGATRIK; LISLILEPGVAQRFV;ISLILEPGVAQRFVL; SLILEPGVAQRFVLI; LILEPGVAQRFVLIF; ILEPGVAQRFVLIFL;LEPGVAQRFVLIFLF; EPGVAQRFVLIFLFA; PGVAQRFVLIFLFAQ; GVAQRFVLIFLFAQI;VAQRFVLIFLFAQIP; AQRFVLIFLFAQIPC; QRFVLIFLFAQIPCT; RFVLIFLFAQIPCTA;FVLIFLFAQIPCTAR; VLIFLFAQIPCTARN; LIFLFAQIPCTARNG; IFLFAQIPCTARNGL;FLFAQIPCTARNGLF; LFAQIPCTARNGLFV; FAQIPCTARNGLFVP; AQIPCTARNGLFVPK;QIPCTARNGLFVPKS; IPCTARNGLFVPKSL; PCTARNGLFVPKSLL; CTARNGLFVPKSLLC;TARNGLFVPKSLLCT; ARNGLFVPKSLLCTA; RNGLFVPKSLLCTAL; NGLFVPKSLLCTALA;GLFVPKSLLCTALAC; LFVPKSLLCTALACY; FVPKSLLCTALACYV; VPKSLLCTALACYVS;PKSLLCTALACYVSL; KSLLCTALACYVSLD; VIIFFIGANLWNRRV; IIFFIGANLWNRRVG;IFFIGANLWNRRVGV; FFIGANLWNRRVGVL; FIGANLWNRRVGVLV; IGANLWNRRVGVLVE;GANLWNRRVGVLVEF; ANLWNRRVGVLVEFL; RSNSRFSTLNTTQKK; SNSRFSTLNTTQKKK;NSRFSTLNTTQKKKK; SRFSTLNTTQKKKKG; RFSTLNTTQKKKKGR; FSTLNTTQKKKKGRR;STLNTTQKKKKGRRP; RSIPYYRRKHSRGLK; SIPYYRRKHSRGLKG; IPYYRRKHSRGLKGA;GCVFIIRYVFRISIQ; CVFIIRYVFRISIQC; VFIIRYVFRISIQCR; FIIRYVFRISIQCRG;IIRYVFRISIQCRGV; KSKKYLSASSRYSFS; KKSRYPSYDQGRNAN; KSRYPSYDQGRNANR;SRYPSYDQGRNANRK; RYPSYDQGRNANRKI; YPSYDQGRNANRKIQ; PSYDQGRNANRKIQS;SYDQGRNANRKIQSY; YDQGRNANRKIQSYI; DQGRNANRKIQSYIR; NGFNIWSSWKCCTRT;GFNIWSSWKCCTRTI; FNIWSSWKCCTRTIY; NIWSSWKCCTRTIYG; IWSSWKCCTRTIYGR;WSSWKCCTRTIYGRC; SSWKCCTRTIYGRCC; SWKCCTRTIYGRCCL; WKCCTRTIYGRCCLA;KCCTRTIYGRCCLAA; CCTRTIYGRCCLAAL; CTRTIYGRCCLAALF; TRTIYGRCCLAALFA;RTIYGRCCLAALFAT; WKNNTSCRVIRFVWW; IKGFAFRTWNKQFRQ; KGFAFRTWNKQFRQF;GFAFRTWNKQFRQFE; FAFRTWNKQFRQFER; AFRTWNKQFRQFERL; FRTWNKQFRQFERLF;RTWNKQFRQFERLFR; TWNKQFRQFERLFRW; WNKQFRQFERLFRWK; NKQFRQFERLFRWKC;GKFRKETFKQKNPNI; KFRKETFKQKNPNIS; FRKETFKQKNPNIST; RKETFKQKNPNISTR;KETFKQKNPNISTRL; ETFKQKNPNISTRLG; TFKQKNPNISTRLGY; FKQKNPNISTRLGYN;KQKNPNISTRLGYNE; AQNIFKKILTKLRVL; QNIFKKILTKLRVLT; KKNFTKWNDLVATAN;KNFTKWNDLVATANL; NFTKWNDLVATANLV; IPITMLFPSLRYFSP; PITMLFPSLRYFSPC;KWLIQKQHLLNVYVQ; KHLFKAFWFAIVPVC; HLFKAFWFAIVPVCQ; LFKAFWFAIVPVCQY;FKAFWFAIVPVCQYI; KAFWFAIVPVCQYIL; AFWFAIVPVCQYILS; FWFAIVPVCQYILSY;WFAIVPVCQYILSYL; FAIVPVCQYILSYLG; AIVPVCQYILSYLGP; IVPVCQYILSYLGPL;VPVCQYILSYLGPLE; PVCQYILSYLGPLEV; VCQYILSYLGPLEVF; CQYILSYLGPLEVFL;QYILSYLGPLEVFLC; YILSYLGPLEVFLCH; ILSYLGPLEVFLCHQ; LSYLGPLEVFLCHQT;SYLGPLEVFLCHQTP; GHLAKRKLGKDSLQI; HLAKRKLGKDSLQIF; LAKRKLGKDSLQIFF;AKRKLGKDSLQIFFS; KRKLGKDSLQIFFSG; RKLGKDSLQIFFSGG; KLGKDSLQIFFSGGS;TGHKYQQLKHTGYQL; GHKYQQLKHTGYQLY; HKYQQLKHTGYQLYK; KYQQLKHTGYQLYKE;YQQLKHTGYQLYKEA; QQLKHTGYQLYKEAP; QLKHTGYQLYKEAPH; LKHTGYQLYKEAPHP;KHTGYQLYKEAPHPV; HTGYQLYKEAPHPVH; TGYQLYKEAPHPVHL; GYQLYKEAPHPVHLA;YQLYKEAPHPVHLAT; QLYKEAPHPVHLATL; LYKEAPHPVHLATLW; LCWSHEVLGEHFPLL;HFHFYWDQVPSTQLD; FHFYWDQVPSTQLDK; HFYWDQVPSTQLDKH; FYWDQVPSTQLDKHC;YWDQVPSTQLDKHCF; WDQVPSTQLDKHCFC; DQVPSTQLDKHCFCP; QVPSTQLDKHCFCPN;VPSTQLDKHCFCPNR; PSTQLDKHCFCPNRP; STQLDKHCFCPNRPY; TQLDKHCFCPNRPYG;QLDKHCFCPNRPYGQ; LDKHCFCPNRPYGQY; DKHCFCPNRPYGQYS; KHCFCPNRPYGQYSL;HCFCPNRPYGQYSLP; CFCPNRPYGQYSLPG; FCPNRPYGQYSLPGT; CPNRPYGQYSLPGTG;PNRPYGQYSLPGTGL; NRPYGQYSLPGTGLL; RPYGQYSLPGTGLLG; PYGQYSLPGTGLLGF;YHQGTLTCNSLALPA; HQGTLTCNSLALPAF; QGTLTCNSLALPAFP; GTLTCNSLALPAFPR;TLTCNSLALPAFPRV; LTCNSLALPAFPRVL; TCNSLALPAFPRVLH; CNSLALPAFPRVLHL;NSLALPAFPRVLHLQ; SLALPAFPRVLHLQQ; LALPAFPRVLHLQQR; ALPAFPRVLHLQQRS;LPAFPRVLHLQQRSG; PAFPRVLHLQQRSGN; AFPRVLHLQQRSGNY; FPRVLHLQQRSGNYC;PRVLHLQQRSGNYCL; RVLHLQQRSGNYCLE; VFLHHAHALFVTLHE; FLHHAHALFVTLHEG;PLFVQLQPPTSVDFH; LFVQLQPPTSVDFHR; FVQLQPPTSVDFHRL; VQLQPPTSVDFHRLG;QLQPPTSVDFHRLGP; LQPPTSVDFHRLGPH; QPPTSVDFHRLGPHL; PPTSVDFHRLGPHLN;PTSVDFHRLGPHLNW; TSVDFHRLGPHLNWG; SVDFHRLGPHLNWGG; VDFHRLGPHLNWGGE;DFHRLGPHLNWGGEF; FHRLGPHLNWGGEFL; HRLGPHLNWGGEFLL; RLGPHLNWGGEFLLC;LGPHLNWGGEFLLCC; GPHLNWGGEFLLCCN; PHLNWGGEFLLCCNR; HLNWGGEFLLCCNRE;LNWGGEFLLCCNREA; NWGGEFLLCCNREAF; WGGEFLLCCNREAFF; GGEFLLCCNREAFFS;GEFLLCCNREAFFSL; EFLLCCNREAFFSLG; FLLCCNREAFFSLGY; LLCCNREAFFSLGYH;LCCNREAFFSLGYHC; GFHLDPPFLGLGSIL; FHLDPPFLGLGSILP; HLDPPFLGLGSILPL;LLELLLLLLLVVLAL; LELLLLLLLVVLALA; ELLLLLLLVVLALAR; LLLLLLLVVLALARV;LLLLLLVVLALARVP; LLLLLVVLALARVPL; LLLLVVLALARVPLA; LLLVVLALARVPLAF;LLVVLALARVPLAFW; LVVLALARVPLAFWE; VVLALARVPLAFWEL; VLALARVPLAFWELP;LALARVPLAFWELPL; ALARVPLAFWELPLD; LARVPLAFWELPLDT; ARVPLAFWELPLDTL;RVPLAFWELPLDTLL; VPLAFWELPLDTLLF; PLAFWELPLDTLLFF; LAFWELPLDTLLFFW;AFWELPLDTLLFFWL; FWELPLDTLLFFWLG; WELPLDTLLFFWLGP; ELPLDTLLFFWLGPS;LPLDTLLFFWLGPSS; PLDTLLFFWLGPSSY; LDTLLFFWLGPSSYA; DTLLFFWLGPSSYAS;TLLFFWLGPSSYASR; LLFFWLGPSSYASRA; LFFWLGPSSYASRAG; FFWLGPSSYASRAGV;FWLGPSSYASRAGVT; WLGPSSYASRAGVTV; LGPSSYASRAGVTVP; GPSSYASRAGVTVPY;PSSYASRAGVTVPYR; SSYASRAGVTVPYRP; SYASRAGVTVPYRPR; YASRAGVTVPYRPRS;ASRAGVTVPYRPRSK; SRAGVTVPYRPRSKG; RAGVTVPYRPRSKGN; AGVTVPYRPRSKGNI;GVTVPYRPRSKGNIH; LAPPGAIVFSINSPE; APPGAIVFSINSPEC; PPGAIVFSINSPECT;PGAIVFSINSPECTL; GAIVFSINSPECTLC; FLKSILCVTSSILSA; LKSILCVTSSILSAS;KSILCVTSSILSASS; SILCVTSSILSASSI; ILCVTSSILSASSIL; VWPKCTRVPSLSATC;WPKCTRVPSLSATCL; PKCTRVPSLSATCLT; KCTRVPSLSATCLTI; CTRVPSLSATCLTIE;TRVPSLSATCLTIEG; RVPSLSATCLTIEGL; VPSLSATCLTIEGLI; PSLSATCLTIEGLIG;SLSATCLTIEGLIGE; LSATCLTIEGLIGER; SATCLTIEGLIGERS; ATCLTIEGLIGERSE;KFIGAFTIVQVVSSK; FIGAFTIVQVVSSKN; IGAFTIVQVVSSKNL; GAFTIVQVVSSKNLA;AFTIVQVVSSKNLAK; FTIVQVVSSKNLAKE; TIVQVVSSKNLAKES; IVQVVSSKNLAKESL;VQVVSSKNLAKESLK; QVVSSKNLAKESLKN; VVSSKNLAKESLKNL; VSSKNLAKESLKNLS;SSKNLAKESLKNLSV; SKNLAKESLKNLSVL; KNLAKESLKNLSVLL; NLAKESLKNLSVLLC;LAKESLKNLSVLLCN; AKESLKNLSVLLCNS; KESLKNLSVLLCNSC; ESLKNLSVLLCNSCE;SLKNLSVLLCNSCEV; LKNLSVLLCNSCEVI; KNLSVLLCNSCEVIE; NLSVLLCNSCEVIEG;LSVLLCNSCEVIEGI; SVLLCNSCEVIEGIS; VLLCNSCEVIEGISS; LLCNSCEVIEGISSL;LCNSCEVIEGISSLI; CNSCEVIEGISSLIT; NSCEVIEGISSLITC; SCEVIEGISSLITCH;CEVIEGISSLITCHK; EVIEGISSLITCHKA; VIEGISSLITCHKAW; IEGISSLITCHKAWE;EGISSLITCHKAWEI; GISSLITCHKAWEIV; ISSLITCHKAWEIVA; SSLITCHKAWEIVAN;SLITCHKAWEIVANK; LITCHKAWEIVANKE; ITCHKAWEIVANKEG; TCHKAWEIVANKEGP;CHKAWEIVANKEGPQ; HKAWEIVANKEGPQC; KAWEIVANKEGPQCL; AWEIVANKEGPQCLG;WEIVANKEGPQCLGS; EIVANKEGPQCLGSR; IVANKEGPQCLGSRY; IKAANPAIAPGAPAI;KAANPAIAPGAPAIT; AANPAIAPGAPAITA; ANPAIAPGAPAITAY; NPAIAPGAPAITAYV;GVRPIAAIASEVLVM; VRPIAAIASEVLVMP; RPIAAIASEVLVMPS; PIAAIASEVLVMPST;IAAIASEVLVMPSTV; AAIASEVLVMPSTVA; AIASEVLVMPSTVAR; IASEVLVMPSTVARD;ASEVLVMPSTVARDA; SEVLVMPSTVARDAI; TSIAAAASPAAISAT; SIAAAASPAAISATE;IAAAASPAAISATEN; AAAASPAAISATENP; AAASPAAISATENPV; AASPAAISATENPVA;ASPAAISATENPVAA; SPAAISATENPVAAA; PAAISATENPVAAAA; AAISATENPVAAAAS;AISATENPVAAAASD; ISATENPVAAAASDT; SATENPVAAAASDTL; ATENPVAAAASDTLA;TENPVAAAASDTLAT; ENPVAAAASDTLATR; NPVAAAASDTLATRS; PVAAAASDTLATRSP;VAAAASDTLATRSPK; AAAASDTLATRSPKS; AAASDTLATRSPKSA; AASDTLATRSPKSAR;ASDTLATRSPKSARA; SDTLATRSPKSARAA; DTLATRSPKSARAAP; TLATRSPKSARAAPM;LATRSPKSARAAPMN; ATRSPKSARAAPMNL; TRSPKSARAAPMNLE; RSPKSARAAPMNLEI;SPKSARAAPMNLEIQ; PKSARAAPMNLEIQK; KSARAAPMNLEIQKK; SARAAPMNLEIQKKR;ARAAPMNLEIQKKRD; RAAPMNLEIQKKRDY; AAPMNLEIQKKRDYL; APMNLEIQKKRDYLP;PMNLEIQKKRDYLPR; MNLEIQKKRDYLPRS; NLEIQKKRDYLPRSL; LEIQKKRDYLPRSLL;EIQKKRDYLPRSLLQ; IQKKRDYLPRSLLQS; QKKRDYLPRSLLQSL; KKRDYLPRSLLQSLL;KRDYLPRSLLQSLLQ; RDYLPRSLLQSLLQQ; DYLPRSLLQSLLQQV; YLPRSLLQSLLQQVK;LPRSLLQSLLQQVKQ; PRSLLQSLLQQVKQW; RSLLQSLLQQVKQWY; SLLQSLLQQVKQWYF;LLQSLLQQVKQWYFC; LQSLLQQVKQWYFCF; QSLLQQVKQWYFCFS; SLLQQVKQWYFCFSR;LLQQVKQWYFCFSRL; LQQVKQWYFCFSRLH; QQVKQWYFCFSRLHC; QVKQWYFCFSRLHCL;VKQWYFCFSRLHCLH; KQWYFCFSRLHCLHL; QWYFCFSRLHCLHLY; WYFCFSRLHCLHLYK;YFCFSRLHCLHLYKI; FCFSRLHCLHLYKIP; CFSRLHCLHLYKIPA; FSRLHCLHLYKIPAK;SRLHCLHLYKIPAKA; RLHCLHLYKIPAKAL; LHCLHLYKIPAKALK; KSSELFFLFQSRFYQ;SSELFFLFQSRFYQL; SELFFLFQSRFYQLS; ELFFLFQSRFYQLSL; LFFLFQSRFYQLSLK;FFLFQSRFYQLSLKL; FLFQSRFYQLSLKLV; LFQSRFYQLSLKLVV; FQSRFYQLSLKLVVT;QSRFYQLSLKLVVTA; SRFYQLSLKLVVTAG; RFYQLSLKLVVTAGA; FYQLSLKLVVTAGAE;YQLSLKLVVTAGAEP; QLSLKLVVTAGAEPW; LSLKLVVTAGAEPWP; SLKLVVTAGAEPWPL;LKLVVTAGAEPWPLS; KLVVTAGAEPWPLSS; LVVTAGAEPWPLSSL; VVTAGAEPWPLSSLT;VTAGAEPWPLSSLTG; TAGAEPWPLSSLTGD; AGAEPWPLSSLTGDK; GAEPWPLSSLTGDKA;AEPWPLSSLTGDKAK; EPWPLSSLTGDKAKI; PWPLSSLTGDKAKIP; WPLSSLTGDKAKIPR;PLSSLTGDKAKIPRL; LSSLTGDKAKIPRLA; SSLTGDKAKIPRLAK; SLTGDKAKIPRLAKH;LTGDKAKIPRLAKHV; TGDKAKIPRLAKHVC; GDKAKIPRLAKHVCH; DKAKIPRLAKHVCHA;KAKIPRLAKHVCHAL; AKIPRLAKHVCHALS; KIPRLAKHVCHALSF; IPRLAKHVCHALSFL;PRLAKHVCHALSFLR; RLAKHVCHALSFLRS; LAKHVCHALSFLRSW; AKHVCHALSFLRSWF;KHVCHALSFLRSWFG; HVCHALSFLRSWFGC; VCHALSFLRSWFGCI; CHALSFLRSWFGCIP;HALSFLRSWFGCIPW; ALSFLRSWFGCIPWV; LSFLRSWFGCIPWVS; SFLRSWFGCIPWVSS;FLRSWFGCIPWVSSS; LRSWFGCIPWVSSSS; RSWFGCIPWVSSSSL; GHGLAAFPCESCTFL;HGLAAFPCESCTFLP; GLAAFPCESCTFLPE; LAAFPCESCTFLPEV; AAFPCESCTFLPEVM;AFPCESCTFLPEVMV; FPCESCTFLPEVMVW; PCESCTFLPEVMVWL; CESCTFLPEVMVWLH;ESCTFLPEVMVWLHS; SCTFLPEVMVWLHSM; CTFLPEVMVWLHSMG; TFLPEVMVWLHSMGK;FLPEVMVWLHSMGKQ; LPEVMVWLHSMGKQL; PEVMVWLHSMGKQLL; EVMVWLHSMGKQLLP;VMVWLHSMGKQLLPV; MVWLHSMGKQLLPVA; VWLHSMGKQLLPVAF; WLHSMGKQLLPVAFF;LHSMGKQLLPVAFFF; HSMGKQLLPVAFFFI; SMGKQLLPVAFFFII; MGKQLLPVAFFFIIY;GKQLLPVAFFFIIYK; KQLLPVAFFFIIYKR; QLLPVAFFFIIYKRP; LLPVAFFFIIYKRPR;LPVAFFFIIYKRPRP; PVAFFFIIYKRPRPP; VAFFFIIYKRPRPPL; AFFFIIYKRPRPPLP;FFFIIYKRPRPPLPP; FFIIYKRPRPPLPPP; FIIYKRPRPPLPPPF; IIYKRPRPPLPPPFL;IYKRPRPPLPPPFLS; YKRPRPPLPPPFLSS; KRPRPPLPPPFLSSS; RPRPPLPPPFLSSSK;PRPPLPPPFLSSSKG; RPPLPPPFLSSSKGV; PPLPPPFLSSSKGVE; PLPPPFLSSSKGVEA;LPPPFLSSSKGVEAF; PPPFLSSSKGVEAFS; PPFLSSSKGVEAFSE; PFLSSSKGVEAFSEA;QNYLGKSLFFCNFCK 16 mers: WIKFLTGKNPWSSWTF; GSVRNFTLTKGATRIK;LISLILEPGVAQRFVL; ISLILEPGVAQRFVLI; SLILEPGVAQRFVLIF; LILEPGVAQRFVLIFL;ILEPGVAQRFVLIFLF; LEPGVAQRFVLIFLFA; EPGVAQRFVLIFLFAQ; PGVAQRFVLIFLFAQI;GVAQRFVLIFLFAQIP; VAQRFVLIFLFAQIPC; AQRFVLIFLFAQIPCT; QRFVLIFLFAQIPCTA;RFVLIFLFAQIPCTAR; FVLIFLFAQIPCTARN; VLIFLFAQIPCTARNG; LIFLFAQIPCTARNGL;IFLFAQIPCTARNGLF; FLFAQIPCTARNGLFV; LFAQIPCTARNGLFVP; FAQIPCTARNGLFVPK;AQIPCTARNGLFVPKS; QIPCTARNGLFVPKSL; IPCTARNGLFVPKSLL; PCTARNGLFVPKSLLC;CTARNGLFVPKSLLCT; TARNGLFVPKSLLCTA; ARNGLFVPKSLLCTAL; RNGLFVPKSLLCTALA;NGLFVPKSLLCTALAC; GLFVPKSLLCTALACY; LFVPKSLLCTALACYV; FVPKSLLCTALACYVS;VPKSLLCTALACYVSL; PKSLLCTALACYVSLD; VIIFFIGANLWNRRVG; IIFFIGANLWNRRVGV;IFFIGANLWNRRVGVL; FFIGANLWNRRVGVLV; FIGANLWNRRVGVLVE; IGANLWNRRVGVLVEF;GANLWNRRVGVLVEFL; RSNSRFSTLNTTQKKK; SNSRFSTLNTTQKKKK; NSRFSTLNTTQKKKKG;SRFSTLNTTQKKKKGR; RFSTLNTTQKKKKGRR; FSTLNTTQKKKKGRRP; RSIPYYRRKHSRGLKG;SIPYYRRKHSRGLKGA; GCVFIIRYVFRISIQC; CVFIIRYVFRISIQCR; VFIIRYVFRISIQCRG;FIIRYVFRISIQCRGV; KKSRYPSYDQGRNANR; KSRYPSYDQGRNANRK; SRYPSYDQGRNANRKI;RYPSYDQGRNANRKIQ; YPSYDQGRNANRKIQS; PSYDQGRNANRKIQSY; SYDQGRNANRKIQSYI;YDQGRNANRKIQSYIR; NGFNIWSSWKCCTRTI; GFNIWSSWKCCTRTIY; FNIWSSWKCCTRTIYG;NIWSSWKCCTRTIYGR; IWSSWKCCTRTIYGRC; WSSWKCCTRTIYGRCC; SSWKCCTRTIYGRCCL;SWKCCTRTIYGRCCLA; WKCCTRTIYGRCCLAA; KCCTRTIYGRCCLAAL; CCTRTIYGRCCLAALF;CTRTIYGRCCLAALFA; TRTIYGRCCLAALFAT; IKGFAFRTWNKQFRQF; KGFAFRTWNKQFRQFE;GFAFRTWNKQFRQFER; FAFRTWNKQFRQFERL; AFRTWNKQFRQFERLF; FRTWNKQFRQFERLFR;RTWNKQFRQFERLFRW; TWNKQFRQFERLFRWK; WNKQFRQFERLFRWKC; GKFRKETFKQKNPNIS;KFRKETFKQKNPNIST; FRKETFKQKNPNISTR; RKETFKQKNPNISTRL; KETFKQKNPNISTRLG;ETFKQKNPNISTRLGY; TFKQKNPNISTRLGYN; FKQKNPNISTRLGYNE; AQNIFKKILTKLRVLT;KKNFTKWNDLVATANL; KNFTKWNDLVATANLV; IPITMLFPSLRYFSPC; KHLFKAFWFAIVPVCQ;HLFKAFWFAIVPVCQY; LFKAFWFAIVPVCQYI; FKAFWFAIVPVCQYIL; KAFWFAIVPVCQYILS;AFWFAIVPVCQYILSY; FWFAIVPVCQYILSYL; WFAIVPVCQYILSYLG; FAIVPVCQYILSYLGP;AIVPVCQYILSYLGPL; IVPVCQYILSYLGPLE; VPVCQYILSYLGPLEV; PVCQYILSYLGPLEVF;VCQYILSYLGPLEVFL; CQYILSYLGPLEVFLC; QYILSYLGPLEVFLCH; YILSYLGPLEVFLCHQ;ILSYLGPLEVFLCHQT; LSYLGPLEVFLCHQTP; GHLAKRKLGKDSLQIF; HLAKRKLGKDSLQIFF;LAKRKLGKDSLQIFFS; AKRKLGKDSLQIFFSG; KRKLGKDSLQIFFSGG; RKLGKDSLQIFFSGGS;TGHKYQQLKHTGYQLY; GHKYQQLKHTGYQLYK; HKYQQLKHTGYQLYKE; KYQQLKHTGYQLYKEA;YQQLKHTGYQLYKEAP; QQLKHTGYQLYKEAPH; QLKHTGYQLYKEAPHP; LKHTGYQLYKEAPHPV;KHTGYQLYKEAPHPVH; HTGYQLYKEAPHPVHL; TGYQLYKEAPHPVHLA; GYQLYKEAPHPVHLAT;YQLYKEAPHPVHLATL; QLYKEAPHPVHLATLW; HFHFYWDQVPSTQLDK; FHFYWDQVPSTQLDKH;HFYWDQVPSTQLDKHC; FYWDQVPSTQLDKHCF; YWDQVPSTQLDKHCFC; WDQVPSTQLDKHCFCP;DQVPSTQLDKHCFCPN; QVPSTQLDKHCFCPNR; VPSTQLDKHCFCPNRP; PSTQLDKHCFCPNRPY;STQLDKHCFCPNRPYG; TQLDKHCFCPNRPYGQ; QLDKHCFCPNRPYGQY; LDKHCFCPNRPYGQYS;DKHCFCPNRPYGQYSL; KHCFCPNRPYGQYSLP; HCFCPNRPYGQYSLPG; CFCPNRPYGQYSLPGT;FCPNRPYGQYSLPGTG; CPNRPYGQYSLPGTGL; PNRPYGQYSLPGTGLL; NRPYGQYSLPGTGLLG;RPYGQYSLPGTGLLGF; YHQGTLTCNSLALPAF; HQGTLTCNSLALPAFP; QGTLTCNSLALPAFPR;GTLTCNSLALPAFPRV; TLTCNSLALPAFPRVL; LTCNSLALPAFPRVLH; TCNSLALPAFPRVLHL;CNSLALPAFPRVLHLQ; NSLALPAFPRVLHLQQ; SLALPAFPRVLHLQQR; LALPAFPRVLHLQQRS;ALPAFPRVLHLQQRSG; LPAFPRVLHLQQRSGN; PAFPRVLHLQQRSGNY; AFPRVLHLQQRSGNYC;FPRVLHLQQRSGNYCL; PRVLHLQQRSGNYCLE; VFLHHAHALFVTLHEG; PLFVQLQPPTSVDFHR;LFVQLQPPTSVDFHRL; FVQLQPPTSVDFHRLG; VQLQPPTSVDFHRLGP; QLQPPTSVDFHRLGPH;LQPPTSVDFHRLGPHL; QPPTSVDFHRLGPHLN; PPTSVDFHRLGPHLNW; PTSVDFHRLGPHLNWG;TSVDFHRLGPHLNWGG; SVDFHRLGPHLNWGGE; VDFHRLGPHLNWGGEF; DFHRLGPHLNWGGEFL;FHRLGPHLNWGGEFLL; HRLGPHLNWGGEFLLC; RLGPHLNWGGEFLLCC; LGPHLNWGGEFLLCCN;GPHLNWGGEFLLCCNR; PHLNWGGEFLLCCNRE; HLNWGGEFLLCCNREA; LNWGGEFLLCCNREAF;NWGGEFLLCCNREAFF; WGGEFLLCCNREAFFS; GGEFLLCCNREAFFSL; GEFLLCCNREAFFSLG;EFLLCCNREAFFSLGY; FLLCCNREAFFSLGYH; LLCCNREAFFSLGYHC; GFHLDPPFLGLGSILP;FHLDPPFLGLGSILPL; LLELLLLLLLVVLALA; LELLLLLLLVVLALAR; ELLLLLLLVVLALARV;LLLLLLLVVLALARVP; LLLLLLVVLALARVPL; LLLLLVVLALARVPLA; LLLLVVLALARVPLAF;LLLVVLALARVPLAFW; LLVVLALARVPLAFWE; LVVLALARVPLAFWEL; VVLALARVPLAFWELP;VLALARVPLAFWELPL; LALARVPLAFWELPLD; ALARVPLAFWELPLDT; LARVPLAFWELPLDTL;ARVPLAFWELPLDTLL; RVPLAFWELPLDTLLF; VPLAFWELPLDTLLFF; PLAFWELPLDTLLFFW;LAFWELPLDTLLFFWL; AFWELPLDTLLFFWLG; FWELPLDTLLFFWLGP; WELPLDTLLFFWLGPS;ELPLDTLLFFWLGPSS; LPLDTLLFFWLGPSSY; PLDTLLFFWLGPSSYA; LDTLLFFWLGPSSYAS;DTLLFFWLGPSSYASR; TLLFFWLGPSSYASRA; LLFFWLGPSSYASRAG; LFFWLGPSSYASRAGV;FFWLGPSSYASRAGVT; FWLGPSSYASRAGVTV; WLGPSSYASRAGVTVP; LGPSSYASRAGVTVPY;GPSSYASRAGVTVPYR; PSSYASRAGVTVPYRP; SSYASRAGVTVPYRPR; SYASRAGVTVPYRPRS;YASRAGVTVPYRPRSK; ASRAGVTVPYRPRSKG; SRAGVTVPYRPRSKGN; RAGVTVPYRPRSKGNI;AGVTVPYRPRSKGNIH; LAPPGAIVFSINSPEC; APPGAIVFSINSPECT; PPGAIVFSINSPECTL;PGAIVFSINSPECTLC; FLKSILCVTSSILSAS; LKSILCVTSSILSASS; KSILCVTSSILSASSI;SILCVTSSILSASSIL; VWPKCTRVPSLSATCL; WPKCTRVPSLSATCLT; PKCTRVPSLSATCLTI;KCTRVPSLSATCLTIE; CTRVPSLSATCLTIEG; TRVPSLSATCLTIEGL; RVPSLSATCLTIEGLI;VPSLSATCLTIEGLIG; PSLSATCLTIEGLIGE; SLSATCLTIEGLIGER; LSATCLTIEGLIGERS;SATCLTIEGLIGERSE; KFIGAFTIVQVVSSKN; FIGAFTIVQVVSSKNL; IGAFTIVQVVSSKNLA;GAFTIVQVVSSKNLAK; AFTIVQVVSSKNLAKE; FTIVQVVSSKNLAKES; TIVQVVSSKNLAKESL;IVQVVSSKNLAKESLK; VQVVSSKNLAKESLKN; QVVSSKNLAKESLKNL; VVSSKNLAKESLKNLS;VSSKNLAKESLKNLSV; SSKNLAKESLKNLSVL; SKNLAKESLKNLSVLL; KNLAKESLKNLSVLLC;NLAKESLKNLSVLLCN; LAKESLKNLSVLLCNS; AKESLKNLSVLLCNSC; KESLKNLSVLLCNSCE;ESLKNLSVLLCNSCEV; SLKNLSVLLCNSCEVI; LKNLSVLLCNSCEVIE; KNLSVLLCNSCEVIEG;NLSVLLCNSCEVIEGI; LSVLLCNSCEVIEGIS; SVLLCNSCEVIEGISS; VLLCNSCEVIEGISSL;LLCNSCEVIEGISSLI; LCNSCEVIEGISSLIT; CNSCEVIEGISSLITC; NSCEVIEGISSLITCH;SCEVIEGISSLITCHK; CEVIEGISSLITCHKA; EVIEGISSLITCHKAW; VIEGISSLITCHKAWE;IEGISSLITCHKAWEI; EGISSLITCHKAWEIV; GISSLITCHKAWEIVA; ISSLITCHKAWEIVAN;SSLITCHKAWEIVANK; SLITCHKAWEIVANKE; LITCHKAWEIVANKEG; ITCHKAWEIVANKEGP;TCHKAWEIVANKEGPQ; CHKAWEIVANKEGPQC; HKAWEIVANKEGPQCL; KAWEIVANKEGPQCLG;AWEIVANKEGPQCLGS; WEIVANKEGPQCLGSR; EIVANKEGPQCLGSRY; IKAANPAIAPGAPAIT;KAANPAIAPGAPAITA; AANPAIAPGAPAITAY; ANPAIAPGAPAITAYV; GVRPIAAIASEVLVMP;VRPIAAIASEVLVMPS; RPIAAIASEVLVMPST; PIAAIASEVLVMPSTV; IAAIASEVLVMPSTVA;AAIASEVLVMPSTVAR; AIASEVLVMPSTVARD; IASEVLVMPSTVARDA; ASEVLVMPSTVARDAI;TSIAAAASPAAISATE; SIAAAASPAAISATEN; IAAAASPAAISATENP; AAAASPAAISATENPV;AAASPAAISATENPVA; AASPAAISATENPVAA; ASPAAISATENPVAAA; SPAAISATENPVAAAA;PAAISATENPVAAAAS; AAISATENPVAAAASD; AISATENPVAAAASDT; ISATENPVAAAASDTL;SATENPVAAAASDTLA; ATENPVAAAASDTLAT; TENPVAAAASDTLATR; ENPVAAAASDTLATRS;NPVAAAASDTLATRSP; PVAAAASDTLATRSPK; VAAAASDTLATRSPKS; AAAASDTLATRSPKSA;AAASDTLATRSPKSAR; AASDTLATRSPKSARA; ASDTLATRSPKSARAA; SDTLATRSPKSARAAP;DTLATRSPKSARAAPM; TLATRSPKSARAAPMN; LATRSPKSARAAPMNL; ATRSPKSARAAPMNLE;TRSPKSARAAPMNLEI; RSPKSARAAPMNLEIQ; SPKSARAAPMNLEIQK; PKSARAAPMNLEIQKK;KSARAAPMNLEIQKKR; SARAAPMNLEIQKKRD; ARAAPMNLEIQKKRDY; RAAPMNLEIQKKRDYL;AAPMNLEIQKKRDYLP; APMNLEIQKKRDYLPR; PMNLEIQKKRDYLPRS; MNLEIQKKRDYLPRSL;NLEIQKKRDYLPRSLL; LEIQKKRDYLPRSLLQ; EIQKKRDYLPRSLLQS; IQKKRDYLPRSLLQSL;QKKRDYLPRSLLQSLL; KKRDYLPRSLLQSLLQ; KRDYLPRSLLQSLLQQ; RDYLPRSLLQSLLQQV;DYLPRSLLQSLLQQVK; YLPRSLLQSLLQQVKQ; LPRSLLQSLLQQVKQW; PRSLLQSLLQQVKQWY;RSLLQSLLQQVKQWYF; SLLQSLLQQVKQWYFC; LLQSLLQQVKQWYFCF; LQSLLQQVKQWYFCFS;QSLLQQVKQWYFCFSR; SLLQQVKQWYFCFSRL; LLQQVKQWYFCFSRLH; LQQVKQWYFCFSRLHC;QQVKQWYFCFSRLHCL; QVKQWYFCFSRLHCLH; VKQWYFCFSRLHCLHL; KQWYFCFSRLHCLHLY;QWYFCFSRLHCLHLYK; WYFCFSRLHCLHLYKI; YFCFSRLHCLHLYKIP; FCFSRLHCLHLYKIPA;CFSRLHCLHLYKIPAK; FSRLHCLHLYKIPAKA; SRLHCLHLYKIPAKAL; RLHCLHLYKIPAKALK;KSSELFFLFQSRFYQL; SSELFFLFQSRFYQLS; SELFFLFQSRFYQLSL; ELFFLFQSRFYQLSLK;LFFLFQSRFYQLSLKL; FFLFQSRFYQLSLKLV; FLFQSRFYQLSLKLVV; LFQSRFYQLSLKLVVT;FQSRFYQLSLKLVVTA; QSRFYQLSLKLVVTAG; SRFYQLSLKLVVTAGA; RFYQLSLKLVVTAGAE;FYQLSLKLVVTAGAEP; YQLSLKLVVTAGAEPW; QLSLKLVVTAGAEPWP; LSLKLVVTAGAEPWPL;SLKLVVTAGAEPWPLS; LKLVVTAGAEPWPLSS; KLVVTAGAEPWPLSSL; LVVTAGAEPWPLSSLT;VVTAGAEPWPLSSLTG; VTAGAEPWPLSSLTGD; TAGAEPWPLSSLTGDK; AGAEPWPLSSLTGDKA;GAEPWPLSSLTGDKAK; AEPWPLSSLTGDKAKI; EPWPLSSLTGDKAKIP; PWPLSSLTGDKAKIPR;WPLSSLTGDKAKIPRL; PLSSLTGDKAKIPRLA; LSSLTGDKAKIPRLAK; SSLTGDKAKIPRLAKH;SLTGDKAKIPRLAKHV; LTGDKAKIPRLAKHVC; TGDKAKIPRLAKHVCH; GDKAKIPRLAKHVCHA;DKAKIPRLAKHVCHAL; KAKIPRLAKHVCHALS; AKIPRLAKHVCHALSF; KIPRLAKHVCHALSFL;IPRLAKHVCHALSFLR; PRLAKHVCHALSFLRS; RLAKHVCHALSFLRSW; LAKHVCHALSFLRSWF;AKHVCHALSFLRSWFG; KHVCHALSFLRSWFGC; HVCHALSFLRSWFGCI; VCHALSFLRSWFGCIP;CHALSFLRSWFGCIPW; HALSFLRSWFGCIPWV; ALSFLRSWFGCIPWVS; LSFLRSWFGCIPWVSS;SFLRSWFGCIPWVSSS; FLRSWFGCIPWVSSSS; LRSWFGCIPWVSSSSL; GHGLAAFPCESCTFLP;HGLAAFPCESCTFLPE; GLAAFPCESCTFLPEV; LAAFPCESCTFLPEVM; AAFPCESCTFLPEVMV;AFPCESCTFLPEVMVW; FPCESCTFLPEVMVWL; PCESCTFLPEVMVWLH; CESCTFLPEVMVWLHS;ESCTFLPEVMVWLHSM; SCTFLPEVMVWLHSMG; CTFLPEVMVWLHSMGK; TFLPEVMVWLHSMGKQ;FLPEVMVWLHSMGKQL; LPEVMVWLHSMGKQLL; PEVMVWLHSMGKQLLP; EVMVWLHSMGKQLLPV;VMVWLHSMGKQLLPVA; MVWLHSMGKQLLPVAF; VWLHSMGKQLLPVAFF; WLHSMGKQLLPVAFFF;LHSMGKQLLPVAFFFI; HSMGKQLLPVAFFFII; SMGKQLLPVAFFFIIY; MGKQLLPVAFFFIIYK;GKQLLPVAFFFIIYKR; KQLLPVAFFFIIYKRP; QLLPVAFFFIIYKRPR; LLPVAFFFIIYKRPRP;LPVAFFFIIYKRPRPP; PVAFFFIIYKRPRPPL; VAFFFIIYKRPRPPLP; AFFFIIYKRPRPPLPP;FFFIIYKRPRPPLPPP; FFIIYKRPRPPLPPPF; FIIYKRPRPPLPPPFL; IIYKRPRPPLPPPFLS;IYKRPRPPLPPPFLSS; YKRPRPPLPPPFLSSS; KRPRPPLPPPFLSSSK; RPRPPLPPPFLSSSKG;PRPPLPPPFLSSSKGV; RPPLPPPFLSSSKGVE; PPLPPPFLSSSKGVEA; PLPPPFLSSSKGVEAF;LPPPFLSSSKGVEAFS; PPPFLSSSKGVEAFSE; PPFLSSSKGVEAFSEA BK virus, reversereading frame 3 13 mers: QGRIHGAHGPFRP; KSCLGKSSLNEKS; SCLGKSSLNEKSL;CLGKSSLNEKSLF; LGKSSLNEKSLFK; GKSSLNEKSLFKE; KSSLNEKSLFKEV;FSSLPRYPVLQGM; SSLPRYPVLQGMA; SLPRYPVLQGMAY; LPRYPVLQGMAYL;PRYPVLQGMAYLF; RYPVLQGMAYLFQ; YPVLQGMAYLFQK; PVLQGMAYLFQKA;VLQGMAYLFQKAF; LQGMAYLFQKAFC; QGMAYLFQKAFCA; GMAYLFQKAFCAL;MAYLFQKAFCALP; AYLFQKAFCALPL; YLFQKAFCALPLH; LFQKAFCALPLHA;FQKAFCALPLHAM; QKAFCALPLHAMS; KAFCALPLHAMSA; KIFKKRALGLDRL;IFKKRALGLDRLL; FKKRALGLDRLLL; KKRALGLDRLLLH; RNSAMVGPNNWRN;NSAMVGPNNWRNS; SAMVGPNNWRNSL; AMVGPNNWRNSLQ; MVGPNNWRNSLQR;VGPNNWRNSLQRS; GPNNWRNSLQRSK; PNNWRNSLQRSKA; NNWRNSLQRSKAL;NWRNSLQRSKALR; VPTYGTEEWESWW; PTYGTEEWESWWS; TYGTEEWESWWSS;YGTEEWESWWSSF; GTEEWESWWSSFN; TEEWESWWSSFNE; EEWESWWSSFNEK;EWESWWSSFNEKW; WESWWSSFNEKWD; ESWWSSFNEKWDE; SWWSSFNEKWDED;WWSSFNEKWDEDL; WSSFNEKWDEDLF; SSFNEKWDEDLFC; SFNEKWDEDLFCH;FNEKWDEDLFCHE; NEKWDEDLFCHED; EKWDEDLFCHEDM; KWDEDLFCHEDMF;WDEDLFCHEDMFA; DEDLFCHEDMFAS; EDLFCHEDMFASD; DLFCHEDMFASDE;LFCHEDMFASDEE; FCHEDMFASDEEA; CHEDMFASDEEAT; HEDMFASDEEATA;EDMFASDEEATAD; DMFASDEEATADS; MFASDEEATADSQ; FASDEEATADSQH;ASDEEATADSQHS; SDEEATADSQHST; DEEATADSQHSTP; EEATADSQHSTPP;EATADSQHSTPPK; ATADSQHSTPPKK; TADSQHSTPPKKK; ADSQHSTPPKKKR;DSQHSTPPKKKRK; SQHSTPPKKKRKV; QHSTPPKKKRKVE; HSTPPKKKRKVED;STPPKKKRKVEDP; TPPKKKRKVEDPK; PPKKKRKVEDPKD; PKKKRKVEDPKDF;KKKRKVEDPKDFP; KKRKVEDPKDFPS; KRKVEDPKDFPSD; RKVEDPKDFPSDL;KVEDPKDFPSDLH; VEDPKDFPSDLHQ; EDPKDFPSDLHQF; DPKDFPSDLHQFL;PKDFPSDLHQFLS; KDFPSDLHQFLSQ; DFPSDLHQFLSQA; FPSDLHQFLSQAV;PSDLHQFLSQAVF; SDLHQFLSQAVFS; DLHQFLSQAVFSN; LHQFLSQAVFSNR;HQFLSQAVFSNRT; QFLSQAVFSNRTL; FLSQAVFSNRTLA; LSQAVFSNRTLAC;SQAVFSNRTLACF; QAVFSNRTLACFA; AVFSNRTLACFAV; VFSNRTLACFAVY;FSNRTLACFAVYT; SNRTLACFAVYTT; NRTLACFAVYTTK; RTLACFAVYTTKE;TLACFAVYTTKEK; LACFAVYTTKEKA; ACFAVYTTKEKAQ; CFAVYTTKEKAQI;FAVYTTKEKAQIL; AVYTTKEKAQILY; VYTTKEKAQILYK; YTTKEKAQILYKK;TTKEKAQILYKKL; TKEKAQILYKKLM; KEKAQILYKKLME; EKAQILYKKLMEK;KAQILYKKLMEKY; AQILYKKLMEKYS; QILYKKLMEKYSV; ILYKKLMEKYSVT;LYKKLMEKYSVTF; YKKLMEKYSVTFI; KKLMEKYSVTFIS; KLMEKYSVTFISR;LMEKYSVTFISRH; MEKYSVTFISRHM; EKYSVTFISRHMC; KYSVTFISRHMCA;YSVTFISRHMCAG; SVTFISRHMCAGH; VTFISRHMCAGHN; TFISRHMCAGHNI;FISRHMCAGHNII; ISRHMCAGHNIIF; SRHMCAGHNIIFF; RHMCAGHNIIFFL;HMCAGHNIIFFLT; MCAGHNIIFFLTP; CAGHNIIFFLTPH; AGHNIIFFLTPHR;GHNIIFFLTPHRH; HNIIFFLTPHRHR; NIIFFLTPHRHRV; IIFFLTPHRHRVS;IFFLTPHRHRVSA; FFLTPHRHRVSAI; FLTPHRHRVSAIN; LTPHRHRVSAINN;TPHRHRVSAINNF; PHRHRVSAINNFC; HRHRVSAINNFCQ; RHRVSAINNFCQK;HRVSAINNFCQKL; RVSAINNFCQKLC; VSAINNFCQKLCT; SAINNFCQKLCTF;AINNFCQKLCTFS; INNFCQKLCTFSF; NNFCQKLCTFSFL; NFCQKLCTFSFLI;FCQKLCTFSFLIC; CQKLCTFSFLICK; QKLCTFSFLICKG; KLCTFSFLICKGV;LCTFSFLICKGVN; CTFSFLICKGVNK; TFSFLICKGVNKE; FSFLICKGVNKEY;SFLICKGVNKEYL; FLICKGVNKEYLL; LICKGVNKEYLLY; ICKGVNKEYLLYS;CKGVNKEYLLYSA; KGVNKEYLLYSAL; GVNKEYLLYSALT; VNKEYLLYSALTR;NKEYLLYSALTRD; KEYLLYSALTRDP; EYLLYSALTRDPY; YLLYSALTRDPYH;LLYSALTRDPYHT; LYSALTRDPYHTI; YSALTRDPYHTIE; SALTRDPYHTIEE;ALTRDPYHTIEES; LTRDPYHTIEESI; TRDPYHTIEESIQ; RDPYHTIEESIQG;DPYHTIEESIQGG; PYHTIEESIQGGL; YHTIEESIQGGLK; HTIEESIQGGLKE;TIEESIQGGLKEH; IEESIQGGLKEHD; EESIQGGLKEHDF; ESIQGGLKEHDFS;SIQGGLKEHDFSP; IQGGLKEHDFSPE; QGGLKEHDFSPEE; GGLKEHDFSPEEP;GLKEHDFSPEEPE; LKEHDFSPEEPEE; KEHDFSPEEPEET; EHDFSPEEPEETK;HDFSPEEPEETKQ; DFSPEEPEETKQV; FSPEEPEETKQVS; SPEEPEETKQVSW;PEEPEETKQVSWK; EEPEETKQVSWKL; EPEETKQVSWKLI; PEETKQVSWKLIT;EETKQVSWKLITE; ETKQVSWKLITEY; TKQVSWKLITEYA; KQVSWKLITEYAV;QVSWKLITEYAVE; VSWKLITEYAVET; SWKLITEYAVETK; WKLITEYAVETKC;KLITEYAVETKCE; LITEYAVETKCED; ITEYAVETKCEDV; TEYAVETKCEDVF;EYAVETKCEDVFL; YAVETKCEDVFLL; AVETKCEDVFLLL; VETKCEDVFLLLG;ETKCEDVFLLLGM; TKCEDVFLLLGMY; KCEDVFLLLGMYL; CEDVFLLLGMYLE;EDVFLLLGMYLEF; DVFLLLGMYLEFQ; VFLLLGMYLEFQY; FLLLGMYLEFQYN;LLLGMYLEFQYNV; LLGMYLEFQYNVE; LGMYLEFQYNVEE; GMYLEFQYNVEEC;MYLEFQYNVEECK; YLEFQYNVEECKK; LEFQYNVEECKKC; EFQYNVEECKKCQ;FQYNVEECKKCQK; QYNVEECKKCQKK; YNVEECKKCQKKD; NVEECKKCQKKDQ;VEECKKCQKKDQP; EECKKCQKKDQPY; ECKKCQKKDQPYH; CKKCQKKDQPYHF;KKCQKKDQPYHFK; KCQKKDQPYHFKY; CQKKDQPYHFKYH; QKKDQPYHFKYHE;KKDQPYHFKYHEK; KDQPYHFKYHEKH; DQPYHFKYHEKHF; QPYHFKYHEKHFA;PYHFKYHEKHFAN; YHFKYHEKHFANA; HFKYHEKHFANAI; FKYHEKHFANAII;KYHEKHFANAIIF; YHEKHFANAIIFA; HEKHFANAIIFAE; EKHFANAIIFAES;KHFANAIIFAESK; HFANAIIFAESKN; FANAIIFAESKNQ; ANAIIFAESKNQK;NAIIFAESKNQKS; AIIFAESKNQKSI; IIFAESKNQKSIC; IFAESKNQKSICQ;FAESKNQKSICQQ; AESKNQKSICQQA; ESKNQKSICQQAV; SKNQKSICQQAVD;KNQKSICQQAVDT; NQKSICQQAVDTV; QKSICQQAVDTVL; KSICQQAVDTVLA;SICQQAVDTVLAK; ICQQAVDTVLAKK; CQQAVDTVLAKKR; QQAVDTVLAKKRV;QAVDTVLAKKRVD; AVDTVLAKKRVDT; VDTVLAKKRVDTL; DTVLAKKRVDTLH;TVLAKKRVDTLHM; VLAKKRVDTLHMT; LAKKRVDTLHMTR; AKKRVDTLHMTRE;KKRVDTLHMTREE; KRVDTLHMTREEM; RVDTLHMTREEML; VDTLHMTREEMLT;DTLHMTREEMLTE; TLHMTREEMLTER; LHMTREEMLTERF; HMTREEMLTERFN;MTREEMLTERFNH; TREEMLTERFNHI; REEMLTERFNHIL; EEMLTERFNHILD;EMLTERFNHILDK; MLTERFNHILDKM; LTERFNHILDKMD; TERFNHILDKMDL;ERFNHILDKMDLI; RFNHILDKMDLIF; FNHILDKMDLIFG; NHILDKMDLIFGA;HILDKMDLIFGAH; ILDKMDLIFGAHG; LDKMDLIFGAHGN; DKMDLIFGAHGNA;KMDLIFGAHGNAV; MDLIFGAHGNAVL; DLIFGAHGNAVLE; LIFGAHGNAVLEQ;IFGAHGNAVLEQY; FGAHGNAVLEQYM; GAHGNAVLEQYMA; AHGNAVLEQYMAG;HGNAVLEQYMAGV; GNAVLEQYMAGVA; NAVLEQYMAGVAW; AVLEQYMAGVAWL;VLEQYMAGVAWLH; LEQYMAGVAWLHC; EQYMAGVAWLHCL; QYMAGVAWLHCLL;YMAGVAWLHCLLP; MAGVAWLHCLLPK; AGVAWLHCLLPKM; GVAWLHCLLPKMD;VAWLHCLLPKMDS; AWLHCLLPKMDSV; WLHCLLPKMDSVI; LHCLLPKMDSVIF;HCLLPKMDSVIFD; CLLPKMDSVIFDF; LLPKMDSVIFDFL; LPKMDSVIFDFLH;PKMDSVIFDFLHC; KMDSVIFDFLHCI; MDSVIFDFLHCIV; DSVIFDFLHCIVF;SVIFDFLHCIVFN; VIFDFLHCIVFNV; IFDFLHCIVFNVP; FDFLHCIVFNVPK;DFLHCIVFNVPKR; FLHCIVFNVPKRR; LHCIVFNVPKRRY; HCIVFNVPKRRYW;CIVFNVPKRRYWL; IVFNVPKRRYWLF; VFNVPKRRYWLFK; FNVPKRRYWLFKG;NVPKRRYWLFKGP; VPKRRYWLFKGPI; PKRRYWLFKGPID; KRRYWLFKGPIDS;RRYWLFKGPIDSG; RYWLFKGPIDSGK; YWLFKGPIDSGKT; WLFKGPIDSGKTT;LFKGPIDSGKTTL; FKGPIDSGKTTLA; KGPIDSGKTTLAA; GPIDSGKTTLAAG;PIDSGKTTLAAGL; IDSGKTTLAAGLL; DSGKTTLAAGLLD; SGKTTLAAGLLDL;GKTTLAAGLLDLC; KTTLAAGLLDLCG; TTLAAGLLDLCGG; TLAAGLLDLCGGK;LAAGLLDLCGGKA; AAGLLDLCGGKAL; AGLLDLCGGKALN; GLLDLCGGKALNV;LLDLCGGKALNVN; LDLCGGKALNVNL; DLCGGKALNVNLP; LCGGKALNVNLPM;CGGKALNVNLPME; GGKALNVNLPMER; GKALNVNLPMERL; KALNVNLPMERLT;ALNVNLPMERLTF; LNVNLPMERLTFE; NVNLPMERLTFEL; VNLPMERLTFELG;NLPMERLTFELGV; LPMERLTFELGVA; PMERLTFELGVAI; MERLTFELGVAID;ERLTFELGVAIDQ; RLTFELGVAIDQY; LTFELGVAIDQYM; TFELGVAIDQYMV;FELGVAIDQYMVV; ELGVAIDQYMVVF; LGVAIDQYMVVFE; GVAIDQYMVVFED;VAIDQYMVVFEDV; AIDQYMVVFEDVK; IDQYMVVFEDVKG; DQYMVVFEDVKGT;QYMVVFEDVKGTG; YMVVFEDVKGTGA; MVVFEDVKGTGAE; VVFEDVKGTGAES;VFEDVKGTGAESK; FEDVKGTGAESKD; EDVKGTGAESKDL; DVKGTGAESKDLP;VKGTGAESKDLPS; KGTGAESKDLPSG; GTGAESKDLPSGH; TGAESKDLPSGHG;GAESKDLPSGHGI; AESKDLPSGHGIN; ESKDLPSGHGINN; SKDLPSGHGINNL;KDLPSGHGINNLD; DLPSGHGINNLDS; LPSGHGINNLDSL; PSGHGINNLDSLR;SGHGINNLDSLRD; GHGINNLDSLRDY; HGINNLDSLRDYL; GINNLDSLRDYLD;INNLDSLRDYLDG; NNLDSLRDYLDGS; NLDSLRDYLDGSV; LDSLRDYLDGSVK;DSLRDYLDGSVKV; SLRDYLDGSVKVN; LRDYLDGSVKVNL; RDYLDGSVKVNLE;DYLDGSVKVNLEK; YLDGSVKVNLEKK; LDGSVKVNLEKKH; DGSVKVNLEKKHL;GSVKVNLEKKHLN; SVKVNLEKKHLNK; VKVNLEKKHLNKR; KVNLEKKHLNKRT;VNLEKKHLNKRTQ; NLEKKHLNKRTQI; LEKKHLNKRTQIF; EKKHLNKRTQIFP;KKHLNKRTQIFPP; KHLNKRTQIFPPG; HLNKRTQIFPPGL; LNKRTQIFPPGLV;NKRTQIFPPGLVT; KRTQIFPPGLVTM; RTQIFPPGLVTMN; TQIFPPGLVTMNE;QIFPPGLVTMNEY; IFPPGLVTMNEYP; FPPGLVTMNEYPV; PPGLVTMNEYPVP;PGLVTMNEYPVPK; GLVTMNEYPVPKT; LVTMNEYPVPKTL; VTMNEYPVPKTLQ;TMNEYPVPKTLQA; MNEYPVPKTLQAR; NEYPVPKTLQARF; EYPVPKTLQARFV;YPVPKTLQARFVR; PVPKTLQARFVRQ; VPKTLQARFVRQI; PKTLQARFVRQID;KTLQARFVRQIDF; TLQARFVRQIDFR; LQARFVRQIDFRP; QARFVRQIDFRPK;ARFVRQIDFRPKI; RFVRQIDFRPKIY; FVRQIDFRPKIYL; VRQIDFRPKIYLR;RQIDFRPKIYLRK; QIDFRPKIYLRKS; IDFRPKIYLRKSL; DFRPKIYLRKSLQ;FRPKIYLRKSLQN; RPKIYLRKSLQNS; PKIYLRKSLQNSE; KIYLRKSLQNSEF;IYLRKSLQNSEFL; YLRKSLQNSEFLL; LRKSLQNSEFLLE; RKSLQNSEFLLEK;KSLQNSEFLLEKR; SLQNSEFLLEKRI; LQNSEFLLEKRIL; QNSEFLLEKRILQ;NSEFLLEKRILQS; SEFLLEKRILQSG; EFLLEKRILQSGM; FLLEKRILQSGMT;LLEKRILQSGMTL; LEKRILQSGMTLL; EKRILQSGMTLLL; KRILQSGMTLLLL;RILQSGMTLLLLL; ILQSGMTLLLLLI; LQSGMTLLLLLIW; QSGMTLLLLLIWF;SGMTLLLLLIWFR; GMTLLLLLIWFRP; MTLLLLLIWFRPV; TLLLLLIWFRPVA;LLLLLIWFRPVAD; LLLLIWFRPVADF; LLLIWFRPVADFA; LLIWFRPVADFAT;LIWFRPVADFATD; IWFRPVADFATDI; WFRPVADFATDIQ; FRPVADFATDIQS;RPVADFATDIQSR; PVADFATDIQSRI; VADFATDIQSRIV; ADFATDIQSRIVE;DFATDIQSRIVEW; FATDIQSRIVEWK; ATDIQSRIVEWKE; TDIQSRIVEWKER;DIQSRIVEWKERL; IQSRIVEWKERLD; QSRIVEWKERLDS; SRIVEWKERLDSE;RIVEWKERLDSEI; IVEWKERLDSEIS; VEWKERLDSEISM; EWKERLDSEISMY;WKERLDSEISMYT; KERLDSEISMYTF; ERLDSEISMYTFS; RLDSEISMYTFSR;LDSEISMYTFSRM; DSEISMYTFSRMK; SEISMYTFSRMKY; EISMYTFSRMKYN;ISMYTFSRMKYNI; SMYTFSRMKYNIC; MYTFSRMKYNICM; YTFSRMKYNICMG;TFSRMKYNICMGK; FSRMKYNICMGKC; SRMKYNICMGKCI; RMKYNICMGKCIL;MKYNICMGKCILD; KYNICMGKCILDI; YNICMGKCILDIT; NICMGKCILDITR;ICMGKCILDITRE; CMGKCILDITREE; MGKCILDITREED; GKCILDITREEDS;KCILDITREEDSE; CILDITREEDSET; ILDITREEDSETE; LDITREEDSETED;DITREEDSETEDS; ITREEDSETEDSG; TREEDSETEDSGH; REEDSETEDSGHG;EEDSETEDSGHGS; EDSETEDSGHGSS; DSETEDSGHGSST; SETEDSGHGSSTE;ETEDSGHGSSTES; TEDSGHGSSTESQ; EDSGHGSSTESQS; DSGHGSSTESQSQ;SGHGSSTESQSQC; GHGSSTESQSQCS; HGSSTESQSQCSS; GSSTESQSQCSSQ;SSTESQSQCSSQV; STESQSQCSSQVS; TESQSQCSSQVSD; ESQSQCSSQVSDT;SQSQCSSQVSDTS; QSQCSSQVSDTSA; SQCSSQVSDTSAP; QCSSQVSDTSAPA;CSSQVSDTSAPAE; SSQVSDTSAPAED; SQVSDTSAPAEDS; QVSDTSAPAEDSQ;VSDTSAPAEDSQR; SDTSAPAEDSQRS; DTSAPAEDSQRSD; TSAPAEDSQRSDP;SAPAEDSQRSDPH; APAEDSQRSDPHS; PAEDSQRSDPHSQ; AEDSQRSDPHSQE;EDSQRSDPHSQEL; DSQRSDPHSQELH; SQRSDPHSQELHL; QRSDPHSQELHLC;RSDPHSQELHLCK; SDPHSQELHLCKG; DPHSQELHLCKGF; PHSQELHLCKGFQ;HSQELHLCKGFQC; SQELHLCKGFQCF; QELHLCKGFQCFK; ELHLCKGFQCFKR;LHLCKGFQCFKRP; HLCKGFQCFKRPK; LCKGFQCFKRPKT; CKGFQCFKRPKTP;KGFQCFKRPKTPP; GFQCFKRPKTPPP; FQCFKRPKTPPPK; HKLKSGLYKSSIY;MYMYNKSTCLKHF; YMYNKSTCLKHFG; MYNKSTCLKHFGL; YNKSTCLKHFGLQ;NKSTCLKHFGLQL; KSTCLKHFGLQLS; STCLKHFGLQLSL; TCLKHFGLQLSLF;CLKHFGLQLSLFV; LKHFGLQLSLFVN; KHFGLQLSLFVNI; HFGLQLSLFVNIS;FGLQLSLFVNISY; GLQLSLFVNISYH; LQLSLFVNISYHI; QLSLFVNISYHIW;LSLFVNISYHIWV; SLFVNISYHIWVP; LFVNISYHIWVPW; FVNISYHIWVPWK;VNISYHIWVPWKS; NISYHIWVPWKSF; ISYHIWVPWKSFC; SYHIWVPWKSFCA;YHIWVPWKSFCAI; HIWVPWKSFCAIK; IWVPWKSFCAIKH; WVPWKSFCAIKHP;VPWKSFCAIKHPN; PWKSFCAIKHPNL; WKSFCAIKHPNLF; KSFCAIKHPNLFY;SFCAIKHPNLFYL; FCAIKHPNLFYLG; CAIKHPNLFYLGF; AIKHPNLFYLGFH;IKHPNLFYLGFHT; KHPNLFYLGFHTI; HPNLFYLGFHTIH; PNLFYLGFHTIHR;NLFYLGFHTIHRL; LFYLGFHTIHRLP; FYLGFHTIHRLPI; YLGFHTIHRLPIH;LGFHTIHRLPIHS; GFHTIHRLPIHSL; FHTIHRLPIHSLG; HTIHRLPIHSLGS;TIHRLPIHSLGSP; IHRLPIHSLGSPV; HRLPIHSLGSPVY; RLPIHSLGSPVYK;LPIHSLGSPVYKV; PIHSLGSPVYKVT; QKGNWVRILYRSF; KGNWVRILYRSFS;GNWVRILYRSFSQ; NWVRILYRSFSQA; WVRILYRSFSQAD; VRILYRSFSQADL;RILYRSFSQADLK; ILYRSFSQADLKI; LYRSFSQADLKIS; YRSFSQADLKISC;RSFSQADLKISCK; SFSQADLKISCKA; FSQADLKISCKAS; SQADLKISCKASP;QADLKISCKASPL; ADLKISCKASPLL; DLKISCKASPLLC; LKISCKASPLLCS;KISCKASPLLCSR; ISCKASPLLCSRA; SCKASPLLCSRAV; CKASPLLCSRAVS;KASPLLCSRAVSK; ASPLLCSRAVSKQ; SPLLCSRAVSKQA; PLLCSRAVSKQAT;LLCSRAVSKQATN; LCSRAVSKQATNI; CSRAVSKQATNIS; SRAVSKQATNISS;NIQAISFTKRPHT; IQAISFTKRPHTL; QAISFTKRPHTLF; AISFTKRPHTLFI;QHCGSCVGHMKYW; HCGSCVGHMKYWG; CGSCVGHMKYWGN; GSCVGHMKYWGNI;SCVGHMKYWGNIF; CVGHMKYWGNIFP; VGHMKYWGNIFPS; GHMKYWGNIFPSC;HMKYWGNIFPSCE; MKYWGNIFPSCES; KYWGNIFPSCESP; YWGNIFPSCESPK;WGNIFPSCESPKI; GNIFPSCESPKIP; NIFPSCESPKIPS; IFPSCESPKIPSI;FPSCESPKIPSIF; PSCESPKIPSIFI; SCESPKIPSIFIS; CESPKIPSIFIST;ESPKIPSIFISTG; SPKIPSIFISTGI; PKIPSIFISTGIR; KIPSIFISTGIRY;IPSIFISTGIRYP; PSIFISTGIRYPA; SIFISTGIRYPAL; IFISTGIRYPALN;FISTGIRYPALNW; ISTGIRYPALNWI; STGIRYPALNWIS; TGIRYPALNWISI;GIRYPALNWISIV; IRYPALNWISIVF; RYPALNWISIVFV; YPALNWISIVFVQ;PALNWISIVFVQI; ALNWISIVFVQIG; LNWISIVFVQIGL; NWISIVFVQIGLM;WISIVFVQIGLMV; ISIVFVQIGLMVS; SIVFVQIGLMVSI; IVFVQIGLMVSIH;VFVQIGLMVSIHY; FVQIGLMVSIHYL; VQIGLMVSIHYLG; QIGLMVSIHYLGL;IGLMVSIHYLGLG; GLMVSIHYLGLGC; LMVSIHYLGLGCW; MVSIHYLGLGCWV;VSIHYLGLGCWVF; SIHYLGLGCWVFR; IHYLGLGCWVFRG; HYLGLGCWVFRGY;YLGLGCWVFRGYS; LGLGCWVFRGYST; GLGCWVFRGYSTI; LGCWVFRGYSTIR;GCWVFRGYSTIRV; CWVFRGYSTIRVL; HSLHFQGFSTYSK; SLHFQGFSTYSKE;LHFQGFSTYSKEV; HFQGFSTYSKEVE; FQGFSTYSKEVEI; QGFSTYSKEVEIT;GFSTYSKEVEITA; FSTYSKEVEITAL; STYSKEVEITALN; TYSKEVEITALNR;YSKEVEITALNRF; SKEVEITALNRFS; KEVEITALNRFSS; EVEITALNRFSST;VEITALNRFSSTM; EITALNRFSSTML; ITALNRFSSTMLM; TALNRFSSTMLMH;ALNRFSSTMLMHF; LNRFSSTMLMHFL; PCMKVKHASYSNN; CMKVKHASYSNNL;MKVKHASYSNNLC; KVKHASYSNNLCL; VKHASYSNNLCLY; KHASYSNNLCLYS;HASYSNNLCLYSY; ASYSNNLCLYSYS; SYSNNLCLYSYSL; YSNNLCLYSYSLP;SNNLCLYSYSLPH; NNLCLYSYSLPHQ; IGEGNSCCAVTGK; GEGNSCCAVTGKH;EGNSCCAVTGKHF; GNSCCAVTGKHFS; NSCCAVTGKHFSL; SCCAVTGKHFSLW;CCAVTGKHFSLWA; CAVTGKHFSLWAI; AVTGKHFSLWAIT; VTGKHFSLWAITA;TGKHFSLWAITAK; GKHFSLWAITAKV; KHFSLWAITAKVI; HFSLWAITAKVIF;FSLWAITAKVIFS; SLWAITAKVIFST; TKAPKVFIWIPHF; KAPKVFIWIPHFW;APKVFIWIPHFWV; EAFYLCNSIYPSF; AFYLCNSIYPSFN; FYLCNSIYPSFNF;FWHLHGFLWLFGS; WHLHGFLWLFGSC; HLHGFLWLFGSCP; LHGFLWLFGSCPW;HGFLWLFGSCPWT; GFLWLFGSCPWTL; FLWLFGSCPWTLS; LWLFGSCPWTLSF;WLFGSCPWTLSFS; LFGSCPWTLSFSF; FGSCPWTLSFSFG; GSCPWTLSFSFGW;SCPWTLSFSFGWG; CPWTLSFSFGWGH; PWTLSFSFGWGHL; WTLSFSFGWGHLH;TLSFSFGWGHLHM; LSFSFGWGHLHML; SFSFGWGHLHMLQ; FSFGWGHLHMLQE;SFGWGHLHMLQEQ; FGWGHLHMLQEQV; GWGHLHMLQEQVL; WGHLHMLQEQVLQ;GHLHMLQEQVLQS; HLHMLQEQVLQSR; LHMLQEQVLQSRT; HMLQEQVLQSRTG;MLQEQVLQSRTGL; LQEQVLQSRTGLE; QEQVLQSRTGLEV; EQVLQSRTGLEVK;QVLQSRTGLEVKA; VLQSRTGLEVKAT; LQSRTGLEVKATS; QSRTGLEVKATSI;SRTGLEVKATSIE; RTGLEVKATSIEE; TGLEVKATSIEEQ; GLEVKATSIEEQF;LEVKATSIEEQFF; EVKATSIEEQFFD; TLLNVHFVDFLSP; LLNVHFVDFLSPF;LNVHFVDFLSPFF; NVHFVDFLSPFFV; LLLYCQHHLYYKY; LLYCQHHLYYKYG;LYCQHHLYYKYGQ; YCQHHLYYKYGQN; CQHHLYYKYGQNV; QHHLYYKYGQNVH;HHLYYKYGQNVHG; HLYYKYGQNVHGY; LYYKYGQNVHGYL; YYKYGQNVHGYLP;YKYGQNVHGYLPF; KYGQNVHGYLPFQ; YGQNVHGYLPFQL; GQNVHGYLPFQLL;QNVHGYLPFQLLV; GKDQNNIVEYNYK; KDQNNIVEYNYKS; DQNNIVEYNYKSL;KIFLFFSAIPVRL; QKYLHQETEYHST; KYLHQETEYHSTH; YLHQETEYHSTHL;LHQETEYHSTHLG; TIPKPCLIADRGL; IPKPCLIADRGLQ; PKPCLIADRGLQW;KPCLIADRGLQWK; PCLIADRGLQWKL; CLIADRGLQWKLC; LIADRGLQWKLCD;IADRGLQWKLCDP; ADRGLQWKLCDPN; DRGLQWKLCDPNH; RGLQWKLCDPNHQ;GLQWKLCDPNHQR; LQWKLCDPNHQRT; QWKLCDPNHQRTY; WKLCDPNHQRTYT;KLCDPNHQRTYTL; LCDPNHQRTYTLL; CDPNHQRTYTLLE; DPNHQRTYTLLEL;PNHQRTYTLLELR; NHQRTYTLLELRN; PQEHQQLQHMFEE; QEHQQLQHMFEEL;EHQQLQHMFEELG; HQQLQHMFEELGL; QQQPPQQQFQPLK; QQPPQQQFQPLKI;QPPQQQFQPLKIL; PPQQQFQPLKILW; PQQQFQPLKILWQ; QQQFQPLKILWQQ;QQFQPLKILWQQQ; QFQPLKILWQQQP; FQPLKILWQQQPQ; QPLKILWQQQPQI;PLKILWQQQPQIH; LKILWQQQPQIHW; KILWQQQPQIHWQ; ILWQQQPQIHWQL;LWQQQPQIHWQLG; WQQQPQIHWQLGP; QQQPQIHWQLGPP; QQPQIHWQLGPPK;QPQIHWQLGPPKV; PQIHWQLGPPKVL; QIHWQLGPPKVLE; IHWQLGPPKVLEQ;HWQLGPPKVLEQH; WQLGPPKVLEQHP; TWKYKKKGITYLG; WKYKKKGITYLGV;KYKKKGITYLGVF; YKKKGITYLGVFY; KKKGITYLGVFYR; KKGITYLGVFYRV;KGITYLGVFYRVF; GITYLGVFYRVFY; ITYLGVFYRVFYS; TYLGVFYRVFYSR;SSGTFVFPVYTVF; SGTFVFPVYTVFT; GTFVFPVYTVFTS; TFVFPVYTVFTST;FVFPVYTVFTSTK; VFPVYTVFTSTKF; FPVYTVFTSTKFQ; PVYTVFTSTKFQQ;VYTVFTSTKFQQK; YTVFTSTKFQQKL; NKNKNPLSSFFCS; KNKNPLSSFFCSS;NKNPLSSFFCSSP; KNPLSSFFCSSPG; NPLSSFFCSSPGF; PLSSFFCSSPGFT;LSSFFCSSPGFTN; SSFFCSSPGFTNF; SFFCSSPGFTNFH; LGTRPRFLGSQNM;GTRPRFLGSQNMS; TRPRFLGSQNMSV; RPRFLGSQNMSVM; PRFLGSQNMSVMH;RFLGSQNMSVMHF; FLGSQNMSVMHFP; LGSQNMSVMHFPS; AAPPCESCTFLPE;APPCESCTFLPEV; PPCESCTFLPEVM; PCESCTFLPEVMV; CESCTFLPEVMVW;ESCTFLPEVMVWL; SCTFLPEVMVWLH; CTFLPEVMVWLHS; TFLPEVMVWLHSP;FLPEVMVWLHSPV; LPEVMVWLHSPVS; PEVMVWLHSPVSH; EVMVWLHSPVSHA;VMVWLHSPVSHAL; MVWLHSPVSHALS; VWLHSPVSHALSF; WLHSPVSHALSFL;LHSPVSHALSFLR; HSPVSHALSFLRS; SPVSHALSFLRSW; PVSHALSFLRSWF;VSHALSFLRSWFG; SHALSFLRSWFGC; HALSFLRSWFGCI; ALSFLRSWFGCIP;LSFLRSWFGCIPW; SFLRSWFGCIPWV; FLRSWFGCIPWVS; LRSWFGCIPWVSS;RSWFGCIPWVSSS; SWFGCIPWVSSSS; WFGCIPWVSSSSL; FGCIPWVSSSSLW;GCIPWVSSSSLWP; CIPWVSSSSLWPF; IPWVSSSSLWPFF; PWVSSSSLWPFFL;YIRGRGRLCLHPF; IRGRGRLCLHPFS; RGRGRLCLHPFSQ; GRGRLCLHPFSQV;RGRLCLHPFSQVV; GRLCLHPFSQVVR; RLCLHPFSQVVRV; LCLHPFSQVVRVW;CLHPFSQVVRVWR; LHPFSQVVRVWRL; HPFSQVVRVWRLF; PFSQVVRVWRLFL;FSQVVRVWRLFLR; SQVVRVWRLFLRP; QVVRVWRLFLRPS; VVRVWRLFLRPSK;VRVWRLFLRPSKT; RVWRLFLRPSKTI; VWRLFLRPSKTIW; WRLFLRPSKTIWG;RLFLRPSKTIWGN; LFLRPSKTIWGNP; FLRPSKTIWGNPY; LRPSKTIWGNPYS;RPSKTIWGNPYSF; PSKTIWGNPYSFA; SKTIWGNPYSFAI; KTIWGNPYSFAIF;TIWGNPYSFAIFA; IWGNPYSFAIFAK 14 mers: KSCLGKSSLNEKSL; SCLGKSSLNEKSLF;CLGKSSLNEKSLFK; LGKSSLNEKSLFKE; GKSSLNEKSLFKEV; FSSLPRYPVLQGMA;SSLPRYPVLQGMAY; SLPRYPVLQGMAYL; LPRYPVLQGMAYLF; PRYPVLQGMAYLFQ;RYPVLQGMAYLFQK; YPVLQGMAYLFQKA; PVLQGMAYLFQKAF; VLQGMAYLFQKAFC;LQGMAYLFQKAFCA; QGMAYLFQKAFCAL; GMAYLFQKAFCALP; MAYLFQKAFCALPL;AYLFQKAFCALPLH; YLFQKAFCALPLHA; LFQKAFCALPLHAM; FQKAFCALPLHAMS;QKAFCALPLHAMSA; KIFKKRALGLDRLL; IFKKRALGLDRLLL; FKKRALGLDRLLLH;RNSAMVGPNNWRNS; NSAMVGPNNWRNSL; SAMVGPNNWRNSLQ; AMVGPNNWRNSLQR;MVGPNNWRNSLQRS; VGPNNWRNSLQRSK; GPNNWRNSLQRSKA; PNNWRNSLQRSKAL;NNWRNSLQRSKALR; VPTYGTEEWESWWS; PTYGTEEWESWWSS; TYGTEEWESWWSSF;YGTEEWESWWSSFN; GTEEWESWWSSFNE; TEEWESWWSSFNEK; EEWESWWSSFNEKW;EWESWWSSFNEKWD; WESWWSSFNEKWDE; ESWWSSFNEKWDED; SWWSSFNEKWDEDL;WWSSFNEKWDEDLF; WSSFNEKWDEDLFC; SSFNEKWDEDLFCH; SFNEKWDEDLFCHE;FNEKWDEDLFCHED; NEKWDEDLFCHEDM; EKWDEDLFCHEDMF; KWDEDLFCHEDMFA;WDEDLFCHEDMFAS; DEDLFCHEDMFASD; EDLFCHEDMFASDE; DLFCHEDMFASDEE;LFCHEDMFASDEEA; FCHEDMFASDEEAT; CHEDMFASDEEATA; HEDMFASDEEATAD;EDMFASDEEATADS; DMFASDEEATADSQ; MFASDEEATADSQH; FASDEEATADSQHS;ASDEEATADSQHST; SDEEATADSQHSTP; DEEATADSQHSTPP; EEATADSQHSTPPK;EATADSQHSTPPKK; ATADSQHSTPPKKK; TADSQHSTPPKKKR; ADSQHSTPPKKKRK;DSQHSTPPKKKRKV; SQHSTPPKKKRKVE; QHSTPPKKKRKVED; HSTPPKKKRKVEDP;STPPKKKRKVEDPK; TPPKKKRKVEDPKD; PPKKKRKVEDPKDF; PKKKRKVEDPKDFP;KKKRKVEDPKDFPS; KKRKVEDPKDFPSD; KRKVEDPKDFPSDL; RKVEDPKDFPSDLH;KVEDPKDFPSDLHQ; VEDPKDFPSDLHQF; EDPKDFPSDLHQFL; DPKDFPSDLHQFLS;PKDFPSDLHQFLSQ; KDFPSDLHQFLSQA; DFPSDLHQFLSQAV; FPSDLHQFLSQAVF;PSDLHQFLSQAVFS; SDLHQFLSQAVFSN; DLHQFLSQAVFSNR; LHQFLSQAVFSNRT;HQFLSQAVFSNRTL; QFLSQAVFSNRTLA; FLSQAVFSNRTLAC; LSQAVFSNRTLACF;SQAVFSNRTLACFA; QAVFSNRTLACFAV; AVFSNRTLACFAVY; VFSNRTLACFAVYT;FSNRTLACFAVYTT; SNRTLACFAVYTTK; NRTLACFAVYTTKE; RTLACFAVYTTKEK;TLACFAVYTTKEKA; LACFAVYTTKEKAQ; ACFAVYTTKEKAQI; CFAVYTTKEKAQIL;FAVYTTKEKAQILY; AVYTTKEKAQILYK; VYTTKEKAQILYKK; YTTKEKAQILYKKL;TTKEKAQILYKKLM; TKEKAQILYKKLME; KEKAQILYKKLMEK; EKAQILYKKLMEKY;KAQILYKKLMEKYS; AQILYKKLMEKYSV; QILYKKLMEKYSVT; ILYKKLMEKYSVTF;LYKKLMEKYSVTFI; YKKLMEKYSVTFIS; KKLMEKYSVTFISR; KLMEKYSVTFISRH;LMEKYSVTFISRHM; MEKYSVTFISRHMC; EKYSVTFISRHMCA; KYSVTFISRHMCAG;YSVTFISRHMCAGH; SVTFISRHMCAGHN; VTFISRHMCAGHNI; TFISRHMCAGHNII;FISRHMCAGHNIIF; ISRHMCAGHNIIFF; SRHMCAGHNIIFFL; RHMCAGHNIIFFLT;HMCAGHNIIFFLTP; MCAGHNIIFFLTPH; CAGHNIIFFLTPHR; AGHNIIFFLTPHRH;GHNIIFFLTPHRHR; HNIIFFLTPHRHRV; NIIFFLTPHRHRVS; IIFFLTPHRHRVSA;IFFLTPHRHRVSAI; FFLTPHRHRVSAIN; FLTPHRHRVSAINN; LTPHRHRVSAINNF;TPHRHRVSAINNFC; PHRHRVSAINNFCQ; HRHRVSAINNFCQK; RHRVSAINNFCQKL;HRVSAINNFCQKLC; RVSAINNFCQKLCT; VSAINNFCQKLCTF; SAINNFCQKLCTFS;AINNFCQKLCTFSF; INNFCQKLCTFSFL; NNFCQKLCTFSFLI; NFCQKLCTFSFLIC;FCQKLCTFSFLICK; CQKLCTFSFLICKG; QKLCTFSFLICKGV; KLCTFSFLICKGVN;LCTFSFLICKGVNK; CTFSFLICKGVNKE; TFSFLICKGVNKEY; FSFLICKGVNKEYL;SFLICKGVNKEYLL; FLICKGVNKEYLLY; LICKGVNKEYLLYS; ICKGVNKEYLLYSA;CKGVNKEYLLYSAL; KGVNKEYLLYSALT; GVNKEYLLYSALTR; VNKEYLLYSALTRD;NKEYLLYSALTRDP; KEYLLYSALTRDPY; EYLLYSALTRDPYH; YLLYSALTRDPYHT;LLYSALTRDPYHTI; LYSALTRDPYHTIE; YSALTRDPYHTIEE; SALTRDPYHTIEES;ALTRDPYHTIEESI; LTRDPYHTIEESIQ; TRDPYHTIEESIQG; RDPYHTIEESIQGG;DPYHTIEESIQGGL; PYHTIEESIQGGLK; YHTIEESIQGGLKE; HTIEESIQGGLKEH;TIEESIQGGLKEHD; IEESIQGGLKEHDF; EESIQGGLKEHDFS; ESIQGGLKEHDFSP;SIQGGLKEHDFSPE; IQGGLKEHDFSPEE; QGGLKEHDFSPEEP; GGLKEHDFSPEEPE;GLKEHDFSPEEPEE; LKEHDFSPEEPEET; KEHDFSPEEPEETK; EHDFSPEEPEETKQ;HDFSPEEPEETKQV; DFSPEEPEETKQVS; FSPEEPEETKQVSW; SPEEPEETKQVSWK;PEEPEETKQVSWKL; EEPEETKQVSWKLI; EPEETKQVSWKLIT; PEETKQVSWKLITE;EETKQVSWKLITEY; ETKQVSWKLITEYA; TKQVSWKLITEYAV; KQVSWKLITEYAVE;QVSWKLITEYAVET; VSWKLITEYAVETK; SWKLITEYAVETKC; WKLITEYAVETKCE;KLITEYAVETKCED; LITEYAVETKCEDV; ITEYAVETKCEDVF; TEYAVETKCEDVFL;EYAVETKCEDVFLL; YAVETKCEDVFLLL; AVETKCEDVFLLLG; VETKCEDVFLLLGM;ETKCEDVFLLLGMY; TKCEDVFLLLGMYL; KCEDVFLLLGMYLE; CEDVFLLLGMYLEF;EDVFLLLGMYLEFQ; DVFLLLGMYLEFQY; VFLLLGMYLEFQYN; FLLLGMYLEFQYNV;LLLGMYLEFQYNVE; LLGMYLEFQYNVEE; LGMYLEFQYNVEEC; GMYLEFQYNVEECK;MYLEFQYNVEECKK; YLEFQYNVEECKKC; LEFQYNVEECKKCQ; EFQYNVEECKKCQK;FQYNVEECKKCQKK; QYNVEECKKCQKKD; YNVEECKKCQKKDQ; NVEECKKCQKKDQP;VEECKKCQKKDQPY; EECKKCQKKDQPYH; ECKKCQKKDQPYHF; CKKCQKKDQPYHFK;KKCQKKDQPYHFKY; KCQKKDQPYHFKYH; CQKKDQPYHFKYHE; QKKDQPYHFKYHEK;KKDQPYHFKYHEKH; KDQPYHFKYHEKHF; DQPYHFKYHEKHFA; QPYHFKYHEKHFAN;PYHFKYHEKHFANA; YHFKYHEKHFANAI; HFKYHEKHFANAII; FKYHEKHFANAIIF;KYHEKHFANAIIFA; YHEKHFANAIIFAE; HEKHFANAIIFAES; EKHFANAIIFAESK;KHFANAIIFAESKN; HFANAIIFAESKNQ; FANAIIFAESKNQK; ANAIIFAESKNQKS;NAIIFAESKNQKSI; AIIFAESKNQKSIC; IIFAESKNQKSICQ; IFAESKNQKSICQQ;FAESKNQKSICQQA; AESKNQKSICQQAV; ESKNQKSICQQAVD; SKNQKSICQQAVDT;KNQKSICQQAVDTV; NQKSICQQAVDTVL; QKSICQQAVDTVLA; KSICQQAVDTVLAK;SICQQAVDTVLAKK; ICQQAVDTVLAKKR; CQQAVDTVLAKKRV; QQAVDTVLAKKRVD;QAVDTVLAKKRVDT; AVDTVLAKKRVDTL; VDTVLAKKRVDTLH; DTVLAKKRVDTLHM;TVLAKKRVDTLHMT; VLAKKRVDTLHMTR; LAKKRVDTLHMTRE; AKKRVDTLHMTREE;KKRVDTLHMTREEM; KRVDTLHMTREEML; RVDTLHMTREEMLT; VDTLHMTREEMLTE;DTLHMTREEMLTER; TLHMTREEMLTERF; LHMTREEMLTERFN; HMTREEMLTERFNH;MTREEMLTERFNHI; TREEMLTERFNHIL; REEMLTERFNHILD; EEMLTERFNHILDK;EMLTERFNHILDKM; MLTERFNHILDKMD; LTERFNHILDKMDL; TERFNHILDKMDLI;ERFNHILDKMDLIF; RFNHILDKMDLIFG; FNHILDKMDLIFGA; NHILDKMDLIFGAH;HILDKMDLIFGAHG; ILDKMDLIFGAHGN; LDKMDLIFGAHGNA; DKMDLIFGAHGNAV;KMDLIFGAHGNAVL; MDLIFGAHGNAVLE; DLIFGAHGNAVLEQ; LIFGAHGNAVLEQY;IFGAHGNAVLEQYM; FGAHGNAVLEQYMA; GAHGNAVLEQYMAG; AHGNAVLEQYMAGV;HGNAVLEQYMAGVA; GNAVLEQYMAGVAW; NAVLEQYMAGVAWL; AVLEQYMAGVAWLH;VLEQYMAGVAWLHC; LEQYMAGVAWLHCL; EQYMAGVAWLHCLL; QYMAGVAWLHCLLP;YMAGVAWLHCLLPK; MAGVAWLHCLLPKM; AGVAWLHCLLPKMD; GVAWLHCLLPKMDS;VAWLHCLLPKMDSV; AWLHCLLPKMDSVI; WLHCLLPKMDSVIF; LHCLLPKMDSVIFD;HCLLPKMDSVIFDF; CLLPKMDSVIFDFL; LLPKMDSVIFDFLH; LPKMDSVIFDFLHC;PKMDSVIFDFLHCI; KMDSVIFDFLHCIV; MDSVIFDFLHCIVF; DSVIFDFLHCIVFN;SVIFDFLHCIVFNV; VIFDFLHCIVFNVP; IFDFLHCIVFNVPK; FDFLHCIVFNVPKR;DFLHCIVFNVPKRR; FLHCIVFNVPKRRY; LHCIVFNVPKRRYW; HCIVFNVPKRRYWL;CIVFNVPKRRYWLF; IVFNVPKRRYWLFK; VFNVPKRRYWLFKG; FNVPKRRYWLFKGP;NVPKRRYWLFKGPI; VPKRRYWLFKGPID; PKRRYWLFKGPIDS; KRRYWLFKGPIDSG;RRYWLFKGPIDSGK; RYWLFKGPIDSGKT; YWLFKGPIDSGKTT; WLFKGPIDSGKTTL;LFKGPIDSGKTTLA; FKGPIDSGKTTLAA; KGPIDSGKTTLAAG; GPIDSGKTTLAAGL;PIDSGKTTLAAGLL; IDSGKTTLAAGLLD; DSGKTTLAAGLLDL; SGKTTLAAGLLDLC;GKTTLAAGLLDLCG; KTTLAAGLLDLCGG; TTLAAGLLDLCGGK; TLAAGLLDLCGGKA;LAAGLLDLCGGKAL; AAGLLDLCGGKALN; AGLLDLCGGKALNV; GLLDLCGGKALNVN;LLDLCGGKALNVNL; LDLCGGKALNVNLP; DLCGGKALNVNLPM; LCGGKALNVNLPME;CGGKALNVNLPMER; GGKALNVNLPMERL; GKALNVNLPMERLT; KALNVNLPMERLTF;ALNVNLPMERLTFE; LNVNLPMERLTFEL; NVNLPMERLTFELG; VNLPMERLTFELGV;NLPMERLTFELGVA; LPMERLTFELGVAI; PMERLTFELGVAID; MERLTFELGVAIDQ;ERLTFELGVAIDQY; RLTFELGVAIDQYM; LTFELGVAIDQYMV; TFELGVAIDQYMVV;FELGVAIDQYMVVF; ELGVAIDQYMVVFE; LGVAIDQYMVVFED; GVAIDQYMVVFEDV;VAIDQYMVVFEDVK; AIDQYMVVFEDVKG; IDQYMVVFEDVKGT; DQYMVVFEDVKGTG;QYMVVFEDVKGTGA; YMVVFEDVKGTGAE; MVVFEDVKGTGAES; VVFEDVKGTGAESK;VFEDVKGTGAESKD; FEDVKGTGAESKDL; EDVKGTGAESKDLP; DVKGTGAESKDLPS;VKGTGAESKDLPSG; KGTGAESKDLPSGH; GTGAESKDLPSGHG; TGAESKDLPSGHGI;GAESKDLPSGHGIN; AESKDLPSGHGINN; ESKDLPSGHGINNL; SKDLPSGHGINNLD;KDLPSGHGINNLDS; DLPSGHGINNLDSL; LPSGHGINNLDSLR; PSGHGINNLDSLRD;SGHGINNLDSLRDY; GHGINNLDSLRDYL; HGINNLDSLRDYLD; GINNLDSLRDYLDG;INNLDSLRDYLDGS; NNLDSLRDYLDGSV; NLDSLRDYLDGSVK; LDSLRDYLDGSVKV;DSLRDYLDGSVKVN; SLRDYLDGSVKVNL; LRDYLDGSVKVNLE; RDYLDGSVKVNLEK;DYLDGSVKVNLEKK; YLDGSVKVNLEKKH; LDGSVKVNLEKKHL; DGSVKVNLEKKHLN;GSVKVNLEKKHLNK; SVKVNLEKKHLNKR; VKVNLEKKHLNKRT; KVNLEKKHLNKRTQ;VNLEKKHLNKRTQI; NLEKKHLNKRTQIF; LEKKHLNKRTQIFP; EKKHLNKRTQIFPP;KKHLNKRTQIFPPG; KHLNKRTQIFPPGL; HLNKRTQIFPPGLV; LNKRTQIFPPGLVT;NKRTQIFPPGLVTM; KRTQIFPPGLVTMN; RTQIFPPGLVTMNE; TQIFPPGLVTMNEY;QIFPPGLVTMNEYP; IFPPGLVTMNEYPV; FPPGLVTMNEYPVP; PPGLVTMNEYPVPK;PGLVTMNEYPVPKT; GLVTMNEYPVPKTL; LVTMNEYPVPKTLQ; VTMNEYPVPKTLQA;TMNEYPVPKTLQAR; MNEYPVPKTLQARF; NEYPVPKTLQARFV; EYPVPKTLQARFVR;YPVPKTLQARFVRQ; PVPKTLQARFVRQI; VPKTLQARFVRQID; PKTLQARFVRQIDF;KTLQARFVRQIDFR; TLQARFVRQIDFRP; LQARFVRQIDFRPK; QARFVRQIDFRPKI;ARFVRQIDFRPKIY; RFVRQIDFRPKIYL; FVRQIDFRPKIYLR; VRQIDFRPKIYLRK;RQIDFRPKIYLRKS; QIDFRPKIYLRKSL; IDFRPKIYLRKSLQ; DFRPKIYLRKSLQN;FRPKIYLRKSLQNS; RPKIYLRKSLQNSE; PKIYLRKSLQNSEF; KIYLRKSLQNSEFL;IYLRKSLQNSEFLL; YLRKSLQNSEFLLE; LRKSLQNSEFLLEK; RKSLQNSEFLLEKR;KSLQNSEFLLEKRI; SLQNSEFLLEKRIL; LQNSEFLLEKRILQ; QNSEFLLEKRILQS;NSEFLLEKRILQSG; SEFLLEKRILQSGM; EFLLEKRILQSGMT; FLLEKRILQSGMTL;LLEKRILQSGMTLL; LEKRILQSGMTLLL; EKRILQSGMTLLLL; KRILQSGMTLLLLL;RILQSGMTLLLLLI; ILQSGMTLLLLLIW; LQSGMTLLLLLIWF; QSGMTLLLLLIWFR;SGMTLLLLLIWFRP; GMTLLLLLIWFRPV; MTLLLLLIWFRPVA; TLLLLLIWFRPVAD;LLLLLIWFRPVADF; LLLLIWFRPVADFA; LLLIWFRPVADFAT; LLIWFRPVADFATD;LIWFRPVADFATDI; IWFRPVADFATDIQ; WFRPVADFATDIQS; FRPVADFATDIQSR;RPVADFATDIQSRI; PVADFATDIQSRIV; VADFATDIQSRIVE; ADFATDIQSRIVEW;DFATDIQSRIVEWK; FATDIQSRIVEWKE; ATDIQSRIVEWKER; TDIQSRIVEWKERL;DIQSRIVEWKERLD; IQSRIVEWKERLDS; QSRIVEWKERLDSE; SRIVEWKERLDSEI;RIVEWKERLDSEIS; IVEWKERLDSEISM; VEWKERLDSEISMY; EWKERLDSEISMYT;WKERLDSEISMYTF; KERLDSEISMYTFS; ERLDSEISMYTFSR; RLDSEISMYTFSRM;LDSEISMYTFSRMK; DSEISMYTFSRMKY; SEISMYTFSRMKYN; EISMYTFSRMKYNI;ISMYTFSRMKYNIC; SMYTFSRMKYNICM; MYTFSRMKYNICMG; YTFSRMKYNICMGK;TFSRMKYNICMGKC; FSRMKYNICMGKCI; SRMKYNICMGKCIL; RMKYNICMGKCILD;MKYNICMGKCILDI; KYNICMGKCILDIT; YNICMGKCILDITR; NICMGKCILDITRE;ICMGKCILDITREE; CMGKCILDITREED; MGKCILDITREEDS; GKCILDITREEDSE;KCILDITREEDSET; CILDITREEDSETE; ILDITREEDSETED; LDITREEDSETEDS;DITREEDSETEDSG; ITREEDSETEDSGH; TREEDSETEDSGHG; REEDSETEDSGHGS;EEDSETEDSGHGSS; EDSETEDSGHGSST; DSETEDSGHGSSTE; SETEDSGHGSSTES;ETEDSGHGSSTESQ; TEDSGHGSSTESQS; EDSGHGSSTESQSQ; DSGHGSSTESQSQC;SGHGSSTESQSQCS; GHGSSTESQSQCSS; HGSSTESQSQCSSQ; GSSTESQSQCSSQV;SSTESQSQCSSQVS; STESQSQCSSQVSD; TESQSQCSSQVSDT; ESQSQCSSQVSDTS;SQSQCSSQVSDTSA; QSQCSSQVSDTSAP; SQCSSQVSDTSAPA; QCSSQVSDTSAPAE;CSSQVSDTSAPAED; SSQVSDTSAPAEDS; SQVSDTSAPAEDSQ; QVSDTSAPAEDSQR;VSDTSAPAEDSQRS; SDTSAPAEDSQRSD; DTSAPAEDSQRSDP; TSAPAEDSQRSDPH;SAPAEDSQRSDPHS; APAEDSQRSDPHSQ; PAEDSQRSDPHSQE; AEDSQRSDPHSQEL;EDSQRSDPHSQELH; DSQRSDPHSQELHL; SQRSDPHSQELHLC; QRSDPHSQELHLCK;RSDPHSQELHLCKG; SDPHSQELHLCKGF; DPHSQELHLCKGFQ; PHSQELHLCKGFQC;HSQELHLCKGFQCF; SQELHLCKGFQCFK; QELHLCKGFQCFKR; ELHLCKGFQCFKRP;LHLCKGFQCFKRPK; HLCKGFQCFKRPKT; LCKGFQCFKRPKTP; CKGFQCFKRPKTPP;KGFQCFKRPKTPPP; GFQCFKRPKTPPPK; MYMYNKSTCLKHFG; YMYNKSTCLKHFGL;MYNKSTCLKHFGLQ; YNKSTCLKHFGLQL; NKSTCLKHFGLQLS; KSTCLKHFGLQLSL;STCLKHFGLQLSLF; TCLKHFGLQLSLFV; CLKHFGLQLSLFVN; LKHFGLQLSLFVNI;KHFGLQLSLFVNIS; HFGLQLSLFVNISY; FGLQLSLFVNISYH; GLQLSLFVNISYHI;LQLSLFVNISYHIW; QLSLFVNISYHIWV; LSLFVNISYHIWVP; SLFVNISYHIWVPW;LFVNISYHIWVPWK; FVNISYHIWVPWKS; VNISYHIWVPWKSF; NISYHIWVPWKSFC;ISYHIWVPWKSFCA; SYHIWVPWKSFCAI; YHIWVPWKSFCAIK; HIWVPWKSFCAIKH;IWVPWKSFCAIKHP; WVPWKSFCAIKHPN; VPWKSFCAIKHPNL; PWKSFCAIKHPNLF;WKSFCAIKHPNLFY; KSFCAIKHPNLFYL; SFCAIKHPNLFYLG; FCAIKHPNLFYLGF;CAIKHPNLFYLGFH; AIKHPNLFYLGFHT; IKHPNLFYLGFHTI; KHPNLFYLGFHTIH;HPNLFYLGFHTIHR; PNLFYLGFHTIHRL; NLFYLGFHTIHRLP; LFYLGFHTIHRLPI;FYLGFHTIHRLPIH; YLGFHTIHRLPIHS; LGFHTIHRLPIHSL; GFHTIHRLPIHSLG;FHTIHRLPIHSLGS; HTIHRLPIHSLGSP; TIHRLPIHSLGSPV; IHRLPIHSLGSPVY;HRLPIHSLGSPVYK; RLPIHSLGSPVYKV; LPIHSLGSPVYKVT; QKGNWVRILYRSFS;KGNWVRILYRSFSQ; GNWVRILYRSFSQA; NWVRILYRSFSQAD; WVRILYRSFSQADL;VRILYRSFSQADLK; RILYRSFSQADLKI; ILYRSFSQADLKIS; LYRSFSQADLKISC;YRSFSQADLKISCK; RSFSQADLKISCKA; SFSQADLKISCKAS; FSQADLKISCKASP;SQADLKISCKASPL; QADLKISCKASPLL; ADLKISCKASPLLC; DLKISCKASPLLCS;LKISCKASPLLCSR; KISCKASPLLCSRA; ISCKASPLLCSRAV; SCKASPLLCSRAVS;CKASPLLCSRAVSK; KASPLLCSRAVSKQ; ASPLLCSRAVSKQA; SPLLCSRAVSKQAT;PLLCSRAVSKQATN; LLCSRAVSKQATNI; LCSRAVSKQATNIS; CSRAVSKQATNISS;NIQAISFTKRPHTL; IQAISFTKRPHTLF; QAISFTKRPHTLFI; QHCGSCVGHMKYWG;HCGSCVGHMKYWGN; CGSCVGHMKYWGNI; GSCVGHMKYWGNIF; SCVGHMKYWGNIFP;CVGHMKYWGNIFPS; VGHMKYWGNIFPSC; GHMKYWGNIFPSCE; HMKYWGNIFPSCES;MKYWGNIFPSCESP; KYWGNIFPSCESPK; YWGNIFPSCESPKI; WGNIFPSCESPKIP;GNIFPSCESPKIPS; NIFPSCESPKIPSI; IFPSCESPKIPSIF; FPSCESPKIPSIFI;PSCESPKIPSIFIS; SCESPKIPSIFIST; CESPKIPSIFISTG; ESPKIPSIFISTGI;SPKIPSIFISTGIR; PKIPSIFISTGIRY; KIPSIFISTGIRYP; IPSIFISTGIRYPA;PSIFISTGIRYPAL; SIFISTGIRYPALN; IFISTGIRYPALNW; FISTGIRYPALNWI;ISTGIRYPALNWIS; STGIRYPALNWISI; TGIRYPALNWISIV; GIRYPALNWISIVF;IRYPALNWISIVFV; RYPALNWISIVFVQ; YPALNWISIVFVQI; PALNWISIVFVQIG;ALNWISIVFVQIGL; LNWISIVFVQIGLM; NWISIVFVQIGLMV; WISIVFVQIGLMVS;ISIVFVQIGLMVSI; SIVFVQIGLMVSIH; IVFVQIGLMVSIHY; VFVQIGLMVSIHYL;FVQIGLMVSIHYLG; VQIGLMVSIHYLGL; QIGLMVSIHYLGLG; IGLMVSIHYLGLGC;GLMVSIHYLGLGCW; LMVSIHYLGLGCWV; MVSIHYLGLGCWVF; VSIHYLGLGCWVFR;SIHYLGLGCWVFRG; IHYLGLGCWVFRGY; HYLGLGCWVFRGYS; YLGLGCWVFRGYST;LGLGCWVFRGYSTI; GLGCWVFRGYSTIR; LGCWVFRGYSTIRV; GCWVFRGYSTIRVL;HSLHFQGFSTYSKE; SLHFQGFSTYSKEV; LHFQGFSTYSKEVE; HFQGFSTYSKEVEI;FQGFSTYSKEVEIT; QGFSTYSKEVEITA; GFSTYSKEVEITAL; FSTYSKEVEITALN;STYSKEVEITALNR; TYSKEVEITALNRF; YSKEVEITALNRFS; SKEVEITALNRFSS;KEVEITALNRFSST; EVEITALNRFSSTM; VEITALNRFSSTML; EITALNRFSSTMLM;ITALNRFSSTMLMH; TALNRFSSTMLMHF; ALNRFSSTMLMHFL; PCMKVKHASYSNNL;CMKVKHASYSNNLC; MKVKHASYSNNLCL; KVKHASYSNNLCLY; VKHASYSNNLCLYS;KHASYSNNLCLYSY; HASYSNNLCLYSYS; ASYSNNLCLYSYSL; SYSNNLCLYSYSLP;YSNNLCLYSYSLPH; SNNLCLYSYSLPHQ; IGEGNSCCAVTGKH; GEGNSCCAVTGKHF;EGNSCCAVTGKHFS; GNSCCAVTGKHFSL; NSCCAVTGKHFSLW; SCCAVTGKHFSLWA;CCAVTGKHFSLWAI; CAVTGKHFSLWAIT; AVTGKHFSLWAITA; VTGKHFSLWAITAK;TGKHFSLWAITAKV; GKHFSLWAITAKVI; KHFSLWAITAKVIF; HFSLWAITAKVIFS;FSLWAITAKVIFST; TKAPKVFIWIPHFW; KAPKVFIWIPHFWV; EAFYLCNSIYPSFN;AFYLCNSIYPSFNF; FWHLHGFLWLFGSC; WHLHGFLWLFGSCP; HLHGFLWLFGSCPW;LHGFLWLFGSCPWT; HGFLWLFGSCPWTL; GFLWLFGSCPWTLS; FLWLFGSCPWTLSF;LWLFGSCPWTLSFS; WLFGSCPWTLSFSF; LFGSCPWTLSFSFG; FGSCPWTLSFSFGW;GSCPWTLSFSFGWG; SCPWTLSFSFGWGH; CPWTLSFSFGWGHL; PWTLSFSFGWGHLH;WTLSFSFGWGHLHM; TLSFSFGWGHLHML; LSFSFGWGHLHMLQ; SFSFGWGHLHMLQE;FSFGWGHLHMLQEQ; SFGWGHLHMLQEQV; FGWGHLHMLQEQVL; GWGHLHMLQEQVLQ;WGHLHMLQEQVLQS; GHLHMLQEQVLQSR; HLHMLQEQVLQSRT; LHMLQEQVLQSRTG;HMLQEQVLQSRTGL; MLQEQVLQSRTGLE; LQEQVLQSRTGLEV; QEQVLQSRTGLEVK;EQVLQSRTGLEVKA; QVLQSRTGLEVKAT; VLQSRTGLEVKATS; LQSRTGLEVKATSI;QSRTGLEVKATSIE; SRTGLEVKATSIEE; RTGLEVKATSIEEQ; TGLEVKATSIEEQF;GLEVKATSIEEQFF; LEVKATSIEEQFFD; TLLNVHFVDFLSPF; LLNVHFVDFLSPFF;LNVHFVDFLSPFFV; LLLYCQHHLYYKYG; LLYCQHHLYYKYGQ; LYCQHHLYYKYGQN;YCQHHLYYKYGQNV; CQHHLYYKYGQNVH; QHHLYYKYGQNVHG; HHLYYKYGQNVHGY;HLYYKYGQNVHGYL; LYYKYGQNVHGYLP; YYKYGQNVHGYLPF; YKYGQNVHGYLPFQ;KYGQNVHGYLPFQL; YGQNVHGYLPFQLL; GQNVHGYLPFQLLV; GKDQNNIVEYNYKS;KDQNNIVEYNYKSL; QKYLHQETEYHSTH; KYLHQETEYHSTHL; YLHQETEYHSTHLG;TIPKPCLIADRGLQ; IPKPCLIADRGLQW; PKPCLIADRGLQWK; KPCLIADRGLQWKL;PCLIADRGLQWKLC; CLIADRGLQWKLCD; LIADRGLQWKLCDP; IADRGLQWKLCDPN;ADRGLQWKLCDPNH; DRGLQWKLCDPNHQ; RGLQWKLCDPNHQR; GLQWKLCDPNHQRT;LQWKLCDPNHQRTY; QWKLCDPNHQRTYT; WKLCDPNHQRTYTL; KLCDPNHQRTYTLL;LCDPNHQRTYTLLE; CDPNHQRTYTLLEL; DPNHQRTYTLLELR; PNHQRTYTLLELRN;PQEHQQLQHMFEEL; QEHQQLQHMFEELG; EHQQLQHMFEELGL; QQQPPQQQFQPLKI;QQPPQQQFQPLKIL; QPPQQQFQPLKILW; PPQQQFQPLKILWQ; PQQQFQPLKILWQQ;QQQFQPLKILWQQQ; QQFQPLKILWQQQP; QFQPLKILWQQQPQ; FQPLKILWQQQPQI;QPLKILWQQQPQIH; PLKILWQQQPQIHW; LKILWQQQPQIHWQ; KILWQQQPQIHWQL;ILWQQQPQIHWQLG; LWQQQPQIHWQLGP; WQQQPQIHWQLGPP; QQQPQIHWQLGPPK;QQPQIHWQLGPPKV; QPQIHWQLGPPKVL; PQIHWQLGPPKVLE; QIHWQLGPPKVLEQ;IHWQLGPPKVLEQH; HWQLGPPKVLEQHP; TWKYKKKGITYLGV; WKYKKKGITYLGVF;KYKKKGITYLGVFY; YKKKGITYLGVFYR; KKKGITYLGVFYRV; KKGITYLGVFYRVF;KGITYLGVFYRVFY; GITYLGVFYRVFYS; ITYLGVFYRVFYSR; SSGTFVFPVYTVFT;SGTFVFPVYTVFTS; GTFVFPVYTVFTST; TFVFPVYTVFTSTK; FVFPVYTVFTSTKF;VFPVYTVFTSTKFQ; FPVYTVFTSTKFQQ; PVYTVFTSTKFQQK; VYTVFTSTKFQQKL;NKNKNPLSSFFCSS; KNKNPLSSFFCSSP; NKNPLSSFFCSSPG; KNPLSSFFCSSPGF;NPLSSFFCSSPGFT; PLSSFFCSSPGFTN; LSSFFCSSPGFTNF; SSFFCSSPGFTNFH;LGTRPRFLGSQNMS; GTRPRFLGSQNMSV; TRPRFLGSQNMSVM; RPRFLGSQNMSVMH;PRFLGSQNMSVMHF; RFLGSQNMSVMHFP; FLGSQNMSVMHFPS; AAPPCESCTFLPEV;APPCESCTFLPEVM; PPCESCTFLPEVMV; PCESCTFLPEVMVW; CESCTFLPEVMVWL;ESCTFLPEVMVWLH; SCTFLPEVMVWLHS; CTFLPEVMVWLHSP; TFLPEVMVWLHSPV;FLPEVMVWLHSPVS; LPEVMVWLHSPVSH; PEVMVWLHSPVSHA; EVMVWLHSPVSHAL;VMVWLHSPVSHALS; MVWLHSPVSHALSF; VWLHSPVSHALSFL; WLHSPVSHALSFLR;LHSPVSHALSFLRS; HSPVSHALSFLRSW; SPVSHALSFLRSWF; PVSHALSFLRSWFG;VSHALSFLRSWFGC; SHALSFLRSWFGCI; HALSFLRSWFGCIP; ALSFLRSWFGCIPW;LSFLRSWFGCIPWV; SFLRSWFGCIPWVS; FLRSWFGCIPWVSS; LRSWFGCIPWVSSS;RSWFGCIPWVSSSS; SWFGCIPWVSSSSL; WFGCIPWVSSSSLW; FGCIPWVSSSSLWP;GCIPWVSSSSLWPF; CIPWVSSSSLWPFF; IPWVSSSSLWPFFL; YIRGRGRLCLHPFS;IRGRGRLCLHPFSQ; RGRGRLCLHPFSQV; GRGRLCLHPFSQVV; RGRLCLHPFSQVVR;GRLCLHPFSQVVRV; RLCLHPFSQVVRVW; LCLHPFSQVVRVWR; CLHPFSQVVRVWRL;LHPFSQVVRVWRLF; HPFSQVVRVWRLFL; PFSQVVRVWRLFLR; FSQVVRVWRLFLRP;SQVVRVWRLFLRPS; QVVRVWRLFLRPSK; VVRVWRLFLRPSKT; VRVWRLFLRPSKTI;RVWRLFLRPSKTIW; VWRLFLRPSKTIWG; WRLFLRPSKTIWGN; RLFLRPSKTIWGNP;LFLRPSKTIWGNPY; FLRPSKTIWGNPYS; LRPSKTIWGNPYSF; RPSKTIWGNPYSFA;PSKTIWGNPYSFAI; SKTIWGNPYSFAIF; KTIWGNPYSFAIFA; TIWGNPYSFAIFAK 15 mers:KSCLGKSSLNEKSLF; SCLGKSSLNEKSLFK; CLGKSSLNEKSLFKE; LGKSSLNEKSLFKEV;FSSLPRYPVLQGMAY; SSLPRYPVLQGMAYL; SLPRYPVLQGMAYLF; LPRYPVLQGMAYLFQ;PRYPVLQGMAYLFQK; RYPVLQGMAYLFQKA; YPVLQGMAYLFQKAF; PVLQGMAYLFQKAFC;VLQGMAYLFQKAFCA; LQGMAYLFQKAFCAL; QGMAYLFQKAFCALP; GMAYLFQKAFCALPL;MAYLFQKAFCALPLH; AYLFQKAFCALPLHA; YLFQKAFCALPLHAM; LFQKAFCALPLHAMS;FQKAFCALPLHAMSA; KIFKKRALGLDRLLL; IFKKRALGLDRLLLH; RNSAMVGPNNWRNSL;NSAMVGPNNWRNSLQ; SAMVGPNNWRNSLQR; AMVGPNNWRNSLQRS; MVGPNNWRNSLQRSK;VGPNNWRNSLQRSKA; GPNNWRNSLQRSKAL; PNNWRNSLQRSKALR; VPTYGTEEWESWWSS;PTYGTEEWESWWSSF; TYGTEEWESWWSSFN; YGTEEWESWWSSFNE; GTEEWESWWSSFNEK;TEEWESWWSSFNEKW; EEWESWWSSFNEKWD; EWESWWSSFNEKWDE; WESWWSSFNEKWDED;ESWWSSFNEKWDEDL; SWWSSFNEKWDEDLF; WWSSFNEKWDEDLFC; WSSFNEKWDEDLFCH;SSFNEKWDEDLFCHE; SFNEKWDEDLFCHED; FNEKWDEDLFCHEDM; NEKWDEDLFCHEDMF;EKWDEDLFCHEDMFA; KWDEDLFCHEDMFAS; WDEDLFCHEDMFASD; DEDLFCHEDMFASDE;EDLFCHEDMFASDEE; DLFCHEDMFASDEEA; LFCHEDMFASDEEAT; FCHEDMFASDEEATA;CHEDMFASDEEATAD; HEDMFASDEEATADS; EDMFASDEEATADSQ; DMFASDEEATADSQH;MFASDEEATADSQHS; FASDEEATADSQHST; ASDEEATADSQHSTP; SDEEATADSQHSTPP;DEEATADSQHSTPPK; EEATADSQHSTPPKK; EATADSQHSTPPKKK; ATADSQHSTPPKKKR;TADSQHSTPPKKKRK; ADSQHSTPPKKKRKV; DSQHSTPPKKKRKVE; SQHSTPPKKKRKVED;QHSTPPKKKRKVEDP; HSTPPKKKRKVEDPK; STPPKKKRKVEDPKD; TPPKKKRKVEDPKDF;PPKKKRKVEDPKDFP; PKKKRKVEDPKDFPS; KKKRKVEDPKDFPSD; KKRKVEDPKDFPSDL;KRKVEDPKDFPSDLH; RKVEDPKDFPSDLHQ; KVEDPKDFPSDLHQF; VEDPKDFPSDLHQFL;EDPKDFPSDLHQFLS; DPKDFPSDLHQFLSQ; PKDFPSDLHQFLSQA; KDFPSDLHQFLSQAV;DFPSDLHQFLSQAVF; FPSDLHQFLSQAVFS; PSDLHQFLSQAVFSN; SDLHQFLSQAVFSNR;DLHQFLSQAVFSNRT; LHQFLSQAVFSNRTL; HQFLSQAVFSNRTLA; QFLSQAVFSNRTLAC;FLSQAVFSNRTLACF; LSQAVFSNRTLACFA; SQAVFSNRTLACFAV; QAVFSNRTLACFAVY;AVFSNRTLACFAVYT; VFSNRTLACFAVYTT; FSNRTLACFAVYTTK; SNRTLACFAVYTTKE;NRTLACFAVYTTKEK; RTLACFAVYTTKEKA; TLACFAVYTTKEKAQ; LACFAVYTTKEKAQI;ACFAVYTTKEKAQIL; CFAVYTTKEKAQILY; FAVYTTKEKAQILYK; AVYTTKEKAQILYKK;VYTTKEKAQILYKKL; YTTKEKAQILYKKLM; TTKEKAQILYKKLME; TKEKAQILYKKLMEK;KEKAQILYKKLMEKY; EKAQILYKKLMEKYS; KAQILYKKLMEKYSV; AQILYKKLMEKYSVT;QILYKKLMEKYSVTF; ILYKKLMEKYSVTFI; LYKKLMEKYSVTFIS; YKKLMEKYSVTFISR;KKLMEKYSVTFISRH; KLMEKYSVTFISRHM; LMEKYSVTFISRHMC; MEKYSVTFISRHMCA;EKYSVTFISRHMCAG; KYSVTFISRHMCAGH; YSVTFISRHMCAGHN; SVTFISRHMCAGHNI;VTFISRHMCAGHNII; TFISRHMCAGHNIIF; FISRHMCAGHNIIFF; ISRHMCAGHNIIFFL;SRHMCAGHNIIFFLT; RHMCAGHNIIFFLTP; HMCAGHNIIFFLTPH; MCAGHNIIFFLTPHR;CAGHNIIFFLTPHRH; AGHNIIFFLTPHRHR; GHNIIFFLTPHRHRV; HNIIFFLTPHRHRVS;NIIFFLTPHRHRVSA; IIFFLTPHRHRVSAI; IFFLTPHRHRVSAIN; FFLTPHRHRVSAINN;FLTPHRHRVSAINNF; LTPHRHRVSAINNFC; TPHRHRVSAINNFCQ; PHRHRVSAINNFCQK;HRHRVSAINNFCQKL; RHRVSAINNFCQKLC; HRVSAINNFCQKLCT; RVSAINNFCQKLCTF;VSAINNFCQKLCTFS; SAINNFCQKLCTFSF; AINNFCQKLCTFSFL; INNFCQKLCTFSFLI;NNFCQKLCTFSFLIC; NFCQKLCTFSFLICK; FCQKLCTFSFLICKG; CQKLCTFSFLICKGV;QKLCTFSFLICKGVN; KLCTFSFLICKGVNK; LCTFSFLICKGVNKE; CTFSFLICKGVNKEY;TFSFLICKGVNKEYL; FSFLICKGVNKEYLL; SFLICKGVNKEYLLY; FLICKGVNKEYLLYS;LICKGVNKEYLLYSA; ICKGVNKEYLLYSAL; CKGVNKEYLLYSALT; KGVNKEYLLYSALTR;GVNKEYLLYSALTRD; VNKEYLLYSALTRDP; NKEYLLYSALTRDPY; KEYLLYSALTRDPYH;EYLLYSALTRDPYHT; YLLYSALTRDPYHTI; LLYSALTRDPYHTIE; LYSALTRDPYHTIEE;YSALTRDPYHTIEES; SALTRDPYHTIEESI; ALTRDPYHTIEESIQ; LTRDPYHTIEESIQG;TRDPYHTIEESIQGG; RDPYHTIEESIQGGL; DPYHTIEESIQGGLK; PYHTIEESIQGGLKE;YHTIEESIQGGLKEH; HTIEESIQGGLKEHD; TIEESIQGGLKEHDF; IEESIQGGLKEHDFS;EESIQGGLKEHDFSP; ESIQGGLKEHDFSPE; SIQGGLKEHDFSPEE; IQGGLKEHDFSPEEP;QGGLKEHDFSPEEPE; GGLKEHDFSPEEPEE; GLKEHDFSPEEPEET; LKEHDFSPEEPEETK;KEHDFSPEEPEETKQ; EHDFSPEEPEETKQV; HDFSPEEPEETKQVS; DFSPEEPEETKQVSW;FSPEEPEETKQVSWK; SPEEPEETKQVSWKL; PEEPEETKQVSWKLI; EEPEETKQVSWKLIT;EPEETKQVSWKLITE; PEETKQVSWKLITEY; EETKQVSWKLITEYA; ETKQVSWKLITEYAV;TKQVSWKLITEYAVE; KQVSWKLITEYAVET; QVSWKLITEYAVETK; VSWKLITEYAVETKC;SWKLITEYAVETKCE; WKLITEYAVETKCED; KLITEYAVETKCEDV; LITEYAVETKCEDVF;ITEYAVETKCEDVFL; TEYAVETKCEDVFLL; EYAVETKCEDVFLLL; YAVETKCEDVFLLLG;AVETKCEDVFLLLGM; VETKCEDVFLLLGMY; ETKCEDVFLLLGMYL; TKCEDVFLLLGMYLE;KCEDVFLLLGMYLEF; CEDVFLLLGMYLEFQ; EDVFLLLGMYLEFQY; DVFLLLGMYLEFQYN;VFLLLGMYLEFQYNV; FLLLGMYLEFQYNVE; LLLGMYLEFQYNVEE; LLGMYLEFQYNVEEC;LGMYLEFQYNVEECK; GMYLEFQYNVEECKK; MYLEFQYNVEECKKC; YLEFQYNVEECKKCQ;LEFQYNVEECKKCQK; EFQYNVEECKKCQKK; FQYNVEECKKCQKKD; QYNVEECKKCQKKDQ;YNVEECKKCQKKDQP; NVEECKKCQKKDQPY; VEECKKCQKKDQPYH; EECKKCQKKDQPYHF;ECKKCQKKDQPYHFK; CKKCQKKDQPYHFKY; KKCQKKDQPYHFKYH; KCQKKDQPYHFKYHE;CQKKDQPYHFKYHEK; QKKDQPYHFKYHEKH; KKDQPYHFKYHEKHF; KDQPYHFKYHEKHFA;DQPYHFKYHEKHFAN; QPYHFKYHEKHFANA; PYHFKYHEKHFANAI; YHFKYHEKHFANAII;HFKYHEKHFANAIIF; FKYHEKHFANAIIFA; KYHEKHFANAIIFAE; YHEKHFANAIIFAES;HEKHFANAIIFAESK; EKHFANAIIFAESKN; KHFANAIIFAESKNQ; HFANAIIFAESKNQK;FANAIIFAESKNQKS; ANAIIFAESKNQKSI; NAIIFAESKNQKSIC; AIIFAESKNQKSICQ;IIFAESKNQKSICQQ; IFAESKNQKSICQQA; FAESKNQKSICQQAV; AESKNQKSICQQAVD;ESKNQKSICQQAVDT; SKNQKSICQQAVDTV; KNQKSICQQAVDTVL; NQKSICQQAVDTVLA;QKSICQQAVDTVLAK; KSICQQAVDTVLAKK; SICQQAVDTVLAKKR; ICQQAVDTVLAKKRV;CQQAVDTVLAKKRVD; QQAVDTVLAKKRVDT; QAVDTVLAKKRVDTL; AVDTVLAKKRVDTLH;VDTVLAKKRVDTLHM; DTVLAKKRVDTLHMT; TVLAKKRVDTLHMTR; VLAKKRVDTLHMTRE;LAKKRVDTLHMTREE; AKKRVDTLHMTREEM; KKRVDTLHMTREEML; KRVDTLHMTREEMLT;RVDTLHMTREEMLTE; VDTLHMTREEMLTER; DTLHMTREEMLTERF; TLHMTREEMLTERFN;LHMTREEMLTERFNH; HMTREEMLTERFNHI; MTREEMLTERFNHIL; TREEMLTERFNHILD;REEMLTERFNHILDK; EEMLTERFNHILDKM; EMLTERFNHILDKMD; MLTERFNHILDKMDL;LTERFNHILDKMDLI; TERFNHILDKMDLIF; ERFNHILDKMDLIFG; RFNHILDKMDLIFGA;FNHILDKMDLIFGAH; NHILDKMDLIFGAHG; HILDKMDLIFGAHGN; ILDKMDLIFGAHGNA;LDKMDLIFGAHGNAV; DKMDLIFGAHGNAVL; KMDLIFGAHGNAVLE; MDLIFGAHGNAVLEQ;DLIFGAHGNAVLEQY; LIFGAHGNAVLEQYM; IFGAHGNAVLEQYMA; FGAHGNAVLEQYMAG;GAHGNAVLEQYMAGV; AHGNAVLEQYMAGVA; HGNAVLEQYMAGVAW; GNAVLEQYMAGVAWL;NAVLEQYMAGVAWLH; AVLEQYMAGVAWLHC; VLEQYMAGVAWLHCL; LEQYMAGVAWLHCLL;EQYMAGVAWLHCLLP; QYMAGVAWLHCLLPK; YMAGVAWLHCLLPKM; MAGVAWLHCLLPKMD;AGVAWLHCLLPKMDS; GVAWLHCLLPKMDSV; VAWLHCLLPKMDSVI; AWLHCLLPKMDSVIF;WLHCLLPKMDSVIFD; LHCLLPKMDSVIFDF; HCLLPKMDSVIFDFL; CLLPKMDSVIFDFLH;LLPKMDSVIFDFLHC; LPKMDSVIFDFLHCI; PKMDSVIFDFLHCIV; KMDSVIFDFLHCIVF;MDSVIFDFLHCIVFN; DSVIFDFLHCIVFNV; SVIFDFLHCIVFNVP; VIFDFLHCIVFNVPK;IFDFLHCIVFNVPKR; FDFLHCIVFNVPKRR; DFLHCIVFNVPKRRY; FLHCIVFNVPKRRYW;LHCIVFNVPKRRYWL; HCIVFNVPKRRYWLF; CIVFNVPKRRYWLFK; IVFNVPKRRYWLFKG;VFNVPKRRYWLFKGP; FNVPKRRYWLFKGPI; NVPKRRYWLFKGPID; VPKRRYWLFKGPIDS;PKRRYWLFKGPIDSG; KRRYWLFKGPIDSGK; RRYWLFKGPIDSGKT; RYWLFKGPIDSGKTT;YWLFKGPIDSGKTTL; WLFKGPIDSGKTTLA; LFKGPIDSGKTTLAA; FKGPIDSGKTTLAAG;KGPIDSGKTTLAAGL; GPIDSGKTTLAAGLL; PIDSGKTTLAAGLLD; IDSGKTTLAAGLLDL;DSGKTTLAAGLLDLC; SGKTTLAAGLLDLCG; GKTTLAAGLLDLCGG; KTTLAAGLLDLCGGK;TTLAAGLLDLCGGKA; TLAAGLLDLCGGKAL; LAAGLLDLCGGKALN; AAGLLDLCGGKALNV;AGLLDLCGGKALNVN; GLLDLCGGKALNVNL; LLDLCGGKALNVNLP; LDLCGGKALNVNLPM;DLCGGKALNVNLPME; LCGGKALNVNLPMER; CGGKALNVNLPMERL; GGKALNVNLPMERLT;GKALNVNLPMERLTF; KALNVNLPMERLTFE; ALNVNLPMERLTFEL; LNVNLPMERLTFELG;NVNLPMERLTFELGV; VNLPMERLTFELGVA; NLPMERLTFELGVAI; LPMERLTFELGVAID;PMERLTFELGVAIDQ; MERLTFELGVAIDQY; ERLTFELGVAIDQYM; RLTFELGVAIDQYMV;LTFELGVAIDQYMVV; TFELGVAIDQYMVVF; FELGVAIDQYMVVFE; ELGVAIDQYMVVFED;LGVAIDQYMVVFEDV; GVAIDQYMVVFEDVK; VAIDQYMVVFEDVKG; AIDQYMVVFEDVKGT;IDQYMVVFEDVKGTG; DQYMVVFEDVKGTGA; QYMVVFEDVKGTGAE; YMVVFEDVKGTGAES;MVVFEDVKGTGAESK; VVFEDVKGTGAESKD; VFEDVKGTGAESKDL; FEDVKGTGAESKDLP;EDVKGTGAESKDLPS; DVKGTGAESKDLPSG; VKGTGAESKDLPSGH; KGTGAESKDLPSGHG;GTGAESKDLPSGHGI; TGAESKDLPSGHGIN; GAESKDLPSGHGINN; AESKDLPSGHGINNL;ESKDLPSGHGINNLD; SKDLPSGHGINNLDS; KDLPSGHGINNLDSL; DLPSGHGINNLDSLR;LPSGHGINNLDSLRD; PSGHGINNLDSLRDY; SGHGINNLDSLRDYL; GHGINNLDSLRDYLD;HGINNLDSLRDYLDG; GINNLDSLRDYLDGS; INNLDSLRDYLDGSV; NNLDSLRDYLDGSVK;NLDSLRDYLDGSVKV; LDSLRDYLDGSVKVN; DSLRDYLDGSVKVNL; SLRDYLDGSVKVNLE;LRDYLDGSVKVNLEK; RDYLDGSVKVNLEKK; DYLDGSVKVNLEKKH; YLDGSVKVNLEKKHL;LDGSVKVNLEKKHLN; DGSVKVNLEKKHLNK; GSVKVNLEKKHLNKR; SVKVNLEKKHLNKRT;VKVNLEKKHLNKRTQ; KVNLEKKHLNKRTQI; VNLEKKHLNKRTQIF; NLEKKHLNKRTQIFP;LEKKHLNKRTQIFPP; EKKHLNKRTQIFPPG; KKHLNKRTQIFPPGL; KHLNKRTQIFPPGLV;HLNKRTQIFPPGLVT; LNKRTQIFPPGLVTM; NKRTQIFPPGLVTMN; KRTQIFPPGLVTMNE;RTQIFPPGLVTMNEY; TQIFPPGLVTMNEYP; QIFPPGLVTMNEYPV; IFPPGLVTMNEYPVP;FPPGLVTMNEYPVPK; PPGLVTMNEYPVPKT; PGLVTMNEYPVPKTL; GLVTMNEYPVPKTLQ;LVTMNEYPVPKTLQA; VTMNEYPVPKTLQAR; TMNEYPVPKTLQARF; MNEYPVPKTLQARFV;NEYPVPKTLQARFVR; EYPVPKTLQARFVRQ; YPVPKTLQARFVRQI; PVPKTLQARFVRQID;VPKTLQARFVRQIDF; PKTLQARFVRQIDFR; KTLQARFVRQIDFRP; TLQARFVRQIDFRPK;LQARFVRQIDFRPKI; QARFVRQIDFRPKIY; ARFVRQIDFRPKIYL; RFVRQIDFRPKIYLR;FVRQIDFRPKIYLRK; VRQIDFRPKIYLRKS; RQIDFRPKIYLRKSL; QIDFRPKIYLRKSLQ;IDFRPKIYLRKSLQN; DFRPKIYLRKSLQNS; FRPKIYLRKSLQNSE; RPKIYLRKSLQNSEF;PKIYLRKSLQNSEFL; KIYLRKSLQNSEFLL; IYLRKSLQNSEFLLE; YLRKSLQNSEFLLEK;LRKSLQNSEFLLEKR; RKSLQNSEFLLEKRI; KSLQNSEFLLEKRIL; SLQNSEFLLEKRILQ;LQNSEFLLEKRILQS; QNSEFLLEKRILQSG; NSEFLLEKRILQSGM; SEFLLEKRILQSGMT;EFLLEKRILQSGMTL; FLLEKRILQSGMTLL; LLEKRILQSGMTLLL; LEKRILQSGMTLLLL;EKRILQSGMTLLLLL; KRILQSGMTLLLLLI; RILQSGMTLLLLLIW; ILQSGMTLLLLLIWF;LQSGMTLLLLLIWFR; QSGMTLLLLLIWFRP; SGMTLLLLLIWFRPV; GMTLLLLLIWFRPVA;MTLLLLLIWFRPVAD; TLLLLLIWFRPVADF; LLLLLIWFRPVADFA; LLLLIWFRPVADFAT;LLLIWFRPVADFATD; LLIWFRPVADFATDI; LIWFRPVADFATDIQ; IWFRPVADFATDIQS;WFRPVADFATDIQSR; FRPVADFATDIQSRI; RPVADFATDIQSRIV; PVADFATDIQSRIVE;VADFATDIQSRIVEW; ADFATDIQSRIVEWK; DFATDIQSRIVEWKE; FATDIQSRIVEWKER;ATDIQSRIVEWKERL; TDIQSRIVEWKERLD; DIQSRIVEWKERLDS; IQSRIVEWKERLDSE;QSRIVEWKERLDSEI; SRIVEWKERLDSEIS; RIVEWKERLDSEISM; IVEWKERLDSEISMY;VEWKERLDSEISMYT; EWKERLDSEISMYTF; WKERLDSEISMYTFS; KERLDSEISMYTFSR;ERLDSEISMYTFSRM; RLDSEISMYTFSRMK; LDSEISMYTFSRMKY; DSEISMYTFSRMKYN;SEISMYTFSRMKYNI; EISMYTFSRMKYNIC; ISMYTFSRMKYNICM; SMYTFSRMKYNICMG;MYTFSRMKYNICMGK; YTFSRMKYNICMGKC; TFSRMKYNICMGKCI; FSRMKYNICMGKCIL;SRMKYNICMGKCILD; RMKYNICMGKCILDI; MKYNICMGKCILDIT; KYNICMGKCILDITR;YNICMGKCILDITRE; NICMGKCILDITREE; ICMGKCILDITREED; CMGKCILDITREEDS;MGKCILDITREEDSE; GKCILDITREEDSET; KCILDITREEDSETE; CILDITREEDSETED;ILDITREEDSETEDS; LDITREEDSETEDSG; DITREEDSETEDSGH; ITREEDSETEDSGHG;TREEDSETEDSGHGS; REEDSETEDSGHGSS; EEDSETEDSGHGSST; EDSETEDSGHGSSTE;DSETEDSGHGSSTES; SETEDSGHGSSTESQ; ETEDSGHGSSTESQS; TEDSGHGSSTESQSQ;EDSGHGSSTESQSQC; DSGHGSSTESQSQCS; SGHGSSTESQSQCSS; GHGSSTESQSQCSSQ;HGSSTESQSQCSSQV; GSSTESQSQCSSQVS; SSTESQSQCSSQVSD; STESQSQCSSQVSDT;TESQSQCSSQVSDTS; ESQSQCSSQVSDTSA; SQSQCSSQVSDTSAP; QSQCSSQVSDTSAPA;SQCSSQVSDTSAPAE; QCSSQVSDTSAPAED; CSSQVSDTSAPAEDS; SSQVSDTSAPAEDSQ;SQVSDTSAPAEDSQR; QVSDTSAPAEDSQRS; VSDTSAPAEDSQRSD; SDTSAPAEDSQRSDP;DTSAPAEDSQRSDPH; TSAPAEDSQRSDPHS; SAPAEDSQRSDPHSQ; APAEDSQRSDPHSQE;PAEDSQRSDPHSQEL; AEDSQRSDPHSQELH; EDSQRSDPHSQELHL; DSQRSDPHSQELHLC;SQRSDPHSQELHLCK; QRSDPHSQELHLCKG; RSDPHSQELHLCKGF; SDPHSQELHLCKGFQ;DPHSQELHLCKGFQC; PHSQELHLCKGFQCF; HSQELHLCKGFQCFK; SQELHLCKGFQCFKR;QELHLCKGFQCFKRP; ELHLCKGFQCFKRPK; LHLCKGFQCFKRPKT; HLCKGFQCFKRPKTP;LCKGFQCFKRPKTPP; CKGFQCFKRPKTPPP; KGFQCFKRPKTPPPK; MYMYNKSTCLKHFGL;YMYNKSTCLKHFGLQ; MYNKSTCLKHFGLQL; YNKSTCLKHFGLQLS; NKSTCLKHFGLQLSL;KSTCLKHFGLQLSLF; STCLKHFGLQLSLFV; TCLKHFGLQLSLFVN; CLKHFGLQLSLFVNI;LKHFGLQLSLFVNIS; KHFGLQLSLFVNISY; HFGLQLSLFVNISYH; FGLQLSLFVNISYHI;GLQLSLFVNISYHIW; LQLSLFVNISYHIWV; QLSLFVNISYHIWVP; LSLFVNISYHIWVPW;SLFVNISYHIWVPWK; LFVNISYHIWVPWKS; FVNISYHIWVPWKSF; VNISYHIWVPWKSFC;NISYHIWVPWKSFCA; ISYHIWVPWKSFCAI; SYHIWVPWKSFCAIK; YHIWVPWKSFCAIKH;HIWVPWKSFCAIKHP; IWVPWKSFCAIKHPN; WVPWKSFCAIKHPNL; VPWKSFCAIKHPNLF;PWKSFCAIKHPNLFY; WKSFCAIKHPNLFYL; KSFCAIKHPNLFYLG; SFCAIKHPNLFYLGF;FCAIKHPNLFYLGFH; CAIKHPNLFYLGFHT; AIKHPNLFYLGFHTI; IKHPNLFYLGFHTIH;KHPNLFYLGFHTIHR; HPNLFYLGFHTIHRL; PNLFYLGFHTIHRLP; NLFYLGFHTIHRLPI;LFYLGFHTIHRLPIH; FYLGFHTIHRLPIHS; YLGFHTIHRLPIHSL; LGFHTIHRLPIHSLG;GFHTIHRLPIHSLGS; FHTIHRLPIHSLGSP; HTIHRLPIHSLGSPV; TIHRLPIHSLGSPVY;IHRLPIHSLGSPVYK; HRLPIHSLGSPVYKV; RLPIHSLGSPVYKVT; QKGNWVRILYRSFSQ;KGNWVRILYRSFSQA; GNWVRILYRSFSQAD; NWVRILYRSFSQADL; WVRILYRSFSQADLK;VRILYRSFSQADLKI; RILYRSFSQADLKIS; ILYRSFSQADLKISC; LYRSFSQADLKISCK;YRSFSQADLKISCKA; RSFSQADLKISCKAS; SFSQADLKISCKASP; FSQADLKISCKASPL;SQADLKISCKASPLL; QADLKISCKASPLLC; ADLKISCKASPLLCS; DLKISCKASPLLCSR;LKISCKASPLLCSRA; KISCKASPLLCSRAV; ISCKASPLLCSRAVS; SCKASPLLCSRAVSK;CKASPLLCSRAVSKQ; KASPLLCSRAVSKQA; ASPLLCSRAVSKQAT; SPLLCSRAVSKQATN;PLLCSRAVSKQATNI; LLCSRAVSKQATNIS; LCSRAVSKQATNISS; NIQAISFTKRPHTLF;IQAISFTKRPHTLFI; QHCGSCVGHMKYWGN; HCGSCVGHMKYWGNI; CGSCVGHMKYWGNIF;GSCVGHMKYWGNIFP; SCVGHMKYWGNIFPS; CVGHMKYWGNIFPSC; VGHMKYWGNIFPSCE;GHMKYWGNIFPSCES; HMKYWGNIFPSCESP; MKYWGNIFPSCESPK; KYWGNIFPSCESPKI;YWGNIFPSCESPKIP; WGNIFPSCESPKIPS; GNIFPSCESPKIPSI; NIFPSCESPKIPSIF;IFPSCESPKIPSIFI; FPSCESPKIPSIFIS; PSCESPKIPSIFIST; SCESPKIPSIFISTG;CESPKIPSIFISTGI; ESPKIPSIFISTGIR; SPKIPSIFISTGIRY; PKIPSIFISTGIRYP;KIPSIFISTGIRYPA; IPSIFISTGIRYPAL; PSIFISTGIRYPALN; SIFISTGIRYPALNW;IFISTGIRYPALNWI; FISTGIRYPALNWIS; ISTGIRYPALNWISI; STGIRYPALNWISIV;TGIRYPALNWISIVF; GIRYPALNWISIVFV; IRYPALNWISIVFVQ; RYPALNWISIVFVQI;YPALNWISIVFVQIG; PALNWISIVFVQIGL; ALNWISIVFVQIGLM; LNWISIVFVQIGLMV;NWISIVFVQIGLMVS; WISIVFVQIGLMVSI; ISIVFVQIGLMVSIH; SIVFVQIGLMVSIHY;IVFVQIGLMVSIHYL; VFVQIGLMVSIHYLG; FVQIGLMVSIHYLGL; VQIGLMVSIHYLGLG;QIGLMVSIHYLGLGC; IGLMVSIHYLGLGCW; GLMVSIHYLGLGCWV; LMVSIHYLGLGCWVF;MVSIHYLGLGCWVFR; VSIHYLGLGCWVFRG; SIHYLGLGCWVFRGY; IHYLGLGCWVFRGYS;HYLGLGCWVFRGYST; YLGLGCWVFRGYSTI; LGLGCWVFRGYSTIR; GLGCWVFRGYSTIRV;LGCWVFRGYSTIRVL; HSLHFQGFSTYSKEV; SLHFQGFSTYSKEVE; LHFQGFSTYSKEVEI;HFQGFSTYSKEVEIT; FQGFSTYSKEVEITA; QGFSTYSKEVEITAL; GFSTYSKEVEITALN;FSTYSKEVEITALNR; STYSKEVEITALNRF; TYSKEVEITALNRFS; YSKEVEITALNRFSS;SKEVEITALNRFSST; KEVEITALNRFSSTM; EVEITALNRFSSTML; VEITALNRFSSTMLM;EITALNRFSSTMLMH; ITALNRFSSTMLMHF; TALNRFSSTMLMHFL; PCMKVKHASYSNNLC;CMKVKHASYSNNLCL; MKVKHASYSNNLCLY; KVKHASYSNNLCLYS; VKHASYSNNLCLYSY;KHASYSNNLCLYSYS; HASYSNNLCLYSYSL; ASYSNNLCLYSYSLP; SYSNNLCLYSYSLPH;YSNNLCLYSYSLPHQ; IGEGNSCCAVTGKHF; GEGNSCCAVTGKHFS; EGNSCCAVTGKHFSL;GNSCCAVTGKHFSLW; NSCCAVTGKHFSLWA; SCCAVTGKHFSLWAI; CCAVTGKHFSLWAIT;CAVTGKHFSLWAITA; AVTGKHFSLWAITAK; VTGKHFSLWAITAKV; TGKHFSLWAITAKVI;GKHFSLWAITAKVIF; KHFSLWAITAKVIFS; HFSLWAITAKVIFST; TKAPKVFIWIPHFWV;EAFYLCNSIYPSFNF; FWHLHGFLWLFGSCP; WHLHGFLWLFGSCPW; HLHGFLWLFGSCPWT;LHGFLWLFGSCPWTL; HGFLWLFGSCPWTLS; GFLWLFGSCPWTLSF; FLWLFGSCPWTLSFS;LWLFGSCPWTLSFSF; WLFGSCPWTLSFSFG; LFGSCPWTLSFSFGW; FGSCPWTLSFSFGWG;GSCPWTLSFSFGWGH; SCPWTLSFSFGWGHL; CPWTLSFSFGWGHLH; PWTLSFSFGWGHLHM;WTLSFSFGWGHLHML; TLSFSFGWGHLHMLQ; LSFSFGWGHLHMLQE; SFSFGWGHLHMLQEQ;FSFGWGHLHMLQEQV; SFGWGHLHMLQEQVL; FGWGHLHMLQEQVLQ; GWGHLHMLQEQVLQS;WGHLHMLQEQVLQSR; GHLHMLQEQVLQSRT; HLHMLQEQVLQSRTG; LHMLQEQVLQSRTGL;HMLQEQVLQSRTGLE; MLQEQVLQSRTGLEV; LQEQVLQSRTGLEVK; QEQVLQSRTGLEVKA;EQVLQSRTGLEVKAT; QVLQSRTGLEVKATS; VLQSRTGLEVKATSI; LQSRTGLEVKATSIE;QSRTGLEVKATSIEE; SRTGLEVKATSIEEQ; RTGLEVKATSIEEQF; TGLEVKATSIEEQFF;GLEVKATSIEEQFFD; TLLNVHFVDFLSPFF; LLNVHFVDFLSPFFV; LLLYCQHHLYYKYGQ;LLYCQHHLYYKYGQN; LYCQHHLYYKYGQNV; YCQHHLYYKYGQNVH; CQHHLYYKYGQNVHG;QHHLYYKYGQNVHGY; HHLYYKYGQNVHGYL; HLYYKYGQNVHGYLP; LYYKYGQNVHGYLPF;YYKYGQNVHGYLPFQ; YKYGQNVHGYLPFQL; KYGQNVHGYLPFQLL; YGQNVHGYLPFQLLV;GKDQNNIVEYNYKSL; QKYLHQETEYHSTHL; KYLHQETEYHSTHLG; TIPKPCLIADRGLQW;IPKPCLIADRGLQWK; PKPCLIADRGLQWKL; KPCLIADRGLQWKLC; PCLIADRGLQWKLCD;CLIADRGLQWKLCDP; LIADRGLQWKLCDPN; IADRGLQWKLCDPNH; ADRGLQWKLCDPNHQ;DRGLQWKLCDPNHQR; RGLQWKLCDPNHQRT; GLQWKLCDPNHQRTY; LQWKLCDPNHQRTYT;QWKLCDPNHQRTYTL; WKLCDPNHQRTYTLL; KLCDPNHQRTYTLLE; LCDPNHQRTYTLLEL;CDPNHQRTYTLLELR; DPNHQRTYTLLELRN; PQEHQQLQHMFEELG; QEHQQLQHMFEELGL;QQQPPQQQFQPLKIL; QQPPQQQFQPLKILW; QPPQQQFQPLKILWQ; PPQQQFQPLKILWQQ;PQQQFQPLKILWQQQ; QQQFQPLKILWQQQP; QQFQPLKILWQQQPQ; QFQPLKILWQQQPQI;FQPLKILWQQQPQIH; QPLKILWQQQPQIHW; PLKILWQQQPQIHWQ; LKILWQQQPQIHWQL;KILWQQQPQIHWQLG; ILWQQQPQIHWQLGP; LWQQQPQIHWQLGPP; WQQQPQIHWQLGPPK;QQQPQIHWQLGPPKV; QQPQIHWQLGPPKVL; QPQIHWQLGPPKVLE; PQIHWQLGPPKVLEQ;QIHWQLGPPKVLEQH; IHWQLGPPKVLEQHP; TWKYKKKGITYLGVF; WKYKKKGITYLGVFY;KYKKKGITYLGVFYR; YKKKGITYLGVFYRV; KKKGITYLGVFYRVF; KKGITYLGVFYRVFY;KGITYLGVFYRVFYS; GITYLGVFYRVFYSR; SSGTFVFPVYTVFTS; SGTFVFPVYTVFTST;GTFVFPVYTVFTSTK; TFVFPVYTVFTSTKF; FVFPVYTVFTSTKFQ; VFPVYTVFTSTKFQQ;FPVYTVFTSTKFQQK; PVYTVFTSTKFQQKL; NKNKNPLSSFFCSSP; KNKNPLSSFFCSSPG;NKNPLSSFFCSSPGF; KNPLSSFFCSSPGFT; NPLSSFFCSSPGFTN; PLSSFFCSSPGFTNF;LSSFFCSSPGFTNFH; LGTRPRFLGSQNMSV; GTRPRFLGSQNMSVM; TRPRFLGSQNMSVMH;RPRFLGSQNMSVMHF; PRFLGSQNMSVMHFP; RFLGSQNMSVMHFPS; AAPPCESCTFLPEVM;APPCESCTFLPEVMV; PPCESCTFLPEVMVW; PCESCTFLPEVMVWL; CESCTFLPEVMVWLH;ESCTFLPEVMVWLHS; SCTFLPEVMVWLHSP; CTFLPEVMVWLHSPV; TFLPEVMVWLHSPVS;FLPEVMVWLHSPVSH; LPEVMVWLHSPVSHA; PEVMVWLHSPVSHAL; EVMVWLHSPVSHALS;VMVWLHSPVSHALSF; MVWLHSPVSHALSFL; VWLHSPVSHALSFLR; WLHSPVSHALSFLRS;LHSPVSHALSFLRSW; HSPVSHALSFLRSWF; SPVSHALSFLRSWFG; PVSHALSFLRSWFGC;VSHALSFLRSWFGCI; SHALSFLRSWFGCIP; HALSFLRSWFGCIPW; ALSFLRSWFGCIPWV;LSFLRSWFGCIPWVS; SFLRSWFGCIPWVSS; FLRSWFGCIPWVSSS; LRSWFGCIPWVSSSS;RSWFGCIPWVSSSSL; SWFGCIPWVSSSSLW; WFGCIPWVSSSSLWP; FGCIPWVSSSSLWPF;GCIPWVSSSSLWPFF; CIPWVSSSSLWPFFL; YIRGRGRLCLHPFSQ; IRGRGRLCLHPFSQV;RGRGRLCLHPFSQVV; GRGRLCLHPFSQVVR; RGRLCLHPFSQVVRV; GRLCLHPFSQVVRVW;RLCLHPFSQVVRVWR; LCLHPFSQVVRVWRL; CLHPFSQVVRVWRLF; LHPFSQVVRVWRLFL;HPFSQVVRVWRLFLR; PFSQVVRVWRLFLRP; FSQVVRVWRLFLRPS; SQVVRVWRLFLRPSK;QVVRVWRLFLRPSKT; VVRVWRLFLRPSKTI; VRVWRLFLRPSKTIW; RVWRLFLRPSKTIWG;VWRLFLRPSKTIWGN; WRLFLRPSKTIWGNP; RLFLRPSKTIWGNPY; LFLRPSKTIWGNPYS;FLRPSKTIWGNPYSF; LRPSKTIWGNPYSFA; RPSKTIWGNPYSFAI; PSKTIWGNPYSFAIF;SKTIWGNPYSFAIFA; KTIWGNPYSFAIFAK 16 mers: KSCLGKSSLNEKSLFK;SCLGKSSLNEKSLFKE; CLGKSSLNEKSLFKEV; FSSLPRYPVLQGMAYL; SSLPRYPVLQGMAYLF;SLPRYPVLQGMAYLFQ; LPRYPVLQGMAYLFQK; PRYPVLQGMAYLFQKA; RYPVLQGMAYLFQKAF;YPVLQGMAYLFQKAFC; PVLQGMAYLFQKAFCA; VLQGMAYLFQKAFCAL; LQGMAYLFQKAFCALP;QGMAYLFQKAFCALPL; GMAYLFQKAFCALPLH; MAYLFQKAFCALPLHA; AYLFQKAFCALPLHAM;YLFQKAFCALPLHAMS; LFQKAFCALPLHAMSA; KIFKKRALGLDRLLLH; RNSAMVGPNNWRNSLQ;NSAMVGPNNWRNSLQR; SAMVGPNNWRNSLQRS; AMVGPNNWRNSLQRSK; MVGPNNWRNSLQRSKA;VGPNNWRNSLQRSKAL; GPNNWRNSLQRSKALR; VPTYGTEEWESWWSSF; PTYGTEEWESWWSSFN;TYGTEEWESWWSSFNE; YGTEEWESWWSSFNEK; GTEEWESWWSSFNEKW; TEEWESWWSSFNEKWD;EEWESWWSSFNEKWDE; EWESWWSSFNEKWDED; WESWWSSFNEKWDEDL; ESWWSSFNEKWDEDLF;SWWSSFNEKWDEDLFC; WWSSFNEKWDEDLFCH; WSSFNEKWDEDLFCHE; SSFNEKWDEDLFCHED;SFNEKWDEDLFCHEDM; FNEKWDEDLFCHEDMF; NEKWDEDLFCHEDMFA; EKWDEDLFCHEDMFAS;KWDEDLFCHEDMFASD; WDEDLFCHEDMFASDE; DEDLFCHEDMFASDEE; EDLFCHEDMFASDEEA;DLFCHEDMFASDEEAT; LFCHEDMFASDEEATA; FCHEDMFASDEEATAD; CHEDMFASDEEATADS;HEDMFASDEEATADSQ; EDMFASDEEATADSQH; DMFASDEEATADSQHS; MFASDEEATADSQHST;FASDEEATADSQHSTP; ASDEEATADSQHSTPP; SDEEATADSQHSTPPK; DEEATADSQHSTPPKK;EEATADSQHSTPPKKK; EATADSQHSTPPKKKR; ATADSQHSTPPKKKRK; TADSQHSTPPKKKRKV;ADSQHSTPPKKKRKVE; DSQHSTPPKKKRKVED; SQHSTPPKKKRKVEDP; QHSTPPKKKRKVEDPK;HSTPPKKKRKVEDPKD; STPPKKKRKVEDPKDF; TPPKKKRKVEDPKDFP; PPKKKRKVEDPKDFPS;PKKKRKVEDPKDFPSD; KKKRKVEDPKDFPSDL; KKRKVEDPKDFPSDLH; KRKVEDPKDFPSDLHQ;RKVEDPKDFPSDLHQF; KVEDPKDFPSDLHQFL; VEDPKDFPSDLHQFLS; EDPKDFPSDLHQFLSQ;DPKDFPSDLHQFLSQA; PKDFPSDLHQFLSQAV; KDFPSDLHQFLSQAVF; DFPSDLHQFLSQAVFS;FPSDLHQFLSQAVFSN; PSDLHQFLSQAVFSNR; SDLHQFLSQAVFSNRT; DLHQFLSQAVFSNRTL;LHQFLSQAVFSNRTLA; HQFLSQAVFSNRTLAC; QFLSQAVFSNRTLACF; FLSQAVFSNRTLACFA;LSQAVFSNRTLACFAV; SQAVFSNRTLACFAVY; QAVFSNRTLACFAVYT; AVFSNRTLACFAVYTT;VFSNRTLACFAVYTTK; FSNRTLACFAVYTTKE; SNRTLACFAVYTTKEK; NRTLACFAVYTTKEKA;RTLACFAVYTTKEKAQ; TLACFAVYTTKEKAQI; LACFAVYTTKEKAQIL; ACFAVYTTKEKAQILY;CFAVYTTKEKAQILYK; FAVYTTKEKAQILYKK; AVYTTKEKAQILYKKL; VYTTKEKAQILYKKLM;YTTKEKAQILYKKLME; TTKEKAQILYKKLMEK; TKEKAQILYKKLMEKY; KEKAQILYKKLMEKYS;EKAQILYKKLMEKYSV; KAQILYKKLMEKYSVT; AQILYKKLMEKYSVTF; QILYKKLMEKYSVTFI;ILYKKLMEKYSVTFIS; LYKKLMEKYSVTFISR; YKKLMEKYSVTFISRH; KKLMEKYSVTFISRHM;KLMEKYSVTFISRHMC; LMEKYSVTFISRHMCA; MEKYSVTFISRHMCAG; EKYSVTFISRHMCAGH;KYSVTFISRHMCAGHN; YSVTFISRHMCAGHNI; SVTFISRHMCAGHNII; VTFISRHMCAGHNIIF;TFISRHMCAGHNIIFF; FISRHMCAGHNIIFFL; ISRHMCAGHNIIFFLT; SRHMCAGHNIIFFLTP;RHMCAGHNIIFFLTPH; HMCAGHNIIFFLTPHR; MCAGHNIIFFLTPHRH; CAGHNIIFFLTPHRHR;AGHNIIFFLTPHRHRV; GHNIIFFLTPHRHRVS; HNIIFFLTPHRHRVSA; NIIFFLTPHRHRVSAI;IIFFLTPHRHRVSAIN; IFFLTPHRHRVSAINN; FFLTPHRHRVSAINNF; FLTPHRHRVSAINNFC;LTPHRHRVSAINNFCQ; TPHRHRVSAINNFCQK; PHRHRVSAINNFCQKL; HRHRVSAINNFCQKLC;RHRVSAINNFCQKLCT; HRVSAINNFCQKLCTF; RVSAINNFCQKLCTFS; VSAINNFCQKLCTFSF;SAINNFCQKLCTFSFL; AINNFCQKLCTFSFLI; INNFCQKLCTFSFLIC; NNFCQKLCTFSFLICK;NFCQKLCTFSFLICKG; FCQKLCTFSFLICKGV; CQKLCTFSFLICKGVN; QKLCTFSFLICKGVNK;KLCTFSFLICKGVNKE; LCTFSFLICKGVNKEY; CTFSFLICKGVNKEYL; TFSFLICKGVNKEYLL;FSFLICKGVNKEYLLY; SFLICKGVNKEYLLYS; FLICKGVNKEYLLYSA; LICKGVNKEYLLYSAL;ICKGVNKEYLLYSALT; CKGVNKEYLLYSALTR; KGVNKEYLLYSALTRD; GVNKEYLLYSALTRDP;VNKEYLLYSALTRDPY; NKEYLLYSALTRDPYH; KEYLLYSALTRDPYHT; EYLLYSALTRDPYHTI;YLLYSALTRDPYHTIE; LLYSALTRDPYHTIEE; LYSALTRDPYHTIEES; YSALTRDPYHTIEESI;SALTRDPYHTIEESIQ; ALTRDPYHTIEESIQG; LTRDPYHTIEESIQGG; TRDPYHTIEESIQGGL;RDPYHTIEESIQGGLK; DPYHTIEESIQGGLKE; PYHTIEESIQGGLKEH; YHTIEESIQGGLKEHD;HTIEESIQGGLKEHDF; TIEESIQGGLKEHDFS; IEESIQGGLKEHDFSP; EESIQGGLKEHDFSPE;ESIQGGLKEHDFSPEE; SIQGGLKEHDFSPEEP; IQGGLKEHDFSPEEPE; QGGLKEHDFSPEEPEE;GGLKEHDFSPEEPEET; GLKEHDFSPEEPEETK; LKEHDFSPEEPEETKQ; KEHDFSPEEPEETKQV;EHDFSPEEPEETKQVS; HDFSPEEPEETKQVSW; DFSPEEPEETKQVSWK; FSPEEPEETKQVSWKL;SPEEPEETKQVSWKLI; PEEPEETKQVSWKLIT; EEPEETKQVSWKLITE; EPEETKQVSWKLITEY;PEETKQVSWKLITEYA; EETKQVSWKLITEYAV; ETKQVSWKLITEYAVE; TKQVSWKLITEYAVET;KQVSWKLITEYAVETK; QVSWKLITEYAVETKC; VSWKLITEYAVETKCE; SWKLITEYAVETKCED;WKLITEYAVETKCEDV; KLITEYAVETKCEDVF; LITEYAVETKCEDVFL; ITEYAVETKCEDVFLL;TEYAVETKCEDVFLLL; EYAVETKCEDVFLLLG; YAVETKCEDVFLLLGM; AVETKCEDVFLLLGMY;VETKCEDVFLLLGMYL; ETKCEDVFLLLGMYLE; TKCEDVFLLLGMYLEF; KCEDVFLLLGMYLEFQ;CEDVFLLLGMYLEFQY; EDVFLLLGMYLEFQYN; DVFLLLGMYLEFQYNV; VFLLLGMYLEFQYNVE;FLLLGMYLEFQYNVEE; LLLGMYLEFQYNVEEC; LLGMYLEFQYNVEECK; LGMYLEFQYNVEECKK;GMYLEFQYNVEECKKC; MYLEFQYNVEECKKCQ; YLEFQYNVEECKKCQK; LEFQYNVEECKKCQKK;EFQYNVEECKKCQKKD; FQYNVEECKKCQKKDQ; QYNVEECKKCQKKDQP; YNVEECKKCQKKDQPY;NVEECKKCQKKDQPYH; VEECKKCQKKDQPYHF; EECKKCQKKDQPYHFK; ECKKCQKKDQPYHFKY;CKKCQKKDQPYHFKYH; KKCQKKDQPYHFKYHE; KCQKKDQPYHFKYHEK; CQKKDQPYHFKYHEKH;QKKDQPYHFKYHEKHF; KKDQPYHFKYHEKHFA; KDQPYHFKYHEKHFAN; DQPYHFKYHEKHFANA;QPYHFKYHEKHFANAI; PYHFKYHEKHFANAII; YHFKYHEKHFANAIIF; HFKYHEKHFANAIIFA;FKYHEKHFANAIIFAE; KYHEKHFANAIIFAES; YHEKHFANAIIFAESK; HEKHFANAIIFAESKN;EKHFANAIIFAESKNQ; KHFANAIIFAESKNQK; HFANAIIFAESKNQKS; FANAIIFAESKNQKSI;ANAIIFAESKNQKSIC; NAIIFAESKNQKSICQ; AIIFAESKNQKSICQQ; IIFAESKNQKSICQQA;IFAESKNQKSICQQAV; FAESKNQKSICQQAVD; AESKNQKSICQQAVDT; ESKNQKSICQQAVDTV;SKNQKSICQQAVDTVL; KNQKSICQQAVDTVLA; NQKSICQQAVDTVLAK; QKSICQQAVDTVLAKK;KSICQQAVDTVLAKKR; SICQQAVDTVLAKKRV; ICQQAVDTVLAKKRVD; CQQAVDTVLAKKRVDT;QQAVDTVLAKKRVDTL; QAVDTVLAKKRVDTLH; AVDTVLAKKRVDTLHM; VDTVLAKKRVDTLHMT;DTVLAKKRVDTLHMTR; TVLAKKRVDTLHMTRE; VLAKKRVDTLHMTREE; LAKKRVDTLHMTREEM;AKKRVDTLHMTREEML; KKRVDTLHMTREEMLT; KRVDTLHMTREEMLTE; RVDTLHMTREEMLTER;VDTLHMTREEMLTERF; DTLHMTREEMLTERFN; TLHMTREEMLTERFNH; LHMTREEMLTERFNHI;HMTREEMLTERFNHIL; MTREEMLTERFNHILD; TREEMLTERFNHILDK; REEMLTERFNHILDKM;EEMLTERFNHILDKMD; EMLTERFNHILDKMDL; MLTERFNHILDKMDLI; LTERFNHILDKMDLIF;TERFNHILDKMDLIFG; ERFNHILDKMDLIFGA; RFNHILDKMDLIFGAH; FNHILDKMDLIFGAHG;NHILDKMDLIFGAHGN; HILDKMDLIFGAHGNA; ILDKMDLIFGAHGNAV; LDKMDLIFGAHGNAVL;DKMDLIFGAHGNAVLE; KMDLIFGAHGNAVLEQ; MDLIFGAHGNAVLEQY; DLIFGAHGNAVLEQYM;LIFGAHGNAVLEQYMA; IFGAHGNAVLEQYMAG; FGAHGNAVLEQYMAGV; GAHGNAVLEQYMAGVA;AHGNAVLEQYMAGVAW; HGNAVLEQYMAGVAWL; GNAVLEQYMAGVAWLH; NAVLEQYMAGVAWLHC;AVLEQYMAGVAWLHCL; VLEQYMAGVAWLHCLL; LEQYMAGVAWLHCLLP; EQYMAGVAWLHCLLPK;QYMAGVAWLHCLLPKM; YMAGVAWLHCLLPKMD; MAGVAWLHCLLPKMDS; AGVAWLHCLLPKMDSV;GVAWLHCLLPKMDSVI; VAWLHCLLPKMDSVIF; AWLHCLLPKMDSVIFD; WLHCLLPKMDSVIFDF;LHCLLPKMDSVIFDFL; HCLLPKMDSVIFDFLH; CLLPKMDSVIFDFLHC; LLPKMDSVIFDFLHCI;LPKMDSVIFDFLHCIV; PKMDSVIFDFLHCIVF; KMDSVIFDFLHCIVFN; MDSVIFDFLHCIVFNV;DSVIFDFLHCIVFNVP; SVIFDFLHCIVFNVPK; VIFDFLHCIVFNVPKR; IFDFLHCIVFNVPKRR;FDFLHCIVFNVPKRRY; DFLHCIVFNVPKRRYW; FLHCIVFNVPKRRYWL; LHCIVFNVPKRRYWLF;HCIVFNVPKRRYWLFK; CIVFNVPKRRYWLFKG; IVFNVPKRRYWLFKGP; VFNVPKRRYWLFKGPI;FNVPKRRYWLFKGPID; NVPKRRYWLFKGPIDS; VPKRRYWLFKGPIDSG; PKRRYWLFKGPIDSGK;KRRYWLFKGPIDSGKT; RRYWLFKGPIDSGKTT; RYWLFKGPIDSGKTTL; YWLFKGPIDSGKTTLA;WLFKGPIDSGKTTLAA; LFKGPIDSGKTTLAAG; FKGPIDSGKTTLAAGL; KGPIDSGKTTLAAGLL;GPIDSGKTTLAAGLLD; PIDSGKTTLAAGLLDL; IDSGKTTLAAGLLDLC; DSGKTTLAAGLLDLCG;SGKTTLAAGLLDLCGG; GKTTLAAGLLDLCGGK; KTTLAAGLLDLCGGKA; TTLAAGLLDLCGGKAL;TLAAGLLDLCGGKALN; LAAGLLDLCGGKALNV; AAGLLDLCGGKALNVN; AGLLDLCGGKALNVNL;GLLDLCGGKALNVNLP; LLDLCGGKALNVNLPM; LDLCGGKALNVNLPME; DLCGGKALNVNLPMER;LCGGKALNVNLPMERL; CGGKALNVNLPMERLT; GGKALNVNLPMERLTF; GKALNVNLPMERLTFE;KALNVNLPMERLTFEL; ALNVNLPMERLTFELG; LNVNLPMERLTFELGV; NVNLPMERLTFELGVA;VNLPMERLTFELGVAI; NLPMERLTFELGVAID; LPMERLTFELGVAIDQ; PMERLTFELGVAIDQY;MERLTFELGVAIDQYM; ERLTFELGVAIDQYMV; RLTFELGVAIDQYMVV; LTFELGVAIDQYMVVF;TFELGVAIDQYMVVFE; FELGVAIDQYMVVFED; ELGVAIDQYMVVFEDV; LGVAIDQYMVVFEDVK;GVAIDQYMVVFEDVKG; VAIDQYMVVFEDVKGT; AIDQYMVVFEDVKGTG; IDQYMVVFEDVKGTGA;DQYMVVFEDVKGTGAE; QYMVVFEDVKGTGAES; YMVVFEDVKGTGAESK; MVVFEDVKGTGAESKD;VVFEDVKGTGAESKDL; VFEDVKGTGAESKDLP; FEDVKGTGAESKDLPS; EDVKGTGAESKDLPSG;DVKGTGAESKDLPSGH; VKGTGAESKDLPSGHG; KGTGAESKDLPSGHGI; GTGAESKDLPSGHGIN;TGAESKDLPSGHGINN; GAESKDLPSGHGINNL; AESKDLPSGHGINNLD; ESKDLPSGHGINNLDS;SKDLPSGHGINNLDSL; KDLPSGHGINNLDSLR; DLPSGHGINNLDSLRD; LPSGHGINNLDSLRDY;PSGHGINNLDSLRDYL; SGHGINNLDSLRDYLD; GHGINNLDSLRDYLDG; HGINNLDSLRDYLDGS;GINNLDSLRDYLDGSV; INNLDSLRDYLDGSVK; NNLDSLRDYLDGSVKV; NLDSLRDYLDGSVKVN;LDSLRDYLDGSVKVNL; DSLRDYLDGSVKVNLE; SLRDYLDGSVKVNLEK; LRDYLDGSVKVNLEKK;RDYLDGSVKVNLEKKH; DYLDGSVKVNLEKKHL; YLDGSVKVNLEKKHLN; LDGSVKVNLEKKHLNK;DGSVKVNLEKKHLNKR; GSVKVNLEKKHLNKRT; SVKVNLEKKHLNKRTQ; VKVNLEKKHLNKRTQI;KVNLEKKHLNKRTQIF; VNLEKKHLNKRTQIFP; NLEKKHLNKRTQIFPP; LEKKHLNKRTQIFPPG;EKKHLNKRTQIFPPGL; KKHLNKRTQIFPPGLV; KHLNKRTQIFPPGLVT; HLNKRTQIFPPGLVTM;LNKRTQIFPPGLVTMN; NKRTQIFPPGLVTMNE; KRTQIFPPGLVTMNEY; RTQIFPPGLVTMNEYP;TQIFPPGLVTMNEYPV; QIFPPGLVTMNEYPVP; IFPPGLVTMNEYPVPK; FPPGLVTMNEYPVPKT;PPGLVTMNEYPVPKTL; PGLVTMNEYPVPKTLQ; GLVTMNEYPVPKTLQA; LVTMNEYPVPKTLQAR;VTMNEYPVPKTLQARF; TMNEYPVPKTLQARFV; MNEYPVPKTLQARFVR; NEYPVPKTLQARFVRQ;EYPVPKTLQARFVRQI; YPVPKTLQARFVRQID; PVPKTLQARFVRQIDF; VPKTLQARFVRQIDFR;PKTLQARFVRQIDFRP; KTLQARFVRQIDFRPK; TLQARFVRQIDFRPKI; LQARFVRQIDFRPKIY;QARFVRQIDFRPKIYL; ARFVRQIDFRPKIYLR; RFVRQIDFRPKIYLRK; FVRQIDFRPKIYLRKS;VRQIDFRPKIYLRKSL; RQIDFRPKIYLRKSLQ; QIDFRPKIYLRKSLQN; IDFRPKIYLRKSLQNS;DFRPKIYLRKSLQNSE; FRPKIYLRKSLQNSEF; RPKIYLRKSLQNSEFL; PKIYLRKSLQNSEFLL;KIYLRKSLQNSEFLLE; IYLRKSLQNSEFLLEK; YLRKSLQNSEFLLEKR; LRKSLQNSEFLLEKRI;RKSLQNSEFLLEKRIL; KSLQNSEFLLEKRILQ; SLQNSEFLLEKRILQS; LQNSEFLLEKRILQSG;QNSEFLLEKRILQSGM; NSEFLLEKRILQSGMT; SEFLLEKRILQSGMTL; EFLLEKRILQSGMTLL;FLLEKRILQSGMTLLL; LLEKRILQSGMTLLLL; LEKRILQSGMTLLLLL; EKRILQSGMTLLLLLI;KRILQSGMTLLLLLIW; RILQSGMTLLLLLIWF; ILQSGMTLLLLLIWFR; LQSGMTLLLLLIWFRP;QSGMTLLLLLIWFRPV; SGMTLLLLLIWFRPVA; GMTLLLLLIWFRPVAD; MTLLLLLIWFRPVADF;TLLLLLIWFRPVADFA; LLLLLIWFRPVADFAT; LLLLIWFRPVADFATD; LLLIWFRPVADFATDI;LLIWFRPVADFATDIQ; LIWFRPVADFATDIQS; IWFRPVADFATDIQSR; WFRPVADFATDIQSRI;FRPVADFATDIQSRIV; RPVADFATDIQSRIVE; PVADFATDIQSRIVEW; VADFATDIQSRIVEWK;ADFATDIQSRIVEWKE; DFATDIQSRIVEWKER; FATDIQSRIVEWKERL; ATDIQSRIVEWKERLD;TDIQSRIVEWKERLDS; DIQSRIVEWKERLDSE; IQSRIVEWKERLDSEI; QSRIVEWKERLDSEIS;SRIVEWKERLDSEISM; RIVEWKERLDSEISMY; IVEWKERLDSEISMYT; VEWKERLDSEISMYTF;EWKERLDSEISMYTFS; WKERLDSEISMYTFSR; KERLDSEISMYTFSRM; ERLDSEISMYTFSRMK;RLDSEISMYTFSRMKY; LDSEISMYTFSRMKYN; DSEISMYTFSRMKYNI; SEISMYTFSRMKYNIC;EISMYTFSRMKYNICM; ISMYTFSRMKYNICMG; SMYTFSRMKYNICMGK; MYTFSRMKYNICMGKC;YTFSRMKYNICMGKCI; TFSRMKYNICMGKCIL; FSRMKYNICMGKCILD; SRMKYNICMGKCILDI;RMKYNICMGKCILDIT; MKYNICMGKCILDITR; KYNICMGKCILDITRE; YNICMGKCILDITREE;NICMGKCILDITREED; ICMGKCILDITREEDS; CMGKCILDITREEDSE; MGKCILDITREEDSET;GKCILDITREEDSETE; KCILDITREEDSETED; CILDITREEDSETEDS; ILDITREEDSETEDSG;LDITREEDSETEDSGH; DITREEDSETEDSGHG; ITREEDSETEDSGHGS; TREEDSETEDSGHGSS;REEDSETEDSGHGSST; EEDSETEDSGHGSSTE; EDSETEDSGHGSSTES; DSETEDSGHGSSTESQ;SETEDSGHGSSTESQS; ETEDSGHGSSTESQSQ; TEDSGHGSSTESQSQC; EDSGHGSSTESQSQCS;DSGHGSSTESQSQCSS; SGHGSSTESQSQCSSQ; GHGSSTESQSQCSSQV; HGSSTESQSQCSSQVS;GSSTESQSQCSSQVSD; SSTESQSQCSSQVSDT; STESQSQCSSQVSDTS; TESQSQCSSQVSDTSA;ESQSQCSSQVSDTSAP; SQSQCSSQVSDTSAPA; QSQCSSQVSDTSAPAE; SQCSSQVSDTSAPAED;QCSSQVSDTSAPAEDS; CSSQVSDTSAPAEDSQ; SSQVSDTSAPAEDSQR; SQVSDTSAPAEDSQRS;QVSDTSAPAEDSQRSD; VSDTSAPAEDSQRSDP; SDTSAPAEDSQRSDPH; DTSAPAEDSQRSDPHS;TSAPAEDSQRSDPHSQ; SAPAEDSQRSDPHSQE; APAEDSQRSDPHSQEL; PAEDSQRSDPHSQELH;AEDSQRSDPHSQELHL; EDSQRSDPHSQELHLC; DSQRSDPHSQELHLCK; SQRSDPHSQELHLCKG;QRSDPHSQELHLCKGF; RSDPHSQELHLCKGFQ; SDPHSQELHLCKGFQC; DPHSQELHLCKGFQCF;PHSQELHLCKGFQCFK; HSQELHLCKGFQCFKR; SQELHLCKGFQCFKRP; QELHLCKGFQCFKRPK;ELHLCKGFQCFKRPKT; LHLCKGFQCFKRPKTP; HLCKGFQCFKRPKTPP; LCKGFQCFKRPKTPPP;CKGFQCFKRPKTPPPK; MYMYNKSTCLKHFGLQ; YMYNKSTCLKHFGLQL; MYNKSTCLKHFGLQLS;YNKSTCLKHFGLQLSL; NKSTCLKHFGLQLSLF; KSTCLKHFGLQLSLFV; STCLKHFGLQLSLFVN;TCLKHFGLQLSLFVNI; CLKHFGLQLSLFVNIS; LKHFGLQLSLFVNISY; KHFGLQLSLFVNISYH;HFGLQLSLFVNISYHI; FGLQLSLFVNISYHIW; GLQLSLFVNISYHIWV; LQLSLFVNISYHIWVP;QLSLFVNISYHIWVPW; LSLFVNISYHIWVPWK; SLFVNISYHIWVPWKS; LFVNISYHIWVPWKSF;FVNISYHIWVPWKSFC; VNISYHIWVPWKSFCA; NISYHIWVPWKSFCAI; ISYHIWVPWKSFCAIK;SYHIWVPWKSFCAIKH; YHIWVPWKSFCAIKHP; HIWVPWKSFCAIKHPN; IWVPWKSFCAIKHPNL;WVPWKSFCAIKHPNLF; VPWKSFCAIKHPNLFY; PWKSFCAIKHPNLFYL; WKSFCAIKHPNLFYLG;KSFCAIKHPNLFYLGF; SFCAIKHPNLFYLGFH; FCAIKHPNLFYLGFHT; CAIKHPNLFYLGFHTI;AIKHPNLFYLGFHTIH; IKHPNLFYLGFHTIHR; KHPNLFYLGFHTIHRL; HPNLFYLGFHTIHRLP;PNLFYLGFHTIHRLPI; NLFYLGFHTIHRLPIH; LFYLGFHTIHRLPIHS; FYLGFHTIHRLPIHSL;YLGFHTIHRLPIHSLG; LGFHTIHRLPIHSLGS; GFHTIHRLPIHSLGSP; FHTIHRLPIHSLGSPV;HTIHRLPIHSLGSPVY; TIHRLPIHSLGSPVYK; IHRLPIHSLGSPVYKV; HRLPIHSLGSPVYKVT;QKGNWVRILYRSFSQA; KGNWVRILYRSFSQAD; GNWVRILYRSFSQADL; NWVRILYRSFSQADLK;WVRILYRSFSQADLKI; VRILYRSFSQADLKIS; RILYRSFSQADLKISC; ILYRSFSQADLKISCK;LYRSFSQADLKISCKA; YRSFSQADLKISCKAS; RSFSQADLKISCKASP; SFSQADLKISCKASPL;FSQADLKISCKASPLL; SQADLKISCKASPLLC; QADLKISCKASPLLCS; ADLKISCKASPLLCSR;DLKISCKASPLLCSRA; LKISCKASPLLCSRAV; KISCKASPLLCSRAVS; ISCKASPLLCSRAVSK;SCKASPLLCSRAVSKQ; CKASPLLCSRAVSKQA; KASPLLCSRAVSKQAT; ASPLLCSRAVSKQATN;SPLLCSRAVSKQATNI; PLLCSRAVSKQATNIS; LLCSRAVSKQATNISS; NIQAISFTKRPHTLFI;QHCGSCVGHMKYWGNI; HCGSCVGHMKYWGNIF; CGSCVGHMKYWGNIFP; GSCVGHMKYWGNIFPS;SCVGHMKYWGNIFPSC; CVGHMKYWGNIFPSCE; VGHMKYWGNIFPSCES; GHMKYWGNIFPSCESP;HMKYWGNIFPSCESPK; MKYWGNIFPSCESPKI; KYWGNIFPSCESPKIP; YWGNIFPSCESPKIPS;WGNIFPSCESPKIPSI; GNIFPSCESPKIPSIF; NIFPSCESPKIPSIFI; IFPSCESPKIPSIFIS;FPSCESPKIPSIFIST; PSCESPKIPSIFISTG; SCESPKIPSIFISTGI; CESPKIPSIFISTGIR;ESPKIPSIFISTGIRY; SPKIPSIFISTGIRYP; PKIPSIFISTGIRYPA; KIPSIFISTGIRYPAL;IPSIFISTGIRYPALN; PSIFISTGIRYPALNW; SIFISTGIRYPALNWI; IFISTGIRYPALNWIS;FISTGIRYPALNWISI; ISTGIRYPALNWISIV; STGIRYPALNWISIVF; TGIRYPALNWISIVFV;GIRYPALNWISIVFVQ; IRYPALNWISIVFVQI; RYPALNWISIVFVQIG; YPALNWISIVFVQIGL;PALNWISIVFVQIGLM; ALNWISIVFVQIGLMV; LNWISIVFVQIGLMVS; NWISIVFVQIGLMVSI;WISIVFVQIGLMVSIH; ISIVFVQIGLMVSIHY; SIVFVQIGLMVSIHYL; IVFVQIGLMVSIHYLG;VFVQIGLMVSIHYLGL; FVQIGLMVSIHYLGLG; VQIGLMVSIHYLGLGC; QIGLMVSIHYLGLGCW;IGLMVSIHYLGLGCWV; GLMVSIHYLGLGCWVF; LMVSIHYLGLGCWVFR; MVSIHYLGLGCWVFRG;VSIHYLGLGCWVFRGY; SIHYLGLGCWVFRGYS; IHYLGLGCWVFRGYST; HYLGLGCWVFRGYSTI;YLGLGCWVFRGYSTIR; LGLGCWVFRGYSTIRV; GLGCWVFRGYSTIRVL; HSLHFQGFSTYSKEVE;SLHFQGFSTYSKEVEI; LHFQGFSTYSKEVEIT; HFQGFSTYSKEVEITA; FQGFSTYSKEVEITAL;QGFSTYSKEVEITALN; GFSTYSKEVEITALNR; FSTYSKEVEITALNRF; STYSKEVEITALNRFS;TYSKEVEITALNRFSS; YSKEVEITALNRFSST; SKEVEITALNRFSSTM; KEVEITALNRFSSTML;EVEITALNRFSSTMLM; VEITALNRFSSTMLMH; EITALNRFSSTMLMHF; ITALNRFSSTMLMHFL;PCMKVKHASYSNNLCL; CMKVKHASYSNNLCLY; MKVKHASYSNNLCLYS; KVKHASYSNNLCLYSY;VKHASYSNNLCLYSYS; KHASYSNNLCLYSYSL; HASYSNNLCLYSYSLP; ASYSNNLCLYSYSLPH;SYSNNLCLYSYSLPHQ; IGEGNSCCAVTGKHFS; GEGNSCCAVTGKHFSL; EGNSCCAVTGKHFSLW;GNSCCAVTGKHFSLWA; NSCCAVTGKHFSLWAI; SCCAVTGKHFSLWAIT; CCAVTGKHFSLWAITA;CAVTGKHFSLWAITAK; AVTGKHFSLWAITAKV; VTGKHFSLWAITAKVI; TGKHFSLWAITAKVIF;GKHFSLWAITAKVIFS; KHFSLWAITAKVIFST; FWHLHGFLWLFGSCPW; WHLHGFLWLFGSCPWT;HLHGFLWLFGSCPWTL; LHGFLWLFGSCPWTLS; HGFLWLFGSCPWTLSF; GFLWLFGSCPWTLSFS;FLWLFGSCPWTLSFSF; LWLFGSCPWTLSFSFG; WLFGSCPWTLSFSFGW; LFGSCPWTLSFSFGWG;FGSCPWTLSFSFGWGH; GSCPWTLSFSFGWGHL; SCPWTLSFSFGWGHLH; CPWTLSFSFGWGHLHM;PWTLSFSFGWGHLHML; WTLSFSFGWGHLHMLQ; TLSFSFGWGHLHMLQE; LSFSFGWGHLHMLQEQ;SFSFGWGHLHMLQEQV; FSFGWGHLHMLQEQVL; SFGWGHLHMLQEQVLQ; FGWGHLHMLQEQVLQS;GWGHLHMLQEQVLQSR; WGHLHMLQEQVLQSRT; GHLHMLQEQVLQSRTG; HLHMLQEQVLQSRTGL;LHMLQEQVLQSRTGLE; HMLQEQVLQSRTGLEV; MLQEQVLQSRTGLEVK; LQEQVLQSRTGLEVKA;QEQVLQSRTGLEVKAT; EQVLQSRTGLEVKATS; QVLQSRTGLEVKATSI; VLQSRTGLEVKATSIE;LQSRTGLEVKATSIEE; QSRTGLEVKATSIEEQ; SRTGLEVKATSIEEQF; RTGLEVKATSIEEQFF;TGLEVKATSIEEQFFD; TLLNVHFVDFLSPFFV; LLLYCQHHLYYKYGQN; LLYCQHHLYYKYGQNV;LYCQHHLYYKYGQNVH; YCQHHLYYKYGQNVHG; CQHHLYYKYGQNVHGY; QHHLYYKYGQNVHGYL;HHLYYKYGQNVHGYLP; HLYYKYGQNVHGYLPF; LYYKYGQNVHGYLPFQ; YYKYGQNVHGYLPFQL;YKYGQNVHGYLPFQLL; KYGQNVHGYLPFQLLV; QKYLHQETEYHSTHLG; TIPKPCLIADRGLQWK;IPKPCLIADRGLQWKL; PKPCLIADRGLQWKLC; KPCLIADRGLQWKLCD; PCLIADRGLQWKLCDP;CLIADRGLQWKLCDPN; LIADRGLQWKLCDPNH; IADRGLQWKLCDPNHQ; ADRGLQWKLCDPNHQR;DRGLQWKLCDPNHQRT; RGLQWKLCDPNHQRTY; GLQWKLCDPNHQRTYT; LQWKLCDPNHQRTYTL;QWKLCDPNHQRTYTLL; WKLCDPNHQRTYTLLE; KLCDPNHQRTYTLLEL; LCDPNHQRTYTLLELR;CDPNHQRTYTLLELRN; PQEHQQLQHMFEELGL; QQQPPQQQFQPLKILW; QQPPQQQFQPLKILWQ;QPPQQQFQPLKILWQQ; PPQQQFQPLKILWQQQ; PQQQFQPLKILWQQQP; QQQFQPLKILWQQQPQ;QQFQPLKILWQQQPQI; QFQPLKILWQQQPQIH; FQPLKILWQQQPQIHW; QPLKILWQQQPQIHWQ;PLKILWQQQPQIHWQL; LKILWQQQPQIHWQLG; KILWQQQPQIHWQLGP; ILWQQQPQIHWQLGPP;LWQQQPQIHWQLGPPK; WQQQPQIHWQLGPPKV; QQQPQIHWQLGPPKVL; QQPQIHWQLGPPKVLE;QPQIHWQLGPPKVLEQ; PQIHWQLGPPKVLEQH; QIHWQLGPPKVLEQHP; TWKYKKKGITYLGVFY;WKYKKKGITYLGVFYR; KYKKKGITYLGVFYRV; YKKKGITYLGVFYRVF; KKKGITYLGVFYRVFY;KKGITYLGVFYRVFYS; KGITYLGVFYRVFYSR; SSGTFVFPVYTVFTST; SGTFVFPVYTVFTSTK;GTFVFPVYTVFTSTKF; TFVFPVYTVFTSTKFQ; FVFPVYTVFTSTKFQQ; VFPVYTVFTSTKFQQK;FPVYTVFTSTKFQQKL; NKNKNPLSSFFCSSPG; KNKNPLSSFFCSSPGF; NKNPLSSFFCSSPGFT;KNPLSSFFCSSPGFTN; NPLSSFFCSSPGFTNF; PLSSFFCSSPGFTNFH; LGTRPRFLGSQNMSVM;GTRPRFLGSQNMSVMH; TRPRFLGSQNMSVMHF; RPRFLGSQNMSVMHFP; PRFLGSQNMSVMHFPS;AAPPCESCTFLPEVMV; APPCESCTFLPEVMVW; PPCESCTFLPEVMVWL; PCESCTFLPEVMVWLH;CESCTFLPEVMVWLHS; ESCTFLPEVMVWLHSP; SCTFLPEVMVWLHSPV; CTFLPEVMVWLHSPVS;TFLPEVMVWLHSPVSH; FLPEVMVWLHSPVSHA; LPEVMVWLHSPVSHAL; PEVMVWLHSPVSHALS;EVMVWLHSPVSHALSF; VMVWLHSPVSHALSFL; MVWLHSPVSHALSFLR; VWLHSPVSHALSFLRS;WLHSPVSHALSFLRSW; LHSPVSHALSFLRSWF; HSPVSHALSFLRSWFG; SPVSHALSFLRSWFGC;PVSHALSFLRSWFGCI; VSHALSFLRSWFGCIP; SHALSFLRSWFGCIPW; HALSFLRSWFGCIPWV;ALSFLRSWFGCIPWVS; LSFLRSWFGCIPWVSS; SFLRSWFGCIPWVSSS; FLRSWFGCIPWVSSSS;LRSWFGCIPWVSSSSL; RSWFGCIPWVSSSSLW; SWFGCIPWVSSSSLWP; WFGCIPWVSSSSLWPF;FGCIPWVSSSSLWPFF; GCIPWVSSSSLWPFFL; YIRGRGRLCLHPFSQV; IRGRGRLCLHPFSQVV;RGRGRLCLHPFSQVVR; GRGRLCLHPFSQVVRV; RGRLCLHPFSQVVRVW; GRLCLHPFSQVVRVWR;RLCLHPFSQVVRVWRL; LCLHPFSQVVRVWRLF; CLHPFSQVVRVWRLFL; LHPFSQVVRVWRLFLR;HPFSQVVRVWRLFLRP; PFSQVVRVWRLFLRPS; FSQVVRVWRLFLRPSK; SQVVRVWRLFLRPSKT;QVVRVWRLFLRPSKTI; VVRVWRLFLRPSKTIW; VRVWRLFLRPSKTIWG; RVWRLFLRPSKTIWGN;VWRLFLRPSKTIWGNP; WRLFLRPSKTIWGNPY; RLFLRPSKTIWGNPYS; LFLRPSKTIWGNPYSF;FLRPSKTIWGNPYSFA; LRPSKTIWGNPYSFAI; RPSKTIWGNPYSFAIF; PSKTIWGNPYSFAIFA;SKTIWGNPYSFAIFAK SEQ ID NOS.: 24957-44888

Preferred BK virus fragments of VP2-3 capable of interacting with one ormore MHC class 2 molecules are listed in Table P.

TABLE PPrediction of BK virus VP2-3 protein specific MHC class 2, 15-merpeptide binders for 14 MHC class 2 alleles (see FIG. 11) using thehttp://www.cbs.dtu.dk/services/NetMHCII/ database. The MHC class 2molecules for which no binders were found are not listed. Allele pospeptide core 1 − log50k(aff) aff(nM) B.L. Identity DRB1_0101 36AAIEVQIASLATVEG VQIASLATV 0.7655 13 SB BK VP2-3 DRB1_0101 37AIEVQIASLATVEGI IASLATVEG 0.7653 13 SB BK VP2-3 DRB1_0101 38IEVQIASLATVEGIT IASLATVEG 0.7535 14 SB BK VP2-3 DRB1_0101 39EVQIASLATVEGITT IASLATVEG 0.7419 16 SB BK VP2-3 DRB1_0101 216QDYYSNLSPIRPSMV YSNLSPIRP 0.7369 17 SB BK VP2-3 DRB1_0101 258VTQRMDLRNKESVHS VTQRMDLRN 0.7362 17 SB BK VP2-3 DRB1_0101 259TQRMDLRNKESVHSG LRNKESVHS 0.7390 17 SB BK VP2-3 DRB1_0101 260QRMDLRNKESVHSGE LRNKESVHS 0.7399 17 SB BK VP2-3 DRB1_0101 261RMDLRNKESVHSGEF LRNKESVHS 0.7383 17 SB BK VP2-3 DRB1_0101 262MDLRNKESVHSGEFI LRNKESVHS 0.7362 17 SB BK VP2-3 DRB1_0101 217DYYSNLSPIRPSMVR YSNLSPIRP 0.7308 18 SB BK VP2-3 DRB1_0101 82AALIQTVTGISSLAQ IQTVTGISS 0.7316 18 SB BK VP2-3 DRB1_0101 83ALIQTVTGISSLAQV VTGISSLAQ 0.7288 19 SB BK VP2-3 DRB1_0101 40VQIASLATVEGITTT IASLATVEG 0.7231 20 SB BK VP2-3 DRB1_0101 66QTYAVIAGAPGAIAG IAGAPGAIA 0.7250 20 SB BK VP2-3 DRB1_0101 65PQTYAVIAGAPGAIA VIAGAPGAI 0.7203 21 SB BK VP2-3 DRB1_0101 67TYAVIAGAPGAIAGF IAGAPGAIA 0.7196 21 SB BK VP2-3 DRB1_0101 68YAVIAGAPGAIAGFA IAGAPGAIA 0.7188 21 SB BK VP2-3 DRB1_0101 213NYIQDYYSNLSPIRP YYSNLSPIR 0.7087 23 SB BK VP2-3 DRB1_0101 214YIQDYYSNLSPIRPS YSNLSPIRP 0.7104 23 SB BK VP2-3 DRB1_0101 215IQDYYSNLSPIRPSM YSNLSPIRP 0.7116 23 SB BK VP2-3 DRB1_0101 219YSNLSPIRPSMVRQV YSNLSPIRP 0.7018 25 SB BK VP2-3 DRB1_0101 84LIQTVTGISSLAQVG VTGISSLAQ 0.7012 25 SB BK VP2-3 DRB1_0101 69AVIAGAPGAIAGFAA IAGAPGAIA 0.6972 26 SB BK VP2-3 DRB1_0101 85IQTVTGISSLAQVGY VTGISSLAQ 0.7004 26 SB BK VP2-3 DRB1_0101 24FSVAEIAAGEAAAAI IAAGEAAAA 0.6947 27 SB BK VP2-3 DRB1_0101 26VAEIAAGEAAAAIEV IAAGEAAAA 0.6967 27 SB BK VP2-3 DRB1_0101 27AEIAAGEAAAAIEVQ IAAGEAAAA 0.6963 27 SB BK VP2-3 DRB1_0101 25SVAEIAAGEAAAAIE IAAGEAAAA 0.6933 28 SB BK VP2-3 DRB1_0101 34AAAAIEVQIASLATV EVQIASLAT 0.6919 28 SB BK VP2-3 DRB1_0101 35AAAIEVQIASLATVE VQIASLATV 0.6928 28 SB BK VP2-3 DRB1_0101 23GFSVAEIAAGEAAAA VAEIAAGEA 0.6867 30 SB BK VP2-3 DRB1_0101 292QWMLPLLLGLYGTVT QWMLPLLLG 0.6800 32 SB BK VP2-3 DRB1_0101 1MGAALALLGDLVASV MGAALALLG 0.6779 33 SB BK VP2-3 DRB1_0101 296PLLLGLYGTVTPALE LLGLYGTVT 0.6771 33 SB BK VP2-3 DRB1_0101 289TAPQWMLPLLLGLYG PQWMLPLLL 0.6746 34 SB BK VP2-3 DRB1_0101 295LPLLLGLYGTVTPAL LLGLYGTVT 0.6709 35 SB BK VP2-3 DRB1_0101 218YYSNLSPIRPSMVRQ YSNLSPIRP 0.6689 36 SB BK VP2-3 DRB1_0101 293WMLPLLLGLYGTVTP LLGLYGTVT 0.6559 41 SB BK VP2-3 DRB1_0101 294MLPLLLGLYGTVTPA LLGLYGTVT 0.6545 42 SB BK VP2-3 DRB1_0101 220SNLSPIRPSMVRQVA IRPSMVRQV 0.6515 43 SB BK VP2-3 DRB1_0101 288RTAPQWMLPLLLGLY PQWMLPLLL 0.6514 43 SB BK VP2-3 DRB1_0101 86QTVTGISSLAQVGYR VTGISSLAQ 0.6515 43 SB BK VP2-3 DRB1_0101 9GDLVASVSEAAAATG LVASVSEAA 0.6476 45 SB BK VP2-3 DRB1_0101 287QRTAPQWMLPLLLGL PQWMLPLLL 0.6469 46 SB BK VP2-3 DRB1_0101 290APQWMLPLLLGLYGT QWMLPLLLG 0.6444 47 SB BK VP2-3 DRB1_0101 263DLRNKESVHSGEFIE LRNKESVHS 0.6362 51 WB BK VP2-3 DRB1_0101 264LRNKESVHSGEFIEK LRNKESVHS 0.6346 52 WB BK VP2-3 DRB1_0101 42IASLATVEGITTTSE IASLATVEG 0.6326 53 WB BK VP2-3 DRB1_0101 5LALLGDLVASVSEAA LGDLVASVS 0.6322 53 WB BK VP2-3 DRB1_0101 170RDDIPAITSQELQRR IPAITSQEL 0.6313 54 WB BK VP2-3 DRB1_0101 171DDIPAITSQELQRRT IPAITSQEL 0.6309 54 WB BK VP2-3 DRB1_0101 186ERFFRDSLARFLEET FRDSLARFL 0.6320 54 WB BK VP2-3 DRB1_0101 184RTERFFRDSLARFLE FRDSLARFL 0.6295 55 WB BK VP2-3 DRB1_0101 185TERFFRDSLARFLEE FRDSLARFL 0.6304 55 WB BK VP2-3 DRB1_0101 183RRTERFFRDSLARFL FFRDSLARF 0.6285 56 WB BK VP2-3 DRB1_0101 187RFFRDSLARFLEETT FRDSLARFL 0.6286 56 WB BK VP2-3 DRB1_0101 70VIAGAPGAIAGFAAL IAGAPGAIA 0.6277 56 WB BK VP2-3 DRB1_0101 75PGAIAGFAALIQTVT IAGFAALIQ 0.6288 56 WB BK VP2-3 DRB1_0101 76GAIAGFAALIQTVTG FAALIQTVT 0.6280 56 WB BK VP2-3 DRB1_0101 41QIASLATVEGITTTS IASLATVEG 0.6263 57 WB BK VP2-3 DRB1_0101 6ALLGDLVASVSEAAA LVASVSEAA 0.6253 58 WB BK VP2-3 DRB1_0101 221NLSPIRPSMVRQVAE IRPSMVRQV 0.6218 60 WB BK VP2-3 DRB1_0101 297LLLGLYGTVTPALEA LLGLYGTVT 0.6216 60 WB BK VP2-3 DRB1_0101 222LSPIRPSMVRQVAER IRPSMVRQV 0.6206 61 WB BK VP2-3 DRB1_0101 291PQWMLPLLLGLYGTV PQWMLPLLL 0.6197 61 WB BK VP2-3 DRB1_0101 298LLGLYGTVTPALEAY LLGLYGTVT 0.6201 61 WB BK VP2-3 DRB1_0101 79AGFAALIQTVTGISS FAALIQTVT 0.6202 61 WB BK VP2-3 DRB1_0101 8LGDLVASVSEAAAAT LVASVSEAA 0.6196 61 WB BK VP2-3 DRB1_0101 155PSLFATISQALWHVI LFATISQAL 0.6154 64 WB BK VP2-3 DRB1_0101 28EIAAGEAAAAIEVQI IAAGEAAAA 0.6146 65 WB BK VP2-3 DRB1_0101 286NQRTAPQWMLPLLLG PQWMLPLLL 0.6139 65 WB BK VP2-3 DRB1_0101 151RHWGPSLFATISQAL RHWGPSLFA 0.6126 66 WB BK VP2-3 DRB1_0101 275FIEKTIAPGGANQRT IAPGGANQR 0.6093 69 WB BK VP2-3 DRB1_0101 29IAAGEAAAAIEVQIA IAAGEAAAA 0.6093 69 WB BK VP2-3 DRB1_0101 7LLGDLVASVSEAAAA LVASVSEAA 0.6068 70 WB BK VP2-3 DRB1_0101 11LVASVSEAAAATGFS VSEAAAATG 0.6048 72 WB BK VP2-3 DRB1_0101 152HWGPSLFATISQALW LFATISQAL 0.6052 72 WB BK VP2-3 DRB1_0101 276IEKTIAPGGANQRTA IAPGGANQR 0.6053 72 WB BK VP2-3 DRB1_0101 154GPSLFATISQALWHV LFATISQAL 0.6040 73 WB BK VP2-3 DRB1_0101 111TVGLYQQSGMALELF LYQQSGMAL 0.6024 74 WB BK VP2-3 DRB1_0101 10DLVASVSEAAAATGF VSEAAAATG 0.6015 75 WB BK VP2-3 DRB1_0101 112VGLYQQSGMALELFN LYQQSGMAL 0.6010 75 WB BK VP2-3 DRB1_0101 277EKTIAPGGANQRTAP IAPGGANQR 0.6011 75 WB BK VP2-3 DRB1_0101 71IAGAPGAIAGFAALI IAGAPGAIA 0.6015 75 WB BK VP2-3 DRB1_0101 153WGPSLFATISQALWH LFATISQAL 0.5994 76 WB BK VP2-3 DRB1_0101 223SPIRPSMVRQVAERE IRPSMVRQV 0.6003 76 WB BK VP2-3 DRB1_0101 110STVGLYQQSGMALEL LYQQSGMAL 0.5977 78 WB BK VP2-3 DRB1_0101 78IAGFAALIQTVTGIS FAALIQTVT 0.5963 79 WB BK VP2-3 DRB1_0101 77AIAGFAALIQTVTGI FAALIQTVT 0.5949 80 WB BK VP2-3 DRB1_0101 278KTIAPGGANQRTAPQ IAPGGANQR 0.5943 81 WB BK VP2-3 DRB1_0101 2GAALALLGDLVASVS LALLGDLVA 0.5930 82 WB BK VP2-3 DRB1_0101 3AALALLGDLVASVSE LGDLVASVS 0.5912 83 WB BK VP2-3 DRB1_0101 81FAALIQTVTGISSLA IQTVTGISS 0.5912 83 WB BK VP2-3 DRB1_0101 173IPAITSQELQRRTER ITSQELQRR 0.5853 89 WB BK VP2-3 DRB1_0101 172DIPAITSQELQRRTE ITSQELQRR 0.5840 90 WB BK VP2-3 DRB1_0101 88VTGISSLAQVGYRFF VTGISSLAQ 0.5828 91 WB BK VP2-3 DRB1_0101 80GFAALIQTVTGISSL IQTVTGISS 0.5817 92 WB BK VP2-3 DRB1_0101 274EFIEKTIAPGGANQR IEKTIAPGG 0.5781 96 WB BK VP2-3 DRB1_0101 320KRRVSRGSSQKAKGT VSRGSSQKA 0.5786 96 WB BK VP2-3 DRB1_0101 167HVIRDDIPAITSQEL IRDDIPAIT 0.5761 98 WB BK VP2-3 DRB1_0101 109VSTVGLYQQSGMALE LYQQSGMAL 0.5756 99 WB BK VP2-3 DRB1_0101 64TPQTYAVIAGAPGAI YAVIAGAPG 0.5756 99 WB BK VP2-3 DRB1_0101 321RRVSRGSSQKAKGTR VSRGSSQKA 0.5746 100 WB BK VP2-3 DRB1_0101 323VSRGSSQKAKGTRAS VSRGSSQKA 0.5730 101 WB BK VP2-3 DRB1_0101 319KKRRVSRGSSQKAKG VSRGSSQKA 0.5712 104 WB BK VP2-3 DRB1_0101 318QKKRRVSRGSSQKAK VSRGSSQKA 0.5695 105 WB BK VP2-3 DRB1_0101 87TVTGISSLAQVGYRF VTGISSLAQ 0.5702 105 WB BK VP2-3 DRB1_0101 299LGLYGTVTPALEAYE LYGTVTPAL 0.5689 106 WB BK VP2-3 DRB1_0101 4ALALLGDLVASVSEA LGDLVASVS 0.5688 106 WB BK VP2-3 DRB1_0101 317NQKKRRVSRGSSQKA RVSRGSSQK 0.5685 107 WB BK VP2-3 DRB1_0101 12VASVSEAAAATGFSV VSEAAAATG 0.5666 109 WB BK VP2-3 DRB1_0101 169IRDDIPAITSQELQR IPAITSQEL 0.5628 113 WB BK VP2-3 DRB1_0101 285ANQRTAPQWMLPLLL RTAPQWMLP 0.5629 113 WB BK VP2-3 DRB1_0101 33EAAAAIEVQIASLAT IEVQIASLA 0.5628 113 WB BK VP2-3 DRB1_0101 74APGAIAGFAALIQTV IAGFAALIQ 0.5631 113 WB BK VP2-3 DRB1_0101 168VIRDDIPAITSQELQ IPAITSQEL 0.5596 117 WB BK VP2-3 DRB1_0101 212YNYIQDYYSNLSPIR IQDYYSNLS 0.5601 117 WB BK VP2-3 DRB1_0101 72AGAPGAIAGFAALIQ AIAGFAALI 0.5598 117 WB BK VP2-3 DRB1_0101 73GAPGAIAGFAALIQT IAGFAALIQ 0.5602 117 WB BK VP2-3 DRB1_0101 108KVSTVGLYQQSGMAL TVGLYQQSG 0.5550 123 WB BK VP2-3 DRB1_0101 156SLFATISQALWHVIR LFATISQAL 0.5526 127 WB BK VP2-3 DRB1_0101 13ASVSEAAAATGFSVA VSEAAAATG 0.5482 133 WB BK VP2-3 DRB1_0101 113GLYQQSGMALELFNP LYQQSGMAL 0.5426 141 WB BK VP2-3 DRB1_0101 157LFATISQALWHVIRD LFATISQAL 0.5415 143 WB BK VP2-3 DRB1_0101 188FFRDSLARFLEETTW FRDSLARFL 0.5345 154 WB BK VP2-3 DRB1_0101 43ASLATVEGITTTSEA LATVEGITT 0.5345 154 WB BK VP2-3 DRB1_0101 149DPRHWGPSLFATISQ RHWGPSLFA 0.5298 162 WB BK VP2-3 DRB1_0101 148LDPRHWGPSLFATIS RHWGPSLFA 0.5294 163 WB BK VP2-3 DRB1_0101 57AIAAIGLTPQTYAVI IAAIGLTPQ 0.5280 165 WB BK VP2-3 DRB1_0101 189FRDSLARFLEETTWT FRDSLARFL 0.5271 167 WB BK VP2-3 DRB1_0101 279TIAPGGANQRTAPQW IAPGGANQR 0.5252 170 WB BK VP2-3 DRB1_0101 174PAITSQELQRRTERF ITSQELQRR 0.5214 177 WB BK VP2-3 DRB1_0101 114LYQQSGMALELFNPD LYQQSGMAL 0.5213 178 WB BK VP2-3 DRB1_0101 199ETTWTIVNAPINFYN IVNAPINFY 0.5209 178 WB BK VP2-3 DRB1_0101 58IAAIGLTPQTYAVIA LTPQTYAVI 0.5203 180 WB BK VP2-3 DRB1_0101 147YLDPRHWGPSLFATI RHWGPSLFA 0.5192 182 WB BK VP2-3 DRB1_0101 56EAIAAIGLTPQTYAV IAAIGLTPQ 0.5190 182 WB BK VP2-3 DRB1_0101 200TTWTIVNAPINFYNY IVNAPINFY 0.5185 183 WB BK VP2-3 DRB1_0101 198EETTWTIVNAPINFY WTIVNAPIN 0.5179 184 WB BK VP2-3 DRB1_0101 224PIRPSMVRQVAEREG IRPSMVRQV 0.5170 186 WB BK VP2-3 DRB1_0101 63LTPQTYAVIAGAPGA YAVIAGAPG 0.5172 186 WB BK VP2-3 DRB1_0101 225IRPSMVRQVAEREGT IRPSMVRQV 0.5152 190 WB BK VP2-3 DRB1_0101 209INFYNYIQDYYSNLS YNYIQDYYS 0.5135 193 WB BK VP2-3 DRB1_0101 55SEAIAAIGLTPQTYA IAAIGLTPQ 0.5133 194 WB BK VP2-3 DRB1_0101 210NFYNYIQDYYSNLSP IQDYYSNLS 0.5129 195 WB BK VP2-3 DRB1_0101 145IQYLDPRHWGPSLFA IQYLDPRHW 0.5100 201 WB BK VP2-3 DRB1_0101 300GLYGTVTPALEAYED LYGTVTPAL 0.5097 201 WB BK VP2-3 DRB1_0101 322RVSRGSSQKAKGTRA VSRGSSQKA 0.5073 207 WB BK VP2-3 DRB1_0101 201TWTIVNAPINFYNYI IVNAPINFY 0.5050 212 WB BK VP2-3 DRB1_0101 202WTIVNAPINFYNYIQ IVNAPINFY 0.5004 223 WB BK VP2-3 DRB1_0101 140TFVNNIQYLDPRHWG IQYLDPRHW 0.4969 231 WB BK VP2-3 DRB1_0101 327SSQKAKGTRASAKTT QKAKGTRAS 0.4971 231 WB BK VP2-3 DRB1_0101 139NTFVNNIQYLDPRHW VNNIQYLDP 0.4965 232 WB BK VP2-3 DRB1_0101 45LATVEGITTTSEAIA VEGITTTSE 0.4966 232 WB BK VP2-3 DRB1_0101 62GLTPQTYAVIAGAPG TPQTYAVIA 0.4959 234 WB BK VP2-3 DRB1_0101 280IAPGGANQRTAPQWM IAPGGANQR 0.4948 237 WB BK VP2-3 DRB1_0101 54TSEAIAAIGLTPQTY IAAIGLTPQ 0.4931 241 WB BK VP2-3 DRB1_0101 142VNNIQYLDPRHWGPS IQYLDPRHW 0.4908 247 WB BK VP2-3 DRB1_0101 211FYNYIQDYYSNLSPI IQDYYSNLS 0.4889 252 WB BK VP2-3 DRB1_0101 53TTSEAIAAIGLTPQT IAAIGLTPQ 0.4889 252 WB BK VP2-3 DRB1_0101 141FVNNIQYLDPRHWGP IQYLDPRHW 0.4885 253 WB BK VP2-3 DRB1_0101 143NNIQYLDPRHWGPSL IQYLDPRHW 0.4867 258 WB BK VP2-3 DRB1_0101 44SLATVEGITTTSEAI VEGITTTSE 0.4868 258 WB BK VP2-3 DRB1_0101 59AAIGLTPQTYAVIAG LTPQTYAVI 0.4849 263 WB BK VP2-3 DRB1_0101 326GSSQKAKGTRASAKT QKAKGTRAS 0.4838 267 WB BK VP2-3 DRB1_0101 14SVSEAAAATGFSVAE VSEAAAATG 0.4826 270 WB BK VP2-3 DRB1_0101 150PRHWGPSLFATISQA WGPSLFATI 0.4823 271 WB BK VP2-3 DRB1_0101 301LYGTVTPALEAYEDG LYGTVTPAL 0.4803 277 WB BK VP2-3 DRB1_0101 129EYYDILFPGVNTFVN LFPGVNTFV 0.4778 284 WB BK VP2-3 DRB1_0101 60AIGLTPQTYAVIAGA LTPQTYAVI 0.4766 288 WB BK VP2-3 DRB1_0101 146QYLDPRHWGPSLFAT RHWGPSLFA 0.4756 291 WB BK VP2-3 DRB1_0101 52TTTSEAIAAIGLTPQ SEAIAAIGL 0.4719 303 WB BK VP2-3 DRB1_0101 130YYDILFPGVNTFVNN LFPGVNTFV 0.4703 308 WB BK VP2-3 DRB1_0101 128DEYYDILFPGVNTFV YYDILFPGV 0.4673 318 WB BK VP2-3 DRB1_0101 325RGSSQKAKGTRASAK QKAKGTRAS 0.4649 327 WB BK VP2-3 DRB1_0101 131YDILFPGVNTFVNNI LFPGVNTFV 0.4632 333 WB BK VP2-3 DRB1_0101 46ATVEGITTTSEAIAA VEGITTTSE 0.4606 342 WB BK VP2-3 DRB1_0101 15VSEAAAATGFSVAEI VSEAAAATG 0.4598 345 WB BK VP2-3 DRB1_0101 328SQKAKGTRASAKTTN QKAKGTRAS 0.4565 358 WB BK VP2-3 DRB1_0101 132DILFPGVNTFVNNIQ LFPGVNTFV 0.4558 361 WB BK VP2-3 DRB1_0101 61IGLTPQTYAVIAGAP LTPQTYAVI 0.4557 361 WB BK VP2-3 DRB1_0101 324SRGSSQKAKGTRASA QKAKGTRAS 0.4547 365 WB BK VP2-3 DRB1_0101 329QKAKGTRASAKTTNK QKAKGTRAS 0.4538 369 WB BK VP2-3 DRB1_0101 22TGFSVAEIAAGEAAA FSVAEIAAG 0.4532 371 WB BK VP2-3 DRB1_0101 32GEAAAAIEVQIASLA AAAIEVQIA 0.4528 372 WB BK VP2-3 DRB1_0101 21ATGFSVAEIAAGEAA FSVAEIAAG 0.4520 376 WB BK VP2-3 DRB1_0101 20AATGFSVAEIAAGEA FSVAEIAAG 0.4471 396 WB BK VP2-3 DRB1_0101 227PSMVRQVAEREGTHV MVRQVAERE 0.4426 416 WB BK VP2-3 DRB1_0101 101FFSDWDHKVSTVGLY WDHKVSTVG 0.4398 429 WB BK VP2-3 DRB1_0101 100RFFSDWDHKVSTVGL WDHKVSTVG 0.4393 431 WB BK VP2-3 DRB1_0101 103SDWDHKVSTVGLYQQ WDHKVSTVG 0.4367 443 WB BK VP2-3 DRB1_0101 158FATISQALWHVIRDD ISQALWHVI 0.4312 471 WB BK VP2-3 DRB1_0101 175AITSQELQRRTERFF ITSQELQRR 0.4287 483 WB BK VP2-3 DRB1_0101 49EGITTTSEAIAAIGL ITTTSEAIA 0.4284 485 WB BK VP2-3 DRB1_0101 102FSDWDHKVSTVGLYQ WDHKVSTVG 0.4283 486 WB BK VP2-3 DRB1_0301 182QRRTERFFRDSLARF RFFRDSLAR 0.4487 390 WB BK VP2-3 DRB1_0301 183RRTERFFRDSLARFL FFRDSLARF 0.4472 396 WB BK VP2-3 DRB1_0301 186ERFFRDSLARFLEET FFRDSLARF 0.4469 397 WB BK VP2-3 DRB1_0301 184RTERFFRDSLARFLE FFRDSLARF 0.4468 398 WB BK VP2-3 DRB1_0301 185TERFFRDSLARFLEE FFRDSLARF 0.4464 399 WB BK VP2-3 DRB1_0401 213NYIQDYYSNLSPIRP YYSNLSPIR 0.5927 82 WB BK VP2-3 DRB1_0401 212YNYIQDYYSNLSPIR IQDYYSNLS 0.5864 88 WB BK VP2-3 DRB1_0401 214YIQDYYSNLSPIRPS YYSNLSPIR 0.5789 95 WB BK VP2-3 DRB1_0401 215IQDYYSNLSPIRPSM YYSNLSPIR 0.5767 97 WB BK VP2-3 DRB1_0401 216QDYYSNLSPIRPSMV YYSNLSPIR 0.5674 108 WB BK VP2-3 DRB1_0401 258VTQRMDLRNKESVHS VTQRMDLRN 0.5284 164 WB BK VP2-3 DRB1_0401 259TQRMDLRNKESVHSG LRNKESVHS 0.5237 173 WB BK VP2-3 DRB1_0401 260QRMDLRNKESVHSGE LRNKESVHS 0.5240 173 WB BK VP2-3 DRB1_0401 261RMDLRNKESVHSGEF LRNKESVHS 0.5213 178 WB BK VP2-3 DRB1_0401 262MDLRNKESVHSGEFI LRNKESVHS 0.5168 187 WB BK VP2-3 DRB1_0401 5LALLGDLVASVSEAA LLGDLVASV 0.5166 187 WB BK VP2-3 DRB1_0401 6ALLGDLVASVSEAAA LVASVSEAA 0.5140 192 WB BK VP2-3 DRB1_0401 7LLGDLVASVSEAAAA LVASVSEAA 0.5130 194 WB BK VP2-3 DRB1_0401 8LGDLVASVSEAAAAT LVASVSEAA 0.5130 194 WB BK VP2-3 DRB1_0401 9GDLVASVSEAAAATG LVASVSEAA 0.5118 197 WB BK VP2-3 DRB1_0401 82AALIQTVTGISSLAQ LIQTVTGIS 0.5068 208 WB BK VP2-3 DRB1_0401 217DYYSNLSPIRPSMVR YYSNLSPIR 0.4779 284 WB BK VP2-3 DRB1_0401 83ALIQTVTGISSLAQV VTGISSLAQ 0.4763 289 WB BK VP2-3 DRB1_0401 84LIQTVTGISSLAQVG VTGISSLAQ 0.4711 306 WB BK VP2-3 DRB1_0401 218YYSNLSPIRPSMVRQ YYSNLSPIR 0.4694 312 WB BK VP2-3 DRB1_0401 198EETTWTIVNAPINFY WTIVNAPIN 0.4557 361 WB BK VP2-3 DRB1_0401 199ETTWTIVNAPINFYN IVNAPINFY 0.4556 362 WB BK VP2-3 DRB1_0401 200TTWTIVNAPINFYNY IVNAPINFY 0.4527 373 WB BK VP2-3 DRB1_0401 85IQTVTGISSLAQVGY VTGISSLAQ 0.4432 414 WB BK VP2-3 DRB1_0401 202WTIVNAPINFYNYIQ IVNAPINFY 0.4421 418 WB BK VP2-3 DRB1_0401 201TWTIVNAPINFYNYI IVNAPINFY 0.4401 427 WB BK VP2-3 DRB1_0401 81FAALIQTVTGISSLA LIQTVTGIS 0.4399 428 WB BK VP2-3 DRB1_0401 36AAIEVQIASLATVEG IEVQIASLA 0.4327 463 WB BK VP2-3 DRB1_0401 132DILFPGVNTFVNNIQ GVNTFVNNI 0.4289 483 WB BK VP2-3 DRB1_0404 213NYIQDYYSNLSPIRP IQDYYSNLS 0.5128 195 WB BK VP2-3 DRB1_0404 82AALIQTVTGISSLAQ LIQTVTGIS 0.4868 258 WB BK VP2-3 DRB1_0404 198EETTWTIVNAPINFY TTWTIVNAP 0.4822 271 WB BK VP2-3 DRB1_0404 215IQDYYSNLSPIRPSM IQDYYSNLS 0.4815 273 WB BK VP2-3 DRB1_0404 295LPLLLGLYGTVTPAL LLGLYGTVT 0.4754 292 WB BK VP2-3 DRB1_0404 214YIQDYYSNLSPIRPS IQDYYSNLS 0.4645 328 WB BK VP2-3 DRB1_0404 296PLLLGLYGTVTPALE LLGLYGTVT 0.4620 337 WB BK VP2-3 DRB1_0404 293WMLPLLLGLYGTVTP LLGLYGTVT 0.4571 356 WB BK VP2-3 DRB1_0404 294MLPLLLGLYGTVTPA LLGLYGTVT 0.4547 365 WB BK VP2-3 DRB1_0404 36AAIEVQIASLATVEG IEVQIASLA 0.4515 378 WB BK VP2-3 DRB1_0404 200TTWTIVNAPINFYNY IVNAPINFY 0.4472 396 WB BK VP2-3 DRB1_0404 194ARFLEETTWTIVNAP FLEETTWTI 0.4467 398 WB BK VP2-3 DRB1_0404 212YNYIQDYYSNLSPIR IQDYYSNLS 0.4449 406 WB BK VP2-3 DRB1_0404 199ETTWTIVNAPINFYN IVNAPINFY 0.4444 408 WB BK VP2-3 DRB1_0404 81FAALIQTVTGISSLA LIQTVTGIS 0.4428 415 WB BK VP2-3 DRB1_0404 292QWMLPLLLGLYGTVT MLPLLLGLY 0.4376 439 WB BK VP2-3 DRB1_0404 297LLLGLYGTVTPALEA LGLYGTVTP 0.4365 445 WB BK VP2-3 DRB1_0404 84LIQTVTGISSLAQVG LIQTVTGIS 0.4287 483 WB BK VP2-3 DRB1_0404 38IEVQIASLATVEGIT IASLATVEG 0.4281 487 WB BK VP2-3 DRB1_0404 78IAGFAALIQTVTGIS AALIQTVTG 0.4270 493 WB BK VP2-3 DRB1_0404 196FLEETTWTIVNAPIN TTWTIVNAP 0.4258 499 WB BK VP2-3 DRB1_0405 213NYIQDYYSNLSPIRP IQDYYSNLS 0.5630 113 WB BK VP2-3 DRB1_0405 212YNYIQDYYSNLSPIR IQDYYSNLS 0.5391 146 WB BK VP2-3 DRB1_0405 209INFYNYIQDYYSNLS YNYIQDYYS 0.5339 155 WB BK VP2-3 DRB1_0405 96QVGYRFFSDWDHKVS YRFFSDWDH 0.5285 164 WB BK VP2-3 DRB1_0405 210NFYNYIQDYYSNLSP IQDYYSNLS 0.5274 166 WB BK VP2-3 DRB1_0405 196FLEETTWTIVNAPIN EETTWTIVN 0.5259 169 WB BK VP2-3 DRB1_0405 214YIQDYYSNLSPIRPS IQDYYSNLS 0.5183 184 WB BK VP2-3 DRB1_0405 215IQDYYSNLSPIRPSM IQDYYSNLS 0.5155 189 WB BK VP2-3 DRB1_0405 135FPGVNTFVNNIQYLD VNTFVNNIQ 0.5129 194 WB BK VP2-3 DRB1_0405 211FYNYIQDYYSNLSPI IQDYYSNLS 0.5093 202 WB BK VP2-3 DRB1_0405 198EETTWTIVNAPINFY WTIVNAPIN 0.5089 203 WB BK VP2-3 DRB1_0405 136PGVNTFVNNIQYLDP VNTFVNNIQ 0.5073 207 WB BK VP2-3 DRB1_0405 95AQVGYRFFSDWDHKV YRFFSDWDH 0.5059 210 WB BK VP2-3 DRB1_0405 132DILFPGVNTFVNNIQ FPGVNTFVN 0.5008 222 WB BK VP2-3 DRB1_0405 133ILFPGVNTFVNNIQY VNTFVNNIQ 0.4983 228 WB BK VP2-3 DRB1_0405 97VGYRFFSDWDHKVST YRFFSDWDH 0.4930 241 WB BK VP2-3 DRB1_0405 194ARFLEETTWTIVNAP EETTWTIVN 0.4887 253 WB BK VP2-3 DRB1_0405 197LEETTWTIVNAPINF WTIVNAPIN 0.4832 268 WB BK VP2-3 DRB1_0405 199ETTWTIVNAPINFYN WTIVNAPIN 0.4813 274 WB BK VP2-3 DRB1_0405 195RFLEETTWTIVNAPI EETTWTIVN 0.4799 278 WB BK VP2-3 DRB1_0405 94LAQVGYRFFSDWDHK GYRFFSDWD 0.4772 286 WB BK VP2-3 DRB1_0405 93SLAQVGYRFFSDWDH GYRFFSDWD 0.4758 291 WB BK VP2-3 DRB1_0405 134LFPGVNTFVNNIQYL VNTFVNNIQ 0.4752 292 WB BK VP2-3 DRB1_0405 193LARFLEETTWTIVNA EETTWTIVN 0.4694 312 WB BK VP2-3 DRB1_0405 158FATISQALWHVIRDD QALWHVIRD 0.4626 335 WB BK VP2-3 DRB1_0405 157LFATISQALWHVIRD SQALWHVIR 0.4616 339 WB BK VP2-3 DRB1_0405 200TTWTIVNAPINFYNY IVNAPINFY 0.4599 345 WB BK VP2-3 DRB1_0405 98GYRFFSDWDHKVSTV YRFFSDWDH 0.4557 361 WB BK VP2-3 DRB1_0405 192SLARFLEETTWTIVN FLEETTWTI 0.4451 405 WB BK VP2-3 DRB1_0405 137GVNTFVNNIQYLDPR VNTFVNNIQ 0.4315 469 WB BK VP2-3 DRB1_0405 138VNTFVNNIQYLDPRH VNTFVNNIQ 0.4315 469 WB BK VP2-3 DRB1_0701 155PSLFATISQALWHVI LFATISQAL 0.6499 44 SB BK VP2-3 DRB1_0701 154GPSLFATISQALWHV LFATISQAL 0.6324 53 WB BK VP2-3 DRB1_0701 153WGPSLFATISQALWH LFATISQAL 0.6252 58 WB BK VP2-3 DRB1_0701 152HWGPSLFATISQALW LFATISQAL 0.6229 59 WB BK VP2-3 DRB1_0701 151RHWGPSLFATISQAL WGPSLFATI 0.6204 61 WB BK VP2-3 DRB1_0701 219YSNLSPIRPSMVRQV LSPIRPSMV 0.6186 62 WB BK VP2-3 DRB1_0701 220SNLSPIRPSMVRQVA LSPIRPSMV 0.6184 62 WB BK VP2-3 DRB1_0701 216QDYYSNLSPIRPSMV YYSNLSPIR 0.6145 65 WB BK VP2-3 DRB1_0701 217DYYSNLSPIRPSMVR LSPIRPSMV 0.6117 67 WB BK VP2-3 DRB1_0701 218YYSNLSPIRPSMVRQ LSPIRPSMV 0.6108 67 WB BK VP2-3 DRB1_0701 194ARFLEETTWTIVNAP FLEETTWTI 0.6047 72 WB BK VP2-3 DRB1_0701 191DSLARFLEETTWTIV FLEETTWTI 0.6040 73 WB BK VP2-3 DRB1_0701 193LARFLEETTWTIVNA FLEETTWTI 0.6028 73 WB BK VP2-3 DRB1_0701 192SLARFLEETTWTIVN FLEETTWTI 0.6024 74 WB BK VP2-3 DRB1_0701 156SLFATISQALWHVIR LFATISQAL 0.5732 101 WB BK VP2-3 DRB1_0701 157LFATISQALWHVIRD LFATISQAL 0.5709 104 WB BK VP2-3 DRB1_0701 195RFLEETTWTIVNAPI LEETTWTIV 0.5523 127 WB BK VP2-3 DRB1_0701 221NLSPIRPSMVRQVAE LSPIRPSMV 0.5258 169 WB BK VP2-3 DRB1_0701 222LSPIRPSMVRQVAER LSPIRPSMV 0.5249 171 WB BK VP2-3 DRB1_0701 196FLEETTWTIVNAPIN FLEETTWTI 0.5082 205 WB BK VP2-3 DRB1_0701 58IAAIGLTPQTYAVIA LTPQTYAVI 0.4999 224 WB BK VP2-3 DRB1_0701 57AIAAIGLTPQTYAVI AIGLTPQTY 0.4992 226 WB BK VP2-3 DRB1_0701 59AAIGLTPQTYAVIAG LTPQTYAVI 0.4959 234 WB BK VP2-3 DRB1_0701 60AIGLTPQTYAVIAGA LTPQTYAVI 0.4955 235 WB BK VP2-3 DRB1_0701 61IGLTPQTYAVIAGAP LTPQTYAVI 0.4924 243 WB BK VP2-3 DRB1_0701 190RDSLARFLEETTWTI RDSLARFLE 0.4903 248 WB BK VP2-3 DRB1_0701 167HVIRDDIPAITSQEL VIRDDIPAI 0.4747 294 WB BK VP2-3 DRB1_0701 131YDILFPGVNTFVNNI LFPGVNTFV 0.4730 299 WB BK VP2-3 DRB1_0701 168VIRDDIPAITSQELQ IPAITSQEL 0.4729 300 WB BK VP2-3 DRB1_0701 132DILFPGVNTFVNNIQ LFPGVNTFV 0.4725 301 WB BK VP2-3 DRB1_0701 169IRDDIPAITSQELQR IPAITSQEL 0.4681 316 WB BK VP2-3 DRB1_0701 170RDDIPAITSQELQRR IPAITSQEL 0.4671 319 WB BK VP2-3 DRB1_0701 171DDIPAITSQELQRRT IPAITSQEL 0.4635 332 WB BK VP2-3 DRB1_0701 129EYYDILFPGVNTFVN LFPGVNTFV 0.4503 383 WB BK VP2-3 DRB1_0701 130YYDILFPGVNTFVNN FPGVNTFVN 0.4488 389 WB BK VP2-3 DRB1_0701 133ILFPGVNTFVNNIQY FPGVNTFVN 0.4334 459 WB BK VP2-3 DRB1_0701 158FATISQALWHVIRDD ISQALWHVI 0.4279 488 WB BK VP2-3 DRB1_0802 214YIQDYYSNLSPIRPS YSNLSPIRP 0.4370 442 WB BK VP2-3 DRB1_0802 213NYIQDYYSNLSPIRP YYSNLSPIR 0.4360 447 WB BK VP2-3 DRB1_0802 215IQDYYSNLSPIRPSM YSNLSPIRP 0.4360 447 WB BK VP2-3 DRB1_0802 216QDYYSNLSPIRPSMV YSNLSPIRP 0.4358 448 WB BK VP2-3 DRB1_0901 110STVGLYQQSGMALEL YQQSGMALE 0.4827 270 WB BK VP2-3 DRB1_0901 111TVGLYQQSGMALELF YQQSGMALE 0.4750 293 WB BK VP2-3 DRB1_0901 112VGLYQQSGMALELFN YQQSGMALE 0.4750 293 WB BK VP2-3 DRB1_0901 109VSTVGLYQQSGMALE LYQQSGMAL 0.4737 297 WB BK VP2-3 DRB1_0901 36AAIEVQIASLATVEG VQIASLATV 0.4709 306 WB BK VP2-3 DRB1_0901 35AAAIEVQIASLATVE VQIASLATV 0.4664 322 WB BK VP2-3 DRB1_0901 198EETTWTIVNAPINFY WTIVNAPIN 0.4656 324 WB BK VP2-3 DRB1_0901 199ETTWTIVNAPINFYN WTIVNAPIN 0.4657 324 WB BK VP2-3 DRB1_0901 37AIEVQIASLATVEGI VQIASLATV 0.4650 326 WB BK VP2-3 DRB1_0901 34AAAAIEVQIASLATV IEVQIASLA 0.4647 328 WB BK VP2-3 DRB1_0901 38IEVQIASLATVEGIT VQIASLATV 0.4639 331 WB BK VP2-3 DRB1_0901 297LLLGLYGTVTPALEA LYGTVTPAL 0.4627 335 WB BK VP2-3 DRB1_0901 200TTWTIVNAPINFYNY WTIVNAPIN 0.4612 340 WB BK VP2-3 DRB1_0901 296PLLLGLYGTVTPALE LYGTVTPAL 0.4611 341 WB BK VP2-3 DRB1_0901 299LGLYGTVTPALEAYE LYGTVTPAL 0.4598 346 WB BK VP2-3 DRB1_0901 298LLGLYGTVTPALEAY LYGTVTPAL 0.4531 372 WB BK VP2-3 DRB1_0901 113GLYQQSGMALELFNP YQQSGMALE 0.4451 405 WB BK VP2-3 DRB1_0901 183RRTERFFRDSLARFL FFRDSLARF 0.4413 422 WB BK VP2-3 DRB1_0901 184RTERFFRDSLARFLE FRDSLARFL 0.4404 426 WB BK VP2-3 DRB1_0901 186ERFFRDSLARFLEET FRDSLARFL 0.4393 431 WB BK VP2-3 DRB1_0901 185TERFFRDSLARFLEE FRDSLARFL 0.4382 436 WB BK VP2-3 DRB1_0901 187RFFRDSLARFLEETT FRDSLARFL 0.4306 474 WB BK VP2-3 DRB1_0901 295LPLLLGLYGTVTPAL LGLYGTVTP 0.4290 482 WB BK VP2-3 DRB1_0901 65PQTYAVIAGAPGAIA VIAGAPGAI 0.4281 487 WB BK VP2-3 DRB1_0901 66QTYAVIAGAPGAIAG VIAGAPGAI 0.4279 488 WB BK VP2-3 DRB1_0901 67TYAVIAGAPGAIAGF VIAGAPGAI 0.4259 499 WB BK VP2-3 DRB1_1302 135FPGVNTFVNNIQYLD VNTFVNNIQ 0.7008 25 SB BK VP2-3 DRB1_1302 136PGVNTFVNNIQYLDP FVNNIQYLD 0.6940 27 SB BK VP2-3 DRB1_1302 137GVNTFVNNIQYLDPR FVNNIQYLD 0.6861 30 SB BK VP2-3 DRB1_1302 138VNTFVNNIQYLDPRH FVNNIQYLD 0.6825 31 SB BK VP2-3 DRB1_1302 139NTFVNNIQYLDPRHW FVNNIQYLD 0.6608 39 SB BK VP2-3 DRB1_1302 213NYIQDYYSNLSPIRP IQDYYSNLS 0.6338 53 WB BK VP2-3 DRB1_1302 216QDYYSNLSPIRPSMV YSNLSPIRP 0.6265 57 WB BK VP2-3 DRB1_1302 215IQDYYSNLSPIRPSM YSNLSPIRP 0.6245 58 WB BK VP2-3 DRB1_1302 214YIQDYYSNLSPIRPS YSNLSPIRP 0.6230 59 WB BK VP2-3 DRB1_1302 217DYYSNLSPIRPSMVR YSNLSPIRP 0.6216 60 WB BK VP2-3 DRB1_1302 293WMLPLLLGLYGTVTP LLGLYGTVT 0.6200 61 WB BK VP2-3 DRB1_1302 296PLLLGLYGTVTPALE LGLYGTVTP 0.6167 63 WB BK VP2-3 DRB1_1302 294MLPLLLGLYGTVTPA LGLYGTVTP 0.6126 66 WB BK VP2-3 DRB1_1302 295LPLLLGLYGTVTPAL LGLYGTVTP 0.6083 69 WB BK VP2-3 DRB1_1302 297LLLGLYGTVTPALEA LGLYGTVTP 0.6067 70 WB BK VP2-3 DRB1_1302 140TFVNNIQYLDPRHWG FVNNIQYLD 0.5962 79 WB BK VP2-3 DRB1_1302 36AAIEVQIASLATVEG VQIASLATV 0.5884 86 WB BK VP2-3 DRB1_1302 141FVNNIQYLDPRHWGP FVNNIQYLD 0.5710 104 WB BK VP2-3 DRB1_1302 37AIEVQIASLATVEGI VQIASLATV 0.5647 111 WB BK VP2-3 DRB1_1302 38IEVQIASLATVEGIT VQIASLATV 0.5646 111 WB BK VP2-3 DRB1_1302 218YYSNLSPIRPSMVRQ YSNLSPIRP 0.5481 133 WB BK VP2-3 DRB1_1302 199ETTWTIVNAPINFYN IVNAPINFY 0.5463 135 WB BK VP2-3 DRB1_1302 200TTWTIVNAPINFYNY IVNAPINFY 0.5452 137 WB BK VP2-3 DRB1_1302 198EETTWTIVNAPINFY WTIVNAPIN 0.5445 138 WB BK VP2-3 DRB1_1302 298LLGLYGTVTPALEAY LGLYGTVTP 0.5383 148 WB BK VP2-3 DRB1_1302 219YSNLSPIRPSMVRQV YSNLSPIRP 0.5366 150 WB BK VP2-3 DRB1_1302 201TWTIVNAPINFYNYI IVNAPINFY 0.5349 153 WB BK VP2-3 DRB1_1302 79AGFAALIQTVTGISS FAALIQTVT 0.5306 161 WB BK VP2-3 DRB1_1302 34AAAAIEVQIASLATV IEVQIASLA 0.5257 169 WB BK VP2-3 DRB1_1302 202WTIVNAPINFYNYIQ IVNAPINFY 0.5240 172 WB BK VP2-3 DRB1_1302 35AAAIEVQIASLATVE VQIASLATV 0.5233 174 WB BK VP2-3 DRB1_1302 299LGLYGTVTPALEAYE LGLYGTVTP 0.5095 202 WB BK VP2-3 DRB1_1302 40VQIASLATVEGITTT IASLATVEG 0.5094 202 WB BK VP2-3 DRB1_1302 80GFAALIQTVTGISSL IQTVTGISS 0.5080 205 WB BK VP2-3 DRB1_1302 39EVQIASLATVEGITT IASLATVEG 0.5076 206 WB BK VP2-3 DRB1_1302 81FAALIQTVTGISSLA IQTVTGISS 0.5054 211 WB BK VP2-3 DRB1_1302 78IAGFAALIQTVTGIS FAALIQTVT 0.4783 283 WB BK VP2-3 DRB1_1302 82AALIQTVTGISSLAQ IQTVTGISS 0.4693 312 WB BK VP2-3 DRB1_1302 83ALIQTVTGISSLAQV IQTVTGISS 0.4437 411 WB BK VP2-3 DRB1_1302 109VSTVGLYQQSGMALE VGLYQQSGM 0.4417 420 WB BK VP2-3 DRB1_1302 132DILFPGVNTFVNNIQ FPGVNTFVN 0.4394 431 WB BK VP2-3 DRB1_1302 133ILFPGVNTFVNNIQY VNTFVNNIQ 0.4339 457 WB BK VP2-3 DRB1_1302 203TIVNAPINFYNYIQD IVNAPINFY 0.4317 468 WB BK VP2-3 DRB1_1302 110STVGLYQQSGMALEL VGLYQQSGM 0.4274 490 WB BK VP2-3 DRB1_1501 259TQRMDLRNKESVHSG LRNKESVHS 0.5055 211 WB BK VP2-3 DRB1_1501 258VTQRMDLRNKESVHS TQRMDLRNK 0.4963 233 WB BK VP2-3 DRB1_1501 260QRMDLRNKESVHSGE LRNKESVHS 0.4888 252 WB BK VP2-3 DRB1_1501 261RMDLRNKESVHSGEF LRNKESVHS 0.4818 272 WB BK VP2-3 DRB1_1501 292QWMLPLLLGLYGTVT MLPLLLGLY 0.4818 272 WB BK VP2-3 DRB1_1501 293WMLPLLLGLYGTVTP LLGLYGTVT 0.4703 308 WB BK VP2-3 DRB1_1501 262MDLRNKESVHSGEFI LRNKESVHS 0.4652 326 WB BK VP2-3 DRB1_1501 294MLPLLLGLYGTVTPA LLGLYGTVT 0.4567 357 WB BK VP2-3 DRB1_1501 295LPLLLGLYGTVTPAL LLGLYGTVT 0.4514 378 WB BK VP2-3 DRB1_1501 296PLLLGLYGTVTPALE LLGLYGTVT 0.4387 434 WB BK VP2-3 DRB4_0101 213NYIQDYYSNLSPIRP IQDYYSNLS 0.4336 458 WB BK VP2-3 DRB5_0101 216QDYYSNLSPIRPSMV YYSNLSPIR 0.5417 142 WB BK VP2-3 DRB5_0101 214YIQDYYSNLSPIRPS YSNLSPIRP 0.5315 159 WB BK VP2-3 DRB5_0101 215IQDYYSNLSPIRPSM YSNLSPIRP 0.5316 159 WB BK VP2-3 DRB5_0101 213NYIQDYYSNLSPIRP YYSNLSPIR 0.5308 160 WB BK VP2-3 DRB5_0101 217DYYSNLSPIRPSMVR YSNLSPIRP 0.5081 205 WB BK VP2-3 DRB5_0101 218YYSNLSPIRPSMVRQ YYSNLSPIR 0.4623 336 WB BK VP2-3 DRB5_0101 174PAITSQELQRRTERF ITSQELQRR 0.4449 406 WB BK VP2-3 DRB5_0101 173IPAITSQELQRRTER ITSQELQRR 0.4422 418 WB BK VP2-3 SEQ ID NOS.:58312-59135

Preferred BK virus fragments of VP1 capable of interacting with one ormore MHC class 2 molecules are listed in Table Q.

TABLE Q Prediction of BK virus VP1 protein specific MHC class 2, 15-merpeptide binders for 14 MHC class 2 alleles (see FIG. 11) using thehttp://www.cbs.dtu.dk/services/NetMHCII/ database. The MHC class 2molecules for which no binders were found are not listed. Bind IdentityAllel pos peptide core 1 − log50k(aff) aff(nM) level DRB1_0101 164QGVLMNYRTKYPQGT LMNYRTKYP 0.7782 11 SB VP1 DRB1_0101 165GVLMNYRTKYPQGTI YRTKYPQGT 0.7768 11 SB VP1 DRB1_0101 166VLMNYRTKYPQGTIT YRTKYPQGT 0.7796 11 SB VP1 DRB1_0101 167LMNYRTKYPQGTITP YRTKYPQGT 0.7798 11 SB VP1 DRB1_0101 168MNYRTKYPQGTITPK YRTKYPQGT 0.7778 11 SB VP1 DRB1_0101 118KTEVIGITSMLNLHA VIGITSMLN 0.7623 13 SB VP1 DRB1_0101 119TEVIGITSMLNLHAG VIGITSMLN 0.7621 13 SB VP1 DRB1_0101 233PPVLHVTNTATTVLL VTNTATTVL 0.7280 19 SB VP1 DRB1_0101 234PVLHVTNTATTVLLD VTNTATTVL 0.7252 20 SB VP1 DRB1_0101 235VLHVTNTATTVLLDE VTNTATTVL 0.7244 20 SB VP1 DRB1_0101 232VPPVLHVTNTATTVL VLHVTNTAT 0.7197 21 SB VP1 DRB1_0101 236LHVTNTATTVLLDEQ VTNTATTVL 0.7207 21 SB VP1 DRB1_0101 121VIGITSMLNLHAGSQ VIGITSMLN 0.7107 23 SB VP1 DRB1_0101 120EVIGITSMLNLHAGS VIGITSMLN 0.7035 25 SB VP1 DRB1_0101 266ADICGLFTNSSGTQQ ICGLFTNSS 0.7009 25 SB VP1 DRB1_0101 262YVSAADICGLFTNSS YVSAADICG 0.6956 27 SB VP1 DRB1_0101 117VKTEVIGITSMLNLH VIGITSMLN 0.6913 28 SB VP1 DRB1_0101 116TVKTEVIGITSMLNL VIGITSMLN 0.6903 29 SB VP1 DRB1_0101 115VTVKTEVIGITSMLN EVIGITSML 0.6842 30 SB VP1 DRB1_0101 169NYRTKYPQGTITPKN YRTKYPQGT 0.6853 30 SB VP1 DRB1_0101 265AADICGLFTNSSGTQ ICGLFTNSS 0.6859 30 SB VP1 DRB1_0101 170YRTKYPQGTITPKNP YRTKYPQGT 0.6835 31 SB VP1 DRB1_0101 264SAADICGLFTNSSGT ICGLFTNSS 0.6829 31 SB VP1 DRB1_0101 263VSAADICGLFTNSSG ICGLFTNSS 0.6809 32 SB VP1 DRB1_0101 305FLLSDLINRRTQKVD LINRRTQKV 0.6730 34 SB VP1 DRB1_0101 304SFLLSDLINRRTQKV LSDLINRRT 0.6723 35 SB VP1 DRB1_0101 105TCGNLLMWEAVTVKT LLMWEAVTV 0.6651 37 SB VP1 DRB1_0101 106CGNLLMWEAVTVKTE LLMWEAVTV 0.6660 37 SB VP1 DRB1_0101 107GNLLMWEAVTVKTEV LLMWEAVTV 0.6675 37 SB VP1 DRB1_0101 306LLSDLINRRTQKVDG LINRRTQKV 0.6610 39 SB VP1 DRB1_0101 307LSDLINRRTQKVDGQ LINRRTQKV 0.6620 39 SB VP1 DRB1_0101 308SDLINRRTQKVDGQP LINRRTQKV 0.6493 44 SB VP1 DRB1_0101 122IGITSMLNLHAGSQK ITSMLNLHA 0.6472 45 SB VP1 DRB1_0101 108NLLMWEAVTVKTEVI MWEAVTVKT 0.6381 50 WB VP1 DRB1_0101 237HVTNTATTVLLDEQG VTNTATTVL 0.6362 51 WB VP1 DRB1_0101 267DICGLFTNSSGTQQW ICGLFTNSS 0.6283 56 WB VP1 DRB1_0101 268ICGLFTNSSGTQQWR ICGLFTNSS 0.6286 56 WB VP1 DRB1_0101 104LTCGNLLMWEAVTVK LLMWEAVTV 0.6269 57 WB VP1 DRB1_0101 317KVDGQPMYGMESQVE VDGQPMYGM 0.6232 59 WB VP1 DRB1_0101 318VDGQPMYGMESQVEE MYGMESQVE 0.6230 59 WB VP1 DRB1_0101 238VTNTATTVLLDEQGV VTNTATTVL 0.6202 61 WB VP1 DRB1_0101 252VGPLCKADSLYVSAA LCKADSLYV 0.6161 64 WB VP1 DRB1_0101 253GPLCKADSLYVSAAD LCKADSLYV 0.6146 65 WB VP1 DRB1_0101 250QGVGPLCKADSLYVS LCKADSLYV 0.6129 66 WB VP1 DRB1_0101 251GVGPLCKADSLYVSA LCKADSLYV 0.6115 67 WB VP1 DRB1_0101 109LLMWEAVTVKTEVIG MWEAVTVKT 0.6104 68 WB VP1 DRB1_0101 249EQGVGPLCKADSLYV VGPLCKADS 0.6000 76 WB VP1 DRB1_0101 123GITSMLNLHAGSQKV ITSMLNLHA 0.5940 81 WB VP1 DRB1_0101 124ITSMLNLHAGSQKVH ITSMLNLHA 0.5895 85 WB VP1 DRB1_0101 320GQPMYGMESQVEEVR MYGMESQVE 0.5805 94 WB VP1 DRB1_0101 103DLTCGNLLMWEAVTV LTCGNLLMW 0.5786 96 WB VP1 DRB1_0101 319DGQPMYGMESQVEEV MYGMESQVE 0.5779 96 WB VP1 DRB1_0101 315TQKVDGQPMYGMESQ VDGQPMYGM 0.5631 113 WB VP1 DRB1_0101 309DLINRRTQKVDGQPM LINRRTQKV 0.5612 115 WB VP1 DRB1_0101 314RTQKVDGQPMYGMES VDGQPMYGM 0.5605 116 WB VP1 DRB1_0101 316QKVDGQPMYGMESQV VDGQPMYGM 0.5604 116 WB VP1 DRB1_0101 321QPMYGMESQVEEVRV MYGMESQVE 0.5604 116 WB VP1 DRB1_0101 310LINRRTQKVDGQPMY LINRRTQKV 0.5595 117 WB VP1 DRB1_0101 161LEMQGVLMNYRTKYP MQGVLMNYR 0.5570 121 WB VP1 DRB1_0101 158GDPLEMQGVLMNYRT MQGVLMNYR 0.5484 132 WB VP1 DRB1_0101 256CKADSLYVSAADICG ADSLYVSAA 0.5470 135 WB VP1 DRB1_0101 257KADSLYVSAADICGL YVSAADICG 0.5462 136 WB VP1 DRB1_0101 84RKMLPCYSTARIPLP RKMLPCYST 0.5450 137 WB VP1 DRB1_0101 258ADSLYVSAADICGLF YVSAADICG 0.5446 138 WB VP1 DRB1_0101 259DSLYVSAADICGLFT YVSAADICG 0.5443 138 WB VP1 DRB1_0101 159DPLEMQGVLMNYRTK MQGVLMNYR 0.5441 139 WB VP1 DRB1_0101 260SLYVSAADICGLFTN YVSAADICG 0.5396 146 WB VP1 DRB1_0101 81SPDRKMLPCYSTARI RKMLPCYST 0.5323 158 WB VP1 DRB1_0101 110LMWEAVTVKTEVIGI MWEAVTVKT 0.5308 160 WB VP1 DRB1_0101 231NVPPVLHVTNTATTV LHVTNTATT 0.5288 164 WB VP1 DRB1_0101 177GTITPKNPTAQSQVM ITPKNPTAQ 0.5283 165 WB VP1 DRB1_0101 82PDRKMLPCYSTARIP RKMLPCYST 0.5256 170 WB VP1 DRB1_0101 254PLCKADSLYVSAADI LCKADSLYV 0.5231 174 WB VP1 DRB1_0101 162EMQGVLMNYRTKYPQ LMNYRTKYP 0.5203 179 WB VP1 DRB1_0101 80DSPDRKMLPCYSTAR RKMLPCYST 0.5206 179 WB VP1 DRB1_0101 255LCKADSLYVSAADIC LCKADSLYV 0.5180 184 WB VP1 DRB1_0101 294KRSVKNPYPISFLLS VKNPYPISF 0.5180 184 WB VP1 DRB1_0101 313RRTQKVDGQPMYGME VDGQPMYGM 0.5170 186 WB VP1 DRB1_0101 157GGDPLEMQGVLMNYR LEMQGVLMN 0.5164 187 WB VP1 DRB1_0101 295RSVKNPYPISFLLSD VKNPYPISF 0.5161 188 WB VP1 DRB1_0101 312NRRTQKVDGQPMYGM KVDGQPMYG 0.5163 188 WB VP1 DRB1_0101 160PLEMQGVLMNYRTKY MQGVLMNYR 0.5148 190 WB VP1 DRB1_0101 269CGLFTNSSGTQQWRG FTNSSGTQQ 0.5138 193 WB VP1 DRB1_0101 292LRKRSVKNPYPISFL VKNPYPISF 0.5094 202 WB VP1 DRB1_0101 163MQGVLMNYRTKYPQG LMNYRTKYP 0.5072 207 WB VP1 DRB1_0101 230ENVPPVLHVTNTATT VLHVTNTAT 0.5053 211 WB VP1 DRB1_0101 293RKRSVKNPYPISFLL VKNPYPISF 0.5053 211 WB VP1 DRB1_0101 270GLFTNSSGTQQWRGL FTNSSGTQQ 0.5035 215 WB VP1 DRB1_0101 175PQGTITPKNPTAQSQ ITPKNPTAQ 0.5026 217 WB VP1 DRB1_0101 176QGTITPKNPTAQSQV ITPKNPTAQ 0.5007 222 WB VP1 DRB1_0101 291RLRKRSVKNPYPISF LRKRSVKNP 0.5005 222 WB VP1 DRB1_0101 125TSMLNLHAGSQKVHE MLNLHAGSQ 0.4968 231 WB VP1 DRB1_0101 62DNLRGYSQHLSAENA LRGYSQHLS 0.4929 241 WB VP1 DRB1_0101 83DRKMLPCYSTARIPL MLPCYSTAR 0.4902 249 WB VP1 DRB1_0101 87LPCYSTARIPLPNLN YSTARIPLP 0.4891 252 WB VP1 DRB1_0101 85KMLPCYSTARIPLPN YSTARIPLP 0.4865 259 WB VP1 DRB1_0101 349IRYIDRQGQLQTKMV YIDRQGQLQ 0.4856 261 WB VP1 DRB1_0101 111MWEAVTVKTEVIGIT MWEAVTVKT 0.4847 264 WB VP1 DRB1_0101 88PCYSTARIPLPNLNE YSTARIPLP 0.4819 272 WB VP1 DRB1_0101 86MLPCYSTARIPLPNL YSTARIPLP 0.4817 273 WB VP1 DRB1_0101 23VQVPKLLIKGGVEVL LLIKGGVEV 0.4803 277 WB VP1 DRB1_0101 61DDNLRGYSQHLSAEN LRGYSQHLS 0.4800 278 WB VP1 DRB1_0101 179ITPKNPTAQSQVMNT ITPKNPTAQ 0.4786 282 WB VP1 DRB1_0101 285ARYFKIRLRKRSVKN FKIRLRKRS 0.4787 282 WB VP1 DRB1_0101 155AVGGDPLEMQGVLMN GDPLEMQGV 0.4780 284 WB VP1 DRB1_0101 284LARYFKIRLRKRSVK FKIRLRKRS 0.4764 289 WB VP1 DRB1_0101 178TITPKNPTAQSQVMN ITPKNPTAQ 0.4755 291 WB VP1 DRB1_0101 282RGLARYFKIRLRKRS YFKIRLRKR 0.4754 292 WB VP1 DRB1_0101 283GLARYFKIRLRKRSV FKIRLRKRS 0.4744 295 WB VP1 DRB1_0101 173KYPQGTITPKNPTAQ PQGTITPKN 0.4716 304 WB VP1 DRB1_0101 174YPQGTITPKNPTAQS ITPKNPTAQ 0.4716 304 WB VP1 DRB1_0101 224GTYTGGENVPPVLHV YTGGENVPP 0.4697 310 WB VP1 DRB1_0101 322PMYGMESQVEEVRVF MYGMESQVE 0.4691 312 WB VP1 DRB1_0101 156VGGDPLEMQGVLMNY LEMQGVLMN 0.4685 314 WB VP1 DRB1_0101 25VPKLLIKGGVEVLEV LLIKGGVEV 0.4678 317 WB VP1 DRB1_0101 24QVPKLLIKGGVEVLE LLIKGGVEV 0.4674 318 WB VP1 DRB1_0101 22PVQVPKLLIKGGVEV VPKLLIKGG 0.4668 320 WB VP1 DRB1_0101 261LYVSAADICGLFTNS YVSAADICG 0.4665 321 WB VP1 DRB1_0101 26PKLLIKGGVEVLEVK LLIKGGVEV 0.4633 332 WB VP1 DRB1_0101 151FHFFAVGGDPLEMQG VGGDPLEMQ 0.4633 333 WB VP1 DRB1_0101 323MYGMESQVEEVRVFD MYGMESQVE 0.4626 335 WB VP1 DRB1_0101 150NFHFFAVGGDPLEMQ AVGGDPLEM 0.4611 340 WB VP1 DRB1_0101 223FGTYTGGENVPPVLH YTGGENVPP 0.4596 346 WB VP1 DRB1_0101 297VKNPYPISFLLSDLI VKNPYPISF 0.4588 349 WB VP1 DRB1_0101 63NLRGYSQHLSAENAF YSQHLSAEN 0.4583 351 WB VP1 DRB1_0101 152HFFAVGGDPLEMQGV VGGDPLEMQ 0.4576 354 WB VP1 DRB1_0101 286RYFKIRLRKRSVKNP FKIRLRKRS 0.4564 358 WB VP1 DRB1_0101 64LRGYSQHLSAENAFE YSQHLSAEN 0.4559 360 WB VP1 DRB1_0101 220TRYFGTYTGGENVPP YFGTYTGGE 0.4546 365 WB VP1 DRB1_0101 301YPISFLLSDLINRRT ISFLLSDLI 0.4540 368 WB VP1 DRB1_0101 126SMLNLHAGSQKVHEN MLNLHAGSQ 0.4520 376 WB VP1 DRB1_0101 34VEVLEVKTGVDAITE VKTGVDAIT 0.4507 381 WB VP1 DRB1_0101 33GVEVLEVKTGVDAIT VEVLEVKTG 0.4499 385 WB VP1 DRB1_0101 226YTGGENVPPVLHVTN YTGGENVPP 0.4471 397 WB VP1 DRB1_0101 303ISFLLSDLINRRTQK LSDLINRRT 0.4468 397 WB VP1 DRB1_0101 153FFAVGGDPLEMQGVL VGGDPLEMQ 0.4446 407 WB VP1 DRB1_0101 225TYTGGENVPPVLHVT YTGGENVPP 0.4439 410 WB VP1 DRB1_0101 302PISFLLSDLINRRTQ LSDLINRRT 0.4439 411 WB VP1 DRB1_0101 36VLEVKTGVDAITEVE VKTGVDAIT 0.4399 429 WB VP1 DRB1_0101 35EVLEVKTGVDAITEV VKTGVDAIT 0.4395 430 WB VP1 DRB1_0101 37LEVKTGVDAITEVEC VKTGVDAIT 0.4381 437 WB VP1 DRB1_0101 127MLNLHAGSQKVHENG MLNLHAGSQ 0.4375 440 WB VP1 DRB1_0101 229GENVPPVLHVTNTAT NVPPVLHVT 0.4368 443 WB VP1 DRB1_0101 60PDDNLRGYSQHLSAE LRGYSQHLS 0.4346 454 WB VP1 DRB1_0101 59DPDDNLRGYSQHLSA LRGYSQHLS 0.4337 458 WB VP1 DRB1_0101 65RGYSQHLSAENAFES YSQHLSAEN 0.4335 459 WB VP1 DRB1_0101 27KLLIKGGVEVLEVKT LIKGGVEVL 0.4331 461 WB VP1 DRB1_0101 221RYFGTYTGGENVPPV YTGGENVPP 0.4318 468 WB VP1 DRB1_0101 296SVKNPYPISFLLSDL VKNPYPISF 0.4317 468 WB VP1 DRB1_0101 222YFGTYTGGENVPPVL YTGGENVPP 0.4313 470 WB VP1 DRB1_0101 271LFTNSSGTQQWRGLA FTNSSGTQQ 0.4313 470 WB VP1 DRB1_0101 58GDPDDNLRGYSQHLS NLRGYSQHL 0.4305 474 WB VP1 DRB1_0101 281WRGLARYFKIRLRKR WRGLARYFK 0.4285 485 WB VP1 DRB1_0101 276SGTQQWRGLARYFKI WRGLARYFK 0.4263 496 WB VP1 DRB1_0101 154FAVGGDPLEMQGVLM VGGDPLEMQ 0.4261 498 WB VP1 DRB1_0101 277GTQQWRGLARYFKIR WRGLARYFK 0.4259 498 WB VP1 DRB1_0101 275SSGTQQWRGLARYFK QQWRGLARY 0.4258 499 WB VP1 DRB1_0401 118KTEVIGITSMLNLHA VIGITSMLN 0.5278 165 WB VP1 DRB1_0401 119TEVIGITSMLNLHAG ITSMLNLHA 0.5243 172 WB VP1 DRB1_0401 266ADICGLFTNSSGTQQ ICGLFTNSS 0.5078 206 WB VP1 DRB1_0401 265AADICGLFTNSSGTQ ICGLFTNSS 0.5038 215 WB VP1 DRB1_0401 120EVIGITSMLNLHAGS ITSMLNLHA 0.4938 239 WB VP1 DRB1_0401 121VIGITSMLNLHAGSQ ITSMLNLHA 0.4931 241 WB VP1 DRB1_0401 262YVSAADICGLFTNSS YVSAADICG 0.4874 256 WB VP1 DRB1_0401 264SAADICGLFTNSSGT ICGLFTNSS 0.4849 263 WB VP1 DRB1_0401 263VSAADICGLFTNSSG ICGLFTNSS 0.4805 276 WB VP1 DRB1_0401 287YFKIRLRKRSVKNPY RLRKRSVKN 0.4585 350 WB VP1 DRB1_0401 304SFLLSDLINRRTQKV LLSDLINRR 0.4554 362 WB VP1 DRB1_0401 288FKIRLRKRSVKNPYP RKRSVKNPY 0.4485 390 WB VP1 DRB1_0401 122IGITSMLNLHAGSQK ITSMLNLHA 0.4473 395 WB VP1 DRB1_0401 291RLRKRSVKNPYPISF RKRSVKNPY 0.4444 408 WB VP1 DRB1_0401 232VPPVLHVTNTATTVL PVLHVTNTA 0.4431 414 WB VP1 DRB1_0401 115VTVKTEVIGITSMLN VKTEVIGIT 0.4422 418 WB VP1 DRB1_0401 289KIRLRKRSVKNPYPI RKRSVKNPY 0.4410 424 WB VP1 DRB1_0401 117VKTEVIGITSMLNLH VIGITSMLN 0.4404 426 WB VP1 DRB1_0401 268ICGLFTNSSGTQQWR ICGLFTNSS 0.4395 430 WB VP1 DRB1_0401 267DICGLFTNSSGTQQW ICGLFTNSS 0.4385 435 WB VP1 DRB1_0401 230ENVPPVLHVTNTATT PVLHVTNTA 0.4370 442 WB VP1 DRB1_0401 290IRLRKRSVKNPYPIS RKRSVKNPY 0.4334 460 WB VP1 DRB1_0401 231NVPPVLHVTNTATTV PVLHVTNTA 0.4332 461 WB VP1 DRB1_0401 301YPISFLLSDLINRRT LLSDLINRR 0.4287 483 WB VP1 DRB1_0401 116TVKTEVIGITSMLNL VIGITSMLN 0.4285 485 WB VP1 DRB1_0401 300PYPISFLLSDLINRR ISFLLSDLI 0.4265 495 WB VP1 DRB1_0404 121VIGITSMLNLHAGSQ ITSMLNLHA 0.6731 34 SB VP1 DRB1_0404 122IGITSMLNLHAGSQK MLNLHAGSQ 0.6665 37 SB VP1 DRB1_0404 124ITSMLNLHAGSQKVH MLNLHAGSQ 0.6499 44 SB VP1 DRB1_0404 123GITSMLNLHAGSQKV MLNLHAGSQ 0.6491 45 SB VP1 DRB1_0404 163MQGVLMNYRTKYPQG LMNYRTKYP 0.6123 66 WB VP1 DRB1_0404 125TSMLNLHAGSQKVHE MLNLHAGSQ 0.6117 67 WB VP1 DRB1_0404 161LEMQGVLMNYRTKYP MQGVLMNYR 0.6109 67 WB VP1 DRB1_0404 164QGVLMNYRTKYPQGT LMNYRTKYP 0.6092 69 WB VP1 DRB1_0404 162EMQGVLMNYRTKYPQ LMNYRTKYP 0.6059 71 WB VP1 DRB1_0404 165GVLMNYRTKYPQGTI LMNYRTKYP 0.6046 72 WB VP1 DRB1_0404 126SMLNLHAGSQKVHEN MLNLHAGSQ 0.5148 190 WB VP1 DRB1_0404 127MLNLHAGSQKVHENG MLNLHAGSQ 0.5132 194 WB VP1 DRB1_0404 166VLMNYRTKYPQGTIT LMNYRTKYP 0.5108 199 WB VP1 DRB1_0404 266ADICGLFTNSSGTQQ ICGLFTNSS 0.5092 202 WB VP1 DRB1_0404 265AADICGLFTNSSGTQ ICGLFTNSS 0.5081 205 WB VP1 DRB1_0404 167LMNYRTKYPQGTITP LMNYRTKYP 0.5069 208 WB VP1 DRB1_0404 304SFLLSDLINRRTQKV LLSDLINRR 0.4931 241 WB VP1 DRB1_0404 301YPISFLLSDLINRRT LLSDLINRR 0.4876 256 WB VP1 DRB1_0404 119TEVIGITSMLNLHAG ITSMLNLHA 0.4851 263 WB VP1 DRB1_0404 302PISFLLSDLINRRTQ LLSDLINRR 0.4821 271 WB VP1 DRB1_0404 303ISFLLSDLINRRTQK LLSDLINRR 0.4816 273 WB VP1 DRB1_0404 118KTEVIGITSMLNLHA VIGITSMLN 0.4807 275 WB VP1 DRB1_0404 46ITEVECFLNPEMGDP TEVECFLNP 0.4807 275 WB VP1 DRB1_0404 47TEVECFLNPEMGDPD FLNPEMGDP 0.4801 277 WB VP1 DRB1_0404 48EVECFLNPEMGDPDD FLNPEMGDP 0.4754 292 WB VP1 DRB1_0404 50ECFLNPEMGDPDDNL FLNPEMGDP 0.4751 293 WB VP1 DRB1_0404 49VECFLNPEMGDPDDN FLNPEMGDP 0.4745 295 WB VP1 DRB1_0404 267DICGLFTNSSGTQQW LFTNSSGTQ 0.4682 315 WB VP1 DRB1_0404 268ICGLFTNSSGTQQWR LFTNSSGTQ 0.4665 321 WB VP1 DRB1_0404 84RKMLPCYSTARIPLP MLPCYSTAR 0.4629 334 WB VP1 DRB1_0404 105TCGNLLMWEAVTVKT LMWEAVTVK 0.4618 338 WB VP1 DRB1_0404 106CGNLLMWEAVTVKTE LMWEAVTVK 0.4597 346 WB VP1 DRB1_0404 232VPPVLHVTNTATTVL LHVTNTATT 0.4584 351 WB VP1 DRB1_0404 300PYPISFLLSDLINRR FLLSDLINR 0.4582 351 WB VP1 DRB1_0404 120EVIGITSMLNLHAGS ITSMLNLHA 0.4575 354 WB VP1 DRB1_0404 107GNLLMWEAVTVKTEV LMWEAVTVK 0.4552 363 WB VP1 DRB1_0404 233PPVLHVTNTATTVLL LHVTNTATT 0.4466 398 WB VP1 DRB1_0404 230ENVPPVLHVTNTATT VLHVTNTAT 0.4465 399 WB VP1 DRB1_0404 108NLLMWEAVTVKTEVI LMWEAVTVK 0.4456 403 WB VP1 DRB1_0404 305FLLSDLINRRTQKVD LLSDLINRR 0.4431 414 WB VP1 DRB1_0404 192NTDHKAYLDKNNAYP KAYLDKNNA 0.4422 418 WB VP1 DRB1_0404 193TDHKAYLDKNNAYPV YLDKNNAYP 0.4402 427 WB VP1 DRB1_0404 231NVPPVLHVTNTATTV LHVTNTATT 0.4401 428 WB VP1 DRB1_0404 194DHKAYLDKNNAYPVE YLDKNNAYP 0.4393 431 WB VP1 DRB1_0404 85KMLPCYSTARIPLPN YSTARIPLP 0.4335 459 WB VP1 DRB1_0404 234PVLHVTNTATTVLLD LHVTNTATT 0.4328 463 WB VP1 DRB1_0404 195HKAYLDKNNAYPVEC YLDKNNAYP 0.4303 476 WB VP1 DRB1_0404 196KAYLDKNNAYPVECW YLDKNNAYP 0.4288 483 WB VP1 DRB1_0404 104LTCGNLLMWEAVTVK LLMWEAVTV 0.4272 492 WB VP1 DRB1_0405 205YPVECWIPDPSRNEN WIPDPSRNE 0.4758 291 WB VP1 DRB1_0405 204AYPVECWIPDPSRNE ECWIPDPSR 0.4737 297 WB VP1 DRB1_0405 118KTEVIGITSMLNLHA VIGITSMLN 0.4649 327 WB VP1 DRB1_0405 119TEVIGITSMLNLHAG VIGITSMLN 0.4617 338 WB VP1 DRB1_0405 88PCYSTARIPLPNLNE YSTARIPLP 0.4515 378 WB VP1 DRB1_0405 206PVECWIPDPSRNENT WIPDPSRNE 0.4387 434 WB VP1 DRB1_0405 115VTVKTEVIGITSMLN TVKTEVIGI 0.4272 492 WB VP1 DRB1_0701 232VPPVLHVTNTATTVL VLHVTNTAT 0.7832 10 SB VP1 DRB1_0701 233PPVLHVTNTATTVLL VTNTATTVL 0.7867 10 SB VP1 DRB1_0701 234PVLHVTNTATTVLLD VTNTATTVL 0.7821 11 SB VP1 DRB1_0701 235VLHVTNTATTVLLDE VTNTATTVL 0.7792 11 SB VP1 DRB1_0701 236LHVTNTATTVLLDEQ VTNTATTVL 0.7807 11 SB VP1 DRB1_0701 237HVTNTATTVLLDEQG VTNTATTVL 0.6865 30 SB VP1 DRB1_0701 238VTNTATTVLLDEQGV VTNTATTVL 0.6833 31 SB VP1 DRB1_0701 304SFLLSDLINRRTQKV LSDLINRRT 0.5382 148 WB VP1 DRB1_0701 308SDLINRRTQKVDGQP LINRRTQKV 0.5370 150 WB VP1 DRB1_0701 305FLLSDLINRRTQKVD LINRRTQKV 0.5365 151 WB VP1 DRB1_0701 306LLSDLINRRTQKVDG LINRRTQKV 0.5340 155 WB VP1 DRB1_0701 307LSDLINRRTQKVDGQ LINRRTQKV 0.5332 156 WB VP1 DRB1_0701 231NVPPVLHVTNTATTV VLHVTNTAT 0.4751 293 WB VP1 DRB1_0701 107GNLLMWEAVTVKTEV LLMWEAVTV 0.4593 347 WB VP1 DRB1_0701 105TCGNLLMWEAVTVKT LLMWEAVTV 0.4539 368 WB VP1 DRB1_0701 106CGNLLMWEAVTVKTE LLMWEAVTV 0.4530 372 WB VP1 DRB1_0701 104LTCGNLLMWEAVTVK LLMWEAVTV 0.4517 377 WB VP1 DRB1_0701 103DLTCGNLLMWEAVTV LTCGNLLMW 0.4475 395 WB VP1 DRB1_0701 230ENVPPVLHVTNTATT VLHVTNTAT 0.4461 401 WB VP1 DRB1_0701 309DLINRRTQKVDGQPM LINRRTQKV 0.4383 436 WB VP1 DRB1_0701 310LINRRTQKVDGQPMY LINRRTQKV 0.4370 442 WB VP1 DRB1_0701 285ARYFKIRLRKRSVKN YFKIRLRKR 0.4289 483 WB VP1 DRB1_0701 249EQGVGPLCKADSLYV PLCKADSLY 0.4260 498 WB VP1 DRB1_0802 282RGLARYFKIRLRKRS RGLARYFKI 0.5826 91 WB VP1 DRB1_0802 283GLARYFKIRLRKRSV FKIRLRKRS 0.5827 91 WB VP1 DRB1_0802 284LARYFKIRLRKRSVK FKIRLRKRS 0.5824 92 WB VP1 DRB1_0802 285ARYFKIRLRKRSVKN FKIRLRKRS 0.5816 92 WB VP1 DRB1_0802 286RYFKIRLRKRSVKNP FKIRLRKRS 0.5825 92 WB VP1 DRB1_0802 287YFKIRLRKRSVKNPY FKIRLRKRS 0.4907 247 WB VP1 DRB1_0802 288FKIRLRKRSVKNPYP FKIRLRKRS 0.4905 248 WB VP1 DRB1_0901 84RKMLPCYSTARIPLP LPCYSTARI 0.5150 190 WB VP1 DRB1_0901 85KMLPCYSTARIPLPN YSTARIPLP 0.5124 195 WB VP1 DRB1_0901 86MLPCYSTARIPLPNL YSTARIPLP 0.4991 226 WB VP1 DRB1_0901 87LPCYSTARIPLPNLN YSTARIPLP 0.4968 231 WB VP1 DRB1_0901 88PCYSTARIPLPNLNE YSTARIPLP 0.4598 345 WB VP1 DRB1_1101 276SGTQQWRGLARYFKI WRGLARYFK 0.5202 180 WB VP1 DRB1_1101 277GTQQWRGLARYFKIR WRGLARYFK 0.5200 180 WB VP1 DRB1_1101 278TQQWRGLARYFKIRL WRGLARYFK 0.5165 187 WB VP1 DRB1_1101 275SSGTQQWRGLARYFK QQWRGLARY 0.5148 191 WB VP1 DRB1_1101 279QQWRGLARYFKIRLR WRGLARYFK 0.5146 191 WB VP1 DRB1_1101 281WRGLARYFKIRLRKR WRGLARYFK 0.4569 357 WB VP1 DRB1_1101 280QWRGLARYFKIRLRK WRGLARYFK 0.4404 426 WB VP1 DRB1_1302 161LEMQGVLMNYRTKYP VLMNYRTKY 0.6366 51 WB VP1 DRB1_1302 162EMQGVLMNYRTKYPQ VLMNYRTKY 0.6357 51 WB VP1 DRB1_1302 163MQGVLMNYRTKYPQG VLMNYRTKY 0.6190 62 WB VP1 DRB1_1302 164QGVLMNYRTKYPQGT VLMNYRTKY 0.6178 63 WB VP1 DRB1_1302 160PLEMQGVLMNYRTKY QGVLMNYRT 0.6118 67 WB VP1 DRB1_1302 233PPVLHVTNTATTVLL VTNTATTVL 0.6016 75 WB VP1 DRB1_1302 234PVLHVTNTATTVLLD VTNTATTVL 0.5831 91 WB VP1 DRB1_1302 232VPPVLHVTNTATTVL VLHVTNTAT 0.5808 93 WB VP1 DRB1_1302 235VLHVTNTATTVLLDE VTNTATTVL 0.5658 110 WB VP1 DRB1_1302 284LARYFKIRLRKRSVK FKIRLRKRS 0.5521 127 WB VP1 DRB1_1302 165GVLMNYRTKYPQGTI VLMNYRTKY 0.5482 133 WB VP1 DRB1_1302 285ARYFKIRLRKRSVKN FKIRLRKRS 0.5453 137 WB VP1 DRB1_1302 286RYFKIRLRKRSVKNP FKIRLRKRS 0.5448 138 WB VP1 DRB1_1302 287YFKIRLRKRSVKNPY IRLRKRSVK 0.5427 141 WB VP1 DRB1_1302 236LHVTNTATTVLLDEQ VTNTATTVL 0.5416 143 WB VP1 DRB1_1302 288FKIRLRKRSVKNPYP IRLRKRSVK 0.5351 153 WB VP1 DRB1_1302 117VKTEVIGITSMLNLH IGITSMLNL 0.5226 175 WB VP1 DRB1_1302 166VLMNYRTKYPQGTIT VLMNYRTKY 0.5220 176 WB VP1 DRB1_1302 116TVKTEVIGITSMLNL EVIGITSML 0.5120 196 WB VP1 DRB1_1302 282RGLARYFKIRLRKRS LARYFKIRL 0.4951 236 WB VP1 DRB1_1302 118KTEVIGITSMLNLHA IGITSMLNL 0.4947 237 WB VP1 DRB1_1302 283GLARYFKIRLRKRSV FKIRLRKRS 0.4916 245 WB VP1 DRB1_1302 304SFLLSDLINRRTQKV LLSDLINRR 0.4893 251 WB VP1 DRB1_1302 305FLLSDLINRRTQKVD LINRRTQKV 0.4877 255 WB VP1 DRB1_1302 119TEVIGITSMLNLHAG IGITSMLNL 0.4792 280 WB VP1 DRB1_1302 120EVIGITSMLNLHAGS IGITSMLNL 0.4786 282 WB VP1 DRB1_1302 91STARIPLPNLNEDLT ARIPLPNLN 0.4726 301 WB VP1 DRB1_1302 237HVTNTATTVLLDEQG VTNTATTVL 0.4703 308 WB VP1 DRB1_1302 95IPLPNLNEDLTCGNL LPNLNEDLT 0.4680 316 WB VP1 DRB1_1302 93ARIPLPNLNEDLTCG LPNLNEDLT 0.4675 318 WB VP1 DRB1_1302 94RIPLPNLNEDLTCGN LPNLNEDLT 0.4673 318 WB VP1 DRB1_1302 159DPLEMQGVLMNYRTK QGVLMNYRT 0.4669 320 WB VP1 DRB1_1302 92TARIPLPNLNEDLTC LPNLNEDLT 0.4645 328 WB VP1 DRB1_1302 158GDPLEMQGVLMNYRT LEMQGVLMN 0.4643 329 WB VP1 DRB1_1302 289KIRLRKRSVKNPYPI RKRSVKNPY 0.4576 354 WB VP1 DRB1_1302 290IRLRKRSVKNPYPIS RKRSVKNPY 0.4565 358 WB VP1 DRB1_1302 306LLSDLINRRTQKVDG LINRRTQKV 0.4527 373 WB VP1 DRB1_1302 122IGITSMLNLHAGSQK IGITSMLNL 0.4502 383 WB VP1 DRB1_1302 115VTVKTEVIGITSMLN VKTEVIGIT 0.4481 392 WB VP1 DRB1_1302 114AVTVKTEVIGITSML VKTEVIGIT 0.4425 417 WB VP1 DRB1_1302 238VTNTATTVLLDEQGV VTNTATTVL 0.4366 444 WB VP1 DRB1_1302 307LSDLINRRTQKVDGQ LINRRTQKV 0.4354 450 WB VP1 DRB1_1302 23VQVPKLLIKGGVEVL LLIKGGVEV 0.4322 466 WB VP1 DRB1_1302 266ADICGLFTNSSGTQQ LFTNSSGTQ 0.4320 466 WB VP1 DRB1_1302 267DICGLFTNSSGTQQW FTNSSGTQQ 0.4291 481 WB VP1 DRB1_1501 283GLARYFKIRLRKRSV YFKIRLRKR 0.6573 41 SB VP1 DRB1_1501 282RGLARYFKIRLRKRS YFKIRLRKR 0.6478 45 SB VP1 DRB1_1501 284LARYFKIRLRKRSVK YFKIRLRKR 0.6478 45 SB VP1 DRB1_1501 285ARYFKIRLRKRSVKN YFKIRLRKR 0.6480 45 SB VP1 DRB1_1501 281WRGLARYFKIRLRKR ARYFKIRLR 0.6307 54 WB VP1 DRB1_1501 286RYFKIRLRKRSVKNP YFKIRLRKR 0.5738 101 WB VP1 DRB1_1501 279QQWRGLARYFKIRLR WRGLARYFK 0.5664 109 WB VP1 DRB1_1501 287YFKIRLRKRSVKNPY YFKIRLRKR 0.5644 111 WB VP1 DRB1_1501 301YPISFLLSDLINRRT FLLSDLINR 0.5442 139 WB VP1 DRB1_1501 280QWRGLARYFKIRLRK ARYFKIRLR 0.5432 140 WB VP1 DRB1_1501 302PISFLLSDLINRRTQ FLLSDLINR 0.5326 157 WB VP1 DRB1_1501 303ISFLLSDLINRRTQK FLLSDLINR 0.5312 160 WB VP1 DRB1_1501 304SFLLSDLINRRTQKV LLSDLINRR 0.5284 165 WB VP1 DRB1_1501 300PYPISFLLSDLINRR FLLSDLINR 0.5247 171 WB VP1 DRB1_1501 305FLLSDLINRRTQKVD FLLSDLINR 0.5067 208 WB VP1 DRB1_1501 104LTCGNLLMWEAVTVK LLMWEAVTV 0.5050 212 WB VP1 DRB1_1501 105TCGNLLMWEAVTVKT LLMWEAVTV 0.5048 212 WB VP1 DRB1_1501 107GNLLMWEAVTVKTEV LLMWEAVTV 0.5033 216 WB VP1 DRB1_1501 106CGNLLMWEAVTVKTE LLMWEAVTV 0.5029 217 WB VP1 DRB1_1501 161LEMQGVLMNYRTKYP MQGVLMNYR 0.4970 231 WB VP1 DRB1_1501 278TQQWRGLARYFKIRL WRGLARYFK 0.4915 245 WB VP1 DRB1_1501 275SSGTQQWRGLARYFK TQQWRGLAR 0.4823 271 WB VP1 DRB1_1501 276SGTQQWRGLARYFKI TQQWRGLAR 0.4818 272 WB VP1 DRB1_1501 163MQGVLMNYRTKYPQG MQGVLMNYR 0.4769 287 WB VP1 DRB1_1501 299NPYPISFLLSDLINR ISFLLSDLI 0.4742 296 WB VP1 DRB1_1501 162EMQGVLMNYRTKYPQ MQGVLMNYR 0.4707 307 WB VP1 DRB1_1501 288FKIRLRKRSVKNPYP IRLRKRSVK 0.4578 353 WB VP1 DRB1_1501 277GTQQWRGLARYFKIR WRGLARYFK 0.4564 358 WB VP1 DRB1_1501 108NLLMWEAVTVKTEVI LLMWEAVTV 0.4524 374 WB VP1 DRB1_1501 160PLEMQGVLMNYRTKY MQGVLMNYR 0.4445 408 WB VP1 DRB1_1501 122IGITSMLNLHAGSQK ITSMLNLHA 0.4316 469 WB VP1 DRB4_0101 205YPVECWIPDPSRNEN VECWIPDPS 0.5233 174 WB VP1 DRB4_0101 203NAYPVECWIPDPSRN VECWIPDPS 0.5154 189 WB VP1 DRB4_0101 204AYPVECWIPDPSRNE VECWIPDPS 0.5145 191 WB VP1 DRB4_0101 202NNAYPVECWIPDPSR VECWIPDPS 0.5002 223 WB VP1 DRB4_0101 201KNNAYPVECWIPDPS YPVECWIPD 0.4824 271 WB VP1 DRB4_0101 206PVECWIPDPSRNENT VECWIPDPS 0.4517 377 WB VP1 DRB4_0101 207VECWIPDPSRNENTR VECWIPDPS 0.4492 388 WB VP1 DRB5_0101 285ARYFKIRLRKRSVKN FKIRLRKRS 0.6288 55 WB VP1 DRB5_0101 284LARYFKIRLRKRSVK FKIRLRKRS 0.6287 56 WB VP1 DRB5_0101 282RGLARYFKIRLRKRS YFKIRLRKR 0.6211 60 WB VP1 DRB5_0101 283GLARYFKIRLRKRSV FKIRLRKRS 0.6196 61 WB VP1 DRB5_0101 286RYFKIRLRKRSVKNP FKIRLRKRS 0.5991 77 WB VP1 DRB5_0101 287YFKIRLRKRSVKNPY FKIRLRKRS 0.5403 145 WB VP1 DRB5_0101 281WRGLARYFKIRLRKR WRGLARYFK 0.4956 235 WB VP1 DRB5_0101 288FKIRLRKRSVKNPYP FKIRLRKRS 0.4834 267 WB VP1 DRB5_0101 164QGVLMNYRTKYPQGT LMNYRTKYP 0.4622 337 WB VP1 DRB5_0101 165GVLMNYRTKYPQGTI YRTKYPQGT 0.4558 361 WB VP1 DRB5_0101 177GTITPKNPTAQSQVM ITPKNPTAQ 0.4497 386 WB VP1 DRB5_0101 71LSAENAFESDSPDRK AFESDSPDR 0.4477 394 WB VP1 DRB5_0101 72SAENAFESDSPDRKM FESDSPDRK 0.4472 396 WB VP1 DRB5_0101 73AENAFESDSPDRKML FESDSPDRK 0.4469 397 WB VP1 DRB5_0101 173KYPQGTITPKNPTAQ QGTITPKNP 0.4468 398 WB VP1 DRB5_0101 74ENAFESDSPDRKMLP FESDSPDRK 0.4464 400 WB VP1 DRB5_0101 275SSGTQQWRGLARYFK TQQWRGLAR 0.4455 403 WB VP1 DRB5_0101 174YPQGTITPKNPTAQS ITPKNPTAQ 0.4442 409 WB VP1 DRB5_0101 276SGTQQWRGLARYFKI WRGLARYFK 0.4440 410 WB VP1 DRB5_0101 279QQWRGLARYFKIRLR WRGLARYFK 0.4423 417 WB VP1 DRB5_0101 277GTQQWRGLARYFKIR WRGLARYFK 0.4408 424 WB VP1 DRB5_0101 278TQQWRGLARYFKIRL WRGLARYFK 0.4408 424 WB VP1 DRB5_0101 176QGTITPKNPTAQSQV ITPKNPTAQ 0.4392 432 WB VP1 DRB5_0101 175PQGTITPKNPTAQSQ ITPKNPTAQ 0.4390 433 WB VP1 DRB5_0101 166VLMNYRTKYPQGTIT YRTKYPQGT 0.4344 455 WB VP1 DRB5_0101 168MNYRTKYPQGTITPK YRTKYPQGT 0.4342 456 WB VP1 DRB5_0101 75NAFESDSPDRKMLPC FESDSPDRK 0.4294 480 WB VP1 SEQ ID NOS.: 59136-59917

Preferred BK virus fragments of small T antigen capable of interactingwith one or more MHC class 2 molecules are listed in Table R.

TABLE RPrediction of BK virus small t protein specific MHC class 2, 15-merpeptide binders for 14 MHC class 2 alleles (see FIG. 11) using thehttp://www.cbs.dtu.dk/services/NetMHCII/ database. The MHC class 2molecules for which no binders were found are not listed. Allele pospeptide core 1 − log50k(aff) aff(nM) B.L. Identity DRB1_0101 21RAAWGNLPLMRKAYL WGNLPLMRK 0.6972 26 SB Small t DRB1_0101 19LERAAWGNLPLMRKA WGNLPLMRK 0.6958 27 SB Small t DRB1_0101 20ERAAWGNLPLMRKAY WGNLPLMRK 0.6940 27 SB Small t DRB1_0101 22AAWGNLPLMRKAYLK WGNLPLMRK 0.6954 27 SB Small t DRB1_0101 18GLERAAWGNLPLMRK ERAAWGNLP 0.6928 28 SB Small t DRB1_0101 24WGNLPLMRKAYLKKC WGNLPLMRK 0.6020 74 WB Small t DRB1_0101 23AWGNLPLMRKAYLKK WGNLPLMRK 0.6000 76 WB Small t DRB1_0101 110PCMLCQLRLRHLNRK LCQLRLRHL 0.5884 86 WB Small t DRB1_0101 111CMLCQLRLRHLNRKF LCQLRLRHL 0.5833 91 WB Small t DRB1_0101 108HCPCMLCQLRLRHLN LCQLRLRHL 0.5732 101 WB Small t DRB1_0101 107VHCPCMLCQLRLRHL PCMLCQLRL 0.5712 104 WB Small t DRB1_0101 109CPCMLCQLRLRHLNR LCQLRLRHL 0.5711 104 WB Small t DRB1_0101 11MELMDLLGLERAAWG MDLLGLERA 0.5102 200 WB Small t DRB1_0101 113LCQLRLRHLNRKFLR LCQLRLRHL 0.5082 205 WB Small t DRB1_0101 112MLCQLRLRHLNRKFL LCQLRLRHL 0.5077 206 WB Small t DRB1_0101 121LNRKFLRKEPLVWID LRKEPLVWI 0.4900 249 WB Small t DRB1_0101 120HLNRKFLRKEPLVWI FLRKEPLVW 0.4888 252 WB Small t DRB1_0101 12ELMDLLGLERAAWGN MDLLGLERA 0.4876 256 WB Small t DRB1_0101 122NRKFLRKEPLVWIDC LRKEPLVWI 0.4836 267 WB Small t DRB1_0101 8EESMELMDLLGLERA LMDLLGLER 0.4834 268 WB Small t DRB1_0101 123RKFLRKEPLVWIDCY LRKEPLVWI 0.4822 271 WB Small t DRB1_0101 9ESMELMDLLGLERAA LMDLLGLER 0.4823 271 WB Small t DRB1_0101 48DEDKMKRMNTLYKKM MKRMNTLYK 0.4796 279 WB Small t DRB1_0101 47GDEDKMKRMNTLYKK MKRMNTLYK 0.4754 292 WB Small t DRB1_0101 10SMELMDLLGLERAAW MDLLGLERA 0.4730 299 WB Small t DRB1_0101 49EDKMKRMNTLYKKME MKRMNTLYK 0.4724 302 WB Small t DRB1_0101 50DKMKRMNTLYKKMEQ MKRMNTLYK 0.4699 310 WB Small t DRB1_0101 46GGDEDKMKRMNTLYK DKMKRMNTL 0.4690 313 WB Small t DRB1_0101 2DKVLNREESMELMDL LNREESMEL 0.4683 315 WB Small t DRB1_0101 3KVLNREESMELMDLL LNREESMEL 0.4672 319 WB Small t DRB1_0101 125FLRKEPLVWIDCYCI LRKEPLVWI 0.4622 337 WB Small t DRB1_0101 13LMDLLGLERAAWGNL LGLERAAWG 0.4572 355 WB Small t DRB1_0101 1MDKVLNREESMELMD LNREESMEL 0.4521 376 WB Small t DRB1_0101 124KFLRKEPLVWIDCYC LRKEPLVWI 0.4493 387 WB Small t DRB1_0101 14MDLLGLERAAWGNLP LGLERAAWG 0.4451 405 WB Small t DRB1_0101 5LNREESMELMDLLGL LNREESMEL 0.4397 429 WB Small t DRB1_0101 126LRKEPLVWIDCYCID LRKEPLVWI 0.4391 432 WB Small t DRB1_0101 7REESMELMDLLGLER MELMDLLGL 0.4355 449 WB Small t DRB1_0101 91DTLYCKEWPICSKKP YCKEWPICS 0.4339 457 WB Small t DRB1_0101 92TLYCKEWPICSKKPS YCKEWPICS 0.4323 465 WB Small t DRB1_0101 140DCFTQWFGLDLTEET FTQWFGLDL 0.4291 482 WB Small t DRB1_0401 92TLYCKEWPICSKKPS YCKEWPICS 0.5564 121 WB Small t DRB1_0401 91DTLYCKEWPICSKKP YCKEWPICS 0.5500 130 WB Small t DRB1_0401 90PDTLYCKEWPICSKK YCKEWPICS 0.5447 138 WB Small t DRB1_0401 89CPDTLYCKEWPICSK YCKEWPICS 0.5423 141 WB Small t DRB1_0401 88LCPDTLYCKEWPICS LYCKEWPIC 0.5400 145 WB Small t DRB1_0401 47GDEDKMKRMNTLYKK MKRMNTLYK 0.5015 220 WB Small t DRB1_0401 48DEDKMKRMNTLYKKM MKRMNTLYK 0.4994 225 WB Small t DRB1_0401 46GGDEDKMKRMNTLYK KMKRMNTLY 0.4992 226 WB Small t DRB1_0401 49EDKMKRMNTLYKKME MKRMNTLYK 0.4991 226 WB Small t DRB1_0401 50DKMKRMNTLYKKMEQ MKRMNTLYK 0.4948 237 WB Small t DRB1_0401 94YCKEWPICSKKPSVH YCKEWPICS 0.4689 313 WB Small t DRB1_0401 93LYCKEWPICSKKPSV YCKEWPICS 0.4677 317 WB Small t DRB1_0405 49EDKMKRMNTLYKKME MKRMNTLYK 0.5687 106 WB Small t DRB1_0405 50DKMKRMNTLYKKMEQ MKRMNTLYK 0.5662 109 WB Small t DRB1_0405 47GDEDKMKRMNTLYKK MKRMNTLYK 0.5447 138 WB Small t DRB1_0405 46GGDEDKMKRMNTLYK DKMKRMNTL 0.5432 140 WB Small t DRB1_0405 48DEDKMKRMNTLYKKM MKRMNTLYK 0.5413 143 WB Small t DRB1_0405 152EETLQWWVQIIGETP LQWWVQIIG 0.5365 151 WB Small t DRB1_0405 151TEETLQWWVQIIGET LQWWVQIIG 0.5328 157 WB Small t DRB1_0405 150LTEETLQWWVQIIGE LQWWVQIIG 0.5314 159 WB Small t DRB1_0405 153ETLQWWVQIIGETPF LQWWVQIIG 0.5290 163 WB Small t DRB1_0405 149DLTEETLQWWVQIIG TLQWWVQII 0.5260 169 WB Small t DRB1_0405 18GLERAAWGNLPLMRK RAAWGNLPL 0.5095 202 WB Small t DRB1_0405 19LERAAWGNLPLMRKA RAAWGNLPL 0.4956 235 WB Small t DRB1_0405 137YCIDCFTQWFGLDLT FTQWFGLDL 0.4951 236 WB Small t DRB1_0405 139IDCFTQWFGLDLTEE TQWFGLDLT 0.4864 259 WB Small t DRB1_0405 51KMKRMNTLYKKMEQD MKRMNTLYK 0.4857 261 WB Small t DRB1_0405 52MKRMNTLYKKMEQDV MKRMNTLYK 0.4857 261 WB Small t DRB1_0405 138CIDCFTQWFGLDLTE TQWFGLDLT 0.4851 263 WB Small t DRB1_0405 155LQWWVQIIGETPFRD LQWWVQIIG 0.4691 312 WB Small t DRB1_0405 140DCFTQWFGLDLTEET TQWFGLDLT 0.4671 319 WB Small t DRB1_0405 69AHQPDFGTWNSSEVC FGTWNSSEV 0.4648 327 WB Small t DRB1_0405 68VAHQPDFGTWNSSEV QPDFGTWNS 0.4624 336 WB Small t DRB1_0405 20ERAAWGNLPLMRKAY WGNLPLMRK 0.4570 356 WB Small t DRB1_0405 71QPDFGTWNSSEVCAD FGTWNSSEV 0.4550 364 WB Small t DRB1_0405 17LGLERAAWGNLPLMR RAAWGNLPL 0.4515 378 WB Small t DRB1_0405 70HQPDFGTWNSSEVCA FGTWNSSEV 0.4467 398 WB Small t DRB1_0405 154TLQWWVQIIGETPFR LQWWVQIIG 0.4465 399 WB Small t DRB1_0405 16LLGLERAAWGNLPLM RAAWGNLPL 0.4465 399 WB Small t DRB1_0405 15DLLGLERAAWGNLPL ERAAWGNLP 0.4401 427 WB Small t DRB1_0405 136CYCIDCFTQWFGLDL IDCFTQWFG 0.4322 465 WB Small t DRB1_0405 141CFTQWFGLDLTEETL TQWFGLDLT 0.4323 465 WB Small t DRB1_0405 72PDFGTWNSSEVCADF FGTWNSSEV 0.4300 477 WB Small t DRB1_0701 95CKEWPICSKKPSVHC ICSKKPSVH 0.4880 255 WB Small t DRB1_0701 96KEWPICSKKPSVHCP ICSKKPSVH 0.4829 269 WB Small t DRB1_0701 97EWPICSKKPSVHCPC ICSKKPSVH 0.4823 271 WB Small t DRB1_0701 98WPICSKKPSVHCPCM ICSKKPSVH 0.4807 276 WB Small t DRB1_0701 94YCKEWPICSKKPSVH PICSKKPSV 0.4738 297 WB Small t DRB1_0701 70HQPDFGTWNSSEVCA FGTWNSSEV 0.4721 303 WB Small t DRB1_0701 71QPDFGTWNSSEVCAD FGTWNSSEV 0.4716 304 WB Small t DRB1_0701 68VAHQPDFGTWNSSEV DFGTWNSSE 0.4709 306 WB Small t DRB1_0701 69AHQPDFGTWNSSEVC FGTWNSSEV 0.4705 308 WB Small t DRB1_0701 72PDFGTWNSSEVCADF FGTWNSSEV 0.4685 314 WB Small t DRB1_1101 47GDEDKMKRMNTLYKK MKRMNTLYK 0.4550 364 WB Small t DRB1_1101 49EDKMKRMNTLYKKME MKRMNTLYK 0.4498 385 WB Small t DRB1_1101 48DEDKMKRMNTLYKKM MKRMNTLYK 0.4495 386 WB Small t DRB1_1101 50DKMKRMNTLYKKMEQ MKRMNTLYK 0.4483 391 WB Small t DRB1_1101 46GGDEDKMKRMNTLYK EDKMKRMNT 0.4433 413 WB Small t DRB1_1101 18GLERAAWGNLPLMRK AWGNLPLMR 0.4312 471 WB Small t DRB1_1101 19LERAAWGNLPLMRKA WGNLPLMRK 0.4311 471 WB Small t DRB1_1101 21RAAWGNLPLMRKAYL WGNLPLMRK 0.4288 483 WB Small t DRB1_1101 20ERAAWGNLPLMRKAY WGNLPLMRK 0.4279 488 WB Small t DRB1_1302 18GLERAAWGNLPLMRK LERAAWGNL 0.5752 99 WB Small t DRB1_1302 21RAAWGNLPLMRKAYL WGNLPLMRK 0.5714 103 WB Small t DRB1_1302 22AAWGNLPLMRKAYLK WGNLPLMRK 0.5704 104 WB Small t DRB1_1302 19LERAAWGNLPLMRKA WGNLPLMRK 0.5702 105 WB Small t DRB1_1302 20ERAAWGNLPLMRKAY WGNLPLMRK 0.5531 126 WB Small t DRB1_1302 48DEDKMKRMNTLYKKM MKRMNTLYK 0.5012 221 WB Small t DRB1_1302 49EDKMKRMNTLYKKME MKRMNTLYK 0.4986 227 WB Small t DRB1_1302 50DKMKRMNTLYKKMEQ MKRMNTLYK 0.4966 232 WB Small t DRB1_1302 47GDEDKMKRMNTLYKK MKRMNTLYK 0.4940 239 WB Small t DRB1_1302 24WGNLPLMRKAYLKKC WGNLPLMRK 0.4926 242 WB Small t DRB1_1302 23AWGNLPLMRKAYLKK WGNLPLMRK 0.4885 253 WB Small t DRB1_1302 153ETLQWWVQIIGETPF WWVQIIGET 0.4827 270 WB Small t DRB1_1302 46GGDEDKMKRMNTLYK DKMKRMNTL 0.4800 278 WB Small t DRB1_1302 155LQWWVQIIGETPFRD VQIIGETPF 0.4679 317 WB Small t DRB1_1302 154TLQWWVQIIGETPFR VQIIGETPF 0.4659 323 WB Small t DRB1_1302 113LCQLRLRHLNRKFLR LRLRHLNRK 0.4607 342 WB Small t DRB1_1302 112MLCQLRLRHLNRKFL LRLRHLNRK 0.4561 360 WB Small t DRB1_1302 114CQLRLRHLNRKFLRK LRLRHLNRK 0.4549 364 WB Small t DRB1_1302 156QWWVQIIGETPFRDL VQIIGETPF 0.4401 427 WB Small t DRB1_1302 51KMKRMNTLYKKMEQD MKRMNTLYK 0.4272 492 WB Small t DRB1_1501 111CMLCQLRLRHLNRKF LRLRHLNRK 0.5327 157 WB Small t DRB1_1501 110PCMLCQLRLRHLNRK QLRLRHLNR 0.5274 166 WB Small t DRB1_1501 48DEDKMKRMNTLYKKM MKRMNTLYK 0.5229 174 WB Small t DRB1_1501 49EDKMKRMNTLYKKME MKRMNTLYK 0.5190 182 WB Small t DRB1_1501 24WGNLPLMRKAYLKKC LMRKAYLKK 0.5176 185 WB Small t DRB1_1501 113LCQLRLRHLNRKFLR LRLRHLNRK 0.5166 187 WB Small t DRB1_1501 50DKMKRMNTLYKKMEQ MKRMNTLYK 0.5153 190 WB Small t DRB1_1501 47GDEDKMKRMNTLYKK MKRMNTLYK 0.5147 191 WB Small t DRB1_1501 112MLCQLRLRHLNRKFL LRLRHLNRK 0.5140 192 WB Small t DRB1_1501 23AWGNLPLMRKAYLKK LPLMRKAYL 0.5076 206 WB Small t DRB1_1501 25GNLPLMRKAYLKKCK LMRKAYLKK 0.5063 209 WB Small t DRB1_1501 46GGDEDKMKRMNTLYK DKMKRMNTL 0.5026 217 WB Small t DRB1_1501 26NLPLMRKAYLKKCKE LMRKAYLKK 0.4961 233 WB Small t DRB1_1501 114CQLRLRHLNRKFLRK LRLRHLNRK 0.4919 244 WB Small t DRB1_1501 27LPLMRKAYLKKCKEF LMRKAYLKK 0.4850 263 WB Small t DRB1_1501 13LMDLLGLERAAWGNL LMDLLGLER 0.4683 315 WB Small t DRB1_1501 11MELMDLLGLERAAWG LMDLLGLER 0.4651 326 WB Small t DRB1_1501 115QLRLRHLNRKFLRKE LRLRHLNRK 0.4643 329 WB Small t DRB1_1501 120HLNRKFLRKEPLVWI FLRKEPLVW 0.4621 337 WB Small t DRB1_1501 121LNRKFLRKEPLVWID FLRKEPLVW 0.4374 440 WB Small t DRB1_1501 28PLMRKAYLKKCKEFH LMRKAYLKK 0.4332 461 WB Small t DRB1_1501 51KMKRMNTLYKKMEQD MKRMNTLYK 0.4331 461 WB Small t DRB1_1501 123RKFLRKEPLVWIDCY FLRKEPLVW 0.4300 477 WB Small t DRB1_1501 10SMELMDLLGLERAAW LMDLLGLER 0.4261 497 WB Small t DRB4_0101 94YCKEWPICSKKPSVH YCKEWPICS 0.5706 104 WB Small t DRB4_0101 112MLCQLRLRHLNRKFL LRLRHLNRK 0.5364 151 WB Small t DRB4_0101 113LCQLRLRHLNRKFLR LRLRHLNRK 0.5342 155 WB Small t DRB4_0101 111CMLCQLRLRHLNRKF LRLRHLNRK 0.5331 156 WB Small t DRB4_0101 110PCMLCQLRLRHLNRK LCQLRLRHL 0.5322 158 WB Small t DRB4_0101 95CKEWPICSKKPSVHC ICSKKPSVH 0.5323 158 WB Small t DRB4_0101 114CQLRLRHLNRKFLRK LRLRHLNRK 0.5291 163 WB Small t DRB4_0101 96KEWPICSKKPSVHCP ICSKKPSVH 0.5267 167 WB Small t DRB4_0101 97EWPICSKKPSVHCPC ICSKKPSVH 0.5247 171 WB Small t DRB4_0101 98WPICSKKPSVHCPCM ICSKKPSVH 0.5172 186 WB Small t DRB4_0101 115QLRLRHLNRKFLRKE LRLRHLNRK 0.4556 361 WB Small t DRB4_0101 116LRLRHLNRKFLRKEP LRLRHLNRK 0.4510 380 WB Small t DRB4_0101 100ICSKKPSVHCPCMLC ICSKKPSVH 0.4432 413 WB Small t DRB4_0101 99PICSKKPSVHCPCML ICSKKPSVH 0.4374 440 WB Small t DRB5_0101 49EDKMKRMNTLYKKME MKRMNTLYK 0.4763 289 WB Small t DRB5_0101 50DKMKRMNTLYKKMEQ MKRMNTLYK 0.4758 290 WB Small t DRB5_0101 48DEDKMKRMNTLYKKM MKRMNTLYK 0.4726 301 WB Small t DRB5_0101 47GDEDKMKRMNTLYKK MKRMNTLYK 0.4617 338 WB Small t DRB5_0101 46GGDEDKMKRMNTLYK DKMKRMNTL 0.4567 357 WB Small t DRB5_0101 112MLCQLRLRHLNRKFL LRLRHLNRK 0.4397 429 WB Small t DRB5_0101 114CQLRLRHLNRKFLRK LRHLNRKFL 0.4398 429 WB Small t DRB5_0101 53KRMNTLYKKMEQDVK KRMNTLYKK 0.4284 485 WB Small t DRB5_0101 22AAWGNLPLMRKAYLK WGNLPLMRK 0.4268 494 WB Small t SEQ ID NOS.: 59918-60257

Preferred BK virus fragments of large T antigen capable of interactingwith one or more MHC class 2 molecules are listed in Table S.

TABLE SPrediction of BK virus Large T protein specific MHC class 2, 15-merpeptide binders for 14 MHC class 2 alleles (see FIG. 11) using thehttp://www.cbs.dtu.dk/services/NetMHCII/database. The MHC class 2molecules for which no binders were found are not listed. Allele pospeptide core 1 − log50k(aff) aff(nM) B.L. Identity DRB1_0101 566LEKRILQSGMTLLLL LQSGMTLLL 0.7526 15 SB Large T DRB1_0101 567EKRILQSGMTLLLLL LQSGMTLLL 0.7519 15 SB Large T DRB1_0101 568KRILQSGMTLLLLLI LQSGMTLLL 0.7525 15 SB Large T DRB1_0101 569RILQSGMTLLLLLIW LQSGMTLLL 0.7504 15 SB Large T DRB1_0101 565LLEKRILQSGMTLLL KRILQSGMT 0.7441 16 SB Large T DRB1_0101 21RAAWGNLPLMRKAYL WGNLPLMRK 0.6972 26 SB Large T DRB1_0101 19LERAAWGNLPLMRKA WGNLPLMRK 0.6958 27 SB Large T DRB1_0101 20ERAAWGNLPLMRKAY WGNLPLMRK 0.6940 27 SB Large T DRB1_0101 22AAWGNLPLMRKAYLK WGNLPLMRK 0.6954 27 SB Large T DRB1_0101 18GLERAAWGNLPLMRK ERAAWGNLP 0.6928 28 SB Large T DRB1_0101 570ILQSGMTLLLLLIWF LQSGMTLLL 0.6646 38 SB Large T DRB1_0101 571LQSGMTLLLLLIWFR LQSGMTLLL 0.6561 41 SB Large T DRB1_0101 383NAVLEQYMAGVAWLH EQYMAGVAW 0.6528 43 SB Large T DRB1_0101 387EQYMAGVAWLHCLLP YMAGVAWLH 0.6516 43 SB Large T DRB1_0101 385VLEQYMAGVAWLHCL YMAGVAWLH 0.6507 44 SB Large T DRB1_0101 384AVLEQYMAGVAWLHC YMAGVAWLH 0.6486 45 SB Large T DRB1_0101 386LEQYMAGVAWLHCLL YMAGVAWLH 0.6483 45 SB Large T DRB1_0101 441LLDLCGGKALNVNLP LCGGKALNV 0.6340 52 WB Large T DRB1_0101 144LHQFLSQAVFSNRTL LHQFLSQAV 0.6329 53 WB Large T DRB1_0101 143DLHQFLSQAVFSNRT LHQFLSQAV 0.6318 54 WB Large T DRB1_0101 442LDLCGGKALNVNLPM LCGGKALNV 0.6310 54 WB Large T DRB1_0101 439AGLLDLCGGKALNVN LCGGKALNV 0.6263 57 WB Large T DRB1_0101 440GLLDLCGGKALNVNL LCGGKALNV 0.6223 60 WB Large T DRB1_0101 438AAGLLDLCGGKALNV LLDLCGGKA 0.6207 61 WB Large T DRB1_0101 142SDLHQFLSQAVFSNR LHQFLSQAV 0.6178 62 WB Large T DRB1_0101 141PSDLHQFLSQAVFSN LHQFLSQAV 0.6165 63 WB Large T DRB1_0101 533YPVPKTLQARFVRQI PKTLQARFV 0.6160 64 WB Large T DRB1_0101 534PVPKTLQARFVRQID LQARFVRQI 0.6136 65 WB Large T DRB1_0101 140FPSDLHQFLSQAVFS LHQFLSQAV 0.6083 69 WB Large T DRB1_0101 138KDFPSDLHQFLSQAV FPSDLHQFL 0.6036 73 WB Large T DRB1_0101 139DFPSDLHQFLSQAVF LHQFLSQAV 0.6019 74 WB Large T DRB1_0101 24WGNLPLMRKAYLKKC WGNLPLMRK 0.6020 74 WB Large T DRB1_0101 23AWGNLPLMRKAYLKK WGNLPLMRK 0.6000 76 WB Large T DRB1_0101 517NKRTQIFPPGLVTMN IFPPGLVTM 0.5951 80 WB Large T DRB1_0101 518KRTQIFPPGLVTMNE IFPPGLVTM 0.5907 84 WB Large T DRB1_0101 428GPIDSGKTTLAAGLL IDSGKTTLA 0.5880 86 WB Large T DRB1_0101 519RTQIFPPGLVTMNEY IFPPGLVTM 0.5871 87 WB Large T DRB1_0101 520TQIFPPGLVTMNEYP IFPPGLVTM 0.5843 90 WB Large T DRB1_0101 268KQVSWKLITEYAVET WKLITEYAV 0.5795 95 WB Large T DRB1_0101 269QVSWKLITEYAVETK LITEYAVET 0.5780 96 WB Large T DRB1_0101 284CEDVFLLLGMYLEFQ VFLLLGMYL 0.5771 97 WB Large T DRB1_0101 285EDVFLLLGMYLEFQY VFLLLGMYL 0.5774 97 WB Large T DRB1_0101 535VPKTLQARFVRQIDF LQARFVRQI 0.5743 100 WB Large T DRB1_0101 536PKTLQARFVRQIDFR LQARFVRQI 0.5746 100 WB Large T DRB1_0101 270VSWKLITEYAVETKC LITEYAVET 0.5715 103 WB Large T DRB1_0101 147FLSQAVFSNRTLACF SQAVFSNRT 0.5698 105 WB Large T DRB1_0101 388QYMAGVAWLHCLLPK YMAGVAWLH 0.5680 107 WB Large T DRB1_0101 603ERLDSEISMYTFSRM LDSEISMYT 0.5669 108 WB Large T DRB1_0101 389YMAGVAWLHCLLPKM YMAGVAWLH 0.5664 109 WB Large T DRB1_0101 448KALNVNLPMERLTFE LNVNLPMER 0.5655 110 WB Large T DRB1_0101 444LCGGKALNVNLPMER LCGGKALNV 0.5641 112 WB Large T DRB1_0101 446GGKALNVNLPMERLT LNVNLPMER 0.5640 112 WB Large T DRB1_0101 425LFKGPIDSGKTTLAA IDSGKTTLA 0.5627 113 WB Large T DRB1_0101 447GKALNVNLPMERLTF LNVNLPMER 0.5619 114 WB Large T DRB1_0101 427KGPIDSGKTTLAAGL IDSGKTTLA 0.5613 115 WB Large T DRB1_0101 599VEWKERLDSEISMYT KERLDSEIS 0.5611 115 WB Large T DRB1_0101 445CGGKALNVNLPMERL LNVNLPMER 0.5598 117 WB Large T DRB1_0101 490GHGINNLDSLRDYLD INNLDSLRD 0.5597 117 WB Large T DRB1_0101 271SWKLITEYAVETKCE LITEYAVET 0.5583 119 WB Large T DRB1_0101 489SGHGINNLDSLRDYL INNLDSLRD 0.5574 120 WB Large T DRB1_0101 491HGINNLDSLRDYLDG INNLDSLRD 0.5573 120 WB Large T DRB1_0101 424WLFKGPIDSGKTTLA KGPIDSGKT 0.5567 121 WB Large T DRB1_0101 487LPSGHGINNLDSLRD LPSGHGINN 0.5568 121 WB Large T DRB1_0101 530MNEYPVPKTLQARFV YPVPKTLQA 0.5570 121 WB Large T DRB1_0101 426FKGPIDSGKTTLAAG IDSGKTTLA 0.5562 122 WB Large T DRB1_0101 600EWKERLDSEISMYTF LDSEISMYT 0.5562 122 WB Large T DRB1_0101 602KERLDSEISMYTFSR LDSEISMYT 0.5560 122 WB Large T DRB1_0101 488PSGHGINNLDSLRDY INNLDSLRD 0.5554 123 WB Large T DRB1_0101 601WKERLDSEISMYTFS LDSEISMYT 0.5538 125 WB Large T DRB1_0101 272WKLITEYAVETKCED LITEYAVET 0.5514 128 WB Large T DRB1_0101 531NEYPVPKTLQARFVR PKTLQARFV 0.5518 128 WB Large T DRB1_0101 521QIFPPGLVTMNEYPV FPPGLVTMN 0.5507 129 WB Large T DRB1_0101 443DLCGGKALNVNLPME LCGGKALNV 0.5488 132 WB Large T DRB1_0101 228VNKEYLLYSALTRDP YLLYSALTR 0.5454 137 WB Large T DRB1_0101 145HQFLSQAVFSNRTLA SQAVFSNRT 0.5437 139 WB Large T DRB1_0101 374MDLIFGAHGNAVLEQ IFGAHGNAV 0.5440 139 WB Large T DRB1_0101 375DLIFGAHGNAVLEQY IFGAHGNAV 0.5439 139 WB Large T DRB1_0101 229NKEYLLYSALTRDPY LYSALTRDP 0.5434 140 WB Large T DRB1_0101 146QFLSQAVFSNRTLAC SQAVFSNRT 0.5423 141 WB Large T DRB1_0101 373KMDLIFGAHGNAVLE IFGAHGNAV 0.5366 150 WB Large T DRB1_0101 564FLLEKRILQSGMTLL KRILQSGMT 0.5369 150 WB Large T DRB1_0101 372DKMDLIFGAHGNAVL IFGAHGNAV 0.5366 151 WB Large T DRB1_0101 230KEYLLYSALTRDPYH LYSALTRDP 0.5334 156 WB Large T DRB1_0101 449ALNVNLPMERLTFEL NVNLPMERL 0.5320 158 WB Large T DRB1_0101 286DVFLLLGMYLEFQYN LLGMYLEFQ 0.5310 160 WB Large T DRB1_0101 232YLLYSALTRDPYHII LYSALTRDP 0.5298 162 WB Large T DRB1_0101 338ICQQAVDTVLAKKRV QQAVDTVLA 0.5273 166 WB Large T DRB1_0101 430IDSGKTTLAAGLLDL IDSGKTTLA 0.5269 167 WB Large T DRB1_0101 149SQAVFSNRTLACFAV FSNRTLACF 0.5259 169 WB Large T DRB1_0101 337SICQQAVDTVLAKKR QQAVDTVLA 0.5252 170 WB Large T DRB1_0101 148LSQAVFSNRTLACFA FSNRTLACF 0.5244 172 WB Large T DRB1_0101 231EYLLYSALTRDPYHI LYSALTRDP 0.5238 173 WB Large T DRB1_0101 522IFPPGLVTMNEYPVP IFPPGLVTM 0.5236 173 WB Large T DRB1_0101 532EYPVPKTLQARFVRQ PKTLQARFV 0.5222 176 WB Large T DRB1_0101 429PIDSGKTTLAAGLLD IDSGKTTLA 0.5198 180 WB Large T DRB1_0101 516LNKRTQIFPPGLVTM RTQIFPPGL 0.5156 189 WB Large T DRB1_0101 287VFLLLGMYLEFQYNV VFLLLGMYL 0.5144 191 WB Large T DRB1_0101 11MELMDLLGLERAAWG MDLLGLERA 0.5102 200 WB Large T DRB1_0101 473VFEDVKGTGAESKDL VKGTGAESK 0.5100 201 WB Large T DRB1_0101 474FEDVKGTGAESKDLP VKGTGAESK 0.5088 203 WB Large T DRB1_0101 537KTLQARFVRQIDFRP LQARFVRQI 0.5092 203 WB Large T DRB1_0101 475EDVKGTGAESKDLPS VKGTGAESK 0.5068 208 WB Large T DRB1_0101 195NIIFFLTPHRHRVSA IFFLTPHRH 0.5062 209 WB Large T DRB1_0101 335QKSICQQAVDTVLAK ICQQAVDTV 0.5063 209 WB Large T DRB1_0101 194HNIIFFLTPHRHRVS IFFLTPHRH 0.5053 211 WB Large T DRB1_0101 336KSICQQAVDTVLAKK ICQQAVDTV 0.5051 212 WB Large T DRB1_0101 334NQKSICQQAVDTVLA ICQQAVDTV 0.5035 215 WB Large T DRB1_0101 450LNVNLPMERLTFELG NVNLPMERL 0.5031 216 WB Large T DRB1_0101 527LVTMNEYPVPKTLQA MNEYPVPKT 0.5027 217 WB Large T DRB1_0101 528VTMNEYPVPKTLQAR YPVPKTLQA 0.5012 221 WB Large T DRB1_0101 371LDKMDLIFGAHGNAV LDKMDLIFG 0.4990 226 WB Large T DRB1_0101 572QSGMTLLLLLIWFRP MTLLLLLIW 0.4975 230 WB Large T DRB1_0101 282TKCEDVFLLLGMYLE VFLLLGMYL 0.4937 239 WB Large T DRB1_0101 283KCEDVFLLLGMYLEF VFLLLGMYL 0.4920 244 WB Large T DRB1_0101 376LIFGAHGNAVLEQYM FGAHGNAVL 0.4919 244 WB Large T DRB1_0101 394AWLHCLLPKMDSVIF LLPKMDSVI 0.4910 246 WB Large T DRB1_0101 604RLDSEISMYTFSRMK LDSEISMYT 0.4900 249 WB Large T DRB1_0101 605LDSEISMYTFSRMKY LDSEISMYT 0.4889 252 WB Large T DRB1_0101 12ELMDLLGLERAAWGN MDLLGLERA 0.4876 256 WB Large T DRB1_0101 472VVFEDVKGTGAESKD VKGTGAESK 0.4858 261 WB Large T DRB1_0101 471MVVFEDVKGTGAESK FEDVKGTGA 0.4853 262 WB Large T DRB1_0101 340QQAVDTVLAKKRVDT VDTVLAKKR 0.4843 265 WB Large T DRB1_0101 172ILYKKLMEKYSVTFI YKKLMEKYS 0.4836 267 WB Large T DRB1_0101 339CQQAVDTVLAKKRVD VDTVLAKKR 0.4837 267 WB Large T DRB1_0101 8EESMELMDLLGLERA LMDLLGLER 0.4834 268 WB Large T DRB1_0101 9ESMELMDLLGLERAA LMDLLGLER 0.4823 271 WB Large T DRB1_0101 395WLHCLLPKMDSVIFD LPKMDSVIF 0.4815 273 WB Large T DRB1_0101 256EHDFNPEEPEETKQV FNPEEPEET 0.4804 276 WB Large T DRB1_0101 152VFSNRTLACFAVYTT TLACFAVYT 0.4803 277 WB Large T DRB1_0101 257HDFNPEEPEETKQVS FNPEEPEET 0.4796 279 WB Large T DRB1_0101 48DEDKMKRMNTLYKKM MKRMNTLYK 0.4796 279 WB Large T DRB1_0101 255KEHDFNPEEPEETKQ FNPEEPEET 0.4792 280 WB Large T DRB1_0101 396LHCLLPKMDSVIFDF LPKMDSVIF 0.4778 284 WB Large T DRB1_0101 254LKEHDFNPEEPEETK FNPEEPEET 0.4775 285 WB Large T DRB1_0101 150QAVFSNRTLACFAVY FSNRTLACF 0.4767 288 WB Large T DRB1_0101 563EFLLEKRILQSGMTL KRILQSGMT 0.4767 288 WB Large T DRB1_0101 226KGVNKEYLLYSALTR EYLLYSALT 0.4763 289 WB Large T DRB1_0101 548DFRPKIYLRKSLQNS FRPKIYLRK 0.4755 291 WB Large T DRB1_0101 47GDEDKMKRMNTLYKK MKRMNTLYK 0.4754 292 WB Large T DRB1_0101 549FRPKIYLRKSLQNSE YLRKSLQNS 0.4751 293 WB Large T DRB1_0101 171QILYKKLMEKYSVTF YKKLMEKYS 0.4745 295 WB Large T DRB1_0101 253GLKEHDFNPEEPEET GLKEHDFNP 0.4744 295 WB Large T DRB1_0101 196IIFFLTPHRHRVSAI LTPHRHRVS 0.4734 298 WB Large T DRB1_0101 397HCLLPKMDSVIFDFL LPKMDSVIF 0.4735 298 WB Large T DRB1_0101 10SMELMDLLGLERAAW MDLLGLERA 0.4730 299 WB Large T DRB1_0101 578LLLLIWFRPVADFSK LIWFRPVAD 0.4729 300 WB Large T DRB1_0101 49EDKMKRMNTLYKKME MKRMNTLYK 0.4724 302 WB Large T DRB1_0101 562SEFLLEKRILQSGMT LEKRILQSG 0.4722 302 WB Large T DRB1_0101 579LLLIWFRPVADFSKD LIWFRPVAD 0.4723 302 WB Large T DRB1_0101 551PKIYLRKSLQNSEFL YLRKSLQNS 0.4719 303 WB Large T DRB1_0101 523FPPGLVTMNEYPVPK FPPGLVTMN 0.4709 306 WB Large T DRB1_0101 197IFFLTPHRHRVSAIN LTPHRHRVS 0.4697 310 WB Large T DRB1_0101 50DKMKRMNTLYKKMEQ MKRMNTLYK 0.4699 310 WB Large T DRB1_0101 550RPKIYLRKSLQNSEF YLRKSLQNS 0.4698 310 WB Large T DRB1_0101 46GGDEDKMKRMNTLYK DKMKRMNTL 0.4690 313 WB Large T DRB1_0101 2DKVLNREESMELMDL LNREESMEL 0.4683 315 WB Large T DRB1_0101 577LLLLLIWFRPVADFS LIWFRPVAD 0.4684 315 WB Large T DRB1_0101 153FSNRTLACFAVYTTK LACFAVYTT 0.4677 317 WB Large T DRB1_0101 3KVLNREESMELMDLL LNREESMEL 0.4672 319 WB Large T DRB1_0101 281ETKCEDVFLLLGMYL EDVFLLLGM 0.4666 321 WB Large T DRB1_0101 573SGMTLLLLLIWFRPV MTLLLLLIW 0.4649 327 WB Large T DRB1_0101 493INNLDSLRDYLDGSV INNLDSLRD 0.4638 331 WB Large T DRB1_0101 524PPGLVTMNEYPVPKT LVTMNEYPV 0.4635 332 WB Large T DRB1_0101 525PGLVTMNEYPVPKTL MNEYPVPKT 0.4633 333 WB Large T DRB1_0101 151AVFSNRTLACFAVYT FSNRTLACF 0.4625 336 WB Large T DRB1_0101 492GINNLDSLRDYLDGS INNLDSLRD 0.4622 336 WB Large T DRB1_0101 227GVNKEYLLYSALTRD YLLYSALTR 0.4619 338 WB Large T DRB1_0101 529TMNEYPVPKTLQARF YPVPKTLQA 0.4598 345 WB Large T DRB1_0101 459LTFELGVAIDQYMVV LGVAIDQYM 0.4589 349 WB Large T DRB1_0101 457ERLTFELGVAIDQYM LTFELGVAI 0.4584 351 WB Large T DRB1_0101 398CLLPKMDSVIFDFLH LPKMDSVIF 0.4578 353 WB Large T DRB1_0101 552KIYLRKSLQNSEFLL YLRKSLQNS 0.4575 354 WB Large T DRB1_0101 13LMDLLGLERAAWGNL LGLERAAWG 0.4572 355 WB Large T DRB1_0101 575MTLLLLLIWFRPVAD MTLLLLLIW 0.4574 355 WB Large T DRB1_0101 451NVNLPMERLTFELGV NVNLPMERL 0.4555 362 WB Large T DRB1_0101 193GHNIIFFLTPHRHRV IFFLTPHRH 0.4529 372 WB Large T DRB1_0101 1MDKVLNREESMELMD LNREESMEL 0.4521 376 WB Large T DRB1_0101 432SGKTTLAAGLLDLCG KTTLAAGLL 0.4504 382 WB Large T DRB1_0101 233LLYSALTRDPYHIIE LYSALTRDP 0.4500 384 WB Large T DRB1_0101 377IFGAHGNAVLEQYMA IFGAHGNAV 0.4493 387 WB Large T DRB1_0101 273KLITEYAVETKCEDV LITEYAVET 0.4490 388 WB Large T DRB1_0101 458RLTFELGVAIDQYMV LGVAIDQYM 0.4476 394 WB Large T DRB1_0101 234LYSALTRDPYHIIEE LYSALTRDP 0.4472 396 WB Large T DRB1_0101 422RYWLFKGPIDSGKTT WLFKGPIDS 0.4473 396 WB Large T DRB1_0101 421RRYWLFKGPIDSGKT WLFKGPIDS 0.4465 399 WB Large T DRB1_0101 274LITEYAVETKCEDVF LITEYAVET 0.4460 401 WB Large T DRB1_0101 14MDLLGLERAAWGNLP LGLERAAWG 0.4451 405 WB Large T DRB1_0101 476DVKGTGAESKDLPSG VKGTGAESK 0.4428 415 WB Large T DRB1_0101 477VKGTGAESKDLPSGH VKGTGAESK 0.4412 422 WB Large T DRB1_0101 526GLVTMNEYPVPKTLQ MNEYPVPKT 0.4408 424 WB Large T DRB1_0101 174YKKLMEKYSVTFISR LMEKYSVTF 0.4406 425 WB Large T DRB1_0101 390MAGVAWLHCLLPKMD VAWLHCLLP 0.4407 425 WB Large T DRB1_0101 173LYKKLMEKYSVTFIS LMEKYSVTF 0.4405 426 WB Large T DRB1_0101 5LNREESMELMDLLGL LNREESMEL 0.4397 429 WB Large T DRB1_0101 580LLIWFRPVADFSKDI WFRPVADFS 0.4370 442 WB Large T DRB1_0101 391AGVAWLHCLLPKMDS VAWLHCLLP 0.4368 443 WB Large T DRB1_0101 7REESMELMDLLGLER MELMDLLGL 0.4355 449 WB Large T DRB1_0101 341QAVDTVLAKKRVDTL VDTVLAKKR 0.4341 456 WB Large T DRB1_0101 431DSGKTTLAAGLLDLC KTTLAAGLL 0.4339 457 WB Large T DRB1_0101 155NRTLACFAVYTTKEK LACFAVYTT 0.4312 471 WB Large T DRB1_0101 192AGHNIIFFLTPHRHR IFFLTPHRH 0.4310 472 WB Large T DRB1_0101 538TLQARFVRQIDFRPK LQARFVRQI 0.4309 472 WB Large T DRB1_0101 266ETKQVSWKLITEYAV VSWKLITEY 0.4307 473 WB Large T DRB1_0101 267TKQVSWKLITEYAVE WKLITEYAV 0.4303 475 WB Large T DRB1_0101 539LQARFVRQIDFRPKI LQARFVRQI 0.4290 482 WB Large T DRB1_0101 225CKGVNKEYLLYSALT VNKEYLLYS 0.4288 483 WB Large T DRB1_0101 677KGFQCFKRPKTPPPK FKRPKTPPP 0.4281 487 WB Large T DRB1_0101 333KNQKSICQQAVDTVL ICQQAVDTV 0.4261 498 WB Large T DRB1_0101 72PDFGTWNSSEVPTYG FGTWNSSEV 0.4258 499 WB Large T DRB1_0401 47GDEDKMKRMNTLYKK MKRMNTLYK 0.5015 220 WB Large T DRB1_0401 48DEDKMKRMNTLYKKM MKRMNTLYK 0.4994 225 WB Large T DRB1_0401 46GGDEDKMKRMNTLYK KMKRMNTLY 0.4992 226 WB Large T DRB1_0401 49EDKMKRMNTLYKKME MKRMNTLYK 0.4991 226 WB Large T DRB1_0401 50DKMKRMNTLYKKMEQ MKRMNTLYK 0.4948 237 WB Large T DRB1_0401 192AGHNIIFFLTPHRHR IIFFLTPHR 0.4859 261 WB Large T DRB1_0401 194HNIIFFLTPHRHRVS IIFFLTPHR 0.4856 261 WB Large T DRB1_0401 193GHNIIFFLTPHRHRV IIFFLTPHR 0.4820 272 WB Large T DRB1_0401 191CAGHNIIFFLTPHRH IIFFLTPHR 0.4700 309 WB Large T DRB1_0401 190MCAGHNIIFFLTPHR MCAGHNIIF 0.4533 371 WB Large T DRB1_0404 194HNIIFFLTPHRHRVS IIFFLTPHR 0.5594 118 WB Large T DRB1_0404 193GHNIIFFLTPHRHRV IIFFLTPHR 0.5580 119 WB Large T DRB1_0404 284CEDVFLLLGMYLEFQ FLLLGMYLE 0.5487 132 WB Large T DRB1_0404 286DVFLLLGMYLEFQYN LLGMYLEFQ 0.5479 133 WB Large T DRB1_0404 285EDVFLLLGMYLEFQY LLGMYLEFQ 0.5470 135 WB Large T DRB1_0404 288FLLLGMYLEFQYNVE LLGMYLEFQ 0.5425 141 WB Large T DRB1_0404 287VFLLLGMYLEFQYNV LLGMYLEFQ 0.5417 142 WB Large T DRB1_0404 192AGHNIIFFLTPHRHR IIFFLTPHR 0.5303 161 WB Large T DRB1_0404 191CAGHNIIFFLTPHRH IIFFLTPHR 0.5272 167 WB Large T DRB1_0404 575MTLLLLLIWFRPVAD LLLLIWFRP 0.5188 182 WB Large T DRB1_0404 389YMAGVAWLHCLLPKM VAWLHCLLP 0.5113 198 WB Large T DRB1_0404 387EQYMAGVAWLHCLLP YMAGVAWLH 0.5087 203 WB Large T DRB1_0404 576TLLLLLIWFRPVADF LLLLIWFRP 0.5091 203 WB Large T DRB1_0404 190MCAGHNIIFFLTPHR HNIIFFLTP 0.5052 211 WB Large T DRB1_0404 390MAGVAWLHCLLPKMD VAWLHCLLP 0.5054 211 WB Large T DRB1_0404 175KKLMEKYSVTFISRH LMEKYSVTF 0.5033 216 WB Large T DRB1_0404 391AGVAWLHCLLPKMDS VAWLHCLLP 0.5004 223 WB Large T DRB1_0404 577LLLLLIWFRPVADFS LLIWFRPVA 0.5001 223 WB Large T DRB1_0404 388QYMAGVAWLHCLLPK VAWLHCLLP 0.4995 225 WB Large T DRB1_0404 195NIIFFLTPHRHRVSA IIFFLTPHR 0.4985 227 WB Large T DRB1_0404 179EKYSVTFISRHMCAG YSVTFISRH 0.4981 228 WB Large T DRB1_0404 177LMEKYSVTFISRHMC YSVTFISRH 0.4969 231 WB Large T DRB1_0404 176KLMEKYSVTFISRHM YSVTFISRH 0.4952 236 WB Large T DRB1_0404 178MEKYSVTFISRHMCA YSVTFISRH 0.4940 239 WB Large T DRB1_0404 578LLLLIWFRPVADFSK LLIWFRPVA 0.4909 247 WB Large T DRB1_0404 196IIFFLTPHRHRVSAI IIFFLTPHR 0.4866 258 WB Large T DRB1_0404 574GMTLLLLLIWFRPVA LLLLIWFRP 0.4835 267 WB Large T DRB1_0404 371LDKMDLIFGAHGNAV MDLIFGAHG 0.4592 348 WB Large T DRB1_0404 290LLGMYLEFQYNVEEC LLGMYLEFQ 0.4448 406 WB Large T DRB1_0404 289LLLGMYLEFQYNVEE LLGMYLEFQ 0.4447 407 WB Large T DRB1_0404 372DKMDLIFGAHGNAVL IFGAHGNAV 0.4437 411 WB Large T DRB1_0405 575MTLLLLLIWFRPVAD LLIWFRPVA 0.7757 11 SB Large T DRB1_0405 576TLLLLLIWFRPVADF LIWFRPVAD 0.7721 12 SB Large T DRB1_0405 577LLLLLIWFRPVADFS LIWFRPVAD 0.7733 12 SB Large T DRB1_0405 578LLLLIWFRPVADFSK LIWFRPVAD 0.7738 12 SB Large T DRB1_0405 579LLLIWFRPVADFSKD LIWFRPVAD 0.7712 12 SB Large T DRB1_0405 85YGTEEWESWWSSFNE WESWWSSFN 0.7453 16 SB Large T DRB1_0405 87TEEWESWWSSFNEKW WESWWSSFN 0.7451 16 SB Large T DRB1_0405 86GTEEWESWWSSFNEK WESWWSSFN 0.7381 17 SB Large T DRB1_0405 88EEWESWWSSFNEKWD WESWWSSFN 0.7402 17 SB Large T DRB1_0405 84TYGTEEWESWWSSFN TEEWESWWS 0.7216 20 SB Large T DRB1_0405 580LLIWFRPVADFSKDI LIWFRPVAD 0.6804 32 SB Large T DRB1_0405 581LIWFRPVADFSKDIQ LIWFRPVAD 0.6771 33 SB Large T DRB1_0405 89EWESWWSSFNEKWDE WESWWSSFN 0.6771 33 SB Large T DRB1_0405 90WESWWSSFNEKWDED WESWWSSFN 0.6504 44 SB Large T DRB1_0405 49EDKMKRMNTLYKKME MKRMNTLYK 0.5687 106 WB Large T DRB1_0405 50DKMKRMNTLYKKMEQ MKRMNTLYK 0.5662 109 WB Large T DRB1_0405 47GDEDKMKRMNTLYKK MKRMNTLYK 0.5447 138 WB Large T DRB1_0405 46GGDEDKMKRMNTLYK DKMKRMNTL 0.5432 140 WB Large T DRB1_0405 48DEDKMKRMNTLYKKM MKRMNTLYK 0.5413 143 WB Large T DRB1_0405 490GHGINNLDSLRDYLD INNLDSLRD 0.5182 184 WB Large T DRB1_0405 491HGINNLDSLRDYLDG INNLDSLRD 0.5113 198 WB Large T DRB1_0405 18GLERAAWGNLPLMRK RAAWGNLPL 0.5095 202 WB Large T DRB1_0405 487LPSGHGINNLDSLRD GHGINNLDS 0.4979 229 WB Large T DRB1_0405 19LERAAWGNLPLMRKA RAAWGNLPL 0.4956 235 WB Large T DRB1_0405 488PSGHGINNLDSLRDY INNLDSLRD 0.4948 237 WB Large T DRB1_0405 489SGHGINNLDSLRDYL INNLDSLRD 0.4858 261 WB Large T DRB1_0405 51KMKRMNTLYKKMEQD MKRMNTLYK 0.4857 261 WB Large T DRB1_0405 52MKRMNTLYKKMEQDV MKRMNTLYK 0.4857 261 WB Large T DRB1_0405 391AGVAWLHCLLPKMDS VAWLHCLLP 0.4831 269 WB Large T DRB1_0405 91ESWWSSFNEKWDEDL WSSFNEKWD 0.4812 274 WB Large T DRB1_0405 390MAGVAWLHCLLPKMD VAWLHCLLP 0.4697 310 WB Large T DRB1_0405 387EQYMAGVAWLHCLLP YMAGVAWLH 0.4648 327 WB Large T DRB1_0405 68VAHQPDFGTWNSSEV QPDFGTWNS 0.4624 336 WB Large T DRB1_0405 418VPKRRYWLFKGPIDS YWLFKGPID 0.4620 337 WB Large T DRB1_0405 388QYMAGVAWLHCLLPK VAWLHCLLP 0.4614 339 WB Large T DRB1_0405 420KRRYWLFKGPIDSGK YWLFKGPID 0.4599 345 WB Large T DRB1_0405 419PKRRYWLFKGPIDSG YWLFKGPID 0.4586 350 WB Large T DRB1_0405 20ERAAWGNLPLMRKAY WGNLPLMRK 0.4570 356 WB Large T DRB1_0405 69AHQPDFGTWNSSEVP FGTWNSSEV 0.4571 356 WB Large T DRB1_0405 389YMAGVAWLHCLLPKM VAWLHCLLP 0.4547 365 WB Large T DRB1_0405 421RRYWLFKGPIDSGKT YWLFKGPID 0.4540 368 WB Large T DRB1_0405 417NVPKRRYWLFKGPID RYWLFKGPI 0.4530 372 WB Large T DRB1_0405 17LGLERAAWGNLPLMR RAAWGNLPL 0.4515 378 WB Large T DRB1_0405 16LLGLERAAWGNLPLM RAAWGNLPL 0.4465 399 WB Large T DRB1_0405 493INNLDSLRDYLDGSV INNLDSLRD 0.4409 424 WB Large T DRB1_0405 492GINNLDSLRDYLDGS INNLDSLRD 0.4405 426 WB Large T DRB1_0405 15DLLGLERAAWGNLPL ERAAWGNLP 0.4401 427 WB Large T DRB1_0405 70HQPDFGTWNSSEVPT FGTWNSSEV 0.4392 432 WB Large T DRB1_0405 653CSSQVSDTSAPDSEN QVSDTSAPD 0.4296 479 WB Large T DRB1_0405 654SSQVSDTSAPDSENP QVSDTSAPD 0.4282 486 WB Large T DRB1_0701 412HCVVFNVPKRRYWLF VFNVPKRRY 0.5438 139 WB Large T DRB1_0701 413CVVFNVPKRRYWLFK VPKRRYWLF 0.5406 144 WB Large T DRB1_0701 414VVFNVPKRRYWLFKG VPKRRYWLF 0.5149 190 WB Large T DRB1_0701 415VFNVPKRRYWLFKGP VPKRRYWLF 0.5009 221 WB Large T DRB1_0701 71QPDFGTWNSSEVPTY FGTWNSSEV 0.4820 272 WB Large T DRB1_0701 72PDFGTWNSSEVPTYG FGTWNSSEV 0.4789 281 WB Large T DRB1_0701 68VAHQPDFGTWNSSEV DFGTWNSSE 0.4709 306 WB Large T DRB1_0701 69AHQPDFGTWNSSEVP FGTWNSSEV 0.4658 324 WB Large T DRB1_0701 70HQPDFGTWNSSEVPT FGTWNSSEV 0.4657 324 WB Large T DRB1_0701 416FNVPKRRYWLFKGPI VPKRRYWLF 0.4627 335 WB Large T DRB1_0701 194HNIIFFLTPHRHRVS IFFLTPHRH 0.4550 364 WB Large T DRB1_0701 195NIIFFLTPHRHRVSA IFFLTPHRH 0.4521 375 WB Large T DRB1_0701 193GHNIIFFLTPHRHRV IFFLTPHRH 0.4386 434 WB Large T DRB1_0701 176KLMEKYSVTFISRHM YSVTFISRH 0.4346 454 WB Large T DRB1_0701 196IIFFLTPHRHRVSAI IFFLTPHRH 0.4331 461 WB Large T DRB1_0701 177LMEKYSVTFISRHMC YSVTFISRH 0.4315 469 WB Large T DRB1_0701 387EQYMAGVAWLHCLLP YMAGVAWLH 0.4303 475 WB Large T DRB1_0701 386LEQYMAGVAWLHCLL YMAGVAWLH 0.4292 481 WB Large T DRB1_0701 192AGHNIIFFLTPHRHR IFFLTPHRH 0.4288 483 WB Large T DRB1_0701 197IFFLTPHRHRVSAIN IFFLTPHRH 0.4289 483 WB Large T DRB1_0901 229NKEYLLYSALTRDPY YLLYSALTR 0.4376 439 WB Large T DRB1_0901 230KEYLLYSALTRDPYH YLLYSALTR 0.4372 441 WB Large T DRB1_0901 72PDFGTWNSSEVPTYG WNSSEVPTY 0.4364 445 WB Large T DRB1_0901 71QPDFGTWNSSEVPTY FGTWNSSEV 0.4355 449 WB Large T DRB1_0901 228VNKEYLLYSALTRDP YLLYSALTR 0.4325 464 WB Large T DRB1_0901 384AVLEQYMAGVAWLHC LEQYMAGVA 0.4270 493 WB Large T DRB1_0901 383NAVLEQYMAGVAWLH LEQYMAGVA 0.4259 499 WB Large T DRB1_1101 232YLLYSALTRDPYHII YSALTRDPY 0.4594 347 WB Large T DRB1_1101 233LLYSALTRDPYHIIE YSALTRDPY 0.4586 350 WB Large T DRB1_1101 231EYLLYSALTRDPYHI YSALTRDPY 0.4552 363 WB Large T DRB1_1101 229NKEYLLYSALTRDPY YLLYSALTR 0.4548 364 WB Large T DRB1_1101 47GDEDKMKRMNTLYKK MKRMNTLYK 0.4550 364 WB Large T DRB1_1101 230KEYLLYSALTRDPYH YSALTRDPY 0.4537 369 WB Large T DRB1_1101 49EDKMKRMNTLYKKME MKRMNTLYK 0.4498 385 WB Large T DRB1_1101 48DEDKMKRMNTLYKKM MKRMNTLYK 0.4495 386 WB Large T DRB1_1101 50DKMKRMNTLYKKMEQ MKRMNTLYK 0.4483 391 WB Large T DRB1_1101 46GGDEDKMKRMNTLYK EDKMKRMNT 0.4433 413 WB Large T DRB1_1101 18GLERAAWGNLPLMRK AWGNLPLMR 0.4312 471 WB Large T DRB1_1101 19LERAAWGNLPLMRKA WGNLPLMRK 0.4311 471 WB Large T DRB1_1101 21RAAWGNLPLMRKAYL WGNLPLMRK 0.4288 483 WB Large T DRB1_1101 20ERAAWGNLPLMRKAY WGNLPLMRK 0.4279 488 WB Large T DRB1_1302 18GLERAAWGNLPLMRK LERAAWGNL 0.5752 99 WB Large T DRB1_1302 21RAAWGNLPLMRKAYL WGNLPLMRK 0.5714 103 WB Large T DRB1_1302 22AAWGNLPLMRKAYLK WGNLPLMRK 0.5704 104 WB Large T DRB1_1302 19LERAAWGNLPLMRKA WGNLPLMRK 0.5702 105 WB Large T DRB1_1302 20ERAAWGNLPLMRKAY WGNLPLMRK 0.5531 126 WB Large T DRB1_1302 285EDVFLLLGMYLEFQY FLLLGMYLE 0.5498 130 WB Large T DRB1_1302 445CGGKALNVNLPMERL LNVNLPMER 0.5476 134 WB Large T DRB1_1302 446GGKALNVNLPMERLT LNVNLPMER 0.5454 137 WB Large T DRB1_1302 566LEKRILQSGMTLLLL ILQSGMTLL 0.5431 140 WB Large T DRB1_1302 444LCGGKALNVNLPMER GKALNVNLP 0.5427 141 WB Large T DRB1_1302 565LLEKRILQSGMTLLL ILQSGMTLL 0.5420 142 WB Large T DRB1_1302 447GKALNVNLPMERLTF LNVNLPMER 0.5392 146 WB Large T DRB1_1302 284CEDVFLLLGMYLEFQ FLLLGMYLE 0.5383 148 WB Large T DRB1_1302 283KCEDVFLLLGMYLEF FLLLGMYLE 0.5363 151 WB Large T DRB1_1302 567EKRILQSGMTLLLLL ILQSGMTLL 0.5327 157 WB Large T DRB1_1302 282TKCEDVFLLLGMYLE VFLLLGMYL 0.5292 163 WB Large T DRB1_1302 568KRILQSGMTLLLLLI ILQSGMTLL 0.5282 165 WB Large T DRB1_1302 286DVFLLLGMYLEFQYN FLLLGMYLE 0.5258 169 WB Large T DRB1_1302 409DFLHCVVFNVPKRRY VVFNVPKRR 0.5112 198 WB Large T DRB1_1302 411LHCVVFNVPKRRYWL VFNVPKRRY 0.5079 205 WB Large T DRB1_1302 410FLHCVVFNVPKRRYW VFNVPKRRY 0.5074 206 WB Large T DRB1_1302 48DEDKMKRMNTLYKKM MKRMNTLYK 0.5012 221 WB Large T DRB1_1302 448KALNVNLPMERLTFE LNVNLPMER 0.4996 225 WB Large T DRB1_1302 49EDKMKRMNTLYKKME MKRMNTLYK 0.4986 227 WB Large T DRB1_1302 609ISMYTFSRMKYNICM MYTFSRMKY 0.4969 231 WB Large T DRB1_1302 50DKMKRMNTLYKKMEQ MKRMNTLYK 0.4966 232 WB Large T DRB1_1302 412HCVVFNVPKRRYWLF VFNVPKRRY 0.4955 235 WB Large T DRB1_1302 47GDEDKMKRMNTLYKK MKRMNTLYK 0.4940 239 WB Large T DRB1_1302 564FLLEKRILQSGMTLL KRILQSGMT 0.4938 239 WB Large T DRB1_1302 608EISMYTFSRMKYNIC ISMYTFSRM 0.4935 240 WB Large T DRB1_1302 24WGNLPLMRKAYLKKC WGNLPLMRK 0.4926 242 WB Large T DRB1_1302 23AWGNLPLMRKAYLKK WGNLPLMRK 0.4885 253 WB Large T DRB1_1302 46GGDEDKMKRMNTLYK DKMKRMNTL 0.4800 278 WB Large T DRB1_1302 487LPSGHGINNLDSLRD HGINNLDSL 0.4764 289 WB Large T DRB1_1302 489SGHGINNLDSLRDYL INNLDSLRD 0.4752 293 WB Large T DRB1_1302 488PSGHGINNLDSLRDY INNLDSLRD 0.4736 298 WB Large T DRB1_1302 569RILQSGMTLLLLLIW LQSGMTLLL 0.4720 303 WB Large T DRB1_1302 287VFLLLGMYLEFQYNV FLLLGMYLE 0.4711 306 WB Large T DRB1_1302 413CVVFNVPKRRYWLFK VFNVPKRRY 0.4581 352 WB Large T DRB1_1302 522IFPPGLVTMNEYPVP PGLVTMNEY 0.4560 360 WB Large T DRB1_1302 490GHGINNLDSLRDYLD INNLDSLRD 0.4532 371 WB Large T DRB1_1302 523FPPGLVTMNEYPVPK PGLVTMNEY 0.4489 389 WB Large T DRB1_1302 232YLLYSALTRDPYHII YSALTRDPY 0.4367 444 WB Large T DRB1_1302 491HGINNLDSLRDYLDG INNLDSLRD 0.4358 448 WB Large T DRB1_1302 570ILQSGMTLLLLLIWF ILQSGMTLL 0.4330 462 WB Large T DRB1_1302 449ALNVNLPMERLTFEL LNVNLPMER 0.4326 463 WB Large T DRB1_1302 607SEISMYTFSRMKYNI ISMYTFSRM 0.4327 463 WB Large T DRB1_1302 51KMKRMNTLYKKMEQD MKRMNTLYK 0.4272 492 WB Large T DRB1_1501 192AGHNIIFFLTPHRHR IIFFLTPHR 0.6526 43 SB Large T DRB1_1501 193GHNIIFFLTPHRHRV IIFFLTPHR 0.6507 44 SB Large T DRB1_1501 575MTLLLLLIWFRPVAD LLLLLIWFR 0.6509 44 SB Large T DRB1_1501 574GMTLLLLLIWFRPVA LLLLLIWFR 0.6462 46 SB Large T DRB1_1501 191CAGHNIIFFLTPHRH IIFFLTPHR 0.6427 48 SB Large T DRB1_1501 194HNIIFFLTPHRHRVS IIFFLTPHR 0.6416 48 SB Large T DRB1_1501 576TLLLLLIWFRPVADF LLLLLIWFR 0.6127 66 WB Large T DRB1_1501 577LLLLLIWFRPVADFS LLIWFRPVA 0.5958 79 WB Large T DRB1_1501 190MCAGHNIIFFLTPHR NIIFFLTPH 0.5914 83 WB Large T DRB1_1501 573SGMTLLLLLIWFRPV LLLLLIWFR 0.5875 87 WB Large T DRB1_1501 195NIIFFLTPHRHRVSA IIFFLTPHR 0.5848 89 WB Large T DRB1_1501 572QSGMTLLLLLIWFRP LLLLLIWFR 0.5640 112 WB Large T DRB1_1501 196IIFFLTPHRHRVSAI IIFFLTPHR 0.5515 128 WB Large T DRB1_1501 578LLLLIWFRPVADFSK LLIWFRPVA 0.5410 144 WB Large T DRB1_1501 571LQSGMTLLLLLIWFR TLLLLLIWF 0.5272 167 WB Large T DRB1_1501 48DEDKMKRMNTLYKKM MKRMNTLYK 0.5229 174 WB Large T DRB1_1501 49EDKMKRMNTLYKKME MKRMNTLYK 0.5190 182 WB Large T DRB1_1501 24WGNLPLMRKAYLKKC LMRKAYLKK 0.5176 185 WB Large T DRB1_1501 50DKMKRMNTLYKKMEQ MKRMNTLYK 0.5153 190 WB Large T DRB1_1501 47GDEDKMKRMNTLYKK MKRMNTLYK 0.5147 191 WB Large T DRB1_1501 23AWGNLPLMRKAYLKK LPLMRKAYL 0.5076 206 WB Large T DRB1_1501 25GNLPLMRKAYLKKCK LMRKAYLKK 0.5063 209 WB Large T DRB1_1501 46GGDEDKMKRMNTLYK DKMKRMNTL 0.5026 217 WB Large T DRB1_1501 26NLPLMRKAYLKKCKE LMRKAYLKK 0.4961 233 WB Large T DRB1_1501 548DFRPKIYLRKSLQNS DFRPKIYLR 0.4942 238 WB Large T DRB1_1501 227GVNKEYLLYSALTRD YLLYSALTR 0.4878 255 WB Large T DRB1_1501 228VNKEYLLYSALTRDP YLLYSALTR 0.4864 259 WB Large T DRB1_1501 229NKEYLLYSALTRDPY YLLYSALTR 0.4863 259 WB Large T DRB1_1501 230KEYLLYSALTRDPYH YLLYSALTR 0.4859 260 WB Large T DRB1_1501 27LPLMRKAYLKKCKEF LMRKAYLKK 0.4850 263 WB Large T DRB1_1501 409DFLHCVVFNVPKRRY CVVFNVPKR 0.4823 271 WB Large T DRB1_1501 410FLHCVVFNVPKRRYW CVVFNVPKR 0.4819 272 WB Large T DRB1_1501 226KGVNKEYLLYSALTR VNKEYLLYS 0.4792 280 WB Large T DRB1_1501 411LHCVVFNVPKRRYWL CVVFNVPKR 0.4791 280 WB Large T DRB1_1501 543FVRQIDFRPKIYLRK DFRPKIYLR 0.4749 293 WB Large T DRB1_1501 544VRQIDFRPKIYLRKS DFRPKIYLR 0.4739 297 WB Large T DRB1_1501 542RFVRQIDFRPKIYLR VRQIDFRPK 0.4731 299 WB Large T DRB1_1501 408FDFLHCVVFNVPKRR CVVFNVPKR 0.4728 300 WB Large T DRB1_1501 579LLLIWFRPVADFSKD LLIWFRPVA 0.4695 311 WB Large T DRB1_1501 13LMDLLGLERAAWGNL LMDLLGLER 0.4683 315 WB Large T DRB1_1501 549FRPKIYLRKSLQNSE YLRKSLQNS 0.4683 315 WB Large T DRB1_1501 11MELMDLLGLERAAWG LMDLLGLER 0.4651 326 WB Large T DRB1_1501 142SDLHQFLSQAVFSNR LHQFLSQAV 0.4611 341 WB Large T DRB1_1501 413CVVFNVPKRRYWLFK CVVFNVPKR 0.4554 362 WB Large T DRB1_1501 169KAQILYKKLMEKYSV ILYKKLMEK 0.4523 375 WB Large T DRB1_1501 170AQILYKKLMEKYSVT ILYKKLMEK 0.4511 379 WB Large T DRB1_1501 546QIDFRPKIYLRKSLQ DFRPKIYLR 0.4502 383 WB Large T DRB1_1501 419PKRRYWLFKGPIDSG WLFKGPIDS 0.4498 385 WB Large T DRB1_1501 418VPKRRYWLFKGPIDS KRRYWLFKG 0.4458 402 WB Large T DRB1_1501 547IDFRPKIYLRKSLQN FRPKIYLRK 0.4373 440 WB Large T DRB1_1501 420KRRYWLFKGPIDSGK WLFKGPIDS 0.4350 452 WB Large T DRB1_1501 414VVFNVPKRRYWLFKG PKRRYWLFK 0.4334 460 WB Large T DRB1_1501 28PLMRKAYLKKCKEFH LMRKAYLKK 0.4332 461 WB Large T DRB1_1501 51KMKRMNTLYKKMEQD MKRMNTLYK 0.4331 461 WB Large T DRB1_1501 172ILYKKLMEKYSVTFI ILYKKLMEK 0.4319 467 WB Large T DRB1_1501 550RPKIYLRKSLQNSEF YLRKSLQNS 0.4316 469 WB Large T DRB1_1501 545RQIDFRPKIYLRKSL DFRPKIYLR 0.4312 471 WB Large T DRB1_1501 580LLIWFRPVADFSKDI LLIWFRPVA 0.4297 479 WB Large T DRB1_1501 412HCVVFNVPKRRYWLF CVVFNVPKR 0.4294 480 WB Large T DRB1_1501 10SMELMDLLGLERAAW LMDLLGLER 0.4261 497 WB Large T DRB4_0101 609ISMYTFSRMKYNICM FSRMKYNIC 0.5682 107 WB Large T DRB4_0101 611MYTFSRMKYNICMGK FSRMKYNIC 0.5289 163 WB Large T DRB4_0101 608EISMYTFSRMKYNIC ISMYTFSRM 0.5272 167 WB Large T DRB4_0101 612YTFSRMKYNICMGKC FSRMKYNIC 0.5271 167 WB Large T DRB4_0101 610SMYTFSRMKYNICMG FSRMKYNIC 0.5243 172 WB Large T DRB4_0101 576TLLLLLIWFRPVADF LIWFRPVAD 0.4721 302 WB Large T DRB4_0101 194HNIIFFLTPHRHRVS IFFLTPHRH 0.4700 309 WB Large T DRB4_0101 193GHNIIFFLTPHRHRV IFFLTPHRH 0.4668 320 WB Large T DRB4_0101 192AGHNIIFFLTPHRHR IFFLTPHRH 0.4660 323 WB Large T DRB4_0101 195NIIFFLTPHRHRVSA IFFLTPHRH 0.4640 330 WB Large T DRB4_0101 541ARFVRQIDFRPKIYL VRQIDFRPK 0.4637 331 WB Large T DRB4_0101 577LLLLLIWFRPVADFS LIWFRPVAD 0.4628 334 WB Large T DRB4_0101 191CAGHNIIFFLTPHRH IIFFLTPHR 0.4583 351 WB Large T DRB4_0101 613TFSRMKYNICMGKCI FSRMKYNIC 0.4575 354 WB Large T DRB4_0101 542RFVRQIDFRPKIYLR VRQIDFRPK 0.4556 362 WB Large T DRB4_0101 578LLLLIWFRPVADFSK LIWFRPVAD 0.4526 373 WB Large T DRB4_0101 614FSRMKYNICMGKCIL FSRMKYNIC 0.4368 443 WB Large T DRB4_0101 579LLLIWFRPVADFSKD LIWFRPVAD 0.4362 446 WB Large T DRB4_0101 539LQARFVRQIDFRPKI VRQIDFRPK 0.4355 449 WB Large T DRB4_0101 575MTLLLLLIWFRPVAD LLLIWFRPV 0.4344 455 WB Large T DRB4_0101 538TLQARFVRQIDFRPK FVRQIDFRP 0.4341 456 WB Large T DRB4_0101 540QARFVRQIDFRPKIY VRQIDFRPK 0.4260 498 WB Large T DRB5_0101 543FVRQIDFRPKIYLRK RQIDFRPKI 0.6349 52 WB Large T DRB5_0101 544VRQIDFRPKIYLRKS FRPKIYLRK 0.6346 52 WB Large T DRB5_0101 545RQIDFRPKIYLRKSL FRPKIYLRK 0.6343 52 WB Large T DRB5_0101 546QIDFRPKIYLRKSLQ FRPKIYLRK 0.6326 53 WB Large T DRB5_0101 547IDFRPKIYLRKSLQN FRPKIYLRK 0.6322 53 WB Large T DRB5_0101 411LHCVVFNVPKRRYWL VVFNVPKRR 0.5655 110 WB Large T DRB5_0101 412HCVVFNVPKRRYWLF VVFNVPKRR 0.5631 113 WB Large T DRB5_0101 410FLHCVVFNVPKRRYW VVFNVPKRR 0.5614 115 WB Large T DRB5_0101 409DFLHCVVFNVPKRRY VVFNVPKRR 0.5437 139 WB Large T DRB5_0101 548DFRPKIYLRKSLQNS FRPKIYLRK 0.5361 151 WB Large T DRB5_0101 549FRPKIYLRKSLQNSE FRPKIYLRK 0.5359 152 WB Large T DRB5_0101 255KEHDFNPEEPEETKQ FNPEEPEET 0.5183 183 WB Large T DRB5_0101 254LKEHDFNPEEPEETK FNPEEPEET 0.5181 184 WB Large T DRB5_0101 256EHDFNPEEPEETKQV FNPEEPEET 0.5168 186 WB Large T DRB5_0101 253GLKEHDFNPEEPEET GLKEHDFNP 0.5161 188 WB Large T DRB5_0101 257HDFNPEEPEETKQVS FNPEEPEET 0.5162 188 WB Large T DRB5_0101 408FDFLHCVVFNVPKRR CVVFNVPKR 0.5052 211 WB Large T DRB5_0101 413CVVFNVPKRRYWLFK VVFNVPKRR 0.5006 222 WB Large T DRB5_0101 84TYGTEEWESWWSSFN TEEWESWWS 0.4988 227 WB Large T DRB5_0101 85YGTEEWESWWSSFNE WESWWSSFN 0.4977 229 WB Large T DRB5_0101 88EEWESWWSSFNEKWD WESWWSSFN 0.4975 230 WB Large T DRB5_0101 87TEEWESWWSSFNEKW WESWWSSFN 0.4963 233 WB Large T DRB5_0101 86GTEEWESWWSSFNEK WESWWSSFN 0.4952 235 WB Large T DRB5_0101 677KGFQCFKRPKTPPPK FQCFKRPKT 0.4816 273 WB Large T DRB5_0101 49EDKMKRMNTLYKKME MKRMNTLYK 0.4763 289 WB Large T DRB5_0101 50DKMKRMNTLYKKMEQ MKRMNTLYK 0.4758 290 WB Large T DRB5_0101 48DEDKMKRMNTLYKKM MKRMNTLYK 0.4726 301 WB Large T DRB5_0101 414VVFNVPKRRYWLFKG VVFNVPKRR 0.4695 311 WB Large T DRB5_0101 47GDEDKMKRMNTLYKK MKRMNTLYK 0.4617 338 WB Large T DRB5_0101 194HNIIFFLTPHRHRVS FFLTPHRHR 0.4587 350 WB Large T DRB5_0101 46GGDEDKMKRMNTLYK DKMKRMNTL 0.4567 357 WB Large T DRB5_0101 193GHNIIFFLTPHRHRV FFLTPHRHR 0.4542 367 WB Large T DRB5_0101 195NIIFFLTPHRHRVSA FFLTPHRHR 0.4419 419 WB Large T DRB5_0101 119TADSQHSTPPKKKRK QHSTPPKKK 0.4363 446 WB Large T DRB5_0101 120ADSQHSTPPKKKRKV QHSTPPKKK 0.4331 461 WB Large T DRB5_0101 259FNPEEPEETKQVSWK FNPEEPEET 0.4320 467 WB Large T DRB5_0101 53KRMNTLYKKMEQDVK KRMNTLYKK 0.4284 485 WB Large T DRB5_0101 22AAWGNLPLMRKAYLK WGNLPLMRK 0.4268 494 WB Large T SEQ ID NOS.: 60258-61275

Preferred BK virus fragments of Agnoprotein capable of interacting withone or more MHC class 2 molecules are listed in Table T.

TABLE T Prediction of BK virus Agnoprotein specific MHC class 2,15-mer peptide binders for 14 MHC class 2 alleles (seeFIG. 11) using the http://www.cbs.dtu.dk/services/NetMHCII/database. The MHC class 2 molecules for which no binderswere found are not listed. 1 − log50k affinity Bind Identity Allele pospeptide core (aff) (nM) Level DRB1_0101 8 LVVLRQLSRQASVKV LRQLSRQAS0.6877 29 SB Agno DRB1_0101 9 VVLRQLSRQASVKVG LSRQASVKV 0.6820 31SB Agno DRB1_0101 10 VLRQLSRQASVKVGK LSRQASVKV 0.6587 40 SB AgnoDRB1_0101 11 LRQLSRQASVKVGKT LSRQASVKV 0.6595 40 SB Agno DRB1_0101 5PKNLVVLRQLSRQAS VLRQLSRQA 0.6455 46 SB Agno DRB1_0101 7NLVVLRQLSRQASVK VLRQLSRQA 0.6439 47 SB Agno DRB1_0101 6KNLVVLRQLSRQASV VLRQLSRQA 0.6410 49 SB Agno DRB1_0101 12RQLSRQASVKVGKTW LSRQASVKV 0.6369 51 WB Agno DRB1_0101 14LSRQASVKVGKTWTG LSRQASVKV 0.6206 61 WB Agno DRB1_0101 18ASVKVGKTWTGTKKR VKVGKTWTG 0.5679 107 WB Agno DRB1_0101 17QASVKVGKTWTGTKK VKVGKTWTG 0.5669 108 WB Agno DRB1_0101 15SRQASVKVGKTWTGT VKVGKTWTG 0.5640 112 WB Agno DRB1_0101 16RQASVKVGKTWTGTK VKVGKTWTG 0.5640 112 WB Agno DRB1_0101 4EPKNLVVLRQLSRQA PKNLVVLRQ 0.5604 116 WB Agno DRB1_0101 13QLSRQASVKVGKTWT LSRQASVKV 0.5447 138 WB Agno DRB1_0101 19SVKVGKTWTGTKKRA VKVGKTWTG 0.4852 263 WB Agno DRB1_0101 20VKVGKTWTGTKKRAQ VKVGKTWTG 0.4749 293 WB Agno DRB1_0401 8LVVLRQLSRQASVKV VLRQLSRQA 0.4745 295 WB Agno DRB1_0401 10VLRQLSRQASVKVGK LSRQASVKV 0.4500 384 WB Agno DRB1_0401 9VVLRQLSRQASVKVG LSRQASVKV 0.4476 394 WB Agno DRB1_0401 11LRQLSRQASVKVGKT LSRQASVKV 0.4393 431 WB Agno DRB1_0401 12RQLSRQASVKVGKTW LSRQASVKV 0.4380 437 WB Agno DRB1_0405 55DGKNKSTTALPAVKD NKSTTALPA 0.4704 308 WB Agno DRB1_0405 56GKNKSTTALPAVKDS TTALPAVKD 0.4657 324 WB Agno DRB1_0405 57KNKSTTALPAVKDSV TTALPAVKD 0.4367 443 WB Agno DRB1_0405 58NKSTTALPAVKDSVK TTALPAVKD 0.4330 462 WB Agno DRB1_1101 8LVVLRQLSRQASVKV LRQLSRQAS 0.4614 340 WB Agno DRB1_1101 5PKNLVVLRQLSRQAS PKNLVVLRQ 0.4605 343 WB Agno DRB1_1101 6KNLVVLRQLSRQASV LRQLSRQAS 0.4594 347 WB Agno DRB1_1101 9VVLRQLSRQASVKVG LRQLSRQAS 0.4595 347 WB Agno DRB1_1101 7NLVVLRQLSRQASVK LRQLSRQAS 0.4579 352 WB Agno DRB1_1302 5PKNLVVLRQLSRQAS VVLRQLSRQ 0.5120 196 WB Agno DRB1_1302 8LVVLRQLSRQASVKV LRQLSRQAS 0.5035 215 WB Agno DRB1_1302 6KNLVVLRQLSRQASV LRQLSRQAS 0.5031 216 WB Agno DRB1_1302 9VVLRQLSRQASVKVG LRQLSRQAS 0.4904 248 WB Agno DRB1_1302 7NLVVLRQLSRQASVK LRQLSRQAS 0.4893 251 WB Agno DRB1_1302 3CEPKNLVVLRQLSRQ LVVLRQLSR 0.4329 462 WB Agno DRB1_1501 5PKNLVVLRQLSRQAS LVVLRQLSR 0.6754 34 SB Agno DRB1_1501 6KNLVVLRQLSRQASV LVVLRQLSR 0.6742 34 SB Agno DRB1_1501 4EPKNLVVLRQLSRQA LVVLRQLSR 0.6596 40 SB Agno DRB1_1501 3CEPKNLVVLRQLSRQ LVVLRQLSR 0.6209 60 WB Agno DRB1_1501 7NLVVLRQLSRQASVK LVVLRQLSR 0.6093 69 WB Agno DRB1_1501 8LVVLRQLSRQASVKV LVVLRQLSR 0.6010 75 WB Agno DRB1_1501 2FCEPKNLVVLRQLSR NLVVLRQLS 0.5977 78 WB Agno DRB1_1501 9VVLRQLSRQASVKVG LRQLSRQAS 0.4406 425 WB Agno DRB4_0101 35RIFIFILELLLEFCR ILELLLEFC 0.4266 494 WB Agno SEQ ID NOS: 61276-61367

Preferred Borrelia afzelli fragments of Osp C capable of interactingwith one or more MHC class 1 and/or MHC class 2 molecules are listed inTable U.

TABLE U Prediction of MHC class 1 and 2 Borrelia afzelii OspCpeptide binders. Prediction of 8-, 9-, 10-, 11-, 13-,14-, 15-, 16-mer peptides were using the program displayed in FIG. 28 mers: MKKNTLSA; KKNTLSAI; KNTLSAIL; NTLSAILM; TLSAILMT; LSAILMTL;SAILMTLF; AILMTLFL; ILMTLFLF; LMTLFLFI; MTLFLFIS; TLFLFISC;LFLFISCN; FLFISCNN; LFISCNNS; FISCNNSG; ISCNNSGK; SCNNSGKG;CNNSGKGG; NNSGKGGD; NSGKGGDS; SGKGGDSA; GKGGDSAS; KGGDSAST;GGDSASTN; GDSASTNP; DSASTNPA; SASTNPAD; ASTNPADE; STNPADES;TNPADESA; NPADESAK; PADESAKG; ADESAKGP; DESAKGPN; ESAKGPNL;SAKGPNLT; AKGPNLTE; KGPNLTEI; GPNLTEIS; PNLTEISK; NLTEISKK;LTEISKKI; TEISKKIT; EISKKITD; ISKKITDS; SKKITDSN; KKITDSNA;KITDSNAF; ITDSNAFV; TDSNAFVL; DSNAFVLA; SNAFVLAV; NAFVLAVK;AFVLAVKE; FVLAVKEV; VLAVKEVE; LAVKEVET; AVKEVETL; VKEVETLV;KEVETLVS; EVETLVSS; VETLVSSI; ETLVSSID; TLVSSIDE; LVSSIDEL;VSSIDELA; SSIDELAN; SIDELANK; IDELANKA; DELANKAI; ELANKAIG;LANKAIGK; ANKAIGKK; NKAIGKKI; KAIGKKIQ; AIGKKIQQ; IGKKIQQN;GKKIQQNG; KKIQQNGL; KIQQNGLG; IQQNGLGA; QQNGLGAE; QNGLGAEA;NGLGAEAN; GLGAEANR; LGAEANRN; GAEANRNE; AEANRNES; EANRNESL;ANRNESLL; NRNESLLA; RNESLLAG; NESLLAGV; ESLLAGVH; SLLAGVHE;LLAGVHEI; LAGVHEIS; AGVHEIST; GVHEISTL; VHEISTLI; HEISTLIT;EISTLITE; ISTLITEK; STLITEKL; TLITEKLS; LITEKLSK; ITEKLSKL;TEKLSKLK; EKLSKLKN; KLSKLKNS; LSKLKNSG; SKLKNSGE; KLKNSGEL;LKNSGELK; KNSGELKA; NSGELKAK; SGELKAKI; GELKAKIE; ELKAKIED;LKAKIEDA; KAKIEDAK; AKIEDAKK; KIEDAKKC; IEDAKKCS; EDAKKCSE;DAKKCSEE; AKKCSEEF; KKCSEEFT; KCSEEFTN; CSEEFTNK; SEEFTNKL;EEFTNKLR; EFTNKLRV; FTNKLRVS; TNKLRVSH; NKLRVSHA; KLRVSHAD;LRVSHADL; RVSHADLG; VSHADLGK; SHADLGKQ; HADLGKQG; ADLGKQGV;DLGKQGVN; LGKQGVND; GKQGVNDD; KQGVNDDD; QGVNDDDA; GVNDDDAK;VNDDDAKK; NDDDAKKA; DDDAKKAI; DDAKKAIL; DAKKAILK; AKKAILKT;KKAILKTN; KAILKTNA; AILKTNAD; ILKTNADK; LKTNADKT; KTNADKTK;TNADKTKG; NADKTKGA; ADKTKGAE; DKTKGAEE; KTKGAEEL; TKGAEELG;KGAEELGK; GAEELGKL; AEELGKLF; EELGKLFK; ELGKLFKS; LGKLFKSV;GKLFKSVE; KLFKSVEG; LFKSVEGL; FKSVEGLV; KSVEGLVK; SVEGLVKA;VEGLVKAA; EGLVKAAQ; GLVKAAQE; LVKAAQEA; VKAAQEAL; KAAQEALT;AAQEALTN; AQEALTNS; QEALTNSV; EALTNSVK; ALTNSVKE; LTNSVKEL;TNSVKELT; NSVKELTS; SVKELTSP; VKELTSPV; KELTSPVV; ELTSPVVA;LTSPVVAE; TSPVVAES; SPVVAESP; PVVAESPK; VVAESPKK; VAESPKKP 9 mers:MKKNTLSAI; KKNTLSAIL; KNTLSAILM; NTLSAILMT; TLSAILMTL;LSAILMTLF; SAILMTLFL; AILMTLFLF; ILMTLFLFI; LMTLFLFIS;MTLFLFISC; TLFLFISCN; LFLFISCNN; FLFISCNNS; LFISCNNSG;FISCNNSGK; ISCNNSGKG; SCNNSGKGG; CNNSGKGGD; NNSGKGGDS;NSGKGGDSA; SGKGGDSAS; GKGGDSAST; KGGDSASTN; GGDSASTNP;GDSASTNPA; DSASTNPAD; SASTNPADE; ASTNPADES; STNPADESA;TNPADESAK; NPADESAKG; PADESAKGP; ADESAKGPN; DESAKGPNL;ESAKGPNLT; SAKGPNLTE; AKGPNLTEI; KGPNLTEIS; GPNLTEISK;PNLTEISKK; NLTEISKKI; LTEISKKIT; TEISKKITD; EISKKITDS;ISKKITDSN; SKKITDSNA; KKITDSNAF; KITDSNAFV; ITDSNAFVL;TDSNAFVLA; DSNAFVLAV; SNAFVLAVK; NAFVLAVKE; AFVLAVKEV;FVLAVKEVE; VLAVKEVET; LAVKEVETL; AVKEVETLV; VKEVETLVS;KEVETLVSS; EVETLVSSI; VETLVSSID; ETLVSSIDE; TLVSSIDEL;LVSSIDELA; VSSIDELAN; SSIDELANK; SIDELANKA; IDELANKAI;DELANKAIG; ELANKAIGK; LANKAIGKK; ANKAIGKKI; NKAIGKKIQ;KAIGKKIQQ; AIGKKIQQN; IGKKIQQNG; GKKIQQNGL; KKIQQNGLG;KIQQNGLGA; IQQNGLGAE; QQNGLGAEA; QNGLGAEAN; NGLGAEANR;GLGAEANRN; LGAEANRNE; GAEANRNES; AEANRNESL; EANRNESLL;ANRNESLLA; NRNESLLAG; RNESLLAGV; NESLLAGVH; ESLLAGVHE;SLLAGVHEI; LLAGVHEIS; LAGVHEIST; AGVHEISTL; GVHEISTLI;VHEISTLIT; HEISTLITE; EISTLITEK; ISTLITEKL; STLITEKLS;TLITEKLSK; LITEKLSKL; ITEKLSKLK; TEKLSKLKN; EKLSKLKNS;KLSKLKNSG; LSKLKNSGE; SKLKNSGEL; KLKNSGELK; LKNSGELKA;KNSGELKAK; NSGELKAKI; SGELKAKIE; GELKAKIED; ELKAKIEDA;LKAKIEDAK; KAKIEDAKK; AKIEDAKKC; KIEDAKKCS; IEDAKKCSE;EDAKKCSEE; DAKKCSEEF; AKKCSEEFT; KKCSEEFTN; KCSEEFTNK;CSEEFTNKL; SEEFTNKLR; EEFTNKLRV; EFTNKLRVS; FTNKLRVSH;TNKLRVSHA; NKLRVSHAD; KLRVSHADL; LRVSHADLG; RVSHADLGK;VSHADLGKQ; SHADLGKQG; HADLGKQGV; ADLGKQGVN; DLGKQGVND;LGKQGVNDD; GKQGVNDDD; KQGVNDDDA; QGVNDDDAK; GVNDDDAKK;VNDDDAKKA; NDDDAKKAI; DDDAKKAIL; DDAKKAILK; DAKKAILKT;AKKAILKTN; KKAILKTNA; KAILKTNAD; AILKTNADK; ILKTNADKT;LKTNADKTK; KTNADKTKG; TNADKTKGA; NADKTKGAE; ADKTKGAEE;DKTKGAEEL; KTKGAEELG; TKGAEELGK; KGAEELGKL; GAEELGKLF;AEELGKLFK; EELGKLFKS; ELGKLFKSV; LGKLFKSVE; GKLFKSVEG;KLFKSVEGL; LFKSVEGLV; FKSVEGLVK; KSVEGLVKA; SVEGLVKAA;VEGLVKAAQ; EGLVKAAQE; GLVKAAQEA; LVKAAQEAL; VKAAQEALT;KAAQEALTN; AAQEALTNS; AQEALTNSV; QEALTNSVK; EALTNSVKE;ALTNSVKEL; LTNSVKELT; TNSVKELTS; NSVKELTSP; SVKELTSPV;VKELTSPVV; KELTSPVVA; ELTSPVVAE; LTSPVVAES; TSPVVAESP;SPVVAESPK; PVVAESPKK; VVAESPKKP 10 mers:MKKNTLSAIL; KKNTLSAILM; KNTLSAILMT; NTLSAILMTL; TLSAILMTLF;LSAILMTLFL; SAILMTLFLF; AILMTLFLFI; ILMTLFLFIS; LMTLFLFISC;MTLFLFISCN; TLFLFISCNN; LFLFISCNNS; FLFISCNNSG; LFISCNNSGK;FISCNNSGKG; ISCNNSGKGG; SCNNSGKGGD; CNNSGKGGDS; NNSGKGGDSA;NSGKGGDSAS; SGKGGDSAST; GKGGDSASTN; KGGDSASTNP; GGDSASTNPA;GDSASTNPAD; DSASTNPADE; SASTNPADES; ASTNPADESA; STNPADESAK;TNPADESAKG; NPADESAKGP; PADESAKGPN; ADESAKGPNL; DESAKGPNLT;ESAKGPNLTE; SAKGPNLTEI; AKGPNLTEIS; KGPNLTEISK; GPNLTEISKK;PNLTEISKKI; NLTEISKKIT; LTEISKKITD; TEISKKITDS; EISKKITDSN;ISKKITDSNA; SKKITDSNAF; KKITDSNAFV; KITDSNAFVL; ITDSNAFVLA;TDSNAFVLAV; DSNAFVLAVK; SNAFVLAVKE; NAFVLAVKEV; AFVLAVKEVE;FVLAVKEVET; VLAVKEVETL; LAVKEVETLV; AVKEVETLVS; VKEVETLVSS;KEVETLVSSI; EVETLVSSID; VETLVSSIDE; ETLVSSIDEL; TLVSSIDELA;LVSSIDELAN; VSSIDELANK; SSIDELANKA; SIDELANKAI; IDELANKAIG;DELANKAIGK; ELANKAIGKK; LANKAIGKKI; ANKAIGKKIQ; NKAIGKKIQQ;KAIGKKIQQN; AIGKKIQQNG; IGKKIQQNGL; GKKIQQNGLG; KKIQQNGLGA;KIQQNGLGAE; IQQNGLGAEA; QQNGLGAEAN; QNGLGAEANR; NGLGAEANRN;GLGAEANRNE; LGAEANRNES; GAEANRNESL; AEANRNESLL; EANRNESLLA;ANRNESLLAG; NRNESLLAGV; RNESLLAGVH; NESLLAGVHE; ESLLAGVHEI;SLLAGVHEIS; LLAGVHEIST; LAGVHEISTL; AGVHEISTLI; GVHEISTLIT;VHEISTLITE; HEISTLITEK; EISTLITEKL; ISTLITEKLS; STLITEKLSK;TLITEKLSKL; LITEKLSKLK; ITEKLSKLKN; TEKLSKLKNS; EKLSKLKNSG;KLSKLKNSGE; LSKLKNSGEL; SKLKNSGELK; KLKNSGELKA; LKNSGELKAK;KNSGELKAKI; NSGELKAKIE; SGELKAKIED; GELKAKIEDA; ELKAKIEDAK;LKAKIEDAKK; KAKIEDAKKC; AKIEDAKKCS; KIEDAKKCSE; IEDAKKCSEE;EDAKKCSEEF; DAKKCSEEFT; AKKCSEEFTN; KKCSEEFTNK; KCSEEFTNKL;CSEEFTNKLR; SEEFTNKLRV; EEFTNKLRVS; EFTNKLRVSH; FTNKLRVSHA;TNKLRVSHAD; NKLRVSHADL; KLRVSHADLG; LRVSHADLGK; RVSHADLGKQ;VSHADLGKQG; SHADLGKQGV; HADLGKQGVN; ADLGKQGVND; DLGKQGVNDD;LGKQGVNDDD; GKQGVNDDDA; KQGVNDDDAK; QGVNDDDAKK; GVNDDDAKKA;VNDDDAKKAI; NDDDAKKAIL; DDDAKKAILK; DDAKKAILKT; DAKKAILKTN;AKKAILKTNA; KKAILKTNAD; KAILKTNADK; AILKTNADKT; ILKTNADKTK;LKTNADKTKG; KTNADKTKGA; TNADKTKGAE; NADKTKGAEE; ADKTKGAEEL;DKTKGAEELG; KTKGAEELGK; TKGAEELGKL; KGAEELGKLF; GAEELGKLFK;AEELGKLFKS; EELGKLFKSV; ELGKLFKSVE; LGKLFKSVEG; GKLFKSVEGL;KLFKSVEGLV; LFKSVEGLVK; FKSVEGLVKA; KSVEGLVKAA; SVEGLVKAAQ;VEGLVKAAQE; EGLVKAAQEA; GLVKAAQEAL; LVKAAQEALT; VKAAQEALTN;KAAQEALTNS; AAQEALTNSV; AQEALTNSVK; QEALTNSVKE; EALTNSVKEL;ALTNSVKELT; LTNSVKELTS; TNSVKELTSP; NSVKELTSPV; SVKELTSPVV;VKELTSPVVA; KELTSPVVAE; ELTSPVVAES; LTSPVVAESP; TSPVVAESPK;SPVVAESPKK; PVVAESPKKP 11 mers:MKKNTLSAILM; KKNTLSAILMT; KNTLSAILMTL; NTLSAILMTLF;TLSAILMTLFL; LSAILMTLFLF; SAILMTLFLFI; AILMTLFLFIS;ILMTLFLFISC; LMTLFLFISCN; MTLFLFISCNN; TLFLFISCNNS;LFLFISCNNSG; FLFISCNNSGK; LFISCNNSGKG; FISCNNSGKGG;ISCNNSGKGGD; SCNNSGKGGDS; CNNSGKGGDSA; NNSGKGGDSAS;NSGKGGDSAST; SGKGGDSASTN; GKGGDSASTNP; KGGDSASTNPA;GGDSASTNPAD; GDSASTNPADE; DSASTNPADES; SASTNPADESA;ASTNPADESAK; STNPADESAKG; TNPADESAKGP; NPADESAKGPN;PADESAKGPNL; ADESAKGPNLT; DESAKGPNLTE; ESAKGPNLTEI;SAKGPNLTEIS; AKGPNLTEISK; KGPNLTEISKK; GPNLTEISKKI;PNLTEISKKIT; NLTEISKKITD; LTEISKKITDS; TEISKKITDSN;EISKKITDSNA; ISKKITDSNAF; SKKITDSNAFV; KKITDSNAFVL;KITDSNAFVLA; ITDSNAFVLAV; TDSNAFVLAVK; DSNAFVLAVKE;SNAFVLAVKEV; NAFVLAVKEVE; AFVLAVKEVET; FVLAVKEVETL;VLAVKEVETLV; LAVKEVETLVS; AVKEVETLVSS; VKEVETLVSSI;KEVETLVSSID; EVETLVSSIDE; VETLVSSIDEL; ETLVSSIDELA;TLVSSIDELAN; LVSSIDELANK; VSSIDELANKA; SSIDELANKAI;SIDELANKAIG; IDELANKAIGK; DELANKAIGKK; ELANKAIGKKI;LANKAIGKKIQ; ANKAIGKKIQQ; NKAIGKKIQQN; KAIGKKIQQNG;AIGKKIQQNGL; IGKKIQQNGLG; GKKIQQNGLGA; KKIQQNGLGAE;KIQQNGLGAEA; IQQNGLGAEAN; QQNGLGAEANR; QNGLGAEANRN;NGLGAEANRNE; GLGAEANRNES; LGAEANRNESL; GAEANRNESLL;AEANRNESLLA; EANRNESLLAG; ANRNESLLAGV; NRNESLLAGVH;RNESLLAGVHE; NESLLAGVHEI; ESLLAGVHEIS; SLLAGVHEIST;LLAGVHEISTL; LAGVHEISTLI; AGVHEISTLIT; GVHEISTLITE;VHEISTLITEK; HEISTLITEKL; EISTLITEKLS; ISTLITEKLSK;STLITEKLSKL; TLITEKLSKLK; LITEKLSKLKN; ITEKLSKLKNS;TEKLSKLKNSG; EKLSKLKNSGE; KLSKLKNSGEL; LSKLKNSGELK;SKLKNSGELKA; KLKNSGELKAK; LKNSGELKAKI; KNSGELKAKIE;NSGELKAKIED; SGELKAKIEDA; GELKAKIEDAK; ELKAKIEDAKK;LKAKIEDAKKC; KAKIEDAKKCS; AKIEDAKKCSE; KIEDAKKCSEE;IEDAKKCSEEF; EDAKKCSEEFT; DAKKCSEEFTN; AKKCSEEFTNK;KKCSEEFTNKL; KCSEEFTNKLR; CSEEFTNKLRV; SEEFTNKLRVS;EEFTNKLRVSH; EFTNKLRVSHA; FTNKLRVSHAD; TNKLRVSHADL;NKLRVSHADLG; KLRVSHADLGK; LRVSHADLGKQ; RVSHADLGKQG;VSHADLGKQGV; SHADLGKQGVN; HADLGKQGVND; ADLGKQGVNDD;DLGKQGVNDDD; LGKQGVNDDDA; GKQGVNDDDAK; KQGVNDDDAKK;QGVNDDDAKKA; GVNDDDAKKAI; VNDDDAKKAIL; NDDDAKKAILK;DDDAKKAILKT; DDAKKAILKTN; DAKKAILKTNA; AKKAILKTNAD;KKAILKTNADK; KAILKTNADKT; AILKTNADKTK; ILKTNADKTKG;LKTNADKTKGA; KTNADKTKGAE; TNADKTKGAEE; NADKTKGAEEL;ADKTKGAEELG; DKTKGAEELGK; KTKGAEELGKL; TKGAEELGKLF;KGAEELGKLFK; GAEELGKLFKS; AEELGKLFKSV; EELGKLFKSVE;ELGKLFKSVEG; LGKLFKSVEGL; GKLFKSVEGLV; KLFKSVEGLVK;LFKSVEGLVKA; FKSVEGLVKAA; KSVEGLVKAAQ; SVEGLVKAAQE;VEGLVKAAQEA; EGLVKAAQEAL; GLVKAAQEALT; LVKAAQEALTN;VKAAQEALTNS; KAAQEALTNSV; AAQEALTNSVK; AQEALTNSVKE;QEALTNSVKEL; EALTNSVKELT; ALTNSVKELTS; LTNSVKELTSP;TNSVKELTSPV; NSVKELTSPVV; SVKELTSPVVA; VKELTSPVVAE;KELTSPVVAES; ELTSPVVAESP; LTSPVVAESPK; TSPVVAESPKK; SPVVAESPKKP;13 mers: MKKNTLSAILMTL; KKNTLSAILMTLF; KNTLSAILMTLFL; NTLSAILMTLFLF;TLSAILMTLFLFI; LSAILMTLFLFIS; SAILMTLFLFISC; AILMTLFLFISCN;ILMTLFLFISCNN; LMTLFLFISCNNS; MTLFLFISCNNSG; TLFLFISCNNSGK;LFLFISCNNSGKG; FLFISCNNSGKGG; LFISCNNSGKGGD; FISCNNSGKGGDS;ISCNNSGKGGDSA; SCNNSGKGGDSAS; CNNSGKGGDSAST; NNSGKGGDSASTN;NSGKGGDSASTNP; SGKGGDSASTNPA; GKGGDSASTNPAD; KGGDSASTNPADE;GGDSASTNPADES; GDSASTNPADESA; DSASTNPADESAK; SASTNPADESAKG;ASTNPADESAKGP; STNPADESAKGPN; TNPADESAKGPNL; NPADESAKGPNLT;PADESAKGPNLTE; ADESAKGPNLTEI; DESAKGPNLTEIS; ESAKGPNLTEISK;SAKGPNLTEISKK; AKGPNLTEISKKI; KGPNLTEISKKIT; GPNLTEISKKITD;PNLTEISKKITDS; NLTEISKKITDSN; LTEISKKITDSNA; TEISKKITDSNAF;EISKKITDSNAFV; ISKKITDSNAFVL; SKKITDSNAFVLA; KKITDSNAFVLAV;KITDSNAFVLAVK; ITDSNAFVLAVKE; TDSNAFVLAVKEV; DSNAFVLAVKEVE;SNAFVLAVKEVET; NAFVLAVKEVETL; AFVLAVKEVETLV; FVLAVKEVETLVS;VLAVKEVETLVSS; LAVKEVETLVSSI; AVKEVETLVSSID; VKEVETLVSSIDE;KEVETLVSSIDEL; EVETLVSSIDELA; VETLVSSIDELAN; ETLVSSIDELANK;TLVSSIDELANKA; LVSSIDELANKAI; VSSIDELANKAIG; SSIDELANKAIGK;SIDELANKAIGKK; IDELANKAIGKKI; DELANKAIGKKIQ; ELANKAIGKKIQQ;LANKAIGKKIQQN; ANKAIGKKIQQNG; NKAIGKKIQQNGL; KAIGKKIQQNGLG;AIGKKIQQNGLGA; IGKKIQQNGLGAE; GKKIQQNGLGAEA; KKIQQNGLGAEAN;KIQQNGLGAEANR; IQQNGLGAEANRN; QQNGLGAEANRNE; QNGLGAEANRNES;NGLGAEANRNESL; GLGAEANRNESLL; LGAEANRNESLLA; GAEANRNESLLAG;AEANRNESLLAGV; EANRNESLLAGVH; ANRNESLLAGVHE; NRNESLLAGVHEI;RNESLLAGVHEIS; NESLLAGVHEIST; ESLLAGVHEISTL; SLLAGVHEISTLI;LLAGVHEISTLIT; LAGVHEISTLITE; AGVHEISTLITEK; GVHEISTLITEKL;VHEISTLITEKLS; HEISTLITEKLSK; EISTLITEKLSKL; ISTLITEKLSKLK;STLITEKLSKLKN; TLITEKLSKLKNS; LITEKLSKLKNSG; ITEKLSKLKNSGE;TEKLSKLKNSGEL; EKLSKLKNSGELK; KLSKLKNSGELKA; LSKLKNSGELKAK;SKLKNSGELKAKI; KLKNSGELKAKIE; LKNSGELKAKIED; KNSGELKAKIEDA;NSGELKAKIEDAK; SGELKAKIEDAKK; GELKAKIEDAKKC; ELKAKIEDAKKCS;LKAKIEDAKKCSE; KAKIEDAKKCSEE; AKIEDAKKCSEEF; KIEDAKKCSEEFT;IEDAKKCSEEFTN; EDAKKCSEEFTNK; DAKKCSEEFTNKL; AKKCSEEFTNKLR;KKCSEEFTNKLRV; KCSEEFTNKLRVS; CSEEFTNKLRVSH; SEEFTNKLRVSHA;EEFTNKLRVSHAD; EFTNKLRVSHADL; FTNKLRVSHADLG; TNKLRVSHADLGK;NKLRVSHADLGKQ; KLRVSHADLGKQG; LRVSHADLGKQGV; RVSHADLGKQGVN;VSHADLGKQGVND; SHADLGKQGVNDD; HADLGKQGVNDDD; ADLGKQGVNDDDA;DLGKQGVNDDDAK; LGKQGVNDDDAKK; GKQGVNDDDAKKA; KQGVNDDDAKKAI;QGVNDDDAKKAIL; GVNDDDAKKAILK; VNDDDAKKAILKT; NDDDAKKAILKTN;DDDAKKAILKTNA; DDAKKAILKTNAD; DAKKAILKTNADK; AKKAILKTNADKT;KKAILKTNADKTK; KAILKTNADKTKG; AILKTNADKTKGA; ILKTNADKTKGAE;LKTNADKTKGAEE; KTNADKTKGAEEL; TNADKTKGAEELG; NADKTKGAEELGK;ADKTKGAEELGKL; DKTKGAEELGKLF; KTKGAEELGKLFK; TKGAEELGKLFKS;KGAEELGKLFKSV; GAEELGKLFKSVE; AEELGKLFKSVEG; EELGKLFKSVEGL;ELGKLFKSVEGLV; LGKLFKSVEGLVK; GKLFKSVEGLVKA; KLFKSVEGLVKAA;LFKSVEGLVKAAQ; FKSVEGLVKAAQE; KSVEGLVKAAQEA; SVEGLVKAAQEAL;VEGLVKAAQEALT; EGLVKAAQEALTN; GLVKAAQEALTNS; LVKAAQEALTNSV;VKAAQEALTNSVK; KAAQEALTNSVKE; AAQEALTNSVKEL; AQEALTNSVKELT;QEALTNSVKELTS; EALTNSVKELTSP; ALTNSVKELTSPV; LTNSVKELTSPVV;TNSVKELTSPVVA; NSVKELTSPVVAE; SVKELTSPVVAES; VKELTSPVVAESP;KELTSPVVAESPK; ELTSPVVAESPKK; LTSPVVAESPKKP 14 mers:MKKNTLSAILMTLF; KKNTLSAILMTLFL; KNTLSAILMTLFLF;NTLSAILMTLFLFI; TLSAILMTLFLFIS; LSAILMTLFLFISC;SAILMTLFLFISCN; AILMTLFLFISCNN; ILMTLFLFISCNNS;LMTLFLFISCNNSG; MTLFLFISCNNSGK; TLFLFISCNNSGKG;LFLFISCNNSGKGG; FLFISCNNSGKGGD; LFISCNNSGKGGDS;FISCNNSGKGGDSA; ISCNNSGKGGDSAS; SCNNSGKGGDSAST;CNNSGKGGDSASTN; NNSGKGGDSASTNP; NSGKGGDSASTNPA;SGKGGDSASTNPAD; GKGGDSASTNPADE; KGGDSASTNPADES;GGDSASTNPADESA; GDSASTNPADESAK; DSASTNPADESAKG;SASTNPADESAKGP; ASTNPADESAKGPN; STNPADESAKGPNL;TNPADESAKGPNLT; NPADESAKGPNLTE; PADESAKGPNLTEI;ADESAKGPNLTEIS; DESAKGPNLTEISK; ESAKGPNLTEISKK;SAKGPNLTEISKKI; AKGPNLTEISKKIT; KGPNLTEISKKITD;GPNLTEISKKITDS; PNLTEISKKITDSN; NLTEISKKITDSNA;LTEISKKITDSNAF; TEISKKITDSNAFV; EISKKITDSNAFVL;ISKKITDSNAFVLA; SKKITDSNAFVLAV; KKITDSNAFVLAVK;KITDSNAFVLAVKE; ITDSNAFVLAVKEV; TDSNAFVLAVKEVE;DSNAFVLAVKEVET; SNAFVLAVKEVETL; NAFVLAVKEVETLV;AFVLAVKEVETLVS; FVLAVKEVETLVSS; VLAVKEVETLVSSI;LAVKEVETLVSSID; AVKEVETLVSSIDE; VKEVETLVSSIDEL;KEVETLVSSIDELA; EVETLVSSIDELAN; VETLVSSIDELANK;ETLVSSIDELANKA; TLVSSIDELANKAI; LVSSIDELANKAIG;VSSIDELANKAIGK; SSIDELANKAIGKK; SIDELANKAIGKKI;IDELANKAIGKKIQ; DELANKAIGKKIQQ; ELANKAIGKKIQQN;LANKAIGKKIQQNG; ANKAIGKKIQQNGL; NKAIGKKIQQNGLG;KAIGKKIQQNGLGA; AIGKKIQQNGLGAE; IGKKIQQNGLGAEA;GKKIQQNGLGAEAN; KKIQQNGLGAEANR; KIQQNGLGAEANRN;IQQNGLGAEANRNE; QQNGLGAEANRNES; QNGLGAEANRNESL;NGLGAEANRNESLL; GLGAEANRNESLLA; LGAEANRNESLLAG;GAEANRNESLLAGV; AEANRNESLLAGVH; EANRNESLLAGVHE;ANRNESLLAGVHEI; NRNESLLAGVHEIS; RNESLLAGVHEIST;NESLLAGVHEISTL; ESLLAGVHEISTLI; SLLAGVHEISTLIT;LLAGVHEISTLITE; LAGVHEISTLITEK; AGVHEISTLITEKL;GVHEISTLITEKLS; VHEISTLITEKLSK; HEISTLITEKLSKL;EISTLITEKLSKLK; ISTLITEKLSKLKN; STLITEKLSKLKNS;TLITEKLSKLKNSG; LITEKLSKLKNSGE; ITEKLSKLKNSGEL;TEKLSKLKNSGELK; EKLSKLKNSGELKA; KLSKLKNSGELKAK;LSKLKNSGELKAKI; SKLKNSGELKAKIE; KLKNSGELKAKIED;LKNSGELKAKIEDA; KNSGELKAKIEDAK; NSGELKAKIEDAKK;SGELKAKIEDAKKC; GELKAKIEDAKKCS; ELKAKIEDAKKCSE;LKAKIEDAKKCSEE; KAKIEDAKKCSEEF; AKIEDAKKCSEEFT;KIEDAKKCSEEFTN; IEDAKKCSEEFTNK; EDAKKCSEEFTNKL;DAKKCSEEFTNKLR; AKKCSEEFTNKLRV; KKCSEEFTNKLRVS;KCSEEFTNKLRVSH; CSEEFTNKLRVSHA; SEEFTNKLRVSHAD;EEFTNKLRVSHADL; EFTNKLRVSHADLG; FTNKLRVSHADLGK;TNKLRVSHADLGKQ; NKLRVSHADLGKQG; KLRVSHADLGKQGV;LRVSHADLGKQGVN; RVSHADLGKQGVND; VSHADLGKQGVNDD;SHADLGKQGVNDDD; HADLGKQGVNDDDA; ADLGKQGVNDDDAK;DLGKQGVNDDDAKK; LGKQGVNDDDAKKA; GKQGVNDDDAKKAI;KQGVNDDDAKKAIL; QGVNDDDAKKAILK; GVNDDDAKKAILKT;VNDDDAKKAILKTN; NDDDAKKAILKTNA; DDDAKKAILKTNAD;DDAKKAILKTNADK; DAKKAILKTNADKT; AKKAILKTNADKTK;KKAILKTNADKTKG; KAILKTNADKTKGA; AILKTNADKTKGAE;ILKTNADKTKGAEE; LKTNADKTKGAEEL; KTNADKTKGAEELG;TNADKTKGAEELGK; NADKTKGAEELGKL; ADKTKGAEELGKLF;DKTKGAEELGKLFK; KTKGAEELGKLFKS; TKGAEELGKLFKSV;KGAEELGKLFKSVE; GAEELGKLFKSVEG; AEELGKLFKSVEGL;EELGKLFKSVEGLV; ELGKLFKSVEGLVK; LGKLFKSVEGLVKA;GKLFKSVEGLVKAA; KLFKSVEGLVKAAQ; LFKSVEGLVKAAQE;FKSVEGLVKAAQEA; KSVEGLVKAAQEAL; SVEGLVKAAQEALT;VEGLVKAAQEALTN; EGLVKAAQEALTNS; GLVKAAQEALTNSV;LVKAAQEALTNSVK; VKAAQEALTNSVKE; KAAQEALTNSVKEL;AAQEALTNSVKELT; AQEALTNSVKELTS; QEALTNSVKELTSP;EALTNSVKELTSPV; ALTNSVKELTSPVV; LTNSVKELTSPVVA;TNSVKELTSPVVAE; NSVKELTSPVVAES; SVKELTSPVVAESP;VKELTSPVVAESPK; KELTSPVVAESPKK; ELTSPVVAESPKKP 15 mers:MKKNTLSAILMTLFL; KKNTLSAILMTLFLF; KNTLSAILMTLFLFI;NTLSAILMTLFLFIS; TLSAILMTLFLFISC; LSAILMTLFLFISCN;SAILMTLFLFISCNN; AILMTLFLFISCNNS; ILMTLFLFISCNNSG;LMTLFLFISCNNSGK; MTLFLFISCNNSGKG; TLFLFISCNNSGKGG;LFLFISCNNSGKGGD; FLFISCNNSGKGGDS; LFISCNNSGKGGDSA;FISCNNSGKGGDSAS; ISCNNSGKGGDSAST; SCNNSGKGGDSASTN;CNNSGKGGDSASTNP; NNSGKGGDSASTNPA; NSGKGGDSASTNPAD;SGKGGDSASTNPADE; GKGGDSASTNPADES; KGGDSASTNPADESA;GGDSASTNPADESAK; GDSASTNPADESAKG; DSASTNPADESAKGP;SASTNPADESAKGPN; ASTNPADESAKGPNL; STNPADESAKGPNLT;TNPADESAKGPNLTE; NPADESAKGPNLTEI; PADESAKGPNLTEIS;ADESAKGPNLTEISK; DESAKGPNLTEISKK; ESAKGPNLTEISKKI;SAKGPNLTEISKKIT; AKGPNLTEISKKITD; KGPNLTEISKKITDS;GPNLTEISKKITDSN; PNLTEISKKITDSNA; NLTEISKKITDSNAF;LTEISKKITDSNAFV; TEISKKITDSNAFVL; EISKKITDSNAFVLA;ISKKITDSNAFVLAV; SKKITDSNAFVLAVK; KKITDSNAFVLAVKE;KITDSNAFVLAVKEV; ITDSNAFVLAVKEVE; TDSNAFVLAVKEVET;DSNAFVLAVKEVETL; SNAFVLAVKEVETLV; NAFVLAVKEVETLVS;AFVLAVKEVETLVSS; FVLAVKEVETLVSSI; VLAVKEVETLVSSID;LAVKEVETLVSSIDE; AVKEVETLVSSIDEL; VKEVETLVSSIDELA;KEVETLVSSIDELAN; EVETLVSSIDELANK; VETLVSSIDELANKA;ETLVSSIDELANKAI; TLVSSIDELANKAIG; LVSSIDELANKAIGK;VSSIDELANKAIGKK; SSIDELANKAIGKKI; SIDELANKAIGKKIQ;IDELANKAIGKKIQQ; DELANKAIGKKIQQN; ELANKAIGKKIQQNG;LANKAIGKKIQQNGL; ANKAIGKKIQQNGLG; NKAIGKKIQQNGLGA;KAIGKKIQQNGLGAE; AIGKKIQQNGLGAEA; IGKKIQQNGLGAEAN;GKKIQQNGLGAEANR; KKIQQNGLGAEANRN; KIQQNGLGAEANRNE;IQQNGLGAEANRNES; QQNGLGAEANRNESL; QNGLGAEANRNESLL;NGLGAEANRNESLLA; GLGAEANRNESLLAG; LGAEANRNESLLAGV;GAEANRNESLLAGVH; AEANRNESLLAGVHE; EANRNESLLAGVHEI;ANRNESLLAGVHEIS; NRNESLLAGVHEIST; RNESLLAGVHEISTL;NESLLAGVHEISTLI; ESLLAGVHEISTLIT; SLLAGVHEISTLITE;LLAGVHEISTLITEK; LAGVHEISTLITEKL; AGVHEISTLITEKLS;GVHEISTLITEKLSK; VHEISTLITEKLSKL; HEISTLITEKLSKLK;EISTLITEKLSKLKN; ISTLITEKLSKLKNS; STLITEKLSKLKNSG;TLITEKLSKLKNSGE; LITEKLSKLKNSGEL; ITEKLSKLKNSGELK;TEKLSKLKNSGELKA; EKLSKLKNSGELKAK; KLSKLKNSGELKAKI;LSKLKNSGELKAKIE; SKLKNSGELKAKIED; KLKNSGELKAKIEDA;LKNSGELKAKIEDAK; KNSGELKAKIEDAKK; NSGELKAKIEDAKKC;SGELKAKIEDAKKCS; GELKAKIEDAKKCSE; ELKAKIEDAKKCSEE;LKAKIEDAKKCSEEF; KAKIEDAKKCSEEFT; AKIEDAKKCSEEFTN;KIEDAKKCSEEFTNK; IEDAKKCSEEFTNKL; EDAKKCSEEFTNKLR;DAKKCSEEFTNKLRV; AKKCSEEFTNKLRVS; KKCSEEFTNKLRVSH;KCSEEFTNKLRVSHA; CSEEFTNKLRVSHAD; SEEFTNKLRVSHADL;EEFTNKLRVSHADLG; EFTNKLRVSHADLGK; FTNKLRVSHADLGKQ;TNKLRVSHADLGKQG; NKLRVSHADLGKQGV; KLRVSHADLGKQGVN;LRVSHADLGKQGVND; RVSHADLGKQGVNDD; VSHADLGKQGVNDDD;SHADLGKQGVNDDDA; HADLGKQGVNDDDAK; ADLGKQGVNDDDAKK;DLGKQGVNDDDAKKA; LGKQGVNDDDAKKAI; GKQGVNDDDAKKAIL;KQGVNDDDAKKAILK; QGVNDDDAKKAILKT; GVNDDDAKKAILKTN;VNDDDAKKAILKTNA; NDDDAKKAILKTNAD; DDDAKKAILKTNADK;DDAKKAILKTNADKT; DAKKAILKTNADKTK; AKKAILKTNADKTKG;KKAILKTNADKTKGA; KAILKTNADKTKGAE; AILKTNADKTKGAEE;ILKTNADKTKGAEEL; LKTNADKTKGAEELG; KTNADKTKGAEELGK;TNADKTKGAEELGKL; NADKTKGAEELGKLF; ADKTKGAEELGKLFK;DKTKGAEELGKLFKS; KTKGAEELGKLFKSV; TKGAEELGKLFKSVE;KGAEELGKLFKSVEG; GAEELGKLFKSVEGL; AEELGKLFKSVEGLV;EELGKLFKSVEGLVK; ELGKLFKSVEGLVKA; LGKLFKSVEGLVKAA;GKLFKSVEGLVKAAQ; KLFKSVEGLVKAAQE; LFKSVEGLVKAAQEA;FKSVEGLVKAAQEAL; KSVEGLVKAAQEALT; SVEGLVKAAQEALTN;VEGLVKAAQEALTNS; EGLVKAAQEALTNSV; GLVKAAQEALTNSVK;LVKAAQEALTNSVKE; VKAAQEALTNSVKEL; KAAQEALTNSVKELT;AAQEALTNSVKELTS; AQEALTNSVKELTSP; QEALTNSVKELTSPV;EALTNSVKELTSPVV; ALTNSVKELTSPVVA; LTNSVKELTSPVVAE;TNSVKELTSPVVAES; NSVKELTSPVVAESP; SVKELTSPVVAESPK;VKELTSPVVAESPKK; KELTSPVVAESPKKP 16 mers:MKKNTLSAILMTLFLF; KKNTLSAILMTLFLFI; KNTLSAILMTLFLFIS;NTLSAILMTLFLFISC; TLSAILMTLFLFISCN; LSAILMTLFLFISCNN;SAILMTLFLFISCNNS; AILMTLFLFISCNNSG; ILMTLFLFISCNNSGK;LMTLFLFISCNNSGKG; MTLFLFISCNNSGKGG; TLFLFISCNNSGKGGD;LFLFISCNNSGKGGDS; FLFISCNNSGKGGDSA; LFISCNNSGKGGDSAS;FISCNNSGKGGDSAST; ISCNNSGKGGDSASTN; SCNNSGKGGDSASTNP;CNNSGKGGDSASTNPA; NNSGKGGDSASTNPAD; NSGKGGDSASTNPADE;SGKGGDSASTNPADES; GKGGDSASTNPADESA; KGGDSASTNPADESAK;GGDSASTNPADESAKG; GDSASTNPADESAKGP; DSASTNPADESAKGPN;SASTNPADESAKGPNL; ASTNPADESAKGPNLT; STNPADESAKGPNLTE;TNPADESAKGPNLTEI; NPADESAKGPNLTEIS; PADESAKGPNLTEISK;ADESAKGPNLTEISKK; DESAKGPNLTEISKKI; ESAKGPNLTEISKKIT;SAKGPNLTEISKKITD; AKGPNLTEISKKITDS; KGPNLTEISKKITDSN;GPNLTEISKKITDSNA; PNLTEISKKITDSNAF; NLTEISKKITDSNAFV;LTEISKKITDSNAFVL; TEISKKITDSNAFVLA; EISKKITDSNAFVLAV;ISKKITDSNAFVLAVK; SKKITDSNAFVLAVKE; KKITDSNAFVLAVKEV;KITDSNAFVLAVKEVE; ITDSNAFVLAVKEVET; TDSNAFVLAVKEVETL;DSNAFVLAVKEVETLV; SNAFVLAVKEVETLVS; NAFVLAVKEVETLVSS;AFVLAVKEVETLVSSI; FVLAVKEVETLVSSID; VLAVKEVETLVSSIDE;LAVKEVETLVSSIDEL; AVKEVETLVSSIDELA; VKEVETLVSSIDELAN;KEVETLVSSIDELANK; EVETLVSSIDELANKA; VETLVSSIDELANKAI;ETLVSSIDELANKAIG; TLVSSIDELANKAIGK; LVSSIDELANKAIGKK;VSSIDELANKAIGKKI; SSIDELANKAIGKKIQ; SIDELANKAIGKKIQQ;IDELANKAIGKKIQQN; DELANKAIGKKIQQNG; ELANKAIGKKIQQNGL;LANKAIGKKIQQNGLG; ANKAIGKKIQQNGLGA; NKAIGKKIQQNGLGAE;KAIGKKIQQNGLGAEA; AIGKKIQQNGLGAEAN; IGKKIQQNGLGAEANR;GKKIQQNGLGAEANRN; KKIQQNGLGAEANRNE; KIQQNGLGAEANRNES;IQQNGLGAEANRNESL; QQNGLGAEANRNESLL; QNGLGAEANRNESLLA;NGLGAEANRNESLLAG; GLGAEANRNESLLAGV; LGAEANRNESLLAGVH;GAEANRNESLLAGVHE; AEANRNESLLAGVHEI; EANRNESLLAGVHEIS;ANRNESLLAGVHEIST; NRNESLLAGVHEISTL; RNESLLAGVHEISTLI;NESLLAGVHEISTLIT; ESLLAGVHEISTLITE; SLLAGVHEISTLITEK;LLAGVHEISTLITEKL; LAGVHEISTLITEKLS; AGVHEISTLITEKLSK;GVHEISTLITEKLSKL; VHEISTLITEKLSKLK; HEISTLITEKLSKLKN;EISTLITEKLSKLKNS; ISTLITEKLSKLKNSG; STLITEKLSKLKNSGE;TLITEKLSKLKNSGEL; LITEKLSKLKNSGELK; ITEKLSKLKNSGELKA;TEKLSKLKNSGELKAK; EKLSKLKNSGELKAKI; KLSKLKNSGELKAKIE;LSKLKNSGELKAKIED; SKLKNSGELKAKIEDA; KLKNSGELKAKIEDAK;LKNSGELKAKIEDAKK; KNSGELKAKIEDAKKC; NSGELKAKIEDAKKCS;SGELKAKIEDAKKCSE; GELKAKIEDAKKCSEE; ELKAKIEDAKKCSEEF;LKAKIEDAKKCSEEFT; KAKIEDAKKCSEEFTN; AKIEDAKKCSEEFTNK;KIEDAKKCSEEFTNKL; IEDAKKCSEEFTNKLR; EDAKKCSEEFTNKLRV;DAKKCSEEFTNKLRVS; AKKCSEEFTNKLRVSH; KKCSEEFTNKLRVSHA;KCSEEFTNKLRVSHAD; CSEEFTNKLRVSHADL; SEEFTNKLRVSHADLG;EEFTNKLRVSHADLGK; EFTNKLRVSHADLGKQ; FTNKLRVSHADLGKQG;TNKLRVSHADLGKQGV; NKLRVSHADLGKQGVN; KLRVSHADLGKQGVND;LRVSHADLGKQGVNDD; RVSHADLGKQGVNDDD; VSHADLGKQGVNDDDA;SHADLGKQGVNDDDAK; HADLGKQGVNDDDAKK; ADLGKQGVNDDDAKKA;DLGKQGVNDDDAKKAI; LGKQGVNDDDAKKAIL; GKQGVNDDDAKKAILK;KQGVNDDDAKKAILKT; QGVNDDDAKKAILKTN; GVNDDDAKKAILKTNA;VNDDDAKKAILKTNAD; NDDDAKKAILKTNADK; DDDAKKAILKTNADKT;DDAKKAILKTNADKTK; DAKKAILKTNADKTKG; AKKAILKTNADKTKGA;KKAILKTNADKTKGAE; KAILKTNADKTKGAEE; AILKTNADKTKGAEEL;ILKTNADKTKGAEELG; LKTNADKTKGAEELGK; KTNADKTKGAEELGKL;TNADKTKGAEELGKLF; NADKTKGAEELGKLFK; ADKTKGAEELGKLFKS;DKTKGAEELGKLFKSV; KTKGAEELGKLFKSVE; TKGAEELGKLFKSVEG;KGAEELGKLFKSVEGL; GAEELGKLFKSVEGLV; AEELGKLFKSVEGLVK;EELGKLFKSVEGLVKA; ELGKLFKSVEGLVKAA; LGKLFKSVEGLVKAAQ;GKLFKSVEGLVKAAQE; KLFKSVEGLVKAAQEA; LFKSVEGLVKAAQEAL;FKSVEGLVKAAQEALT; KSVEGLVKAAQEALTN; SVEGLVKAAQEALTNS;VEGLVKAAQEALTNSV; EGLVKAAQEALTNSVK; GLVKAAQEALTNSVKE;LVKAAQEALTNSVKEL; VKAAQEALTNSVKELT; KAAQEALTNSVKELTS;AAQEALTNSVKELTSP; AQEALTNSVKELTSPV; QEALTNSVKELTSPVV;EALTNSVKELTSPVVA; ALTNSVKELTSPVVAE; LTNSVKELTSPVVAES;TNSVKELTSPVVAESP; NSVKELTSPVVAESPK; SVKELTSPVVAESPKK; VKELTSPVVAESPKKPSEQ ID NOS: 49527-51126

Preferred Borrelia burgdorferi fragments of Osp A capable of interactingwith one or more MHC molecules are listed in Table V.

TABLE V Prediction of Borrelia burgdorferi OspAprotein specific MHC class1, 8-, 9-, 10-,11-mer peptide binders for 42 MHC class1 alleles (see FIG. 11) using the http://www.cbs.dtu.dk/services/NetMHC/database. The MHC class 1 molecules forwhich no binders were found are not listed. CAA44492.1|Outer surfaceHLA- protein A [Borrelia burgdorferi] A0101 Seq9 HLA- YLLGIGLIL A0201FTLEGTLAA KTSTLTISV FTKEDTITV ALIACKQNV LLGIGLILA SLEATVDKL ILKSGEITVKVTEGTVVL STLDEKNSV TLVSKKVTL GIGLILALI YLLGIGLILA TLDEKNSVSV ALDDSDTTQALLGIGLILAL NILKSGEITV TLAADGKTTL VLKDFTLEGT YSLEATVDKL YLLGIGLILALLVFTKEDTITV LLGIGLILALI ILALIACKQNV STLDEKNSVSV ALDDSDTTQAT VLKDFTLEGTLSLEATVDKLEL ILKSGEITVAL ALIACKQNVST TTLKVTEGTVV LAADGKTTLKV LIACKQNVSTLHLA- VVLSKNILK A0301 KTKNLVFTK LVSKKVTLK LILALIACK LTISVNSQK KAVEITTLKAADGKTTLK ISVNSQKTK RANGTRLEY SQTKFEIFK KSDGSGKAK TQATKKTGK MTELVSKEKTLVSKKVTLK TLTISVNSQK TVVLSKNILK GLILALIACK TLKELKNALK LSQTKFEIFKLAADGKTTLK VTEGTVVLSK KLELKGTSDK TTQATKKTGK GMTELVSKEK KYSLEATVDKKQNVSTLDEK TIADDLSQTK TISVNSQKTK KEDAKTLVSK GSGKAKEVLK KTIVRANGTRGTLEGEKTDK GKAVEITTLK GTRLEYTDIK VSKKVTLKDK IKSDGSGKAK TLAADGKTTLKSTLTISVNSQK KTLVSKKVTLK KVTEGTVVLSK TTLKELKNALK LTISVNSQKTK GTVVLSKNILKFTKEDTITVQK IVRANGTRLEY TLKDKSSTEEK LVSKKVTLKDK KFNEKGETSEK LTIADDLSQTKSQKTKNLVFTK KSSTEEKFNEK ATKKTGKWDSK HLA- VVLSKNILK A1101 KTKNLVFTKSQTKFEIFK LTISVNSQK ATVDKLELK LILALIACK STEEKFNEK KAVEITTLK LVSKKVTLKMTELVSKEK AADGKTTLK SAGTNLEGK YSLEATVDK GSGTLEGEK TQATKKTGK RANGTRLEYIADDLSQTK ISVNSQKTK KSDGSGKAK GGMTELVSK TEGTVVLSK EITTLKELK TIVRANGTRTVVLSKNILK TTQATKKTGK TIADDLSQTK VTEGTVVLSK LSQTKFEIFK SSTEEKFNEKGLILALIACK KQNVSTLDEK TLTISVNSQK TLVSKKVTLK TISVNSQKTK LAADGKTTLKGMTELVSKEK TLKELKNALK KTIVRANGTR GSGKAKEVLK GTLEGEKTDK VSKKVTLKDKGTRLEYTDIK KLELKGTSDK DSAGTNLEGK STLTISVNSQK TTLKELKNALK KVTEGTVVLSKKTLVSKKVTLK GTVVLSKNILK LTIADDLSQTK TLAADGKTTLK AVEITTLKELK LTISVNSQKTKSQKTKNLVFTK KSSTEEKFNEK ATKKTGKWDSK TLKDKSSTEEK FTKEDTITVQK TLEGTLAADGKLVSKKVTLKDK MTELVSKEKDK DLSQTKFEIFK YTDIKSDGSGK LVSKEKDKDGK KFNEKGETSEKIGLILALIACK HLA- KYLLGIGLI A2402 KWDSKTSTL KYDSAGTNL KYLLGIGLILKWDSKTSTLTI KYSLEATVDKL HLA- IVRANGTRLEY A2902 TIADDLSQTKF HLA-LTISVNSQK A6801 ETSEKTIVR MTELVSKEK EITTLKELK TIVRANGTR KAVEITTLKDAKTLVSKK KTKNLVFTK STEEKFNEK ATVDKLELK LVSKKVTLK SQTKFEIFK YSLEATVDKEGTLAADGK ISVNSQKTK LILALIACK DIKSDGSGK VVLSKNILK EDAKTLVSK DSDTTQATKSAGTNLEGK TVVLSKNILK TLTISVNSQK EATVDKLELK TIADDLSQTK DSAGTNLEGKTTQATKKTGK LAADGKTTLK KTIVRANGTR TISVNSQKTK TLVSKKVTLK SSTEEKFNEKTLKELKNALK LSQTKFEIFK VTEGTVVLSK EDAKTLVSKK DSDTTQATKK GLILALIACK HLA-IVRANGTRL B0702 KVTEGTVVL LAADGKTTL LPGGMTELV TVVLSKNIL KAVEITTLKEL HLA-TLKELKNAL B0801 ILKSGEITVAL YLLGIGLILAL TLKVTEGTVVL HLA- SQKTKNLVF B1501RANGTRLEY YLLGIGLIL KVTEGTVVL TLKELKNAL KAKEVLKDF IVRANGTRL LGIGLILALTLAADGKTTL IVRANGTRLEY YLLGIGLILAL VQKYDSAGTNL ILKSGEITVAL VSKEKDKDGKYVLKDFTLEGTL TLKVTEGTVVL VNSQKTKNLVF HLA- KKYLLGIGL B2705 VRANGTRLEYGKWDSKTSTL KKYLLGIGLIL HLA- LAADGKTTL B3501 RANGTRLEY FTLEGTLAATVVLSKNIL VALDDSDTT YLLGIGLIL LPGGMTELV IADDLSQTKF LPGGMTELVS LKVTEGTVVLYSLEATVDKL YLLGIGLILAL NSVSVDLPGGM IVRANGTRLEY TIADDLSQTKF KAVEITTLKELHLA- KEVLKDFTL B4403 GEITVALDD KEKDKDGKY KEDAKTLVS GEITVALDDS KEDTITVQKYGEITVALDDSD KEVLKDFTLEG HLA- LPGGMTELV B5101 HLA- TTQATKKTGKW B5701 SEQID NOS: 51127-51380

Preferred Borrelia garinii fragments of FlaB capable of interacting withone or more MHC molecules are listed in Table X.

TABLE X Prediction of Borrelia garinii FlaB proteinspecific MHC class 2, 15-mer peptidebinders for 14 MHC class 2 alleles (seeFIG. 11) using the http://www.cbs.dtu.dk/services/NetMHCII/ database. The MHCclass 2 molecules for which no binders were found are not listed.BAD18055.1 HLA-A0101 NQDEAIAVNIY FlaB protein ELAVQSGNGTY[Borrelia garinii] HLA-A0201 SQASWTLRV Seq15 QLTDEINRI AQAAQTAPVAIAVNIYAA SLAKIENAI AVNIYAANV AQYNQMHML TTVDANTSL SQGGVNSPV QTAPVQEGVNIYAANVANL NLNEVEKVLV VLVRMKELAV QLTDEINRIA NLFSGEGAQA IAVNIYAANVSLSGSQASWTL MLSNKSASQNV AIAVNIYAANV SQASWTLRVHV GMQPAKINTPA KVLVRMKELAVSLAKIENAIRM NLFSGEGAQAA HLA-A0301 NQMHMLSNK GSQASWTLR TVDANTSLAKYNQMHMLSNK LSGSQASWTLR TTVDANTSLAK LSNKSASQNVR HLA-A1101 NQMHMLSNKGSQASWTLR AVQSGNGTY TVDANTSLAK YNQMHMLSNK EVEKVLVRMK TTVDANTSLAKTTEGNLNEVEK TAEELGMQPAK TSLAKIENAIR QYNQMHMLSNK LSGSQASWTLR LSNKSASQNVRHLA-A2402 IYAANVANL YAANVANLF IYAANVANLF TYSDADRGSI IYAANVANLFSHLA-A2902 AVQSGNGTY YAANVANLF ELAVQSGNGTY EINRIADQAQY HLA-A6801LAKIENAIR EGNLNEVEK YAANVANLF NGTYSDADR GSQASWTLR NQMHMLSNK TSKAINFIQNKSASQNVR EVEKVLVRMK SLAKIENAIR TVDANTSLAK NTSKAINFIQ SGSQASWTLRTTVDANTSLA TTVDANTSLAK TTEGNLNEVEK EIEQLTDEINR LSNKSASQNVR TSLAKIENAIREINRIADQAQY NLNEVEKVLVR LSGSQASWTLR TAEELGMQPAK QYNQMHMLSNK NIYAANVANLFQTAPVQEGVQQ HLA-B0702 SPVNVTTTV QPAKINTPA QPAPATAPS LVRMKELAV TPASLSGSQAPSQGGVNS APATAPSQG APVQEGVQQ TPASLSGSQA SPVNVTTTVD APSQGGVNSPQPAKINTPAS APSQGGVNSPV QPAKINTPASL APATAPSQGGV SPVNVTTTVDA TPASLSGSQASHLA-B0801 KVLVRMKEL VEKVLVRMKEL HLA-B1501 YAANVANLF AVQSGNGTY AQAAQTAPVAQYNQMHML SQGGVNSPV SLSGSQASW SQASWTLRV IQIEIEQLT LAVQSGNGTY SQASWTLRVHSQNVRTAEEL VQQEGAQQPA INRIADQAQY AQAAQTAPVQ MQPAKINTPA ELAVQSGNGTYNIYAANVANLF NQDEAIAVNIY SLSGSQASWTL HLA-B2705 NRIADQAQY HLA-B3501YAANVANLF QPAPATAPS SPVNVTTTV DEAIAVNIY TTVDANTSL LAVQSGNGT QPAKINTPAAVQSGNGTY QASWTLRVH IAVNIYAAN LAVQSGNGTY IADQAQYNQM QPAKINTPASLAKIENAIRM QPAPATAPSQ YAANVANLFS TAEELGMQPA EAIAVNIYAA QAQYNQMHMLTPASLSGSQA SPVNVTTTVD TPASLSGSQAS ELAVQSGNGTY NQDEAIAVNIY QPAKINTPASLIAVNIYAANVA NIYAANVANLF SPVNVTTTVDA EINRIADQAQY IADQAQYNQMH APSQGGVNSPVLAVQSGNGTYS HLA-B4403 EELGMQPAKI NEVEKVLVRM DEINRIADQA DEINRIADQAQHLA-B5101 SPVNVTTTV APATAPSQGGV APSQGGVNSPV HLA-B5701 ASLSGSQASW SEQ IDNOS: 51381-51540

Preferred Mycobacterium tuberculosis fragments of CFP10 protein (Rv3874)capable of interacting with one or more class 1 and/or one or more class2 MHC molecules are listed in Table Y.

TABLE Y Prediction of MHC class 1 and 2 Mycobacterium tuberculosisCFP10 peptide binders. Prediction of 8-, 9-, 10-, 11-, 13-,14-, 15-, 16-mer peptides were using the program displayed in FIG. 28 mers: MAEMKTDA; AEMKTDAA; EMKTDAAT; MKTDAATL; KTDAATLA; TDAATLAQ;DAATLAQE; AATLAQEA; ATLAQEAG; TLAQEAGN; LAQEAGNF; AQEAGNFE;QEAGNFER; EAGNFERI; AGNFERIS; GNFERISG; NFERISGD; FERISGDL;ERISGDLK; RISGDLKT; ISGDLKTQ; SGDLKTQI; GDLKTQID; DLKTQIDQ;LKTQIDQV; KTQIDQVE; TQIDQVES; QIDQVEST; IDQVESTA; DQVESTAG;QVESTAGS; VESTAGSL; ESTAGSLQ; STAGSLQG; TAGSLQGQ; AGSLQGQW;GSLQGQWR; SLQGQWRG; LQGQWRGA; QGQWRGAA; GQWRGAAG; QWRGAAGT;WRGAAGTA; RGAAGTAA; GAAGTAAQ; AAGTAAQA; AGTAAQAA; GTAAQAAV;TAAQAAVV; AAQAAVVR; AQAAVVRF; QAAVVRFQ; AAVVRFQE; AVVRFQEA;VVRFQEAA; VRFQEAAN; RFQEAANK; FQEAANKQ; QEAANKQK; EAANKQKQ;AANKQKQE; ANKQKQEL; NKQKQELD; KQKQELDE; QKQELDEI; KQELDEIS;QELDEIST; ELDEISTN; LDEISTNI; DEISTNIR; EISTNIRQ; ISTNIRQA;STNIRQAG; TNIRQAGV; NIRQAGVQ; IRQAGVQY; RQAGVQYS; QAGVQYSR;AGVQYSRA; GVQYSRAD; VQYSRADE; QYSRADEE; YSRADEEQ; SRADEEQQ;RADEEQQQ; ADEEQQQA; DEEQQQAL; EEQQQALS; EQQQALSS; QQQALSSQ;QQALSSQM; QALSSQMG; ALSSQMGF 9 mers:MAEMKTDAA; AEMKTDAAT; EMKTDAATL; MKTDAATLA; KTDAATLAQ;TDAATLAQE; DAATLAQEA; AATLAQEAG; ATLAQEAGN; TLAQEAGNF;LAQEAGNFE; AQEAGNFER; QEAGNFERI; EAGNFERIS; AGNFERISG;GNFERISGD; NFERISGDL; FERISGDLK; ERISGDLKT; RISGDLKTQ;ISGDLKTQI; SGDLKTQID; GDLKTQIDQ; DLKTQIDQV; LKTQIDQVE;KTQIDQVES; TQIDQVEST; QIDQVESTA; IDQVESTAG; DQVESTAGS;QVESTAGSL; VESTAGSLQ; ESTAGSLQG; STAGSLQGQ; TAGSLQGQW;AGSLQGQWR; GSLQGQWRG; SLQGQWRGA; LQGQWRGAA; QGQWRGAAG;GQWRGAAGT; QWRGAAGTA; WRGAAGTAA; RGAAGTAAQ; GAAGTAAQA;AAGTAAQAA; AGTAAQAAV; GTAAQAAVV; TAAQAAVVR; AAQAAVVRF;AQAAVVRFQ; QAAVVRFQE; AAVVRFQEA; AVVRFQEAA; VVRFQEAAN;VRFQEAANK; RFQEAANKQ; FQEAANKQK; QEAANKQKQ; EAANKQKQE;AANKQKQEL; ANKQKQELD; NKQKQELDE; KQKQELDEI; QKQELDEIS;KQELDEIST; QELDEISTN; ELDEISTNI; LDEISTNIR; DEISTNIRQ;EISTNIRQA; ISTNIRQAG; STNIRQAGV; TNIRQAGVQ; NIRQAGVQY;IRQAGVQYS; RQAGVQYSR; QAGVQYSRA; AGVQYSRAD; GVQYSRADE;VQYSRADEE; QYSRADEEQ; YSRADEEQQ; SRADEEQQQ; RADEEQQQA;ADEEQQQAL; DEEQQQALS; EEQQQALSS; EQQQALSSQ; QQQALSSQM;QQALSSQMG; QALSSQMGF; 10 mers:MAEMKTDAAT; AEMKTDAATL; EMKTDAATLA; MKTDAATLAQ; KTDAATLAQE;TDAATLAQEA; DAATLAQEAG; AATLAQEAGN; ATLAQEAGNF; TLAQEAGNFE;LAQEAGNFER; AQEAGNFERI; QEAGNFERIS; EAGNFERISG; AGNFERISGD;GNFERISGDL; NFERISGDLK; FERISGDLKT; ERISGDLKTQ; RISGDLKTQI;ISGDLKTQID; SGDLKTQIDQ; GDLKTQIDQV; DLKTQIDQVE; LKTQIDQVES;KTQIDQVEST; TQIDQVESTA; QIDQVESTAG; IDQVESTAGS; DQVESTAGSL;QVESTAGSLQ; VESTAGSLQG; ESTAGSLQGQ; STAGSLQGQW; TAGSLQGQWR;AGSLQGQWRG; GSLQGQWRGA; SLQGQWRGAA; LQGQWRGAAG; QGQWRGAAGT;GQWRGAAGTA; QWRGAAGTAA; WRGAAGTAAQ; RGAAGTAAQA; GAAGTAAQAA;AAGTAAQAAV; AGTAAQAAVV; GTAAQAAVVR; TAAQAAVVRF; AAQAAVVRFQ;AQAAVVRFQE; QAAVVRFQEA; AAVVRFQEAA; AVVRFQEAAN; VVRFQEAANK;VRFQEAANKQ; RFQEAANKQK; FQEAANKQKQ; QEAANKQKQE; EAANKQKQEL;AANKQKQELD; ANKQKQELDE; NKQKQELDEI; KQKQELDEIS; QKQELDEIST;KQELDEISTN; QELDEISTNI; ELDEISTNIR; LDEISTNIRQ; DEISTNIRQA;EISTNIRQAG; ISTNIRQAGV; STNIRQAGVQ; TNIRQAGVQY; NIRQAGVQYS;IRQAGVQYSR; RQAGVQYSRA; QAGVQYSRAD; AGVQYSRADE; GVQYSRADEE;VQYSRADEEQ; QYSRADEEQQ; YSRADEEQQQ; SRADEEQQQA; RADEEQQQAL;ADEEQQQALS; DEEQQQALSS; EEQQQALSSQ; EQQQALSSQM; QQQALSSQMG; QQALSSQMGF;11 mers: MAEMKTDAATL; AEMKTDAATLA; EMKTDAATLAQ; MKTDAATLAQE;KTDAATLAQEA; TDAATLAQEAG; DAATLAQEAGN; AATLAQEAGNF;ATLAQEAGNFE; TLAQEAGNFER; LAQEAGNFERI; AQEAGNFERIS;QEAGNFERISG; EAGNFERISGD; AGNFERISGDL; GNFERISGDLK;NFERISGDLKT; FERISGDLKTQ; ERISGDLKTQI; RISGDLKTQID;ISGDLKTQIDQ; SGDLKTQIDQV; GDLKTQIDQVE; DLKTQIDQVES;LKTQIDQVEST; KTQIDQVESTA; TQIDQVESTAG; QIDQVESTAGS;IDQVESTAGSL; DQVESTAGSLQ; QVESTAGSLQG; VESTAGSLQGQ;ESTAGSLQGQW; STAGSLQGQWR; TAGSLQGQWRG; AGSLQGQWRGA;GSLQGQWRGAA; SLQGQWRGAAG; LQGQWRGAAGT; QGQWRGAAGTA;GQWRGAAGTAA; QWRGAAGTAAQ; WRGAAGTAAQA; RGAAGTAAQAA;GAAGTAAQAAV; AAGTAAQAAVV; AGTAAQAAVVR; GTAAQAAVVRF;TAAQAAVVRFQ; AAQAAVVRFQE; AQAAVVRFQEA; QAAVVRFQEAA;AAVVRFQEAAN; AVVRFQEAANK; VVRFQEAANKQ; VRFQEAANKQK;RFQEAANKQKQ; FQEAANKQKQE; QEAANKQKQEL; EAANKQKQELD;AANKQKQELDE; ANKQKQELDEI; NKQKQELDEIS; KQKQELDEIST;QKQELDEISTN; KQELDEISTNI; QELDEISTNIR; ELDEISTNIRQ;LDEISTNIRQA; DEISTNIRQAG; EISTNIRQAGV; ISTNIRQAGVQ;STNIRQAGVQY; TNIRQAGVQYS; NIRQAGVQYSR; IRQAGVQYSRA;RQAGVQYSRAD; QAGVQYSRADE; AGVQYSRADEE; GVQYSRADEEQ;VQYSRADEEQQ; QYSRADEEQQQ; YSRADEEQQQA; SRADEEQQQAL;RADEEQQQALS; ADEEQQQALSS; DEEQQQALSSQ; EEQQQALSSQM;EQQQALSSQMG; QQQALSSQMGF 13 mers:MAEMKTDAATLAQ; AEMKTDAATLAQE; EMKTDAATLAQEA; MKTDAATLAQEAG;KTDAATLAQEAGN; TDAATLAQEAGNF; DAATLAQEAGNFE; AATLAQEAGNFER;ATLAQEAGNFERI; TLAQEAGNFERIS; LAQEAGNFERISG; AQEAGNFERISGD;QEAGNFERISGDL; EAGNFERISGDLK; AGNFERISGDLKT; GNFERISGDLKTQ;NFERISGDLKTQI; FERISGDLKTQID; ERISGDLKTQIDQ; RISGDLKTQIDQV;ISGDLKTQIDQVE; SGDLKTQIDQVES; GDLKTQIDQVEST; DLKTQIDQVESTA;LKTQIDQVESTAG; KTQIDQVESTAGS; TQIDQVESTAGSL; QIDQVESTAGSLQ;IDQVESTAGSLQG; DQVESTAGSLQGQ; QVESTAGSLQGQW; VESTAGSLQGQWR;ESTAGSLQGQWRG; STAGSLQGQWRGA; TAGSLQGQWRGAA; AGSLQGQWRGAAG;GSLQGQWRGAAGT; SLQGQWRGAAGTA; LQGQWRGAAGTAA; QGQWRGAAGTAAQ;GQWRGAAGTAAQA; QWRGAAGTAAQAA; WRGAAGTAAQAAV; RGAAGTAAQAAVV;GAAGTAAQAAVVR; AAGTAAQAAVVRF; AGTAAQAAVVRFQ; GTAAQAAVVRFQE;TAAQAAVVRFQEA; AAQAAVVRFQEAA; AQAAVVRFQEAAN; QAAVVRFQEAANK;AAVVRFQEAANKQ; AVVRFQEAANKQK; VVRFQEAANKQKQ; VRFQEAANKQKQE;RFQEAANKQKQEL; FQEAANKQKQELD; QEAANKQKQELDE; EAANKQKQELDEI;AANKQKQELDEIS; ANKQKQELDEIST; NKQKQELDEISTN; KQKQELDEISTNI;QKQELDEISTNIR; KQELDEISTNIRQ; QELDEISTNIRQA; ELDEISTNIRQAG;LDEISTNIRQAGV; DEISTNIRQAGVQ; EISTNIRQAGVQY; ISTNIRQAGVQYS;STNIRQAGVQYSR; TNIRQAGVQYSRA; NIRQAGVQYSRAD; IRQAGVQYSRADE;RQAGVQYSRADEE; QAGVQYSRADEEQ; AGVQYSRADEEQQ; GVQYSRADEEQQQ;VQYSRADEEQQQA; QYSRADEEQQQAL; YSRADEEQQQALS; SRADEEQQQALSS;RADEEQQQALSSQ; ADEEQQQALSSQM; DEEQQQALSSQMG; EEQQQALSSQMGF; 14 mers:MAEMKTDAATLAQE; AEMKTDAATLAQEA; EMKTDAATLAQEAG;MKTDAATLAQEAGN; KTDAATLAQEAGNF; TDAATLAQEAGNFE;DAATLAQEAGNFER; AATLAQEAGNFERI; ATLAQEAGNFERIS;TLAQEAGNFERISG; LAQEAGNFERISGD; AQEAGNFERISGDL;QEAGNFERISGDLK; EAGNFERISGDLKT; AGNFERISGDLKTQ;GNFERISGDLKTQI; NFERISGDLKTQID; FERISGDLKTQIDQ;ERISGDLKTQIDQV; RISGDLKTQIDQVE; ISGDLKTQIDQVES;SGDLKTQIDQVEST; GDLKTQIDQVESTA; DLKTQIDQVESTAG;LKTQIDQVESTAGS; KTQIDQVESTAGSL; TQIDQVESTAGSLQ;QIDQVESTAGSLQG; IDQVESTAGSLQGQ; DQVESTAGSLQGQW;QVESTAGSLQGQWR; VESTAGSLQGQWRG; ESTAGSLQGQWRGA;STAGSLQGQWRGAA; TAGSLQGQWRGAAG; AGSLQGQWRGAAGT;GSLQGQWRGAAGTA; SLQGQWRGAAGTAA; LQGQWRGAAGTAAQ;QGQWRGAAGTAAQA; GQWRGAAGTAAQAA; QWRGAAGTAAQAAV;WRGAAGTAAQAAVV; RGAAGTAAQAAVVR; GAAGTAAQAAVVRF;AAGTAAQAAVVRFQ; AGTAAQAAVVRFQE; GTAAQAAVVRFQEA;TAAQAAVVRFQEAA; AAQAAVVRFQEAAN; AQAAVVRFQEAANK;QAAVVRFQEAANKQ; AAVVRFQEAANKQK; AVVRFQEAANKQKQ;VVRFQEAANKQKQE; VRFQEAANKQKQEL; RFQEAANKQKQELD;FQEAANKQKQELDE; QEAANKQKQELDEI; EAANKQKQELDEIS;AANKQKQELDEIST; ANKQKQELDEISTN; NKQKQELDEISTNI;KQKQELDEISTNIR; QKQELDEISTNIRQ; KQELDEISTNIRQA;QELDEISTNIRQAG; ELDEISTNIRQAGV; LDEISTNIRQAGVQ;DEISTNIRQAGVQY; EISTNIRQAGVQYS; ISTNIRQAGVQYSR;STNIRQAGVQYSRA; TNIRQAGVQYSRAD; NIRQAGVQYSRADE;IRQAGVQYSRADEE; RQAGVQYSRADEEQ; QAGVQYSRADEEQQ;AGVQYSRADEEQQQ; GVQYSRADEEQQQA; VQYSRADEEQQQAL;QYSRADEEQQQALS; YSRADEEQQQALSS; SRADEEQQQALSSQ;RADEEQQQALSSQM; ADEEQQQALSSQMG; DEEQQQALSSQMGF 15 mers:MAEMKTDAATLAQEA; AEMKTDAATLAQEAG; EMKTDAATLAQEAGN;MKTDAATLAQEAGNF; KTDAATLAQEAGNFE; TDAATLAQEAGNFER;DAATLAQEAGNFERI; AATLAQEAGNFERIS; ATLAQEAGNFERISG;TLAQEAGNFERISGD; LAQEAGNFERISGDL; AQEAGNFERISGDLK;QEAGNFERISGDLKT; EAGNFERISGDLKTQ; AGNFERISGDLKTQI;GNFERISGDLKTQID; NFERISGDLKTQIDQ; FERISGDLKTQIDQV;ERISGDLKTQIDQVE; RISGDLKTQIDQVES; ISGDLKTQIDQVEST;SGDLKTQIDQVESTA; GDLKTQIDQVESTAG; DLKTQIDQVESTAGS;LKTQIDQVESTAGSL; KTQIDQVESTAGSLQ; TQIDQVESTAGSLQG;QIDQVESTAGSLQGQ; IDQVESTAGSLQGQW; DQVESTAGSLQGQWR;QVESTAGSLQGQWRG; VESTAGSLQGQWRGA; ESTAGSLQGQWRGAA;STAGSLQGQWRGAAG; TAGSLQGQWRGAAGT; AGSLQGQWRGAAGTA;GSLQGQWRGAAGTAA; SLQGQWRGAAGTAAQ; LQGQWRGAAGTAAQA;QGQWRGAAGTAAQAA; GQWRGAAGTAAQAAV; QWRGAAGTAAQAAVV;WRGAAGTAAQAAVVR; RGAAGTAAQAAVVRF; GAAGTAAQAAVVRFQ;AAGTAAQAAVVRFQE; AGTAAQAAVVRFQEA; GTAAQAAVVRFQEAA;TAAQAAVVRFQEAAN; AAQAAVVRFQEAANK; AQAAVVRFQEAANKQ;QAAVVRFQEAANKQK; AAVVRFQEAANKQKQ; AVVRFQEAANKQKQE;VVRFQEAANKQKQEL; VRFQEAANKQKQELD; RFQEAANKQKQELDE;FQEAANKQKQELDEI; QEAANKQKQELDEIS; EAANKQKQELDEIST;AANKQKQELDEISTN; ANKQKQELDEISTNI; NKQKQELDEISTNIR;KQKQELDEISTNIRQ; QKQELDEISTNIRQA; KQELDEISTNIRQAG;QELDEISTNIRQAGV; ELDEISTNIRQAGVQ; LDEISTNIRQAGVQY;DEISTNIRQAGVQYS; EISTNIRQAGVQYSR; ISTNIRQAGVQYSRA;STNIRQAGVQYSRAD; TNIRQAGVQYSRADE; NIRQAGVQYSRADEE;IRQAGVQYSRADEEQ; RQAGVQYSRADEEQQ; QAGVQYSRADEEQQQ;AGVQYSRADEEQQQA; GVQYSRADEEQQQAL; VQYSRADEEQQQALS;QYSRADEEQQQALSS; YSRADEEQQQALSSQ; SRADEEQQQALSSQM;RADEEQQQALSSQMG; ADEEQQQALSSQMGF 16 mers:MAEMKTDAATLAQEAG; AEMKTDAATLAQEAGN; EMKTDAATLAQEAGNF;MKTDAATLAQEAGNFE; KTDAATLAQEAGNFER; TDAATLAQEAGNFERI;DAATLAQEAGNFERIS; AATLAQEAGNFERISG; ATLAQEAGNFERISGD;TLAQEAGNFERISGDL; LAQEAGNFERISGDLK; AQEAGNFERISGDLKT;QEAGNFERISGDLKTQ; EAGNFERISGDLKTQI; AGNFERISGDLKTQID;GNFERISGDLKTQIDQ; NFERISGDLKTQIDQV; FERISGDLKTQIDQVE;ERISGDLKTQIDQVES; RISGDLKTQIDQVEST; ISGDLKTQIDQVESTA;SGDLKTQIDQVESTAG; GDLKTQIDQVESTAGS; DLKTQIDQVESTAGSL;LKTQIDQVESTAGSLQ; KTQIDQVESTAGSLQG; TQIDQVESTAGSLQGQ;QIDQVESTAGSLQGQW; IDQVESTAGSLQGQWR; DQVESTAGSLQGQWRG;QVESTAGSLQGQWRGA; VESTAGSLQGQWRGAA; ESTAGSLQGQWRGAAG;STAGSLQGQWRGAAGT; TAGSLQGQWRGAAGTA; AGSLQGQWRGAAGTAA;GSLQGQWRGAAGTAAQ; SLQGQWRGAAGTAAQA; LQGQWRGAAGTAAQAA;QGQWRGAAGTAAQAAV; GQWRGAAGTAAQAAVV; QWRGAAGTAAQAAVVR;WRGAAGTAAQAAVVRF; RGAAGTAAQAAVVRFQ; GAAGTAAQAAVVRFQE;AAGTAAQAAVVRFQEA; AGTAAQAAVVRFQEAA; GTAAQAAVVRFQEAAN;TAAQAAVVRFQEAANK; AAQAAVVRFQEAANKQ; AQAAVVRFQEAANKQK;QAAVVRFQEAANKQKQ; AAVVRFQEAANKQKQE; AVVRFQEAANKQKQEL;VVRFQEAANKQKQELD; VRFQEAANKQKQELDE; RFQEAANKQKQELDEI;FQEAANKQKQELDEIS; QEAANKQKQELDEIST; EAANKQKQELDEISTN;AANKQKQELDEISTNI; ANKQKQELDEISTNIR; NKQKQELDEISTNIRQ;KQKQELDEISTNIRQA; QKQELDEISTNIRQAG; KQELDEISTNIRQAGV;QELDEISTNIRQAGVQ; ELDEISTNIRQAGVQY; LDEISTNIRQAGVQYS;DEISTNIRQAGVQYSR; EISTNIRQAGVQYSRA; ISTNIRQAGVQYSRAD;STNIRQAGVQYSRADE; TNIRQAGVQYSRADEE; NIRQAGVQYSRADEEQ;IRQAGVQYSRADEEQQ; RQAGVQYSRADEEQQQ; QAGVQYSRADEEQQQA;AGVQYSRADEEQQQAL; GVQYSRADEEQQQALS; VQYSRADEEQQQALSS;QYSRADEEQQQALSSQ; YSRADEEQQQALSSQM; SRADEEQQQALSSQMG; RADEEQQQALSSQMGFSEQ ID NOS: 51541-52252

INDEX TO SEQUENCE LIST SEQ ID NO Table C: Bcl-2 fragments (class I)44893-45800 Table B: BclX(L) fragments (class I) 45801-46593 Table A:Cancer antigens 44889-44892 Table H: BK virus antigens 1-6 Table I: BKvirus 8-11 mers class I   7-24956 Table J: BK virus 8-11 mers class I52253-53779 Table K: BK virus 8-11 mers class I 53780-54917 Table L: BKvirus 8-11 mers class I 54918-55453 Table M: BK virus 8-11 mers class I55454-58054 Table N: BK virus 8-11 mers class I 58055-58311 Table E:Bcl-2 fragments (class II) 46594-47133 Table D: BclX(L) fragments (classII) 47134-47645 Table O: BK 13-16 mers class II 24957-44888 Table P: BK13-16 mers class II 58312-59135 Table Q: BK 13-16 mers class II59136-59917 Table R: BK 13-16 mers class II 59918-60257 Table S: BK13-16 mers class II 60258-61275 Table T: BK 13-16 mers class II61276-61367 Table F: Survivin fragments (class I) 47646-48180 Table G:Mcl-1 fragments (class II) 48181-49526 Table U: Borrelia OspC 8-11 mersand 13-16 mers 49527-51126 Table V: Borrelia OspA fragments 51127-51380Table X: Borrelia FlaB fragments 51381-51540 Table Y: Mycobacteriumtuberculosis CFP10 8-11 51541-52252 mers and 13-16 mers

EXAMPLES Example 1

This example describes how to make a MHC class I complex with a peptidein the peptide binding-groove using in vitro refolding. The MHC-complexin this example consisted of light chain β2m, the MHC class I HeavyChain allele HLA-A*0201 (a truncated version in which the intracellularand transmembrane domains have been deleted) and the peptide QLFEELQEL.MHC I-complexes consists of 3 components; Light Chain (β2m), Heavy Chainand a peptide of typically 8-10 amino acids. In this exampleMHC-complexes was generated by in vitro refolding of heavy chain, β2mand peptide in a buffer containing reduced and oxidized glutathione. Byincubation in this buffer a non-covalent complex between Heavy Chain,β2m and peptide was formed. Heavy chain and β2m was expressed asinclusion bodies in E. coli prior to in vitro refolding followingstandard procedures as described in Garboczi et al., (1996), Nature 384,134-141. Following refolding the MHC complexes was biotinylated usingBirA enzyme able to biotinylate a specific amino acid residue in arecognition sequence fused to the C-terminal of the Heavy Chain bygenetic fusion. Monomer MHC complexes was then purified by sizeexclusion chromatography.

-   1. 200 ml of refolding buffer (100 mM Tris, 400 mM L-arginin-HCL, 2    mM NaEDTA, 0.5 mM oxidized Gluthathione, 5 mM reduced Glutathione,    pH 8.0) was supplied with protease inhibitors PMSF    (phenylmethylsulphonyl fluoride), Pepstatin A and Leupeptin (to a    final concentration of 1 mM, 1 mg/l and 1 mg/l, respectively).    -   The refolding buffer was placed at 10° C. on a stirrer.-   2. 12 mg of peptide QLFEELQEL was dissolved in DMSO or another    suitable solvent (300-500 μl), and added drop-wise to the refolding    buffer at vigorous stirring.-   3. 4.4 mg of human Light Chain β2m was added drop-wise to the    refolding buffer at vigorous stirring.-   4. 6.2 mg of Heavy Chain HLA-A*0201 (supplied with DTT to a    concentration of 0.1 mM) was added drop-wise to the refolding buffer    at vigorous stirring.-   5. The folding reaction was placed at 10° C. at slow stirring for    4-8 hours.-   6. After 4-8 hours, step 3 and 4 was repeated and the folding    reaction is placed at 10° C. at slow stirring O/N.-   7. Step 3 and 4 was repeated, and the folding reaction is placed at    10° C. at slow stirring for 6-8 hours.

Optionally, steps 5-7 may be done in less time, e.g. a total of 0.5-5hours.

-   8. After 6-8 hours the folding reaction was filtrated through a 0.2    μm filter to remove aggregates.-   9. The folding reaction was concentrated O/N at 10° C. shaking    gently in a suitable concentrator with a 5000 mw cut-off filter. The    folding reaction was concentrated to approximately 5-10 ml.    (Optionally the filtrate can be stored at 4° C. and reused for    another folding with the same peptide and heavy chain.)-   10. The concentrated folding reaction was buffer-exchanged at least    8 times, into a MHC-buffer (20 mM Tris-HCl, 50 mM NaCl, pH 8.0) and    concentrated (at 10° C. in a suitable concentrator with a 5000 mw    cut-off filter) down to approximately 1 ml.-   11. The heavy chain part of the MHC-complex was biotinylated by    mixing the following components: approximately 1000 μl folded    MHC-complex, 100 μl each of Biomix-A, Biomix-B and d-Biotin (all 3    from Biotin Protein Ligase Kit from Avidity, 10 μl birA enzyme (3    mg/ml, from Biotin Protein Ligase Kit from Avidity, 0.5 μl Pepstatin    A (2 mg/ml) and 0.5 μl Leupeptin (2 mg/ml). The above was gently    mixed and incubated O/N at room temperature.-   12. The biotinylated and folded MHC-complex solution was centrifuged    for 5 min. at 1700×g, room temperature.-   13. Correctly folded MHC-complex was separated and purified from    excess biotin, excess β2m, excess heavy chain and aggregates    thereof, by size exclusion chromatography on a column that separates    proteins in the 10-100 kDa range. Correctly folded monomer    MHC-complex was eluted with a MHC-buffer (20 mM Tris-HCl, 50 mM    NaCl, pH 8.0). The elution profile consisted of 4 peaks,    corresponding to aggregated Heavy Chain, correctly folded monomer    MHC-complex, β2m and excess biotin and peptide (See FIG. 8).-   14. Fractions containing the folded MHC-complex were pooled and    concentrated to approximately 1 ml in a suitable concentrator with a    5000 mw cut-off filter. The protein-concentration was estimated from    its absorption at 280 nm.-   15. Folded MHC-complex can optionally be stored at −170° C. before    further use.-   16. The grade of biotinylation was analyzed by a SDS PAGE    SHIFT-assay with Streptavidin (FIG. 9) and correct folding was    confirmed by ELISA, using the antibody W6/32 that recognizes    correctly folded MHC-peptide complex.-   17.

The above procedure may be used for folding any MHC I complexesconsisting of any β2m, any heavy chain and any peptide approx. 8-11amino acids long. Either of the components can be truncated or otherwisemodified. The above procedure can also be used for generation of “empty”MHC I complexes consisting of β2m and heavy chain without peptide.

Example 2

This example describes how to generate soluble biotinylated MHC IIcomplexes using a baculovirus expression system, where the MHC IIcomplex was DR4 consisting of the α-chain DRA1*0101 and the β-chainDRB1*0401 as described by Svendsen et al., (2004), J. Immunol.173(11):7037-45. Briefly, The hydrophobic transmembrane regions of theDRα and DRβ chains of DR4 were replaced by leucine zipper dimerizationdomains from the transcription factors Fos and Jun to promote DR α/βassembly. This was done by ligating cytoplasmic cDNA sequences ofDRA1*0101 and DRB1*0401 to fos- and jun-encoding sequences. A birA siteGLNDIFEAQKIEWH was added to the 3′ end of the DRA1*0101-fos template.Covalently bound peptide AGFKGEQGPKGEP derived from collagen II aminoacid 261-273 were genetically attached by a flexible linker peptide tothe N terminus of the DRβ-chain. Finally, the modified DRA1*0101 andDRB1*0401 inserts were cloned into the expression vector pAcAb3. ThepAcAB3-DRA1*0101/DRB1*0401 plasmids were cotransfected with linearizedbaculovirus DNA (BD Pharmingen; BaculoGold kit) into Sf9 insect cells,according to the manufacturer's instructions. Following two rounds ofplaque purification, clonal virus isolates were further amplified threetimes before preparation of high-titer virus (10⁸-10¹⁰/ml). These stockswere used to infect High Five or serum-free Sf21 insect cells(Invitrogen Life Technologies, Carlsbad, Calif.) for protein production.Spinner cultures (2-3×10⁶ cells/ml) were infected at a multiplicity ofinfection of 1-3 in a volume of 150 ml per 2 L spinner flask.Supernatants were harvested and proteinase inhibitor tablets (Roche,Basel, Switzerland) were added before affinity purification onMiniLeak-Low columns (Kem-En-Tec) coupled with the anti-HLA-DRmonoclonal antibody L243. HLA-DR4 complexes were eluted withdiethylamine (pH 11) into neutralization buffer (2 M Tris, pH 6.5) andimmediately buffer exchanged and concentrated in PBS, 0.01% NaN₃, usingMillipore (Bedford, Mass.) concentrators. The purity of protein wasconfirmed by SDS-PAGE. The purified DR4 complexes were biotinylated invitro as described for MHC I complexes elsewhere herein. These complexesmay now be used for coupling to any dimerization domain, e.g.divynylsulfone activated dextran 270 coupled with SA and a fluorochrome.

Example 3

This example describes how to generate empty biotinylated MHC IIcomplexes using a baculovirus expression system, where the MHC IIcomplex consist of any α-chain and any β-chain, including truncated andotherwise modified versions of the two. Briefly, The hydrophobictransmembrane regions of the DRα and DRβ chains of MHC II are replacedby leucine zipper dimerization domains from the transcription factorsFos and Jun to promote DR α/β assembly. This is done by ligatingcytoplasmic cDNA sequences of DRα and DRβ to fos- and jun-encodingsequences. A birA site GLNDIFEAQKIEWH is added to the 3′ end of eitherthe DRα-fos/DRα-jun or the DRβ-jun/DR13-fos template. The modified DRαand DRβ inserts is cloned into the expression vector pAcAb3 andcotransfected with linearized baculovirus DNA into Sf9 insect cells,according to the manufacturer's instructions. Following rounds of plaquepurification, clonal virus isolates is further amplified beforepreparation of high-titer virus. These stocks are used to infect HighFive or serum-free Sf21 insect cells (Invitrogen Life Technologies,Carlsbad, Calif.) for protein production, e.g. as Spinner cultures.Supernatants are harvested and proteinase inhibitors added beforeaffinity purification, e.g. using a MiniLeak-Low columns (Kem-En-Tec)coupled with anti-MHC II antibody. The purified MHC II complexes isbiotinylated in vitro as described for MHC I complexes elsewhere herein.These biotinylated MHC II complexes may now be used for coupling to anydimerization domain, e.g. divynylsulfone activated dextran 270 coupledwith SA and a fluorochrome.

Example 4

This example describes how to generate biotinylated MHC II complexesusing a cell based protein expression system, where the MHC II complexconsist of any α-chain and any β-chain, including truncated andotherwise modified versions of the two. The MHC II complex may also havea peptide bound in the peptide binding cleft.

The hydrophobic transmembrane regions of the MHC II α-chain and MHC IIβ-chain are replaced by leucine zipper dimerization domains from thetranscription factors Fos and Jun to promote α/β chain assembly. This isdone by ligating cytoplasmic cDNA sequences of α-chain and β-chain tofos- and jun-encoding sequences. A birA site GLNDIFEAQKIEWH is added tothe 3′ end of the DRα-fos template. Optionally covalently bound peptideis genetically attached by a flexible linker peptide to the N terminusof the DRβ-chain. The modified DRα and DRβ inserts is cloned into asuitable expression vector and transfected into a cell line capable ofprotein expression, e.g. insect cells, CHO cells or similar. Transfectedcells are grown in culture, supernatants are harvested and proteinaseinhibitors added before affinity purification, e.g. using a MiniLeak-Lowcolumns (Kem-En-Tec) coupled with anti-MHC II antibody. Alternativelythe expressed MHC II complexes may be purified by anion- orcation-exchange chromatography. The purified MHC II complexes isbiotinylated in vitro as described for MHC I complexes elsewhere herein.These biotinylated MHC II complexes may now be used for coupling to anydimerization domain, e.g. divynylsulfone activated dextran 270 coupledwith SA and a fluorochrome.

Example 5

This is an example of how to make a MHC multimer that is a tetramer andwhere the MHC are attached to the multimerization domain through anon-covalent interaction The multimerization domain consist ofStreptavidin. The MHC molecule was biotinylated DR4 consisting of theα-chain DRA1*0101 and the β-chain DRB1*0401 and the peptideAGFKGEQGPKGEP derived from collagen II amino acid 261-273. Thebiotinylated MHC-peptide complexes was generated as described in aprevious example herein.

Fluorescent DR4-peptide tetramer complexes were assembled by addition ofultra-avidin-R-PE (Leinco Technologies, St. Louis, Mo.) at a final molarratio of biotinylated to DR4-peptide ultra-avidin-R-PE of 6:1. Theresulting DR4-peptide multimer complexes were subjected to sizeexclusion on a Superdex-200 column to separate the tetramer complexesfrom protein aggregates and lower molecular weight complexes and excessfre DR4-peptide. The tetramer complexes were concentrated usingCenticon-30 concentrators and stored at 0.1-0.3 mg/ml in a mixture ofprotease inhibitors.

These complexes could be used to detect specific T cells in a flowcytometry assay as described by Svendsen et al. (2004) Tracking ofProinflammatory Collagen-Specific T cells in Early and LateCollagen-Induced Arthritis in Humanized mice. J. Immunol. 173:7037-7045.

Example 6

This example describes how an activated divinylsylfone-dextran(270 kDa)(VS-dex270) was coupled with streptavidin (SA) and Allophycocyanin(APC).

-   -   1. Streptavidin (approx. 100 mg SA/ml in 10 mM HEPES, 0.1M NaCl,        pH 7.85) was dialysed with gentle stirring for 2 days against 10        mM HEPES, 0.1M NaCl, pH 7.85 (20 fold excess volume) at 2-8° C.        with 1 buffer change/day.    -   2. 5 ml of APC from a homogen suspension (approx. 10 mg/ml) was        centrifuged 40 min. at 3000 rpm. The supernatant was discharged        and the precipitate dissolved in 5 ml of 10 mM HEPES, 0.1M NaCl,        pH 7.85. This APC solution was dialysed with gentle stirring in        the dark for 2 days against 10 mM HEPES, 0.1M NaCl, pH 7.85 (20        fold excess volume) at 2-8° C. with 1 buffer change/day.    -   3. The APC-solution was concentrated to 1 ml and the        concentration measured to 47 g/L at UV 650 nm. The        A650/A278-ratio was measured to 4.2.    -   4. The SA-solution was filtrated through a 0.45 μm filter and        the protein concentration was measured to 61.8 g SA/L at UV 278        nm.    -   5. Conjugation: The reagents was mixed to a total volume of 500        μl in the following order with 8.1 mol SA/mol Dex and 27 mol        APC/mol Dex.:        -   a) 90 μl water        -   b) 160 μl activated VS-dex270        -   c) 23 μl SA (61.8 g/L) ˜8.1 equivalents,        -   d) 177 μl APC (47 g/L) ˜27 equivalents,        -   e) 50 μl of 100 mM HEPES, 1M NaCl, pH 8

The reaction was placed in a water bath with stirring at 30° C. in thedark for 18 hours.

-   -   6. The coupling was stopped by adding 50 μl 0.1M ethanolamine,        pH 8.0.    -   7. The conjugate was purified on a Sephacryl S-200 column with        10 mM HEPES, 0.1M NaCl buffer, pH 7.2.    -   8. 3 peaks were collected (peak 1: APC-SA-dex270; peak 2: Free        APC; peak 3: Free SA). Volume, UV A650 and UV A278 were        measured.    -   9. The concentration of dextran270, APC/Dex and SA/Dex were        calculated to 22.4×10⁻⁸ M; 3.48 and 9.54 respectively.    -   10. The conjugate were added NaN₃ and BSA to a final        concentration of 15 mM and 1% respectively. The volume was        adjusted with 10 mM HEPES, 0.1M NaCl, pH 7.2 to a final        concentration of 16×10⁻⁸ M Dex270.    -   11. The conjugate were kept at 2-8° C. in dark until further        use.

Example 7

This example describes how an activated divinylsylfone-dextran(270 kDa)(VS-dex270) was coupled with streptavidin (SA) and R-phycoerythrin(RPE).

The coupling procedure described for coupling of SA and APC to VS-dex270(as described elsewhere herein) were followed with the exception thatAPC were replaced with RPE

Example 8

This example describes how to couple an empty MHC or a MHC-complex to adextran multimerization domain through a non-covalent coupling, togenerate a MHC-dextramer. The MHC-dextramer in this example consisted ofAPC-streptavidin (APC-SA)-conjugated 270 kDA dextran and a biotinylated,folded MHC-complex composed of β2m, HLA-A*0201 heavy chain and thepeptide NLVPMVATV.

The APC-SA conjugated 270 kDA dextran contained 3.7 molecules of SA perdextran (each SA can bind 3 MHC-complexes) and the concentration was16×10⁻⁸ M. The concentration of the HLA-A*0201/NLVPMVATV-complex was 4mg/ml (1 μg=20,663 pmol). The molecular concentration of the MHC-complexwas 8.27×10⁻⁵M.

The MHC-complex was attached to the dextran by a non-covalentBiotin-Streptavidin interaction between the biotinylated Heavy Chainpart of the MHC-complex and the SA, conjugated to dextran.

Here follows a protocol for how to produce 1000 μl of a MHC-dextramersolution with a final concentration of approximately 32×10⁻⁹M:

-   1. 200 μL 270 kDA vinylsulfone-activated dextran, corresponding to    3.2×10⁻¹¹ mol, and 4 μl MHC-complex, corresponding to 3.55×10⁻¹⁰ mol    was mixed and incubated at room temperature in the dark for 30 min.    -   2. A buffer of 0.05M Tris-HCl, 15 mM NaN₃, 1% BSA, pH 7.2 was        added to a total volume of 1000 μl.    -   3. The resulting MHC-dextramer preparation may now be used in        flow cytometry eksperiments.

Example 9

This is an example of how to make and use MHC multimers that are trimersconsisting of a streptavidin multimerization domain with 3 biotinylatedMHC complexs and 1 fluorophore molecule attached to the biotin bindingpockets of streptavidin. MHC complexs consisting of HLA-A*0201 heavychain, beta2microglobulin and NLVPMVATV peptide or the negative controlpeptide GLAGDVSAV were generated as described elsewhere herein. Thefluorophore in this example was Fluorescein-linker molecules as shown inFIG. 10. Each of these molecules consist of a linker-biotin moleculemounted with 4 trippel fluorescein-linker molecules. The linker-biotinmolecule was hereH-L30-Lys(NH₂)-L30-Lys(NH₂)-L30-Lys(NH₂)L300Lys(caproylamidobiotin)-NH₂where L30 was a 30 atom large linker and L300 was a 300 atom largelinker. Both L30 and L300 was composed of multiple L15 linkers with thestructure shown in FIG. 10B. Linker-biotin molecules were generated asfollows: Downloaded Boc-L300-Lys(Fmoc) resin (100 mg) was deprotectedand subjected to coupling with Boc-Lys(2ClZ)—OH, Boc-L30-OH,Boc-Lys(2ClZ)—OH, Boc-L30-OH, Boc-Lys(2ClZ)—OH then Boc-L30-OH. Theresin was Fmoc deprotected and reacted twice (2×2 h) with caproylamidobiotin NHS ester (25 mg in 0.5 mL NMP+25 microL DIPEA). The resin waswashed with TFA and the product cleaved off withTFA:TFMSA:mCresol:thioanisol (6:2:1:1), 1 mL, precipitated with diethylether and purified by RP-HPLC. MS calculated for C₃₀₀H₅₄₄N₆₄O₁₃₇S is7272.009 Da, found 7271.19 Da.

Alternatively linker-biotin molecule wasH-L60-Lys(NH₂)-L60-Lys(NH₂)-L60-Lys(NH₂)L300Lys(caproylamidobiotin)-NH₂and made from downloaded Boc-L300-Lys(Fmoc) resin (100 mg), and thenprepared analogously toH-L30-Lys(NH₂)-L30-Lys(NH₂)-L30-Lys(NH₂)L300Lys(caproylamidobiotin)-NH₂.MS calculated for C₃₆₀H₆₅₂N₇₆O₁₆₇S is 8749.5848 Da and was found to be7271.19 Da. Yield 3 mg.

The trippel fluorescein-linker molecules was herebetaalanin-L90-Lys(Flu)-L90-Lys(Flu)-L90-Lys(Flu)-NH₂ where Lys=Lysine,Flu=Fluorescein and L90 is a 90 atom linker (se FIG. 10 for furtherdetails). The trippel-fluorescein-linker molecule was generated asfollows: Downloaded Boc-Lys(Fmoc) resin, 2 g, was Boc deprotected andsubjected to 3× coupling with Boc-L30-OH, Boc-Lys(Fmoc)-OH,3×Boc-L30-OH, Boc-Lys(Fmoc)-OH, 3×Boc-L30-OH. The three Fmoc groups wereremoved and carboxyfluorescein, 301 mg, activated with HATU, 274 mg, andDIPEA, 139 μL, in 8 mL NMP, was added to the resin twice for 30 min. Theresin was Boc deprotected and subjected to 2×30 min coupling withbeta-alanine-N,N-diacetic acid benzyl ester, followed by 5 min treatmentwith 20% piperidine in NMP. The resin was washed with DCM, then TFA andthe product was cleaved off the resin, precipitated with diethyl etherand purified by RP-HPLC. Yield was 621 mg. MS calculated forC268H402N44O116 is 6096.384 Da, while MS found was 6096 Da.

Biotin-linker molecule were coupled together with 4 trippelfluorescein-linker molecules as follows: (500 nmol) was dissolved in 88microliter NMP+2 μl pyridine and activated for 10 min at roomtemperature (conversion to cyclic anhydride) by addition of 10 μl N,N′diisopropylcarbodiimide. Following activation the trippelfluorescein-linker was precipitated with diethyl ether and redissolvedin 100 microliter NMP containing 10 nmol biotin-linker Once dissolvedthe coupling was initiated by addition of 5 μl diisopropyl ethyl amine,and was complete after 30 min.

Streptavidin and Fluorescein-linker molecules are then mixed in a molarration of 1:1 and incubated for ½ hour. Then MHC complexes are added in3-fold molar excess in respect to streptavidin and incubated for another½ hour. Alternatively, MHC complexes are added first, thenFluorescein-linker molecules or MHC complexes are mixed withFluorescein-linker molecules before addition to Streptavidin.

These MHC multimers are then used to stain CMV specific T cells in aflow Cytometry experiment. 1×10⁶ purified HPBMC from a donor with Tcells specific for HLA-A*0201(NLVPMVATV) are incubated with 10 μl ofeach of the two HLA-A*0201(peptide)/Fluorescein constructs describedabove for 10 minutes in the dark at room temperature with a cellconcentration of 2×10⁷ cells/ml. 10 μl of mouse-anti-human CD8/PB (cloneDK25 from Dako) are added and the incubation continued for another 20minutes at 4° C. in the dark. The samples are then washed by adding 2 mlPBS; pH=7.2 followed by centrifugation for 5 minutes at 200×g and thesupernatant removed. The cells are resuspended in 400-500 μl PBS; pH=7.2and analyzed on a flowcytometer.

In the above described example the Fluorescein-linker is as shown inFIG. 10 but the linker molecule can be any linker molecule as describedin patent application WO 2007/015168 A2 (Lohse (2007)) or alternativelychemical biotinylated fluorochrom can be used instead ofFluorescein-linker molecules. The MHC complexes described in thisexample is a MHC I molecule composed of HLA-A*0201 heavy chain,beta2microglobulin and NLVPMVATV peptide but can in principle be any MHCcomplex or MHC like molecule as described elsewhere herein.

Example 10

This is an example of how to make MHC multimers consisting of astreptavidin multimerization domain with 3 biotinylated MHC complexsattached to the biotin binding pockets of streptavidin and how to usesuch trimer MHC complexs to detect specific T cells by direct detectionof individual cells in a flow cytometry experiment by addition of abiotinylated fluorophore molecule. In this example the fluorophore isFluorescein linker molecules constructed as described elsewhere herein.

MHC complexs consisting of HLA-A*0201 heavy chain, beta2microglobulinand peptide are generated as described elsewhere. MHC complexs areincubated with streptavidin in a molar ratio of 3:1 for ½ hour.

These trimer MHC multimers are then used to stain CMV specific T cellsin a flow Cytometry experiment. 1×10⁶ purified HPBMC from a donor with Tcells specific for HLA-A*0201(NLVPMVATV) are incubated with 10 μlHLA-A*0201(peptide) multimer construct for 10 minutes in the dark atroom temperature with a cell concentration of 2×10⁷ cells/ml. ThenFluorescein linker molecules (as described in Example 42) are added andincubation continued for 5 minutes. 10 μl mouse-anti-human CD8/PBantibody (clone DK25 from Dako) is added and the incubation continuedfor another 20 minutes at 4° C. in the dark. The samples are then washedby addition of 2 ml PBS; pH=7.2 followed by centrifugation for 5 minutesat 200×g and the supernatant removed. Cells are resuspended in 400-500μl PBS; pH=7.2 and analyzed on a flowcytometer.

In this example the Fluorescein-linker is as shown in FIG. 10 but thelinker molecule can be any linker molecule as described in Lohse,Jesper, (2007), WO 2007/015168 A2 or alternative chemically biotinylatedfluorochrome may be used. The MHC complexes described in this example isa MHC I molecule composed of HLA-A*0201 heavy chain, beta2microglobulinand NLVPMVATV peptide but can in principle be any MHC complex or MHClike molecule as described elsewhere herein.

Example 11

This is an example of how to make MHC multimers where themultimerization domain is dextran and the MHC complexs are chemicallyconjugated to the dextran multimerization domain.

MHC complexs consisting of HLA-A*0201 heavy chain, beta2microglobulinand NLVPMVATV peptide or the negative control peptide GLAGDVSAV aregenerated as described elsewhere herein. Dextran with a molecular weightof 270 kDa is activated with divinylsulfone. Activated Dextran is thenincubated with MHC and RPE in a 0.05 M NaCHO₃ buffer; pH=9.5 with amolar ratio between MHC and Dextran of 30-60 and a molar ratio betweenRPE and dextran of 3-7:1 The mixture is placed in a water bath at 30° C.for 16 hours. Excess fluorochrome, MHC and dextran are removed by FPLCusing a sephacryl S-300 column.

These MHC/RPE dextramers are then used to stain CMV specific T cells ina flow Cytometry experiment. Briefly, 1×10⁶ purified HPBMC from a donorwith T cells specific for HLA-A*0201(NLVPMVATV) are incubated with 10 μlof each of the two HLA-A*0201(peptide)/RPE constructs described abovefor 10 minutes in the dark at room temperature with a cell concentrationof 2×10⁷ cells/ml. 10 μl mouse-anti-human CD8/PB antibody (clone DK25from Dako) are added and the incubation continued for another 20 minutesat 4° C. in the dark. The samples are then washed by adding 2 ml PBS;pH=7.2 followed by centrifugation for 5 minutes at 200×g and thesupernatant removed. The cells are then resuspended in 400-500 μl PBS;pH=7.2 and analyzed on a flow cytometer.

Example 12

This is an example of how to make MHC multimers where themultimerization domain is dextran and MHC complexs are MHC I moleculeschemically conjugated to dextran multimerization domain and the dextranmultimerization domain also have fluorochrome chemically coupled.

Human beta2microglobulin is coupled to dextran as follows. Dextran witha molecular weight of 270 kDa is activated with divinylsulfone.Activated dextran is incubated with human beta2microglobulin and RPE ina 0.05 M NaCHO₃ buffer; pH=9.5 with a molar ratio betweenbeta2microglobulin and Dextran of 30-60 and a molar ratio between RPEand dextran of 3-7:1. The molar ratio of the final product is preferable4-6 RPE and 15-24 beta2microglobulin per dextran. The mixture is placedin a water bath at 30° C. for 16 hours. Excess fluorochrome,beta2microglobulin and dextran are removed by FPLC using a sephacrylS-300 column. The beta2microglobulin-RPE-dextran construct is thenrefolded in vitro together with heavy chain and peptide using thefollowing procedure. 200 ml refolding buffer (100 mM Tris, 400 mML-arginin-HCL, 2 mM NaEDTA, 0.5 mM oxidized Gluthathione, 5 mM reducedGlutathione, pH 8.0) supplied with protease inhibitors PMSF, Pepstatin Aand Leupeptin (to a final concentration of 1 mM, 1 mg/l and 1 mg/l,respectively) is made and cooled to 10° C. 12 mg NLVPMVATV peptide isdissolved in DMSO and added to the refolding buffer together with 20-30mg beta2microglobulin-RPE-dex and 6 mg HLA-A*0201 heavy chain.Incubation at 10° C. for 4-8 hours, then 20-30 mgbeta2microglobulin-RPE-dex and 6 mg HLA-A*0201 heavy chain is added andincubation continued for 4-8 hours. Another 20-30 mgbeta2microglobulin-RPE-dex and 6 mg HLA-A*0201 heavy chain is added andincubation continued for 6-8 hours. The folding reaction is filtratedthrough a 0.2 μm filter to remove larger aggregates and then bufferexchanged into a buffer containing 20 mM Tris-HCl, 50 nM NaCl; pH=8.0followed by concentration to 1-2 ml sample. Dextran-RPE-MHC complexs arethen separated from excess heavy chain and peptide by size exclusionchromatography using a sephacryl S-300, S-400 or sephacryl S-500 column.

These MHC/RPE dextramers may be used to stain CMV specific T cells in aflow Cytometry experiment. Briefly, 1×10⁶ purified HPBMC from a donorwith T cells specific for HLA-A*0201(NLVPMVATV) are incubated with 10 μlof each of the two HLA-A*0201(peptide)/RPE constructs described abovefor 10 minutes in the dark at room temperature with a cell concentrationof 2×10⁷ cells/ml. 10 μl of mouse-anti-human CD8/PB antibody (clone DK25from Dako) are added and the incubation continued for another 20 minutesat 4° C. in the dark. The samples are then washed by adding 2 ml PBS;pH=7.2 followed by centrifugation for 5 minutes at 200×g and thesupernatant removed. The cells are then resuspended in 400-500 μl PBS;pH=7.2 and analyzed on a flowcytometer.

Example 13

The preparation of a Pentamer is described in e.g. (United States Patentapplication 20040209295). Briefly, the following steps lead to afluorescent Pentamer reagent:

The following is a detailed example for cloning, expressing, andpurifying a pentameric class I MHC complex, which comprises a chimericfusion of .beta.2m with COMP. The chimeric .beta.2m-COMP protein isexpressed in insoluble inclusion bodies in E. coli and subsequentlyassembled as pentameric .beta.2m-COMP in vitro. The pentameric class IMHC peptide complex is then formed in a second refolding reaction bycombining beta.2m-COMP pentamers and the human MHC class I .alpha.molecule known as HLA-A*0201, in the presence of an appropriatesynthetic binding peptide representing the T cell antigen. In thisexample, a well characterized antigen derived from Epstein-Barr virusBMLF1 protein, GLCTLVAML (a.a. 289-297) [SEQ ID NO: 1], is used. Theresultant complex is labelled with a fluorescent entity and used as astaining reagent for detecting antigen-specific T cells from a mixedlymphocyte population, in a flow cytometry application.

The strategy involves the sequential cloning into pET-24c vector of.beta.2m, yielding a construct referred to as pETBMC01, followed by theinsertion of the oligomerisation domain of cartilage oligomeric matrixprotein (COMP) with a biotin acceptor sequence (BP) for site-specificbiotinylation with the biotin-protein ligase BirA, yielding a constructreferred to as pETBMC02. Thirdly a polyglycine linker is cloned inbetween .beta.2m and COMP, yielding a construct referred to as pETBMC03,and finally, a serine-residue is removed by site-directed mutagenesis,which serine residue precedes the poly-glycine linker, to give the final.beta.2m-COMP/pET-24c construct, referred to as pETBMC04 (see also FIG.3). Removal of the serine residue is carried out to avoid sterichindrance when the .beta.2m molecule is associated with the MHC class Ichain protein.

The extracellular portion of .beta.2m comprises of 99 amino acids(equivalent to Ile1-Met99 of the mature protein) encoded by 74 bp-370 byof the DNA sequence. This region of the .beta.2m sequence is amplifiedfrom a normal human lymphocyte cDNA library, by polymerase chainreaction (PCR)

beta.2m PCR product is purified from the above reaction mix using aQIAquick® PCR purification kit according to the manufacturer'sinstructions (Qiagen). 200 ng of purified PCR product and 1.mu.g pET-24cvector (Novagen) are each digested with BamH I (10 U) and Nde I (10 U)restriction enzymes (New England Biolabs, NEB) for 4 h at 37.degree. C.,in accordance with the manufacturer's instructions, and purified.

The gel-purified insert and vector DNA are ligated at a 1:3 molar ratio(vector:insert, 50 ng: 7.5 ng) using T4 DNA ligase (5 U; Bioline), in T4DNA ligase buffer (as supplied) for 16 hrs at 16.degree. C.

The ligation mixtures and appropriate controls are subsequentlytransformed into XL1-Blue strain competent E. coli cells, according tothe manufacturer's instructions (Stratagene). Successful transformantsare selected by plating the cells on Luria-Bertani (LB) agar platescontaining 30 .mu.g/ml kanamycin, and incubating overnight at 37.degree.C.

A selection of single colonies from the bacterial transformation platesare screened by PCR with T7 promoter [SEQ ID NO: 4] (1 .mu.M) and T7terminator [SEQ ID NO: 5] (1 .mu.M) primers (Sigma Genosys, see AppendixI for primer sequences), which are complementary to regions of the pETvector flanking the cloning site. Amplification is carried out using TaqDNA polymerase (1 U, Bioline) in Taq reaction buffer (as supplied),supplemented with 2 mM MgSO.sub.4 and 0.2 mM dNTPs, using 25thermal-cycling reactions as detailed above. Successful transformantsgenerated a DNA fragment of approximately 500 bp, ascertained by 1.5%agarose gel electrophoresis.

Bacterial transformants that generated the correct size of PCR productsare inoculated into 6 ml of sterile LB-kanamycin medium and incubatedovernight at 37.degree. C. with 200 rpm shaking. pETBMC01 plasmid DNA isrecovered from the bacterial cultures using a QIAprep® Spin Mini-prepkit according to the manufacturer's instructions (Qiagen). The presenceof the .beta.2m fragment in these plasmids is further verified byautomated DNA sequencing.

The sequence of the oligomerisation domain of COMP is obtained from theGenbank database (accession #1705995) and a region encoding thecoiled-coil domain (amino acids 21-85) is selected based onself-association experiments of COMP (Efinov et al., FEBS Letters341:54-58 (1994)). A biotin acceptor sequence ‘BP’: SLNDIFEAQKIEWHE [SEQID NO: 6] is incorporated at the C terminus and an additional 14 aminoacid linker, PQPQPKPQPKPEPET [SEQ ID NO:7] is included to provide aphysical separation between the COMP oligomerising domain and BP.

The whole region is synthesized using the overlapping complementaryoligonucleotides, and purified COMP-BP and 1 mu.g pETBMC01 vector aredigested for 4 hrs at 37.degree. C. using Hind III (10 U) and Xho I (10U) restriction enzymes (NEB), as described in Section 1.1. The digestionproducts are purified, ligated, transformed and PCR screened as inSection 1.1. Plasmids positive from the screen are purified andsequenced as described in Section 1.1.

The poly-glycine linker is synthesized by annealing overlappingoligonucleotides. Since the nucleotide sequence of the polyGlycinelinker only incorporates the 5′ overhang of the cut BamH I restrictionsite, and the 3′ overhang of the cut Hind III nucleotide recognitionmotifs, there is no need to digest the annealed product to produce thecomplementary single-stranded overhangs suitable for subsequentligation. The oligonucleotides are phosphorylated and annealed asdescribed in Section 1.2.

pETBMC02 is digested with BamH I (10 U) and Hind III (10 U). Ligation ofthe annealed poly-glycine linker into pETBMC02 was as describedpreviously (Section 1.1), assuming 96 fmoles of annealedoligonucleotide/.mu.l. The transformation and PCR-screening reactionsare as described in Section 1.1, but in addition, the presence of aninserted linker is verified by a restriction enzyme digestion of the PCRscreen product to ascertain the presence or absence of a Sal Irestriction site. Successful transformants are not susceptible to Sal Idigestion, given the removal of the site from the plasmid vectorbackbone. Purification of pETBMC03 and automated sequencing is asdescribed in Section 1.1.

Analysis of X-ray crystallography models of MHC class I molecules revealthat the C terminus of .beta.2m closely abuts the .alpha.3 domain of the.alpha. chain. It is therefore desirable to achieve maximum flexibilityat the start of the poly-glycine linker

The extracellular portion of HLA-A*0201 alpha. chain (EMBL M84379)comprises of 276 amino acids (equivalent to Gly1-Pro276 of the matureprotein) encoded by bases 73-900 of the messenger RNA sequence. Thisregion of the A*0201 sequence is amplified from a normal humanlymphocyte cDNA library by PCR, using the primers A2S#1 [SEQ ID NO: 20]and A2S#2 [SEQ ID NO: 21] which incorporated NcoI and BamHI restrictionsites respectively. The procedure for cloning the A*0201 insert into NcoI/BamH I-digested pET-11d vector (Novagen) is essentially as describedfor .beta.2m in Section 1.1.

An identical procedure is carried out to produce either .beta.2m-COMP orA*0201 alpha. chain proteins. Plasmid DNA is transformed into an E. coliexpression host strain in preparation for a large scale bacterial prep.Protein is produced as insoluble inclusion bodies within the bacterialcells, and is recovered by sonication. Purified inclusion bodies aresolubilised in denaturing buffer and stored at −80.degree. C. untilrequired.

Purified plasmid DNA is transformed into the BL21(DE3)pLysS E. colistrain, which carries a chromosomal copy of the T7 RNA polymeraserequired to drive protein expression from pET-based constructs.Transformations into BL21(DE3)pLysS competent cells (Stratagene) arecarried out with appropriate controls.

A single bacterial transformant colony is innoculated into 60 ml sterileLB medium, containing appropriate antibiotics for selection, and left tostand overnight in a warm room (.about.24.degree. C.) The resultingovernight culture is added to 6 litres of LB and grown at 37.degree. C.with shaking (.about.240 rpm), up to mid-log phase (OD.sub.600=0.3-0.4).Protein expression is induced at this stage by addition of 1.0 ml of 1MIPTG to each flask. The cultures are left for a further 4 h at37.degree. C. with shaking, after which the cells are harvested bycentrifugation and the supernatant discarded.

The bacterial cell pellet is resuspended in ice-cold balanced saltsolution and sonicated (XL series sonicator; Misonix Inc., USA) in asmall glass beaker on ice in order to lyse the cells and release theprotein inclusion bodies. Once the cells are completely lysed theinclusion bodies are spun down in 50 ml polycarbonate Oak Ridgecentrifuge tubes in a Beckman high-speed centrifuge (J2 series) at15,000 rpm for 10 min. The inclusion bodies are then washed three timesin chilled Triton® wash This is followed by a final wash indetergent-free wash buffer.

The resultant purified protein preparation is solubilised in 20-50 ml of8 M urea buffer, containing 50 mM MES, pH 6.5, 0.1 mM EDTA and 1 mM DTT,and left on an end-over-end rotator overnight at 4.degree. C. Insolubleparticles are removed by centrifugation and the protein yield isdetermined using Bradford's protein assay reagent (Bio-Rad Laboratories)and by comparison with known standards. Urea-solubilised protein isdispensed in 10 mg aliquots and stored at −80.degree. C. for future use.

Assembly of .beta.2m-COMP from the urea-solubilised inclusion bodies isperformed by diluting the protein into 20 mM CAPS buffer, pH 11.0,containing 0.2 M sodium chloride and 1 mM EDTA, to give a final proteinconcentration of 1.5 mg/ml. The protein is oxidised at room temperatureby addition of oxidised and reduced glutathione to final concentrationsof 20 mM and 2 mM, respectively. Following an overnight incubation,disulphide bond formation is analysed by non-reducing SDS-PAGE on 10%bis-tricine gels (Invitrogen).

The protein mixture is subsequently buffer exchanged into 20 mM Tris, pH8.0, 50 mM sodium chloride (‘S200 buffer’), and concentrated to a finalvolume of 4.5 ml, in preparation for enzymatic biotinylation with BirA(Affinity, Denver, Colo.). 0.5 ml of 10.times. BirA reaction buffer (assupplied) is added, and recombinant BirA enzyme at 10 mu.M finalconcentration, supplemented with 10 mM ATP, pH 7.0. A selection ofprotease inhibitors is also used to preserve the proteins: 0.2 mM PMSF,2 mu.g/ml pepstatin and 2 mu.g/ml leupeptin. The reaction is left for 4hours at room temperature.

Biotinylated .beta.2m-COMP is purified by size exclusion chromatography(SEC) on a Superdex®200 HR 26/60 column (Amersham Biosciences), runningS200 buffer.

500 ml of refolding buffer is prepared as follows: 100 mM Tris, pH 8.0,400 mM Larginine hydrochloride, 2 mM EDTA, 5 mM reduced glutathione and0.5 mM oxidised glutathione, dissolved in deionised water and leftstirring at 4.degree. C. 15 mg of lyophilised synthetic peptideGLCTLVAML is dissolved in 0.5 ml dimethylsulfoxide and added to therefolding buffer whilst stirring. 50 mg of biotinylated pentameric.beta.2m-COMP and 30 mg of A*0201 .alpha. chain is added sequentially,injected through a 23 gauge hypodermic needle directly into thevigorously-stirred buffer, to ensure adequate dispersion. The refoldingmixture is then left stirring gently for 16 hours at 4.degree. C.

The protein refolding mixture is subsequently concentrated from 500 mlto 20 ml using a MiniKros hollow fibre ultrafiltration cartridge(Spectrum Labs, Rancho Dominguez, Calif.) with a 30 kD molecular weightcutoff. Further concentration of the complex from 20 ml to 5 ml iscarried out in Centricon Plus-20 centrifugal concentrators (30 kDmolecular weight cut-off) according to the manufacturers instructions,followed by buffer exchange into S200 buffer using disposable PD10desalting columns (Amersham Biosciences), according to themanufacturer's instructions. Final volume is 7.5 ml. The concentratedprotein refold mixture is first purified by SEC on a Superdex® 200 HR26/60 gel filtration chromatography column, as in Section 4.2. Fractionscontaining protein complexes in the region of 310 kD is collected.

Fractions collected from SEC are pooled and subjected to furtherpurification by anion exchange chromatography on a MonoQ® HR 5/5 column(Amersham Biosciences), running a salt gradient from 0-0.5 M sodiumchloride in 20 mM Tris over 15 column volumes. The dominant peak iscollected. Protein recovery is determined using the Bradford assay.

Since each streptavidin molecule is able to bind up to 4 biotinentities, final labelling with phycoerythrin (PE)-conjugatedstreptavidin is carried out in a molar ratio of 1:0.8, streptavidin tobiotinylated pentamer complex respectively, taking into account theinitial biotinylation efficiency measurement made for .beta.2m-COMP inSection 4.2. The total required amount of pentamer complex is subdivided(e.g. into 5 equal amounts) and titrated successively intostreptavidin-PE. The concentration of A*0201 pentamer-streptavidincomplex is adjusted to 1 mg/ml with phosphate buffered saline (PBS),supplemented with 0.01% azide and 1% BSA.

This resultant fluorescent Pentamer reagent is stored at 4.degree. C.

Example 14 Prediction of MHC Class 1 BK Virus Peptide Binders

This example describes the total approach, applied to the BK virusgenome. It thus involves the translation of the genome in bothdirections, i.e. in six possible reading frames. Prediction of MHCclass1 BK virus peptide sequences for use in construction of MHC′mersdesigned to be used for analytical, diagnostic, prognostic, therapeuticand vaccine purposes, through the interaction of the MHC′mers with BKvirus-specific T-cells. Prediction is carried out using the totalapproach. Thus, the 8-, 9-, 10- and 11-mer peptide sequences aregenerated from six amino acid sequences representing direct translationof the BK virus genome sequence in all six reading frames. The 8-, 9-,10- and 11-mer peptide sequences are derived from the genome sequence byapplication of the software program described in (FIG. 2). The 8-, 9-,10- and 11-mer peptide sequences are shown in table I.

Example 15 Prediction of MHC Class 2 BK Virus Peptide Binders

This example describes the total approach, applied to the BK virusgenome. It thus involves the translation of the genome in bothdirections, i.e. in six possible reading frames. Prediction of MHC class2 BK virus peptide sequences for use in construction of MHC′mersdesigned to be used for analytical, diagnostic, prognostic, therapeuticand vaccine purposes, through the interaction of the MHC′mers with BKvirus-specific T-cells. Prediction is carried out using the totalapproach. Thus, the 13-, 14-, 15- and 16-mer peptide sequences aregenerated from six amino acid sequences representing direct translationof the BK virus genome sequence in all six reading frames. The 13-, 14-,15- and 16-mer peptide sequences are derived from the genome sequence byapplication of the software program described in (FIG. 2). The 13-, 14-,15- and 16-mer peptide sequences are shown in table O.

Example 16 Prediction of MHC Class 1 Peptide Binders for BK AgnoproteinUsing Directed Approach

This example describes the directed approach, applied to a known proteinsequence, the Agnoprotein encoded by the BK virus genome. The purpose isto predict BK virus peptide sequences that binds to MHC class 1molecules for use in construction of MHC′mers designed to be used foranalytical, diagnostic, prognostic, therapeutic and vaccine purposes,through the interaction of the MHC′mers with BK virus specific T-cells.Prediction is carried out using the known preferences of the 42 HLAclass 1 alleles included in thehttp://www.cbs.dtu.dk/services/NetMHC/database (FIG. 11).

The result of the prediction software is used to find all strong andweak 8-, 9-, 10- and 11-mer peptide binders of the 42 HLA class 1alleles. The result can be seen in table N. The MHC class 1 alleles forwhom no binders are predicted are omitted from the list. The listedpeptides are ranked according to decreased binding affinity for theindividual MHC alleles. Strong binders are defined as binders with anaffinity value of less than 50 nM and weak binders with a value of lessthan 500 nM. Only peptides defined as weak or strong binders are shown.

Example 17 Prediction of MHC Class 1 Peptide Binders for BK Small tProtein Using Directed Approach

This example describes the directed approach, applied to a known proteinsequence, the small t protein encoded by the BK virus genome. Thepurpose is to predict BK virus peptide sequences that binds to MHC class1 molecules for use in construction of MHC′mers designed to be used foranalytical, diagnostic, prognostic, therapeutic and vaccine purposes,through the interaction of the MHC′mers with BK virus specific T-cells.Prediction is carried out using the known preferences of the 42 HLAclass 1 alleles included in thehttp://www.cbs.dtu.dk/services/NetMHC/database (FIG. 11).

The result of the prediction software is used to find all strong andweak 8-, 9-, 10- and 11-mer peptide binders of the 42 HLA class 1alleles. The result can be seen in table L. The MHC class 1 alleles forwhom no binders are predicted are omitted from the list. The listedpeptides are ranked according to decreased binding affinity for theindividual MHC alleles. Strong binders are defined as binders with anaffinity value of less than 50 nM and weak binders with a value of lessthan 500 nM. Only peptides defined as weak or strong binders are shown.

Example 18 Prediction of MHC Class 1 Peptide Binders for BK Large TProtein Using Directed Approach

This example describes the directed approach, applied to a known proteinsequence, the Large T protein encoded by the BK virus genome. Thepurpose is to predict BK virus peptide sequences that binds to MHC class1 molecules for use in construction of MHC′mers designed to be used foranalytical, diagnostic, prognostic, therapeutic and vaccine purposes,through the interaction of the MHC′mers with BK virus specific T-cells.Prediction is carried out using the known preferences of the 42 HLAclass 1 alleles included in thehttp://www.cbs.dtu.dk/services/NetMHC/database (FIG. 11).

The result of the prediction software is used to find all strong andweak 8-, 9-, 10- and 11-mer peptide binders of the 42 HLA class 1alleles. The result can be seen in table M. The MHC class 1 alleles forwhom no binders are predicted are omitted from the list. The listedpeptides are ranked according to decreased binding affinity for theindividual MHC alleles. Strong binders are defined as binders with anaffinity value of less than 50 nM and weak binders with a value of lessthan 500 nM. Only peptides defined as weak or strong binders are shown.

Example 19 Prediction of MHC Class 1 Peptide Binders for BK VP1 ProteinUsing Directed Approach

This example describes the directed approach, applied to a known proteinsequence, the VP1 protein encoded by the BK virus genome. The purpose isto predict BK virus peptide sequences that binds to MHC class 1molecules for use in construction of MHC′mers designed to be used foranalytical, diagnostic, prognostic, therapeutic and vaccine purposes,through the interaction of the MHC′mers with BK virus specific T-cells.Prediction is carried out using the known preferences of the 42 HLAclass 1 alleles included in thehttp://www.cbs.dtu.dk/services/NetMHC/database (FIG. 11).

The result of the prediction software is used to find all strong andweak 8-, 9-, 10- and 11-mer peptide binders of the 42 HLA class 1alleles. The result can be seen in table K. The MHC class 1 alleles forwhom no binders are predicted are omitted from the list. The listedpeptides are ranked according to decreased binding affinity for theindividual MHC alleles. Strong binders are defined as binders with anaffinity value of less than 50 nM and weak binders with a value of lessthan 500 nM. Only peptides defined as weak or strong binders are shown.

Example 20 Prediction of MHC Class 1 Peptide Binders for BK VP2-3Protein Using Directed Approach

This example describes the directed approach, applied to a known proteinsequence, the VP2-3 protein encoded by the human genome. The purpose isto predict BK virus peptide sequences that binds to MHC class 1molecules for use in construction of MHC′mers designed to be used foranalytical, diagnostic, prognostic, therapeutic and vaccine purposes,through the interaction of the MHC′mers with BK virus specific T-cells.Prediction is carried out using the known preferences of the 42 HLAclass 1 alleles included in thehttp://www.cbs.dtu.dk/services/NetMHC/database (FIG. 11).

The result of the prediction software is used to find all strong andweak 8-, 9-, 10- and 11-mer peptide binders of the 42 HLA class 1alleles. The result can be seen in table J. The MHC class 1 alleles forwhom no binders are predicted are omitted from the list. The listedpeptides are ranked according to decreased binding affinity for theindividual MHC alleles. Strong binders are defined as binders with anaffinity value of less than 50 nM and weak binders with a value of lessthan 500 nM. Only peptides defined as weak or strong binders are shown.

Example 21 Prediction of MHC Class 1 Peptide Binders for Human CancerProtein Bcl-2 Using Directed Approach

This example describes the directed approach, applied to a known proteinsequence, the cancer protein Bcl-2 encoded by the human genome. Thepurpose is to predict Bcl-2 peptide sequences that binds to MHC class 1molecules for use in construction of MHC′mers designed to be used foranalytical, diagnostic, prognostic, therapeutic and vaccine purposes,through the interaction of the MHC′mers with human Bcl-2 specificT-cells. Prediction is carried out using the known preferences of the 42HLA class 1 alleles included in thehttp://www.cbs.dtu.dk/services/NetMHC/database (FIG. 11).

The result of the prediction software is used to find all strong andweak 8-, 9-, 10- and 11-mer peptide binders of the 42 HLA class 1alleles. The result can be seen in table C. The MHC class 1 alleles forwhom no binders are predicted are omitted from the list. The listedpeptides are ranked according to decreased binding affinity for theindividual MHC alleles. Strong binders are defined as binders with anaffinity value of less than 50 nM and weak binders with a value of lessthan 500 nM. Only peptides defined as weak or strong binders are shown.

Example 22 Prediction of MHC Class 1 Peptide Binders for Human CancerProtein BclX(L) Using Directed Approach

This example describes the directed approach, applied to a known proteinsequence, the cancer protein BclX(L) encoded by the human genome. Thepurpose is to predict BclX(L) peptide sequences that binds to MHC class1 molecules for use in construction of MHC′mers designed to be used foranalytical, diagnostic, prognostic, therapeutic and vaccine purposes,through the interaction of the MHC′mers with human BclX(L) specificT-cells. Prediction is carried out using the known preferences of the 42HLA class 1 alleles included in thehttp://www.cbs.dtu.dk/services/NetMHC/database (FIG. 11).

The result of the prediction software is used to find all strong andweak 8-, 9-, 10- and 11-mer peptide binders of the 42 HLA class 1alleles. The result can be seen in table B. The MHC class 1 alleles forwhom no binders are predicted are omitted from the list. The listedpeptides are ranked according to decreased binding affinity for theindividual MHC alleles. Strong binders are defined as binders with anaffinity value of less than 50 nM and weak binders with a value of lessthan 500 nM. Only peptides defined as weak or strong binders are shown.

Example 23 Prediction of MHC Class 1 Human Cancer Protein SurvivinPeptide Binders

This example describes the prediction of MHC class1 human Survivinpeptide sequences for use in construction of MHC′mers designed to beused for analytical, diagnostic, prognostic, therapeutic and vaccinepurposes, through the interaction of the MHC′mers with human Survivinspecific T-cells. Prediction of the 8-, 9-, 10- and 11-mer peptidesequences are carried out using the peptide generation software programdescribed in FIG. 2. The outcome is shown in table F.

Example 24 Prediction of MHC Class 2 Peptide Binders for BK AgnoproteinUsing Directed Approach

This example describes the directed approach, applied to a known proteinsequence, the Agnoprotein encoded by the BK virus genome. The purpose isto predict BK virus peptide sequences that binds to MHC class 2molecules for use in construction of MHC′mers designed to be used foranalytical, diagnostic, prognostic, therapeutic and vaccine purposes,through the interaction of the MHC′mers with BK virus specific T-cells.Prediction is carried out using the known preferences of the 14 HLAclass 2 alleles included in thehttp://www.cbs.dtu.dk/services/NetMHC/database (FIG. 11).

The result of the prediction software is used to find all strong andweak 15-mer peptide binders of the 14 HLA class 2 alleles. It also findsthe important central nonamer core peptide sequence of each bindingpeptide. The result can be seen in table T. The MHC class 2 alleles forwhom no binders are predicted are omitted from the list. The listedpeptides are ranked according to decreased binding affinity for theindividual MHC alleles. Strong binders are defined as binders with anaffinity value of less than 50 nM and weak binders with a value of lessthan 500 nM. Only peptides defined as weak or strong binders are shown.

Example 25 Prediction of MHC Class 2 Peptide Binders for BK Small tProtein Using Directed Approach

This example describes the directed approach, applied to a known proteinsequence, the small t protein encoded by the BK virus genome. Thepurpose is to predict BK virus peptide sequences that binds to MHC class2 molecules for use in construction of MHC′mers designed to be used foranalytical, diagnostic, prognostic, therapeutic and vaccine purposes,through the interaction of the MHC′mers with BK virus specific T-cells.Prediction is carried out using the known preferences of the 14 HLAclass 2 alleles included in thehttp://www.cbs.dtu.dk/services/NetMHC/database (FIG. 11).

The result of the prediction software is used to find all strong andweak 15-mer peptide binders of the 14 HLA class 2 alleles. It also findsthe important central nonamer core peptide sequence of each bindingpeptide. The result can be seen in table R. The MHC class 2 alleles forwhom no binders are predicted are omitted from the list. The listedpeptides are ranked according to decreased binding affinity for theindividual MHC alleles. Strong binders are defined as binders with anaffinity value of less than 50 nM and weak binders with a value of lessthan 500 nM. Only peptides defined as weak or strong binders are shown.

Example 26 Prediction of MHC Class 2 Peptide Binders for BK Large TProtein Using Directed Approach

This example describes the directed approach, applied to a known proteinsequence, the Large T protein encoded by the BK virus genome. Thepurpose is to predict BK virus peptide sequences that binds to MHC class2 molecules for use in construction of MHC′mers designed to be used foranalytical, diagnostic, prognostic, therapeutic and vaccine purposes,through the interaction of the MHC′mers with BK virus specific T-cells.Prediction is carried out using the known preferences of the 14 HLAclass 2 alleles included in thehttp://www.cbs.dtu.dk/services/NetMHC/database (FIG. 11).

The result of the prediction software is used to find all strong andweak 15-mer peptide binders of the 14 HLA class 2 alleles. It also findsthe important central nonamer core peptide sequence of each bindingpeptide. The result can be seen in table S. The MHC class 2 alleles forwhom no binders are predicted are omitted from the list. The listedpeptides are ranked according to decreased binding affinity for theindividual MHC alleles. Strong binders are defined as binders with anaffinity value of less than 50 nM and weak binders with a value of lessthan 500 nM. Only peptides defined as weak or strong binders are shown.

Example 27 Prediction of MHC Class 2 Peptide Binders for BK VP1 ProteinUsing Directed Approach

This example describes the directed approach, applied to a known proteinsequence, the VP1 protein encoded by the BK virus genome. The purpose isto predict BK virus peptide sequences that binds to MHC class 2molecules for use in construction of MHC′mers designed to be used foranalytical, diagnostic, prognostic, therapeutic and vaccine purposes,through the interaction of the MHC′mers with BK virus specific T-cells.Prediction is carried out using the known preferences of the 14 HLAclass 2 alleles included in thehttp://www.cbs.dtu.dk/services/NetMHC/database (FIG. 11).

The result of the prediction software is used to find all strong andweak 15-mer peptide binders of the 14 HLA class 2 alleles. It also findsthe important central nonamer core peptide sequence of each bindingpeptide. The result can be seen in table Q. The MHC class 2 alleles forwhom no binders are predicted are omitted from the list. The listedpeptides are ranked according to decreased binding affinity for theindividual MHC alleles. Strong binders are defined as binders with anaffinity value of less than 50 nM and weak binders with a value of lessthan 500 nM. Only peptides defined as weak or strong binders are shown.

Example 28 Prediction of MHC Class 2 Peptide Binders for BK VP2-3Protein Using Directed Approach

This example describes the directed approach, applied to a known proteinsequence, the VP2-3 protein encoded by the BK virus genome. The purposeis to predict BK virus peptide sequences that binds to MHC class 2molecules for use in construction of MHC′mers designed to be used foranalytical, diagnostic, prognostic, therapeutic and vaccine purposes,through the interaction of the MHC′mers with BK virus specific T-cells.Prediction is carried out using the known preferences of the 14 HLAclass 2 alleles included in thehttp://www.cbs.dtu.dk/services/NetMHC/database (FIG. 11).

The result of the prediction software is used to find all strong andweak 15-mer peptide binders of the 14 HLA class 2 alleles. It also findsthe important central nonamer core peptide sequence of each bindingpeptide. The result can be seen in table P. The MHC class 2 alleles forwhom no binders are predicted are omitted from the list. The listedpeptides are ranked according to decreased binding affinity for theindividual MHC alleles. Strong binders are defined as binders with anaffinity value of less than 50 nM and weak binders with a value of lessthan 500 nM. Only peptides defined as weak or strong binders are shown.

Example 29 Prediction of MHC Class 2 Human Cancer Protein Mcl-1 PeptideBinders

This example describes the prediction of MHC class 2 human Mcl-1 peptidesequences for use in construction of MHC′mers designed to be used foranalytical, diagnostic, prognostic, therapeutic and vaccine purposes,through the interaction of the MHC′mers with human Mcl-1 specificT-cells. Prediction of the 13-, 14-, 15- and 16-mer peptide sequencesare carried out using the peptide generation software program describedin FIG. 2. The outcome is shown in table G.

Example 30 Prediction of MHC Class 2 Peptide Binders for Human CancerProtein Bcl-2 Using Directed Approach

This example describes the directed approach, applied to a known proteinsequence, the cancer protein Bcl-2 encoded by the human genome. Thepurpose is to predict Bcl-2 peptide sequences that binds to MHC class 2molecules for use in construction of MHC′mers designed to be used foranalytical, diagnostic, prognostic, therapeutic and vaccine purposes,through the interaction of the MHC′mers with human Bcl-2 specificT-cells. Prediction is carried out using the known preferences of the 14HLA class 2 alleles included in thehttp://www.cbs.dtu.dk/services/NetMHCII/database (FIG. 11).

The result of the prediction software is used to find all strong andweak 15-mer peptide binders of the 14 HLA class 2 alleles. It also findsthe important central nonamer core peptide sequence of each bindingpeptide. The result can be seen in table E. The MHC class 2 alleles forwhom no binders are predicted are omitted from the list. The listedpeptides are ranked according to decreased binding affinity for theindividual MHC alleles. Strong binders are defined as binders with anaffinity value of less than 50 nM and weak binders with a value of lessthan 500 nM. Only peptides defined as weak or strong binders are shown.

Example 31 Prediction of MHC Class 2 Peptide Binders for Human CancerProtein BclX(L) Using Directed Approach

This example describes the directed approach, applied to a known proteinsequence, the cancer protein BclX(L) encoded by the human genome. Thepurpose is to predict BclX(L) peptide sequences that binds to MHC class2 molecules for use in construction of MHC′mers designed to be used foranalytical, diagnostic, prognostic, therapeutic and vaccine purposes,through the interaction of the MHC′mers with human BclX(L) specificT-cells. Prediction is carried out using the known preferences of the 14HLA class 2 alleles included in thehttp://www.cbs.dtu.dk/services/NetMHCII/database (FIG. 11).

The result of the prediction software is used to find all strong andweak 15-mer peptide binders of the 14 HLA class 2 alleles. It also findsthe important central nonamer core peptide sequence of each bindingpeptide. The result can be seen in table D. The MHC class 2 alleles forwhom no binders are predicted are omitted from the list. The listedpeptides are ranked according to decreased binding affinity for theindividual MHC alleles. Strong binders are defined as binders with anaffinity value of less than 50 nM and weak binders with a value of lessthan 500 nM. Only peptides defined as weak or strong binders are shown.

Example 32 Prediction of MHC Class 1 and 2 Borrelia afzelii OspC PeptideBinders

This example describes the prediction of MHC class 1 and 2 Borreliaafzelii OspC peptide sequences for use in construction of MHC′mersdesigned to be used for analytical, diagnostic, prognostic, therapeuticand vaccine purposes, through the interaction of the MHC′mers withBorrelia afzelii OspC specific T-cells. Prediction of the 8-, 9-, 10-,11-, 13-, 14-, 15- and 16-mer peptide sequences are carried out usingthe peptide generation software program described in FIG. 2. The outcomeis shown in table U.

Example 33 Prediction of MHC Class 1 Borrelia burgdorferi OspA PeptideBinders

This example describes the directed approach, applied to a known proteinsequence, the Borrelia burgdorferi protein OspA encoded by the Borreliagenome. The purpose is to predict OspA peptide sequences that binds toMHC class 1 molecules for use in construction of MHC′mers designed to beused for analytical, diagnostic, prognostic, therapeutic and vaccinepurposes, through the interaction of the MHC′mers with human OspAspecific T-cells. Prediction is carried out using the known preferencesof the 42 HLA class 1 alleles included in thehttp://www.cbs.dtu.dk/services/NetMHC/database (FIG. 11).

The result of the prediction software is used to find all strong andweak 8-, 9-, 10- and 11-mer peptide binders of the 42 HLA class 1alleles. The result can be seen in table V. The MHC class 1 alleles forwhom no binders are predicted are omitted from the list. The listedpeptides are ranked according to decreased binding affinity for theindividual MHC alleles. Strong binders are defined as binders with anaffinity value of less than 50 nM and weak binders with a value of lessthan 500 nM. Only peptides defined as weak or strong binders are shown.

Example 34 Prediction of MHC Class 1 Borrelia garinii Flab PeptideBinders

This example describes the directed approach, applied to a known proteinsequence, the Borrelia garinii protein FlaB encoded by the Borreliagenome. The purpose is to predict FlaB peptide sequences that binds toMHC class 1 molecules for use in construction of MHC′mers designed to beused for analytical, diagnostic, prognostic, therapeutic and vaccinepurposes, through the interaction of the MHC′mers with human FlaBspecific T-cells. Prediction is carried out using the known preferencesof the 42 HLA class 1 alleles included in thehttp://www.cbs.dtu.dk/services/NetMHC/database (FIG. 11).

The result of the prediction software is used to find all strong andweak 8-, 9-, 10- and 11-mer peptide binders of the 42 HLA class 1alleles. The result can be seen in table X. The MHC class 1 alleles forwhom no binders are predicted are omitted from the list. The listedpeptides are ranked according to decreased binding affinity for theindividual MHC alleles. Strong binders are defined as binders with anaffinity value of less than 50 nM and weak binders with a value of lessthan 500 nM. Only peptides defined as weak or strong binders are shown.

Example 35 Prediction of MHC Class 1 and 2 Mycobacterium tuberculosisCFP10 Peptide Binders

This example describes the prediction of MHC class 1 and 2 Mycobacteriumtuberculosis CFP10 peptide sequences for use in construction of MHC′mersdesigned to be used for analytical, diagnostic, prognostic, therapeuticand vaccine purposes, through the interaction of the MHC′mers withMycobacterium tuberculosis CFP10 specific T-cells. Prediction of the 8-,9-, 10-, 11-, 13-, 14-, 15- and 16-mer peptide sequences are carried outusing the peptide generation software program described in FIG. 2. Theoutcome is shown in table Y.

Example 36 Prediction of MHC Class 1 LCMV gp1 Nonamer Peptide Bindersfor Mouse H-2 Kd An Example of Non-Human MHC Peptide Binding Motifs.

This example describes the directed approach, applied to the knownprotein sequence of a mouse virus protein LCMV gp1 in context of mouseMHC class 1.

Prediction of LCMV gp1 peptide sequences that binds to the MHC class 1molecule H-2 Kd for use in construction of MHC′mers designed to be usedfor as analytical, diagnostic, prognostic, therapeutic and vaccinepurposes, through the interaction of the MHC′mers with LCMV specificmouse T-cells. Prediction is carried out using the known preferences ofthe given H-2 molecules for peptide binding as laid down in theprediction program found on www.syfpeithi.de. The generated 9-merpeptides are ranked according to their binding efficiency to theindividual HLA class 1 molecules. The output is shown in FIG. 2.

Example 37 Test of Predicted BclX(L) 10-mer Binding PeptideFunctionality in Elispot

In example 22 the best binding BclX(L) 10-mer peptide for HLA-A*0201 wasidentified to be YLNDHLEPWI (SEQ ID NO.: 46196). This peptide has thenbeen tested in ELISPOT to see if it were able to detect the presenceBcl-X(L)-specific, CD8 positive T cells in PBL (Peripheral BloodLymphocytes) from a breast cancer patient. PBL from a breast cancerpatient was analyzed by ELISPOT ex vivo either with or without theBcl-X(L)173-182 peptide (YLNDHLEPWI (SEQ ID NO.: 46196)), 106 PBL/wellin doublets. The number of spots was counted using the Immunospot Series2.0 Analyzer (CTL Analysers). The result is given as number of spotsabove the pictures of the result as shown in FIG. 15 and it clearlyshows the presence of BclX(L) specific T-cells and thereby thefunctionality of the peptide as compared to the absence of addedpeptide.

Example 38 Test of Predicted BclX(L) 10-Mer Binding PeptideFunctionality in Flow Cytometry

In example 22 the best binding BclX(L) 10-mer peptide for HLA-A*0201 wasidentified to be YLNDHLEPWI (SEQ ID NO.: 46196). In the present examplethe functionality of the peptide is shown in a flow cytometric analysisof PBL from the patient was analyzed ex vivo by Flow cytometry toidentify Bcl-X(L)173-182 specific CD8 T cells using the dextramercomplex HLA-A2/Bcl-X(L)173-182-APC, 7-AAD-PerCP, CD3-FITC, andCD8-APC-Cy7. The dextramer complex HLA-A2/HIV-1 pol476-484-APC was usedas negative control. The result (FIG. 16) clearly demonstrate that a MHCDextramer HLA-A*0201/YLNDHLEPWI (SEQ ID NO.: 46196) complex detectsBclX(L) antigen specific CD-8 cells in the patient sample at a level of0.03% as compared with the negative control using HIV specific MHCDextramer.

Example 39 Use of BclX(L) specific MHC Dextramer for sorting of antigenspecific CD8 T cells from patient sample

The antigen specific CD8 positive T-cells of example 38 were sorted outduring the flow cytometric analysis using the MHC DextramerHLA-A*0201/YLNDHLEPWI (SEQ ID NO.: 46196). The detectable population ofdextramer positive CD8 T cells was sorted as single cells into 96 wellplates using the following protocol:

Small lymphocytes were gated by forward and side scatter profile, beforecloning according to CD8/MHC-multimer double staining. CD8/MHC-multimerdouble-positive cells were sorted as single cells into 96 well plates(Nunc) already containing 10⁵ cloning mix cells/well. The cloning mixwas prepared containing 10⁶ irradiated (20 Gy) lymphocytes from threehealthy donors per nil in X-vivo with 5% heat-inactivated human serum,25 mM HEPES buffer (GibcoBRL), 1 μg/ml phytohemagglutinin (PHA)(Peprotech) and 120 U/ml IL-2. The cloning mix was incubated for twohours at 37° C./5% CO₂, prior to cloning. After cloning, the plates wereincubated at 37° C./5% CO₂. Every 3-4 days 50 μL1 fresh media were addedcontaining IL-2 to a final concentration of 120 U/ml. Following 10-14days of incubation, growing clones were further expanded using cloningmix cells. Consequently, each of the growing clones were transferred(split) into two or three wells (depending on the number of growingcells) of a new 96 well plate containing 5×10⁴ cloning mix cells/well.Clones that were not growing at this time were incubated for anotherweek with IL-2, and then expanded. Subsequently, the specificity of thegrowing clones was tested in a ⁵¹Cr-release assay or by FACS.

Out of twenty-isolated dextramer positive CD8 T cells, ten were able tobe expanded into T-cell clones.

Example 40 Demonstration of Specific Cytolytic Activity of IsolatedBclX(L) Specific CD8 T-Cells

The ten expanded T cell clones isolated by Flow sorting as shown inexample 39 were tested for their specificity by analysis in a standard51-Cr release assay. For this purpose, T2 cells loaded with eitherBcl-X(L)173-182 peptide or an irrelevant peptide (BA4697-105, GLQHWVPEL)were used as target cells. Five CD8 T-cell clones (Clone 8, 9, 10, 11,and 12) effectively lysed T2 cells pulsed with Bcl-X(L)173-182 withoutkilling of T2 cells pulsed with an irrelevant peptide (FIG. 17). One ofthese BclX(L)173-182 specific CD8 T-cell clones [Clone 9] were expandedfor further analyses. The remaining five expanded clones (Clone 7, 13,15, 17, and 18) did not show specific lysis against T2 cells pulsed withBcl-X(L)173-182 peptide (FIG. 8).

Example 41 Demonstration of the Cytotoxic Capacity of a BclX(L)173-182Specific CD8 T Cell Clone Isolated by Flow Aided Sorting of Antigen(HLA-A*0201/YLNDHLEPWI (SEQ ID NO.: 46196) specific T cells.

The Bcl-X(L)173-182 specific clone 9 was expanded for additional 2 weeksbefore the cytotoxic potential was examined further in 51Cr-releaseassays. Two assays were performed a Cell lysis of T2 cells pulsed withBcl-X(L)173-182 peptide or an irrelevant peptide (BA4697-105, GLQHWVPEL)in three E:T ratios. b Cell lysis of T2 cells pulsed with differentconcentrations of Bcl-X(L)173-182 peptide at the E:T ratio 1:1 Theresult is given in FIG. 18. As can be seen the presence of the specificpeptide is necessary to get killing of the target cell and the effect ofthe peptide is significant even at low concentrations.

Example 42 Synthesis of a Comprehensive Library of Antigenic Peptides ofVariable Size Derived from a Full-Length Antigen Sequence

In this example it is described how virtually all of the possible 8′- to20′-mer peptide epitopes of an antigen may be synthetically prepared bymodification of the standard Fmoc peptide synthesis protocol.

N-□-amino acids are incorporated into a peptide of the desired sequencewith one end of the sequence remaining attached to a solid supportmatrix. All soluble reagents can be removed from the peptide-solidsupport matrix by filtration and washed away at the end of each couplingstep. After each of the coupling steps, and after the removal ofreagents, a fraction of the generated peptides are removed and recoveredfrom the polymeric support by cleavage of the cleavable linker thatlinks the growing peptide to solid support.

The solid support can be a synthetic polymer that bears reactive groupssuch as —OH. These groups are made so that they can react easily withthe carboxyl group of an N-□-protected amino acid, thereby covalentlybinding it to the polymer. The amino protecting group can then beremoved and a second N-□-protected amino acid can be coupled to theattached amino acid. These steps are repeated until the desired sequenceis obtained. At the end of the synthesis, a different reagent is appliedto cleave the bond between the C-terminal amino acid and the polymersupport; the peptide then goes into solution and can be obtained fromthe solution.

Initially, the first Fmoc amino acid (starting at the C-terminal end ofthe antigen sequence) is coupled to a precursor molecule on an insolublesupport resin via an acid labile linker Deprotection of Fmoc isaccomplished by treatment of the amino acid with a base, usuallypiperidine. Before coupling the next amino acid, a fraction of thesynthesized peptide (for example 0. 1%) is detached from the solidsupport, and recovered. Then additional beads carrying only theprecursor molecule including the linker (for example corresponding to0.1% of the total amount of solid support in the reaction) is added.Then the next Fmoc amino acid is coupled utilizing a pre-activatedspecies or in situ activation.

This cycle of amino acid coupling, removal of reagents, detachment of asmall fraction of synthesized peptide and recovery of these, andactivation of the immobilized peptide to prepare for the next round ofcoupling, goes on until the entire antigen sequence has been processed.

The recovered peptides thus represent different fragments of theantigen, with varying lengths. The peptide pool thus contains most orall of the possible peptide epitopes of the antigen, and may be used inthe preparation of MHC multimers as a pool.

The entire process, including the detachment of a fraction of thepeptides after each round of coupling, follows standard Fmoc peptidesynthesis protocols, and involves weak acids such as TFA or TMSBr,typical scavengers such as thiol compounds, phenol and water, andinvolves standard protecting groups.

Example 43

This is an example of how MHC multimers may be used for detection ofcancer specific T cells in blood samples from patients.

In this example the MHC multimer used are MHC complexes coupled tofluorophor-labelled dextran (Dextramers). The dextramers are used fordirect detection of TCR in flow Cytometry. The antigen origin is cancer,thus, immune monitoring of a cancer.

MHC multimers carrying cancer specific peptides is in this example usedto detect the presence of cancer specific T cells in the blood fromcancer patients.

Purified MHC-peptide complexes consisting of HLA-A*1101 heavy chain,human beta2microglobulin and peptide derived from a region in Survivin(Table F) or a negative control peptide were generated by in vitrorefolding, purified and biotinylated as described elsewhere herein.Biotinylated MHC-peptide complexes were then coupled to a 270 kDadextran multimerization domain labelled with APC by interaction withstreptavidin (SA) on the dextran multimerization domain. Thedextran-APC-SA multimerization domain was generated as describedelsewhere herein. MHC-peptide complexes were added in an amountcorresponding to a ratio of three MHC-peptide molecules per SA moleculeand each molecule dextran contains 3.7 SA molecule and 8.95 moleculesAPC. The final concentration of dextran was 3.8×10e-8 M. The followingMHC(peptide)/APC dextran constructs were made:

-   -   1. APC-SA conjugated 270 kDa dextran coupled with HLA-A*1101 in        complex with beta2microglobulin and the peptide DLAQCFFCFK        derived from Survivin.    -   2. APC-SA conjugated 270 kDa dextran coupled with HLA-A*1101 in        complex with beta2microglobulin and the non-sense peptide.

The binding of the above described MHC(peptide)/APC dextran was used todetermine the presence of Survivin specific T cells in the blood fromcancer patients by flow cytometry following a standard flow cytometryprotocol.

Blood from a cancer patient is isolated and 100 ul of this blood isincubated with 10 μl of the MHC(peptide)/APC dextran constructsdescribed above for 10 minutes in the dark at room temperature. 5 μl ofeach of each of the antibodies mouse-anti-human CD3/PB (clone UCHT1 fromDako), and mouse-anti-human CD8/PE (clone DK25 from Dako) are added andthe incubation continues for another 20 minutes at 4° C. in the dark.The samples are then washed by adding 2 ml PBS; pH=7.2 followed bycentrifugation for 5 minutes at 200×g and the supernatant removed. Thewashing step is repeated. The washed cells are resuspended in 400-500 μlPBS; pH=7.2 and analyzed on flowcytometer.

The presence of cells labeled with anti-CD3/PB, anti-CD8/PE and theMHC(peptide)/APC dextran construct 1 described above and thereby thepresence of Survivin specific T cells in the blood. Blood analysed withMHC(peptide)/APC dextran construct 2 show no staining of CD3 and CD8positive cells with this MHC(peptide)/APC dextran construct.

The sensitivity of the above described test may be enhanced by additionof labeled antibodies specific for activation markers expressed in or onthe surface of the Survivin specific T cells.

We conclude that the MHC(peptide)/APC dextran constructs can be used todetect the presence of Survivin specific T cells in the blood of cancer.

Example 44

This is an example of how MHC multimers may be used for detection ofcancer specific T cells in blood samples from patients.

In this example the MHC multimer used are MHC complexes coupled tofluorophor-labelled multimerisation domain Streptavidin (SA, used fordirect detection of TCR in flow Cytometry. The antigen origin is cancer,thus, immune monitoring of a cancer.

MHC multimers carrying cancer specific peptides is in this example usedto detect the presence of cancer specific T cells in the blood fromcancer patients.

Purified MHC-peptide complexes consisting of HLA-A*1101 heavy chain,human beta2microglobulin and peptide derived from a region in Survivin(Table F) or a negative control peptide were generated by in vitrorefolding, purified and biotinylated as described elsewhere herein.Biotinylated MHC-peptide complexes are then coupled SA labelled withAPC. MHC-peptide complexes were added in an amount corresponding to aratio of 5 MHC-peptide molecules per SA molecule. Then SA/APC carryingfour MHC complexes were purified from free SA, free monomeric MHCcomplex, SA carrying three, two and one MHC complexes.

The following SA-MHC(peptide)/APC tetramers are made:

-   -   3. APC-SA coupled with HLA-A*1101 in complex with        beta2microglobulin and the peptide DLAQCFFCFK derived from        Survivin.    -   4. APC-SA coupled with HLA-A*1101 in complex with        beta2microglobulin and the non-sense peptide.

The binding of the above described MHC(peptide)/APC dextran can be usedto determine the presence of Survivin specific T cells in the blood fromcancer patients by flow cytometry following a standard flow cytometryprotocol.

Blood from a cancer patient is isolated and 100 ul of this blood isincubated with either of the SA-MHC(peptide)/APC tetramers describedabove for 10 minutes in the dark at room temperature. 5 μl of each ofeach of the antibodies mouse-anti-human CD3/PB (clone UCHT1 from Dako)and mouse-anti-human CD8/PE (clone DK25 from Dako) are added and theincubation continued for another 20 minutes at 4° C. in the dark. Thesamples are then washed by adding 2 ml PBS; pH=7.2 followed bycentrifugation for 5 minutes at 200×g and the supernatant removed. Thewashing step is repeated. The washed cells are resuspended in 400-500 μlPBS; pH=7.2 and analyzed on flowcytometer.

The presence of cells labeled with anti-CD3/PB, anti-CD8/PE and theSA-MHC(peptide)/APC tetramers 3 described above and thereby the presenceof Survivin specific T cells in the blood. Blood analysed withSA-MHC(peptide)/APC tetramers 4 should show no staining of CD3 and CD8positive cells with this SA-MHC(peptide)/APC tetramer.

The sensitivity of the above described test may be enhanced by additionof labeled antibodies specific for activation markers expressed in or onthe surface of the Survivin specific T cells.

We conclude that the APC-SA coupled MHC(peptide) constructs may be usedto detect the presence of Survivin specific T cells in the blood ofcancer patients.

Example 45

This is an example of how MHC multimers may be used for detection ofcancer specific T cells in blood samples from patients.

In this example the MHC multimer used are MHC complexes coupled to anyfluorophor-labelled multimerisation as described elsewhere herein. TheMHC multimers are used for direct detection of TCR in flow Cytometry.The antigen origin is cancer, thus, immune monitoring of a cancer.

MHC multimers carrying cancer specific peptides is in this example usedto detect the presence of cancer specific T cells in the blood fromcancer patients.

Purified MHC-peptide complexes consisting of HLA-A*1101 heavy chain,human beta2microglobulin and peptide derived a region in Survivin (TableF) or a negative control peptide were generated by in vitro refoldingand purified or purified from antigen presenting cells. MHC-peptidecomplexes are then coupled to a multimerisation domain together withAPC.

The following MHC(peptide)/APC multimers are made:

-   -   5. APC-multimerisation domain coupled with HLA-A*1101 in complex        with beta2microglobulin and the peptide DLAQCFFCFK derived from        Survivin.    -   6. APC-multimerisation domain coupled with HLA-A*1101 in complex        with beta2microglobulin and the non-sense peptide.

The binding of the above described MHC(peptide)/APC multimers can beused to determine the presence of Survivin specific T cells in the bloodfrom cancer patients by flow cytometry following a standard flowcytometry protocol.

Blood from a cancer patient is isolated and 100 ul of this blood isincubated with either of the MHC(peptide)/APC multimers described abovefor 10 minutes in the dark at room temperature. 5 μl of each of each ofthe antibodies mouse-anti-human CD3/PB (clone UCHT1 from Dako) andmouse-anti-human CD8/PE (clone DK25 from Dako) are added and theincubation continued for another 20 minutes at 4° C. in the dark. Thesamples are then washed by adding 2 ml PBS; pH=7.2 followed bycentrifugation for 5 minutes at 200×g and the supernatant removed. Thewashing step is repeated. The washed cells are resuspended in 400-500 μlPBS; pH=7.2 and analyzed on flowcytometer.

The presence of cells labeled with anti-CD3/PB, anti-CD8/PE and theMHC(peptide)/APC multimers 5 described above and thereby the presence ofSurvivin specific T cells in the blood. Blood analysed withMHC(peptide)/APC multimer 6 should show no staining of CD3 and CD8positive cells with this SA-MHC(peptide)/APC multimer.

The sensitivity of the above described test may be enhanced by additionof labeled antibodies specific for activation markers expressed in or onthe surface of the Survivin specific T cells.

We conclude that the APC-multimerisation domain coupled MHC(peptide)constructs may be used to detect the presence of Survivin specific Tcells in the blood of cancer patients.

Example 46

This is an example of how MHC multimers may be used for detection ofEpstein-Barr Virus (EBV) specific T cells in blood samples from humansinfected with EBV.

In this example the MHC multimer used are MHC complexes coupled tofluorophor-labelled dextran (Dextramers). The dextramers are used fordirect detection of TCR in flow cytometry.

The antigen origin is EBV, thus, immune monitoring of EBV infection MHCmultimers carrying EBV specific peptides is in this example used todetect the presence of EBV specific T cells in the blood of patientsinfected with Epstein-Barr virus.

Purified MHC-peptide complexes consisting of HLA-B*0702 heavy chain,human beta2microglobulin and peptide derived from a region in EBVnuclear antigen (EBNA) or a negative control peptide are generated by invitro refolding, purified and biotinylated as described elsewhereherein. Biotinylated MHC-peptide complexes are then coupled to a 270 kDadextran multimerization domain labelled with APC by interaction withstreptavidin (SA) on the dextran multimerization domain. Thedextran-APC-SA multimerization domain is generated as describedelsewhere herein. MHC-peptide complexes are added in an amountcorresponding to a ratio of three MHC-peptide molecules per SA moleculeand each molecule dextran contains 3.7 SA molecule and 8.95 moleculesAPC. The final concentration of dextran is 3.8×10e-8 M. The followingMHC(peptide)/APC dextran constructs are made:

-   -   7. APC-SA conjugated 270 kDa dextran coupled with HLA-B*0702 in        complex with beta2microglobulin and the peptide RPPIFIRRL        derived from EBNA 3A.    -   8. APC-SA conjugated 270 kDa dextran coupled with HLA-B*0702 in        complex with beta2microglobulin and the peptide QPRAPIRPI        derived from EBNA 6.    -   9. APC-SA conjugated 270 kDa dextran coupled with HLA-B*0702 in        complex with beta2microglobulin and the HIV peptide TPGPGVRYPL.

The binding of the above described MHC(peptide)/APC dextran is used todetermine the presence of EBV specific T cells in the blood from EBVinfected individuals by flow cytometry following a standard flowcytometry protocol.

Blood from a patient with EBV infection is isolated and 100 ul of thisblood is incubated with 10 μl of the MHC(peptide)/APC dextran constructsdescribed above for 10 minutes in the dark at room temperature. 5 μl ofeach of each of the antibodies mouse-anti-human CD3/PB (clone UCHT1 fromDako), and mouse-anti-human CD8/PE (clone DK25 from Dako) are added andthe incubation continues for another 20 minutes at 4° C. in the dark.The samples are then washed by adding 2 ml PBS; pH=7.2 followed bycentrifugation for 5 minutes at 300×g and the supernatant removed. Thewashing step is repeated. The washed cells are resuspended in 400-500 μlPBS; pH=7.2 and analyzed on flowcytometer.

The presence of cells labeled with anti-CD3/PB, anti-CD8/PE and eitherof the MHC(peptide)/APC dextran construct 1 or 2 described above andthereby the presence of EBV specific T cells indicate that the patientare infected with Epstein-Barr virus. Blood analysed withMHC(peptide)/APC dextran construct 3 show no staining of CD3 and CD8positive cells with this MHC(peptide)/APC dextran construct.

The sensitivity of the above described test may be enhanced by additionof labeled antibodies specific for activation markers expressed in or onthe surface of the EBV specific T cells.

We conclude that the MHC(peptide)/APC dextran constructs can be used todetect the presence of EBV specific T cells in the blood of patientsinfected with Epstein-Barr virus.

Example 47

This is an example of how MHC multimers may be used for detection ofEpstein-Barr Virus (EBV) specific T cells in blood samples from humansinfected with EBV.

In this example the MHC multimer used are MHC complexes coupled tofluorophor-labelled multimerisation domain Streptavidin (SA), used fordirect detection of TCR in flow cytometry. The antigen origin is EBV,thus, immune monitoring of EBV infection

MHC multimers carrying EBV specific peptides is in this example used todetect the presence of EBV specific T cells in the blood of patientsinfected with Epstein-Barr virus.

Purified MHC-peptide complexes consisting of HLA-B*0702 heavy chain,human beta2microglobulin and peptide derived from a region in EBVnuclear antigen (EBNA) or a negative control peptide were generated byin vitro refolding, purified and biotinylated as described elsewhereherein. Biotinylated MHC-peptide complexes are then coupled SA labelledwith APC. MHC-peptide complexes were added in an amount corresponding toa ratio of 5 MHC-peptide molecules per SA molecule. Then SA/APC carryingfour MHC complexes were purified from free SA, free monomeric MHCcomplex, SA carrying three, two and one MHC complexes.

The following SA-MHC(peptide)/APC tetramers are made:

-   -   10. APC-SA coupled with HLA-B*0702 in complex with        beta2microglobulin and the peptide RPPIFIRRL derived from EBNA        3A.    -   11. APC-SA coupled with HLA-B*0702 in complex with        beta2microglobulin and the peptide QPRAPIRPI derived from EBNA        6.    -   12. APC-SA coupled with HLA-B*0702 in complex with        beta2microglobulin and the HIV peptide TPGPGVRYPL.

The binding of the above described MHC(peptide)/APC dextran can be usedto determine the presence of EBV specific T cells in the blood fromEpstein-Barr virus infected individuals by flow cytometry following astandard flow cytometry protocol.

Blood from a patient with EBV is isolated and 100 ul of this blood isincubated with either of the SA-MHC(peptide)/APC tetramers describedabove for 10 minutes in the dark at room temperature. 5 μl of each ofeach of the antibodies mouse-anti-human CD3/PB (clone UCHT1 from Dako)and mouse-anti-human CD8/PE (clone DK25 from Dako) are added and theincubation continued for another 20 minutes at 4° C. in the dark. Thesamples are then washed by adding 2 ml PBS; pH=7.2 followed bycentrifugation for 5 minutes at 200×g and the supernatant removed. Thewashing step is repeated. The washed cells are resuspended in 400-500 μlPBS; pH=7.2 and analyzed on flowcytometer.

The presence of cells labeled with anti-CD3/PB, anti-CD8/PE and eitherof the SA-MHC(peptide)/APC tetramers 4 or 5 described above and therebythe presence of EBV specific T cells will indicate that the patient areinfected with Epstein-Barr virus. Blood analysed withSA-MHC(peptide)/APC tetramers 6 should show no staining of CD3 and CD8positive cells with this SA-MHC(peptide)/APC tetramer.

The sensitivity of the above described test may be enhanced by additionof labeled antibodies specific for activation markers expressed in or onthe surface of the EBV specific T cells.

We conclude that the APC-SA coupled MHC(peptide) constructs may be usedto detect the presence of EBV specific T cells in the blood of patientsinfected with Epstein-Barr virus

Example 48

This is an example of how MHC multimers may be used for detection ofEpstein-Barr Virus (EBV) specific T cells in blood samples from humansinfected with EBV.

In this example the MHC multimer used are MHC complexes coupled to anyfluorophor-labelled multimerisation as described elsewhere herein. TheMHC multimers are used for direct detection of TCR in flow cytometry.The antigen origin is EBV, thus, immune monitoring of EBV infection

MHC multimers carrying EBV specific peptides is in this example used todetect the presence of EBV specific T cells in the blood of patientsinfected with Epstein-Barr virus.

Purified MHC-peptide complexes consisting of HLA-B*0702 heavy chain,human beta2microglobulin and peptide derived a region in EBV nuclearantigen (EBNA) or a negative control peptide were generated by in vitrorefolding and purified or purified from antigen presenting cells.MHC-peptide complexes are then coupled to a multimerisation domaintogether with APC.

The following MHC(peptide)/APC multimers are made:

-   -   13. APC-multimerisation domain coupled with HLA-B*0702 in        complex with beta2microglobulin and the peptide RPPIFIRRL        derived from EBNA 3A.    -   14. APC-multimerisation domain coupled with HLA-B*0702 in        complex with beta2microglobulin and the peptide QPRAPIRPI        derived from EBNA 6.    -   15. APC-multimerisation domain coupled with HLA-A*0201 in        complex with beta2microglobulin and the HIV peptide TPGPGVRYPL.

The binding of the above described MHC(peptide)/APC multimers can beused to determine the presence of EBV specific T cells in the blood fromEBV infected individuals by flow cytometry following a standard flowcytometry protocol.

Blood from a patient with EBV infection is isolated and 100 ul of thisblood is incubated with either of the MHC(peptide)/APC multimersdescribed above for 10 minutes in the dark at room temperature. 5 μl ofeach of each of the antibodies mouse-anti-human CD3/PB (clone UCHT1 fromDako) and mouse-anti-human CD8/PE (clone DK25 from Dako) are added andthe incubation continued for another 20 minutes at 4° C. in the dark.The samples are then washed by adding 2 ml PBS; pH=7.2 followed bycentrifugation for 5 minutes at 200×g and the supernatant removed. Thewashing step is repeated. The washed cells are resuspended in 400-500 μlPBS; pH=7.2 and analyzed on flowcytometer.

The presence of cells labeled with anti-CD3/PB, anti-CD8/PE and eitherof the MHC(peptide)/APC multimers 7 or 8 described above and thereby thepresence of EBV specific T cells will indicate that the patient areinfected with Epstein-Barr virus. Blood analysed with MHC(peptide)/APCmultimer 9 should show no staining of CD3 and CD8 positive cells withthis SA-MHC(peptide)/APC multimer.

The sensitivity of the above described test may be enhanced by additionof labeled antibodies specific for activation markers expressed in or onthe surface of the EBV specific T cells.

We conclude that the APC-multimerisation domain coupled MHC(peptide)constructs may be used to detect the presence of EBV specific T cells inthe blood of patients infected with Epstein-Barr virus.

Example 49

This is an example of how MHC multimers may be used for detection ofinfluenza matrix peptide in blood samples from humans infected withinfluenza.

In this example the MHC multimer used are MHC complexes coupled tofluorophor-labelled dextran (Dextramers). The dextramers are used fordirect detection of TCR in flow cytometry. The antigen origin isInfluenza, thus, immune monitoring of influenza.

The MHC multimer used are MHC complexes coupled to labeled dextran.

MHC multimers carrying influenza specific peptides is in this exampleused to detect the presence of influenza specific T cells in the bloodof patients infected with influenza virus.

Purified MHC-peptide complexes consisting of HLA-A*0201 heavy chain,human beta2microglobulin and peptide derived from a region in influenzamatrix peptide (Flu-MP) or a negative control peptide were generated byin vitro refolding, purified and biotinylated as described elsewhereherein. Biotinylated MHC-peptide complexes were then coupled to a 270kDa dextran multimerization domain labelled with APC by interaction withstreptavidin (SA) on the dextran multimerization domain. Thedextran-APC-SA multimerization domain was generated as describedelsewhere herein. MHC-peptide complexes were added in an amountcorresponding to a ratio of three MHC-peptide molecules per SA moleculeand each molecule dextran contains 3.7 SA molecule and 8.95 moleculesAPC. The final concentration of dextran was 3.8×10e-8 M. The followingMHC(peptide)/APC dextran constructs were made:

-   -   16. APC-SA conjugated 270 kDa dextran coupled with HLA-A*0201 in        complex with beta2microglobulin and the peptide GILGFVFTL        derived from Flu-MP.    -   17. APC-SA conjugated 270 kDa dextran coupled with HLA-A*0201 in        complex with beta2microglobulin and the non-sense peptide        GLAGDVSAV.

The binding of the above described MHC(peptide)/APC dextran was used todetermine the presence of influenza specific T cells in the blood frominfluenza infected individuals by flow cytometry following a standardflow cytometry protocol.

Blood from a influenza infected patient is isolated and 100 ul of thisblood is incubated with 10 μl of the MHC(peptide)/APC dextran constructsdescribed above for 10 minutes in the dark at room temperature. 5 μl ofeach of each of the antibodies mouse-anti-human CD3/PB (clone UCHT1 fromDako), and mouse-anti-human CD8/PE (clone DK25 from Dako) are added andthe incubation continues for another 20 minutes at 4° C. in the dark.The samples are then washed by adding 2 ml PBS; pH=7.2 followed bycentrifugation for 5 minutes at 200×g and the supernatant removed. Thewashing step is repeated. The washed cells are resuspended in 400-500 μlPBS; pH=7.2 and analyzed on flowcytometer.

The presence of cells labeled with anti-CD3/PB, anti-CD8/PE and theMHC(peptide)/APC dextran construct 1 described above and thereby thepresence of influenza specific T cells indicate that the patient areinfected with influenza virus. Blood analysed with MHC(peptide)/APCdextran construct 2 show no staining of CD3 and CD8 positive cells withthis MHC(peptide)/APC dextran construct.

The sensitivity of the above described test may be enhanced by additionof labeled antibodies specific for activation markers expressed in or onthe surface of the influenza specific T cells.

We conclude that the MHC(peptide)/APC dextran constructs can be used todetect the presence of influenza specific T cells in the blood ofpatients infected with influenza virus.

Example 50

This is an example of how MHC multimers may be used for detection ofinfluenza matrix peptide in blood samples from humans infected withinfluenza.

In this example the MHC multimer used are MHC complexes coupled tofluorophor-labelled multimerisation domain Streptavidin (SA), used fordirect detection of TCR in flow cytometry. The antigen origin isInfluenza, thus, immune monitoring of influenza.

The MHC multimer used are MHC complexes coupled to labeled dextran.

MHC multimers carrying influenza specific peptides is in this exampleused to detect the presence of influenza specific T cells in the bloodof patients infected with influenza virus.

Purified MHC-peptide complexes consisting of HLA-A*0201 heavy chain,human beta2microglobulin and peptide derived from a region in influenzamatrix peptide (Flu-MP) or a negative control peptide were generated byin vitro refolding, purified and biotinylated as described elsewhereherein. Biotinylated MHC-peptide complexes are then coupled SA labelledwith APC. MHC-peptide complexes were added in an amount corresponding toa ratio of 5 MHC-peptide molecules per SA molecule. Then SA/APC carryingfour MHC complexes were purified from free SA, free monomeric MHCcomplex, SA carrying three, two and one MHC complexes.

The following SA-MHC(peptide)/APC tetramers are made:

-   -   18. APC-SA coupled with HLA-A*0201 in complex with        beta2microglobulin and the peptide GILGFVFTL derived from        Flu-MP.    -   19. APC-SA coupled with HLA-A*0201 in complex with        beta2microglobulin and the non-sense peptide GLAGDVSAV.

The binding of the above described MHC(peptide)/APC dextran can be usedto determine the presence of influenza specific T cells in the bloodfrom influenza infected individuals by flow cytometry following astandard flow cytometry protocol.

Blood from a cancer patient is isolated and 100 ul of this blood isincubated with either of the SA-MHC(peptide)/APC tetramers describedabove for 10 minutes in the dark at room temperature. 5 μl of each ofeach of the antibodies mouse-anti-human CD3/PB (clone UCHT1 from Dako)and mouse-anti-human CD8/PE (clone DK25 from Dako) are added and theincubation continued for another 20 minutes at 4° C. in the dark. Thesamples are then washed by adding 2 ml PBS; pH=7.2 followed bycentrifugation for 5 minutes at 200×g and the supernatant removed. Thewashing step is repeated. The washed cells are resuspended in 400-500 μlPBS; pH=7.2 and analyzed on flowcytometer.

The presence of cells labeled with anti-CD3/PB, anti-CD8/PE and theSA-MHC(peptide)/APC tetramers 3 described above and thereby the presenceof influenza specific T cells will indicate that the patient areinfected with influenza virus. Blood analysed with SA-MHC(peptide)/APCtetramers 4 should show no staining of CD3 and CD8 positive cells withthis SA-MHC(peptide)/APC tetramer.

The sensitivity of the above described test may be enhanced by additionof labeled antibodies specific for activation markers expressed in or onthe surface of the influenza specific T cells.

We conclude that the APC-SA coupled MHC(peptide) constructs may be usedto detect the presence of influenza specific T cells in the blood ofpatients infected with influenza virus.

Example 51

This is an example of how MHC multimers may be used for detection ofinfluenza matrix peptide in blood samples from humans infected withinfluenza.

In this example the MHC multimer used are MHC complexes coupled to anyfluorophor-labelled multimerisation as described elsewhere herein. TheMHC multimers are used for direct detection of TCR in flow cytometry.The antigen origin is Influenza, thus, immune monitoring of influenza.

The MHC multimer used are MHC complexes coupled to labeled dextran.

MHC multimers carrying influenza specific peptides is in this exampleused to detect the presence of influenza specific T cells in the bloodof patients infected with influenza virus. Purified MHC-peptidecomplexes consisting of HLA-A*0201 heavy chain, human beta2microglobulinand peptide derived a region in influenza matrix peptide (Flu-MP) or anegative control peptide were generated by in vitro refolding andpurified or purified from antigen presenting cells. MHC-peptidecomplexes are then coupled to a multimerisation domain together withAPC.

The following MHC(peptide)/APC multimers are made:

-   -   20. APC-multimerisation domain coupled with HLA-A*0201 in        complex with beta2microglobulin and the peptide GILGFVFTL        derived from Flu-MP.    -   21. APC-multimerisation domain coupled with HLA-A*0201 in        complex with beta2microglobulin and the non-sense peptide        GLAGDVSAV.

The binding of the above described MHC(peptide)/APC multimers can beused to determine the presence of influenza specific T cells in theblood from influenza infected by flow cytometry following a standardflow cytometry protocol.

Blood from a influenza infected patient is isolated and 100 ul of thisblood is incubated with either of the MHC(peptide)/APC multimersdescribed above for 10 minutes in the dark at room temperature. 5 μl ofeach of each of the antibodies mouse-anti-human CD3/PB (clone UCHT1 fromDako) and mouse-anti-human CD8/PE (clone DK25 from Dako) are added andthe incubation continued for another 20 minutes at 4° C. in the dark.The samples are then washed by adding 2 ml PBS; pH=7.2 followed bycentrifugation for 5 minutes at 200×g and the supernatant removed. Thewashing step is repeated. The washed cells are resuspended in 400-500 μlPBS; pH=7.2 and analyzed on flowcytometer.

The presence of cells labeled with anti-CD3/PB, anti-CD8/PE and theMHC(peptide)/APC multimers 5 described above and thereby the presence ofinfluenza specific T cells will indicate that the patient are infectedwith influenza virus. Blood analysed with MHC(peptide)/APC multimer 6should show no staining of CD3 and CD8 positive cells with thisSA-MHC(peptide)/APC multimer.

The sensitivity of the above described test may be enhanced by additionof labeled antibodies specific for activation markers expressed in or onthe surface of the influenza specific T cells.

We conclude that the APC-multimerisation domain coupled MHC(peptide)constructs may be used to detect the presence of influenza specific Tcells in the blood of patients infected with influenza virus.

Example 52

This is an example of how MHC multimers may be used for detection ofMultiple sclerosis (MS) specific T cells in blood samples from MSpatients.

In this example the MHC multimer used are MHC complexes coupled tofluorophor-labelled dextran (Dextramers). The dextramers are used fordirect detection of TCR in flow Cytometry. The antigen origin is MS,thus, immune monitoring of MS.

MHC multimers carrying MS specific peptides is in this example used todetect the presence of MS specific T cells in the blood of MS patients.

Purified MHC-peptide complexes consisting of HLA-DR2 heavy chains andpeptide derived from a region in Myelin Basic Protein (MBP) in MS or anegative control peptide are generated as described elsewhere herein.Biotinylated MHC-peptide complexes are then coupled to a 270 kDa dextranmultimerization domain labelled with APC by interaction withstreptavidin (SA) on the dextran multimerization domain. Thedextran-APC-SA multimerization domain was generated as describedelsewhere herein. MHC-peptide complexes are added in an amountcorresponding to a ratio of three MHC-peptide molecules per SA moleculeand each molecule dextran contains 3.7 SA molecule and 8.95 moleculesAPC. The final concentration of dextran was 3.8×10e-8 M. The followingMHC(peptide)/APC dextran constructs are made:

-   -   22. APC-SA conjugated 270 kDa dextran coupled with HLA-DR2 in        complex with the peptide MBP 83-102 YDENPVVHFF KNIVTPRTPP        derived from Multiple sclerosis.    -   23. APC-SA conjugated 270 kDa dextran coupled with HLA-DR2 in        complex with the peptide MBP 144-163 VDAQGTLSKIFKLGGRDSRS        derived from Multiple sclerosis.    -   24. APC-SA conjugated 270 kDa dextran coupled with HLA-DR2 in        complex with a non-sense peptide.

The binding of the above described MHC(peptide)/APC dextran was used todetermine the presence of MS specific T cells in the blood from MSpatients by flow cytometry following a standard flow cytometry protocol.

Blood from a MS patient is isolated and 100 ul of this blood isincubated with 10 μl of the MHC(peptide)/APC dextran constructsdescribed above for 10 minutes in the dark at room temperature. 5 μl ofeach of each of the antibodies mouse-anti-human CD3/PB (clone UCHT1 fromDako), and mouse-anti-human CD4/PE (clone MT310 from Dako) are added andthe incubation continues for another 20 minutes at 4° C. in the dark.The samples are then washed by adding 2 ml PBS; pH=7.2 followed bycentrifugation for 5 minutes at 200×g and the supernatant removed. Thewashing step is repeated. The washed cells are resuspended in 400-500 μlPBS; pH=7.2 and analyzed on flowcytometer.

The presence of cells labeled with anti-CD3/PB, anti-CD4/PE and eitherof the MHC(peptide)/APC dextran construct 1 or 2 described above andthereby the presence of MS specific T cells in the blood. Blood analysedwith MHC(peptide)/APC dextran construct 3 show no staining of CD3 andCD4 positive cells with this MHC(peptide)/APC dextran construct.

The sensitivity of the above described test may be enhanced by additionof labeled antibodies specific for activation markers expressed in or onthe surface of the MS specific T cells.

We conclude that the MHC(peptide)/APC dextran constructs can be used todetect the presence of MS specific T cells in the blood of MS patients.

Example 53

This is an example of how MHC multimers may be used for detection ofMultiple sclerosis (MS) specific T cells in blood samples from MSpatients.

In this example the MHC multimer used are MHC complexes coupled tofluorophor-labelled multimerisation domain Streptavidin (SA, used fordirect detection of TCR in flow Cytometry. The antigen origin is MS,thus, immune monitoring of MS.

MHC multimers carrying MS specific peptides is in this example used todetect the presence of MS specific T cells in the blood of MS patients.

Purified MHC-peptide complexes consisting of HLA-DR2 heavy chains andpeptide derived from a region in Myelin Basic Protein (MBP) in MS or anegative control peptide are generated as described elsewhere herein.Biotinylated MHC-peptide complexes are then coupled SA labelled withAPC. MHC-peptide complexes are added in an amount corresponding to aratio of 5 MHC-peptide molecules per SA molecule. Then SA/APC carryingfour MHC complexes are purified from free SA, free monomeric MHCcomplex, SA carrying three, two and one MHC complexes.

The following SA-MHC(peptide)/APC tetramers are made:

-   -   25. APC-SA coupled with HLA-DR2 in complex with the peptide MBP        83-102 YDENPVVHFFKNIVTPRTPP derived from Multiple sclerosis.    -   26. APC-SA coupled with HLA-DR2 in complex with the peptide MBP        144-163 VDAQGTLSKIFKLGGRDSRS derived from Multiple sclerosis.    -   27. APC-SA coupled with HLA-DR2 in complex with a non-sense        peptide.

The binding of the above described MHC(peptide)/APC dextran can be usedto determine the presence of MS specific T cells in the blood from MSpatients by flow cytometry following a standard flow cytometry protocol.

Blood from a MS patient is isolated and 100 ul of this blood isincubated with either of the SA-MHC(peptide)/APC tetramers describedabove for 10 minutes in the dark at room temperature. 5 μl of each ofeach of the antibodies mouse-anti-human CD3/PB (clone UCHT1 from Dako)and mouse-anti-human CD4/PE (clone MT310 from Dako) are added and theincubation continued for another 20 minutes at 4° C. in the dark. Thesamples are then washed by adding 2 ml PBS; pH=7.2 followed bycentrifugation for 5 minutes at 200×g and the supernatant removed. Thewashing step is repeated. The washed cells are resuspended in 400-500 μlPBS; pH=7.2 and analyzed on flowcytometer.

The presence of cells labeled with anti-CD3/PB, anti-CD4/PE and eitherof the SA-MHC(peptide)/APC tetramers 4 or 5 described above and therebythe presence of MS specific T cells in the blood. Blood analysed withSA-MHC(peptide)/APC tetramers 6 should show no staining of CD3 and CD4positive cells with this SA-MHC(peptide)/APC tetramer.

The sensitivity of the above described test may be enhanced by additionof labeled antibodies specific for activation markers expressed in or onthe surface of the MS specific T cells.

We conclude that the APC-SA coupled MHC(peptide) constructs may be usedto detect the presence of MS specific T cells in the blood of MSpatients.

Example 54

This is an example of how MHC multimers may be used for detection ofMultiple sclerosis (MS) specific T cells in blood samples from MSpatients.

In this example the MHC multimer used are MHC complexes coupled to anyfluorophor-labelled multimerisation as described elsewhere herein. TheMHC multimers are used for direct detection of TCR in flow Cytometry.The antigen origin is MS, thus, immune monitoring of MS.

MHC multimers carrying MS specific peptides is in this example used todetect the presence of MS specific T cells in the blood of MS patients.

Purified MHC-peptide complexes consisting of HLA-DR2 heavy chains andpeptide derived from a region in Myelin Basic Protein (MBP) in MS or anegative control peptide are generated. MHC-peptide complexes are thencoupled to a multimerisation domain together with APC.

The following MHC(peptide)/APC multimers are made:

-   -   28. APC-multimerisation domain coupled with HLA-DR2 in complex        with the peptide MBP 83-102 YDENPVVHFFKNIVTPRTPP derived from        Multiple sclerosis.    -   29. APC-multimerisation domain coupled with HLA-DR2 in complex        with the peptide MBP 144-163 VDAQGTLSKIFKLGGRDSRS derived from        Multiple sclerosis.    -   30. APC-multimerisation domain coupled with HLA-DR2 in complex        with a non-sense peptide.

The binding of the above described MHC(peptide)/APC multimers can beused to determine the presence of MS specific T cells in the blood fromMS patients by flow cytometry following a standard flow cytometryprotocol.

Blood from a MS patient is isolated and 100 ul of this blood isincubated with either of the MHC(peptide)/APC multimers described abovefor 10 minutes in the dark at room temperature. 5 μl of each of each ofthe antibodies mouse-anti-human CD3/PB (clone UCHT1 from Dako) andmouse-anti-human CD4/PE (clone MT310 from Dako) are added and theincubation continued for another 20 minutes at 4° C. in the dark. Thesamples are then washed by adding 2 ml PBS; pH=7.2 followed bycentrifugation for 5 minutes at 200×g and the supernatant removed. Thewashing step is repeated. The washed cells are resuspended in 400-500 μlPBS; pH=7.2 and analyzed on flowcytometer.

The presence of cells labeled with anti-CD3/PB, anti-CD4/PE and eitherof the MHC(peptide)/APC multimers 7 or 8 described above and thereby thepresence of MS specific T cells in the blood. Blood analysed withMHC(peptide)/APC multimer 9 should show no staining of CD3 and CD4positive cells with this SA-MHC(peptide)/APC multimer.

The sensitivity of the above described test may be enhanced by additionof labeled antibodies specific for activation markers expressed in or onthe surface of the MS specific T cells.

We conclude that the APC-multimerisation domain coupled MHC(peptide)constructs may be used to detect the presence of MS specific T cells inthe blood of MS patients.

Example 55

This is an example of how MHC multimers may be used for detection ofRheumatoid arthritis (RA) specific T cells in blood samples from RApatients.

In this example the MHC multimer used are MHC complexes coupled tofluorophor-labelled dextran (Dextramers). The dextramers are used fordirect detection of TCR in flow cytometry. The antigen origin is RA,thus, immune monitoring of RA.

MHC multimers carrying RA specific peptides is in this example used todetect the presence of RA specific T cells in the blood of MS patients.

Purified MHC-peptide complexes consisting of HLA-DR4 heavy chains andpeptide derived from a region in Collagen Type II (CII) in RA or anegative control peptide are generated as described elsewhere herein.Biotinylated MHC-peptide complexes are then coupled to a 270 kDa dextranmultimerization domain labelled with APC by interaction withstreptavidin (SA) on the dextran multimerization domain. Thedextran-APC-SA multimerization domain was generated as describedelsewhere herein. MHC-peptide complexes are added in an amountcorresponding to a ratio of three MHC-peptide molecules per SA moleculeand each molecule dextran contains 3.7 SA molecule and 8.95 moleculesAPC. The final concentration of dextran was 3.8×10e-8 M. The followingMHC(peptide)/APC dextran constructs are made:

-   -   31. APC-SA conjugated 270 kDa dextran coupled with HLA-DR4 in        complex with the peptide CII 261-273 AGFKGEQGPKGEP derived from        Rheumatoid arthritis    -   32. APC-SA conjugated 270 kDa dextran coupled with HLA-DR4 in        complex with a non-sense peptide.

The binding of the above described MHC(peptide)/APC dextran was used todetermine the presence of RA specific T cells in the blood from RApatients by flow cytometry following a standard flow cytometry protocol.

Blood from a RA patient is isolated and 100 ul of this blood isincubated with 10 μl of the MHC(peptide)/APC dextran constructsdescribed above for 10 minutes in the dark at room temperature. 5 μl ofeach of each of the antibodies mouse-anti-human CD3/PB (clone UCHT1 fromDako), and mouse-anti-human CD4/PE (clone MT310 from Dako) are added andthe incubation continues for another 20 minutes at 4° C. in the dark.The samples are then washed by adding 2 ml PBS; pH=7.2 followed bycentrifugation for 5 minutes at 200×g and the supernatant removed. Thewashing step is repeated. The washed cells are resuspended in 400-500 μlPBS; pH=7.2 and analyzed on flowcytometer.

The presence of cells labeled with anti-CD3/PB, anti-CD4/PE and theMHC(peptide)/APC dextran construct 1 described above and thereby thepresence of RA specific T cells in the blood. Blood analysed withMHC(peptide)/APC dextran construct 2 show no staining of CD3 and CD4positive cells with this MHC(peptide)/APC dextran construct.

The sensitivity of the above described test may be enhanced by additionof labeled antibodies specific for activation markers expressed in or onthe surface of the RA specific T cells.

We conclude that the MHC(peptide)/APC dextran constructs can be used todetect the presence of RA specific T cells in the blood of RA patients.

Example 56

This is an example of how MHC multimers may be used for detection ofRheumatoid arthritis (RA) specific T cells in blood samples from RApatients In this example the MHC multimer used are MHC complexes coupledto fluorophor-labelled multimerisation domain Streptavidin (SA), usedfor direct detection of TCR in flow cytometry. The antigen origin is RA,thus, immune monitoring of RA.

MHC multimers carrying RA specific peptides is in this example used todetect the presence of RA specific T cells in the blood of RA patients.

Purified MHC-peptide complexes consisting of HLA-DR4 heavy chains andpeptide derived from a region in Collagen type II (CII) in RA or anegative control peptide are generated as described elsewhere herein.Biotinylated MHC-peptide complexes are then coupled SA labelled withAPC. MHC-peptide complexes are added in an amount corresponding to aratio of 5 MHC-peptide molecules per SA molecule. Then SA/APC carryingfour MHC complexes are purified from free SA, free monomeric MHCcomplex, SA carrying three, two and one MHC complexes.

The following SA-MHC(peptide)/APC tetramers are made:

-   -   33. APC-SA coupled with HLA-DR4 in complex with the peptide CII        261-273 AGFKGEQGPKGEP derived from Rheumatoid arthritis.    -   34. APC-SA coupled with HLA-DR4 in complex with a non-sense        peptide.

The binding of the above described MHC(peptide)/APC dextran can be usedto determine the presence of RA specific T cells in the blood from RApatients by flow cytometry following a standard flow cytometry protocol.

Blood from a RA patient is isolated and 100 ul of this blood isincubated with either of the SA-MHC(peptide)/APC tetramers describedabove for 10 minutes in the dark at room temperature. 5 μl of each ofeach of the antibodies mouse-anti-human CD3/PB (clone UCHT1 from Dako)and mouse-anti-human CD4/PE (clone MT310 from Dako) are added and theincubation continued for another 20 minutes at 4° C. in the dark. Thesamples are then washed by adding 2 ml PBS; pH=7.2 followed bycentrifugation for 5 minutes at 200×g and the supernatant removed. Thewashing step is repeated. The washed cells are resuspended in 400-500 μlPBS; pH=7.2 and analyzed on flowcytometer.

The presence of cells labeled with anti-CD3/PB, anti-CD4/PE and theSA-MHC(peptide)/APC tetramers 3 described above and thereby the presenceof RA specific T cells in the blood. Blood analysed withSA-MHC(peptide)/APC tetramers 4 should show no staining of CD3 and CD4positive cells with this SA-MHC(peptide)/APC tetramer.

The sensitivity of the above described test may be enhanced by additionof labeled antibodies specific for activation markers expressed in or onthe surface of the RA specific T cells.

We conclude that the APC-SA coupled MHC(peptide) constructs may be usedto detect the presence of RA specific T cells in the blood of RApatients.

Example 57

This is an example of how MHC multimers may be used for detection ofRheumatoid arthritis (RA) specific T cells in blood samples from RApatients.

In this example the MHC multimer used are MHC complexes coupled to anyfluorophor-labelled multimerisation as described elsewhere herein. TheMHC multimers are used for direct detection of TCR in flow cytometry.The antigen origin is RA, thus, immune monitoring of RA. MHC multimerscarrying RA specific peptides is in this example used to detect thepresence of RA specific T cells in the blood of MS patients.

This is an example of how MHC multimers may be used for detection ofRheumatoid arthritis (RA) specific T cells in blood samples from RApatients. The MHC multimer used are MHC complexes coupled to

MHC multimers carrying RA specific peptides is in this example used todetect the presence of RA specific T cells in the blood of RA patients.

Purified MHC-peptide complexes consisting of HLA-DR4 heavy chains andpeptide derived from a region in Myelin Basic Protein (MBP) in MS or anegative control peptide are generated. MHC-peptide complexes are thencoupled to a multimerisation domain together with APC.

The following MHC(peptide)/APC multimers are made:

-   -   35. APC-multimerisation domain coupled with HLA-DR4 in complex        with the peptide CII 261-273 AGFKGEQGPKGEP derived from        Rheumatoid arthritis.    -   36. APC-multimerisation domain coupled with HLA-DR4 in complex        with a non-sense peptide.

The binding of the above described MHC(peptide)/APC multimers can beused to determine the presence of RA specific T cells in the blood fromRA patients by flow cytometry following a standard flow cytometryprotocol.

Blood from a RA patient is isolated and 100 ul of this blood isincubated with either of the MHC(peptide)/APC multimers described abovefor 10 minutes in the dark at room temperature. 5 μl of each of each ofthe antibodies mouse-anti-human CD3/PB (clone UCHT1 from Dako) andmouse-anti-human CD4/PE (clone MT310 from Dako) are added and theincubation continued for another 20 minutes at 4° C. in the dark. Thesamples are then washed by adding 2 ml PBS; pH=7.2 followed bycentrifugation for 5 minutes at 200×g and the supernatant removed. Thewashing step is repeated. The washed cells are resuspended in 400-500 μlPBS; pH=7.2 and analyzed on flowcytometer.

The presence of cells labeled with anti-CD3/PB, anti-CD4/PE and theMHC(peptide)/APC multimers 5 described above and thereby the presence ofRA specific T cells in the blood. Blood analysed with MHC(peptide)/APCmultimer 6 should show no staining of CD3 and CD4 positive cells withthis SA-MHC(peptide)/APC multimers.

The sensitivity of the above described test may be enhanced by additionof labeled antibodies specific for activation markers expressed in or onthe surface of the RA specific T cells.

We conclude that the APC-multimerisation domain coupled MHC(peptide)constructs may be used to detect the presence of RA specific T cells inthe blood of RA patients.

Example 58

This is an example of how MHC multimers may be used for diagnosis ofTuberculosis (TB) in blood samples from humans infected withMycobacterium tuberculosis.

In this example the MHC multimer used are MHC complexes coupled tofluorophor-labelled dextran (Dextramers). The dextramers are used fordirect detection of TCR in flow cytometry. The antigen origin is TB,thus, immune monitoring of TB.

TB is caused by infection by Mycobacterium tuberculosis. During acuteinfection TB specific activated T cells will be present in increasedamounts in an activated state compared to healthy individuals. Thepresences of an increased amount of activated TB specific T cells maythereby act as a surrogate marker for infection with Mycobacteriumtuberculosis. MHC multimers carrying TB specific peptides is in thisexample used to detect the presence of TB specific T cells in the bloodof patients infected with Mycobacterium tuberculosis.

Purified MHC-peptide complexes consisting of HLA-A*0201 heavy chain,human beta2microglobulin and peptide derived from regions inMycobacterium tuberculosis Antigen 85B (Ag85B) or a negative controlpeptide are generated by in vitro refolding, purified and biotinylatedas described elsewhere herein. Biotinylated MHC-peptide complexes arethen coupled to a 270 kDa dextran multimerization domain labelled withAPC by interaction with streptavidin (SA) on the dextran multimerizationdomain. The dextran-APC-SA multimerization domain is generated asdescribed elsewhere herein. MHC-peptide complexes are added in an amountcorresponding to a ratio of three MHC-peptide molecules per SA moleculeand each molecule dextran contained 3.7 SA molecule and 8.95 moleculesAPC. The final concentration of dextran was 3.8×10e-8 M. The followingMHC(peptide)/APC dextran constructs are made:

-   -   37. APC-SA conjugated 270 kDa dextran coupled with HLA-A*0201 in        complex with beta2microglobulin and the peptide KLVANNTRL        derived from Ag85B.    -   38. APC-SA conjugated 270 kDa dextran coupled with HLA-A*0201 in        complex with beta2microglobulin and the peptide YLLDGLRAQ        derived from Ag85B.    -   39. APC-SA conjugated 270 kDa dextran coupled with HLA-A*0201 in        complex with beta2microglobulin and the peptide FLTSELPQW        derived from Ag85B.    -   40. APC-SA conjugated 270 kDa dextran coupled with HLA-A*0201 in        complex with beta2microglobulin and the non-sense peptide        GLAGDVSAV.

The binding of the above described MHC(peptide)/APC dextran can be usedto determine the presence of Ag85B specific T cells in the blood from TBinfected individuals by flow cytometry following a standard flowcytometry protocol.

Blood from a patient with TB is isolated and 100 ul of this blood isincubated with 10 μl of one of the MHC(peptide)/APC dextran constructsdescribed above for 10 minutes in the dark at room temperature. 5 μl ofeach of each of the antibodies mouse-anti-human CD3/PB (clone UCHT1 fromDako) and mouse-anti-human CD8/PE (clone DK25 from Dako) are added andthe incubation continued for another 20 minutes at 4° C. in the dark.The samples are then washed by adding 2 ml PBS; pH=7.2 followed bycentrifugation for 5 minutes at 200×g and the supernatant removed. Thewashing step is repeated. The washed cells are resuspended in 400-500 μlPBS; pH=7.2 and analyzed on flowcytometer.

The presence of cells labeled with anti-CD3/PB, anti-CD8/PE and eitherof the MHC(peptide)/APC dextran constructs 1, 2 or 3 described above andthereby the presence of TB specific T cells will indicate that thepatient are infected with Mycobacterium tuberculosis. Blood analysedwith MHC(peptide)/APC dextran construct 4 should show no staining of CD3and CD8 positive cells with this MHC(peptide)/APC dextran construct.

The sensitivity of the above described diagnostic test may be enhancedby addition of labeled antibodies specific for activation markersexpressed in or on the surface of the TB specific T cells.

We conclude that the MHC(peptide)/APC dextran constructs can be used todetect the presence of TB specific T cells in the blood of patientsinfected with Mycobacterium tuberculosis.

Example 59

This is an example of how MHC multimers may be used for diagnosis ofTuberculosis (TB) in blood samples from humans infected withMycobacterium tuberculosis.

In this example the MHC multimer used are MHC complexes coupled tofluorophor-labelled the multimerisation domain Streptavidin (SA), usedfor direct detection of TCR in flow cytometry. The antigen origin is TB,thus, immune monitoring of TB.

TB is caused by infection by Mycobacterium tuberculosis. During acuteinfection TB specific activated T cells will be present in increasedamounts in an activated state compared to healthy individuals. Thepresences of an increased amount of activated TB specific T cells maythereby act as a surrogate marker for infection with Mycobacteriumtuberculosis. MHC multimers carrying TB specific peptides is in thisexample used to detect the presence of TB specific T cells in the bloodof patients infected with Mycobacterium tuberculosis.

Purified MHC-peptide complexes consisting of HLA-A*0201 heavy chain,human beta2microglobulin and peptide derived from regions inMycobacterium tuberculosis Antigen 85B (Ag85B) or a negative controlpeptide were generated by in vitro refolding, purified and biotinylatedas described elsewhere herein. Biotinylated MHC-peptide complexes arethen coupled SA labelled with APC. MHC-peptide complexes were added inan amount corresponding to a ratio of 5 MHC-peptide molecules per SAmolecule. Then SA/APC carrying four MHC complexes were purified fromfree SA, free monomeric MHC complex, SA carrying three, two and one MHCcomplexes.

The following SA-MHC(peptide)/APC tetramers are made:

-   -   41. APC-SA coupled with HLA-A*0201 in complex with        beta2microglobulin and the peptide KLVANNTRL derived from Ag85B.    -   42. APC-SA coupled with HLA-A*0201 in complex with        beta2microglobulin and the peptide YLLDGLRAQ derived from Ag85B.    -   43. APC-SA coupled with HLA-A*0201 in complex with        beta2microglobulin and the peptide FLTSELPQW derived from Ag85B.    -   44. APC-SA coupled with HLA-A*0201 in complex with        beta2microglobulin and the non-sense peptide GLAGDVSAV

The binding of the above described MHC(peptide)/APC dextran can be usedto determine the presence of Ag85B specific T cells in the blood from TBinfected individuals by flow cytometry following a standard flowcytometry protocol.

Blood from a patient with TB is isolated and 100 ul of this blood isincubated with either of the four SA-MHC(peptide)/APC tetramersdescribed above for 10 minutes in the dark at room temperature. 5 μl ofeach of each of the antibodies mouse-anti-human CD3/PB (clone UCHT1 fromDako) and mouse-anti-human CD8/PE (clone DK25 from Dako) are added andthe incubation continued for another 20 minutes at 4° C. in the dark.The samples are then washed by adding 2 ml PBS; pH=7.2 followed bycentrifugation for 5 minutes at 200×g and the supernatant removed. Thewashing step is repeated. The washed cells are resuspended in 400-500 μlPBS; pH=7.2 and analyzed on flowcytometer.

The presence of cells labeled with anti-CD3/PB, anti-CD8/PE and eitherof the SA-MHC(peptide)/APC tetramers 5, 6 or 7 described above andthereby the presence of TB specific T cells will indicate that thepatient are infected with Mycobacterium tuberculosis. Blood analysedwith SA-MHC(peptide)/APC tetramers 8 should show no staining of CD3 andCD8 positive cells with this SA-MHC(peptide)/APC tetramer.

The sensitivity of the above described diagnostic test may be enhancedby addition of labeled antibodies specific for activation markersexpressed in or on the surface of the TB specific T cells.

We conclude that the MHC(peptide)/APC dextran constructs can be used todetect the presence of TB specific T cells in the blood of patientsinfected with Mycobacterium tuberculosis.

Example 60

This is an example of how MHC multimers may be used for diagnosis ofTuberculosis (TB) in blood samples from humans infected withMycobacterium tuberculosis.

In this example the MHC multimer used are MHC complexes coupled to anyfluorophor-labelled multimerisation as described elsewhere herein. TheMHC multimers are used for direct detection of TCR in flow cytometry.The antigen origin is TB, thus, immune monitoring of TB. TB is caused byinfection by Mycobacterium tuberculosis. During acute infection TBspecific activated T cells will be present in increased amounts in anactivated state compared to healthy individuals. The presences of anincreased amount of activated TB specific T cells may thereby act as asurrogate marker for infection with Mycobacterium tuberculosis. MHCmultimers carrying TB specific peptides is in this example used todetect the presence of TB specific T cells in the blood of patientsinfected with Mycobacterium tuberculosis.

This is an example of how MHC multimers may be used for diagnosis ofTuberculosis (TB) in blood samples from humans infected withMycobacterium tuberculosis. The MHC multimer used are MHC complexescoupled to

TB is caused by infection by Mycobacterium tuberculosis. During acuteinfection TB specific activated T cells will be present in increasedamounts in an activated state compared to healthy individuals. Thepresences of an increased amount of activated TB specific T cells maythereby act as a surrogate marker for infection with Mycobacteriumtuberculosis. MHC multimers carrying TB specific peptides is in thisexample used to detect the presence of TB specific T cells in the bloodof patients infected with Mycobacterium tuberculosis.

Purified MHC-peptide complexes consisting of HLA-A*0201 heavy chain,human beta2microglobulin and peptide derived from regions inMycobacterium tuberculosis Antigen 85B (Ag85B) or a negative controlpeptide are generated by in vitro refolding and purified or purifiedfrom antigen presenting cells. MHC-peptide complexes are then coupled toa multimerisation domain together with APC.

The following MHC(peptide)/APC multimers are made:

-   -   45. APC-multimerisation domain coupled with HLA-A*0201 in        complex with beta2microglobulin and the peptide KLVANNTRL        derived from Ag85B.    -   46. APC-multimerisation domain coupled with HLA-A*0201 in        complex with beta2microglobulin and the peptide YLLDGLRAQ        derived from Ag85B.    -   47. APC-multimerisation domain coupled with HLA-A*0201 in        complex with beta2microglobulin and the peptide FLTSELPQW        derived from Ag85B.    -   48. APC-multimerisation domain coupled with HLA-A*0201 in        complex with beta2microglobulin and the non-sense peptide        GLAGDVSAV

The binding of the above described MHC(peptide)/APC multimers can beused to determine the presence of Ag85B specific T cells in the bloodfrom TB infected individuals by flow cytometry following a standard flowcytometry protocol.

Blood from a patient with TB is isolated and 100 ul of this blood isincubated with either of the four MHC(peptide)/APC multimers describedabove for 10 minutes in the dark at room temperature. 5 μl of each ofeach of the antibodies mouse-anti-human CD3/PB (clone UCHT1 from Dako)and mouse-anti-human CD8/PE (clone DK25 from Dako) are added and theincubation continued for another 20 minutes at 4° C. in the dark. Thesamples are then washed by adding 2 ml PBS; pH=7.2 followed bycentrifugation for 5 minutes at 200×g and the supernatant removed. Thewashing step is repeated. The washed cells are resuspended in 400-500 μlPBS; pH=7.2 and analyzed on flowcytometer.

The presence of cells labeled with anti-CD3/PB, anti-CD8/PE and eitherof the MHC(peptide)/APC multimers 9, 10 or 11 described above andthereby the presence of TB specific T cells will indicate that thepatient are infected with Mycobacterium tuberculosis. Blood analysedwith MHC(peptide)/APC multimer 12 should show no staining of CD3 and CD8positive cells with this SA-MHC(peptide)/APC multimer.

The sensitivity of the above described diagnostic test may be enhancedby addition of labeled antibodies specific for activation markersexpressed in or on the surface of the TB specific T cells.

We conclude that the MHC(peptide)/APC dextran constructs can be used todetect the presence of TB specific T cells in the blood of patientsinfected with Mycobacterium tuberculosis.

Example 61

This is an example of how MHC multimers may be used for diagnosis ofTuberculosis (TB) in blood samples from humans infected withMycobacterium tuberculosis.

In this example the MHC multimer used are MHC complexes coupled tofluorophor-labelled dextran (Dextramers). The dextramers are used fordirect detection of TCR in flow cytometry. The antigen origin is TB,thus, immune monitoring of TB.

TB is caused by infection by Mycobacterium tuberculosis. During acuteinfection TB specific activated T cells will be present in increasedamounts in an activated state compared to healthy individuals. Thepresences of an increased amount of activated TB specific T cells maythereby act as a surrogate marker for infection with Mycobacteriumtuberculosis. MHC multimers carrying TB specific peptides is in thisexample used to detect the presence of TB specific T cells in the bloodof patients infected with Mycobacterium tuberculosis.

Purified MHC-peptide complexes consisting of HLA-B*0801 heavy chain,human beta2microglobulin and peptide derived from regions inMycobacterium tuberculosis Antigen 85B (Ag85B) or a negative controlpeptide are generated by in vitro refolding, purified and biotinylatedas described elsewhere herein. Biotinylated MHC-peptide complexes arethen coupled to a 270 kDa dextran multimerization domain labelled withAPC by interaction with streptavidin (SA) on the dextran multimerizationdomain. The dextran-APC-SA multimerization domain is generated asdescribed elsewhere herein. MHC-peptide complexes are added in an amountcorresponding to a ratio of three MHC-peptide molecules per SA moleculeand each molecule dextran contained 3.7 SA molecule and 8.95 moleculesAPC. The final concentration of dextran was 3.8×10e-8 M. The followingMHC(peptide)/APC dextran constructs are made:

-   -   49. APC-SA conjugated 270 kDa dextran coupled with HLA-B*0801 in        complex with beta2microglobulin and the peptide MGRDIKVQF        derived from Ag85B.    -   50. APC-SA conjugated 270 kDa dextran coupled with HLA-B*0801 in        complex with beta2microglobulin and the peptide DIKVQFQSG        derived from Ag85B.    -   51. APC-SA conjugated 270 kDa dextran coupled with HLA-B*0801 in        complex with beta2microglobulin and the peptide ENFVRSSNL        derived from Ag85B.    -   52. APC-SA conjugated 270 kDa dextran coupled with HLA-B*0801 in        complex with beta2microglobulin and the non-sense peptide.

The binding of the above described MHC(peptide)/APC dextran can be usedto determine the presence of Ag85B specific T cells in the blood from TBinfected individuals by flow cytometry following a standard flowcytometry protocol.

Blood from a patient with TB is isolated and 100 ul of this blood isincubated with 10 μl of one of the MHC(peptide)/APC dextran constructsdescribed above for 10 minutes in the dark at room temperature. 5 μl ofeach of each of the antibodies mouse-anti-human CD3/PB (clone UCHT1 fromDako) and mouse-anti-human CD8/PE (clone DK25 from Dako) are added andthe incubation continued for another 20 minutes at 4° C. in the dark.The samples are then washed by adding 2 ml PBS; pH=7.2 followed bycentrifugation for 5 minutes at 200×g and the supernatant removed. Thewashing step is repeated. The washed cells are resuspended in 400-500 μlPBS; pH=7.2 and analyzed on flowcytometer.

The presence of cells labeled with anti-CD3/PB, anti-CD8/PE and eitherof the MHC(peptide)/APC dextran constructs 13, 14 or 15 described aboveand thereby the presence of TB specific T cells will indicate that thepatient are infected with Mycobacterium tuberculosis. Blood analysedwith MHC(peptide)/APC dextran construct 16 should show no staining ofCD3 and CD8 positive cells with this MHC(peptide)/APC dextran construct.

The sensitivity of the above described diagnostic test may be enhancedby addition of labeled antibodies specific for activation markersexpressed in or on the surface of the TB specific T cells.

We conclude that the MHC(peptide)/APC dextran constructs can be used todetect the presence of TB specific T cells in the blood of patientsinfected with Mycobacterium tuberculosis.

Example 62

This is an example of how MHC multimers may be used for diagnosis ofTuberculosis (TB) in blood samples from humans infected withMycobacterium tuberculosis.

In this example the MHC multimer used are MHC complexes coupled tofluorophor-labelled the multimerisation domain Streptavidin (SA), usedfor direct detection of TCR in flow cytometry. The antigen origin is TB,thus, immune monitoring of TB.

TB is caused by infection by Mycobacterium tuberculosis. During acuteinfection TB specific activated T cells will be present in increasedamounts in an activated state compared to healthy individuals. Thepresences of an increased amount of activated TB specific T cells maythereby act as a surrogate marker for infection with Mycobacteriumtuberculosis. MHC multimers carrying TB specific peptides is in thisexample used to detect the presence of TB specific T cells in the bloodof patients infected with Mycobacterium tuberculosis.

Purified MHC-peptide complexes consisting of HLA-A*0201 heavy chain,human beta2microglobulin and peptide derived from regions inMycobacterium tuberculosis Antigen 85B (Ag85B) or a negative controlpeptide were generated by in vitro refolding, purified and biotinylatedas described elsewhere herein. Biotinylated MHC-peptide complexes arethen coupled SA labelled with APC. MHC-peptide complexes were added inan amount corresponding to a ratio of 5 MHC-peptide molecules per SAmolecule. Then SA/APC carrying four MHC complexes were purified fromfree SA, free monomeric MHC complex, SA carrying three, two and one MHCcomplexes.

The following SA-MHC(peptide)/APC tetramers are made:

-   -   53. APC-SA coupled with HLA-B*0801 in complex with        beta2microglobulin and the peptide MGRDIKVQF derived from Ag85B.    -   54. APC-SA coupled with HLA-B*0801 in complex with        beta2microglobulin and the peptide DIKVQFQSG derived from Ag85B.    -   55. APC-SA coupled with HLA-B*0801 in complex with        beta2microglobulin and the peptide ENFVRSSNL derived from Ag85B.    -   56. APC-SA coupled with HLA-B*0801 in complex with        beta2microglobulin and the non-sense peptide.

The binding of the above described MHC(peptide)/APC dextran can be usedto determine the presence of Ag85B specific T cells in the blood from TBinfected individuals by flow cytometry following a standard flowcytometry protocol.

Blood from a patient with TB is isolated and 100 ul of this blood isincubated with either of the four SA-MHC(peptide)/APC tetramersdescribed above for 10 minutes in the dark at room temperature. 5 μl ofeach of each of the antibodies mouse-anti-human CD3/PB (clone UCHT1 fromDako) and mouse-anti-human CD8/PE (clone DK25 from Dako) are added andthe incubation continued for another 20 minutes at 4° C. in the dark.The samples are then washed by adding 2 ml PBS; pH=7.2 followed bycentrifugation for 5 minutes at 200×g and the supernatant removed. Thewashing step is repeated. The washed cells are resuspended in 400-500 μlPBS; pH=7.2 and analyzed on flowcytometer.

The presence of cells labeled with anti-CD3/PB, anti-CD8/PE and eitherof the SA-MHC(peptide)/APC tetramers 17, 18 or 19 described above andthereby the presence of TB specific T cells will indicate that thepatient are infected with Mycobacterium tuberculosis. Blood analysedwith SA-MHC(peptide)/APC tetramers 20 should show no staining of CD3 andCD8 positive cells with this SA-MHC(peptide)/APC tetramer.

The sensitivity of the above described diagnostic test may be enhancedby addition of labeled antibodies specific for activation markersexpressed in or on the surface of the TB specific T cells.

We conclude that the MHC(peptide)/APC dextran constructs can be used todetect the presence of TB specific T cells in the blood of patientsinfected with Mycobacterium tuberculosis.

Example 63

This is an example of how MHC multimers may be used for diagnosis ofTuberculosis (TB) in blood samples from humans infected withMycobacterium tuberculosis. In this example the MHC multimer used areMHC complexes coupled to any fluorophor-labelled multimerisation asdescribed elsewhere herein. The MHC multimers are used for directdetection of TCR in flow cytometry. The antigen origin is TB, thus,immune monitoring of TB. TB is caused by infection by Mycobacteriumtuberculosis. During acute infection TB specific activated T cells willbe present in increased amounts in an activated state compared tohealthy individuals. The presences of an increased amount of activatedTB specific T cells may thereby act as a surrogate marker for infectionwith Mycobacterium tuberculosis. MHC multimers carrying TB specificpeptides is in this example used to detect the presence of TB specific Tcells in the blood of patients infected with Mycobacterium tuberculosis.

Purified MHC-peptide complexes consisting of HLA-B*0801 heavy chain,human beta2microglobulin and peptide derived from regions inMycobacterium tuberculosis Antigen 85B (Ag85B) or a negative controlpeptide are generated by in vitro refolding and purified or purifiedfrom antigen presenting cells. MHC-peptide complexes are then coupled toa multimerisation domain together with APC.

The following MHC(peptide)/APC multimers are made:

-   -   57. APC-multimerisation domain coupled with HLA-B*0801 in        complex with beta2microglobulin and the peptide MGRDIKVQF        derived from Ag85B.    -   58. APC-multimerisation domain coupled with HLA-B*0801 in        complex with beta2microglobulin and the peptide DIKVQFQSG        derived from Ag85B.    -   59. APC-multimerisation domain coupled with HLA-B*0801 in        complex with beta2microglobulin and the peptide ENFVRSSNL        derived from Ag85B.    -   60. APC-multimerisation domain coupled with HLA-B*0801 in        complex with beta2microglobulin and the non-sense peptide.

The binding of the above described MHC(peptide)/APC multimers can beused to determine the presence of Ag85B specific T cells in the bloodfrom TB infected individuals by flow cytometry following a standard flowcytometry protocol.

Blood from a patient with TB is isolated and 100 ul of this blood isincubated with either of the four MHC(peptide)/APC multimers describedabove for 10 minutes in the dark at room temperature. 5 μl of each ofeach of the antibodies mouse-anti-human CD3/PB (clone UCHT1 from Dako)and mouse-anti-human CD8/PE (clone DK25 from Dako) are added and theincubation continued for another 20 minutes at 4° C. in the dark. Thesamples are then washed by adding 2 ml PBS; pH=7.2 followed bycentrifugation for 5 minutes at 200×g and the supernatant removed. Thewashing step is repeated. The washed cells are resuspended in 400-500 μlPBS; pH=7.2 and analyzed on flowcytometer.

The presence of cells labeled with anti-CD3/PB, anti-CD8/PE and eitherof the MHC(peptide)/APC multimers 21, 22 or 23 described above andthereby the presence of TB specific T cells will indicate that thepatient are infected with Mycobacterium tuberculosis. Blood analysedwith MHC(peptide)/APC multimer 24 should show no staining of CD3 and CD8positive cells with this SA-MHC(peptide)/APC multimer.

The sensitivity of the above described diagnostic test may be enhancedby addition of labeled antibodies specific for activation markersexpressed in or on the surface of the TB specific T cells.

We conclude that the MHC(peptide)/APC dextran constructs can be used todetect the presence of TB specific T cells in the blood of patientsinfected with Mycobacterium tuberculosis.

Example 64

This is an example of how MHC multimers may be used for diagnosis ofTuberculosis (TB) in blood samples from humans infected withMycobacterium tuberculosis.

In this example the MHC multimer used are MHC complexes coupled tofluorophor-labelled dextran (Dextramers). The dextramers are used fordirect detection of TCR in flow cytometry. The antigen origin is TB,thus, immune monitoring of TB.

TB is caused by infection by Mycobacterium tuberculosis. During acuteinfection TB specific activated T cells will be present in increasedamounts in an activated state compared to healthy individuals. Thepresences of an increased amount of activated TB specific T cells maythereby act as a surrogate marker for infection with Mycobacteriumtuberculosis. MHC multimers carrying TB specific peptides is in thisexample used to detect the presence of TB specific T cells in the bloodof patients infected with Mycobacterium tuberculosis.

Purified MHC-peptide complexes consisting of HLA-B*44 heavy chain, humanbeta2microglobulin and peptide derived from regions in antigen Mtb39 ora negative control peptide are generated by in vitro refolding, purifiedand biotinylated as described elsewhere herein. Biotinylated MHC-peptidecomplexes are then coupled to a 270 kDa dextran multimerization domainlabelled with APC by interaction with streptavidin (SA) on the dextranmultimerization domain. The dextran-APC-SA multimerization domain isgenerated as described elsewhere herein. MHC-peptide complexes are addedin an amount corresponding to a ratio of three MHC-peptide molecules perSA molecule and each molecule dextran contained 3.7 SA molecule and 8.95molecules APC. The final concentration of dextran was 3.8×10e-8 M. Thefollowing MHC(peptide)/APC dextran constructs are made:

-   -   61. APC-SA conjugated 270 kDa dextran coupled with HLA-B*44 in        complex with beta2microglobulin and the peptide MWAQDAAAMF        derived from Mtb39.    -   62. APC-SA conjugated 270 kDa dextran coupled with HLA-B*44 in        complex with beta2microglobulin and the peptide AAERGPGQML        derived from Mtb39.    -   63. APC-SA conjugated 270 kDa dextran coupled with HLA-B*44 in        complex with beta2microglobulin and the non-sense peptide.

The binding of the above described MHC(peptide)/APC dextran can be usedto determine the presence of Mtb39 specific T cells in the blood from TBinfected individuals by flow cytometry following a standard flowcytometry protocol.

Blood from a patient with TB is isolated and 100 ul of this blood isincubated with 10 μl of one of the MHC(peptide)/APC dextran constructsdescribed above for 10 minutes in the dark at room temperature. 5 μl ofeach of each of the antibodies mouse-anti-human CD3/PB (clone UCHT1 fromDako) and mouse-anti-human CD8/PE (clone DK25 from Dako) are added andthe incubation continued for another 20 minutes at 4° C. in the dark.The samples are then washed by adding 2 ml PBS; pH=7.2 followed bycentrifugation for 5 minutes at 200×g and the supernatant removed. Thewashing step is repeated. The washed cells are resuspended in 400-500 μlPBS; pH=7.2 and analyzed on flowcytometer.

The presence of cells labeled with anti-CD3/PB, anti-CD8/PE and eitherof the MHC(peptide)/APC dextran constructs 25 or 26 described above andthereby the presence of TB specific T cells will indicate that thepatient are infected with Mycobacterium tuberculosis. Blood analysedwith MHC(peptide)/APC dextran construct 27 should show no staining ofCD3 and CD8 positive cells with this MHC(peptide)/APC dextran construct.

The sensitivity of the above described diagnostic test may be enhancedby addition of labeled antibodies specific for activation markersexpressed in or on the surface of the TB specific T cells.

We conclude that the MHC(peptide)/APC dextran constructs can be used todetect the presence of TB specific T cells in the blood of patientsinfected with Mycobacterium tuberculosis.

Example 65

This is an example of how MHC multimers may be used for diagnosis ofTuberculosis (TB) in blood samples from humans infected withMycobacterium tuberculosis. In this example the MHC multimer used areMHC complexes coupled to fluorophor-labelled the multimerisation domainStreptavidin (SA), used for direct detection of TCR in flow cytometry.The antigen origin is TB, thus, immune monitoring of TB. TB is caused byinfection by Mycobacterium tuberculosis. During acute infection TBspecific activated T cells will be present in increased amounts in anactivated state compared to healthy individuals. The presences of anincreased amount of activated TB specific T cells may thereby act as asurrogate marker for infection with Mycobacterium tuberculosis. MHCmultimers carrying TB specific peptides is in this example used todetect the presence of TB specific T cells in the blood of patientsinfected with Mycobacterium tuberculosis.

Purified MHC-peptide complexes consisting of HLA-B*44 heavy chain, humanbeta2microglobulin and peptide derived from regions in antigen Mtb39 ora negative control peptide are generated by in vitro refolding, purifiedand biotinylated as described elsewhere herein. Biotinylated MHC-peptidecomplexes are then coupled SA labelled with APC. MHC-peptide complexesare added in an amount corresponding to a ratio of 5 MHC-peptidemolecules per SA molecule. Then SA/APC carrying four MHC complexes arepurified from free SA, free monomeric MHC complex, SA carrying three,two and one MHC complexes. The following SA-MHC(peptide)/APC tetramersare made:

-   -   64. APC-SA coupled with HLA-B*44 in complex with        beta2microglobulin and the peptide MWAQDAAAMF derived from        Ag85B.    -   65. APC-SA coupled with HLA-B*44 in complex with        beta2microglobulin and the peptide AAERGPGQML derived from        Ag85B.    -   66. APC-SA coupled with HLA-B*44 in complex with        beta2microglobulin and the non-sense peptide.

The binding of the above described MHC(peptide)/APC dextran can be usedto determine the presence of Mtb39 specific T cells in the blood from TBinfected individuals by flow cytometry following a standard flowcytometry protocol.

Blood from a patient with TB is isolated and 100 ul of this blood isincubated with either of the four SA-MHC(peptide)/APC tetramersdescribed above for 10 minutes in the dark at room temperature. 5 μl ofeach of each of the antibodies mouse-anti-human CD3/PB (clone UCHT1 fromDako) and mouse-anti-human CD8/PE (clone DK25 from Dako) are added andthe incubation continued for another 20 minutes at 4° C. in the dark.The samples are then washed by adding 2 ml PBS; pH=7.2 followed bycentrifugation for 5 minutes at 200×g and the supernatant removed. Thewashing step is repeated. The washed cells are resuspended in 400-500 μlPBS; pH=7.2 and analyzed on flowcytometer.

The presence of cells labeled with anti-CD3/PB, anti-CD8/PE and eitherof the SA-MHC(peptide)/APC tetramers 28 or 29 described above andthereby the presence of TB specific T cells will indicate that thepatient are infected with Mycobacterium tuberculosis. Blood analysedwith SA-MHC(peptide)/APC tetramers 30 should show no staining of CD3 andCD8 positive cells with this SA-MHC(peptide)/APC tetramer.

The sensitivity of the above described diagnostic test may be enhancedby addition of labeled antibodies specific for activation markersexpressed in or on the surface of the TB specific T cells.

We conclude that the MHC(peptide)/APC dextran constructs can be used todetect the presence of TB specific T cells in the blood of patientsinfected with Mycobacterium tuberculosis.

Example 66

This is an example of how MHC multimers may be used for diagnosis ofTuberculosis (TB) in blood samples from humans infected withMycobacterium tuberculosis.

In this example the MHC multimer used are MHC complexes coupled to anyfluorophor-labelled multimerisation as described elsewhere herein. TheMHC multimers are used for direct detection of TCR in flow cytometry.The antigen origin is TB, thus, immune monitoring of TB. TB is caused byinfection by Mycobacterium tuberculosis. During acute infection TBspecific activated T cells will be present in increased amounts in anactivated state compared to healthy individuals. The presences of anincreased amount of activated TB specific T cells may thereby act as asurrogate marker for infection with Mycobacterium tuberculosis. MHCmultimers carrying TB specific peptides is in this example used todetect the presence of TB specific T cells in the blood of patientsinfected with Mycobacterium tuberculosis.

Purified MHC-peptide complexes consisting of HLA-B*44 heavy chain, humanbeta2microglobulin and peptide derived from regions in antigen Mtb39 ora negative control peptide are generated by in vitro refolding andpurified or purified from antigen presenting cells. MHC-peptidecomplexes are then coupled to a multimerisation domain together withAPC.

The following MHC(peptide)/APC multimers are made:

-   -   67. APC-multimerisation domain coupled with HLA-B*44 in complex        with beta2microglobulin and the peptide MWAQDAAAMF derived from        Mtb39.    -   68. APC-multimerisation domain coupled with HLA-B*44 in complex        with beta2microglobulin and the peptide AAERGPGQML derived from        Mtb39.    -   69. APC-multimerisation domain coupled with HLA-B*44 in complex        with beta2microglobulin and the non-sense peptide.

The binding of the above described MHC(peptide)/APC multimers can beused to determine the presence of Mtb39 specific T cells in the bloodfrom TB infected individuals by flow cytometry following a standard flowcytometry protocol.

Blood from a patient with TB is isolated and 100 ul of this blood isincubated with either of the four MHC(peptide)/APC multimers describedabove for 10 minutes in the dark at room temperature. 5 μl of each ofeach of the antibodies mouse-anti-human CD3/PB (clone UCHT1 from Dako)and mouse-anti-human CD8/PE (clone DK25 from Dako) are added and theincubation continued for another 20 minutes at 4° C. in the dark. Thesamples are then washed by adding 2 ml PBS; pH=7.2 followed bycentrifugation for 5 minutes at 200×g and the supernatant removed. Thewashing step is repeated. The washed cells are resuspended in 400-500 μlPBS; pH=7.2 and analyzed on flowcytometer.

The presence of cells labeled with anti-CD3/PB, anti-CD8/PE and eitherof the MHC(peptide)/APC multimers 31 or 32 described above and therebythe presence of TB specific T cells will indicate that the patient areinfected with Mycobacterium tuberculosis. Blood analysed withMHC(peptide)/APC multimer 33 should show no staining of CD3 and CD8positive cells with this SA-MHC(peptide)/APC multimer.

The sensitivity of the above described diagnostic test may be enhancedby addition of labeled antibodies specific for activation markersexpressed in or on the surface of the TB specific T cells.

We conclude that the MHC(peptide)/APC dextran constructs can be used todetect the presence of TB specific T cells in the blood of patientsinfected with Mycobacterium tuberculosis.

Example 67

This is an example of how MHC multimers may be used for diagnosis ofTuberculosis (TB) in blood samples from humans infected withMycobacterium tuberculosis.

In this example the MHC multimer used are MHC complexes coupled tofluorophor-labelled dextran (Dextramers). The dextramers are used fordirect detection of TCR in flow cytometry. The antigen origin is TB,thus, immune monitoring of TB.

TB is caused by infection by Mycobacterium tuberculosis. During acuteinfection TB specific activated T cells will be present in increasedamounts in an activated state compared to healthy individuals. Thepresences of an increased amount of activated TB specific T cells maythereby act as a surrogate marker for infection with Mycobacteriumtuberculosis. MHC multimers carrying TB specific peptides is in thisexample used to detect the presence of TB specific T cells in the bloodof patients infected with Mycobacterium tuberculosis.

Purified MHC-peptide complexes consisting of HLA-B*14 heavy chain, humanbeta2microglobulin and peptide derived from regions in culture filtrateprotein 10 (CFP10) antigen (Table Y) or a negative control peptide aregenerated by in vitro refolding, purified and biotinylated as describedelsewhere herein. Biotinylated MHC-peptide complexes are then coupled toa 270 kDa dextran multimerization domain labelled with APC byinteraction with streptavidin (SA) on the dextran multimerizationdomain. The dextran-APC-SA multimerization domain is generated asdescribed elsewhere herein. MHC-peptide complexes are added in an amountcorresponding to a ratio of three MHC-peptide molecules per SA moleculeand each molecule dextran contained 3.7 SA molecule and 8.95 moleculesAPC. The final concentration of dextran was 3.8×10e-8 M. The followingMHC(peptide)/APC dextran constructs are made:

-   -   70. APC-SA conjugated 270 kDa dextran coupled with HLA-B*14 in        complex with beta2microglobulin and the peptide RADEEQQQAL        derived from CFP10.    -   71. APC-SA conjugated 270 kDa dextran coupled with HLA-B*14 in        complex with beta2microglobulin and the non-sense peptide.

The binding of the above described MHC(peptide)/APC dextran can be usedto determine the presence of CFP10 specific T cells in the blood from TBinfected individuals by flow cytometry following a standard flowcytometry protocol.

Blood from a patient with TB is isolated and 100 ul of this blood isincubated with 10 μl of one of the MHC(peptide)/APC dextran constructsdescribed above for 10 minutes in the dark at room temperature. 5 μl ofeach of each of the antibodies mouse-anti-human CD3/PB (clone UCHT1 fromDako) and mouse-anti-human CD8/PE (clone DK25 from Dako) are added andthe incubation continued for another 20 minutes at 4° C. in the dark.The samples are then washed by adding 2 ml PBS; pH=7.2 followed bycentrifugation for 5 minutes at 200×g and the supernatant removed. Thewashing step is repeated. The washed cells are resuspended in 400-500 μlPBS; pH=7.2 and analyzed on flowcytometer.

The presence of cells labeled with anti-CD3/PB, anti-CD8/PE and theMHC(peptide)/APC dextran constructs 34 described above and thereby thepresence of TB specific T cells will indicate that the patient areinfected with Mycobacterium tuberculosis. Blood analysed withMHC(peptide)/APC dextran construct 25 should show no staining of CD3 andCD8 positive cells with this MHC(peptide)/APC dextran construct.

The sensitivity of the above described diagnostic test may be enhancedby addition of labeled antibodies specific for activation markersexpressed in or on the surface of the TB specific T cells.

We conclude that the MHC(peptide)/APC dextran constructs can be used todetect the presence of TB specific T cells in the blood of patientsinfected with Mycobacterium tuberculosis.

Example 68

This is an example of how MHC multimers may be used for diagnosis ofTuberculosis (TB) in blood samples from humans infected withMycobacterium tuberculosis.

In this example the MHC multimer used are MHC complexes coupled tofluorophor-labelled the multimerisation domain Streptavidin (SA), usedfor direct detection of TCR in flow cytometry. The antigen origin is TB,thus, immune monitoring of TB.

TB is caused by infection by Mycobacterium tuberculosis. During acuteinfection TB specific activated T cells will be present in increasedamounts in an activated state compared to healthy individuals. Thepresences of an increased amount of activated TB specific T cells maythereby act as a surrogate marker for infection with Mycobacteriumtuberculosis. MHC multimers carrying TB specific peptides is in thisexample used to detect the presence of TB specific T cells in the bloodof patients infected with Mycobacterium tuberculosis.

Purified MHC-peptide complexes consisting of HLA-B*14 heavy chain, humanbeta2microglobulin and peptide derived from regions in culture filtrateprotein 10 (CFP10) antigen (Table Y) or a negative control peptide aregenerated by in vitro refolding, purified and biotinylated as describedelsewhere herein. Biotinylated MHC-peptide complexes are then coupled SAlabelled with APC. MHC-peptide complexes are added in an amountcorresponding to a ratio of 5 MHC-peptide molecules per SA molecule.Then SA/APC carrying four MHC complexes are purified from free SA, freemonomeric MHC complex, SA carrying three, two and one MHC complexes.

The following SA-MHC(peptide)/APC tetramers are made:

-   -   72. APC-SA coupled with HLA-B*14 in complex with        beta2microglobulin and the peptide RADEEQQQAL derived from        CFP10.    -   73. APC-SA coupled with HLA-B*44 in complex with        beta2microglobulin and the non-sense peptide.

The binding of the above described MHC(peptide)/APC dextran can be usedto determine the presence of CFP10 specific T cells in the blood from TBinfected individuals by flow cytometry following a standard flowcytometry protocol.

Blood from a patient with TB is isolated and 100 ul of this blood isincubated with either of the four SA-MHC(peptide)/APC tetramersdescribed above for 10 minutes in the dark at room temperature. 5 μl ofeach of each of the antibodies mouse-anti-human CD3/PB (clone UCHT1 fromDako) and mouse-anti-human CD8/PE (clone DK25 from Dako) are added andthe incubation continued for another 20 minutes at 4° C. in the dark.The samples are then washed by adding 2 ml PBS; pH=7.2 followed bycentrifugation for 5 minutes at 200×g and the supernatant removed. Thewashing step is repeated. The washed cells are resuspended in 400-500 μlPBS; pH=7.2 and analyzed on flowcytometer.

The presence of cells labeled with anti-CD3/PB, anti-CD8/PE and theSA-MHC(peptide)/APC tetramers 36 described above and thereby thepresence of TB specific T cells will indicate that the patient areinfected with Mycobacterium tuberculosis. Blood analysed withSA-MHC(peptide)/APC tetramers 37 should show no staining of CD3 and CD8positive cells with this SA-MHC(peptide)/APC tetramer.

The sensitivity of the above described diagnostic test may be enhancedby addition of labeled antibodies specific for activation markersexpressed in or on the surface of the TB specific T cells.

We conclude that the MHC(peptide)/APC dextran constructs can be used todetect the presence of TB specific T cells in the blood of patientsinfected with Mycobacterium tuberculosis.

Example 69

This is an example of how MHC multimers may be used for diagnosis ofTuberculosis (TB) in blood samples from humans infected withMycobacterium tuberculosis.

In this example the MHC multimer used are MHC complexes coupled to anyfluorophor-labelled multimerisation as described elsewhere herein. TheMHC multimers are used for direct detection of TCR in flow cytometry.The antigen origin is TB, thus, immune monitoring of TB. TB is caused byinfection by Mycobacterium tuberculosis. During acute infection TBspecific activated T cells will be present in increased amounts in anactivated state compared to healthy individuals. The presences of anincreased amount of activated TB specific T cells may thereby act as asurrogate marker for infection with Mycobacterium tuberculosis. MHCmultimers carrying TB specific peptides is in this example used todetect the presence of TB specific T cells in the blood of patientsinfected with Mycobacterium tuberculosis.

Purified MHC-peptide complexes consisting of HLA-B*14 heavy chain, humanbeta2microglobulin and peptide derived from regions in culture filtrateprotein 10 (CFP10) antigen (Table Y) or a negative control peptide aregenerated by in vitro refolding and purified or purified from antigenpresenting cells. MHC-peptide complexes are then coupled to amultimerisation domain together with APC.

The following MHC(peptide)/APC multimers are made:

-   -   74. APC-multimerisation domain coupled with HLA-B*14 in complex        with beta2microglobulin and the peptide RADEEQQQAL derived from        CFP10.    -   75. APC-multimerisation domain coupled with HLA-B*14 in complex        with beta2microglobulin and the non-sense peptide.

The binding of the above described MHC(peptide)/APC multimers can beused to determine the presence of CFP10 specific T cells in the bloodfrom TB infected individuals by flow cytometry following a standard flowcytometry protocol.

Blood from a patient with TB is isolated and 100 ul of this blood isincubated with either of the four MHC(peptide)/APC multimers describedabove for 10 minutes in the dark at room temperature. 5 μl of each ofeach of the antibodies mouse-anti-human CD3/PB (clone UCHT1 from Dako)and mouse-anti-human CD8/PE (clone DK25 from Dako) are added and theincubation continued for another 20 minutes at 4° C. in the dark. Thesamples are then washed by adding 2 ml PBS; pH=7.2 followed bycentrifugation for 5 minutes at 200×g and the supernatant removed. Thewashing step is repeated. The washed cells are resuspended in 400-500 μlPBS; pH=7.2 and analyzed on flowcytometer.

The presence of cells labeled with anti-CD3/PB, anti-CD8/PE and theMHC(peptide)/APC multimers 38 described above and thereby the presenceof TB specific T cells will indicate that the patient are infected withMycobacterium tuberculosis. Blood analysed with MHC(peptide)/APCmultimer 39 should show no staining of CD3 and CD8 positive cells withthis SA-MHC(peptide)/APC multimer.

The sensitivity of the above described diagnostic test may be enhancedby addition of labeled antibodies specific for activation markersexpressed in or on the surface of the TB specific T cells.

We conclude that the MHC(peptide)/APC dextran constructs can be used todetect the presence of TB specific T cells in the blood of patientsinfected with Mycobacterium tuberculosis.

Example 70

This is an example of how MHC multimers may be used for diagnosis ofLyme Disease in blood samples from humans infected with Borreliabacteria.

In this example the MHC multimer used are MHC complexes coupled tofluorophor-labelled dextran (Dextramers). The dextramers are used fordirect detection of TCR in flow Cytometry. The antigen origin isBorrelia, thus, immune monitoring of a Borrelia infection.

Lyme disease is caused by infection by Borrelia bacteria. During acuteinfection Borrelia specific activated T cells will be present inincreased amounts in an activated state compared to healthy individuals.The presences of an increased amount of activated Borrelia specific Tcells may thereby act as a surrogate marker for infection with Borreliabacterium. MHC multimers carrying borrelia specific peptides is in thisexample used to detect the presence of Borrelia specific T cells in theblood of patients infected with Borrelia.

Purified MHC-peptide complexes consisting of HLA-A*0201 heavy chain,human beta2microglobulin and peptide derived from regions in Outersurface protein A (Table V) or Flagellin B (Table X) conserved among thethree species Borrelia Burgdorferi, Borrelia Garinii and BorreliaAfzelii or a negative control peptide are generated by in vitrorefolding, purified and biotinylated as described elsewhere herein.Biotinylated MHC-peptide complexes are then coupled to a 270 kDa dextranmultimerization domain labelled with APC by interaction withstreptavidin (SA) on the dextran multimerization domain. Thedextran-APC-SA multimerization domain is generated as describedelsewhere herein. MHC-peptide complexes are added in an amountcorresponding to a ratio of three MHC-peptide molecules per SA moleculeand each molecule dextran contains 3.7 SA molecule and 8.95 moleculesAPC. The final concentration of dextran is 3.8×10e-8 M. The followingMHC(peptide)/APC dextran constructs are made:

-   -   76. APC-SA conjugated 270 kDa dextran coupled with HLA-A*0201 in        complex with beta2microglobulin and the peptide ALIACKQNV        derived from OspA.    -   77. APC-SA conjugated 270 kDa dextran coupled with HLA-A*0201 in        complex with beta2microglobulin and the peptide FTKEDTIT derived        from OspA.    -   78. APC-SA conjugated 270 kDa dextran coupled with HLA-A*0201 in        complex with beta2microglobulin and the peptide SIQIEIEQL        derived from Fla B    -   79. APC-SA conjugated 270 kDa dextran coupled with HLA-A*0201 in        complex with beta2microglobulin and the peptide NLNEVEKVL        derived from Fla B    -   80. APC-SA conjugated 270 kDa dextran coupled with HLA-A*0201 in        complex with beta2microglobulin and the peptide SLAKIENAI        derived from Fla B    -   81. APC-SA conjugated 270 kDa dextran coupled with HLA-A*0201 in        complex with beta2microglobulin and the non-sense peptide        GLAGDVSAV

The binding of the above described MHC(peptide)/APC dextran is used todetermine the presence of Osp A or Fla B specific T cells in the bloodfrom Borrelia infected individuals by flow cytometry following astandard flow cytometry protocol.

Blood from a patient with Lyme disease is isolated and 100 ul of thisblood is incubated with 10 μl of each of the MHC(peptide)/APC dextranconstructs described above for 10 minutes in the dark at roomtemperature. 5 μl of each of each of the antibodies mouse-anti-humanCD3/PB (clone UCHT1 from Dako), mouse-anti-human CD4/FITC (clone MT310from Dako) and mouse-anti-human CD8/PE (clone DK25 from Dako) are addedand the incubation continues for another 20 minutes at 4° C. in thedark. The samples are then washed by adding 2 ml PBS; pH=7.2 followed bycentrifugation for 5 minutes at 300×g and the supernatant removed. Thewashing step is repeated twice. The washed cells are resuspended in400-500 μl PBS+1% BSA; pH=7.2 and analyzed on flowcytometer.

The presence of cells labeled with anti-CD3/PB, anti-CD8/PE and theMHC(peptide)/APC dextran constructs 1, 2, 3, 4 and 5 described above andthereby the presence of Borrelia specific T cells indicate that thepatient are infected with Borrelia bacteria. Blood analysed withMHC(peptide)/APC dextran construct 6 show no staining of CD3 and CD8positive cells with this MHC(peptide)/APC dextran construct.

The result is shown in FIG. 19.

The sensitivity of the above described diagnostic test may be enhancedby addition of labeled antibodies specific for activation markersexpressed in or on the surface of the Borrelia specific T cells.

We conclude that the MHC(peptide)/APC dextran constructs can be used todetect the presence of Borrelia specific T cells in the blood ofpatients infected with Borrelia.

Example 71

This is an example of how MHC multimers may be used for diagnosis ofLyme Disease in blood samples from humans infected with Borreliabacteria.

In this example the MHC multimer used are MHC complexes coupled to thefluorophor-labelled multimerisation domain Streptavidin (SA), used fordirect detection of TCR in flow Cytometry. The antigen origin isBorrelia, thus, immune monitoring of a Borrelia infection. Lyme diseaseis caused by infection by Borrelia bacteria. During acute infectionBorrelia specific activated T cells will be present in increased amountsin an activated state compared to healthy individuals. The presences ofan increased amount of activated Borrelia specific T cells may therebyact as a surrogate marker for infection with Borrelia bacterium. MHCmultimers carrying borrelia specific peptides is in this example used todetect the presence of Borrelia specific T cells in the blood ofpatients infected with Borrelia.

Purified MHC-peptide complexes consisting of HLA-A*0201 heavy chain,human beta2microglobulin and peptide derived from regions in Outersurface protein A (Table V) or Flagellin B (Table X) conserved among thethree species Borrelia Burgdorferi, Borrelia Garinii and BorreliaAfzelii or a negative control peptide were generated by in vitrorefolding, purified and biotinylated as described elsewhere herein.Biotinylated MHC-peptide complexes are then coupled SA labelled withAPC. MHC-peptide complexes were added in an amount corresponding to aratio of 5 MHC-peptide molecules per SA molecule. Then SA/APC carryingfour MHC complexes were purified from free SA, free monomeric MHCcomplex, SA carrying three, two and one MHC complexes.

The following SA-MHC(peptide)/APC tetramers are made:

-   -   82. APC-SA coupled with HLA-A*0201 in complex with        beta2microglobulin and the peptide ALIACKQNV derived from OspA.    -   83. APC-SA coupled with HLA-A*0201 in complex with        beta2microglobulin and the peptide FTKEDTIT derived from OspA.    -   84. APC-SA coupled with HLA-A*0201 in complex with        beta2microglobulin and the peptide SIQIEIEQL derived from Fla B.    -   85. APC-SA coupled with HLA-A*0201 in complex with        beta2microglobulin and the peptide NLNEVEKVL derived from Fla B.    -   86. APC-SA coupled with HLA-A*0201 in complex with        beta2microglobulin and the peptide SLAKIENAI derived from Fla B.    -   87. APC-SA coupled with HLA-A*0201 in complex with        beta2microglobulin and the non-sense peptide GLAGDVSAV

The binding of the above described MHC(peptide)/APC dextran can be usedto determine the presence of Osp A or Fla B specific T cells in theblood from Borrelia infected individuals by flow cytometry following astandard flow cytometry protocol.

Blood from a patient with Lyme disease is isolated and 100 ul of thisblood is incubated with either of the four SA-MHC(peptide)/APC tetramersdescribed above for 10 minutes in the dark at room temperature. 5 μl ofeach of each of the antibodies mouse-anti-human CD3/PB (clone UCHT1 fromDako) and mouse-anti-human CD8/PE (clone DK25 from Dako) are added andthe incubation continued for another 20 minutes at 4° C. in the dark.The samples are then washed by adding 2 ml PBS; pH=7.2 followed bycentrifugation for 5 minutes at 200×g and the supernatant removed. Thewashing step is repeated. The washed cells are resuspended in 400-500 μlPBS; pH=7.2 and analyzed on flowcytometer.

The presence of cells labeled with anti-CD3/PB, anti-CD8/PE and eitherof the SA-MHC(peptide)/APC tetramers 7, 8, 9, 10 or 11 described aboveand thereby the presence of Borrelia specific T cells will indicate thatthe patient are infected with Borrelia bacteria. Blood analysed withSA-MHC(peptide)/APC tetramers 12 should show no staining of CD3 and CD8positive cells with this SA-MHC(peptide)/APC tetramer.

The sensitivity of the above described diagnostic test may be enhancedby addition of labeled antibodies specific for activation markersexpressed in or on the surface of the Borrelia specific T cells.

We conclude that the APC-SA coupled MHC(peptide) constructs may be usedto detect the presence of Borrelia specific T cells in the blood ofpatients infected with Borrelia.

Example 72

This is an example of how MHC multimers may be used for diagnosis ofLyme Disease in blood samples from humans infected with Borreliabacteria.

In this example the MHC multimer used are MHC complexes coupled to anyfluorophor-labelled multimerisation as described elsewhere herein. TheMHC multimers are used for direct detection of TCR in flow cytometry.The antigen origin is Borrelia, thus, immune monitoring of a Borreliainfection.

Lyme disease is caused by infection by Borrelia bacteria. During acuteinfection Borrelia specific activated T cells will be present inincreased amounts in an activated state compared to healthy individuals.The presences of an increased amount of activated Borrelia specific Tcells may thereby act as a surrogate marker for infection with Borreliabacterium. MHC multimers carrying borrelia specific peptides is in thisexample used to detect the presence of Borrelia specific T cells in theblood of patients infected with Borrelia.

Purified MHC-peptide complexes consisting of HLA-A*0201 heavy chain,human beta2microglobulin and peptide derived from regions in Outersurface protein A (Table V) or Flagellin B (Table X) conserved among thethree species Borrelia Burgdorferi, Borrelia Garinii and BorreliaAfzelii or a negative control peptide were generated by in vitrorefolding and purified or purified from antigen presenting cells.MHC-peptide complexes are then coupled to a multimerisation domaintogether with APC.

The following MHC(peptide)/APC multimers are made:

-   -   88. APC-multimerisation domain coupled with HLA-A*0201 in        complex with beta2microglobulin and the peptide ALIACKQNV        derived from OspA.    -   89. APC-multimerisation domain coupled with HLA-A*0201 in        complex with beta2microglobulin and the peptide FTKEDTIT derived        from OspA.    -   90. APC-multimerisation domain coupled with HLA-A*0201 in        complex with beta2microglobulin and the peptide SIQIEIEQL        derived from Fla B.    -   91. APC-multimerisation domain coupled with HLA-A*0201 in        complex with beta2microglobulin and the peptide NLNEVEKVL        derived from Fla B.    -   92. APC-multimerisation domain coupled with HLA-A*0201 in        complex with beta2microglobulin and the peptide SLAKIENAI        derived from Fla B.    -   93. APC-multimerisation domain coupled with HLA-A*0201 in        complex with beta2microglobulin and the non-sense peptide        GLAGDVSAV

The binding of the above described MHC(peptide)/APC multimers can beused to determine the presence of Osp A or Fla B specific T cells in theblood from Borrelia infected individuals by flow cytometry following astandard flow cytometry protocol.

Blood from a patient with Lyme disease is isolated and 100 ul of thisblood is incubated with either of the four MHC(peptide)/APC multimersdescribed above for 10 minutes in the dark at room temperature. 5 μl ofeach of each of the antibodies mouse-anti-human CD3/PB (clone UCHT1 fromDako) and mouse-anti-human CD8/PE (clone DK25 from Dako) are added andthe incubation continued for another 20 minutes at 4° C. in the dark.The samples are then washed by adding 2 ml PBS; pH=7.2 followed bycentrifugation for 5 minutes at 200×g and the supernatant removed. Thewashing step is repeated. The washed cells are resuspended in 400-500 μlPBS; pH=7.2 and analyzed on flowcytometer.

The presence of cells labeled with anti-CD3/PB, anti-CD8/PE and eitherof the MHC(peptide)/APC multimers 13, 14, 15, 16 or 17 described aboveand thereby the presence of Borrelia specific T cells will indicate thatthe patient are infected with Borrelia bacteria.

Blood analysed with MHC(peptide)/APC multimer 18 should show no stainingof CD3 and CD8 positive cells with this SA-MHC(peptide)/APC multimer.

The sensitivity of the above described diagnostic test may be enhancedby addition of labeled antibodies specific for activation markersexpressed in or on the surface of the Borrelia specific T cells.

We conclude that the APC-multimerisation domain coupled MHC(peptide)constructs may be used to detect the presence of Borrelia specific Tcells in the blood of patients infected with Borrelia.

Example 73

This is an example of how MHC multimers may be used for diagnosis ofLyme Disease in blood samples from humans infected with Borreliabacteria.

In this example the MHC multimer used are MHC complexes coupled tofluorophor-labelled dextran (Dextramers). The dextramers are used fordirect detection of TCR in flow Cytometry. The antigen origin isBorrelia, thus, immune monitoring of a Borrelia infection.

Lyme disease is caused by infection by Borrelia bacteria. During acuteinfection Borrelia specific activated T cells will be present inincreased amounts in an activated state compared to healthy individuals.The presences of an increased amount of activated Borrelia specific Tcells may thereby act as a surrogate marker for infection with Borreliabacterium. MHC multimers carrying borrelia specific peptides is in thisexample used to detect the presence of Borrelia specific T cells in theblood of patients infected with Borrelia.

Purified MHC-peptide complexes consisting of HLA-A*0301 heavy chain,human beta2microglobulin and peptide derived from regions in Outersurface protein C (Table U) conserved among the three species BorreliaBurgdorferi, Borrelia Garinii and Borrelia Afzelii or a negative controlpeptide were generated by in vitro refolding, purified and biotinylatedas described elsewhere herein. Biotinylated MHC-peptide complexes werethen coupled to a 270 kDa dextran multimerization domain labelled withAPC by interaction with streptavidin (SA) on the dextran multimerizationdomain. The dextran-APC-SA multimerization domain was generated asdescribed elsewhere herein. MHC-peptide complexes were added in anamount corresponding to a ratio of three MHC-peptide molecules per SAmolecule and each molecule dextran contained 3.7 SA molecule and 8.95molecules APC. The final concentration of dextran was 3.8×10e-8 M. Thefollowing MHC(peptide)/APC dextran constructs were made:

-   -   94. APC-SA conjugated 270 kDa dextran coupled with HLA-A*0301 in        complex with beta2microglobulin and the peptide TLITEKLSK        derived from OspC.    -   95. APC-SA conjugated 270 kDa dextran coupled with HLA-A*0301 in        complex with beta2microglobulin and the peptide ELANKAIGK        derived from OspC.    -   96. APC-SA conjugated 270 kDa dextran coupled with HLA-A*0301 in        complex with beta2microglobulin and the HIV peptide QVPLRPMTYK.

The binding of the above described MHC(peptide)/APC dextran can be usedto determine the presence of Osp C specific T cells in the blood fromBorrelia infected individuals by flow cytometry following a standardflow cytometry protocol.

Blood from a patient with Lyme disease is isolated and 100 ul of thisblood is incubated with 10 μl of one of the MHC(peptide)/APC dextranconstructs described above for 10 minutes in the dark at roomtemperature. 5 μl of each of each of the antibodies mouse-anti-humanCD3/PB (clone UCHT1 from Dako) and mouse-anti-human CD8/PE (clone DK25from Dako) are added and the incubation continued for another 20 minutesat 4° C. in the dark. The samples are then washed by adding 2 ml PBS;pH=7.2 followed by centrifugation for 5 minutes at 200×g and thesupernatant removed. The washing step is repeated. The washed cells areresuspended in 400-500 μl PBS; pH=7.2 and analyzed on flowcytometer.

The presence of cells labeled with anti-CD3/PB, anti-CD8/PE and eitherof the MHC(peptide)/APC dextran constructs 19 or 20 described above andthereby the presence of Borrelia specific T cells will indicate that thepatient are infected with Borrelia bacteria. Blood analysed withMHC(peptide)/APC dextran construct 21 should show no staining of CD3 andCD8 positive cells with this MHC(peptide)/APC dextran construct.

The sensitivity of the above described diagnostic test may be enhancedby addition of labeled antibodies specific for activation markersexpressed in or on the surface of the Borrelia specific T cells.

We conclude that the APC-SA conjugated 270 kDa dextran coupledMHC(peptide) constructs may be used to detect the presence of Borreliaspecific T cells in the blood of patients infected with Borrelia.

Example 74

This is an example of how MHC multimers may be used for diagnosis ofLyme Disease in blood samples from humans infected with Borreliabacteria.

In this example the MHC multimer used are MHC complexes coupled to thefluorophor-labelled multimerisation domain Streptavidin (SA), used fordirect detection of TCR in flow Cytometry. The antigen origin isBorrelia, thus, immune monitoring of a Borrelia infection. Lyme diseaseis caused by infection by Borrelia bacteria. During acute infectionBorrelia specific activated T cells will be present in increased amountsin an activated state compared to healthy individuals. The presences ofan increased amount of activated Borrelia specific T cells may therebyact as a surrogate marker for infection with Borrelia bacterium. MHCmultimers carrying borrelia specific peptides is in this example used todetect the presence of Borrelia specific T cells in the blood ofpatients infected with Borrelia.

Purified MHC-peptide complexes consisting of HLA-A*0301 heavy chain,human beta2microglobulin and peptide derived from regions in Outersurface protein C (Table U) conserved among the three species BorreliaBurgdorferi, Borrelia Garinii and Borrelia Afzelii or a negative controlpeptide were generated by in vitro refolding, purified and biotinylatedas described elsewhere herein. Biotinylated MHC-peptide complexes arethen coupled SA labelled with APC. MHC-peptide complexes were added inan amount corresponding to a ratio of 5 MHC-peptide molecules per SAmolecule. Then SA/APC carrying four MHC complexes were purified fromfree SA, free monomeric MHC complex, SA carrying three, two and one MHCcomplexes.

The following SA-MHC(peptide)/APC tetramers are made:

-   -   97. APC-SA coupled with HLA-A*0301 in complex with        beta2microglobulin and the peptide TLITEKLSK derived from OspC.    -   98. APC-SA coupled with HLA-A*0301 in complex with        beta2microglobulin and the peptide ELANKAIGK derived from OspC.    -   99. APC-SA coupled with HLA-A*0201 in complex with        beta2microglobulin and the HIV peptide QVPLRPMTYK.

The binding of the above described MHC(peptide)/APC dextran can be usedto determine the presence of Osp C specific T cells in the blood fromBorrelia infected individuals by flow cytometry following a standardflow cytometry protocol.

Blood from a patient with Lyme disease is isolated and 100 ul of thisblood is incubated with either of the four SA-MHC(peptide)/APC tetramersdescribed above for 10 minutes in the dark at room temperature. 5 μl ofeach of each of the antibodies mouse-anti-human CD3/PB (clone UCHT1 fromDako) and mouse-anti-human CD8/PE (clone DK25 from Dako) are added andthe incubation continued for another 20 minutes at 4° C. in the dark.The samples are then washed by adding 2 ml PBS; pH=7.2 followed bycentrifugation for 5 minutes at 200×g and the supernatant removed. Thewashing step is repeated. The washed cells are resuspended in 400-500 μlPBS; pH=7.2 and analyzed on flowcytometer.

The presence of cells labeled with anti-CD3/PB, anti-CD8/PE and eitherof the SA-MHC(peptide)/APC tetramers 22 or 23 described above andthereby the presence of Borrelia specific T cells will indicate that thepatient are infected with Borrelia bacteria. Blood analysed withSA-MHC(peptide)/APC tetramers 24 should show no staining of CD3 and CD8positive cells with this SA-MHC(peptide)/APC tetramer.

The sensitivity of the above described diagnostic test may be enhancedby addition of labeled antibodies specific for activation markersexpressed in or on the surface of the Borrelia specific T cells.

We conclude that the APC-SA coupled MHC(peptide) constructs may be usedto detect the presence of Borrelia specific T cells in the blood ofpatients infected with Borrelia.

Example 75

This is an example of how MHC multimers may be used for diagnosis ofLyme Disease in blood samples from humans infected with Borreliabacteria.

In this example the MHC multimer used are MHC complexes coupled to anyfluorophor-labelled multimerisation as described elsewhere herein. TheMHC multimers are used for direct detection of TCR in flow cytometry.The antigen origin is Borrelia, thus, immune monitoring of a Borreliainfection.

Lyme disease is caused by infection by Borrelia bacteria. During acuteinfection Borrelia specific activated T cells will be present inincreased amounts in an activated state compared to healthy individuals.The presences of an increased amount of activated Borrelia specific Tcells may thereby act as a surrogate marker for infection with Borreliabacterium. MHC multimers carrying borrelia specific peptides is in thisexample used to detect the presence of Borrelia specific T cells in theblood of patients infected with Borrelia.

Purified MHC-peptide complexes consisting of HLA-A*0201 heavy chain,human beta2microglobulin and peptide derived from regions in Outersurface protein C (Table U) conserved among the three species BorreliaBurgdorferi, Borrelia Garinii and Borrelia Afzelii or a negative controlpeptide were generated by in vitro refolding and purified or purifiedfrom antigen presenting cells. MHC-peptide complexes are then coupled toa multimerisation domain together with APC.

The following MHC(peptide)/APC multimers are made:

-   -   100. APC-multimerisation domain coupled with HLA-A*0201 in        complex with beta2microglobulin and the peptide TLITEKLSK        derived from OspC.    -   101. APC-multimerisation domain coupled with HLA-A*0201 in        complex with beta2microglobulin and the peptide ELANKAIG derived        from OspC.    -   102. APC-multimerisation domain coupled with HLA-A*0201 in        complex with beta2microglobulin and the HIV peptide QVPLRPMTYK.

The binding of the above described MHC(peptide)/APC multimers can beused to determine the presence of Osp C specific T cells in the bloodfrom Borrelia infected individuals by flow cytometry following astandard flow cytometry protocol.

Blood from a patient with Lyme disease is isolated and 100 ul of thisblood is incubated with either of the four MHC(peptide)/APC multimersdescribed above for 10 minutes in the dark at room temperature. 5 μl ofeach of each of the antibodies mouse-anti-human CD3/PB (clone UCHT1 fromDako) and mouse-anti-human CD8/PE (clone DK25 from Dako) are added andthe incubation continued for another 20 minutes at 4° C. in the dark.The samples are then washed by adding 2 ml PBS; pH=7.2 followed bycentrifugation for 5 minutes at 200×g and the supernatant removed. Thewashing step is repeated. The washed cells are resuspended in 400-500 μlPBS; pH=7.2 and analyzed on flowcytometer.

The presence of cells labeled with anti-CD3/PB, anti-CD8/PE and eitherof the MHC(peptide)/APC multimers 25 or 26 described above and therebythe presence of Borrelia specific T cells will indicate that the patientare infected with Borrelia bacteria. Blood analysed withMHC(peptide)/APC multimer 27 should show no staining of CD3 and CD8positive cells with this SA-MHC(peptide)/APC multimer.

The sensitivity of the above described diagnostic test may be enhancedby addition of labeled antibodies specific for activation markersexpressed in or on the surface of the Borrelia specific T cells.

We conclude that the APC-multimerisation domain coupled MHC(peptide)constructs may be used to detect the presence of Borrelia specific Tcells in the blood of patients infected with Borrelia.

Example 76

This is an example of how MHC multimers may be used for detection ofCytomegalovirus (CMV) specific T cells in blood samples from humansinfected with CMV.

In this example the MHC multimer used are MHC complexes coupled tofluorophor-labelled dextran (Dextramers). The dextramers are used fordirect detection of TCR in flow cytometry. The antigen origin is CMV,thus, immune monitoring of CMV.

MHC multimers carrying CMV specific peptides is in this example used todetect the presence of CMV specific T cells in the blood of patientsinfected with Cytomegalovirus.

Purified MHC-peptide complexes consisting of HLA-A*0201 heavy chain,human beta2microglobulin and peptide derived from a region in CMVinternal matrix protein pp 65 or a negative control peptide aregenerated by in vitro refolding, purified and biotinylated as describedelsewhere herein. Biotinylated MHC-peptide complexes are then coupled toa 270 kDa dextran multimerization domain labelled with APC byinteraction with streptavidin (SA) on the dextran multimerizationdomain. The dextran-APC-SA multimerization domain is generated asdescribed elsewhere herein. MHC-peptide complexes are added in an amountcorresponding to a ratio of three MHC-peptide molecules per SA moleculeand each molecule dextran contains 3.7 SA molecule and 8.95 moleculesAPC. The final concentration of dextran is 3.8×10e-8 M. The followingMHC(peptide)/APC dextran constructs are made:

-   -   103. APC-SA conjugated 270 kDa dextran coupled with HLA-A*0201        in complex with beta2microglobulin and the peptide NLVPMVATV        derived from CMV pp 65.    -   104. APC-SA conjugated 270 kDa dextran coupled with HLA-A*0201        in complex with beta2microglobulin and the non-sense peptide        GLAGDVSAV

The binding of the above described MHC(peptide)/APC dextran is used todetermine the presence of CMV pp 65 specific T cells in the blood fromCMV infected individuals by flow cytometry following a standard flowcytometry protocol.

Blood from a patient with CMV infection is isolated and 100 ul of thisblood is incubated with 10 μl of the MHC(peptide)/APC dextran constructsdescribed above for 10 minutes in the dark at room temperature. 5 μl ofeach of each of the antibodies mouse-anti-human CD3/PB (clone UCHT1 fromDako), and mouse-anti-human CD8/PE (clone DK25 from Dako) are added andthe incubation continues for another 20 minutes at 4° C. in the dark.The samples are then washed by adding 2 ml PBS; pH=7.2 followed bycentrifugation for 5 minutes at 300×g and the supernatant removed. Thewashing step is repeated twice. The washed cells are resuspended in400-500 μl PBS+1% BSA; pH=7.2 and analyzed on flowcytometer. Thepresence of cells labeled with anti-CD3/PB, anti-CD8/PE and theMHC(peptide)/APC dextran construct 1 described above and thereby thepresence of CMV specific T cells indicate that the patient are infectedwith Cytomegalovirus. Blood analysed with MHC(peptide)/APC dextranconstruct 2 show no staining of CD3 and CD8 positive cells with thisMHC(peptide)/APC dextran construct. The result is shown I FIG. 20

The sensitivity of the above described test may be enhanced by additionof labeled antibodies specific for activation markers expressed in or onthe surface of the CMV specific T cells.

We conclude that the MHC(peptide)/APC dextran constructs can be used todetect the presence of CMV specific T cells in the blood of patientsinfected with Cytomegalovirus.

Example 77

This is an example of how MHC multimers may be used for detection ofCytomegalovirus (CMV) specific T cells in blood samples from humansinfected with CMV.

In this example the MHC multimer used are MHC complexes coupled tofluorophor-labelled multimerisation domain Streptavidin (SA), used fordirect detection of TCR in flow cytometry. The antigen origin is CMV,thus, immune monitoring of CMV.

MHC multimers carrying CMV specific peptides is in this example used todetect the presence of CMV specific T cells in the blood of patientsinfected with Cytomegalovirus.

Purified MHC-peptide complexes consisting of HLA-A*0201 heavy chain,human beta2microglobulin and peptide derived from a region in CMVinternal matrix protein pp 65 or a negative control peptide weregenerated by in vitro refolding, purified and biotinylated as describedelsewhere herein. Biotinylated MHC-peptide complexes are then coupled SAlabelled with APC. MHC-peptide complexes were added in an amountcorresponding to a ratio of 5 MHC-peptide molecules per SA molecule.Then SA/APC carrying four MHC complexes were purified from free SA, freemonomeric MHC complex, SA carrying three, two and one MHC complexes.

The following SA-MHC(peptide)/APC tetramers are made:

-   -   105. APC-SA coupled with HLA-A*0201 in complex with        beta2microglobulin and the peptide NLVPMVATV derived from CMV pp        65.    -   106. APC-SA coupled with HLA-A*0201 in complex with        beta2microglobulin and the non-sense peptide GLAGDVSAV

The binding of the above described MHC(peptide)/APC dextran can be usedto determine the presence of CMV pp 65 specific T cells in the bloodfrom Cytomegalovirus infected individuals by flow cytometry following astandard flow cytometry protocol.

Blood from a patient with CMV is isolated and 100 ul of this blood isincubated with either of the SA-MHC(peptide)/APC tetramers describedabove for 10 minutes in the dark at room temperature. 5 μl of each ofeach of the antibodies mouse-anti-human CD3/PB (clone UCHT1 from Dako)and mouse-anti-human CD8/PE (clone DK25 from Dako) are added and theincubation continued for another 20 minutes at 4° C. in the dark. Thesamples are then washed by adding 2 ml PBS; pH=7.2 followed bycentrifugation for 5 minutes at 200×g and the supernatant removed. Thewashing step is repeated. The washed cells are resuspended in 400-500 μlPBS; pH=7.2 and analyzed on flowcytometer.

The presence of cells labeled with anti-CD3/PB, anti-CD8/PE and theSA-MHC(peptide)/APC tetramers 3 described above and thereby the presenceof CMV specific T cells will indicate that the patient are infected withCytomegalovirus. Blood analysed with SA-MHC(peptide)/APC tetramers 4should show no staining of CD3 and CD8 positive cells with thisSA-MHC(peptide)/APC tetramer.

The sensitivity of the above described test may be enhanced by additionof labeled antibodies specific for activation markers expressed in or onthe surface of the CMV specific T cells.

We conclude that the APC-SA coupled MHC(peptide) constructs may be usedto detect the presence of CMV specific T cells in the blood of patientsinfected with Cytomegalovirus.

Example 78

This is an example of how MHC multimers may be used for detection ofCytomegalovirus (CMV) specific T cells in blood samples from humansinfected with CMV.

In this example the MHC multimer used are MHC complexes coupled to anyfluorophor-labelled multimerisation as described elsewhere herein. TheMHC multimers are used for direct detection of TCR in flow cytometry.The antigen origin is CMV, thus, immune monitoring of CMV.

MHC multimers carrying CMV specific peptides is in this example used todetect the presence of CMV specific T cells in the blood of patientsinfected with Cytomegalovirus.

Purified MHC-peptide complexes consisting of HLA-A*0201 heavy chain,human beta2microglobulin and peptide derived a region in CMV internalmatrix protein pp 65 or a negative control peptide were generated by invitro refolding and purified or purified from antigen presenting cells.MHC-peptide complexes are then coupled to a multimerisation domaintogether with APC.

The following MHC(peptide)/APC multimers are made:

-   -   107. APC-multimerisation domain coupled with HLA-A*0201 in        complex with beta2microglobulin and the peptide NLVPMVATV        derived from CMV pp 65.    -   108. APC-multimerisation domain coupled with HLA-A*0201 in        complex with beta2microglobulin and the non-sense peptide        GLAGDVSAV.

The binding of the above described MHC(peptide)/APC multimers can beused to determine the presence of CMV pp 65 specific T cells in theblood from CMV infected individuals by flow cytometry following astandard flow cytometry protocol.

Blood from a patient with CMV infection is isolated and 100 ul of thisblood is incubated with either of the MHC(peptide)/APC multimersdescribed above for 10 minutes in the dark at room temperature. 5 μl ofeach of each of the antibodies mouse-anti-human CD3/PB (clone UCHT1 fromDako) and mouse-anti-human CD8/PE (clone DK25 from Dako) are added andthe incubation continued for another 20 minutes at 4° C. in the dark.The samples are then washed by adding 2 ml PBS; pH=7.2 followed bycentrifugation for 5 minutes at 200×g and the supernatant removed. Thewashing step is repeated. The washed cells are resuspended in 400-500 μlPBS; pH=7.2 and analyzed on flowcytometer.

The presence of cells labeled with anti-CD3/PB, anti-CD8/PE and theMHC(peptide)/APC multimers 5 described above and thereby the presence ofCMV specific T cells will indicate that the patient are infected withCytomegalovirus. Blood analysed with MHC(peptide)/APC multimer 6 shouldshow no staining of CD3 and CD8 positive cells with thisSA-MHC(peptide)/APC multimer.

The sensitivity of the above described test may be enhanced by additionof labeled antibodies specific for activation markers expressed in or onthe surface of the CMV specific T cells.

We conclude that the APC-multimerisation domain coupled MHC(peptide)constructs may be used to detect the presence of CMV specific T cells inthe blood of patients infected with Cytomegalovirus.

Example 79

This is an example of how MHC multimers may be used for detection ofCytomegalovirus

(CMV) specific T cells in blood samples from humans infected with CMV.

In this example the MHC multimer used are MHC complexes coupled tofluorophor-labelled dextran (Dextramers). The dextramers are used fordirect detection of TCR in flow cytometry. The antigen origin is CMV,thus, immune monitoring of CMV.

MHC multimers carrying CMV specific peptides is in this example used todetect the presence of CMV specific T cells in the blood of patientsinfected with Cytomegalovirus.

Purified MHC-peptide complexes consisting of HLA-A*2402 heavy chain,human beta2microglobulin and peptide derived from a region in CMVinternal matrix protein pp 65 or a negative control peptide aregenerated by in vitro refolding, purified and biotinylated as describedelsewhere herein. Biotinylated MHC-peptide complexes are then coupled toa 270 kDa dextran multimerization domain labelled with APC byinteraction with streptavidin (SA) on the dextran multimerizationdomain. The dextran-APC-SA multimerization domain is generated asdescribed elsewhere herein. MHC-peptide complexes are added in an amountcorresponding to a ratio of three MHC-peptide molecules per SA moleculeand each molecule dextran contains 3.7 SA molecule and 8.95 moleculesAPC. The final concentration of dextran is 3.8×10e-8 M. The followingMHC(peptide)/APC dextran constructs are made:

-   -   109. APC-SA conjugated 270 kDa dextran coupled with HLA-A*2402        in complex with beta2microglobulin and the peptide QYDPVAALF        derived from CMV pp 65.    -   110. APC-SA conjugated 270 kDa dextran coupled with HLA-A*2402        in complex with beta2microglobulin and the peptide VYALPLKML        derived from CMV pp 65.    -   111. APC-SA conjugated 270 kDa dextran coupled with HLA-A*2402        in complex with beta2microglobulin and the non-sense peptide.

The binding of the above described MHC(peptide)/APC dextran is used todetermine the presence of CMV pp 65 specific T cells in the blood fromCMV infected individuals by flow cytometry following a standard flowcytometry protocol.

Blood from a patient with CMV infection is isolated and 100 ul of thisblood is incubated with 10 μl of the MHC(peptide)/APC dextran constructsdescribed above for 10 minutes in the dark at room temperature. 5 μl ofeach of each of the antibodies mouse-anti-human CD3/PB (clone UCHT1 fromDako), and mouse-anti-human CD8/PE (clone DK25 from Dako) are added andthe incubation continues for another 20 minutes at 4° C. in the dark.The samples are then washed by adding 2 ml PBS; pH=7.2 followed bycentrifugation for 5 minutes at 300×g and the supernatant removed. Thewashing step is repeated. The washed cells are resuspended in 400-500 μlPBS+1% BSA; pH=7.2 and analyzed on flowcytometer.

The presence of cells labeled with anti-CD3/PB, anti-CD8/PE and theMHC(peptide)/APC dextran constructs 7 or 8 described above and therebythe presence of CMV specific T cells indicate that the patient areinfected with Cytomegalovirus. Blood analysed with MHC(peptide)/APCdextran construct 9 show no staining of CD3 and CD8 positive cells withthis MHC(peptide)/APC dextran construct.

The sensitivity of the above described test may be enhanced by additionof labeled antibodies specific for activation markers expressed in or onthe surface of the CMV specific T cells. We conclude that theMHC(peptide)/APC dextran constructs can be used to detect the presenceof CMV specific T cells in the blood of patients infected withCytomegalovirus.

Example 80

This is an example of how MHC multimers may be used for detection ofCytomegalovirus (CMV) specific T cells in blood samples from humansinfected with CMV.

In this example the MHC multimer used are MHC complexes coupled tofluorophor-labelled multimerisation domain Streptavidin (SA), used fordirect detection of TCR in flow cytometry.

The antigen origin is CMV, thus, immune monitoring of CMV. MHC multimerscarrying CMV specific peptides is in this example used to detect thepresence of CMV specific T cells in the blood of patients infected withCytomegalovirus.

Purified MHC-peptide complexes consisting of HLA-A*2402 heavy chain,human beta2microglobulin and peptide derived from a region in CMVinternal matrix protein pp 65 or a negative control peptide weregenerated by in vitro refolding, purified and biotinylated as describedelsewhere herein. Biotinylated MHC-peptide complexes are then coupled SAlabelled with APC. MHC-peptide complexes were added in an amountcorresponding to a ratio of 5 MHC-peptide molecules per SA molecule.Then SA/APC carrying four MHC complexes were purified from free SA, freemonomeric MHC complex, SA carrying three, two and one MHC complexes.

The following SA-MHC(peptide)/APC tetramers are made:

-   -   112. APC-SA coupled with HLA-A*2402 in complex with        beta2microglobulin and the peptide QYDPVAALF derived from CMV pp        65.    -   113. APC-SA coupled with HLA-A*2402 in complex with        beta2microglobulin and the peptide VYALPLKML derived from CMV pp        65.    -   114. APC-SA coupled with HLA-A*2402 in complex with        beta2microglobulin and the non-sense peptide.

The binding of the above described MHC(peptide)/APC dextran can be usedto determine the presence of CMV pp 65 specific T cells in the bloodfrom Cytomegalovirus infected individuals by flow cytometry following astandard flow cytometry protocol.

Blood from a patient with CMV is isolated and 100 ul of this blood isincubated with either of the SA-MHC(peptide)/APC tetramers describedabove for 10 minutes in the dark at room temperature. 5 μl of each ofeach of the antibodies mouse-anti-human CD3/PB (clone UCHT1 from Dako)and mouse-anti-human CD8/PE (clone DK25 from Dako) are added and theincubation continued for another 20 minutes at 4° C. in the dark. Thesamples are then washed by adding 2 ml PBS; pH=7.2 followed bycentrifugation for 5 minutes at 200×g and the supernatant removed. Thewashing step is repeated. The washed cells are resuspended in 400-500 μlPBS; pH=7.2 and analyzed on flowcytometer.

The presence of cells labeled with anti-CD3/PB, anti-CD8/PE and eitherof the SA-MHC(peptide)/APC tetramers 10 or 11 described above andthereby the presence of CMV specific T cells will indicate that thepatient are infected with Cytomegalovirus. Blood analysed withSA-MHC(peptide)/APC tetramers 12 should show no staining of CD3 and CD8positive cells with this SA-MHC(peptide)/APC tetramer.

The sensitivity of the above described test may be enhanced by additionof labeled antibodies specific for activation markers expressed in or onthe surface of the CMV specific T cells.

We conclude that the APC-SA coupled MHC(peptide) constructs may be usedto detect the presence of CMV specific T cells in the blood of patientsinfected with Cytomegalovirus.

Example 81

This is an example of how MHC multimers may be used for detection ofCytomegalovirus (CMV) specific T cells in blood samples from humansinfected with CMV.

In this example the MHC multimer used are MHC complexes coupled to anyfluorophor-labelled multimerisation as described elsewhere herein. TheMHC multimers are used for direct detection of TCR in flow cytometry.The antigen origin is CMV, thus, immune monitoring of CMV.

MHC multimers carrying CMV specific peptides is in this example used todetect the presence of CMV specific T cells in the blood of patientsinfected with Cytomegalovirus.

Purified MHC-peptide complexes consisting of HLA-A*2402 heavy chain,human beta2microglobulin and peptide derived a region in CMV internalmatrix protein pp 65 or a negative control peptide were generated by invitro refolding and purified or purified from antigen presenting cells.MHC-peptide complexes are then coupled to a multimerisation domaintogether with APC.

The following MHC(peptide)/APC multimers are made:

-   -   115. APC-multimerisation domain coupled with HLA-A*2402 in        complex with beta2microglobulin and the peptide QYDPVAALF        derived from CMV pp 65.    -   116. APC-multimerisation domain coupled with HLA-A*2402 in        complex with beta2microglobulin and the peptide VYALPLKML        derived from CMV pp 65.    -   117. APC-multimerisation domain coupled with HLA-A*2402 in        complex with beta2microglobulin and the non-sense peptide.

The binding of the above described MHC(peptide)/APC multimers can beused to determine the presence of CMV pp 65 specific T cells in theblood from CMV infected individuals by flow cytometry following astandard flow cytometry protocol.

Blood from a patient with CMV infection is isolated and 100 ul of thisblood is incubated with either of the MHC(peptide)/APC multimersdescribed above for 10 minutes in the dark at room temperature. 5 μl ofeach of each of the antibodies mouse-anti-human CD3/PB (clone UCHT1 fromDako) and mouse-anti-human CD8/PE (clone DK25 from Dako) are added andthe incubation continued for another 20 minutes at 4° C. in the dark.The samples are then washed by adding 2 ml PBS; pH=7.2 followed bycentrifugation for 5 minutes at 200×g and the supernatant removed. Thewashing step is repeated. The washed cells are resuspended in 400-500 μlPBS; pH=7.2 and analyzed on flowcytometer.

The presence of cells labeled with anti-CD3/PB, anti-CD8/PE and eitherof the MHC(peptide)/APC multimers 13 or 14 described above and therebythe presence of CMV specific T cells will indicate that the patient areinfected with Cytomegalovirus. Blood analysed with MHC(peptide)/APCmultimer 15 should show no staining of CD3 and CD8 positive cells withthis SA-MHC(peptide)/APC multimer.

The sensitivity of the above described test may be enhanced by additionof labeled antibodies specific for activation markers expressed in or onthe surface of the CMV specific T cells.

We conclude that the APC-multimerisation domain coupled MHC(peptide)constructs may be used to detect the presence of CMV specific T cells inthe blood of patients infected with Cytomegalovirus.

Example 82

This is an example of measurement of antigen reactive T-Cells by IFN-γcapture in blood samples by ELISPOT.

This is an example of indirect detection of TCR, where individual cellsare immobilized and measured by a chromogen assay.

The example provides a sensitive assay for the detection of T-cellsreactive to an antigen by detecting a soluble factor whose secretion isinduced by stimulation of the T-cell by the antigen.

A summary flow chart of the method is shown in FIG. 20. In brief,peripheral blood is diluted threefold in Dulbecco's phosphate bufferedsaline (DPBS), underlain with 15 ml of Ficoll (Pharmacia Ficoll-Paque#17-0840-02, Piscataway, N.J.) per 40 ml diluted blood in a 50 mlpolypropylene centrifuge tube, and spun at 2000 RPM for 20 minutes in aBeckman CS-6R centrifuge (Beckman Inc., Palo Alto, Calif.). The buffylayer at the DPBS/Ficoll interface is removed, washed twice with DPBSand once with human tissue culture medium (hTCM: αMEM+5% heatinactivated human AB serum (Ultraserum, BioWhittaker, Walkersville,Md.), penicillin/streptomycin, 1-glutamine) at low RCF to removeplatelets. Sixty percent of the PBMCs are resuspended in freezing medium(10% dimethyl sulfoxide (Sigma Chemical Co., St. Louis, Mo.), 90% fetalbovine serum to a concentration of 5×10⁶ cells/ml, frozen in aprogrammable Cryo-Med (New Baltimore, Mich.) cell freezer, and storedunder liquid nitrogen until needed.

The purified PBMCs are plated at 2×10⁵ cells/well at a volume of 0.1 mlin 96 well Costar cell culture plates. An equal volume of antigen at 10μg/ml is added to triplicate or sextuplet sets of wells and the plate isincubated in a 37° C., 5% CO₂ incubator. On day five, 10 μl/well of 100U/ml stock recombinant IL-2 (Advanced Biotechnologies Inc., Columbia,Md.) is added to each well. On day 8, frozen PBMCs are thawed, washed inDPBS+0.5% bovine serum albumin (BSA) to remove DMSO, resuspended to aconcentration of 4×10⁶ cells/ml in hTCM, and γ-irradiated (3,000 RADS).Fifty microliters/well are dispensed along with 50 μl of the appropriateantigen at a stock concentration of 40 μl/ml to give a final antigenconcentration of 10 μg/ml.

To prepare a capture plate, IFN-γ capture antibody (monoclonal mouseanti-human IFN-g, Endogen #M700A, Cambridge, Mass.) is diluted to 10μg/ml in sterile 0.1 M Na(CO₃)₂ pH 8.2 buffer, aliquotted at 50 μl/wellin flat bottomed 96 well sterile microtiter plates (Corning CostarCorp.), and incubated at 4° C. for a minimum of 24 hours. Prior to use,excess antibody is removed and wells are washed twice with dPBS+1% Tween20 (PBST). To block further nonspecific protein binding, plates areincubated with 250 μl/well of PBS+5% BSA at room temperature for 1 hour.After discarding the blocking solution, wells are washed once with PBST(0.1% Tween), followed by hTCM in preparation for the antigen stimulatedcells.

On day 9 of the assay, twenty four hours after the second antigenstimulation, the stimulation plate is spun for 5 minutes at 1500 RPM ina Beckman CS-6R centrifuge and 90 μl of supernatant is carefully removedfrom each well with a micropipette. The pelleted cells are resuspendedin 100 μl of hTCM, pooled in sterile tubes (Corning Costar corp sterileClusterTAb #4411, Cambridge, Mass.), mixed and transferred into an equalnumber of wells of an anti IFN-γ capture plate. Capture plates areincubated undisturbed at 37° C. for 16-20 hours. At the end of the IFN-γsecretion phase, the cells are discarded and the plates are washed threetimes with 0.1% PBST. A final aliquot of PBST is added to the wells forten minutes, removed, and 100 μl of a 1:500 dilution of rabbitanti-human IFN-γ polyclonal antibody (Endogen #P700, Cambridge, Mass.)in PBST+1% BSA is added to each well for 3.5 hours at room temperaturewith gentle rocking. Unbound anti-IFN-γ polyclonal antibody is removedby three washes with PBST, followed by a wash with 250 μl of1×Tris-buffered saline+0.05% Tween 20 (TBST). Next, a 100 μl aliquot of1:5000 alkaline phosphatase-conjugated mouse anti-rabbit polyclonalantibody (Jackson Immunological #211-055-109, West Grove, Pa.) dilutedin TBST is added to each well and incubated at room temperature for1.5-2 hours with gentle rocking. Excess enzyme-conjugated antibody isremoved by three washes with PBST and two washes with alkalinephosphatase buffer (APB=0.1 M NaCl, 0.05 M MgCl.sub.2, 0.1 M Tris HCl,pH 9.5) followed by addition of the substrate mix of p-Toluidine saltand nitroblue tetrazolium chloride (BCIP/NBT, GIBCO BRL #18280-016,Gaithersburg, Md.). To stop the calorimetric reaction, plates werewashed three times in dH₂O, inverted to minimize deposition of dust inthe wells, and dried overnight at 28° C. in a dust free drying oven.

Images of the spots corresponding to the lymphokine secreted byindividual antigen-stimulated T cells are captured with a CCD videocamera and the image is analyzed by NIH image software. Captured imagesare enhanced using the Look Up Table which contrasts the images.Thresholding is then applied to every image and a wand tool is used tohighlight the border to effectively subtract the edge of the well sothat background counts won't be high and artificial. Density slicingover a narrow range is then used to highlight the spots produced fromsecreting cells. Pixel limits are set to subtract out small debris andlarge particles, and the number of spots falling within the prescribedpixel range are counted by the software program. Totals from each wellare then manually recorded for future analysis. Alternatively, spots canbe counted by other commercially available or customized softwareapplications, or may be quantitated manually by a technician usingstandard light microscopy. Spots can also be counted manually under alight microscope.

We conclude that the protocol detailed above can be used for theenumeration of single IFN-γ secreting T cells.

Example 83

This is an example of measurement of antigen reactive T-Cells by IFN-γcapture in blood samples from Multiple Sclerosis (MS) patients byELISPOT.

This is an example of indirect detection of TCR, where individual cellsare immobilized and measured by a chromogen assay. The antigenic peptideorigin is MS, thus, immune monitoring of MS.

The example provides a sensitive assay for the detection of T-cellsreactive to the antigen Myelin Basic Protein (MBP), by detecting asoluble factor whose secretion is induced by stimulation of the T-cellby the antigen.

This example is similar to the experiment above. PBMCs from MultipleSclerosis patients are isolated, prepared and stored as described in theexample above.

The purified PBMCs are plated at 2×10⁵ cells/well at a volume of 0.1 mlin 96 well Costar cell culture plates. An equal volume of antigen, MBP83-102 (YDENPVVHFF KNIVTPRTPP) or 144-163 (VDAQGTLSKIFKLGGRDSRS), at 10μg/ml is added to triplicate or sextuplet sets of wells and the plate isincubated in a 37° C., 5% CO₂ incubator. On day five, 10 μl/well of 100U/ml stock recombinant IL-2 is added to each well. On day 8, frozenPBMCs are thawed, washed in DPBS+0.5% BSA to remove DMSO, resuspended toa concentration of 4×10⁶ cells/ml in hTCM, and γ-irradiated (3,000RADS). 50 μl/well are dispensed along with 50 μl of the appropriateantigen at a stock concentration of 40 μl/ml to give a final antigenconcentration of 10 μg/ml.

A capture plate with IFN-γ antibody is prepared, washed and blocked asdescribed in the example above.

On day 9 of the assay, twenty four hours after the second antigenstimulation, the stimulation plate is spun for 5 minutes at 1500 RPM and90 μl of supernatant is carefully removed from each well with amicropipette. The pelleted cells are resuspended in 100 μl of hTCM,pooled in sterile tubes, mixed and transferred into an equal number ofwells of an anti IFN-γ capture plate. Capture plates are incubatedundisturbed at 37° C. for 16-20 hours. At the end of the IFN-γ secretionphase, the cells are discarded and the plates are washed three timeswith 0.1% PBST. A final aliquot of PBST is added to the wells for tenminutes, removed, and 100 μl of a 1:500 dilution of rabbit anti-humanIFN-γ polyclonal antibody in PBST+1% BSA is added to each well for 3.5hours at room temperature with gentle rocking. Unbound anti-IFN-γpolyclonal antibody is removed by three washes with PBST, followed by awash with 250 μl of 1×Tris-buffered saline+0.05% Tween 20 (TBST). Next,a 100 μl aliquot of 1:5000 alkaline phosphatase-conjugated mouseanti-rabbit polyclonal antibody diluted in TBST is added to each welland incubated at room temperature for 1.5-2 hours with gentle rocking.Excess enzyme-conjugated antibody is removed by three washes with PBSTand two washes with alkaline phosphatase followed by addition of thesubstrate mix of p-Toluidine salt and nitroblue tetrazolium chloride. Tostop the calorimetric reaction, plates were washed three times in dH₂O,inverted to minimize deposition of dust in the wells, and driedovernight at 28° C. in a dust free drying oven.

Images of the spots corresponding to the lymphokine secreted byindividual antigen-stimulated T cells are captured with a CCD videocamera and the image is analyzed as described in the example above

We conclude that the experiment detailed above can be used for theenumeration of single IFN-γ secreting T cells in blood from MultipleSclerosis patients.

Example 84

This is an example of measurement of antigen reactive T-Cells by IFN-γcapture in blood samples from Multiple Sclerosis (MS) patients byELISPOT.

This is an example of indirect detection of TCR, where individual cellsare immobilized and measured by a chromogen assay. Antigenic peptideorigin is MS, thus, immune monitoring of MS.

The example provides a sensitive assay for the detection of T-cellsreactive to the antigen Myelin Oligodendrocyte Glycoprotein (MOG), bydetecting a soluble factor whose secretion is induced by stimulation ofthe T-cell by the antigen.

This example is similar to the experiment above PBMCs from MultipleSclerosis patients are isolated, prepared and stored as described in theexample above.

The purified PBMCs are plated at 2×10⁵ cells/well at a volume of 0.1 mlin 96 well Costar cell culture plates. An equal volume of antigen, MOG1-20 (GQFRVIGPRHPIRALVGDEV) or 41-60 (RPPFSRVVHLYRNGKDQDGD), at 10 μg/mlis added to triplicate or sextuplet sets of wells and the plate isincubated in a 37° C., 5% CO₂ incubator. On day five, 10 μl/well of 100U/ml stock recombinant IL-2 is added to each well. On day 8, frozenPBMCs are thawed, washed in DPBS+0.5% BSA to remove DMSO, resuspended toa concentration of 4×10⁶ cells/ml in hTCM, and γ-irradiated (3,000RADS). 50 μl/well are dispensed along with 50 μl of the appropriateantigen at a stock concentration of 40 μl/ml to give a final antigenconcentration of 10 μg/ml.

A capture plate with IFN-γ antibody is prepared, washed and blocked asdescribed in the example above.

On day 9 of the assay, twenty four hours after the second antigenstimulation, the stimulation plate is spun for 5 minutes at 1500 RPM and90 μl of supernatant is carefully removed from each well with amicropipette. The pelleted cells are resuspended in 100 μl of hTCM,pooled in sterile tubes, mixed and transferred into an equal number ofwells of an anti IFN-γ capture plate. Capture plates are incubatedundisturbed at 37° C. for 16-20 hours. At the end of the IFN-γ secretionphase, the cells are discarded and the plates are washed three timeswith 0.1% PBST. A final aliquot of PBST is added to the wells for tenminutes, removed, and 100 μl of a 1:500 dilution of rabbit anti-humanIFN-γ polyclonal antibody in PBST+1% BSA is added to each well for 3.5hours at room temperature with gentle rocking. Unbound anti-IFN-γpolyclonal antibody is removed by three washes with PBST, followed by awash with 250 μl of 1×Tris-buffered saline+0.05% Tween 20 (TBST). Next,a 100 μl aliquot of 1:5000 alkaline phosphatase-conjugated mouseanti-rabbit polyclonal antibody diluted in TBST is added to each welland incubated at room temperature for 1.5-2 hours with gentle rocking.Excess enzyme-conjugated antibody is removed by three washes with PBSTand two washes with alkaline phosphatase followed by addition of thesubstrate mix of p-Toluidine salt and nitroblue tetrazolium chloride. Tostop the calorimetric reaction, plates were washed three times in dH₂O,inverted to minimize deposition of dust in the wells, and driedovernight at 28° C. in a dust free drying oven.

Images of the spots corresponding to the lymphokine secreted byindividual antigen-stimulated T cells are captured with a CCD videocamera and the image is analyzed as described in the example above

We conclude that the experiment detailed above can be used for theenumeration of single IFN-δ secreting T cells in blood from MultipleSclerosis patients.

Example 85

This is an example of measurement of antigen reactive T-Cells by IFN-γcapture in blood samples from Rheumatoid Arthritis (RA) patients byELISPOT.

This is an example of indirect detection of TCR, where individual cellsare immobilized and measured by a chromogen assay. Antigenic peptideorigin is RA, thus, immune monitoring of RA.

The example provides a sensitive assay for the detection of T-cellsreactive to the antigen type II collagen (CII) 261-273, by detecting asoluble factor whose secretion is induced by stimulation of the T-cellby the antigen.

This example is similar to the experiment above. PBMCs from RheumatoidArthritis patients are isolated, prepared and stored as described in theexample above.

The purified PBMCs are plated at 2×10⁵ cells/well at a volume of 0.1 mlin 96 well Costar cell culture plates. An equal volume of antigen, CII261-273 (AGFKGEQGPKGEP), at 10 μg/ml is added to triplicate or sextupletsets of wells and the plate is incubated in a 37° C., 5% CO₂ incubator.On day five, 10 μl/well of 100 U/ml stock recombinant IL-2 is added toeach well. On day 8, frozen PBMCs are thawed, washed in DPBS+0.5% BSA toremove DMSO, resuspended to a concentration of 4×10⁶ cells/ml in hTCM,and γ-irradiated (3,000 RADS). 50 μl/well are dispensed along with 50 μlof the appropriate antigen at a stock concentration of 40 μl/ml to givea final antigen concentration of 10 μg/ml.

A capture plate with IFN-γ antibody is prepared, washed and blocked asdescribed in the example above.

On day 9 of the assay, twenty four hours after the second antigenstimulation, the stimulation plate is spun for 5 minutes at 1500 RPM and90 μl of supernatant is carefully removed from each well with amicropipette. The pelleted cells are resuspended in 100 μl of hTCM,pooled in sterile tubes, mixed and transferred into an equal number ofwells of an anti IFN-γ capture plate. Capture plates are incubatedundisturbed at 37° C. for 16-20 hours. At the end of the IFN-γ secretionphase, the cells are discarded and the plates are washed three timeswith 0.1% PBST. A final aliquot of PBST is added to the wells for tenminutes, removed, and 100 μl of a 1:500 dilution of rabbit anti-humanIFN-γ polyclonal antibody in PBST+1% BSA is added to each well for 3.5hours at room temperature with gentle rocking. Unbound anti-IFN-γpolyclonal antibody is removed by three washes with PBST, followed by awash with 250 μl of 1×Tris-buffered saline+0.05% Tween 20 (TBST). Next,a 100 μl aliquot of 1:5000 alkaline phosphatase-conjugated mouseanti-rabbit polyclonal antibody diluted in TBST is added to each welland incubated at room temperature for 1.5-2 hours with gentle rocking.Excess enzyme-conjugated antibody is removed by three washes with PBSTand two washes with alkaline phosphatase followed by addition of thesubstrate mix of p-Toluidine salt and nitroblue tetrazolium chloride. Tostop the calorimetric reaction, plates were washed three times in dH₂O,inverted to minimize deposition of dust in the wells, and driedovernight at 28° C. in a dust free drying oven.

Images of the spots corresponding to the lymphokine secreted byindividual antigen-stimulated T cells are captured with a CCD videocamera and the image is analyzed as described in the example above

We conclude that the experiment detailed above can be used for theenumeration of single IFN-γ secreting T cells in blood from RheumatoidArthritis patients.'

Example 86

This is an example of measurement of antigen reactive T-Cells by IFN-γcapture in blood samples from Melanoma patients by ELISPOT.

This is an example of indirect detection of TCR, where individual cellsare immobilized and measured by a chromogen assay. The antigenic peptideorigin is Melanoma, thus, immune monitoring of cancer.

The example provides a sensitive assay for the detection of T-cellsreactive to the antigen MELAN-A/MART-1 27-35, by detecting a solublefactor whose secretion is induced by stimulation of the T-cell by theantigen.

This example is similar to the experiment above. PBMCs from Melanomapatients are isolated, prepared and stored as described in the exampleabove.

The purified PBMCs are plated at 2×10⁵ cells/well at a volume of 0.1 mlin 96 well Costar cell culture plates. An equal volume of antigen,MELAN-A/MART-1 27-35 (AAGIGILTV), at 10 μg/ml is added to triplicate orsextuplet sets of wells and the plate is incubated in a 37° C., 5% CO₂incubator. On day five, 10 μl/well of 100 U/ml stock recombinant IL-2 isadded to each well. On day 8, frozen PBMCs are thawed, washed inDPBS+0.5% BSA to remove DMSO, resuspended to a concentration of 4×10⁶cells/ml in hTCM, and γ-irradiated (3,000 RADS). 50 μl/well aredispensed along with 50 μl of the appropriate antigen at a stockconcentration of 40 μl/ml to give a final antigen concentration of 10μg/ml.

A capture plate with IFN-γ antibody is prepared, washed and blocked asdescribed in the example above.

On day 9 of the assay, twenty four hours after the second antigenstimulation, the stimulation plate is spun for 5 minutes at 1500 RPM and90 μl of supernatant is carefully removed from each well with amicropipette. The pelleted cells are resuspended in 100 μl of hTCM,pooled in sterile tubes, mixed and transferred into an equal number ofwells of an anti IFN-γ capture plate. Capture plates are incubatedundisturbed at 37° C. for 16-20 hours. At the end of the IFN-γ secretionphase, the cells are discarded and the plates are washed three timeswith 0.1% PBST. A final aliquot of PBST is added to the wells for tenminutes, removed, and 100 μl of a 1:500 dilution of rabbit anti-humanIFN-γ polyclonal antibody in PBST+1% BSA is added to each well for 3.5hours at room temperature with gentle rocking. Unbound anti-IFN-γpolyclonal antibody is removed by three washes with PBST, followed by awash with 250 μl of 1×Tris-buffered saline+0.05% Tween 20 (TBST). Next,a 100 μl aliquot of 1:5000 alkaline phosphatase-conjugated mouseanti-rabbit polyclonal antibody diluted in TBST is added to each welland incubated at room temperature for 1.5-2 hours with gentle rocking.Excess enzyme-conjugated antibody is removed by three washes with PBSTand two washes with alkaline phosphatase followed by addition of thesubstrate mix of p-Toluidine salt and nitroblue tetrazolium chloride. Tostop the calorimetric reaction, plates were washed three times in dH₂O,inverted to minimize deposition of dust in the wells, and driedovernight at 28° C. in a dust free drying oven.

Images of the spots corresponding to the lymphokine secreted byindividual antigen-stimulated T cells are captured with a CCD videocamera and the image is analyzed as described in the example above

We conclude that the experiment detailed above can be used for theenumeration of single IFN-γ secreting T cells in blood from Melanomapatients.

Example 87

This is an example of measurement of antigen reactive T-Cells by IFN-γcapture in blood samples by ELISPOT.

This is an example of indirect detection of TCR, where individual cellsare immobilized and measured by a chromogen assay. The antigenic peptideorigin is a library of antigens.

The example provides a sensitive assay for the detection of T-cellsreactive to the antigen of a library generated as described in example42, by detecting a soluble factor whose secretion is induced bystimulation of the T-cell by the antigen.

This example is similar to the experiment above. PMBC are isolated,prepared and stored as described in the example above.

The purified PBMCs are plated at 2×10⁵ cells/well at a volume of 0.1 mlin 96 well Costar cell culture plates. An equal volume of antigens fromthe library, at 10 μg/ml is added to triplicate or sextuplet sets ofwells and the plate is incubated in a 37° C., 5% CO₂ incubator. On dayfive, 10 μl/well of 100 U/ml stock recombinant IL-2 is added to eachwell. On day 8, frozen PBMCs are thawed, washed in DPBS+0.5% BSA toremove DMSO, resuspended to a concentration of 4×10⁶ cells/ml in hTCM,and γ-irradiated (3,000 RADS). 50 μl/well are dispensed along with 50 μlof the appropriate antigen at a stock concentration of 40 μl/ml to givea final antigen concentration of 10 μg/ml.

A capture plate with IFN-γ antibody is prepared, washed and blocked asdescribed in the example above.

On day 9 of the assay, twenty four hours after the second antigenstimulation, the stimulation plate is spun for 5 minutes at 1500 RPM and90 μl of supernatant is carefully removed from each well with amicropipette. The pelleted cells are resuspended in 100 μl of hTCM,pooled in sterile tubes, mixed and transferred into an equal number ofwells of an anti IFN-γ capture plate. Capture plates are incubatedundisturbed at 37° C. for 16-20 hours. At the end of the IFN-γ secretionphase, the cells are discarded and the plates are washed three timeswith 0.1% PBST. A final aliquot of PBST is added to the wells for tenminutes, removed, and 100 μl of a 1:500 dilution of rabbit anti-humanIFN-γ polyclonal antibody in PBST+1% BSA is added to each well for 3.5hours at room temperature with gentle rocking. Unbound anti-IFN-γpolyclonal antibody is removed by three washes with PBST, followed by awash with 250 μl of 1×Tris-buffered saline+0.05% Tween 20 (TBST). Next,a 100 μl aliquot of 1:5000 alkaline phosphatase-conjugated mouseanti-rabbit polyclonal antibody diluted in TBST is added to each welland incubated at room temperature for 1.5-2 hours with gentle rocking.Excess enzyme-conjugated antibody is removed by three washes with PBSTand two washes with alkaline phosphatase followed by addition of thesubstrate mix of p-Toluidine salt and nitroblue tetrazolium chloride. Tostop the calorimetric reaction, plates were washed three times in dH₂O,inverted to minimize deposition of dust in the wells, and driedovernight at 28° C. in a dust free drying oven.

Images of the spots corresponding to the lymphokine secreted byindividual antigen-stimulated T cells are captured with a CCD videocamera and the image is analyzed as described in the example above

We conclude that the experiment detailed above can be used for theenumeration of single IFN-γ secreting T cells in blood.

Example 88

This is an example of how antigen specific T-cells can be detected usinga direct detection method detecting T cell immobilized in solid tissue.In this example MHC dextramers are used to detect antigen specific Tcells on frozen tissue sections using enzymatic chromogenicprecipitation detection.

Equilibrate the cryosection tissue (e.g. section of spleen fromtransgenic mice) to −20° C. in the cryostate. Cut 5 μm sections and thendry sections on slides at room temperature. Store slides frozen untiluse at −20° C.

Equilibrate frozen sections to room temperature. Fix with acetone for 5min.

Immediately after fixation transfer slides to TBS buffer (50 mM Tris-HCLpH 7.6, 150 mM NaCl) for 10 min.

Incubate slides with FITC-conjugated MHC-dextramers at appropriatedilution (1:40-1:80) and incubate for 30 min at room temperature. Otherdilution ranges, as well as incubation time and temperature, may bedesirable.

Decant solution and gently tap slides against filter paper, submerge inTBS buffer.

Decant and wash for 10 min in TBS buffer.

Incubate with rabbit polyclonal anti-FITC antibody (Dako P5100) at 1:100dilution in TBS at room temperature for 30 min.

Repeat step 5 and 6.

Incubate with Envision anti-Rabbit HRP (Dako K4003) at room temperaturefor 30 min. Other visualization systems may be used.

Repeat step 5 and 6.

Develop with DAB+ (Dako K3468) in fume hood for 10 min. Other substratesmay be used Rinse slides in tap-water for 5 min.

Counterstain with hematoxylin (Dako 53309) for 2 min.

Repeat step 12, mount slides.

The slides stained with MHC-Dextramers can now be evaluated bymicroscopy.

Example 89

This is an example of how antigen specific T-cells can be detected usinga direct detection method detecting T cell immobilized in solid tissue.In this example MHC dextramers are used to detect antigen specific Tcells on paraffin embedded tissue sections using enzymatic chromogenicprecipitation detection.

Formaldehyde fixed paraffin-embedded tissue are cut in section andmounted on the glass slice, for subsequent IHC staining withMHC-dextramers. Tissue fixed and prepared according to other protocolsmay be used as well. E.g. fresh tissue, lightly fixed tissue section(e.g. tissue fixed in 2% formaldehyde) or formalin-fixed,paraffin-embedded tissue section.

Optimal staining may require target retrieval treatment with enzymes aswell as heating in a suitable buffer before incubation with antibodiesand MHC-dextramer.

The sample is stained for DNA using DAPI stain, followed by incubatedwith an antigen specific MHCdex/FITC reagent, followed by addition ofanti-FITC antibody labeled with HRP. Then the substrate for HRP, “DAP”is added and the reaction allows to progress.

The sample is analyzed by light microscopy for the present of a coloredprecipitate on the cells (DAPI stained nucleus) positive for thespecific MHC/dex reagent.

A digital image of the stained sample is obtained, and this can beanalyzed manually in the same way as by microscopy. However, a digitalimage may be used for automatic determination of where and how manycells that are positive, related to the total amount of cells,determined by the DAPI staining, or other criteria or stainings.

Items

The present invention is further disclosed herein below by citation ofthe following, non-limiting items of the invention.

1. A MHC complex comprising one or more functional MHC molecule(s)capable of binding a peptide P,

wherein, when more than one MHC molecule is present, the MHC complexfurther comprises a multimerization domain preferably comprising atleast one binding entity and/or a carrier,wherein, when the multimerization domain is present, the more than onefunctional MHC molecules are attached either to the at least one bindingentity and/or to the carrier,wherein, when the more than one functional MHC molecules are attached tothe carrier, the MHC molecules are either attached directly to thecarrier or attached to the carrier via one or more binding entities.

2. The MHC complex according to item 1, wherein the MHC molecule is avertebrate MHC molecule such as a human, a murine, a rat, a porcine, abovine or an avian molecule.

3. The MHC complex according to item 1 or 2, wherein the MHC molecule isa human MHC molecule.

4. The MHC complex according to any one of items 1-3, wherein the MHCmolecule is a MHC Class I molecule selected from the group consisting ofa heavy chain, a heavy chain combined with a β₂m, a heavy chain combinedwith a peptide, and a heavy chain/□₂m dimer with a peptide;

or a MHC Class II molecule selected from the group consisting of an α/βdimer, an α/β dimer with a peptide, α/β dimer combined through anaffinity tag and a α/β dimer combined through an affinity tag with apeptide;or a MHC Class I like molecule or MHC Class II like molecule.

5. The MHC complex according to any one of items 1-4, wherein the MHCmolecule is a peptide free MHC molecule.

6. The MHC complex according to any one of items 1-5, wherein more thanone MHC molecule is present, and wherein at least two of said MHCmolecules are different.

7. The MHC complex according to any one of items 1-5, wherein more thanone MHC molecule is present, and wherein the MHC molecules are the same.

8. The MHC complex according to any one of items 1-7, wherein at leasttwo of the peptides harboured by the MHC complexes are different.

9. The MHC complex according to any one of items 1-7, wherein thepeptides harboured by the MHC complexes are the same.

10. The MHC complex according to any one of items 1-9, wherein the MHCmolecule(s) are attached to the carrier directly.

11. The MHC complex according to any one of items 1-9, wherein the MHCmolecule(s) are attached to the carrier via one or more bindingentities.

12. The MHC complex according to item 11, wherein each binding entityhas attached thereto from 1 to 10 MHC molecules.

13. The MHC complex according to item 11, wherein each binding entityhas attached thereto from 1 to 8 MHC molecules.

14. The MHC complex according to item 11, wherein each binding entityhas attached thereto from 1 to 6 MHC molecules.

15. The MHC complex according to item 11, wherein each binding entityhas attached thereto from 1 to 4 MHC molecules.

16. The MHC complex according to item 11, wherein each binding entityhas attached thereto from 1 to 3 MHC molecules.

17. The MHC complex according to item 11, wherein each binding entityhas attached thereto 1 or 2 MHC molecules.

18. The MHC complex according to any one of items 1-17, wherein thetotal number of MHC molecules of the construct is from 1 to 100.

19. The MHC complex according to any one of items 1-17, wherein thetotal number of MHC molecules of the construct is from 1 to 50.

20. The MHC complex according to any one of items 1-17, wherein thetotal number of MHC molecules of the construct is from 1 to 25.

21. The MHC complex according to item 1, wherein the binding entity isselected from streptavidin (SA) and avidin and derivatives thereof,biotin, immunoglobulins, antibodies (monoclonal, polyclonal, andrecombinant), antibody fragments and derivatives thereof, leucine zipperdomain of AP-1 (jun and fos), hexa-his (metal chelate moiety), hexa-hatGST (glutathione S-tranferase) glutathione affinity, Calmodulin-bindingpeptide (CBP), Strep-tag, Cellulose Binding Domain, Maltose BindingProtein, S-Peptide Tag, Chitin Binding Tag, Immuno-reactive Epitopes,Epitope Tags, E2Tag, HA Epitope Tag, Myc Epitope, FLAG Epitope, AU1 andAU5 Epitopes, Glu-Glu Epitope, KT3 Epitope, IRS Epitope, Btag Epitope,Protein Kinase-C Epitope, VSV Epitope, lectins that mediate binding to adiversity of compounds, including carbohydrates, lipids and proteins,e.g. Con A (Canavalia ensiformis) or WGA (wheat germ agglutinin) andtetranectin or Protein A or G (antibody affinity).

22. The MHC complex according to any one of items 1-21, furthercomprising one or more biologically active molecules.

23. The MHC complex according to clam 22, wherein the biologicallyactive molecules is selected from proteins, co-stimulatory molecules,cell modulating molecules, receptors, accessory molecules, adhesionmolecules, natural ligands, and toxic molecules, and antibodies andrecombinant binding molecules thereto, and combinations thereof.

24. The MHC complex according to items 22 or 23, wherein thebiologically active molecule is attached to the carrier either directlyor via one or more of the binding entities.

25. The MHC complex according to any one of items 22-24, wherein thebiologically active molecule is selected from proteins such as MHC ClassI-like proteins like MIC A, MIC B, CD1d, HLA E, HLA F, HLA G, HLA H,ULBP-1, ULBP-2, and ULBP-3,

co-stimulatory molecules such as CD2, CD3, CD4, CD5, CD8, CD9, CD27,CD28, CD30, CD69, CD134 (OX40), CD137 (4-1BB), CD147, CDw150 (SLAM),CD152 (CTLA-4), CD153 (CD30L), CD40L (CD154), NKG2D, ICOS, HVEM, HLAClass II, PD-1, Fas (CD95), FasL expressed on T and/or NK cells, CD40,CD48, CD58, CD70, CD72, B7.1 (CD80), B7.2 (CD86), B7RP-1, B7-H3, PD-L1,PD-L2, CD134L, CD137L, ICOSL, LIGHT expressed on APC and/or tumourcells,cell modulating molecules such as CD16, NKp30, NKp44, NKp46, NKp80, 2B4,KIR, LIR, CD94/NKG2A, CD94/NKG2C expressed on NK cells, IFN-alpha,IFN-beta, IFN-gamma, IL-1, IL-2, IL-3, IL-4, IL-6, IL-7, IL-8, IL-10,IL-11, IL-12, IL-15, CSFs (colony-stimulating factors), vitamin D3, IL-2toxins, cyclosporin, FK-506, rapamycin, TGF-beta, clotrimazole,nitrendipine, and charybdotoxin,accessory molecules such as LFA-1, CD11a/18, CD54 (ICAM-1), CD106(VCAM), and CD49a,b,c,d,e,f/CD29 (VLA-4),adhesion molecules such as ICAM-1, ICAM-2, GlyCAM-1, CD34, anti-LFA-1,anti-CD44, anti-beta7, chemokines, CXCR4, CCR5, anti-selectin L,anti-selectin E, and anti-selectin P,toxic molecules such as cyclophosphamide, methrotrexate, Azathioprine,mizoribine, 15-deoxuspergualin, neomycin, staurosporine, genestein,herbimycin A, Pseudomonas exotoxin A, saporin, Rituxan, Ricin,gemtuzumab ozogamicin, Shiga toxin, heavy metals like inorganic andorganic mercurials, and FN18-CRM9, radioisotopes such as incorporatedisotopes of iodide, cobalt, selenium, tritium, and phosphor, and haptenssuch as DNP, and digoxiginin,and antibodies thereto, or antibody derivatives or fragments thereof,and combinations thereof.

26. The MHC complex according to any of items 1-25 further comprisingone or more labelling compounds.

27. The MHC complex according to item 26, wherein one or more labellingcompounds are attached to the carrier.

28. The MHC complex according to item 26, wherein one or more labellingcompounds are attached to one or more of the binding entities.

29. The MHC complex according to item 26, wherein one or more labellingcompounds are attached to the MHC molecule(s).

30. The MHC complex according to item 26, wherein one or more labellingcompounds are attached to the carrier and/or one or more of the bindingentities and/or one or more of the MHC molecules.

31. The MHC complex according to any one of items 26-30, wherein thelabelling compound is directly or indirectly detectable.

32. The MHC complex according to any of items 26-31, wherein thelabelling compound is a fluorescent label, an enzyme label, aradioisotope, a chemiluminescent label, a bioluminescent label, apolymer, a metal particle, a hapten, an antibody, or a dye.

33. The MHC complex according to any one of items 26-32, wherein thelabelling compound

is selected from fluorescent labels such as 5-(and6)-carboxyfluorescein, 5- or 6-carboxy-fluorescein,6-(fluorescein)-5-(and 6)-carboxamido hexanoic acid, fluoresceinisothiocyanate (F)TC), rhodamine, tetramethylrhodamine, and dyes such asCy2, Cy3, and Cy5, optionally substituted coumarin including AMCA,PerCP, phycobiliproteins including R-phycoerythrin (RPE) andallophycoerythrin (APC), Texas Red, Princeston Red, Green fluorescentprotein (GFP) and analogues thereof, and conjugates of R-phycoerythrinor allophycoerythrin and e.g. Cy5 or Texas Red, and inorganicfluorescent labels based on semiconductor nanocrystals (like quantum dotand Qdot™ nanocrystals), and time-resolved fluorescent labels based onlanthanides like Eu3+ and Sm3+,from haptens such as DNP, biotin, and digoxiginin, oris selected from enzymatic labels such as horse radish peroxidase (HRP),alkaline phosphatase (AP), beta-galactosidase (GAL), glucose-6-phosphatedehydrogenase, beta-N-acetyl-glucosaminidase, β-glucuronidase,invertase, Xanthine Oxidase, firefly luciferase and glucose oxidase(GO), oris selected from luminiscence labels such as luminol, isoluminol,acridinium esters, 1,2-dioxetanes and pyridopyridazines, oris selected from radioactivity labels such as incorporated isotopes ofiodide, cobalt, selenium, tritium, and phosphor.

34. The MHC complex according to any one of items 1-33, wherein thecarrier is selected from

polysaccharides including dextrans, carboxy methyl dextran, dextranpolyaldehyde, carboxymethyl dextran lactone, and cyclodextrins,pullulans, schizophyllan, scleroglucan, xanthan, gellan, O-ethylaminoguaran, chitins and chitosans including 6-O-carboxymethyl chitin andN-carboxymethyl chitosan,derivatised cellolosics including carboxymethyl cellulose, carboxymethylhydroxyethyl cellulose, hydroxyethyl cellulose, 6-amino-6-deoxycellulose and O-ethylamine cellulose,hydroxylated starch, hydroxypropyl starch, hydroxyethyl starch,carrageenans, alginates, and agarose,synthetic polysaccharides including ficoll and carboxymethylated ficoll,vinyl polymers including poly(acrylic acid), poly(acryl amides),poly(acrylic esters), poly(2-hydroxy ethyl methacrylate), poly(methylmethacrylate), poly(maleic acid), poly(maleic anhydride),poly(acrylamide), poly(ethyl-co-vinyl acetate), poly(methacrylic acid),poly(vinyl-alcohol), poly(vinyl alcohol-co-vinyl chloroacetate),aminated poly(vinyl alcohol), and co block polymers thereof,poly ethylene glycol (PEG) or polypropylene glycol or poly(ethyleneoxide-co-propylene oxides) containing polymer backbones includinglinear, comb-shaped or StarBurst™ dendrimers,poly amino acids including polylysines, polyglutamic acid,polyurethanes, poly(ethylene imines), pluriol.proteins including albumins, immunoglobulins, and virus-like proteins(VLP), andpolynucleotides, DNA, PNA, LNA, oligonucleotides and oligonucleotidedendrimer constructs.

35. The MHC complex according to any one of items 1-34, wherein thecarrier is a soluble carrier.

36. The MHC complex according to any one of items 1-35 in soluble form.

37. The MHC complex according to any one of items 1-36 immobilised ontoa solid or semi-solid support.

38. The MHC complex according to item 37, immobilised directly to thesolid or semi-solid support.

39. The MHC complex according to item 37, immobilised to the solid orsemi-solid support via a linker, a spacer, or an antibody, an antibodyderivative or a fragment thereof.

40. The MHC complex according to any one of items 37-39, wherein thesupport is selected from particles, beads, biodegradable particles,sheets, gels, filters, membranes (e.g. nylon membranes), fibres,capillaries, needles, microtitre strips, tubes, plates or wells, combs,pipette tips, micro arrays, and chips.

41. The MHC complex according to item 40, wherein the support isselected from beads and particles.

42. The MHC complex according to item 41, wherein the beads andparticles are polymeric beads, polymeric particles, magnetic beads,magnetic particles, supermagnetic beads, or supermagnetic particles.

43. The MHC complex according to any one of items 1-42 for use in a flowcytometric method.

44. The MHC complex according to any one of items 1-42 for use in ahistological method.

45. The MHC complex according to any one of items 1-42 for use in acytological method.

46. A method for detecting the presence of MHC recognising cells in asample comprising the steps of

(a) providing a sample suspected of comprising MHC recognising cells,(b) contacting the sample with a MHC complex according to items 1-42,and(c) determining any binding of the MHC complex, which binding indicatesthe presence of MHC recognising cells.

47. A method for monitoring MHC recognising cells comprising the stepsof (a) providing a sample suspected of comprising MHC recognising cells,

(b) contacting the sample with a MHC complex according to items 1-42,and(c) determining any binding of the MHC complex, thereby monitoring MHCrecognising cells.

48. A method for establishing a prognosis of a disease involving MHCrecognising cells comprising the steps of

(a) providing a sample suspected of comprising MHC recognising cells,(b) contacting the sample with a MHC complex according to items 1-42,and(c) determining any binding of the MHC complex, thereby establishing aprognosis of a disease involving MHC recognising cells.

49. A method for determining the status of a disease involving MHCrecognising cells comprising the steps of

(a) providing a sample suspected of comprising MHC recognising cells,(b) contacting the sample with a MHC complex according to items 1-42,and(c) determining any binding of the MHC complex, thereby determining thestatus of a disease involving MHC recognising cells.

50. A method for diagnosing a disease involving MHC recognising cellscomprising the steps of

(a) providing a sample suspected of comprising MHC recognising cells,(b) contacting the sample with a MHC complex according to items 1-42,and(c) determining any binding of the MHC complex, thereby diagnosing adisease involving MHC recognising cells.

51. A method for determining the effectiveness of a medicament against adisease involving MHC recognising cells comprising the steps of

(a) providing a sample from a subject receiving treatment with amedicament,(b) contacting the sample with a MHC complex according to items 1-42,and(c) determining any binding of the MHC complex, thereby determining theeffectiveness of the medicament.

52. The method according to any one of items 46-51, wherein the MHCrecognising cells are involved in a disease of inflammatory,auto-immune, allergic, viral, cancerous, infectious, allo- or xenogene(graft versus host and host versus graft) origin.

53. The method according to item 52, wherein the disease is a chronicinflammatory bowel disease such as Crohn's disease or ulcerativecolitis, sclerosis, type I diabetes, rheumatoid arthritis, psoriasis,atopic dermatitis, asthma, malignant melanoma, renal carcinoma, breastcancer, lung cancer, cancer of the uterus, cervical cancer, prostaticcancer, brain cancer, head and neck cancer, leukaemia, cutaneouslymphoma, hepatic carcinoma, colorectal cancer, bladder cancer,rejection-related disease, Graft-versus-host-related disease, or a viraldisease associated with hepatitis, AIDS, measles, pox, chicken pox,rubella or herpes.

54. The method according to any one of items 46-53, wherein the MHCrecognising cells selected from subpopulations of CD3+ T-cells,gamma,delta T-cells, alpha,beta T-cells, CD4+ T-cells, T helper cells,CD8+ T-cells, Suppressor T-cells, CD8+ cytotoxic T-cells, CTLs, NKcells, NKT cells, LAK cells, and MAK.

55. The method according to any one of items 46-51, wherein the sampleis selected from histological material, cytological material, primarytumours, secondary organ metastasis, fine needle aspirates, spleentissue, bone marrow specimens, cell smears, exfoliative cytologicalspecimens, touch preparations, oral swabs, laryngeal swabs, vaginalswabs, bronchial lavage, gastric lavage, from the umbilical cord, andfrom body fluids such as blood (e.g. from a peripheral blood mononuclearcell (PBMC) population isolated from blood or from other blood-derivedpreparations such as leukopheresis products), from sputum samples,expectorates, and bronchial aspirates.

56. The method according to any one of items 46-55, wherein thedetermination of the binding is carried out by inspection in amicroscope, by light, by fluorescence, by electron transmission, or byflow cytometry.

57. The method according to any one of items 46-56, wherein the sampleis mounted on a support.

58. The method according to item 57, wherein the support is a solid orsemi-solid support.

59. The method according to item 57 or 58, wherein the support isselected from glass slides, microtiter plates having one or more wells,beads, particles, membranes, filters, filter membranes, polymer slides,polymer membranes, chamber slides, dishes, and petridishes.

60. A composition comprising a MHC complex according to any one of items1-42 in a solubilising medium.

61. The composition according to item 60, wherein the MHC complexcomprises peptide filled MHC molecules.

62. The composition according to item 60, wherein the MHC complexcomprises peptide free MHC molecules.

63. The composition according to item 62, wherein peptides to fill thepeptide free MHC molecules, and the MHC complex comprising peptide freemolecules are provided separately.

64. A composition comprising a MHC complex according to any one of items1-42, wherein the MHC complex is immobilised onto a solid or semi-solidsupport.

65. The composition according to item 64, wherein the support isselected from glass slides, microtiter plates having one or more wells,beads, particles, membranes, filters, filter membranes, polymer slides,polymer membranes, chamber slides, dishes, and petridishes.

66. The composition according to item 64 or 65, wherein the beads andparticles are polymeric beads, polymeric particles, magnetic beads,magnetic particles, supermagnetic beads, or supermagnetic particles.

67. The composition according to item 64, wherein the MHC complexcomprises peptide filled MHC molecules.

68. The composition according to item 64, wherein the MHC complexcomprises peptide free MHC molecules.

69. The composition according to item 68, wherein peptides to fill thepeptide free MHC molecules, and the MHC complex comprising peptide freemolecules are provided separately.

70. Use of a MHC complex according to any one of items 1-42 as adetection system.

71. Use of a MHC complex according to any one of items 1-42 fordiagnosing a disease involving MHC recognising cells.

72. Use of a MHC complex according to any one of items 1-42 formonitoring a disease involving MHC recognising cells.

73. Use of a MHC complex according to any one of items 1-42 forestablishing a prognosis for a disease involving MHC recognising cells.

74. Use of a MHC complex according to any one of items 1-42 fordetermining the status of a disease involving MHC recognising cells.

75. Use of a MHC complex according to any one of items 1-42 fordetermining the effectiveness of a medicament against a diseaseinvolving MHC recognising cells.

76. Use according to any one of items 71, wherein the MHC recognisingcells are involved in a disease of inflammatory, auto-immune, allergic,viral, cancerous, infectious, allo- or xenogene (graft-versus-host andhost-versus-graft) origin.

77. Use according to item 76, wherein the disease is a chronicinflammatory bowel disease such as Crohn's disease or ulcerativecolitis, sclerosis, type I diabetes, rheumatoid arthritis, psoriasis,atopic dermatitis, asthma, malignant melanoma, renal carcinoma, breastcancer, lung cancer, cancer of the uterus, cervical cancer, prostaticcancer, brain cancer, head and neck cancer, leukaemia, cutaneouslymphoma, hepatic carcinoma, colorectal cancer, bladder cancer,rejection-related disease, Graft-versus-host-related disease, or a viraldisease associated with hepatitis, AIDS, measles, pox, chicken pox,rubella or herpes.

78. Use according to any one of items 70-77, wherein the MHC recognisingcells are selected from subpopulations of CD3+ T-cells, gamma,deltaT-cells, alpha,beta T-cells, CD4+ T-cells, T helper cells, CD8+ T-cells,Suppressor T-cells, CD8+ cytotoxic T-cells, CTLs, NK cells, NKT cells,LAK cells, and MAK.

79. The MHC complex according to any one of items 1-42 for use as atherapeutic composition.

80. The MHC complex according to any one of items 1-42 for use in invivo therapy.

81. The MHC complex according to any one of items 1-42 for use in exvivo therapy.

82. A therapeutic composition comprising as active ingredient a MHCcomplex as defined in any one of items 1-42.

83. The therapeutic composition according to item 82, wherein the MHCcomplex is immobilised to a biodegradable solid or semi-solid support.

84. The therapeutic composition according to item 82 or 83, wherein theMHC complex comprises

a carrier having attached thereto one or more MHC molecules, said MHCmolecules being attached to the carrier either directly or via one ormore binding entities.

85. The therapeutic composition according to item 82 or 83, wherein theMHC molecule is a vertebrate MHC molecule such as a human, a murine, arat, a porcine, a bovine or an avian molecule.

86. The therapeutic composition according to any one of items 82-85,wherein the MHC molecule is a human MHC molecule.

87. The therapeutic composition according to any one of items 82-86,wherein the MHC molecule is

a MHC Class I molecule selected from the group consisting of a heavychain, a heavy chain combined with a β₂m, a heavy chain combined with apeptide, and a heavy chain/□₂m dimer with a peptide;

or a MHC Class II molecule selected from the group consisting of an α/βdimer, an α/β dimer with a peptide, α/β dimer combined through anaffinity tag and a α/β dimer combined through an affinity tag with apeptideor a MHC Class I like molecule or a MHC Class II like molecule.

88. The therapeutic composition according to any one of items 82-87,wherein the MHC molecule is a peptide free MHC molecule.

89. The therapeutic composition according to any one of items 82-88,wherein at least two of the MHC molecules are different.

90. The therapeutic composition according to any one of items 82-88,wherein the MHC molecules are the same.

91. The therapeutic composition according to any one of items 82-88,wherein at least two of the peptides harboured by the MHC molecules aredifferent.

92. The therapeutic composition according to any one of items 82-88,wherein the peptides harboured by the MHC molecules are the same.

93. The therapeutic composition according to any one of items 82-92,wherein the MHC molecules are attached to the carrier directly.

94. The therapeutic composition according to any one of items 82-92,wherein the MHC molecules are attached to the carrier via one or morebinding entities.

95. The therapeutic composition according to item 94, wherein eachbinding entity has attached thereto from 1 to 10 MHC molecules.

96. The therapeutic composition according to item 94, wherein eachbinding entity has attached thereto from 1 to 8 MHC molecules.

97. The therapeutic composition according to item 94, wherein eachbinding entity has attached thereto from 1 to 6 MHC molecules.

98. The therapeutic composition according to item 94, wherein eachbinding entity has attached thereto from 1 to 4 MHC molecules.

99. The therapeutic composition according to item 94, wherein eachbinding entity has attached thereto from 1 to 3 MHC molecules.

100. The therapeutic composition according to item 94, wherein eachbinding entity has attached thereto 1 or 2 MHC molecules.

101. The therapeutic composition according to any one of items 82-100,wherein the total number of MHC molecules of the construct is from 1 to100.

102. The therapeutic composition according to any one of items 82-100,wherein the total number of MHC molecules of the construct is from 1 to50.

103. The therapeutic composition according to any one of items 82-100,wherein the total number of MHC molecules of the construct is from 1 to25.

104. The therapeutic composition according to item 94, wherein thebinding entity is selected from streptavidin (SA) and avidin andderivatives thereof, biotin, immunoglobulins, antibodies (monoclonal,polyclonal, and recombinant), antibody fragments and derivativesthereof, leucine zipper domain of AP-1 (jun and fos), hexa-his (metalchelate moiety), hexa-hat GST (glutathione S-tranferase) glutathioneaffinity, Calmodulin-binding peptide (CBP), Strep-tag, Cellulose BindingDomain, Maltose Binding Protein, S-Peptide Tag, Chitin Binding Tag,Immuno-reactive Epitopes, Epitope Tags, E2Tag, HA Epitope Tag, MycEpitope, FLAG Epitope, AU1 and AU5 Epitopes, Glu-Glu Epitope, KT3Epitope, IRS Epitope, Btag Epitope, Protein Kinase-C Epitope, VSVEpitope, lectins that mediate binding to a diversity of compounds,including carbohydrates, lipids and proteins, e.g. Con A (Canavaliaensiformis) or WGA (wheat germ agglutinin) and tetranectin or Protein Aor G (antibody affinity).

105. The therapeutic composition according to any one of items 82-104further comprising one or more biologically active molecules.

106. The therapeutic composition according to item 105, wherein thebiologically active molecules is selected from proteins, co-stimulatorymolecules, cell modulating molecules, receptors, accessory molecules,adhesion molecules, natural ligands, and toxic molecules, and antibodiesand recombinant binding molecules thereto, and combinations thereof.

107. The therapeutic composition according to item 105 or 106, whereinthe biologically active molecule is attached to the carrier eitherdirectly or via one or more of the binding entities.

108. The therapeutic composition according to any one of items 105-107,wherein the biologically active molecule is selected from

proteins such as MHC Class I-like proteins like MIC A, MIC B, CD1d, HLAE, HLA F, HLA G, HLA H, ULBP-1, ULBP-2, and ULBP-3,co-stimulatory molecules such as CD2, CD3, CD4, CD5, CD8, CD9, CD27,CD28, CD30, CD69, CD134 (OX40), CD137 (4-1BB), CD147, CDw150 (SLAM),CD152 (CTLA-4), CD153 (CD30L), CD40L (CD154), NKG2D, ICOS, HVEM, HLAClass II, PD-1, Fas (CD95), FasL expressed on T and/or NK cells, CD40,CD48, CD58, CD70, CD72, B7.1 (CD80), B7.2 (CD86), B7RP-1, B7-H3, PD-L1,PD-L2, CD134L, CD137L, ICOSL, LIGHT expressed on APC and/or tumourcells,cell modulating molecules such as CD16, NKp30, NKp44, NKp46, NKp80, 2B4,KIR, LIR, CD94/NKG2A, CD94/NKG2C expressed on NK cells, IFN-alpha,IFN-beta, IFN-gamma, IL-1, IL-2, IL-3, IL-4, IL-6, IL-7, IL-8, IL-10,IL-11, IL-12, IL-15, CSFs (colony-stimulating factors), vitamin D3, IL-2toxins, cyclosporin, FK-506, rapamycin, TGF-beta, clotrimazole,nitrendipine, and charybdotoxin,accessory molecules such as LFA-1, CD11a/18, CD54 (ICAM-1), CD106(VCAM), and CD49a,b,c,d,e,f/CD29 (VLA-4),adhesion molecules such as ICAM-1, ICAM-2, GlyCAM-1, CD34, anti-LFA-1,anti-CD44, anti-beta7, chemokines, CXCR4, CCR5, anti-selectin L,anti-selectin E, and anti-selectin P,toxic molecules such as cyclophosphamide, methrotrexate, Azathioprine,mizoribine, 15-deoxuspergualin, neomycin, staurosporine, genestein,herbimycin A, Pseudomonas exotoxin A, saporin, Rituxan, Ricin,gemtuzumab ozogamicin, Shiga toxin, heavy metals like inorganic andorganic mercurials, and FN18-CRM9, radioisotopes such as incorporatedisotopes of iodide, cobalt, selenium, tritium, and phosphor, and haptenssuch as DNP, and digoxiginin,and antibodies thereto, or antibody derivatives or fragments thereof,and combinations thereof.

109. The therapeutic composition according to any one of items 82-108,wherein the carrier is selected from

polysaccharides including dextrans, carboxy methyl dextran, dextranpolyaldehyde, carboxymethyl dextran lactone, and cyclodextrins,pullulans, schizophyllan, scleroglucan, xanthan, gellan, O-ethylaminoguaran, chitins and chitosans including 6-O-carboxymethyl chitin andN-carboxymethyl chitosan,derivatised cellolosics including carboxymethyl cellulose, carboxymethylhydroxyethyl cellulose, hydroxyethyl cellulose, 6-amino-6-deoxycellulose and O-ethylamine cellulose,hydroxylated starch, hydroxypropyl starch, hydroxyethyl starch,carrageenans, alginates, and agarose,synthetic polysaccharides including ficoll and carboxymethylated ficoll,vinyl polymers including poly(acrylic acid), poly(acryl amides),poly(acrylic esters), poly(2-hydroxy ethyl methacrylate), poly(methylmethacrylate), poly(maleic acid), poly(maleic anhydride),poly(acrylamide), poly(ethyl-co-vinyl acetate), poly(methacrylic acid),poly(vinyl-alcohol), poly(vinyl alcohol-co-vinyl chloroacetate),aminated poly(vinyl alcohol), and co block polymers thereof,poly ethylene glycol (PEG) or polypropylene glycol or poly(ethyleneoxide-co-propylene oxides) containing polymer backbones includinglinear, comb-shaped or StarBurst™ dendrimers,poly amino acids including polylysines, polyglutamic acid,polyurethanes, poly(ethylene imines), pluriol.proteins including albumins, immunoglobulins, and virus-like proteins(VLP), andpolynucleotides, DNA, PNA, LNA, oligonucleotides and oligonucleotidedendrimer constructs.

110. The therapeutic composition according to any one of items 82-109,wherein the carrier is a soluble carrier.

111. The therapeutic composition according to any one of items 82-110further comprising one or more adjuvants and/or excipients.

112. The therapeutic composition according to item 111, wherein theadjuvant is selected from saponins such as Quil A and Qs-21, oil inwater emulsions such as MF59, MPL, PLG, PLGA, aluminium salts, calciumphosphate, water in oil emulsions such as IFA (Freund's incompleteadjuvant) and CFA (Freund's complete adjuvant), interleukins such asIL-1β, IL-2, IL-7, IL-12, and INFγ, Adju-Phos®, glucan, antigenformulation, biodegradable microparticles, Cholera Holotoxin, liposomes,DDE, DHEA, DMPC, DMPG, DOC/Alum Complex, ISCOMs®, muramyl dipeptide,monophosphoryl lipid A, muramyl tripeptide, and phospatidylethanolamineIn a preferred embodiment, the adjuvant is selected from saponins suchas Quil A and Qs-21, MF59, MPL, PLG, PLGA, calcium phosphate, andaluminium salts.

113. The therapeutic composition according to item 113, wherein theexcipient is selected from diluents, buffers, suspending agents, wettingagents, solubilising agents, pH-adjusting agents, dispersing agents,preserving agents, and/or colorants.

114. The therapeutic composition according to any one of items 82-113for the treatment, prevention, stabilisation, or alleviation of diseaseinvolving MHC recognising cells.

115. The therapeutic composition according to item 114, wherein the MHCrecognising cells are involved in a disease of inflammatory,auto-immune, allergic, viral, cancerous, infectious, allo- or xenogene(graft versus host and host versus graft) origin.

116. The therapeutic composition according to item 115, wherein thedisease is a chronic inflammatory bowel disease such as Crohn's diseaseor ulcerative colitis, sclerosis, type I diabetes, rheumatoid arthritis,psoriasis, atopic dermatitis, asthma, malignant melanoma, renalcarcinoma, breast cancer, lung cancer, cancer of the uterus, prostaticcancer, brain cancer, head and neck cancer, leukaemia, cutaneouslymphoma, hepatic carcinoma, colorectal cancer, bladder cancer,rejection-related disease, Graft-versus-host-related disease, or a viraldisease associated with hepatitis, AIDS, measles, pox, chicken pox,rubella or herpes.

117. The therapeutic composition according to any one of items 82-116formulated for parenteral administration, including intravenous,intramuscular, intraarticular, subcutaneous, intradermal,epicutantous/transdermal, and intraperitoneal administration, forinfusion, for oral administration, for nasal administration, for rectaladministration, or for topic administration.

118. A therapeutic composition comprising as active ingredient aneffective amount of MHC recognising cells, the MHC recognising cellsbeing obtained by

bringing a sample from a subject comprising MHC recognising cells intocontact with the MHC complex according to any one of items 1-42, wherebythe MHC recognising cells become bound to the MHC complex,isolating the bound MHC complex and the MHC recognising cells, andexpanding such MHC recognising cells to a clinically relevant number.

119. The therapeutic composition according to item 118, wherein theisolated MHC recognising cells are liberated from the MHC complex priorto expansion.

120. The therapeutic composition according to items 118 or 119, whereinthe MHC complex is immobilised onto a solid or semi-solid support.

121. The therapeutic composition according to item 120, wherein the MHCcomplex is immobilised onto the solid or semi-solid support prior tocontact with the sample.

122. The therapeutic composition according to item 120, wherein the MHCcomplex is immobilised onto the solid or semi-solid support followingcontact with the sample.

123. The therapeutic composition according to any one of items 118-122,wherein the expansion is carried out in the presence of one or more MHCcomplexes, optionally one or more biologically active molecules andoptionally feeder cells such as dendritic cells or feeder cells.

124. The therapeutic composition according to any one of items 120-123,wherein the MHC complex is immobilised onto the solid or semi-solidsupport directly.

125. The therapeutic composition according to any one of items 120-124,wherein the MHC complex is immobilised to the solid or semi-solidsupport via a linker, a spacer, or an antibody, an antibody derivativeor a fragment thereof.

126. The therapeutic composition according to any one of items 120-125,wherein the solid or semi-solid support is selected from particles,beads, biodegradable particles, sheets, gels, filters, membranes,fibres, capillaries, needles, microtitre strips, tubes, plates or wells,combs, pipette tips, micro arrays, chips, and microtiter plates havingone or more wells.

127. The therapeutic composition according to any one of items 120-126,wherein the solid support is selected from particles and beads.

128. The therapeutic composition according to item 127, wherein theparticles and beads are polymeric, magnetic or superparamagnetic.

129. The therapeutic composition according to any one of items 118-128,wherein the isolation is performed by applying a magnetic field or byflow cytometry.

130. The therapeutic composition according to any one of items 118-128,wherein the MHC complex comprises

a carrier having attached thereto one or more MHC molecules, said MHCmolecules being attached to the carrier either directly or via one ormore binding entities.

131. The therapeutic composition according to any one of items 118-130,wherein the MHC molecule is a vertebrate MHC molecule such as a human, amurine, a rat, a porcine, a bovine or an avian molecule.

132. The therapeutic composition according to any one of items 118-131,wherein the MHC molecule is a human MHC molecule.

133. The therapeutic composition according to any one of items 118-132,wherein the MHC molecule is

a MHC Class I molecule selected from the group consisting of a heavychain, a heavy chain combined with a □₂m, a heavy chain combined with apeptide, and a heavy chain/□₂m dimer with a peptide;or a MHC Class II molecule selected from the group consisting of an{tilde over (α)}□ dimer, an {tilde over (α)}□ dimer with a peptide,{tilde over (□)}□dimer combined through an affinity tag and a {tildeover (□)}□dimer combined through an affinity tag with a peptide;or a MHC Class I like molecule or a MHC Class II molecule.

134. The therapeutic composition according to any one of items 118-133,wherein the MHC molecule is a peptide free MHC molecule.

135. The therapeutic composition according to any one of items 118-134,wherein at least two of the MHC molecules are different.

136. The therapeutic composition according to any one of items 118-135,wherein the MHC molecules are the same.

137. The therapeutic composition according to any one of items 118-136,wherein at least two of the peptides harboured by the MHC molecules aredifferent.

138. The therapeutic composition according to any one of items 118-137,wherein the peptides harboured by the MHC molecules are the same.

139. The therapeutic composition according to any one of items 118-138,wherein the MHC molecules are attached to the carrier directly.

140. The therapeutic composition according to any one of items 118-138,wherein the MHC molecules are attached to the carrier via one or morebinding entities.

141. The therapeutic composition according to item 140, wherein eachbinding entity has attached thereto from 1 to 10 MHC molecules.

142. The therapeutic composition according to item 140, wherein eachbinding entity has attached thereto from 1 to 8 MHC molecules.

143. The therapeutic composition according to item 140, wherein eachbinding entity has attached thereto from 1 to 6 MHC molecules.

144. The therapeutic composition according to item 140, wherein eachbinding entity has attached thereto from 1 to 4 MHC molecules.

145. The therapeutic composition according to item 140, wherein eachbinding entity has attached thereto from 1 to 3 MHC molecules.

146. The therapeutic composition according to item 140, wherein eachbinding entity has attached thereto 1 or 2 MHC molecules.

147. The therapeutic composition according to any one of items 118-146,wherein the total number of MHC molecules of the construct is from 1 to100.

148. The therapeutic composition according to any one of items 118-146,wherein the total number of MHC molecules of the construct is from 1 to50.

149. The therapeutic composition according to any one of items 118-146,wherein the total number of MHC molecules of the construct is from 1 to25.

150. The therapeutic composition according to item 140, wherein thebinding entity is selected from streptavidin streptavidin (SA) andavidin and derivatives thereof, biotin, immunoglobulins, antibodies(monoclonal, polyclonal, and recombinant), antibody fragments andderivatives thereof, leucine zipper domain of AP-1 (jun and fos),hexa-his (metal chelate moiety), hexa-hat GST (glutathione S-tranferase)glutathione affinity, Calmodulin-binding peptide (CBP), Strep-tag,Cellulose Binding Domain, Maltose Binding Protein, S-Peptide Tag, ChitinBinding Tag, Immuno-reactive Epitopes, Epitope Tags, E2Tag, HA EpitopeTag, Myc Epitope, FLAG Epitope, AU1 and AU5 Epitopes, Glu-Glu Epitope,KT3 Epitope, IRS Epitope, Btag Epitope, Protein Kinase-C Epitope, VSVEpitope, lectins that mediate binding to a diversity of compounds,including carbohydrates, lipids and proteins, e.g. Con A (Canavaliaensiformis) or WGA (wheat germ agglutinin) and tetranectin or Protein Aor G (antibody affinity).

151. The therapeutic composition according to any one of items 118-150further comprising one or more biologically active molecules.

152. The therapeutic composition according to item 151, wherein thebiologically active molecules is selected from proteins, co-stimulatorymolecules, cell modulating molecules, receptors, accessory molecules,adhesion molecules, natural ligands, and toxic molecules, and antibodiesand recombinant binding molecules thereto, and combinations thereof.

153. The therapeutic composition according to item 150 or 151, whereinthe biologically active molecule is attached to the carrier eitherdirectly or via one or more of the binding entities.

154. The therapeutic composition according to any one of items 151-153,wherein the biologically active molecule is selected from proteins suchas MHC Class I-like proteins like MIC A, MIC B, CD1d, HLA E, HLA F, HLAG, HLA H, ULBP-1, ULBP-2, and ULBP-3,

co-stimulatory molecules such as CD2, CD3, CD4, CD5, CD8, CD9, CD27,CD28, CD30, CD69, CD134 (OX40), CD137 (4-1BB), CD147, CDw150 (SLAM),CD152 (CTLA-4), CD153 (CD30L), CD40L (CD154), NKG2D, ICOS, HVEM, HLAClass II, PD-1, Fas (CD95), FasL expressed on T and/or NK cells, CD40,CD48, CD58, CD70, CD72, B7.1 (CD80), B7.2 (CD86), B7RP-1, B7-H3, PD-L1,PD-L2, CD134L, CD137L, ICOSL, LIGHT expressed on APC and/or tumourcells,cell modulating molecules such as CD16, NKp30, NKp44, NKp46, NKp80, 2B4,KIR, LIR, CD94/NKG2A, CD94/NKG2C expressed on NK cells, IFN-alpha,IFN-beta, IFN-gamma, IL-1, IL-2, IL-3, IL-4, IL-6, IL-7, IL-8, IL-10,IL-11, IL-12, IL-15, CSFs (colony-stimulating factors), vitamin D3, IL-2toxins, cyclosporin, FK-506, rapamycin, TGF-beta, clotrimazole,nitrendipine, and charybdotoxin,accessory molecules such as LFA-1, CD11a/18, CD54 (ICAM-1), CD106(VCAM), and CD49a,b,c,d,e,f/CD29 (VLA-4), adhesion molecules such asICAM-1, ICAM-2, GlyCAM-1, CD34, anti-LFA-1, anti-CD44, anti-beta7,chemokines, CXCR4, CCR5, anti-selectin L, anti-selectin E, andanti-selectin P,toxic molecules such as cyclophosphamide, methrotrexate, Azathioprine,mizoribine, 15-deoxuspergualin, neomycin, staurosporine, genestein,herbimycin A, Pseudomonas exotoxin A, saporin, Rituxan, Ricin,gemtuzumab ozogamicin, Shiga toxin, heavy metals like inorganic andorganic mercurials, and FN18-CRM9, radioisotopes such as incorporatedisotopes of iodide, cobalt, selenium, tritium, and phosphor, and haptenssuch as DNP, and digoxiginin,and antibodies thereto, or antibody derivatives or fragments thereof,and combinations thereof.

155. The therapeutic composition according to any one of items 118-154,wherein the carrier is selected from

polysaccharides including dextrans, carboxy methyl dextran, dextranpolyaldehyde, carboxymethyl dextran lactone, and cyclodextrins,pullulans, schizophyllan, scleroglucan, xanthan, gellan, O-ethylaminoguaran, chitins and chitosans including 6-O-carboxymethyl chitin andN-carboxymethyl chitosan,derivatised cellolosics including carboxymethyl cellulose, carboxymethylhydroxyethyl cellulose, hydroxyethyl cellulose, 6-amino-6-deoxycellulose and O-ethylamine cellulose,hydroxylated starch, hydroxypropyl starch, hydroxyethyl starch,carrageenans, alginates, and agarose,synthetic polysaccharides including ficoll and carboxymethylated ficoll,vinyl polymers including poly(acrylic acid), poly(acryl amides),poly(acrylic esters), poly(2-hydroxy ethyl methacrylate), poly(methylmethacrylate), poly(maleic acid), poly(maleic anhydride),poly(acrylamide), poly(ethyl-co-vinyl acetate), poly(methacrylic acid),poly(vinyl-alcohol), poly(vinyl alcohol-co-vinyl chloroacetate),aminated poly(vinyl alcohol), and co block polymers thereof,poly ethylene glycol (PEG) or polypropylene glycol or poly(ethyleneoxide-co-propylene oxides) containing polymer backbones includinglinear, comb-shaped or StarBurst™ dendrimers,poly amino acids including polylysines, polyglutamic acid,polyurethanes, poly(ethylene imines), pluriol.proteins including albumins, immunoglobulins, and virus-like proteins(VLP), and polynucleotides, DNA, PNA, LNA, oligonucleotides andoligonucleotide dendrimer constructs.

156. The therapeutic composition according to any one of items 118-155further comprising one or more labelling compounds.

157. The therapeutic composition according to item 156, wherein one ormore labelling compounds are attached to the carrier.

158. The therapeutic composition according to item 156, wherein one ormore labelling compounds are attached to one or more of the bindingentities.

159. The therapeutic composition according to item 156, wherein one ormore labelling compounds are attached to the one or more MHC molecules.

160. The therapeutic composition according to item 156, wherein one ormore labelling compounds are attached to the carrier and/or one or moreof the binding entities and/or one or more of the MHC molecules.

161. The therapeutic composition according to any one of items 156-160,wherein the labelling compound is directly or indirectly detectable.

162. The therapeutic composition according to any one of items 156-161,wherein the labelling compound is a fluorescent label, an enzyme label,a radioisotope, a chemiluminescent label, a bioluminescent label, apolymer, a metal particle, a hapten, an antibody, or a dye.

163. The therapeutic composition according to any one of items 156-162,wherein the labelling compound is selected from fluorescent labels suchas 5-(and 6)-carboxyfluorescein, 5- or 6-carboxy-fluorescein,6-(fluorescein)-5-(and 6)-carboxamido hexanoic acid, fluoresceinisothiocyanate (FITC), rhodamine, tetramethylrhodamine, and dyes such asCy2, Cy3, and Cy5, optionally substituted coumarin including AMCA,PerCP, phycobiliproteins including R-phycoerythrin (RPE) andallophycoerythrin (APC), Texas Red, Princeston Red, Green fluorescentprotein (GFP) and analogues thereof, and conjugates of R-phycoerythrinor allophycoerythrin and e.g. Cy5 or Texas Red, and inorganicfluorescent labels based on semiconductor nanocrystals (like quantum dotand Qdot™ nanocrystals), and time-resolved fluorescent labels based onlanthanides like Eu3+ and Sm3+,

from haptens such as DNP, biotin, and digoxiginin, oris selected from haptens such as DNP, fluorescein isothiocyanate (FITC),biotin, and digoxiginin, oris selected from enzymatic labels such as horse radish peroxidase (HRP),alkaline phosphatase (AP), beta-galactosidase (GAL), glucose-6-phosphatedehydrogenase, beta-N-acetyl-glucosaminidase, β-glucuronidase,invertase, Xanthine Oxidase, firefly luciferase and glucose oxidase(GO), oris selected from luminiscence labels such as luminol, isoluminol,acridinium esters, 1,2-dioxetanes and pyridopyridazines, oris selected from radioactivity labels such as incorporated isotopes ofiodide, cobalt, selenium, tritium, and phosphor.

164. The therapeutic composition according to any one of items 118-163,wherein the carrier is a soluble carrier.

165. The therapeutic composition according to any one of items 118-164further comprising one or more excipients.

166. The therapeutic composition according to items 165, wherein theexcipient is selected from diluents, buffers, suspending agents, wettingagents, solubilising agents, pH-adjusting agents, dispersing agents,preserving agents, and/or colorants.

167. The therapeutic composition according to any one of items 118-166for the treatment, prevention, stabilisation, or alleviation of adisease involving MHC recognising cells.

168. The therapeutic composition according to item 167, wherein MHCrecognising cells are involved in a disease of inflammatory,auto-immune, allergic, viral, cancerous, infectious, allo- or xenogene(graft versus host and host versus graft) origin.

169. The therapeutic composition according to item 167 or 168, whereinthe disease is a chronic inflammatory bowel disease such as Crohn'sdisease or ulcerative colitis, sclerosis, type I diabetes, rheumatoidarthritis, psoriasis, atopic dermatitis, asthma, malignant melanoma,renal carcinoma, breast cancer, lung cancer, cancer of the uterus,prostatic cancer, brain cancer, head and neck cancer, leukaemia,cutaneous lymphoma, hepatic carcinoma, colorectal cancer, bladdercancer, rejection-related disease, Graft-versus-host-related disease, ora viral disease associated with hepatitis, AIDS, measles, pox, chickenpox, rubella or herpes.

170. The therapeutic composition according to any one of items 118-169formulated for parenteral administration, including intravenous,intramuscular, intraarticular, subcutaneous, intradermal,epicutantous/transdermal, and intraperitoneal administration, forinfusion, for oral administration, for nasal administration, for rectaladministration, or for topic administration.

171. The therapeutic composition according to any one of items 82-170for use in in vivo therapy.

172. A method of treating an animal, including a human being, comprisingadministering a therapeutic composition according to any one of items82-170 in an effective amount.

173. A method of up-regulating, down-regulating, modulate an immuneresponse in an animal, including a human being, comprising administeringa therapeutic composition according to any one of items 82-170 in aneffective amount.

174. A method of inducing anergy of a cell in an animal, including ahuman being, comprising administering a therapeutic compositionaccording to any one of items 82-170 in an effective amount.

175. An adoptive cellular immunotherapeutic method comprisingadministrating to an animal, including a human being, a therapeuticcomposition according to any one of items 82-170.

176. A method of obtaining MHC recognising cells comprising

bringing into contact a MHC complex according to any one of items 1-42and a sample suspected of comprising MHC recognising cells underconditions whereby the MHC recognising cells bind to the MHC complex,andisolating the bound MHC complex and MHC recognising cells.

177. The method according to item 176, wherein the isolation is carriedout by applying a magnetic field or by flow cytometry.

178. A method for producing a therapeutic composition according to anyone of items 82-170, comprising

providing a MHC complex as defined in items 1-42,solubilising or dispersing the MHC complex in a medium suitable fortherapeutic substances, and optionally adding other adjuvants and/orexcipients.

179. A method for producing a therapeutic composition according to anyone of items 118-170, comprising

obtaining MHC recognising cells using a MHC complex according to any oneof items 1-42,expanding such MHC recognising cells to a clinically relevant number,formulating the obtained cells in a medium suitable for administration,andoptionally adding adjuvants and/or excipients.

180. Use of a MHC complex according to any one of items 1-42 for ex vivoexpansion of MHC recognising cells.

181. Use according to item 180, wherein the MHC complex is in solubleform.

182. Use according to item 180, wherein the MHC complex is immobilisedonto a solid or semi-solid support.

183. Use according to item 182, wherein the solid or semi-solid supportis selected from particles, beads, biodegradable particles, sheets,gels, filters, membranes (e.g. nylon membranes), fibres, capillaries,needles, microtitre strips, tubes, plates or wells, combs, pipette tips,micro arrays, chips, and slides.

184. Use according to item 182 or 183, wherein the solid or semi-solidsupport is selected from beads and particles.

185. Use according to item 184, wherein the solid or semi-solid supportis selected from polymeric, magnetic or superparamagnetic particles andbeads.

186. Use according to any one of items 180-185, wherein the MHC complexfurther comprises one or more biologically active molecules.

187. Use according to any one of items 180-186, wherein the biologicallyactive molecule is selected from proteins such as MHC Class I-likeproteins like MIC A, MIC B, CD1d, HLA E, HLA F, HLA G, HLA H, ULBP-1,ULBP-2, and ULBP-3,

co-stimulatory molecules such as CD2, CD3, CD4, CD5, CD8, CD9, CD27,CD28, CD30, CD69, CD134 (OX40), CD137 (4-1BB), CD147, CDw150 (SLAM),CD152 (CTLA-4), CD153 (CD30L), CD40L (CD154), NKG2D, ICOS, HVEM, HLAClass II, PD-1, Fas (CD95), FasL expressed on T and/or NK cells, CD40,CD48, CD58, CD70, CD72, B7.1 (CD80), B7.2 (CD86), B7RP-1, B7-H3, PD-L1,PD-L2, CD134L, CD137L, ICOSL, LIGHT expressed on APC and/or tumourcells,cell modulating molecules such as CD16, NKp30, NKp44, NKp46, NKp80, 2B4,KIR, LIR, CD94/NKG2A, CD94/NKG2C expressed on NK cells, IFN-alpha,IFN-beta, IFN-gamma, IL-1, IL-2, IL-3, IL-4, IL-6, IL-7, IL-8, IL-10,IL-11, IL-12, IL-15, CSFs (colony-stimulating factors), vitamin D3, IL-2toxins, cyclosporin, FK-506, rapamycin, TGF-beta, clotrimazole,nitrendipine, and charybdotoxin,accessory molecules such as LFA-1, CD11a/18, CD54 (ICAM-1), CD106(VCAM), and CD49a,b,c,d,e,f/CD29 (VLA-4),adhesion molecules such as ICAM-1, ICAM-2, GlyCAM-1, CD34, anti-LFA-1,anti-CD44, anti-beta7, chemokines, CXCR4, CCR5, anti-selectin L,anti-selectin E, and anti-selectin P, toxic molecules such ascyclophosphamide, methrotrexate, Azathioprine, mizoribine,15-deoxuspergualin, neomycin, staurosporine, genestein, herbimycin A,Pseudomonas exotoxin A, saporin, Rituxan, Ricin, gemtuzumab ozogamicin,Shiga toxin, heavy metals like inorganic and organic mercurials, andFN18-CRM9, radioisotopes such as incorporated isotopes of iodide,cobalt, selenium, tritium, and phosphor, and haptens such as DNP, anddigoxiginin,and antibodies thereto, or antibody derivatives or fragments thereof,and combinations thereof.

187. Use of a MHC molecule in a histological method.

188. Use of a MHC molecule in a cytological method.

189. Use of a MHC molecule according to item 187 or 188 in a method fordetermining the presence of MHC recognising cells in a sample, in whichmethod the MHC recognising cells of the sample are mounted on a support.

190. Use of a MHC molecule according to item 187 or 188, in a method formonitoring the presence of MHC recognising cells in a sample, in whichmethod the MHC recognising cells of the sample are mounted on a support.

191. Use of a MHC molecule according to item 187 or 188 in a method fordetermining the status of a disease involving MHC recognising cells, inwhich method the MHC recognising cells of the sample are mounted on asupport.

192. Use of a MHC molecule according to item 187 or 188 in a method forestablishing a prognosis of a disease involving MHC recognising cells,in which method the MHC recognising cells of the sample are mounted on asupport.

193. Use of a MHC molecule according to any one of items 187-192,wherein the support is a solid or semi-solid support.

194. Use of a MHC molecule according to any one of items 187-193,wherein the support is selected from glass slides, membranes, filters,polymer slides, chamber slides, dishes, and petridishes.

195. Use according to any one of items 187-194, wherein the sample isselected from histological material, cytological material, primarytumours, secondary organ metastasis, fine needle aspirates, spleentissue, bone marrow specimens, cell smears, exfoliative cytologicalspecimens, touch preparations, oral swabs, laryngeal swabs, vaginalswabs, bronchial lavage, gastric lavage, from the umbilical cord, andfrom body fluids such as blood (e.g. from a peripheral blood mononuclearcell (PBMC) population isolated from blood or from other blood-derivedpreparations such as leukopheresis products), from sputum samples,expectorates, and bronchial aspirates.

196. The use according to any one of items 187-195, wherein the MHCmolecule is

a MHC Class I molecule selected from the group consisting of a heavychain, a heavy chain combined with a □₂m, a heavy chain combined with apeptide, and a heavy chain/□₂m dimer with a peptide;or a MHC Class II molecule selected from the group consisting of anα/□dimer, an α/□ dimer with a peptide, □/□ dimer combined through anaffinity tag and a □/□ dimer combined through an affinity tag with apeptide;or a MHC Class I like molecule or a MHC Class II like molecule.

197. The use according to any one of items 187-196, wherein the MHCmolecule is a vertebrate MHC molecule such as a human, a murine, a rat,a porcine, a bovine or an avian molecule.

198. The use according to any one of items 187-197, wherein the MHCmolecule is a human MHC molecule.

199. The use according to any one of items 187-198, wherein the MHCmolecule is a peptide free MHC molecule.

200. The use according to any one of items 187-199, wherein the MHCmolecule is attached to a binding entity.

201. Use according to item 200, wherein the binding entity has attachedthereto from 1 to 10 MHC molecules, such as from 1 to 9, from 1 to 8,from 1 to 7, from 1 to 6, from 1 to 5, from 1 to 4, from 1 to 3, or 1 or2 MHC molecules.

202. Use according to item 200, wherein the binding entity is selectedfrom streptavidin streptavidin (SA) and avidin and derivatives thereof,biotin, immunoglobulins, antibodies (monoclonal, polyclonal, andrecombinant), antibody fragments and derivatives thereof, leucine zipperdomain of AP-1 (jun and fos), hexa-his (metal chelate moiety), hexa-hatGST (glutathione S-tranferase) glutathione affinity, Calmodulin-bindingpeptide (CBP), Strep-tag, Cellulose Binding Domain, Maltose BindingProtein, S-Peptide Tag, Chitin Binding Tag, Immuno-reactive Epitopes,Epitope Tags, E2Tag, HA Epitope Tag, Myc Epitope, FLAG Epitope, AU1 andAU5 Epitopes, Glu-Glu Epitope, KT3 Epitope, IRS Epitope, Btag Epitope,Protein Kinase-C Epitope, VSV Epitope, lectins that mediate binding to adiversity of compounds, including carbohydrates, lipids and proteins,e.g. Con A (Canavalia ensiformis) or WGA (wheat germ agglutinin) andtetranectin or Protein A or G (antibody affinity).

203. Use according to any one of items 187-202, wherein the MHC moleculefurther comprises a labelling compound.

204. Use according to item 203, wherein the labelling compound can bedetected directly or indirectly.

205. Use according to item 203 or 204, wherein the labelling compound isa fluorescent label, an enzyme label, a radioisotope, a chemiluminescentlabel, a bioluminescent label, a polymer, a metal particle, a hapten, anantibody, or a dye.

206. Use according to any one of items 203-205, wherein the labellingcompound is selected from

5-(and 6)-carboxyfluorescein, 5- or 6-carboxyfluorescein,6-(fluorescein)-5-(and 6)-carbox-amido hexanoic acid, fluoresceinisothiocyanate (FITC), rhodamine, tetramethylrhodamine, and dyes such asCy2, Cy3, and Cy5, optionally substituted coumarin including AMCA,PerCP, phycobiliproteins including R-phycoerythrin (RPE) andallophycoerythrin (APC), Texas Red, Princeston Red, Green fluorescentprotein (GFP) and analogues thereof, and conjugates of R-phycoerythrinor allophycoerythrin and e.g. Cy5 or Texas Red, and inorganicfluorescent labels based on semiconductor nanocrystals (like quantum dotand Qdot™ nanocrystals), and time-resolved fluorescent labels based onlanthanides like Eu3+ and Sm3+,from haptens such as DNP, biotin, and digoxiginin, oris selected from enzymatic labels such as horse radish peroxidase (HRP),alkaline phosphatase (AP), beta-galactosidase (GAL), glucose-6-phosphatedehydrogenase, beta-N-acetyl-glucosaminidase, β-glucuronidase,invertase, Xanthine Oxidase, firefly luciferase and glucose oxidase(GO), oris selected from luminiscence labels such as luminol, isoluminol,acridinium esters, 1,2-dioxetanes and pyridopyridazines, oris selected from radioactivity labels such as incorporated isotopes ofiodide, cobalt, selenium, tritium, and phosphor.

207. The use according to any one of items 203-206, wherein thelabelling compound is attached to the MHC molecule and/or the bindingentity.

208. A method for detecting the presence of MHC recognising cells in asample comprising the steps of

(a) providing a sample suspected of comprising MHC recognising cellsmounted on a support,(b) contacting the sample with a MHC molecule as defined in items187-207, and(c) determining any binding of the MHC molecule, which binding indicatesthe presence of MHC recognising cells.

209. A method for monitoring MHC recognising cells comprising the stepsof

(a) providing a sample suspected comprising MHC recognising cellsmounted on a support,(b) contacting the sample with a MHC molecule as defined in items187-207, and(c) determining any binding of the MHC molecule, thereby monitoring MHCrecognising cells.

210. A method for the prognosis of a disease involving MHC recognisingcells comprising the steps of

(a) providing a sample suspected comprising MHC recognising cellsmounted on a support,(b) contacting the sample with a MHC molecule as defined in items187-207, and(c) determining any binding of the MHC molecule, thereby establishing aprognosis of a disease involving MHC recognising cells.

211. A method for determining the status of a disease involving MHCrecognising cells comprising the steps of

(a) providing a sample suspected comprising MHC recognising cellsmounted on a support,(b) contacting the sample with a MHC molecule as defined in items187-207, and(c) determining any binding of the MHC molecule, thereby determining thestatus of a disease involving MHC recognising cells.

212. A method for the diagnosis of a disease involving MHC recognisingcells comprising the steps of

(a) providing a sample suspected comprising MHC recognising cellsmounted on a support,(b) contacting the sample with a MHC molecule as defined in items187-207, and(c) determining any binding of the MHC molecule, thereby diagnosing adisease involving MHC recognising cells.

213. A method for the effectiveness of a medicament against a diseaseinvolving MHC recognising cells comprising the steps of

(a) providing a sample from a subject receiving treatment with amedicament mounted on a support,(b) contacting the sample with a MHC molecule as defined in items187-207, and(c) determining any binding of the MHC molecule, thereby determining theeffectiveness of the medicament.

214. The method according to any one of items 208-213, wherein the MHCrecognising cells are involved in a disease of inflammatory,auto-immune, allergic, viral, cancerous, infectious, allo- or xenogene(graft-versus-host and host-versus-graft) origin.

215. The method according to item 214, wherein the disease is a chronicinflammatory bowel disease such as Crohn's disease or ulcerativecolitis, sclerosis, type I diabetes, rheumatoid arthritis, psoriasis,atopic dermatitis, asthma, malignant melanoma, renal carcinoma, breastcancer, lung cancer, cancer of the uterus, cervical cancer, prostaticcancer, brain cancer, head and neck cancer, leukaemia, cutaneouslymphoma, hepatic carcinoma, colorectal cancer, bladder cancer,rejection-related disease, Graft-versus-host-related disease, or a viraldisease associated with hepatitis, AIDS, measles, pox, chicken pox,rubella or herpes.

216. The method according to any one of items 208-214, wherein the MHCrecognising cells are selected from subpopulations of CD3+ T-cells,gamma,delta T-cells, alpha,beta T-cells, CD4+ T-cells, T helper cells,CD8+ T-cells, Suppressor T-cells, CD8+ cytotoxic T-cells, CTLs, NKcells, NKT cells, LAK cells, and MAK.

217. The method or use according to any one of items 201-216, whereinthe sample is selected from histological material, cytological material,primary tumours, secondary organ metastasis, fine needle aspirates,spleen tissue, bone marrow specimens, cell smears, exfoliativecytological specimens, touch preparations, oral swabs, laryngeal swabs,vaginal swabs, bronchial lavage, gastric lavage, from the umbilicalcord, and from body fluids such as blood (e.g. from a peripheral bloodmononuclear cell (PBMC) population isolated from blood or from otherblood-derived preparations such as R

1. An isolated MHC multimer for detection of Borrelia specific CD8+ Tcells, the MHC multimer comprising (a-b-P)_(n), wherein n>1, wherein aand b together form a functional MHC protein which is bound to thepeptide P, wherein (a-b-P) is the MHC peptide complex formed when thepeptide P is bound to the functional MHC protein, wherein each MHCpeptide complex of an MHC multimer is associated with one or moremultimerization domains, wherein in at least one MHC peptide complex,the sequence of P originates from a Borrelia antigen.
 2. The isolatedMHC multimer according to claim 1, wherein in at least one MHC peptidecomplex, P is an 8-mer, 9-mer, 10-mer, 11-mer or 12-mer.
 3. The isolatedMHC multimer according to claim 1, wherein in at least one MHC peptidecomplex, P is capable of binding to MHC class I.
 4. The isolated MHCmultimer according to claim 1, wherein in at least one MHC peptidecomplex, the sequence of P is contained in a Borrelia burgdorferiantigen and is capable of interacting with one or more MHC class Imolecules.
 5. The isolated MHC multimer according to claim 1, wherein inat least one MHC peptide complex, the sequence of P is contained in aBorrelia afzelii antigen and is capable of interacting with one or moreMHC class I molecules.
 6. The isolated MHC multimer according to claim1, wherein in at least one MHC peptide complex, the sequence of P iscontained in a Borrelia Garinii antigen and is capable of interactingwith one or more MHC class I molecules.
 7. The isolated MHC multimeraccording to claim 1, wherein in at least one MHC peptide complex, thesequence of P is contained in Osp C derived from Borrelia afzelli and iscapable of interacting with one or more MHC class I molecules.
 8. Theisolated MHC multimer according to claim 1, wherein in at least one MHCpeptide complex, the sequence of P is contained in OspA derived fromBorrelia burgdorferi and is capable of interacting with one or more MHCclass I molecules.
 9. The isolated MHC multimer according to claim 1,wherein in at least one MHC peptide complex, the sequence of P iscontained in FlaB derived from Borrelia garinii and is capable ofinteracting with one or more MHC class I molecules.
 10. A method forimmune monitoring one or more Borrelia infections comprising thefollowing steps: i) providing the MHC multimer according to any one ofclaims 1 to 9, or the individual components thereof, ii) providing apopulation of T cells, and iii) measuring the number, activity or stateof T cells specific for said MHC multimer, thereby immune monitoringsaid one or more Borrelia infections.
 11. A method for diagnosing one ormore Borrelia infections comprising the following steps: i) providingthe MHC multimer according to any one of claims 1 to 9, or individualcomponents thereof, ii) providing a population T cells, and iii)measuring the number, activity or state of T cells specific for said MHCmultimer, thereby diagnosing said one or more diseases.
 12. A method forisolation of one or more Borrelia antigen specific T cells, said methodcomprising the steps of: i) providing the MHC multimer according to anyone of claims 1 to 9, or individual components thereof, ii) providing apopulation of T cells, and iii) isolating T cells specific for said MHCmultimer.